<SEC-DOCUMENT>0000875045-21-000028.txt : 20210422
<SEC-HEADER>0000875045-21-000028.hdr.sgml : 20210422
<ACCEPTANCE-DATETIME>20210422161439
ACCESSION NUMBER:		0000875045-21-000028
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		114
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210422
DATE AS OF CHANGE:		20210422

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		21844953

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:b54f3254-567d-4813-a83c-54bbe0ebf523,g:5bfc82e5-4d8f-4b59-aa4e-ce589875722a,d:6fe84bc7e101462ea41fc07416803961--><html xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:biib="http://www.biogenidec.com/20210331" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>biib-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80L2ZyYWc6ZjhiNTk2MmNiMzRiNGU4MDk0YmE5OWVhNjMwNjk2ZmMvdGFibGU6MDM2M2Q0NzYyOTg4NDM3ZGJhZmZjZWM3NGZhOGQxZTEvdGFibGVyYW5nZTowMzYzZDQ3NjI5ODg0MzdkYmFmZmNlYzc0ZmE4ZDFlMV8xLTEtMS0xLTA_71d4ef7a-66b1-43e9-8baf-49081bd86b1b">0000875045</ix:nonNumeric><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80L2ZyYWc6ZjhiNTk2MmNiMzRiNGU4MDk0YmE5OWVhNjMwNjk2ZmMvdGFibGU6MDM2M2Q0NzYyOTg4NDM3ZGJhZmZjZWM3NGZhOGQxZTEvdGFibGVyYW5nZTowMzYzZDQ3NjI5ODg0MzdkYmFmZmNlYzc0ZmE4ZDFlMV8yLTEtMS0xLTA_7117525d-07ce-4220-9ee7-263f9b8baebc">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80L2ZyYWc6ZjhiNTk2MmNiMzRiNGU4MDk0YmE5OWVhNjMwNjk2ZmMvdGFibGU6MDM2M2Q0NzYyOTg4NDM3ZGJhZmZjZWM3NGZhOGQxZTEvdGFibGVyYW5nZTowMzYzZDQ3NjI5ODg0MzdkYmFmZmNlYzc0ZmE4ZDFlMV8zLTEtMS0xLTA_4ee334b5-2f8b-4971-bb67-2cd3f8efd6de">2021</ix:nonNumeric><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80L2ZyYWc6ZjhiNTk2MmNiMzRiNGU4MDk0YmE5OWVhNjMwNjk2ZmMvdGFibGU6MDM2M2Q0NzYyOTg4NDM3ZGJhZmZjZWM3NGZhOGQxZTEvdGFibGVyYW5nZTowMzYzZDQ3NjI5ODg0MzdkYmFmZmNlYzc0ZmE4ZDFlMV80LTEtMS0xLTA_24662367-fd19-4742-a459-0369b234127e">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80L2ZyYWc6ZjhiNTk2MmNiMzRiNGU4MDk0YmE5OWVhNjMwNjk2ZmMvdGFibGU6MDM2M2Q0NzYyOTg4NDM3ZGJhZmZjZWM3NGZhOGQxZTEvdGFibGVyYW5nZTowMzYzZDQ3NjI5ODg0MzdkYmFmZmNlYzc0ZmE4ZDFlMV81LTEtMS0xLTA_abf31984-ac12-4efb-9cd8-613e466e7b46">false</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="ic6f45d28d5d8449d9712a20039e0697e_I20210421" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80L2ZyYWc6ZjhiNTk2MmNiMzRiNGU4MDk0YmE5OWVhNjMwNjk2ZmMvdGFibGU6MDM2M2Q0NzYyOTg4NDM3ZGJhZmZjZWM3NGZhOGQxZTEvdGFibGVyYW5nZTowMzYzZDQ3NjI5ODg0MzdkYmFmZmNlYzc0ZmE4ZDFlMV82LTItMS0xLTA_8aef9027-2078-45fd-8c2c-cd46508d3b2a">150,554,750</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yOC9mcmFnOjYxOTExZjEwYjYzOTQ3NDQ5MGRkNjNmZmRjZDA0YmM1L3RhYmxlOjE3MzQxN2U2ZTVhNTRmYWQ5NWIwNmY0NzI1N2UzYmFmL3RhYmxlcmFuZ2U6MTczNDE3ZTZlNWE1NGZhZDk1YjA2ZjQ3MjU3ZTNiYWZfMS0xLTEtMS0w_1627580b-bbca-4463-871a-4ef77fe5cf47">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yOC9mcmFnOjYxOTExZjEwYjYzOTQ3NDQ5MGRkNjNmZmRjZDA0YmM1L3RhYmxlOjE3MzQxN2U2ZTVhNTRmYWQ5NWIwNmY0NzI1N2UzYmFmL3RhYmxlcmFuZ2U6MTczNDE3ZTZlNWE1NGZhZDk1YjA2ZjQ3MjU3ZTNiYWZfMS0zLTEtMS0w_f016a8ca-cedc-4fff-82d2-0970df41d14c">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yOC9mcmFnOjYxOTExZjEwYjYzOTQ3NDQ5MGRkNjNmZmRjZDA0YmM1L3RhYmxlOjE3MzQxN2U2ZTVhNTRmYWQ5NWIwNmY0NzI1N2UzYmFmL3RhYmxlcmFuZ2U6MTczNDE3ZTZlNWE1NGZhZDk1YjA2ZjQ3MjU3ZTNiYWZfMi0xLTEtMS0w_1db8461e-c1bd-430c-a8d4-a44bd69eb2fe">0.0005</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yOC9mcmFnOjYxOTExZjEwYjYzOTQ3NDQ5MGRkNjNmZmRjZDA0YmM1L3RhYmxlOjE3MzQxN2U2ZTVhNTRmYWQ5NWIwNmY0NzI1N2UzYmFmL3RhYmxlcmFuZ2U6MTczNDE3ZTZlNWE1NGZhZDk1YjA2ZjQ3MjU3ZTNiYWZfMi0zLTEtMS0w_ccc3951a-6ea5-42d7-b6a5-b0f959da2ec7">0.0005</ix:nonFraction><ix:nonNumeric contextRef="ifff98e73ce134eadb812f6e1419eb1bd_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfMS0xLTEtMS0w_f80a3ee7-f13a-49a8-ac8e-8e760d30550c">13</ix:nonNumeric><ix:nonNumeric contextRef="ied5ebc033f5042cfba2d1d9018f9eb58_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfMi0xLTEtMS0w_35d8ba0b-cf57-4930-9360-9e6a4d06251a">23</ix:nonNumeric><ix:nonNumeric contextRef="i583e423036fc4cabb98562f54f1b61ad_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfMy0xLTEtMS0w_0cac72d8-dec1-499d-9eaa-5737976e1414">15</ix:nonNumeric><ix:nonNumeric contextRef="i2bf61e1da4cb4085ab83a72725b9c364_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfNC0xLTEtMS0w_61afb743-25cd-4175-b05e-d3780ddfea66">28</ix:nonNumeric><ix:nonNumeric contextRef="i7d0bb3392f8b437d85af0d89b58fbe65_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfNS0xLTEtMS0w_3e13df59-fb87-4e71-9aeb-f13b06f1d76d">4</ix:nonNumeric><ix:nonNumeric contextRef="ib7f6d94534c94c69950875e422123904_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfNi0xLTEtMS0w_2ad48f53-8928-4192-b6db-4dae8188e54e">18</ix:nonNumeric><ix:nonNumeric contextRef="i3a69b4c3dc9c4aba925cc1b9bb62aad5_D20210101-20210331" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfNy0xLTEtMS0w_4a645591-247b-49f9-83c1-ef6e500d049c">Indefinite until commercialization</ix:nonNumeric><ix:nonNumeric contextRef="i59ae9b2ac6bd42a5aa75417ce4eb6bc5_D20210101-20210331" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfOC0xLTEtMS0w_5f4caf69-579f-4e47-84b6-9400c305b6e1">Indefinite</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RleHRyZWdpb246OTU2ZTM0Nzc5Y2U0NGNiNDlmNmY2ZWNjNDliNmQ0OTRfMzk_caee377f-6e75-4e7a-9b37-cbdd79049ac1">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RleHRyZWdpb246OTU2ZTM0Nzc5Y2U0NGNiNDlmNmY2ZWNjNDliNmQ0OTRfNTI_38403ddc-655d-4c1c-96d0-94ee56076008">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RleHRyZWdpb246OTU2ZTM0Nzc5Y2U0NGNiNDlmNmY2ZWNjNDliNmQ0OTRfNTU_ad9b9056-0f4a-4b25-ad10-b334cb8620ea">0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i86ba11dc3301448dab6e7f9202ed71a0_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOmI3NjYxZTY5ZmIyZTQzNDM5YTJhODJlNmJiM2M0ZDM1L3RhYmxlcmFuZ2U6Yjc2NjFlNjlmYjJlNDM0MzlhMmE4MmU2YmIzYzRkMzVfNS0xLTEtMS0w_9d71b880-8d85-46b0-91af-713a885dd735">2.900</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i169c8b70cdd149968938de9db5a8c380_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOmI3NjYxZTY5ZmIyZTQzNDM5YTJhODJlNmJiM2M0ZDM1L3RhYmxlcmFuZ2U6Yjc2NjFlNjlmYjJlNDM0MzlhMmE4MmU2YmIzYzRkMzVfNi0xLTEtMS0w_b8d6b019-0802-4fa6-a8ed-f8d3ad27c430">3.625</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i73f7b949b4c740929fa619fc13968293_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOmI3NjYxZTY5ZmIyZTQzNDM5YTJhODJlNmJiM2M0ZDM1L3RhYmxlcmFuZ2U6Yjc2NjFlNjlmYjJlNDM0MzlhMmE4MmU2YmIzYzRkMzVfNy0xLTEtMS0w_4a5b5efc-c404-456f-acd4-b15a05498e01">4.050</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i21ec6c5ff89547ff8dc1226630ef60ef_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOmI3NjYxZTY5ZmIyZTQzNDM5YTJhODJlNmJiM2M0ZDM1L3RhYmxlcmFuZ2U6Yjc2NjFlNjlmYjJlNDM0MzlhMmE4MmU2YmIzYzRkMzVfOC0xLTEtMS0w_e86dd38f-a998-4407-8abb-bd2501e6cfba">5.200</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i28131b2b3d0447c08a69cc0b6f4781f6_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOmI3NjYxZTY5ZmIyZTQzNDM5YTJhODJlNmJiM2M0ZDM1L3RhYmxlcmFuZ2U6Yjc2NjFlNjlmYjJlNDM0MzlhMmE4MmU2YmIzYzRkMzVfOS0xLTEtMS0w_86dbabc1-35ea-4d59-8fdf-7217fadfaf48">2.250</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="id15e963a15e44c2b8d3baeb9b65f28b2_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOmI3NjYxZTY5ZmIyZTQzNDM5YTJhODJlNmJiM2M0ZDM1L3RhYmxlcmFuZ2U6Yjc2NjFlNjlmYjJlNDM0MzlhMmE4MmU2YmIzYzRkMzVfMTAtMS0xLTEtMA_00151ff0-4cfc-441b-b5bb-1dfe10dbb00e">3.150</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7f1bb2f05a734c40a4736b73629c222f_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOmI3NjYxZTY5ZmIyZTQzNDM5YTJhODJlNmJiM2M0ZDM1L3RhYmxlcmFuZ2U6Yjc2NjFlNjlmYjJlNDM0MzlhMmE4MmU2YmIzYzRkMzVfMTEtMS0xLTEtMTA4OTE_9d03f53a-b2bb-4aee-a0fb-ad9d07344f64">3.250</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i72bff1f88c9641b0852976834a354215_I20210331" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOjdiMmVkMTgyN2I5NzQ2NTY5ZGJmMzBkZDI1MDhkNDgxL3RhYmxlcmFuZ2U6N2IyZWQxODI3Yjk3NDY1NjlkYmYzMGRkMjUwOGQ0ODFfNS00LTEtMS0w_ebc7a2a0-eb08-44b7-93bc-5b35b92a2908">0.83</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i3330c709f4b24368ac40f72d927eeaef_I20210331" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOjdiMmVkMTgyN2I5NzQ2NTY5ZGJmMzBkZDI1MDhkNDgxL3RhYmxlcmFuZ2U6N2IyZWQxODI3Yjk3NDY1NjlkYmYzMGRkMjUwOGQ0ODFfNi00LTEtMS0w_8990c877-746e-4c25-a263-6dd630a8be7d">1.18</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="0" name="us-gaap:AssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RleHRyZWdpb246MGU4YTM4M2M5Y2I3NDRmMzljZjYyZjdmNmQzNWExYmVfMTI_44408971-1493-49f3-a110-d96e6c954a0c">0</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="biib-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic6f45d28d5d8449d9712a20039e0697e_I20210421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iabf5fb72476641e09225cdff0259f43e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3b12581badd45819dafd1517b58aa13_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2837c6bcf6604a1884f52b184bbc1cec_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57cd91f7d9604cf09b048c87050e1776_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16255170d7464fce8565c267cce60805_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa5be06727e54c9cb7a5c0a5c65b597e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="idba00d136f3e43eaacc59e503a3d5706_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0294157534ec4829a838f8161a2c6f76_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i179564f7a5394a3f985b2394c890de98_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bcd6f60e86446259cb8c43a0e3ff280_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c42b2175447497d8b49e20666071bb3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie120e7590f014512a9ef0196920b2c3a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d06f4201d6a4f44b0a65c949966d4e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9252b21ce96b49a69be79d8b5818a4ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc014f149d4e4da3b04fb867fc354a98_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id15755e5a765478580cfde8eca39da00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21790366b5d34ac8a31ee2475fb7022d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb70c7eb20e44693a04fd0260417f330_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie108b38fb78a4b4da6071b1fe46e0f25_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic45e43914f444bff8f68d0156608b715_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2bb63a28893418589d2a0d1b7f927b3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a7e0d0eeaae4c5fbfb21c1d2f81bbb4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af889133b864bf1a8251cd94b577064_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b08cd90671441109d1d585c71239784_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2518d36e7af44bec9c3acb750c2ab582_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db0313c47544e3fb07cfe61f64dae32_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide40cd25587c44479c7cca25c2ab1a1e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b5f6b8e642b4f3a90e77ef64fc86959_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc7d49e416884359a033c98c994d3d6b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35398fa4187c4561961299a90d05fde1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1883df2e84b34bfca009f1a107f517a7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i989a9664b51f425385c353e18a6b1db2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57282d9aaf344b8abc4365220d50d8e6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddda61c522014ea6bd671c91e77efd7e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id84b8595cae94c46aea8144165c16cda_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id368506338ba40cd8adbea5e573a2f3c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a8b05db811a4f6ca919149ab120e3a6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c2ba83c536b409e96a426d0bba7cc72_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba06f05e2faf4c708920aa5dcbd7ed0b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieca63027783a4ffc875d6d9098166871_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c713484677b4927ab70281250be20cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b1784bb7804f8f9620259ab8942db6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i605d5a6bd4e44da0afb2826209cab9c7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c932859892f490180aa279af5a06b03_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7435b888c753443186dba3ab3fe1fcba_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53a16d72df8e41e7aefc354fdce5be4a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea2f0d23ff44653bc3b6b5156c34bf1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04d5d70d39294b36b58ac20c0780157b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6578a3afa6b483fafcf2459661d9944_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3952e97a9994176bda1554c91960383_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25ca0d3089b9406197bdca98e4d63b1b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i075e0c23d6b34d67b56b7fc63b0c8f6e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f5558f45caa429b943890bb21370bb4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i406d62794dcb4950a1781265fcdca4d2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6b1bf8966fe4b6f8d97788a368f7f09_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia559d28a9b914b37b44c9d7c95222096_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf91e91201b044939704b3ea806b2ead_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieee5bd4f86704007b1420b9b498ddbc6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51813489fb6b4bbeac18a5336356a074_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89f2f3090dc54fea8e95c8bcfdc8bf2b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib357d23217b547d997470e7d0012d37e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00af2e110361494a882a140f60e249ae_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f1fb990e4ee44be863aa4437fa57293_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if823fb42eb284177aa1ddbf216b2c1be_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i512bb80727434c12bca0775dbd5e2137_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ae486e871284c88a17b126221465865_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i670f018181f04ca3a3f0bd64e5623f2f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ec1a33127cb42fb9fe3fdce711fae15_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ee3ab86dd9a44bba034cdb3caf707fc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff1e167122b54794a75d887f91010ca6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>biib:product</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>biib:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id08a82497aa04887a9c810084e90cb86_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BIIB118Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i448c0442bf0a4adfa28c5d18001b08f1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1193489ec1264f35a2ac5971bf81f6f7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia487fdfe567b401b86ede458e9ba75e7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3d2c097d12347678a78a057aaf039aa_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d2fc407d1ec4ed380b5e106ffb0c831_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i940d0ffed9724139916f62bf6dad8a7b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf4bd59b7c3249f0bc24ef3c1c48d31c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8f8e721203449fc86db69bab7e7cd9e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcf12665755e4093a4220cda52ac3eb9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id77770628748461faf30529d99622607_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1646afc7440542fcb255ec823d3c9c2c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e14d4e11831452ba137891a9396c862_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i184b1c6940b2461e8557af90326d21e4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8caf7eb3d8046008f3982503a64cade_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08d0fb5bb1cb45d99a7b3491c2593e22_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4341139d31d645e89e76c26bfb4231ca_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cb99b30cbf54b00852f7084359ac9d6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b70a2acef674d0985ecb568772c3258_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i505c2e793fca48ae9a343f83d10b25a2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff026a1b98554dfbbc131b0472cb5b7b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i734c667a854e4365bfb4b48aef78b038_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0962648e31c1402ab3c19a4f421155fe_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia83423de217c44a9be015f40ff27c33d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec00ec53a19f4ea9a63dace92b6da302_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f2ba3fb90464ab29d64a5353775989d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6132d3c924c414e84a28b2389d20a41_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf832a6fefc64c7582c337b5ffea1c29_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ad6065fa88e4b7abff61a49206a7d0b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14524fbcf9df4b2281933e4d60f10f02_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bf0c4a015a74ded850336575e8289b8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i325454d8aeec4098bfa98cf14b372c51_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife6066c0c6bb49d7b1ea35be7c87f0c8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida5dda8845084cdda4c2aa27909ab988_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d4f5eaef8fe43309f839c1c36e3c80d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i059f4365445242aeb92df9e0e10de132_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i061b1e268b544b26a76c0707fad02355_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d5370a9ea274139a341c5cfdd8d6d9b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc51673e08bc4f3b82f3b472a4a90973_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27035e9563074fbbaca4c77997b66921_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78f64ee14005421481ed9d38025dbe95_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i031fb4884755410b845a81795c4ec551_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib01eeb32d79b4571ad8f11070dc2da48_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i202bf8566c7042b784c6445ebd363725_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7824a2335ba4ddd968c947099502057_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c8b061168814140b09c590b540bb10e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia908504887ca40f181856648cf0956ae_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06fc398cd34146d982acc4911a986595_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7700739d178e441d91b2f50f6c7798c6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1f9b4973848433abff09c45a64c9143_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75a352d78f7d43fa8a05b645e4f6e3c7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34be7a6433744d2f8766ca37a26efa37_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i324196a294bc4b538065228274cc76fb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic67c201687dd40b69b77091684731883_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i017ebf20529f44b5bff42d9e6dc8fb53_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8fbe7359e294d698c58806b13fe20f3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d43bda4427a42e18236a50750cfe714_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06a69682358b4f1a99c21d088b5c487b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30b44b2a9e3643ec956383c1b647c5d8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26bd19762f294c71b22709ebc3c0418f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87f248578d7441ec88a211f0018d2a05_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1145a015534643fbbd914351f2d3303c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i601c9a44b1bd4cf6abb5e0a17029e845_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50e81697f8c14de383f2c496c7483109_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2c9127e05b04ef281beba3d1321c62d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1003e56b7b748e9bf5a15cef4022aeb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e358b0c99a14c348aafac03e2a37487_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3d8f1b9751745c9b3b1484d9d3b8c54_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1586eb35090b4a5faabb9c8a8e822582_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i666d1e67c4384945af3d0da636c7d0f9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b9ce56cc0624826bb2b6dd3b2be83c7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="wholesaler"><xbrli:measure>biib:wholesaler</xbrli:measure></xbrli:unit><xbrli:context id="iea1a2bf4c66943a5b003368cf21dfc2d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8384ea1bc75497bbace5e319dccb2bf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee8610004f734b68b4cba17dcff8b4e3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47a0a8c9dbdf45d583161449e4534cc8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1013b869080645d59d75e657f4c58e4a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i330c93cac85e420b898ca9c3a01dcf52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bf47792d6ea4f0b86fdb02f0d4eb158_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb86fe950bc5486cbb58985525874f0c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7cdcbb6052942698e96461e2cd71321_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9ec3f38a20a46ce85926bdad24da8d0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01e3449ffe264832baf2481923cbabff_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1806a0bbaa2b43889412b0fa97abc98a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05eb3d02985844119473f90fa44e496a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0003b815e2554577be2bdf249035d3a5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaef079cdccfb48ee83054f60bf01c254_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice62402188f941eab28ef8bd9b65e16d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i569ed47008414979a6cf0d109c369b32_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42fd999637364cbe9c5eda2d3135fe5d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i423da7297412458f999e416eb001a0d7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i163da90ecfbd4f72bc274463a9d22cf0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82cbd68005204f25a28991bb50e01dff_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04e77e2252074a059d584ff066314e70_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if37d2490542d485c8ad9bc6897f9286d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d6131440c1f431ebe00dc7e4e529db3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15a9a358435d49609a85d97413f3a145_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6844ffa5076f4ec887dfd7ec445c0918_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fdb2840b630460ea506d4ec51307590_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48f0b595ff7d4f3fa1e56358ca157244_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i848aad0fd824420fbb889c08f40d826c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e8e8ec88cba4cae96ec769e8eb5ed50_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56017bab075244608da3bd636cc69661_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58534be095d54aff98f1243bb85b6ca4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b71bbb6a21a486ba7bb214d1686f8f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b53409c6c594be1ab5a8373c301e1e4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i448d8c39b77d40a1a669d30b8086ecce_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icadfd8009ae541009e58a0809c8614f7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ae7d791a7214f65b96db9c10da5155e_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifff98e73ce134eadb812f6e1419eb1bd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied5ebc033f5042cfba2d1d9018f9eb58_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i583e423036fc4cabb98562f54f1b61ad_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bf61e1da4cb4085ab83a72725b9c364_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d0bb3392f8b437d85af0d89b58fbe65_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7f6d94534c94c69950875e422123904_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a69b4c3dc9c4aba925cc1b9bb62aad5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59ae9b2ac6bd42a5aa75417ce4eb6bc5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffd6a4591290426db41339963f8e38f4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9f2cde76a524b86a12cd39d526d2166_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6313636dcf65492fa6f7d60c52fd4998_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59301081b8cf45a5865f1a2a1ab1ec95_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8acf8de01b6427b817fce044f2a4e9b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a8abceadc64d56a584c21adbd55e3d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7421225a760648fc82e6b371affef596_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1eeebc1e9184fccacb6886b20d57c4d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2198a535d9bb49138f087e2bb335b702_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c8b1ee36549403a98b32587e6ec8cd9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic41685432e3248a59842e2de1fb70cff_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i468b8e383f3a4aacbb111243c54c712d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d0f121a5d2a4cfdab80fd27727da939_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i987da2e6227b4752bc28e59e5ea5bb71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dc664875b4f4032a0d03aa34c2b125e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70e71b4af6c648a389be21d19d778315_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34d18f6adbce485d821cfdf85f012a05_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i617d7850a63a41f2bc0aa19d2bf5d52c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad7dbe081b0c470ea090b36551d58a20_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab798705a4e64563b60d02c9ae738dc6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie88067b08ed84a50987e6337ea2943d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46e6eb7334b641e596a5a01f6b114522_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if689c10ac2da4ce6b808d487a91d2f1c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i155f305329d64fa484887596324eabf7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie77eae55b0fc4a578615133eff105580_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9411092d0e6487aaf6d0cee300ee74a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic63fa3a5459c443a84d6bf3111b5ac38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c75bf61e4794546ad3c50a9595bf109_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9cea109dd524584a788c485533262c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ca99bdbf85840cdbe24f4bc565124b6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3564cbcff5074d8ea8625d2d79f78da3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8a4ae2d553645bc9749c80ed7469758_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9a6326f3d6b477c8eb27a1cad5d7cf7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i169c8b70cdd149968938de9db5a8c380_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i136e48c6cc4844139e58cca3660d4fcc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73f7b949b4c740929fa619fc13968293_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ef7cceb1dba455a9aa7de4d2a40176f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28131b2b3d0447c08a69cc0b6f4781f6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i329e0692712544d2a17055bb01361858_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21ec6c5ff89547ff8dc1226630ef60ef_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6fa8a83ea8344a9ab2cdaab6b6079d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id15e963a15e44c2b8d3baeb9b65f28b2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i690df7ed80534227b8dd81f1affbc47a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f1bb2f05a734c40a4736b73629c222f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1fdd327c9a54a7b94459dc7adec7e4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9541283653d242f48d85e9890e9c2777_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92e65fe683a2421f94f2dc6385f162f6_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c3b6e1aa1a4f37a556ea55e078b7e6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08a615c71cd74bfaab31f5afbd166043_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86ba11dc3301448dab6e7f9202ed71a0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72bff1f88c9641b0852976834a354215_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3330c709f4b24368ac40f72d927eeaef_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i097294e10f804864872cedb1009ca2d6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06cbd4baf6c64cbb882e64d7af251fd7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i662a2807e7f441dea26090ecaa66ff73_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e9534615d4d4fa08ea2113342a064bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6265a293284648a6901f1c195af48f3a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0a442e099ce48c194c0139fdf69655e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b51b2d00bc5437689fb1ac29bc46a56_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e2cdebf2e34461bb476ad2299cb6ae6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if058af87c70046e2aadf2969cb8ec339_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieede5634af6341efa55cd03c69ce9e7b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f367843cd4a459aa904731e38a571f0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife34e8173e884133b5b5df3663402806_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1b6fdc993a44cf79b869e8688a3062f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b3875a8852c4f49b9e644e0c9158374_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4bb284119504ac8a1c8c4175099a908_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3553a83d95842ccbe6c7675c97c9f6d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2ada1e061ed4917bbce94eeb6b5933f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2692b6a2c3a470caa2bb0ed4268a1d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e9431c0a0744979af0821b912532c37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56be570639ec418f834fc04f5746b4d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5b995470fa14c99ae213810dba2dae0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85140128d15a442892fcc26f8abda120_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0570f45a09344ee88a9bbbf9b677aef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17bad89df3f34651a5f6e776704460f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff71e9fbc56d4559bdd9a623ccc89b89_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a283fbf212a4481af4e7343abe77f50_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ee9e38341534af88bad1e7379c5795d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i131a6d5dd4084afa8625aea4291a03a4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibed8defa2fe84947a4f4b459fdd0d10f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id355e63804de46f2b00142ad2e9766d4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d61eda3c47a477a87953bd9435f3fdc_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia617f0f0d1234327a3119ea448c3da76_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9113178df6744dbebe8d536cedbb476d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0888eb887324fbcb06a48bb48e3d178_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ef2ea3f8af4435f8e0f9aeefee13306_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied82434791db403c955ea793bffb2f0e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9c72eafd68c4e398efd063c308f2dbd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i536f8ba047234c319b7406ff767147dd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb70d5c3848d414f9ce893ad215d4dec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02b2de87f30d4c6f8b03613d9c2807d2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07af47860d104f6d8ed73f6a89548b2b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40059c26d0bb4c04a23a67aef6915a45_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa2654f256764c58a2843f3f977d1dfa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0457c0290322402daedccdba35db7c6d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib58b6d257da24ff8b4839e62a689e898_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f749230a90846feaffa937710c3bd7f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6a1954375c4428c8c9f1e2459422a19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5684eeb894e948e795d7ba13a0a9821b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe1bc0a4b4384b369f562b05efbd0f01_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide647841e7044ab48b55cda50f1d1520_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a595e77e9024184a813ff4337b0408b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52305514d2d248ef8eac2ce5da013356_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a87c0642d8c4661b4616dcafaf98925_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic532929c81174c56bed2bcbdbaad621f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87deea9139694467a9fdc201db179c76_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i374fbb6203a34bf4944599f7c1e45415_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c7748a642e745f88a124b19bc7f4714_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17821dc2bf9b41c6b08b07a41c8ce707_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i979c6df8053649cfb7b8b90a285b165d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14942974e4f2452cad88e831cc7cddda_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d8e15ff35ac44bab6ffcdf343f511ac_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9201821f02cc43b3b8f8fabadde5754b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="ibe4be84a93994def8ed976d74fd1dfec_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee1f4bcc0a9b4476bc090cfa49e3c034_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1236ccb8b6ae4703835b4052a03f112b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aaed4b4b8474e7e9b340a6d01f5046c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e5e89f06e804ddc81397c8b1168e259_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25755164c7c047c2ac74d54b1cdcb1d8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54eb17b8eef44296a8fdc3c7b6bd76af_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78981389f5f94e5eadeefbd380f6d4ef_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83451001a11e4d698aaaf41cfef4dc3e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i868b061cb602497db91dcef241c70a3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia665bc2c1fc141a1a5ca42007baa03e9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia08a43cc4bff411ca2c03d302026578f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i888cda8777754c04ac0cb1995bd7bfa8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6d155f75ea4423db88f5212a2c98b00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ecf3d9b5a444b63953faed5774226de_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b3a3bb2800746138b838c49892a8c1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51a5027177624992b876d1ea94cede10_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad77af33cb984b0e9bb3ef62ed1ebb74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i731212cbf9b94995850d82a2311a7c17_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f8e35902ecf4f34b94a8d17d9489454_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57f385654e1742b6a56d8fb4d0ade38e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7228047741514b81981471c02ea16f0e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d7974ac17f340839427c22253a75e1a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0901c785f9c4846b1b5c357e1bf4da5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ad5e6108b894c5681f7fde6c91cbfc2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f44a3b624d34174b5f92cb92f67b731_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i6d21834e33c0420f926fcb969d864201_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5944e21d13b439296ad6220144c780e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeecea45f6d1449081d0846aaae7ef11_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i724f2b0183a64064a5b4c3edbfee2752_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5111c584bd441549e34423b141b35c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf27a73b87464b70a24f4215cf6a7822_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1203eeb4805841f0ac2cd72de89f499a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i016c570732cb4e06b13838775a874ce8_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id947942c69fa44ce89256cc80c1e696a_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id662c0ca4fe34fb99b51e17485cdad55_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9e2646cf66a4acea08af56195b01b34_I20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb46cac46d2848cfad57259f2ed1d632_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd1b2f47353e4aaebcecdfcb602f4de9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d015ecb936405daf574b4e3105f141_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i790882cea9a743939fad5f1974b20135_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ee194f83e384c83974d24f728c5145b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b8709d2eae04591a6115e04171e59b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f5341349d2f494d97ea527c3a617208_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee2acff297c64ff1859c44405ba33de8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6d9591af95346bca52a790ec1831e51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i121f989f64d54d71990d30584fc92371_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc0e23fcbfe244b5914449511bb9de9a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33ed22d7f19146a98e5ed27cdcf69af6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9a1a6add6db45b6a1cc3687b957361e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89cad3952c464507908e42ec76b9683b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie56cc9b03fcc4f6d9a86477a5270a889_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6617815be784402785f12c6988e1beee_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if08aec04c4324a64a5bb6af5a48753a2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52012835f8e245adb31aeec016f4112a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccb1237016b141a5b01be03b134ebd55_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02a25f52836a44c688f515291d314595_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52a09764d13c4694a6f1f3b0b58dd09e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd1befbf13d647bbbbce80021df07746_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6655179b6b2649759f156341cd1be463_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia26f4bf0d205499492e015dc1f5f9d6a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58c1b21402d94dac9e67581cf6e009b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ee0d5eaff614476bcb905bbd08373bf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4eda08b11c34ae9a36408a31801e4ec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa803a04b06e4d9cb1a5f96364d792dd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b7d97c6a13d4e7a91efccbf9a7a80a6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62772410ea3b48f99b42dec5a933607a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i754c37b6ef7645eb9afbdbbda44b09f6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i590c8062df384811a4631c1a3f4c03cb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cc821229a0b466caa70f9efb4cbb784_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice4da96682e14bf78bf22af3dd2a4a8c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5d97abb270e493da281ba2ce68e7c8b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59583d2b241145dd9da8f108498b7d3e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9144d29ad0b4e8b89f55ce739a9ee63_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85e0459de37d462abb7762f5b8952479_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e0e08b5a819440bb14c90345397b2db_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id601e29bcd854d9a871868d6cb4b232e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d783d882d2347499c93910b2745c786_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc093e060e9247b3b645204a28e9693f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9c160a38b934622ae05b249135e9fba_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29b0a6b12ff841faa09ff1e9b8731d8e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib347ee221e7745e397b6e1c44ca1f262_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8793b775d015434e94d2639ea24a0cd7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5814e7fb32fa4b229429ed5c681d9f9a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c91e4f53b324f398e35bf230235f119_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74e5599741ad4a8b9f6a247bbdd89697_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdfa95b717f940c18648cae8c6f84a2b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c803a1bd2b24613850cb9d1888f1471_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20625d3cd2ef4a8797d00c27d1627625_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia034f5fb9e314569bb5e919e953a76f7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if042c7a7464c42fe8dd45965e651f723_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a3878b3cdc54bddb2a915e956935ea2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63ab73c921484907b93d62dc34ab72bd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1134208d9b3347088ec3ac4ca9b1f0e0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c4590aede5149a797bc4699fd289712_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea96acd5ebf344c0bd0de05f5f18e7ba_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic130d01037a74b06b9d042ae75b7659f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90a6a4cf318b432dba2b2758ed6fb58b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8d31d1727454b0ba645a673b928faf0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecdb89b7a5934dd2ae846178573005f8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic60ece36c57b4554886f84f64ca30d1e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib81a65b32a8e4a00ad66b6254231bdda_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46142d7f2ab141ffb334e6b33caf19cf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66e68173c701483d84c579c57a8c212d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebcbf3a6149a4a9289109aa4855ff343_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2765e12d82da461e9794964574b53f42_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ff86437e3aa4e37930e1206c73cfb00_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54e58411691c4fbf853552c0ff6a6d05_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0d1b57d4a0c4741b41196908e3c38b1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87fa0cfd9f644bdbb719a9473bc87605_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9e828d7b7bf4f43bc6657cc9326807e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07234f661df448cb8a6a14d7961cf1a1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e54ac3de781499f9cab24ff66dd0c11_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30647a5eccee4a888f75b3abd844ebdf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65457dc54fbc417690f3f9dfc74324b1_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia09bc9241ad54438b01f90b39ada6215_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f5259f6537145b1b52dcc10ca5b10fc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2017d3bce86c4e1f9ab0a83bcf38491c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91efa7f34820455f9945f65b1db8ead5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77da4b737e504001a90944aeda31b91f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice34644db491436ba604aaf4f60a0d7c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i968b5e6a9c734bba858d0e6913254760_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad7d1365baac43d6945215ce6b8816f7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72965d9649fb4d17a86322fadd05e4e3_I20181107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie90411741db34c3b961e743e971e67dd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9290a0d035874af8ac1688475a9c6fda_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69cf49f1dcbd46fbbdb79f66912dd8ca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aae7a15859845fc95e18fa3c0eaaf33_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c61857768f4045b23a12b5bd57d3e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47d16efb9f3f4c09872f1f6d2b724400_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61802b3b7d4442588559391d63737368_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i412bdd987d70473f8492259ec4e93e3c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb7e6ad713d4670b6e038cfbb2130de_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50fc7b747b554ee88ca10781e8675077_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7111de4bd0294ff9a9a3ad920d505e32_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7dc064ffb824915a213b2bafa7eadc1_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i443ec97d551d4f19819d518a28e3dcde_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i058baac90e1841039cf4ef78a041460d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c605c95790545c0995faf5707af1bfa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ExpectedPaymentTimelineofMilestoneAxis">biib:TwelvemonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i925bce57d9bf415ba43b031db49f8b12_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:NeurimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e351ee8c7e84208bbcdd85dd32c6e63_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6fe84bc7e101462ea41fc07416803961_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDEz_c107e827-a936-461e-9d4b-cf48b5292d3e">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6ZjI5MDg3MzgwYTJlNDQyYmI0MDM0OTk2NzgyZTc5NjAvdGFibGVyYW5nZTpmMjkwODczODBhMmU0NDJiYjQwMzQ5OTY3ODJlNzk2MF8wLTAtMS0xLTA_d20d5a89-d63b-4da9-9850-794056c7e333">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8xMjQ_332ca729-0fec-449d-a725-51e75d44e65a">March 31, 2021</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6NjQ5Y2RiMjczZGQ4NGVkMmJmMTE1ZDU2OWNiZGFjYWIvdGFibGVyYW5nZTo2NDljZGIyNzNkZDg0ZWQyYmYxMTVkNTY5Y2JkYWNhYl8wLTAtMS0xLTA_cf114954-7945-44cc-9e7d-2fe0971bf551">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDE3_112d0a4b-91a4-4d8f-875c-194348c05b91">0-19311</ix:nonNumeric></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><img src="biib-20210331_g1.jpg" alt="biib-20210331_g1.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:92px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDE0_ea6a1546-8417-4d4a-b1c1-61963686f405">BIOGEN INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6Zjc0ZmYzOGFhOGFlNDBlNWFkYWYxN2IyNzIzMjJjZGMvdGFibGVyYW5nZTpmNzRmZjM4YWE4YWU0MGU1YWRhZjE3YjI3MjMyMmNkY18wLTAtMS0xLTA_3e1feb2e-750a-4730-8f35-5cf5d455fce1">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6Zjc0ZmYzOGFhOGFlNDBlNWFkYWYxN2IyNzIzMjJjZGMvdGFibGVyYW5nZTpmNzRmZjM4YWE4YWU0MGU1YWRhZjE3YjI3MjMyMmNkY18wLTItMS0xLTA_7dbfbd49-84cb-4910-8c9c-e894f7c5e8c1">33-0112644</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDE1_59d14219-592a-4f96-b043-ae3978503f79">225 Binney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDA4_26f01bd9-6711-4eea-9a39-5de0c8bca888">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDA5_56a54e36-03e5-4f86-85b5-a464a1662d79">MA</ix:nonNumeric> <ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDEw_c680b784-27f5-4d7f-82bf-8518948f4d6c">02142</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDEx_9e886f8f-30a8-486c-9de7-d434ab410aa2">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDE4_953f3565-474e-4f98-9c0c-b32fc93845ff">679-2000</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:35.463%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6Mzk3NzA1ZTliMmM2NDA3YTkwNTc4Zjg4NzBjZmMzNzgvdGFibGVyYW5nZTozOTc3MDVlOWIyYzY0MDdhOTA1NzhmODg3MGNmYzM3OF8xLTAtMS0xLTA_a2dec643-c0b3-444a-bc39-6464b8b74099">Common Stock, $0.0005 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6Mzk3NzA1ZTliMmM2NDA3YTkwNTc4Zjg4NzBjZmMzNzgvdGFibGVyYW5nZTozOTc3MDVlOWIyYzY0MDdhOTA1NzhmODg3MGNmYzM3OF8xLTItMS0xLTA_9a477eea-f96e-44ab-9411-dd8c4112b1ff">BIIB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6Mzk3NzA1ZTliMmM2NDA3YTkwNTc4Zjg4NzBjZmMzNzgvdGFibGVyYW5nZTozOTc3MDVlOWIyYzY0MDdhOTA1NzhmODg3MGNmYzM3OF8xLTQtMS0xLTEwODI3_3e8da1f3-709a-45ac-a132-e65b7748b616">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDEy_0ca5c0bd-94ec-4a27-bdd3-16af1b61952f">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDE2_a0783280-8a22-46a3-a3d9-f0895f7c2527">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6MDE4M2QzY2IxMThjNGI5MzkzOWY3NDlmNjI2OGMxZGIvdGFibGVyYW5nZTowMTgzZDNjYjExOGM0YjkzOTM5Zjc0OWY2MjY4YzFkYl8wLTAtMS0xLTA_d3c76b7d-1c97-4d2f-a8c1-be5778df637a">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6MDE4M2QzY2IxMThjNGI5MzkzOWY3NDlmNjI2OGMxZGIvdGFibGVyYW5nZTowMTgzZDNjYjExOGM0YjkzOTM5Zjc0OWY2MjY4YzFkYl8xLTQtMS0xLTA_18394a7c-da49-4348-8bbe-f3ed4651b35c">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6MDE4M2QzY2IxMThjNGI5MzkzOWY3NDlmNjI2OGMxZGIvdGFibGVyYW5nZTowMTgzZDNjYjExOGM0YjkzOTM5Zjc0OWY2MjY4YzFkYl8yLTQtMS0xLTA_b1265f86-da8d-4685-89d2-a933b2ff3b74">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDE5_dd3c44d8-b438-4e42-bd3c-af70796cce68">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of April&#160;21, 2021, was <ix:nonFraction unitRef="shares" contextRef="ic6f45d28d5d8449d9712a20039e0697e_I20210421" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8xOTk2_8aef9027-2078-45fd-8c2c-cd46508d3b2a">150,554,750</ix:nonFraction> shares.</span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC.</span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM&#160;10-Q &#8212; Quarterly Report</span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the Quarterly Period Ended March 31, 2021 </span></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;I&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_13">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_16">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_19">Condensed Consolidated Statements of Income&#160;&#8212; For the Three Months Ended March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_19">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_22">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three Months Ended March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_22">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_25">Condensed Consolidated Balance Sheets&#160;&#8212; As of March 31, 2021 and December&#160;31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_25">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_1">Condensed Consolidated Statements of Cash Flow&#160;&#8212; For the Three Months Ended March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_31">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_34">Condensed Consolidated Statements of Equity &#8212; For the Three Months Ended March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_34">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_37">11</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_130">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_130">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_208">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_208">61</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_211">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_211">64</a></span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;II&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_214">OTHER INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_217">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_217">65</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_220">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_220">65</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_223">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_223">80</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_226">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_226">81</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_232">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_232">82</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; "goal," &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our plans and investments in our core and emerging growth areas as well as implementation of our corporate strategy;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of certain business development transactions;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expense, supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the Solothurn manufacturing facility to be partially operational and for the gene therapy manufacturing facility in Research Triangle Park, North Carolina to be operational;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements involve risks and uncertainties, including those that are described in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report and elsewhere in this report, that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and VUMERITY&#174; are registered trademarks of Biogen. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BENEPALI&#8482;, FLIXABI&#8482;, FUMADERM&#8482; and IMRALDI&#8482; are trademarks of Biogen. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ENBREL&#174;, EYLEA&#174;, FAMPYRA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GAZYVA&#174;, HUMIRA&#174;, LUCENTIS&#174;, OCREVUS&#174;, REMICADE&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other trademarks referenced in this report are the property of their respective owners. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I FINANCIAL INFORMATION</span></div><div id="i6fe84bc7e101462ea41fc07416803961_16"></div><div style="text-align:center"><span><br/></span></div><div id="i6fe84bc7e101462ea41fc07416803961_19"></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product, net</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf5fb72476641e09225cdff0259f43e_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMy0xLTEtMS0w_a631cac0-71bc-466e-97c9-c04d31071c5a">2,211.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b12581badd45819dafd1517b58aa13_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMy0zLTEtMS0w_c38612ff-12c4-46bc-888e-6f6b316391a8">2,904.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2837c6bcf6604a1884f52b184bbc1cec_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfNC0xLTEtMS0w_8196480a-6f98-4c32-92d4-9dca72e661a4">389.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57cd91f7d9604cf09b048c87050e1776_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfNC0zLTEtMS0w_d968045b-42d4-48d9-8778-b5d9c287c1df">520.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16255170d7464fce8565c267cce60805_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfNS0xLTEtMS0w_c8308450-e58a-4358-aa68-bfcb4a1e0f18">93.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5be06727e54c9cb7a5c0a5c65b597e_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfNS0zLTEtMS0w_9d5d8034-db1d-4e50-a4dc-1cf028e13bff">109.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfNi0xLTEtMS0w_39af262b-72c2-4e6f-a4f5-1a9d7ab720a5">2,694.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfNi0zLTEtMS0w_f90cc6e6-68c7-4516-9841-89d6ada85179">3,534.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost and expense:</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfOC0xLTEtMS0w_a0262cfc-001b-487b-bc90-22454fb0cb02">478.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfOC0zLTEtMS0w_8ea4f712-4a6b-46bb-9e7c-3da40f91a962">454.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfOS0xLTEtMS0w_2df578c7-fc7f-4c02-8283-97d2a738a25c">514.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfOS0zLTEtMS0w_9ec0e7e2-ea5e-4434-b3a8-8a8e838f29e5">476.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTAtMS0xLTEtMA_6510860d-bfba-4119-841b-febbf8ee9abf">595.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTAtMy0xLTEtMA_004d01a9-d2b7-4acf-81db-a706f7c2dfd2">570.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTEtMS0xLTEtMA_60298ee3-0957-4884-99dd-acedfde73cbf">98.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTEtMy0xLTEtMA_0de0c9b6-d36d-47de-a060-5992bed3e0f2">71.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration profit (loss) sharing</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTItMS0xLTEtMA_f1957ab0-5230-4c0d-8894-aa699ac5bd51">68.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTItMy0xLTEtMA_68588346-c6cf-4734-b6e4-a67a1f9ab44f">71.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTQtMS0xLTEtMA_e92db03c-fb17-4430-a844-3458ac8dcd01">33.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTQtMy0xLTEtMA_be33258f-2018-4160-9d9a-05b5c6196572">4.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTYtMS0xLTEtMA_7b9ded31-7674-45e4-854e-443b31f03ccf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTYtMy0xLTEtMA_a98f088f-b706-43a0-a3f3-2e7d5837b188">75.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTctMS0xLTEtMA_f1694b3a-2396-4449-ab89-4cdd27f71918">1,720.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTctMy0xLTEtMA_b1e31e5c-9d93-4b0e-bd89-5057b9f0d43a">1,714.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTgtMS0xLTEtMA_4d20d422-3fca-4b77-931b-03e30f6ede8e">973.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTgtMy0xLTEtMA_0e2a7b1b-5489-4a53-aa50-4b48953e9b9f">1,819.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTktMS0xLTEtMA_eacd6c25-bc7f-415a-a819-ba9d9170257a">506.9</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTktMy0xLTEtMA_a0968257-457f-4e99-8f3b-a525b0be3fda">120.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense and equity in loss of investee, net of tax</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjAtMS0xLTEtMA_31e6bb85-b640-45af-b0bb-4b94a3d382ea">467.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjAtMy0xLTEtMA_8ff8a192-a767-439d-a07c-b6938f4fc5e7">1,699.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjEtMS0xLTEtMA_0e4602b6-2f1d-41da-83f8-6f390cade500">44.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjEtMy0xLTEtMA_be42c132-2a88-41a4-9879-8b4440cbf5ee">292.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in (income) loss of investee, net of tax</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjItMS0xLTEtMA_7ebf1038-2c1d-4841-bd39-7ac54d07d4be">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjItMy0xLTEtMA_90ad8396-4fa8-46ca-b6ef-c0240708d730">14.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjMtMS0xLTEtMA_c8d77338-569c-492f-8fb7-edb84f1d88cd">404.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjMtMy0xLTEtMA_61ae2ef4-80cc-4431-a903-7a3da346a553">1,392.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjQtMS0xLTEtMA_f1f41bb3-885f-4f3c-a625-a37b9ae8670a">5.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjQtMy0xLTEtMA_ee68ddb0-e919-498b-be3e-d6ff2324e2e0">6.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjUtMS0xLTEtMA_3c55058a-db03-4501-9a8d-772d98de7792">410.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjUtMy0xLTEtMA_bea062c7-e281-480e-9aee-83e13bb9471d">1,399.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjgtMS0xLTEtMA_660bd388-e1f4-4c26-b4b4-0625c982bc11">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjgtMy0xLTEtMA_6eff6cb6-54f2-4767-a410-8fd49744054a">8.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjktMS0xLTEtMA_713f5de9-ebfb-4d23-ae7a-213fdc3ef3f8">2.69</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjktMy0xLTEtMA_11f42678-9048-48fa-af62-c5f4365aaa6d">8.08</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMzItMS0xLTEtMA_c5dc597c-6163-4b47-b2e8-ebed155833a8">151.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMzItMy0xLTEtMA_499c134b-8309-4460-8951-023c27a91bb3">172.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMzMtMS0xLTEtMA_00e484dc-b7ad-434b-9c78-d9eb9f69ed21">152.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMzMtMy0xLTEtMA_e54cb460-b599-498d-a1bc-7b1630bbf53b">173.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMi0xLTEtMS0w_eeb87cdd-1517-44ba-bff3-d74cdd6360e9">410.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMi0zLTEtMS0w_efbd9ddd-7030-44dc-87a4-fdabe3004cb5">1,399.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on securities available for sale, net of tax</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNC0xLTEtMS0w_f7a1feb8-16e4-4daf-be82-8f1d8289f0a3">0.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNC0zLTEtMS0w_4150149e-536d-4a1f-b4c0-29fa2e61c4c6">7.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNS0xLTEtMS0w_6ff1e377-2872-42f4-9574-983eda877e14">149.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNS0zLTEtMS0w_518799c8-4763-4680-b0e7-bd1e89deb6c6">33.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNi0xLTEtMS0w_bcb0a727-d4fe-4ecd-92c4-2d75368422dc">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNi0zLTEtMS0w_9a613497-e744-42de-95d1-2cf35701a645">23.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNy0xLTEtMS0w_c31781f3-3f90-4ce7-acfb-96646d8b0646">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNy0zLTEtMS0w_b709a2df-f558-43ec-9774-7253e8471b15">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustment</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfOC0xLTEtMS0w_066d8123-f271-4d5f-8f14-7077ab990b43">48.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfOC0zLTEtMS0w_081ece0c-ab61-479d-a92d-271f486c0c30">63.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfOS0xLTEtMS0w_c4c54377-7ab2-47d3-b0ab-619d7fd4c889">124.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfOS0zLTEtMS0w_8582ef23-2401-44e6-82bd-d4dc3419b9e0">14.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMTAtMS0xLTEtMA_56d0d73a-1832-46d1-bc9c-5b9460ba5223">534.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMTAtMy0xLTEtMA_b8a3cedf-de01-4402-9b14-c5e32d1a9f26">1,385.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMTEtMS0xLTEtMA_8dc9d47d-6db1-4a62-b130-a1d182dd8449">4.9</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMTEtMy0xLTEtMA_f381ab99-e009-4b26-afc1-c6d2b832eb7a">5.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMTItMS0xLTEtMA_c9a7a346-d475-4198-a812-f0871386840d">530.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMTItMy0xLTEtMA_732fc787-f647-4af1-918d-6d90efb47f5b">1,379.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMy0xLTEtMS0w_33cde063-e4c9-4ca2-ae5b-ec9529f2d78b">1,217.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMy0zLTEtMS0w_7f7dba3e-a912-4433-aa33-41b2213bdfec">1,331.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNC0xLTEtMS0w_c08fd3bc-9299-4cdf-b220-54ea10dac0f6">1,320.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNC0zLTEtMS0w_74e4edb7-4570-47f4-8c54-871a3fc685f2">1,278.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNS0xLTEtMS0w_5f46cc44-47d3-423f-9d49-8d3cafeeb0a3">1,854.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNS0zLTEtMS0w_52ab03e5-dc66-4041-8f21-88ffd72ed73c">1,913.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="biib:DuefromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNi0xLTEtMS0w_8b3bd29f-d8ee-40ce-b590-bf6365fbfde7">369.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="biib:DuefromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNi0zLTEtMS0w_f323a5f3-089d-4dbb-9b1a-728391ad3dad">413.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNy0xLTEtMS0w_3a2d493f-92d1-4444-a893-9af62ad0caca">1,171.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNy0zLTEtMS0w_84c945f2-5caf-4935-a4c2-d19aed8e09d6">1,068.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfOC0xLTEtMS0w_4c53be3e-ef84-4f3b-8959-557a857bf222">786.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfOC0zLTEtMS0w_e0aa1c94-572c-4cde-99e6-ffd522c09cc5">881.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfOS0xLTEtMS0w_7c6bc9b5-af94-48d5-9580-bd8def2af8e7">6,719.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfOS0zLTEtMS0w_8d8ad925-ee76-47ba-94b3-295af3957183">6,887.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTAtMS0xLTEtMA_ccf67375-cc23-4367-8be8-245d48581bcf">821.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTAtMy0xLTEtMA_2e2066d5-38c7-4891-808d-e5c0fbaefadf">772.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTEtMS0xLTEtMA_b2d970a6-b623-41a8-acca-51d411f54232">3,438.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTEtMy0xLTEtMA_99588c72-5f07-41c7-9346-d6a66dc7bdee">3,411.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTItMS0xLTEtMA_546e051b-6318-448f-8d7c-6052e0e9fc95">414.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTItMy0xLTEtMA_b35061bb-3ba2-4d7b-a504-50dd22b06124">433.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTMtMS0xLTEtMA_36003e48-bb43-4ad4-8b35-d088f383dc7e">2,988.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTMtMy0xLTEtMA_dd6b8b6a-c895-4322-9cd7-335192561c95">3,084.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTQtMS0xLTEtMA_c4c78bbc-5d67-4c92-958a-36d95ca979fd">5,763.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTQtMy0xLTEtMA_369def82-f395-46f2-9e12-9dda6273f562">5,762.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTUtMS0xLTEtMA_408cbc95-efa4-47d0-a38b-873133f0f97f">1,286.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTUtMy0xLTEtMA_adda6877-0de4-4108-b2da-8c5f0cc868ef">1,369.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTYtMS0xLTEtMA_2e26d10d-1a60-40f2-9d54-bd928d2573f6">2,423.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTYtMy0xLTEtMA_a3b5fa1c-71ae-410b-a304-abcf07700dbe">2,899.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTctMS0xLTEtMA_61007eda-8650-4183-bf46-9902ba56335e">23,854.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTctMy0xLTEtMA_bd46e50e-df74-4c07-8d9d-29e45f973ebd">24,618.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjEtMS0xLTEtMA_e2eaa687-b77d-4ee1-91af-b99dbc5cf52b">143.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjEtMy0xLTEtMA_b63aaca6-be19-4f99-be3c-c8fcd045584a">142.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjItMS0xLTEtMA_2064d57e-91fd-40df-b9e2-9f3b3532ea2a">430.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjItMy0xLTEtMA_2f713252-2feb-4906-8f66-9f222ec06f32">454.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjMtMS0xLTEtMA_07d04ae2-b839-4cdb-bd5b-7cc0f9c593b3">2,592.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjMtMy0xLTEtMA_3ad9343c-ed10-46ca-b1b3-07bb9f30c25d">3,145.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjQtMS0xLTEtMA_c0be81d1-b939-4189-ad6e-06ea79da5dc9">3,165.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjQtMy0xLTEtMA_d8aec876-1ab2-4d86-b43d-f605299a413b">3,742.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjUtMS0xLTEtMA_0bc1a3c6-027e-43ca-b305-df8310d41b8e">7,267.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjUtMy0xLTEtMA_c2e0319c-f5af-44ac-a28f-0848e93034c8">7,426.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjYtMS0xLTEtMA_be38360f-fb2a-429e-ad65-d63807c1dede">966.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjYtMy0xLTEtMA_4cf227ea-ddeb-4d50-aecf-b979e6d0feb0">1,032.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjctMS0xLTEtMA_ebe9c7e3-de22-4cd0-bee7-ec14a58e1598">380.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjctMy0xLTEtMA_a946e2dd-1f91-40d7-b41b-ec71eab5f22e">402.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjgtMS0xLTEtMA_e5374fef-205c-4448-91fe-0815394ad99b">1,411.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjgtMy0xLTEtMA_44cdbc07-448a-4258-8b26-c41190d3815e">1,329.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjktMS0xLTEtMA_6d4c5f04-40f1-49ff-89f8-06254e0ef4ee">13,191.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjktMy0xLTEtMA_c1686289-851c-4ce4-ba92-461d48086eae">13,932.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzAtMS0xLTEtMA_b03664f2-1533-48da-ab13-0b9d24a97174"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzAtMy0xLTEtMA_06b2c732-8b14-43ed-ac91-c1e67f837a16"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biogen Inc. shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, par value $0.001 per share</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzMtMS0xLTEtMA_57ca2af4-e07f-406b-bf8e-07d723d40755">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzMtMy0xLTEtMA_8cd7dd6c-4df4-40a8-8452-e629ae856516">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $0.0005 per share</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzQtMS0xLTEtMA_2395bf0c-2023-497f-a815-20a01e374cbd">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzQtMy0xLTEtMA_5a393da3-96bd-47f8-b2d3-6eefe93b709b">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzUtMS0xLTEtMA_ce384262-373a-434e-a0ef-3c37ba3777ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzUtMy0xLTEtMA_84cfed9f-3016-43b5-a9fa-730e8cdad496">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzYtMS0xLTEtMA_2085fea0-ea04-46a8-ad3e-6c902f0b8fdf">174.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzYtMy0xLTEtMA_2cf7afe0-b85a-434a-b9cd-30112daf6103">299.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzctMS0xLTEtMA_fdf7608d-4825-43c9-a674-fc4e3b3205ff">13,833.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzctMy0xLTEtMA_50f01463-c6d4-46cf-a89c-deac54bfd577">13,976.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzgtMS0xLTEtMA_6144ce7f-2095-4045-8ce3-35384624ed1b">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzgtMy0xLTEtMA_e3947dfc-c29a-42b9-a4de-cf3dbe33e2ae">2,977.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Biogen Inc. shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzktMS0xLTEtMA_929b7190-bc1e-434a-ae24-3cce7d7dda81">10,682.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzktMy0xLTEtMA_f09d41cc-3d79-477d-ba4d-9c726ea35c09">10,700.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNDAtMS0xLTEtMA_c856a145-8281-42d8-b62f-67535a1d755b">19.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNDAtMy0xLTEtMA_1c1d6a24-a8f7-4011-ae08-566b5b1cc4a4">14.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNDEtMS0xLTEtMA_4040f65e-8f90-4827-9a01-192067505c11">10,663.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNDEtMy0xLTEtMA_f5d04ea5-de53-4d2d-9a05-482081f101d4">10,686.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNDItMS0xLTEtMA_858070a2-2702-44b0-831d-280da1b0f394">23,854.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNDItMy0xLTEtMA_993ec186-6a8b-4990-b328-5e1829fd2d2f">24,618.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:14pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMy0xLTEtMS0w_899a8828-d4fa-45a1-bdc2-ebb57f45b0bc">404.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMy0zLTEtMS0w_6cfb1b9e-28ae-4298-8965-4aaf3e8dcfd7">1,392.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Depreciation, amortization and impairments</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNS0xLTEtMS0w_49b1f3ee-461b-41c5-a450-3c2e7bdd57d4">146.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNS0zLTEtMS0w_850fc8fc-da83-4a79-9172-2f1a596adf5b">119.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNi0xLTEtMS0w_18d8127f-20c7-4706-a2cd-e931c060c33b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNi0zLTEtMS0w_142c4a64-2153-442c-b018-e93b5337329f">75.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNy0xLTEtMS0w_82143742-a47b-4030-9eda-c9139563b502">70.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNy0zLTEtMS0w_b131ab8e-20d7-4bcf-a65c-4360aedaee76">67.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfOS0xLTEtMS0w_0ded3f29-3f89-4cd0-b8d4-d07b10873ce8">33.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfOS0zLTEtMS0w_77c36d03-fd22-4a69-a7d3-352589f3deb2">4.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTEtMS0xLTEtMA_9d579a29-a2cf-4498-b1ce-a582107b842f">15.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTEtMy0xLTEtMA_1547e9f6-75f7-4499-ade7-6c10d17667ba">36.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(Gain) loss on strategic investments</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTItMS0xLTEtMA_ac7ae258-7429-486c-8017-75715c641fcd">437.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTItMy0xLTEtMA_7b13e844-3cb9-4ca2-bb79-3786a7c0a8a9">62.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTMtMS0xLTEtMA_3ae5bee1-bad5-4de4-a4af-185b54605827">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTMtMy0xLTEtMA_cbb1c3ed-adac-47c6-a486-9e7f61acaff8">16.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTQtMS0xLTEtMA_a4b042d5-fac3-404c-a4e0-f9dfb56717c8">71.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTQtMy0xLTEtMA_a7c09bd6-f7d9-4c74-b2a4-313160331086">28.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTYtMS0xLTEtMA_54e7ffed-2691-4e8a-92ab-81cfd58b659f">37.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTYtMy0xLTEtMA_9295aeeb-ca76-4ff7-b2c4-154defff9ca8">238.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTctMS0xLTEtMA_5ca48445-ab42-4400-9889-b69cef3478b2">43.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTctMy0xLTEtMA_7a6958ed-eeca-4868-af20-12f020ff0fc1">78.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTgtMS0xLTEtMA_a22b1535-ed7c-495a-84b8-aa5df69491a0">112.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTgtMy0xLTEtMA_398a76a6-6665-4290-8874-23c1727bd119">62.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Accrued expense and other current liabilities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTktMS0xLTEtMA_0bf70fa2-3ecb-4351-8c44-63cb5f1a678c">283.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTktMy0xLTEtMA_d2787618-c4c2-4f1b-a83b-f5a9b055c7ea">347.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Income tax assets and liabilities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjAtMS0xLTEtMA_463f4578-52fd-4253-b0a7-68e1c3124778">64.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjAtMy0xLTEtMA_16b3ef3f-0eda-4953-9ec3-11b49e6a4407">223.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjEtMS0xLTEtMA_59fd3a7f-4db8-496b-90b6-6f44a50b7ddd">80.9</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjEtMy0xLTEtMA_aed0cb95-22b3-4c3b-a0da-8d547c499651">18.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net cash flow provided by operating activities</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjItMS0xLTEtMA_9fcea49f-8f0a-4b3d-bdf7-2a4873e39cdc">769.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjItMy0xLTEtMA_f37ae9de-d72c-4b70-81f3-5eb1d7faffef">1,467.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">Cash flow from investing activities:</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjQtMS0xLTEtMA_975a9599-ac0b-4ecb-b2e4-dd968ddc5799">819.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjQtMy0xLTEtMA_0a72d3c2-7339-4bc7-90ae-c80a669bb5b6">2,389.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjUtMS0xLTEtMA_97078807-8793-47c8-a25f-c05d2d24878a">913.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjUtMy0xLTEtMA_10426c8c-bc07-464b-8aa5-dc5eb00c46ac">1,684.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzAtMS0xLTEtMA_ad8eeeb7-261b-4689-b3f8-98fa7447e080">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzAtMy0xLTEtMA_af669ed5-e76a-4b6f-8df2-bfa385a066ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzEtMS0xLTEtMA_0be17996-66b5-480f-9bbb-eb14272bea37">92.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzEtMy0xLTEtMA_79f8897a-5f25-4029-b26d-b7299701cd48">149.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzItMS0xLTEtMA_c8fe2883-6a66-4644-8046-ff9d8ce380af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzItMy0xLTEtMA_b7728e09-bd90-4600-80c8-b4e495bce2b3">75.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Acquisitions of intangible assets</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzMtMS0xLTEtMA_cf0ff97f-5b6a-4ba5-ae8a-e136b5d049c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzMtMy0xLTEtMA_2259388d-4e9c-4eaa-8488-2f6b0b469755">37.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from sales of strategic investments</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzYtMS0xLTEtMA_d26613af-6af9-4d60-ac35-f48fe42af1be">91.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzYtMy0xLTEtMA_cba7778d-2295-44b4-9fd7-4642d6e5f8a1">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzctMS0xLTEtMA_c1a5b70a-bd64-4d04-aa3e-548024582a87">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzctMy0xLTEtMA_bca9b09b-92b4-4d98-be81-ffca3f5a1d3e">0.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net cash flow (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzgtMS0xLTEtMA_195c4ce0-4f0a-4013-b7d2-af3ddb19e7b9">64.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzgtMy0xLTEtMA_fb6cccd6-40c6-487c-9d2d-d04bc6a2775e">442.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">Cash flow from financing activities:</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDAtMS0xLTEtMA_434a3c81-9808-4b59-a4d9-cb90b62419c1">600.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDAtMy0xLTEtMA_634903b8-3139-4f5d-8b3b-cc615434c0ff">2,220.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Payments related to issuance of stock for share-based compensation arrangements, net</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDEtMS0xLTEtMA_0948c23f-1854-4ed1-bede-fb57f0fb70c2">27.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDEtMy0xLTEtMA_019f4764-49cc-4472-81d8-12b51fb7ad25">29.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Repayment of borrowings and premiums paid on debt exchange</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzktMS0xLTEtMzUyOA_ccf5aed0-c009-49ea-94ca-d3e358c3900a">169.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzktMy0xLTEtMzUyOA_b7b0377f-fe49-4f9e-8270-6dbdc46d7fce">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDYtMS0xLTEtMA_2f24dd2a-0fa9-4b8b-ac55-fbb4880d1704">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDYtMy0xLTEtMA_f56c7cc3-86d5-4453-b14a-4b50b09d4dea">4.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net cash flow used in financing activities</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDctMS0xLTEtMA_57046886-f009-4f47-b1c4-71c09e7c2525">785.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDctMy0xLTEtMA_5a05c79b-c061-4167-9024-660415396630">2,245.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDgtMS0xLTEtMA_4a5dbe15-7458-4b53-94c9-f2664b22d17d">80.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDgtMy0xLTEtMA_b5610b29-4957-410f-9ac1-da10cba6d6f8">335.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDktMS0xLTEtMA_d80ec047-a01e-4a18-8a15-f1f7aafbc152">33.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDktMy0xLTEtMA_6c50a889-7c8b-4883-aa30-d6f11bdfa241">12.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of the period</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNTAtMS0xLTEtMA_ee4358b4-0d4b-4c30-a361-8d1080367ee4">1,331.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0294157534ec4829a838f8161a2c6f76_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNTAtMy0xLTEtMA_c1c54178-f031-4d02-8275-fe7bafc71289">2,913.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of the period</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNTEtMS0xLTEtMA_6c88fef9-b6c1-4f1d-a8f2-02a627fda33f">1,217.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179564f7a5394a3f985b2394c890de98_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNTEtMy0xLTEtMA_7bc495b5-ed72-4112-988a-2e45da705abb">2,591.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:19.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.105%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bcd6f60e86446259cb8c43a0e3ff280_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0xLTEtMS0w_90df8b31-725e-4765-b904-870717c3b48b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bcd6f60e86446259cb8c43a0e3ff280_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0zLTEtMS0w_751a33f0-a934-4925-b5a0-54570ebdec85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c42b2175447497d8b49e20666071bb3_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi01LTEtMS0w_e6c931a3-c737-47c3-8f1a-e25a077f063c">176.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c42b2175447497d8b49e20666071bb3_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi03LTEtMS0w_fa2b810c-ab3d-4e01-9e6c-c9e9b4ee4a9a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie120e7590f014512a9ef0196920b2c3a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi05LTEtMS0w_ee7f3d81-0c43-44a4-b212-a3d85063ea34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d06f4201d6a4f44b0a65c949966d4e3_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0xMS0xLTEtMA_743709bf-af24-48af-bb37-d37bdad037e1">299.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9252b21ce96b49a69be79d8b5818a4ce_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0xMy0xLTEtMA_847e13af-83a3-4c6c-8449-bfa9f6f3fde3">13,976.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idc014f149d4e4da3b04fb867fc354a98_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0xNS0xLTEtMA_5a6d1e65-21b5-4c44-9477-0cff5d6cc73f">23.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc014f149d4e4da3b04fb867fc354a98_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0xNy0xLTEtMA_dae042a0-808d-4eb6-b03a-12002ac0f5b5">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15755e5a765478580cfde8eca39da00_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0xOS0xLTEtMA_f76f31bf-fa9f-4bd4-9348-ce24efa72abf">10,700.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21790366b5d34ac8a31ee2475fb7022d_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0yMS0xLTEtMA_b9e6edeb-d2bd-4ee1-a447-045f1792e470">14.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0yMy0xLTEtMA_a1d2af6c-d696-4e9a-86ac-216ab3f2ed51">10,686.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb70c7eb20e44693a04fd0260417f330_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMy0xMy0xLTEtMA_cd148870-1fb6-4c33-8743-595c778084d7">410.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMy0xOS0xLTEtMA_d8e4c283-d4c9-4bee-b7f9-db6af80b5a15">410.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie108b38fb78a4b4da6071b1fe46e0f25_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMy0yMS0xLTEtMA_1a4f5342-471c-4e80-8dbd-d492e3c30059">5.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMy0yMy0xLTEtMA_61093f4f-8824-44eb-9ba8-12ad0ae84767">404.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic45e43914f444bff8f68d0156608b715_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfNC0xMS0xLTEtMA_55e82763-560c-474c-916a-b99813fc0eb0">124.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfNC0xOS0xLTEtMA_ec761614-ec24-482f-9095-b15662044c26">124.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie108b38fb78a4b4da6071b1fe46e0f25_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfNC0yMS0xLTEtMA_ce87cb37-a886-473d-aed0-d9e25eca4089">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfNC0yMy0xLTEtMA_82a05e2d-37e0-4fac-bca8-5126a858b739">125.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution by noncontrolling interest</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfNS0xOS0xLTEtMA_8b40b753-5bab-4fb1-a15a-60681b98ce17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie108b38fb78a4b4da6071b1fe46e0f25_D20210101-20210331" decimals="-5" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfNS0yMS0xLTEtMA_e6e73569-15fc-48fc-af88-cd288b9fbac5">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfNS0yMy0xLTEtMA_4c99371e-2796-46b6-8855-6fea83168369">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2bb63a28893418589d2a0d1b7f927b3_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOC01LTEtMS0w_e4a253b8-5783-48b9-8ef2-9af22cca5763">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9a7e0d0eeaae4c5fbfb21c1d2f81bbb4_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOC0xNS0xLTEtMA_7501eaf9-772c-455b-bdef-415c8a052eb0">2.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a7e0d0eeaae4c5fbfb21c1d2f81bbb4_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOC0xNy0xLTEtMA_ed7c5b39-5f38-4511-8776-1eb38ceffe7c">600.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7af889133b864bf1a8251cd94b577064_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOC0xOS0xLTEtMA_36cd8b84-c6d8-4e7b-bf66-c2c16d7dd010">600.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b08cd90671441109d1d585c71239784_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOC0yMy0xLTEtMA_5a58a075-9767-40f3-82f8-13930db3e353">600.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2518d36e7af44bec9c3acb750c2ab582_D20210101-20210331" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS01LTEtMS0w_e6c7400d-df76-4365-b7db-0173d3f41c90">2.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2518d36e7af44bec9c3acb750c2ab582_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS03LTEtMS0w_f3338caf-859f-415f-9112-5746a3b279bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9db0313c47544e3fb07cfe61f64dae32_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS05LTEtMS0w_8041e4af-322e-42fa-9c80-996043961f38">93.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide40cd25587c44479c7cca25c2ab1a1e_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS0xMy0xLTEtMA_93ac057c-4595-482d-8ec7-69210f99771b">506.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a7e0d0eeaae4c5fbfb21c1d2f81bbb4_D20210101-20210331" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS0xNS0xLTEtMA_5c3bc415-ba71-41e5-97ea-9bdabd6c0f50">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7e0d0eeaae4c5fbfb21c1d2f81bbb4_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS0xNy0xLTEtMA_dadaa402-6e83-466b-8dfd-a3b94ab5a60f">600.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af889133b864bf1a8251cd94b577064_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS0xOS0xLTEtMA_966fd80b-6251-490a-a15b-6b6c1f858e53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b08cd90671441109d1d585c71239784_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS0yMy0xLTEtMA_d696c1bd-65a0-4736-8715-cb738aaf8788">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2bb63a28893418589d2a0d1b7f927b3_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTAtNS0xLTEtMA_76395398-03a7-40c6-903c-4f142b239494">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2bb63a28893418589d2a0d1b7f927b3_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTAtNy0xLTEtMA_78f50098-49a8-44e3-bd6c-94a8937c2a8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5f6b8e642b4f3a90e77ef64fc86959_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTAtOS0xLTEtMA_3b13b831-c3b2-4ccb-9ef0-8b27beae04be">19.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTAtMTktMS0xLTA_213c07cd-6b21-474c-99f9-f35351db3530">19.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTAtMjMtMS0xLTA_0e28b2eb-2b82-46c3-ab2f-cd1ca87fe59d">19.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2bb63a28893418589d2a0d1b7f927b3_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTEtNS0xLTEtMA_17250228-c87e-412a-8bfc-d9e1db032353">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2bb63a28893418589d2a0d1b7f927b3_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTEtNy0xLTEtMA_c8fce833-a425-49ee-af24-11dde5199e84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5f6b8e642b4f3a90e77ef64fc86959_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTEtOS0xLTEtMA_b94a8f7f-1a61-4100-83bc-d85efa28994d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb70c7eb20e44693a04fd0260417f330_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTEtMTMtMS0xLTA_be4a0647-53af-4473-9530-c54176c14d7a">46.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTEtMTktMS0xLTA_d64887dd-2b3a-4271-a589-d5276c7a3fe4">46.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTEtMjMtMS0xLTA_aabaa801-17ab-4234-85aa-a96290d0b7a6">46.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5f6b8e642b4f3a90e77ef64fc86959_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTItOS0xLTEtMA_9fd69184-c462-4b8a-847a-541f6d81d9fc">72.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTItMTktMS0xLTA_6b77c831-4442-4c6d-a85b-ae4b218a5746">72.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTItMjMtMS0xLTA_87535cfa-c8a7-4be7-847a-391d64967cb5">72.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5f6b8e642b4f3a90e77ef64fc86959_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTMtOS0xLTEtMA_862360c8-f9ec-48f4-aadc-ba1c85b26550">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb70c7eb20e44693a04fd0260417f330_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTMtMTMtMS0xLTA_63376508-bbe7-453a-884b-05a406fbbba3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTMtMTktMS0xLTA_14cd7ef0-6499-4f59-8e07-5708d213490d">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTMtMjMtMS0xLTA_fa2c19d7-820a-4f3f-99ed-a89ade1c4f8c">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc7d49e416884359a033c98c994d3d6b_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMS0xLTEtMA_38f6d8ac-b8cd-41a9-915a-bac97b79e220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc7d49e416884359a033c98c994d3d6b_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMy0xLTEtMA_c32189b2-76fd-40c1-b880-deb4f3a8a3f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35398fa4187c4561961299a90d05fde1_I20210331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtNS0xLTEtMA_c5832f16-b663-4670-adfb-944aa6b4af09">174.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35398fa4187c4561961299a90d05fde1_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtNy0xLTEtMA_9159e936-984e-43f2-be42-d9f300c658f0">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1883df2e84b34bfca009f1a107f517a7_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtOS0xLTEtMA_814b850c-f609-42cd-8f6c-bde6f1db9e22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i989a9664b51f425385c353e18a6b1db2_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMTEtMS0xLTA_7f5d468a-f469-4c33-9e78-86411e97e8f6">174.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57282d9aaf344b8abc4365220d50d8e6_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMTMtMS0xLTA_f3bacd28-4751-49c5-b21d-f387c9ede813">13,833.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iddda61c522014ea6bd671c91e77efd7e_I20210331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMTUtMS0xLTA_35578458-9c4e-40a3-8887-96d534a0e26a">23.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddda61c522014ea6bd671c91e77efd7e_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMTctMS0xLTA_763ead26-e961-48fc-a4b3-7181b0dcc12a">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id84b8595cae94c46aea8144165c16cda_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMTktMS0xLTA_4b0599c0-27c0-4ae5-b45c-fd01858a0e85">10,682.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id368506338ba40cd8adbea5e573a2f3c_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMjEtMS0xLTA_eb5c175b-f852-46ab-a076-6144374962bf">19.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMjMtMS0xLTA_ba3aadaf-e37c-4c7e-8b05-4e6b54dfbe84">10,663.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:19.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.872%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a8b05db811a4f6ca919149ab120e3a6_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0xLTEtMS0w_25e6190a-7ad3-41e4-8a8c-89b76a4de791">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8b05db811a4f6ca919149ab120e3a6_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0zLTEtMS0w_45527f9d-d394-45b0-898c-a359b5d0912b">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c2ba83c536b409e96a426d0bba7cc72_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi01LTEtMS0w_d61b5f1e-4162-4721-a73a-61d20fd0b4d9">198.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c2ba83c536b409e96a426d0bba7cc72_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi03LTEtMS0w_8233cd5c-2b34-4cb8-a3d1-6c4d2b9c7d6c">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba06f05e2faf4c708920aa5dcbd7ed0b_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi05LTEtMS0w_43a541c2-5237-41c0-82ef-1f88b5c4ecf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieca63027783a4ffc875d6d9098166871_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0xMS0xLTEtMA_e0fcb94b-d892-4d34-badd-9bd59fbe3f2a">135.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c713484677b4927ab70281250be20cf_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0xMy0xLTEtMA_94d4bb39-79d4-4ca5-a627-5db07679a31f">16,455.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib3b1784bb7804f8f9620259ab8942db6_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0xNS0xLTEtMA_4335a6d6-fcb7-4b0e-aa47-831adf56928e">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b1784bb7804f8f9620259ab8942db6_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0xNy0xLTEtMA_6103635e-6184-4210-b026-808da6bcf55a">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i605d5a6bd4e44da0afb2826209cab9c7_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0xOS0xLTEtMA_fe37fac3-d71a-4aa1-97fc-0db8b76d21e7">13,343.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c932859892f490180aa279af5a06b03_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0yMS0xLTEtMA_63288211-d41c-48ab-b596-336990eae7ea">4.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0294157534ec4829a838f8161a2c6f76_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0yMy0xLTEtMA_88814632-da51-4e3d-ac1f-c691c497564a">13,339.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7435b888c753443186dba3ab3fe1fcba_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMy0xMy0xLTEtMA_a0511ef8-7872-47e5-9f63-e0d2c6e44bd1">1,399.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a16d72df8e41e7aefc354fdce5be4a_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMy0xOS0xLTEtMA_72cc927f-fa39-48c2-9ea1-3deae823c3c6">1,399.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ea2f0d23ff44653bc3b6b5156c34bf1_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMy0yMS0xLTEtMA_a709379f-9dc5-40d6-b1aa-bb4f3261806a">6.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMy0yMy0xLTEtMA_d0c6732f-16c9-4f95-99d2-03da95ca9e1a">1,392.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04d5d70d39294b36b58ac20c0780157b_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNC0xMS0xLTEtMA_a395e0b3-e9a3-4856-aed5-f4f20c958b7a">14.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a16d72df8e41e7aefc354fdce5be4a_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNC0xOS0xLTEtMA_9e756b72-17df-47ff-87bf-32357ebec1a0">14.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea2f0d23ff44653bc3b6b5156c34bf1_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNC0yMS0xLTEtMA_cbf853ce-1d87-487a-9458-4cdb7dfd77d7">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNC0yMy0xLTEtMA_cefb2e92-5b36-4d39-9948-72c67a7f8ec4">13.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id6578a3afa6b483fafcf2459661d9944_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNi0xNS0xLTEtMA_b647979e-7777-4280-bfe2-ea95bff1df32">4.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6578a3afa6b483fafcf2459661d9944_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNi0xNy0xLTEtMA_1c15e508-9677-43e2-8d82-3ed867008132">1,279.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3952e97a9994176bda1554c91960383_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNi0xOS0xLTEtMA_0e0d10dc-dc54-4a86-b7ab-99b0cc32cd75">1,279.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25ca0d3089b9406197bdca98e4d63b1b_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNi0yMy0xLTEtMA_d05260de-1f3e-4953-ad3d-7a6491cb10f8">1,279.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i075e0c23d6b34d67b56b7fc63b0c8f6e_D20200101-20200331" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNy01LTEtMS0w_17f74a07-2eeb-44dd-a45a-9fcc861a261d">4.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f5558f45caa429b943890bb21370bb4_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNy05LTEtMS0w_7f7785d9-c27e-470c-b201-6745ca8a8d7d">71.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i406d62794dcb4950a1781265fcdca4d2_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNy0xMy0xLTEtMA_3740c5b9-3b17-4f43-b6f7-4ad681bca5d1">1,208.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6578a3afa6b483fafcf2459661d9944_D20200101-20200331" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNy0xNS0xLTEtMA_934bb26b-89a4-4e22-9fdf-81146b0eec36">4.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6578a3afa6b483fafcf2459661d9944_D20200101-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNy0xNy0xLTEtMA_9dda9106-a9fa-4a6f-b7dc-e29994b31430">1,279.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie6b1bf8966fe4b6f8d97788a368f7f09_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOC0xNS0xLTEtMA_8369213d-fef8-4621-af66-fbe908eb1caf">3.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6b1bf8966fe4b6f8d97788a368f7f09_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOC0xNy0xLTEtMA_2159af17-0c0b-4871-a304-245758e18889">941.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia559d28a9b914b37b44c9d7c95222096_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOC0xOS0xLTEtMA_9d1001d5-3e32-4569-a052-92204ee8e576">941.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf91e91201b044939704b3ea806b2ead_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOC0yMy0xLTEtMA_85b292f5-1e1c-4b9e-8eb8-ad14e4f1e498">941.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ieee5bd4f86704007b1420b9b498ddbc6_D20200101-20200331" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS01LTEtMS0w_9d7263ce-d7eb-44a2-9029-fe2d23c5e89a">3.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieee5bd4f86704007b1420b9b498ddbc6_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS03LTEtMS0w_a88bfcc0-1602-481c-8118-2dcc72399f4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51813489fb6b4bbeac18a5336356a074_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS05LTEtMS0w_2a152d73-4bc7-4f5d-b946-3083cb08d6ce">15.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89f2f3090dc54fea8e95c8bcfdc8bf2b_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS0xMy0xLTEtMA_85d28f9e-cb6d-4a25-abb0-2a1112526f2c">925.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6b1bf8966fe4b6f8d97788a368f7f09_D20200101-20200331" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS0xNS0xLTEtMA_7bdb8882-8f0f-4135-9511-50c97050b344">3.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6b1bf8966fe4b6f8d97788a368f7f09_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS0xNy0xLTEtMA_e1511bdc-44a7-438a-a98e-6930e50de1db">941.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia559d28a9b914b37b44c9d7c95222096_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS0xOS0xLTEtMA_a7da4826-f4fe-4946-ac72-41895ffddb64">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf91e91201b044939704b3ea806b2ead_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS0yMy0xLTEtMA_ee0a92ee-8630-4508-b464-fac65c11d04f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib357d23217b547d997470e7d0012d37e_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTAtNS0xLTEtMA_1cef59db-8b83-4bed-971b-d9da95759613">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib357d23217b547d997470e7d0012d37e_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTAtNy0xLTEtMA_6cc545ca-21d4-4cfc-ade7-6806c7959beb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00af2e110361494a882a140f60e249ae_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTAtOS0xLTEtMA_4f37e378-d827-4333-84b5-1d54cbd3bd06">18.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a16d72df8e41e7aefc354fdce5be4a_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTAtMTktMS0xLTA_7a4ad6d7-4a52-4939-af3a-34b16772c166">18.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTAtMjMtMS0xLTA_5e628569-8d33-4f54-90f3-1c10c594e321">18.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib357d23217b547d997470e7d0012d37e_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTEtNS0xLTEtMA_46c51c20-b310-45e2-ac51-b1ae7749ffd1">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib357d23217b547d997470e7d0012d37e_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTEtNy0xLTEtMA_ffc8dee0-778e-4089-b001-438746963a65">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00af2e110361494a882a140f60e249ae_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTEtOS0xLTEtMA_a5c5e903-bf7d-49cb-89fa-3757d62d9a5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7435b888c753443186dba3ab3fe1fcba_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTEtMTMtMS0xLTA_97e3df4b-499b-4be1-ae3f-5ef3f88ea708">47.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a16d72df8e41e7aefc354fdce5be4a_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTEtMTktMS0xLTA_feb67956-afd1-4eb6-b024-7bd27cc5e913">47.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTEtMjMtMS0xLTA_71280368-bc74-4a6d-b421-e2d80fcb62f5">47.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00af2e110361494a882a140f60e249ae_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTItOS0xLTEtMA_2de2c463-c4e3-49ae-a1ed-ecd8e51ae77e">69.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7435b888c753443186dba3ab3fe1fcba_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTItMTMtMS0xLTA_26be4adc-d0ee-4ea5-abcc-79bb4af758ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a16d72df8e41e7aefc354fdce5be4a_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTItMTktMS0xLTA_db43fa8e-04df-4375-b770-68d0a5f79df6">69.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTItMjMtMS0xLTA_498d09d6-ad7b-4e0f-b9f1-45a5c0788c9a">69.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00af2e110361494a882a140f60e249ae_D20200101-20200331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtOS0xLTEtMjIzNQ_0d86bafb-7116-4710-9256-ac227214ff12">0.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a16d72df8e41e7aefc354fdce5be4a_D20200101-20200331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMTktMS0xLTIyMzU_3390df16-5238-48ec-a219-32882f47f70a">0.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMjMtMS0xLTIyMzU_579373d9-6693-411d-a8da-652fe8e82eb0">0.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f1fb990e4ee44be863aa4437fa57293_I20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMS0xLTEtMA_ad4bfb47-1507-4168-b6d1-f42d508e9c05">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f1fb990e4ee44be863aa4437fa57293_I20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMy0xLTEtMA_fa025d63-8fa6-45b7-ac8b-eaf8df2cdba9">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if823fb42eb284177aa1ddbf216b2c1be_I20200331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtNS0xLTEtMA_01f38f4b-c717-468b-a2e3-cae99cbb2218">191.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if823fb42eb284177aa1ddbf216b2c1be_I20200331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtNy0xLTEtMA_2399e704-024d-40c7-9f2c-e993c33ef190">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512bb80727434c12bca0775dbd5e2137_I20200331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtOS0xLTEtMA_e26e0ca8-46da-4139-92e9-72b994e22b53">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae486e871284c88a17b126221465865_I20200331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMTEtMS0xLTA_d99e2628-fccd-4d27-a6a0-da82ba636662">149.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670f018181f04ca3a3f0bd64e5623f2f_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMTMtMS0xLTA_6973eff6-4593-4836-8777-0cde41215d49">15,673.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0ec1a33127cb42fb9fe3fdce711fae15_I20200331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMTUtMS0xLTA_e29bd3f7-d91f-4bd2-99f1-cac033455a04">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ec1a33127cb42fb9fe3fdce711fae15_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMTctMS0xLTA_9c5f4fdc-cdea-4fd6-9a8b-3872299a0b86">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ee3ab86dd9a44bba034cdb3caf707fc_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMTktMS0xLTA_ac7a3a47-40db-4445-a936-bef6ede1d7e6">12,546.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff1e167122b54794a75d887f91010ca6_I20200331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMjEtMS0xLTA_e0f1b6fe-0059-48be-a6d6-ba42d8587130">10.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179564f7a5394a3f985b2394c890de98_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMjMtMS0xLTA_ab8ea9bc-e321-4937-8c22-00bf07d0d4b2">12,536.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_37"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div><span><br/></span></div><div id="i6fe84bc7e101462ea41fc07416803961_40"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfMTIwNzQ_0e71fde6-8c0b-4bd6-87dd-b4ac95f5e3e1" continuedAt="i63d5c79e49d647aeb10b05ceddad2532" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="biib:BusinessOverviewPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfMTIwNzc_8a712068-bb53-4384-a0f5-ff9581684223" continuedAt="i385c7f18a14f4463a02ffe179ef69873" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="i385c7f18a14f4463a02ffe179ef69873" continuedAt="i6758cc87bd764907b6e02db9623535a9"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have an option to acquire exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize <ix:nonFraction unitRef="product" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="0" format="ixt-sec:numwordsen" name="biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfMjc5OA_eeb247b6-c348-43ff-a332-23cd28ebc66c">two</ix:nonFraction> potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6758cc87bd764907b6e02db9623535a9"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfMTIwNTM_7a534d2b-58ae-4eec-a9ae-f705060c3b9e" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2020 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three months ended March 31, 2021, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as <ix:nonFraction unitRef="segment" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfNDI5Ng_7fd9c4fa-8125-48b6-9f17-86340a8bd7a1">one</ix:nonFraction> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i63d5c79e49d647aeb10b05ceddad2532"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfMTIwOTA_bbca82ec-3d96-4593-a6c7-c79d8887c223" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than <ix:nonFraction unitRef="number" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="INF" name="biib:InterestInSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfNDgwNg_366ccf87-ebbf-45a4-af5b-4315a0daa6e1">100.0</ix:nonFraction>% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfMTIwNDY_a571e67a-4260-4ad7-ae01-35a3cdd212d2" continuedAt="i4e3e1274447543ceb7c2ccc33ef67577" escape="true">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4e3e1274447543ceb7c2ccc33ef67577">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfMTIwNjA_2f441d5f-d6d6-47f6-815c-bd7c8b9e0f14" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt;text-indent:9pt"><span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 the FASB issued Accounting Standards Update No. 2019-12, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i6fe84bc7e101462ea41fc07416803961_43"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Acquisitions </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80My9mcmFnOjFkZTQxYTllNDQxYjQyODQ5Yjg3YjVjZTYzNzU2MjM0L3RleHRyZWdpb246MWRlNDFhOWU0NDFiNDI4NDliODdiNWNlNjM3NTYyMzRfMjk3Nw_057a574d-23aa-467d-9701-de4f682f13b9" continuedAt="i8b6c474707f1449ab4357c6185f0a2d1" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIIB118 Acquisition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020 we acquired BIIB118 (CK1 inhibitor) for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We are developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder in Parkinson's disease and plan to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8b6c474707f1449ab4357c6185f0a2d1">In connection with this acquisition, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="id08a82497aa04887a9c810084e90cb86_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80My9mcmFnOjFkZTQxYTllNDQxYjQyODQ5Yjg3YjVjZTYzNzU2MjM0L3RleHRyZWdpb246MWRlNDFhOWU0NDFiNDI4NDliODdiNWNlNjM3NTYyMzRfNTY1_33598816-72f4-4528-8a5c-825a9cec3395">75.0</ix:nonFraction> million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;D) in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to $<ix:nonFraction unitRef="usd" contextRef="id08a82497aa04887a9c810084e90cb86_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80My9mcmFnOjFkZTQxYTllNDQxYjQyODQ5Yjg3YjVjZTYzNzU2MjM0L3RleHRyZWdpb246MWRlNDFhOWU0NDFiNDI4NDliODdiNWNlNjM3NTYyMzRfODM0_a7728379-4799-4a5d-94e6-4df918fbc460">635.0</ix:nonFraction> million in potential additional development and commercialization milestone payments as well as tiered royalties in the high single digits to sub-teens.</ix:continuation></span></div><div id="i6fe84bc7e101462ea41fc07416803961_52"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Revenue </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfMjgwMg_9e231c79-e3d6-4070-ae58-24a20c8070e2" continuedAt="ib4773fd2d99c4c2daa7488422da87101" escape="true"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfMjc4Mw_1615f6ca-10f5-4f85-a306-0a5c55c2dc33" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i448c0442bf0a4adfa28c5d18001b08f1_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNC0yLTEtMS0w_97b6eb15-f825-4155-876a-2fe68af3e36d">236.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1193489ec1264f35a2ac5971bf81f6f7_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNC00LTEtMS0w_4134892b-ff53-4de9-a377-aa3b6f1fdda5">316.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia487fdfe567b401b86ede458e9ba75e7_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNC02LTEtMS0w_668cb67d-b4ed-4ba2-ad3e-f704b9aa9e47">552.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d2c097d12347678a78a057aaf039aa_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNC04LTEtMS0w_60ae1302-2ef6-4aa9-8ffb-ccc0d9a1e288">777.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2fc407d1ec4ed380b5e106ffb0c831_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNC0xMC0xLTEtMA_97981462-73d9-4482-b723-d65744271b93">323.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940d0ffed9724139916f62bf6dad8a7b_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNC0xMi0xLTEtMA_a8f6af48-15ea-4528-be7a-1c7bccb4e79e">1,100.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4bd59b7c3249f0bc24ef3c1c48d31c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNS0yLTEtMS0w_f9784bc3-1b30-4646-a112-e9835d40ab0c">241.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8f8e721203449fc86db69bab7e7cd9e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNS00LTEtMS0w_aa96cd79-930d-46c7-8371-d209e02912df">158.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcf12665755e4093a4220cda52ac3eb9_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNS02LTEtMS0w_46da3dff-e778-4ba0-a4a6-37920e8bc4e8">400.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id77770628748461faf30529d99622607_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNS04LTEtMS0w_808d27b8-6f49-4f93-9fc7-310d8938d2bc">292.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1646afc7440542fcb255ec823d3c9c2c_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNS0xMC0xLTEtMA_8dfaa990-f2f8-4197-bd79-7448cad7d94a">173.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e14d4e11831452ba137891a9396c862_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNS0xMi0xLTEtMA_23e64f28-4e9d-4fe4-8a7b-7ca353c9c872">466.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i184b1c6940b2461e8557af90326d21e4_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNi0yLTEtMS0w_1d5c3930-ae99-4d7b-afe3-4fb7c352891b">273.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8caf7eb3d8046008f3982503a64cade_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNi00LTEtMS0w_86938313-7dfa-4ec4-b235-fea9d680ef5f">230.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d0fb5bb1cb45d99a7b3491c2593e22_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNi02LTEtMS0w_0f2793a8-286b-4d7c-be3e-c8c3c75d3377">503.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4341139d31d645e89e76c26bfb4231ca_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNi04LTEtMS0w_d19a022e-868e-4b9a-9a91-dcf4f52953f1">277.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb99b30cbf54b00852f7084359ac9d6_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNi0xMC0xLTEtMA_0f59ba91-c894-4c97-aed4-847dc7d38b50">244.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b70a2acef674d0985ecb568772c3258_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNi0xMi0xLTEtMA_fb703357-ac04-4ab8-b6e0-b09e32d3acd9">522.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505c2e793fca48ae9a343f83d10b25a2_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNy0yLTEtMS0w_fe4230e5-9949-4296-8e2d-9a8704a491c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff026a1b98554dfbbc131b0472cb5b7b_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNy00LTEtMS0w_b413e08a-6cbd-4f02-9c17-a95260837a57">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734c667a854e4365bfb4b48aef78b038_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNy02LTEtMS0w_189c0020-7848-499c-a0f5-95d4a9bb1987">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0962648e31c1402ab3c19a4f421155fe_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNy04LTEtMS0w_fc5321dc-36e3-4283-9773-1a01cb483da2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83423de217c44a9be015f40ff27c33d_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNy0xMC0xLTEtMA_f63dd5fe-9649-4bcc-ab3f-7dee6819b586">28.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec00ec53a19f4ea9a63dace92b6da302_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNy0xMi0xLTEtMA_8ed4abc2-24dd-4cac-aac8-9807ec9c7daa">28.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2ba3fb90464ab29d64a5353775989d_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfOC0yLTEtMS0w_597b1c51-8928-43a0-af57-c79fc2eaee4c">751.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6132d3c924c414e84a28b2389d20a41_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfOC00LTEtMS0w_e19c3290-b5d8-4d10-98a9-baf743f346cd">732.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf832a6fefc64c7582c337b5ffea1c29_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfOC02LTEtMS0w_d7db4661-ac43-4ab6-874d-a6f193481dc6">1,483.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad6065fa88e4b7abff61a49206a7d0b_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfOC04LTEtMS0w_db13d3ca-42ef-43b6-8ad1-a2682eab91cd">1,347.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14524fbcf9df4b2281933e4d60f10f02_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfOC0xMC0xLTEtMA_4df5640c-c2d9-47e7-9014-093b6e097dba">769.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bf0c4a015a74ded850336575e8289b8_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfOC0xMi0xLTEtMA_d744df79-9f2d-4199-868c-ad8a41b3b16d">2,117.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325454d8aeec4098bfa98cf14b372c51_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTEtMi0xLTEtMA_407e426d-0954-45c8-8ccf-3bd7ec00feb0">148.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6066c0c6bb49d7b1ea35be7c87f0c8_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTEtNC0xLTEtMA_18346303-7df6-4883-a45f-4a1b4568329a">371.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5dda8845084cdda4c2aa27909ab988_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTEtNi0xLTEtMA_75f4b000-91f5-44db-8e95-a550e9f103d3">520.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d4f5eaef8fe43309f839c1c36e3c80d_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTEtOC0xLTEtMA_eadc536a-2adf-48a8-9370-71a0f44028d3">235.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i059f4365445242aeb92df9e0e10de132_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTEtMTAtMS0xLTA_322989d4-3fbc-4f87-9e63-3b8af882a8a6">329.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i061b1e268b544b26a76c0707fad02355_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTEtMTItMS0xLTA_ab5132a3-1bb7-4e2e-a9a5-7ad17e2e17a4">565.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d5370a9ea274139a341c5cfdd8d6d9b_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTQtMi0xLTEtMA_b7e46fb0-0830-4bc0-824c-f7b952cd7966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc51673e08bc4f3b82f3b472a4a90973_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTQtNC0xLTEtMA_016c3d27-6545-44e0-8c6b-f50097111841">121.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27035e9563074fbbaca4c77997b66921_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTQtNi0xLTEtMA_c71cc6be-f215-4b52-92a5-6bd1959be767">121.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f64ee14005421481ed9d38025dbe95_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTQtOC0xLTEtMA_723992ba-7808-4a3d-a0a5-dd75b761f2a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i031fb4884755410b845a81795c4ec551_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTQtMTAtMS0xLTA_43bf84d9-01f3-4c98-8972-01469bdcff31">133.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01eeb32d79b4571ad8f11070dc2da48_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTQtMTItMS0xLTA_fc5b3eb1-8720-48a4-b239-c2c77ea70add">133.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202bf8566c7042b784c6445ebd363725_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTUtMi0xLTEtMA_b79754eb-2822-4973-80d6-def43cdb72cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7824a2335ba4ddd968c947099502057_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTUtNC0xLTEtMA_30555b2e-ff0e-4a65-8dd9-aaa7f5643728">57.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8b061168814140b09c590b540bb10e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTUtNi0xLTEtMA_300ba7eb-8bb0-4d97-8d9e-92de844dc1b8">57.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia908504887ca40f181856648cf0956ae_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTUtOC0xLTEtMA_80632177-cc49-4c87-9f68-eb9121a9df6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06fc398cd34146d982acc4911a986595_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTUtMTAtMS0xLTA_af23a72a-ab6e-4450-bc16-ac1d92149795">61.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7700739d178e441d91b2f50f6c7798c6_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTUtMTItMS0xLTA_32344940-068b-4493-b4ce-c5c407273d49">61.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f9b4973848433abff09c45a64c9143_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTYtMi0xLTEtMA_a63f0eba-7c1c-4c16-bce5-b0def0158f05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a352d78f7d43fa8a05b645e4f6e3c7_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTYtNC0xLTEtMA_f17b92da-f818-4426-9020-a86d1c82e249">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34be7a6433744d2f8766ca37a26efa37_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTYtNi0xLTEtMA_4171fe6b-686a-4e6b-b326-6b926dd96dcf">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i324196a294bc4b538065228274cc76fb_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTYtOC0xLTEtMA_e5c33ef8-eda6-4f61-8f2e-0e383d59bf99">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic67c201687dd40b69b77091684731883_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTYtMTAtMS0xLTA_4d22cdc2-7ede-4a60-85c9-b27668730e00">23.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017ebf20529f44b5bff42d9e6dc8fb53_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTYtMTItMS0xLTA_8055d231-f1ae-4ed5-99a0-a49b3b9b18cb">23.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8fbe7359e294d698c58806b13fe20f3_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTctMi0xLTEtMA_d5013b6f-c240-4394-99cb-5989dbdb5d96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d43bda4427a42e18236a50750cfe714_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTctNC0xLTEtMA_50b58510-9d09-403f-a7eb-42e8e6ed7174">205.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a69682358b4f1a99c21d088b5c487b_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTctNi0xLTEtMA_d84f8edf-2090-44e3-89e3-f65470b3fa09">205.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b44b2a9e3643ec956383c1b647c5d8_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTctOC0xLTEtMA_620be730-cf97-4fbc-8e99-1fb75b980446">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26bd19762f294c71b22709ebc3c0418f_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTctMTAtMS0xLTA_41005d1e-9660-47ec-b266-c1c9a6d5f95e">218.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f248578d7441ec88a211f0018d2a05_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTctMTItMS0xLTA_6320cf98-e76a-4fbe-9d68-b4beff9fbab9">218.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1145a015534643fbbd914351f2d3303c_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjAtMi0xLTEtMA_6ee29800-969a-4c17-b1bf-03107854ab33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i601c9a44b1bd4cf6abb5e0a17029e845_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjAtNC0xLTEtMA_4beebb64-6a68-4156-a5a1-9c7f024b4828">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e81697f8c14de383f2c496c7483109_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjAtNi0xLTEtMA_597d5f77-75e9-467c-9531-15acb338ce83">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2c9127e05b04ef281beba3d1321c62d_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjAtOC0xLTEtMA_b3a59466-2d32-4d74-a911-8421295e47d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1003e56b7b748e9bf5a15cef4022aeb_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjAtMTAtMS0xLTA_8165b160-ab56-44d5-bf9b-a2c81cf6c7f4">3.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e358b0c99a14c348aafac03e2a37487_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjAtMTItMS0xLTA_66befe2f-2206-4922-b5dc-932de8828f2e">3.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3d8f1b9751745c9b3b1484d9d3b8c54_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjEtMi0xLTEtMA_0d207b92-32be-4241-b6e7-e2141bc135c5">899.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1586eb35090b4a5faabb9c8a8e822582_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjEtNC0xLTEtMA_ed1a0189-3b7f-41da-be7e-a9ffef23d640">1,311.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf5fb72476641e09225cdff0259f43e_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjEtNi0xLTEtMA_3cd7ae73-d603-4b44-9dd7-9637cf440747">2,211.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666d1e67c4384945af3d0da636c7d0f9_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjEtOC0xLTEtMA_2f237765-1350-4490-b18d-5bfe72735706">1,583.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b9ce56cc0624826bb2b6dd3b2be83c7_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjEtMTAtMS0xLTA_26a167b7-f0ba-427f-b440-5cae0cc72e74">1,321.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b12581badd45819dafd1517b58aa13_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjEtMTItMS0xLTA_da47653e-255c-44ac-b5cd-06fdf4d25f26">2,904.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfNDI1_491b5675-2779-4288-9364-015852ec6be8"><ix:nonFraction unitRef="wholesaler" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfNDI1_6e220bab-7f73-4754-97b9-f2803fa48c77">two</ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="iea1a2bf4c66943a5b003368cf21dfc2d_D20210101-20210331" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfNDU1_e5ea611b-5df9-453e-8fc9-bcfe02510247">30.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if8384ea1bc75497bbace5e319dccb2bf_D20210101-20210331" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfNDYy_a4840793-d993-4326-b20b-e9dabcc780eb">9.3</ix:nonFraction>% of gross product revenue for the three months ended March 31, 2021, and <ix:nonFraction unitRef="number" contextRef="iee8610004f734b68b4cba17dcff8b4e3_D20200101-20200331" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfNjQ1_bbc504e9-c2cf-4ddc-83e9-8eeb7741657c">30.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i47a0a8c9dbdf45d583161449e4534cc8_D20200101-20200331" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfNjUy_fa6638b6-cf0b-4ef9-a54b-748a5f6a0665">14.6</ix:nonFraction>% for the three months ended March 31, 2020.</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfMjc3NQ_d785064c-c2e2-4c01-8bf4-19e75c4d4f23" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1013b869080645d59d75e657f4c58e4a_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMS0yLTEtMS0w_ae7d2a7e-98eb-4745-97b5-1324d06ee05e">141.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i330c93cac85e420b898ca9c3a01dcf52_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMS00LTEtMS0w_ab5b14e2-30b9-49ce-a272-ad4a0981ff16">1,093.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bf47792d6ea4f0b86fdb02f0d4eb158_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMS02LTEtMS0w_a373b499-30f1-4305-aaff-14c426bb3c7f">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMS04LTEtMS0w_2388e37a-776c-476a-9aa6-4ffea8191740">1,276.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb86fe950bc5486cbb58985525874f0c_D20210101-20210331" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMi0yLTEtMS0w_d9964e38-ab6a-42aa-9821-1277368824e9">185.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cdcbb6052942698e96461e2cd71321_D20210101-20210331" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMi00LTEtMS0w_d6c60137-a72c-4421-afef-f2d5907b1893">775.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ec3f38a20a46ce85926bdad24da8d0_D20210101-20210331" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMi02LTEtMS0w_63e1e7ff-741e-45f7-b823-7179dc20ecc8">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMi04LTEtMS0w_176dc93f-acba-4b7e-8b65-7e142b02e1ff">964.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb86fe950bc5486cbb58985525874f0c_D20210101-20210331" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMy0yLTEtMS0w_68856e85-af0c-4187-ae6e-809ebd4fb086">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7cdcbb6052942698e96461e2cd71321_D20210101-20210331" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMy00LTEtMS0w_22423a9b-4c25-434f-8118-179922466766">32.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ec3f38a20a46ce85926bdad24da8d0_D20210101-20210331" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMy02LTEtMS0w_2795fa9c-5040-4120-af67-21a9f24b09ac">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMy04LTEtMS0w_479aea44-c1c4-4b08-8ead-1a741a34f175">30.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb86fe950bc5486cbb58985525874f0c_D20210101-20210331" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNC0yLTEtMS0w_99d72531-0d92-4bd9-bf5e-acdd657b3010">111.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7cdcbb6052942698e96461e2cd71321_D20210101-20210331" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNC00LTEtMS0w_ce82dd91-1907-4f24-9047-002fdd07a225">284.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ec3f38a20a46ce85926bdad24da8d0_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNC02LTEtMS0w_80719e94-61d4-4f47-8473-31b07b334dae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNC04LTEtMS0w_6d84aae5-3da0-4f0b-b91b-105bdef4121c">396.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb86fe950bc5486cbb58985525874f0c_D20210101-20210331" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNS0yLTEtMS0w_8e37fa47-71c6-4ad6-b11d-72619cdf888e">82.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7cdcbb6052942698e96461e2cd71321_D20210101-20210331" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNS00LTEtMS0w_dc3d664a-ab20-4b7d-96fd-e1659fc5a8e8">562.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9ec3f38a20a46ce85926bdad24da8d0_D20210101-20210331" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNS02LTEtMS0w_568e9822-d6cf-49c5-b27d-7940c607ab82">1.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNS04LTEtMS0w_369a466c-d6cd-4de1-bb21-173a7e78c2c2">647.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e3449ffe264832baf2481923cbabff_I20210331" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNi0yLTEtMS0w_30ee9d9a-e347-4da9-85e4-f6ed657d9f41">132.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1806a0bbaa2b43889412b0fa97abc98a_I20210331" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNi00LTEtMS0w_be07fa7f-b24e-4e95-a382-5da8788b9522">988.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05eb3d02985844119473f90fa44e496a_I20210331" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNi02LTEtMS0w_9d1765fd-bbab-44f6-b927-ebabb8ce7aa6">44.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNi04LTEtMS0w_4a421c24-27f5-40f4-b054-1d00b0ce29a5">1,166.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ib4773fd2d99c4c2daa7488422da87101"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfMjgwNw_92fb49db-cf06-4640-82e6-325507475d43" escape="true"><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0003b815e2554577be2bdf249035d3a5_I20210331" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjRiNThjYmQ2NmRlMDQ4ZThhMWNlMDI2MTc3NDZhZDQwL3RhYmxlcmFuZ2U6NGI1OGNiZDY2ZGUwNDhlOGExY2UwMjYxNzc0NmFkNDBfMS0yLTEtMS0w_90c57599-8b03-47ec-8b92-569526a18178">173.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaef079cdccfb48ee83054f60bf01c254_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjRiNThjYmQ2NmRlMDQ4ZThhMWNlMDI2MTc3NDZhZDQwL3RhYmxlcmFuZ2U6NGI1OGNiZDY2ZGUwNDhlOGExY2UwMjYxNzc0NmFkNDBfMS00LTEtMS0w_583af395-227c-4bb0-ab69-c7e076f05d2b">195.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice62402188f941eab28ef8bd9b65e16d_I20210331" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjRiNThjYmQ2NmRlMDQ4ZThhMWNlMDI2MTc3NDZhZDQwL3RhYmxlcmFuZ2U6NGI1OGNiZDY2ZGUwNDhlOGExY2UwMjYxNzc0NmFkNDBfMi0yLTEtMS0w_d1c158f3-5d50-4bb7-9799-600f9219e74c">993.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569ed47008414979a6cf0d109c369b32_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjRiNThjYmQ2NmRlMDQ4ZThhMWNlMDI2MTc3NDZhZDQwL3RhYmxlcmFuZ2U6NGI1OGNiZDY2ZGUwNDhlOGExY2UwMjYxNzc0NmFkNDBfMi00LTEtMS0w_3699db25-774d-43e9-9f3b-77adc8a96cb3">1,080.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjRiNThjYmQ2NmRlMDQ4ZThhMWNlMDI2MTc3NDZhZDQwL3RhYmxlcmFuZ2U6NGI1OGNiZDY2ZGUwNDhlOGExY2UwMjYxNzc0NmFkNDBfMy0yLTEtMS0w_994091ee-46b8-4a38-84da-f7c79f4ab08c">1,166.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjRiNThjYmQ2NmRlMDQ4ZThhMWNlMDI2MTc3NDZhZDQwL3RhYmxlcmFuZ2U6NGI1OGNiZDY2ZGUwNDhlOGExY2UwMjYxNzc0NmFkNDBfMy00LTEtMS0w_584158fa-6b97-4e2d-916e-5881109c77ba">1,276.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfMjc4MQ_2bf68a9d-e035-4185-a97a-623803e4b59b" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42fd999637364cbe9c5eda2d3135fe5d_D20210101-20210331" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOmM5YjU5NTA0Yjc1MzRlZDE5NGEwYmIwYzlmZTJhODJjL3RhYmxlcmFuZ2U6YzliNTk1MDRiNzUzNGVkMTk0YTBiYjBjOWZlMmE4MmNfMi0yLTEtMS0w_ed1122a3-9fd5-4423-9a96-68db490f9eff">174.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i423da7297412458f999e416eb001a0d7_D20200101-20200331" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOmM5YjU5NTA0Yjc1MzRlZDE5NGEwYmIwYzlmZTJhODJjL3RhYmxlcmFuZ2U6YzliNTk1MDRiNzUzNGVkMTk0YTBiYjBjOWZlMmE4MmNfMi00LTEtMS0w_b1607def-a2f6-4025-90b5-523a5e07e598">341.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42fd999637364cbe9c5eda2d3135fe5d_D20210101-20210331" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOmM5YjU5NTA0Yjc1MzRlZDE5NGEwYmIwYzlmZTJhODJjL3RhYmxlcmFuZ2U6YzliNTk1MDRiNzUzNGVkMTk0YTBiYjBjOWZlMmE4MmNfMy0yLTEtMS0w_78b53bd6-5a0c-4fac-ae57-eedd8ee8434c">214.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i423da7297412458f999e416eb001a0d7_D20200101-20200331" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOmM5YjU5NTA0Yjc1MzRlZDE5NGEwYmIwYzlmZTJhODJjL3RhYmxlcmFuZ2U6YzliNTk1MDRiNzUzNGVkMTk0YTBiYjBjOWZlMmE4MmNfMy00LTEtMS0w_392859dc-abb5-423a-8ff3-321adc633999">179.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2837c6bcf6604a1884f52b184bbc1cec_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOmM5YjU5NTA0Yjc1MzRlZDE5NGEwYmIwYzlmZTJhODJjL3RhYmxlcmFuZ2U6YzliNTk1MDRiNzUzNGVkMTk0YTBiYjBjOWZlMmE4MmNfNC0yLTEtMS0w_898eb3aa-d2e4-4521-80fd-9890eb0cc464">389.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57cd91f7d9604cf09b048c87050e1776_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOmM5YjU5NTA0Yjc1MzRlZDE5NGEwYmIwYzlmZTJhODJjL3RhYmxlcmFuZ2U6YzliNTk1MDRiNzUzNGVkMTk0YTBiYjBjOWZlMmE4MmNfNC00LTEtMS0w_5caf3715-25c9-4d89-a1a6-2158be448a83">520.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-right:2.25pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="biib:OtherrevenuesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfMjc4Nw_c5d7b4e5-77de-48bc-9bb1-ba2e3649f562" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i163da90ecfbd4f72bc274463a9d22cf0_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfMy0yLTEtMS00Mjgw_756e7422-85f4-4e17-8bb2-37f159351377">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82cbd68005204f25a28991bb50e01dff_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfMy00LTEtMS00Mjgw_ef2bab4a-882d-4d0a-b927-013c235e8104">3.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e77e2252074a059d584ff066314e70_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfMy0yLTEtMS0w_ed4372d3-b54a-4264-b17c-df704e517c7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if37d2490542d485c8ad9bc6897f9286d_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfMy00LTEtMS0w_7d63dfda-5b63-400e-90cb-150b28e23f91">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6131440c1f431ebe00dc7e4e529db3_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfNi0yLTEtMS0w_67066118-659b-4966-ba2e-275d70b36227">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15a9a358435d49609a85d97413f3a145_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfNi00LTEtMS0w_07979125-28e2-42fa-afef-690c69928899">11.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6844ffa5076f4ec887dfd7ec445c0918_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfNy0yLTEtMS0w_6949dce7-2cbf-4536-b023-36b025aa224a">83.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdb2840b630460ea506d4ec51307590_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfNy00LTEtMS0w_92695123-cf38-4fbd-b456-6433bd2aca58">94.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16255170d7464fce8565c267cce60805_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfOC0yLTEtMS0w_c912d679-c172-4b72-85fb-855f34047e82">93.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5be06727e54c9cb7a5c0a5c65b597e_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfOC00LTEtMS0w_fc77607d-1d34-4b2a-aff1-57c511499e87">109.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_58"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;Inventory </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RleHRyZWdpb246YTM4ZWVhNWE1ODZmNDMzNmIwYzQ2YTFkOTk1NTYyMGNfNzM_75e1bb1a-6d3b-441d-87a8-a3eb4fb0d0f1" escape="true"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RleHRyZWdpb246YTM4ZWVhNWE1ODZmNDMzNmIwYzQ2YTFkOTk1NTYyMGNfODU_05ea8e8c-0ed7-46ae-90ea-c414f719f33d" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:58.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfMS0yLTEtMS0w_d8b695f4-813b-4b60-b585-bdba32f8372b">331.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfMS00LTEtMS0w_4c484e13-6ea3-41d7-94cb-24de998bf7f9">314.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfMi0yLTEtMS0w_ab0e3804-8d92-4b63-839e-50e580918563">634.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfMi00LTEtMS0w_3cf1a193-743c-45db-a73a-024ad351859f">544.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfMy0yLTEtMS0w_b557c9ae-6de4-47c1-9d37-a6317c9cb8ac">205.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfMy00LTEtMS0w_23834e93-e3c8-4ac2-bc9e-869347c71a40">209.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:Inventorynetcurrentandnoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfNC0yLTEtMS0w_6d67aaa3-119e-492f-be4e-37d2417fe9ff">1,171.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:Inventorynetcurrentandnoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfNC00LTEtMS0w_3b84e31f-0962-4b22-bf21-52c2e6a6c41c">1,068.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_61"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;Intangible Assets and Goodwill </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMzQ2MQ_131db84f-c232-466f-9a2a-85e10ce1c09a" continuedAt="i7cfd20180b5a4c65908b008a1c11151a" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMzQ3Mg_64e74d91-ac37-4a96-8d61-4d9aad02fddb" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:22.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f0b595ff7d4f3fa1e56358ca157244_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMi0zLTEtMS0w_fecceabd-bde2-469e-8a77-cc6d8f1034e6">7,394.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f0b595ff7d4f3fa1e56358ca157244_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMi01LTEtMS0w_e5c13502-c954-4cca-9a4f-ab43c67a78ab">5,190.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f0b595ff7d4f3fa1e56358ca157244_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMi03LTEtMS0w_1bcd69b1-a8a0-4cef-9f5d-2e322978c669">2,204.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848aad0fd824420fbb889c08f40d826c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMi05LTEtMS0w_fa04d370-21ad-4b67-a59b-99104861cb2b">7,394.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i848aad0fd824420fbb889c08f40d826c_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMi0xMS0xLTEtMA_976741c6-6983-4817-a9c8-6455b25d8353">5,136.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848aad0fd824420fbb889c08f40d826c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMi0xMy0xLTEtMA_a5a9e1e2-04bb-43dc-aff5-01eacc5f4efc">2,257.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e8e8ec88cba4cae96ec769e8eb5ed50_I20210331" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMy0zLTEtMS0w_2a81b832-f986-42bf-b15e-a977917a16a8">720.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e8e8ec88cba4cae96ec769e8eb5ed50_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMy01LTEtMS0w_d5cd8f29-c9bd-4eb5-8128-de8428d6f18a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e8e8ec88cba4cae96ec769e8eb5ed50_I20210331" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMy03LTEtMS0w_10cae748-7d1a-4666-9cc3-941f5be7b38b">720.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56017bab075244608da3bd636cc69661_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMy05LTEtMS0w_a6e7ddbd-04f5-48be-9c6e-b25a676bcf37">762.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56017bab075244608da3bd636cc69661_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMy0xMS0xLTEtMA_c1af8a5c-ad61-4655-a74d-720dd994e4f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56017bab075244608da3bd636cc69661_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMy0xMy0xLTEtMA_902f5102-ce0d-4e62-8bac-eed5a73ba44b">762.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58534be095d54aff98f1243bb85b6ca4_I20210331" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNC0zLTEtMS0w_9258bc39-9c03-4f0c-8de1-c8a900f81e75">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58534be095d54aff98f1243bb85b6ca4_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNC01LTEtMS0w_7e448e25-3d69-4af0-89e4-23967c76396c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58534be095d54aff98f1243bb85b6ca4_I20210331" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNC03LTEtMS0w_e4f6504d-e24d-4f18-8233-9ca68d718c86">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b71bbb6a21a486ba7bb214d1686f8f8_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNC05LTEtMS0w_09a87a6e-806b-4669-8400-1aeeae49e463">64.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b71bbb6a21a486ba7bb214d1686f8f8_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNC0xMS0xLTEtMA_94aac8e7-285c-46b6-ac4a-bc9bdd2c4c81">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b71bbb6a21a486ba7bb214d1686f8f8_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNC0xMy0xLTEtMA_9bed9789-5ba8-4bc8-b03c-8b0618f25aff">64.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNS0zLTEtMS0w_c9b9a62d-b5f4-461e-90a8-1e9733a2ee5c">8,178.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNS01LTEtMS0w_17050a4d-ead6-44c6-9601-e6965a14df07">5,190.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNS03LTEtMS0w_23797f1f-7905-4ef5-9fd8-4a0863c47357">2,988.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNS05LTEtMS0w_2ccf9d02-2261-49dd-b06e-a33356793b1f">8,220.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNS0xMS0xLTEtMA_90e9c915-2c2d-420e-a75e-5d83271930ae">5,136.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNS0xMy0xLTEtMA_dd6b8b6a-c895-4322-9cd7-335192561c95">3,084.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, amortization and impairment of acquired intangible assets totaled $<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMjQ5_60298ee3-0957-4884-99dd-acedfde73cbf">98.1</ix:nonFraction> million, compared to $<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMjg2_0de0c9b6-d36d-47de-a060-5992bed3e0f2">71.5</ix:nonFraction> million in the prior year comparative period. For the three months ended March 31, 2021, amortization and impairment of acquired intangible assets reflects a $<ix:nonFraction unitRef="usd" contextRef="i0b53409c6c594be1ab5a8373c301e1e4_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMTA5OTUxMTY0MzYwMw_0764facf-f457-481d-8aa6-cc05f2b0c80c">44.3</ix:nonFraction>&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN). For the three months ended March 31, 2020, we had <ix:nonFraction unitRef="usd" contextRef="i448d8c39b77d40a1a669d30b8086ecce_D20200101-20200331" decimals="-5" format="ixt-sec:numwordsen" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMTA5OTUxMTY0MDY5Mw_59a0ae0c-099f-47f3-b9f2-da2d9ad0cc1d">no</ix:nonFraction> impairment charges.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of March 31, 2021, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of Nightstar Therapeutics plc (NST) and Convergence Pharmaceuticals Holdings Ltd. (Convergence). The majority of the balance relates to our acquisition of NST in June 2019. For additional information on our acquisition of NST, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies of vixotrigine for TGN and DPN and now plan to perform an additional clinical trial of vixotrigine before initiating a Phase 3 study of DPN.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i0b53409c6c594be1ab5a8373c301e1e4_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMTA5OTUxMTY0NTA4Mg_0764facf-f457-481d-8aa6-cc05f2b0c80c">44.3</ix:nonFraction>&#160;million related to vixotrigine for the potential treatment of TGN during the first quarter of 2021. As of March 31, 2021, the carrying value associated with our remaining vixotrigine IPR&amp;D assets was $<ix:nonFraction unitRef="usd" contextRef="icadfd8009ae541009e58a0809c8614f7_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMTA5OTUxMTY1MDE3OQ_92fe3b28-3585-405d-a8c8-206a000923d3">135.1</ix:nonFraction>&#160;million, all of which is related to DPN.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111 and BIIB112</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020 we recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i3ae7d791a7214f65b96db9c10da5155e_D20201001-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMTA5OTUxMTY0MTQ0OQ_5594a477-106b-4b60-9004-c216494c4fba">115.0</ix:nonFraction>&#160;million related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, as a result of third-party manufacturing delays that may impact our timeline for a potential filing of a Biologics License Application (BLA) for regulatory approval by up to one year, and increase the costs associated with advancing BIIB111 through Phase 3 development.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i7cfd20180b5a4c65908b008a1c11151a" continuedAt="i8cf93bd003d0459ba0a10e2e24737b6b"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to monitor the manufacturing issues encountered with BIIB111 and their potential impact on that program's timing. As of March 31, 2021, we have no indication that BIIB111 or BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments, were impaired; however, we will continue to monitor the capabilities of our manufacturing partners and how any additional new manufacturing issues might affect the planned timing of such gene therapy programs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span><span style="color:#679acb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMzQ4Nw_1dad3f0e-ceb8-478b-aa8b-ee359cfbd909" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining nine months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjIzNWY1YjIzNjQ4ZjRhMzliZmUxN2MyMDMwMjEyNWFkL3RhYmxlcmFuZ2U6MjM1ZjViMjM2NDhmNGEzOWJmZTE3YzIwMzAyMTI1YWRfMS0yLTEtMS0w_ab012e9b-5bfe-448c-b62b-3f10e620cff1">165.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjIzNWY1YjIzNjQ4ZjRhMzliZmUxN2MyMDMwMjEyNWFkL3RhYmxlcmFuZ2U6MjM1ZjViMjM2NDhmNGEzOWJmZTE3YzIwMzAyMTI1YWRfMi0yLTEtMS0w_a470a287-6eab-44dd-815e-ffaf09e69b4c">215.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjIzNWY1YjIzNjQ4ZjRhMzliZmUxN2MyMDMwMjEyNWFkL3RhYmxlcmFuZ2U6MjM1ZjViMjM2NDhmNGEzOWJmZTE3YzIwMzAyMTI1YWRfMy0yLTEtMS0w_aa75d99f-db60-4fc1-9478-d9894a3ade95">215.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjIzNWY1YjIzNjQ4ZjRhMzliZmUxN2MyMDMwMjEyNWFkL3RhYmxlcmFuZ2U6MjM1ZjViMjM2NDhmNGEzOWJmZTE3YzIwMzAyMTI1YWRfNC0yLTEtMS0w_c0f66983-98e6-4b3e-959c-98c170fe7906">225.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjIzNWY1YjIzNjQ4ZjRhMzliZmUxN2MyMDMwMjEyNWFkL3RhYmxlcmFuZ2U6MjM1ZjViMjM2NDhmNGEzOWJmZTE3YzIwMzAyMTI1YWRfNS0yLTEtMS0w_93eec573-b044-41c0-b120-f2738683384b">220.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjIzNWY1YjIzNjQ4ZjRhMzliZmUxN2MyMDMwMjEyNWFkL3RhYmxlcmFuZ2U6MjM1ZjViMjM2NDhmNGEzOWJmZTE3YzIwMzAyMTI1YWRfNi0yLTEtMS0w_01e34f3e-1632-46c9-993c-9193ca02f7cc">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMzQ4Mg_80fbe398-05bf-4ad8-9575-8ad84712ad02" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjdjZjYwYmQyNDU1MTQyZGRiODU4Yzk4Y2Q1OGE0MmVmL3RhYmxlcmFuZ2U6N2NmNjBiZDI0NTUxNDJkZGI4NThjOThjZDU4YTQyZWZfMS0yLTEtMS0w_369def82-f395-46f2-9e12-9dda6273f562">5,762.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjdjZjYwYmQyNDU1MTQyZGRiODU4Yzk4Y2Q1OGE0MmVmL3RhYmxlcmFuZ2U6N2NmNjBiZDI0NTUxNDJkZGI4NThjOThjZDU4YTQyZWZfMy0yLTEtMS0w_388389eb-4bae-450b-bef8-3731267eb627">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjdjZjYwYmQyNDU1MTQyZGRiODU4Yzk4Y2Q1OGE0MmVmL3RhYmxlcmFuZ2U6N2NmNjBiZDI0NTUxNDJkZGI4NThjOThjZDU4YTQyZWZfNC0yLTEtMS0w_a0656b6c-f524-407d-9ca6-9e94eb94dc43">5,763.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8cf93bd003d0459ba0a10e2e24737b6b">As of March 31, 2021, we had <ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMzMyNA_7f6c74dc-a72c-476a-b339-f132748fed5e">no</ix:nonFraction> accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_67"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;Fair Value Measurements </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfNDcyOA_87737c16-d4d7-43a2-b669-2be483f95825" continuedAt="ib7f2101292874084b1dfe31254ba1947" escape="true"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfNDcwMQ_0f9715f5-b927-4d5a-801b-4eeefb4e216e" escape="true"><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMy0yLTEtMS0w_4a573008-aa27-4e52-b6be-2bb07dcc70b8">745.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMy00LTEtMS0w_2cd761ee-2eb4-4b4b-ab02-c165ef6190b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMy02LTEtMS0w_7517cd46-b59a-43a1-8f50-6d0a35dde91c">745.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd6a4591290426db41339963f8e38f4_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMy04LTEtMS0w_f6c84075-bd1b-4b9a-8197-a0060643aab5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f2cde76a524b86a12cd39d526d2166_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNS0yLTEtMS0w_2136ded3-795f-4816-b136-0dae016de08f">1,336.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6313636dcf65492fa6f7d60c52fd4998_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNS00LTEtMS0w_e69c7d91-6e26-4900-8b87-f8aa6013e053">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59301081b8cf45a5865f1a2a1ab1ec95_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNS02LTEtMS0w_3b4bbda7-b3e8-4227-8190-8be9800cb1dc">1,336.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8acf8de01b6427b817fce044f2a4e9b_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNS04LTEtMS0w_f7acc68d-d6db-41c9-941a-8f7322029250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a8abceadc64d56a584c21adbd55e3d_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNi0yLTEtMS0w_dbcbfc5d-5786-4956-8268-72bbf4ea267c">677.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7421225a760648fc82e6b371affef596_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNi00LTEtMS0w_f874907b-7fd2-4c95-9379-5dd7992c4810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1eeebc1e9184fccacb6886b20d57c4d_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNi02LTEtMS0w_fed077d3-cdac-4802-8f98-5273f6b29b3f">677.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2198a535d9bb49138f087e2bb335b702_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNi04LTEtMS0w_36318807-da57-40d0-8fd3-9d602336fe07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8b1ee36549403a98b32587e6ec8cd9_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNy0yLTEtMS0w_1bfe83ad-445d-455c-bd1f-0c3dbb17c4b5">128.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic41685432e3248a59842e2de1fb70cff_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNy00LTEtMS0w_cfeed270-3768-4c18-9d7f-b391c33b5781">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468b8e383f3a4aacbb111243c54c712d_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNy02LTEtMS0w_1fc4f101-5bf5-40f1-bf75-ed2e6f5fea79">128.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d0f121a5d2a4cfdab80fd27727da939_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNy04LTEtMS0w_b5b30be5-d332-44ce-9b6c-bfc247ab4b53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOC0yLTEtMS0w_0e81501c-9e1b-4b75-ae3f-f8492c02a9a8">1,442.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOC00LTEtMS0w_ee46334a-a17f-42d7-9a12-d73aa1065222">148.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOC02LTEtMS0w_62be7de6-0ea0-4386-adc7-271681f78f8f">1,294.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd6a4591290426db41339963f8e38f4_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOC04LTEtMS0w_13f1d497-6b1f-48cc-924f-e421f8ee21db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOS0yLTEtMS0w_3872b2e9-aa80-4dde-b068-e78b338b69dd">51.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOS00LTEtMS0w_c4b8eb1a-8d60-42ec-b657-a9d16fc942e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOS02LTEtMS0w_970098cb-5912-4e66-80dc-fc24576c5c64">51.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd6a4591290426db41339963f8e38f4_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOS04LTEtMS0w_ca825b23-6f9a-4899-8af9-f1f44b3bea5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTAtMi0xLTEtMA_bf72a015-c73e-47be-82ad-712054252f66">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTAtNC0xLTEtMA_9d7008fb-de61-42de-96d3-fb9eec9d8f9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTAtNi0xLTEtMA_840512e0-25e1-4566-b7b3-fb6e7b80d2d5">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd6a4591290426db41339963f8e38f4_I20210331" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTAtOC0xLTEtMA_b9e2e7a8-62ac-46f6-88ba-17da996ff724">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTEtMi0xLTEtMA_9f15f07e-3bda-4e95-beed-1112ce3d481c">4,412.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTEtNC0xLTEtMA_b4c68d17-eae5-472b-a5c0-acecc42cf5e2">148.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTEtNi0xLTEtMA_f9bbac98-602b-4fc2-9087-2b859626b645">4,264.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd6a4591290426db41339963f8e38f4_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTEtOC0xLTEtMA_2f08e028-525e-49df-9663-56e04ed8927c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTMtMi0xLTEtMA_b8cc480d-bb25-4456-8a4e-fde914d3e3fc">88.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTMtNC0xLTEtMA_5bbc6079-49b7-4d7d-9022-2263f7d2429e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTMtNi0xLTEtMA_ddc3ced8-957a-4563-b3a7-d3163d3d9f75">88.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd6a4591290426db41339963f8e38f4_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTMtOC0xLTEtMA_3817fb3f-d6a3-4f24-b3d9-fb8cc1bf154e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTQtMi0xLTEtMA_7c593570-7861-45fe-b15c-ed4bf7e89379">226.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTQtNC0xLTEtMA_51ca9122-d27b-4d3c-a377-044da7777734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTQtNi0xLTEtMA_5332ee0a-3be0-433a-a6e5-53393f0bad34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd6a4591290426db41339963f8e38f4_I20210331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTQtOC0xLTEtMA_6bd5f128-af04-4a74-9b50-06b28a18a8d8">226.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTUtMi0xLTEtMA_27b865ef-95e1-48ec-8983-9b9945c26209">314.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTUtNC0xLTEtMA_31d1b75e-2c39-45be-ad72-02b6ff63d1b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTUtNi0xLTEtMA_92935f77-83f0-4114-a477-28b629d48c21">88.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd6a4591290426db41339963f8e38f4_I20210331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTUtOC0xLTEtMA_28deb2e3-d2ca-4ebd-b644-61589daa084c">226.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMy0yLTEtMS0w_4b293fa9-f473-4dd9-a572-bd273132e31a">626.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMy00LTEtMS0w_d5ee7fb5-84b9-4d65-8268-52330f61691a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e71b4af6c648a389be21d19d778315_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMy02LTEtMS0w_12c81901-0d46-4fea-9b29-f1daab7032a6">626.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMy04LTEtMS0w_4b8d2d49-5fd7-4352-9796-fccaab70ed9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i617d7850a63a41f2bc0aa19d2bf5d52c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNS0yLTEtMS0w_4e56a918-dc0c-4656-8bf6-27fa46846c38">1,301.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad7dbe081b0c470ea090b36551d58a20_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNS00LTEtMS0w_6345ba4e-5316-4ee8-b389-2c2073e9c29a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab798705a4e64563b60d02c9ae738dc6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNS02LTEtMS0w_14267835-3147-425c-99f1-484dc63f95cb">1,301.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88067b08ed84a50987e6337ea2943d6_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNS04LTEtMS0w_838e577a-2d2b-48ec-ad46-2003ef1f513c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46e6eb7334b641e596a5a01f6b114522_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNi0yLTEtMS0w_e9a0b7ef-35c5-4948-ab71-47a55ce42862">627.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if689c10ac2da4ce6b808d487a91d2f1c_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNi00LTEtMS0w_7fd19616-7071-49c7-93d1-dc3efbacfddc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i155f305329d64fa484887596324eabf7_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNi02LTEtMS0w_b0609299-d2f4-452b-b750-2050682e117b">627.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie77eae55b0fc4a578615133eff105580_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNi04LTEtMS0w_47db2d88-2dd3-4024-9aba-5287c4a728ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9411092d0e6487aaf6d0cee300ee74a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNy0yLTEtMS0w_bdb984c6-bc7e-4f67-957d-b1fd8604931f">122.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic63fa3a5459c443a84d6bf3111b5ac38_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNy00LTEtMS0w_5f7460a5-7054-4460-a4b9-eee4cb467319">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c75bf61e4794546ad3c50a9595bf109_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNy02LTEtMS0w_135d07c3-ded1-4a5d-ad60-43a589e856cb">122.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9cea109dd524584a788c485533262c6_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNy04LTEtMS0w_306b04f7-f1e3-478d-834c-dd2a77fba586">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOC0yLTEtMS0w_30fcd632-9634-406f-b449-c98873602e9f">1,974.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOC00LTEtMS0w_812f525f-603d-448f-ac2a-ce86f0109b6d">271.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e71b4af6c648a389be21d19d778315_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOC02LTEtMS0w_f21226fc-1b80-414b-9c6f-4dc6f4bda1c7">1,703.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOC04LTEtMS0w_399d1ed6-6fb8-419b-8a7d-1e2e26d16466">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOS0yLTEtMS0w_3642b624-8a17-474d-a131-3b15795681ad">20.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOS00LTEtMS0w_27435e56-50dd-4d65-bb22-c51a422e6a1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e71b4af6c648a389be21d19d778315_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOS02LTEtMS0w_c80569ea-fa10-492d-a62e-82a9af4aea24">20.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOS04LTEtMS0w_30973e1c-aec8-418a-9b8f-cdd416d2d7d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTAtMi0xLTEtMA_8bb5733a-0b38-490d-82d3-b42a31f90160">28.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTAtNC0xLTEtMA_ef3a77a6-2814-4cc1-ae7d-051f820bc72b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e71b4af6c648a389be21d19d778315_I20201231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTAtNi0xLTEtMA_7c604078-5207-4996-ab52-c8e5b680177e">28.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTAtOC0xLTEtMA_8077e804-85b9-41ab-bee5-a019b1e62a31">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTEtMi0xLTEtMA_f424aa1a-051e-432d-9dcb-5b1b4f00bae4">4,700.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTEtNC0xLTEtMA_39bbbc65-8d41-447f-9e26-a8f276c0704d">271.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e71b4af6c648a389be21d19d778315_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTEtNi0xLTEtMA_f3293954-d3b2-4f58-872b-e27d60faef69">4,429.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTEtOC0xLTEtMA_a3aa61dd-8df4-4c38-a96b-15c5adc7b443">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTMtMi0xLTEtMA_ce91da48-2dbc-4fa7-94b5-25cc26c72737">217.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTMtNC0xLTEtMA_6106c7f2-479e-45d8-8e0c-293f57def528">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e71b4af6c648a389be21d19d778315_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTMtNi0xLTEtMA_410407c7-9fc6-4d5a-914e-0184e0cbc974">217.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTMtOC0xLTEtMA_a954a993-e770-40ab-a94e-9a2f482ec6d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTQtMi0xLTEtMA_c24fa44f-f119-4353-bd1f-115a105123ef">259.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTQtNC0xLTEtMA_a22fe9fd-cac7-49a3-ad6f-0382e83931c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e71b4af6c648a389be21d19d778315_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTQtNi0xLTEtMA_b192e06f-7a49-4507-8949-dbf81d39c1c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTQtOC0xLTEtMA_c7eb8e27-64a0-4381-b22c-eb2a2e8c11cb">259.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTUtMi0xLTEtMA_b5c517a9-ca49-432b-a3ba-54b2b03c6938">477.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTUtNC0xLTEtMA_e04e0b0e-e5a5-4809-ae51-d94fc4826462">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e71b4af6c648a389be21d19d778315_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTUtNi0xLTEtMA_f977dd52-dff0-48fc-97d8-4609cc76ca22">217.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTUtOC0xLTEtMA_acd25668-0d1b-4724-843a-f3413d0162bb">259.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been <ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfMjgz_43abe692-55b0-4b23-a9c7-9aecd8c5d6a9">no</ix:nonFraction> material impairments of our assets measured and carried at fair value during the three months ended March 31, 2021. In addition, there have been no changes in valuation techniques during the three months ended March 31, 2021. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo), Denali Therapeutics Inc. (Denali) and Sage Therapeutics, Inc. (Sage) and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. For additional information on our investments in Sangamo, Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Financial Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ib7f2101292874084b1dfe31254ba1947" continuedAt="i3dd7f9274bd049f0bf1d98a3a10ea259"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of March 31, 2021 and December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:24.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligation</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td rowspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU0NjUyN2RiZTY2ZTRlYzliMzQ1Yzk5ZDU5YWE5YTU1L3RhYmxlcmFuZ2U6ZTQ2NTI3ZGJlNjZlNGVjOWIzNDVjOTlkNTlhYTlhNTVfMy0yLTEtMS0w_7c593570-7861-45fe-b15c-ed4bf7e89379">226.0</ix:nonFraction>&#160;</span></td><td rowspan="2" style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ca99bdbf85840cdbe24f4bc565124b6_I20210331" decimals="4" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU0NjUyN2RiZTY2ZTRlYzliMzQ1Yzk5ZDU5YWE5YTU1L3RhYmxlcmFuZ2U6ZTQ2NTI3ZGJlNjZlNGVjOWIzNDVjOTlkNTlhYTlhNTVfMy04LTEtMS0xMDg3Ng_f5316398-9780-4e50-8d3e-f6a1c7f81300">0.77</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3564cbcff5074d8ea8625d2d79f78da3_I20210331" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU0NjUyN2RiZTY2ZTRlYzliMzQ1Yzk5ZDU5YWE5YTU1L3RhYmxlcmFuZ2U6ZTQ2NTI3ZGJlNjZlNGVjOWIzNDVjOTlkNTlhYTlhNTVfMy0xMC0xLTEtMA_8d806991-7cd6-4225-8343-4abe659a1c6d">0.77</ix:nonFraction>%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 to 2027</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligation</span></td><td colspan="3" style="padding:0 1pt"></td><td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU0NjUyN2RiZTY2ZTRlYzliMzQ1Yzk5ZDU5YWE5YTU1L3RhYmxlcmFuZ2U6ZTQ2NTI3ZGJlNjZlNGVjOWIzNDVjOTlkNTlhYTlhNTVfOS0yLTEtMS00MTM4_c24fa44f-f119-4353-bd1f-115a105123ef">259.8</ix:nonFraction>&#160;</span></td><td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8a4ae2d553645bc9749c80ed7469758_I20201231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU0NjUyN2RiZTY2ZTRlYzliMzQ1Yzk5ZDU5YWE5YTU1L3RhYmxlcmFuZ2U6ZTQ2NTI3ZGJlNjZlNGVjOWIzNDVjOTlkNTlhYTlhNTVfOS04LTEtMS0xMDg3OA_1e257afc-9f23-4c0c-8251-0b96d307b6cf">0.60</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9a6326f3d6b477c8eb27a1cad5d7cf7_I20201231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU0NjUyN2RiZTY2ZTRlYzliMzQ1Yzk5ZDU5YWE5YTU1L3RhYmxlcmFuZ2U6ZTQ2NTI3ZGJlNjZlNGVjOWIzNDVjOTlkNTlhYTlhNTVfOS0xMC0xLTEtMTA4ODA_fcd35811-baaf-4d9f-99fd-b8098f34af8e">0.60</ix:nonFraction>%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 to 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from <ix:nonFraction unitRef="number" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="3" name="biib:TechnologicalAndRegulatorySuccessProbability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfMTA5OTUxMTYzODI0NQ_b2701325-5fb2-4cc8-ac7c-222a70c27c7a">21.7</ix:nonFraction>% to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfNDcyNg_24d24969-db39-4638-be01-3de3b29135ff" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169c8b70cdd149968938de9db5a8c380_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfMy0yLTEtMS0w_832e3a49-29a3-4b23-80af-f2f339170602">1,044.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169c8b70cdd149968938de9db5a8c380_I20210331" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfMy00LTEtMS0w_8a8d874c-a0c8-4f9b-ba09-aaaae86f54cc">998.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136e48c6cc4844139e58cca3660d4fcc_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfMy02LTEtMS0w_b6311300-2e27-44ea-90cc-1e7d533a04c3">1,054.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136e48c6cc4844139e58cca3660d4fcc_I20201231" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfMy04LTEtMS0w_2f303628-d52f-4e22-b684-67e0e8349565">997.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f7b949b4c740929fa619fc13968293_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNC0yLTEtMS0w_4f6e4062-0a9f-45a5-b9b4-4ae79ff2e73a">1,940.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f7b949b4c740929fa619fc13968293_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNC00LTEtMS0w_e7c76e46-bc9c-4277-9bbe-57dc605d435e">1,741.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef7cceb1dba455a9aa7de4d2a40176f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNC02LTEtMS0w_a611ac7f-ad40-46ba-be99-598e0f02193f">2,003.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef7cceb1dba455a9aa7de4d2a40176f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNC04LTEtMS0w_87ac560d-0e82-481a-a9ac-baf3b97e8316">1,741.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28131b2b3d0447c08a69cc0b6f4781f6_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNS0yLTEtMS0w_fefd646e-14ed-4450-8b91-6bb675b918ad">1,455.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28131b2b3d0447c08a69cc0b6f4781f6_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNS00LTEtMS0w_e77d603b-009d-4e4c-8a92-a27a0901b634">1,491.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329e0692712544d2a17055bb01361858_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNS02LTEtMS0w_2bae44aa-1bb0-45b5-8273-58f95afcf258">1,557.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329e0692712544d2a17055bb01361858_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNS04LTEtMS0w_62a77862-fa19-4149-a2eb-88af0caa6d63">1,491.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ec6c5ff89547ff8dc1226630ef60ef_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNi0yLTEtMS0w_6bf8cf42-0da2-40fa-a01f-e203ca697954">1,394.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ec6c5ff89547ff8dc1226630ef60ef_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNi00LTEtMS0w_0f7575ac-7974-4472-a9d1-3f84ba76540a">1,099.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6fa8a83ea8344a9ab2cdaab6b6079d7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNi02LTEtMS0w_b81e899d-e2de-4f54-8cbe-eef28cd59ce6">2,365.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6fa8a83ea8344a9ab2cdaab6b6079d7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNi04LTEtMS0w_51a65d1e-6b82-401b-b606-3ea9165b3039">1,723.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15e963a15e44c2b8d3baeb9b65f28b2_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNy0yLTEtMS0w_6bf02d30-c97c-446e-a73d-cb6423f2c99d">1,369.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15e963a15e44c2b8d3baeb9b65f28b2_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNy00LTEtMS0w_8b5a2afa-fff3-41da-b884-fe73edd7249b">1,472.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i690df7ed80534227b8dd81f1affbc47a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNy02LTEtMS0w_a7a0c66f-e1da-4224-a07f-982f03f04882">1,536.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i690df7ed80534227b8dd81f1affbc47a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNy04LTEtMS0w_61b82b25-b966-4fff-96d0-a1a2a0d1adcf">1,472.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1bb2f05a734c40a4736b73629c222f_I20210331" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC0yLTEtMS0zNjE0_7ecfd16a-de8f-4858-b4ef-42d0b0ab47c5">654.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1bb2f05a734c40a4736b73629c222f_I20210331" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC00LTEtMS0zNjIw_4bf895aa-6ebc-4982-9905-ebb6c8e00ab2">463.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1fdd327c9a54a7b94459dc7adec7e4c_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC02LTEtMS0zNjE3_2a3309d5-7c64-4b74-a337-ff0fef092761">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1fdd327c9a54a7b94459dc7adec7e4c_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC04LTEtMS0zNjIz_0525bfa1-015b-4f98-87bc-2bd51a101e04">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC0yLTEtMS0w_23f8988f-9fb7-422c-91d3-7ac2940ffdfe">7,859.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC00LTEtMS0w_d8f79ca0-4934-44c1-be07-adb7263badba">7,267.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC02LTEtMS0w_ad393e5e-5146-4b53-8a32-c14123de74c8">8,515.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC04LTEtMS0w_01777bdd-c787-47d6-b2fb-0377894f1e0c">7,426.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2021 we completed a private offer to exchange (Exchange Offer) our <ix:nonFraction unitRef="number" contextRef="i21ec6c5ff89547ff8dc1226630ef60ef_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfNzY5NjU4MTQwNTcxMQ_3fd2cf32-fabc-46a3-974d-513d8c942957">5.200</ix:nonFraction>% Senior Notes due September 15, 2045 (2045 Senior Notes), whereby approximately $<ix:nonFraction unitRef="usd" contextRef="i9541283653d242f48d85e9890e9c2777_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="biib:LongTermDebtExchangedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfMTA5OTUxMTYzNjU1MQ_4759265c-6895-40fc-a3f0-3182eb79cffb">624.6</ix:nonFraction>&#160;million of our 2045 Senior Notes were exchanged for approximately $<ix:nonFraction unitRef="usd" contextRef="i92e65fe683a2421f94f2dc6385f162f6_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="biib:LongTermDebtExchangedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfMTA5OTUxMTYzNjU2Nw_4f1a8b7d-d927-47ce-8986-04c9c8f901fe">700.7</ix:nonFraction>&#160;million of a new series of <ix:nonFraction unitRef="number" contextRef="i7f1bb2f05a734c40a4736b73629c222f_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfNzY5NjU4MTQwNTcwMw_1930a398-b9f8-45df-bda8-4a07f99a5999">3.250</ix:nonFraction>% Senior Notes due February 15, 2051 (2051 Senior Notes). For additional information on our Exchange Offer, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes issued on April 30, 2020 and September 15, 2015, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i3dd7f9274bd049f0bf1d98a3a10ea259"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. <ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfNDcxNg_09e4c13c-f61f-4202-aa65-28494d614aea" continuedAt="ibd928dba73e34a019ba40b41e8ab7e52" escape="true">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</ix:nonNumeric></span></div><div style="margin-bottom:5pt"><ix:continuation id="ibd928dba73e34a019ba40b41e8ab7e52"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjIxNzVkNjIzZTgzNzQzMjM5OTZkZTVjYWY5ODcxOWRjL3RhYmxlcmFuZ2U6MjE3NWQ2MjNlODM3NDMyMzk5NmRlNWNhZjk4NzE5ZGNfMi0yLTEtMS0w_c24fa44f-f119-4353-bd1f-115a105123ef">259.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c3b6e1aa1a4f37a556ea55e078b7e6_I20191231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjIxNzVkNjIzZTgzNzQzMjM5OTZkZTVjYWY5ODcxOWRjL3RhYmxlcmFuZ2U6MjE3NWQ2MjNlODM3NDMyMzk5NmRlNWNhZjk4NzE5ZGNfMi00LTEtMS0w_f6a803b7-c283-4cae-9355-5cf8523aca59">346.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjIxNzVkNjIzZTgzNzQzMjM5OTZkZTVjYWY5ODcxOWRjL3RhYmxlcmFuZ2U6MjE3NWQ2MjNlODM3NDMyMzk5NmRlNWNhZjk4NzE5ZGNfMy0yLTEtMS0w_e92db03c-fb17-4430-a844-3458ac8dcd01">33.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjIxNzVkNjIzZTgzNzQzMjM5OTZkZTVjYWY5ODcxOWRjL3RhYmxlcmFuZ2U6MjE3NWQ2MjNlODM3NDMyMzk5NmRlNWNhZjk4NzE5ZGNfMy00LTEtMS0w_be33258f-2018-4160-9d9a-05b5c6196572">4.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjIxNzVkNjIzZTgzNzQzMjM5OTZkZTVjYWY5ODcxOWRjL3RhYmxlcmFuZ2U6MjE3NWQ2MjNlODM3NDMyMzk5NmRlNWNhZjk4NzE5ZGNfNS0yLTEtMS0w_6aa28e0b-d1da-43fa-aab9-d7b360057da0">226.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a615c71cd74bfaab31f5afbd166043_I20200331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjIxNzVkNjIzZTgzNzQzMjM5OTZkZTVjYWY5ODcxOWRjL3RhYmxlcmFuZ2U6MjE3NWQ2MjNlODM3NDMyMzk5NmRlNWNhZjk4NzE5ZGNfNS00LTEtMS0w_33e7f624-b73d-4b16-bc95-68895fc8a6dd">341.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, approximately $<ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfMzYwMQ_9e918291-6c4d-4272-88f8-9e243585f446">226.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfMzYwOA_abcf2bf1-8d00-4775-a696-fc6b46f37dbc">110.3</ix:nonFraction> million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expense and other.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div></ix:continuation><div id="i6fe84bc7e101462ea41fc07416803961_73"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;Financial Instruments </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMzc5MA_d3d4cfe2-deea-40da-9840-4196c757bf99" continuedAt="i0640bbb4a46b434fa4fc149f7148a107" escape="true"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMzc5Mw_7c42e4d6-c537-47c5-88eb-18507ad00828" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097294e10f804864872cedb1009ca2d6_I20210331" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfMS0yLTEtMS0w_f2ad446e-7162-437d-ad5b-6e8255be250a">50.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06cbd4baf6c64cbb882e64d7af251fd7_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfMS00LTEtMS0w_d6f3c26c-3846-4b49-a619-ec162f4a1362">61.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i662a2807e7f441dea26090ecaa66ff73_I20210331" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfMi0yLTEtMS0w_c34d5da0-e18e-4edf-bfdc-c01991018457">93.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e9534615d4d4fa08ea2113342a064bb_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfMi00LTEtMS0w_f847042d-e93f-47b9-8721-49376e4f8e96">37.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6265a293284648a6901f1c195af48f3a_I20210331" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfMy0yLTEtMS0w_be4636e2-0533-4b75-a9c8-d45a41be48fb">541.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a442e099ce48c194c0139fdf69655e_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfMy00LTEtMS0w_71f33935-5038-4f4a-b604-77affad45922">505.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b51b2d00bc5437689fb1ac29bc46a56_I20210331" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfNC0yLTEtMS0w_a7ba8ea9-01a7-40ca-a8db-d791e003ccad">59.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2cdebf2e34461bb476ad2299cb6ae6_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfNC00LTEtMS0w_e98db7e0-8f94-4c57-ab33-99818ac94c2a">23.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfNS0yLTEtMS0w_318b03f7-644e-4924-bad0-1fe2ecadbf41">745.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfNS00LTEtMS0w_88048ef2-1d65-4e6c-bbdb-cf16a2dafac6">626.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i0640bbb4a46b434fa4fc149f7148a107" continuedAt="ibc1604e78b104df38dcaf7a05f1e43f9"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. <ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMzgxMw_f514b483-b45d-4974-aa28-6d1c1ac695d8" continuedAt="ie157ce2620bb498cbef6bc14b0d63eb5" escape="true">The following tables summarize our marketable debt and equity securities, classified as available for sale:</ix:nonNumeric></span></div><ix:continuation id="ie157ce2620bb498cbef6bc14b0d63eb5"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if058af87c70046e2aadf2969cb8ec339_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMy0yLTEtMS0w_1d621c74-fbce-4a21-9dd4-ee91ddd54beb">979.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if058af87c70046e2aadf2969cb8ec339_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMy00LTEtMS0w_0bd4f623-b625-4f1f-b650-a76338567bb2">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if058af87c70046e2aadf2969cb8ec339_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMy02LTEtMS0w_b44b9e94-1028-4b65-b8a8-04ec54618a79">0.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if058af87c70046e2aadf2969cb8ec339_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMy04LTEtMS0w_5aa70a07-52b1-4a2a-b664-99251b6b756a">979.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieede5634af6341efa55cd03c69ce9e7b_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNC0yLTEtMS0w_3299a3bd-5e9a-4453-a199-f9efd862736e">356.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieede5634af6341efa55cd03c69ce9e7b_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNC00LTEtMS0w_6f9180ab-7453-452d-9c39-fe5b841e00dd">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieede5634af6341efa55cd03c69ce9e7b_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNC02LTEtMS0w_000f3c6a-550e-4b1e-8265-1a4ed84ccc9b">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieede5634af6341efa55cd03c69ce9e7b_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNC04LTEtMS0w_f0af7c0c-82a1-4ef7-af92-db8cfb2b42be">356.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f367843cd4a459aa904731e38a571f0_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNi0yLTEtMS0w_5b18c0dc-db8d-42d2-9e3a-6264b3bedb9a">340.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f367843cd4a459aa904731e38a571f0_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNi00LTEtMS0w_85c2f1bb-4c93-4648-9f60-c1cd23efbdec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f367843cd4a459aa904731e38a571f0_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNi02LTEtMS0w_ad2fbe7a-b284-4320-9aca-df8c343b7102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f367843cd4a459aa904731e38a571f0_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNi04LTEtMS0w_ab118fcd-fbf1-4c46-92c5-442f329f8c8b">340.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34e8173e884133b5b5df3663402806_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNy0yLTEtMS0w_5df604ca-323f-49e8-92d6-993ccdde2bd0">336.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34e8173e884133b5b5df3663402806_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNy00LTEtMS0w_f5a164f7-cf30-461c-ad55-e1db7cdde848">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34e8173e884133b5b5df3663402806_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNy02LTEtMS0w_7f2e5d0f-af7b-4c61-9427-01008bf0a101">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34e8173e884133b5b5df3663402806_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNy04LTEtMS0w_7f293a25-d5a5-4e12-bf7f-56ecc8c7185f">336.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b6fdc993a44cf79b869e8688a3062f_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfOS0yLTEtMS0w_fbd89e62-8fae-4970-8a6a-d32eaa77c72d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b6fdc993a44cf79b869e8688a3062f_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfOS00LTEtMS0w_cc147d5a-15d8-4f8d-a3f3-3bb1bf2c0896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b6fdc993a44cf79b869e8688a3062f_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfOS02LTEtMS0w_764586af-789c-49b7-ba97-0ab8fa949783">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b6fdc993a44cf79b869e8688a3062f_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfOS04LTEtMS0w_012fcee9-bb39-4b5d-8e10-2c0c615d744c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b3875a8852c4f49b9e644e0c9158374_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTAtMi0xLTEtMA_f9601292-397f-41c3-bee5-c165094f2068">128.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b3875a8852c4f49b9e644e0c9158374_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTAtNC0xLTEtMA_49f391a4-6189-4d71-90a3-b84ac3ca2f9f">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b3875a8852c4f49b9e644e0c9158374_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTAtNi0xLTEtMA_39c5fa9f-3a35-474a-bf11-7e30c6c950a0">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b3875a8852c4f49b9e644e0c9158374_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTAtOC0xLTEtMA_c05008a4-9a59-4b31-b21f-2edff3a9d057">128.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTEtMi0xLTEtMA_00c40e3f-0e34-40df-9cb4-01ff15e400ef">2,140.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTEtNC0xLTEtMA_b7aae3e9-bc21-4ccf-bac4-d7660d501a2a">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTEtNi0xLTEtMA_52b0ac6c-9f05-4047-a06a-9048387470d5">0.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTEtOC0xLTEtMA_6ecbef5f-6bfa-4efc-9516-905be99193bd">2,141.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4bb284119504ac8a1c8c4175099a908_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTItMi0xLTEtMA_3e985324-c37b-4f0b-9ea3-4d4aad7c958a">1,168.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4bb284119504ac8a1c8c4175099a908_I20210331" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTItNC0xLTEtMA_f7cb91d5-d8ba-4440-95f5-60bbc3efd3a7">351.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4bb284119504ac8a1c8c4175099a908_I20210331" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTItNi0xLTEtMA_bf2b7809-2b30-4713-a787-ec1512f210d5">77.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4bb284119504ac8a1c8c4175099a908_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTItOC0xLTEtMA_7319b5c7-de14-459c-a063-d23e7d0c9bc1">1,442.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3553a83d95842ccbe6c7675c97c9f6d_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTctMi0xLTEtMTA5MTE_aabfe612-ac47-4855-a3b5-e7228d666fe2">1,168.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3553a83d95842ccbe6c7675c97c9f6d_I20210331" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTctNC0xLTEtMTA5MTE_e896dddb-2b14-409d-9fb9-291e29d22376">351.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3553a83d95842ccbe6c7675c97c9f6d_I20210331" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTctNi0xLTEtMTA5MTE_33ee7504-7a9b-4ece-a9a0-77f0a72425be">77.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3553a83d95842ccbe6c7675c97c9f6d_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTctOC0xLTEtMTA5MTE_f706453a-a44a-46c9-abbc-a98e9bc0bab0">1,442.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ada1e061ed4917bbce94eeb6b5933f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMy0yLTEtMS0w_bd2a9309-b614-45ad-988a-a32607070562">897.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ada1e061ed4917bbce94eeb6b5933f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMy00LTEtMS0w_eeb9b5eb-61ea-48bc-880f-98a11ab7cb55">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2ada1e061ed4917bbce94eeb6b5933f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMy02LTEtMS0w_e554b425-fa9f-4061-a4e4-8d7bac1508b9">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ada1e061ed4917bbce94eeb6b5933f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMy04LTEtMS0w_2b4969dc-5509-405d-88da-773c86467d7e">898.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2692b6a2c3a470caa2bb0ed4268a1d1_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNC0yLTEtMS0w_6795d90a-3fb4-4345-9ab1-1dbb95ac4945">402.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2692b6a2c3a470caa2bb0ed4268a1d1_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNC00LTEtMS0w_0c0b6b11-fadd-4d50-b485-3af47550805f">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2692b6a2c3a470caa2bb0ed4268a1d1_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNC02LTEtMS0w_b912860a-9a44-4033-b832-258ae815611c">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2692b6a2c3a470caa2bb0ed4268a1d1_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNC04LTEtMS0w_c4add659-dd2d-425a-bdb0-f1bf39b54320">403.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9431c0a0744979af0821b912532c37_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNi0yLTEtMS0w_8a8998a0-c177-4b0d-ac77-793000810ec5">380.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9431c0a0744979af0821b912532c37_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNi00LTEtMS0w_dd3f7ccf-93df-4be8-bf67-770c93fa357d">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9431c0a0744979af0821b912532c37_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNi02LTEtMS0w_a4375479-e952-4675-a6a8-f925c07080c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9431c0a0744979af0821b912532c37_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNi04LTEtMS0w_18a75e54-c5d6-4aa7-81b8-457bc7f30353">380.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56be570639ec418f834fc04f5746b4d7_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNy0yLTEtMS0w_d41237d3-5fdf-45b4-822b-6759ad003c61">245.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56be570639ec418f834fc04f5746b4d7_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNy00LTEtMS0w_09e9202d-0d6d-405f-9d7a-8bcb129b9f71">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56be570639ec418f834fc04f5746b4d7_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNy02LTEtMS0w_74fc4633-0bf0-46ef-91f3-302f2bc91059">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56be570639ec418f834fc04f5746b4d7_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNy04LTEtMS0w_7c49964e-493d-49e1-84c0-2dcb6cb5a072">246.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b995470fa14c99ae213810dba2dae0_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfOS0yLTEtMS0w_76d27b2b-0a4f-4052-a8b8-98cb95c6b01f">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b995470fa14c99ae213810dba2dae0_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfOS00LTEtMS0w_38a88b32-abc1-4b0d-9778-babba43b4915">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b995470fa14c99ae213810dba2dae0_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfOS02LTEtMS0w_2cfe24de-6dec-41b3-846d-18b13c2b14d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b995470fa14c99ae213810dba2dae0_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfOS04LTEtMS0w_ccacdb51-107d-4b9e-85d4-4bc7ae1963e6">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85140128d15a442892fcc26f8abda120_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTAtMi0xLTEtMA_1d342ecc-64d1-4337-92cf-7163462cf854">122.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85140128d15a442892fcc26f8abda120_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTAtNC0xLTEtMA_017ff718-dcde-4ac1-96c1-10796faee370">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85140128d15a442892fcc26f8abda120_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTAtNi0xLTEtMA_c7dbddf5-f9eb-410d-af59-7ab235774aa9">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85140128d15a442892fcc26f8abda120_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTAtOC0xLTEtMA_fd70a573-ec8c-4900-ba73-503d5a1821e8">122.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTEtMi0xLTEtMA_69489ce2-39a0-4e2c-8a12-3178a763cb1a">2,049.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTEtNC0xLTEtMA_91043b6e-4c3c-4d0a-a6a5-197181ec9f4d">2.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTEtNi0xLTEtMA_f0535d9c-91c1-4b0f-af0a-c6916c5b4f02">0.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTEtOC0xLTEtMA_d7a5bff9-9dad-473c-8c8a-2eefd41a0689">2,051.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0570f45a09344ee88a9bbbf9b677aef_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTUtMi0xLTEtNTMz_66e7fac7-8317-4b10-9c7f-42eb51d14b38">70.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0570f45a09344ee88a9bbbf9b677aef_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTUtNC0xLTEtNTMz_4ada50a7-01f7-45aa-9426-e79c5730af46">15.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0570f45a09344ee88a9bbbf9b677aef_I20201231" decimals="-5" format="ixt:zerodash" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTUtNi0xLTEtNTMz_d3f29989-678e-40d2-b8c7-2c6845f69adf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0570f45a09344ee88a9bbbf9b677aef_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTUtOC0xLTEtMTA5MTQ_27928dcd-51ee-4ed7-ab2e-c7f3bdd25770">86.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17bad89df3f34651a5f6e776704460f7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTItMi0xLTEtMA_95246c62-8eae-4f61-9abe-d7ed0e533547">1,168.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17bad89df3f34651a5f6e776704460f7_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTItNC0xLTEtMA_2bf252b9-251d-4999-aec7-af0a4a1d0388">733.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17bad89df3f34651a5f6e776704460f7_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTItNi0xLTEtMA_202ac294-631f-4dd8-a2b9-bc7b4a7ada54">14.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17bad89df3f34651a5f6e776704460f7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTItOC0xLTEtMA_d16c71be-6fa2-44a9-af86-51d593ce4922">1,887.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTctMi0xLTEtMTA5MTY_dd68f05f-4898-4dad-a1ea-cb7aa1643698">1,239.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTctNC0xLTEtMTA5MTY_360407a0-8367-45f4-b46c-8cde418609fa">749.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTctNi0xLTEtMTA5MTY_bab75cc5-d579-4d3d-8daa-e67bb34c848f">14.9</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTctOC0xLTEtMTA5MTY_a9cac46f-d09a-4306-a83f-a799db19925b">1,974.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ibc1604e78b104df38dcaf7a05f1e43f9" continuedAt="iec43df5bab714edba639e57edd83ad31"><div style="margin-top:12pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMzc4Nw_55912244-9b56-45c8-9e95-1139f8c0b216" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMi0yLTEtMS0w_31a2e07d-20e2-4ee9-96e6-bf32772b8d92">1,320.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMi00LTEtMS0w_4b7d0d20-9754-4c82-82c5-8f0e8e32131f">1,320.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMi02LTEtMS0w_5a9f11e1-51ba-487e-86fc-a3d4b28ed187">1,278.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMi04LTEtMS0w_75d59d1b-28ba-497f-b37b-f863a99a1026">1,278.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMy0yLTEtMS0w_2020e620-edd4-42b0-ba5a-3fd98432e4ea">781.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMy00LTEtMS0w_70e7821c-b432-407e-b71f-82a422ae3a0d">780.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMy02LTEtMS0w_ce3868f1-dabc-4170-862f-ec41a9f2e2d2">722.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMy04LTEtMS0w_9792e7b1-3ab1-42ab-8723-e02e44d0f1ce">721.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNC0yLTEtMS0w_6b974a88-b8f2-4f00-9d7e-b5b8ae8180c2">40.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNC00LTEtMS0w_ab54054a-d1b1-45f0-89ba-4576d4744838">40.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNC02LTEtMS0w_153be251-a354-4584-81bf-0a3970594ba7">49.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNC04LTEtMS0w_eda888e1-9902-496b-aab7-579481e09de4">49.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNS0yLTEtMS0w_eeca888b-2de1-415d-beb1-b1b8977bfa57">2,141.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNS00LTEtMS0w_3d747350-07ce-4c37-a92c-2e265f061592">2,140.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNS02LTEtMS0w_54eea19a-17ac-4c0f-9302-238ec8cee529">2,051.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNS04LTEtMS0w_9c67592d-dec6-4913-a4c9-d02672feb185">2,049.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities available-for-sale as of March 31, 2021 and December 31, 2020, was approximately <ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" format="ixt-sec:durmonth" name="biib:AverageMaturityOfMarketableSecurities" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfOTkw_0a2133ec-6553-43cb-b8e7-789a804e6de0">12</ix:nonNumeric> months and <ix:nonNumeric contextRef="iff71e9fbc56d4559bdd9a623ccc89b89_D20200101-20200630" format="ixt-sec:durmonth" name="biib:AverageMaturityOfMarketableSecurities" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTAwNA_a48298ba-34f9-4460-b5fe-6a123bec486d">11</ix:nonNumeric> months, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMzc5OA_f02dab0b-3ede-41e8-9fd2-41fb4da065d4" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmZiOWM2MWEwMGJhNjRkZWM4Y2JmZTg5Y2UzYmYwMjZmL3RhYmxlcmFuZ2U6ZmI5YzYxYTAwYmE2NGRlYzhjYmZlODljZTNiZjAyNmZfMi0yLTEtMS0w_bf90e444-49b0-4ef9-a34a-10dded9247e4">819.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmZiOWM2MWEwMGJhNjRkZWM4Y2JmZTg5Y2UzYmYwMjZmL3RhYmxlcmFuZ2U6ZmI5YzYxYTAwYmE2NGRlYzhjYmZlODljZTNiZjAyNmZfMi00LTEtMS0w_50dd5911-513d-4d37-9989-5e370d4a958a">2,389.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmZiOWM2MWEwMGJhNjRkZWM4Y2JmZTg5Y2UzYmYwMjZmL3RhYmxlcmFuZ2U6ZmI5YzYxYTAwYmE2NGRlYzhjYmZlODljZTNiZjAyNmZfMy0yLTEtMS0w_bc03006b-f0d3-4310-8fe6-0839dd923a39">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmZiOWM2MWEwMGJhNjRkZWM4Y2JmZTg5Y2UzYmYwMjZmL3RhYmxlcmFuZ2U6ZmI5YzYxYTAwYmE2NGRlYzhjYmZlODljZTNiZjAyNmZfMy00LTEtMS0w_22e9ca3e-94e5-4307-b504-dff8257f20f8">5.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmZiOWM2MWEwMGJhNjRkZWM4Y2JmZTg5Y2UzYmYwMjZmL3RhYmxlcmFuZ2U6ZmI5YzYxYTAwYmE2NGRlYzhjYmZlODljZTNiZjAyNmZfNC0yLTEtMS0w_4039e056-9be6-42fd-a695-882e5a768ba9">0.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmZiOWM2MWEwMGJhNjRkZWM4Y2JmZTg5Y2UzYmYwMjZmL3RhYmxlcmFuZ2U6ZmI5YzYxYTAwYmE2NGRlYzhjYmZlODljZTNiZjAyNmZfNC00LTEtMS0w_9716b4ac-426e-41f1-a5bc-87c23242d711">19.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, our strategic investment portfolio was comprised of investments totaling $<ix:nonFraction unitRef="usd" contextRef="i0a283fbf212a4481af4e7343abe77f50_I20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:StrategicInvestmentPortfolio" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTMyMA_2ab4fbb5-2cef-4616-9c31-db5a1e38913a">1,493.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0ee9e38341534af88bad1e7379c5795d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:StrategicInvestmentPortfolio" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTMyNw_a464151b-ce35-4ef9-8acd-6a15587d7c38">2,024.6</ix:nonFraction> million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio for the three months ended March 31, 2021, was primarily due to decreases in the fair values of our investments in Ionis Pharmaceuticals Inc. (Ionis), Sage, Denali and Sangamo common stock.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage. In connection with the closing of this transaction in December 2020 we purchased $<ix:nonFraction unitRef="usd" contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTA5OTUxMTYzMzc4OA_44734746-f102-471a-b5fc-5b19f1b4dfe7">650.0</ix:nonFraction>&#160;million of Sage common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTA5OTUxMTYzMzc5NA_2b6bc054-4a8e-4ac6-9909-ae30110511b2">6.2</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130" decimals="INF" name="biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTA5OTUxMTYzMzgwMA_b12f352d-cd88-455b-a33b-531af218ab60">104.14</ix:nonFraction> per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sage common stock and a dividend yield of <ix:nonFraction unitRef="number" contextRef="i131a6d5dd4084afa8625aea4291a03a4_D20210101-20210331" decimals="-6" format="ixt-sec:numwordsen" name="biib:DividendYieldPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTA5OTUxMTYzMjc1OA_a5b47e99-748b-49e8-bc37-e2dc6d1b2f14">zero</ix:nonFraction> based upon the fact that Sage and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020 we entered into a collaboration and license agreement with Denali. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="iec43df5bab714edba639e57edd83ad31"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this collaboration we purchased approximately $<ix:nonFraction unitRef="usd" contextRef="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTY0OTI2NzQ0ODI2OQ_62248d21-a735-43bf-906b-e6cc0b9f72dd">465.0</ix:nonFraction>&#160;million of Denali common stock in September 2020, or approximately <ix:nonFraction unitRef="shares" contextRef="ibed8defa2fe84947a4f4b459fdd0d10f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="biib:Investmentincommonstocksharespurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTY0OTI2NzQ0ODI4MQ_18c12515-4851-4a41-855c-b328a2ab72fb">13</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331" decimals="2" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTY0OTI2NzQ0ODI4Nw_27ed4e1e-2dc1-4bda-a294-4de8d482a33f">34.94</ix:nonFraction> per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali's common stock and a dividend yield of <ix:nonFraction unitRef="number" contextRef="id355e63804de46f2b00142ad2e9766d4_D20210101-20210331" decimals="-6" format="ixt-sec:numwordsen" name="biib:DividendYieldPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMjQyNA_5d9f02ed-23b2-47be-b724-6402acc447d6">zero</ix:nonFraction> based upon the fact that Denali and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Denali, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased $<ix:nonFraction unitRef="usd" contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTY0OTI2NzQ0ODQ2NA_666d324c-34de-48bc-b5f1-eb12ed63bfbf">225.0</ix:nonFraction> million of Sangamo common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229" decimals="-6" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTY0OTI2NzQ0ODQ3MA_e5cfced4-ad82-4831-9b41-3a838b50c201">24</ix:nonFraction> million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229" decimals="2" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTY0OTI2NzQ0ODQ3Ng_529e6695-cf4a-4a66-86a2-e44f3f6796c0">9.21</ix:nonFraction> per share, which are subject to transfer restrictions.&#160;This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo&#8217;s common stock and a dividend yield of <ix:nonFraction unitRef="number" contextRef="i7d61eda3c47a477a87953bd9435f3fdc_D20200401-20200430" decimals="-6" format="ixt-sec:numwordsen" name="biib:DividendYieldPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMzUxNw_92a0a6a9-5c0e-46f2-a6d9-7447e2b2762e">zero</ix:nonFraction> based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sangamo, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to these condensed consolidated financial statements.</span></div></ix:continuation><div id="i6fe84bc7e101462ea41fc07416803961_79"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;Derivative Instruments </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjk4Ng_bf084455-79da-47f0-bfd0-e0719571e36c" continuedAt="ifce4ffdea84844f0bda98bcebe8ebc97" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenue and operating expense.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts in effect as of March 31, 2021 and December 31, 2020, had durations of <ix:nonNumeric contextRef="ia617f0f0d1234327a3119ea448c3da76_D20210101-20210331" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjI5_6a0fe9ff-8c3d-4222-9a91-1a740a600916">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i9113178df6744dbebe8d536cedbb476d_D20210101-20210331" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjM1_3baba6d2-11b4-4046-b32c-acc85b0068b4">21</ix:nonNumeric> months and <ix:nonNumeric contextRef="ia0888eb887324fbcb06a48bb48e3d178_D20200101-20200630" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjQy_9926c7e7-31e4-4603-bff0-137ad57e5031">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i6ef2ea3f8af4435f8e0f9aeefee13306_D20200101-20200630" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjQ4_0b605b3a-bce6-4885-8e80-22ff5f620769">24</ix:nonNumeric> months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ifce4ffdea84844f0bda98bcebe8ebc97" continuedAt="i05fedd375daa4dda893b9850a131a9af"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjk1MQ_bd438366-5237-4280-bc25-e79ae194e17c" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied82434791db403c955ea793bffb2f0e_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfMi0yLTEtMS0w_1299224a-4078-413e-9079-72150edfbfa4">2,657.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9c72eafd68c4e398efd063c308f2dbd_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfMi00LTEtMS0w_2a188d0b-a8ce-430d-b417-a1054e3584fb">2,979.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i536f8ba047234c319b7406ff767147dd_I20210331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfMy0yLTEtMS0w_3cb39643-7cc2-4936-a34d-ab530f85ed8e">190.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb70d5c3848d414f9ce893ad215d4dec_I20201231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfMy00LTEtMS0w_569f025c-bfd6-4205-b885-9e72e1fe3e98">250.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b2de87f30d4c6f8b03613d9c2807d2_I20210331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNC0yLTEtMS0w_40fed773-f717-4b3f-b5fe-60d432ad6071">159.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07af47860d104f6d8ed73f6a89548b2b_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNC00LTEtMS0w_02e07b8b-776f-4c33-b88b-0b848ab51dbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40059c26d0bb4c04a23a67aef6915a45_I20210331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNS0yLTEtMS0w_66ee5187-61cb-44d4-ac7c-bbd3766c392b">98.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa2654f256764c58a2843f3f977d1dfa_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNS00LTEtMS0w_5c7e239e-fade-43f4-91d9-c13200ec41a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0457c0290322402daedccdba35db7c6d_I20210331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNi0yLTEtMS0w_c47640f3-30f5-4aa4-a595-ceb637ac528d">80.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib58b6d257da24ff8b4839e62a689e898_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNi00LTEtMS0w_cc9371a7-37c6-4c4c-8dd7-8e772a17f061">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f749230a90846feaffa937710c3bd7f_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNy0yLTEtMS0w_91011373-6267-4b3f-a712-4a49cbd596e0">3,186.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a1954375c4428c8c9f1e2459422a19_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNy00LTEtMS0w_4b3f299c-41f1-4dc4-a20e-aad42d294000">3,229.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity as of March 31, 2021, reflected aggregate net unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTc5OA_26f4b30b-57a5-4bb9-9954-038481f06c9c">41.5</ix:nonFraction> million, composed of gross unrealized losses of approximately $<ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTA5OTUxMTYzNTk1Mw_4f596e87-a9be-455a-bf91-18724a69c5e1">73.5</ix:nonFraction>&#160;million and gross unrealized gains of approximately $<ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTA5OTUxMTYzNTk2OA_872747ca-713c-4432-b6f1-955593264960">32.0</ix:nonFraction>&#160;million, compared to aggregate net unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTgxOA_e8f6315c-77e3-4ecc-9c46-1b11abf007b5">212.5</ix:nonFraction> million as of December 31, 2020. We expect the net unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTg4MA_26f4b30b-57a5-4bb9-9954-038481f06c9c">41.5</ix:nonFraction> million to be settled over the next <ix:nonNumeric contextRef="i9113178df6744dbebe8d536cedbb476d_D20210101-20210331" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTkxMQ_699517c9-d0dc-40a2-81b6-ef9bead43eaf">21</ix:nonNumeric> months, of which $<ix:nonFraction unitRef="usd" contextRef="i5684eeb894e948e795d7ba13a0a9821b_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTkyNA_fb056673-e345-49b7-aabe-144e596edb3d">54.3</ix:nonFraction> million of unrealized losses are expected to be settled over the next <ix:nonNumeric contextRef="ibe1bc0a4b4384b369f562b05efbd0f01_D20210101-20210331" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTk4NA_c0040cdc-774e-4a0a-b8d3-1b1e9a7f9631">12</ix:nonNumeric> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of March 31, 2021 and December 31, 2020, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjk2OQ_991b2c44-3628-4cfc-a179-be69d979c7cd" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide647841e7044ab48b55cda50f1d1520_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfMy0yLTEtMS0w_02f48963-d038-402f-8020-349c5c9d16d8">23.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a595e77e9024184a813ff4337b0408b_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfMy00LTEtMS0w_47ba2ca5-874a-4a8b-962b-e0a5db518158">27.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52305514d2d248ef8eac2ce5da013356_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfMy04LTEtMS0w_7322fe76-b525-4b17-b84b-3b1cd1221b7c">3.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a87c0642d8c4661b4616dcafaf98925_D20200101-20200331" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfMy0xMC0xLTEtMA_8d810c9a-6df6-41ef-954b-7f772d633a3e">9.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic532929c81174c56bed2bcbdbaad621f_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfNC0yLTEtMS0w_9afc6b80-f090-4e83-8142-fe92e76f245b">0.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87deea9139694467a9fdc201db179c76_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfNC00LTEtMS0w_3885e590-e202-4ca2-98c7-8787d386d6d1">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i374fbb6203a34bf4944599f7c1e45415_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfNC04LTEtMS0w_788abe3d-99ff-4d08-8e6c-8ad9b1c13af3">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c7748a642e745f88a124b19bc7f4714_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfNC0xMC0xLTEtMA_e50de7d4-f504-4fbe-9115-71dd86597949">0.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Contracts</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of our <ix:nonFraction unitRef="number" contextRef="i86ba11dc3301448dab6e7f9202ed71a0_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMjkxNQ_c1a69865-b78a-40e5-b4e1-03bb430d7af3">2.90</ix:nonFraction>% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="i17821dc2bf9b41c6b08b07a41c8ce707_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMzAyOA_d4490e58-f561-4fc3-9b33-578ac530f184">675.0</ix:nonFraction> million, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our <ix:nonFraction unitRef="number" contextRef="i86ba11dc3301448dab6e7f9202ed71a0_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMzE4Mw_c1a69865-b78a-40e5-b4e1-03bb430d7af3">2.90</ix:nonFraction>% Senior Notes attributable to changes in interest rates. The carrying value of our <ix:nonFraction unitRef="number" contextRef="i86ba11dc3301448dab6e7f9202ed71a0_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMzI2OA_c1a69865-b78a-40e5-b4e1-03bb430d7af3">2.90</ix:nonFraction>% Senior Notes as of December 31, 2020, included approximately $<ix:nonFraction unitRef="usd" contextRef="i979c6df8053649cfb7b8b90a285b165d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTA5OTUxMTYzNTE1NQ_cc494a59-d4db-4604-976b-aa11226ca7fa">2.3</ix:nonFraction>&#160;million related to changes in the fair value of these interest rate swap contracts. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our <ix:nonFraction unitRef="number" contextRef="i86ba11dc3301448dab6e7f9202ed71a0_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMzQ5NQ_c1a69865-b78a-40e5-b4e1-03bb430d7af3">2.90</ix:nonFraction>% Senior Notes, resulting in a gain of approximately $<ix:nonFraction unitRef="usd" contextRef="i14942974e4f2452cad88e831cc7cddda_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMzU0OQ_00fea8c1-d5ec-4c62-98a7-565391524190">3.3</ix:nonFraction> million, which was recorded as a component of interest expense in our condensed consolidated statements of income during the second quarter of 2020.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately <ix:nonFraction unitRef="number" contextRef="i6d8e15ff35ac44bab6ffcdf343f511ac_I20200331" decimals="2" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNDA1NQ_924a95f9-a9fa-4a24-8b98-4c740badb7a5">5.0</ix:nonFraction>% to approximately <ix:nonFraction unitRef="number" contextRef="i9201821f02cc43b3b8f8fabadde5754b_I20210331" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNDA3NQ_7469fd6a-8dc2-4dc9-a5fd-58515022a743">49.9</ix:nonFraction>%. The share purchase transaction was completed in November 2018 and, upon closing, we paid <ix:nonFraction unitRef="krw" contextRef="ibe4be84a93994def8ed976d74fd1dfec_D20181101-20181130" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNDE2OA_6a5d5329-7835-40b8-8130-74dcded7828d">759.5</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="ibe4be84a93994def8ed976d74fd1dfec_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNDE4OQ_b01543e3-4392-4315-9c31-ed014e936ecf">676.6</ix:nonFraction> million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i05fedd375daa4dda893b9850a131a9af"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of March 31, 2021, had a remaining duration of <ix:nonNumeric contextRef="iee1f4bcc0a9b4476bc090cfa49e3c034_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:DerivativeTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNDU2Mg_0958cd8a-99e7-45a1-8234-84813537beaf">seven months</ix:nonNumeric>. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $<ix:nonFraction unitRef="usd" contextRef="iee1f4bcc0a9b4476bc090cfa49e3c034_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNDkxNQ_f2fa7455-6d7c-4925-a6bf-2828b3ff3277">2.7</ix:nonFraction> million and net losses of $<ix:nonFraction unitRef="usd" contextRef="i1236ccb8b6ae4703835b4052a03f112b_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNDkzNg_f8a8bf3a-7f3c-432e-850f-bf16e0104713">21.2</ix:nonFraction> million as of March 31, 2021 and December 31, 2020, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of $<ix:nonFraction unitRef="usd" contextRef="i9aaed4b4b8474e7e9b340a6d01f5046c_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNTM3MQ_ae9ebb4d-d761-463b-a210-df3a6d0769a0">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2e5e89f06e804ddc81397c8b1168e259_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNTM3OA_4f99cae7-7663-4f8b-92bc-d4f849dabe67">0.2</ix:nonFraction> million as of March 31, 2021 and December 31, 2020, respectively.</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjk2MA_26087be4-ba8e-4508-8475-67e9b959d668" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.202%"></td><td style="width:0.1%"></td></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1f4bcc0a9b4476bc090cfa49e3c034_D20210101-20210331" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOmYxZjhlNTllNGFjYzQwM2NhZjk2YjczYTAxMTUyOWUzL3RhYmxlcmFuZ2U6ZjFmOGU1OWU0YWNjNDAzY2FmOTZiNzNhMDExNTI5ZTNfMy0yLTEtMS0w_c6203b19-fd1d-4a89-86e7-cbf976b96e92">23.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25755164c7c047c2ac74d54b1cdcb1d8_D20200101-20200331" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOmYxZjhlNTllNGFjYzQwM2NhZjk2YjczYTAxMTUyOWUzL3RhYmxlcmFuZ2U6ZjFmOGU1OWU0YWNjNDAzY2FmOTZiNzNhMDExNTI5ZTNfMy00LTEtMS0w_1ef4a963-5760-46b9-985c-91698ce712b9">24.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee1f4bcc0a9b4476bc090cfa49e3c034_D20210101-20210331" decimals="-5" sign="-" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOmYxZjhlNTllNGFjYzQwM2NhZjk2YjczYTAxMTUyOWUzL3RhYmxlcmFuZ2U6ZjFmOGU1OWU0YWNjNDAzY2FmOTZiNzNhMDExNTI5ZTNfMy04LTEtMS0w_5c4ce876-6422-4bd7-b90b-d792633b2502">1.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25755164c7c047c2ac74d54b1cdcb1d8_D20200101-20200331" decimals="-5" sign="-" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOmYxZjhlNTllNGFjYzQwM2NhZjk2YjczYTAxMTUyOWUzL3RhYmxlcmFuZ2U6ZjFmOGU1OWU0YWNjNDAzY2FmOTZiNzNhMDExNTI5ZTNfMy0xMC0xLTEtMA_7801f686-e45e-439f-9ba3-6b9085863020">0.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54eb17b8eef44296a8fdc3c7b6bd76af_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOmYxZjhlNTllNGFjYzQwM2NhZjk2YjczYTAxMTUyOWUzL3RhYmxlcmFuZ2U6ZjFmOGU1OWU0YWNjNDAzY2FmOTZiNzNhMDExNTI5ZTNfMy0xNC0xLTEtMA_1c140e4f-b22b-4ac8-85a6-0b169d397fc5">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78981389f5f94e5eadeefbd380f6d4ef_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOmYxZjhlNTllNGFjYzQwM2NhZjk2YjczYTAxMTUyOWUzL3RhYmxlcmFuZ2U6ZjFmOGU1OWU0YWNjNDAzY2FmOTZiNzNhMDExNTI5ZTNfMy0xNi0xLTEtMA_45108322-e670-44f3-a17b-de4ee579db30">0.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $<ix:nonFraction unitRef="usd" contextRef="i83451001a11e4d698aaaf41cfef4dc3e_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjA5Nw_e1a7ba4e-86f5-403b-bc80-b7cf00b3009b">1,358.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i868b061cb602497db91dcef241c70a3b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjEwNA_5d5de798-bad6-4db1-8fe6-22fd30f472fc">1,158.0</ix:nonFraction> million as of March 31, 2021 and December 31, 2020, respectively. Net losses of $<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTA5OTUxMTYzNTEwOA_8a59382e-a30c-4995-b2fa-441a89dfd393">17.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTA5OTUxMTYzNTQ0MQ_3e0d6801-fc9c-47a9-a0b0-5b61b0f1745d">2.4</ix:nonFraction> million related to these contracts were recorded as a component of other income (expense), net for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjk2NQ_1d391748-321d-47f8-b976-936156d6c887" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia665bc2c1fc141a1a5ca42007baa03e9_I20210331" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMi00LTEtMS0w_6439f984-d86b-4617-b4cd-9adfccdd7a98">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08a43cc4bff411ca2c03d302026578f_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMi02LTEtMS0w_5fc79da6-4e72-4432-8912-ebdea76b8e19">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i888cda8777754c04ac0cb1995bd7bfa8_I20210331" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMy00LTEtMS0w_efe2a155-e23d-4e86-9f1d-e666914e46c4">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d155f75ea4423db88f5212a2c98b00_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMy02LTEtMS0w_82758c5e-ba07-4f64-9127-c2e678deca84">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ecf3d9b5a444b63953faed5774226de_I20210331" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfNC00LTEtMS0w_c12f64b7-1f11-4d2e-883e-22998ed29e97">60.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3a3bb2800746138b838c49892a8c1b_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfNC02LTEtMS0w_8e140871-f98f-46e7-a20f-492c8db5979f">157.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a5027177624992b876d1ea94cede10_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfNS00LTEtMS0w_70772050-6683-46a2-aeff-30e544022588">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad77af33cb984b0e9bb3ef62ed1ebb74_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfNS02LTEtMS0w_fd200b1c-26c7-44a9-9632-05c164a117b9">35.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i731212cbf9b94995850d82a2311a7c17_I20210331" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfOC00LTEtMS0w_c2e16450-9c3a-4569-9f5f-c381507f7716">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f8e35902ecf4f34b94a8d17d9489454_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfOC02LTEtMS0w_14804fc0-277b-4929-9772-0bf6f932cfe0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f385654e1742b6a56d8fb4d0ade38e_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfOS00LTEtMS0yMzkw_0b7b79ad-ce99-49f2-acaf-01e179d91e5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7228047741514b81981471c02ea16f0e_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfOS02LTEtMS0yMzkw_1ea6299d-0d9c-41d7-a86b-0f0e15886b22">19.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d7974ac17f340839427c22253a75e1a_I20210331" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMTUtNC0xLTEtMA_ae98b125-948c-4d87-b9c3-cd539bc578d7">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0901c785f9c4846b1b5c357e1bf4da5_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMTUtNi0xLTEtMA_8137569b-b6b3-4f0d-8237-5c547e6749bc">20.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad5e6108b894c5681f7fde6c91cbfc2_I20210331" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMTYtNC0xLTEtMA_6ce6c942-14ef-472f-a722-274200fc3265">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f44a3b624d34174b5f92cb92f67b731_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMTYtNi0xLTEtMA_362805e3-4b64-4654-aa7b-2eb7240fe07f">4.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_85"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;Property, Plant and Equipment </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfMTI0Mg_ab6de1f9-dfc5-4fd3-81be-a594d40676ff" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $<ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfMTcx_534c69be-6d37-4da2-9946-2b3368826d08">1,827.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfMTc4_c42fa15a-fddb-4543-9e4f-20a4adfe6f9e">1,782.3</ix:nonFraction> million as of March 31, 2021 and December 31, 2020, respectively. For the three months ended March 31, 2021, depreciation expense totaled $<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfMjc2_d6e7c8aa-5e4d-4b86-a29a-c031f1a3fce6">48.8</ix:nonFraction> million compared to $<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfMzEz_a89c62e2-9246-49ff-afbc-49514a6e290a">48.4</ix:nonFraction> million in the prior year comparative period.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021. Upon completion, this facility will include <ix:nonFraction unitRef="sqft" contextRef="i6d21834e33c0420f926fcb969d864201_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="biib:NumberOfSquareFeet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfNzA5_0cbd67c0-e0fd-4ac7-a098-6a2d810569b6">393,000</ix:nonFraction> square feet related to a large-scale biologics manufacturing facility, <ix:nonFraction unitRef="sqft" contextRef="ic5944e21d13b439296ad6220144c780e_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="biib:NumberOfSquareFeet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfNzgz_c9defdf2-d643-4ca2-8d22-ba1c3d8eb43b">290,000</ix:nonFraction> square feet of warehouse, utilities and support space and <ix:nonFraction unitRef="sqft" contextRef="iaeecea45f6d1449081d0846aaae7ef11_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="biib:NumberOfSquareFeet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfODQ0_a3708ed9-270e-4e6f-948c-72a7790e9d54">51,000</ix:nonFraction> square feet of administrative space. As of March 31, 2021 and December 31, 2020, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i724f2b0183a64064a5b4c3edbfee2752_I20210331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfOTIy_417d0a8c-2b3e-4e82-8a83-873d8e90b3bd">1.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="if5111c584bd441549e34423b141b35c9_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfOTI5_61a93ab5-4c45-4a88-b910-51e0424eb1d3">1.8</ix:nonFraction> billion, respectively, capitalized as construction in progress related to this facility.</span></div></ix:nonNumeric><div id="i6fe84bc7e101462ea41fc07416803961_88"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</span><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMjQyMA_02afe631-d2da-463d-8ff4-b2d2c19c7471" continuedAt="i9853c634d6c84f77a726ce94a7ff99f0" escape="true"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indebtedness</span><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></ix:nonNumeric></div><ix:continuation id="i9853c634d6c84f77a726ce94a7ff99f0" continuedAt="i5d5ae604178c47af929ebb7ba8305d56"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i9541283653d242f48d85e9890e9c2777_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="biib:LongTermDebtExchangedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTM3NA_d889e5e9-438d-4933-b75b-00aefc85fd12">624.6</ix:nonFraction>&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i92e65fe683a2421f94f2dc6385f162f6_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="biib:LongTermDebtExchangedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTM5Nw_dee727dc-b57b-46ad-b846-3c577185cbf6">700.7</ix:nonFraction>&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="icf27a73b87464b70a24f4215cf6a7822_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTQxMw_76866ad6-6b7a-4145-89b0-dff0e1080f61">151.8</ix:nonFraction>&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we redeemed an aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i9541283653d242f48d85e9890e9c2777_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="biib:DebtInstrumentRedemptionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTQyOQ_f5d3f63f-357d-413f-a70d-ce053ad7cdae">8.9</ix:nonFraction>&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i9541283653d242f48d85e9890e9c2777_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTQ0Mw_1640b807-b8c0-45c0-abd9-cdfb9cae73fa">12.1</ix:nonFraction>&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i1203eeb4805841f0ac2cd72de89f499a_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTQ5MQ_86f0211b-231b-4edd-a5ba-c7564488c6d1">3.2</ix:nonFraction>&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the three months ended March 31, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement, we also made aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i1203eeb4805841f0ac2cd72de89f499a_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTU3NQ_415a72bd-2aee-4a99-9726-5bcb3e3b2722">13.8</ix:nonFraction>&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i1203eeb4805841f0ac2cd72de89f499a_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTYzNQ_bee639cd-59b0-4e32-9134-7e3472a3263b">6.1</ix:nonFraction>&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the three months ended March 31, 2021.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Senior Notes </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i016c570732cb4e06b13838775a874ce8_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5_39834a4a-5fc6-4014-ab32-6d5a46cfb2a6">3.0</ix:nonFraction> billion (2020 Senior Notes), consisting of the following:</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">$<ix:nonFraction unitRef="usd" contextRef="id947942c69fa44ce89256cc80c1e696a_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTYz_537f60ce-206a-4761-97b9-5bddbf270dbb">1.5</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="id947942c69fa44ce89256cc80c1e696a_I20200430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTY5_674a6a18-c253-4750-ac9f-a5420e56fe4f">2.25</ix:nonFraction>% Senior Notes due May 1, 2030, valued at <ix:nonFraction unitRef="number" contextRef="id947942c69fa44ce89256cc80c1e696a_I20200430" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMjAz_36e7205c-70aa-4665-b892-8eed691372e9">99.973</ix:nonFraction>% of par; and</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">$<ix:nonFraction unitRef="usd" contextRef="id662c0ca4fe34fb99b51e17485cdad55_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMjE4_181b3717-5114-4e33-ba71-a5582a419f46">1.5</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="id662c0ca4fe34fb99b51e17485cdad55_I20200430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMjI0_3dd93c8e-a684-48d5-a893-8a6ff8b3a9d9">3.15</ix:nonFraction>% Senior Notes due May 1, 2050, valued at <ix:nonFraction unitRef="number" contextRef="id662c0ca4fe34fb99b51e17485cdad55_I20200430" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMjU4_a0c9159e-a573-4497-bbc3-9806bfb39fd2">99.174</ix:nonFraction>% of par.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfNzc3_ffb7f935-9252-4e28-8e49-e1de49882566">24.4</ix:nonFraction> million of costs associated with this offering, which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. For additional information on our 2020 Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.90% Senior Notes due September 15, 2020</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $<ix:nonFraction unitRef="usd" contextRef="id9e2646cf66a4acea08af56195b01b34_I20150915" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTQxNg_68097fce-4988-41ac-b233-831bfede076c">1.5</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="id9e2646cf66a4acea08af56195b01b34_I20150915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTQ0OQ_b6fabe24-4477-441d-80cf-ec7622e2de62">2.90</ix:nonFraction>% Senior Notes due September 15, 2020, at <ix:nonFraction unitRef="number" contextRef="id9e2646cf66a4acea08af56195b01b34_I20150915" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTQ5Mg_e6b25ae1-4cd6-480f-894d-b6003ee8850d">99.792</ix:nonFraction>% of par. Our <ix:nonFraction unitRef="number" contextRef="id9e2646cf66a4acea08af56195b01b34_I20150915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTUwNw_f715cedb-add1-4ec5-a598-c1992157eb97">2.90</ix:nonFraction>% Senior Notes were senior unsecured obligations. In connection with the <ix:nonFraction unitRef="number" contextRef="id9e2646cf66a4acea08af56195b01b34_I20150915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfNzY5NjU4MTQxMzk5MQ_b6fabe24-4477-441d-80cf-ec7622e2de62">2.90</ix:nonFraction>% Senior Notes, we entered into interest rate swap contracts where we received a fixed rate and paid a </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:6pt"><ix:continuation id="i5d5ae604178c47af929ebb7ba8305d56"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our <ix:nonFraction unitRef="number" contextRef="id9e2646cf66a4acea08af56195b01b34_I20150915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTc1NQ_251104fc-c100-462a-9e87-e6a4c9978b01">2.90</ix:nonFraction>% Senior Notes prior to their maturity and recognized a net pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="ibb46cac46d2848cfad57259f2ed1d632_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTgzNA_5bac70a0-bc60-4f37-8f74-be2538de8b92">9.4</ix:nonFraction> million upon the extinguishment of these notes during the second quarter of 2020. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income and reflects the payment of a $<ix:nonFraction unitRef="usd" contextRef="ibd1b2f47353e4aaebcecdfcb602f4de9_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMjA2Nw_f9dc0846-b4bc-4398-bfb7-476acb0d77a6">12.7</ix:nonFraction> million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $<ix:nonFraction unitRef="usd" contextRef="i14942974e4f2452cad88e831cc7cddda_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMjIwNg_00fea8c1-d5ec-4c62-98a7-565391524190">3.3</ix:nonFraction> million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate swap contracts, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></ix:continuation></div><div id="i6fe84bc7e101462ea41fc07416803961_94"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;Equity </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTQ5MQ_2998c8be-b1a0-4bb2-8ac3-39bf5e66c9dd" continuedAt="iad1342ee01b84627bf49f883c5ab3c26" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="if4d015ecb936405daf574b4e3105f141_I20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTEx_be0dd634-955d-4a19-adc1-097bb8437b5c">5.0</ix:nonFraction> billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i790882cea9a743939fad5f1974b20135_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTA5OTUxMTYyOTYzOA_0fbf322c-01ab-4d2a-9b4a-938dc90c834e">2.2</ix:nonFraction> million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i790882cea9a743939fad5f1974b20135_D20210101-20210331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTA5OTUxMTYyOTY0OA_5cdb1395-a00d-418d-9ec8-aad6811acff6">600.0</ix:nonFraction> million during the three months ended March 31, 2021. Approximately $<ix:nonFraction unitRef="usd" contextRef="i5ee194f83e384c83974d24f728c5145b_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMzg0ODI5MDY5OTI0OQ_ad17bbb8-5de2-4923-b507-2afccd1c1b26">4.0</ix:nonFraction> billion remained available under our 2020 Share Repurchase Program as of March 31, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i5b8709d2eae04591a6115e04171e59b0_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMzg0_6e31cb23-b8e4-4129-9b65-242191c2f254">5.0</ix:nonFraction> billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i5f5341349d2f494d97ea527c3a617208_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTA5OTUxMTYyOTI5Mw_bf96d9cc-d8b1-4f70-bf48-c9ecb1747c81">3.2</ix:nonFraction>&#160;million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i5f5341349d2f494d97ea527c3a617208_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTA5OTUxMTYyOTI5OA_a54451ad-4a2c-4493-a524-5bcc8438ecf6">941.1</ix:nonFraction>&#160;million during the three months ended March 31, 2020.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="iee2acff297c64ff1859c44405ba33de8_I20200331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfODM2_c1bd1df3-f251-4887-82cc-e50a97ef5f5e">5.0</ix:nonFraction> billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i25ca0d3089b9406197bdca98e4d63b1b_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTA5OTUxMTYyOTMxNw_9cb3bf11-61fc-42c9-81c8-bde984bb9ac1">4.1</ix:nonFraction>&#160;million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i25ca0d3089b9406197bdca98e4d63b1b_D20200101-20200331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTA5OTUxMTYyOTMyNg_d2b8ba43-48d3-4b4e-8673-625bb019208d">1.3</ix:nonFraction>&#160;billion during the three months ended March 31, 2020. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTQ3Mg_35197989-cca0-4b24-b6da-e5d8d4591aed" continuedAt="id60b0939aaf243f0b0dd68d6a6c46413" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6d9591af95346bca52a790ec1831e51_I20201231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMS0yLTEtMS0w_b0fd366e-f89d-4105-bf2a-aa9ea94ca44a">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i121f989f64d54d71990d30584fc92371_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMS00LTEtMS0w_2000bff2-9461-42a0-b592-a6b46f9f06fa">179.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc0e23fcbfe244b5914449511bb9de9a_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMS02LTEtMS0w_f88e2288-dae3-4dda-b2b5-e46179a2d49f">8.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33ed22d7f19146a98e5ed27cdcf69af6_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMS04LTEtMS0w_28bc5df2-e3c3-4101-bce1-191454701e0a">66.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9a1a6add6db45b6a1cc3687b957361e_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMS0xMC0xLTEtMA_e6fd63b2-a552-4c90-9926-29e609394ced">46.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMS0xMi0xLTEtMA_2cf7afe0-b85a-434a-b9cd-30112daf6103">299.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89cad3952c464507908e42ec76b9683b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMi0yLTEtMS0w_cfe213e1-fe15-4561-8dc3-2c806438c2e9">1.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie56cc9b03fcc4f6d9a86477a5270a889_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMi00LTEtMS0w_3df17193-11b7-43d6-a0a6-68fdfc6ba35b">128.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6617815be784402785f12c6988e1beee_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMi02LTEtMS0w_0870ace5-5063-48c9-a50d-4f1e859137ad">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08aec04c4324a64a5bb6af5a48753a2_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMi04LTEtMS0w_ecc9832b-5d12-4d53-b892-cc39579306ed">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52012835f8e245adb31aeec016f4112a_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMi0xMC0xLTEtMA_4bb96bb3-41c7-4a14-a4c2-9030b7c76766">48.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMi0xMi0xLTEtMA_c4c8633a-fccc-4426-8e0b-7c54956c637e">103.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89cad3952c464507908e42ec76b9683b_D20210101-20210331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMy0yLTEtMS0w_b00f3237-1047-4b20-9e6e-163476eb2399">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie56cc9b03fcc4f6d9a86477a5270a889_D20210101-20210331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMy00LTEtMS0w_84516de6-b8ef-441d-865b-f9f41ea46f87">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6617815be784402785f12c6988e1beee_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMy02LTEtMS0w_166a9776-d278-4b0f-a4bd-07cf93f6fdbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08aec04c4324a64a5bb6af5a48753a2_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMy04LTEtMS0w_2be20f28-3b6a-463a-ac58-e98209fc71e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52012835f8e245adb31aeec016f4112a_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMy0xMC0xLTEtMA_acfdf32b-7a13-474f-934a-367179b894f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMy0xMi0xLTEtMA_605edff5-0503-467e-ab9a-b849d64993a3">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89cad3952c464507908e42ec76b9683b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNC0yLTEtMS0w_b6832102-7f53-4a3b-b845-4b3f320abdd4">0.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie56cc9b03fcc4f6d9a86477a5270a889_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNC00LTEtMS0w_59b0492f-dc5a-49fc-a569-f2584bcebe29">149.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6617815be784402785f12c6988e1beee_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNC02LTEtMS0w_f89539fd-ef79-4abe-954c-301e5e2cb7fd">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08aec04c4324a64a5bb6af5a48753a2_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNC04LTEtMS0w_aea88981-3856-4dbb-9ebc-cc1e24b4b82e">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52012835f8e245adb31aeec016f4112a_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNC0xMC0xLTEtMA_4755cbe9-b61c-429f-ba0e-075c4c92f383">48.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNC0xMi0xLTEtMA_5c0a7a8f-851e-4fb6-9fc7-ed9348786c79">124.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb1237016b141a5b01be03b134ebd55_I20210331" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNS0yLTEtMS0w_2112cebf-f797-4b7c-93a2-aca1029a4475">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a25f52836a44c688f515291d314595_I20210331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNS00LTEtMS0w_053318fe-d4c8-428d-a8a0-9016660e0330">29.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a09764d13c4694a6f1f3b0b58dd09e_I20210331" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNS02LTEtMS0w_6a52e8b6-b5c0-4877-85c3-0f1ba40117cc">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd1befbf13d647bbbbce80021df07746_I20210331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNS04LTEtMS0w_db1acb7d-c699-4293-b54b-f062a10c14f5">64.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6655179b6b2649759f156341cd1be463_I20210331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNS0xMC0xLTEtMA_8f0fdd9f-a0c6-4272-bae7-081a86817138">95.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNS0xMi0xLTEtMA_aadc81ba-60c7-49fa-93d7-99760c2b341b">174.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="iad1342ee01b84627bf49f883c5ab3c26"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="id60b0939aaf243f0b0dd68d6a6c46413"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia26f4bf0d205499492e015dc1f5f9d6a_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMS0yLTEtMS0w_41ecbd21-2098-4c30-8e7d-0b8442b0a6d7">4.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c1b21402d94dac9e67581cf6e009b9_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMS00LTEtMS0w_6850c580-17c0-42c4-8727-392467e50b4e">7.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee0d5eaff614476bcb905bbd08373bf_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMS02LTEtMS0w_03679ed0-b6f8-467e-8a62-19e3d2b1ad9c">25.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4eda08b11c34ae9a36408a31801e4ec_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMS04LTEtMS0w_53102286-806c-4333-956d-1a26319e7832">32.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa803a04b06e4d9cb1a5f96364d792dd_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMS0xMC0xLTEtMA_d8b80ab5-948a-43ff-b1fc-6a9dca7240df">139.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0294157534ec4829a838f8161a2c6f76_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMS0xMi0xLTEtMA_d879c6f7-d02b-4173-a17a-00136de9d3cc">135.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b7d97c6a13d4e7a91efccbf9a7a80a6_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMi0yLTEtMS0w_84c16f7e-63e6-4de0-b63b-96a0aae1c3c9">20.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62772410ea3b48f99b42dec5a933607a_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMi00LTEtMS0w_6aaa1b66-94aa-420e-8d42-e11b790e71b4">60.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754c37b6ef7645eb9afbdbbda44b09f6_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMi02LTEtMS0w_fa1a7d5a-75a2-48cf-9244-3948d872d1bc">23.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590c8062df384811a4631c1a3f4c03cb_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMi04LTEtMS0w_29af9d9e-402c-4840-b39c-19e29ae8c523">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc821229a0b466caa70f9efb4cbb784_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMi0xMC0xLTEtMA_f55c9718-ef7a-4606-a758-f50e0fe7d364">63.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMi0xMi0xLTEtMA_1d3952ff-217f-4965-8586-be27c77024e6">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7d97c6a13d4e7a91efccbf9a7a80a6_D20200101-20200331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMy0yLTEtMS0w_005553fd-1383-46bf-8284-71aa7de682d1">13.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62772410ea3b48f99b42dec5a933607a_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMy00LTEtMS0w_96613e90-8073-4180-b61f-b1c019bac17e">26.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i754c37b6ef7645eb9afbdbbda44b09f6_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMy02LTEtMS0w_a1090efb-22cf-4a46-ab68-76f75356240a">0.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590c8062df384811a4631c1a3f4c03cb_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMy04LTEtMS0w_b26d2880-8288-45ef-ad5a-5f94306dafa7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc821229a0b466caa70f9efb4cbb784_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMy0xMC0xLTEtMA_bb6de018-b0f3-4a9d-982b-0b92c738742f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMy0xMi0xLTEtMA_f9286e4b-0116-4ada-8960-1198923f445d">14.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b7d97c6a13d4e7a91efccbf9a7a80a6_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNC0yLTEtMS0w_cfa2c539-2c84-42e3-9f8a-31cf037da357">7.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62772410ea3b48f99b42dec5a933607a_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNC00LTEtMS0w_969b0427-7203-4f3c-abce-66f8d8e5aad9">33.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754c37b6ef7645eb9afbdbbda44b09f6_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNC02LTEtMS0w_a1f1a284-01a2-458e-b689-faeb0cfa04fc">23.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590c8062df384811a4631c1a3f4c03cb_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNC04LTEtMS0w_b1e6790f-a0b4-4940-aa43-925e2e5807b5">0.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc821229a0b466caa70f9efb4cbb784_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNC0xMC0xLTEtMA_65a8bde1-6508-4372-a8dc-895c5dadfeae">63.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNC0xMi0xLTEtMA_2b7285b4-1e1e-4088-9760-7f07d168065f">14.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice4da96682e14bf78bf22af3dd2a4a8c_I20200331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNS0yLTEtMS0w_291f8da4-0996-46cf-abdb-5286bc50c2e3">3.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d97abb270e493da281ba2ce68e7c8b_I20200331" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNS00LTEtMS0w_f0c7b50e-99a4-49c0-926c-170315b39ba7">41.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59583d2b241145dd9da8f108498b7d3e_I20200331" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNS02LTEtMS0w_7401ac2c-6082-4b8b-9793-af86df66d947">48.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9144d29ad0b4e8b89f55ce739a9ee63_I20200331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNS04LTEtMS0w_b04180de-7ec7-46ae-880a-fa299e30c7f0">32.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85e0459de37d462abb7762f5b8952479_I20200331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNS0xMC0xLTEtMA_a30cba90-df6f-42ca-8a14-bf0b21b52386">203.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179564f7a5394a3f985b2394c890de98_I20200331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNS0xMi0xLTEtMA_02adaf8b-e381-4913-b47c-4a5b16905f7b">149.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTQ2OQ_b115b107-48b7-4e7d-9fae-9376b600999f" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.547%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e0e08b5a819440bb14c90345397b2db_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfMy0zLTEtMS0w_665616b4-d52d-4b86-838b-58deb9b8e4a6">0.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id601e29bcd854d9a871868d6cb4b232e_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfMy01LTEtMS0w_3843c291-00e9-4a3b-bf4d-19f6b2590053">16.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0e08b5a819440bb14c90345397b2db_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfNC0zLTEtMS0w_82a6d06f-6c0c-4fdd-9607-04c907d2d4ed">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id601e29bcd854d9a871868d6cb4b232e_D20200101-20200331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfNC01LTEtMS0w_32abb44f-566b-4e7b-a252-b69b1d2e7d32">3.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d783d882d2347499c93910b2745c786_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfNi0zLTEtMS0w_f889fb55-1add-4f49-81f0-3c4303608e3b">23.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc093e060e9247b3b645204a28e9693f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfNi01LTEtMS0w_461f8983-6974-4c6a-a8bd-d3c48318ff28">27.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d783d882d2347499c93910b2745c786_D20210101-20210331" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfNy0zLTEtMS0w_79db85b1-87f3-49f2-a72f-feff6dcfee61">0.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc093e060e9247b3b645204a28e9693f_D20200101-20200331" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfNy01LTEtMS0w_3c99da8c-16ed-46d0-afae-f759a376b678">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d783d882d2347499c93910b2745c786_D20210101-20210331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfOC0zLTEtMS0w_6b875ecf-2a45-486d-aa51-b0719fc23894">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc093e060e9247b3b645204a28e9693f_D20200101-20200331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfOC01LTEtMS0w_9b8be9f8-5bb0-4823-9cf2-bc9b11b92177">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d783d882d2347499c93910b2745c786_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfOS0zLTEtMS0w_13e0798e-fcd9-42ee-baf6-7e61ca4bbb75">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc093e060e9247b3b645204a28e9693f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfOS01LTEtMS0w_19077d62-1f01-46e7-a1ec-9ab88f8f0d59">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c160a38b934622ae05b249135e9fba_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfMTEtMy0xLTEtMA_bd9acf2b-ead2-4a92-bba7-b883f04c19b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b0a6b12ff841faa09ff1e9b8731d8e_D20200101-20200331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfMTEtNS0xLTEtMA_4f0f4d43-8825-4ea0-8bab-6a56b69807fa">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib347ee221e7745e397b6e1c44ca1f262_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfMTQtMy0xLTEtMA_c03dad13-26e2-4c3f-a6ec-eb24adeec90f">21.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8793b775d015434e94d2639ea24a0cd7_D20200101-20200331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfMTQtNS0xLTEtMA_3e88768c-efcf-4c59-8055-1c0a757d7129">14.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i6fe84bc7e101462ea41fc07416803961_97"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;Earnings per Share </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RleHRyZWdpb246MDJjYWZjZmNlOTRmNGUxNWI3MGZiZDcyZDg4ZjU2NzBfMjEz_7508ba10-9739-4536-8916-315b484cfd6a" escape="true"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RleHRyZWdpb246MDJjYWZjZmNlOTRmNGUxNWI3MGZiZDcyZDg4ZjU2NzBfMjA4_5951490d-025a-444c-b2ef-0104e972b89b" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share are calculated as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMy0yLTEtMS0w_3c55058a-db03-4501-9a8d-772d98de7792">410.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMy00LTEtMS0w_bea062c7-e281-480e-9aee-83e13bb9471d">1,399.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfNS0yLTEtMS0w_c5dc597c-6163-4b47-b2e8-ebed155833a8">151.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfNS00LTEtMS0w_499c134b-8309-4460-8951-023c27a91bb3">172.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5814e7fb32fa4b229429ed5c681d9f9a_D20210101-20210331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfOC0yLTEtMS0w_f7f484c6-41dc-4013-bad9-9a0722208a45">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c91e4f53b324f398e35bf230235f119_D20200101-20200331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfOC00LTEtMS0w_885b3b06-cb9e-431b-b54e-c5ff986d231a">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74e5599741ad4a8b9f6a247bbdd89697_D20210101-20210331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfOS0yLTEtMS0w_827254ea-c160-469f-ad04-1a78299b3b2c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdfa95b717f940c18648cae8c6f84a2b_D20200101-20200331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfOS00LTEtMS0w_83812885-5d61-42ba-8ea3-45531a638902">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c803a1bd2b24613850cb9d1888f1471_D20210101-20210331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMTAtMi0xLTEtMA_f85fc6e1-455a-4013-90cf-5a9f6c99f15c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20625d3cd2ef4a8797d00c27d1627625_D20200101-20200331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMTAtNC0xLTEtMA_8c09aaa4-9b0c-4b06-900c-1d8951c5f9ec">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMTEtMi0xLTEtMA_a40e65bb-3a0c-497a-a2ae-a7d92385bf15">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMTEtNC0xLTEtMA_99e06e6d-2168-4705-a3c2-f1425892645b">0.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMTItMi0xLTEtMA_00e484dc-b7ad-434b-9c78-d9eb9f69ed21">152.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMTItNC0xLTEtMA_e54cb460-b599-498d-a1bc-7b1630bbf53b">173.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_100"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;Share-based Payments </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90ZXh0cmVnaW9uOmZhOTViMDZkYjlkZTQ3N2I5MDBkZGNjZDlmNGI5OGNmXzY1NQ_8c55c102-0442-4789-89b7-a908080cf161" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90ZXh0cmVnaW9uOmZhOTViMDZkYjlkZTQ3N2I5MDBkZGNjZDlmNGI5OGNmXzY0Mg_582a20e4-6ae2-4b6c-9c7b-3a8209c6074f" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia034f5fb9e314569bb5e919e953a76f7_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzItMi0xLTEtMA_d00c9fe1-3b29-4411-8d58-57f0e2f94dbe">33.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if042c7a7464c42fe8dd45965e651f723_D20200101-20200331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzItNC0xLTEtMA_db8679e7-ae45-4f5b-8c0d-158e68f6a425">33.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3878b3cdc54bddb2a915e956935ea2_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzMtMi0xLTEtMA_8c07229b-69db-4673-94d3-8baf8740f4f8">44.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ab73c921484907b93d62dc34ab72bd_D20200101-20200331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzMtNC0xLTEtMA_073b1cbd-8595-4c94-9f48-0c780d0e37a6">43.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzQtMi0xLTEtMA_f485e23c-4b36-440f-8944-42a823aa8e51">78.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzQtNC0xLTEtMA_39098a68-fe45-4537-ba59-36507ca6b7df">76.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzUtMi0xLTEtMA_39e9a9c8-bb5d-4da9-b4bb-4fae2a44af09">2.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzUtNC0xLTEtMA_967e28c6-87f8-4c21-b164-f9d43820cf89">1.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzYtMi0xLTEtMA_91f7ae4f-3454-49a8-a02b-73b646482ebd">75.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzYtNC0xLTEtMA_0ebb4163-6d61-479a-a3ed-8fac25236964">74.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzctMi0xLTEtMA_a019615b-a453-4409-8c46-b9866680ec70">14.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzctNC0xLTEtMA_a3bbd322-2696-4f3a-8edd-7cdd8a457211">13.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1134208d9b3347088ec3ac4ca9b1f0e0_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzgtMi0xLTEtMA_ce30694d-ab11-4831-913d-f720c4da6215">61.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c4590aede5149a797bc4699fd289712_D20200101-20200331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzgtNC0xLTEtMA_98df2aad-479b-4035-b335-4b8532c74fd7">61.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90ZXh0cmVnaW9uOmZhOTViMDZkYjlkZTQ3N2I5MDBkZGNjZDlmNGI5OGNmXzY1Ng_fcc5b927-9dec-471d-9fe2-487f97d09c14" escape="true"><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea96acd5ebf344c0bd0de05f5f18e7ba_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzItMi0xLTEtMA_42db15e3-390f-4a09-befd-189200490bdb">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic130d01037a74b06b9d042ae75b7659f_D20200101-20200331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzItNC0xLTEtMA_2fe181ec-f01b-42e3-92fb-05ab76c886d4">19.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a6a4cf318b432dba2b2758ed6fb58b_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzMtMi0xLTEtMA_22915589-571c-4b7b-9be0-5e4feaad239b">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8d31d1727454b0ba645a673b928faf0_D20200101-20200331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzMtNC0xLTEtMA_87748e6e-65cf-4f42-be76-0facada77d95">37.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash settled performance units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecdb89b7a5934dd2ae846178573005f8_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzQtMi0xLTEtMA_9245476d-baad-49c1-9b7d-532bb6c66fad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic60ece36c57b4554886f84f64ca30d1e_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzQtNC0xLTEtMA_229cc258-816a-4bd9-980b-542fb734de2e">1.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81a65b32a8e4a00ad66b6254231bdda_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzUtMi0xLTEtMA_13dfb72f-dc05-4dd0-838f-be08ffa10f99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46142d7f2ab141ffb334e6b33caf19cf_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzUtNC0xLTEtMA_f33ba3ee-8f98-40d2-9388-e7043a7016d6">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66e68173c701483d84c579c57a8c212d_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzYtMi0xLTEtMA_1d0f2d0e-a3a1-4d12-9067-259affc9afe2">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebcbf3a6149a4a9289109aa4855ff343_D20200101-20200331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzYtNC0xLTEtMA_fd9090b8-0054-4ac4-892f-3aabb1b3c0d7">10.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2765e12d82da461e9794964574b53f42_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzctMi0xLTEtMA_3ec53952-afaa-41ec-8658-25f2075e32ad">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff86437e3aa4e37930e1206c73cfb00_D20200101-20200331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzctNC0xLTEtMA_73cdb5cf-b09d-40de-950c-f3c255378205">8.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54e58411691c4fbf853552c0ff6a6d05_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzgtMi0xLTEtMA_13a0d286-db72-4e90-b31b-dc454c09ff9f">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0d1b57d4a0c4741b41196908e3c38b1_D20200101-20200331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzgtNC0xLTEtMA_66c21ce2-1e6c-46be-9998-4316daf458b6">2.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzEwLTItMS0xLTA_a35ccd8c-978b-48fd-98b7-dfa23ee58d6f">78.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzEwLTQtMS0xLTA_6ea5894f-428e-406c-a731-46b08cfbdf2a">76.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzExLTItMS0xLTA_9b7e1afa-7478-484b-852a-4468810be2cc">2.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzExLTQtMS0xLTA_f84540f6-f817-4bc9-a439-df946740310b">1.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzEyLTItMS0xLTA_5d4caace-9bcc-4351-bfbd-7b11ab721b69">75.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzEyLTQtMS0xLTA_a25234f3-a0eb-4259-971d-33e0553f78f8">74.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div></ix:nonNumeric><div id="i6fe84bc7e101462ea41fc07416803961_103"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;Income Taxes</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90ZXh0cmVnaW9uOjM4ZWIyODZlOGYyNDQ4ZmM4YTEzMjQ4ZTg3MDVhODM0XzQ5Mzk_c3406c20-7c12-4e94-a805-8d46d537722f" continuedAt="i37a514757eed4357ae6d94506c235368" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the value of certain deferred tax assets by </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i37a514757eed4357ae6d94506c235368"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $<ix:nonFraction unitRef="usd" contextRef="i87fa0cfd9f644bdbb719a9473bc87605_I20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:DeferredTaxAssetsValueReductioninValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90ZXh0cmVnaW9uOjM4ZWIyODZlOGYyNDQ4ZmM4YTEzMjQ4ZTg3MDVhODM0XzE2NDE_066ff66a-d280-472f-b499-95c51f9fb323">1.7</ix:nonFraction> billion and reduced the value of deferred tax liabilities associated with global intangible low-taxed income (GILTI) and tax credits by approximately $<ix:nonFraction unitRef="usd" contextRef="i87fa0cfd9f644bdbb719a9473bc87605_I20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:DeferredTaxLiabilitiesValueReductioninValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90ZXh0cmVnaW9uOjM4ZWIyODZlOGYyNDQ4ZmM4YTEzMjQ4ZTg3MDVhODM0XzE3ODY_b5f365e1-d6c8-4af5-b091-6da3cd04f452">1.6</ix:nonFraction> billion. We continue to assess the realizability of these deferred tax assets and have not recorded a change to these deferred assets for the three months ended March 31, 2021.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Rate</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90ZXh0cmVnaW9uOjM4ZWIyODZlOGYyNDQ4ZmM4YTEzMjQ4ZTg3MDVhODM0XzQ5NDI_0ce43584-76e4-46e3-a3ec-3d0bc332bb57" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzItMS0xLTEtMA_7ebe2834-be55-4686-8b82-8de3a0f0ac93">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzItMy0xLTEtMA_05423735-0c82-4b7a-af61-fbcf593e311a">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzMtMS0xLTEtMA_51f8fd7c-9938-4ee7-89b3-40052614ca95">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzMtMy0xLTEtMA_6ca758fd-a1f5-4d60-8adc-ac225a298323">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzQtMS0xLTEtMA_68dfe6ec-6cd1-4e7e-b7af-80165a77aa26">10.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzQtMy0xLTEtMA_d54a68dd-dbc7-4eb5-a142-99fd1b0662f4">4.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzUtMS0xLTEtMA_5794af65-e316-46bb-9859-4605615d8bfe">3.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzUtMy0xLTEtMA_2ccd554a-1a68-473b-86f8-8bc4e70977a8">1.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzYtMS0xLTEtMA_29b4c720-777f-420c-aafd-7508626d5ba8">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzYtMy0xLTEtMA_a5b028d3-4495-4981-a9b0-bc59c05e1598">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzEwLTEtMS0xLTA_0bdf7e1e-8767-4bf0-871b-125537dbcc7c">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzEwLTMtMS0xLTA_a197ce45-fca3-4073-aa47-d3edbb15a32f">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzE0LTEtMS0xLTA_e5665a93-24cc-4c13-9f66-2ba7122a0181">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzE0LTMtMS0xLTA_a1b51d27-ca07-49be-8e63-7eb638a1184f">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzE1LTEtMS0xLTA_919de22e-81e4-42cd-b398-726c9fa5fe79">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzE1LTMtMS0xLTA_43074cef-926a-4178-999e-a3f739b67656">17.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease in our effective tax rate was primarily due to the change in the territorial mix of our profitability, which included the effect of generic competition for TECFIDERA in the U.S. market, and the non-cash tax effects of changes in the value of our equity investments, where we recorded a reduction of value in the first quarter of 2021. The tax effects of this change in value of our equity investments were recorded discretely, since changes in value of equity investments cannot be forecasted.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $<ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90ZXh0cmVnaW9uOjM4ZWIyODZlOGYyNDQ4ZmM4YTEzMjQ4ZTg3MDVhODM0XzQ4MDI_21ae1319-94ac-45be-b992-bd28eb91d57d">25.0</ix:nonFraction> million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_109"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;Other Consolidated Financial Statement Detail </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzE0Njg_ad03a1b0-4f5f-4aee-94c4-829433e131b4" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzE0NDE_074970b3-a4d8-43ba-9d4b-a8f0cd9434ce" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other income (expense), net, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzItMi0xLTEtMA_f0c6e20b-df26-4651-97b1-a031bcec232a">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzItNC0xLTEtMA_c2dafdeb-744e-41a5-882b-1e746cc72197">24.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzMtMi0xLTEtMA_30872481-85ac-4649-957a-2cf9fb474e91">64.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzMtNC0xLTEtMA_d60932bd-cd86-40c3-9c7e-fc1d1ec84bfd">44.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzQtMi0xLTEtMA_60fb0f76-6461-458f-9e25-12edaaba2c1a">436.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzQtNC0xLTEtMA_d0eb65bd-3d9b-4abd-b3fa-1a21e8eddfb2">77.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzUtMi0xLTEtMA_ad5523f2-b4b0-4fb1-9956-02fc4d9294fc">8.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzUtNC0xLTEtMA_ac764867-bd43-4ac1-8cca-44df02a110f2">18.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzYtMi0xLTEtMA_55c1be04-2ab5-4754-a812-927953c750de">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzYtNC0xLTEtMA_bc4ffac3-8e80-4a17-b61f-f2a51f42aec3">4.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzctMi0xLTEtMA_eacd6c25-bc7f-415a-a819-ba9d9170257a">506.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzctNC0xLTEtMA_a0968257-457f-4e99-8f3b-a525b0be3fda">120.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzEwOTk1MTE2MzA1OTc_7d80c40e-c218-4bb3-b801-44624ff1c0bc">442.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzEwOTk1MTE2MzA1ODQ_02d00275-8a14-4075-9f26-7e4616506c3f">6.2</ix:nonFraction> million, respectively, compared to net unrealized and realized losses of $<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzEwOTk1MTE2MzA1NzA_8983408b-c175-44b6-9abd-9e33fdf90a30">60.9</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzEwOTk1MTE2MzA1Nzc_ce864a0c-8d93-4749-a107-9b0cecdde271">zero</ix:nonFraction>, respectively, in the prior year comparative period. The net unrealized losses recognized during the three months ended March 31, 2021, primarily reflect a decrease in the fair value of Ionis, Sangamo, Denali and Sage common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="ib9e828d7b7bf4f43bc6657cc9326807e_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzEwOTk1MTE2MzA1Mzc_9f01c4d2-9931-4de3-a454-c80b945e5992">442.0</ix:nonFraction> million.</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzE0NjE_5236ef28-47e6-4ecc-b644-a418b3c3cea7" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of March 31, 2021 and 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo3NjIyNWYxYmIyM2U0ZjJiYWM0NmE2NDQyZDY2ZWQ5MC90YWJsZXJhbmdlOjc2MjI1ZjFiYjIzZTRmMmJhYzQ2YTY0NDJkNjZlZDkwXzItMi0xLTEtMA_794280c8-7c73-4c52-8f51-3f80d1f632da">436.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo3NjIyNWYxYmIyM2U0ZjJiYWM0NmE2NDQyZDY2ZWQ5MC90YWJsZXJhbmdlOjc2MjI1ZjFiYjIzZTRmMmJhYzQ2YTY0NDJkNjZlZDkwXzItNC0xLTEtMA_50553d52-42c5-45ac-b4b1-71ad2e5b04ea">60.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo3NjIyNWYxYmIyM2U0ZjJiYWM0NmE2NDQyZDY2ZWQ5MC90YWJsZXJhbmdlOjc2MjI1ZjFiYjIzZTRmMmJhYzQ2YTY0NDJkNjZlZDkwXzMtMi0xLTEtMA_02d00275-8a14-4075-9f26-7e4616506c3f">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo3NjIyNWYxYmIyM2U0ZjJiYWM0NmE2NDQyZDY2ZWQ5MC90YWJsZXJhbmdlOjc2MjI1ZjFiYjIzZTRmMmJhYzQ2YTY0NDJkNjZlZDkwXzMtNC0xLTEtMA_ce864a0c-8d93-4749-a107-9b0cecdde271">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo3NjIyNWYxYmIyM2U0ZjJiYWM0NmE2NDQyZDY2ZWQ5MC90YWJsZXJhbmdlOjc2MjI1ZjFiYjIzZTRmMmJhYzQ2YTY0NDJkNjZlZDkwXzQtMi0xLTEtMA_7d80c40e-c218-4bb3-b801-44624ff1c0bc">442.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo3NjIyNWYxYmIyM2U0ZjJiYWM0NmE2NDQyZDY2ZWQ5MC90YWJsZXJhbmdlOjc2MjI1ZjFiYjIzZTRmMmJhYzQ2YTY0NDJkNjZlZDkwXzQtNC0xLTEtMA_8983408b-c175-44b6-9abd-9e33fdf90a30">60.9</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzE0NTI_904efdfd-6c83-4c5d-b77a-0c3d4af42c58" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice62402188f941eab28ef8bd9b65e16d_I20210331" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzEtMi0xLTEtMA_154c112d-f6fc-4cac-a55b-964e995853e4">993.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569ed47008414979a6cf0d109c369b32_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzEtNC0xLTEtMA_1f0a2c9a-069c-4807-81b9-6c20c4293dad">1,080.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzItMi0xLTEtOTcxMA_6ac1e324-5421-4224-a07c-942b99611e8b">390.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzItNC0xLTEtOTcxMA_ca69f155-7950-42a4-b9f8-8039d2a90910">389.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzMtMi0xLTEtOTcxNg_b40c2823-b406-4a0e-bc5d-c294efb5fee6">212.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzMtNC0xLTEtOTcxNg_308c5fed-a822-45b1-b9c0-8416e52c0b1a">218.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzItMi0xLTEtMA_d50c4adc-4ffc-417d-a04c-5f7751071c74">207.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzItNC0xLTEtMA_50c3fd31-286a-432c-88e7-41b636f34cbc">333.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzMtMi0xLTEtMA_ca5115d9-5312-4326-a246-08f380f5ee0a">88.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzMtNC0xLTEtMA_4aa9a200-d358-454a-879a-cf03d6b65cde">181.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzUtMi0xLTEtMA_e695397b-fbca-46d0-9910-c56a8ec2ef54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzUtNC0xLTEtMA_e66fbf1c-9bae-4252-9fa4-0099af3a2b80">149.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzctMi0xLTEtMA_6c830777-2bd7-4ed3-b190-afbf12d91ea4">700.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzctNC0xLTEtMA_eaf61bed-a511-4363-aa6b-9e70ce64ec22">791.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzgtMi0xLTEtMA_d5dbd379-abfd-4f08-8565-6ce6366337a0">2,592.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzgtNC0xLTEtMA_3ad9343c-ed10-46ca-b1b3-07bb9f30c25d">3,145.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $<ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzEwNjc_e5374fef-205c-4448-91fe-0815394ad99b">1,411.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzEwNzQ_44cdbc07-448a-4258-8b26-c41190d3815e">1,329.6</ix:nonFraction> million as of March 31, 2021 and December 31, 2020, respectively, and included accrued income taxes totaling $<ix:nonFraction unitRef="usd" contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzExNTE_b94c0819-7ca6-4e87-8db6-6c53f705131c">725.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzExNTg_663f8b4a-a71a-4969-8d51-a7f964f13595">709.9</ix:nonFraction> million, respectively.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_112"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;Collaborative and Other Relationships </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE3Mzg3_d83a866f-7433-4850-b726-099d91a917ba" continuedAt="id3fa444038b74026bb8f4f297285a031" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BAN2401 Collaboration</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401 (lecanemab), a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, <ix:nonFraction unitRef="product" contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfProductCandidates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzMxMQ_d08eddf6-cacb-4f4e-bf9d-0b4cc79e9d21">two</ix:nonFraction> Eisai product candidates for the potential treatment of Alzheimer's disease (the BAN2401 Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If BAN2401 receives marketing approval, we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BAN2401 Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, an anti-amyloid beta antibody candidate for the potential treatment of Alzheimer's disease (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (the Aducanumab Collaboration Agreement).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments. Eisai has not yet exercised its Anti-Tau Option. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the BAN2401 Collaboration is as follows:</span></div><div style="margin-bottom:5pt"><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE3Mzg5_98a5d5c5-e30a-4c2f-b185-fde1fcefc672" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzItMi0xLTEtMA_9db56f86-04e9-4663-9c00-e29905e95645">55.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07234f661df448cb8a6a14d7961cf1a1_D20200101-20200331" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzItNC0xLTEtMA_d4e56167-78ce-468b-a6d9-4a5985963b10">43.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzMtMi0xLTEtMA_b23bd485-9778-4fde-85ce-6dfdb1224c3b">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07234f661df448cb8a6a14d7961cf1a1_D20200101-20200331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzMtNC0xLTEtMA_2f54d849-b551-450d-b37a-906a288d8d6a">21.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the BAN2401 collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e54ac3de781499f9cab24ff66dd0c11_D20210101-20210331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzQtMi0xLTEtMA_30f0a6c0-123e-4a36-84bf-f48a37cc37c9">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30647a5eccee4a888f75b3abd844ebdf_D20200101-20200331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzQtNC0xLTEtMA_94a9b27e-dfed-49a4-843e-adc850cb9598">4.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e54ac3de781499f9cab24ff66dd0c11_D20210101-20210331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzUtMi0xLTEtMA_4e1bf2c2-faf3-4da1-afe7-09ff9e6feb2d">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30647a5eccee4a888f75b3abd844ebdf_D20200101-20200331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzUtNC0xLTEtMA_2aacbea3-c73c-4294-8731-f71174c21634">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our BAN2401 Collaboration, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aducanumab Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Aducanumab Collaboration Agreement, we lead the ongoing development of aducanumab and, if approved, we and Eisai will co-promote aducanumab with a region-based profit split. Beginning January 1, 2019, Eisai is reimbursing us for&#160;<ix:nonFraction unitRef="number" contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzI3MzA_274ba7bd-3eff-4af4-ac56-9034c11087b8">45.0</ix:nonFraction>%&#160;of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early Alzheimer's disease. A new analysis of a larger dataset from these trials, conducted in scientific collaboration with the FDA, showed that the Phase 3 EMERGE trial met its pre-specified primary and secondary endpoints. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued and subsequently paid approximately $<ix:nonFraction unitRef="usd" contextRef="i65457dc54fbc417690f3f9dfc74324b1_D20191001-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossOnContractTermination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzM0MzE_adc6319c-67eb-4c94-8b5b-276e01ed508d">45.0</ix:nonFraction> million related to the termination of various clinical trials and research and development contracts net of the expected <ix:nonFraction unitRef="number" contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzM1Mzg_274ba7bd-3eff-4af4-ac56-9034c11087b8">45.0</ix:nonFraction>% Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="id3fa444038b74026bb8f4f297285a031" continuedAt="i01fa86e15af3462287ea145936436b29"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 we and Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S. In July 2020 we completed the submission of a BLA for the approval of aducanumab to the FDA. We recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzM4MzM_1e58fb90-04c8-40ca-a73c-0952123c9453">33.8</ix:nonFraction> million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzM4NTU_274ba7bd-3eff-4af4-ac56-9034c11087b8">45.0</ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzM4NzE_f0671d2b-7b7e-4f55-ae91-2efb0bf9ee26">75.0</ix:nonFraction> million milestone expense related to the submission of the BLA for the approval of aducanumab to the FDA.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expense are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab. <ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE3NDAy_00977d30-566b-40e1-a4f8-0fde7bda5eb2" continuedAt="ic24b0243eae049a6a3cc63da571221e7" escape="true">A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:5pt"><ix:continuation id="ic24b0243eae049a6a3cc63da571221e7"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total aducanumab development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia09bc9241ad54438b01f90b39ada6215_D20210101-20210331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzItMi0xLTEtMA_8ee7e221-5275-4d6c-b96a-2a44b719172c">47.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f5259f6537145b1b52dcc10ca5b10fc_D20200101-20200331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzItNC0xLTEtMA_6120a272-10b1-4874-9c5f-5cf55b75670d">19.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia09bc9241ad54438b01f90b39ada6215_D20210101-20210331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzMtMi0xLTEtMA_b29bcf6d-62f9-4180-bc94-110e2ad6ceea">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f5259f6537145b1b52dcc10ca5b10fc_D20200101-20200331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzMtNC0xLTEtMA_757bad5d-8907-48a4-b681-666c9f741729">10.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total aducanumab sales and marketing expense incurred by the Aducanumab Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2017d3bce86c4e1f9ab0a83bcf38491c_D20210101-20210331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzQtMi0xLTEtMA_e465e9f8-b2e9-4a41-85e1-a3369e4568fc">111.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91efa7f34820455f9945f65b1db8ead5_D20200101-20200331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzQtNC0xLTEtMA_8a7b127f-1568-408f-97ce-685ed4069543">22.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2017d3bce86c4e1f9ab0a83bcf38491c_D20210101-20210331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzUtMi0xLTEtMA_705504ba-a177-48d6-b4d6-f409f64cd00f">60.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91efa7f34820455f9945f65b1db8ead5_D20200101-20200331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzUtNC0xLTEtMA_af2c8d49-44c2-4632-bf24-570e42b785d4">12.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the Aducanumab Collaboration Agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UCB Pharma S.A.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB Pharma S.A. (UCB) to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77da4b737e504001a90944aeda31b91f_D20210101-20210331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTowZGIzODgyOTYzZWU0YzRjOWVkMTAzNjZlOTgxNTBjOS90YWJsZXJhbmdlOjBkYjM4ODI5NjNlZTRjNGM5ZWQxMDM2NmU5ODE1MGM5XzItMi0xLTEtMA_b531a8fa-e04d-4e0c-b0fd-455cd92b7510">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice34644db491436ba604aaf4f60a0d7c_D20200101-20200331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTowZGIzODgyOTYzZWU0YzRjOWVkMTAzNjZlOTgxNTBjOS90YWJsZXJhbmdlOjBkYjM4ODI5NjNlZTRjNGM5ZWQxMDM2NmU5ODE1MGM5XzItNC0xLTEtMA_727bc7e5-13b9-4ea8-81e0-4237db2ae9f1">19.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77da4b737e504001a90944aeda31b91f_D20210101-20210331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTowZGIzODgyOTYzZWU0YzRjOWVkMTAzNjZlOTgxNTBjOS90YWJsZXJhbmdlOjBkYjM4ODI5NjNlZTRjNGM5ZWQxMDM2NmU5ODE1MGM5XzMtMi0xLTEtMA_04468821-3c89-4d40-adb6-f8996435cfd6">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice34644db491436ba604aaf4f60a0d7c_D20200101-20200331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTowZGIzODgyOTYzZWU0YzRjOWVkMTAzNjZlOTgxNTBjOS90YWJsZXJhbmdlOjBkYjM4ODI5NjNlZTRjNGM5ZWQxMDM2NmU5ODE1MGM5XzMtNC0xLTEtMA_ba7ed4e1-e5b2-4a6f-b665-9bd379e8acf4">9.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020 we entered into a collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the closing of this transaction in December 2020 we purchased $<ix:nonFraction unitRef="usd" contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTM0NDI_44734746-f102-471a-b5fc-5b19f1b4dfe7">650.0</ix:nonFraction>&#160;million of Sage common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTM0NTg_2b6bc054-4a8e-4ac6-9909-ae30110511b2">6.2</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130" decimals="INF" name="biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTM0NzE_b12f352d-cd88-455b-a33b-531af218ab60">104.14</ix:nonFraction> per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sage common stock acquired and a charge of approximately $<ix:nonFraction unitRef="usd" contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTM0ODA_b293e38b-8fa2-4bce-8350-795c7b6b45d1">209.0</ix:nonFraction>&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sage common stock. We also made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTM0OTY_24db2ed3-202b-4b4c-a09d-c5a7bf6afde7">875.0</ix:nonFraction>&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also pay Sage development and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTM1MTI_828ba396-9d21-437a-a632-cd938440901c">1.6</ix:nonFraction>&#160;billion if all the specified milestones set forth in this agreement are achieved. Both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i01fa86e15af3462287ea145936436b29" continuedAt="ic5dacb207e1f49b4be42e09594ed7e91"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and will pay Sage potential tiered royalties in the high teens to low twenties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to this collaboration is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this collaboration we purchased approximately $<ix:nonFraction unitRef="usd" contextRef="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzY1NjI_62248d21-a735-43bf-906b-e6cc0b9f72dd">465.0</ix:nonFraction>&#160;million of Denali common stock in September 2020, or approximately <ix:nonFraction unitRef="shares" contextRef="ibed8defa2fe84947a4f4b459fdd0d10f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="biib:Investmentincommonstocksharespurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzY2MTI_18c12515-4851-4a41-855c-b328a2ab72fb">13</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331" decimals="2" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzY2Mzk_27ed4e1e-2dc1-4bda-a294-4de8d482a33f">34.94</ix:nonFraction> per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzY4OTU_bc199ff0-2d9b-416a-97cb-58cb9affebad">41.3</ix:nonFraction>&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzcwNzc_3a8697bc-6360-47fd-a1ee-e859a4a6c608">560.0</ix:nonFraction>&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Denali development and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzcyMzQ_11a8e7cf-69da-4b6a-ba20-87bbb7e511d3">1.1</ix:nonFraction>&#160;billion if the milestones related to LRRK2 are achieved. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages and we are responsible for commercialization and will pay Denali potential tiered royalties.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a <ix:nonNumeric contextRef="i968b5e6a9c734bba858d0e6913254760_D20210101-20210331" format="ixt-sec:durwordsen" name="biib:Termofcollaborationagreement" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzc2OTY1ODE0Mjc5MTc_c3f8696e-7135-433f-bdb1-55e68aaa5084">five-year</ix:nonNumeric> period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger protein technology delivered via adeno-associated virus with the aim to modulate the expression of key genes involved in neurological diseases. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of this transaction in April 2020 we purchased $<ix:nonFraction unitRef="usd" contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzgwNDQ_666d324c-34de-48bc-b5f1-eb12ed63bfbf">225.0</ix:nonFraction> million of Sangamo common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229" decimals="-6" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzgwODk_e5cfced4-ad82-4831-9b41-3a838b50c201">24</ix:nonFraction> million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229" decimals="2" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzgxMTY_529e6695-cf4a-4a66-86a2-e44f3f6796c0">9.21</ix:nonFraction> per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately $<ix:nonFraction unitRef="usd" contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzgzNzM_33234bea-6d3d-4ccc-83c9-520944ae5d9a">83.0</ix:nonFraction> million&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzg1NTY_d70b43b6-0dae-40ef-8754-41628367f60a">125.0</ix:nonFraction> million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Sangamo research, development, regulatory and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzg3MzU_4971be71-be6d-45b7-84ad-b935d30ff0da">2.4</ix:nonFraction> billion if we select all of the targets allowed under this agreement and all the specified milestones set forth in this agreement are achieved. Of this amount, up to $<ix:nonFraction unitRef="usd" contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzg4OTY_819bef5a-1264-4f0a-97e1-d76f00bf1109">80.0</ix:nonFraction> million relates to the selection of targets, $<ix:nonFraction unitRef="usd" contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzg5MzY_dfb9868e-56cb-47f6-8579-4a2d32222370">1.9</ix:nonFraction> billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $<ix:nonFraction unitRef="usd" contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzkwNjM_f8f65ed1-bf8e-46aa-8831-6b4c7aa3e5d1">380.0</ix:nonFraction> million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay Sangamo tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ic5dacb207e1f49b4be42e09594ed7e91" continuedAt="ie97349fe2cff41a1b0c861680bf9c584"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately <ix:nonFraction unitRef="number" contextRef="i6d8e15ff35ac44bab6ffcdf343f511ac_I20200331" decimals="2" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTg3_924a95f9-a9fa-4a24-8b98-4c740badb7a5">5.0</ix:nonFraction>% to approximately <ix:nonFraction unitRef="number" contextRef="i9201821f02cc43b3b8f8fabadde5754b_I20210331" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzExMDA3_7469fd6a-8dc2-4dc9-a5fd-58515022a743">49.9</ix:nonFraction>%. The share purchase transaction was completed in November 2018 and, upon closing, we paid <ix:nonFraction unitRef="krw" contextRef="ibe4be84a93994def8ed976d74fd1dfec_D20181101-20181130" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzExMTAw_6a5d5329-7835-40b8-8130-74dcded7828d">759.5</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="iad7d1365baac43d6945215ce6b8816f7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzExMTIx_d02e1ca0-d3a2-4a82-a5a4-abd2d88cced0">676.6</ix:nonFraction> million) to Samsung BioLogics. As of March 31, 2021, our ownership percentage remained at approximately <ix:nonFraction unitRef="number" contextRef="i9201821f02cc43b3b8f8fabadde5754b_I20210331" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzExMjA4_7469fd6a-8dc2-4dc9-a5fd-58515022a743">49.9</ix:nonFraction>%.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $<ix:nonFraction unitRef="usd" contextRef="i72965d9649fb4d17a86322fadd05e4e3_I20181107" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEyMjIz_3545e9bc-ea84-472f-b295-7d90271c7412">675.0</ix:nonFraction> million and relates to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="ie90411741db34c3b961e743e971e67dd_D20210101-20210331" format="ixt-sec:duryear" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEyNDE1_9d08a502-aaa9-4379-9a0e-ac8692275650">1.5</ix:nonNumeric> years, and the basis differences related to developed technology and IPR&amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="i9290a0d035874af8ac1688475a9c6fda_D20210101-20210331" format="ixt-sec:duryear" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEyNTgz_dcb1244e-a633-4706-bb23-c6315cc589fe">15</ix:nonNumeric> years. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain officers and affiliates of our joint venture partner, Samsung BioLogics, are currently subject to an ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020, we recognized net losses on our investment of $<ix:nonFraction unitRef="usd" contextRef="i69cf49f1dcbd46fbbdb79f66912dd8ca_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzMDYw_e68e55bb-4d30-4591-aa27-f8899a7b87af">18.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5aae7a15859845fc95e18fa3c0eaaf33_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTY0NjM_1dc4f0a8-53e6-442d-8e67-6208183b871e">14.8</ix:nonFraction> million, respectively, reflecting our share of Samsung Bioepis' operating results and amortization of basis differences, net of tax.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the carrying value of our investment in Samsung Bioepis totaled <ix:nonFraction unitRef="krw" contextRef="i9201821f02cc43b3b8f8fabadde5754b_I20210331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzMjY0_95cf9959-dd49-4ab9-88ab-3b53b922c2f2">653.4</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i9201821f02cc43b3b8f8fabadde5754b_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzMjg1_0897b243-b61c-4cf8-aa4f-03e29cb85999">576.3</ix:nonFraction> million) and <ix:nonFraction unitRef="krw" contextRef="i94c61857768f4045b23a12b5bd57d3e6_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzMjkz_caae6662-d684-4ba0-b2a7-1bbeac1d46d1">673.8</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i94c61857768f4045b23a12b5bd57d3e6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzMzE0_69fbc93c-cc76-47a2-8454-af1e13b31f5d">620.2</ix:nonFraction> million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize <ix:nonFraction unitRef="product" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="0" format="ixt-sec:numwordsen" name="biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzNTc4_eeb247b6-c348-43ff-a332-23cd28ebc66c">two</ix:nonFraction> potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i47d16efb9f3f4c09872f1f6d2b724400_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzOTIx_880a6149-e7f0-42e9-b9d9-79e06cdf101d">100.0</ix:nonFraction> million to Samsung Bioepis in January 2020, of which $<ix:nonFraction unitRef="usd" contextRef="i47d16efb9f3f4c09872f1f6d2b724400_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzOTY5_ce4c0f24-3fce-4565-a9c5-ee069e5529b2">63.0</ix:nonFraction> million was recorded as research and development expense in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i61802b3b7d4442588559391d63737368_I20200131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE0MDMz_05d21c49-c775-4104-b504-dc0bd08bcb6a">37.0</ix:nonFraction> million was recorded as an intangible asset in 2019. Additionally, during the third quarter of 2020, we paid Samsung Bioepis a $<ix:nonFraction unitRef="usd" contextRef="i412bdd987d70473f8492259ec4e93e3c_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE0MTU1_8bce2fd0-3428-4902-b3e4-f00dec6fe6bf">15.0</ix:nonFraction>&#160;million development milestone, which was included in research and development expense in our condensed consolidated statements of income. We may pay Samsung Bioepis up to $<ix:nonFraction unitRef="usd" contextRef="i412bdd987d70473f8492259ec4e93e3c_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE0MzEx_c875d709-908b-46eb-ab6f-59a22e576d13">195.0</ix:nonFraction> million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional <ix:nonNumeric contextRef="i412bdd987d70473f8492259ec4e93e3c_D20210101-20210331" format="ixt-sec:durwordsen" name="biib:CollaborationAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE0NTEw_99fb14f9-afe5-43d6-a312-bc652417c77b">five years</ix:nonNumeric>, subject to payment of an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="i47d16efb9f3f4c09872f1f6d2b724400_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="biib:ContractOptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE0NTY4_963c7f55-38e6-47fa-b7f6-b088be347c6a">60.0</ix:nonFraction> million, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ie97349fe2cff41a1b0c861680bf9c584" continuedAt="i9e55c0407fc442e0b8be558157438a42"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share <ix:nonFraction unitRef="number" contextRef="i69cf49f1dcbd46fbbdb79f66912dd8ca_D20210101-20210331" decimals="2" name="biib:Biogenshareofcopromotionprofitsorlosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE1MDIx_546cfe82-2d65-44c7-9378-3c8d6204660c">50.0</ix:nonFraction>% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three months ended March 31, 2021, we recognized net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="i69cf49f1dcbd46fbbdb79f66912dd8ca_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE1Mjk0_3a0b8468-8877-4cef-b984-d8ef13d70196">68.5</ix:nonFraction> million to reflect Samsung Bioepis' <ix:nonFraction unitRef="number" contextRef="i69cf49f1dcbd46fbbdb79f66912dd8ca_D20210101-20210331" decimals="2" name="biib:Biogenshareofcopromotionprofitsorlosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE1MzQ3_546cfe82-2d65-44c7-9378-3c8d6204660c">50.0</ix:nonFraction>% sharing of the net collaboration profits, compared to $<ix:nonFraction unitRef="usd" contextRef="i5aae7a15859845fc95e18fa3c0eaaf33_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE1NDA0_31434ecc-c3f8-4e4e-8b02-545b5d978bac">71.8</ix:nonFraction> million in the prior year comparative period. As discussed above, we have an option to extend this agreement by an additional five years, subject to the payment of an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="i47d16efb9f3f4c09872f1f6d2b724400_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="biib:ContractOptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE1NjEy_963c7f55-38e6-47fa-b7f6-b088be347c6a">60.0</ix:nonFraction> million.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Services</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services are reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts payable to Samsung Bioepis related to the agreements discussed above were $<ix:nonFraction unitRef="usd" contextRef="iaeb7e6ad713d4670b6e038cfbb2130de_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE2OTc0_e461254d-ba96-4f51-ba36-bc9eb88e32d4">188.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i50fc7b747b554ee88ca10781e8675077_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTYwMzM_bd9873c5-9ada-47da-9724-d35784c38cd8">99.0</ix:nonFraction>&#160;million as of March 31, 2021 and December 31, 2020, respectively.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="i9e55c0407fc442e0b8be558157438a42" continuedAt="i41124459f17544dba83e6cca66f7314a"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i41124459f17544dba83e6cca66f7314a"> to our consolidated financial statements included in our 2020 Form 10-K.</ix:continuation> </span></div><div id="i6fe84bc7e101462ea41fc07416803961_118"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;Investments in Variable Interest Entities </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzUzMjg_ef21d4cd-53a0-400e-8e93-e2c603753e24" continuedAt="id30fa529c3de4ee6aa780cc9d44ef14e" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or <ix:nonNumeric contextRef="i7111de4bd0294ff9a9a3ad920d505e32_D20210101-20210331" format="ixt-sec:duryear" name="biib:CollaborationAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzc2OA_1930e015-575a-487c-9f53-48c78690786a">12</ix:nonNumeric> years from the first commercial sale of a licensed product.  </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund <ix:nonFraction unitRef="number" contextRef="i7111de4bd0294ff9a9a3ad920d505e32_D20210101-20210331" decimals="0" name="biib:ResearchAndDevelopmentCostsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzExMTE_b4d746c6-1c26-4e3f-9fce-a6e7ecc669a8">100.0</ix:nonFraction>% of the research and development costs incurred in support of the collaboration. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017 we amended the terms of the Neurimmune Agreement and made a $<ix:nonFraction unitRef="usd" contextRef="ie7dc064ffb824915a213b2bafa7eadc1_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzEyNzE_8ad02ac9-87fb-4f22-80e1-d86e79c9fcc0">150.0</ix:nonFraction> million payment to Neurimmune in exchange for a <ix:nonFraction unitRef="number" contextRef="ie7dc064ffb824915a213b2bafa7eadc1_D20171001-20171031" decimals="2" name="biib:Reductioninroyaltyratepayableoncommercialsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzEzMTQ_d33c7450-4f31-4061-a527-866d1485866f">15.0</ix:nonFraction>% reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional $<ix:nonFraction unitRef="usd" contextRef="i443ec97d551d4f19819d518a28e3dcde_D20180501-20180531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzE1Mzk_00b36070-681a-44a1-8d5f-9424c0de2a92">50.0</ix:nonFraction> million payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional <ix:nonFraction unitRef="number" contextRef="i443ec97d551d4f19819d518a28e3dcde_D20180501-20180531" decimals="2" name="biib:Additionalreductioninroyaltyratepayableoncommercialsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzE3NzQ_fc2b2f2f-6da0-4fbf-b8eb-55740f1ba711">5.0</ix:nonFraction>%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of&#160;$<ix:nonFraction unitRef="usd" contextRef="i058baac90e1841039cf4ef78a041460d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzIzMjc_848be194-29e4-459b-ad2c-8145d2e739a7">75.0</ix:nonFraction> million&#160;upon the regulatory filing with the FDA for the approval of aducanumab. During the second quarter of </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="id30fa529c3de4ee6aa780cc9d44ef14e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020, we paid Neurimmune $<ix:nonFraction unitRef="usd" contextRef="i058baac90e1841039cf4ef78a041460d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzI2MTE_848be194-29e4-459b-ad2c-8145d2e739a7">75.0</ix:nonFraction> million upon the completed submission of the BLA for the approval of aducanumab to the FDA, which was recognized as a charge to noncontrolling interests. In addition, during the second quarter of 2020, we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzI4NTc_a0224b0c-7f8b-4b70-9fb2-bb9942ae0786">33.8</ix:nonFraction> million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzI4Nzk_e56b0ddf-adcf-418d-8884-e0b18e4a34d7">45.0</ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="i058baac90e1841039cf4ef78a041460d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzI4OTU_848be194-29e4-459b-ad2c-8145d2e739a7">75.0</ix:nonFraction> million milestone payment.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to approximately $<ix:nonFraction unitRef="usd" contextRef="i6c605c95790545c0995faf5707af1bfa_I20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzEwOTk1MTE2MzQ1MDM_8b30ddf2-4eaa-40b0-8753-964e87413609">150.0</ix:nonFraction>&#160;million in milestones to Neurimmune in 2021, which includes $<ix:nonFraction unitRef="usd" contextRef="i925bce57d9bf415ba43b031db49f8b12_I20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzEwOTk1MTE2MzQ1MTk_2edf7b2c-7d05-4c36-9e02-503333216d7b">100.0</ix:nonFraction>&#160;million if launched in the U.S. and $<ix:nonFraction unitRef="usd" contextRef="i8e351ee8c7e84208bbcdd85dd32c6e63_I20210331" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzEwOTk1MTE2MzQ1NTA_3edf3795-7fa4-4843-9de6-a9bfe95bf07e">50.0</ix:nonFraction>&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the Aducanumab Collaboration Agreement with Eisai.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the three months ended March 31, 2021 and 2020, amounts reimbursed were immaterial.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $<ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzQ1MTU_d4cac63b-506d-4451-ac9f-5c0ee8c845e6">12.8</ix:nonFraction> million. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div></ix:continuation><div id="i6fe84bc7e101462ea41fc07416803961_124"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;Litigation </span></div><ix:nonNumeric contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMjQvZnJhZzo2Y2ExNjg3N2Q3ODc0NzQzYmFlZjNlOTM1NmE0N2VhOC90ZXh0cmVnaW9uOjZjYTE2ODc3ZDc4NzQ3NDNiYWVmM2U5MzU2YTQ3ZWE4XzEzNTgw_46c2ef64-4a06-4379-a39e-1193c5083620" continuedAt="iebd69251536846c587b32637308430aa" escape="true"><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="iebd69251536846c587b32637308430aa" continuedAt="ie962c3601d5e4af286d687ec1466e554"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aducanumab Securities Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are named as defendants in an action filed by a shareholder on November 13, 2020, in the U.S. District Court for the Central District of California and transferred to the U.S. District Court for the District of Massachusetts in March 2021. The action alleges violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeks a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time. No trial date has been set. A second class action, filed by another shareholder on January 5, 2021, in the U.S. District Court for the District of Massachusetts, was dismissed in March 2021.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing has been scheduled.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. The request for preliminary injunction was denied in June 2019 and the decision was affirmed on appeal in February 2021. In July 2020 the Danish Patent Board of Appeal revoked the Danish Utility Models that were the subject of Fresenius Kabi&#8217;s October 2018 request for a preliminary injunction and Fresenius Kabi has appealed those revocations to Denmark&#8217;s Maritime and Commercial High Court. No hearing has been scheduled in that appeal.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen (Denmark) A/S in Denmark&#8217;s Maritime and Commercial High Court alleging infringement of another Danish Utility Model. A hearing has been scheduled for May 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. A hearing has been set for August 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019 Gedeon Richter PLC commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ie962c3601d5e4af286d687ec1466e554" continuedAt="i05fb46da770343b7abc6664f25936033"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispute with Former Convergence Shareholders</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $<ix:nonFraction unitRef="usd" contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMjQvZnJhZzo2Y2ExNjg3N2Q3ODc0NzQzYmFlZjNlOTM1NmE0N2VhOC90ZXh0cmVnaW9uOjZjYTE2ODc3ZDc4NzQ3NDNiYWVmM2U5MzU2YTQ3ZWE4XzUyNzQ_ad888015-5de5-4c21-b712-b66377b40001">200.0</ix:nonFraction> million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Samsung BioLogics Arbitration</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020 we requested arbitration in the International Chamber of Commerce Court of International Arbitration against Samsung BioLogics seeking interpretation of certain provisions in the Joint Venture Agreement executed on December 6, 2011, as amended, by and between Biogen and Samsung BioLogics (the Joint Venture Agreement). Samsung BioLogics has asserted counterclaims, including breach of the Joint Venture Agreement, and seeks declaratory relief and unspecified damages. An estimate of the possible loss or range of loss cannot be made at this time. No hearing date has been set.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Petition for Inter Partes Review</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit), which is pending. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017 to 2020, we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#8216;514 Patent are invalid for lack of written description. We appealed the judgment to the Federal Circuit and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. We have appealed the judgments and the appeal is pending.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,699,281, 9,090,558 and 10,080,733) pursuant to the Hatch-Waxman Act in the Delaware Court against Teva Pharmaceuticals Development, Inc.  A trial date has not yet been set.</span></div><div style="margin-top:9pt;text-indent:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Office Oppositions</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016 the European Patent Office (EPO) revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing date has been set for January 2022. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i05fb46da770343b7abc6664f25936033"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018 the EPO revoked Forward Pharma A/S' (Forward Pharma) European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for September 2021.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI Patent Revocation Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. The Polish Patent Office dismissed the action in February 2021. In August 2020 a related entity, Polpharma Biologics S.A., also brought an action seeking to revoke the Polish &#8216;263 Patent in the Polish Patent Office. The action was suspended by the Polish Patent Office in April 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and the German appeal has been withdrawn. No hearing has been set in the Italian action.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annulment Proceedings in General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) have each filed applications in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) seeking to annul decisions of the European Medicines Agency (EMA) refusing to validate Polpharma&#8217;s and Mylan Ireland&#8217;s respective applications to market a generic version of TECFIDERA. The EMA&#8217;s refusals were on the grounds that TECFIDERA benefits from regulatory data protection. Biogen and the European Commission were granted leave to intervene in support of the EMA in the case brought by Polpharma and the court will announce its decision in that case on May 5, 2021. We intend to seek leave to intervene in support of the EMA in the case brought by Mylan Ireland. No hearing has been set in that matter.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;</span><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).</span></div><div id="i6fe84bc7e101462ea41fc07416803961_133"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Executive Summary</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have an option to acquire exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize <ix:nonFraction unitRef="product" contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331" decimals="0" format="ixt-sec:numwordsen" name="biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMzMvZnJhZzozMTY3ZjlmN2Y0ZDY0ZGJmOTNiOGVmNDNjYzYxZDc1OS90ZXh0cmVnaW9uOjMxNjdmOWY3ZjRkNjRkYmY5M2I4ZWY0M2NjNjFkNzU5XzE2NDkyNjc0OTY5NDU_eeb247b6-c348-43ff-a332-23cd28ebc66c">two</ix:nonFraction> potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to ensure an uninterrupted supply of medicines to our patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland, which we expect to be partially operational during the first half of 2021. We believe that the Solothurn manufacturing facility will provide us with the ability to further expand if our future growth and drug development plans increase.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development efforts and/or successful execution of external business development opportunities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Environment</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and revenue streams continue to face increasing competition in many markets from generic versions, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products. Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments, foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our competition and pricing risks that could negatively impact our product sales, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk and Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition. For additional information, please read the discussion under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations - Product Revenue - Multiple Sclerosis (MS) - Fumarate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aducanumab (AB mAb)</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020 we completed the submission of a Biologics License Application (BLA) for the approval of aducanumab, an anti-amyloid beta antibody candidate for the potential treatment of Alzheimer's disease that we are developing in collaboration with Eisai Co., Ltd. (Eisai), to the U.S. Food and Drug Administration (FDA). In August 2020 the FDA accepted the BLA and granted Priority Review with a Prescription Drug User Fee Act (PDUFA) action date on March 7, 2021. In November 2020 the FDA held a virtual meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (the Advisory Committee) to review data supporting the BLA for aducanumab and to vote on questions presented at the meeting. A majority of the Advisory Committee members voted against each of the questions presented at the meeting.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 the FDA extended the review period for the BLA for aducanumab by three months. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The updated PDUFA action date is June 7, 2021. As part of the ongoing review, we submitted a response to an information request by the FDA, including additional analyses and clinical data, which the FDA considered a Major Amendment to the application that will require additional time for review.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application for aducanumab and in December 2020 the Ministry of Health, Labor and Welfare accepted for review the Japanese New Drug Application for aducanumab.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made, and will continue to make, commercial, medical and infrastructure investments in support of activities associated with the potential launch of aducanumab, including the adding of headcount and the manufacture of pre-launch inventory. If we do not receive regulatory approval or are unable to successfully commercialize aducanumab, our financial condition, business and operations may be adversely affected. If aducanumab is approved in the U.S., we expect an immediate launch with only modest revenue in 2021, ramping thereafter.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Update Regarding COVID-19</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are monitoring the demand for our products, including the duration and degree to which we may see delays in starting new patients on a product due to hospitals diverting the resources that are necessary to administer certain of our products to care for COVID-19 patients, including products, such as TYSABRI and SPINRAZA, that are administered in a physician's office or hospital setting. We may also see reduced demand for immunosuppressant therapies during the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are currently continuing the clinical trials we have underway in sites across the globe, COVID-19 precautions have impacted the timeline for some of our clinical trials and these precautions may, directly or indirectly, have a further impact on timing in </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the future. For example, our Phase 3 study of BIIB093 (glibenclamide IV) for large hemispheric infarction (LHI), a severe form of ischemic stroke, has been delayed as this study involves administration of BIIB093 in an acute hospital setting. To help mitigate the impact of the COVID-19 pandemic to our clinical trials, we are pursuing innovative approaches such as remote monitoring, remote patient visits and supporting home infusions. These alternative measures have resulted in an immaterial increase to the cost of the clinical trials underway.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the various risks posed by the COVID-19 pandemic, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share attributable to Biogen Inc. was $2.69 for the three months ended March 31, 2021, representing a decrease of 66.7% compared to $8.08 in the same period in 2020.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our net income and diluted earnings per share attributable to Biogen Inc. for the three months ended March 31, 2021, compared to the three months ended March 31, 2020, reflects the following:</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Total revenue was $2,694.0 million for the first quarter of 2021, representing an $840.3 million, or 23.8%, decrease compared to $3,534.3 million in the same period in 2020.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Product revenue, net totaled $2,211.7 million for the first quarter of 2021, representing a $692.9 million, or 23.9%, decrease compared to $2,904.6 million in the same period in 2020. This decrease was primarily due to a $634.2 million, or 30.0%, decrease in MS product revenue and a $44.5 million, or 7.9%, decrease in SPINRAZA product revenue.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">The decrease in MS product revenue was primarily due to a decrease in U.S. TECFIDERA demand as well as higher discounts and allowances as a result of multiple TECFIDERA generic entrants in the U.S. market.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">We believe that, due to the COVID-19 pandemic, there was an acceleration in sales in the first quarter of 2020, primarily in the European Union (E.U.), that increased product revenue by approximately $100.0&#160;million.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Revenue from anti-CD20 therapeutic programs totaled $389.0 million for the first quarter of 2021, representing a $131.4 million, or 25.2%, decrease compared to $520.4 million in the same period in 2020. This decrease was primarily due to a $183.6&#160;million, or 53.6%, decrease in RITUXAN revenue, partially offset by a $47.1&#160;million, or 29.0%, increase in royalty revenue on sales of OCREVUS. We believe that sales of RITUXAN have been adversely affected by the onset of biosimilars competition.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Other revenue totaled $93.3 million for the first quarter of 2021, representing a 14.6% decrease from $109.3 million in the same period in 2020.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expense</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Total cost and expense was $1,720.1 million for the first quarter of 2021, representing a $5.7 million increase compared to $1,714.4 million in the same period in 2020.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Condition, Liquidity and Capital Resources:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We generated $769.0 million of net cash flows from operations for the first quarter of 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Cash, cash equivalents and marketable securities totaled approximately $3,359.4 million as of March 31, 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We repurchased and retired approximately 2.2 million shares of our common stock at a cost of approximately $600.0 million during the first quarter of 2021 under a program authorized by our Board of Directors in October 2020 to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Approximately $4.0 billion remained available under our 2020 Share Repurchase Program as of March 31, 2021.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Key Developments</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Offer</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed a private offer to exchange (Exchange Offer) our tendered 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes) for a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes) and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. For additional information on our Exchange Offer, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">North Carolina Gene Therapy Manufacturing Facility</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021 we announced our plans to build a new gene therapy manufacturing facility in Research Triangle Park, North Carolina to support our growing gene therapy pipeline across multiple therapeutic areas. The new facility will be 175,000 square feet and is expected to be operational by 2023, with an estimated total investment of approximately $200.0&#160;million.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:13pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is summarized as follows:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">899.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,583.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(683.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,311.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,321.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,211.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,904.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(692.9)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.9)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(131.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,694.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,534.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(840.3)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.8)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div id="i6fe84bc7e101462ea41fc07416803961_142"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Revenue</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is summarized as follows:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(547.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">503.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,483.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,117.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(634.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">565.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,211.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,904.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(692.9)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.9)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multiple Sclerosis (MS)</span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fumarate</span></div><div><img src="biib-20210331_g2.jpg" alt="biib-20210331_g2.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fumarate revenue includes sales from TECFIDERA and VUMERITY. In October 2019 the FDA approved VUMERITY for the treatment of RMS and VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease of 69.6% in U.S. Fumarate revenue was primarily due to a decrease in TECFIDERA demand as well as higher discounts and allowances as a result of multiple TECFIDERA generic entrants in the U.S. market. Additionally, revenue in the first quarter</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 2020 reflected higher volume associated with additional shipping days. The decrease was partially offset by an increase in VUMERITY sales volume.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease in rest of world Fumarate revenue was primarily due to a decrease in sales volume of 2.0% and unfavorable impact of foreign currency exchange, partially offset by price increases. We believe that, due to the COVID-19 pandemic, there was an acceleration in sales during the first quarter of 2020 that increased rest of world Fumarate revenue by approximately $28.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Hatch-Waxman Act in West Virginia and Delaware. We have appealed the judgments in both actions.</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate an increase in TECFIDERA sales volume in rest of world in 2021, compared to 2020, notwithstanding the increasing competition from additional treatments for MS and potential disruptions due, directly or indirectly, to the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect an increase in VUMERITY sales volume in the U.S., mostly driven by the continued launch of VUMERITY.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interferon</span></div><div><img src="biib-20210331_g3.jpg" alt="biib-20210331_g3.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease of 17.4% in U.S. Interferon revenue was primarily due to a decrease in Interferon sales volumes of 17.5%. The net decline in sales volume reflects the continued decline of the Interferon market as patients transition to other higher efficacy and oral MS therapies, which negatively impacted comparative revenue by approximately $50.0 million. Additionally, revenue in the first quarter of 2020 reflected higher volume associated with shipping days.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease of 8.5% in rest of world Interferon revenue was primarily due to a decrease in Interferon sales volumes of 8.8%. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that, due to the COVID-19 pandemic, there was an acceleration in sales during the first quarter of 2020 that increased worldwide Interferon revenue by approximately $25.0&#160;million, primarily in the E.U.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that Interferon revenue will continue to decline in both the U.S. and rest of world markets in 2021, compared to 2020, as a result of increasing competition from our other MS products as well as other treatments for MS, including biosimilars, and pricing reductions in certain European markets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div><img src="biib-20210331_g4.jpg" alt="biib-20210331_g4.jpg" style="height:333px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease of 1.6% in U.S. TYSABRI revenue was due to unfavorable volume impacts, primarily resulting from additional shipping days in the first quarter of 2020, partially offset by price increases.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease of 6.0% in rest of world TYSABRI revenue was primarily due to a decrease in pricing of approximately $30.5 million. Revenue in the first quarter of 2020 included a $20.0&#160;million change in estimate related to pharmaceutical taxes. The decrease was partially offset by a favorable volume impact of approximately $13.7 million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate TYSABRI sales volume to modestly increase on a global basis in 2021, compared to 2020, despite increasing competition from additional treatments for MS, including OCREVUS. We expect to continue to face price reductions in certain European markets.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Spinal Muscular Atrophy</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div><img src="biib-20210331_g5.jpg" alt="biib-20210331_g5.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease of 36.8% in U.S. SPINRAZA revenue was due to a decrease in sales volumes of 36.8% resulting from increased competition as well as lower loading and maintenance doses due, directly or indirectly, to the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the increase of 12.8% in rest of world SPINRAZA revenue was primarily due to an increase in sales volumes of 17.3%, due in part by additional shipments in developing markets. The increase was partially offset by a decrease in pricing of 7.8%.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 we expect that SPINRAZA revenue will be subject to increased competition resulting in higher discontinuations and a lower rate of new patient starts combined with the impact of loading dose dynamics as patients transition to dosing once every four months and lower prices in certain rest of world countries.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition from a gene therapy product and an oral product. We expect that we will experience competition from both products in additional jurisdictions in the future. Additionally, we are aware of other products now in development that, if launched, may also compete with SPINRAZA. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our collaboration arrangements with Ionis Pharmaceuticals, Inc. (Ionis), please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BENEPALI, IMRALDI and FLIXABI</span></div><div><img src="biib-20210331_g6.jpg" alt="biib-20210331_g6.jpg" style="height:333px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease of 6.3% in biosimilar revenue was primarily due to the unfavorable impact of lower volumes and price decreases, partially offset by favorable foreign currency impact. We believe that, due to the COVID-19 pandemic, there was an acceleration in sales during the first quarter of 2020 that increased biosimilar revenue by approximately $15.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 we expect modest to moderate revenue growth for our biosimilars business depending on the impact of the COVID-19 pandemic. We expect to continue to face price reductions in certain European countries.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_145"></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech (Roche Group)</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits in the U.S. and other revenue from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><img src="biib-20210331_g7.jpg" alt="biib-20210331_g7.jpg" style="height:346px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of amounts comprising our share of pre-tax profits in the U.S. for RITUXAN and GAZYVA:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.371%"><tr><td style="width:1.0%"></td><td style="width:52.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,078.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax profits in the U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">930.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.1&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease in U.S.&#160;product revenue, net was primarily due to a decrease in sales volumes of RITUXAN in the U.S. of 47.8%, primarily due to the onset of competition from multiple biosimilar products.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, product revenue, net also reflected an increase in GAZYVA sales volume of 0.7%.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease in collaboration costs and expense was primarily due to lower cost of sales on RITUXAN.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several other anti-CD20 molecules, including biosimilar products, that have recently been approved and are expected to compete with RITUXAN and GAZYVA in the oncology and other markets. In November 2019, January 2020 and January 2021 biosimilar products referencing RITUXAN were launched in the U.S. and are being offered at lower prices. This competition has had a significant adverse impact on the pre-tax profits of our collaboration arrangements with Genentech, as the sales of RITUXAN have decreased substantially compared to prior periods. We expect that biosimilar competition will continue to increase as these products capture additional market share and that this will have a significant adverse impact on our co-promotion profits in the U.S. in future years.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue from anti-CD20 therapeutic programs consist of royalty revenue on sales of OCREVUS and our share of pre-tax co-promotion profits from RITUXAN in Canada. </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the increase in other revenue from anti-CD20 therapeutic programs was primarily due to sales growth of OCREVUS. Royalty revenue recognized on sales of OCREVUS for the three months ended March 31, 2021, totaled $209.3 million compared to $162.2 million in the prior year comparative period.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenue from anti-CD20 therapeutic programs, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note&#160;18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_148"></div></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div style="margin-bottom:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:36.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.612%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Collaborative and Other Relationships</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from collaborative and other relationships primarily includes royalty revenue on biosimilar products from Samsung Bioepis.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaborative arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Royalty and Corporate Revenue</span></div><div><img src="biib-20210331_g8.jpg" alt="biib-20210331_g8.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease in other royalty and corporate revenue was primarily due to a decrease in royalty revenue and lower contract manufacturing revenue.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_151"></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reserves for Discounts and Allowances</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for discounts, contractual adjustments and returns that reduced gross product revenue are summarized as follows:</span></div><div><img src="biib-20210331_g9.jpg" alt="biib-20210331_g9.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, reserves for discounts and allowances as a percentage of gross product revenue was 29.0% compared to 25.7% in the prior year comparative period. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discounts</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts include trade term discounts and wholesaler incentives.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease in discounts was primarily driven by a decrease in gross sales. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Adjustments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual adjustments primarily relate to Medicaid and managed care rebates, pharmacy rebates, co-payment (copay) assistance, Veterans Administration, Public Health Service discounts, specialty pharmacy program fees and other government rebates or applicable allowances.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease in contractual adjustments was primarily due to lower Medicaid and managed care rebates, partially offset by pharmacy rebates.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Returns</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenue is recognized, resulting in a reduction to product sales.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, return reserves were relatively consistent.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our revenue reserves, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Revenue,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_154"></div></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cost and Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of total cost and expense is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">514.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit (loss) sharing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,720.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,714.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div id="i6fe84bc7e101462ea41fc07416803961_157"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales, Excluding Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20210331_g10.jpg" alt="biib-20210331_g10.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Cost of Sales</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the increase in product cost of sales was primarily due to higher cost of sales associated with contract manufacturing agreements.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Cost of Sales</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, royalty cost of sales remained flat.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_160"></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div><img src="biib-20210331_g11.jpg" alt="biib-20210331_g11.jpg" style="height:366px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20210331_g12.jpg" alt="biib-20210331_g12.jpg" style="height:766px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant amount of our research and development costs consists of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the increase in research and development expense was primarily due to an increase in spending related to the EMBARK redosing study for aducanumab, the development of BIIB125 (zuranolone) for the potential treatment of major depressive disorder (MDD) and postpartum depression (PPD), which we are developing in collaboration with Sage Therapeutics, Inc. (Sage), and BIIB124 (SAGE-324) for the potential treatment of essential tremor, which we are developing in collaboration with Sage.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, we capitalized approximately $124.7&#160;million and $93.8&#160;million, respectively, of pre-launch inventory for aducanumab. If aducanumab does not receive regulatory approval in the U.S., we would expense this inventory as research and development expense and, under the terms of the collaboration agreement with Eisai to jointly develop and commercialize aducanumab (the Aducanumab Collaboration Agreement), Eisai would reimburse us for 45.0% of the costs.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Stage Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the increase in spending related to our early stage programs was primarily due to an increase in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">spending in the development of BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa;</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">spending in the development of BIIB122 (DNL151) for the potential treatment of Parkinson's disease, which we are developing in collaboration with Denali Therapeutics Inc. (Denali); and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">spending in the development of BIIB124 for the potential treatment of essential tremor.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase was partially offset by a decrease in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of gosuranemab (BIIB092) in progressive supraneuclear palsy; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of dapirolizumab pego, an anti-CD40L pegylated Fab that we are developing in collaboration with UCB Pharma S.A., for the potential treatment of systemic lupus erytheatosus (SLE) into late stage. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Late Stage Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the increase in spending associated with our late stage programs was primarily due to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">spending in the development of zuranolone for the potential treatment of MDD and PPD;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending related to the EMBARK redosing study for aducanumab and other development activities, net of reimbursement from Eisai;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of dapirolizumab pego for the potential treatment of SLE into late stage; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending related to BAN2401 (lecanemab), an anti-amyloid beta antibody, in early Alzheimer's disease that we are developing in collaboration with Eisai.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020 we completed the submission of a BLA for the approval of aducanumab to the FDA. In August 2020 the FDA accepted the BLA and granted Priority Review with a PDUFA action data on March 7, 2021. In January 2021 the FDA extended the review period for the BLA for aducanumab by three months. The updated PDUFA action date is June 7, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 Eisai initiated a global Phase 3 trial for the development of BAN2401 in early Alzheimer's disease. Under our collaboration arrangement, Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expense, are shared equally between us and Eisai.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_2087"></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div><img src="biib-20210331_g13.jpg" alt="biib-20210331_g13.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, selling, general and administrative expense increased 4.4%, primarily due to increases in personnel in support of the potential launch of aducanumab.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_163"></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20210331_g14.jpg" alt="biib-20210331_g14.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant amortizable intangible assets are related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products and other programs acquired through business combinations. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the increase in amortization and impairment of acquired intangible assets was primarily related to a $44.3&#160;million impairment charge recorded during the first quarter of 2021 related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN). For the three months ended March 31, 2020, we had no impairment charges.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenue of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development (IPR&amp;D) represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, the value of our acquired IPR&amp;D assets is dependent upon several variables, including estimates of future revenue and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and efficacy based on data from clinical trials and regulatory feedback, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next. We are continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies, research and development priorities and development risk, changes in program and portfolio economics and related impact of foreign currency exchange rates and economic trends and evaluating industry and company data regarding the productivity of clinical research and the development process. Changes in our estimates may result in a significant change to our valuation of our IPR&amp;D assets.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for TGN and DPN and now plan to perform an additional clinical trial of vixotrigine before initiating a Phase 3 study of DPN.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the first quarter of 2021. As of March 31, 2021, the carrying value associated with our remaining vixotrigine IPR&amp;D assets was $135.1&#160;million, all of which is related to DPN.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111 and BIIB112</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020 we recognized an impairment charge of $115.0&#160;million related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, as a result of third-party manufacturing delays that may impact our timeline for a potential filing of a BLA for regulatory approval by up to one year, and increase the costs associated with advancing BIIB111 through Phase 3 development.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to monitor the manufacturing issues encountered with BIIB111 and their potential impact on that program's timing. As of March 31, 2021, we have no indication that BIIB111 or BIIB112 were impaired; however, we will continue to monitor the capabilities of our manufacturing partners and how any additional new manufacturing issues might affect the planned timing of such gene therapy programs.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Profit (Loss) Sharing</span></div><div><img src="biib-20210331_g15.jpg" alt="biib-20210331_g15.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration profit (loss) sharing primarily includes Samsung Bioepis' 50.0% share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, we recognized net profit-sharing expense of $68.5 million  to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits compared to $71.8 million in the prior year comparative period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div id="i6fe84bc7e101462ea41fc07416803961_172"></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</span></div><div><img src="biib-20210331_g16.jpg" alt="biib-20210331_g16.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-Process Research and Development</span></div><div><img src="biib-20210331_g17.jpg" alt="biib-20210331_g17.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB118 Acquisition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020 we acquired BIIB118 (CK1 inhibitor) for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). In connection with this acquisition, we made an upfront payment of $75.0 million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired IPR&amp;D in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of BIIB118, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_178"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div><img src="biib-20210331_g18.jpg" alt="biib-20210331_g18.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the change in </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other income (expense), net primarily reflects net unrealized losses on our holdings in equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $442.3 million and $6.2 million, respectively, compared to net unrealized and realized losses of $60.9 million and zero, respectively, in the prior year comparative period. The net unrealized losses recognized during the three months ended March 31, 2021, primarily reflect a decrease in the fair value of Ionis, Sangamo Therapeutics, Inc. (Sangamo), Denali and Sage common stock of approximately $442.0 million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect interest expense for 2021 to be relatively consistent with 2020.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_181"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income Tax Provision</span></div><div><img src="biib-20210331_g19.jpg" alt="biib-20210331_g19.jpg" style="height:425px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expense, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our effective tax rate was primarily due to the change in the territorial mix of our profitability, which included the effect of generic competition for TECFIDERA in the U.S. market, and the non-cash tax effects of changes in the value of our equity investments, where we recorded a reduction of value in the first quarter of 2021. The tax effects of this change in value of our equity investments were recorded discretely, since changes in value of equity investments cannot be forecasted.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our income taxes please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14, Income Taxes,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_184"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Equity in (Income) Loss of Investee, Net of Tax</span></div><div><img src="biib-20210331_g20.jpg" alt="biib-20210331_g20.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018. As of March 31, 2021, our ownership percentage remained at approximately 49.9%.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in </span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(income) loss of investee, net of tax in our consolidated statements of income. We recognize amortization on certain basis differences resulting from our November 2018 investment.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain officers and affiliates of our joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, we recognized net losses on our investment of $18.2 million reflecting our share of Samsung Bioepis' operating results and amortization of basis differences, net of tax.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Condition, Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:14pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change&#160;%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,217.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,331.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,320.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">821.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">772.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,359.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,382.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,267.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,267.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,719.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,887.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,165.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,742.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total working capital</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,553.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,144.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="i6fe84bc7e101462ea41fc07416803961_193"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, certain significant cash flows were as follows:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$769.0 million in net cash flow provided by operating activities;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$600.0 million used for share repurchases;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$169.3&#160;million used in connection with our Exchange Offer; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$92.6 million used for purchases of property, plant and equipment.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have historically financed our operating and capital expenditures primarily through cash flow earned through our operations. We expect our operating expenditures, particularly those related to research and development, clinical trials, commercialization of new products and international expansion to continue to grow. However, we expect to continue funding our current and planned operating requirements primarily through our cash flow earned from our operations as well as our existing cash resources. We believe generic competition for TECFIDERA in the U.S. will continue to reduce our cash flow from operations in 2021 and will have a significant adverse impact on our future cash flow from operations. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">additional equity and debt financings or from other sources should we identify a significant new opportunity</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Aducanumab</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020 we completed the submission of a BLA for the approval of aducanumab to the FDA. In August 2020 the FDA accepted the BLA and granted Priority Review with a PDUFA action date on March 7, 2021. In January 2021 the FDA extended the review period for the BLA for aducanumab by three months. The updated PDUFA action date is June 7, 2021. If we do not receive regulatory approval or are unable to successfully commercialize aducanumab, our financial condition, business and operations may be adversely affected.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Item 3. Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, we had cash, cash equivalents and marketable securities totaling approximately $3.4 billion. The </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">change in cash, cash equivalents and marketable securities at March 31, 2021, from December 31, 2020, was primarily due to cash used for share repurchases and capital expenditures as well as cash payments made in connection with our Exchange Offer, partially offset by net cash flow provided by operating activities.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments and other assets in our condensed consolidated balance sheets as of March 31, 2021 and December 31, 2020, include the carrying value of our investment in Samsung Bioepis of $576.3 million and $620.2 million, respectively. As Samsung Bioepis is a privately-held entity, our ability to liquidate our investment may be limited and we may realize significantly less than the value of such investment. This investment is also subject to foreign currency exchange fluctuations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our collaboration with Sangamo, we purchased approximately 24 million shares of Sangamo common stock in April 2020. As of March 31, 2021 and December 31, 2020, the fair value of this investment was $277.8 million and $333.7&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our collaboration with Denali, we purchased approximately 13&#160;million shares of Denali common stock in September 2020. As of March 31, 2021 and December 31, 2020, the fair value of this investment was $638.5&#160;million and $935.7&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our collaboration with Sage, we purchased approximately 6.2&#160;million shares of Sage common stock in December 2020. As of March 31, 2021 and December 31, 2020, the fair value of this investment was $378.3&#160;million and $433.9&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment in Ionis common stock had a fair value of $129.3&#160;million and $249.1&#160;million as of March 31, 2021 and December 31, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, Sangamo, Denali and Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020 we issued our 2020 Senior Notes for an aggregate principal amount of $3.0 billion, consisting of the following:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5 billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5 billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our currently outstanding senior secured notes issued in 2015 (2015 Senior Notes):</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.12 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 Senior Notes and our 2015 Senior Notes were issued at a discount, which are amortized as additional interest expense over the period from issuance through maturity.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer, whereby an aggregate principal amount of approximately $624.6&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $700.7&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $151.8&#160;million. In addition, we redeemed an aggregate principal amount of approximately $8.9&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $12.1&#160;million, excluding accrued and unpaid interest.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a summary of the fair and carrying values of our outstanding borrowings as of March 31, 2021 and December 31, 2020, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of March 31, 2021, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital is defined as current assets less current liabilities. The change in working capital at </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021, from December 31, 2020, reflects a decrease in total current assets of approximately $167.6 million and a decrease in total current liabilities of approximately $576.4 million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in total current assets was primarily driven by a decrease in net cash, cash equivalents and marketable securities, due to cash used for share repurchases and capital expenditures as well as cash payments made in conjunction with our exchange and redemption of a portion of our 2045 Senior Notes, partially offset by $769.0&#160;million in cash flow from operations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net decrease in current liabilities was primarily due to a reduction in accrued expense and other, which was primarily related to decreases in the accrual of contingent payments, the accrual for employee compensation and benefits and the fair values of derivative liabilities.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.2 million shares of our common stock </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at a cost of approximately $600.0 million during the three months ended March 31, 2021. Approximately $4.0 billion remained available under our 2020 Share Repurchase Program as of March 31, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 3.2&#160;million shares of our common stock at a cost of approximately $941.1&#160;million during the three months ended March&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1&#160;million shares of our common stock at a cost of approximately $1.3&#160;billion during the three months ended March&#160;31, 2020.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span><br/></span></div><div id="i6fe84bc7e101462ea41fc07416803961_196"></div></div></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activity:</span></div><div style="margin-bottom:14pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">769.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,467.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow (used in) provided by  investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">442.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow used in financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(785.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,245.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow is derived by adjusting our net income for:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">non-cash operating items such as depreciation and amortization, impairment charges, unrealized gain (loss) on strategic investments, acquired IPR&amp;D and share-based compensation;</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease in net cash flow provided by operating activities was primarily due to lower net income.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the increase in </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net cash flow used in investing activities was primarily due to lower net proceeds received from the sale of investments as compared to the prior year, partially offset by higher capital expenditures and acquisitions of IPR&amp;D and other intangible assets in 2020.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease in net cash flow used in financing activities was primarily due to the greater number of shares repurchased in 2020 as compared to the comparative period in 2021, partially offset by cash used in connection with our Exchange Offer.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_199"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contractual Obligations and Off-Balance Sheet Arrangements</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our contractual obligations since December 31, 2020.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Payments</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make contingent payments of 18.0% on annual worldwide net sales of TYSABRI up to $2.0 billion and 25.0% on annual worldwide net sales of TYSABRI that exceed $2.0 billion. Royalty payments are recognized as cost of sales in our condensed consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make royalty payments on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11.0% and 15.0%, which are recognized as cost of sales in our condensed consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VUMERITY</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 the FDA approved VUMERITY for the treatment of RMS. Under our agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), we make royalty payments to Alkermes on worldwide net commercial sales of VUMERITY using a royalty rate of 15.0%, which are recorded as cost of sales in our condensed consolidated statements of income.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes. We have elected to initiate a technology transfer and, following a transition period, to manufacture VUMERITY or have VUMERITY manufactured by a third party we have engaged in exchange for paying an increased royalty rate to Alkermes on any portion of future worldwide net commercial sales of VUMERITY that is manufactured by us or our designee. For additional information on our collaboration arrangement with Alkermes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd., we agreed to make additional payments based upon the achievement of certain milestone events.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the contingent consideration liabilities associated with this acquisition at its fair value on the acquisition date and revalue this obligation each reporting period. We may pay up to approximately $400.0 million in remaining milestones related to this acquisition.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our development plans as of March 31, 2021, we could trigger potential future milestone payments to third parties of up to approximately $10.1 billion, including approximately $1.9 billion in development milestones, approximately $1.2 billion in regulatory milestones and approximately $7.0 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of March 31, 2021, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain clinical and commercial milestones are met, we may pay up to $86.2&#160;million in milestones in 2021 under our current agreements. In addition, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to approximately $150.0&#160;million in milestones to Neurimmune SubOne AG (Neurimmune) in 2021, which includes $100.0&#160;million if launched in the U.S. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $50.0&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the Aducanumab Collaboration Agreement with Eisai.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expense of approximately $27.1 million in our condensed consolidated balance sheet for expenditures incurred by CROs as of March 31, 2021. We have approximately $554.9 million in cancellable future commitments based on existing CRO contracts as of March 31, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM Corporation (FUJIFILM), we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we do not expect to incur an adverse commitment obligation associated with such guarantees. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may further adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the divestiture of Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Related Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of March 31, 2021, we have approximately $100.0 million of liabilities associated with uncertain tax positions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, we have accrued income tax liabilities of </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $697.0&#160;million under a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). Of the amounts accrued as of March 31, 2021, $62.0&#160;million is expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_202"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of new accounting standards please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_205"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our critical accounting estimates, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part&#160;II,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form&#160;10-K. There have been no material changes to our critical accounting estimates since our 2020 Form&#160;10-K.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_208"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks that may affect our results of operations, cash flow and fair values of </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements and pricing pressures worldwide as well as changes in economic conditions in the markets in which we operate as a result of the COVID-19 pandemic. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.  </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. As a result, our consolidated financial position, results of operations and cash flow can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Japanese yen and South Korean won.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue and expense will increase when reported in U.S. dollars.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flow and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100.0%, which indicated that Argentina's economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of March 31, 2021, and is not expected to have a material impact on our </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results of operations or financial position in the future.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Operating Expense Hedging Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenue and operating expense. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next 21 months. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to mitigate the impact of foreign currency exchange rate changes on revenue and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet Risk Management Hedging Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of March 31, 2021 and December 31, 2020, a hypothetical adverse 10.0% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $456.1 million and $458.2 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Hedge Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment hedging program is designed to mitigate currency fluctuations between the U.S. dollar and the South Korean won as a result of our approximately 49.9% ownership interest in Samsung Bioepis. We entered into foreign currency forward contracts to manage the foreign currency risk with our forward contracts used to hedge changes in the spot rate over the next seven months. As of March 31, 2021 and December 31, 2020, a hypothetical adverse 10.0% movement would result in a hypothetical decrease in fair value of approximately $54.7 million and $56.9 million, respectively. The estimated fair value was determined by measuring the impact of the hypothetical spot rate movement on outstanding forward contracts.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of March 31, 2021 and December 31, 2020, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $12.6 million and $13.2 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing Pressure</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governments in certain international markets in which we operate have implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Our inability to obtain and maintain adequate prices in a particular country may not only limit the revenue from our products within that country but may also adversely affect our ability to secure </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the way our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our consolidated financial position or results of operations. There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, impose restrictions on the coverage of certain drugs.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products continue to face increasing competition in many markets from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways.&#160;Such products are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">markets using our products as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions, including as a result of the COVID-19 pandemic, can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our allowance for doubtful accounts was adequate as of March 31, 2021 and December 31, 2020. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_211"></div><div style="margin-top:12pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:8pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures and Internal Control over Financial Reporting</span></div><div style="margin-top:8pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of March 31, 2021. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms; and </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:8pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended March 31, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_214"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part&#160;II&#160;&#8212; OTHER INFORMATION</span></div><div id="i6fe84bc7e101462ea41fc07416803961_217"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of legal proceedings as of March 31, 2021, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_220"></div><div style="margin-top:6pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on revenue from our products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs. A significant portion of our revenue is concentrated on sales of our products in increasingly competitive markets and in markets affected directly and indirectly by the COVID-19 pandemic. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenue and results of operations or could cause a decline in our stock price: </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction or greater acceptance of competing products, including new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">safety or efficacy issues;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements; increased competition, including from generic or biosimilar versions of our products; or changes in, or implementation of, reimbursement policies and practices of payors and other third parties;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse legal, administrative, regulatory or legislative developments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to maintain a positive reputation among patients, healthcare providers and others, which may be impacted by our pricing and reimbursement decisions; or</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability or reluctance of patients to receive a diagnosis, prescription or administration of our products or a decision to prescribe and administer competitive therapies as a direct or indirect result of the COVID-19 pandemic.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term success depends upon the successful development of new products and additional indications for our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success will depend upon the successful development of new products and technologies from our research and development activities or our licenses or acquisitions from third parties, including our commercialization agreements with Samsung Bioepis, as well as additional indications for our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product development is very expensive and involves a high degree of uncertainty and risk and may not be successful. Only a small number of research and development programs result in the commercialization of a product. It is difficult to predict the success and the time and cost of product development of novel approaches for the treatment of diseases. The development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the antisense oligonucleotide platform and gene therapy, may present additional challenges and risks, including obtaining approval from regulatory authorities that have limited experience with the development of such therapies.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trial data are subject to differing interpretations and even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, limit the scope of the approval or deny approval altogether. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we could successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or we prefer to pursue other opportunities in our pipeline. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of new products or products with additional indications may also not meet investor expectations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing, research and development and other resources and other technological or competitive advantages. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products continue to face increasing competition from the introduction of new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways. Some of these products are likely to be sold at substantially lower prices than our branded products. The introduction of such products as well as other lower-priced competing products has reduced, and may in the future, significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. For instance, demand and price for TECFIDERA declined significantly as a result of multiple TECFIDERA generic entrants entering the U.S. market during the year ended December 31, 2020. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to compete, maintain and grow our business may be adversely affected due to a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our products, including our own products and products of our collaborators; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction of generic versions of branded products, including our own products, biosimilars, follow-on products, prodrugs or products approved under abbreviated regulatory pathways, which would be significantly less costly than our products to bring to market and would be offered for sale at lower prices, and could result in a significant percentage of the sales of our products being lost to such products;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the off-label use by physicians of therapies indicated for other conditions to treat patients; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patient dynamics, including the size of the patient population and our ability to attract and maintain new and current patients to our therapies; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">damage to physician and patient confidence in any of our products, generic or biosimilars of our products or any other product from the same class as one of our products, or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our products or generic or biosimilars of our products;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inability to obtain appropriate pricing and reimbursement for our products compared to our competitors in key international markets; or</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain patent, data or market exclusivity for our products.</span></div><div style="margin-top:9pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives and external opportunities, which may include the acquisition and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. We have made, and may continue to make, significant operating and capital expenditures for potential new products prior to regulatory </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may fail to initiate or complete transactions for many reasons, including failure to obtain regulatory or other approvals as well as disputes or litigation. Furthermore, we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and reimbursement for our products may be adversely affected by a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">pressure by employers on private health insurance plans to reduce costs;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">consolidation and increasing assertiveness of payors seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to set the price for our products varies significantly from country to country and, as a result, so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Our inability to obtain and maintain adequate prices in a particular country may not only limit the revenue from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenue.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. Competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products marketed by our competitors could cause our revenue to decrease due to potential price reductions and lower sales volumes. Additionally, the introduction of generic or biosimilar versions of our products, follow-on products, prodrugs or products approved under abbreviated regulatory pathways may significantly reduce the price that we are able to charge for our products and the volume of products we sell.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients, including more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Additional </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on relationships with collaborators, joint venture partners and other third parties for revenue, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of significant collaborative, joint venture and other third-party relationships for revenue and the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource certain aspects of our regulatory affairs and clinical development relating to our products and product candidates to third parties. Reliance on third parties subjects us to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">we may be unable to control the resources our collaborators, joint venture partners or third parties devote to our programs, products or product candidates;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">disputes may arise under an agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed, and the underlying agreement may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators, joint ventures partners or third parties fail to perform; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the interests of our collaborators, joint venture partners or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenue, or may adopt tax strategies that could have an adverse effect on our business, results of operations or financial condition; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">third-party relationships require the parties to cooperate, and failure to do so effectively could adversely affect product sales or the clinical development or regulatory approvals of product candidates under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any failure on the part of our collaborators, joint venture partners or other third parties to comply with applicable laws, including tax laws, regulatory requirements and/or applicable contractual obligations or to fulfill any responsibilities they may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenue as well as involve us in possible legal proceedings; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any improper conduct or actions on the part of our collaborators, joint venture partners or other third parties could subject us to civil or criminal investigations and monetary and injunctive penalties, impact the accuracy and timing of our financial reporting and/or adversely impact our ability to conduct business, our operating results and our reputation.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain officers and affiliates of our joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that may impact its operations and business or divert the attention of the Samsung Bioepis management team from its ongoing operations. </span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as Samsung Bioepis is a privately-held entity, our ability to liquidate our investment may be limited and we may realize significantly less than the value of such investment.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, revenue from products could decline and/or we may not realize the anticipated benefits of these arrangements.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is increasing public attention on the costs of prescription drugs and there have been, are expected to continue to be, legislative proposals to address prescription drug pricing. Some of these proposals could have significant effects on our business, including an executive order issued in September 2020 to test a &#8220;most favored nation&#8221; model for Part B and Part D drugs that tie reimbursement rates to international drug pricing metrics. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant economic pressure on state budgets, including as a result of the COVID-19 pandemic, that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenue and may continue to adversely affect our revenue and results of operations in the future.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful in such activities, our business may be adversely affected.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture and commercialization of biosimilar products require specialized expertise and are very costly and subject to complex regulation. Our success in commercializing biosimilars is subject to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Reliance on Third Parties.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are dependent, in part, on the efforts of Samsung Bioepis, collaboration partners and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. If these third parties fail to perform successfully, our biosimilar product development or commercialization of biosimilar products could be delayed, revenue from biosimilar products could decline and/or we may not realize the anticipated benefits of these arrangements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Regulatory Compliance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Intellectual Property and Regulatory Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Failure to Gain Market and Patient Acceptance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Ability to Provide Adequate Supply.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Manufacturing biosimilars is complex. If we encounter any manufacturing or supply chain difficulties we may be unable to meet higher than anticipated demand. We are dependent on a third-party for the manufacture of biosimilar products and such third-party may not perform its obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Competitive Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products face significant competition, including from innovator products and biosimilar products offered by other companies. Local tendering processes may restrict biosimilar products from being marketed and sold in some jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area.</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. Even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated, including limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expense, have an adverse effect on our business, financial condition and results of operations and/or cause our stock price to decline or experience periods of volatility.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors, including protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or denied.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials and if such CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs, which may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or products from the same class as one of our products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and/or the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in adverse impacts on our results of operations. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase claims against us and may also cause our product sales to decline or our stock price to experience periods of volatility.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy (PML) in the label for certain of our products, may significantly reduce expected revenue for those products and require significant expense and management time.</span></div><div style="margin-top:9pt;text-indent:22.3pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="margin-top:9pt;text-indent:22.3pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear and creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. In addition, we may encounter criticism on social media regarding our company, management, product candidates or products. The immediacy of social media precludes us from having real-time control over postings made regarding us via social media, whether matters of fact or opinion. Our reputation could be damaged by negative publicity or if adverse information concerning us is posted on social media platforms or similar mediums, which we may not be able to reverse. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Intellectual Property</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success, including our long-term viability and growth, depends, in part, on our ability to obtain and defend patent and other intellectual property rights, including certain regulatory forms of exclusivity, that are important to the commercialization of our products and product candidates. Patent protection and/or regulatory exclusivity in the U.S. and other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to obtain or preserve patent and other intellectual property rights, including certain regulatory forms of exclusivity, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business, which could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price. In addition, settlements of such proceedings often result in reducing the period of patent and other protections, resulting in a reduction in revenue from affected products.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many markets, including the U.S., manufacturers may be allowed to rely on the safety and efficacy data of the innovator's product and do not need to conduct clinical trials before marketing a competing version of a product after there is no longer patent or regulatory exclusivity. In such cases, manufacturers often charge significantly lower prices and a major portion of the company's revenue may be reduced in a short period of time. In addition, manufacturers of generics and biosimilars may choose to launch or attempt to launch their products before the expiration of our patent or other intellectual property protections.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third parties. Legal proceedings, administrative challenges or other types of proceedings are and may in the future be necessary to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be pertinent to the manufacture, use or sale of our products.&#160;Such proceedings are unpredictable and are often protracted and expensive. Negative outcomes of such proceedings could hinder or prevent us from manufacturing and marketing our products, could require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. A failure to obtain necessary licenses for an infringed product or technology could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be materially adversely affected, directly or indirectly, by the ongoing COVID-19 pandemic. National, state and local governments in affected regions have implemented and may continue to implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter in place orders and shutdowns, business closures and other measures. These measures may disrupt normal business operations both in and outside of affected areas and may have significant negative impacts on businesses and financial markets worldwide.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic, including limiting travel and working from home. We have also suspended the vast majority of our in-person interactions by our customer-facing professionals in healthcare settings. This limits our ability to market our products and educate physicians, which, in turn, could have an adverse effect on our ability to compete in the marketing and sales of our products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prolonged remote working arrangements could impact employees&#8217; productivity and morale, strain our technology resources and introduce operational risks. Operating requirements may continually change due to the COVID-19 pandemic and we may experience unpredictability in our expenses, employee productivity and employee work culture. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our moving increasingly towards a remote working environment, which may be less secure and more susceptible to hacking attacks.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic could affect the health and availability of our workforce as well as those of the third parties we rely on. If members of our management and other key personnel in critical functions across our organization are unable to perform their duties or have limited availability due to the COVID-19 pandemic, we may not be able to execute on our business strategy and/or our operations may be negatively impacted. Furthermore, delays and disruptions experienced by our collaborators, joint venture partners or other third parties due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect product sales or the clinical development or regulatory approvals of product candidates under joint control.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to continue our existing clinical trials or to initiate new clinical trials may be adversely affected, directly or indirectly, by the COVID-19 pandemic. For example, our Phase 3 study of BIIB093 for LHI has been delayed as this study involves administration of BIIB093 in an acute hospital setting. Restrictions on travel and/or transport of clinical materials as well as diversion of hospital staff and resources to COVID-19 infected patients could disrupt trial operations and recruitment, possibly resulting in a slowdown in enrollment and/or deviations from or disruptions in key clinical trial activities, such as clinical trial site monitoring. These challenges may lead to difficulties in meeting protocol-specified procedures. We may need to make certain adjustments to the operation of clinical trials in an effort to minimize risks to trial data integrity during the COVID-19 pandemic. In addition, the impact of the COVID-19 pandemic on the operations of the FDA and other health authorities may delay potential approvals of our product candidates.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in the U.S. in March 2020 and is aimed at providing emergency assistance and health care for individuals, families and businesses and generally supporting the U.S. economy. We expect that additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures. The COVID-19 pandemic may introduce temporary or permanent healthcare reform measures for which we cannot predict the financial implication of on our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is not possible at this time to estimate the entirety of the impact that the COVID-19 pandemic will have on our business, operations, employees, customers, suppliers or collaboration partners, continued spread of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19, measures taken by governments, actions taken to protect employees and the broad impact of the pandemic on all business activities may materially and adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon technology systems and data to operate our business. Further, the COVID-19 pandemic has caused us to modify our business practices, including the requirement that most of our office-based employees in the U.S. and our other key markets work from home. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). A breakdown, invasion, corruption, destruction or breach of our technology systems, including our cloud technologies, and/or unauthorized access to our data and information could subject us to liability or negatively impact the operation of our business. Our technology systems, including our cloud technologies, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Data privacy or security breaches also pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks could also include supply chain attacks, which could cause a delay in the manufacturing of our products or products produced for contract manufacturing. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies could heighten these and other operational risks, and any failure by cloud technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators are imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the E.U.&#8217;s General Data Protection Regulation established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance. New U.S. data privacy and security laws, such as the California Consumer Privacy Act (CCPA), and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with the CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Failure to comply with these current and future laws, policies, industry standards or legal obligations or any security incident resulting in the unauthorized access to, or acquisition, release or transfer of personal information may result in governmental enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. New members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new opportunities or reduce or change emphasis on our existing programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, including management changes, the underperformance or discontinuation of one or more late stage programs or recruitment by competitors. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight in the U.S.&#160;and in foreign jurisdictions, and are subject to change and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. The FDA and comparable foreign agencies directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting, product risk management and our compliance with good practice quality guidelines and regulations. Our interactions with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies are facing heightened scrutiny of their relationships with health care providers and have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the FDA and foreign regulatory approval processes or perspectives that may delay or prevent the approval of new products and result in lost market opportunity; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of governmental regulation may be punishable by criminal and civil sanctions, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">well as against executives overseeing our business. We could also be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we submitted to the government. In addition, legal proceedings and investigations are inherently unpredictable, and large judgments or settlements sometimes occur. While we believe that we have appropriate compliance controls, policies and procedures in place to comply with the laws or regulations of the jurisdictions in which we operate, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate such laws or regulations. Whether or not we have complied with the law, an investigation or litigation related to alleged unlawful conduct could increase our expense, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasing our presence in international markets, subjecting us to many risks that could adversely affect our business and revenue. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements previously utilized by companies we collaborate with or acquire in emerging markets.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on the global economy and the delivery of healthcare treatments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">less favorable intellectual property or other applicable laws; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on our ability to obtain and maintain product pricing or receive price increases, including those resulting from governmental or regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">fluctuations in foreign currency exchange rates that may adversely impact our revenue, net income and value of certain of our investments; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of governmental controls; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">diverse data privacy and protection requirements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the far-reaching anti-bribery and anti-corruption legislation in the United Kingdom (U.K.), including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">compliance with complex import and export control laws;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in tax laws; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of tariffs or embargoes and other trade restrictions.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our international operations are subject to regulation under U.S. law. For example, the U.S. Foreign Corrupt Practices Act (FCPA) prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results. In addition, while we believe that we have appropriate compliance controls, policies and procedures in place to comply with the FCPA, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate the FCPA and we might be held responsible. If our employees, agents, distributors, collaborators or third-party providers are found to have engaged in such practices, we could suffer severe penalties and may be subject to other liabilities, which could negatively affect our business, operating results and financial condition.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required or this investment will be recouped.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the Solothurn facility to be partially operational during the first half of 2021; however, there can be no assurance that we will be able to meet our expected timeline or that there will not be any direct or indirect delays resulting from the COVID-19 pandemic. We have had delays, and if there are additional delays, in bringing the Solothurn facility online, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenue.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risks of Reliance on Third Parties and Single Source Providers.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control, including the impact of the COVID-19 pandemic. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risks Relating to Compliance with current Good Manufacturing Practices (cGMP).</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and other regulatory authorities to confirm compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or operations or those of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Global Bulk Supply Risks. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, public health epidemics, natural disasters, power failures, cyber-attacks and many other factors. In addition, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland, which we expect to be partially operational during the first half of 2021. However, there can be no assurance that we will be able to meet our expected timeline or that there will not be any direct or indirect delays resulting from the COVID-19 pandemic. We have had </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delays, and if there are additional delays, in bringing the Solothurn facility online, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk of Product Loss.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk Relating to Government Actions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We and/or our third-party providers may be required by the U.S. federal government to manufacture medical supplies needed to treat COVID-19 patients under the Defense Production Act or other acts or orders of government entities, which may result in delays in the manufacturing and supply of our products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expense for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates, including withholding taxes, in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate may be different than experienced in the past or our current expectations due to many factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of tax cases, changes in accounting for income taxes and changes in tax laws and regulations either prospectively or retrospectively. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. Our estimates concerning the impact of the 2017 Tax Act on our accounting and on our business remain subject to developing interpretations of the provisions of the 2017 Tax Act, which may require further adjustments and changes in our estimates, which could have a material adverse effect on our business, results of operations or financial condition. Further, the new administration could introduce new tax laws or revise or issue new interpretations of the 2017 Tax Act.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Swiss Federal Act on Tax Reform and AHV Financing (TRAF) resulted in significant changes to the Swiss cantonal income tax system. Final interpretation of the transitional and new regimes of the TRAF may require further adjustments and changes in our estimates, which could have a significant adverse effect on our business, results of operations or financial condition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enactment of some or all of the recommendations set forth or that may be forthcoming in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities and economic blocs in the countries in which we operate, could unfavorably impact our effective tax rate. These initiatives focus on common international principles for the entitlement to taxation of global corporate profits and minimum global tax rates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Holding Our Common Stoc</span><span style="color:#008080;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">k</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results are subject to significant fluctuations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenue, expense and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">impairments with respect to investments, fixed assets and long-lived assets, including IPR&amp;D and other intangible assets; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent consideration or our equity investments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">bad debt expense and increased bad debt reserves; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">payments in connection with acquisitions, divestitures and other business development activities and under license and collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">failure to meet certain contractual commitments; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments in properties may not be fully realized.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. We may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate a property, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investment portfolio is subject to market, interest and credit risk that may reduce its value.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a portfolio of marketable securities for investment of our cash as well as investments in equity securities of certain biotechnology companies. Changes in the value of our investment portfolio could adversely affect our earnings. The value of our investments may decline due to, among other things, increases in interest rates, downgrades of the bonds and other securities in our portfolio, instability in the global financial markets that reduces the liquidity of securities in our portfolio, declines in the value of collateral underlying the securities in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time our Board of Directors authorizes share repurchase programs. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our applicable agreements. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in repurchases under, or the completion of, our share repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets are experiencing, and have in the past experienced, extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development, research and development and mergers and acquisitions;&#160;and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our common stock repurchase activity under our 2020 Share Repurchase Program during the first quarter of 2021:</span></div><div style="margin-bottom:5pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price<br/>Paid&#160;per&#160;Share<br/>($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>as&#160;Part&#160;of&#160;Publicly<br/>Announced Programs<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value<br/>of Shares That May Yet Be Purchased Under<br/>Our Programs<br/>($ in millions)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,600.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">675,000&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279.13&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">675,000&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,411.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,532,874&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268.51&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,532,874&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,207,874&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.75&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.2 million shares of our common stock at a cost of approximately $600.0 million during the three months ended March 31, 2021. Approximately $4.0 billion remained available under our 2020 Share Repurchase Program as of March 31, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized our December 2019 Share Repurchase Program, which was a program to repurchase up to $5.0 billion of our common stock that was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 3.2&#160;million shares of our common stock at a cost of approximately $941.1&#160;million during the three months ended March&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized our March 2019 Share Repurchase Program, which was a program to repurchase up to $5.0 billion of our common stock that was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1&#160;million shares of our common stock at a cost of approximately $1.3&#160;billion during the three months ended March&#160;31, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_226"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</span></div><div id="i6fe84bc7e101462ea41fc07416803961_229"></div><div style="-sec-extract:summary;margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT&#160;INDEX&#160;</span></div><div style="margin-bottom:5pt;margin-top:19pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000875045/000119312521044891/d124092dex42.htm">Third Supplemental Indenture, dated February 16, 2021, between Biogen Inc. and U.S. Bank National Association. Filed as Exhibit 4.2 to our Current Report on Form 8-K filed on February 16, 2021.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000875045/000119312521044891/d124092dex43.htm">Form of 3.250% Senior Notes due 2051, in the form of a Global Note bearing a private placement legend. Filed as Exhibit 4.3 to our Current Report on Form 8-K filed on February 16, 2021.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000875045/000119312521044891/d124092dex44.htm">Form of 3.250% Senior Notes due 2051, in the form of a Global Note bearing a Regulation S legend. Filed as Exhibit 4.4 to our Current Report on Form 8-K filed on February 16, 2021.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000875045/000119312521044891/d124092dex45.htm">Registration Rights Agreement, dated February 16, 2021, between Biogen Inc. and Deutsche Bank Securities Inc. and Citigroup Global Markets, Inc. with respect to the 3.250% Senior Notes due 2051. Filed as Exhibit 4.5 to our Current Report on Form 8-K filed on February 16, 2021.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#8224;+ </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2021331xex101.htm">Joint Venture Agreement, dated December 6, 2011, by and between Samsung BioLogics Co., Ltd. and Biogen Therapeutics Inc. (f/k/a Biogen Idec Therapeutics Inc.), as amended February 28, 2012, September 29, 2014, and February 20, 2019.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2021331xex311.htm">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2021331xex312.htm">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2021331xex321.htm">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended March 31, 2021, formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flow, (v) the Condensed Consolidated Statements of Equity and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104++</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, formatted in Inline XBRL.</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Certain confidential information contained in this exhibit has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Filed herewith </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i6fe84bc7e101462ea41fc07416803961_232"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i6fe84bc7e101462ea41fc07416803961_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:297pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:44.590%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BIOGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;22, 2021 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>biib-2021331xex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i36664d842c684354808ac8304a860669_1"></div><div style="min-height:99.25pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT BIOGEN INC. TREATS AS PRIVATE OR CONFIDENTIAL.</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JOINT VENTURE AGREEMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIS JOINT VENTURE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into as of the 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> day of December 2011 by and between&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung BioLogics Co., Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a company organized and existing under the laws of Korea with its principal offices at 27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Floor, Samsung Electronics Building, 1320-10 Seocho 2-dong, Seocho-gu, Seoul 137-857, Korea (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Idec Therapeutics Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a company organized and existing under the laws of Delaware, U.S.A. with its principal offices at 14 Cambridge Center, Cambridge, Massachusetts 02142, U.S.A. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Biogen and Samsung are hereinafter referred to collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">W I T N E S S E T H&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Samsung and Biogen have agreed to enter into a joint venture (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Venture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the purpose of development, manufacture, commercialization, distribution and sale of Biosimilar Pharmaceutical Products&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in order to carry out the Joint Venture, the Parties intend to form a Korean stock corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Samsung and Biogen desire to enter into this Agreement to memorialize their mutual agreements and understandings on the establishment, financing, operation and management of the Company and their respective rights and obligations relative thereto.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in consideration of the foregoing premises and the mutual covenants and agreements hereinbelow contained, and intending to be legally bound hereby, the Parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.73pt">Definitions</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The terms defined in this Article shall have the meanings ascribed to them herein whenever they are used in this Agreement, unless otherwise clearly indicated by the context.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquired TP Biosimilar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 15.2(a).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any Biosimilar Pharmaceutical Product based on an Additional Reference Product, including a Combination Product containing any such Biosimilar Pharmaceutical Product.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Reference Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any biopharmaceutical reference product (other than the Initial Reference Products, and Biogen Reserved Products) (i) agreed by the Parties in writing and determined by the General Meeting of Shareholders to be an Additional Reference Product at any time during the Biogen Consent Period or (ii) determined by the General Meeting of Shareholders to be an Additional Reference Product at any time after the expiration of the Biogen Consent Period. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affected CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 6.5(f). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as of any point in time and for so long as such relationship continues to exist with respect to any Person, (i) any other Person that, directly or indirectly, Controls such Person or is Controlled by such Person or is under common Control with such Person and (ii) any director, officer or general partner of such Person or of any other Person falling under clause (i) above&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that neither Party nor any of the Parties&#8217; respective Affiliates shall be deemed to be an Affiliate of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Antitrust Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the approval of the establishment of the Company by the Parties pursuant to the terms of this Agreement (i) by the Korean Fair Trade Commission (under the Monopoly Regulation and Fair Trade Act of Korea), and (ii) if required under applicable law, by the competition authorities of other relevant jurisdictions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that each such approval shall be unconditional or subject to conditions reasonably acceptable to both Parties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appointing Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the non-breaching Party under Section 13.7, the Terminating Party under Section 17.5 or the Non-Responsible Party under Section 15.2(a), as the case may be.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Arbitral Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 18.2(a).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Arbitration Tribunal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 18.2(a).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Articles of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Articles of Incorporation of the Company, as amended from time to time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 6.5.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Consent Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the period consisting of (i) the Initial Funding Period and (ii) an additional period thereafter, if any, during which (x) the Shareholding of Samsung is equal to or greater than fifty-one percent (51%) and (y) the Shareholding of Biogen is greater than ten percent (10%).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 4.1.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 4.1.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Option Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 4.1.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Biogen Idec Inc., a company organized and existing under the laws of Delaware, U.S.A. with its principal offices at133 Boston Post Road, Weston, Massachusetts, U.S.A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Parent Guarantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 20.1(a).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Reserved Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean those biopharmaceutical reference products listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biosimilar Pharmaceutical Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an antibody product, FC fragment or fusion protein composed of macromolecules, which contains the same principal molecular structural features (but not necessarily all of the same structural features) and is intended to be sufficiently similar to an approved biopharmaceutical reference product to permit the biosimilar applicant to rely for approval on certain existing scientific knowledge about the safety and effectiveness of such approved biopharmaceutical reference product.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the duly constituted board of directors of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a day on which banks are open for normal banking business in Seoul, Korea, Boston, Massachusetts and New York, New York (excluding Saturdays).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Buyout</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 17.6.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Buyout Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 17.6(a).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Buyout Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 17.6.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Buyout Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 17.6(d).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Buyout Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 17.6.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change of Control&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean (a) in the case of Biogen, Biogen Idec Inc. ceasing to have direct or indirect Control over Biogen other than pursuant to one or more internal corporate restructurings or reorganizations which result in Biogen being Controlled directly or indirectly by an Affiliate of Biogen Idec Inc.&#59; and (b) and in the case of Samsung, Samsung ceasing to be a company belonging to the Samsung Group (as defined under the Monopoly Regulation and Fair Trade Act of Korea).  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 3.1.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 3.1.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CoC Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 15.2(a).</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean any pharmaceutical product containing both (a) a Biosimilar Pharmaceutical Product based on a Reference Product and (b) one or more pharmaceutically active compounds or substances that do not constitute an Initial Product or an Additional Product.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 6.7.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to the efforts to be exercised by a Party or the Company with respect to any objective, reasonable, diligent, good faith efforts to accomplish such objective as a similarly situated (with respect to size, stage of development and assets) biotechnology or pharmaceutical company or its principal shareholder, as the case may be (or, in the case of Biogen, a similarly situated biotechnology or pharmaceutical company with size, stage of development and assets comparable to Biogen Idec MA Inc. or its successor in interest), would use to accomplish a similar objective under similar circumstances exercising reasonable business judgment.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the second WHEREAS clause.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Conditions Precedent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 3.1.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 14.1.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the power and ability to direct the management and policies of the controlled enterprise, whether directly or indirectly through one or more intermediaries, through ownership of voting securities of the controlled enterprise or by contract or otherwise&#59; and the terms &#8220;Controls,&#8221; &#8220;Controlled&#8221; and &#8220;Controlling&#8221; shall be construed accordingly.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the duly elected members of the Board and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a duly elected member of the Board.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 14.1.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exempted Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 15.2(a).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Share(s), the fair market value of such Share(s) of the Company as determined by a reputable independent appraiser experienced in the valuation of enterprises in Korea that is appointed by the Appointing Party considering the Company as a going concern and assuming a sale and purchase transaction between a willing seller and a willing buyer&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such appraiser shall be selected pursuant to the procedures set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">General Meeting of Shareholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a duly constituted general meeting of Shareholders of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Government Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of any action to be taken by a Party hereunder shall mean such approval, authorization or confirmation of, consent to, or acceptance of report on the action, </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">together with such licenses, permits or other permissions reasonably required for the action, all as the applicable statutes, decrees, rules, regulations and rulings of governmental authority may require to be obtained in connection with such action from any governmental authority or political subdivision thereof.</font></div><div style="padding-right:-0.05pt;text-align:justify"><font><br></font></div><div style="padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IBA Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 18.2(g).</font></div><div style="padding-right:-0.05pt;text-align:justify"><font><br></font></div><div style="padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ICC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 18.2(a).</font></div><div style="padding-right:-0.05pt;text-align:justify"><font><br></font></div><div style="padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IFRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the International Financial Reporting Standards issued by the International Accounting Standards Board.</font></div><div style="padding-right:-0.05pt;text-align:justify"><font><br></font></div><div style="padding-right:-0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 2.5.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Development Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the initial development plans attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and as may be adjusted and amended pursuant to Section 6.5(a), which includes indicative criteria relating to the progression of the Initial Products around such areas as timelines, responsibilities and activities to be performed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Funding Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the period from the Closing Date until the earlier of (i) Biogen&#8217;s exercise of the Biogen Option and the purchase of the Biogen Option Shares pursuant thereto and (ii) the expiration of the Biogen Option Period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any Biosimilar Pharmaceutical Product based on an Initial Reference Product, including a Combination Product containing any such Biosimilar Pharmaceutical Product.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Reference Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean &#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean (i) any intellectual property or related proprietary rights in any jurisdiction, whether owned or held for use under license, whether registered or unregistered, including such rights in (A) all inventions, invention disclosures and improvements thereto (whether patentable or unpatentable and whether or not reduced to practice), all issued patents and pending patent applications, any divisions, continuations, continuations-in-part, reissues, continuing patent applications, reexaminations and extensions thereof and any counterparts claiming priority therefrom, and all utility models, design patents, patents of importation&#47;confirmation, certificates of invention, certificates of registration and similar rights, (B) all trademarks, service marks, certification marks, trade dresses, logos, trade names and corporate names, including all goodwill associated therewith, and all applications, registrations and renewals in connection therewith, (C) all works of authorship (whether or not copyrightable), all copyrights, all moral rights and all applications, registrations and renewals in connection therewith, (D) all trade secrets and confidential business information and any rights to limit the use or disclosure thereof by any Person (including ideas, research and development, know-how, formulas, compositions, manufacturing and production processes and techniques, technical data, designs, drawings, </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">specifications, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals), (E) all computer software, operating systems, data files, source and object codes, user interfaces, manuals, databases, technical specifications and documentation, and (F) all mask works, designs and Internet domain names, (ii) all copies and tangible embodiments of any of the foregoing (in whatever form or medium) and (iii) any goodwill associated with the foregoing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IP License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 6.1.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issue Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.3(a).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Venture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the first WHEREAS clause.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Korea</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Republic of Korea.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Korean Won</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">KRW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the lawful currency of Korea.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 6.5.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Responsible Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 15.2(a).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Terminating Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 17.5.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Transferring Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 13.3(a).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision or department or agency of a government.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">President Arbitrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 18.2(b).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Private Label Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an innovator molecule sold or manufactured by its marketer or manufacturer, which is packaged and sold under a different brand name for the purpose of distinguishing an offering of such innovator molecule from its branded counterpart. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any Initial Product and any Additional Product.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 14.1.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reference Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any Initial Reference Product and any Additional Reference Product.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Representative Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the duly elected representative director of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Responsible Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 15.2(a).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 13.1.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 6.1A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 6.5.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 4.2.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 4.2.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Samsung Option Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 4.2.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as determined by Samsung and notified to Biogen prior to the Closing, any one of, or collectively all of, Samsung Electronics Co., Ltd., Samsung Everland, Inc. and Samsung C&#38;T Corporation, each a Korean corporation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung Parent Guarantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 20.1(b).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Senior Officer(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 8.3.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Service Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 6.3.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean shares of voting common stock of the Company with a par value of Five Thousand Korean Won (KRW5,000) each&#59; except where the context does not permit such construction, all references to the Shares of a Party shall be deemed to include Share Equivalents, if any, held by that Party (calculated for this purpose as if all Share Equivalents had been fully converted into, exchanged for or exercised for subscription of Shares).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean convertible bonds, warrants, options (other than the Biogen Option or the Samsung Option) or other similar instruments or securities which are convertible into or exchangeable for, or which carry a right to subscribe for, Shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shareholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a registered owner of Shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shareholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the ratio of the Shares held by a Party over the total issued and outstanding Shares of the Company or (as the context may require) the number of Shares held by a Party&#59; except where the context does not permit such construction, all references to the Shareholding of a Party shall be deemed to include Share Equivalents, if any, held by that Party (calculated for this purpose as if all Share Equivalents had been fully converted into, exchanged for or exercised for subscription of Shares).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Statutory Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a duly elected statutory auditor of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Terminating Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 17.5.</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Third Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any Person other than Biogen, Samsung or their respective Affiliates.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party Biosimilar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 15.2(a).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.3(a).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.3(a).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transfer Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 13.3(a).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transferring Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 13.3(a).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">United States Dollar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">US$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the lawful currency of the United States of America.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Unless otherwise required by the context or unless otherwise specified herein, (a)&#160;the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b)&#160;the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation,&#8221; (c)&#160;the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall,&#8221; (d)&#160;any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any Person shall be construed to include the Person&#8217;s successors and assigns, (f) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Articles, Sections, Exhibits or Schedules shall be construed to refer to Articles, Sections, Exhibits or Schedules of this Agreement, and references to this Agreement include all Exhibits and Schedules hereto, (h) the word &#8220;notice&#8221; shall mean notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and (k) the term &#8220;or&#8221; shall be interpreted in the inclusive sense commonly associated with the term &#8220;and&#47;or.&#8221;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 2. Organization and Capitalization of the Company</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As soon as practicable following the Closing, Biogen and Samsung shall establish and register the Company as a stock corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">chu-shik-hoe-sa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in accordance with the laws of Korea.  The Parties shall both serve as promoters for the establishment of the Company and agree that the Company shall not be established or registered unless approved by both promoters&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that once the Closing occurs in accordance with Article 3, neither Party shall withhold or delay its approval of the establishment and registration of the Company.</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Corporate Name</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The name of the Company shall be determined by Samsung with the prior consent of Biogen (which consent shall not be unreasonably withheld or delayed) prior to the incorporation of the Company. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Business Objective</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The business objectives and activities of the Company shall be limited to the development, manufacture, commercialization, distribution and sale of Biosimilar Pharmaceutical Products and any and all activities related or incidental thereto.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Articles of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties shall adopt initial Articles of Incorporation for the Company at the time of its incorporation in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event any conflict or discrepancy arises between the Articles of Incorporation and the terms of this Agreement (as amended from time to time), the Parties shall promptly take and cause to be taken all necessary actions to amend the Articles of Incorporation so that it will conform to and be consistent with the terms of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that until such time as the Articles of Incorporation are so amended, the terms of this Agreement shall control between the Parties to the maximum extent permitted by applicable law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Capitalization of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall be initially capitalized with paid-in capital of KRW330,000,000,000 (the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> &#8220;Initial Capital&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), of which amount KRW280,500,000,000 shall be contributed by Samsung and KRW49,500,000,000 shall be contributed by Biogen.  The first installment of such capital contributions of the Parties shall be made at the Closing as set forth below.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Date of Contribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Samsung</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Biogen</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Closing Date&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;KRW139,995,000,000&#160;&#160;&#160;&#160;KRW24,705,000,000</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Following the Closing, the Parties shall contribute the remaining portion of the Initial Capital in proportion to their respective Shareholdings in such installments and at such times as the Board determines&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the Company shall give the Parties at least thirty (30) days&#8217; prior written notice of each such additional capital contribution.  All contributions of the Initial Capital by Samsung and Biogen shall be made in cash.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Issuance of Shares by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In return for the capital contributions made by the Parties pursuant to Section 2.5 above (the aggregate amount of which shall be KRW330,000,000,000), the Company shall issue Shares to the Parties at the issue price of Fifty Thousand Korean Won (KRW50,000) per Share, and upon completion of all such </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">capital contributions described in Section 2.5 to the Company, Samsung and Biogen shall respectively own the following Shares&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Number of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ownership Percentage</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Samsung&#160;&#160;&#160;&#160;5,610,000 Shares&#160;&#160;&#160;&#160;85%</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Biogen&#160;&#160;&#160;&#160;990,000 Shares&#160;&#160;&#160;&#160;15%</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 3. Closing of Subscription of Shares</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the fulfillment of the conditions precedent specified in Sections 3.2 and 3.3 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Conditions Precedent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the subscription of Shares by the Parties as contemplated herein shall be consummated at a closing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to be held at 10&#58;00 a.m., Korea time, on February 28, 2012 at the Seocho offices of Samsung located at 27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Floor, Samsung Electronics Building, 1320-10 Seocho 2-dong, Seocho-gu, Seoul 137-857, Korea&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if all of the Conditions Precedent have not been satisfied (or waived by the Party entitled to waive the relevant Condition Precedent) as of that date, the Closing shall take place on&#58; (i) the third (3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Business Day following the satisfaction or waiver (by the Party entitled to waive the relevant Condition Precedent) of all of the Conditions Precedent to the Closing and the prompt notification thereof by the Party satisfying or waiving the Conditions Precedent to the other Party&#59; or (ii) at such other time as the Parties may agree in writing (such date and time being herein referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Conditions Precedent to Biogen&#8217;s Obligation to Subscribe for Shares at Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The obligation of Biogen to complete the Closing hereunder shall be subject to the fulfillment prior to or at the Closing of each of the following conditions, any one or more of which may be waived by Biogen at its sole discretion&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Samsung shall have performed and complied with, in all material respects, all covenants, agreements and conditions required by this Agreement to be performed or complied with by it prior to or at the time of Closing&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">All of the representations and warranties made by Samsung in this Agreement shall be true and correct in all material respects at and as of the Closing Date as though such representations and warranties were made at and as of the Closing Date&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">No order, injunction, decision or ruling shall have been made or issued by any court, arbitration tribunal or other governmental authority that disallows, challenges, enjoins, prohibits or imposes any damages, penalties or restrictions on, or otherwise makes illegal the consummation of, the transactions contemplated by this Agreement&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">No suit, action or other legal proceeding shall be pending or threatened against Samsung before any court, arbitration tribunal or other governmental authority, which seeks to disallow, challenge, enjoin, prohibit or impose any damages, penalties or </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">restrictions on, or otherwise make illegal the consummation of, the transactions contemplated by this Agreement, and no investigation that could reasonably be expected to result in any such suit, action or proceeding shall be pending or threatened against Samsung&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">The Antitrust Approvals shall have been duly obtained&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.01pt">All other Government Approvals and all authorizations, consents, approvals and waivers from any Person other than governmental authorities required to be obtained by Samsung in connection with the execution, delivery and performance of this Agreement or the consummation of the transactions contemplated hereby shall have been duly obtained&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The Parties shall have finalized and  agreed on  the forms of (i) the Service Agreement to be entered into between the Company and Biogen and&#47;or its Affiliates pursuant to Section 6.3 and (ii) the Manufacturing Agreements to be entered into between the Company and the Samsung CMO and between the Company and the Biogen CMO pursuant to Section 6.5&#59; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Samsung shall have taken all corporate action necessary to approve the consummation of the transactions contemplated by this Agreement&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt">Samsung shall, on behalf of Samsung Parent, have delivered to Biogen an executed copy of the Samsung Parent Guarantee described in Section 20.1(b).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Conditions Precedent to Samsung&#8217;s Obligation to Subscribe for Shares at Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The obligation of Samsung to complete the Closing hereunder shall be subject to the fulfillment prior to or at the Closing of each of the following conditions, any one or more of which may be waived by Samsung at its sole discretion&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Biogen shall have performed and complied with, in all material respects, all covenants, agreements and conditions required by this Agreement to be performed or complied with by it prior to or at the time of Closing&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">All of the representations and warranties made by Biogen in this Agreement shall be true and correct in all material respects at and as of the Closing Date as though such representations and warranties were made at and as of the Closing Date&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">No order, injunction, decision or ruling shall have been made or issued by any court, arbitration tribunal or other governmental authority that disallows, challenges, enjoins, prohibits or imposes any damages, penalties or restrictions on, or otherwise makes illegal the consummation of, the transactions contemplated by this Agreement&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">No suit, action or other legal proceeding shall be pending or threatened against Biogen before any court, arbitration tribunal or other governmental authority, which seeks to </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">disallow, challenge, enjoin, prohibit or impose any damages, penalties or restrictions on, or otherwise make illegal the consummation of, the transactions contemplated by this Agreement, and no investigation that could reasonably be expected to result in any such suit, action or proceeding shall be pending or threatened against Biogen&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">The Antitrust Approvals shall have been duly obtained&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.01pt">All other Government Approvals and all authorizations, consents, approvals and waivers from any Person other than governmental authorities required to be obtained by Biogen in connection with the execution, delivery and performance of this Agreement or the consummation of the transactions contemplated hereby shall have been duly obtained&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The Parties shall have finalized and agreed on  the forms of (i) the Service Agreement to be entered into between the Company and Biogen and&#47;or its Affiliates pursuant to Section 6.3 and (ii) the Manufacturing Agreements to be entered into between the Company and the Samsung CMO and between the Company and the Biogen CMO pursuant to Section 6.5&#59; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Biogen shall have taken all corporate actions necessary to approve the consummation of the transactions contemplated by this Agreement and Biogen shall have taken all corporate actions necessary to approve the consummation of the transactions contemplated by the IP License Agreement&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-42.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:36pt">Biogen shall, on behalf of the Biogen Parent, have delivered to Samsung an executed copy of the Biogen Parent Guarantee described in Section 20.1(a).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Closing Deliveries of Biogen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  At the Closing, Biogen shall pay the subscription price for the Shares to be subscribed for by it at the Closing pursuant to Sections 2.5 and 2.6 by means of a wire transfer in immediately available funds to a share subscription account established for the Company.  In addition, at the Closing, Biogen shall deliver, or have delivered, to Samsung the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">A certificate of a duly authorized officer of Biogen, which shall be dated as of the Closing Date, certifying (i) that the representations and warranties of Biogen contained in this Agreement are true and correct in all material respects at and as of the Closing Date with the same effect as though such representations and warranties were made at and as of such date and (ii) that all other Conditions Precedent set forth in Section 3.3 have been fulfilled&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">An instrument evidencing that Biogen has duly taken all corporate actions necessary to approve the consummation of the transactions contemplated by this Agreement&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">An instrument evidencing that Biogen has duly taken all corporate actions necessary to approve the consummation of the transactions contemplated by the IP License Agreement&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">An executed copy of the Biogen Parent Guarantee and an instrument evidencing that Biogen Parent has duly taken all corporate actions necessary to approve the execution, delivery and performance of the Biogen Parent Guarantee&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Such other certificates, instruments and documents as may be reasonably requested by Samsung as evidence of the fulfillment of the Conditions Precedent set forth in Section 3.3.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Closing Deliveries of Samsung</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  At the Closing, Samsung shall pay the subscription price for the Shares to be subscribed for by it pursuant to Sections 2.5 and 2.6 by means of a wire transfer in immediately available funds to a share subscription account established for the Company.  In addition, at the Closing, Samsung shall deliver, or have delivered, to Biogen the following&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">A certificate of a duly authorized officer of Samsung, which shall be dated as of the Closing Date, certifying (i) that the representations and warranties of Samsung contained in this Agreement are true and correct in all material respects at and as of the Closing Date with the same effect as though such representations and warranties were made at and as of such date and (ii) that all other Conditions Precedent set forth in Section 3.2 have been fulfilled&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">An instrument evidencing that Samsung has duly taken all corporate actions necessary to approve the consummation of the transactions contemplated by this Agreement&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">An executed copy of the Samsung Parent Guarantee and an instrument evidencing that Samsung Parent has duly taken all corporate actions necessary to approve the execution, delivery and performance of the Samsung Parent Guarantee&#59; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">An English version of a valuation report issued by an independent Third Party appraisal institution in respect of the Samsung Assets&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Such other certificates, instruments and documents as may be reasonably requested by Biogen as evidence of the fulfillment of any of the Conditions Precedent set forth in Section 3.2.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 4. Biogen Option and Samsung Option</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Biogen Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Biogen shall have an option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to increase its Shareholding in the Company to be equal to (but not less than) (i) fifty percent (50%) of the combined Shareholding (including Share Equivalents) of Samsung (and its Affiliates) and Biogen (and its Affiliates) at the time of exercise of such option (ii) less one (1) Share (if such </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">combined Shareholding consists of an even number of Shares) or one-half (1&#47;2) of a Share (if such combined Shareholding consists of an odd number of Shares) by purchasing such number of Shares (and not Share Equivalents) held by Samsung and&#47;or its Affiliates as to achieve such Shareholding (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Option Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as a result of which, immediately following the exercise of the Biogen Option, Biogen will hold one (1) less Share or two (2) less Shares, as applicable, than the number of Shares (including Share Equivalents) held by Samsung and its Affiliates.  Biogen may exercise the Biogen Option by giving written notice thereof to Samsung at any time from the date of incorporation of the Company until the earlier of (i) ninety (90) days following the end of the first fiscal year in which the Company has a net profit (under the IFRS) and (ii) ninety (90) days following the end of the fiscal quarter in which the sixth (6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) anniversary of the date of incorporation of the Company occurs (as may be extended pursuant to the following proviso, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if no commercial sale of the Products (as defined in the IP License Agreement) occurs in the United States and in the European Union prior to the sixth (6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) anniversary of the date of incorporation of the Company, the Biogen Option Period shall be extended for an additional one-year period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, until ninety (90) days following the end of the fiscal quarter in which the seventh (7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) anniversary of the date of incorporation of the Company occurs).  If any Affiliate(s) of Samsung holds any Shares at the time of exercise of the Biogen Option, Samsung shall have the right to decide how the Biogen Option Shares to be sold to Biogen are to be allocated between Samsung and such Affiliate(s).  The purchase price to be paid by Biogen to Samsung and&#47;or its Affiliate(s) for the Biogen Option Shares shall be determined as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Purchase Price for the Biogen Option Shares &#61; &#91;(SC + BC) x 0.5&#93; &#8211; BC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">where&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)  &#8220;SC&#8221; is (i) the total amount of capital Samsung (including its Affiliates) has contributed to the Company since incorporation, minus (ii) any returns or distributions of previously contributed capital (including any cash dividends paid, but not including any of the purchase prices paid for the Samsung Assets) by the Company to Samsung (including its Affiliates), plus (iii) an amount of interest calculated using an internal rate of return of fourteen percent (14%) per annum, compounded annually, on such capital contributed by Samsung (including its Affiliates) to the Company from the respective dates of contribution of such capital to the Company until the date of payment of the purchase price for the Biogen Option Shares by Biogen to Samsung and&#47;or the selling Affiliates of Samsung, except for any capital returned or distributed as referred to in clause (ii) above, for which such interest shall be calculated from the date(s) of contribution of such capital to the Company (which date(s) of contribution shall be determined on a &#8220;last-in-first-out&#8221; basis) until the date of such return or distribution&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if, as of the date of exercise of the Biogen Option, the Company has not made material use of the Intellectual Property sold by Samsung to the Company as part of the Samsung Assets in the Company&#8217;s business, the amount of the first installment of Samsung&#8217;s capital contribution to the Company shall be reduced by an amount equal to the purchase price (as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">paid by the Company to Samsung for such Intellectual Property for the purpose of determining the purchase price for the Biogen Option Shares&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)  &#8220;BC&#8221; is (i) the total amount of capital Biogen (including its Affiliates) has contributed to the Company since incorporation, minus (ii) any returns or distributions of previously contributed capital (including any cash dividends paid) by the Company to Biogen (including its Affiliates), plus (iii) an amount of interest calculated using an internal rate of return of fourteen percent (14%) per annum, compounded annually, on such capital contributed by Biogen (including its Affiliates) to the Company from the respective dates of contribution of such capital to the Company until the date of payment of the purchase price for the Biogen Option Shares by Biogen to Samsung and&#47;or the selling Affiliates of Samsung, except for any capital returned or distributed as referred to in clause (ii) above, for which such interest shall be calculated from the date(s) of contribution of such capital to the Company (which date(s) of contribution shall be determined on a &#8220;last-in-first-out&#8221; basis) until the date of such return or distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the avoidance of doubt, the Biogen Option may be exercised (i) only once during the Biogen Option Period and (ii) only in respect of all (and not less than all) of the Biogen Option Shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Following the execution of this Agreement, the Parties shall explore and negotiate in good faith to agree on an alternative transaction to the Biogen Option, which will achieve in a more tax-efficient way substantially the same economic results (including the respective amounts of investment by the Parties in the Company and the resulting ownership structure of the Company) than would be attained by way of the exercise of the Biogen Option by Biogen as contemplated above, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that in no event shall either Party be obligated to implement an alternative transaction to replace the Biogen Option transaction as contemplated above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Samsung Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event Biogen does not exercise the Biogen Option during the Biogen Option Period for any reason, Samsung shall have the option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to buy out all (but not less than all) of the Shares held by Biogen and its Affiliates (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung Option Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for a purchase price equal to (i) the total amount of capital Biogen (including its Affiliates) has contributed to the Company since incorporation, minus (ii) any returns or distributions of previously contributed capital (including any cash dividends paid) by the Company to Biogen (including its Affiliates), plus (iii) an amount of interest calculated using an internal rate of return of fourteen percent (14%) per annum, compounded annually, on such capital contributed by Biogen (including its Affiliates) to the Company from the respective dates of contribution of such capital to the Company until the date of payment of the purchase price for the Samsung Option Shares by Samsung to Biogen and&#47;or the selling Affiliate(s) of Biogen, except for any capital returned or distributed as referred to in clause (ii) above, for which such interest shall be calculated from the date(s) of contribution of such capital to the Company (which date(s) of contribution shall be determined on a &#8220;last-in-first-out&#8221; basis) until the date of such return or distribution.  Samsung may exercise the </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Samsung Option by giving written notice thereof to Biogen at any time within sixty (60) days following the expiration of the Biogen Option Period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  For the avoidance of doubt, the Samsung Option may be exercised only once during such sixty (60) day period and (ii) only in respect of all (and not less than all) of the Samsung Option Shares.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Closing of Sale and Purchase of Option Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon the exercise of the Biogen Option, the Parties shall complete the sale and purchase of the Biogen Option Shares on the date specified in the written notice of exercise of the Biogen Option, which date shall be no earlier than fifteen (15) days and no later than thirty (30) days after the date of exercise of the Biogen Option.  Upon the exercise of the Samsung Option, the Parties shall complete the sale and purchase of the Samsung Option Shares on the date specified in the written notice of exercise of the Samsung Option, which date shall be no earlier than fifteen (15) days and no later than thirty (30) days after the date of exercise of the Samsung Option.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Representations and Warranties&#59; Provision of Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">The sale of the Biogen Option Shares shall be made without any representations or warranties on the part of Samsung other than&#58; (i) that Samsung is the lawful owner of the Biogen Option Shares and has the full right and power to transfer such Shares to Biogen, free and clear of any pledge, mortgage, charge, lien, security interest, option, third-party right, interest or claim or other encumbrances of a nature similar to any of the foregoing, (ii) the due authorization of the transfer of the Biogen Option Shares pursuant to this Agreement, (iii) the enforceability of the transfer of the Biogen Option Shares pursuant to this Agreement, (iv) in connection with the transfer of the Biogen Option Shares, the absence of conflicts with or violation or breach of Samsung&#8217;s organizational documents, any law, rule, regulation, judgment, order or decree applicable to Samsung or any agreement or instrument by which Samsung is bound&#59; and (v) that to the actual knowledge of CEO, CFO and CTO of Samsung, no event has occurred with respect to the Company that has, or would reasonably be expected to have, a material adverse effect on the business of the Company taken as a whole, except as (A) reported to the Board, (B) disclosed or reflected in the financial statements or other information or materials provided or made available to Biogen or its nominated Director or designated observer to the Board, whether pursuant to Section 7.5 or Article 11 of this Agreement or otherwise, (C) disclosed or made available to Biogen in connection with the provision of information and materials under Section 4.4(b) below, or (D) as demonstrated by written evidence, otherwise known to Biogen or its nominated Director or designated observer to the Board from any sources or by any means.  The sale of the Samsung Option Shares shall be made without any representations or warranties on the part of Biogen other than (i) that Biogen is the lawful owner of the Samsung Option Shares and has the full right and power to transfer such Shares to Samsung, free and clear of any pledge, mortgage, charge, lien, security interest, option, third-party right, interest or claim or other encumbrances of a nature similar to any of the foregoing, (ii) the due authorization of the transfer of the Samsung Option Shares pursuant to this Agreement, (iii) the </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">enforceability of the transfer of the Samsung Option Shares pursuant to this Agreement, and (iv) in connection with the transfer of the Samsung Option Shares, the absence of conflicts with or violation or breach of Biogen&#8217;s organizational documents, any law, rule, regulation, judgment, order or decree applicable to Biogen or any agreement or instrument by which Biogen is bound.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">In connection with the exercise of the Biogen Option, within thirty (30) days of Biogen&#8217;s request (which request may be made up to three (3) times, and not more, during the Biogen Option Period), Samsung shall exercise (and shall cause each of its Affiliates to exercise) any and all of its voting rights and other authority and control available to it in relation to the Company (including by causing the Directors designated by Samsung) to cause the Company to provide Biogen and its representatives with such information and materials available to the Company concerning the business, assets, liabilities, financial condition, contracts, officers, employees and other operational matters of the Company as Biogen may reasonably request for the purpose of determining whether or not to exercise the Biogen Option&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (i) that such information and materials shall be provided during normal business hours of the Company and in a manner that is not unduly disruptive to the normal operations of the Company or its business&#59; and (ii) that the Company shall not be obligated to provide Biogen or its representatives with any information or material the provision of which is prohibited by applicable law or contractual obligation so long as the Company has used Commercially Reasonable Efforts to secure exemption from such prohibition.  In no event shall the provision of such information and materials by the Company obligate Biogen to exercise the Biogen Option.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Government and Other Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall be responsible for obtaining all Government Approvals and other authorizations, consents, approvals and waivers from any Third Party required to be obtained by such Party in connection with the sale and purchase of the Biogen Option Shares or the Samsung Option Shares.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Shares Transferred to Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If, at the time of exercise of the Biogen Option, Samsung has transferred all or part of its Shares to any of its Affiliates pursuant to Section 13.2 and thus owns less than the number of Shares required to be sold to Biogen pursuant to the exercise of the Biogen Option, Samsung shall ensure that such Affiliate(s), together with or instead of Samsung, sells such number of Shares to Biogen in accordance with the terms of this Article 4.  If, at the time of exercise of the Samsung Option, Biogen has transferred all or part of its Shares to any of its Affiliates pursuant to Section 13.2, Biogen shall ensure that such Affiliate(s) sells all of such transferred Shares (together with any Shares then held by Biogen) to Samsung in accordance with the terms of this Article 4.  Nothing in this Section 4.6 shall be construed to relieve the Parties of, or otherwise affect, any of their respective obligations under Sections 4.3, 4.4 and 4.5.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Korean securities transaction tax and any similar taxes (other than the deemed acquisition tax) applicable to the transfer of Shares pursuant to this Article 4 shall be payable by the transferor of such Shares. </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 5. Additional Funding&#59; Acquisition and Ownership of Shares</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Additional Funding during the Initial Funding Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Initial Funding Period, other than the Initial Capital to be contributed by the Parties pursuant to Section 2.5, Samsung shall provide, or arrange to be provided, all additional funding required by the Company as determined by the Board (whether in the form of capital contributions, shareholder loans or guarantees or otherwise).  Such additional funding provided by Samsung to the Company in the form of capital contributions shall be in amounts (and not more than such amounts) as is reasonably required to carry out the objectives of the Company as set forth in the Initial Development Plans and&#47;or as determined by the Board in good faith from time to time.  During the Initial Funding Period, (i) all such additional funding in the form of capital contributions shall be made at the same issue price per Share that is specified in Section 2.6, unless a different issue price per Share is required pursuant to the Monopoly Regulation and Fair Trade Act of Korea or other applicable laws (including tax laws) and (ii) all such additional funding in the form of debt financing shall be made on arm&#8217;s length terms. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Preemptive Subscription Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Initial Funding Period, each Shareholder shall have the preemptive right (subject to the Parties&#8217; obligations to make capital contributions pursuant to Section 2.5) to subscribe for and purchase a pro rata portion (equal to such Shareholder&#8217;s then current Shareholding) of any additional Shares or Share Equivalents newly issued by the Company at a price determined by the Board and paid by the other purchasers of such Shares or Share Equivalents.  Thereafter, except as otherwise provided in the Articles of Incorporation, each Shareholder shall have the preemptive right to subscribe for and purchase up to its pro rata portion (equal to such Shareholder&#8217;s then current Shareholding) of any additional Shares or Share Equivalents newly issued by the Company at a price determined by the Board and paid by the other purchasers of such Shares or Share Equivalents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Biogen&#8217;s Right of First Refusal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">During the Biogen Consent Period, in the event the Company intends to issue to one or more Third Parties (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) any new Shares or Share Equivalents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; which shall not include (i) any Shares for which Biogen is required to subscribe pursuant to Section 2.5 but fails to do so and which the Company intends to issue to one or more Third Party Purchasers and (ii) any Shares or Share Equivalents that the Company offers for sale to one or more Third Parties that are Shareholders in proportion to their respective ownership percentages in the Company), Samsung shall exercise (and shall cause each of its Affiliates to exercise) any and all of its voting rights and other authority and control available to it in relation to the Company (including by taking necessary actions to amend the Articles of Incorporation, if necessary, and causing the Directors designated by Samsung) to cause the Company to first offer to Biogen the opportunity to subscribe for and purchase such Third Party Shares by giving written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issue Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of its intention to issue the Third Party Shares, setting forth the number of the Third </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Party Shares intended to be issued, the identity of the Third Party Purchaser, the proposed issue price and other major terms and conditions of the issue of the Third Party Shares. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Biogen shall then have the right to subscribe for and purchase all (but not less than all) of the Third Party Shares at the proposed issue price and upon the major terms and conditions specified in the Issue Notice by giving written notice to the Company and Samsung of its acceptance of such offer within thirty (30) days after its receipt of the Issue Notice from the Company.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">If Biogen exercises its right under Section 5.3(b), the closing of the subscription and issue of the Third Party Shares shall take place within thirty (30) days after Biogen gives notice of such exercise or such other date as may be mutually agreed upon by the Parties.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">If Biogen rejects the offer contained in the Issue Notice or fails to respond to the Company and Samsung within thirty (30) days after its receipt of the Issue Notice from the Company, the Company shall be free, during the period of sixty (60) days following the earlier of its receipt of such rejection from Biogen and the expiration of such thirty (30) day period, to issue all (but not less than all) of the Third Party Shares so offered to Biogen to the Third Party Purchaser specified in the Issue Notice at an issue price equal to or higher than, and upon terms and conditions no more favorable to the Third Party Purchaser than, the proposed issue price and other terms and conditions set forth in the Issue Notice.  In the event the Company fails to issue such Third Party Shares to the Third Party Purchaser within the above sixty (60) day period, any subsequent issue of all or any part of the Third Party Shares shall again be subject to the provisions of this Section 5.3.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Exercise of Voting Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party agrees to take all actions necessary to ensure that the Company shall be managed, and the rights and obligations of the Parties shall be implemented and enforced, in accordance with the terms of this Agreement, including voting all Shares held by it and causing the Directors nominated by it to vote to give effect to the terms of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Parties shall not be restricted from voting their respective Shares as they see fit so long as such exercise of voting rights does not conflict with the terms of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Additional Shares Acquired by the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The provisions of this Agreement shall apply to any other or additional Shares issued to, purchased or acquired by either Party, whether such other or additional Shares are received, subscribed for, purchased or acquired by reason of any stock dividend, stock split or consolidation, capital increase, corporate merger or split, reorganization or other transactions or events.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Shares and Share Equivalents Held by Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any Shares or Share Equivalents held by any Affiliate(s) of a Party shall be deemed owned and held by such Party for all purposes of this Agreement (including for the purpose of determining such Party&#8217;s </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Shareholding), and such Party shall procure that all such Shares will be voted to give effect to and in accordance with the terms of this Agreement and that no such Shares or Share Equivalents will be sold, transferred, disposed of or subject to any pledge, mortgage or other encumbrances except in accordance with the terms of this Agreement, in each case as if they were directly owned and held by such Party.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Regaining Rights and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For the avoidance of doubt, it is understood and agreed that, except as otherwise provided in Section 17.4, a Party that has lost its rights and&#47;or obligations under this Agreement by reducing its Shareholding shall regain such rights and&#47;or obligations when its Shareholding increases at a later time while this Agreement remains in effect.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 6. Undertakings and Agreements of the Parties</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">License of Biogen Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Immediately upon the incorporation of the Company, Biogen shall, and the Parties shall cause the Company to, enter into a license agreement substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (as amended from time to time by the Parties pursuant to its terms, the &#8220;IP License Agreement&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1A&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sale and Purchase of Samsung Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Immediately upon the incorporation of the Company, Samsung shall cause Samsung Electronics Co., Ltd. to sell to the Company, and the Parties shall cause the Company to purchase from Samsung Electronics Co., Ltd., pursuant to a separate sale and purchase agreement containing terms consistent with this Section 6.1A, the buildings under construction, laboratory equipment, tools and devices, non-clinical programs, cell-lines, assays, regulatory files and other documents, and Intellectual Property that are owned by Samsung and used in or related to its biosimilar pharmaceutical business, as specifically listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), for the respective purchase prices therefor set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In connection with such sale of the Samsung Assets to the Company, Samsung shall take all necessary actions to ensure that Samsung Electronics Co., Ltd. represents to the Company that the Samsung Assets include all Intellectual Property that is (i) owned or licensed from a Third Party by Samsung Electronics Co., Ltd. and (ii) necessary or useful in Samsung Electronics Co., Ltd.&#8217;s biopharmaceutical business relating to the Initial Reference Products.  Each Party shall exercise (and shall cause each of its Affiliates to exercise) any and all of its voting rights and other authority or control available to it in relation to the Company, including by causing the Directors designated by such Party, to ensure that the Company enters into such sale and purchase agreement with Samsung Electronics Co., Ltd. and purchases the Samsung Assets pursuant thereto.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Work Conducted by Biogen During the Interim Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Unless otherwise expressly agreed upon by the Parties in writing, the Parties agree that the internal (based on an FTE rate agreed upon by the Parties) and out-of-pocket costs of any work conducted by employees of Biogen and its Affiliates for the period from the date of this Agreement and until the Closing Date in accordance with the Initial Development Plans or manufacturing work plans agreed upon by the Parties shall be reimbursed by the Company (only if the Company is incorporated pursuant to this Agreement and the Biogen Technology (as defined in the IP License </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agreement) is licensed to the Company pursuant to the IP License Agreement) in full by the later of (i) thirty (30) days following the Company&#8217;s receipt of an invoice from Biogen therefor and (ii) thirty (30) days following the Company&#8217;s incorporation.  Each Party shall exercise (and shall cause each of its Affiliates to exercise) any and all of its voting rights and other authority or control available to it in relation to the Company, including by causing the Directors designated by such Party, to ensure that the Company pays the amounts described in this Section 6.2.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Service Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon request from the Company following the Closing, Biogen shall enter into one or more service agreements (the &#8220;Service Agreement&#8221;) with the Company for the use of additional experienced employees of Biogen and&#47;or its Affiliates by the Company in connection with the research, development and commercialization of the Products, upon the terms set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and such other terms and conditions as are reasonably agreed between Biogen and the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Provision of Employees by Samsung</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Samsung shall assign or otherwise provide, or arrange to be assigned or otherwise provided, to the Company all employees necessary from time to time following the incorporation of the Company for the business and operation of the Company.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> sets forth an itemized list of the number and job descriptions of the employees to be initially hired by the Company, which list may, subject to the prior consent of Biogen (which consent shall not be unreasonably withheld or delayed), be updated by Samsung prior to the incorporation of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Manufacturing of Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#91;***&#93;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Development of Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall be responsible for all aspects of research and development for each Product from cell-line development to making regulatory filings and obtaining regulatory approvals and for all costs associated with such research and development, including pre-clinical and clinical manufacturing.  The Parties shall cause the Company to use Commercially Reasonable Efforts to pursue the research and development of the Initial Products in accordance with the Initial Development Plans and adhere to the indicative criteria set forth therein when making decisions on the progression or termination of each Initial Product.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall have the right to commercialize, distribute and sell the Products worldwide.  The Company may (i) commercialize, distribute and sell the Products by utilizing its own sales team and&#47;or (ii) enter into commercialization, distribution and sales agency agreements with Biogen, Samsung and&#47;or other Persons to carry out commercialization, distribution and sales activities relating to the Products on its behalf (the &#8220;Commercialization Agreements&#8221;).  If the Company decides to use an external service provider to commercialize, distribute and sell a Product in a particular country or region, the Parties shall cause the Company to first negotiate in good faith with each of Samsung and Biogen to enter into a Commercialization Agreement for such Product covering such country or region.  Notwithstanding the foregoing sentence, the Company shall in no event be </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">obligated to enter into any Commercialization Agreement with either Party and shall have the ultimate right to decide the Person(s) to carry out commercialization, distribution and sales activities relating to each Product on its behalf in each country and region.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Services to the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">In addition to the services to be provided by Samsung, Biogen and their respective Affiliates pursuant to Sections 6.2, 6.3, 6.5 and 6.7 above, the Company may engage the Parties, any of their respective Affiliates and&#47;or Third Party contractors to provide certain key services for the Company, as determined by the Board from time to time.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">All services provided to the Company by Samsung, Biogen and their respective Affiliates, including manufacturing services provided by the Samsung CMO and the Biogen CMO under the Manufacturing Agreements and commercialization services provided by Samsung, Biogen and their respective Affiliates under the Commercialization Agreements, shall be provided on a cost-plus basis where the mark-up shall be based on market terms and rates and meet applicable legal, tax and regulatory requirements concerning transfer pricing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that each Party shall use Commercially Reasonable Efforts to provide the most competitive pricing for all services provided to the Company by such Party or any of its Affiliates.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">All services provided to the Company by Third Parties (other than Samsung, Biogen and their respective Affiliates) shall be provided pursuant to agreements negotiated on an arm&#8217;s length basis.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Services to the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party may engage the Company, any of its respective Affiliates and&#47;or Third Party contractors to provide certain key services for it or its Affiliates from time to time.  The Company shall use Commercially Reasonable Efforts to provide the most competitive pricing for all services provided to a Party or its Affiliates by the Company or any of its Affiliates, provided that such pricing shall be at a reasonable fair market value for the services rendered.  All services provided to a Party or its Affiliates by the Company or its Affiliates shall be provided pursuant to agreements negotiated on an arm&#8217;s length basis.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Regulatory Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall have the right and responsibility to carry out all regulatory matters relating to the Products.  The Company may, as determined by the Board, contract with third parties to support (i) interactions with regulatory authorities with respect to the development and commercialization of the Products, including assuming responsibility for face-to-face and telephonic meetings with regulatory authorities, addressing and deciding product labeling issues and&#47;or maintaining regulatory approvals, and (ii) preparation of regulatory filings (including biologic license applications) to be made to regulatory authorities and notification and reporting of adverse events in relation thereto.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Product Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise provided in the IP License Agreement, as between the Company, on the one hand, and the Parties and their respective Affiliates, on the </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">other, the Company shall be solely responsible for all product and other liability relating to the Products.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 7. Board of Directors of the Company</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Authority and Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise required by mandatory provisions of applicable law or this Agreement, ultimate responsibility for the management, direction and control of the Company shall be vested in the Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the matters listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto shall require approval of the General Meeting of Shareholders of the Company.  The Board may delegate authority for the day-to-day management of the Company to the Representative Director in accordance with resolutions duly adopted by the Board and consistent with this Agreement and the Articles of Incorporation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Composition of the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">The Board shall consist of no less than three (3) but no more than six (6) Directors, with one (1) Director nominated by Biogen and all the other Directors nominated by Samsung&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (i) that upon Biogen (together with its Affiliates) becoming a Shareholder holding the same number of Shares held by Samsung and its Affiliates less one (1) or two (2) Shares (as applicable) by way of exercising the Biogen Option pursuant to Section 4.1, the Board shall consist of, as determined by the General Meeting of Shareholders, either (A) four (4) Directors, two (2) of whom shall be nominated by Samsung and two (2) of whom shall be nominated by Biogen, or (B) six (6) Directors, three (3) of whom shall be nominated by Samsung and three (3) of whom shall be nominated by Biogen&#59; and (ii) that upon the occurrence of any subsequent change in the Shareholding of either Party after the purchase by Biogen of the Biogen Option Shares, or if the Biogen Option is not exercised within the Biogen Option Period, after the expiration of the Biogen Option Period, each Party shall have the right to nominate the number of Directors that is obtained by multiplying the total number of Directors of the Company by the ratio of its respective Shareholding over the combined Shareholdings of the Parties, provided that any resulting decimal shall be rounded to the nearest whole number.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">At least one (1) Director nominated by each Party shall be an officer of such Party or any of its Affiliates who is not otherwise related to the Company.  Each Party entitled to nominate one or more Directors shall consult in good faith with the other Party prior to making such nomination, although the final decision to appoint such Director(s) shall ultimately reside with such Party.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Each Party shall have the right to replace any of its nominated Directors at any time for any reason, whether the term of his office has expired or not, without the consent of the other Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Party who so replaces its nominated Director shall indemnify the Company for any claims, damages or expenses made or claimed by the replaced Director by reason of such replacement.  If a Party gives written notice of such replacement to the other Party, the Parties shall take and cause </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to be taken all necessary actions (including causing their respective nominated Directors to hold a meeting of the Board and adopt necessary resolutions) to convene a General Meeting of Shareholders as soon as practicable to elect a replacement Director nominated by the Party who desires to replace its nominated Director.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">If the number of Directors that a Party is entitled to nominate is reduced hereunder, such Party shall determine which Director or Directors nominated by it are to be removed and cause such Director or Directors to resign or to be removed forthwith, and shall indemnify and hold the Company harmless against any claims, damages or expenses made or incurred by reason of such resignation or removal.  Furthermore, such Party shall exercise its voting rights in favor of the election of the person(s) nominated by the other Party as new Director or Directors, if such other Party is entitled to fill the vacant office(s) of the resigning or removed Director or Directors hereunder. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Each Party shall exercise (and shall cause each of its Affiliates to exercise) its voting rights so that the nominees of the other Party shall be elected as Directors in accordance with this Section 7.2 during the term of this Agreement.  In addition, in connection with a General Meeting of Shareholders at which the election of any Directors nominated by either Samsung or Biogen is proposed, Biogen or Samsung, as the case may be, shall exercise (and shall cause each of its Affiliates to exercise) any and all voting rights it may have through proxies or powers of attorney in favor of the election of such Directors&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Parties shall have no obligation to solicit proxies.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Cumulative Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall not adopt a cumulative voting system with respect to the election of Directors.  The Articles of Incorporation of the Company shall so provide to ensure that the Parties&#8217; rights to nominate Directors pursuant to this Article 7 shall be secured.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Term of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The term of office of a Director shall be three (3) years&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if such term expires before the close of the ordinary General Meeting of Shareholders concerning the last fiscal year that ended during the three-year term, it shall be extended until the close of such General Meeting of Shareholders.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Meetings of the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Meetings of the Board shall be held at least once every fiscal quarter at the head office of the Company unless otherwise determined by the Board as to frequency and&#47;or location.  Meetings of the Board may also be convened by the Representative Director at his discretion or at the request of any Director by written notice to the Representative Director.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">In convening a meeting of the Board, a written notice (in English and in Korean) stating the agenda, date, time and place of the meeting shall be sent by the </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Representative Director to all of the Directors and the Statutory Auditors at least seven (7) days prior to the date of such meeting.  Such notice may be given by e-mail or facsimile.  Each notice of a meeting of the Board shall be accompanied by a copy of all reports and materials that are necessary or appropriate for prior review and consideration by the Directors of the matters on the agenda.  The notice period set forth herein may be shortened or omitted with the written consent of all of the Directors and the Statutory Auditors.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">The Representative Director shall preside over each meeting of the Board as chairman. In the event the Representative Director is unable or unwilling to perform such duty with respect to a meeting of the Board, another Director appointed by the Board shall act as chairman of such meeting.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Each meeting of the Board shall be conducted in English.  The Company shall provide a Korean-English interpreter and such other support as is necessary to ensure that all participants are able to fully understand and participate in the meeting.  Directors may participate in and vote at a meeting of the Board via video conferencing equipment whereby all participants in the meeting can simultaneously see and hear each other or, to the extent permissible under applicable law, via telephone conferencing equipment whereby all participants in the meeting can simultaneously hear each other.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">For so long as Biogen has the right to nominate at least one (1) Director under this Agreement, Biogen shall have the right to designate one of its officers or employees to attend all meetings of the Board as a non-Director observer with no voting right and to be given such prior notice of meetings of the Board (together with materials prepared for the Directors for such meetings) as are given to the Directors.  As soon as practicable following the designation of each such observer by Biogen, Biogen shall cause the observer to execute and deliver to the Company a confidentiality agreement, in form and substance reasonably satisfactory to the Company, with respect to all information, data and materials relating to the Company or any of its Affiliates that are provided or made available to such observer in his capacity as an observer to the Board. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.01pt">Minutes of each meeting of the Board shall be prepared both in English and in Korean&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that in the event of any conflict or discrepancy between the English and Korean versions of such minutes, the English version shall control.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">A quorum for a meeting of the Board shall be the presence of a majority of the Directors then in office.  All actions and resolutions taken at a meeting of the Board shall be adopted by an affirmative vote of a majority of the Directors present at the meeting.  The chairman of the meeting shall have no casting or tie-breaking vote.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Report to the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The following information shall be reported to the Board once each fiscal quarter&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">The unaudited financial statements of the Company (prepared in accordance with accounting principles and practices generally accepted in Korea (including the IFRS)) consisting of a balance sheet as of the end of the preceding fiscal quarter and the related statements of income (including earnings per share), shareholders&#8217; equity and cash flows for the fiscal quarter then ended, certified by the chief financial officer of the Company&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">A written report comparing actual results for such fiscal quarter to the annual budget and business plan and containing comments on any other significant operational or other developments which may have material impact on the business of the Company.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 8. Officers&#59; Management of the Company</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Representative Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall have one (1) Representative Director, who shall be elected by a resolution of the Board.  The Representative Director shall serve as president and chief executive officer of the Company and shall represent the Company, observe and enforce the matters resolved by the Board and the General Meeting of Shareholders and the provisions of this Agreement and be responsible for the general management of the Company.  The term of office of the Representative Director shall be three (3) years&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if such term expires before the close of the ordinary General Meeting of Shareholders concerning the last fiscal year that ended during the three-year term, it shall be extended until the close of such General Meeting of Shareholders.  The Representative Director shall be nominated and elected as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">For so long as Samsung has a Shareholding of at least fifty percent (50%) or the largest Shareholding (including where Samsung is one of the largest Shareholders having the same Shareholding), Samsung shall have the right to nominate one of the Directors nominated by it for election at a meeting of the Board as Representative Director, and Biogen shall procure for its nominated Directors to exercise voting rights so that such nominee of Samsung shall be elected as Representative Director.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">In the event that Biogen becomes entitled to nominate a majority of the total number of Directors under this Agreement, Biogen shall have the right to nominate one of the Directors nominated by it for election at a meeting of the Board as Representative Director, and Samsung shall procure for its nominated Directors to exercise voting rights so that such nominee of Biogen shall be elected as Representative Director.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">In all other cases (other than the cases falling under Section 8.1(a) or 8.1(b) above), the Representative Director shall be elected in accordance with the Articles of Incorporation and applicable law, with no nomination right exercised by either Party.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The Party entitled to nominate the Representative Director shall consult in good faith with the other Party prior to making such nomination.</font></div><div><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">The provisions of Section 7.2(c) and (d) shall apply to the Representative Director, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that for so long as Biogen has the right to nominate the same number of Directors as Samsung under this Agreement following the exercise by Biogen of the Biogen Option, in the event Samsung decides to replace the Representative Director nominated by it whether his term of office has expired or not, Samsung shall obtain prior written consent from Biogen for any replacement Representative Director to be nominated by Samsung for election at a meeting of the Board, which consent shall not be unreasonably withheld, delayed or conditioned.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Statutory Auditors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall have at least one (1) Statutory Auditor.  For so long as a Party&#8217;s Shareholding is no less than thirty percent (30%), it shall have the right to nominate one (1) Statutory Auditor for election at the General Meeting of Shareholders and the other Party shall exercise its voting rights so that the nominee of such Party shall be elected as Statutory Auditor.  Initially, the Company shall have one (1) Statutory Auditor who shall be nominated by Samsung.  Each Party entitled to nominate a Statutory Auditor shall consult in good faith with the other Party prior to making such nomination.  The provisions of Section 7.2(c), (d) and (e) shall apply to the Statutory Auditors, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Other Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall also have a chief financial officer, a chief technology officer (which officers are referred to herein collectively as the &#8220;Senior Officers&#8221; and individually as a &#8220;Senior Officer&#8221;) and such other officers as may be necessary for the operation of the Company.  The Senior Officers shall be appointed and removed by the Board and other officers shall be appointed and removed by the Representative Director.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Powers and Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms of this Agreement and the powers reserved to the Board and to the General Meeting of Shareholders by the Articles of Incorporation and applicable law, the powers and duties of the Representative Director and the Senior Officers shall be determined from time to time by the Board, and the powers and duties of all other officers of the Company (other than the Statutory Auditors) shall be determined from time to time by the Representative Director.  The Statutory Auditors shall have the powers and duties prescribed by the Korean Commercial Code.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The maximum aggregate amount of remuneration, bonuses and severance allowances payable to the Directors (including the Representative Director) and the maximum aggregate amount of remuneration, bonuses and severance allowances payable to the Statutory Auditors shall be determined by a resolution of the General Meeting of Shareholders.  The power and authority to determine the remuneration and bonuses payable to the Representative Director, each Director and Statutory Auditor shall be delegated by the General Meeting of Shareholders to the Board, and such remuneration and bonuses shall be determined by a resolution of the Board with due consideration given to Samsung Group compensation guidelines.  Severance allowances payable to the Directors (including the Representative Director), Statutory Auditors and Senior Officers shall be determined in accordance with the officer severance pay regulations of the Company adopted by the General Meeting of Shareholders.  Notwithstanding the foregoing, a Director or Statutory Auditor </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">performing no executive or officer functions shall receive no compensation from the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Indemnification of Directors and Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To the maximum extent permitted by applicable law, the Company shall indemnify the Representative Director and each Director, Statutory Auditor and other officer against all claims, judgments, liabilities (including liabilities to the Company), damages, expenses and costs (including attorneys&#8217; fees and disbursements) for which he has been held liable or which he has incurred in connection with or arising out of the performance of his duties in his official capacity as Representative Director or as a Director, Statutory Auditor or other officer, if such Representative Director, Director, Statutory Auditor or other officer acted in good faith and for a purpose and in a manner that he reasonably believed to be in the best interests of the Company.  With respect to all claims, judgments, liabilities (including liabilities to the Company), damages, expenses and costs (including attorneys&#8217; fees and disbursements) for which a Representative Director, Director, Statutory Auditor or other officer has been held liable or which he has incurred in connection with or arising out of the performance of his duties in his official capacity as Representative Director or as a Director, Statutory Auditor or other officer but which are not indemnifiable by the Company pursuant to this Section 8.6 and are insurable at commercially reasonable cost, the Company shall obtain and maintain a directors&#8217; and officers&#8217; liability insurance policy with commercially reasonable coverage.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 9. General Meeting of Shareholders</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Authority and Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The General Meeting of Shareholders shall decide and resolve the matters listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto and other matters reserved to the general meeting of shareholders by the Korean Commercial Code and other applicable laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">General Meetings of Shareholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">An ordinary General Meeting of Shareholders shall be held within three (3) months after the close of each fiscal year of the Company.  An extraordinary General Meeting of Shareholders may be held at any time pursuant to the resolution of the Board.  The Representative Director shall convene each General Meeting of Shareholders in accordance with the resolutions of the Board.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">In convening a General Meeting of Shareholders, a written notice (in English and in Korean) stating the agenda, date, time and place of the meeting shall be sent by the Representative Director to all of the Shareholders at least fourteen (14) days prior to the date of such meeting.  Each notice of a General Meeting of Shareholders shall be accompanied by a copy of all reports and materials that are necessary or appropriate for prior review and consideration by the Shareholders of the matters on the agenda.  The notice period set forth herein may be shortened or omitted with the written consent of all of the Shareholders.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">The Representative Director shall preside over each General Meeting of Shareholders as chairman.  In the event the Representative Director is unable or unwilling to perform such duty with respect to a General Meeting of Shareholders, another Director or an officer appointed by the Shareholders attending such meeting (by an affirmative vote of a majority of the Shares represented in person or by proxy at such meeting) shall act as chairman of such meeting.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">General Meetings of Shareholders shall be conducted in English.  The Company shall provide a Korean-English interpreter and such other support as is necessary to ensure that all participants are able to fully understand and participate in the meetings.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Minutes of each General Meeting of Shareholders shall be prepared both in English and in Korean&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that in the event of any conflict or discrepancy between the English and Korean versions of such minutes, the English version shall control.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Quorum and Voting Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except to the extent otherwise required by mandatory provisions of applicable law (such as the matters requiring a special resolution of the general meeting of shareholders under the Korean Commercial Code) or the Articles of Incorporation, any resolution or action at a General Meeting of Shareholders shall require an affirmative vote (whether in person or by proxy) of fifty-two percent (52%) of the total issued and outstanding Shares. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Prior Consent Requirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Biogen Consent Period, the matters listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto shall require the prior consent of Biogen in writing.  During the Biogen Consent Period, the Parties shall take necessary actions to ensure that no resolutions are adopted by the General Meeting of Shareholders (or by the Board) with respect to any such matters without the prior written consent of Biogen.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 10. Intellectual Property</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Ownership and License of Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">As between the Parties and subject to the terms of the IP License Agreement, each Party shall own any Intellectual Property owned or controlled by such Party as of the Closing Date.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Subject to the terms of the IP License Agreement, (i) any and all inventions and other Intellectual Property that are conceived, discovered, developed or reduced to practice by the Company as a result of or in connection with the research, development, manufacturing, commercialization, distribution or sale of the Products shall vest in and be owned by the Company, and (ii) the Company shall bear all costs of registering, maintaining, protecting and enforcing such Intellectual Property owned by the Company.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Without prejudice to Section 6.5(f) and subject to the terms of the IP License Agreement, the Company may license any of its Intellectual Property to Samsung and&#47;or Biogen upon terms and conditions approved by the Board.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Ownership of Clinical Data and Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms of the IP License Agreement, the Company shall own all clinical data and trademarks related to the Products.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Ownership of Regulatory Filings and Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall own all regulatory filings and regulatory approvals related to the Products.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Conflict with Terms of the IP License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For the avoidance of doubt, in the event of any inconsistency between the terms of this Article 10 and the terms of the IP License Agreement, the terms of the IP License Agreement shall control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 11. Information Rights</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Financial Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As long as a Party is a Shareholder, the Parties shall cause the Company to furnish such Party with the information and materials set forth in paragraphs (a) through (c) below (in the case of Biogen, together with an English version or translation thereof)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Within thirty (30) days after the end of each fiscal year, draft audited financial statements (including footnotes thereto) consisting of at least a balance sheet as of the end of such fiscal year and the related statements of income (including earnings per share) for the fiscal year then ended, prepared in accordance with accounting principles and practices generally accepted in Korea (including the IFRS) audited by a firm of independent public accountants of recognized standing which is not the accounting firm that serves as the external auditors to either Party&#59; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Within sixty (60) days after the end of each fiscal year, (i) annual management reports and (ii) audited financial statements (including footnotes thereto) consisting of a balance sheet as of the end of such fiscal year and the related statements of income (including earnings per share), shareholders&#8217; equity and cash flows for the fiscal year then ended, prepared in accordance with accounting principles and practices generally accepted in Korea (including the IFRS) audited by a firm of independent public accountants of recognized standing which is not the accounting firm that serves as the external auditors to either Party&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Within thirty (30) days after the end of each fiscal quarter, unaudited financial statements (including footnotes thereto) consisting of a balance sheet as of the end of such fiscal quarter and the related statements of income (including earnings per share), shareholders&#8217; equity and cash flows for the fiscal quarter then ended, certified by the chief financial officer of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Other Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As long as a Party is entitled to nominate at least one (1) Director under this Agreement, the Parties shall cause the Company to furnish such Party with such </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">information and&#47;or materials as may be reasonably requested by such Party to make an informed judgment with respect to the agenda of a meeting of the Board or a General Meeting of Shareholders, as soon as such information and&#47;or materials are available (in the case of Biogen, together with an English version or translation thereof).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As long as a Party has a Shareholding of five percent (5%) or more, the Parties shall cause the Company to make its financial management personnel available to such Party so that such Party can consult with, and receive information from, such personnel as necessary to comply with any regulatory or governmental requirements, including Securities and Exchange Commission reporting requirements.  Furthermore, the Parties agree to, from time to time, amend this Article 11 at either Party&#8217;s request to allow a Party to receive information of a certain type (and&#47;or at such a time) necessary for such Party to comply with any regulatory or governmental requirements, including Securities and Exchange Commission reporting requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 12. Financial Policies</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Fiscal year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties shall cause the fiscal year of the Company to commence on January 1st and end on December 31 of each year&#59; provided, however, that the first fiscal year shall commence on the date of incorporation and end on December 31st of that year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Business Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties agree that the initial business plan and each subsequent business plan for the Company shall cover the next fiscal year in detail and the next three (3) fiscal years at a high level and that the business plan shall be prepared by the Company&#8217;s management and submitted to the Board for approval by November 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of each year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Dividend Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties shall cause the Company to pay such dividends out of its distributable net earnings as are consistent with its operating and investment plans as approved by the Board.  The payment and level of any dividend shall be determined by the Board and approved by the General Meeting of Shareholders.  In determining the amount of dividends to be distributed for each fiscal year, the Board shall take into account the debt-to-equity ratio of the Company and the financial operating needs of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 13. Restrictions on Transfer of Shares </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Prohibition of Transfer of or Creation of Encumbrance over Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Unless otherwise agreed by the Parties in writing, during the period from the Closing Date until (and including) the later of (i) the sixth (6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) anniversary of the date of incorporation of the Company and (ii) the date on which the Samsung Option Period expires (the &#8220;Restricted Period&#8221;), neither Party shall sell, transfer, pledge, mortgage or encumber, or agree to sell, transfer, pledge, mortgage or encumber, or otherwise dispose of any Shares or any interest in the Shares owned by such Party, except in accordance with Article 4 or Section 13.2.  Any sale, transfer, pledge, mortgage, encumbrance or disposition made or created in breach of this Section 13.1 shall be null and void </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">ab initio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Transfer to Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding Section 13.1&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Biogen may at any time transfer any or all of its Shares to any of its Affiliates&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Samsung may at any time transfer any or all of its Shares to any of its Affiliates&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the transferring Party shall notify the other Party of its intention to do so by not less than thirty (30) days prior written notice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that such transfer to an Affiliate shall be subject to the following conditions&#58; (i) if the Affiliate to which the transferring Party has transferred any of its Shares pursuant to this Section 13.2 ceases to be an Affiliate of the transferring Party at any time after such transfer, the transferring Party shall procure that all such Shares are transferred back to the transferring Party or to another Affiliate of the transferring Party prior to the date of such cessation&#59; (ii) the transferring Party shall remain jointly and severally liable together with such Affiliate transferee under this Agreement as if the transferring Party had not transferred any of its Shares to such Affiliate transferee&#59; and (iii) such Affiliate shall not be a Person conducting or engaged in, or intending to conduct or engage in, any business that directly or indirectly relates to the development, commercialization, distribution and&#47;or sale of any Biosimilar Pharmaceutical Product(s) based upon an Initial Reference Product or an Additional Reference Product.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#91;***&#93;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Creation of Encumbrances on Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Following the expiration of the Restricted Period, in the event a Party desires to pledge, mortgage or otherwise encumber any of the Shares that it owns, such Party shall, prior to the creation of such pledge, mortgage or encumbrance, procure for the relevant security interest holder to provide a written undertaking to the other Party, in form and substance reasonably satisfactory to such other Party, that the provisions of Sections 13.3 and 13.5 shall apply to any foreclosure of the relevant security interest as if the security interest holder were the Party that has provided such security interest.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#91;***&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">&#91;Intentionally left blank&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#91;***&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 14. Confidentiality of Information</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party (the &#8220;Receiving Party&#8221;) agrees to keep in strict confidence (i) the terms and conditions of this Agreement, (ii) all background technology, trade secrets and other information and materials (including all tangible and intangible embodiments thereof) that the other Party (the &#8220;Disclosing Party&#8221;) provides, communicates or otherwise </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">32</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">makes available to the Receiving Party and&#47;or the Company and (iii) any non-public information obtained from the Disclosing Party or the Company in connection with or pursuant to this Agreement or the transactions contemplated hereby (collectively, &#8220;Confidential Information&#8221;) and to protect the Confidential Information with the same degree of care normally used to protect its own confidential information of a similar nature.  The Receiving Party shall not disclose or allow disclosure of any Confidential Information to any third party and shall not use any Confidential Information in any manner, except, in each case, for the purposes of implementing and enforcing this Agreement, without the prior written consent of the Disclosing Party. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The restrictions set forth in Section 14.1 shall not apply to any Confidential Information&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">which is or becomes generally available to the public through no fault on the part of the Receiving Party&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">which is lawfully in the possession of the Receiving Party prior to the disclosure of such information by or on behalf of the Disclosing Party or the Company, as reasonably evidenced by appropriate documentation&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">which lawfully becomes available to the Receiving Party from a source other than the Disclosing Party and the Company without any duty as to confidentiality or non-use&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">which is independently developed or otherwise created by the Receiving Party without the use of any Confidential Information of the Disclosing Party, as reasonably evidenced by appropriate documentation&#59; or</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">which is required to be disclosed or provided to any court, government or regulatory body of competent jurisdiction (including any relevant securities exchange) (i) pursuant to any law, rule, regulation, judgment, decree or order or (ii) as necessary to make regulatory filings and communications related to any Products&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that (x) any such information discloseable pursuant to this Section 14.2(e) shall be disclosed only to the extent required by applicable law, rule, regulation, judgment, decree or order&#59; (y) except with respect to required disclosure to tax authorities, the Party seeking to disclose or provide such information shall give the other Party prompt written notice of such requirement and fully cooperate with the other Party so that the other Party and&#47;or the Company (as the case may be) may obtain reasonable assurances that confidential treatment will be accorded to such information&#59; and (z) without limiting the generality of the foregoing, the Parties shall use Commercially Reasonable Efforts to ensure that the list of the Initial Products is redacted from any copy of this Agreement required to be filed with any government or regulatory body.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Measures to Keep Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party agrees that, prior to giving access to any Confidential Information to any of its Affiliates or any of its or such Affiliates&#8217; respective </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">33</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">directors, officers, employees, advisors, consultants and agents pursuant to the exception provided in the second sentence of Section 14.1, it shall require each such Person to agree to be bound by all obligations of confidentiality and non-use under this Article 14, and shall take all reasonable steps and measures to ensure that each such Person will comply with and perform such obligations, in each case to the same extent as if they were direct parties to this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties agree to coordinate all publicity with respect to their relationships and plans as Shareholders of the Company.  The Parties shall consult with each other before issuing any press release or making any other public announcement with respect to this Agreement, the IP License Agreement, the transactions contemplated hereby or thereby or the business, operations or activities of the Company and, except as required by any court, government or regulatory body of competent jurisdiction (including any relevant securities exchange) or by any law, rule, regulation, judgment, decree or order, neither Party shall make any press release or other public announcement with respect to this Agreement, the IP License Agreement, the transactions contemplated hereby or thereby or the business, operations or activities of the Company without the prior written consent of the other Party, which consent shall not be unreasonably withheld, delayed or conditioned.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Survival of Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The obligations undertaken by the Parties under this Article 14 (other than Section 14.4) shall survive the termination of this Agreement for any reason and shall remain in effect and be binding on the Parties for a period of ten (10) years after the termination of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that to the extent any Confidential Information constitutes a trade secret, as defined in the U.S. Uniform Trade Secrets Act or the Korean Unfair Competition Prevention and Trade Secrets Protection Act, where applicable, then the Receiving Party shall keep such trade secret confidential until such time as the Confidential Information no longer qualifies as a trade secret under the applicable law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 15. Non-Competition</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Additional Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">For the period of &#91;***&#93; years after the date of this Agreement, which may be extended by mutual agreement between the Parties, neither Party shall, directly or indirectly (including through any of its Affiliates), develop, manufacture, commercialize, distribute or sell any Biosimilar Pharmaceutical Product (other than Biosimilar Pharmaceutical Products that reference any Biogen Reserved Products) anywhere in the world without first offering such Biosimilar Pharmaceutical Product to the Company for consideration as an Additional Product&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that neither Party shall be required to offer to the Company, and nothing in this Agreement shall prohibit a Party or any of its Affiliates from developing, manufacturing, commercializing, distributing or selling, any Private Label Product version of an innovator product being marketed by such Party or its Affiliates.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">34</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">In the event the Company accepts the above offer within thirty (30) days after receipt thereof, the Parties shall negotiate in good faith to determine the terms and conditions governing the development, manufacturing, commercialization, distribution and sale of such Biosimilar Pharmaceutical Product using the terms and conditions set forth in this Agreement for the Initial Products as the basis for such negotiation.  Upon the Parties reaching agreement on the terms and conditions governing the development, manufacturing, commercialization, distribution and sale of such Biosimilar Pharmaceutical Product, such Biosimilar Pharmaceutical Product shall be added to the business of the Company as an Additional Product under this Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">In the event the Company fails to accept the above offer within thirty (30) days after receipt thereof or the Parties fail to reach agreement on the terms and conditions governing the development, manufacturing, commercialization, distribution and sale of such Biosimilar Pharmaceutical Product within ninety (90) days after the acceptance of such offer by the Company, the Party offering such Biosimilar Pharmaceutical Product to the Company shall have the right to develop, manufacture, commercialize, distribute and&#47;or sell such Biosimilar Pharmaceutical Product outside of the Joint Venture, without any further obligations or compensation to the non-offering Party or the Company.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Non-Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">During the term of this Agreement, without the prior written consent of the other Party, neither Party shall, directly or indirectly (including through any of its Affiliates), develop, manufacture, commercialize, distribute and&#47;or sell any alternative Biosimilar Pharmaceutical Product(s) that references any of the Reference Products anywhere in the world, except through the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the provisions of this Section 15.2(a) shall not apply to (x) in the case of an acquisition (by way of a merger or consolidation or purchase of shares or assets) of a Party (or a Controlling Affiliate thereof) by a Third Party pursuant to a Change of Control (which term, in respect of Biogen, shall, for the purpose of this Section 15.2(a), also include any transaction that results in such Third Party and&#47;or any Affiliate thereof Controlling Biogen Idec Inc. or, in the case of one or more corporate restructurings or reorganizations referred to in the definition of &#8220;Change of Control,&#8221; the Person that has become the ultimate parent company of Biogen upon the consummation of such corporate restructurings or reorganizations), any Biosimilar Pharmaceutical Product(s) that references any of the Reference Products which Biosimilar Pharmaceutical Product(s) was Controlled (as defined in the IP License Agreement) by such Third Party or any of its Affiliates immediately prior to such acquisition (a &#8220;Third Party Biosimilar&#8221;) so long as no Biogen Technology, Joint Technology or Licensee Technology (as those terms are defined in the IP License Agreement) is used during the term of this Agreement in connection with the development, manufacture, commercialization, distribution and&#47;or sale of such Third Party Biosimilar (an &#8220;Exempted Program&#8221;), or (y) in the case of an acquisition (by way of a merger, consolidation or purchase of shares or assets) by a Party or any of its Affiliates of a </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">35</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Third Party that directly or indirectly Controls (as defined in the IP License Agreement) any Biosimilar Pharmaceutical Product(s) that references any of the Reference Products outside of an Exempted Program (an &#8220;Acquired TP Biosimilar&#8221;), such Acquired TP Biosimilar so long as it is either divested or discontinued entirely within one (1) year after such acquisition.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event a Party (or a Controlling Affiliate thereof) is acquired pursuant to a Change of Control and the acquiring Third Party or any of its Affiliates Controls (as defined in the IP License Agreement) a Third Party Biosimilar (as set forth in clause (x) of the foregoing paragraph) (such acquisition being hereinafter referred to as the &#8220;CoC Acquisition&#8221;), such acquired Party (the &#8220;Responsible Party&#8221;) shall give written notice thereof to the other Party (the &#8220;Non-Responsible Party&#8221;), as soon as practicable following the earlier of the announcement or consummation of the CoC Acquisition and the Non-Responsible Party shall have the option (which option may be exercised by written notice to the Responsible Party within six (6) months after its receipt of the foregoing notice) to have the Fair Market Value of the Shares held by the Responsible Party and its Affiliates determined as soon as practicable.  If the Non-Responsible Party elects to have such Fair Market Value determined, the Responsible Party shall render such cooperation as may be necessary for the appraiser appointed by the Non-Responsible Party to determine the Fair Market Value and shall bear all costs and expenses associated with the determination of such Fair Market Value.  Once such Fair Market Value has been determined and notified to the Non-Responsible Party and the Responsible Party in writing, the Non-Responsible Party shall have the option (which option may be exercised by written notice to the Responsible Party within ninety (90) days after receipt by the Parties of written notice of such Fair Market Value) to purchase or have a Person designated by it purchase all (but not less than all) of the Shares of the Responsible Party and its Affiliates at the Fair Market Value so determined (or if the CoC Acquisition occurs within one (1) year after the date of incorporation of the Company, at 75% of the Fair Market Value so determined).  The provisions of Section 17.6 shall apply to the sale and purchase of the Shares held by the Responsible Party and its Affiliates under this Section 15.2(a), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as if the Responsible Party were the Non-Terminating Party and the Non-Responsible Party were the Terminating Party.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event the CoC Acquisition occurs, in addition to (and without prejudice to) the foregoing option to purchase the Shares held by the Responsible Party and its Affiliates, the Non-Responsible Party shall (notwithstanding Sections 6.3 and 6.5 of this Agreement) have the right (but not the obligation), at any time within six (6) months after the consummation of the CoC Acquisition, to cause the Company to terminate any or all of the Manufacturing Agreements and&#47;or Service Agreement between the Company and the Responsible Party (and&#47;or one or more of its Affiliates).  If the Non-Responsible Party exercises the foregoing right, the Parties shall take all necessary actions to cause such Manufacturing Agreement(s) and&#47;or Service Agreement to be terminated as soon as practicable thereafter.  Upon termination of such Manufacturing Agreement(s), the Responsible Party shall, upon demand from the </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">36</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Non-Responsible Party, reimburse the Company for any incremental technology transfer costs or expenses incurred by the Company in connection with the substitution of CMO(s) resulting from such termination.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If a Party fails to divest or discontinue any Acquired TP Biosimilar entirely within one (1) year after acquisition (as required under clause (y) in the first paragraph of this Section 15.2(a)), such failure shall be deemed to constitute a material breach of such Party under this Agreement as set forth in Section 17.2(b) or 17.3(b), as the case may be.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the avoidance of doubt, nothing in this Agreement shall in any way restrict (i) Samsung in its ability to engage in the CMO business, even if such CMO business relates to or involves the manufacturing of Biosimilar Pharmaceutical Products that reference any of the Reference Products, or (ii) Biogen Idec MA Inc. (or its designated Affiliate) in its ability to engage in the CMO business, even if such CMO business relates to or involves the manufacturing of Biosimilar Pharmaceutical Products that reference any of the Reference Products.  For the purpose of the preceding sentence, the &#8220;CMO business&#8221; described in clause (i) and clause (ii) of this Section 15.2(a) (x) shall include process development services which are related or incidental to the contract manufacturing of any Biosimilar Pharmaceutical Product that references a Reference Product and for which fees are charged on a time and material basis without any license fee or royalty element and (y) shall not include any other cell line or process development activities related to any Biosimilar Pharmaceutical Product that references a Reference Product.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">During the term of this Agreement, neither Party shall, directly or indirectly (including through any of its Affiliates), exercise its voting rights or other authority or power available to it in relation to the Company, including by causing the Director(s) designated by such Party, to allow the Company to develop, manufacture, commercialize, distribute and&#47;or sell a Biogen Reserved Product or any Biosimilar Pharmaceutical Product(s) that references a Biogen Reserved Product anywhere in the world.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Notwithstanding anything in this Agreement to the contrary, Sections 15.1 and 15.2 shall terminate and have no further force and effect in the event that either Party and its Affiliates are no longer Shareholders of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 16. Representations and Warranties of the Parties</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Party represents and warrants to the other Party as of the date of this Agreement and as of the Closing Date (as though such representations and warranties were made at and as of the Closing Date) as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Corporate Existence and Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  It is a company duly organized and validly existing under the laws of its jurisdiction of incorporation.  It has all requisite corporate or </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">37</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">other applicable power and authority to enter into and perform its obligations under this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Governmental Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Other than (i) the Antitrust Approvals, (ii) a foreign investment report required to be filed by Biogen with a foreign exchange bank in Korea (pursuant to the Korean Foreign Investment Promotion Act), (iii) a derivative transaction report required to be filed by Samsung or Biogen with the Bank of Korea in respect of the Biogen Option, the Samsung Option, the Non-Responsible Party&#8217;s option set forth in Section 15.2(a) and the Terminating Party&#8217;s option set forth in Section 17.5 (pursuant to the Korean Foreign Exchange Transaction Act) and (iv) a guarantee report required to be filed by Samsung Parent with the Bank of Korea in respect of the Samsung Parent Guarantee to be provided under this Agreement (pursuant to the Korean Foreign Exchange Transaction Act), all consents, permits, licenses, approvals and authorizations of, and registrations, declarations and other filings with, any governmental agency, official or authority required in connection with the execution, delivery and performance of this Agreement by such Party (to the extent such consents, permits, licenses, approvals, authorizations, registrations, declarations and filings are required to be obtained or made prior to the Closing under applicable law) have been duly obtained or made and are in full force and effect. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Due Authorization and Execution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Its execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on its part.  This Agreement has been duly and validly executed and delivered by it and, assuming due and valid authorization, execution and delivery of this Agreement by the other Party, constitutes legally binding obligations enforceable against it in accordance with the terms of this Agreement, except as the enforceability hereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the enforcement of creditors&#8217; rights generally and equitable principles of general application.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">No Violation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Its execution, delivery and performance of this Agreement do not and will not violate, breach or conflict with (i) its organizational documents, (ii) any law, rule, regulation, judgment, order or decree applicable to it or (iii) any agreement or instrument by which it is bound or to which any of its assets or properties are subject.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">No Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  There is no suit, action or other legal proceeding pending or, to the best of its knowledge, threatened against it, which could reasonably be expected to have a material adverse effect on its ability to enter into and perform its obligations under this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 17. Term and Termination</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Term of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The term of this Agreement shall begin upon the execution hereof by the Parties and shall continue for an indefinite period thereafter until (i) the Company is dissolved and liquidated or (ii) this Agreement is sooner terminated by the mutual agreement of the Parties or pursuant to the provisions of this Article 17.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">38</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Termination by Biogen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Biogen may terminate this Agreement upon written notice to Samsung if and only if&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">The Closing does not occur by March 31, 2012&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that Biogen may terminate this Agreement pursuant to this Section 17.2(a) only if the Closing has not occurred by such date for a reason other than Biogen&#8217;s failure to fulfill any of its obligations under this Agreement, which failure has been the cause of or has resulted in the failure of the Closing to occur on or before such date&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Samsung commits a material breach of any of its representations, warranties, covenants or obligations under this Agreement and fails to cure such breach within thirty (30) days after receipt of written notice from Biogen specifying the particulars of such breach and requiring such breach to be remedied&#59; or</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Samsung, any of its creditors or any other eligible party files or commences a proceeding for the liquidation, bankruptcy, receivership, reorganization, rehabilitation, composition or dissolution of Samsung (and, in the case of any such proceeding brought against Samsung, such proceeding has not been stayed or dismissed within ninety (90) days after the filing thereof), or Samsung is unable to pay or has suspended payment of its debts generally as they become due (except debts being contested in good faith), or the creditors of Samsung have taken over its management, or the relevant financial institutions have suspended the clearing house privileges of Samsung.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Termination by Samsung</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Samsung may terminate this Agreement upon notice to Biogen if and only if&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">The Closing does not occur by March 31, 2012&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that Samsung may terminate this Agreement pursuant to this Section 17.3(a) only if the Closing has not occurred by such date for a reason other than Samsung&#8217;s failure to fulfill any of its obligations under this Agreement, which failure has been the cause of or has resulted in the failure of the Closing to occur on or before such date&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Biogen commits a material breach of any of its representations, warranties, covenants or obligations under this Agreement and fails to cure such breach within thirty (30) days after receipt of written notice from Samsung specifying the particulars of such breach and requiring such breach to be remedied&#59; or</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Biogen, any of its creditors or any other eligible party files or commences a proceeding for the liquidation, bankruptcy, receivership, reorganization, rehabilitation, composition or dissolution of Biogen (and, in the case of any such proceeding brought against Biogen, such proceeding has not been stayed or dismissed within ninety (90) days after the filing thereof), or Biogen is unable to pay or has suspended payment of its debts generally as they become due (except debts being contested in good faith), or </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">39</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the creditors of Biogen have taken over its management, or the relevant financial institutions have suspended the clearing house privileges of Biogen.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Termination upon Transfer of All Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If either Party (together with its Affiliates) has sold, transferred or otherwise disposed of all of its Shares and no longer owns any Shares, this Agreement shall be automatically terminated and shall be of no further force or effect thereafter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#91;***&#93; </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#91;***&#93;</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Other Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing in this Article 17 shall prevent a Party from enforcing any rights or remedies that may be available to it under the other provisions of this Agreement or under applicable law.  The termination of this Agreement for any reason shall be without prejudice to (i) any such rights or remedies and (ii) any rights or obligations that have accrued or arisen prior to the effective date of such termination.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Survival of Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The provisions of Article 14, Article 17, Article 18, Article 19 and Article 20 shall survive the termination of this Agreement for any reason.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 18. Governing Law and Dispute Resolution</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall be governed by and construed in accordance with the laws of Korea without giving effect to the conflict of laws rules thereof. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Any dispute or controversy which may arise out of or in connection to this Agreement shall be submitted to the International Chamber of Commerce (the &#8220;ICC&#8221;) for resolution by arbitration before three arbitrators (such arbitrators, collectively, the &#8220;Arbitral Tribunal&#8221;) under the Arbitration Rules of the ICC in effect as of the date of commencement of the arbitration proceeding (the &#8220;Arbitration Rules&#8221;), as modified by this Section 18.2.  Except as expressly limited by Section 18.2(g), the arbitrators shall have the authority to grant any equitable and legal remedies that would be available in any judicial proceeding instituted to resolve a disputed matter under the substantive laws of Korea.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The number of arbitrators shall be three (3), who shall be selected as follows&#58;  each of Biogen, on the one hand, and Samsung on the other hand, shall nominate one (1) arbitrator, in the Request for Arbitration and in the Answer (as the case may be), and those Party-nominated arbitrators shall unanimously nominate the third arbitrator (who will act as president of the Arbitral Tribunal, referred to in this Section 18.2 as the &#8220;President Arbitrator&#8221;) within ten (10) Business Days of the appointment of the last Party-nominated arbitrator. If the Party-nominated arbitrators are unable to agree upon </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">40</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the nomination of the President Arbitrator within ten (10) Business Days of the nomination of the last Party-nominated arbitrator, such President Arbitrator shall be appointed by the ICC within ten (10) Business Days thereafter.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">The place of arbitration shall be London, United Kingdom at a suitable venue to be agreed by the Parties and arbitrators within twenty (20) Business Days of the nomination or appointment of the President Arbitrator.  The proceedings shall be conducted in the English language.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The decision and award of the Arbitral Tribunal shall be made by majority decision and shall be final, nonappealable and binding on the Parties hereto and their successors and assigns.  The arbitral award shall be accompanied by a reasoned opinion.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">The arbitral award may include both pre-and post-award interest, at a rate to be determined by the Arbitral Tribunal.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.01pt">The Arbitral Tribunal shall be empowered to award damages only to the extent of actual damages suffered, and only to the extent consistent with this Agreement.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The Arbitral Tribunal&#8217;s final award shall be rendered within the six (6)-month period specified in Article 24(1) of the Arbitration Rules, and any extension thereof pursuant to Article 24(2) of the Arbitration Rules shall not exceed an additional three (3) months.  Notwithstanding any provision of the Arbitration Rules&#58; (i) each Party shall be permitted to serve up to ten (10) interrogatories, to take up to five (5) depositions of the other Party, and to obtain production of documents pursuant to Article 3 of the International Bar Association Rules on the Taking of Evidence in International Arbitration as current on the date of this Agreement (the &#8220;IBA Rules&#8221;), and to exchange exhibits and information as provided for in the Arbitration Rules, all of the foregoing on dates and locations to be mutually agreed upon (or, failing such agreement, as the President Arbitrator shall select after hearing from the Parties)&#59; (ii) any documents not in English that are produced by a Party shall be accompanied by a translation into English, which translation shall not be binding upon the other Party or the arbitrators&#59; (iii) each Party covenants and agrees that it shall produce documents, information, and deposition and hearing witnesses, as required by this Section 18.2 and as otherwise required by the Arbitration Rules&#59; and (iv) without limiting Article 3.9 or 3.10 of the IBA Rules, subpoenas to non-Parties, for production of documents and&#47;or for testimony, shall be issued at the request of a Party, up to ten (10) subpoenas per Party.  The Parties will make their respective employees available for depositions and hearing testimony as reasonably requested by the other Party. Judgment on the arbitral award may be entered in any court having jurisdiction thereof. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Except as required by applicable law or as necessary for recognition and enforcement of the arbitral decision and award, neither a Party nor an arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">41</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">consent of the Parties.  Any documents submitted to the arbitrators shall be kept confidential and shall not be disclosed, except that any such documents may be disclosed (i) as reasonably necessary in connection with any action to enforce or collect the award or (ii) to the extent discoverable or admissible in any action arising out of or in connection with this Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt">Notwithstanding this Section 18.2, each Party may apply to any court having competent jurisdiction (a) to enforce the arbitration provisions of this Agreement, or (b) to seek provisional injunctive relief so as to maintain the status quo (including, but not limited to, maintaining the confidentiality of any arbitration proceedings and non-public information) until the final arbitration award is rendered and is finally judicially confirmed if challenged judicially, or the dispute is otherwise resolved. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 19. Notice</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any communication (including any notice, consent, approval, request, demand or response) required or permitted to be given under this Agreement (i) shall be in writing and in the English language, (ii) shall be given by registered airmail, hand delivery, prepaid express air courier or facsimile transmission (with a confirmation of transmission) to the addresses written below and (iii) shall be effective upon deemed receipt in accordance with Section 19.3 below&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">If to Samsung</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Samsung BioLogics Co., Ltd.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Floor, Samsung Electronics Building</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;1320-10 Seocho 2-dong, Seocho-gu</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Seoul 137-857, Korea</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Attention&#58; &#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Facsimile&#58; &#91;***&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">If to Biogen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Biogen Idec Therapeutics Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;14 Cambridge Center</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cambridge, Massachusetts 02142 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;U.S.A.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Attention&#58; &#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Facsimile&#58; &#91;***&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Change of Address for Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party may amend its address and facsimile number set forth above by giving written notice to the other Party in accordance with the provisions of this Article 19.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">42</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Effective Date of Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any communication under this Article 19 shall be deemed to have been received by the addressee&#58; (i) if by registered airmail, hand delivery or prepaid express air courier, on the date of delivery&#59; or (ii) if by facsimile transmission, on the date of transmission as indicated on the confirmation of transmission or on the next Business Day if the date of transmission is not a Business Day&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if a facsimile transmission is made after 5&#58;00 p.m. in the country of the recipient according to the confirmation of transmission, it shall be deemed to have been received on the immediately following Business Day.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 20. Miscellaneous Provisions</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Parent Guarantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Biogen Parent shall guarantee and remain liable for any and all payment obligations of Biogen under or arising out of this Agreement and the IP License Agreement pursuant to the terms of a corporate guarantee in form and substance reasonably acceptable to Samsung (the &#8220;Biogen Parent Guarantee&#8221;).  At or prior to Closing, Biogen shall cause Biogen Parent to duly execute and deliver to Samsung the Biogen Parent Guarantee.</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.6pt">Samsung Parent shall guarantee and remain liable (if Samsung determines that Samsung Parent shall be collectively Samsung Electronics Co., Ltd., Samsung Everland, Inc. and Samsung C&#38;T Corporation, (i) on a several (and not joint) basis and (ii) in proportion to their shareholdings in Samsung relative to one another as of the Closing Date) for any and all payment obligations of Samsung under or arising out of this Agreement pursuant to the terms of a corporate guarantee in form and substance reasonably acceptable to Biogen (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung Parent Guarantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  At or prior to Closing, Samsung shall cause Samsung Parent to duly execute and deliver to Biogen the Samsung Parent Guarantee.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Assignability&#59; Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and each and every covenant, term and condition hereof shall be binding upon and inure to the benefit of the Parties hereto and their respective successors and permitted assigns.  Except as provided in Sections 13.2, 13.3 and 13.5, neither this Agreement nor any rights or obligations hereunder may be assigned, delegated or transferred, directly or indirectly, by a Party to any Third Party without the prior written consent of the other Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that each Party shall have the right to assign this Agreement and all of its rights and obligations hereunder to one (but not more than one) of its Affiliates prior to the Closing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (a) that the assigning Party shall give advance notice of such assignment to other Party in writing&#59; and (b) the assigning Party shall remain liable to the other Party, on a joint and several basis with the assignee, for full performance of its obligations and covenants under this Agreement.  A Change of Control of either Party shall require the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Company Tagline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The Company may, with the prior written consent of Biogen (which consent shall not be unreasonably withheld or delayed), use a tagline &#8220;a Samsung-</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">43</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Biogen Idec joint venture&#8221; or words of similar import in conjunction with the Company&#8217;s official name in the Company&#8217;s corporate communications (excluding labeling, packaging and other materials that are made part of a regulatory submission or are otherwise subject to regulatory approval, for which use of any such tagline is prohibited).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement embodies the entire agreement of the Parties with respect to the subject matter hereof and supersedes and cancels any and all prior understandings or agreements, oral or written, in relation hereto, which may exist between the Parties.  No oral explanation or oral information provided by either Party shall alter the meaning or interpretation of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth in Section 4.7, each Party shall be solely responsible for the payment of any taxes assessed by any governmental authority on such Party in connection with or arising out of this Agreement or the transactions contemplated hereby.  For the avoidance of doubt, Biogen acknowledges that Samsung is obligated to, and will, withhold from the purchase price payable to Biogen for the Samsung Option Shares or any other Shares sold by Biogen or any of its Affiliates to Samsung any taxes levied or payable in Korea under the applicable tax treaty (if any) and Korean laws, rules and regulations.  Samsung shall reasonably assist and cooperate with Biogen in its efforts to obtain the relevant tax credit in its jurisdiction, including providing Biogen with the receipts of such tax payments by Samsung and other information and documents reasonably requested by Biogen. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Costs and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any costs or expenses (including fees and disbursements of legal counsel and other professional advisors) incurred in connection with this Agreement or the transactions contemplated hereby shall be borne by the Party who incurs such costs or expenses.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No amendment or change hereof or addition hereto shall be effective or binding on the Parties unless reduced to writing and executed by the duly authorized representative of each Party.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Unenforceable Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any of the provisions of this Agreement is held invalid or unenforceable under the applicable law of any jurisdiction, the remaining provisions of this Agreement shall not be affected thereby, and such invalidity or unenforceability shall not invalidate or render unenforceable that provision in any other jurisdiction.  In such event, the Parties agree that the provisions of this Agreement shall be modified and reformed so as to give effect to the original intent of the Parties as closely as possible with respect to the provision that has been held invalid or unenforceable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Non-Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The failure or delay of a Party to require performance by the other Party of any provision of, or any obligation under, this Agreement shall not constitute a waiver thereof, nor shall such failure or delay affect that Party&#8217;s right to require performance of such or any other provision or obligation at a later time.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">44</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall, at the request and cost of the other Party, execute or procure the execution of such documents and do or procure the doing of such other acts and things as such other Party may reasonably request for the purpose of giving effect to the terms of this Agreement or giving such other Party the full benefit of the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Default Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any sum payable by either Party to the other Party hereunder that is not paid when due shall bear default interest at the rate of ten percent (10%) per annum from the due date until the date on which payment of such sum is made in full.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Disclaimer of Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall not be deemed to constitute either Party the agent of the other Party.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement is executed in the English language, which version shall prevail over any translation thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument, it being understood that the Parties need not sign the same counterpart.  Facsimile or portable document format (e.g., .pdf) execution and delivery of this Agreement by either Party constitutes a legal, valid and binding execution and delivery of this Agreement by such Party.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Headings of Articles and Sections in this Agreement have been inserted for convenience of reference only and are not to be used in construing or interpreting this Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signatures on the Following Page</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">45</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Parties have caused this Agreement to be executed and delivered by their duly authorized representatives as of the date first written above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung BioLogics Co., Ltd.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; ____</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Tae Han Kim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_______ </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Tae Han Kim</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Representative Director</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Idec Therapeutics Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; _____</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; George Scangos </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">______</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; George Scangos</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Chief Executive Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">46</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i36664d842c684354808ac8304a860669_4"></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of the Articles of Incorporation</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="i36664d842c684354808ac8304a860669_148"></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLES OF INCORPORATION</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OF</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;*&#93; CO., LTD.</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLES OF INCORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;*&#93; CO., LTD.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CHAPTER I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.36pt"><br>GENERAL PROVISIONS</font></div><div style="margin-bottom:12pt;padding-left:61.2pt;text-indent:-63.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Name</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The name of this company (&#8220;Company&#8221;) shall be called &#8220;&#91;*&#93; CHUSHIK HOESA&#8221;, which shall be written in English as &#8220;&#91;*&#93; CO., LTD.&#8221;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Objectives</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The business objectives of the Company shall be as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">To develop, manufacture, commercialize, distribute and sell biosimilar  pharmaceutical products&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">To engage in any and all acts, things, businesses and activities that are related, incidental or conducive, directly or indirectly, to the attainment of the foregoing objective.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Head Office and Branch Offices</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall have its head office in &#91;*&#93;, Republic of Korea.  The Company may establish its branch offices at such places as may be required in accordance with a resolution of the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Public Notices</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Public notices of the Company shall be given on the Company&#8217;s website (http&#58;&#47;&#47;www.&#91;*&#93;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if a public notice cannot be given on such website due to a telecommunication problem or for any other unavoidable reason, it shall be published in the &#8220;Joongang Daily Newspaper,&#8221; a daily newspaper of general circulation published in the Special City of Seoul.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Existence</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The existence of the Company shall be perpetual.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CHAPTER II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.37pt"><br>CAPITAL AND SHARES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 6.&#160;&#160;&#160;&#160;Authorized Shares</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The total number of shares that the Company is authorized to issue shall be 13,000,000.</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Issued Shares</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The total number of shares to be issued at the time of incorporation of the Company shall be 3,294,000.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Class and Par Value of Shares</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All shares issued by the Company shall be common shares in non-bearer form and shall have a par value of Five Thousand Won (KRW5,000) per share.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Share Certificates</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Share certificates of the Company shall be numbered, shall set forth the number of shares represented thereby and the holder&#8217;s name, and shall be entered in the Register of Shareholders of the Company when they are issued.  Share certificates shall be issued in such denominations as prescribed by the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pre-emptive Rights</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The shareholders shall have pre-emptive rights to subscribe for shares newly issued by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Notwithstanding the provisions of Paragraph 1, the Company may allocate and issue new shares to certain existing shareholders or persons other than the existing shareholders by a resolution of the general meeting of shareholders in accordance with Chapter III, in any of the following cases&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Where the Company issues new shares preferentially to the members of its employee stock ownership association&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Where the Company issues new shares to achieve its management purposes, such as introducing new technology, improving its financial structure, forming a strategic alliance, etc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Where the Company issues new shares to a foreign investor to induce foreign investment or to a foreign investor who is in strategic alliance with the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Where the Company issues new shares through a public offering or engages an underwriter to underwrite new shares for the purpose of listing the shares of the Company on the Stock Market or KOSDAQ Market of the Korea Exchange.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">If the Company issues new shares in any of the circumstances specified in Paragraph 2 above, the class, number and issue price of the shares to be newly issued shall be determined by resolutions of the general meeting of shareholders.</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">If any shareholder waives or fails to exercise its pre-emptive subscription right or if fractional shares result from the allocation of new shares, the shares that have not been allocated and&#47;or subscribed shall be disposed of in accordance with a resolution of the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Date of Commencement of Dividend Accrual for New Shares</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the Company issues new shares by way of a capital increase for or without consideration or a stock dividend, such new shares shall, for the purpose of payment of dividends, be deemed to have been issued as of the end of the fiscal year immediately preceding the fiscal year in which they are issued.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transfer of Shares</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A transfer of shares of the Company shall be effected by delivery of the relevant share certificate(s).  A transfer of shares shall not be effective against the Company until the name and address of the new owner have been properly entered in the Register of Shareholders of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Alteration of Entries</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any shareholder desiring an alteration of any entries in the Register of Shareholders shall submit to the Company an application therefor in the form prescribed by the Company, together with the relevant share certificate(s).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Re-issuance of Share Certificates</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any shareholder desiring re-issuance of a new share certificate in lieu of a share certificate previously held by it shall submit to the Company an application therefor in the form prescribed by the Company, together with any of the following documents&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">An original or certified copy of a judgment of nullification in case of a certificate which has been lost or damaged beyond recognition&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The relevant share certificate in case of damage to the certificate, except when the certificate has been damaged beyond recognition&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">The share certificate involved in case of a split or consolidation of shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Registration of Shareholders</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All shareholders, pledgees, trustees, legal representatives or their attorneys shall register, in the form prescribed by the Company, their names, titles, addresses and seal impressions (including signatures in case of foreign nationals who normally use signatures instead of seals), and any changes thereto.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Suspension of Entry into Register of Shareholders</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall suspend entry into the Register of Shareholders of any change of shareholders from the day following the last day of each fiscal year until the date of completion of the ordinary general meeting of shareholders pertaining to such fiscal year, and may suspend, when deemed necessary, the entry of any changes in the matters registered in the Register of Shareholders for a specified period of time upon giving public notice thereof at least two (2) weeks in advance. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CHAPTER III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:35.38pt"><br>GENERAL MEETINGS OF SHAREHOLDERS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Authority and Responsibility</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following matters shall require resolution of the general meeting of shareholders&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Amendment of the Articles of Incorporation&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Issuance of any shares or other equity or equity-linked securities of the Company to a third party investor without giving the existing shareholders preemptive subscription rights in proportion to their respective shareholdings, other than for stock options or grants to employees&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Any material reorganization or change (including cessation) to the nature or scope of the business of the Company, but excluding any such change resulting from the use or development of its existing assets&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Any merger, joint venture involving a transfer or license of intellectual property by the Company, profit and&#47;or loss sharing partnership, spin-off or any other kind of corporate reorganization involving the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Acquisition of assets or investment in another entity or person (including joint ventures) in excess of US$60,000,000 or its equivalent in any single transaction or series of related transactions&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.01pt">Sale, assignment, exchange, transfer or other disposition of assets of the Company with a book value or market value exceeding US$30,000,000 or its equivalent in any single transaction or series of related transactions&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Sale, assignment, transfer or other disposition of all or substantially all of the intellectual property and other assets for any biosimilar pharmaceutical product of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Taking or instituting any proceeding for voluntary winding-up, dissolution or liquidation of the Company or any entity or person controlled by the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt">Borrowing any money in excess of US$120,000,000 or its equivalent (except borrowings in the ordinary course of business to finance working capital requirements or matters specified in the business plan)&#59; making any loan or </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">granting credit in excess of US$60,000,000 or its equivalent (other than in the ordinary course of business)&#59; or granting or creating any mortgage, pledge, charge or other security interests over any assets of the Company with a book value exceeding US$160,000,000 or its equivalent&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt">Redemption, retirement or repurchase of any shares or other equity or equity-linked securities of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Altering the fiscal year or material accounting policies or practices of the Company or changing the external auditors of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt">Addition of any biosimilar pharmaceutical product (other than any biosimilar pharmaceutical products based on the products marketed under the following names&#58; &#91;***&#93;) to the business of the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.67pt">Any other matters reserved to the general meeting of shareholders by the Commercial Code or other applicable laws.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Time of Meeting</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An ordinary general meeting of shareholders of the Company shall be convened within three (3) months after the close of each fiscal year by resolution of the Board of Directors.  An extraordinary general meeting of shareholders of the Company may be convened at any time by resolution of the Board of Directors. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Place of Meeting</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each general meeting of shareholders shall be held at the head office of the Company in the Republic of Korea or such other place as may be determined by the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Meeting</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Written notice (both in English and in Korean) of each general meeting of shareholders of the Company stating the date, time and place of the meeting and the purposes for which the meeting is convened shall be dispatched via registered regular mail to the shareholders who are residents of the Republic of Korea and via registered airmail to all other shareholders at least fourteen (14) days prior to the date set for such meeting.  Each such notice shall be accompanied by a copy of all reports and materials that are necessary or appropriate for prior review and consideration by the shareholders of the matters on the agenda for the meeting.  The shareholders may act only with respect to the matters set forth in such written notice at a general meeting of shareholders.  A general meeting of shareholders may be held without complying with the foregoing procedures (i) with the written consent of all of the shareholders or (ii) if all of the shareholders attend the meeting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Person to Convene and Preside at Meeting</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as otherwise provided by law, each general meeting of shareholders of the Company shall be convened by the Representative Director in accordance with a resolution of the Board of Directors.  The Representative Director shall preside over all general meetings of shareholders as chairman.  If for any reason the Representative Director is unable or unwilling to perform his&#47;her duty with respect to a general meeting of shareholders, another director or officer designated by the shareholders attending such meeting (by an affirmative vote of a majority of the shares represented at such meeting in person or by proxy) shall preside over such meeting as chairman.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Right to Vote</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With respect to all matters submitted to the general meeting of shareholder for resolution, each shareholder shall have one (1) vote for each share registered in the name of such shareholder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Voting by Proxy</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A shareholder may exercise its voting rights at any general meeting of shareholders in person or by proxy.  A proxy is not required to be a shareholder of the Company.  A proxy shall present a document establishing his power of representation to the general meeting of shareholders.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Adoption of Resolutions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as otherwise required by the mandatory provisions of the Commercial Code or other applicable laws, all resolutions at a general meeting of shareholders shall be adopted by an affirmative vote (whether in person or by proxy) of at least fifty-two percent (52%) of the total issued and outstanding voting shares of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Conduct of Meeting and Minutes</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each general meeting of shareholders shall be conducted in English.  The Company shall provide a Korean-English interpreter and such other support as is necessary to ensure that all participants are able to fully understand and participate in the meeting.  Minutes shall be taken of the proceedings and actions taken at each general meeting of shareholders.  Such minutes shall be prepared both in English and in Korean&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that in the event of any conflict or discrepancy between the English and Korean versions, the English version shall control.  The chairman and directors who were present at the meeting shall sign such minutes or affix their seals thereon.  The minutes shall be kept in the Company&#8217;s records.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CHAPTER IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:34.7pt"><br>DIRECTORS, STATUTORY AUDITORS AND OFFICERS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 26.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Number and Election of Directors and Statutory Auditors</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The Company shall have at least three (3) but no more than six (6) directors and at least one (1) statutory auditor, all of whom shall be elected at a general meeting of shareholders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">When two (2) or more directors are elected at a general meeting of shareholders, the cumulative voting system provided in Article 382-2 of the Commercial Code shall not be used.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Term of Office</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The term of office of each director shall be three (3) years&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if such term expires before the close of the ordinary general meeting of shareholders held for the settlement of accounts of the last fiscal year that ended during the three-year term, it shall be extended until the close of such general meeting of shareholders.  The term of office of each statutory auditor shall expire at the close of the ordinary general meeting of shareholders held for the settlement of accounts of the last fiscal year ended within three (3) years after such statutory auditor&#8217;s assumption of office.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vacancy</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">In case of any vacancy in the office of director, a substitute director shall be elected at a general meeting of shareholders that shall be convened for that purpose.  The term of office of a director so elected shall be for the remainder of the term of the directors serving in office at the time of such election.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">In case of any vacancy in the office of statutory auditor, a substitute statutory auditor shall be elected at a general meeting of shareholders that shall be convened for that purpose.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 29.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representative Director and Other Officers</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The Board of Directors shall elect one (1) Representative Director, who shall also hold the title of President and Chief Executive Officer, from among the directors of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Unless otherwise decided by the Board of Directors, the term of office of the Representative Director shall be three (3) years&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if such term expires before the close of the ordinary general meeting of shareholders held for the settlement of accounts of the last fiscal year that ended during the three-year term, it shall be extended until the close of such general meeting of shareholders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The Representative Director shall have the authority and duty to represent the Company, enforce matters resolved by the Board of Directors and the general meeting of shareholders and carry out the day-to-day operations of the Company, and such other authorities and duties as may be determined from time to time by the Board of Directors.</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The Board of Directors may appoint and remove a chief financial officer and a chief technology officer as senior officers of the Company.  The Representative Director may appoint and remove such other officers as he&#47;she deems necessary for the operation of the Company.  The powers and duties of such senior officers shall be determined from time to time by the Board of Directors and the powers and duties of such other officers shall be determined from time to time by the Representative Director.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 30.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Powers and Duties of Statutory Auditor</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Each statutory auditor shall inspect the directors&#8217; performance of their duties and shall examine the accounting and financial records of the Company.  Each statutory auditor may at any time demand a report concerning the business of the Company from the directors and may investigate the affairs of the Company and the state of its property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Each statutory auditor shall examine agenda and documents which the directors submit to a general meeting of shareholders and shall state his&#47;her opinion before such meeting as to whether there are any matters extremely unjust or conducted in contravention of any law or decree or these Articles of Incorporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 31.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Audit Records</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each statutory auditor shall prepare audit records with respect to any audit conducted by him&#47;her.  Such audit records shall reflect the proceedings and results of the audit and the statutory auditor who conducted the audit shall sign or affix his&#47;her seal thereon.  Such audit records shall be kept as part of the Company&#8217;s records.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 32.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification of Directors and Officers</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the maximum extent permitted by Article 400 of the Commercial Code and other applicable laws, the Company shall indemnify the Representative Director and each director, statutory auditor and other officer (including former Representative Directors, directors, statutory auditors and other officers who are no longer associated with the Company) against all claims, judgments, liabilities (including liabilities to the Company), damages, expenses and costs (including reasonable attorneys&#8217; fees and disbursements) for which he&#47;she has been held liable or which he&#47;she has incurred in connection with or arising out of the performance of his&#47;her duties in his&#47;her official capacity as Representative Director or as a director, statutory auditor or other officer of the Company, if such Representative Director, director, statutory auditor or other officer acted in good faith and for a purpose and in a manner that he&#47;she reasonably believed to be in the best interests of the Company.  With respect to all claims, judgments, liabilities (including liabilities to the Company), damages, expenses and costs (including attorneys&#8217; fees and disbursements) for which a Representative Director, director, statutory auditor or other officer has been held liable or which he&#47;she has incurred in connection with or arising out of the performance of his&#47;her duties in his&#47;her official capacity as Representative Director or as a director, statutory auditor or other officer but which are not indemnifiable by the Company pursuant to this Article 32 and are insurable at commercially reasonable cost, the Company shall obtain and maintain a directors&#8217; and officers&#8217; liability insurance policy with commercially reasonable coverage.</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 33.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Allowances of Directors, Statutory Auditors and Other Officers</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The maximum aggregate amount of remuneration, bonuses and severance allowances payable to the directors and those payable to the statutory auditors shall be respectively determined by a resolution of the general meeting of shareholders.  The power and authority to determine the remuneration and bonuses payable to the Representative Director, each director and statutory auditor may be delegated by the general meeting of shareholders to the Board of Directors.  The severance allowances payable to the directors, statutory auditors and other officers shall be determined in accordance with the officer severance pay regulations adopted by a resolution of the general meeting of shareholders.  Notwithstanding the foregoing, a director or statutory auditor performing no executive or officer functions shall receive no compensation from the Company.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CHAPTER V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:2.69pt"><br>MEETINGS OF THE BOARD OF DIRECTORS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 34.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Authority of the Board of Directors</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The Board of Directors of the Company shall consist of all directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Except as otherwise required by mandatory provisions of law or these Articles of Incorporation, the Board of Directors shall determine all important policies of the Company and direct the Company&#8217;s overall management and operations.  The Board of Directors shall also be responsible for the development and implementation of strategic direction, annual budget and business plan (including the evaluation and adjustment thereof) and the monitoring and evaluation of overall performance of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The Board of Directors may establish such committees within the Board of Directors as the Board of Directors deems necessary.  The authorities, operations and other details of each such committee shall be determined by resolution of the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The Board of Directors may delegate, to the extent permitted under applicable law, the day-to-day management of the Company and any other rights, powers or authorities for the management of the Company to the Representative Director and&#47;or any other officers of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 35.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Convention</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Meetings of the Board of Directors shall be held at least once every fiscal quarter unless otherwise determined by the Board of Directors.  Meetings of the Board of Directors may also be convened from time to time by the Representative Director at his&#47;her discretion or at the request of any director by written notice to the Representative Director.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 36.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Meeting</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notice (both in English and in Korean) of each meeting of the Board of Directors stating the date, time and place of the meeting and the purpose for which the meeting is </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">convened shall be dispatched by the Representative Director via post, facsimile or e-mail to all of the directors and statutory auditors at least seven (7) days prior to the date set for such meeting.  Each such notice shall be accompanied by a copy of all reports and materials that are necessary or appropriate for prior review and consideration by the directors of the matters on the agenda for the meeting.  Meetings of the Board of Directors may be held without conforming to the foregoing procedures with the written consent of all of the directors and statutory auditors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 37.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Place of Meeting</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All meetings of the Board of Directors shall be held at the head office of the Company or such other place as may be determined by the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 38.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Chairman of Meeting</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Representative Director shall preside over all meetings of the Board of Director as chairman.  If for any reason the Representative Director is unable or unwilling to perform his&#47;her duty with respect to a meeting of the Board of Directors, another director designated by the Board of Directors shall preside over such meeting as chairman.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 39.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Quorum and Voting Requirements</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">A quorum at each meeting of the Board of Directors shall be attained by the presence of a majority of the directors in office.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">All resolutions at a meeting of the Board of Directors shall be adopted by an affirmative vote of a majority of the directors present at the meeting where a quorum is present.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">No director, including the chairman of the meeting, shall have any tie-breaking vote at a meeting of the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 40.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Attendance of Statutory Auditor</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each statutory auditor may attend and express his&#47;her opinion at any meeting of the Board of Directors, and where any director has acted or is likely to act in contravention of any law or decree or these Articles of Incorporation, shall report it to the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 41.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Conduct of Meeting and Minutes</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Each meeting of the Board of Directors shall be conducted in English.  The Company shall provide a Korean-English interpreter and such other support as is necessary to ensure that all participants are able to fully understand and participate in the meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Directors may participate and vote at a meeting of the Board of Directors via video conferencing equipment whereby all participants in the meeting can simultaneously see and hear each other or, to the extent permitted under applicable law, via telephone </font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">conferencing equipment whereby all participants in the meeting can simultaneously hear each other.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Minutes shall be taken of the proceedings and actions taken at each meeting of the Board of Directors.  Such minutes shall be prepared both in English and in Korean&#59; provided that in the event of any conflict or discrepancy between the English and Korean versions, the English version shall control.  The directors and statutory auditors who were present at the meeting shall sign such minutes or affix their seals thereon.  The minutes shall be kept in the Company&#8217;s records.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CHAPTER VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:34.7pt"><br>ACCOUNTING</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 42.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Year</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The fiscal year of the Company shall begin on the first day of January of each year and end on the last day of December of the same year.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 43.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting System</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The accounting books of the Company shall be kept in accordance with the applicable laws and regulations of the Republic of Korea and with accounting principles and practices generally accepted in the Republic of Korea (including, if applicable, the International Financial Reporting Standards).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 44.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Statements</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The directors shall prepare an annual business report and the following financial statements, together with supporting specifications, for each fiscal year for the settlement of accounts of the Company, and shall obtain approval thereof from the Board of Directors and submit the same to the statutory auditor(s) at least six (6) weeks before the date set for the ordinary general meeting of shareholders&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">A balance sheet&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">A profit and loss statement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">A statement of appropriation of earned surplus or a statement of disposition of net loss.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Such financial statements and business report, together with the related audit report, shall be kept at the head office for five (5) years, and copies of the same shall be kept at each branch office for three (3) years, from one (1) week before the date set for the ordinary general meeting of shareholders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The financial statements shall be submitted to the general meeting of shareholders for approval and the business report shall be submitted to the meeting only for reporting purposes.</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 45.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Public Notice</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">After the above financial statements have been approved by the general meeting of shareholders, the Representative Director shall give public notice of the balance sheet so approved without delay.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 46.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disposition of Retained Earnings</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company&#8217;s retained earnings shall be appropriated in the following order of priority&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Replenishment of any capital deficit carried over from the previous fiscal year&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Establishment of a profit reserve required by law&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Establishment of other reserves required by law&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Payment of dividends to the shareholders&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Retained earnings to be carried forward to the next fiscal year.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 47.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment of Dividends</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Regular dividends may be declared in cash or in shares.  The payment and level of any dividends shall be determined by the Board of Directors and approved by resolution at the ordinary general meeting of shareholders held for each fiscal year.  Such dividends shall be paid to the shareholders of record in the Register of Shareholders of the Company as of the last day of the relevant fiscal year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Interim dividends may also be paid in cash once a fiscal year to the shareholders of record in the Register of Shareholders as of a date fixed during a fiscal year, pursuant to a resolution of the Board of Directors specifying such record date.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CHAPTER VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30.71pt"><br>ADDENDA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 48.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">By-laws</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may adopt by-laws and other regulations as may be required for the administration of the affairs of the Company and may revise or repeal the same, in each case by resolution of the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 49.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Application of the Commercial Code</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Matters not specifically provided for herein shall be determined in accordance with resolutions adopted by the general meeting of shareholders or the Board of Directors and relevant provisions of the Commercial Code.</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 50.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">First Fiscal Year</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The first fiscal year of the Company shall commence on the date of establishment of the Company and end on December 31 of the year of establishment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 51.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Promoter Information</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The names and addresses of the promoters of the Company are as set forth below.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, these Articles of Incorporation have been executed this &#91;*&#93; day of &#91;*&#93; 2012.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93; CO., LTD.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Name of Promoter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Address of Promoter</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Samsung BioLogics Co., Ltd.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;address&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Biogen Idec Therapeutics Inc.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;address&#93;</font></div><div><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><div id="i36664d842c684354808ac8304a860669_7"></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT B</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i36664d842c684354808ac8304a860669_10"></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT D</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT E</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SCHEDULE I</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i36664d842c684354808ac8304a860669_13"></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SCHEDULE II</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Matters Requiring Resolution of the General Meeting of Shareholders</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following matters shall require resolution of the General Meeting of Shareholders (which resolutions shall be adopted in accordance with the voting requirements of the Articles of Incorporation and applicable laws)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Amendment of the Articles of Incorporation&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Issuance of any Shares, Share Equivalents or other equity or equity-linked securities of the Company to a new third party investor without giving the existing Shareholders preemptive subscription rights in proportion to their respective Shareholdings, other than for stock options or grants to employees&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Any material reorganization or change (including cessation) to the nature or scope of the business of the Company, but excluding any such change resulting from the use or development of its existing assets&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Any merger, joint venture involving a transfer or license of Intellectual Property by the Company, profit and&#47;or loss sharing partnership, spin-off or any other kind of corporate reorganization involving the Company&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Acquisition of assets or equity investment in another Person (including joint ventures) in excess of US$60,000,000 or its equivalent in any single transaction or series of related transactions&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Sale, assignment, exchange, transfer or other disposition of any assets of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a book value or market value exceeding US$30,000,000 or its equivalent in any single transaction or series of related transactions&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Sale, assignment, transfer or other disposition of all or substantially all of the Intellectual Property and other assets for any Product&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Taking or instituting any proceeding for voluntary winding-up, dissolution or liquidation of the Company or any Person Controlled by the Company&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Borrowing any money in excess of US$120,000,000 or its equivalent (except borrowings in the ordinary course of business to finance working capital requirements or matters specified in the initial or annual business plan)&#59; making any loan or granting credit in excess of US$60,000,000 or its equivalent (other than in the ordinary course of business)&#59; or granting or creating any mortgage, pledge, charge or other security interests over any assets of the Company with a book value exceeding US$160,000,000 or its equivalent&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;Redemption, retirement or repurchase of any Shares, Share Equivalents or other equity or equity-linked securities of the Company&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Altering the fiscal year or material accounting policies or practices of the Company or changing the external auditors of the Company&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;Addition of any Additional Product to the business of the Company&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;Any other matters reserved to the general meeting of shareholders by the Korean Commercial Code or other applicable laws.</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i36664d842c684354808ac8304a860669_16"></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SCHEDULE III</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Matters Requiring Prior Consent of Biogen</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.69pt">Amendment of the Articles of Incorporation concerning the following matters&#58; (i) the business objectives of the Company&#59; (ii) class and par value of Shares (except that no consent of Biogen shall be required where Biogen&#8217;s voting rights and economic interests under this Agreement are not adversely effected by the proposed amendment with respect to the class and&#47;or par value of Shares)&#59; (iii) the preemptive subscription rights of the Shareholders&#59; (iv) the list of matters requiring resolutions of the General Meeting of Shareholders&#59; (v) the voting requirements for resolutions at the General Meeting of Shareholders&#59; (vi) the number of Directors and Statutory Auditors&#59; (vii) the term of Directors&#59; (viii) the authority of the Board&#59; (ix) the convention of meetings of the Board&#59; (x) the voting and quorum requirements for meetings of the Board&#59; (xi) the conduct of General Meetings of Shareholders and Board meetings&#59; (xii) the indemnification of Directors, Statutory Auditors and officers&#59; (xiii) the fiscal year of the Company&#59; and (xiv) payment of dividends.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.01pt">Any material reorganization or change (including cessation) to the nature or scope of the business of the Company, but excluding any such change resulting from the use or development of its existing assets&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.69pt">Any merger, joint venture involving a transfer or license of Intellectual Property by the Company, profit and&#47;or loss sharing partnership, spin-off or any other kind of corporate reorganization involving the Company&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.01pt">Acquisition of assets (for the avoidance of doubt, other than the purchase of the Samsung Assets pursuant to Section 6.1A hereof) or equity investment in another Person (including joint ventures) in excess of US$60,000,000 or its equivalent in any single transaction or series of related transactions&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.69pt">Sale, assignment, transfer or other disposition of all or substantially all of the Intellectual Property and other assets for any Product&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:28.02pt">Taking or instituting any proceeding for voluntary winding-up, dissolution or liquidation of the Company or any Person Controlled by the Company&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.01pt">Borrowing any money in excess of US$120,000,000 or its equivalent (except borrowings in the ordinary course of business to finance working capital requirements or matters specified in the initial or annual business plan)&#59; making any loan or granting credit in excess of US$60,000,000 or its equivalent (other than in the ordinary course of business)&#59; or granting or creating any mortgage, pledge, charge or other security interests over any assets of the Company with a book value exceeding US$160,000,000 or its equivalent&#59;</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.01pt">Redemption, retirement or repurchase of any Shares, Share Equivalents or other equity or equity-linked securities of the Company&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:28.68pt">Altering the fiscal year or material accounting policies or practices of the Company or changing the external auditors of the Company&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:28.68pt">Addition of any Additional Product to the business of the Company.</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SCHEDULE IV</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Method for Selecting Appraiser</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The method for selecting an appraiser shall be as set forth below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)  &#160;&#160;&#160;&#160;Within twenty (20) days after the Appointing Party elects to have the Fair Market Value of the relevant Shares determined, the Appointing Party shall propose a list of no less than three (3) but no more than ten (10) candidates (each of which shall be an investment banking firm, securities company or accounting firm and which may not include the accounting firm that serves as external auditors to the Appointing Party) to the other Party in writing&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Within fifteen (15) days after receipt of the above list from the Appointing Party, the other Party shall (i) select three (3) candidates from such list, and (ii) notify the Appointing Party of its selection in writing&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Within ten (10) days after the earlier of (x) the receipt of written notice of the three (3) candidates from the other Party and (y) the expiration of the fifteen (15) day period referred to in paragraph (b) above, the Appointing Party shall (i) select the appraiser to determine the Fair Market Value of the relevant Shares from the three (3) candidates notified by the other Party, or if the other Party fails to notify the Appointing Party of the three (3) candidates selected by it in accordance with paragraph (b) above, from the list initially proposed by the Appointing Party pursuant to paragraph (a) above, and (ii) notify the other Party of its selection in writing.</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SCHEDULE V</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Antitrust Approvals</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U.S.A. and Brazil</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SCHEDULE VI</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.25pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SCHEDULE VII</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="height:85.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i36664d842c684354808ac8304a860669_358"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">February 28, 2012</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Samsung BioLogics Co., Ltd.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Floor, Samsung Electronics Building</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1320-10 Seocho 2-dong, Seocho-gu</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Seoul 137-857</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Republic of Korea</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Re&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment of the Joint Venture Agreement</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear Sirs&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reference is made to the Joint Venture Agreement dated December 6, 2011 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JVA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) between Samsung BioLogics Co., Ltd. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Biogen Idec Therapeutics Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Capitalized terms used but not otherwise defined in this letter agreement have the same meanings ascribed to them in the JVA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Samsung and Biogen hereby agree to amend the JVA as follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment of the Scope of the Biogen Parent Guarantee</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Under Section 20.1(a) of the JVA, Biogen is required to cause Biogen Parent to duly execute and deliver to Samsung at or prior to Closing the Biogen Parent Guarantee, in form and substance reasonably acceptable to Samsung, whereby Biogen Parent shall guarantee and be liable for any and all payment obligations of Biogen under or arising out of the JVA and the IP License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Samsung and Biogen hereby agree that under and pursuant to the Biogen Parent Guarantee, Biogen Parent shall guarantee and be liable for any and all payment obligations of Biogen under or arising out of the JVA and the IP License Agreement, except Biogen&#8217;s payment obligation under or arising out of its exercise of the Biogen Option pursuant to the JVA.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver of the Samsung Parent Guarantee</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Under Section 20.1(b) of the JVA, Samsung is required to cause Samsung Parent to duly execute and deliver to Biogen at or prior to Closing the Samsung Parent Guarantee, in form and substance reasonably acceptable to Biogen, whereby Samsung Parent shall guarantee and be liable for any and all payment obligations of Samsung under or arising out of the JVA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Biogen hereby waives the Samsung Parent Guarantee, and Samsung and Biogen hereby agree to delete from the JVA (i) the definitions of &#8220;Samsung Parent&#8221; and &#8220;Samsung Parent Guarantee&#8221; in Section 1.1 of the JVA and (ii) Sections 3.2(i), 3.5(c) and 20.1(b) of the JVA and (iii) clause (iv) of Section 16.2 of the JVA&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that each of Samsung Everland Inc., Samsung C&#38;T Corporation and Samsung Electronics Co., Ltd. maintains the board resolution approving its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">proportional investment in Samsung as set forth in the notarized English translation of the minutes of a meeting of the board of directors of each such company that has been provided to Biogen.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as specifically stated above, all other terms and conditions of the JVA shall remain in full force and effect.  The provisions of Articles 18 and 19 of the JVA shall apply to this letter agreement,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the foregoing accurately reflects our mutual understanding, please indicate your acceptance thereof by signing the attached duplicate copy of this letter agreement and returning it to us.</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sincerely yours,</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Biogen Idec Therapeutics Inc.</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Richard Brudnick&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  Richard Brudnick</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;  Vice President and Assistant Secretary</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The foregoing is hereby accepted and agreed to by&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Samsung BioLogics Co., Ltd.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Tae Han Kim&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  Tae Han Kim</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;  Representative Director</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;  February 28, 2012</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div id="i36664d842c684354808ac8304a860669_172"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT NO. 2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JOINT VENTURE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIS AMENDMENT NO. 2 TO JOINT VENTURE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into as of the 29th day of September 2014 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung BioLogics Co., Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a company organized and existing under the laws of Korea with its principal offices at 125 Cheomdan-daero, Yeonsu-gu, Incheon, Republic of Korea (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Idec Therapeutics Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a company organized and existing under the laws of Delaware, U.S.A, with its principal offices at 14 Cambridge Center, Cambridge, Massachusetts 02142, U.S.A. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Samsung and Biogen are hereinafter referred to collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">W I T N E S E T H&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Samsung and Biogen entered into a Joint Venture Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JVA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) as of December 6, 2011, as amended by that certain letter agreement, dated February 28, 2012 (the JVA as so amended referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Venture Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and pursuant to the Joint Venture Agreement, established Samsung Bioepis Co., Ltd., a Korean stock corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as a joint venture company to engage in the development, manufacture, commercialization, distribution and sale of Biosimilar Pharmaceutical Products&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Samsung and Biogen now desire to amend the Joint Venture Agreement upon the terms and conditions set forth herein, in order to expand the business objectives of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the foregoing premises and the mutual covenants and agreements herein below contained, and intending to be legally bound hereby, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.73pt">Definitions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Capitalized terms used but not otherwise defined in this Amendment shall have the meanings ascribed to them in the Joint Venture Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Section 1.2 of the Joint Venture Agreement is incorporated herein by reference as if fully set forth in this Amendment.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 2.&#160;&#160;&#160;&#160;Amendment of the Joint Venture Agreement</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">The definition of the term &#8220;Product&#8221; in Section 1.1 of the Joint Venture Agreement is hereby amended to read in its entirety as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (i) any Initial Product, (ii) any Additional Product and (iii) any biopharmaceutical product that is not a Biosimilar Pharmaceutical Product, which, in the case of clause (ii) and clause (iii) of this definition, is either (a) agreed by the Parties in writing and determined by the General Meeting of Shareholders to be a Product at any time during the Biogen Consent Period or (b) determined by the General Meeting of Shareholders to be a Product at any time after the expiration of the Biogen Consent Period.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Section 2.3 of the Joint Venture Agreement is hereby amended to read in its entirety as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business Objective</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The business objectives and activities of the Company shall be limited to the development, manufacture, commercialization, distribution and sale of biopharmaceutical products, including Biosimilar Pharmaceutical Products, and any and all activities related or incidental thereto.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Schedule II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Matters Requiring Resolution of the General Meeting of Shareholders) to the Joint Venture Agreement is hereby amended by deleting paragraph (1) thereof and substituting the following therefor&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;(l) &#160;&#160;&#160;&#160;Addition to the business of the Company of (i) any Additional Product or (ii) any biopharmaceutical product that is not a Biosimilar Pharmaceutical Product&#59; and&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Schedule III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Matters Requiring Prior Consent of Biogen) to the Joint Venture Agreement is hereby amended by deleting paragraph j) thereof and substituting the following therefor&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;(j) &#160;&#160;&#160;&#160;Addition to the business of the Company of (i) any Additional Product or (ii) any biopharmaceutical product that is not a Biosimilar Pharmaceutical Product.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Except as expressly amended by this Amendment, the Joint Venture Agreement shall remain in full force and effect in accordance with its terms.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 3.&#160;&#160;&#160;&#160;Amendment of the Articles of Incorporation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As soon as practicable following the execution of this Amendment, the Parties shall promptly take and cause to be taken all necessary actions to adopt an amendment to the Articles of Incorporation in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, which amendment amends Article 2 (Objectives) and Article 17 (Authority and Responsibility) of the Articles of Incorporation to be consistent with the terms of the Joint Venture Agreement as amended by this Amendment.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 4.&#160;&#160;&#160;&#160;Miscellaneous Provisions </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Articles 18 and 19 and Sections 20.7, 20.8, 20.9, 20.13, 20.14 and 20.15 of the Joint Venture Agreement shall each apply to this Amendment, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">The Joint Venture Agreement, together with the Exhibits and Schedules thereto, as amended by this Amendment, embodies the entire agreement of the Parties with respect to the subject matter of the Joint Venture Agreement and supersedes and cancels any and all prior understandings or agreements, oral or written, in relation hereto, which may exist between the Parties.  No oral explanation or oral information provided by either Party shall alter the meaning or interpretation of the Joint Venture Agreement as amended by this Amendment.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signatures on the Following Page</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i36664d842c684354808ac8304a860669_175"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties have caused this Amendment to be executed and delivered by their duly authorized representatives as of the Amendment Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung BioLogics Co., Ltd.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Tae Han Kim&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  Tae Han Kim</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;  Representative Director</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Idec Therapeutics Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; George Scangos&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  George Scangos</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;  Chief Executive Officer &#8195;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i36664d842c684354808ac8304a860669_178"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment to Articles of Incorporation</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Current Provisions</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Proposed Amendments</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 2.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Objectives</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The business objectives of the Company shall be as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:71.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;To develop, manufacture, commercialize, distribute and sell biosimilar pharmaceutical products&#59; and</font></div><div style="margin-bottom:12pt;padding-left:71.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;To engage in any and all acts, things, businesses and activities that are related, incidental or conducive, directly or indirectly, to the attainment of the foregoing objective.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 2.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Objectives</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The business objectives of the Company shall be as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:71.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;To develop, manufacture, commercialize, distribute and sell pharmaceutical products, including biosimilar pharmaceutical products&#59; and</font></div><div style="margin-bottom:12pt;padding-left:71.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;To engage in any and all acts, things, businesses and activities that are related, incidental or conducive, directly or indirectly, to the attainment of the foregoing objective.</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 17.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Authority and Responsibility</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following matters shall require resolution of the general meeting of shareholders&#58;</font></div><div style="margin-bottom:12pt;padding-left:53.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)  through (f)&#58; Omitted</font></div><div style="margin-bottom:12pt;padding-left:53.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Sale, assignment, transfer or other disposition of all or substantially all of the intellectual property and other assets for any biosimilar pharmaceutical product of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:53.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h) through (k)&#58; Omitted</font></div><div style="margin-bottom:12pt;padding-left:53.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Addition of any biosimilar pharmaceutical product (other than any biosimilar pharmaceutical products based on the products marketed under the following names&#58;  &#91;***&#93; to the business of the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:71.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;Omitted</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 17.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Authority and Responsibility</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following matters shall require resolution of the general meeting of shareholders&#58;</font></div><div style="margin-bottom:12pt;padding-left:71.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) through (f)&#58;  Same as current clauses</font></div><div style="margin-bottom:12pt;padding-left:71.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Sale, assignment, transfer or other disposition of all or substantially all of the intellectual property and other assets for any pharmaceutical product of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:71.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h) through (k)&#58; Same as current clauses</font></div><div style="margin-bottom:12pt;padding-left:71.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Addition to the business of the Company of (1) any biosimilar pharmaceutical product (other than any biosimilar pharmaceutical products based on the products marketed under the following names&#58;  &#91;***&#93; or (2) any pharmaceutical product that is not a biosimilar pharmaceutical product&#59; and</font></div><div style="margin-bottom:12pt;padding-left:71.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;Same as current clause</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:35.2pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;These amended Articles of Incorporation shall take effect as of October &#91;*&#93;, 2014.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div id="i36664d842c684354808ac8304a860669_230"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT NO. 3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JOINT VENTURE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIS AMENDMENT NO. 3 TO JOINT VENTURE AGREEMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is executed as of the 20th day of February 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Execution Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung BioLogics Co., Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a company organized and existing under the laws of Korea with its principal offices at 125 Cheomdan-daero, Yeonsu-gu, Incheon, Republic of Korea (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Therapeutics Inc. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(formerly known as &#8220;Biogen Idec Therapeutics Inc.&#8221;), a company organized and existing under the laws of Delaware, U.S.A, with its principal offices at 225 Binney Street, Cambridge, Massachusetts 02142, U.S.A. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Samsung and Biogen are hereinafter referred to collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">W I T N E S E T H &#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Samsung and Biogen entered into a Joint Venture Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JVA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) dated December 6, 2011, as amended on February 28, 2012 and on September 29, 2014 (the JVA as so amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Venture Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, pursuant to the Joint Venture Agreement, Samsung and Biogen established Samsung Bioepis Co., Ltd., a Korean stock corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as a joint venture company to engage in the development, manufacture, commercialization, distribution and sale of Biosimilar Pharmaceutical Products (the business objectives of the Company were subsequently expanded to the development, manufacture, commercialization, distribution and sale of biopharmaceutical products, including Biosimilar Pharmaceutical Products)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Samsung and Biogen now desire to amend the Joint Venture Agreement upon the terms and conditions set forth herein.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the foregoing premises and the mutual covenants and agreements herein below contained, and intending to be legally bound hereby, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.73pt">Effectiveness</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 2.&#160;&#160;&#160;&#160;Definitions</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Capitalized terms used but not otherwise defined in this Amendment No. 3 shall have the meanings ascribed to them in the Joint Venture Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Section 1.2 of the Joint Venture Agreement is incorporated herein by reference as if fully set forth in this Amendment No. 3.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 3.&#160;&#160;&#160;&#160;Amendment of the Joint Venture Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Amendment of Section 1.1 of the Joint Venture Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Amendment of Section 6.5 of the Joint Venture Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Company Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Other Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as expressly amended by this Amendment No. 3, the Joint Venture Agreement shall remain in full force and effect in accordance with its terms.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 4.&#160;&#160;&#160;&#160;Miscellaneous Provisions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Articles 18 and 19 and Sections 20.7, 20.8, 20.9, 20.13, 20.14 and 20.15 of the Joint Venture Agreement shall each apply to this Amendment No. 3, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">The Joint Venture Agreement, together with the Exhibits and Schedules thereto, as amended by this Amendment No. 3, embodies the entire agreement of the Parties with respect to the subject matter of the Joint Venture Agreement and supersedes and cancels any and all prior understandings or agreements, oral or written, in relation hereto, which may exist between the Parties, including the Term Sheet entered into as of November 16, 2018, by and between the Parties.  No oral explanation or oral information provided by either Party shall alter the meaning or interpretation of the Joint Venture Agreement as amended by this Amendment No. 3.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signatures on the Following Page</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-10-</font></div></div></div><div id="i36664d842c684354808ac8304a860669_233"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties have caused this Amendment No. 3 to be executed and delivered by their duly authorized representatives as of the Amendment No. 3 Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Samsung BioLogics Co., Ltd.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Tae Han Kim&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  Tae Han Kim</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;  Representative Director</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biogen Therapeutics Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Paul F. McKenzie&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  Paul F. McKenzie</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;  EVP, PO&#38;T</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i36664d842c684354808ac8304a860669_236"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i36664d842c684354808ac8304a860669_239"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i36664d842c684354808ac8304a860669_242"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit C</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i36664d842c684354808ac8304a860669_245"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit D</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i36664d842c684354808ac8304a860669_248"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit E</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>biib-2021331xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i00901548dca2422f85976d7b60cc5e90_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michel Vounatsos, certify that&#58;</font></div><div style="margin-top:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:14pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; April 22, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>biib-2021331xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib86d5af2f44f47059486307ec3a50f3e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael R. McDonnell, certify that&#58;</font></div><div style="margin-top:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; April 22, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>biib-2021331xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i8b9423cc29174d5286271d7a0288a820_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; April 22, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal executive officer&#93;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; April 22, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal financial officer&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>biib-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:b54f3254-567d-4813-a83c-54bbe0ebf523,g:5bfc82e5-4d8f-4b59-aa4e-ce589875722a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:biib="http://www.biogenidec.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement">
        <link:definition>1006007 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2104102 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionDetailsTextual" roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual">
        <link:definition>2405402 - Disclosure - Business Acquisition (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.biogenidec.com/role/Revenues">
        <link:definition>2106103 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>2307301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesbyProductDetails" roleURI="http://www.biogenidec.com/role/RevenuesbyProductDetails">
        <link:definition>2408403 - Disclosure - Revenues by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforDiscountsandAllowancesDetails1" roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1">
        <link:definition>2409404 - Disclosure - Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforDiscountsandAllowancesDetails2" roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2">
        <link:definition>2410405 - Disclosure - Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesfromAntiCD20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails">
        <link:definition>2411406 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails">
        <link:definition>2412407 - Disclosure - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetailsTextual" roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual">
        <link:definition>2413408 - Disclosure - Revenues (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2114104 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2315302 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2416409 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2117105 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2318303 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails">
        <link:definition>2419410 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1">
        <link:definition>2420411 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2121106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2322304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2423412 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2424413 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
        <link:definition>2425414 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2426415 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2427416 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2128107 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2329305 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2430417 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2431418 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2432419 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2433420 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2434421 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2435422 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2136108 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2337306 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2438423 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentPropertyPlantandEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment">
        <link:definition>2139109 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails">
        <link:definition>2440424 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessNotes" roleURI="http://www.biogenidec.com/role/IndebtednessNotes">
        <link:definition>2141110 - Disclosure - Indebtedness (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>2442425 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2143111 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2344307 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails">
        <link:definition>2445426 - Disclosure - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2446427 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2447428 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.biogenidec.com/role/EarningsperShare">
        <link:definition>2148112 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.biogenidec.com/role/EarningsperShareTables">
        <link:definition>2349308 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareDetails" roleURI="http://www.biogenidec.com/role/EarningsperShareDetails">
        <link:definition>2450429 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedPayments" roleURI="http://www.biogenidec.com/role/SharebasedPayments">
        <link:definition>2151113 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2352309 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2453430 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2454431 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2155114 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2356310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2457432 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2458433 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2159115 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2360311 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2461434 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2462435 - Disclosure - Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships">
        <link:definition>2163116 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables">
        <link:definition>2364312 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails">
        <link:definition>2465436 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2466437 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities">
        <link:definition>2167117 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails">
        <link:definition>2468438 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2169118 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2470439 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Biogenshareofcopromotionprofitsorlosses" abstract="false" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_IonisSangamoDenaliAndSageMember" abstract="true" name="IonisSangamoDenaliAndSageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_OtherrevenuesTableTextBlock" abstract="false" name="OtherrevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_NumberOfSquareFeet" abstract="false" name="NumberOfSquareFeet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="biib_Inventorynetcurrentandnoncurrent" abstract="false" name="Inventorynetcurrentandnoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_MSProductRevenuesMember" abstract="true" name="MSProductRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FacilityLocationDomain" abstract="true" name="FacilityLocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_InterestInSubsidiary" abstract="false" name="InterestInSubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_Expenseincurredbythecollaboration" abstract="false" name="Expenseincurredbythecollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FacilityTypeDomain" abstract="true" name="FacilityTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_TimeVestedRestrictedStockUnitsMember" abstract="true" name="TimeVestedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Reductioninroyaltyratepayableoncommercialsales" abstract="false" name="Reductioninroyaltyratepayableoncommercialsales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" abstract="false" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TwelvemonthsMember" abstract="true" name="TwelvemonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NumberOfWholesalers" abstract="false" name="NumberOfWholesalers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_TGNMember" abstract="true" name="TGNMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShorttermderivativeMember" abstract="true" name="ShorttermderivativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BiologicsManufacturingMember" abstract="true" name="BiologicsManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BIIB111Member" abstract="true" name="BIIB111Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_InvestmentsInVariableInterestEntitiesAbstract" abstract="true" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_A2.90SeniorNotesDueSept152020Member" abstract="true" name="A2.90SeniorNotesDueSept152020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" abstract="false" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" abstract="true" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SamsungBiosimilarAgreementMember" abstract="true" name="SamsungBiosimilarAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" abstract="false" name="UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NumberOfProductCandidates" abstract="false" name="NumberOfProductCandidates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_DenaliTherapeuticsIncMember" abstract="true" name="DenaliTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ResearchanddevelopmentassetAxis" abstract="true" name="ResearchanddevelopmentassetAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_NightstarMember" abstract="true" name="NightstarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PercentageParValueOfSeniorNotes" abstract="false" name="PercentageParValueOfSeniorNotes" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_OutLicensedPatentsMember" abstract="true" name="OutLicensedPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DeferredTaxLiabilitiesValueReductioninValue" abstract="false" name="DeferredTaxLiabilitiesValueReductioninValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" abstract="false" name="GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" abstract="false" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OthercorporaterevenuesMember" abstract="true" name="OthercorporaterevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShareOfCoPromotionProfits" abstract="false" name="ShareOfCoPromotionProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesNonCurrentMember" abstract="true" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" abstract="false" name="NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" abstract="true" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesCurrentMember" abstract="true" name="CorporateDebtSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_E2609andBAN2401Member" abstract="true" name="E2609andBAN2401Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" abstract="false" name="GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_LongTermDebtExchangedAmount" abstract="false" name="LongTermDebtExchangedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SPINRAZAMember" abstract="true" name="SPINRAZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_VixotrigineMember" abstract="true" name="VixotrigineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AcquisitionsAbstract" abstract="true" name="AcquisitionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_IMRALDIMember" abstract="true" name="IMRALDIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" abstract="false" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Noncontrollinginterestincreasedecreaseother" abstract="false" name="Noncontrollinginterestincreasedecreaseother" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Expensereflectedwithinstatementsofincome" abstract="false" name="Expensereflectedwithinstatementsofincome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesAxis" abstract="true" name="FutureContingentMilestoneTypesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" abstract="false" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_BENEPALIMember" abstract="true" name="BENEPALIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DerivativeMaturityAxis" abstract="true" name="DerivativeMaturityAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_Collaborationprofitlosssharing" abstract="false" name="Collaborationprofitlosssharing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_ResearchAndDevelopmentCostsPercentage" abstract="false" name="ResearchAndDevelopmentCostsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_DuefromantiCD20therapeuticprograms" abstract="false" name="DuefromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementSharesPurchased" abstract="false" name="GlobalLicensingCollaborationAgreementSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="biib_FLIXABIMember" abstract="true" name="FLIXABIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BusinessOverviewPolicyTextBlock" abstract="false" name="BusinessOverviewPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" abstract="true" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" abstract="false" name="Equitymethodinvestmentbasisdifferenceamortizationperiod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" abstract="false" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_MarketStockUnitsMember" abstract="true" name="MarketStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_A2018ShareRepurchaseProgramMember" abstract="true" name="A2018ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CashflowsoperatingexpensesMember" abstract="true" name="CashflowsoperatingexpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" abstract="false" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_AdditionalMilestonePayment" abstract="false" name="AdditionalMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TECFIDERAMember" abstract="true" name="TECFIDERAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DebtInstrumentRedemptionAmount" abstract="false" name="DebtInstrumentRedemptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A3.15SeniorNotesdueMay12050Member" abstract="true" name="A3.15SeniorNotesdueMay12050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CollaborationAgreementTerm" abstract="false" name="CollaborationAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" abstract="true" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ExpectedPaymentTimelineOfMilestoneDomain" abstract="true" name="ExpectedPaymentTimelineOfMilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FacilityLocationAxis" abstract="true" name="FacilityLocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_UCBPharmaS.A.Member" abstract="true" name="UCBPharmaS.A.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" abstract="true" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_ResearchanddevelopmentassetDomain" abstract="true" name="ResearchanddevelopmentassetDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ReserveforCashDiscountsMember" abstract="true" name="ReserveforCashDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" abstract="false" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_StrategicInvestmentPortfolio" abstract="false" name="StrategicInvestmentPortfolio" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_March2019ShareRepurchaseProgramMember" abstract="true" name="March2019ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FUMADERMMember" abstract="true" name="FUMADERMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ZINBRYTAMember" abstract="true" name="ZINBRYTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AdministrativeSpaceMember" abstract="true" name="AdministrativeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DistributorTwoMember" abstract="true" name="DistributorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" abstract="false" name="UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NeurimmuneMember" abstract="true" name="NeurimmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DividendYieldPercentage" abstract="false" name="DividendYieldPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_Investmentincommonstocksharespurchased" abstract="false" name="Investmentincommonstocksharespurchased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinStockMember" abstract="true" name="PerformanceStockUnitsSettledinStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BiosimilarsMember" abstract="true" name="BiosimilarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_StrategicInvestmentsMember" abstract="true" name="StrategicInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" abstract="true" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_InLicensedPatentsMember" abstract="true" name="InLicensedPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_OtherrevenuesAbstract" abstract="true" name="OtherrevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_A3250SeniorNotesDueFebruary152051Member" abstract="true" name="A3250SeniorNotesDueFebruary152051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ContractOptionExerciseFee" abstract="false" name="ContractOptionExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TechnologicalAndRegulatorySuccessProbability" abstract="false" name="TechnologicalAndRegulatorySuccessProbability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_ExpenseIncurredByCollaboration" abstract="false" name="ExpenseIncurredByCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_RocheGroupGenentechMember" abstract="true" name="RocheGroupGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SangamoCommonStockMember" abstract="true" name="SangamoCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinCashMember" abstract="true" name="PerformanceStockUnitsSettledinCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" abstract="false" name="GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" abstract="false" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" abstract="false" name="Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Additionalreductioninroyaltyratepayableoncommercialsales" abstract="false" name="Additionalreductioninroyaltyratepayableoncommercialsales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" abstract="false" name="GlobalLicensingCollaborationAgreementPurchasePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" abstract="false" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_EquitySecuritiesCurrentMember" abstract="true" name="EquitySecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ContractualAdjustmentsMember" abstract="true" name="ContractualAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AverageMaturityOfMarketableSecurities" abstract="false" name="AverageMaturityOfMarketableSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" abstract="false" name="GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" abstract="false" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" abstract="false" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="us-types:durationStringItemType"/>
  <xs:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" abstract="false" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_December2019ShareRepurchaseProgramMember" abstract="true" name="December2019ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GovernmentSecuritiesCurrentMember" abstract="true" name="GovernmentSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_A2.25SeniorNotesdueMay12030Member" abstract="true" name="A2.25SeniorNotesdueMay12030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" abstract="false" name="EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SolothurnSwitzerlandMember" abstract="true" name="SolothurnSwitzerlandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" abstract="false" name="AmortizationAndImpairmentOfAcquiredIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_October2020ShareRepurchaseProgramMember" abstract="true" name="October2020ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BIIB118Member" abstract="true" name="BIIB118Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationGILTItax" abstract="false" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" abstract="false" name="GlobalLicensingCollaborationAgreementAmountSharesPurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Revenuesfromanticd20therapeuticprogramsMember" abstract="true" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SageTherapeuticsIncMember" abstract="true" name="SageTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Collaborationexpensesaccrual" abstract="false" name="Collaborationexpensesaccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesDomain" abstract="true" name="FutureContingentMilestoneTypesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" abstract="false" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ExpectedPaymentTimelineofMilestoneAxis" abstract="true" name="ExpectedPaymentTimelineofMilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" abstract="false" name="GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BasicAndDilutedEarningsPerShareAbstract" abstract="true" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_WarehouseUtilitiesAndSupportSpaceMember" abstract="true" name="WarehouseUtilitiesAndSupportSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesNonCurrentMember" abstract="true" name="EquitySecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" abstract="false" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Termofcollaborationagreement" abstract="false" name="Termofcollaborationagreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_InterferonMember" abstract="true" name="InterferonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DistributorOneMember" abstract="true" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DerivativeMaturityDomain" abstract="true" name="DerivativeMaturityDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DeferredTaxAssetsValueReductioninValue" abstract="false" name="DeferredTaxAssetsValueReductioninValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FacilityTypeAxis" abstract="true" name="FacilityTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_TysabriProductMember" abstract="true" name="TysabriProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" abstract="false" name="IncomeLossFromEquityMethodInvestmentsNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CashSettledPerformanceSharesMember" abstract="true" name="CashSettledPerformanceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FAMPYRAMember" abstract="true" name="FAMPYRAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CashflowsrevenueMember" abstract="true" name="CashflowsrevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GovernmentSecuritiesNonCurrentMember" abstract="true" name="GovernmentSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" abstract="false" name="PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FumarateMember" abstract="true" name="FumarateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AducanumabMember" abstract="true" name="AducanumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SangamoTherapeuticsInc.AgreementMember" abstract="true" name="SangamoTherapeuticsInc.AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" abstract="false" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>biib-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:b54f3254-567d-4813-a83c-54bbe0ebf523,g:5bfc82e5-4d8f-4b59-aa4e-ce589875722a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_187b798f-fca3-4725-90c6-88266b472c71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f98b03e3-491a-4ff0-a597-270d6d5f109a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_187b798f-fca3-4725-90c6-88266b472c71" xlink:to="loc_us-gaap_OperatingIncomeLoss_f98b03e3-491a-4ff0-a597-270d6d5f109a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9a4cdcc4-f93f-4d56-8183-7dd99fb4d922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_187b798f-fca3-4725-90c6-88266b472c71" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9a4cdcc4-f93f-4d56-8183-7dd99fb4d922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b97b3cf4-0c0e-4fa2-a383-2bb055e59956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_242874ba-7cec-48ee-9def-56e543a096c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b97b3cf4-0c0e-4fa2-a383-2bb055e59956" xlink:to="loc_us-gaap_ProfitLoss_242874ba-7cec-48ee-9def-56e543a096c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6884bfcf-0e94-4170-add5-d6bd14290e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b97b3cf4-0c0e-4fa2-a383-2bb055e59956" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6884bfcf-0e94-4170-add5-d6bd14290e37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_be88cefe-4eb7-4c52-b3ca-171cad3e0807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_99797487-1fc4-4543-aea6-ef414c93a2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_be88cefe-4eb7-4c52-b3ca-171cad3e0807" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_99797487-1fc4-4543-aea6-ef414c93a2dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_75cd3038-ee81-4628-82f5-c4ff66eb95b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_be88cefe-4eb7-4c52-b3ca-171cad3e0807" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_75cd3038-ee81-4628-82f5-c4ff66eb95b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c0f17b50-592a-40e8-80de-9d069f9b3c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_be88cefe-4eb7-4c52-b3ca-171cad3e0807" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c0f17b50-592a-40e8-80de-9d069f9b3c15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_0833dab7-bee4-4bd9-b622-b03c87de6e74" xlink:href="biib-20210331.xsd#biib_Collaborationprofitlosssharing"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_be88cefe-4eb7-4c52-b3ca-171cad3e0807" xlink:to="loc_biib_Collaborationprofitlosssharing_0833dab7-bee4-4bd9-b622-b03c87de6e74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_98f25559-4e09-45b2-9e21-fac90b721b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_be88cefe-4eb7-4c52-b3ca-171cad3e0807" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_98f25559-4e09-45b2-9e21-fac90b721b7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c1b4344b-8904-4787-8d8f-5b10d0020fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_be88cefe-4eb7-4c52-b3ca-171cad3e0807" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c1b4344b-8904-4787-8d8f-5b10d0020fbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_b1ba528c-dee5-4d29-96e6-1ce4cf11e932" xlink:href="biib-20210331.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_be88cefe-4eb7-4c52-b3ca-171cad3e0807" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_b1ba528c-dee5-4d29-96e6-1ce4cf11e932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cebf11e9-61ad-4367-9890-4e02a8bd59fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fbc10cca-aa1a-49fb-b29a-33acb904a8e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cebf11e9-61ad-4367-9890-4e02a8bd59fb" xlink:to="loc_us-gaap_Revenues_fbc10cca-aa1a-49fb-b29a-33acb904a8e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_172782ab-eac0-488d-a4e9-3e47774f5d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cebf11e9-61ad-4367-9890-4e02a8bd59fb" xlink:to="loc_us-gaap_CostsAndExpenses_172782ab-eac0-488d-a4e9-3e47774f5d88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3a52c0ab-5e93-47a5-ae52-f4214bec5db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d7f81175-477a-4483-babe-9875e7833dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_3a52c0ab-5e93-47a5-ae52-f4214bec5db7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d7f81175-477a-4483-babe-9875e7833dd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_176ece64-eeb9-4396-a70e-e4326183fa68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_3a52c0ab-5e93-47a5-ae52-f4214bec5db7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_176ece64-eeb9-4396-a70e-e4326183fa68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_f92423e2-f333-4bb4-897a-072b6d33e764" xlink:href="biib-20210331.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_3a52c0ab-5e93-47a5-ae52-f4214bec5db7" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_f92423e2-f333-4bb4-897a-072b6d33e764" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a2029014-a6b6-4be9-9edc-b3f2154d4c68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_22b98f7c-4ccb-40e3-acdf-24c8b4f8c706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a2029014-a6b6-4be9-9edc-b3f2154d4c68" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_22b98f7c-4ccb-40e3-acdf-24c8b4f8c706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c9ec45b1-5763-4687-b295-033b52c2a306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a2029014-a6b6-4be9-9edc-b3f2154d4c68" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c9ec45b1-5763-4687-b295-033b52c2a306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ae6de596-262f-4c43-a803-31980488308d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3e0fe97d-d7fa-49f1-b14f-8bcddca93a63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ae6de596-262f-4c43-a803-31980488308d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3e0fe97d-d7fa-49f1-b14f-8bcddca93a63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_6ab7a122-830f-4633-90be-21081fba26e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ae6de596-262f-4c43-a803-31980488308d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_6ab7a122-830f-4633-90be-21081fba26e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_115f727e-ea9e-427e-99a0-b7d48a94ef50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ae6de596-262f-4c43-a803-31980488308d" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_115f727e-ea9e-427e-99a0-b7d48a94ef50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_890a771e-8147-443a-97c3-d03ee3a0b140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ae6de596-262f-4c43-a803-31980488308d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_890a771e-8147-443a-97c3-d03ee3a0b140" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4a13db98-e656-43ed-838a-e79efffba146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ae6de596-262f-4c43-a803-31980488308d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4a13db98-e656-43ed-838a-e79efffba146" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_15798904-864d-4932-b600-80cb117ad851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_160fffa8-52ef-4485-a4de-80e3b2c4efcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_15798904-864d-4932-b600-80cb117ad851" xlink:to="loc_us-gaap_NetIncomeLoss_160fffa8-52ef-4485-a4de-80e3b2c4efcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_cd3c4bf3-0a9c-401e-aac8-0e6a798a97d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_15798904-864d-4932-b600-80cb117ad851" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_cd3c4bf3-0a9c-401e-aac8-0e6a798a97d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_51fe36de-a80e-46d0-9794-af9526c34c73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dceb0305-8520-4ca8-90e4-fcd5448c8699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51fe36de-a80e-46d0-9794-af9526c34c73" xlink:to="loc_us-gaap_AssetsCurrent_dceb0305-8520-4ca8-90e4-fcd5448c8699" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c7d2775d-c4d0-4373-ae33-ee0756b82c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51fe36de-a80e-46d0-9794-af9526c34c73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c7d2775d-c4d0-4373-ae33-ee0756b82c30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b612de1b-60e7-495f-8b45-b121a1249201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51fe36de-a80e-46d0-9794-af9526c34c73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b612de1b-60e7-495f-8b45-b121a1249201" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_703d08a1-20d4-41d1-9b58-35cb29acb193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51fe36de-a80e-46d0-9794-af9526c34c73" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_703d08a1-20d4-41d1-9b58-35cb29acb193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b15f2a2d-fc8c-412a-bf0b-56aec8a33b70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51fe36de-a80e-46d0-9794-af9526c34c73" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b15f2a2d-fc8c-412a-bf0b-56aec8a33b70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_39c712df-552c-46ff-b23c-ca2616d68dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51fe36de-a80e-46d0-9794-af9526c34c73" xlink:to="loc_us-gaap_Goodwill_39c712df-552c-46ff-b23c-ca2616d68dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_36471a12-4e5d-4b52-863c-db37aebf416a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51fe36de-a80e-46d0-9794-af9526c34c73" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_36471a12-4e5d-4b52-863c-db37aebf416a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cdae7933-9a1a-437a-bf7b-04675fc51fe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51fe36de-a80e-46d0-9794-af9526c34c73" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cdae7933-9a1a-437a-bf7b-04675fc51fe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f929daad-0cdc-4b07-aa11-9ad024cbedfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8917a8b5-19d9-4396-a2bc-59380bb8f076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f929daad-0cdc-4b07-aa11-9ad024cbedfb" xlink:to="loc_us-gaap_PreferredStockValue_8917a8b5-19d9-4396-a2bc-59380bb8f076" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_43a9e9d5-a267-4ff2-8735-4dc2ada82c49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f929daad-0cdc-4b07-aa11-9ad024cbedfb" xlink:to="loc_us-gaap_CommonStockValue_43a9e9d5-a267-4ff2-8735-4dc2ada82c49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ff1d354e-5a1a-493d-a4db-f3a995aa89b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f929daad-0cdc-4b07-aa11-9ad024cbedfb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ff1d354e-5a1a-493d-a4db-f3a995aa89b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_364dd5e9-3566-4a53-b872-42a6fade03f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f929daad-0cdc-4b07-aa11-9ad024cbedfb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_364dd5e9-3566-4a53-b872-42a6fade03f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d6c92833-ccac-4793-991c-f8d439e2731f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f929daad-0cdc-4b07-aa11-9ad024cbedfb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d6c92833-ccac-4793-991c-f8d439e2731f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_31a0e90b-f50c-46f4-a213-1406434e5528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f929daad-0cdc-4b07-aa11-9ad024cbedfb" xlink:to="loc_us-gaap_TreasuryStockValue_31a0e90b-f50c-46f4-a213-1406434e5528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6ea48595-8185-4bcd-baa2-c679057100a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0ef22349-b092-419f-8c35-3e4383618a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea48595-8185-4bcd-baa2-c679057100a1" xlink:to="loc_us-gaap_LiabilitiesCurrent_0ef22349-b092-419f-8c35-3e4383618a6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_cc262cb7-8c75-43b8-a866-5075f7317ee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea48595-8185-4bcd-baa2-c679057100a1" xlink:to="loc_us-gaap_LongTermDebt_cc262cb7-8c75-43b8-a866-5075f7317ee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a97b3a60-f69b-456d-bb65-860f3b503526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea48595-8185-4bcd-baa2-c679057100a1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a97b3a60-f69b-456d-bb65-860f3b503526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f6d73c8f-2c93-4e66-b8bf-3d9aa008a368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea48595-8185-4bcd-baa2-c679057100a1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f6d73c8f-2c93-4e66-b8bf-3d9aa008a368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6a3c1b04-7304-456c-a2f2-3b4a4954b7f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea48595-8185-4bcd-baa2-c679057100a1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6a3c1b04-7304-456c-a2f2-3b4a4954b7f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c81cce1b-be7b-4be0-9ccc-131158e0303f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c2ddec68-c402-4b44-90d4-6dab99f4e352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c81cce1b-be7b-4be0-9ccc-131158e0303f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c2ddec68-c402-4b44-90d4-6dab99f4e352" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b04226dd-eddc-48c5-824b-b502f1738ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c81cce1b-be7b-4be0-9ccc-131158e0303f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b04226dd-eddc-48c5-824b-b502f1738ff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_af09dd40-ebaf-4329-aae5-d82e5c5f2074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c81cce1b-be7b-4be0-9ccc-131158e0303f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_af09dd40-ebaf-4329-aae5-d82e5c5f2074" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_9a6973ae-1d17-46d3-af58-6004930e6f31" xlink:href="biib-20210331.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c81cce1b-be7b-4be0-9ccc-131158e0303f" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_9a6973ae-1d17-46d3-af58-6004930e6f31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_491e8268-cb72-4021-b488-c89fc9d2e6c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c81cce1b-be7b-4be0-9ccc-131158e0303f" xlink:to="loc_us-gaap_InventoryNet_491e8268-cb72-4021-b488-c89fc9d2e6c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9bc0144a-b7bc-4035-a231-53d08f4ba6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c81cce1b-be7b-4be0-9ccc-131158e0303f" xlink:to="loc_us-gaap_OtherAssetsCurrent_9bc0144a-b7bc-4035-a231-53d08f4ba6ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_016335c5-f1af-4548-be4f-488b877d80f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_62778f5a-1a6d-4409-b14f-93177916028a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_016335c5-f1af-4548-be4f-488b877d80f1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_62778f5a-1a6d-4409-b14f-93177916028a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_72efb049-cde7-441c-8955-d32c9221e935" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_016335c5-f1af-4548-be4f-488b877d80f1" xlink:to="loc_us-gaap_Liabilities_72efb049-cde7-441c-8955-d32c9221e935" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b5cf3c8d-ddc5-4e09-9f70-2f92dfc5cef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_016335c5-f1af-4548-be4f-488b877d80f1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b5cf3c8d-ddc5-4e09-9f70-2f92dfc5cef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0751d9c8-8c99-4612-aece-35a5e97aa5e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_935c1e2f-8fbd-42f8-bc72-0f4a3921f919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0751d9c8-8c99-4612-aece-35a5e97aa5e1" xlink:to="loc_us-gaap_StockholdersEquity_935c1e2f-8fbd-42f8-bc72-0f4a3921f919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_36dee01a-971c-405d-801c-4c319cae395f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0751d9c8-8c99-4612-aece-35a5e97aa5e1" xlink:to="loc_us-gaap_MinorityInterest_36dee01a-971c-405d-801c-4c319cae395f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c27187e4-dbc6-43a8-a883-3477801fb988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_878ff00a-c4c0-4fd4-8667-6b6b8b205efb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c27187e4-dbc6-43a8-a883-3477801fb988" xlink:to="loc_us-gaap_TaxesPayableCurrent_878ff00a-c4c0-4fd4-8667-6b6b8b205efb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_00bc4f11-2b0e-48e4-80db-502dfc6a87d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c27187e4-dbc6-43a8-a883-3477801fb988" xlink:to="loc_us-gaap_AccountsPayableCurrent_00bc4f11-2b0e-48e4-80db-502dfc6a87d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6f725b9c-a608-4343-845e-ca18f749a9cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c27187e4-dbc6-43a8-a883-3477801fb988" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6f725b9c-a608-4343-845e-ca18f749a9cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_628edd37-26ec-41e6-b138-a5a76fab6f28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_43201934-3dd0-43a1-bcb7-8dc2e82b541e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_628edd37-26ec-41e6-b138-a5a76fab6f28" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_43201934-3dd0-43a1-bcb7-8dc2e82b541e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_57585bb3-5845-406d-b2a3-a9e91f19aa87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_628edd37-26ec-41e6-b138-a5a76fab6f28" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_57585bb3-5845-406d-b2a3-a9e91f19aa87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30f6450e-8494-42c3-966a-c92bbe52f66a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_628edd37-26ec-41e6-b138-a5a76fab6f28" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30f6450e-8494-42c3-966a-c92bbe52f66a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_d2a155e3-e0de-42e9-8cd3-cc1d96e7a777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_628edd37-26ec-41e6-b138-a5a76fab6f28" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_d2a155e3-e0de-42e9-8cd3-cc1d96e7a777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f2b20629-7ea7-484b-b55f-7820ddc1bf3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_628edd37-26ec-41e6-b138-a5a76fab6f28" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f2b20629-7ea7-484b-b55f-7820ddc1bf3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_f7d3ea4f-9281-46ff-badd-36686a459ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_628edd37-26ec-41e6-b138-a5a76fab6f28" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_f7d3ea4f-9281-46ff-badd-36686a459ca7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3f047adc-3cc1-4bd2-9a2b-6da98fdbfdf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_628edd37-26ec-41e6-b138-a5a76fab6f28" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3f047adc-3cc1-4bd2-9a2b-6da98fdbfdf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_58cd2500-ef3e-41ba-a7d7-c9d98cdd28ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_628edd37-26ec-41e6-b138-a5a76fab6f28" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_58cd2500-ef3e-41ba-a7d7-c9d98cdd28ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0087b399-b560-4208-8c12-70f59a3203f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:to="loc_us-gaap_ProfitLoss_0087b399-b560-4208-8c12-70f59a3203f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2cbeff12-fd01-4578-8dec-7fabc6e11232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2cbeff12-fd01-4578-8dec-7fabc6e11232" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_256c8276-ec2a-4fcd-ac45-ebbb2691bec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_256c8276-ec2a-4fcd-ac45-ebbb2691bec7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c751c072-b4c2-428e-be4c-f43061842ece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:to="loc_us-gaap_ShareBasedCompensation_c751c072-b4c2-428e-be4c-f43061842ece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c15ff284-f4a2-4ea4-a90f-657bd851b21a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c15ff284-f4a2-4ea4-a90f-657bd851b21a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1945160e-d14d-48ea-a5f6-f0bb56ab6a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1945160e-d14d-48ea-a5f6-f0bb56ab6a98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_fd65de5c-1026-4725-b12c-d0c4a3e8d93a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_fd65de5c-1026-4725-b12c-d0c4a3e8d93a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e703f751-11d0-40bf-85b1-460d10f9321f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e703f751-11d0-40bf-85b1-460d10f9321f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5508a7b4-45ee-4345-bac3-904da6b9cee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5508a7b4-45ee-4345-bac3-904da6b9cee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_33fe2994-3632-4f73-9a9c-aa0b6149f80b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_33fe2994-3632-4f73-9a9c-aa0b6149f80b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_670c388b-03d7-4b53-a014-2a2d443d0a18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_670c388b-03d7-4b53-a014-2a2d443d0a18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7abe7267-835d-4f6c-8ba4-cdfad9341956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7abe7267-835d-4f6c-8ba4-cdfad9341956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3ab377c0-6b06-4ce6-a85f-6e6253634186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3ab377c0-6b06-4ce6-a85f-6e6253634186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_69fcce94-f426-4ea4-a3b5-08d508fe0d39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_69fcce94-f426-4ea4-a3b5-08d508fe0d39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_25b8396a-9f3d-4951-b290-e6f09d140a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ded20aa3-bbde-4d70-9d3d-528452a4eefb" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_25b8396a-9f3d-4951-b290-e6f09d140a2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_833ba51a-5f80-436b-a449-fefe9763a2d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d9e60b5-6bd4-4b34-bb30-e8bfc8d6edb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_833ba51a-5f80-436b-a449-fefe9763a2d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d9e60b5-6bd4-4b34-bb30-e8bfc8d6edb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9fc832d9-b42e-466b-afff-60cbadbd7444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_833ba51a-5f80-436b-a449-fefe9763a2d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9fc832d9-b42e-466b-afff-60cbadbd7444" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_820bcc1f-b04a-4d02-9fb0-f31985be78b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_833ba51a-5f80-436b-a449-fefe9763a2d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_820bcc1f-b04a-4d02-9fb0-f31985be78b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fd58b60-1292-4477-a590-3431ae9c46b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_20eaeefb-7cec-48ab-8213-2a4029e4062e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fd58b60-1292-4477-a590-3431ae9c46b2" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_20eaeefb-7cec-48ab-8213-2a4029e4062e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b2e46486-eb23-4c96-b9c2-039d6f2a2610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fd58b60-1292-4477-a590-3431ae9c46b2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b2e46486-eb23-4c96-b9c2-039d6f2a2610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0bc931c6-60fa-4070-a006-27f921ed5952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fd58b60-1292-4477-a590-3431ae9c46b2" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0bc931c6-60fa-4070-a006-27f921ed5952" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_1308b6cb-7a6e-46a0-bcfa-8d5e4dc564e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fd58b60-1292-4477-a590-3431ae9c46b2" xlink:to="loc_us-gaap_RepaymentsOfDebt_1308b6cb-7a6e-46a0-bcfa-8d5e4dc564e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20210331.xsd#SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:type="simple" xlink:href="biib-20210331.xsd#Acquisitions"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#BusinessAcquisitionDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20210331.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20210331.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#RevenuesbyProductDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20210331.xsd#ReservesforDiscountsandAllowancesDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20210331.xsd#ReservesforDiscountsandAllowancesDetails2"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#RevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_89e6daf6-0504-43a1-81de-453e4a54f1ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_ecc7c128-c132-4583-8588-27890c5da140" xlink:href="biib-20210331.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_89e6daf6-0504-43a1-81de-453e4a54f1ee" xlink:to="loc_biib_ShareOfCoPromotionProfits_ecc7c128-c132-4583-8588-27890c5da140" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#OtherRevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#RevenuesDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20210331.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20210331.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_2d93ee73-e09f-4c51-88d5-272700d5faf5" xlink:href="biib-20210331.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5ed9a3ac-f582-4658-9b87-36bfceb12d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_2d93ee73-e09f-4c51-88d5-272700d5faf5" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5ed9a3ac-f582-4658-9b87-36bfceb12d9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_89a53c73-ac44-4fd3-974f-1ca48347eda2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_2d93ee73-e09f-4c51-88d5-272700d5faf5" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_89a53c73-ac44-4fd3-974f-1ca48347eda2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e249a602-a4ec-4309-bcb8-c3b28241e7dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_2d93ee73-e09f-4c51-88d5-272700d5faf5" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e249a602-a4ec-4309-bcb8-c3b28241e7dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20210331.xsd#IntangibleAssetsandGoodwill"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20210331.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b007e957-6c0e-4613-9a0b-f5e39469410d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6bf9094c-66e1-469d-b82e-21a3ae634665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b007e957-6c0e-4613-9a0b-f5e39469410d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6bf9094c-66e1-469d-b82e-21a3ae634665" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_68ae1eed-81a3-4217-9a40-fcac077bbc63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b007e957-6c0e-4613-9a0b-f5e39469410d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_68ae1eed-81a3-4217-9a40-fcac077bbc63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8f2be780-2a20-48e4-87cc-e37c542a80e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b007e957-6c0e-4613-9a0b-f5e39469410d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8f2be780-2a20-48e4-87cc-e37c542a80e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c1fe3e97-960a-425b-b5b6-20699c022bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9559aaf6-cc20-4a82-96e0-62bacd3ffc6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c1fe3e97-960a-425b-b5b6-20699c022bd5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9559aaf6-cc20-4a82-96e0-62bacd3ffc6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_45e0c62d-a396-470b-9f9b-cabc0a57ec47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c1fe3e97-960a-425b-b5b6-20699c022bd5" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_45e0c62d-a396-470b-9f9b-cabc0a57ec47" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="simple" xlink:href="biib-20210331.xsd#IntangibleAssetsandGoodwillDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_229af83e-fc1e-4eb7-81e8-006ddbcfb11e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_03876265-4cba-49a8-9db4-3a5289712bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_229af83e-fc1e-4eb7-81e8-006ddbcfb11e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_03876265-4cba-49a8-9db4-3a5289712bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_9220356d-4dd6-4ad9-a9ff-f181c99893ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_229af83e-fc1e-4eb7-81e8-006ddbcfb11e" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_9220356d-4dd6-4ad9-a9ff-f181c99893ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsDetails2"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8d06a5f0-3c4d-4b1a-a2a2-51bb02ed0f3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b557c736-7c3c-4794-85d7-dce689d789e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8d06a5f0-3c4d-4b1a-a2a2-51bb02ed0f3d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b557c736-7c3c-4794-85d7-dce689d789e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7645160e-9d13-4eab-9218-2107ac1a73da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8d06a5f0-3c4d-4b1a-a2a2-51bb02ed0f3d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7645160e-9d13-4eab-9218-2107ac1a73da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_150c89d2-4098-4d54-be7a-c77bfa71b744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8d06a5f0-3c4d-4b1a-a2a2-51bb02ed0f3d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_150c89d2-4098-4d54-be7a-c77bfa71b744" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsDetails2"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_92e97337-8c4a-48c1-81b7-4606106a0309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a7beb101-a71b-42a2-acdc-ae5052698afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_92e97337-8c4a-48c1-81b7-4606106a0309" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a7beb101-a71b-42a2-acdc-ae5052698afe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_4a702db9-7c9f-48a5-8c03-8f53bb381575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_92e97337-8c4a-48c1-81b7-4606106a0309" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_4a702db9-7c9f-48a5-8c03-8f53bb381575" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_9a29e5dc-a336-4ba5-8687-e34eeae4aa32" xlink:href="biib-20210331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_92e97337-8c4a-48c1-81b7-4606106a0309" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_9a29e5dc-a336-4ba5-8687-e34eeae4aa32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94589a7b-c807-4d16-abd8-4c9569a9d591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4b4aa8cc-7a16-42a4-81d6-8e99ebccbdf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94589a7b-c807-4d16-abd8-4c9569a9d591" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4b4aa8cc-7a16-42a4-81d6-8e99ebccbdf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_4f3b8029-9b50-4a12-8b85-a3c433fde754" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94589a7b-c807-4d16-abd8-4c9569a9d591" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_4f3b8029-9b50-4a12-8b85-a3c433fde754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_317f4b50-2efe-4dc3-9fce-ef0b98b5976b" xlink:href="biib-20210331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94589a7b-c807-4d16-abd8-4c9569a9d591" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_317f4b50-2efe-4dc3-9fce-ef0b98b5976b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsDetails3"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20210331.xsd#DerivativeInstruments"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20210331.xsd#DerivativeInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#DerivativeInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20210331.xsd#PropertyPlantandEquipmentPropertyPlantandEquipment"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#PropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="simple" xlink:href="biib-20210331.xsd#IndebtednessNotes"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#IndebtednessDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20210331.xsd#Equity"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="biib-20210331.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#ShareRepurchasesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20210331.xsd#EarningsperShare"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20210331.xsd#EarningsperShareTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#EarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8fc72ad1-a05d-4254-9b25-74df2cf5e9e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3d38e4bd-1658-4655-8626-e73d934ad83d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8fc72ad1-a05d-4254-9b25-74df2cf5e9e8" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3d38e4bd-1658-4655-8626-e73d934ad83d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b49de92-628c-493a-bc4b-dea6d716830e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7e95e96c-0b34-44a1-bba6-a9d401ae3183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b49de92-628c-493a-bc4b-dea6d716830e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7e95e96c-0b34-44a1-bba6-a9d401ae3183" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d2e248c4-65b4-43a4-a80d-924b235a4204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b49de92-628c-493a-bc4b-dea6d716830e" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d2e248c4-65b4-43a4-a80d-924b235a4204" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="simple" xlink:href="biib-20210331.xsd#SharebasedPayments"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20210331.xsd#ShareBasedPaymentsTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#ShareBasedPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_663aa9de-9562-441a-9091-288881ff3679" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_665062e2-33e1-4c75-838a-d1dfaf119afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_663aa9de-9562-441a-9091-288881ff3679" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_665062e2-33e1-4c75-838a-d1dfaf119afb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2488aaf7-c663-426f-91bc-f813509e5f38" xlink:href="biib-20210331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_663aa9de-9562-441a-9091-288881ff3679" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2488aaf7-c663-426f-91bc-f813509e5f38" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20210331.xsd#ShareBasedPaymentsDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20210331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20210331.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#IncomeTaxesDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1ed02e1a-00ff-4d2e-8f20-06d277351a85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c294959f-dd1f-409a-a4f4-118120f6f155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1ed02e1a-00ff-4d2e-8f20-06d277351a85" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c294959f-dd1f-409a-a4f4-118120f6f155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1b10acd0-3688-40c7-acb6-148be45d2507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1ed02e1a-00ff-4d2e-8f20-06d277351a85" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1b10acd0-3688-40c7-acb6-148be45d2507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5deb9089-0a50-4912-8396-a666e64b0606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1ed02e1a-00ff-4d2e-8f20-06d277351a85" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5deb9089-0a50-4912-8396-a666e64b0606" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_acc6c184-1cac-4d3c-bd03-2dec9193d8c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1ed02e1a-00ff-4d2e-8f20-06d277351a85" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_acc6c184-1cac-4d3c-bd03-2dec9193d8c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_30fd3d2d-0bf6-499b-a38c-97526cd2cc4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1ed02e1a-00ff-4d2e-8f20-06d277351a85" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_30fd3d2d-0bf6-499b-a38c-97526cd2cc4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_77d0a1a4-f8c7-4863-880d-7c1e74ff496e" xlink:href="biib-20210331.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1ed02e1a-00ff-4d2e-8f20-06d277351a85" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_77d0a1a4-f8c7-4863-880d-7c1e74ff496e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_cc0e892e-f53e-4aa1-826b-43794dbdd748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1ed02e1a-00ff-4d2e-8f20-06d277351a85" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_cc0e892e-f53e-4aa1-826b-43794dbdd748" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20210331.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20210331.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f6057772-9aac-45d9-8177-2513eaf1445a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_bbae2949-ffa1-4acb-8740-b2ad344c2512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f6057772-9aac-45d9-8177-2513eaf1445a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_bbae2949-ffa1-4acb-8740-b2ad344c2512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5a08e630-981d-4897-be06-80c343d17d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f6057772-9aac-45d9-8177-2513eaf1445a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5a08e630-981d-4897-be06-80c343d17d0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f01cfe39-51e5-4d98-b79f-f6e824e09d32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_51c3d35e-9430-41ab-b9e8-1c2c6d75c21a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f01cfe39-51e5-4d98-b79f-f6e824e09d32" xlink:to="loc_us-gaap_InvestmentIncomeInterest_51c3d35e-9430-41ab-b9e8-1c2c6d75c21a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d514ad1f-3498-4eb9-84ac-4273c7942227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f01cfe39-51e5-4d98-b79f-f6e824e09d32" xlink:to="loc_us-gaap_InterestExpense_d514ad1f-3498-4eb9-84ac-4273c7942227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_4146c0dd-0476-4d3a-899f-f3ce9741f25b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f01cfe39-51e5-4d98-b79f-f6e824e09d32" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_4146c0dd-0476-4d3a-899f-f3ce9741f25b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_27dcffc6-b602-4a24-bad3-b3a093eecac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f01cfe39-51e5-4d98-b79f-f6e824e09d32" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_27dcffc6-b602-4a24-bad3-b3a093eecac2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_149098fa-fbc7-417f-8e02-417dc0854b07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f01cfe39-51e5-4d98-b79f-f6e824e09d32" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_149098fa-fbc7-417f-8e02-417dc0854b07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20210331.xsd#CollaborativeandOtherRelationships"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20210331.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20210331.xsd#InvestmentsinVariableInterestEntities"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20210331.xsd#Litigation"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#LitigationDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>biib-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:b54f3254-567d-4813-a83c-54bbe0ebf523,g:5bfc82e5-4d8f-4b59-aa4e-ce589875722a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20210331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended" id="ia7c618d7c664402bbb6188067942942c_CoverPage"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended" id="i3c7ec814509b4c939fe00064454e658e_CondensedConsolidatedStatementsofIncomeUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4beaad53-be55-475f-bb10-e308810ad288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_Revenues_4beaad53-be55-475f-bb10-e308810ad288" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_86aa259e-5cb8-470e-9dbe-fed96557b414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_86aa259e-5cb8-470e-9dbe-fed96557b414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_b99f4af4-e144-4c7d-91d0-04f8a1d79c79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_b99f4af4-e144-4c7d-91d0-04f8a1d79c79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fac2ad61-eb77-4ba1-b5e6-45f6531622c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fac2ad61-eb77-4ba1-b5e6-45f6531622c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_4da53bd1-23f2-4401-9894-5fb8aba6a4a9" xlink:href="biib-20210331.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_4da53bd1-23f2-4401-9894-5fb8aba6a4a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_9fbb5412-f532-4bb8-9003-3d7d18ac1c58" xlink:href="biib-20210331.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_biib_Collaborationprofitlosssharing_9fbb5412-f532-4bb8-9003-3d7d18ac1c58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_af6ef87e-b1f3-44d8-8b28-c9b1213c2d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_af6ef87e-b1f3-44d8-8b28-c9b1213c2d6e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3cb7287a-aef3-4892-9008-c456396cf7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3cb7287a-aef3-4892-9008-c456396cf7cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5136b2eb-8012-4135-87a9-8e8ce6db65d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_us-gaap_CostsAndExpenses_5136b2eb-8012-4135-87a9-8e8ce6db65d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9b433eb6-fec0-4400-ba36-62700315099b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_OperatingIncomeLoss_9b433eb6-fec0-4400-ba36-62700315099b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d6e87b58-cac6-4fc9-8615-0043ccf93e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d6e87b58-cac6-4fc9-8615-0043ccf93e96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8766441d-20d8-422c-912d-5a1865c1cfda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8766441d-20d8-422c-912d-5a1865c1cfda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_77cb5c53-eb3b-42fd-8cb1-77d4c7284057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_77cb5c53-eb3b-42fd-8cb1-77d4c7284057" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_d4b56736-f940-4991-83c7-4634d00b5865" xlink:href="biib-20210331.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_d4b56736-f940-4991-83c7-4634d00b5865" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cd8e925e-3ca2-4e0d-8eb7-4274b018d97d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_ProfitLoss_cd8e925e-3ca2-4e0d-8eb7-4274b018d97d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ea499d8c-7284-4fe4-b828-0eea5470ab9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ea499d8c-7284-4fe4-b828-0eea5470ab9e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bec2bf33-0fc2-48a1-be6d-22decf9f085d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_NetIncomeLoss_bec2bf33-0fc2-48a1-be6d-22decf9f085d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_01f0af05-7052-4433-b83e-a4a2758edc06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_EarningsPerShareAbstract_01f0af05-7052-4433-b83e-a4a2758edc06" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6b84de99-9a2c-4c64-8457-3d522e18528e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_01f0af05-7052-4433-b83e-a4a2758edc06" xlink:to="loc_us-gaap_EarningsPerShareBasic_6b84de99-9a2c-4c64-8457-3d522e18528e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1c0153de-0f9c-410d-bcb7-2bd144bd89bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_01f0af05-7052-4433-b83e-a4a2758edc06" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1c0153de-0f9c-410d-bcb7-2bd144bd89bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b690cb3f-d934-4065-b771-f0abcd8d7184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b690cb3f-d934-4065-b771-f0abcd8d7184" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4bc34bc3-06a8-4ac9-9f05-9b6db455cc52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b690cb3f-d934-4065-b771-f0abcd8d7184" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4bc34bc3-06a8-4ac9-9f05-9b6db455cc52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_48532b88-0a73-4177-8b28-107f31dc95a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b690cb3f-d934-4065-b771-f0abcd8d7184" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_48532b88-0a73-4177-8b28-107f31dc95a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ce8af73f-fe2d-42b9-9a24-652a838e17b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_StatementTable_ce8af73f-fe2d-42b9-9a24-652a838e17b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4aabcdac-6acf-415b-9eef-31e01b048ba2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ce8af73f-fe2d-42b9-9a24-652a838e17b0" xlink:to="loc_srt_ProductOrServiceAxis_4aabcdac-6acf-415b-9eef-31e01b048ba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4aabcdac-6acf-415b-9eef-31e01b048ba2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4aabcdac-6acf-415b-9eef-31e01b048ba2" xlink:to="loc_srt_ProductsAndServicesDomain_4aabcdac-6acf-415b-9eef-31e01b048ba2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_effeb9b1-413e-41a3-9c89-788ee4af8f9c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4aabcdac-6acf-415b-9eef-31e01b048ba2" xlink:to="loc_srt_ProductsAndServicesDomain_effeb9b1-413e-41a3-9c89-788ee4af8f9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c86650d7-a954-422f-84fd-7da2243db3f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_effeb9b1-413e-41a3-9c89-788ee4af8f9c" xlink:to="loc_us-gaap_ProductMember_c86650d7-a954-422f-84fd-7da2243db3f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3da64bb9-00e1-4685-8707-2fb8059640ae" xlink:href="biib-20210331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_effeb9b1-413e-41a3-9c89-788ee4af8f9c" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3da64bb9-00e1-4685-8707-2fb8059640ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_29519da9-cdb8-4d05-8352-f1919b8afc22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_effeb9b1-413e-41a3-9c89-788ee4af8f9c" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_29519da9-cdb8-4d05-8352-f1919b8afc22" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended" id="i771950bf3e924a66bc447b6f48233c54_CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" id="i79beb5a6c0f54c27875979c07c97ab3b_CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" id="id573965863894fd5a8abf3ebc347cee2_CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="i86e4584ac6fd4a6084e681e7b9932998_CondensedConsolidatedStatementsofCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08f35490-ad0e-4cb7-bf81-219fbf7155a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08f35490-ad0e-4cb7-bf81-219fbf7155a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fd11bffe-b639-4f1c-84fd-9bd66a63e64a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08f35490-ad0e-4cb7-bf81-219fbf7155a1" xlink:to="loc_us-gaap_ProfitLoss_fd11bffe-b639-4f1c-84fd-9bd66a63e64a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08f35490-ad0e-4cb7-bf81-219fbf7155a1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_48867ee1-f530-4f0e-895f-77f3ca78f4ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_48867ee1-f530-4f0e-895f-77f3ca78f4ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_138ba6f2-2111-46c6-a853-b4f6ce778465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_138ba6f2-2111-46c6-a853-b4f6ce778465" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_feb5d3a6-aeed-4c9b-8e14-faa4525eedb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_ShareBasedCompensation_feb5d3a6-aeed-4c9b-8e14-faa4525eedb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_000cc5e5-b48a-48ee-99dc-80119b5ba862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_000cc5e5-b48a-48ee-99dc-80119b5ba862" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2a07c5c5-486a-433a-aca0-fb335061dfc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2a07c5c5-486a-433a-aca0-fb335061dfc5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_c481c254-0816-41e6-bcc2-e8c63ab667e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_c481c254-0816-41e6-bcc2-e8c63ab667e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c8210a76-70cc-4190-a08b-ed3cfb4e6fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c8210a76-70cc-4190-a08b-ed3cfb4e6fc5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d098cbf8-6d08-4b3d-a042-fd26ad9db94e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d098cbf8-6d08-4b3d-a042-fd26ad9db94e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_77705f3f-ee3e-4e0b-af56-5ef17deda182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_77705f3f-ee3e-4e0b-af56-5ef17deda182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_3be29a59-d43e-4b35-8f52-62132fb30d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_3be29a59-d43e-4b35-8f52-62132fb30d84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8c101837-ed8b-463d-abad-c02338e88c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8c101837-ed8b-463d-abad-c02338e88c81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b55d6af0-0d9a-4b85-b7f3-166ebed9f709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b55d6af0-0d9a-4b85-b7f3-166ebed9f709" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_35736edb-f26f-4182-9921-b76f04db12b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_35736edb-f26f-4182-9921-b76f04db12b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_895b83d0-cd72-41c1-92bf-e26a9b60d5cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_895b83d0-cd72-41c1-92bf-e26a9b60d5cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bea13299-06ee-4eb8-8952-e84e71881c84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bea13299-06ee-4eb8-8952-e84e71881c84" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8b857d64-4bfd-4ef6-94d0-f3a6f06304b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8b857d64-4bfd-4ef6-94d0-f3a6f06304b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8e365366-0cb9-47d0-b06c-e7c91a34ae6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8e365366-0cb9-47d0-b06c-e7c91a34ae6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_36d35af1-8492-41f8-a54e-fc436f686547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_36d35af1-8492-41f8-a54e-fc436f686547" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e39671ec-a37c-4459-a55f-cfe967c9dced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e39671ec-a37c-4459-a55f-cfe967c9dced" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_bf20104d-0ce6-4a72-a9e5-d5f797ca2baa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_bf20104d-0ce6-4a72-a9e5-d5f797ca2baa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a78d65f5-9de2-46a2-a4aa-dd4ed04d4b09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a78d65f5-9de2-46a2-a4aa-dd4ed04d4b09" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_9bb55474-3eda-4ac8-9bcb-1b779f6978d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_9bb55474-3eda-4ac8-9bcb-1b779f6978d2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a9817c6d-3702-41c5-ab30-9320719198ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a9817c6d-3702-41c5-ab30-9320719198ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_06c5d609-af53-4d98-88a9-de80dbbd6f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_06c5d609-af53-4d98-88a9-de80dbbd6f71" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b7b6872-1351-464a-b221-132e53f7f6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b7b6872-1351-464a-b221-132e53f7f6f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d6c9d94f-34ea-4094-b809-99583a5b3537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b7b6872-1351-464a-b221-132e53f7f6f5" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d6c9d94f-34ea-4094-b809-99583a5b3537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cb1846ad-4336-4538-ab0a-99e53949c32d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b7b6872-1351-464a-b221-132e53f7f6f5" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cb1846ad-4336-4538-ab0a-99e53949c32d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_0023131f-2615-49da-ae28-68f1691764e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b7b6872-1351-464a-b221-132e53f7f6f5" xlink:to="loc_us-gaap_RepaymentsOfDebt_0023131f-2615-49da-ae28-68f1691764e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6627142d-0d49-47d3-8c40-bd98dac8c64b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b7b6872-1351-464a-b221-132e53f7f6f5" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6627142d-0d49-47d3-8c40-bd98dac8c64b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb74b01a-2916-49d5-8421-fb3d908adbdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b7b6872-1351-464a-b221-132e53f7f6f5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb74b01a-2916-49d5-8421-fb3d908adbdf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_085475d7-721d-441b-99d2-2ceff3b5a077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_085475d7-721d-441b-99d2-2ceff3b5a077" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_82373674-135c-48b0-9fe6-acb122bc92fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_82373674-135c-48b0-9fe6-acb122bc92fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ebdadec3-167d-4a45-a6f6-a97e9812d868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ebdadec3-167d-4a45-a6f6-a97e9812d868" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_391011ad-0d2b-45e9-9dd5-6d7b92d5fe89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1dcec8ad-0651-4af2-aa67-90559a7cb22c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:to="loc_us-gaap_StatementTable_1dcec8ad-0651-4af2-aa67-90559a7cb22c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eb376eef-887b-49f4-a7d0-fe02eac2ca04" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1dcec8ad-0651-4af2-aa67-90559a7cb22c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eb376eef-887b-49f4-a7d0-fe02eac2ca04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_eb376eef-887b-49f4-a7d0-fe02eac2ca04_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eb376eef-887b-49f4-a7d0-fe02eac2ca04" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_eb376eef-887b-49f4-a7d0-fe02eac2ca04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e99614fe-24d7-4947-80e9-314b6fb1c7bb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eb376eef-887b-49f4-a7d0-fe02eac2ca04" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e99614fe-24d7-4947-80e9-314b6fb1c7bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_94f4adea-3d49-422f-99b1-c3f276a75815" xlink:href="biib-20210331.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e99614fe-24d7-4947-80e9-314b6fb1c7bb" xlink:to="loc_biib_SangamoCommonStockMember_94f4adea-3d49-422f-99b1-c3f276a75815" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_1a21a629-97ad-47d0-90ff-c45820466a15" xlink:href="biib-20210331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e99614fe-24d7-4947-80e9-314b6fb1c7bb" xlink:to="loc_biib_DenaliTherapeuticsIncMember_1a21a629-97ad-47d0-90ff-c45820466a15" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended" id="id16614d242f447a0940a0e805a7dee57_CondensedConsolidatedStatementofEquityStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_56a6136d-81ef-4a42-95f5-4905a380fcb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_56a6136d-81ef-4a42-95f5-4905a380fcb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a1653532-187a-43d7-8c7b-f2c0f8d1d2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a1653532-187a-43d7-8c7b-f2c0f8d1d2dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4ac898e5-90f0-48ba-89d1-9248075d25f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_ProfitLoss_4ac898e5-90f0-48ba-89d1-9248075d25f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2b731064-18cc-43b0-85bf-b5db90491b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2b731064-18cc-43b0-85bf-b5db90491b43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_8c9af085-e364-490a-ab6d-75aca364aaab" xlink:href="biib-20210331.xsd#biib_Noncontrollinginterestincreasedecreaseother"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_8c9af085-e364-490a-ab6d-75aca364aaab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_76e3c340-6ffe-4383-b963-33389c87c9d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_76e3c340-6ffe-4383-b963-33389c87c9d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b81a0cff-e58b-409c-91ea-22b481f70f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b81a0cff-e58b-409c-91ea-22b481f70f6d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_df03e776-02fa-4883-93b9-58e1568305f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_df03e776-02fa-4883-93b9-58e1568305f3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_33cf24c3-94e0-4e95-a347-d788875ef162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_33cf24c3-94e0-4e95-a347-d788875ef162" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_d6c3bf1f-42b8-49ac-867d-e0e9ba6d4452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_d6c3bf1f-42b8-49ac-867d-e0e9ba6d4452" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_de8af93d-f30d-4617-8e65-6a8a60b8c4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_de8af93d-f30d-4617-8e65-6a8a60b8c4d9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_91e29761-b944-4198-885e-a0a9710370b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_91e29761-b944-4198-885e-a0a9710370b2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a30044b3-c5e5-4d29-bb70-6ce5af6ad44e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a30044b3-c5e5-4d29-bb70-6ce5af6ad44e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8340154d-114e-4695-8468-3febcf8c45e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8340154d-114e-4695-8468-3febcf8c45e5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_cd6671d1-9f33-4360-806b-0067c3bb55f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StockholdersEquityOther_cd6671d1-9f33-4360-806b-0067c3bb55f0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0e09b4e-9b47-47e1-b7ad-a98a3177a763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ca01460f-3853-47b8-8292-af74e150959e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_72aadab9-410f-4336-8b5c-05a5e1afc7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StatementTable_72aadab9-410f-4336-8b5c-05a5e1afc7fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_e53279b3-cdf3-4996-8850-a6a18841d7c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_72aadab9-410f-4336-8b5c-05a5e1afc7fc" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_e53279b3-cdf3-4996-8850-a6a18841d7c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_e53279b3-cdf3-4996-8850-a6a18841d7c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_e53279b3-cdf3-4996-8850-a6a18841d7c8" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_e53279b3-cdf3-4996-8850-a6a18841d7c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_2faaf28e-a797-4280-9d45-3093bf688215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_e53279b3-cdf3-4996-8850-a6a18841d7c8" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_2faaf28e-a797-4280-9d45-3093bf688215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_dc017e28-2eb0-44b9-857d-f6368efc1957" xlink:href="biib-20210331.xsd#biib_A2018ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_2faaf28e-a797-4280-9d45-3093bf688215" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_dc017e28-2eb0-44b9-857d-f6368efc1957" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_19f9fed8-e9ef-4504-9fa5-3fed03b521c8" xlink:href="biib-20210331.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_2faaf28e-a797-4280-9d45-3093bf688215" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_19f9fed8-e9ef-4504-9fa5-3fed03b521c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_4d405acc-6e9f-46df-8899-68039e8eba50" xlink:href="biib-20210331.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_2faaf28e-a797-4280-9d45-3093bf688215" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_4d405acc-6e9f-46df-8899-68039e8eba50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f591db1d-77b2-4bfe-b15a-b509e93a7ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_72aadab9-410f-4336-8b5c-05a5e1afc7fc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f591db1d-77b2-4bfe-b15a-b509e93a7ae9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f591db1d-77b2-4bfe-b15a-b509e93a7ae9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f591db1d-77b2-4bfe-b15a-b509e93a7ae9" xlink:to="loc_us-gaap_EquityComponentDomain_f591db1d-77b2-4bfe-b15a-b509e93a7ae9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f591db1d-77b2-4bfe-b15a-b509e93a7ae9" xlink:to="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c485cd8d-722f-4e16-85c7-55204e357152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_PreferredStockMember_c485cd8d-722f-4e16-85c7-55204e357152" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_572fc37d-5288-4193-a37c-e092b5a48bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_CommonStockMember_572fc37d-5288-4193-a37c-e092b5a48bd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_caaee2de-a354-4a3b-abbc-ef07c93e7d40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_caaee2de-a354-4a3b-abbc-ef07c93e7d40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4e8a8164-ba6f-4a5e-bf7f-a8e3c22d0aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4e8a8164-ba6f-4a5e-bf7f-a8e3c22d0aaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9f2f3ce9-bd4b-4bef-b0c3-d7d6822e27af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_RetainedEarningsMember_9f2f3ce9-bd4b-4bef-b0c3-d7d6822e27af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_338ca384-45b2-439a-8e03-06a6da3cf990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_TreasuryStockMember_338ca384-45b2-439a-8e03-06a6da3cf990" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_53a97a76-612f-446c-aabf-2f588c5b8630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_ParentMember_53a97a76-612f-446c-aabf-2f588c5b8630" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_57483946-d0c7-423b-89d8-a42a39ee4d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_NoncontrollingInterestMember_57483946-d0c7-423b-89d8-a42a39ee4d38" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i9efcb913b92e49b59c9a5bc11734e036_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20210331.xsd#SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ibe9ba36f4d1d488396fb0f27849b6afc_SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i2f77a4c3da3a4cd78e332754de7a0bcf_SummaryofSignificantAccountingPoliciesDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:type="simple" xlink:href="biib-20210331.xsd#Acquisitions"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" id="i44c921de3cf9468f9aaf17deb80292ed_Acquisitions"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#BusinessAcquisitionDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended" id="i3ec312ef562a4afab03008e176d75e66_BusinessAcquisitionDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4f8eeed3-00f3-4099-8549-fe4bb8c87088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_0402b212-b9d5-421f-afd6-b7e1efaa9cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4f8eeed3-00f3-4099-8549-fe4bb8c87088" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_0402b212-b9d5-421f-afd6-b7e1efaa9cc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1d258cfd-9876-4eba-a28b-93b72307c1c6" xlink:href="biib-20210331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4f8eeed3-00f3-4099-8549-fe4bb8c87088" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1d258cfd-9876-4eba-a28b-93b72307c1c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5def6f58-cfbd-471f-ba8f-f40c5a55b66b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4f8eeed3-00f3-4099-8549-fe4bb8c87088" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5def6f58-cfbd-471f-ba8f-f40c5a55b66b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_541b7eba-0da8-4e42-bdab-16e1d203bcf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5def6f58-cfbd-471f-ba8f-f40c5a55b66b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_541b7eba-0da8-4e42-bdab-16e1d203bcf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_541b7eba-0da8-4e42-bdab-16e1d203bcf6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_541b7eba-0da8-4e42-bdab-16e1d203bcf6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_541b7eba-0da8-4e42-bdab-16e1d203bcf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc48d214-5078-4bdb-8492-cebc1fa3d382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_541b7eba-0da8-4e42-bdab-16e1d203bcf6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc48d214-5078-4bdb-8492-cebc1fa3d382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB118Member_fa3585a6-7c30-442e-9093-d07f8cb47eb9" xlink:href="biib-20210331.xsd#biib_BIIB118Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc48d214-5078-4bdb-8492-cebc1fa3d382" xlink:to="loc_biib_BIIB118Member_fa3585a6-7c30-442e-9093-d07f8cb47eb9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20210331.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended" id="i8fa1c037ce164932b59e42bfa2731abd_Revenues"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20210331.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended" id="i6c0e5ba0e8564f3a8a361e935e1dc95d_RevenuesTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#RevenuesbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="extended" id="i7952fc904b984705b1c091a467f4acf8_RevenuesbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a5e844fc-1092-4dee-a66d-d04cbbca4d61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_23554560-732a-49d4-8ef5-075129d61ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a5e844fc-1092-4dee-a66d-d04cbbca4d61" xlink:to="loc_us-gaap_Revenues_23554560-732a-49d4-8ef5-075129d61ae0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_bc6277cd-64f0-493c-99c9-3b12fd7e423d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a5e844fc-1092-4dee-a66d-d04cbbca4d61" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_bc6277cd-64f0-493c-99c9-3b12fd7e423d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_412e4afa-c80f-40af-91b9-c29e78fd3562" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bc6277cd-64f0-493c-99c9-3b12fd7e423d" xlink:to="loc_srt_ProductOrServiceAxis_412e4afa-c80f-40af-91b9-c29e78fd3562" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_412e4afa-c80f-40af-91b9-c29e78fd3562_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_412e4afa-c80f-40af-91b9-c29e78fd3562" xlink:to="loc_srt_ProductsAndServicesDomain_412e4afa-c80f-40af-91b9-c29e78fd3562_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_412e4afa-c80f-40af-91b9-c29e78fd3562" xlink:to="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_71f79755-879f-4b40-b177-2c25f9b40c95" xlink:href="biib-20210331.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_FumarateMember_71f79755-879f-4b40-b177-2c25f9b40c95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_115666e3-7543-4f00-a9df-379ed973ae6e" xlink:href="biib-20210331.xsd#biib_InterferonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_InterferonMember_115666e3-7543-4f00-a9df-379ed973ae6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_b4fc0c09-f16c-4a5b-bb35-8129c2f08f56" xlink:href="biib-20210331.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_TysabriProductMember_b4fc0c09-f16c-4a5b-bb35-8129c2f08f56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_9fe14bd6-a35e-457d-a46b-ec8de7d9f1e3" xlink:href="biib-20210331.xsd#biib_FAMPYRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_FAMPYRAMember_9fe14bd6-a35e-457d-a46b-ec8de7d9f1e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_039e06a9-e80c-4983-b1ad-987d896091b1" xlink:href="biib-20210331.xsd#biib_ZINBRYTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_ZINBRYTAMember_039e06a9-e80c-4983-b1ad-987d896091b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_4ef9ebf3-900c-4073-881b-951310eb3617" xlink:href="biib-20210331.xsd#biib_MSProductRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_MSProductRevenuesMember_4ef9ebf3-900c-4073-881b-951310eb3617" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_8aaae8ab-99f0-4c4d-a803-63e43060449b" xlink:href="biib-20210331.xsd#biib_SPINRAZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_SPINRAZAMember_8aaae8ab-99f0-4c4d-a803-63e43060449b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_c1318357-c1ac-4bd4-8c52-4c1fd3643464" xlink:href="biib-20210331.xsd#biib_BENEPALIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_BENEPALIMember_c1318357-c1ac-4bd4-8c52-4c1fd3643464" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_9c308c88-8eab-4883-a080-1e310dd7a7c3" xlink:href="biib-20210331.xsd#biib_IMRALDIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_IMRALDIMember_9c308c88-8eab-4883-a080-1e310dd7a7c3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_7dca03ab-cd34-43d4-9747-715c1b568e8e" xlink:href="biib-20210331.xsd#biib_FLIXABIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_FLIXABIMember_7dca03ab-cd34-43d4-9747-715c1b568e8e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_bba5fbce-8a27-464a-9cb7-2b116e65c1d9" xlink:href="biib-20210331.xsd#biib_BiosimilarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_BiosimilarsMember_bba5fbce-8a27-464a-9cb7-2b116e65c1d9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_094d819b-bbcd-4d98-afaa-74cf32e61a31" xlink:href="biib-20210331.xsd#biib_FUMADERMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_FUMADERMMember_094d819b-bbcd-4d98-afaa-74cf32e61a31" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ad77fd2e-36b4-4d87-a9d6-f6729f85de8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_us-gaap_ProductMember_ad77fd2e-36b4-4d87-a9d6-f6729f85de8f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d1374088-2649-4227-b4d7-91755566e003" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bc6277cd-64f0-493c-99c9-3b12fd7e423d" xlink:to="loc_srt_StatementGeographicalAxis_d1374088-2649-4227-b4d7-91755566e003" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d1374088-2649-4227-b4d7-91755566e003_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d1374088-2649-4227-b4d7-91755566e003" xlink:to="loc_srt_SegmentGeographicalDomain_d1374088-2649-4227-b4d7-91755566e003_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_55e94f1d-84f1-41af-aa40-d16d6260e3e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d1374088-2649-4227-b4d7-91755566e003" xlink:to="loc_srt_SegmentGeographicalDomain_55e94f1d-84f1-41af-aa40-d16d6260e3e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b50dcbb7-b1cf-4764-a342-11bf6bcc6abc" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_55e94f1d-84f1-41af-aa40-d16d6260e3e3" xlink:to="loc_country_US_b50dcbb7-b1cf-4764-a342-11bf6bcc6abc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_908bd40c-2139-4980-b26c-b380f01330a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_55e94f1d-84f1-41af-aa40-d16d6260e3e3" xlink:to="loc_us-gaap_NonUsMember_908bd40c-2139-4980-b26c-b380f01330a9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20210331.xsd#ReservesforDiscountsandAllowancesDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="extended" id="ib8089fceabb74c05a0a7c95d75391d28_ReservesforDiscountsandAllowancesDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c755e57-909d-4cd8-9e1a-7828585551eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d1a1c682-79e3-4c95-a869-69b67c24417d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c755e57-909d-4cd8-9e1a-7828585551eb" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_d1a1c682-79e3-4c95-a869-69b67c24417d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_6909042c-82ad-40e9-a60e-96d4bad941eb" xlink:href="biib-20210331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c755e57-909d-4cd8-9e1a-7828585551eb" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_6909042c-82ad-40e9-a60e-96d4bad941eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_936ec3ef-106f-40d5-984e-ac6a81797555" xlink:href="biib-20210331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c755e57-909d-4cd8-9e1a-7828585551eb" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_936ec3ef-106f-40d5-984e-ac6a81797555" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3314970b-703e-4e2b-8c10-ee475a15f8ea" xlink:href="biib-20210331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c755e57-909d-4cd8-9e1a-7828585551eb" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3314970b-703e-4e2b-8c10-ee475a15f8ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_ad8b7b02-2e66-473e-b64e-748e38f2f617" xlink:href="biib-20210331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c755e57-909d-4cd8-9e1a-7828585551eb" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_ad8b7b02-2e66-473e-b64e-748e38f2f617" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_f2c4f04e-cf68-487f-8daa-c72cc2641db0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_948f7c12-4982-44f2-a292-7b0eef44e0c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c755e57-909d-4cd8-9e1a-7828585551eb" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_948f7c12-4982-44f2-a292-7b0eef44e0c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_21cb6140-27ca-48c4-87f4-502af9e658a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_948f7c12-4982-44f2-a292-7b0eef44e0c8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_21cb6140-27ca-48c4-87f4-502af9e658a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_21cb6140-27ca-48c4-87f4-502af9e658a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_21cb6140-27ca-48c4-87f4-502af9e658a1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_21cb6140-27ca-48c4-87f4-502af9e658a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_69811935-27cd-4020-a995-757ee82dd10e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_21cb6140-27ca-48c4-87f4-502af9e658a1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_69811935-27cd-4020-a995-757ee82dd10e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_4de4e79f-1d7c-4f0a-be39-8d4ddf1ffc90" xlink:href="biib-20210331.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_69811935-27cd-4020-a995-757ee82dd10e" xlink:to="loc_biib_ReserveforCashDiscountsMember_4de4e79f-1d7c-4f0a-be39-8d4ddf1ffc90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_2b3846bb-3fc5-4771-8bdd-d83385eae578" xlink:href="biib-20210331.xsd#biib_ContractualAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_69811935-27cd-4020-a995-757ee82dd10e" xlink:to="loc_biib_ContractualAdjustmentsMember_2b3846bb-3fc5-4771-8bdd-d83385eae578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_1449115b-d382-47c0-86ad-d5ba6cf0c285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_69811935-27cd-4020-a995-757ee82dd10e" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_1449115b-d382-47c0-86ad-d5ba6cf0c285" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20210331.xsd#ReservesforDiscountsandAllowancesDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="extended" id="i436301018a07439fb035816661a0d711_ReservesforDiscountsandAllowancesDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_20aacd4d-c4cd-498f-b3d9-df810928da29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_709d11b0-6134-4d87-a6b0-8d2517747dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20aacd4d-c4cd-498f-b3d9-df810928da29" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_709d11b0-6134-4d87-a6b0-8d2517747dbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_45af5299-39c3-4a2c-8bf0-0fbcf49d3e41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_20aacd4d-c4cd-498f-b3d9-df810928da29" xlink:to="loc_us-gaap_StatementTable_45af5299-39c3-4a2c-8bf0-0fbcf49d3e41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_33e9124f-dd9f-4d6f-a024-4539d163921f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_45af5299-39c3-4a2c-8bf0-0fbcf49d3e41" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_33e9124f-dd9f-4d6f-a024-4539d163921f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_33e9124f-dd9f-4d6f-a024-4539d163921f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_33e9124f-dd9f-4d6f-a024-4539d163921f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_33e9124f-dd9f-4d6f-a024-4539d163921f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_51d8831c-f2ca-458e-ad06-a49483087a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_33e9124f-dd9f-4d6f-a024-4539d163921f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_51d8831c-f2ca-458e-ad06-a49483087a0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_b95fb5a8-198d-445d-9e8f-2db7136b9a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_51d8831c-f2ca-458e-ad06-a49483087a0c" xlink:to="loc_us-gaap_AccountsReceivableMember_b95fb5a8-198d-445d-9e8f-2db7136b9a05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_d19d1a6d-7e9b-4221-bbdc-1c948485aa6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_51d8831c-f2ca-458e-ad06-a49483087a0c" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_d19d1a6d-7e9b-4221-bbdc-1c948485aa6b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#RevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended" id="i098e27d09c2a419facfb515a028eee0a_RevenuesfromAntiCD20TherapeuticProgramsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0df9aa69-2fce-4043-a07c-18800916721a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_55f4cd4b-b3ba-4ee2-890f-e8759445021e" xlink:href="biib-20210331.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0df9aa69-2fce-4043-a07c-18800916721a" xlink:to="loc_biib_ShareOfCoPromotionProfits_55f4cd4b-b3ba-4ee2-890f-e8759445021e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_4e427326-b32e-4ded-b4df-defa8868595d" xlink:href="biib-20210331.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0df9aa69-2fce-4043-a07c-18800916721a" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_4e427326-b32e-4ded-b4df-defa8868595d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_82a2381a-cfd1-4000-8178-d8d85a6d7000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0df9aa69-2fce-4043-a07c-18800916721a" xlink:to="loc_us-gaap_Revenues_82a2381a-cfd1-4000-8178-d8d85a6d7000" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1b361010-acb1-454f-b7d9-0f2e727d89d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0df9aa69-2fce-4043-a07c-18800916721a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1b361010-acb1-454f-b7d9-0f2e727d89d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f0636687-dc99-4a70-9f52-085de926e858" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1b361010-acb1-454f-b7d9-0f2e727d89d0" xlink:to="loc_srt_ProductOrServiceAxis_f0636687-dc99-4a70-9f52-085de926e858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f0636687-dc99-4a70-9f52-085de926e858_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f0636687-dc99-4a70-9f52-085de926e858" xlink:to="loc_srt_ProductsAndServicesDomain_f0636687-dc99-4a70-9f52-085de926e858_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_76f36cd5-577a-4cb4-ad12-63010a224885" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f0636687-dc99-4a70-9f52-085de926e858" xlink:to="loc_srt_ProductsAndServicesDomain_76f36cd5-577a-4cb4-ad12-63010a224885" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_2c1e47aa-9842-4c76-a97f-4b189c476616" xlink:href="biib-20210331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_76f36cd5-577a-4cb4-ad12-63010a224885" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_2c1e47aa-9842-4c76-a97f-4b189c476616" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0610bf6e-3536-4646-9dd7-8fe879fcf397" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1b361010-acb1-454f-b7d9-0f2e727d89d0" xlink:to="loc_srt_MajorCustomersAxis_0610bf6e-3536-4646-9dd7-8fe879fcf397" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0610bf6e-3536-4646-9dd7-8fe879fcf397_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0610bf6e-3536-4646-9dd7-8fe879fcf397" xlink:to="loc_srt_NameOfMajorCustomerDomain_0610bf6e-3536-4646-9dd7-8fe879fcf397_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_19ca9956-2df5-4aa0-bc25-a4e7db7f79fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0610bf6e-3536-4646-9dd7-8fe879fcf397" xlink:to="loc_srt_NameOfMajorCustomerDomain_19ca9956-2df5-4aa0-bc25-a4e7db7f79fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_9674e8de-0273-4f5c-a1a1-f5a56eb4b975" xlink:href="biib-20210331.xsd#biib_RocheGroupGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_19ca9956-2df5-4aa0-bc25-a4e7db7f79fd" xlink:to="loc_biib_RocheGroupGenentechMember_9674e8de-0273-4f5c-a1a1-f5a56eb4b975" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#OtherRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended" id="i43afe776d0e740ab849482feb2e61f14_OtherRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e0029a92-6161-44f7-9e4b-2de214122aef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4fce2cb9-ba35-45b3-a9be-94318ad915e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e0029a92-6161-44f7-9e4b-2de214122aef" xlink:to="loc_us-gaap_Revenues_4fce2cb9-ba35-45b3-a9be-94318ad915e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e0550b4e-7c4f-46b2-8dd2-06a653a12798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e0029a92-6161-44f7-9e4b-2de214122aef" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e0550b4e-7c4f-46b2-8dd2-06a653a12798" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bf8dc191-67e9-47d9-aed3-4d2ca6bfa0a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e0550b4e-7c4f-46b2-8dd2-06a653a12798" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bf8dc191-67e9-47d9-aed3-4d2ca6bfa0a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf8dc191-67e9-47d9-aed3-4d2ca6bfa0a4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bf8dc191-67e9-47d9-aed3-4d2ca6bfa0a4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf8dc191-67e9-47d9-aed3-4d2ca6bfa0a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1732254f-47d8-452f-b18a-6f526f5b3063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bf8dc191-67e9-47d9-aed3-4d2ca6bfa0a4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1732254f-47d8-452f-b18a-6f526f5b3063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_2611af4c-645c-42a4-82b7-60c8d5399f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1732254f-47d8-452f-b18a-6f526f5b3063" xlink:to="loc_us-gaap_CollaborativeArrangementMember_2611af4c-645c-42a4-82b7-60c8d5399f80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ed7b5aa6-6ae1-45db-b139-fb7d4d312454" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e0550b4e-7c4f-46b2-8dd2-06a653a12798" xlink:to="loc_srt_ProductOrServiceAxis_ed7b5aa6-6ae1-45db-b139-fb7d4d312454" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ed7b5aa6-6ae1-45db-b139-fb7d4d312454_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ed7b5aa6-6ae1-45db-b139-fb7d4d312454" xlink:to="loc_srt_ProductsAndServicesDomain_ed7b5aa6-6ae1-45db-b139-fb7d4d312454_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ddbb3351-fc9b-4b34-a09a-9f4edae8f467" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ed7b5aa6-6ae1-45db-b139-fb7d4d312454" xlink:to="loc_srt_ProductsAndServicesDomain_ddbb3351-fc9b-4b34-a09a-9f4edae8f467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_8f5c311c-c845-410e-a9ed-b21d6e07d6b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddbb3351-fc9b-4b34-a09a-9f4edae8f467" xlink:to="loc_us-gaap_RoyaltyMember_8f5c311c-c845-410e-a9ed-b21d6e07d6b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_2bec92d5-458b-4225-80cf-d52fe6904425" xlink:href="biib-20210331.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddbb3351-fc9b-4b34-a09a-9f4edae8f467" xlink:to="loc_biib_OthercorporaterevenuesMember_2bec92d5-458b-4225-80cf-d52fe6904425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_10034357-1a63-48ee-8eaf-fbe34c04c00f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddbb3351-fc9b-4b34-a09a-9f4edae8f467" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_10034357-1a63-48ee-8eaf-fbe34c04c00f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_5b0ad00e-813b-4170-8394-58bf8847b0e6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e0550b4e-7c4f-46b2-8dd2-06a653a12798" xlink:to="loc_srt_MajorCustomersAxis_5b0ad00e-813b-4170-8394-58bf8847b0e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5b0ad00e-813b-4170-8394-58bf8847b0e6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_5b0ad00e-813b-4170-8394-58bf8847b0e6" xlink:to="loc_srt_NameOfMajorCustomerDomain_5b0ad00e-813b-4170-8394-58bf8847b0e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_81ff6d21-c2af-402c-b226-b923d0c06545" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_5b0ad00e-813b-4170-8394-58bf8847b0e6" xlink:to="loc_srt_NameOfMajorCustomerDomain_81ff6d21-c2af-402c-b226-b923d0c06545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_9e11d5c9-af12-47a8-ae73-08c449f68705" xlink:href="biib-20210331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_81ff6d21-c2af-402c-b226-b923d0c06545" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_9e11d5c9-af12-47a8-ae73-08c449f68705" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_752b0b6e-c20b-45ed-b1a8-dd8386b2f5e2" xlink:href="biib-20210331.xsd#biib_ZINBRYTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_81ff6d21-c2af-402c-b226-b923d0c06545" xlink:to="loc_biib_ZINBRYTAMember_752b0b6e-c20b-45ed-b1a8-dd8386b2f5e2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#RevenuesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended" id="id0bf41e7ea6c4d908356968f71429138_RevenuesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2c4a41cb-ad5c-4e7e-b405-00afbfc18603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_81e08d08-6cbf-4567-b091-4dadf6873a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2c4a41cb-ad5c-4e7e-b405-00afbfc18603" xlink:to="loc_us-gaap_Revenues_81e08d08-6cbf-4567-b091-4dadf6873a39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7864b783-d556-491a-af7e-32c4b214f1f1" xlink:href="biib-20210331.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2c4a41cb-ad5c-4e7e-b405-00afbfc18603" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7864b783-d556-491a-af7e-32c4b214f1f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_9712ebbb-e1b0-41ec-abb0-d9073395f372" xlink:href="biib-20210331.xsd#biib_NumberOfWholesalers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2c4a41cb-ad5c-4e7e-b405-00afbfc18603" xlink:to="loc_biib_NumberOfWholesalers_9712ebbb-e1b0-41ec-abb0-d9073395f372" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3b591225-ee1a-44fc-9b6f-13e50a9be999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2c4a41cb-ad5c-4e7e-b405-00afbfc18603" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3b591225-ee1a-44fc-9b6f-13e50a9be999" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7dad99d8-74a1-4b7e-a2bb-e810167baa1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3b591225-ee1a-44fc-9b6f-13e50a9be999" xlink:to="loc_srt_ProductOrServiceAxis_7dad99d8-74a1-4b7e-a2bb-e810167baa1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7dad99d8-74a1-4b7e-a2bb-e810167baa1f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7dad99d8-74a1-4b7e-a2bb-e810167baa1f" xlink:to="loc_srt_ProductsAndServicesDomain_7dad99d8-74a1-4b7e-a2bb-e810167baa1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f3e25a9c-4ba4-4fad-9291-9d8e03cbd81e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7dad99d8-74a1-4b7e-a2bb-e810167baa1f" xlink:to="loc_srt_ProductsAndServicesDomain_f3e25a9c-4ba4-4fad-9291-9d8e03cbd81e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_6908c6c4-78e9-4665-8066-6127f31838c7" xlink:href="biib-20210331.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f3e25a9c-4ba4-4fad-9291-9d8e03cbd81e" xlink:to="loc_biib_OthercorporaterevenuesMember_6908c6c4-78e9-4665-8066-6127f31838c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_64656d7f-32f3-4ecc-9ecd-24cf15176fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f3e25a9c-4ba4-4fad-9291-9d8e03cbd81e" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_64656d7f-32f3-4ecc-9ecd-24cf15176fa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c3beb28e-26d1-4540-9c98-163853dda374" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3b591225-ee1a-44fc-9b6f-13e50a9be999" xlink:to="loc_srt_MajorCustomersAxis_c3beb28e-26d1-4540-9c98-163853dda374" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c3beb28e-26d1-4540-9c98-163853dda374_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c3beb28e-26d1-4540-9c98-163853dda374" xlink:to="loc_srt_NameOfMajorCustomerDomain_c3beb28e-26d1-4540-9c98-163853dda374_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_950ae2aa-b94c-4325-a663-bfc81b73cf66" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c3beb28e-26d1-4540-9c98-163853dda374" xlink:to="loc_srt_NameOfMajorCustomerDomain_950ae2aa-b94c-4325-a663-bfc81b73cf66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_c7695334-fcb0-43cb-80c6-ef369e514e08" xlink:href="biib-20210331.xsd#biib_DistributorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_950ae2aa-b94c-4325-a663-bfc81b73cf66" xlink:to="loc_biib_DistributorOneMember_c7695334-fcb0-43cb-80c6-ef369e514e08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_29fd46b5-2192-4b44-90f1-5e245f4982ac" xlink:href="biib-20210331.xsd#biib_DistributorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_950ae2aa-b94c-4325-a663-bfc81b73cf66" xlink:to="loc_biib_DistributorTwoMember_29fd46b5-2192-4b44-90f1-5e245f4982ac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20210331.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" id="i17a16d51afe14afb857801dd20bf99a1_Inventory"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20210331.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" id="id4fe7964612640998de9fa576388d893_InventoryTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" id="ic626b53e3114472ca96b02e16dc6e4e7_InventoryDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20210331.xsd#IntangibleAssetsandGoodwill"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended" id="ie690c92929cd400ea173e255d748a965_IntangibleAssetsandGoodwill"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20210331.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended" id="i9b372dccaf914ad1a05ded11861204e3_IntangibleAssetsandGoodwillTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended" id="iee307f1f7d1340b484dd924606e03721_IntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_635b9038-fd28-4e83-a08c-0bde7b5c7914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_635b9038-fd28-4e83-a08c-0bde7b5c7914" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_944cd3eb-7464-4472-a4d0-18d525bb34eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_944cd3eb-7464-4472-a4d0-18d525bb34eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_7316bedd-ecc7-4293-b5b0-ec43e9c014d2" xlink:href="biib-20210331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_7316bedd-ecc7-4293-b5b0-ec43e9c014d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_077adb51-e669-49dd-8cbb-4cf4d5448f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_077adb51-e669-49dd-8cbb-4cf4d5448f5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c6657c63-b1d3-43e8-a445-91d3a96f5754" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c6657c63-b1d3-43e8-a445-91d3a96f5754" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c9c6c82a-27e9-4952-a698-82a49324c73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c9c6c82a-27e9-4952-a698-82a49324c73a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5fd00ae1-aeed-4f8e-9694-37e9da45fc5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5fd00ae1-aeed-4f8e-9694-37e9da45fc5f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_008e8c99-69c4-48d2-88e9-a02a469c2179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_008e8c99-69c4-48d2-88e9-a02a469c2179" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bfc95225-0bda-4a32-a095-0a99a60fa789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bfc95225-0bda-4a32-a095-0a99a60fa789" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7840fbff-6f49-4c3a-960f-09db474db216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7840fbff-6f49-4c3a-960f-09db474db216" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d7f97076-7979-4dbc-be8e-84e200c0efe6" xlink:href="biib-20210331.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d7f97076-7979-4dbc-be8e-84e200c0efe6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_625a65b0-cad3-4563-b362-0263c404e288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_625a65b0-cad3-4563-b362-0263c404e288" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b539f353-def2-4be9-8865-5aec1208d0b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b539f353-def2-4be9-8865-5aec1208d0b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e9b4bd02-6e5a-4885-8003-f07d0b9bdd4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e9b4bd02-6e5a-4885-8003-f07d0b9bdd4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6be94ace-9f32-45dd-ace4-b826b167066c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6be94ace-9f32-45dd-ace4-b826b167066c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_80a53f1b-9eef-4729-867e-f4275478f18a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_80a53f1b-9eef-4729-867e-f4275478f18a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ecebb7ad-8f3b-49f1-a7d1-af2e9123e906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ecebb7ad-8f3b-49f1-a7d1-af2e9123e906" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7cbcbd55-096a-4165-b903-ed53a4a9fa93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7cbcbd55-096a-4165-b903-ed53a4a9fa93" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_b1af87f6-0d93-480e-a084-b6f2f331fb3f" xlink:href="biib-20210331.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_b1af87f6-0d93-480e-a084-b6f2f331fb3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_b1af87f6-0d93-480e-a084-b6f2f331fb3f_default" xlink:href="biib-20210331.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_b1af87f6-0d93-480e-a084-b6f2f331fb3f" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_b1af87f6-0d93-480e-a084-b6f2f331fb3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_8c69cb2a-46af-4ea0-a7ff-a93493b50157" xlink:href="biib-20210331.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_b1af87f6-0d93-480e-a084-b6f2f331fb3f" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_8c69cb2a-46af-4ea0-a7ff-a93493b50157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_43dab68c-45a4-4855-bcc0-0bc9581a7e1d" xlink:href="biib-20210331.xsd#biib_TGNMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_8c69cb2a-46af-4ea0-a7ff-a93493b50157" xlink:to="loc_biib_TGNMember_43dab68c-45a4-4855-bcc0-0bc9581a7e1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember_147ce6b5-5589-4b26-b576-8811ef002f03" xlink:href="biib-20210331.xsd#biib_VixotrigineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_8c69cb2a-46af-4ea0-a7ff-a93493b50157" xlink:to="loc_biib_VixotrigineMember_147ce6b5-5589-4b26-b576-8811ef002f03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_8642efc3-09a9-40ab-865d-2c61517f106a" xlink:href="biib-20210331.xsd#biib_BIIB111Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_8c69cb2a-46af-4ea0-a7ff-a93493b50157" xlink:to="loc_biib_BIIB111Member_8642efc3-09a9-40ab-865d-2c61517f106a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1cb85f51-0197-4684-98d9-4f6bc9e8f888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1cb85f51-0197-4684-98d9-4f6bc9e8f888" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1cb85f51-0197-4684-98d9-4f6bc9e8f888_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1cb85f51-0197-4684-98d9-4f6bc9e8f888" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1cb85f51-0197-4684-98d9-4f6bc9e8f888_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90793bad-b48c-4d91-995b-c9533ba75504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1cb85f51-0197-4684-98d9-4f6bc9e8f888" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90793bad-b48c-4d91-995b-c9533ba75504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_4b94ba04-ef1d-40a8-849b-452565e2dd08" xlink:href="biib-20210331.xsd#biib_NightstarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90793bad-b48c-4d91-995b-c9533ba75504" xlink:to="loc_biib_NightstarMember_4b94ba04-ef1d-40a8-849b-452565e2dd08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f7daa7f0-4bfc-41a3-9b06-b42141f5e3ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f7daa7f0-4bfc-41a3-9b06-b42141f5e3ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7daa7f0-4bfc-41a3-9b06-b42141f5e3ad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f7daa7f0-4bfc-41a3-9b06-b42141f5e3ad" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7daa7f0-4bfc-41a3-9b06-b42141f5e3ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4f0dc1ed-eaec-400f-b68b-4ccca717e16e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f7daa7f0-4bfc-41a3-9b06-b42141f5e3ad" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4f0dc1ed-eaec-400f-b68b-4ccca717e16e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e531bcc6-2a2f-4cad-ad8a-472945e27cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4f0dc1ed-eaec-400f-b68b-4ccca717e16e" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e531bcc6-2a2f-4cad-ad8a-472945e27cf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_61129974-4a4e-4861-87e8-3c95bcbad941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4f0dc1ed-eaec-400f-b68b-4ccca717e16e" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_61129974-4a4e-4861-87e8-3c95bcbad941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43465c44-8b29-4c9d-a2e0-e28216d03a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43465c44-8b29-4c9d-a2e0-e28216d03a8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_43465c44-8b29-4c9d-a2e0-e28216d03a8a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43465c44-8b29-4c9d-a2e0-e28216d03a8a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_43465c44-8b29-4c9d-a2e0-e28216d03a8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ec973424-767f-4dbe-b6bc-bb4801e12ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43465c44-8b29-4c9d-a2e0-e28216d03a8a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ec973424-767f-4dbe-b6bc-bb4801e12ce2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_71801396-a236-4093-bf22-75c6e2e36e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ec973424-767f-4dbe-b6bc-bb4801e12ce2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_71801396-a236-4093-bf22-75c6e2e36e8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_b5984275-baee-4bf0-a8ea-b39872021848" xlink:href="biib-20210331.xsd#biib_OutLicensedPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ec973424-767f-4dbe-b6bc-bb4801e12ce2" xlink:to="loc_biib_OutLicensedPatentsMember_b5984275-baee-4bf0-a8ea-b39872021848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4f42f594-8b4b-4231-ad7b-8bbf45afcd78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ec973424-767f-4dbe-b6bc-bb4801e12ce2" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4f42f594-8b4b-4231-ad7b-8bbf45afcd78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InLicensedPatentsMember_c894ee61-64f6-4790-8182-87e42a1624f0" xlink:href="biib-20210331.xsd#biib_InLicensedPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ec973424-767f-4dbe-b6bc-bb4801e12ce2" xlink:to="loc_biib_InLicensedPatentsMember_c894ee61-64f6-4790-8182-87e42a1624f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7ce7746e-2cda-4f7d-89f7-b8c7cccea586" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:to="loc_srt_ProductOrServiceAxis_7ce7746e-2cda-4f7d-89f7-b8c7cccea586" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7ce7746e-2cda-4f7d-89f7-b8c7cccea586_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7ce7746e-2cda-4f7d-89f7-b8c7cccea586" xlink:to="loc_srt_ProductsAndServicesDomain_7ce7746e-2cda-4f7d-89f7-b8c7cccea586_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4b136c0d-1c18-44f1-ac01-4421ca149110" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7ce7746e-2cda-4f7d-89f7-b8c7cccea586" xlink:to="loc_srt_ProductsAndServicesDomain_4b136c0d-1c18-44f1-ac01-4421ca149110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_dfd106bd-119c-4ccd-b132-dbc4fb331920" xlink:href="biib-20210331.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4b136c0d-1c18-44f1-ac01-4421ca149110" xlink:to="loc_biib_TysabriProductMember_dfd106bd-119c-4ccd-b132-dbc4fb331920" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_75da00d7-65ab-4888-9744-7f5d04de912a" xlink:href="biib-20210331.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4b136c0d-1c18-44f1-ac01-4421ca149110" xlink:to="loc_biib_FumarateMember_75da00d7-65ab-4888-9744-7f5d04de912a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdd31614-ff10-4516-a895-1b024cee0ba2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:to="loc_srt_RangeAxis_fdd31614-ff10-4516-a895-1b024cee0ba2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fdd31614-ff10-4516-a895-1b024cee0ba2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fdd31614-ff10-4516-a895-1b024cee0ba2" xlink:to="loc_srt_RangeMember_fdd31614-ff10-4516-a895-1b024cee0ba2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0350cc23-a49b-45b0-9654-716c9dfc1df2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fdd31614-ff10-4516-a895-1b024cee0ba2" xlink:to="loc_srt_RangeMember_0350cc23-a49b-45b0-9654-716c9dfc1df2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_99b67f61-e9b2-434a-b0a5-ea6af4e5a1d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0350cc23-a49b-45b0-9654-716c9dfc1df2" xlink:to="loc_srt_MinimumMember_99b67f61-e9b2-434a-b0a5-ea6af4e5a1d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0ba85162-ed03-4974-a42f-15d629852f09" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0350cc23-a49b-45b0-9654-716c9dfc1df2" xlink:to="loc_srt_MaximumMember_0ba85162-ed03-4974-a42f-15d629852f09" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="simple" xlink:href="biib-20210331.xsd#IntangibleAssetsandGoodwillDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="extended" id="i81467e03f55a407086bfa4e70039101e_IntangibleAssetsandGoodwillDetails1"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" id="iee9106be486d4f3b8a3106edc5ce2a3f_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i7bb38f1b99fc435286ac13bf8826cf98_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i2332ca161b854305874d415247807722_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff6bad12-4a33-46e8-ae0c-9abb36912d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a5c9e9cc-e17a-4b78-ab5b-03d69c96b523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff6bad12-4a33-46e8-ae0c-9abb36912d5a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a5c9e9cc-e17a-4b78-ab5b-03d69c96b523" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a5c9e9cc-e17a-4b78-ab5b-03d69c96b523" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8229c5ef-3d81-4e6c-8b2c-055916450a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8229c5ef-3d81-4e6c-8b2c-055916450a0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c8dee661-59e8-4c00-8db9-4b82f45ff1b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c8dee661-59e8-4c00-8db9-4b82f45ff1b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_dc57dd30-3205-4499-af91-e768d6970ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_dc57dd30-3205-4499-af91-e768d6970ed2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_501b573b-ae60-411f-8149-75b2bfc2b2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_501b573b-ae60-411f-8149-75b2bfc2b2c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_1c1d6bcc-1872-4a15-8c5d-0985d91df1c3" xlink:href="biib-20210331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_1c1d6bcc-1872-4a15-8c5d-0985d91df1c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_abe2c31f-fe4e-4350-b9c8-c9608e55487a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_abe2c31f-fe4e-4350-b9c8-c9608e55487a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_48e2ec01-0b82-4923-8038-c50b99d7ef47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a5c9e9cc-e17a-4b78-ab5b-03d69c96b523" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_48e2ec01-0b82-4923-8038-c50b99d7ef47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_9eb5bf32-2f3d-4147-b052-ae7c42dbd89e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_48e2ec01-0b82-4923-8038-c50b99d7ef47" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_9eb5bf32-2f3d-4147-b052-ae7c42dbd89e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d9a9d7c-d30f-44ab-bf5c-07899dd5ec15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_48e2ec01-0b82-4923-8038-c50b99d7ef47" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d9a9d7c-d30f-44ab-bf5c-07899dd5ec15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4e5eb49f-c72e-4ddc-a6ea-c5f67e46cb86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_48e2ec01-0b82-4923-8038-c50b99d7ef47" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_4e5eb49f-c72e-4ddc-a6ea-c5f67e46cb86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d595671-59e8-47b1-9467-2199caa5e68d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff6bad12-4a33-46e8-ae0c-9abb36912d5a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d595671-59e8-47b1-9467-2199caa5e68d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_617fab1b-2038-4fb3-9e0b-342d5d5f08bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d595671-59e8-47b1-9467-2199caa5e68d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_617fab1b-2038-4fb3-9e0b-342d5d5f08bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_617fab1b-2038-4fb3-9e0b-342d5d5f08bd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_617fab1b-2038-4fb3-9e0b-342d5d5f08bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_617fab1b-2038-4fb3-9e0b-342d5d5f08bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c630ba2-7b72-411e-bd53-57b540d45a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_617fab1b-2038-4fb3-9e0b-342d5d5f08bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c630ba2-7b72-411e-bd53-57b540d45a57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_de9a62dc-0275-45a4-9905-edc7ef6ed6a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c630ba2-7b72-411e-bd53-57b540d45a57" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_de9a62dc-0275-45a4-9905-edc7ef6ed6a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_34d61fec-f7b0-4f98-9477-de5d3627c0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c630ba2-7b72-411e-bd53-57b540d45a57" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_34d61fec-f7b0-4f98-9477-de5d3627c0e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6ad486b8-65dc-4ea4-ba2d-f1a4fd8bbb4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c630ba2-7b72-411e-bd53-57b540d45a57" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6ad486b8-65dc-4ea4-ba2d-f1a4fd8bbb4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6fa567b7-42a3-4d51-a317-e0e7a29bbb0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d595671-59e8-47b1-9467-2199caa5e68d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6fa567b7-42a3-4d51-a317-e0e7a29bbb0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6fa567b7-42a3-4d51-a317-e0e7a29bbb0e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6fa567b7-42a3-4d51-a317-e0e7a29bbb0e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6fa567b7-42a3-4d51-a317-e0e7a29bbb0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5fc92b9a-d0dd-44fa-88ad-707fc5ca8562" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6fa567b7-42a3-4d51-a317-e0e7a29bbb0e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5fc92b9a-d0dd-44fa-88ad-707fc5ca8562" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f64eba84-d2f6-4dff-ad37-e577565ac086" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5fc92b9a-d0dd-44fa-88ad-707fc5ca8562" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f64eba84-d2f6-4dff-ad37-e577565ac086" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_a008e94b-baff-40ec-8ddc-93e9e178b6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d595671-59e8-47b1-9467-2199caa5e68d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_a008e94b-baff-40ec-8ddc-93e9e178b6bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a008e94b-baff-40ec-8ddc-93e9e178b6bb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_a008e94b-baff-40ec-8ddc-93e9e178b6bb" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a008e94b-baff-40ec-8ddc-93e9e178b6bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f0ae0854-36e1-4588-95cc-0dfeac57e762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_a008e94b-baff-40ec-8ddc-93e9e178b6bb" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f0ae0854-36e1-4588-95cc-0dfeac57e762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6abb203e-303c-4e1d-9448-7f12a7dad17d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f0ae0854-36e1-4588-95cc-0dfeac57e762" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6abb203e-303c-4e1d-9448-7f12a7dad17d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_f35269a0-f3ba-4ff3-80d7-5eb5607d34cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f0ae0854-36e1-4588-95cc-0dfeac57e762" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_f35269a0-f3ba-4ff3-80d7-5eb5607d34cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_2d22dc38-c6c4-4209-a4e5-9efaaf0a1597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f0ae0854-36e1-4588-95cc-0dfeac57e762" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_2d22dc38-c6c4-4209-a4e5-9efaaf0a1597" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" id="i36a23ebfa0c64eec82e087e66b9ec193_FairValueMeasurementsDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_30415afd-4bc5-4f10-ad36-a923946a16d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_201b4c2c-ad8b-40a7-a725-3050c9f233d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_30415afd-4bc5-4f10-ad36-a923946a16d8" xlink:to="loc_us-gaap_AssetImpairmentCharges_201b4c2c-ad8b-40a7-a725-3050c9f233d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ee45bee4-f8f9-45dd-88b1-f1858a4825cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_30415afd-4bc5-4f10-ad36-a923946a16d8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ee45bee4-f8f9-45dd-88b1-f1858a4825cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_236117d5-d4ec-4512-afed-78eab8c81395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_30415afd-4bc5-4f10-ad36-a923946a16d8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_236117d5-d4ec-4512-afed-78eab8c81395" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability_b51617f2-4eff-4de3-90fc-5ddd78eff944" xlink:href="biib-20210331.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_30415afd-4bc5-4f10-ad36-a923946a16d8" xlink:to="loc_biib_TechnologicalAndRegulatorySuccessProbability_b51617f2-4eff-4de3-90fc-5ddd78eff944" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ef4ca3cf-8140-47bc-b716-a1b1e18e3df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_30415afd-4bc5-4f10-ad36-a923946a16d8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ef4ca3cf-8140-47bc-b716-a1b1e18e3df5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_47bcd5db-8342-449f-9dff-6466ed4193ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ef4ca3cf-8140-47bc-b716-a1b1e18e3df5" xlink:to="loc_us-gaap_DebtInstrumentAxis_47bcd5db-8342-449f-9dff-6466ed4193ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_47bcd5db-8342-449f-9dff-6466ed4193ad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_47bcd5db-8342-449f-9dff-6466ed4193ad" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_47bcd5db-8342-449f-9dff-6466ed4193ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4ebb5a4f-9067-4670-8cc3-8fcdc4a78589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_47bcd5db-8342-449f-9dff-6466ed4193ad" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4ebb5a4f-9067-4670-8cc3-8fcdc4a78589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_111a736c-c933-4eb6-97b5-5269ba794ef5" xlink:href="biib-20210331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4ebb5a4f-9067-4670-8cc3-8fcdc4a78589" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_111a736c-c933-4eb6-97b5-5269ba794ef5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_58beb8b8-92ba-46e2-bca4-03469bc54291" xlink:href="biib-20210331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4ebb5a4f-9067-4670-8cc3-8fcdc4a78589" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_58beb8b8-92ba-46e2-bca4-03469bc54291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_a23072e2-0196-4c6c-8c65-ddf804021275" xlink:href="biib-20210331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4ebb5a4f-9067-4670-8cc3-8fcdc4a78589" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_a23072e2-0196-4c6c-8c65-ddf804021275" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_dd154454-e9e1-4acb-a35c-f3cb77a24524" xlink:href="biib-20210331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4ebb5a4f-9067-4670-8cc3-8fcdc4a78589" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_dd154454-e9e1-4acb-a35c-f3cb77a24524" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" id="ibcc3a77baabb48088dae425102244e83_FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aaec7a2-3557-4324-aa5c-a8547a079412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6b2aba01-261e-4f87-bfe4-5870c0a8baad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aaec7a2-3557-4324-aa5c-a8547a079412" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6b2aba01-261e-4f87-bfe4-5870c0a8baad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_2077c340-421f-4b2a-828f-04a6386011ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aaec7a2-3557-4324-aa5c-a8547a079412" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_2077c340-421f-4b2a-828f-04a6386011ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca38140d-7c95-4ef3-a1df-67c666943260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aaec7a2-3557-4324-aa5c-a8547a079412" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca38140d-7c95-4ef3-a1df-67c666943260" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cb651716-a2e6-4225-b2c9-baaec7ea2ac3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca38140d-7c95-4ef3-a1df-67c666943260" xlink:to="loc_srt_RangeAxis_cb651716-a2e6-4225-b2c9-baaec7ea2ac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb651716-a2e6-4225-b2c9-baaec7ea2ac3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cb651716-a2e6-4225-b2c9-baaec7ea2ac3" xlink:to="loc_srt_RangeMember_cb651716-a2e6-4225-b2c9-baaec7ea2ac3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c10d9adf-d1c0-4b88-810b-d4b44e26a7d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cb651716-a2e6-4225-b2c9-baaec7ea2ac3" xlink:to="loc_srt_RangeMember_c10d9adf-d1c0-4b88-810b-d4b44e26a7d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b73ab138-90c3-4038-ad82-dcc179497539" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c10d9adf-d1c0-4b88-810b-d4b44e26a7d7" xlink:to="loc_srt_MinimumMember_b73ab138-90c3-4038-ad82-dcc179497539" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c1f9da5e-61a3-4833-aaf4-348a9f70b1a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c10d9adf-d1c0-4b88-810b-d4b44e26a7d7" xlink:to="loc_srt_MaximumMember_c1f9da5e-61a3-4833-aaf4-348a9f70b1a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_4ddfa75d-c960-4133-a814-ea1ca91f59d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c10d9adf-d1c0-4b88-810b-d4b44e26a7d7" xlink:to="loc_srt_WeightedAverageMember_4ddfa75d-c960-4133-a814-ea1ca91f59d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1b913203-f9e8-416e-a15a-a14553a10288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca38140d-7c95-4ef3-a1df-67c666943260" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1b913203-f9e8-416e-a15a-a14553a10288" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1b913203-f9e8-416e-a15a-a14553a10288_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1b913203-f9e8-416e-a15a-a14553a10288" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1b913203-f9e8-416e-a15a-a14553a10288_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f5b64900-5657-4af5-ac13-e8a3df56c217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1b913203-f9e8-416e-a15a-a14553a10288" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f5b64900-5657-4af5-ac13-e8a3df56c217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_5bb171b9-8069-427f-9e3a-85fa83bf6aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f5b64900-5657-4af5-ac13-e8a3df56c217" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_5bb171b9-8069-427f-9e3a-85fa83bf6aa1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="id1cbe08e92804460907ecfe6fea5f816_FairValueMeasurementsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_03a72d6e-c680-4e4c-8988-5373b5a4f2d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_03a72d6e-c680-4e4c-8988-5373b5a4f2d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_a150c421-480c-446d-a4a0-14a47537f9e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:to="loc_us-gaap_NotesPayable_a150c421-480c-446d-a4a0-14a47537f9e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_d8af24c1-a337-46b6-a06b-97ad9ef94092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:to="loc_us-gaap_DebtInstrumentFairValue_d8af24c1-a337-46b6-a06b-97ad9ef94092" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7f62a801-d2e4-47fc-a05c-cdbcaf1c6742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7f62a801-d2e4-47fc-a05c-cdbcaf1c6742" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6b70b691-5125-4d1d-83ce-ea0f1ff122ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6b70b691-5125-4d1d-83ce-ea0f1ff122ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_53e7e43c-3337-4b81-9d50-5309e4e2e261" xlink:href="biib-20210331.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:to="loc_biib_LongTermDebtExchangedAmount_53e7e43c-3337-4b81-9d50-5309e4e2e261" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e88af41b-e32d-40b0-a5c5-14163f4f8367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:to="loc_us-gaap_DebtInstrumentTable_e88af41b-e32d-40b0-a5c5-14163f4f8367" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_05a249f9-683b-494a-97de-765dae533beb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e88af41b-e32d-40b0-a5c5-14163f4f8367" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_05a249f9-683b-494a-97de-765dae533beb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_05a249f9-683b-494a-97de-765dae533beb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_05a249f9-683b-494a-97de-765dae533beb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_05a249f9-683b-494a-97de-765dae533beb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_758a7607-f91e-4ddb-952c-be4181ddacdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_05a249f9-683b-494a-97de-765dae533beb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_758a7607-f91e-4ddb-952c-be4181ddacdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_b0725a2e-899b-467c-9cc9-bbf9ef5c45e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_758a7607-f91e-4ddb-952c-be4181ddacdc" xlink:to="loc_us-gaap_SeniorNotesMember_b0725a2e-899b-467c-9cc9-bbf9ef5c45e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_18c65309-e5a6-46a9-a0f6-e2671a66b43c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e88af41b-e32d-40b0-a5c5-14163f4f8367" xlink:to="loc_us-gaap_DebtInstrumentAxis_18c65309-e5a6-46a9-a0f6-e2671a66b43c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_18c65309-e5a6-46a9-a0f6-e2671a66b43c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_18c65309-e5a6-46a9-a0f6-e2671a66b43c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_18c65309-e5a6-46a9-a0f6-e2671a66b43c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_18c65309-e5a6-46a9-a0f6-e2671a66b43c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_0c56a8b6-3fd5-4524-acc8-535b9064c2df" xlink:href="biib-20210331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_0c56a8b6-3fd5-4524-acc8-535b9064c2df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_04dfc252-617a-41c9-8306-97c42209c83f" xlink:href="biib-20210331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_04dfc252-617a-41c9-8306-97c42209c83f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8ecea23a-ee13-4b36-a72f-0eded39f9054" xlink:href="biib-20210331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8ecea23a-ee13-4b36-a72f-0eded39f9054" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_17ad5f1c-4ec5-4eea-be37-f99e8c5cb91a" xlink:href="biib-20210331.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_17ad5f1c-4ec5-4eea-be37-f99e8c5cb91a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_5abe4805-7510-4068-a8ff-994baf56bebe" xlink:href="biib-20210331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_5abe4805-7510-4068-a8ff-994baf56bebe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_8a6313f3-308a-4ee5-9e20-858b5307907e" xlink:href="biib-20210331.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_8a6313f3-308a-4ee5-9e20-858b5307907e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_512d5dd0-33d8-4899-9b1a-82e8e1b509f6" xlink:href="biib-20210331.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_512d5dd0-33d8-4899-9b1a-82e8e1b509f6" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" id="ideb2db5d1fdf40749a4a68d98d02b453_FairValueMeasurementsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_39e62d41-6d6e-4ef6-a48f-ab85a461cacf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c8ee5935-5d24-468c-ada1-2b6fa7902de3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_39e62d41-6d6e-4ef6-a48f-ab85a461cacf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c8ee5935-5d24-468c-ada1-2b6fa7902de3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_42814434-7a83-4df9-8c28-ac5f0b09e64c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_39e62d41-6d6e-4ef6-a48f-ab85a461cacf" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_42814434-7a83-4df9-8c28-ac5f0b09e64c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_967c125c-a42c-4877-96fc-3d0a71f1534c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_82d3f7d1-09b9-405c-88cb-e6e17f68a856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_39e62d41-6d6e-4ef6-a48f-ab85a461cacf" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_82d3f7d1-09b9-405c-88cb-e6e17f68a856" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_18b82669-313e-479e-8355-be7ee0a81718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_82d3f7d1-09b9-405c-88cb-e6e17f68a856" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_18b82669-313e-479e-8355-be7ee0a81718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_18b82669-313e-479e-8355-be7ee0a81718_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_18b82669-313e-479e-8355-be7ee0a81718" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_18b82669-313e-479e-8355-be7ee0a81718_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5fce46c-a1cb-406e-8dbf-f99a42eefa57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_18b82669-313e-479e-8355-be7ee0a81718" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5fce46c-a1cb-406e-8dbf-f99a42eefa57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_90166c7d-ac8f-45d1-ad77-1a77aa184ef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5fce46c-a1cb-406e-8dbf-f99a42eefa57" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_90166c7d-ac8f-45d1-ad77-1a77aa184ef0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" id="i004374a776b742f0bf3b991e15ca5b7a_FinancialInstruments"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" id="ib112eb6222f6484c8eab981c63591892_FinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" id="id26133e9c587458a8a36483c0e174a42_FinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_73e08b87-8b04-4ffc-a0ae-3224cd91d411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_993bf73a-ccc1-43ef-bfc2-9b6c656591dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_73e08b87-8b04-4ffc-a0ae-3224cd91d411" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_993bf73a-ccc1-43ef-bfc2-9b6c656591dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_de83e70d-dbf2-4ef9-bfff-823944e548b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_993bf73a-ccc1-43ef-bfc2-9b6c656591dd" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_de83e70d-dbf2-4ef9-bfff-823944e548b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9a1539f3-9d62-4db6-95e0-56d97498b746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_73e08b87-8b04-4ffc-a0ae-3224cd91d411" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9a1539f3-9d62-4db6-95e0-56d97498b746" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c0ae14a0-0db0-4091-b1a4-7d17571f226a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9a1539f3-9d62-4db6-95e0-56d97498b746" xlink:to="loc_us-gaap_InvestmentTypeAxis_c0ae14a0-0db0-4091-b1a4-7d17571f226a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c0ae14a0-0db0-4091-b1a4-7d17571f226a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_c0ae14a0-0db0-4091-b1a4-7d17571f226a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c0ae14a0-0db0-4091-b1a4-7d17571f226a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b9e3e2ff-ea03-49e3-9a0f-3e6192c5bcba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_c0ae14a0-0db0-4091-b1a4-7d17571f226a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b9e3e2ff-ea03-49e3-9a0f-3e6192c5bcba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f8170340-943a-4074-8968-71bdbafd526d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b9e3e2ff-ea03-49e3-9a0f-3e6192c5bcba" xlink:to="loc_us-gaap_CommercialPaperMember_f8170340-943a-4074-8968-71bdbafd526d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_f6f36e9c-48e9-445e-b53c-816f73e761a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b9e3e2ff-ea03-49e3-9a0f-3e6192c5bcba" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_f6f36e9c-48e9-445e-b53c-816f73e761a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2ba8d034-dc15-40b2-8c74-d258a5e6d07e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b9e3e2ff-ea03-49e3-9a0f-3e6192c5bcba" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2ba8d034-dc15-40b2-8c74-d258a5e6d07e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_0490c375-9c40-41e3-93be-1bec6b571221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b9e3e2ff-ea03-49e3-9a0f-3e6192c5bcba" xlink:to="loc_us-gaap_DebtSecuritiesMember_0490c375-9c40-41e3-93be-1bec6b571221" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended" id="i2ef760d16e46410986e2d198d5378333_FinancialInstrumentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_672ffdc4-9128-4eb4-bf3f-70a5eaa1ac04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_672ffdc4-9128-4eb4-bf3f-70a5eaa1ac04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6aae065f-36e3-4a1a-a67c-47e55b5f4956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6aae065f-36e3-4a1a-a67c-47e55b5f4956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e25e71db-26fc-4fcc-9765-5a0056d7cc8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e25e71db-26fc-4fcc-9765-5a0056d7cc8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d04fa36b-bb60-40fd-a7f4-46cd547eccef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d04fa36b-bb60-40fd-a7f4-46cd547eccef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_7eb8deb3-3b7f-4cb6-a2c4-f84a761b8d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_us-gaap_AvailableForSaleSecurities_7eb8deb3-3b7f-4cb6-a2c4-f84a761b8d41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_4e71a57f-582c-4324-b622-c5b1af0c189c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_4e71a57f-582c-4324-b622-c5b1af0c189c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_ae80cf56-a2de-464f-a860-926472d8da3b" xlink:href="biib-20210331.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_ae80cf56-a2de-464f-a860-926472d8da3b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_835245de-c179-4dee-a20b-9be12051d0fc" xlink:href="biib-20210331.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_835245de-c179-4dee-a20b-9be12051d0fc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_9e2f0b17-21bf-4410-bdae-df07baf0d40e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_9e2f0b17-21bf-4410-bdae-df07baf0d40e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9ec7642-8970-46f0-9885-0bb1f7bd6915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9ec7642-8970-46f0-9885-0bb1f7bd6915" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5d22cf75-2bc4-41d5-ac69-f31913e5f774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9ec7642-8970-46f0-9885-0bb1f7bd6915" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5d22cf75-2bc4-41d5-ac69-f31913e5f774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5d22cf75-2bc4-41d5-ac69-f31913e5f774_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5d22cf75-2bc4-41d5-ac69-f31913e5f774" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5d22cf75-2bc4-41d5-ac69-f31913e5f774_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_791901c2-6503-4b6d-82fc-a55fb50983cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5d22cf75-2bc4-41d5-ac69-f31913e5f774" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_791901c2-6503-4b6d-82fc-a55fb50983cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_a4c7c466-15fd-45a1-a4dd-42283f887ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_791901c2-6503-4b6d-82fc-a55fb50983cd" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_a4c7c466-15fd-45a1-a4dd-42283f887ea7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_e3413b06-7fd1-4bba-8c22-e1bd7a842766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_791901c2-6503-4b6d-82fc-a55fb50983cd" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_e3413b06-7fd1-4bba-8c22-e1bd7a842766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6692065a-bc73-48c9-b11f-6df6d51b6ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9ec7642-8970-46f0-9885-0bb1f7bd6915" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6692065a-bc73-48c9-b11f-6df6d51b6ef8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6692065a-bc73-48c9-b11f-6df6d51b6ef8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6692065a-bc73-48c9-b11f-6df6d51b6ef8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6692065a-bc73-48c9-b11f-6df6d51b6ef8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6692065a-bc73-48c9-b11f-6df6d51b6ef8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_60c8b927-b2b2-4f29-8b53-4fdabe50d7e3" xlink:href="biib-20210331.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_60c8b927-b2b2-4f29-8b53-4fdabe50d7e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_9e651321-1c5f-4489-a457-c74fda3f86d4" xlink:href="biib-20210331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_9e651321-1c5f-4489-a457-c74fda3f86d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_21352c2e-a193-4e9d-b7f2-33b1a8f5d3dd" xlink:href="biib-20210331.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_21352c2e-a193-4e9d-b7f2-33b1a8f5d3dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_9536a68f-52b6-4245-834c-4184ae397496" xlink:href="biib-20210331.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_9536a68f-52b6-4245-834c-4184ae397496" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_baad85bd-26f8-4735-87d0-c000f8c978e7" xlink:href="biib-20210331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_baad85bd-26f8-4735-87d0-c000f8c978e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_a56f9318-1611-47b7-9a00-b2162a46ab12" xlink:href="biib-20210331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_a56f9318-1611-47b7-9a00-b2162a46ab12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_5e260895-f6a6-4e78-b5d0-e5e70e46300f" xlink:href="biib-20210331.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_EquitySecuritiesCurrentMember_5e260895-f6a6-4e78-b5d0-e5e70e46300f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_839fd711-57a9-4345-87f2-e486da42d9af" xlink:href="biib-20210331.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_839fd711-57a9-4345-87f2-e486da42d9af" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" id="i611e5fc0dfe7436cae923f479993bbac_FinancialInstrumentsDetails2"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsDetails3"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" id="i7f6723cf4f794ac9a64867684619a480_FinancialInstrumentsDetails3"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" id="i68aef690d83e4a7291aa3cdf2fa3d1b5_FinancialInstrumentsDetailsTextual"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" id="i9db84cb6e1324d99b320905445b7d146_FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_303e82ea-d3cc-453d-8a80-de0adcfb62a8" xlink:href="biib-20210331.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_biib_StrategicInvestmentPortfolio_303e82ea-d3cc-453d-8a80-de0adcfb62a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_b90bb604-937b-4d4c-aab3-47f09a0d4fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_b90bb604-937b-4d4c-aab3-47f09a0d4fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Investmentincommonstocksharespurchased_0999a113-c4a8-43e0-82d2-b8836ddd0487" xlink:href="biib-20210331.xsd#biib_Investmentincommonstocksharespurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_biib_Investmentincommonstocksharespurchased_0999a113-c4a8-43e0-82d2-b8836ddd0487" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_0a76c297-79d7-40d1-b7da-b9367f7844ab" xlink:href="biib-20210331.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_biib_CollaborationAgreementTerm_0a76c297-79d7-40d1-b7da-b9367f7844ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_c4cb719b-317d-48d9-a5c4-03480849e53a" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_c4cb719b-317d-48d9-a5c4-03480849e53a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_a3db4bde-f19e-4e4b-b502-2191eee3dd89" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_a3db4bde-f19e-4e4b-b502-2191eee3dd89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_dad23362-579a-4dc7-b232-24c42e578a2c" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_dad23362-579a-4dc7-b232-24c42e578a2c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DividendYieldPercentage_33c3273e-ea1b-43a3-b624-12bbeb93ae41" xlink:href="biib-20210331.xsd#biib_DividendYieldPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_biib_DividendYieldPercentage_33c3273e-ea1b-43a3-b624-12bbeb93ae41" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6649c39d-84f9-4514-acf2-19030a24eb57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6649c39d-84f9-4514-acf2-19030a24eb57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_029a7c68-dea5-4639-b762-25fa883d389d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6649c39d-84f9-4514-acf2-19030a24eb57" xlink:to="loc_dei_LegalEntityAxis_029a7c68-dea5-4639-b762-25fa883d389d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_029a7c68-dea5-4639-b762-25fa883d389d_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_029a7c68-dea5-4639-b762-25fa883d389d" xlink:to="loc_dei_EntityDomain_029a7c68-dea5-4639-b762-25fa883d389d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1dd99152-9300-4a20-81cd-1e9fc77e5dd7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_029a7c68-dea5-4639-b762-25fa883d389d" xlink:to="loc_dei_EntityDomain_1dd99152-9300-4a20-81cd-1e9fc77e5dd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_9f317a51-7467-4c9c-ab4a-648bbf41966e" xlink:href="biib-20210331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1dd99152-9300-4a20-81cd-1e9fc77e5dd7" xlink:to="loc_biib_DenaliTherapeuticsIncMember_9f317a51-7467-4c9c-ab4a-648bbf41966e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_aa7e2528-19eb-446c-90f3-d502665e8792" xlink:href="biib-20210331.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1dd99152-9300-4a20-81cd-1e9fc77e5dd7" xlink:to="loc_biib_SangamoCommonStockMember_aa7e2528-19eb-446c-90f3-d502665e8792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1857ef52-978f-48c0-9406-0d728302ddea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6649c39d-84f9-4514-acf2-19030a24eb57" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1857ef52-978f-48c0-9406-0d728302ddea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1857ef52-978f-48c0-9406-0d728302ddea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1857ef52-978f-48c0-9406-0d728302ddea" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1857ef52-978f-48c0-9406-0d728302ddea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d153824f-6b8d-4471-9300-895bf05788b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1857ef52-978f-48c0-9406-0d728302ddea" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d153824f-6b8d-4471-9300-895bf05788b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_abbab9f2-c225-4c8f-b321-5633619d7726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d153824f-6b8d-4471-9300-895bf05788b4" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_abbab9f2-c225-4c8f-b321-5633619d7726" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_1583f494-aca3-48b8-8a35-f4674a38f870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d153824f-6b8d-4471-9300-895bf05788b4" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_1583f494-aca3-48b8-8a35-f4674a38f870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6a81753e-4ece-436a-80cc-9d6b84b28272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6649c39d-84f9-4514-acf2-19030a24eb57" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6a81753e-4ece-436a-80cc-9d6b84b28272" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a81753e-4ece-436a-80cc-9d6b84b28272_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6a81753e-4ece-436a-80cc-9d6b84b28272" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a81753e-4ece-436a-80cc-9d6b84b28272_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_586be095-aea8-4c97-95cf-c68beccb9547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6a81753e-4ece-436a-80cc-9d6b84b28272" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_586be095-aea8-4c97-95cf-c68beccb9547" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_2c09d54e-4d71-4d5d-be98-30cbb55370dd" xlink:href="biib-20210331.xsd#biib_StrategicInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_586be095-aea8-4c97-95cf-c68beccb9547" xlink:to="loc_biib_StrategicInvestmentsMember_2c09d54e-4d71-4d5d-be98-30cbb55370dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_92c18ed6-ec82-4adb-aa67-e8d0f59cd279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6649c39d-84f9-4514-acf2-19030a24eb57" xlink:to="loc_us-gaap_TypeOfArrangementAxis_92c18ed6-ec82-4adb-aa67-e8d0f59cd279" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92c18ed6-ec82-4adb-aa67-e8d0f59cd279_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92c18ed6-ec82-4adb-aa67-e8d0f59cd279" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92c18ed6-ec82-4adb-aa67-e8d0f59cd279_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_278fa430-7521-40a3-9249-ba03ce7572ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92c18ed6-ec82-4adb-aa67-e8d0f59cd279" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_278fa430-7521-40a3-9249-ba03ce7572ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_a8ddd493-674f-4403-856a-3d052de3de7c" xlink:href="biib-20210331.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_278fa430-7521-40a3-9249-ba03ce7572ec" xlink:to="loc_biib_SageTherapeuticsIncMember_a8ddd493-674f-4403-856a-3d052de3de7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_3b50925a-0de4-46ad-a39a-f1d40622bf90" xlink:href="biib-20210331.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_278fa430-7521-40a3-9249-ba03ce7572ec" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_3b50925a-0de4-46ad-a39a-f1d40622bf90" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20210331.xsd#DerivativeInstruments"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" id="iaf93288c399a40b99619134c6343260e_DerivativeInstruments"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20210331.xsd#DerivativeInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" id="i76a795fb92cc4b289d22539bc58affc4_DerivativeInstrumentsTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#DerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" id="i6b8f9ba6ffdb42bfac45f9270af89e26_DerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_46e0d141-6c35-4575-a630-e7114e7c0062" xlink:href="biib-20210331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_46e0d141-6c35-4575-a630-e7114e7c0062" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_04cf9fec-3ecf-43b0-90a1-dd85fd690934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_04cf9fec-3ecf-43b0-90a1-dd85fd690934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b7e3aa70-73bb-4c94-ac48-43d7cccc332c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b7e3aa70-73bb-4c94-ac48-43d7cccc332c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3bb01cc2-1343-4daa-83b3-9be769f1f84b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3bb01cc2-1343-4daa-83b3-9be769f1f84b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2a884ced-f21b-44fa-aeee-8baa8624c0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2a884ced-f21b-44fa-aeee-8baa8624c0cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_ec871ffd-f909-43b0-8827-4357a2554a42" xlink:href="biib-20210331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_ec871ffd-f909-43b0-8827-4357a2554a42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b810a145-de99-42d0-99fa-6f51be634177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b810a145-de99-42d0-99fa-6f51be634177" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_d88ff7c2-8ea6-49d9-9785-ea6a9152d375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_d88ff7c2-8ea6-49d9-9785-ea6a9152d375" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_cd472677-7f86-44ea-96b6-a50b47c97881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_DerivativeTermOfContract_cd472677-7f86-44ea-96b6-a50b47c97881" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_72176000-99a3-489c-a3f9-0e516c57cf8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_72176000-99a3-489c-a3f9-0e516c57cf8f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_796a0082-7c4f-4469-9f81-da0e49cb5914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_796a0082-7c4f-4469-9f81-da0e49cb5914" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_bdeaa2b8-71e1-4376-b60e-be5e2cd38293" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_bdeaa2b8-71e1-4376-b60e-be5e2cd38293" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_014fcd8e-71c2-4b4c-aefb-770982f5fb0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_014fcd8e-71c2-4b4c-aefb-770982f5fb0c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_cd5e994e-a354-4021-9f73-a8fffa13b448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_cd5e994e-a354-4021-9f73-a8fffa13b448" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_84f25867-86c0-413d-a310-83b0491cc826" xlink:href="biib-20210331.xsd#biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_84f25867-86c0-413d-a310-83b0491cc826" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_d457ba22-a623-4344-9542-66094d67dbd4" xlink:href="biib-20210331.xsd#biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_d457ba22-a623-4344-9542-66094d67dbd4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_465c42fb-5557-4d9a-bbe2-c9de58ef1cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_465c42fb-5557-4d9a-bbe2-c9de58ef1cfe" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_4dbc47aa-5103-4b9f-8143-4e0878c9abac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_4dbc47aa-5103-4b9f-8143-4e0878c9abac" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_477b2f7c-e0c4-449b-8e70-616816855b8e" xlink:href="biib-20210331.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_477b2f7c-e0c4-449b-8e70-616816855b8e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_afbe1730-657c-4ec8-ab2c-9aae6c75c696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_afbe1730-657c-4ec8-ab2c-9aae6c75c696" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_7f2ab22a-462c-408a-85a6-140868b47802" xlink:href="biib-20210331.xsd#biib_DerivativeMaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_biib_DerivativeMaturityAxis_7f2ab22a-462c-408a-85a6-140868b47802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_7f2ab22a-462c-408a-85a6-140868b47802_default" xlink:href="biib-20210331.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_7f2ab22a-462c-408a-85a6-140868b47802" xlink:to="loc_biib_DerivativeMaturityDomain_7f2ab22a-462c-408a-85a6-140868b47802_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_8503ac08-df0f-44b9-8f85-691ed488742c" xlink:href="biib-20210331.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_7f2ab22a-462c-408a-85a6-140868b47802" xlink:to="loc_biib_DerivativeMaturityDomain_8503ac08-df0f-44b9-8f85-691ed488742c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_f0f8d734-a4d3-4e29-80d6-9e96da90af72" xlink:href="biib-20210331.xsd#biib_ShorttermderivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_8503ac08-df0f-44b9-8f85-691ed488742c" xlink:to="loc_biib_ShorttermderivativeMember_f0f8d734-a4d3-4e29-80d6-9e96da90af72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_67606d0f-3813-4040-a00d-1bd034bd49ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_67606d0f-3813-4040-a00d-1bd034bd49ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_67606d0f-3813-4040-a00d-1bd034bd49ce_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_67606d0f-3813-4040-a00d-1bd034bd49ce" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_67606d0f-3813-4040-a00d-1bd034bd49ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_55b931d8-cc39-4773-b327-d28744b70a53" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_67606d0f-3813-4040-a00d-1bd034bd49ce" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_55b931d8-cc39-4773-b327-d28744b70a53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_965d5404-c5e7-4732-8952-beef162c04b4" xlink:href="biib-20210331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_55b931d8-cc39-4773-b327-d28744b70a53" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_965d5404-c5e7-4732-8952-beef162c04b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aca86bc1-bd9c-497c-878f-c220fe68345c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_us-gaap_DebtInstrumentAxis_aca86bc1-bd9c-497c-878f-c220fe68345c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aca86bc1-bd9c-497c-878f-c220fe68345c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_aca86bc1-bd9c-497c-878f-c220fe68345c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aca86bc1-bd9c-497c-878f-c220fe68345c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0448e0f8-0fb7-4469-8ef3-f9e0bd330464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_aca86bc1-bd9c-497c-878f-c220fe68345c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0448e0f8-0fb7-4469-8ef3-f9e0bd330464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_2a844466-7f6f-43d1-8ea5-75a89e4c2e8f" xlink:href="biib-20210331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0448e0f8-0fb7-4469-8ef3-f9e0bd330464" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_2a844466-7f6f-43d1-8ea5-75a89e4c2e8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_cea3c84e-502a-4d01-89f9-297b895c0905" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_srt_CurrencyAxis_cea3c84e-502a-4d01-89f9-297b895c0905" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_cea3c84e-502a-4d01-89f9-297b895c0905_default" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_cea3c84e-502a-4d01-89f9-297b895c0905" xlink:to="loc_currency_AllCurrenciesDomain_cea3c84e-502a-4d01-89f9-297b895c0905_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_70b09e01-1630-4802-aa2b-ce2f832ee36d" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_cea3c84e-502a-4d01-89f9-297b895c0905" xlink:to="loc_currency_AllCurrenciesDomain_70b09e01-1630-4802-aa2b-ce2f832ee36d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_459c969c-c59b-4d7c-97b3-bb762c56e194" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_70b09e01-1630-4802-aa2b-ce2f832ee36d" xlink:to="loc_currency_EUR_459c969c-c59b-4d7c-97b3-bb762c56e194" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_85a21282-d921-463c-bd86-a826661e5eaf" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_70b09e01-1630-4802-aa2b-ce2f832ee36d" xlink:to="loc_currency_GBP_85a21282-d921-463c-bd86-a826661e5eaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_65a49908-2bce-4129-9d64-bab15f74ce18" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_70b09e01-1630-4802-aa2b-ce2f832ee36d" xlink:to="loc_currency_CHF_65a49908-2bce-4129-9d64-bab15f74ce18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_b8b4ae53-8601-465b-b745-6268142bb8ff" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_JPY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_70b09e01-1630-4802-aa2b-ce2f832ee36d" xlink:to="loc_currency_JPY_b8b4ae53-8601-465b-b745-6268142bb8ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_61c18e4b-067d-4f9d-b793-6d1f4590444a" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CAD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_70b09e01-1630-4802-aa2b-ce2f832ee36d" xlink:to="loc_currency_CAD_61c18e4b-067d-4f9d-b793-6d1f4590444a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4531c67a-f562-40e7-9931-d72547c014dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4531c67a-f562-40e7-9931-d72547c014dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4531c67a-f562-40e7-9931-d72547c014dc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4531c67a-f562-40e7-9931-d72547c014dc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4531c67a-f562-40e7-9931-d72547c014dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0c3c130f-7daa-46a3-90d4-eb96334cd175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4531c67a-f562-40e7-9931-d72547c014dc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0c3c130f-7daa-46a3-90d4-eb96334cd175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_1efa6b4e-7a32-4159-b91a-ad9da8a81fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c3c130f-7daa-46a3-90d4-eb96334cd175" xlink:to="loc_us-gaap_InterestExpenseMember_1efa6b4e-7a32-4159-b91a-ad9da8a81fc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_69fcca4f-aad7-4dbc-ab5f-ec0948ddba5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c3c130f-7daa-46a3-90d4-eb96334cd175" xlink:to="loc_us-gaap_SalesMember_69fcca4f-aad7-4dbc-ab5f-ec0948ddba5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_89f6cc28-adf8-4fc7-8fd4-84060706dc2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c3c130f-7daa-46a3-90d4-eb96334cd175" xlink:to="loc_us-gaap_OperatingExpenseMember_89f6cc28-adf8-4fc7-8fd4-84060706dc2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6facd026-6370-405f-8eca-85f37f2b5133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c3c130f-7daa-46a3-90d4-eb96334cd175" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6facd026-6370-405f-8eca-85f37f2b5133" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f5e9a480-f913-4b48-ac3c-adb194c64867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f5e9a480-f913-4b48-ac3c-adb194c64867" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f5e9a480-f913-4b48-ac3c-adb194c64867_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f5e9a480-f913-4b48-ac3c-adb194c64867" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f5e9a480-f913-4b48-ac3c-adb194c64867_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_925e2d7a-30bb-4b17-8e14-eba69e8c771f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f5e9a480-f913-4b48-ac3c-adb194c64867" xlink:to="loc_us-gaap_HedgingRelationshipDomain_925e2d7a-30bb-4b17-8e14-eba69e8c771f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9b955e14-4e25-4e19-bb4f-d10113866e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_925e2d7a-30bb-4b17-8e14-eba69e8c771f" xlink:to="loc_us-gaap_CashFlowHedgingMember_9b955e14-4e25-4e19-bb4f-d10113866e03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_1d98a98a-0273-4cf1-8133-7dd0722718dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_925e2d7a-30bb-4b17-8e14-eba69e8c771f" xlink:to="loc_us-gaap_FairValueHedgingMember_1d98a98a-0273-4cf1-8133-7dd0722718dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_b117db85-825e-4f0c-a444-eb871165760b" xlink:href="biib-20210331.xsd#biib_CashflowsrevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_925e2d7a-30bb-4b17-8e14-eba69e8c771f" xlink:to="loc_biib_CashflowsrevenueMember_b117db85-825e-4f0c-a444-eb871165760b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_eb069495-68b6-4a0f-9e6c-80d83113d2f7" xlink:href="biib-20210331.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_925e2d7a-30bb-4b17-8e14-eba69e8c771f" xlink:to="loc_biib_CashflowsoperatingexpensesMember_eb069495-68b6-4a0f-9e6c-80d83113d2f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_97328ea2-24a2-475c-be1f-f68bfe0b32c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_925e2d7a-30bb-4b17-8e14-eba69e8c771f" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_97328ea2-24a2-475c-be1f-f68bfe0b32c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_df384a9f-4339-4aca-b8ce-4fa9870d55eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_df384a9f-4339-4aca-b8ce-4fa9870d55eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_df384a9f-4339-4aca-b8ce-4fa9870d55eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_df384a9f-4339-4aca-b8ce-4fa9870d55eb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_df384a9f-4339-4aca-b8ce-4fa9870d55eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1d20aff0-1635-403e-97ad-2a7c0673d4be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_df384a9f-4339-4aca-b8ce-4fa9870d55eb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1d20aff0-1635-403e-97ad-2a7c0673d4be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5b62e0c1-4994-4c36-a652-424fb3ec30d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1d20aff0-1635-403e-97ad-2a7c0673d4be" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5b62e0c1-4994-4c36-a652-424fb3ec30d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_24540cde-f30a-48c8-af50-ceeb3822aec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1d20aff0-1635-403e-97ad-2a7c0673d4be" xlink:to="loc_us-gaap_InterestRateSwapMember_24540cde-f30a-48c8-af50-ceeb3822aec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8bb3b20f-57e4-48a9-90ba-496c16cc1d59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8bb3b20f-57e4-48a9-90ba-496c16cc1d59" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8bb3b20f-57e4-48a9-90ba-496c16cc1d59_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8bb3b20f-57e4-48a9-90ba-496c16cc1d59" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8bb3b20f-57e4-48a9-90ba-496c16cc1d59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b8556d36-0e25-4c1b-8bc9-c58b7d43183c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8bb3b20f-57e4-48a9-90ba-496c16cc1d59" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b8556d36-0e25-4c1b-8bc9-c58b7d43183c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_c112e3a3-32b8-4ebc-9c8e-61ab640aa6a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b8556d36-0e25-4c1b-8bc9-c58b7d43183c" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_c112e3a3-32b8-4ebc-9c8e-61ab640aa6a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_65be6cd1-3d64-41f1-b8d5-cfa26860e9d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b8556d36-0e25-4c1b-8bc9-c58b7d43183c" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_65be6cd1-3d64-41f1-b8d5-cfa26860e9d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_c6260c29-5329-4f61-985e-3f38330f5087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b8556d36-0e25-4c1b-8bc9-c58b7d43183c" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_c6260c29-5329-4f61-985e-3f38330f5087" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1417f671-4c21-4c48-aff9-be491cf06cc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b8556d36-0e25-4c1b-8bc9-c58b7d43183c" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1417f671-4c21-4c48-aff9-be491cf06cc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e2f2bd04-588d-416d-a19e-6921367c574c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_us-gaap_HedgingDesignationAxis_e2f2bd04-588d-416d-a19e-6921367c574c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e2f2bd04-588d-416d-a19e-6921367c574c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_e2f2bd04-588d-416d-a19e-6921367c574c" xlink:to="loc_us-gaap_HedgingDesignationDomain_e2f2bd04-588d-416d-a19e-6921367c574c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ede510aa-60a1-4b85-9d83-1872207ae308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_e2f2bd04-588d-416d-a19e-6921367c574c" xlink:to="loc_us-gaap_HedgingDesignationDomain_ede510aa-60a1-4b85-9d83-1872207ae308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5d4646dc-72b0-4c87-9db0-7220c449a622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_ede510aa-60a1-4b85-9d83-1872207ae308" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5d4646dc-72b0-4c87-9db0-7220c449a622" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_e6a892fd-2806-42b3-936f-6c0a594e235e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_ede510aa-60a1-4b85-9d83-1872207ae308" xlink:to="loc_us-gaap_NondesignatedMember_e6a892fd-2806-42b3-936f-6c0a594e235e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_afa1c1d8-05b7-4031-a978-3f13a68a2bf2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_srt_RangeAxis_afa1c1d8-05b7-4031-a978-3f13a68a2bf2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_afa1c1d8-05b7-4031-a978-3f13a68a2bf2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_afa1c1d8-05b7-4031-a978-3f13a68a2bf2" xlink:to="loc_srt_RangeMember_afa1c1d8-05b7-4031-a978-3f13a68a2bf2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc629548-159f-4a2d-bb1f-611a93a975b9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_afa1c1d8-05b7-4031-a978-3f13a68a2bf2" xlink:to="loc_srt_RangeMember_bc629548-159f-4a2d-bb1f-611a93a975b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9be33c5d-f9d4-4463-b2f8-47491129259b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bc629548-159f-4a2d-bb1f-611a93a975b9" xlink:to="loc_srt_MinimumMember_9be33c5d-f9d4-4463-b2f8-47491129259b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3d70f945-e872-4b17-bf4e-43f2fed18dcd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bc629548-159f-4a2d-bb1f-611a93a975b9" xlink:to="loc_srt_MaximumMember_3d70f945-e872-4b17-bf4e-43f2fed18dcd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20210331.xsd#PropertyPlantandEquipmentPropertyPlantandEquipment"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment" xlink:type="extended" id="if172aebe0dd845dca6348814ef86fee6_PropertyPlantandEquipmentPropertyPlantandEquipment"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#PropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended" id="i8fa77e8c65fe430f944d8543b999c08b_PropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_326cbeea-8884-4bd0-97e1-7c3df30330b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8c86e44c-fb4b-4731-8587-a0f15d7edef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_326cbeea-8884-4bd0-97e1-7c3df30330b7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8c86e44c-fb4b-4731-8587-a0f15d7edef5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_67ca1d56-be42-453e-91bd-143ca94e5481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_326cbeea-8884-4bd0-97e1-7c3df30330b7" xlink:to="loc_us-gaap_Depreciation_67ca1d56-be42-453e-91bd-143ca94e5481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_a42359c0-d338-4acb-973c-62758bdf7d47" xlink:href="biib-20210331.xsd#biib_NumberOfSquareFeet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_326cbeea-8884-4bd0-97e1-7c3df30330b7" xlink:to="loc_biib_NumberOfSquareFeet_a42359c0-d338-4acb-973c-62758bdf7d47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_fb33a35d-2ee5-4f7d-ac02-e62299f7575a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_326cbeea-8884-4bd0-97e1-7c3df30330b7" xlink:to="loc_us-gaap_ConstructionInProgressGross_fb33a35d-2ee5-4f7d-ac02-e62299f7575a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b9dfab4-59fd-4bc5-a857-4b968947fee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_326cbeea-8884-4bd0-97e1-7c3df30330b7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b9dfab4-59fd-4bc5-a857-4b968947fee0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_95af3ab6-b436-43ec-9345-f105eeb7c140" xlink:href="biib-20210331.xsd#biib_FacilityLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b9dfab4-59fd-4bc5-a857-4b968947fee0" xlink:to="loc_biib_FacilityLocationAxis_95af3ab6-b436-43ec-9345-f105eeb7c140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_95af3ab6-b436-43ec-9345-f105eeb7c140_default" xlink:href="biib-20210331.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_95af3ab6-b436-43ec-9345-f105eeb7c140" xlink:to="loc_biib_FacilityLocationDomain_95af3ab6-b436-43ec-9345-f105eeb7c140_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_67cf6c24-d664-419e-93de-0dfc32edcc97" xlink:href="biib-20210331.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_95af3ab6-b436-43ec-9345-f105eeb7c140" xlink:to="loc_biib_FacilityLocationDomain_67cf6c24-d664-419e-93de-0dfc32edcc97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_3bb0cf32-dc08-4446-992b-d5b03490b94f" xlink:href="biib-20210331.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_67cf6c24-d664-419e-93de-0dfc32edcc97" xlink:to="loc_biib_SolothurnSwitzerlandMember_3bb0cf32-dc08-4446-992b-d5b03490b94f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_74646ff2-2616-4443-be08-8be41a4ca25b" xlink:href="biib-20210331.xsd#biib_FacilityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b9dfab4-59fd-4bc5-a857-4b968947fee0" xlink:to="loc_biib_FacilityTypeAxis_74646ff2-2616-4443-be08-8be41a4ca25b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_74646ff2-2616-4443-be08-8be41a4ca25b_default" xlink:href="biib-20210331.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityTypeAxis_74646ff2-2616-4443-be08-8be41a4ca25b" xlink:to="loc_biib_FacilityTypeDomain_74646ff2-2616-4443-be08-8be41a4ca25b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_955a6645-9a1e-4d16-81e8-d97f692b9874" xlink:href="biib-20210331.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityTypeAxis_74646ff2-2616-4443-be08-8be41a4ca25b" xlink:to="loc_biib_FacilityTypeDomain_955a6645-9a1e-4d16-81e8-d97f692b9874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_c2670794-fdd8-45b5-8614-f6dad7e6a4a6" xlink:href="biib-20210331.xsd#biib_BiologicsManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_955a6645-9a1e-4d16-81e8-d97f692b9874" xlink:to="loc_biib_BiologicsManufacturingMember_c2670794-fdd8-45b5-8614-f6dad7e6a4a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_bb459de8-07f0-46c9-827e-11b46de5111d" xlink:href="biib-20210331.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_955a6645-9a1e-4d16-81e8-d97f692b9874" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_bb459de8-07f0-46c9-827e-11b46de5111d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_8c8de12d-da06-4951-ac7e-b17839202c09" xlink:href="biib-20210331.xsd#biib_AdministrativeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_955a6645-9a1e-4d16-81e8-d97f692b9874" xlink:to="loc_biib_AdministrativeSpaceMember_8c8de12d-da06-4951-ac7e-b17839202c09" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="simple" xlink:href="biib-20210331.xsd#IndebtednessNotes"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="extended" id="ic047b310e3ca4b2687017fa23e5006e6_IndebtednessNotes"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#IndebtednessDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended" id="ibc2786b1c05342a7a18cfbf4bf2d86af_IndebtednessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8e8d9e02-3e31-49ce-a99a-8ad445aba788" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8e8d9e02-3e31-49ce-a99a-8ad445aba788" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2526c2ba-3d1b-42d5-a5f9-97682f00e863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2526c2ba-3d1b-42d5-a5f9-97682f00e863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_e5e55e56-3f3e-45a4-ba68-0d33a92b471e" xlink:href="biib-20210331.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_e5e55e56-3f3e-45a4-ba68-0d33a92b471e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_23da6ee3-a752-473b-8bd2-e1c492dadc99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_23da6ee3-a752-473b-8bd2-e1c492dadc99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_d9d89b7e-ff0c-43f2-ba07-02a97ca21117" xlink:href="biib-20210331.xsd#biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_d9d89b7e-ff0c-43f2-ba07-02a97ca21117" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_46aba5a8-da4f-4526-a339-f872fd4cae2f" xlink:href="biib-20210331.xsd#biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_46aba5a8-da4f-4526-a339-f872fd4cae2f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_565122da-3b96-4e39-abd7-f50169265cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_565122da-3b96-4e39-abd7-f50169265cc7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_432fe90e-cd03-4a0a-84e3-39437f47b01b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_432fe90e-cd03-4a0a-84e3-39437f47b01b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount_aa7a16fb-9739-4f3f-b555-04f6f9e75b9d" xlink:href="biib-20210331.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_biib_DebtInstrumentRedemptionAmount_aa7a16fb-9739-4f3f-b555-04f6f9e75b9d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_e0b4a7eb-8dba-4651-9aa8-8d9b4e3b9de7" xlink:href="biib-20210331.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_biib_LongTermDebtExchangedAmount_e0b4a7eb-8dba-4651-9aa8-8d9b4e3b9de7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dde0f63a-2ec9-4166-9d36-1e868a486524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dde0f63a-2ec9-4166-9d36-1e868a486524" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_10a983c8-e330-4fdc-8374-cb7b6c4bc1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_RepaymentsOfDebt_10a983c8-e330-4fdc-8374-cb7b6c4bc1dc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3ff88773-ead9-474a-ad2d-1cb64013c7d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_InterestExpense_3ff88773-ead9-474a-ad2d-1cb64013c7d3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_dcd6a906-a397-4492-b75f-0fa3e16a1c66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_DebtInstrumentTable_dcd6a906-a397-4492-b75f-0fa3e16a1c66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1f8348e4-b03e-4865-bef5-a57daeb0d814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dcd6a906-a397-4492-b75f-0fa3e16a1c66" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1f8348e4-b03e-4865-bef5-a57daeb0d814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1f8348e4-b03e-4865-bef5-a57daeb0d814_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1f8348e4-b03e-4865-bef5-a57daeb0d814" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1f8348e4-b03e-4865-bef5-a57daeb0d814_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_43998bff-7397-4401-833d-12ab1d348edd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1f8348e4-b03e-4865-bef5-a57daeb0d814" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_43998bff-7397-4401-833d-12ab1d348edd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_d8e0650a-cf74-4806-a4fa-69b02888dc15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43998bff-7397-4401-833d-12ab1d348edd" xlink:to="loc_us-gaap_InterestExpenseMember_d8e0650a-cf74-4806-a4fa-69b02888dc15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8966ad39-1ac4-4400-8512-e530e9abaabd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dcd6a906-a397-4492-b75f-0fa3e16a1c66" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8966ad39-1ac4-4400-8512-e530e9abaabd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8966ad39-1ac4-4400-8512-e530e9abaabd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8966ad39-1ac4-4400-8512-e530e9abaabd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8966ad39-1ac4-4400-8512-e530e9abaabd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7965926b-42dc-4e2c-8f56-8c6dc00773a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8966ad39-1ac4-4400-8512-e530e9abaabd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7965926b-42dc-4e2c-8f56-8c6dc00773a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_f7a9efce-3de2-43db-b8f7-1659bb922954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7965926b-42dc-4e2c-8f56-8c6dc00773a0" xlink:to="loc_us-gaap_InterestRateSwapMember_f7a9efce-3de2-43db-b8f7-1659bb922954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_90754c25-3b45-4803-ae3c-0d2b3015b483" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dcd6a906-a397-4492-b75f-0fa3e16a1c66" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_90754c25-3b45-4803-ae3c-0d2b3015b483" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_90754c25-3b45-4803-ae3c-0d2b3015b483_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_90754c25-3b45-4803-ae3c-0d2b3015b483" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_90754c25-3b45-4803-ae3c-0d2b3015b483_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_817c5361-62d4-4b0e-8b91-67b88e72233e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_90754c25-3b45-4803-ae3c-0d2b3015b483" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_817c5361-62d4-4b0e-8b91-67b88e72233e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_12d7a8b7-fc75-466d-ba38-b8129eb53683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_817c5361-62d4-4b0e-8b91-67b88e72233e" xlink:to="loc_us-gaap_SeniorNotesMember_12d7a8b7-fc75-466d-ba38-b8129eb53683" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_82706aa0-7456-49b5-a0e4-6fb7ff3ce4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dcd6a906-a397-4492-b75f-0fa3e16a1c66" xlink:to="loc_us-gaap_DebtInstrumentAxis_82706aa0-7456-49b5-a0e4-6fb7ff3ce4fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_82706aa0-7456-49b5-a0e4-6fb7ff3ce4fb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_82706aa0-7456-49b5-a0e4-6fb7ff3ce4fb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_82706aa0-7456-49b5-a0e4-6fb7ff3ce4fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_30b92099-95e3-43cb-8903-9336b665d184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_82706aa0-7456-49b5-a0e4-6fb7ff3ce4fb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_30b92099-95e3-43cb-8903-9336b665d184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_475f9d72-c7db-49e0-8e86-e022f1c842e2" xlink:href="biib-20210331.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30b92099-95e3-43cb-8903-9336b665d184" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_475f9d72-c7db-49e0-8e86-e022f1c842e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_9a38096f-dab8-41b4-a5ac-6b5b48a84cb8" xlink:href="biib-20210331.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30b92099-95e3-43cb-8903-9336b665d184" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_9a38096f-dab8-41b4-a5ac-6b5b48a84cb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.90SeniorNotesDueSept152020Member_9eed356b-33d0-4681-86ee-96307a4bf7bd" xlink:href="biib-20210331.xsd#biib_A2.90SeniorNotesDueSept152020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30b92099-95e3-43cb-8903-9336b665d184" xlink:to="loc_biib_A2.90SeniorNotesDueSept152020Member_9eed356b-33d0-4681-86ee-96307a4bf7bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_47cef1da-91d6-4103-9d8d-5264df8af2f2" xlink:href="biib-20210331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30b92099-95e3-43cb-8903-9336b665d184" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_47cef1da-91d6-4103-9d8d-5264df8af2f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_205e6c04-4f52-4a5d-82e6-502e86d05e31" xlink:href="biib-20210331.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30b92099-95e3-43cb-8903-9336b665d184" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_205e6c04-4f52-4a5d-82e6-502e86d05e31" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20210331.xsd#Equity"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" id="idb87322a17d34682a6c1b870c49ca1e0_Equity"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="biib-20210331.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" id="i5f7c9e27b68440659e2456c4711bf67e_AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#ShareRepurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended" id="i6dd73b36505f4d44a46147241cc51448_ShareRepurchasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_01d75bec-6995-4a60-9a0c-72d280dc6fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_5ccf1ecd-b4f3-4108-a1a6-c6f6e99173da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01d75bec-6995-4a60-9a0c-72d280dc6fbf" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_5ccf1ecd-b4f3-4108-a1a6-c6f6e99173da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_83b09cd1-1996-46df-bd22-ebbb1c2fbb53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01d75bec-6995-4a60-9a0c-72d280dc6fbf" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_83b09cd1-1996-46df-bd22-ebbb1c2fbb53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_79e06a85-a9e0-40b9-b51d-4ee0ab441dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01d75bec-6995-4a60-9a0c-72d280dc6fbf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_79e06a85-a9e0-40b9-b51d-4ee0ab441dd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_72dcf086-5090-4240-be18-ed2fcaa9b157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01d75bec-6995-4a60-9a0c-72d280dc6fbf" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_72dcf086-5090-4240-be18-ed2fcaa9b157" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d6fa6954-a55c-4839-9d9a-c62c0d37b8a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_01d75bec-6995-4a60-9a0c-72d280dc6fbf" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d6fa6954-a55c-4839-9d9a-c62c0d37b8a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_1f0baee6-7800-4f79-8987-8189e87438bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d6fa6954-a55c-4839-9d9a-c62c0d37b8a6" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_1f0baee6-7800-4f79-8987-8189e87438bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_1f0baee6-7800-4f79-8987-8189e87438bd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1f0baee6-7800-4f79-8987-8189e87438bd" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_1f0baee6-7800-4f79-8987-8189e87438bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_77950641-f7d7-4650-8d2e-03a207a144dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1f0baee6-7800-4f79-8987-8189e87438bd" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_77950641-f7d7-4650-8d2e-03a207a144dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_c98fa584-9b0f-4a8f-86b1-cae568b47e1e" xlink:href="biib-20210331.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_77950641-f7d7-4650-8d2e-03a207a144dc" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_c98fa584-9b0f-4a8f-86b1-cae568b47e1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_4939df68-9545-4b3c-9ae3-d986bf72d014" xlink:href="biib-20210331.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_77950641-f7d7-4650-8d2e-03a207a144dc" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_4939df68-9545-4b3c-9ae3-d986bf72d014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_October2020ShareRepurchaseProgramMember_9c14f27e-e8c9-43bc-b23c-2e31ee3fa854" xlink:href="biib-20210331.xsd#biib_October2020ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_77950641-f7d7-4650-8d2e-03a207a144dc" xlink:to="loc_biib_October2020ShareRepurchaseProgramMember_9c14f27e-e8c9-43bc-b23c-2e31ee3fa854" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="id2aea903913c46a682bbee8879cdbaba_AccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4c258dc2-6847-44c3-a60b-b3fbd54608c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4c258dc2-6847-44c3-a60b-b3fbd54608c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a2812dd8-0497-46c3-adff-8316cc05b7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_58f218f0-d80b-471a-8195-c4d5d0135edc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_58f218f0-d80b-471a-8195-c4d5d0135edc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7694555a-fbe4-46ed-9511-1905002bc2d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7694555a-fbe4-46ed-9511-1905002bc2d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7c39a4cf-3c1f-4c7b-be9a-a54c124e7796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7c39a4cf-3c1f-4c7b-be9a-a54c124e7796" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a153aed3-eadd-4585-9cca-8dba1ebd099c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6aba15f1-5cbc-4996-90df-af4bb663a041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6aba15f1-5cbc-4996-90df-af4bb663a041" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_37cd642a-d82d-4887-9692-321bf04bba62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_37cd642a-d82d-4887-9692-321bf04bba62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_af92b921-fbc5-417a-8f5d-c60a1245e92b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_37cd642a-d82d-4887-9692-321bf04bba62" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_af92b921-fbc5-417a-8f5d-c60a1245e92b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_af92b921-fbc5-417a-8f5d-c60a1245e92b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_af92b921-fbc5-417a-8f5d-c60a1245e92b" xlink:to="loc_us-gaap_EquityComponentDomain_af92b921-fbc5-417a-8f5d-c60a1245e92b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_05a742bb-ce79-41fd-9711-f60831327966" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_af92b921-fbc5-417a-8f5d-c60a1245e92b" xlink:to="loc_us-gaap_EquityComponentDomain_05a742bb-ce79-41fd-9711-f60831327966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0704b96a-110a-4125-95ce-77fa3eac1681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05a742bb-ce79-41fd-9711-f60831327966" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0704b96a-110a-4125-95ce-77fa3eac1681" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_103d8ab9-14f9-4dc5-8220-82ace05f59c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05a742bb-ce79-41fd-9711-f60831327966" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_103d8ab9-14f9-4dc5-8220-82ace05f59c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_bea44e15-f6ff-4c53-a065-9d5f88129269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05a742bb-ce79-41fd-9711-f60831327966" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_bea44e15-f6ff-4c53-a065-9d5f88129269" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_504775a1-d14e-43d8-b5a2-de70b3e399b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05a742bb-ce79-41fd-9711-f60831327966" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_504775a1-d14e-43d8-b5a2-de70b3e399b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_119b8ca7-48e8-4884-bc94-e0674910e024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05a742bb-ce79-41fd-9711-f60831327966" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_119b8ca7-48e8-4884-bc94-e0674910e024" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="ic07897db58954dabbea1b3b8b9a40989_ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_cb59da6d-e167-4417-a909-d1c38fb59820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_079e0e50-7199-4218-80c1-bdcc7e58c2ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_cb59da6d-e167-4417-a909-d1c38fb59820" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_079e0e50-7199-4218-80c1-bdcc7e58c2ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_946e8d0f-8cb6-406c-8394-75b2c2f57572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_cb59da6d-e167-4417-a909-d1c38fb59820" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_946e8d0f-8cb6-406c-8394-75b2c2f57572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_59991e0e-2f09-4a6d-b6c6-eed3b01b5e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_cb59da6d-e167-4417-a909-d1c38fb59820" xlink:to="loc_us-gaap_Revenues_59991e0e-2f09-4a6d-b6c6-eed3b01b5e4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e60b3995-9b24-47dd-84d8-097fbeb894ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_cb59da6d-e167-4417-a909-d1c38fb59820" xlink:to="loc_us-gaap_OperatingExpenses_e60b3995-9b24-47dd-84d8-097fbeb894ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9c3d564a-ab7f-4795-bebc-d76568aae6f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_cb59da6d-e167-4417-a909-d1c38fb59820" xlink:to="loc_us-gaap_NetIncomeLoss_9c3d564a-ab7f-4795-bebc-d76568aae6f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_aee83c41-f3bc-4445-8536-54d00d0ea37b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_cb59da6d-e167-4417-a909-d1c38fb59820" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_aee83c41-f3bc-4445-8536-54d00d0ea37b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9cd28b51-23d4-4c7b-8410-bfd88f6342b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_aee83c41-f3bc-4445-8536-54d00d0ea37b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9cd28b51-23d4-4c7b-8410-bfd88f6342b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9cd28b51-23d4-4c7b-8410-bfd88f6342b9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9cd28b51-23d4-4c7b-8410-bfd88f6342b9" xlink:to="loc_us-gaap_EquityComponentDomain_9cd28b51-23d4-4c7b-8410-bfd88f6342b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1e042874-0bc6-49f5-ad63-5cf6dec093d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9cd28b51-23d4-4c7b-8410-bfd88f6342b9" xlink:to="loc_us-gaap_EquityComponentDomain_1e042874-0bc6-49f5-ad63-5cf6dec093d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1b4c450c-e0a5-4822-8d58-f984ecb48323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1e042874-0bc6-49f5-ad63-5cf6dec093d8" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1b4c450c-e0a5-4822-8d58-f984ecb48323" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_be9a651b-d740-4df5-81e7-1dc3b8978ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1e042874-0bc6-49f5-ad63-5cf6dec093d8" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_be9a651b-d740-4df5-81e7-1dc3b8978ba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_906226d5-3033-4bd3-9b68-efb4e93d54ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1e042874-0bc6-49f5-ad63-5cf6dec093d8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_906226d5-3033-4bd3-9b68-efb4e93d54ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_65b0f937-efd7-4b63-8adb-6289a28e2ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_aee83c41-f3bc-4445-8536-54d00d0ea37b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_65b0f937-efd7-4b63-8adb-6289a28e2ad3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_65b0f937-efd7-4b63-8adb-6289a28e2ad3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_65b0f937-efd7-4b63-8adb-6289a28e2ad3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_65b0f937-efd7-4b63-8adb-6289a28e2ad3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ef0dc763-9be1-4b8d-bad0-5760f18adc53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_65b0f937-efd7-4b63-8adb-6289a28e2ad3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ef0dc763-9be1-4b8d-bad0-5760f18adc53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_2bb59d62-9735-4df7-be4b-8d7bbc650206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ef0dc763-9be1-4b8d-bad0-5760f18adc53" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_2bb59d62-9735-4df7-be4b-8d7bbc650206" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20210331.xsd#EarningsperShare"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended" id="i82f07f184baa4814a45f09c5ca29f443_EarningsperShare"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20210331.xsd#EarningsperShareTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended" id="i6ee8db48c34c4f548cd3e4cda082a90b_EarningsperShareTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#EarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended" id="i70bf6bd5681941269b8a37e5a27985eb_EarningsperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_82994c36-0e3b-4d36-92b6-b773456544c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ee0be738-5cc8-4fb4-9355-795362b0fd4c" xlink:href="biib-20210331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_82994c36-0e3b-4d36-92b6-b773456544c6" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ee0be738-5cc8-4fb4-9355-795362b0fd4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_4388a450-32b6-440e-9395-1074c3332c14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ee0be738-5cc8-4fb4-9355-795362b0fd4c" xlink:to="loc_us-gaap_NetIncomeLossAbstract_4388a450-32b6-440e-9395-1074c3332c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_de0f0ff9-b2c3-4c4a-8823-6480dd90f93c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_4388a450-32b6-440e-9395-1074c3332c14" xlink:to="loc_us-gaap_NetIncomeLoss_de0f0ff9-b2c3-4c4a-8823-6480dd90f93c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fd197c89-cbd6-462c-acaf-9cbb462a9049" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ee0be738-5cc8-4fb4-9355-795362b0fd4c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fd197c89-cbd6-462c-acaf-9cbb462a9049" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_984612ae-9993-45f6-834d-9a6adbb3d56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fd197c89-cbd6-462c-acaf-9cbb462a9049" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_984612ae-9993-45f6-834d-9a6adbb3d56f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_971fa54d-37a3-4b93-9814-abed985fc466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fd197c89-cbd6-462c-acaf-9cbb462a9049" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_971fa54d-37a3-4b93-9814-abed985fc466" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cd2cb632-2222-43c3-b0e7-0fdffac9c054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_971fa54d-37a3-4b93-9814-abed985fc466" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cd2cb632-2222-43c3-b0e7-0fdffac9c054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_438a1430-d10b-424b-9915-52077e05e90a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_971fa54d-37a3-4b93-9814-abed985fc466" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_438a1430-d10b-424b-9915-52077e05e90a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1216d9e8-052b-4b49-94b9-5d3a61a761d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fd197c89-cbd6-462c-acaf-9cbb462a9049" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1216d9e8-052b-4b49-94b9-5d3a61a761d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f211651e-7f2a-4531-b29e-378c242a136e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_82994c36-0e3b-4d36-92b6-b773456544c6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f211651e-7f2a-4531-b29e-378c242a136e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_497580b4-6ec2-4dcb-8fa3-305c608abd0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f211651e-7f2a-4531-b29e-378c242a136e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_497580b4-6ec2-4dcb-8fa3-305c608abd0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_497580b4-6ec2-4dcb-8fa3-305c608abd0f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_497580b4-6ec2-4dcb-8fa3-305c608abd0f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_497580b4-6ec2-4dcb-8fa3-305c608abd0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac202fab-7a48-4f21-9676-28c54e290410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_497580b4-6ec2-4dcb-8fa3-305c608abd0f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac202fab-7a48-4f21-9676-28c54e290410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_f580066e-8cbf-40a0-b917-c09ef0725287" xlink:href="biib-20210331.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac202fab-7a48-4f21-9676-28c54e290410" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_f580066e-8cbf-40a0-b917-c09ef0725287" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_43838de5-bb1e-42f9-9274-72ac98998936" xlink:href="biib-20210331.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac202fab-7a48-4f21-9676-28c54e290410" xlink:to="loc_biib_MarketStockUnitsMember_43838de5-bb1e-42f9-9274-72ac98998936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_73b3741c-1c33-4c9e-903f-1204e9153d04" xlink:href="biib-20210331.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac202fab-7a48-4f21-9676-28c54e290410" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_73b3741c-1c33-4c9e-903f-1204e9153d04" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="simple" xlink:href="biib-20210331.xsd#SharebasedPayments"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="extended" id="i26e2e8507e5c42968c478886f47457d0_SharebasedPayments"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20210331.xsd#ShareBasedPaymentsTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" id="i1122ce4dcd074cecb6fcd4ee61e5f6a3_ShareBasedPaymentsTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#ShareBasedPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended" id="i48471f3891d247088b5da0634daaae2a_ShareBasedPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2ba1b990-791a-4246-8849-307b2ae1aab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2f7e6a66-cff5-4ca7-86f7-0213c1b03f27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2ba1b990-791a-4246-8849-307b2ae1aab4" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2f7e6a66-cff5-4ca7-86f7-0213c1b03f27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_113d45d2-7add-49fe-a02e-08c71cf96313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2f7e6a66-cff5-4ca7-86f7-0213c1b03f27" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_113d45d2-7add-49fe-a02e-08c71cf96313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_14dcf136-b377-40b2-90c3-2b2ed0407e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2f7e6a66-cff5-4ca7-86f7-0213c1b03f27" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_14dcf136-b377-40b2-90c3-2b2ed0407e9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bdaa4e8a-bb7a-483b-8b59-0646f59fbe11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2f7e6a66-cff5-4ca7-86f7-0213c1b03f27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bdaa4e8a-bb7a-483b-8b59-0646f59fbe11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7dbf541a-9755-4afe-b773-7cd7bf5258b2" xlink:href="biib-20210331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2f7e6a66-cff5-4ca7-86f7-0213c1b03f27" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7dbf541a-9755-4afe-b773-7cd7bf5258b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2ab0cca5-2601-4544-8a7d-d86bcdbf04ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2f7e6a66-cff5-4ca7-86f7-0213c1b03f27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2ab0cca5-2601-4544-8a7d-d86bcdbf04ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_81cd58f6-204e-46c2-ae1c-042e8c6893a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2ba1b990-791a-4246-8849-307b2ae1aab4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_81cd58f6-204e-46c2-ae1c-042e8c6893a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9969860e-48ce-4205-966f-4b19671d2ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_81cd58f6-204e-46c2-ae1c-042e8c6893a3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9969860e-48ce-4205-966f-4b19671d2ff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9969860e-48ce-4205-966f-4b19671d2ff4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9969860e-48ce-4205-966f-4b19671d2ff4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9969860e-48ce-4205-966f-4b19671d2ff4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_75a2afc6-b2fc-4d6d-b25e-716b1e0dc02b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9969860e-48ce-4205-966f-4b19671d2ff4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_75a2afc6-b2fc-4d6d-b25e-716b1e0dc02b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4742eec6-c014-4157-9e1e-a239051a33ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_75a2afc6-b2fc-4d6d-b25e-716b1e0dc02b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4742eec6-c014-4157-9e1e-a239051a33ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_237dda5a-485f-4bef-8a36-84e31347ac06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_75a2afc6-b2fc-4d6d-b25e-716b1e0dc02b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_237dda5a-485f-4bef-8a36-84e31347ac06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_e5583fc6-1556-47c7-9119-d65dff87a3e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_75a2afc6-b2fc-4d6d-b25e-716b1e0dc02b" xlink:to="loc_us-gaap_ParentMember_e5583fc6-1556-47c7-9119-d65dff87a3e7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20210331.xsd#ShareBasedPaymentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" id="i273ce913d4fa4c9c9b2e4bb7ed73fecf_ShareBasedPaymentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_611bba31-0bf3-4bbc-8a73-920fd4643df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_0227689f-02e1-4b1a-a0fb-423e47bb48c1" xlink:href="biib-20210331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_611bba31-0bf3-4bbc-8a73-920fd4643df8" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_0227689f-02e1-4b1a-a0fb-423e47bb48c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a07b6dae-9a9c-4bb3-9cff-2e710fc0852e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_0227689f-02e1-4b1a-a0fb-423e47bb48c1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a07b6dae-9a9c-4bb3-9cff-2e710fc0852e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_0a548712-0e15-412a-83a6-c7814f6aed37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_0227689f-02e1-4b1a-a0fb-423e47bb48c1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_0a548712-0e15-412a-83a6-c7814f6aed37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_6148ed61-8e16-43f0-b4dd-b976fadf0ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_0227689f-02e1-4b1a-a0fb-423e47bb48c1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_6148ed61-8e16-43f0-b4dd-b976fadf0ca4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_0113269e-6031-43f3-a67b-a2b782446a94" xlink:href="biib-20210331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_0227689f-02e1-4b1a-a0fb-423e47bb48c1" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_0113269e-6031-43f3-a67b-a2b782446a94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_761218a1-2b81-4a14-9543-20c0fe835c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_611bba31-0bf3-4bbc-8a73-920fd4643df8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_761218a1-2b81-4a14-9543-20c0fe835c97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8dbbb239-fdb8-441f-bc7c-e165495a1f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_761218a1-2b81-4a14-9543-20c0fe835c97" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8dbbb239-fdb8-441f-bc7c-e165495a1f7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8dbbb239-fdb8-441f-bc7c-e165495a1f7a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8dbbb239-fdb8-441f-bc7c-e165495a1f7a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8dbbb239-fdb8-441f-bc7c-e165495a1f7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a208db4b-2cf6-4eda-8545-5fa09bc458a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8dbbb239-fdb8-441f-bc7c-e165495a1f7a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a208db4b-2cf6-4eda-8545-5fa09bc458a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_b4d99a13-5e9e-45be-a98c-cbe99a0dd876" xlink:href="biib-20210331.xsd#biib_NightstarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a208db4b-2cf6-4eda-8545-5fa09bc458a2" xlink:to="loc_biib_NightstarMember_b4d99a13-5e9e-45be-a98c-cbe99a0dd876" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_80545905-e7fe-490d-a726-bba1edaf7ee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_761218a1-2b81-4a14-9543-20c0fe835c97" xlink:to="loc_us-gaap_AwardTypeAxis_80545905-e7fe-490d-a726-bba1edaf7ee4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80545905-e7fe-490d-a726-bba1edaf7ee4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_80545905-e7fe-490d-a726-bba1edaf7ee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80545905-e7fe-490d-a726-bba1edaf7ee4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_80545905-e7fe-490d-a726-bba1edaf7ee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_9456fe8f-8ded-4dbb-b484-16f2d37f41fe" xlink:href="biib-20210331.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:to="loc_biib_MarketStockUnitsMember_9456fe8f-8ded-4dbb-b484-16f2d37f41fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_07fbed05-acdb-42d6-a64e-76bd9f0bcde3" xlink:href="biib-20210331.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_07fbed05-acdb-42d6-a64e-76bd9f0bcde3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember_cd7221e7-ecf0-420e-84cf-e8b10acb4615" xlink:href="biib-20210331.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:to="loc_biib_CashSettledPerformanceSharesMember_cd7221e7-ecf0-420e-84cf-e8b10acb4615" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_536c0392-94e4-4d4f-8115-f96f8a614829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:to="loc_us-gaap_PerformanceSharesMember_536c0392-94e4-4d4f-8115-f96f8a614829" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_b25ab807-6d50-4c66-a35d-32b0df2a5d0e" xlink:href="biib-20210331.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_b25ab807-6d50-4c66-a35d-32b0df2a5d0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_64824f4c-c03d-48d3-aec8-fbb941d879db" xlink:href="biib-20210331.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_64824f4c-c03d-48d3-aec8-fbb941d879db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_08fa82cf-4798-45df-8e23-e55de1688bcb" xlink:href="biib-20210331.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_08fa82cf-4798-45df-8e23-e55de1688bcb" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20210331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" id="i80f7af03dcf942d6878e40f02e3b1073_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20210331.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" id="i7e485c192c29458496345b398637ddc9_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="iee60cac85d1544f1b54f9498c5d6c85a_IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_1f005065-9467-443e-a01c-3622e84c9dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetsValueReductioninValue_3d2ee8aa-aa1d-4d0e-ac3c-a34ca81716a1" xlink:href="biib-20210331.xsd#biib_DeferredTaxAssetsValueReductioninValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_1f005065-9467-443e-a01c-3622e84c9dc0" xlink:to="loc_biib_DeferredTaxAssetsValueReductioninValue_3d2ee8aa-aa1d-4d0e-ac3c-a34ca81716a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_1bf0750f-7856-4924-946c-144f82cd1d26" xlink:href="biib-20210331.xsd#biib_DeferredTaxLiabilitiesValueReductioninValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_1f005065-9467-443e-a01c-3622e84c9dc0" xlink:to="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_1bf0750f-7856-4924-946c-144f82cd1d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e191fa00-2bb6-48a1-bbca-8bf862115794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_1f005065-9467-443e-a01c-3622e84c9dc0" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e191fa00-2bb6-48a1-bbca-8bf862115794" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_85925409-ea66-406a-b5a2-d096709361ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_1f005065-9467-443e-a01c-3622e84c9dc0" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_85925409-ea66-406a-b5a2-d096709361ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_452df7fa-0b31-4a6b-8d98-6df22c51639d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_85925409-ea66-406a-b5a2-d096709361ad" xlink:to="loc_srt_ProductOrServiceAxis_452df7fa-0b31-4a6b-8d98-6df22c51639d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_452df7fa-0b31-4a6b-8d98-6df22c51639d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_452df7fa-0b31-4a6b-8d98-6df22c51639d" xlink:to="loc_srt_ProductsAndServicesDomain_452df7fa-0b31-4a6b-8d98-6df22c51639d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d3d99762-81a0-40f3-85c6-8efaf3daaf85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_452df7fa-0b31-4a6b-8d98-6df22c51639d" xlink:to="loc_srt_ProductsAndServicesDomain_d3d99762-81a0-40f3-85c6-8efaf3daaf85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_b8bf602d-784b-4b86-94b1-dd642cba7a0c" xlink:href="biib-20210331.xsd#biib_TECFIDERAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d3d99762-81a0-40f3-85c6-8efaf3daaf85" xlink:to="loc_biib_TECFIDERAMember_b8bf602d-784b-4b86-94b1-dd642cba7a0c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" id="i79e59aeb4c474beebf59a564da8cba6a_IncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20210331.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" id="i0ab2a0d6f4804102a23bd80f9206c6d2_OtherConsolidatedFinancialStatementDetail"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20210331.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" id="ie32a26d468784f2b87d0b83a0ccb54c2_OtherConsolidatedFinancialStatementDetailTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended" id="i9c6ba0c9be4441638239b6036e074411_OtherConsolidatedFinancialStatementDetailDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_022f6457-012b-4456-9d5e-5c87d3af1df7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_022f6457-012b-4456-9d5e-5c87d3af1df7" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c7a75174-0637-4499-b89e-2f50d538f555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c7a75174-0637-4499-b89e-2f50d538f555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dddde5f9-b2ec-49a4-9aac-fa7a87990626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:to="loc_us-gaap_InterestExpense_dddde5f9-b2ec-49a4-9aac-fa7a87990626" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_b40f1cb1-d1a2-4fc8-be21-adabdd27b108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_b40f1cb1-d1a2-4fc8-be21-adabdd27b108" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_acb915b9-1bc6-43c3-a4c5-e9ce3d22127b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_acb915b9-1bc6-43c3-a4c5-e9ce3d22127b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_24abb442-a344-4a37-9570-9d2ae968646c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_24abb442-a344-4a37-9570-9d2ae968646c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5ba2577e-a60e-45d7-ab2f-3f7ebae385ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5ba2577e-a60e-45d7-ab2f-3f7ebae385ed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_ca1fce86-6cfb-4a5f-a55a-ac29a2cb61b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_022f6457-012b-4456-9d5e-5c87d3af1df7" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_ca1fce86-6cfb-4a5f-a55a-ac29a2cb61b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_03f6cb92-50e3-4d1a-95b2-270e8642c9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_ca1fce86-6cfb-4a5f-a55a-ac29a2cb61b8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_03f6cb92-50e3-4d1a-95b2-270e8642c9b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_3dcf7114-6797-4201-891c-990572941fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_ca1fce86-6cfb-4a5f-a55a-ac29a2cb61b8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_3dcf7114-6797-4201-891c-990572941fe6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_26543a4d-c7b5-4a38-9e53-c078648e05c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_ca1fce86-6cfb-4a5f-a55a-ac29a2cb61b8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_26543a4d-c7b5-4a38-9e53-c078648e05c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_022f6457-012b-4456-9d5e-5c87d3af1df7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_edeed13f-0a94-47f2-90bb-027737691825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_edeed13f-0a94-47f2-90bb-027737691825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_776541db-ebc0-44a6-b1ec-2240e80e58bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_776541db-ebc0-44a6-b1ec-2240e80e58bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_4849e247-3bb9-4034-a881-2f8bc37459b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_4849e247-3bb9-4034-a881-2f8bc37459b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_947ddd6c-567e-4ded-9123-9ee6450fbf85" xlink:href="biib-20210331.xsd#biib_Collaborationexpensesaccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_biib_Collaborationexpensesaccrual_947ddd6c-567e-4ded-9123-9ee6450fbf85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_df1d87b1-bb52-4928-8b9a-44de7a069b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_df1d87b1-bb52-4928-8b9a-44de7a069b82" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_e1ff109a-fdc6-4583-97b3-c804614d662d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_e1ff109a-fdc6-4583-97b3-c804614d662d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e5f4a861-60b7-4c13-ba2d-0a74eceef9ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e5f4a861-60b7-4c13-ba2d-0a74eceef9ec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3f3055f7-6004-434a-a352-a3a6ad8422be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3f3055f7-6004-434a-a352-a3a6ad8422be" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_47e6f089-205e-442e-8a83-9862df1579d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_022f6457-012b-4456-9d5e-5c87d3af1df7" xlink:to="loc_us-gaap_StatementTable_47e6f089-205e-442e-8a83-9862df1579d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_65aa32f2-bf6e-4f2f-a627-87f269120357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_47e6f089-205e-442e-8a83-9862df1579d0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_65aa32f2-bf6e-4f2f-a627-87f269120357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_65aa32f2-bf6e-4f2f-a627-87f269120357_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_65aa32f2-bf6e-4f2f-a627-87f269120357" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_65aa32f2-bf6e-4f2f-a627-87f269120357_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4184a7d2-dc0e-4381-a3a4-f8627456ce78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_65aa32f2-bf6e-4f2f-a627-87f269120357" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4184a7d2-dc0e-4381-a3a4-f8627456ce78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_353d9f8e-2eaa-4a0d-87c0-9551aa2b1869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4184a7d2-dc0e-4381-a3a4-f8627456ce78" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_353d9f8e-2eaa-4a0d-87c0-9551aa2b1869" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" id="i6c013999b59d456cb6b921678c6cd29c_OtherConsolidatedFinancialStatementDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_24e5373e-3a25-4291-8ff7-c03e462c795a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_278abec5-90b0-4d83-9d91-97b958d42d20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_24e5373e-3a25-4291-8ff7-c03e462c795a" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_278abec5-90b0-4d83-9d91-97b958d42d20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9370d7a7-04db-4058-ab96-866a825ad1fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_24e5373e-3a25-4291-8ff7-c03e462c795a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9370d7a7-04db-4058-ab96-866a825ad1fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_cadcce57-09d4-4a9b-81cb-aeecfaeb8f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_24e5373e-3a25-4291-8ff7-c03e462c795a" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_cadcce57-09d4-4a9b-81cb-aeecfaeb8f9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e9d84cf7-cece-4883-ba54-7a0c35e3bb4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_24e5373e-3a25-4291-8ff7-c03e462c795a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e9d84cf7-cece-4883-ba54-7a0c35e3bb4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_1a5713fc-95a0-4bd9-872a-b5d3c7d9ed67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_24e5373e-3a25-4291-8ff7-c03e462c795a" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_1a5713fc-95a0-4bd9-872a-b5d3c7d9ed67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9677fcd7-01f7-4142-9472-0bad7b59d9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_24e5373e-3a25-4291-8ff7-c03e462c795a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9677fcd7-01f7-4142-9472-0bad7b59d9fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_62889210-99b8-46d3-a163-0bc1481c2459" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9677fcd7-01f7-4142-9472-0bad7b59d9fa" xlink:to="loc_dei_LegalEntityAxis_62889210-99b8-46d3-a163-0bc1481c2459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_62889210-99b8-46d3-a163-0bc1481c2459_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_62889210-99b8-46d3-a163-0bc1481c2459" xlink:to="loc_dei_EntityDomain_62889210-99b8-46d3-a163-0bc1481c2459_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b12af274-dcef-4079-be28-98bc8cd54649" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_62889210-99b8-46d3-a163-0bc1481c2459" xlink:to="loc_dei_EntityDomain_b12af274-dcef-4079-be28-98bc8cd54649" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_0db771f6-1a81-4061-8ea6-aba5e0d2a053" xlink:href="biib-20210331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b12af274-dcef-4079-be28-98bc8cd54649" xlink:to="loc_biib_DenaliTherapeuticsIncMember_0db771f6-1a81-4061-8ea6-aba5e0d2a053" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_0b149454-4720-49f7-b326-4d8d4a3d325d" xlink:href="biib-20210331.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b12af274-dcef-4079-be28-98bc8cd54649" xlink:to="loc_biib_SangamoCommonStockMember_0b149454-4720-49f7-b326-4d8d4a3d325d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_42bcef48-5657-4722-b9c8-4555919a38d4" xlink:href="biib-20210331.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b12af274-dcef-4079-be28-98bc8cd54649" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_42bcef48-5657-4722-b9c8-4555919a38d4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20210331.xsd#CollaborativeandOtherRelationships"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended" id="ia53a2b4f844040a3a051d18f335e3635_CollaborativeandOtherRelationships"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20210331.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended" id="i618c060a5dc2424c89421c1b515468c8_CollaborativeandOtherRelationshipsTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended" id="i00506216da8340ddacc5b48c8b57c9fa_CollaborativeandOtherRelationshipsCollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfProductCandidates_a7a7d117-edf0-4106-a3fd-2d56e8e5a1ee" xlink:href="biib-20210331.xsd#biib_NumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_NumberOfProductCandidates_a7a7d117-edf0-4106-a3fd-2d56e8e5a1ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_7c711713-a934-4a80-8666-f58e7e29471e" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_7c711713-a934-4a80-8666-f58e7e29471e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_e93e9687-4cb9-4659-905a-d1a4fd685026" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_e93e9687-4cb9-4659-905a-d1a4fd685026" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_7ef93bea-b0a7-4569-8c02-eef8a6ba5fb5" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_7ef93bea-b0a7-4569-8c02-eef8a6ba5fb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_9de6034c-ea14-468e-b282-e46becaf2ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_9de6034c-ea14-468e-b282-e46becaf2ed8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_5ca23973-6861-4f05-80ec-7893e698a893" xlink:href="biib-20210331.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_ExpenseIncurredByCollaboration_5ca23973-6861-4f05-80ec-7893e698a893" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_bcdeb537-7458-4195-a69f-aab95bd94461" xlink:href="biib-20210331.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_Expenseincurredbythecollaboration_bcdeb537-7458-4195-a69f-aab95bd94461" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_090bebc7-7693-427e-ba1c-9b2f25e09b41" xlink:href="biib-20210331.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_090bebc7-7693-427e-ba1c-9b2f25e09b41" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_476f805d-b64c-4dc6-82f3-81dbd035efe9" xlink:href="biib-20210331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_476f805d-b64c-4dc6-82f3-81dbd035efe9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_9bdb1b95-73a3-4491-8f96-30b2903fe171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_us-gaap_LossOnContractTermination_9bdb1b95-73a3-4491-8f96-30b2903fe171" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_3a9f60d0-2eef-4a97-b61c-c4619e3562b2" xlink:href="biib-20210331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_3a9f60d0-2eef-4a97-b61c-c4619e3562b2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_2a099f42-11b4-4452-86f3-84ff58850aaf" xlink:href="biib-20210331.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_CollaborationAgreementTerm_2a099f42-11b4-4452-86f3-84ff58850aaf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_474ba39c-5cc5-4f0f-9b04-d9c59ed6260a" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_474ba39c-5cc5-4f0f-9b04-d9c59ed6260a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_04b3486d-8771-428f-abaf-fc1f764bee2e" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_04b3486d-8771-428f-abaf-fc1f764bee2e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_bc08930a-43c1-4325-91bb-bb41fcbc3cc5" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_bc08930a-43c1-4325-91bb-bb41fcbc3cc5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_51bb6f5a-f078-46cf-9f3c-e7a91ab5112e" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_51bb6f5a-f078-46cf-9f3c-e7a91ab5112e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3cb12533-240f-4d71-b0ef-73570ac4ad36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3cb12533-240f-4d71-b0ef-73570ac4ad36" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_e6a077aa-9ed4-4a1e-9f5f-3e0d369cca96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_e6a077aa-9ed4-4a1e-9f5f-3e0d369cca96" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2b59efa9-c60f-47fb-b24e-3f53f11fc8c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2b59efa9-c60f-47fb-b24e-3f53f11fc8c3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_5111f9a5-4199-49dc-bbae-89abe9fa94e4" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_5111f9a5-4199-49dc-bbae-89abe9fa94e4" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_6268da5c-9f81-4373-8f5d-c274f859d8d0" xlink:href="biib-20210331.xsd#biib_Termofcollaborationagreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_Termofcollaborationagreement_6268da5c-9f81-4373-8f5d-c274f859d8d0" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57aabd93-7271-4c0b-a31d-528628fab42c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57aabd93-7271-4c0b-a31d-528628fab42c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f4190ea1-f7c8-4954-9af0-78c8ca0ceb50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57aabd93-7271-4c0b-a31d-528628fab42c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f4190ea1-f7c8-4954-9af0-78c8ca0ceb50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f4190ea1-f7c8-4954-9af0-78c8ca0ceb50_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f4190ea1-f7c8-4954-9af0-78c8ca0ceb50" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f4190ea1-f7c8-4954-9af0-78c8ca0ceb50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8b2729f8-a13d-421b-bb2d-a3feccd9e82b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f4190ea1-f7c8-4954-9af0-78c8ca0ceb50" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8b2729f8-a13d-421b-bb2d-a3feccd9e82b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22ed3009-fd8e-4a3b-9337-68762960d2de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b2729f8-a13d-421b-bb2d-a3feccd9e82b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22ed3009-fd8e-4a3b-9337-68762960d2de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cfb0cef2-bc98-47a8-92e3-eca24ec1032b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b2729f8-a13d-421b-bb2d-a3feccd9e82b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cfb0cef2-bc98-47a8-92e3-eca24ec1032b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_804b3cf2-cb55-4e57-979f-0eb78ca123aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57aabd93-7271-4c0b-a31d-528628fab42c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_804b3cf2-cb55-4e57-979f-0eb78ca123aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_804b3cf2-cb55-4e57-979f-0eb78ca123aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_804b3cf2-cb55-4e57-979f-0eb78ca123aa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_804b3cf2-cb55-4e57-979f-0eb78ca123aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_804b3cf2-cb55-4e57-979f-0eb78ca123aa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_fd7f4b22-92de-4f07-8af9-9cdecf47f1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:to="loc_us-gaap_CollaborativeArrangementMember_fd7f4b22-92de-4f07-8af9-9cdecf47f1e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_d55c8c9a-12c9-4e4c-9a42-ad0c919e38c9" xlink:href="biib-20210331.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:to="loc_biib_EisaiMember_d55c8c9a-12c9-4e4c-9a42-ad0c919e38c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_11bac62d-85c6-4843-968f-d5e50ef72aeb" xlink:href="biib-20210331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:to="loc_biib_DenaliTherapeuticsIncMember_11bac62d-85c6-4843-968f-d5e50ef72aeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_e86bbad8-df4d-41e9-ab54-31531690f757" xlink:href="biib-20210331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_6ff783a9-387b-4bec-a624-2267b7c50da3" xlink:href="biib-20210331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_6ff783a9-387b-4bec-a624-2267b7c50da3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_89880766-2909-4dc5-868f-f8b7669671c1" xlink:href="biib-20210331.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:to="loc_biib_SageTherapeuticsIncMember_89880766-2909-4dc5-868f-f8b7669671c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_efed8453-2031-4b10-9ec4-c29ace86ec5d" xlink:href="biib-20210331.xsd#biib_UCBPharmaS.A.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:to="loc_biib_UCBPharmaS.A.Member_efed8453-2031-4b10-9ec4-c29ace86ec5d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_1c3308d7-927b-45f8-9f14-eb913214689a" xlink:href="biib-20210331.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_1c3308d7-927b-45f8-9f14-eb913214689a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c9636f21-fdbd-4933-8874-d970522cf167" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57aabd93-7271-4c0b-a31d-528628fab42c" xlink:to="loc_srt_ProductOrServiceAxis_c9636f21-fdbd-4933-8874-d970522cf167" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c9636f21-fdbd-4933-8874-d970522cf167_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c9636f21-fdbd-4933-8874-d970522cf167" xlink:to="loc_srt_ProductsAndServicesDomain_c9636f21-fdbd-4933-8874-d970522cf167_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_365ee79b-a6ae-48e5-9896-69a5b5c9ff82" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c9636f21-fdbd-4933-8874-d970522cf167" xlink:to="loc_srt_ProductsAndServicesDomain_365ee79b-a6ae-48e5-9896-69a5b5c9ff82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_a6787658-5d65-438e-a18b-963258ffc902" xlink:href="biib-20210331.xsd#biib_E2609andBAN2401Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_365ee79b-a6ae-48e5-9896-69a5b5c9ff82" xlink:to="loc_biib_E2609andBAN2401Member_a6787658-5d65-438e-a18b-963258ffc902" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AducanumabMember_1b69a2c7-d90b-4945-9aa9-4e86721f5924" xlink:href="biib-20210331.xsd#biib_AducanumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_365ee79b-a6ae-48e5-9896-69a5b5c9ff82" xlink:to="loc_biib_AducanumabMember_1b69a2c7-d90b-4945-9aa9-4e86721f5924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1395efbf-0df0-4d7a-acd6-693e96f639b5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57aabd93-7271-4c0b-a31d-528628fab42c" xlink:to="loc_dei_LegalEntityAxis_1395efbf-0df0-4d7a-acd6-693e96f639b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1395efbf-0df0-4d7a-acd6-693e96f639b5_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1395efbf-0df0-4d7a-acd6-693e96f639b5" xlink:to="loc_dei_EntityDomain_1395efbf-0df0-4d7a-acd6-693e96f639b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c5523dd9-2989-4c7d-aeac-e9a6071fc508" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1395efbf-0df0-4d7a-acd6-693e96f639b5" xlink:to="loc_dei_EntityDomain_c5523dd9-2989-4c7d-aeac-e9a6071fc508" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_b2c6f9be-2de4-4004-adc7-e14d6305cc06" xlink:href="biib-20210331.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c5523dd9-2989-4c7d-aeac-e9a6071fc508" xlink:to="loc_biib_SangamoCommonStockMember_b2c6f9be-2de4-4004-adc7-e14d6305cc06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_34607de3-2ed1-4f8c-ac84-3a4b593cb5b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57aabd93-7271-4c0b-a31d-528628fab42c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_34607de3-2ed1-4f8c-ac84-3a4b593cb5b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_34607de3-2ed1-4f8c-ac84-3a4b593cb5b7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_34607de3-2ed1-4f8c-ac84-3a4b593cb5b7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_34607de3-2ed1-4f8c-ac84-3a4b593cb5b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a855ee46-a730-48f7-bf25-02df5fb4d289" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_34607de3-2ed1-4f8c-ac84-3a4b593cb5b7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a855ee46-a730-48f7-bf25-02df5fb4d289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_e1242292-f832-4f19-ad29-4d25c62c67b7" xlink:href="biib-20210331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a855ee46-a730-48f7-bf25-02df5fb4d289" xlink:to="loc_biib_DenaliTherapeuticsIncMember_e1242292-f832-4f19-ad29-4d25c62c67b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_7c676b06-c004-4184-9f53-d0b662c336ba" xlink:href="biib-20210331.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a855ee46-a730-48f7-bf25-02df5fb4d289" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_7c676b06-c004-4184-9f53-d0b662c336ba" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" id="i07a447bfce8c4b059a8332baf4895176_CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0e95c01b-3307-41de-b87c-4160ea09f5c9" xlink:href="biib-20210331.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0e95c01b-3307-41de-b87c-4160ea09f5c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_6a8f05a2-6b05-4834-8afe-9fce89d6fecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_LossOnContractTermination_6a8f05a2-6b05-4834-8afe-9fce89d6fecb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_a323db1f-d6af-4654-b093-39d15b53de0b" xlink:href="biib-20210331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_a323db1f-d6af-4654-b093-39d15b53de0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_73959320-14d4-4c7f-b8cc-31d8345b2592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_73959320-14d4-4c7f-b8cc-31d8345b2592" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_edd92aad-5bba-45c0-8541-18789ff27dfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_edd92aad-5bba-45c0-8541-18789ff27dfa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_9ad97962-4a21-4a67-be45-4df47f1a3f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_9ad97962-4a21-4a67-be45-4df47f1a3f2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_d4f7939c-8878-4659-8d60-0cfb441b58c5" xlink:href="biib-20210331.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_d4f7939c-8878-4659-8d60-0cfb441b58c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_d85aa846-561f-4f46-8399-df0fc1a9f6f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_d85aa846-561f-4f46-8399-df0fc1a9f6f0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_15b3a56b-f8ca-4521-8153-50cfec7ad4b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_15b3a56b-f8ca-4521-8153-50cfec7ad4b1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b219c55f-f593-46eb-ab23-3b5b3006d96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_EquityMethodInvestments_b219c55f-f593-46eb-ab23-3b5b3006d96a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_9c48c99f-a2be-4d57-b8a5-cd3182da9718" xlink:href="biib-20210331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_9c48c99f-a2be-4d57-b8a5-cd3182da9718" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_53dbfafd-3737-42f1-a49f-f4466121a114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_53dbfafd-3737-42f1-a49f-f4466121a114" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_b0c82585-50d7-491c-b73c-87979ce09e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_b0c82585-50d7-491c-b73c-87979ce09e6a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_a1f55157-5810-4c53-9644-649eac457fe8" xlink:href="biib-20210331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_a1f55157-5810-4c53-9644-649eac457fe8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_bef704fe-f07d-42bb-88f6-45d86a587ccc" xlink:href="biib-20210331.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_AdditionalMilestonePayment_bef704fe-f07d-42bb-88f6-45d86a587ccc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_35aa4e99-713d-48c0-9c27-b83fea421a6b" xlink:href="biib-20210331.xsd#biib_ContractOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_ContractOptionExerciseFee_35aa4e99-713d-48c0-9c27-b83fea421a6b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_60242499-fb55-4563-897d-b40931f8676a" xlink:href="biib-20210331.xsd#biib_Biogenshareofcopromotionprofitsorlosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_60242499-fb55-4563-897d-b40931f8676a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_0dc3e770-f45b-44fd-a3f4-227cf6aaeefe" xlink:href="biib-20210331.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_Collaborationprofitlosssharing_0dc3e770-f45b-44fd-a3f4-227cf6aaeefe" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1ede9728-2332-4821-9c4a-e5194d9a5b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_Revenues_1ede9728-2332-4821-9c4a-e5194d9a5b7f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_61bd60d1-d42a-4213-b6f1-7368d6d5b2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_61bd60d1-d42a-4213-b6f1-7368d6d5b2cc" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_be3436d2-d5f7-4d30-b5e2-04180d42bf37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_be3436d2-d5f7-4d30-b5e2-04180d42bf37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_46746d88-fd1b-4c79-96c5-5a99007bd14f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_be3436d2-d5f7-4d30-b5e2-04180d42bf37" xlink:to="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_46746d88-fd1b-4c79-96c5-5a99007bd14f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_46746d88-fd1b-4c79-96c5-5a99007bd14f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_46746d88-fd1b-4c79-96c5-5a99007bd14f" xlink:to="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_46746d88-fd1b-4c79-96c5-5a99007bd14f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_74e5663e-e9e7-42ff-b6ff-79c4acc43350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_46746d88-fd1b-4c79-96c5-5a99007bd14f" xlink:to="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_74e5663e-e9e7-42ff-b6ff-79c4acc43350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_6f200e4a-85d4-4e73-a629-a8bf01aad82d" xlink:href="biib-20210331.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_74e5663e-e9e7-42ff-b6ff-79c4acc43350" xlink:to="loc_biib_NeurimmuneMember_6f200e4a-85d4-4e73-a629-a8bf01aad82d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_9817fbf8-fb2f-40b4-a5e5-e8808185b2e2" xlink:href="biib-20210331.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_be3436d2-d5f7-4d30-b5e2-04180d42bf37" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_9817fbf8-fb2f-40b4-a5e5-e8808185b2e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_9817fbf8-fb2f-40b4-a5e5-e8808185b2e2_default" xlink:href="biib-20210331.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_9817fbf8-fb2f-40b4-a5e5-e8808185b2e2" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_9817fbf8-fb2f-40b4-a5e5-e8808185b2e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_2db89149-525b-410d-8fd9-7df7a09b028a" xlink:href="biib-20210331.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_9817fbf8-fb2f-40b4-a5e5-e8808185b2e2" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_2db89149-525b-410d-8fd9-7df7a09b028a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_4896ca7d-30e2-4bcc-a61e-bee1fdb9116f" xlink:href="biib-20210331.xsd#biib_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_2db89149-525b-410d-8fd9-7df7a09b028a" xlink:to="loc_biib_RegulatoryMilestonesMember_4896ca7d-30e2-4bcc-a61e-bee1fdb9116f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_c2b4a2ab-852a-44fc-b770-aafe4ca4050e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_be3436d2-d5f7-4d30-b5e2-04180d42bf37" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_c2b4a2ab-852a-44fc-b770-aafe4ca4050e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c2b4a2ab-852a-44fc-b770-aafe4ca4050e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c2b4a2ab-852a-44fc-b770-aafe4ca4050e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c2b4a2ab-852a-44fc-b770-aafe4ca4050e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861ad7bd-4361-4ac7-8cd7-f6126f50efc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c2b4a2ab-852a-44fc-b770-aafe4ca4050e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861ad7bd-4361-4ac7-8cd7-f6126f50efc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_5e65a73a-2d76-4e01-9e31-e55701bcbf42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861ad7bd-4361-4ac7-8cd7-f6126f50efc2" xlink:to="loc_us-gaap_InventoriesMember_5e65a73a-2d76-4e01-9e31-e55701bcbf42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_ca72e396-6a2d-40b8-bd64-3380c6c78aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861ad7bd-4361-4ac7-8cd7-f6126f50efc2" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_ca72e396-6a2d-40b8-bd64-3380c6c78aeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_1fc96015-c763-4b0f-bc26-671b8a7ce459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861ad7bd-4361-4ac7-8cd7-f6126f50efc2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_1fc96015-c763-4b0f-bc26-671b8a7ce459" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0f12ea1a-0489-4c5b-8125-4c1c36407dbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_be3436d2-d5f7-4d30-b5e2-04180d42bf37" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0f12ea1a-0489-4c5b-8125-4c1c36407dbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0f12ea1a-0489-4c5b-8125-4c1c36407dbc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0f12ea1a-0489-4c5b-8125-4c1c36407dbc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0f12ea1a-0489-4c5b-8125-4c1c36407dbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13d6c4b9-8185-4890-8e01-1619fe7a5af4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0f12ea1a-0489-4c5b-8125-4c1c36407dbc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13d6c4b9-8185-4890-8e01-1619fe7a5af4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_fb77d352-731f-4889-a131-60e07d65f5cd" xlink:href="biib-20210331.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13d6c4b9-8185-4890-8e01-1619fe7a5af4" xlink:to="loc_biib_EisaiMember_fb77d352-731f-4889-a131-60e07d65f5cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_05618274-0706-4d0f-beac-ac986d4928f2" xlink:href="biib-20210331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13d6c4b9-8185-4890-8e01-1619fe7a5af4" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_05618274-0706-4d0f-beac-ac986d4928f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_6f29a35e-0122-430e-9a73-4377f653de14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13d6c4b9-8185-4890-8e01-1619fe7a5af4" xlink:to="loc_us-gaap_CollaborativeArrangementMember_6f29a35e-0122-430e-9a73-4377f653de14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_335e4442-9fef-47fa-9b3b-bf2d6daee762" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_be3436d2-d5f7-4d30-b5e2-04180d42bf37" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_335e4442-9fef-47fa-9b3b-bf2d6daee762" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_335e4442-9fef-47fa-9b3b-bf2d6daee762_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_335e4442-9fef-47fa-9b3b-bf2d6daee762" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_335e4442-9fef-47fa-9b3b-bf2d6daee762_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8b7c6aea-2082-479d-8cde-4018e85134da" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_335e4442-9fef-47fa-9b3b-bf2d6daee762" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8b7c6aea-2082-479d-8cde-4018e85134da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_49ca4fb8-cea6-42b4-8f51-31aba8eba925" xlink:href="biib-20210331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8b7c6aea-2082-479d-8cde-4018e85134da" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_49ca4fb8-cea6-42b4-8f51-31aba8eba925" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20210331.xsd#InvestmentsinVariableInterestEntities"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended" id="i76403ebdb867413ca5f583a3e9c67d91_InvestmentsinVariableInterestEntities"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended" id="i85fd9cb50a8e4eaab332f372daa7df4a_InvestmentsinVariableInterestEntitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_9cc657d3-ed8b-488e-b074-b6ed3a47c702" xlink:href="biib-20210331.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_biib_CollaborationAgreementTerm_9cc657d3-ed8b-488e-b074-b6ed3a47c702" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_67c6fe50-4d9d-4974-bc3a-c127461d8706" xlink:href="biib-20210331.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_67c6fe50-4d9d-4974-bc3a-c127461d8706" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_5a9868be-b6d7-4f8a-80b1-3178eb3318c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_5a9868be-b6d7-4f8a-80b1-3178eb3318c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_44e00b01-7ff3-4623-a2a5-e8e2149358f9" xlink:href="biib-20210331.xsd#biib_Reductioninroyaltyratepayableoncommercialsales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_44e00b01-7ff3-4623-a2a5-e8e2149358f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_60a27afe-db09-48df-8887-b74c12010bf8" xlink:href="biib-20210331.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_60a27afe-db09-48df-8887-b74c12010bf8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6a08a66b-83e7-4158-8f4f-99c0535a02c4" xlink:href="biib-20210331.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6a08a66b-83e7-4158-8f4f-99c0535a02c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3858db63-d2b3-4c2d-a878-a28beadede3f" xlink:href="biib-20210331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3858db63-d2b3-4c2d-a878-a28beadede3f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2caf69e4-fdb9-4270-9715-cb864787b1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2caf69e4-fdb9-4270-9715-cb864787b1b6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4ce3547c-d7c9-4b5c-b1d7-f2e1c287fc85" xlink:href="biib-20210331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4ce3547c-d7c9-4b5c-b1d7-f2e1c287fc85" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_21dc4dc6-0f8f-4bdc-ba78-77cee4d051c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_21dc4dc6-0f8f-4bdc-ba78-77cee4d051c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b69826c4-56fa-4a8a-be59-8796c63547a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_21dc4dc6-0f8f-4bdc-ba78-77cee4d051c9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b69826c4-56fa-4a8a-be59-8796c63547a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b69826c4-56fa-4a8a-be59-8796c63547a2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b69826c4-56fa-4a8a-be59-8796c63547a2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b69826c4-56fa-4a8a-be59-8796c63547a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edb5200f-c3b3-4c16-bf93-24bf204a89da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b69826c4-56fa-4a8a-be59-8796c63547a2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edb5200f-c3b3-4c16-bf93-24bf204a89da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_6cf32381-e4f6-4d55-b8cb-6aa5273e56c3" xlink:href="biib-20210331.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edb5200f-c3b3-4c16-bf93-24bf204a89da" xlink:to="loc_biib_EisaiMember_6cf32381-e4f6-4d55-b8cb-6aa5273e56c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AducanumabMember_f76e3f77-6239-4d41-9046-862aab686581" xlink:href="biib-20210331.xsd#biib_AducanumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edb5200f-c3b3-4c16-bf93-24bf204a89da" xlink:to="loc_biib_AducanumabMember_f76e3f77-6239-4d41-9046-862aab686581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_ce30f492-40ae-4289-93f3-4c6eee30e717" xlink:href="biib-20210331.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edb5200f-c3b3-4c16-bf93-24bf204a89da" xlink:to="loc_biib_NeurimmuneMember_ce30f492-40ae-4289-93f3-4c6eee30e717" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_85ab48fd-9009-4909-a92f-4f16d49753f1" xlink:href="biib-20210331.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_21dc4dc6-0f8f-4bdc-ba78-77cee4d051c9" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_85ab48fd-9009-4909-a92f-4f16d49753f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_85ab48fd-9009-4909-a92f-4f16d49753f1_default" xlink:href="biib-20210331.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_85ab48fd-9009-4909-a92f-4f16d49753f1" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_85ab48fd-9009-4909-a92f-4f16d49753f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_1f0e2aec-b972-4317-a1d2-bc407644dc88" xlink:href="biib-20210331.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_85ab48fd-9009-4909-a92f-4f16d49753f1" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_1f0e2aec-b972-4317-a1d2-bc407644dc88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_d0a0cd59-3899-4091-8d18-437f8e80b6ca" xlink:href="biib-20210331.xsd#biib_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_1f0e2aec-b972-4317-a1d2-bc407644dc88" xlink:to="loc_biib_RegulatoryMilestonesMember_d0a0cd59-3899-4091-8d18-437f8e80b6ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7a5b81b1-1288-4b7f-9433-236a212761d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_21dc4dc6-0f8f-4bdc-ba78-77cee4d051c9" xlink:to="loc_srt_StatementGeographicalAxis_7a5b81b1-1288-4b7f-9433-236a212761d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7a5b81b1-1288-4b7f-9433-236a212761d5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7a5b81b1-1288-4b7f-9433-236a212761d5" xlink:to="loc_srt_SegmentGeographicalDomain_7a5b81b1-1288-4b7f-9433-236a212761d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_15c58e5f-bb58-4056-9660-aca3fc674546" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7a5b81b1-1288-4b7f-9433-236a212761d5" xlink:to="loc_srt_SegmentGeographicalDomain_15c58e5f-bb58-4056-9660-aca3fc674546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_0c8e901e-80d2-4ca9-8aa4-3ba1a50ad563" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_15c58e5f-bb58-4056-9660-aca3fc674546" xlink:to="loc_country_JP_0c8e901e-80d2-4ca9-8aa4-3ba1a50ad563" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_b59d50ba-febb-4bad-bc76-a4c57cc0a2d0" xlink:href="biib-20210331.xsd#biib_ExpectedPaymentTimelineofMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_21dc4dc6-0f8f-4bdc-ba78-77cee4d051c9" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_b59d50ba-febb-4bad-bc76-a4c57cc0a2d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineOfMilestoneDomain_b59d50ba-febb-4bad-bc76-a4c57cc0a2d0_default" xlink:href="biib-20210331.xsd#biib_ExpectedPaymentTimelineOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_b59d50ba-febb-4bad-bc76-a4c57cc0a2d0" xlink:to="loc_biib_ExpectedPaymentTimelineOfMilestoneDomain_b59d50ba-febb-4bad-bc76-a4c57cc0a2d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineOfMilestoneDomain_9de91747-d8d5-4560-8ea7-9234f62596d9" xlink:href="biib-20210331.xsd#biib_ExpectedPaymentTimelineOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_b59d50ba-febb-4bad-bc76-a4c57cc0a2d0" xlink:to="loc_biib_ExpectedPaymentTimelineOfMilestoneDomain_9de91747-d8d5-4560-8ea7-9234f62596d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TwelvemonthsMember_1f6468ae-be55-417e-a6fa-2c357233295b" xlink:href="biib-20210331.xsd#biib_TwelvemonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ExpectedPaymentTimelineOfMilestoneDomain_9de91747-d8d5-4560-8ea7-9234f62596d9" xlink:to="loc_biib_TwelvemonthsMember_1f6468ae-be55-417e-a6fa-2c357233295b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_bb786dcb-a51e-42c6-9990-e6da935f5dd7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_21dc4dc6-0f8f-4bdc-ba78-77cee4d051c9" xlink:to="loc_srt_ConsolidatedEntitiesAxis_bb786dcb-a51e-42c6-9990-e6da935f5dd7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_bb786dcb-a51e-42c6-9990-e6da935f5dd7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_bb786dcb-a51e-42c6-9990-e6da935f5dd7" xlink:to="loc_srt_ConsolidatedEntitiesDomain_bb786dcb-a51e-42c6-9990-e6da935f5dd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d73689f9-d7b0-480d-8a0a-a05762355713" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_bb786dcb-a51e-42c6-9990-e6da935f5dd7" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d73689f9-d7b0-480d-8a0a-a05762355713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_3220fac9-2d1a-4c4e-8f95-e18d51d6b530" xlink:href="biib-20210331.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d73689f9-d7b0-480d-8a0a-a05762355713" xlink:to="loc_biib_NeurimmuneMember_3220fac9-2d1a-4c4e-8f95-e18d51d6b530" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20210331.xsd#Litigation"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" id="i9be548c41ff14b368a733470e833920f_Litigation"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#LitigationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended" id="i6b102d2334f64cd189579343920456f9_LitigationDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>biib-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:b54f3254-567d-4813-a83c-54bbe0ebf523,g:5bfc82e5-4d8f-4b59-aa4e-ce589875722a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_biib_Expenseincurredbythecollaboration_da3f235f-fc5f-4aaf-9fdc-13cf701bb023_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration" xlink:href="biib-20210331.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration" xlink:to="lab_biib_Expenseincurredbythecollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5ec672e3-2c75-42b7-8930-331562949b39_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0fe850b5-1d1e-41b7-a267-b78c664c36d8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9ccc3ef0-5853-41ee-849d-3945c38ff0fa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_097e7fbf-9f82-4f59-8519-6a09a2073043_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:href="biib-20210331.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_61018767-798d-406b-92d5-7e40aee25850_terseLabel_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_label_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_documentation_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability" xlink:href="biib-20210331.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TechnologicalAndRegulatorySuccessProbability" xlink:to="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_0db1fc3e-8a12-4857-863a-b2fb1f1fb471_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7aa5cf4a-d850-486a-aa09-af938ac432d2_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_680f5d86-6e3e-486a-9f6d-c9cb0d6328e1_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_d5f62c50-00d9-46a3-9369-e3f0d0df7c2b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_32edf0d8-97b6-40a8-aa2b-6f369f78d63c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ZINBRYTAMember_3b90ba65-2926-4bc7-b858-3445b8d6f5f9_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_label_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember" xlink:href="biib-20210331.xsd#biib_ZINBRYTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember" xlink:to="lab_biib_ZINBRYTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b31d5830-a4c9-4bae-8ba1-8614e54b01cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_7506dadd-fe0f-4e8d-aef2-e9ef08d52cae_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_39795f2c-7220-4333-8578-54586497f40e_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_9dabe101-3b51-4bbc-96c0-660b14618676_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_f96a2621-c07f-4272-9fd7-2ca8b780278e_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:href="biib-20210331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_29920f1a-89c1-46b8-81db-cd59eecda4ae_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, decrease in value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Value, Reduction in Value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Value, Reduction in Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:href="biib-20210331.xsd#biib_DeferredTaxLiabilitiesValueReductioninValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:to="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_5708d78d-5507-4087-854f-f3deddb4ac6c_terseLabel_en-US" xlink:label="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_documentation_en-US" xlink:label="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="biib-20210331.xsd#biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_385df2e1-22d6-4bbf-b4f1-c327476bd842_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d1b9f5b9-2353-4443-8a6c-6dc741f66f74_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4b6e1f6b-155c-4f28-ae8b-1c6332e27afe_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_f3fb36d3-ad48-4a44-85d9-44bed795fc03_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_ecaaae83-e9d9-46c1-9715-531eb1f6fa00_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_db6992c4-f296-4a4b-af12-c0c864d86c13_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_b08fcac1-1c60-4f15-b6fe-197c5a4d2a70_terseLabel_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc [Member]</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember" xlink:href="biib-20210331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenaliTherapeuticsIncMember" xlink:to="lab_biib_DenaliTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_218b9b9a-ac9d-4b64-b9fb-f813e61bc0bb_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_fcdd7c79-a5b0-44f1-8699-3b6333f1b824_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7de8ed18-0a22-4ab2-80cd-87a12773fc35_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_8c1c2338-9b4e-4091-bf2e-8ac5249b5b93_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SPINRAZAMember_8118ff7d-7433-4945-8a62-27b1566b492f_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_label_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember" xlink:href="biib-20210331.xsd#biib_SPINRAZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember" xlink:to="lab_biib_SPINRAZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a7d54878-5b31-49a0-a2ab-6fe2f8faf4f8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_7c9df6f1-b893-4e47-85fc-8bf3adb2acd9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Progams, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TysabriProductMember_4cd5830d-4932-4618-a923-8fe0cefee95d_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_label_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_documentation_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember" xlink:href="biib-20210331.xsd#biib_TysabriProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember" xlink:to="lab_biib_TysabriProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a42d0bb2-bec2-4a3c-8e27-d3a8e76d20f3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_86a7cadf-5bf7-491c-b438-41e939587f9a_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_9e67ba53-861e-4942-b139-0be63bb31cc3_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_310897d3-02c8-49a3-b3ef-cb3545b3c3cb_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits" xlink:href="biib-20210331.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits" xlink:to="lab_biib_ShareOfCoPromotionProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_eda521de-bbf6-4c9f-9022-44042bedd946_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by Consolidated and Nonconsolidated Entities [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by Consolidated and Nonconsolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:to="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_f6cced9b-0f96-4f50-a6e2-13636b9ebf39_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c714e325-0969-4cbe-adb9-054d884cd4b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_558d5096-719c-42b1-b886-5eae621bb694_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e546d9cd-503c-4719-be39-9433780981fc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_a1fe9111-9b30-4544-bed3-c7ba69b4c85c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_f852f40f-9f17-42a0-97f6-c392a588a96b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2651b5b1-e7c5-4e57-a1a8-b0ed8aeeee54_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1770790e-4dd5-4f3d-aeca-521891400195_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_587b0d7f-c3e6-41ae-a1c4-21d14439f56d_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_399414db-a18e-40ea-8cdf-37c178b0517f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_d1265419-6c98-4561-b142-26778fe7f2d8_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_843dc798-03fa-4e1b-8300-961cbaf88b74_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Research and development asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain" xlink:href="biib-20210331.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetDomain" xlink:to="lab_biib_ResearchanddevelopmentassetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8c9fef59-072d-491d-9b36-ff91d655cf06_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_9483965b-89ab-45b8-8be8-cd68f142c41d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5565ecde-242f-407e-91e5-bfcd286e9e2d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_81a4866d-82f5-4a4a-9f63-0a9d35651da4_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_14ebb2a5-c4e8-4350-83cb-3ed5f6677e5b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_8319da03-e99c-4bd3-b5f9-475de9f03321_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_ee4b4693-1524-486b-bde9-57a7b198ae10_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_8335d469-33e5-404a-b5df-c2c2ef08cde3_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_6da67ed3-342a-4a80-9bd3-effb3b3e57fa_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_61ac6140-9c2b-4c1f-b0d4-e80d302feeb8_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0b1d8c24-9bba-4d92-be12-6112f6359301_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_00980413-3a9b-4d72-bf40-e7bf19bdf563_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractualAdjustmentsMember_0c999b2c-c279-4a03-8a5c-f541a2e9319e_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember" xlink:href="biib-20210331.xsd#biib_ContractualAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember" xlink:to="lab_biib_ContractualAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_a2968811-3f4c-4e71-9714-1594e0e76d90_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_fd974899-21ee-45df-b06e-c673020f92c0_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OutLicensedPatentsMember_e633f243-348e-47fa-a596-38f10e924af6_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember" xlink:href="biib-20210331.xsd#biib_OutLicensedPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember" xlink:to="lab_biib_OutLicensedPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_fc4261f1-6030-427e-839c-f8fc01409781_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorTwoMember_9c96e430-dd84-4130-8834-e7da7dd5bc71_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_label_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember" xlink:href="biib-20210331.xsd#biib_DistributorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember" xlink:to="lab_biib_DistributorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_cc4ea5a5-4d0e-44bc-b10c-16e205e08b51_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:href="biib-20210331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_eaa0af8a-735e-4b92-bc83-4a1f14edb43d_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stake in entity</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:href="biib-20210331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_c9421c87-f62b-4f16-a62e-a6fa388b90bb_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_a8a15954-e439-41e5-8f6f-bc9cc4ab259c_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_a4e376ae-e74a-4bbe-b043-6439979052bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_37676eec-0d03-4d51-a8d0-649c225bedd7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional investment in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_97321d9b-1d71-4ee5-ba80-9ee6c6ae4ba1_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_af2fff31-5a28-4c12-915a-594b76a0d3bc_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_61214543-348c-4646-893d-b8f970d60493_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_bd951a0e-f3d2-4dd1-b597-37367d393fe1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_9b8539f7-970e-423e-a569-817962749b3b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c06a6085-1fa5-45ca-88a9-7451358aed3c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0d507728-a6b5-41ab-92d6-a164fc0888c2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MarketStockUnitsMember_17cdd28d-53cb-4e66-bf0c-c0b7a74bd1c5_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember" xlink:href="biib-20210331.xsd#biib_MarketStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember" xlink:to="lab_biib_MarketStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_f2dddbc8-4c0e-47fb-9992-e837bc6f7fea_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:href="biib-20210331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_487c6e63-75da-4ba4-a402-77acc5ca1132_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_a19af951-d305-49bb-8ccd-2bc0baecdae2_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_f6be8766-27c9-468e-b5b9-aba2c01adf75_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:href="biib-20210331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_dd4c34b3-4ea0-4e4e-b23e-c1cb3f804b73_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_a1fccf05-6c0d-4ef7-8170-d529cf78991d_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_ada2addc-580b-426d-9a2e-4c218c34b331_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2.90SeniorNotesDueSept152020Member_7c15d691-0965-44db-86c4-9e3725da2ee5_terseLabel_en-US" xlink:label="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Senior Notes Due Sept 15, 2020</link:label>
    <link:label id="lab_biib_A2.90SeniorNotesDueSept152020Member_label_en-US" xlink:label="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Senior Notes Due Sept 15, 2020 [Member]</link:label>
    <link:label id="lab_biib_A2.90SeniorNotesDueSept152020Member_documentation_en-US" xlink:label="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Senior Notes Due Sept 15, 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.90SeniorNotesDueSept152020Member" xlink:href="biib-20210331.xsd#biib_A2.90SeniorNotesDueSept152020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.90SeniorNotesDueSept152020Member" xlink:to="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpectedPaymentTimelineOfMilestoneDomain_418bef99-ae61-476d-b0a8-8c3373bb194b_terseLabel_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineOfMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Payment Timeline of Milestone [Domain]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineOfMilestoneDomain_label_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineOfMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Payment Timeline of Milestone [Domain]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineOfMilestoneDomain_documentation_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineOfMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Payment Timeline of Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineOfMilestoneDomain" xlink:href="biib-20210331.xsd#biib_ExpectedPaymentTimelineOfMilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedPaymentTimelineOfMilestoneDomain" xlink:to="lab_biib_ExpectedPaymentTimelineOfMilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_577ff404-908f-492b-b0d4-8e591ed4f4e5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_44a2fdd9-a655-4c07-b753-138381311ebf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_80990b36-1caf-4753-bf29-9dc8c863dcdd_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:href="biib-20210331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_c3e617e8-b4a0-443e-ac9b-aa821712e401_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_cdb865e6-5b76-4c81-b528-a73e331ecb87_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f20bfa0b-6719-4706-a23c-bdb5438ffe8c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IMRALDIMember_2f51d212-f7da-413b-93dc-3bdb94f4a36a_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_label_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_documentation_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember" xlink:href="biib-20210331.xsd#biib_IMRALDIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember" xlink:to="lab_biib_IMRALDIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1c86b7a-75ce-410f-a689-96d97cd3c4d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_ab17f58c-85f4-44de-8341-69054eae1e9e_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:href="biib-20210331.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_96365195-a104-47fa-b061-d0ef396e51e6_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_c7fd5674-2b9b-4d73-94ab-b53624cffd42_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4e55763f-e012-478e-8a20-b30db13e6dcb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5fb6f487-d010-4aba-9642-9ccbb98594fb_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_22417d74-b793-4306-832f-d875022986fe_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_b208bc52-48da-4b66-8162-6a23fd9e19f9_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_4b058a82-896a-41fa-902c-2036487667d0_terseLabel_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:href="biib-20210331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_824927c3-a785-40e4-acf2-ab9f7f81216a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on net investment hedges in AOCI</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_3bb3eda0-f55b-4a37-bde4-4a3f0cbfc78a_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c0e7177d-0071-4285-a5d0-85c6c930c259_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_05c25eaf-ded5-4a90-8909-33600e110a0f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1a6b9252-ca66-47b0-9369-6f1ac57a40f4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_330358b8-e43c-47ea-bb2d-528a7dae678e_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_49aacabd-23e4-4158-b76a-adf77630f9cb_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:href="biib-20210331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_8e1a7da0-40ad-4963-92eb-ab485d0bf49a_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:href="biib-20210331.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:to="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_d4e13c02-c5c8-466f-9575-3aeec23ac08a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_350819ce-74a3-4fee-8235-52c5630c7060_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_ba478b13-25a9-4d9e-80d2-34b2936ed556_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_97c0c15c-dc72-4897-a046-66c1a1d40855_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:href="biib-20210331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8afa5599-51ec-4de2-a5e9-6570816fe4b7_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FumarateMember_b1cac225-50d9-48f9-9ee5-43e08d14ca3d_terseLabel_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate</link:label>
    <link:label id="lab_biib_FumarateMember_label_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:label id="lab_biib_FumarateMember_documentation_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember" xlink:href="biib-20210331.xsd#biib_FumarateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumarateMember" xlink:to="lab_biib_FumarateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_73e23c4a-fffe-4113-8485-e40ae23ffb39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_7bd06aea-2b88-4a68-9998-cb10206ef98b_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_d27bffe6-ca90-427c-a180-397f4852ccbb_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_d8975932-8aaf-4415-bd9b-8c8a88e5b901_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_22634720-f126-4476-a6ad-3d1662818898_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0a8894ac-8b23-48f0-b4bb-bfa888813f05_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_80ace96b-5893-4a0e-998b-43b420990c01_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0d90f26-2b1d-4381-acca-2dd84d27f73b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_7ea7a2a1-b946-4f15-aad5-71b1b44e60a8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_1090c387-c9e3-4084-8507-819736d70ce8_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_f956a691-38b7-4b41-9ecd-b4e87dcaf555_terseLabel_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.150% Senior Notes due May 1, 2050</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_label_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_documentation_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:href="biib-20210331.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:to="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1a7b20ba-55ed-452e-bf2e-cb200a28d1e6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_a82cadf6-80f4-4273-9909-354bde89f1d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings and premiums paid on debt exchange</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_725e286e-eb55-4404-a977-e603ab3229ae_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings and premiums paid on debt exchange</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_a8c96b84-d20d-4834-9022-4d14f89e7562_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember" xlink:href="biib-20210331.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember" xlink:to="lab_biib_ReserveforCashDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfWholesalers_3cd51b92-a829-4b43-8aba-c75f38da9bbb_terseLabel_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_label_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_documentation_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers" xlink:href="biib-20210331.xsd#biib_NumberOfWholesalers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfWholesalers" xlink:to="lab_biib_NumberOfWholesalers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_acfa40c6-19cb-46a5-ba04-0b18ba992459_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_ea897896-6e77-4742-8964-d6f2e04f92da_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:href="biib-20210331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4cde8715-5452-40e6-85b5-d85f7ca6c0f4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a1b94d61-b64e-41c5-9c0c-1a2e2e56d981_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InLicensedPatentsMember_f7993402-9f34-45aa-95bc-7022c5c460fc_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InLicensedPatentsMember" xlink:href="biib-20210331.xsd#biib_InLicensedPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember" xlink:to="lab_biib_InLicensedPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_76fe4785-b8ec-4ffe-be05-e1437b2201e8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_73d399fd-cfe0-4e1f-b97c-699266e03a4d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_65035f74-a1ac-4beb-84fa-84f8af39376d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_af986dd5-8e34-461f-afd5-0b34bfee9ad4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bf3174d-e17e-41d3-a29c-082a20db3fd5_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_bcd61ee7-8a60-4d24-9420-c2ab7d057baa_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_76a1931c-2f24-419a-b230-ea0537d921df_terseLabel_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember" xlink:href="biib-20210331.xsd#biib_A2018ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2018ShareRepurchaseProgramMember" xlink:to="lab_biib_A2018ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_def8d682-43f7-4366-8b99-b6436c9f1b53_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_0af39247-95a2-4ba6-a606-4ba7c22e291d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_f6198c4e-c75f-4c2c-a91c-ee8b7b95d0e5_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:href="biib-20210331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_f7fcd568-13a4-420d-96b2-b6ae1332ad42_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_23fae385-acaa-4b57-ae9a-11ec1e7d6568_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_b6045458-f518-4425-abb2-f0f0acc231d7_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_a9d57f06-cdd3-4eea-8c9b-288fe834fc75_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:href="biib-20210331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_e37400ea-5522-47f2-94c9-24b747d85146_terseLabel_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_label_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage [Member]</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_documentation_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember" xlink:href="biib-20210331.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisSangamoDenaliAndSageMember" xlink:to="lab_biib_IonisSangamoDenaliAndSageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_445c368b-a074-480b-8bd8-f794ad956522_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5922006d-c805-4587-9871-89d6a8dfc9ac_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_80837ae9-84bb-4251-9749-646ac9b8365c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_3a7552bf-f6de-4b07-b44c-e4b34e239aae_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_9edccd00-9567-47aa-94b8-77020f3f1f83_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8a045f76-dacf-415b-8de4-ea0cd378a361_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_e7722501-a5d3-48c6-b792-bf4e8ef9f890_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_8cb29a98-f890-4dfe-9863-f43053fcd8fe_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_192fe08e-5e74-4812-9d70-5184c6fa7550_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_e07bf97d-b9d3-4198-80ed-94c157db1059_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_3c5628b9-a09f-4f8c-9716-b2fa116f891a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6ee852c8-3cdf-4767-9868-4f1b6b69b1d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_bbe014c8-0cbd-448f-80d6-bcb16027bd8b_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedges</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2717e7b4-217a-4a74-902b-fbd9622ea50f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_23a6e52e-958e-47d1-8a32-76d81863bf63_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_212f77a6-fd4c-444e-a99b-3f5497133cfd_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c3bf1afb-25de-4698-9919-a409356fb255_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f563c845-2491-4a15-8ca6-4a86ea831c1b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_146f1ffc-0ff2-4c28-a692-2742b5b3e64d_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_cc203193-ce62-4cad-bd3f-61cc57b28db7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FUMADERMMember_3dce5242-dd43-49c8-8e76-d99200683e59_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_label_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_documentation_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember" xlink:href="biib-20210331.xsd#biib_FUMADERMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember" xlink:to="lab_biib_FUMADERMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_d6943312-b0cd-4bcb-b808-066dc1bc0650_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationDomain_bffcce9b-94f1-4f3b-a282-d7d7da3dcfcb_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_label_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain" xlink:href="biib-20210331.xsd#biib_FacilityLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain" xlink:to="lab_biib_FacilityLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiologicsManufacturingMember_afe32ba7-f7f6-4cfe-b683-74ad1c7281d0_terseLabel_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_label_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing [Member]</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_documentation_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember" xlink:href="biib-20210331.xsd#biib_BiologicsManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiologicsManufacturingMember" xlink:to="lab_biib_BiologicsManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7a35c583-2ea1-4827-87fe-2b7d072ab6b2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_db89a902-e7e2-41ff-966a-0793d0393c7b_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2465df5c-b592-4ae9-8355-f1655ab92881_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfProductCandidates_c2313b92-7742-4e79-9c75-4f7ead3be3d0_terseLabel_en-US" xlink:label="lab_biib_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product candidates</link:label>
    <link:label id="lab_biib_NumberOfProductCandidates_label_en-US" xlink:label="lab_biib_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Product Candidates</link:label>
    <link:label id="lab_biib_NumberOfProductCandidates_documentation_en-US" xlink:label="lab_biib_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfProductCandidates" xlink:href="biib-20210331.xsd#biib_NumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfProductCandidates" xlink:to="lab_biib_NumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_99cbbe4f-9f71-46cf-b642-c89ff867664d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7969707c-a38a-4284-9eb1-b7df65973455_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a9af812b-54ab-49a2-9016-ef6ab9ec4817_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c1560a60-d713-45d6-86d6-986e26829843_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_cf09d7ab-9d79-4918-a7c2-2f13248eaffc_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0aa9b887-f49e-4840-b4f2-660445cb37c1_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_06d8fec3-2193-4170-9f05-fe25ddd3759c_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_8250625d-4af9-467d-a79d-eb999350bb55_terseLabel_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage par value of senior notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_label_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_documentation_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes" xlink:href="biib-20210331.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageParValueOfSeniorNotes" xlink:to="lab_biib_PercentageParValueOfSeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9d92f39f-44d8-4b47-8b29-32a0d8534377_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_9d1a6852-6530-4e17-ab0e-0f0f923d15ee_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_68495914-c35e-40d1-9cb1-2038bb87daff_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_f6b480fa-5c95-4427-ad68-5c2b32a31aa3_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:href="biib-20210331.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_22b9bfd9-d5da-486f-bcef-3e08809fd10e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_JPY_7b4181c2-f704-4cd1-b036-6dd666e28b6e_terseLabel_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_label_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_JPY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY" xlink:to="lab_currency_JPY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_6ca52357-db2a-45df-b290-37f7cf65e75b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_989bb713-6feb-4241-bfbb-ee7c6f5ce272_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeDomain_a5f0fe9f-7fcb-445e-ab51-c846e31b6d94_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_label_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_documentation_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain" xlink:href="biib-20210331.xsd#biib_FacilityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeDomain" xlink:to="lab_biib_FacilityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_7454a90b-14e1-42da-8277-3c4f0cf9b2f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_595280cd-bb21-4a6b-8c0c-5e3056b2105c_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, amortization and impairments</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BENEPALIMember_ca046a65-226f-4dbc-b960-24414f91b593_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_label_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_documentation_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember" xlink:href="biib-20210331.xsd#biib_BENEPALIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember" xlink:to="lab_biib_BENEPALIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_dc1aa1df-71a0-4ed7-9e91-9118694a47ba_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6dc5fac6-ae37-4dd7-a9b5-a9585a37855b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains recognized on the increase in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB118Member_7b7187b2-6a74-458c-ae4a-44de4dfaf5d7_terseLabel_en-US" xlink:label="lab_biib_BIIB118Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB118</link:label>
    <link:label id="lab_biib_BIIB118Member_label_en-US" xlink:label="lab_biib_BIIB118Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB118 [Member]</link:label>
    <link:label id="lab_biib_BIIB118Member_documentation_en-US" xlink:label="lab_biib_BIIB118Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB118 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB118Member" xlink:href="biib-20210331.xsd#biib_BIIB118Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB118Member" xlink:to="lab_biib_BIIB118Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_39854f69-b538-4d87-9a45-d767001f4a1e_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_bc69ac73-6fe3-46bd-b9a1-6c4f3250633f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_ae368edb-d2fe-42dd-b3a1-3564e45cbece_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CAD_69260feb-e5cd-49a1-9794-6a230afeb42b_verboseLabel_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_label_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CAD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD" xlink:to="lab_currency_CAD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_ba334cf1-e68f-4cf4-9254-9ceea7c7f62d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_c0d8da12-5c53-433f-8b8f-48c8f3a912c4_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_b5ecd5f7-0b45-4568-84c2-fa0b09315f13_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_64487ee6-6720-4f05-bea0-68e08138aeb5_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent" xlink:href="biib-20210331.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_05ae480a-f5c5-4a58-9831-965384f13f91_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_3e061074-3f92-41c7-9a0e-3960816726bb_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_40d55653-99a8-4b4c-b865-d429798c8cba_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="biib-20210331.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentsMember_3ade199f-8544-4f54-b0fb-d1ab482fdffd_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember" xlink:href="biib-20210331.xsd#biib_StrategicInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember" xlink:to="lab_biib_StrategicInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_c1d4cd96-bf86-482c-bc46-6904e9b7f868_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:href="biib-20210331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_c43fa3e0-d584-40e3-9b50-88b57990bbee_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_27c51f0b-dd4c-4dc1-9b97-feb8a9400e3e_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_b79c6e4c-05a3-43c4-9850-82bb687b182d_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain" xlink:href="biib-20210331.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_eff99a93-c553-4210-bf00-4a859a84c557_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95880467-5dd1-4749-81b1-ad1c118ccd95_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractOptionExerciseFee_578d10ab-e716-4198-ba63-c379d2c4e8e7_terseLabel_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_label_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_documentation_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee" xlink:href="biib-20210331.xsd#biib_ContractOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractOptionExerciseFee" xlink:to="lab_biib_ContractOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_36e4be68-26ca-4128-8e1b-fe1544bc9354_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:href="biib-20210331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_925bb296-395f-425a-8689-5a730cd22e5a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_ce0fa2a3-d024-4145-acd7-0fa0d1456778_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_b4ea5f1f-2493-4906-a79e-7889ffb82905_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_372135cf-bf8a-4b1f-b403-59deb8dde68d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of available-for-sale securities, equity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_9ec8bf29-8c0b-4aee-b9e3-c2c5632bdc7a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2a333da7-aa55-4891-a821-566f2eedf1dd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6789212b-6488-4cb2-b471-6367d33d6e14_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TECFIDERAMember_adda7b6c-9f56-491e-aadf-02d3b3ba2b5b_terseLabel_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TECFIDERAMember_label_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TECFIDERAMember_documentation_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember" xlink:href="biib-20210331.xsd#biib_TECFIDERAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TECFIDERAMember" xlink:to="lab_biib_TECFIDERAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_63d9c675-c84f-45fa-a1ac-d866ea3634af_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_96a86043-9f92-45f1-b5de-03cab78ff51e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_64f6fa5a-61b7-48bb-b356-2d0d56be8364_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_dfe3bc9c-6a60-441c-97df-a683db883ab3_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_4c7b3ff1-861f-442f-86fa-d24b9da373bc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_a8019808-61d8-42ea-8e59-dde0080f9646_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_34a6c343-bde8-4adc-aa87-5cac06bfd882_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e89af5c4-a5af-4670-bc3e-d267358aec36_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_8b143447-0f22-4669-aee2-2d9d29c652b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_1a428c53-a9ba-4e09-a367-21229567beb0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_9997d047-6048-417e-8347-884cdde45a81_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_233de876-c633-4bc2-9c64-276905a47ace_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_1bc1890a-c58c-4a56-89ed-fd75331f05b6_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_5bc238cf-79fa-462e-a3f8-2e637247954e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_2fa9f755-8d4e-4478-b649-220b5c820a14_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_5b16de85-e3b6-4519-977c-263d8b2b2212_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_cf0976a5-d78e-4103-bcbb-bc9bf8da6c1f_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember" xlink:to="lab_us-gaap_RepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c27f8dcf-2cfa-4f74-a96a-d49d4af580b6_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ca3e0777-4f8e-4362-ae67-af39c706d9a5_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_5c34e903-51a5-4525-84b5-76ddb7e908e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_da519a68-abb7-4ebf-84a5-d5f562ac7194_terseLabel_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_label_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_documentation_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:href="biib-20210331.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:to="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_a8976ccf-65df-44ef-8bec-0e1815c8748d_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdministrativeSpaceMember_55eed7f0-17e4-49c2-8491-74e2c03da9f1_terseLabel_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_label_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space [Member]</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_documentation_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember" xlink:href="biib-20210331.xsd#biib_AdministrativeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdministrativeSpaceMember" xlink:to="lab_biib_AdministrativeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f18c8ff2-0d8b-4221-8e4e-0c665ca759fb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_84bddaac-2cdf-4e73-a589-4ebb511c90c3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining duration of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7198cae2-6dc7-4b78-aa1e-f078a38637a5_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityAxis_c9015a09-563c-409d-8136-3986219fe5c1_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis" xlink:href="biib-20210331.xsd#biib_DerivativeMaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis" xlink:to="lab_biib_DerivativeMaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_3b14e96e-c122-4496-9413-1c1a41b87725_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c91b2e7d-64e1-4671-ab33-b9ef0c6fcae4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_17306f41-f1ba-4266-bf2c-51a8703cebca_negatedTerseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="biib-20210331.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_8ecc0a10-7810-4c47-8857-ef2409b95a3a_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_6980aa66-d388-4059-820c-6020293bd7b1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfSquareFeet_acfddca8-dd3a-4cfc-bd41-7c0e0996b8bd_terseLabel_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of square feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_label_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_documentation_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet" xlink:href="biib-20210331.xsd#biib_NumberOfSquareFeet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSquareFeet" xlink:to="lab_biib_NumberOfSquareFeet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_b330209c-27fd-4dd0-8771-6dfa7297ae25_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_a75fcf13-6c96-4873-9de9-bba09ef7d3ec_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:href="biib-20210331.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterferonMember_4fdfcf36-2127-46b7-871c-2948b906ed0e_terseLabel_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_label_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_documentation_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember" xlink:href="biib-20210331.xsd#biib_InterferonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember" xlink:to="lab_biib_InterferonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b29c917d-ac7f-47d0-b47e-16b831199b0a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_592ceb42-2b6b-454c-b034-3659187398c5_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_0129dc3e-0e2c-47f2-83e5-1dd4754c598f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_d94948c0-206d-49ad-83f4-3f821fcdd59e_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:href="biib-20210331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_df48dba5-74b5-4c15-9ce3-46300cc7c837_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_2023bff0-c2de-4b0d-b565-29b73d9be6ba_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_b8adfdfb-e8be-4f92-86ea-79c89e3424ec_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_61bd4298-5960-4204-ad6f-81f017fef840_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember" xlink:href="biib-20210331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember" xlink:to="lab_biib_SamsungBiosimilarAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_90f72afe-49ee-4c0a-b26d-812091f838c5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6558797c-d6ac-4696-a354-5540ad1bb1d9_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_831b2123-655a-4549-b907-526cbfea932c_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_4e6fcd35-c4a1-4dba-8bf8-903027976ab7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_c634b91f-588e-47f5-a0e4-0d8fcae8d57a_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs, percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:href="biib-20210331.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:to="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShorttermderivativeMember_05f6783b-8d09-4cf8-a12f-d5d4fb3ec353_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember" xlink:href="biib-20210331.xsd#biib_ShorttermderivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember" xlink:to="lab_biib_ShorttermderivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_abee92d2-af05-4d9b-baf3-83db569c5d5c_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d5667c1d-2cef-47ee-a968-ecd2cc6ad0a9_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_b583692c-7beb-44e5-b9e9-6fca0a10889d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_082f5866-8c3b-4ba2-aaaa-949a54003a89_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_92cc8818-b8ae-491c-aec0-43fadcfb202a_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_label_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_documentation_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount" xlink:href="biib-20210331.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentRedemptionAmount" xlink:to="lab_biib_DebtInstrumentRedemptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_674c5425-d319-420a-8712-c97623510005_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount remaining under 2019 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_ed4b195b-70eb-4bbb-932f-60693d407d34_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6d524e4a-8d59-441f-8f89-a10e8c206def_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TwelvemonthsMember_cfce2fdf-ae52-4a30-9d58-006bcee8db25_terseLabel_en-US" xlink:label="lab_biib_TwelvemonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twelve months</link:label>
    <link:label id="lab_biib_TwelvemonthsMember_label_en-US" xlink:label="lab_biib_TwelvemonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twelve months [Member]</link:label>
    <link:label id="lab_biib_TwelvemonthsMember_documentation_en-US" xlink:label="lab_biib_TwelvemonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twelve months [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TwelvemonthsMember" xlink:href="biib-20210331.xsd#biib_TwelvemonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TwelvemonthsMember" xlink:to="lab_biib_TwelvemonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_74922dc9-9f71-4b65-86f6-b405bfbe48ee_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ee9ee81c-af1d-4353-81c7-b6748b524517_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_9584d8ef-63b4-4167-8e6f-ac1fc84d7b71_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_3488d275-f316-4805-b5c8-c81f67206b70_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a0ffcfcf-29ec-470f-abda-1b933dadf875_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_35cac73d-0c5b-48f1-a964-bf3e4419fdee_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9f714d9e-5dc0-4516-a2ec-05a8c5ad7179_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1fdb085e-736b-4530-9d15-542effee5086_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_52d3c5b3-447b-419c-bd6a-2b6c5484d0cc_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_f4fda04d-9820-4bc4-bf5b-0fb3a68e47c2_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8ff831ba-5103-4417-ad32-beb52a67f923_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_059990ad-cabc-4652-9f49-5ec85f1dc81f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterestInSubsidiary_b28c746b-fd92-43b3-b999-b052a57b823a_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_label_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary" xlink:href="biib-20210331.xsd#biib_InterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary" xlink:to="lab_biib_InterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_9f38a2c7-c762-4756-8816-7d596fe400c2_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AcquisitionsAbstract_20020084-db87-47d3-b21e-f7678015f586_terseLabel_en-US" xlink:label="lab_biib_AcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:label id="lab_biib_AcquisitionsAbstract_label_en-US" xlink:label="lab_biib_AcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:label id="lab_biib_AcquisitionsAbstract_documentation_en-US" xlink:label="lab_biib_AcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquisitionsAbstract" xlink:href="biib-20210331.xsd#biib_AcquisitionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcquisitionsAbstract" xlink:to="lab_biib_AcquisitionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NeurimmuneMember_8f3e6170-1388-491c-84b2-e070c319a5db_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_label_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember" xlink:href="biib-20210331.xsd#biib_NeurimmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember" xlink:to="lab_biib_NeurimmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_e6e8ca2c-7f9c-4d23-87b6-a015f487396a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Our share of Samsung Bioepis gains (losses)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_6893cb19-e862-4a00-84d7-b63ea9ad4051_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_968f31c3-f96d-4525-9b84-9f0721375155_terseLabel_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Payment Timeline of Milestone [Axis]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_label_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Payment Timeline of Milestone [Axis]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_documentation_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Payment Timeline of Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:href="biib-20210331.xsd#biib_ExpectedPaymentTimelineofMilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:to="lab_biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_f6d7ac6a-4432-4547-ab15-102cae3c2923_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_79a0a642-740e-4fb8-8cb9-d7d1f432ced6_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on interest rate swap</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_1910817d-60a2-4793-a1cb-c48c78f16262_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, gain on derivative</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_d5abaf58-524c-4fc9-ae15-a0f047626658_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_e61e6c71-c340-436e-8920-44c4c7f878b9_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_701f5f6d-05f4-4a8f-b6b9-900b1e1aa479_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_E2609andBAN2401Member_c67d4d36-6ed6-44b8-abe1-d1eb5a992297_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BAN2401 and Elenbecestat</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member" xlink:href="biib-20210331.xsd#biib_E2609andBAN2401Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member" xlink:to="lab_biib_E2609andBAN2401Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_266c97da-70f9-4930-9b09-b252c0f5a9aa_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_056c142b-3cab-41cc-b625-55e119833cbf_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_2680c54d-529c-481b-9400-b09c30eb6ac2_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_ccd3f500-d3c9-4e01-b31c-7b604f75b819_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_1b61760d-7b39-4460-ba0b-1b273f06f6aa_terseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:href="biib-20210331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_f4693b74-6d45-4e60-8f73-1f8c92979f80_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_286cc895-bc22-4de2-bdfa-1fb0917a98e9_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Purchase Price Per Share</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Purchase Price Per Share</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Purchase Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_952159be-197a-4bcc-bd57-28498104937c_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_c756c1df-5c35-412c-ba05-bdf224f04d54_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_868cc331-2681-4272-b29e-699240f3bc71_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e0a3283e-334c-425b-baaf-dda7d949d60f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a0b50263-a962-4911-b402-5528e93fa3e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_46e4631b-ed52-448e-b1b3-457399b684f9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_cb0867cd-2e14-444e-ad55-b35bc018df1f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_50b19464-4f1c-44e3-9c51-940475f098e1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_591805a8-4c25-4bda-a5f2-b90b6abf4649_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_ce4e833c-455b-4150-8f8e-a784c31cd417_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_b440602a-22b0-4fb1-9c1a-ed67025166da_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bba01f94-178c-4b23-ad32-32b0ea935a72_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_085cfd4e-9d54-4477-9f3f-bb653e14a4ee_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_25db4280-a3ac-40ba-8190-596cb15ffc6e_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e30fc97b-717b-4346-bd78-bca21225a8ac_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ecec9e9b-b455-4959-abd8-750e970b08ab_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_41a6a47c-faa7-4859-888a-a84560a94120_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationexpensesaccrual_0ea4de02-2a66-42db-b42c-30e709c005c5_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual" xlink:href="biib-20210331.xsd#biib_Collaborationexpensesaccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual" xlink:to="lab_biib_Collaborationexpensesaccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8b0d955b-9dae-4e69-a1dc-14b0d4b00c22_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a829445c-2545-4eb0-abf5-06f6fcf8238f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_731765e6-07d0-48fe-b182-cba079ff9e14_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock" xlink:href="biib-20210331.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock" xlink:to="lab_biib_OtherrevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_3c57ab18-7ca8-4e89-a128-947cc57d2fe8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityDomain_a1d6b420-b5f2-45d0-b310-125463fed69b_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain" xlink:href="biib-20210331.xsd#biib_DerivativeMaturityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain" xlink:to="lab_biib_DerivativeMaturityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_745c68eb-b0d0-4119-9af5-abde7227a8fa_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis" xlink:href="biib-20210331.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_862c2d09-c80a-436d-88d4-f8417676fe7e_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember" xlink:href="biib-20210331.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember" xlink:to="lab_biib_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_63f168bc-fe19-4264-a2a4-243b1cd091da_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_bed00893-dc70-47a7-a081-e72c7bfb1a56_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_cdac728e-2cc6-4ecc-81d3-f24934438290_terseLabel_en-US" xlink:label="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_documentation_en-US" xlink:label="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="biib-20210331.xsd#biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_2e60dd26-598d-47c3-8858-7e3bf89566e9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6d098dd1-faa6-40a0-8a92-f3d94fb2c09d_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:href="biib-20210331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_40f01d79-85df-4c18-9027-2160c008bfdf_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4cffdffb-a473-4606-9f11-3cedd38d868c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bfc28cee-79a3-45a0-a9b8-ba7d8f7055e3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_19e65026-077f-4d12-bbf5-53d1579e7a71_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_c4575883-2a9e-4ac9-9ce0-cb545db96aaf_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost and expense</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f846b6ee-b1c7-412e-9794-cb5d34a0c4d6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_fe7249b5-5f81-4455-8ba1-8b0fb9ce1cba_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_965215f8-a53a-46ab-ac65-02d8161b4c67_negatedTerseLabel_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in (income) loss of investee, net of tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_label_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_documentation_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:href="biib-20210331.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:to="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2467c202-5c2c-4bf1-a91b-9003ad4097c3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_1664b4d2-4d49-4d6b-8b54-f597e904fb92_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_edf03735-6e40-4f72-bb9d-bf99e39b456d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3e5e1005-bae8-4fbc-89ae-805ed9a723ab_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_10547035-77ec-498c-93ac-4134ea596aa2_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_d37db272-cde7-47f5-8dc8-eda8d36002a5_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_4c91d34d-ae5d-41ef-98d3-2268f9b2b8fc_terseLabel_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Senior Notes due May 1, 2030</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_label_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_documentation_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:href="biib-20210331.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:to="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_128c3abe-5037-4e24-936f-82b1c6a77490_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Termofcollaborationagreement_18e0a74b-8575-4796-8750-55ce6c01503a_terseLabel_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_label_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_documentation_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement" xlink:href="biib-20210331.xsd#biib_Termofcollaborationagreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Termofcollaborationagreement" xlink:to="lab_biib_Termofcollaborationagreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_d8676762-67c4-448a-bc33-4e6e32277331_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UCBPharmaS.A.Member_79f13556-4521-4efa-b49f-4020a436da61_terseLabel_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_label_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_documentation_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member" xlink:href="biib-20210331.xsd#biib_UCBPharmaS.A.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UCBPharmaS.A.Member" xlink:to="lab_biib_UCBPharmaS.A.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bc221765-ac0c-41d9-b1a4-15d9f9987742_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_a9fb48de-69cd-449a-bb47-940cac7843c4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_1b8bffd4-53b9-4fd1-9152-3f7bb1bf221b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_13e0f304-3493-4311-b461-b004cefc300d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_74d4d156-61f6-4eed-8db3-406342992a0c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_43c0c3fa-229f-4f4e-8ee7-13ecc1dacaba_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_39c612bd-c7e4-42e4-b642-d30c53334a74_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7b12f24d-591a-4e7e-a5ff-384ff4df5902_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ec727548-2d36-4b9a-af68-8075912f8eb8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_439c087f-7dc1-438e-9cd8-bbe28632b3ca_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_805451ed-ddbb-4585-91c4-cc0cdddcdf1e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_d522d74d-ba47-48ea-854a-773cf3774201_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2c30c530-1109-4c3b-ba3b-4135402df922_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2019 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_add50702-73b2-49ed-897c-f6e51b9578cb_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_30f5120f-75c0-44b2-bc58-a9f0beca50b4_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiosimilarsMember_58e95a7d-f1ef-44f5-bc6b-7861b6bb25aa_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_label_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember" xlink:href="biib-20210331.xsd#biib_BiosimilarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember" xlink:to="lab_biib_BiosimilarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_94156cdb-5ea2-4780-beb5-cd7610648a8f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_4c00bfd9-7a55-42f3-9b9a-3ec82d66f638_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_ab46d3d7-a06c-4db5-a10a-07043f7f10df_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_f91ba20e-69dc-4ac2-83e6-44fdf4f9c26e_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_dafda93b-6bc5-4429-a131-35b535df9528_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_4b342541-d87c-4ab2-a10c-8dcd72bde1bb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_a76c5d8e-bbd4-4043-8ddf-8a78824e3e4f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_b39763f1-c658-46eb-9736-c5257f436d39_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8ff78159-baf2-4550-9561-019f0ab5827c_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_8f7ba9d1-0faa-4132-97d4-69dc89f0877a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_6688ac01-eef5-41b8-95da-5a85769571a9_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_51a3eccc-c286-46d0-893e-c9a8c66bba01_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_abf84ee7-6251-4770-bd9d-f6c031b65ced_terseLabel_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_label_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_documentation_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount" xlink:href="biib-20210331.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LongTermDebtExchangedAmount" xlink:to="lab_biib_LongTermDebtExchangedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5febbb49-f233-463c-a529-c1b7459a9fe8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_154593c4-59e5-47d6-a1cf-e6008ed6b9fa_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_27f97b8a-bcce-40e5-99f5-660235323ff9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NightstarMember_e4c92a98-bf08-4a7e-a9b8-abf2f6ac6d66_terseLabel_en-US" xlink:label="lab_biib_NightstarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nightstar</link:label>
    <link:label id="lab_biib_NightstarMember_label_en-US" xlink:label="lab_biib_NightstarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:label id="lab_biib_NightstarMember_documentation_en-US" xlink:label="lab_biib_NightstarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember" xlink:href="biib-20210331.xsd#biib_NightstarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NightstarMember" xlink:to="lab_biib_NightstarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_287a88aa-c78a-410b-89d5-c440b2d5b2aa_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_18dc6184-1970-40bf-a858-41389a0bf385_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_c6294d73-ea3f-4bd5-9b66-78eda95c8ee8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_96d1d201-0236-4990-b900-e7d340504de6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_60b5c613-cf5e-4d65-8f81-9906c10d9884_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_fd954c08-2ee1-4012-92c8-a8ff7b021e2e_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember" xlink:href="biib-20210331.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_34f0b078-7f5e-4baa-b71e-9e255e001f47_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_1bbef271-8c18-4087-81a7-6aa58a7e4cee_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:href="biib-20210331.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_44a8bb96-60a9-4157-9b31-6f82dc9918aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recorded on Samsung Bioepis joint venture</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborationAgreementTerm_c26a7324-92f3-4c2e-b32f-23b7dbd38af0_terseLabel_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_label_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_documentation_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm" xlink:href="biib-20210331.xsd#biib_CollaborationAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationAgreementTerm" xlink:to="lab_biib_CollaborationAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3ded586b-3527-416c-a02b-c1546cca6d4e_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_ea3e0475-4c1c-4d5b-b7aa-5b547bca72cb_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:href="biib-20210331.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c76a6534-f152-4678-8e18-b755829c00d2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RocheGroupGenentechMember_fb9777f9-b1bb-4b34-9983-7bbc8f0637b3_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember" xlink:href="biib-20210331.xsd#biib_RocheGroupGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember" xlink:to="lab_biib_RocheGroupGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_494de739-adeb-4cb5-a333-3d0ca8c3e508_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:href="biib-20210331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_b3263968-994b-43f9-b7d7-c8f6f251a41f_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:href="biib-20210331.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_b771101d-2087-4831-9272-78d523a601e2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_af5d8df2-b8c9-4dea-8b75-9bc45388684d_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_ec6295ac-d3a8-4a52-9e77-0b1d519e8492_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_e94d3ecc-838d-4b25-8096-74bf677486bc_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_859ed90e-5cd9-43fe-af2d-0b9eb25aca49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_70d99851-338f-4c99-b6c2-7b024ad89d00_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c0e01015-674a-4d35-b6aa-a9b92576c013_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1aa92240-c512-412b-8c9b-33c55251a1fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6bb8e582-544f-4e98-9216-92baf3c057ff_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2702cf95-2a60-46c2-970b-6ce8f6d1480f_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_3188ebe9-89c0-4e98-9118-c4c0637d2c94_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember" xlink:href="biib-20210331.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember" xlink:to="lab_biib_SolothurnSwitzerlandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2379dcae-81c7-4795-860d-b907e77f30b6_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bea8fe1c-382f-4a35-9616-cff16c5ce7cd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_38b04300-2ac8-495f-a58a-a021b7aa925b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeAxis_aa74a05d-0151-4a25-9fd6-7522778d4396_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_label_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_documentation_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis" xlink:href="biib-20210331.xsd#biib_FacilityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeAxis" xlink:to="lab_biib_FacilityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_51eba4bd-9643-4447-9fe1-ad67e483a920_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_f866e8d7-04c4-4232-bd34-55f59b99f446_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d8c59c15-bf6c-41b8-9864-2eaf15555615_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net gains (losses) recognized during the period on equity securities sold during the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_c2a66a25-b92d-4200-8521-f65cc4dc2a64_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_a7e8b566-ad5d-4c58-ae5c-e2cc94f23bd4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_b0f42d46-598f-4fdd-a923-fc37d249d040_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_224cfbe8-2fc1-4f4d-ae21-1ed7a9f04355_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_de065b64-62a5-4bdb-82c7-84b09578bf51_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:href="biib-20210331.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_d9086c98-6312-44ac-9896-5990d2400d68_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_4c6314c7-3abe-4f07-b544-a08fc2a8b273_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesAbstract_57564188-d4ca-49db-a305-293d9d07f8b8_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract" xlink:href="biib-20210331.xsd#biib_OtherrevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract" xlink:to="lab_biib_OtherrevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_73be4d7a-f5c6-46c3-983a-c3fa78b0ec7a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2f6251ba-2465-47c5-a4b2-d04cc82f6641_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_14c6a0e9-0bb9-46d6-98ca-f7fba01af564_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_555da93f-1abb-45c2-adc6-3b0d3b2f36db_terseLabel_en-US" xlink:label="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential products, exclusive rights</link:label>
    <link:label id="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_label_en-US" xlink:label="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Ophthalmolgy Biosimilar Products, Exclusive Rights</link:label>
    <link:label id="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_documentation_en-US" xlink:label="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Ophthalmolgy Biosimilar Products, Exclusive Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:href="biib-20210331.xsd#biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:to="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_24a456cc-751c-4209-a0ab-a7fa9af5bede_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_b692f906-00c4-471f-941c-5447ac173dd4_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_VixotrigineMember_43f1707b-db09-4c2e-97d6-6fb9fbd850aa_terseLabel_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine</link:label>
    <link:label id="lab_biib_VixotrigineMember_label_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine [Member]</link:label>
    <link:label id="lab_biib_VixotrigineMember_documentation_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember" xlink:href="biib-20210331.xsd#biib_VixotrigineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_VixotrigineMember" xlink:to="lab_biib_VixotrigineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1e66b75b-07b6-4fad-a509-d6f10c10ced9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_5343926a-3b59-4182-a47b-75a308957625_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_a5d83bd9-3e70-4c48-a237-23354998a205_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses" xlink:href="biib-20210331.xsd#biib_Biogenshareofcopromotionprofitsorlosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_4e0ad091-399b-41a8-a1bb-13dabed7ffa8_terseLabel_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_label_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_documentation_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Investmentincommonstocksharespurchased" xlink:href="biib-20210331.xsd#biib_Investmentincommonstocksharespurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Investmentincommonstocksharespurchased" xlink:to="lab_biib_Investmentincommonstocksharespurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_f5c24a24-8a22-4df3-a59b-ae1f3db8585b_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationprofitlosssharing_518fb0f0-5147-4e24-aa79-e243c8337b46_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing" xlink:href="biib-20210331.xsd#biib_Collaborationprofitlosssharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing" xlink:to="lab_biib_Collaborationprofitlosssharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_1817c347-e2e3-45d5-9391-92b0ad8800e9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7964b904-49b9-4388-a0e0-a4a6b6548627_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0515d984-3f27-4e5a-a849-634d2d41e774_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eba0c1c3-8449-48ec-9841-0d2defe4f1da_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_d3b96edc-64b6-41b7-96cf-5b5dce49e659_terseLabel_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember" xlink:href="biib-20210331.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_March2019ShareRepurchaseProgramMember" xlink:to="lab_biib_March2019ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_4524de8f-9f0a-4bb5-8cab-0badaed094b0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_dcf0abc2-5132-429b-9068-785499602e9d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_df0e33c0-6423-4b51-883d-2cbd266724b3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_0b412593-8e4f-4f11-b6d7-d49ea8accafb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_9e5c7e00-d443-4676-82d3-0b14b4544b34_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_6c3ad762-2ae0-4345-a2f2-c21dd322a460_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:href="biib-20210331.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SangamoCommonStockMember_5ed69870-2022-415a-af11-61fc745c909d_terseLabel_en-US" xlink:label="lab_biib_SangamoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo</link:label>
    <link:label id="lab_biib_SangamoCommonStockMember_label_en-US" xlink:label="lab_biib_SangamoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Common Stock [Member]</link:label>
    <link:label id="lab_biib_SangamoCommonStockMember_documentation_en-US" xlink:label="lab_biib_SangamoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember" xlink:href="biib-20210331.xsd#biib_SangamoCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoCommonStockMember" xlink:to="lab_biib_SangamoCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7287ff6e-cd53-4409-ba14-13d38d31086f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5b63873b-98a0-4b10-b09d-aad27168a5b2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7c0603df-3a37-46ed-9695-cdf8ca63f0da_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_9a08debf-247d-45e6-98e0-c6b1dd7e1fe3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_5981b0a3-e76d-4b15-b774-7007e6731194_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_682ed9c6-6b2e-4174-ad7f-31df24247352_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by Consolidated and Nonconsolidated Entities [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_label_en-US" xlink:label="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by Consolidated and Nonconsolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:to="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_636a0aff-3822-4c04-9566-f7220d6ece1c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fdf7a897-6b43-4e6d-859a-2162ab6764ee_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OthercorporaterevenuesMember_d6d59c56-19c0-4a6c-96d6-7a6d54fbb18b_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember" xlink:href="biib-20210331.xsd#biib_OthercorporaterevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember" xlink:to="lab_biib_OthercorporaterevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_64aa3712-9dda-438c-89ed-5eb7a2e7e973_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a37bd40f-86d4-4eee-bd11-d6481f5b06b6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_2ae95ef0-6cde-4dde-950f-8fe0c2777e12_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:href="biib-20210331.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b62eb09d-85b7-4683-8f15-4879ed8e109d_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsrevenueMember_9005867f-b786-45d1-960b-aac34230098b_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember" xlink:href="biib-20210331.xsd#biib_CashflowsrevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember" xlink:to="lab_biib_CashflowsrevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_3c8225b7-1d81-4434-a05b-34f869eed935_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_ba1589f1-9d37-4f64-ae99-24cde4f93f60_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome" xlink:href="biib-20210331.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_21f2bb8c-d1a1-403c-af22-3b3cab202672_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_54e9709c-6740-4589-82bc-655106f8db67_terseLabel_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:href="biib-20210331.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_c2483559-6c93-4424-bf1b-ed1dfa7c7d72_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5e44abf7-908b-4619-b859-236ffa8b4514_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_5356fa2e-fa19-4220-9138-6cff18bafd09_terseLabel_en-US" xlink:label="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax charge, payment of early call premium and write off of remaining unamortized debt issuance costs, net of derivative gain</link:label>
    <link:label id="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_label_en-US" xlink:label="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</link:label>
    <link:label id="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_documentation_en-US" xlink:label="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:href="biib-20210331.xsd#biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:to="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f89d4335-8cb8-436b-8641-66e9c94ee1e3_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c0e8c963-c9b0-455c-bb2d-a0b43d897daf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_dbe5470c-610d-4916-a9a0-17eab921465a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration impairment</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_e4a8c045-dc40-4e93-ac76-39ac279c805f_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2391d9f8-d422-49db-ba55-20b91533d339_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_306df7b6-81cd-4b38-a438-e549208b7835_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_c0b29244-2aee-4d1a-a828-bceadf732b86_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_808cec36-d8da-4f88-a6c0-89fcdeba085c_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_fa23ec09-5610-4616-99c1-b9624416e0b8_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_72d5a969-123e-4394-a98f-d3891edc473f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2eeef562-560b-4368-b62e-59008ff3ab49_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_58c623b3-c554-498d-a039-d37cfb8797de_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_056cc97d-4dbb-4b05-a5b0-badf18c6a295_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:href="biib-20210331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_01643fdd-4808-436c-a62a-ea7a87d21ed5_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:href="biib-20210331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_4252a29e-674a-4c8a-907f-4054a23da4d5_terseLabel_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_label_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_documentation_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember" xlink:href="biib-20210331.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoTherapeuticsInc.AgreementMember" xlink:to="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_3565b533-2c9d-43fa-98ad-306013240027_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_a18abcb2-48d8-4a7d-b1a8-16c5dd1b45b2_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_29527ffc-1dfd-4703-937f-0cb9ad5ac2e5_negatedLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="biib-20210331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_da5603ec-debc-443e-871e-2b787ef51b62_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:href="biib-20210331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_8db674d5-8847-4fbb-98a7-e906009b31ef_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_ea1e9533-485e-4024-8af5-cdc3112c2250_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_684f1149-272c-4163-9c2e-5fbf43267e1c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_f1fb4ef8-5041-4870-a07b-706ff887f342_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_30e8ec45-3b78-4478-8b6f-ec6ce9d8c52e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e22fd3b5-73ed-4b95-9bdd-4913a7265f8f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_0e468b68-b064-4ee6-9910-1d5915469373_terseLabel_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_label_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space [Member]</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_documentation_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:href="biib-20210331.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:to="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_e61d99ea-84f6-4172-b6eb-f57774a28daa_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember" xlink:href="biib-20210331.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember" xlink:to="lab_biib_CashSettledPerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_9365478c-bb46-414e-a9e0-6c6b2e384308_terseLabel_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_label_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051 [Member]</link:label>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_documentation_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member" xlink:href="biib-20210331.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3250SeniorNotesDueFebruary152051Member" xlink:to="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2978957e-0cb1-4092-8355-3a1b0fcf5425_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d69044f0-5b02-47d0-8e72-155c6342707e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_efdf4504-d2a0-4cd7-ab8a-99eca7a3c628_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_64209331-3dae-4b43-ab4d-b0054754452c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b75208a4-ffe8-4808-8130-bece6cfeafad_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c88a6706-690f-400b-afdb-d13a2d55e5df_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_48475d95-e5e7-462c-af1e-7c7efac4c5f0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_f59c8419-0937-4427-813b-430e4002cbb6_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_c2b9278a-da1c-4126-80b9-5596d4905d01_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_b637434a-a77d-4d05-975c-4f0a4d41617c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_46fc1f7b-7525-42f7-99d1-42c55284955c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_6e760c4c-e7a1-47a1-8b5b-366c8861da5b_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_18085c89-1630-47e8-b165-164929b7cbb8_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember" xlink:href="biib-20210331.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember" xlink:to="lab_biib_CashflowsoperatingexpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_0428c5cc-ef54-438c-83d3-6365fc53e95f_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_9eef64ad-b677-421e-8627-82fcf74d1d05_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f8e7f8a0-6164-41c6-bd42-a29aa8139df0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d38519fd-a019-4c4c-bcdb-a07c4fbca7cc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ce443461-7f25-405b-a09c-3a2a49e6181f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_79d6be88-ce81-4c54-a74b-a8089529af3c_terseLabel_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember" xlink:href="biib-20210331.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_December2019ShareRepurchaseProgramMember" xlink:to="lab_biib_December2019ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_a886a8e9-ae67-439f-84e9-8ea31cca5698_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_5a3c51ad-4986-49ba-b0b2-dc3f03bfe9e7_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b642a927-c3e2-4e59-bf61-1797270a29c2_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_b755e243-0a6a-43b6-ab23-2b775f94314b_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:href="biib-20210331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_87c02c95-565b-4f10-9333-d0913a714e0d_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated life, (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_be4da15f-7c46-40af-9ccf-89120f917a0a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_0091ceee-bb73-435a-99fe-863f86885575_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d6261514-ab46-4149-85ca-b3547b08970a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_ea3c7ad3-e88b-4193-b5d4-1ab1e55f4f9d_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_label_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:href="biib-20210331.xsd#biib_Reductioninroyaltyratepayableoncommercialsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:to="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_87ddaf25-056d-4eb3-8283-fefd41f89a0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_03af999a-9fe6-4366-9269-6b917746d78b_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities" xlink:href="biib-20210331.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9cdc7574-5863-4959-8b7e-2b0cc350471e_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9ab153c2-f934-4fd8-8805-e9fc76324efb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a9971127-3874-4e74-ba6e-c5fd09723bff_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_d53cefa3-0a85-4366-a013-e8cee3db3407_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_733286dd-c8ca-4ee1-a621-2ec9ab804da7_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:href="biib-20210331.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_235c7256-3065-4c5b-bfc0-a08cdcbb2693_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_eccebf8f-78b9-43b0-b4ab-01bb682a1da9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b84c50d1-673a-4e57-9ae0-a247f0a258c3_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_47371e69-2632-420c-bec7-fd625fe2f628_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember" xlink:href="biib-20210331.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesCurrentMember" xlink:to="lab_biib_EquitySecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c53b76b9-a11e-4d3f-bb3a-658dd90ef7e9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_a675a405-6678-4d43-99de-7ff20a958699_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_747745a6-8944-42ca-84d8-063959675f2a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_855daacd-8e93-4663-9c6c-5c71ffc2f53d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_039f3028-5f1a-42c8-b76f-5f95979081ae_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_2deebf18-36e8-4648-a5bd-4e1bf5df2f51_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_78a115f3-22a2-4328-94de-83a4ea77ee32_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock" xlink:href="biib-20210331.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0b03913e-962e-4179-999f-0a3e387cf86f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_81999a83-ff17-4624-ba58-0038d88e7178_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_c05c2859-a359-4c11-b392-be051fe0ddfb_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:href="biib-20210331.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_4db67a80-1ee2-4a89-907d-b33f73c9f132_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6ec0ba12-ed90-4673-8a59-a6d4cf3d679c_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_9afae816-d755-4e85-981a-8a23f9482647_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2cf1b672-56b8-4b71-bf5c-7485e278c2eb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_09007637-64d7-4814-99c6-1992b387cc2a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdditionalMilestonePayment_bf6a4282-997f-4366-82b7-5a64c3971f46_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment" xlink:href="biib-20210331.xsd#biib_AdditionalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment" xlink:to="lab_biib_AdditionalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_October2020ShareRepurchaseProgramMember_f4f4e1fe-6421-48d4-9e3c-8e85a3516b34_terseLabel_en-US" xlink:label="lab_biib_October2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2020 Share Repurchase Program</link:label>
    <link:label id="lab_biib_October2020ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_October2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2020 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_October2020ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_October2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2020 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_October2020ShareRepurchaseProgramMember" xlink:href="biib-20210331.xsd#biib_October2020ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_October2020ShareRepurchaseProgramMember" xlink:to="lab_biib_October2020ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_dfdb8eae-9d74-4f52-b6e1-8b0f32b36a4e_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_f3f71123-f47d-4dfa-b8b6-20bb1d72edef_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a1a6f58f-8eca-4937-98d2-734796303b8e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_195e7234-c488-4797-a91d-8ec0aadb90e3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5d845d03-f732-48fc-8beb-8c7e760dc842_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_8cc451a5-e7cd-427d-a6df-7a181830f7a2_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:href="biib-20210331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TGNMember_2f2ea84b-d407-4faa-8596-b1768d1e36cb_terseLabel_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_label_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_documentation_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember" xlink:href="biib-20210331.xsd#biib_TGNMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TGNMember" xlink:to="lab_biib_TGNMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_0dd05bb9-b3f2-439b-b076-3570fdfdd1fc_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration" xlink:href="biib-20210331.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration" xlink:to="lab_biib_ExpenseIncurredByCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RegulatoryMilestonesMember_7db38060-319d-4b1b-8bd7-a68588e324e0_terseLabel_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember" xlink:href="biib-20210331.xsd#biib_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryMilestonesMember" xlink:to="lab_biib_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_6973b53f-cfd9-416e-9ace-a8d943682ccf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DividendYieldPercentage_752acabb-90b0-4d39-a8d8-67db28b3ccb2_terseLabel_en-US" xlink:label="lab_biib_DividendYieldPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield percentage</link:label>
    <link:label id="lab_biib_DividendYieldPercentage_label_en-US" xlink:label="lab_biib_DividendYieldPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield Percentage</link:label>
    <link:label id="lab_biib_DividendYieldPercentage_documentation_en-US" xlink:label="lab_biib_DividendYieldPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DividendYieldPercentage" xlink:href="biib-20210331.xsd#biib_DividendYieldPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DividendYieldPercentage" xlink:to="lab_biib_DividendYieldPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_36976d15-f4c2-482e-888f-b0d0c443bf0f_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_ba10c2bc-2fef-4119-90b0-30f4b501cbad_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_27ad70df-bc55-471f-90a0-7516ef8e5231_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_ab1e051d-1651-4d4e-a031-19b45a42195e_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0463ed70-44e5-4e7c-992d-3b5d1cba99f3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ab4122a7-a391-4dab-a0c3-c1481ab2c1dd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_a9dcdac5-c6e8-48c7-a56d-46e3b07d60e0_verboseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_6c9f66a9-74e0-4055-9d53-eadccec6644e_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_477d936b-0e0c-476c-87a4-ba7988f22c00_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_f4dea136-6445-4eeb-aeb4-b2392dc9114f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6f6ddcc9-fb21-40ae-acf5-b09bff6a34ab_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_0929dae8-959e-4463-b2cd-8f23dee76fb6_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:href="biib-20210331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_9268fc5e-dd4f-4f08-a70a-3fdbd7313ff0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_094ec3f9-a522-4b5c-8cca-0d65db14598e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a47f03e3-bbc5-4044-8a13-8117a7a2f247_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c8d842fe-e5b6-4d51-a6e7-46e384642ed2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_b22a5ba0-ef58-4424-b08e-06cb0c33086e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6aeacb8d-e7a1-4c55-b203-422fb8bfa790_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_51ec7c69-2b8a-4390-a6d5-6c5350cf3365_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_f952840c-0094-4e9e-ad89-34490ea81250_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_806434ad-2331-4672-96c8-230cb593d855_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_6700c9d4-f369-40d5-a629-4d7bd876899e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB111Member_32a3865b-8905-475b-a146-54d628555e2a_terseLabel_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111</link:label>
    <link:label id="lab_biib_BIIB111Member_label_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:label id="lab_biib_BIIB111Member_documentation_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member" xlink:href="biib-20210331.xsd#biib_BIIB111Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111Member" xlink:to="lab_biib_BIIB111Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_a44630a0-bfb9-4d69-b457-12946a8d663c_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio" xlink:href="biib-20210331.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio" xlink:to="lab_biib_StrategicInvestmentPortfolio" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductioninValue_5f3bdb27-2e6a-40da-9947-8273d2244254_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, decrease in value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductioninValue_label_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Value, Reduction in Value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductioninValue_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Value, Reduction in Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetsValueReductioninValue" xlink:href="biib-20210331.xsd#biib_DeferredTaxAssetsValueReductioninValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetsValueReductioninValue" xlink:to="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FLIXABIMember_0832bd50-6c79-45d6-836e-c89dc8646b82_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_label_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_documentation_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember" xlink:href="biib-20210331.xsd#biib_FLIXABIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember" xlink:to="lab_biib_FLIXABIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_11dcc5cd-b750-4c76-9b0c-bf62200e5973_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_dbd433a9-ee49-4a90-92d9-c9b4dfd8339a_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms" xlink:href="biib-20210331.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_fa2faa7a-c347-40fc-95e7-707cad0b4126_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_d11d972f-1bc8-4758-8e49-df62cf167c72_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative qualifying as net investment hedge, excluded component</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8a8ef09e-a5a9-4f35-abfc-86b884c18f9e_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossOnContractTermination_e15a8333-325a-463d-925d-215703bcc03a_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on research and development contracts terminated with Eisai</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination" xlink:to="lab_us-gaap_LossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_bc31f28f-745f-4c8b-a25e-b1cb4d8b337d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cbcffdc7-c3fd-4653-8053-d5aa019094c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_58247823-9219-4de2-b996-b78ccfb169ad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_c09a7582-11e4-4d59-8897-00459825822d_terseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother" xlink:href="biib-20210331.xsd#biib_Noncontrollinginterestincreasedecreaseother"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_ea068718-533c-484c-874a-94da395d0e52_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5b331115-c396-4fdc-ac95-623dcc269ca6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationAxis_15634157-ba13-4078-9abd-30c1b5d1a498_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_label_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis" xlink:href="biib-20210331.xsd#biib_FacilityLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis" xlink:to="lab_biib_FacilityLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_fb50eaeb-d6d2-4f0b-9090-cdcd84b1f479_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_18477cee-2e91-4ae3-8e63-f05ba7de749d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8427e90f-0f1f-4ef9-a50f-caf2338e81f0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under award plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_28cb7974-60d6-4ce5-a5a1-0ac0a820ff14_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_36beb8f1-e15d-4a6d-8074-4f2f6ba4ad6d_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_d5b7554b-4bbe-4805-8fcd-be0f1df830de_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_fd3fe9e3-163c-4ea7-a948-315dc6e3771b_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_7c5635ac-24e6-4743-8690-fffb7d2dbd1b_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_209107cd-620b-44fe-bbe5-0f0a3802dcf9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c49259dd-2587-4e6e-b3ef-7d6cb8e7ac75_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c64f88a7-ec1d-415e-bc5a-ad6c4000dd4f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_38a83b80-d900-4b22-b477-d0b291eda51e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_1b0aa42d-5c02-438b-993a-3b14835967b0_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_48d659c5-8cdd-4fcb-aa0d-f9baea431db0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_04914597-f533-4530-916f-ffe11cb096c9_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_35de8d9a-3e6f-46a3-a217-65da5b676a25_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:href="biib-20210331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SageTherapeuticsIncMember_3a0fe8e3-baaa-4749-b0f5-e22d71bc744f_terseLabel_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember" xlink:href="biib-20210331.xsd#biib_SageTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SageTherapeuticsIncMember" xlink:to="lab_biib_SageTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_04ce5586-5cee-4b1f-a4b4-9ef6316a5e3e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_5342027c-66f9-4f61-86cb-74066eb925e9_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_95dac0d8-e8fd-4a53-b61b-143e7d214e41_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ba23180-0ab9-41bc-9121-2b39a3c1adb2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d17d6a8c-8d61-49fe-9812-d86fea94d455_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b44d7680-84b9-4857-a3fc-d75b9498387f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_a8c2d475-5ed5-4469-9afb-67a41ea3dc7f_terseLabel_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_label_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:href="biib-20210331.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:to="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MSProductRevenuesMember_3a492dd0-fa15-44b6-a665-54f25a1eb68b_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember" xlink:href="biib-20210331.xsd#biib_MSProductRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember" xlink:to="lab_biib_MSProductRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_459f6781-9919-4315-ad4d-944d914ef129_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7df5ab02-c830-4b44-9b33-ebc08ff95815_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_01becb0d-6eeb-48a6-8b12-541716d36b6c_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_420968df-0531-4b12-9706-6bae78f9a205_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_c3bf8ccb-a500-463b-870d-12b3f96e84aa_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_Revenues_b73aacda-f680-40e7-9a34-fed22d49bd63_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_479317d4-ac07-48d8-b2ce-4e3495f5c9b3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_14b17a81-7b52-4a3f-ae92-31c3b99369e5_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b5552d75-6ce7-4d38-9d7e-db6003d4f062_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4868950a-13ee-4c91-80c6-87d779b90620_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_6dd2a771-0f32-4ccc-95db-94d9f2e15e08_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_cc1442a0-c20c-41dd-9be0-3fab8d350b4f_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_586e6692-1432-4dcd-af2e-067a8f35f3e4_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1cdbd6d6-0a07-4fdb-b6d8-cc1b60e5d8b8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_905e67bf-3952-4427-b903-1b4272f11cf1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_9252d6fe-8eef-4d8d-9f1c-69ab76eb210b_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis" xlink:href="biib-20210331.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetAxis" xlink:to="lab_biib_ResearchanddevelopmentassetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_fc761bfe-d658-4bc8-bdb9-01fa972b01b3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d54b4e93-bafd-4028-80aa-390fa396071d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1e0a6b5d-78b8-4096-aef4-eb3cf12162b5_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_f21f1a25-a59f-49af-b43c-6c76a198d1d2_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8feb9b4f-8ff2-40e5-abaa-d7a9b33934ba_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_681a0cac-d9b6-410e-ba52-5882235e67c7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_ca450316-bbcc-4d1f-b30e-7ca14f9aa9e8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_bb614735-7686-49e8-b52e-f417a8f827e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_14632a1a-7224-45fc-8483-164286fd3f21_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f231a0b5-1abe-44ba-866a-ef15b86a8402_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_571e939b-cca5-4bf5-b8e4-fff8945405ae_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_488fa5fd-ec2e-4d2d-a482-6a24de5660e7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FAMPYRAMember_9379d6c4-c284-450c-a85a-5ca7ded20579_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_label_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember" xlink:href="biib-20210331.xsd#biib_FAMPYRAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember" xlink:to="lab_biib_FAMPYRAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_95bd2528-72fb-4de8-9428-d8bec60767ca_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c6caa9f8-8797-4be1-bfa6-12f618db1471_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_14f53d47-5313-4196-80fb-691e59e830b7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fe68d257-e767-4f09-a63a-728529df8664_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8b518b05-a5c0-45a3-b9a0-f1fbcd833b61_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8e5abfc7-1b3b-415d-85e1-81e18c53a75d_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_26fa3ea6-4cad-4f31-a909-e8c5599246fc_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6ac4fff4-fc39-4bf2-bf4e-ca763a807d12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_08f8121d-229d-4434-bd17-daa50ef313ba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_60d0681d-efea-47fc-85f0-808e848bbf70_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EisaiMember_7096748c-024e-4617-b651-efbf4399c525_terseLabel_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_label_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_documentation_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember" xlink:href="biib-20210331.xsd#biib_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember" xlink:to="lab_biib_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f628022c-0d45-4639-be1f-dafde702efda_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_bf281dc9-5812-4242-aa20-91b69aadadea_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_4029449b-c79b-4cdb-8103-b3e9d0c787fe_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_87608378-b6b4-410d-9de1-eda9ff1e064e_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d4dcf2a4-ca5c-48ae-9a46-96ad9cbfcf7a_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_a0a95964-98c3-457d-835f-079b0043685b_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AducanumabMember_b4f34761-c7ea-4807-9d79-1db21f7b15f7_terseLabel_en-US" xlink:label="lab_biib_AducanumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aducanumab</link:label>
    <link:label id="lab_biib_AducanumabMember_label_en-US" xlink:label="lab_biib_AducanumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:label id="lab_biib_AducanumabMember_documentation_en-US" xlink:label="lab_biib_AducanumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AducanumabMember" xlink:href="biib-20210331.xsd#biib_AducanumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AducanumabMember" xlink:to="lab_biib_AducanumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_78f2c3be-69f7-4541-a07a-54e64641f78d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorOneMember_fec46e3d-9444-42b2-ae17-7cfa5006b54e_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_label_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_documentation_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember" xlink:href="biib-20210331.xsd#biib_DistributorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember" xlink:to="lab_biib_DistributorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f9d6ca80-de9c-4639-9cec-35e5c1a9ff1e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aafad357-01ae-4b0c-8d47-cab361882ce8_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_288650bd-deea-47e7-91e3-dbf87034213e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_ae74ef32-8254-4a76-8c4b-190659d20e2d_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_45f0c34f-d484-45a9-94d0-31ebe75cd460_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ff7c915-3fd2-4c96-8292-6556b554acdf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_442c0e1a-8768-48cc-a84d-daf1479b574d_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:href="biib-20210331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_da53d0a4-3825-4b98-8a0a-43363025fefd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_df96d354-b7b8-4a93-ad7a-4590f023fd98_terseLabel_en-US" xlink:label="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of early call premium and write off of remaining unamortized debt issuance costs</link:label>
    <link:label id="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_label_en-US" xlink:label="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs</link:label>
    <link:label id="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_documentation_en-US" xlink:label="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:href="biib-20210331.xsd#biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:to="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_f7d2e750-7a41-4d80-aefc-0549282cce8e_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_028f9efb-595d-4d1e-91d9-3593639d6982_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_ebb479ca-73c9-46e1-bfa9-0bd7e295cbcf_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5861414b-32d2-4286-91e2-fefc23d2c85b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fb94baec-989b-4551-89a0-afd0a7504754_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_9947dfb3-69c5-43f7-8374-c70deae7ade0_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_38e49bd4-a366-4063-9230-63f27903bd32_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember" xlink:href="biib-20210331.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesNonCurrentMember" xlink:to="lab_biib_EquitySecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_e622c6fa-c961-4e03-99bc-68d1fd40301b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_50bcea80-e810-4c74-aba4-2a5804bb19e3_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4acbc0d-84d3-4835-98e1-cd18ae076db6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_316bfc30-f86d-46b5-90d8-2461ad71df1d_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_56adc1ec-26ab-437f-90df-869beb16df2a_terseLabel_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_label_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_documentation_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:href="biib-20210331.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:to="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e8236466-962b-4bab-82c8-f60a3a28a084_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_eb5b92ff-95e9-40ac-98b7-260cc1652847_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9061387f-f6ef-470f-8307-60aa3e6301aa_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_0b234814-6b2c-4afd-ba44-eddd04972ad3_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_6ec57806-4b48-4adf-947a-261d3f9871c7_terseLabel_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge, excluded component</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_label_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_documentation_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:href="biib-20210331.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:to="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_1e742499-9662-45f4-bff4-210f24c8a542_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c2bae9ed-4668-490c-b479-007cd4c0984b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_d50fdc57-26d2-416c-afe0-7a6c8e30ccc0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_20bdde6f-cc8a-44ae-b124-6f8e32e0bd5c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_d5cec31f-33f7-4932-bc4d-e81683415f19_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:href="biib-20210331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>biib-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:b54f3254-567d-4813-a83c-54bbe0ebf523,g:5bfc82e5-4d8f-4b59-aa4e-ce589875722a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20210331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_78b72410-f29b-4ac3-8f98-0f168ee758b8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_DocumentType_78b72410-f29b-4ac3-8f98-0f168ee758b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_31d41c25-560d-4e85-aa0f-65e877e18a1a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_DocumentQuarterlyReport_31d41c25-560d-4e85-aa0f-65e877e18a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_294bdc9d-8e58-4ea0-ab27-59e604bb9461" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_DocumentPeriodEndDate_294bdc9d-8e58-4ea0-ab27-59e604bb9461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b622b484-b1f8-442f-b3f6-c980cd0e5138" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_DocumentTransitionReport_b622b484-b1f8-442f-b3f6-c980cd0e5138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e6b9f56d-10bf-415b-b908-c9c4cf4457da" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntityFileNumber_e6b9f56d-10bf-415b-b908-c9c4cf4457da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0100d0f0-c320-4adc-9213-cb14833054d9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntityRegistrantName_0100d0f0-c320-4adc-9213-cb14833054d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_75468ab5-3a2b-4756-ba66-95a8bc83818b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntityCentralIndexKey_75468ab5-3a2b-4756-ba66-95a8bc83818b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2de1fbdb-f1e5-4188-820f-7eb3505dde5f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_CurrentFiscalYearEndDate_2de1fbdb-f1e5-4188-820f-7eb3505dde5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_170f2256-f398-438c-927d-d652e7efc8fd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_DocumentFiscalYearFocus_170f2256-f398-438c-927d-d652e7efc8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_638f3e94-cc29-4753-acc5-961c151239df" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_638f3e94-cc29-4753-acc5-961c151239df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ace95f1f-3f6c-4d9f-915f-38997ffcdfa6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_AmendmentFlag_ace95f1f-3f6c-4d9f-915f-38997ffcdfa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6248d080-f1a6-4bb5-8ce6-748a1a74c4fa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6248d080-f1a6-4bb5-8ce6-748a1a74c4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d8df826a-e11c-4c6b-b38e-5de043ce3d1d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntityTaxIdentificationNumber_d8df826a-e11c-4c6b-b38e-5de043ce3d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ca819568-4ab4-4f75-be46-009ff02534dd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntityAddressAddressLine1_ca819568-4ab4-4f75-be46-009ff02534dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ece4b3ba-6467-4d66-88ec-548a3657d0e6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntityAddressCityOrTown_ece4b3ba-6467-4d66-88ec-548a3657d0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6ed646fe-645b-477a-b05d-bf780ae857e3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntityAddressStateOrProvince_6ed646fe-645b-477a-b05d-bf780ae857e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9302a021-c36d-4cf0-b3a5-e6b1f8546f69" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntityAddressPostalZipCode_9302a021-c36d-4cf0-b3a5-e6b1f8546f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9ace63b9-c98c-41b4-bd67-4d6a466589f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_CityAreaCode_9ace63b9-c98c-41b4-bd67-4d6a466589f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9ac13cb7-bf8f-4c4b-970e-b5f823f72f8c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_LocalPhoneNumber_9ac13cb7-bf8f-4c4b-970e-b5f823f72f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8183b15f-fb73-413a-945c-0486c6bd6ec1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_Security12bTitle_8183b15f-fb73-413a-945c-0486c6bd6ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_cd5c0b4c-56e9-4676-a2f5-08d8187a66f5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_TradingSymbol_cd5c0b4c-56e9-4676-a2f5-08d8187a66f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1fbbcbb4-e019-4d8a-a3c9-93b53be7904c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_SecurityExchangeName_1fbbcbb4-e019-4d8a-a3c9-93b53be7904c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e22788c7-3fed-4ee4-a248-5cf02ff48e3a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntityCurrentReportingStatus_e22788c7-3fed-4ee4-a248-5cf02ff48e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a0b11d69-3c91-4b4c-ad0f-368b64cd74d2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntityInteractiveDataCurrent_a0b11d69-3c91-4b4c-ad0f-368b64cd74d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f6805599-d465-4482-b234-beb4f7518cf5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntityFilerCategory_f6805599-d465-4482-b234-beb4f7518cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7df30605-c67f-4a92-97c1-9063beae2b1f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntitySmallBusiness_7df30605-c67f-4a92-97c1-9063beae2b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cf54ebe2-7be5-469a-b528-decc5a85ff4d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntityEmergingGrowthCompany_cf54ebe2-7be5-469a-b528-decc5a85ff4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_0312cfa0-4e36-4cb6-95c9-316492650929" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntityShellCompany_0312cfa0-4e36-4cb6-95c9-316492650929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6be7e403-aced-4a16-a529-4d2fba97610c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_638469f8-1d5a-4bc9-be51-4647ac278a9f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6be7e403-aced-4a16-a529-4d2fba97610c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d1121e7c-c5e7-4c6a-b4bc-43fee25ffe75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ce8af73f-fe2d-42b9-9a24-652a838e17b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d1121e7c-c5e7-4c6a-b4bc-43fee25ffe75" xlink:to="loc_us-gaap_StatementTable_ce8af73f-fe2d-42b9-9a24-652a838e17b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4aabcdac-6acf-415b-9eef-31e01b048ba2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ce8af73f-fe2d-42b9-9a24-652a838e17b0" xlink:to="loc_srt_ProductOrServiceAxis_4aabcdac-6acf-415b-9eef-31e01b048ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_effeb9b1-413e-41a3-9c89-788ee4af8f9c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4aabcdac-6acf-415b-9eef-31e01b048ba2" xlink:to="loc_srt_ProductsAndServicesDomain_effeb9b1-413e-41a3-9c89-788ee4af8f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c86650d7-a954-422f-84fd-7da2243db3f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_effeb9b1-413e-41a3-9c89-788ee4af8f9c" xlink:to="loc_us-gaap_ProductMember_c86650d7-a954-422f-84fd-7da2243db3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3da64bb9-00e1-4685-8707-2fb8059640ae" xlink:href="biib-20210331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_effeb9b1-413e-41a3-9c89-788ee4af8f9c" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3da64bb9-00e1-4685-8707-2fb8059640ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_29519da9-cdb8-4d05-8352-f1919b8afc22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_effeb9b1-413e-41a3-9c89-788ee4af8f9c" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_29519da9-cdb8-4d05-8352-f1919b8afc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ce8af73f-fe2d-42b9-9a24-652a838e17b0" xlink:to="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4beaad53-be55-475f-bb10-e308810ad288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_Revenues_4beaad53-be55-475f-bb10-e308810ad288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_86aa259e-5cb8-470e-9dbe-fed96557b414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_86aa259e-5cb8-470e-9dbe-fed96557b414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_b99f4af4-e144-4c7d-91d0-04f8a1d79c79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_b99f4af4-e144-4c7d-91d0-04f8a1d79c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fac2ad61-eb77-4ba1-b5e6-45f6531622c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fac2ad61-eb77-4ba1-b5e6-45f6531622c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_4da53bd1-23f2-4401-9894-5fb8aba6a4a9" xlink:href="biib-20210331.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_4da53bd1-23f2-4401-9894-5fb8aba6a4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_9fbb5412-f532-4bb8-9003-3d7d18ac1c58" xlink:href="biib-20210331.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_biib_Collaborationprofitlosssharing_9fbb5412-f532-4bb8-9003-3d7d18ac1c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_af6ef87e-b1f3-44d8-8b28-c9b1213c2d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_af6ef87e-b1f3-44d8-8b28-c9b1213c2d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3cb7287a-aef3-4892-9008-c456396cf7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3cb7287a-aef3-4892-9008-c456396cf7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5136b2eb-8012-4135-87a9-8e8ce6db65d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_94691869-a3fb-4ba0-8531-2aa345c48663" xlink:to="loc_us-gaap_CostsAndExpenses_5136b2eb-8012-4135-87a9-8e8ce6db65d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9b433eb6-fec0-4400-ba36-62700315099b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_OperatingIncomeLoss_9b433eb6-fec0-4400-ba36-62700315099b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d6e87b58-cac6-4fc9-8615-0043ccf93e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d6e87b58-cac6-4fc9-8615-0043ccf93e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8766441d-20d8-422c-912d-5a1865c1cfda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8766441d-20d8-422c-912d-5a1865c1cfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_77cb5c53-eb3b-42fd-8cb1-77d4c7284057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_77cb5c53-eb3b-42fd-8cb1-77d4c7284057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_d4b56736-f940-4991-83c7-4634d00b5865" xlink:href="biib-20210331.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_d4b56736-f940-4991-83c7-4634d00b5865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cd8e925e-3ca2-4e0d-8eb7-4274b018d97d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_ProfitLoss_cd8e925e-3ca2-4e0d-8eb7-4274b018d97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ea499d8c-7284-4fe4-b828-0eea5470ab9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ea499d8c-7284-4fe4-b828-0eea5470ab9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bec2bf33-0fc2-48a1-be6d-22decf9f085d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_NetIncomeLoss_bec2bf33-0fc2-48a1-be6d-22decf9f085d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_01f0af05-7052-4433-b83e-a4a2758edc06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_EarningsPerShareAbstract_01f0af05-7052-4433-b83e-a4a2758edc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6b84de99-9a2c-4c64-8457-3d522e18528e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_01f0af05-7052-4433-b83e-a4a2758edc06" xlink:to="loc_us-gaap_EarningsPerShareBasic_6b84de99-9a2c-4c64-8457-3d522e18528e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1c0153de-0f9c-410d-bcb7-2bd144bd89bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_01f0af05-7052-4433-b83e-a4a2758edc06" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1c0153de-0f9c-410d-bcb7-2bd144bd89bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b690cb3f-d934-4065-b771-f0abcd8d7184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0551f5dc-c241-47bc-afb5-3993883d3369" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b690cb3f-d934-4065-b771-f0abcd8d7184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4bc34bc3-06a8-4ac9-9f05-9b6db455cc52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b690cb3f-d934-4065-b771-f0abcd8d7184" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4bc34bc3-06a8-4ac9-9f05-9b6db455cc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_48532b88-0a73-4177-8b28-107f31dc95a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b690cb3f-d934-4065-b771-f0abcd8d7184" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_48532b88-0a73-4177-8b28-107f31dc95a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3bc5963c-5b41-45aa-bd91-3aec3532fba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ee17bb33-535d-4639-af92-fb2c2bcd2a11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3bc5963c-5b41-45aa-bd91-3aec3532fba5" xlink:to="loc_us-gaap_NetIncomeLoss_ee17bb33-535d-4639-af92-fb2c2bcd2a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_63894702-456c-47fd-9049-683c95b73b17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3bc5963c-5b41-45aa-bd91-3aec3532fba5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_63894702-456c-47fd-9049-683c95b73b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fb303a75-7d8d-4e41-93b0-378558309e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_63894702-456c-47fd-9049-683c95b73b17" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fb303a75-7d8d-4e41-93b0-378558309e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_9026920a-383b-4207-99f1-bfcfde82b6c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_63894702-456c-47fd-9049-683c95b73b17" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_9026920a-383b-4207-99f1-bfcfde82b6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_56f3c466-8d33-4178-9b13-da10a8448249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_63894702-456c-47fd-9049-683c95b73b17" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_56f3c466-8d33-4178-9b13-da10a8448249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_712f5c9c-b62b-4852-b378-0c6b3eedb38c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_63894702-456c-47fd-9049-683c95b73b17" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_712f5c9c-b62b-4852-b378-0c6b3eedb38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5636efea-8609-4961-a3c5-9a6cdfc4bb35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_63894702-456c-47fd-9049-683c95b73b17" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5636efea-8609-4961-a3c5-9a6cdfc4bb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bf975b1e-58fc-4265-9ee2-bdec09a32991" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_63894702-456c-47fd-9049-683c95b73b17" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bf975b1e-58fc-4265-9ee2-bdec09a32991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f5923e17-9510-4fc3-abc8-3017009fb4ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_63894702-456c-47fd-9049-683c95b73b17" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f5923e17-9510-4fc3-abc8-3017009fb4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7c43dd19-4a65-4151-b6d2-ab99cc73637c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_63894702-456c-47fd-9049-683c95b73b17" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7c43dd19-4a65-4151-b6d2-ab99cc73637c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_70ac1947-3bd8-4854-8583-ae7f86c03660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_63894702-456c-47fd-9049-683c95b73b17" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_70ac1947-3bd8-4854-8583-ae7f86c03660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_914594d1-f11b-41cf-a338-71e502e010e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d3c7916a-9c2d-4be9-b483-5fba5c9a0e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_914594d1-f11b-41cf-a338-71e502e010e4" xlink:to="loc_us-gaap_AssetsAbstract_d3c7916a-9c2d-4be9-b483-5fba5c9a0e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_20694a27-82c8-4beb-a277-fec558a55ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d3c7916a-9c2d-4be9-b483-5fba5c9a0e38" xlink:to="loc_us-gaap_AssetsCurrentAbstract_20694a27-82c8-4beb-a277-fec558a55ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6dd30d51-1e93-434b-b7e0-7a0853a66296" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_20694a27-82c8-4beb-a277-fec558a55ea4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6dd30d51-1e93-434b-b7e0-7a0853a66296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ce2b6796-a30b-42eb-a638-3d8fa0ddb69b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_20694a27-82c8-4beb-a277-fec558a55ea4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ce2b6796-a30b-42eb-a638-3d8fa0ddb69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_74adae9a-236c-4a7c-9b0c-225854f7b1a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_20694a27-82c8-4beb-a277-fec558a55ea4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_74adae9a-236c-4a7c-9b0c-225854f7b1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_0b3b3ea9-f814-4636-91b7-ed975fee45f1" xlink:href="biib-20210331.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_20694a27-82c8-4beb-a277-fec558a55ea4" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_0b3b3ea9-f814-4636-91b7-ed975fee45f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_069f032c-dbe0-4cd1-a29b-98784f350676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_20694a27-82c8-4beb-a277-fec558a55ea4" xlink:to="loc_us-gaap_InventoryNet_069f032c-dbe0-4cd1-a29b-98784f350676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_8d3a1dd6-7286-414d-a4c0-06211e1ae856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_20694a27-82c8-4beb-a277-fec558a55ea4" xlink:to="loc_us-gaap_OtherAssetsCurrent_8d3a1dd6-7286-414d-a4c0-06211e1ae856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b5bb7dc8-6cbf-43ec-911b-b9a143900008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_20694a27-82c8-4beb-a277-fec558a55ea4" xlink:to="loc_us-gaap_AssetsCurrent_b5bb7dc8-6cbf-43ec-911b-b9a143900008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_29930637-1521-4e52-8cb7-5af6a1bfab39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d3c7916a-9c2d-4be9-b483-5fba5c9a0e38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_29930637-1521-4e52-8cb7-5af6a1bfab39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b4bc7180-991e-46a9-99d3-e8811082f8e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d3c7916a-9c2d-4be9-b483-5fba5c9a0e38" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b4bc7180-991e-46a9-99d3-e8811082f8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_abe18e26-e9ac-41eb-9049-b1b1fd1fc27f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d3c7916a-9c2d-4be9-b483-5fba5c9a0e38" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_abe18e26-e9ac-41eb-9049-b1b1fd1fc27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_646bbcf5-4ff6-4f74-82d4-cd37a6fc6bc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d3c7916a-9c2d-4be9-b483-5fba5c9a0e38" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_646bbcf5-4ff6-4f74-82d4-cd37a6fc6bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8e90d0cd-f4c8-46e5-a2b0-9e8b2d2f734b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d3c7916a-9c2d-4be9-b483-5fba5c9a0e38" xlink:to="loc_us-gaap_Goodwill_8e90d0cd-f4c8-46e5-a2b0-9e8b2d2f734b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_c53ba075-b1e3-49d1-a2f9-c555497e0c9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d3c7916a-9c2d-4be9-b483-5fba5c9a0e38" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_c53ba075-b1e3-49d1-a2f9-c555497e0c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5d0c7dbb-d5b6-44df-a152-4a0015dfbb26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d3c7916a-9c2d-4be9-b483-5fba5c9a0e38" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5d0c7dbb-d5b6-44df-a152-4a0015dfbb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3990d099-f368-40d5-a105-ef9968359498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d3c7916a-9c2d-4be9-b483-5fba5c9a0e38" xlink:to="loc_us-gaap_Assets_3990d099-f368-40d5-a105-ef9968359498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4917ef7a-ad4a-4226-ade5-b2ea58a87f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_914594d1-f11b-41cf-a338-71e502e010e4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4917ef7a-ad4a-4226-ade5-b2ea58a87f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_84a4e7f8-1c0d-4ab0-a042-42e2deb68906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4917ef7a-ad4a-4226-ade5-b2ea58a87f42" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_84a4e7f8-1c0d-4ab0-a042-42e2deb68906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_e7af273f-4e1a-4f67-ad4a-f1623d28bf3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_84a4e7f8-1c0d-4ab0-a042-42e2deb68906" xlink:to="loc_us-gaap_TaxesPayableCurrent_e7af273f-4e1a-4f67-ad4a-f1623d28bf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2e050517-13b0-4001-818a-4734c32fe8f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_84a4e7f8-1c0d-4ab0-a042-42e2deb68906" xlink:to="loc_us-gaap_AccountsPayableCurrent_2e050517-13b0-4001-818a-4734c32fe8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0bb6c5a4-8129-462c-a782-680aa3e2e395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_84a4e7f8-1c0d-4ab0-a042-42e2deb68906" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0bb6c5a4-8129-462c-a782-680aa3e2e395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_188525c0-a075-4be5-b2dd-cb0e4efb45c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_84a4e7f8-1c0d-4ab0-a042-42e2deb68906" xlink:to="loc_us-gaap_LiabilitiesCurrent_188525c0-a075-4be5-b2dd-cb0e4efb45c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d475ebbd-a3b5-4fba-a8e0-26cf4171a8bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4917ef7a-ad4a-4226-ade5-b2ea58a87f42" xlink:to="loc_us-gaap_LongTermDebt_d475ebbd-a3b5-4fba-a8e0-26cf4171a8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a5de5306-fec0-482d-bdc7-dd18f5212eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4917ef7a-ad4a-4226-ade5-b2ea58a87f42" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a5de5306-fec0-482d-bdc7-dd18f5212eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0fe8420d-fc2f-4008-8ecb-833264f045d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4917ef7a-ad4a-4226-ade5-b2ea58a87f42" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0fe8420d-fc2f-4008-8ecb-833264f045d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6f807501-9fdb-4917-b5bf-ac858fa5baee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4917ef7a-ad4a-4226-ade5-b2ea58a87f42" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6f807501-9fdb-4917-b5bf-ac858fa5baee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c5616041-e66b-4f48-ac3d-b5de4006bcee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4917ef7a-ad4a-4226-ade5-b2ea58a87f42" xlink:to="loc_us-gaap_Liabilities_c5616041-e66b-4f48-ac3d-b5de4006bcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7511ff68-f23e-4356-b3ce-7f1ca633e51b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4917ef7a-ad4a-4226-ade5-b2ea58a87f42" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7511ff68-f23e-4356-b3ce-7f1ca633e51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_dd5a6bc6-1adc-4e76-a9df-fe769ce27712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4917ef7a-ad4a-4226-ade5-b2ea58a87f42" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_dd5a6bc6-1adc-4e76-a9df-fe769ce27712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_52333cbb-0cb4-49ac-a2db-155302b542ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_dd5a6bc6-1adc-4e76-a9df-fe769ce27712" xlink:to="loc_us-gaap_StockholdersEquityAbstract_52333cbb-0cb4-49ac-a2db-155302b542ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b0753e31-5307-4b73-ace7-067f2f047141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_52333cbb-0cb4-49ac-a2db-155302b542ef" xlink:to="loc_us-gaap_PreferredStockValue_b0753e31-5307-4b73-ace7-067f2f047141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_608958cc-f438-4e4f-8e9a-a9764ad7fa67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_52333cbb-0cb4-49ac-a2db-155302b542ef" xlink:to="loc_us-gaap_CommonStockValue_608958cc-f438-4e4f-8e9a-a9764ad7fa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_29ea9c16-ace8-4e1a-b317-f484c094ed22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_52333cbb-0cb4-49ac-a2db-155302b542ef" xlink:to="loc_us-gaap_AdditionalPaidInCapital_29ea9c16-ace8-4e1a-b317-f484c094ed22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e3e8c4fa-d1af-4f3e-84d5-8027675bc418" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_52333cbb-0cb4-49ac-a2db-155302b542ef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e3e8c4fa-d1af-4f3e-84d5-8027675bc418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1530d106-9020-4068-81bd-ce6e95e6df3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_52333cbb-0cb4-49ac-a2db-155302b542ef" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1530d106-9020-4068-81bd-ce6e95e6df3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_6bcea4c6-66e0-4752-bbc7-a68977249a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_52333cbb-0cb4-49ac-a2db-155302b542ef" xlink:to="loc_us-gaap_TreasuryStockValue_6bcea4c6-66e0-4752-bbc7-a68977249a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cd5bcfcb-b653-4af8-a186-60a28c9f8e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_52333cbb-0cb4-49ac-a2db-155302b542ef" xlink:to="loc_us-gaap_StockholdersEquity_cd5bcfcb-b653-4af8-a186-60a28c9f8e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_419845d6-1085-4cef-9833-804152465e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_dd5a6bc6-1adc-4e76-a9df-fe769ce27712" xlink:to="loc_us-gaap_MinorityInterest_419845d6-1085-4cef-9833-804152465e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_abe0062b-00ea-4184-9c3a-e5119102a422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_dd5a6bc6-1adc-4e76-a9df-fe769ce27712" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_abe0062b-00ea-4184-9c3a-e5119102a422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_653ee04b-17aa-4a0b-9ce4-2f9083a93bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4917ef7a-ad4a-4226-ade5-b2ea58a87f42" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_653ee04b-17aa-4a0b-9ce4-2f9083a93bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d2649d01-5c70-4712-8f67-891a5ae1c35d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4b8be910-64d2-4d01-9d20-1b8a0d481464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d2649d01-5c70-4712-8f67-891a5ae1c35d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4b8be910-64d2-4d01-9d20-1b8a0d481464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4e9517db-45cf-4bbc-b59c-30ef06827839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d2649d01-5c70-4712-8f67-891a5ae1c35d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4e9517db-45cf-4bbc-b59c-30ef06827839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c83478af-cdca-4fc4-a69f-e156e1db7870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1dcec8ad-0651-4af2-aa67-90559a7cb22c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c83478af-cdca-4fc4-a69f-e156e1db7870" xlink:to="loc_us-gaap_StatementTable_1dcec8ad-0651-4af2-aa67-90559a7cb22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eb376eef-887b-49f4-a7d0-fe02eac2ca04" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1dcec8ad-0651-4af2-aa67-90559a7cb22c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eb376eef-887b-49f4-a7d0-fe02eac2ca04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e99614fe-24d7-4947-80e9-314b6fb1c7bb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eb376eef-887b-49f4-a7d0-fe02eac2ca04" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e99614fe-24d7-4947-80e9-314b6fb1c7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_94f4adea-3d49-422f-99b1-c3f276a75815" xlink:href="biib-20210331.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e99614fe-24d7-4947-80e9-314b6fb1c7bb" xlink:to="loc_biib_SangamoCommonStockMember_94f4adea-3d49-422f-99b1-c3f276a75815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_1a21a629-97ad-47d0-90ff-c45820466a15" xlink:href="biib-20210331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e99614fe-24d7-4947-80e9-314b6fb1c7bb" xlink:to="loc_biib_DenaliTherapeuticsIncMember_1a21a629-97ad-47d0-90ff-c45820466a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1dcec8ad-0651-4af2-aa67-90559a7cb22c" xlink:to="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08f35490-ad0e-4cb7-bf81-219fbf7155a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08f35490-ad0e-4cb7-bf81-219fbf7155a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fd11bffe-b639-4f1c-84fd-9bd66a63e64a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08f35490-ad0e-4cb7-bf81-219fbf7155a1" xlink:to="loc_us-gaap_ProfitLoss_fd11bffe-b639-4f1c-84fd-9bd66a63e64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08f35490-ad0e-4cb7-bf81-219fbf7155a1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_48867ee1-f530-4f0e-895f-77f3ca78f4ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_48867ee1-f530-4f0e-895f-77f3ca78f4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_138ba6f2-2111-46c6-a853-b4f6ce778465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_138ba6f2-2111-46c6-a853-b4f6ce778465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_feb5d3a6-aeed-4c9b-8e14-faa4525eedb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_ShareBasedCompensation_feb5d3a6-aeed-4c9b-8e14-faa4525eedb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_000cc5e5-b48a-48ee-99dc-80119b5ba862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_000cc5e5-b48a-48ee-99dc-80119b5ba862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2a07c5c5-486a-433a-aca0-fb335061dfc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2a07c5c5-486a-433a-aca0-fb335061dfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_c481c254-0816-41e6-bcc2-e8c63ab667e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_c481c254-0816-41e6-bcc2-e8c63ab667e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c8210a76-70cc-4190-a08b-ed3cfb4e6fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c8210a76-70cc-4190-a08b-ed3cfb4e6fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d098cbf8-6d08-4b3d-a042-fd26ad9db94e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d098cbf8-6d08-4b3d-a042-fd26ad9db94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_77705f3f-ee3e-4e0b-af56-5ef17deda182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_77705f3f-ee3e-4e0b-af56-5ef17deda182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_3be29a59-d43e-4b35-8f52-62132fb30d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_3be29a59-d43e-4b35-8f52-62132fb30d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8c101837-ed8b-463d-abad-c02338e88c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8c101837-ed8b-463d-abad-c02338e88c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b55d6af0-0d9a-4b85-b7f3-166ebed9f709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b55d6af0-0d9a-4b85-b7f3-166ebed9f709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_35736edb-f26f-4182-9921-b76f04db12b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_35736edb-f26f-4182-9921-b76f04db12b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_895b83d0-cd72-41c1-92bf-e26a9b60d5cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_acd2c82a-f8a2-40c4-8084-d8c8f9d7f00b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_895b83d0-cd72-41c1-92bf-e26a9b60d5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bea13299-06ee-4eb8-8952-e84e71881c84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1635ea76-94ca-4474-8a01-e2f857c5fed7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bea13299-06ee-4eb8-8952-e84e71881c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8b857d64-4bfd-4ef6-94d0-f3a6f06304b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8b857d64-4bfd-4ef6-94d0-f3a6f06304b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8e365366-0cb9-47d0-b06c-e7c91a34ae6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8e365366-0cb9-47d0-b06c-e7c91a34ae6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_36d35af1-8492-41f8-a54e-fc436f686547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_36d35af1-8492-41f8-a54e-fc436f686547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e39671ec-a37c-4459-a55f-cfe967c9dced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e39671ec-a37c-4459-a55f-cfe967c9dced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_bf20104d-0ce6-4a72-a9e5-d5f797ca2baa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_bf20104d-0ce6-4a72-a9e5-d5f797ca2baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a78d65f5-9de2-46a2-a4aa-dd4ed04d4b09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a78d65f5-9de2-46a2-a4aa-dd4ed04d4b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_9bb55474-3eda-4ac8-9bcb-1b779f6978d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_9bb55474-3eda-4ac8-9bcb-1b779f6978d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a9817c6d-3702-41c5-ab30-9320719198ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a9817c6d-3702-41c5-ab30-9320719198ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_06c5d609-af53-4d98-88a9-de80dbbd6f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3931e7c5-b0f1-4694-8912-727d78a3c4f3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_06c5d609-af53-4d98-88a9-de80dbbd6f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b7b6872-1351-464a-b221-132e53f7f6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b7b6872-1351-464a-b221-132e53f7f6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d6c9d94f-34ea-4094-b809-99583a5b3537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b7b6872-1351-464a-b221-132e53f7f6f5" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d6c9d94f-34ea-4094-b809-99583a5b3537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cb1846ad-4336-4538-ab0a-99e53949c32d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b7b6872-1351-464a-b221-132e53f7f6f5" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cb1846ad-4336-4538-ab0a-99e53949c32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_0023131f-2615-49da-ae28-68f1691764e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b7b6872-1351-464a-b221-132e53f7f6f5" xlink:to="loc_us-gaap_RepaymentsOfDebt_0023131f-2615-49da-ae28-68f1691764e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6627142d-0d49-47d3-8c40-bd98dac8c64b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b7b6872-1351-464a-b221-132e53f7f6f5" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6627142d-0d49-47d3-8c40-bd98dac8c64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb74b01a-2916-49d5-8421-fb3d908adbdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b7b6872-1351-464a-b221-132e53f7f6f5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb74b01a-2916-49d5-8421-fb3d908adbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_085475d7-721d-441b-99d2-2ceff3b5a077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_085475d7-721d-441b-99d2-2ceff3b5a077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_82373674-135c-48b0-9fe6-acb122bc92fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_82373674-135c-48b0-9fe6-acb122bc92fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ebdadec3-167d-4a45-a6f6-a97e9812d868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ebdadec3-167d-4a45-a6f6-a97e9812d868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_391011ad-0d2b-45e9-9dd5-6d7b92d5fe89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69ca4b95-de2e-48b3-bdf5-4f51a3de5ca0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_391011ad-0d2b-45e9-9dd5-6d7b92d5fe89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20210331.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_bd0ec45b-7801-4050-96f7-33e1cd811590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_72aadab9-410f-4336-8b5c-05a5e1afc7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_bd0ec45b-7801-4050-96f7-33e1cd811590" xlink:to="loc_us-gaap_StatementTable_72aadab9-410f-4336-8b5c-05a5e1afc7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_e53279b3-cdf3-4996-8850-a6a18841d7c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_72aadab9-410f-4336-8b5c-05a5e1afc7fc" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_e53279b3-cdf3-4996-8850-a6a18841d7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_2faaf28e-a797-4280-9d45-3093bf688215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_e53279b3-cdf3-4996-8850-a6a18841d7c8" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_2faaf28e-a797-4280-9d45-3093bf688215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_dc017e28-2eb0-44b9-857d-f6368efc1957" xlink:href="biib-20210331.xsd#biib_A2018ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_2faaf28e-a797-4280-9d45-3093bf688215" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_dc017e28-2eb0-44b9-857d-f6368efc1957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_19f9fed8-e9ef-4504-9fa5-3fed03b521c8" xlink:href="biib-20210331.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_2faaf28e-a797-4280-9d45-3093bf688215" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_19f9fed8-e9ef-4504-9fa5-3fed03b521c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_4d405acc-6e9f-46df-8899-68039e8eba50" xlink:href="biib-20210331.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_2faaf28e-a797-4280-9d45-3093bf688215" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_4d405acc-6e9f-46df-8899-68039e8eba50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f591db1d-77b2-4bfe-b15a-b509e93a7ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_72aadab9-410f-4336-8b5c-05a5e1afc7fc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f591db1d-77b2-4bfe-b15a-b509e93a7ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f591db1d-77b2-4bfe-b15a-b509e93a7ae9" xlink:to="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c485cd8d-722f-4e16-85c7-55204e357152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_PreferredStockMember_c485cd8d-722f-4e16-85c7-55204e357152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_572fc37d-5288-4193-a37c-e092b5a48bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_CommonStockMember_572fc37d-5288-4193-a37c-e092b5a48bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_caaee2de-a354-4a3b-abbc-ef07c93e7d40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_caaee2de-a354-4a3b-abbc-ef07c93e7d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4e8a8164-ba6f-4a5e-bf7f-a8e3c22d0aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4e8a8164-ba6f-4a5e-bf7f-a8e3c22d0aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9f2f3ce9-bd4b-4bef-b0c3-d7d6822e27af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_RetainedEarningsMember_9f2f3ce9-bd4b-4bef-b0c3-d7d6822e27af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_338ca384-45b2-439a-8e03-06a6da3cf990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_TreasuryStockMember_338ca384-45b2-439a-8e03-06a6da3cf990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_53a97a76-612f-446c-aabf-2f588c5b8630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_ParentMember_53a97a76-612f-446c-aabf-2f588c5b8630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_57483946-d0c7-423b-89d8-a42a39ee4d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14792531-3bef-4a5a-9fff-181410fd9a8d" xlink:to="loc_us-gaap_NoncontrollingInterestMember_57483946-d0c7-423b-89d8-a42a39ee4d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_72aadab9-410f-4336-8b5c-05a5e1afc7fc" xlink:to="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_56a6136d-81ef-4a42-95f5-4905a380fcb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_56a6136d-81ef-4a42-95f5-4905a380fcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a1653532-187a-43d7-8c7b-f2c0f8d1d2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a1653532-187a-43d7-8c7b-f2c0f8d1d2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4ac898e5-90f0-48ba-89d1-9248075d25f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_ProfitLoss_4ac898e5-90f0-48ba-89d1-9248075d25f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2b731064-18cc-43b0-85bf-b5db90491b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2b731064-18cc-43b0-85bf-b5db90491b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_8c9af085-e364-490a-ab6d-75aca364aaab" xlink:href="biib-20210331.xsd#biib_Noncontrollinginterestincreasedecreaseother"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_8c9af085-e364-490a-ab6d-75aca364aaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_76e3c340-6ffe-4383-b963-33389c87c9d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_76e3c340-6ffe-4383-b963-33389c87c9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b81a0cff-e58b-409c-91ea-22b481f70f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b81a0cff-e58b-409c-91ea-22b481f70f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_df03e776-02fa-4883-93b9-58e1568305f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_df03e776-02fa-4883-93b9-58e1568305f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_33cf24c3-94e0-4e95-a347-d788875ef162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_33cf24c3-94e0-4e95-a347-d788875ef162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_d6c3bf1f-42b8-49ac-867d-e0e9ba6d4452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_d6c3bf1f-42b8-49ac-867d-e0e9ba6d4452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_de8af93d-f30d-4617-8e65-6a8a60b8c4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_de8af93d-f30d-4617-8e65-6a8a60b8c4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_91e29761-b944-4198-885e-a0a9710370b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_91e29761-b944-4198-885e-a0a9710370b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a30044b3-c5e5-4d29-bb70-6ce5af6ad44e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a30044b3-c5e5-4d29-bb70-6ce5af6ad44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8340154d-114e-4695-8468-3febcf8c45e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8340154d-114e-4695-8468-3febcf8c45e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_cd6671d1-9f33-4360-806b-0067c3bb55f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StockholdersEquityOther_cd6671d1-9f33-4360-806b-0067c3bb55f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0e09b4e-9b47-47e1-b7ad-a98a3177a763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0e09b4e-9b47-47e1-b7ad-a98a3177a763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ca01460f-3853-47b8-8292-af74e150959e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20a388b5-f18b-4d0c-be9b-50d4fb0af0ac" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ca01460f-3853-47b8-8292-af74e150959e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bd6e8c65-6583-4088-bbd4-bcd99b50a496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4a3eb0e5-5a8f-4ed3-997d-6a150d662c66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd6e8c65-6583-4088-bbd4-bcd99b50a496" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4a3eb0e5-5a8f-4ed3-997d-6a150d662c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20210331.xsd#SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6e5284b7-350a-415b-aa4d-2b5da69fc045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_a50db717-a677-43e7-bbdd-746f21874c0d" xlink:href="biib-20210331.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6e5284b7-350a-415b-aa4d-2b5da69fc045" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_a50db717-a677-43e7-bbdd-746f21874c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d4da0d0b-96e3-416f-92ed-7caa271821a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6e5284b7-350a-415b-aa4d-2b5da69fc045" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d4da0d0b-96e3-416f-92ed-7caa271821a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_9ae4bdec-2cc9-4645-b772-a3568d6046ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6e5284b7-350a-415b-aa4d-2b5da69fc045" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_9ae4bdec-2cc9-4645-b772-a3568d6046ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_554a3472-11a4-4046-a720-0513ece6877a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6e5284b7-350a-415b-aa4d-2b5da69fc045" xlink:to="loc_us-gaap_UseOfEstimates_554a3472-11a4-4046-a720-0513ece6877a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a63a29ad-2436-4098-8164-2a26db173e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6e5284b7-350a-415b-aa4d-2b5da69fc045" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a63a29ad-2436-4098-8164-2a26db173e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1ab11a87-312a-42ab-83f9-9a50534eeccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_144e8c09-8489-4564-a373-523f1530ffb2" xlink:href="biib-20210331.xsd#biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1ab11a87-312a-42ab-83f9-9a50534eeccf" xlink:to="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_144e8c09-8489-4564-a373-523f1530ffb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_1ee29694-2531-4114-9d69-84120caeb3f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1ab11a87-312a-42ab-83f9-9a50534eeccf" xlink:to="loc_us-gaap_NumberOfReportableSegments_1ee29694-2531-4114-9d69-84120caeb3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary_109a0507-2452-423d-94d5-ccfad72616e5" xlink:href="biib-20210331.xsd#biib_InterestInSubsidiary"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1ab11a87-312a-42ab-83f9-9a50534eeccf" xlink:to="loc_biib_InterestInSubsidiary_109a0507-2452-423d-94d5-ccfad72616e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:type="simple" xlink:href="biib-20210331.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7ad28959-889e-49fa-b2d9-11283c1c765a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_c5b4224a-3f16-46f6-bdbc-3ea0d3f0deb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7ad28959-889e-49fa-b2d9-11283c1c765a" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_c5b4224a-3f16-46f6-bdbc-3ea0d3f0deb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#BusinessAcquisitionDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquisitionsAbstract_c56291d1-2ec4-4819-9c2a-c19667e42f62" xlink:href="biib-20210331.xsd#biib_AcquisitionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5def6f58-cfbd-471f-ba8f-f40c5a55b66b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_c56291d1-2ec4-4819-9c2a-c19667e42f62" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5def6f58-cfbd-471f-ba8f-f40c5a55b66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_541b7eba-0da8-4e42-bdab-16e1d203bcf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5def6f58-cfbd-471f-ba8f-f40c5a55b66b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_541b7eba-0da8-4e42-bdab-16e1d203bcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc48d214-5078-4bdb-8492-cebc1fa3d382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_541b7eba-0da8-4e42-bdab-16e1d203bcf6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc48d214-5078-4bdb-8492-cebc1fa3d382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB118Member_fa3585a6-7c30-442e-9093-d07f8cb47eb9" xlink:href="biib-20210331.xsd#biib_BIIB118Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc48d214-5078-4bdb-8492-cebc1fa3d382" xlink:to="loc_biib_BIIB118Member_fa3585a6-7c30-442e-9093-d07f8cb47eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4f8eeed3-00f3-4099-8549-fe4bb8c87088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5def6f58-cfbd-471f-ba8f-f40c5a55b66b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_4f8eeed3-00f3-4099-8549-fe4bb8c87088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_0402b212-b9d5-421f-afd6-b7e1efaa9cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4f8eeed3-00f3-4099-8549-fe4bb8c87088" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_0402b212-b9d5-421f-afd6-b7e1efaa9cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1d258cfd-9876-4eba-a28b-93b72307c1c6" xlink:href="biib-20210331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4f8eeed3-00f3-4099-8549-fe4bb8c87088" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1d258cfd-9876-4eba-a28b-93b72307c1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20210331.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_11eab34d-90ad-4a38-8a68-00d30ba30cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_c6a97a7c-e822-41f8-b2da-9b75f5b8522e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_11eab34d-90ad-4a38-8a68-00d30ba30cd1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_c6a97a7c-e822-41f8-b2da-9b75f5b8522e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20210331.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f92a6a92-8196-43f9-944e-b40ce4021ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_04a1a4bb-1a80-4fe2-920d-5d85cdfc8beb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f92a6a92-8196-43f9-944e-b40ce4021ecf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_04a1a4bb-1a80-4fe2-920d-5d85cdfc8beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_cc6077cd-4745-40fd-aeb5-8277fabd514e" xlink:href="biib-20210331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f92a6a92-8196-43f9-944e-b40ce4021ecf" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_cc6077cd-4745-40fd-aeb5-8277fabd514e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_eacf94d4-93f0-47a5-923e-335aac27e26d" xlink:href="biib-20210331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f92a6a92-8196-43f9-944e-b40ce4021ecf" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_eacf94d4-93f0-47a5-923e-335aac27e26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_70277cc9-e9ec-484d-bece-181a93ff1cbc" xlink:href="biib-20210331.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f92a6a92-8196-43f9-944e-b40ce4021ecf" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_70277cc9-e9ec-484d-bece-181a93ff1cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock_99dda198-f2f4-4c58-8d70-c893b48970fb" xlink:href="biib-20210331.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f92a6a92-8196-43f9-944e-b40ce4021ecf" xlink:to="loc_biib_OtherrevenuesTableTextBlock_99dda198-f2f4-4c58-8d70-c893b48970fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#RevenuesbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_00d525ce-19b9-4cee-84e0-8cda585fc479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_bc6277cd-64f0-493c-99c9-3b12fd7e423d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_00d525ce-19b9-4cee-84e0-8cda585fc479" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_bc6277cd-64f0-493c-99c9-3b12fd7e423d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_412e4afa-c80f-40af-91b9-c29e78fd3562" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bc6277cd-64f0-493c-99c9-3b12fd7e423d" xlink:to="loc_srt_ProductOrServiceAxis_412e4afa-c80f-40af-91b9-c29e78fd3562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_412e4afa-c80f-40af-91b9-c29e78fd3562" xlink:to="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_71f79755-879f-4b40-b177-2c25f9b40c95" xlink:href="biib-20210331.xsd#biib_FumarateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_FumarateMember_71f79755-879f-4b40-b177-2c25f9b40c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_115666e3-7543-4f00-a9df-379ed973ae6e" xlink:href="biib-20210331.xsd#biib_InterferonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_InterferonMember_115666e3-7543-4f00-a9df-379ed973ae6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_b4fc0c09-f16c-4a5b-bb35-8129c2f08f56" xlink:href="biib-20210331.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_TysabriProductMember_b4fc0c09-f16c-4a5b-bb35-8129c2f08f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_9fe14bd6-a35e-457d-a46b-ec8de7d9f1e3" xlink:href="biib-20210331.xsd#biib_FAMPYRAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_FAMPYRAMember_9fe14bd6-a35e-457d-a46b-ec8de7d9f1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_039e06a9-e80c-4983-b1ad-987d896091b1" xlink:href="biib-20210331.xsd#biib_ZINBRYTAMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_ZINBRYTAMember_039e06a9-e80c-4983-b1ad-987d896091b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_4ef9ebf3-900c-4073-881b-951310eb3617" xlink:href="biib-20210331.xsd#biib_MSProductRevenuesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_MSProductRevenuesMember_4ef9ebf3-900c-4073-881b-951310eb3617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_8aaae8ab-99f0-4c4d-a803-63e43060449b" xlink:href="biib-20210331.xsd#biib_SPINRAZAMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_SPINRAZAMember_8aaae8ab-99f0-4c4d-a803-63e43060449b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_c1318357-c1ac-4bd4-8c52-4c1fd3643464" xlink:href="biib-20210331.xsd#biib_BENEPALIMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_BENEPALIMember_c1318357-c1ac-4bd4-8c52-4c1fd3643464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_9c308c88-8eab-4883-a080-1e310dd7a7c3" xlink:href="biib-20210331.xsd#biib_IMRALDIMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_IMRALDIMember_9c308c88-8eab-4883-a080-1e310dd7a7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_7dca03ab-cd34-43d4-9747-715c1b568e8e" xlink:href="biib-20210331.xsd#biib_FLIXABIMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_FLIXABIMember_7dca03ab-cd34-43d4-9747-715c1b568e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_bba5fbce-8a27-464a-9cb7-2b116e65c1d9" xlink:href="biib-20210331.xsd#biib_BiosimilarsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_BiosimilarsMember_bba5fbce-8a27-464a-9cb7-2b116e65c1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_094d819b-bbcd-4d98-afaa-74cf32e61a31" xlink:href="biib-20210331.xsd#biib_FUMADERMMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_biib_FUMADERMMember_094d819b-bbcd-4d98-afaa-74cf32e61a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ad77fd2e-36b4-4d87-a9d6-f6729f85de8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_72e4a6be-bd88-467c-a2d2-343d4a6ca169" xlink:to="loc_us-gaap_ProductMember_ad77fd2e-36b4-4d87-a9d6-f6729f85de8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d1374088-2649-4227-b4d7-91755566e003" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bc6277cd-64f0-493c-99c9-3b12fd7e423d" xlink:to="loc_srt_StatementGeographicalAxis_d1374088-2649-4227-b4d7-91755566e003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_55e94f1d-84f1-41af-aa40-d16d6260e3e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d1374088-2649-4227-b4d7-91755566e003" xlink:to="loc_srt_SegmentGeographicalDomain_55e94f1d-84f1-41af-aa40-d16d6260e3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b50dcbb7-b1cf-4764-a342-11bf6bcc6abc" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_55e94f1d-84f1-41af-aa40-d16d6260e3e3" xlink:to="loc_country_US_b50dcbb7-b1cf-4764-a342-11bf6bcc6abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_908bd40c-2139-4980-b26c-b380f01330a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_55e94f1d-84f1-41af-aa40-d16d6260e3e3" xlink:to="loc_us-gaap_NonUsMember_908bd40c-2139-4980-b26c-b380f01330a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a5e844fc-1092-4dee-a66d-d04cbbca4d61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bc6277cd-64f0-493c-99c9-3b12fd7e423d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a5e844fc-1092-4dee-a66d-d04cbbca4d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_23554560-732a-49d4-8ef5-075129d61ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a5e844fc-1092-4dee-a66d-d04cbbca4d61" xlink:to="loc_us-gaap_Revenues_23554560-732a-49d4-8ef5-075129d61ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20210331.xsd#ReservesforDiscountsandAllowancesDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_f425d4c3-ba41-4869-b3ec-90d2eb23dd35" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_948f7c12-4982-44f2-a292-7b0eef44e0c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_f425d4c3-ba41-4869-b3ec-90d2eb23dd35" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_948f7c12-4982-44f2-a292-7b0eef44e0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_21cb6140-27ca-48c4-87f4-502af9e658a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_948f7c12-4982-44f2-a292-7b0eef44e0c8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_21cb6140-27ca-48c4-87f4-502af9e658a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_69811935-27cd-4020-a995-757ee82dd10e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_21cb6140-27ca-48c4-87f4-502af9e658a1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_69811935-27cd-4020-a995-757ee82dd10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_4de4e79f-1d7c-4f0a-be39-8d4ddf1ffc90" xlink:href="biib-20210331.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_69811935-27cd-4020-a995-757ee82dd10e" xlink:to="loc_biib_ReserveforCashDiscountsMember_4de4e79f-1d7c-4f0a-be39-8d4ddf1ffc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_2b3846bb-3fc5-4771-8bdd-d83385eae578" xlink:href="biib-20210331.xsd#biib_ContractualAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_69811935-27cd-4020-a995-757ee82dd10e" xlink:to="loc_biib_ContractualAdjustmentsMember_2b3846bb-3fc5-4771-8bdd-d83385eae578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_1449115b-d382-47c0-86ad-d5ba6cf0c285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_69811935-27cd-4020-a995-757ee82dd10e" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_1449115b-d382-47c0-86ad-d5ba6cf0c285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c755e57-909d-4cd8-9e1a-7828585551eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_948f7c12-4982-44f2-a292-7b0eef44e0c8" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c755e57-909d-4cd8-9e1a-7828585551eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d1a1c682-79e3-4c95-a869-69b67c24417d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c755e57-909d-4cd8-9e1a-7828585551eb" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_d1a1c682-79e3-4c95-a869-69b67c24417d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_6909042c-82ad-40e9-a60e-96d4bad941eb" xlink:href="biib-20210331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c755e57-909d-4cd8-9e1a-7828585551eb" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_6909042c-82ad-40e9-a60e-96d4bad941eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_936ec3ef-106f-40d5-984e-ac6a81797555" xlink:href="biib-20210331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c755e57-909d-4cd8-9e1a-7828585551eb" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_936ec3ef-106f-40d5-984e-ac6a81797555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3314970b-703e-4e2b-8c10-ee475a15f8ea" xlink:href="biib-20210331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c755e57-909d-4cd8-9e1a-7828585551eb" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3314970b-703e-4e2b-8c10-ee475a15f8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_ad8b7b02-2e66-473e-b64e-748e38f2f617" xlink:href="biib-20210331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c755e57-909d-4cd8-9e1a-7828585551eb" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_ad8b7b02-2e66-473e-b64e-748e38f2f617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_f2c4f04e-cf68-487f-8daa-c72cc2641db0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c755e57-909d-4cd8-9e1a-7828585551eb" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_f2c4f04e-cf68-487f-8daa-c72cc2641db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20210331.xsd#ReservesforDiscountsandAllowancesDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_0479c876-9a93-4590-9023-9756d6c4f542" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_45af5299-39c3-4a2c-8bf0-0fbcf49d3e41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_0479c876-9a93-4590-9023-9756d6c4f542" xlink:to="loc_us-gaap_StatementTable_45af5299-39c3-4a2c-8bf0-0fbcf49d3e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_33e9124f-dd9f-4d6f-a024-4539d163921f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_45af5299-39c3-4a2c-8bf0-0fbcf49d3e41" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_33e9124f-dd9f-4d6f-a024-4539d163921f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_51d8831c-f2ca-458e-ad06-a49483087a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_33e9124f-dd9f-4d6f-a024-4539d163921f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_51d8831c-f2ca-458e-ad06-a49483087a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_b95fb5a8-198d-445d-9e8f-2db7136b9a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_51d8831c-f2ca-458e-ad06-a49483087a0c" xlink:to="loc_us-gaap_AccountsReceivableMember_b95fb5a8-198d-445d-9e8f-2db7136b9a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_d19d1a6d-7e9b-4221-bbdc-1c948485aa6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_51d8831c-f2ca-458e-ad06-a49483087a0c" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_d19d1a6d-7e9b-4221-bbdc-1c948485aa6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_20aacd4d-c4cd-498f-b3d9-df810928da29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_45af5299-39c3-4a2c-8bf0-0fbcf49d3e41" xlink:to="loc_us-gaap_StatementLineItems_20aacd4d-c4cd-498f-b3d9-df810928da29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_709d11b0-6134-4d87-a6b0-8d2517747dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20aacd4d-c4cd-498f-b3d9-df810928da29" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_709d11b0-6134-4d87-a6b0-8d2517747dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#RevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ddbd3236-beca-400c-a861-4aa1beef9685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1b361010-acb1-454f-b7d9-0f2e727d89d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ddbd3236-beca-400c-a861-4aa1beef9685" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1b361010-acb1-454f-b7d9-0f2e727d89d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f0636687-dc99-4a70-9f52-085de926e858" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1b361010-acb1-454f-b7d9-0f2e727d89d0" xlink:to="loc_srt_ProductOrServiceAxis_f0636687-dc99-4a70-9f52-085de926e858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_76f36cd5-577a-4cb4-ad12-63010a224885" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f0636687-dc99-4a70-9f52-085de926e858" xlink:to="loc_srt_ProductsAndServicesDomain_76f36cd5-577a-4cb4-ad12-63010a224885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_2c1e47aa-9842-4c76-a97f-4b189c476616" xlink:href="biib-20210331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_76f36cd5-577a-4cb4-ad12-63010a224885" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_2c1e47aa-9842-4c76-a97f-4b189c476616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0610bf6e-3536-4646-9dd7-8fe879fcf397" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1b361010-acb1-454f-b7d9-0f2e727d89d0" xlink:to="loc_srt_MajorCustomersAxis_0610bf6e-3536-4646-9dd7-8fe879fcf397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_19ca9956-2df5-4aa0-bc25-a4e7db7f79fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0610bf6e-3536-4646-9dd7-8fe879fcf397" xlink:to="loc_srt_NameOfMajorCustomerDomain_19ca9956-2df5-4aa0-bc25-a4e7db7f79fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_9674e8de-0273-4f5c-a1a1-f5a56eb4b975" xlink:href="biib-20210331.xsd#biib_RocheGroupGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_19ca9956-2df5-4aa0-bc25-a4e7db7f79fd" xlink:to="loc_biib_RocheGroupGenentechMember_9674e8de-0273-4f5c-a1a1-f5a56eb4b975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0df9aa69-2fce-4043-a07c-18800916721a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1b361010-acb1-454f-b7d9-0f2e727d89d0" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0df9aa69-2fce-4043-a07c-18800916721a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_55f4cd4b-b3ba-4ee2-890f-e8759445021e" xlink:href="biib-20210331.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0df9aa69-2fce-4043-a07c-18800916721a" xlink:to="loc_biib_ShareOfCoPromotionProfits_55f4cd4b-b3ba-4ee2-890f-e8759445021e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_4e427326-b32e-4ded-b4df-defa8868595d" xlink:href="biib-20210331.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0df9aa69-2fce-4043-a07c-18800916721a" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_4e427326-b32e-4ded-b4df-defa8868595d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_82a2381a-cfd1-4000-8178-d8d85a6d7000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0df9aa69-2fce-4043-a07c-18800916721a" xlink:to="loc_us-gaap_Revenues_82a2381a-cfd1-4000-8178-d8d85a6d7000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#OtherRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract_63258837-e059-443f-9124-e23f7698d409" xlink:href="biib-20210331.xsd#biib_OtherrevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e0550b4e-7c4f-46b2-8dd2-06a653a12798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_63258837-e059-443f-9124-e23f7698d409" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e0550b4e-7c4f-46b2-8dd2-06a653a12798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bf8dc191-67e9-47d9-aed3-4d2ca6bfa0a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e0550b4e-7c4f-46b2-8dd2-06a653a12798" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bf8dc191-67e9-47d9-aed3-4d2ca6bfa0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1732254f-47d8-452f-b18a-6f526f5b3063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bf8dc191-67e9-47d9-aed3-4d2ca6bfa0a4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1732254f-47d8-452f-b18a-6f526f5b3063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_2611af4c-645c-42a4-82b7-60c8d5399f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1732254f-47d8-452f-b18a-6f526f5b3063" xlink:to="loc_us-gaap_CollaborativeArrangementMember_2611af4c-645c-42a4-82b7-60c8d5399f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ed7b5aa6-6ae1-45db-b139-fb7d4d312454" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e0550b4e-7c4f-46b2-8dd2-06a653a12798" xlink:to="loc_srt_ProductOrServiceAxis_ed7b5aa6-6ae1-45db-b139-fb7d4d312454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ddbb3351-fc9b-4b34-a09a-9f4edae8f467" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ed7b5aa6-6ae1-45db-b139-fb7d4d312454" xlink:to="loc_srt_ProductsAndServicesDomain_ddbb3351-fc9b-4b34-a09a-9f4edae8f467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_8f5c311c-c845-410e-a9ed-b21d6e07d6b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddbb3351-fc9b-4b34-a09a-9f4edae8f467" xlink:to="loc_us-gaap_RoyaltyMember_8f5c311c-c845-410e-a9ed-b21d6e07d6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_2bec92d5-458b-4225-80cf-d52fe6904425" xlink:href="biib-20210331.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddbb3351-fc9b-4b34-a09a-9f4edae8f467" xlink:to="loc_biib_OthercorporaterevenuesMember_2bec92d5-458b-4225-80cf-d52fe6904425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_10034357-1a63-48ee-8eaf-fbe34c04c00f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddbb3351-fc9b-4b34-a09a-9f4edae8f467" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_10034357-1a63-48ee-8eaf-fbe34c04c00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_5b0ad00e-813b-4170-8394-58bf8847b0e6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e0550b4e-7c4f-46b2-8dd2-06a653a12798" xlink:to="loc_srt_MajorCustomersAxis_5b0ad00e-813b-4170-8394-58bf8847b0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_81ff6d21-c2af-402c-b226-b923d0c06545" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_5b0ad00e-813b-4170-8394-58bf8847b0e6" xlink:to="loc_srt_NameOfMajorCustomerDomain_81ff6d21-c2af-402c-b226-b923d0c06545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_9e11d5c9-af12-47a8-ae73-08c449f68705" xlink:href="biib-20210331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_81ff6d21-c2af-402c-b226-b923d0c06545" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_9e11d5c9-af12-47a8-ae73-08c449f68705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_752b0b6e-c20b-45ed-b1a8-dd8386b2f5e2" xlink:href="biib-20210331.xsd#biib_ZINBRYTAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_81ff6d21-c2af-402c-b226-b923d0c06545" xlink:to="loc_biib_ZINBRYTAMember_752b0b6e-c20b-45ed-b1a8-dd8386b2f5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e0029a92-6161-44f7-9e4b-2de214122aef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e0550b4e-7c4f-46b2-8dd2-06a653a12798" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e0029a92-6161-44f7-9e4b-2de214122aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4fce2cb9-ba35-45b3-a9be-94318ad915e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e0029a92-6161-44f7-9e4b-2de214122aef" xlink:to="loc_us-gaap_Revenues_4fce2cb9-ba35-45b3-a9be-94318ad915e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#RevenuesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8a6a4d64-4f43-4f60-b6c0-6a75d50e0179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3b591225-ee1a-44fc-9b6f-13e50a9be999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8a6a4d64-4f43-4f60-b6c0-6a75d50e0179" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3b591225-ee1a-44fc-9b6f-13e50a9be999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7dad99d8-74a1-4b7e-a2bb-e810167baa1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3b591225-ee1a-44fc-9b6f-13e50a9be999" xlink:to="loc_srt_ProductOrServiceAxis_7dad99d8-74a1-4b7e-a2bb-e810167baa1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f3e25a9c-4ba4-4fad-9291-9d8e03cbd81e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7dad99d8-74a1-4b7e-a2bb-e810167baa1f" xlink:to="loc_srt_ProductsAndServicesDomain_f3e25a9c-4ba4-4fad-9291-9d8e03cbd81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_6908c6c4-78e9-4665-8066-6127f31838c7" xlink:href="biib-20210331.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f3e25a9c-4ba4-4fad-9291-9d8e03cbd81e" xlink:to="loc_biib_OthercorporaterevenuesMember_6908c6c4-78e9-4665-8066-6127f31838c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_64656d7f-32f3-4ecc-9ecd-24cf15176fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f3e25a9c-4ba4-4fad-9291-9d8e03cbd81e" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_64656d7f-32f3-4ecc-9ecd-24cf15176fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c3beb28e-26d1-4540-9c98-163853dda374" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3b591225-ee1a-44fc-9b6f-13e50a9be999" xlink:to="loc_srt_MajorCustomersAxis_c3beb28e-26d1-4540-9c98-163853dda374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_950ae2aa-b94c-4325-a663-bfc81b73cf66" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c3beb28e-26d1-4540-9c98-163853dda374" xlink:to="loc_srt_NameOfMajorCustomerDomain_950ae2aa-b94c-4325-a663-bfc81b73cf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_c7695334-fcb0-43cb-80c6-ef369e514e08" xlink:href="biib-20210331.xsd#biib_DistributorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_950ae2aa-b94c-4325-a663-bfc81b73cf66" xlink:to="loc_biib_DistributorOneMember_c7695334-fcb0-43cb-80c6-ef369e514e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_29fd46b5-2192-4b44-90f1-5e245f4982ac" xlink:href="biib-20210331.xsd#biib_DistributorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_950ae2aa-b94c-4325-a663-bfc81b73cf66" xlink:to="loc_biib_DistributorTwoMember_29fd46b5-2192-4b44-90f1-5e245f4982ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2c4a41cb-ad5c-4e7e-b405-00afbfc18603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3b591225-ee1a-44fc-9b6f-13e50a9be999" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_2c4a41cb-ad5c-4e7e-b405-00afbfc18603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_81e08d08-6cbf-4567-b091-4dadf6873a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2c4a41cb-ad5c-4e7e-b405-00afbfc18603" xlink:to="loc_us-gaap_Revenues_81e08d08-6cbf-4567-b091-4dadf6873a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7864b783-d556-491a-af7e-32c4b214f1f1" xlink:href="biib-20210331.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2c4a41cb-ad5c-4e7e-b405-00afbfc18603" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7864b783-d556-491a-af7e-32c4b214f1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_9712ebbb-e1b0-41ec-abb0-d9073395f372" xlink:href="biib-20210331.xsd#biib_NumberOfWholesalers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2c4a41cb-ad5c-4e7e-b405-00afbfc18603" xlink:to="loc_biib_NumberOfWholesalers_9712ebbb-e1b0-41ec-abb0-d9073395f372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20210331.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_046661bf-a2f7-4a29-bd4e-13898d7fdcf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_e043353e-8722-40f5-8e50-e0086d28d2e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_046661bf-a2f7-4a29-bd4e-13898d7fdcf4" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_e043353e-8722-40f5-8e50-e0086d28d2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20210331.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f8237c69-0715-4c18-842e-85536cb8cdcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5ab41ff0-c723-4260-9067-5dbb61a2261b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f8237c69-0715-4c18-842e-85536cb8cdcb" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5ab41ff0-c723-4260-9067-5dbb61a2261b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e8e8fe08-b9b0-4ab6-91b9-fb9af35bfd70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_12896846-800a-4ad0-9b0f-30828a87a315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e8e8fe08-b9b0-4ab6-91b9-fb9af35bfd70" xlink:to="loc_us-gaap_InventoryNetAbstract_12896846-800a-4ad0-9b0f-30828a87a315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_8206be8d-b28a-4465-a719-6f7b8cd58447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_12896846-800a-4ad0-9b0f-30828a87a315" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_8206be8d-b28a-4465-a719-6f7b8cd58447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6dcba9a2-fec2-4c16-bc47-c9ac9ab2dec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_12896846-800a-4ad0-9b0f-30828a87a315" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6dcba9a2-fec2-4c16-bc47-c9ac9ab2dec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7b3e06c6-7da0-462a-bdeb-6e1ef2788e1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_12896846-800a-4ad0-9b0f-30828a87a315" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7b3e06c6-7da0-462a-bdeb-6e1ef2788e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_ef983d7e-8225-4994-8357-5d296c077ded" xlink:href="biib-20210331.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_12896846-800a-4ad0-9b0f-30828a87a315" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_ef983d7e-8225-4994-8357-5d296c077ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20210331.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2eb83c4e-9832-4109-aff0-02756c3e74ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b7cc8b6f-24a6-4e46-8a39-43ae5ab5852c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2eb83c4e-9832-4109-aff0-02756c3e74ad" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b7cc8b6f-24a6-4e46-8a39-43ae5ab5852c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20210331.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_225f0ee2-3d54-4449-9831-e9a9426f6913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_ff4e7b1c-5d7d-45f3-a3f6-80f441a44c29" xlink:href="biib-20210331.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_225f0ee2-3d54-4449-9831-e9a9426f6913" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_ff4e7b1c-5d7d-45f3-a3f6-80f441a44c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_fb0d5f30-fdd7-4828-8b86-7c04b80ff4ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_225f0ee2-3d54-4449-9831-e9a9426f6913" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_fb0d5f30-fdd7-4828-8b86-7c04b80ff4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_d0e32b9d-28eb-41ba-8df7-53f29744bf02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_225f0ee2-3d54-4449-9831-e9a9426f6913" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_d0e32b9d-28eb-41ba-8df7-53f29744bf02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_912672aa-221d-4a29-ab3d-e77f0623abfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_912672aa-221d-4a29-ab3d-e77f0623abfd" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_b1af87f6-0d93-480e-a084-b6f2f331fb3f" xlink:href="biib-20210331.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_b1af87f6-0d93-480e-a084-b6f2f331fb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_8c69cb2a-46af-4ea0-a7ff-a93493b50157" xlink:href="biib-20210331.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_b1af87f6-0d93-480e-a084-b6f2f331fb3f" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_8c69cb2a-46af-4ea0-a7ff-a93493b50157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_43dab68c-45a4-4855-bcc0-0bc9581a7e1d" xlink:href="biib-20210331.xsd#biib_TGNMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_8c69cb2a-46af-4ea0-a7ff-a93493b50157" xlink:to="loc_biib_TGNMember_43dab68c-45a4-4855-bcc0-0bc9581a7e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember_147ce6b5-5589-4b26-b576-8811ef002f03" xlink:href="biib-20210331.xsd#biib_VixotrigineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_8c69cb2a-46af-4ea0-a7ff-a93493b50157" xlink:to="loc_biib_VixotrigineMember_147ce6b5-5589-4b26-b576-8811ef002f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_8642efc3-09a9-40ab-865d-2c61517f106a" xlink:href="biib-20210331.xsd#biib_BIIB111Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_8c69cb2a-46af-4ea0-a7ff-a93493b50157" xlink:to="loc_biib_BIIB111Member_8642efc3-09a9-40ab-865d-2c61517f106a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1cb85f51-0197-4684-98d9-4f6bc9e8f888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1cb85f51-0197-4684-98d9-4f6bc9e8f888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90793bad-b48c-4d91-995b-c9533ba75504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1cb85f51-0197-4684-98d9-4f6bc9e8f888" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90793bad-b48c-4d91-995b-c9533ba75504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_4b94ba04-ef1d-40a8-849b-452565e2dd08" xlink:href="biib-20210331.xsd#biib_NightstarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90793bad-b48c-4d91-995b-c9533ba75504" xlink:to="loc_biib_NightstarMember_4b94ba04-ef1d-40a8-849b-452565e2dd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f7daa7f0-4bfc-41a3-9b06-b42141f5e3ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f7daa7f0-4bfc-41a3-9b06-b42141f5e3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4f0dc1ed-eaec-400f-b68b-4ccca717e16e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f7daa7f0-4bfc-41a3-9b06-b42141f5e3ad" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4f0dc1ed-eaec-400f-b68b-4ccca717e16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e531bcc6-2a2f-4cad-ad8a-472945e27cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4f0dc1ed-eaec-400f-b68b-4ccca717e16e" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e531bcc6-2a2f-4cad-ad8a-472945e27cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_61129974-4a4e-4861-87e8-3c95bcbad941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4f0dc1ed-eaec-400f-b68b-4ccca717e16e" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_61129974-4a4e-4861-87e8-3c95bcbad941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43465c44-8b29-4c9d-a2e0-e28216d03a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43465c44-8b29-4c9d-a2e0-e28216d03a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ec973424-767f-4dbe-b6bc-bb4801e12ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43465c44-8b29-4c9d-a2e0-e28216d03a8a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ec973424-767f-4dbe-b6bc-bb4801e12ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_71801396-a236-4093-bf22-75c6e2e36e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ec973424-767f-4dbe-b6bc-bb4801e12ce2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_71801396-a236-4093-bf22-75c6e2e36e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_b5984275-baee-4bf0-a8ea-b39872021848" xlink:href="biib-20210331.xsd#biib_OutLicensedPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ec973424-767f-4dbe-b6bc-bb4801e12ce2" xlink:to="loc_biib_OutLicensedPatentsMember_b5984275-baee-4bf0-a8ea-b39872021848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4f42f594-8b4b-4231-ad7b-8bbf45afcd78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ec973424-767f-4dbe-b6bc-bb4801e12ce2" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4f42f594-8b4b-4231-ad7b-8bbf45afcd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InLicensedPatentsMember_c894ee61-64f6-4790-8182-87e42a1624f0" xlink:href="biib-20210331.xsd#biib_InLicensedPatentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ec973424-767f-4dbe-b6bc-bb4801e12ce2" xlink:to="loc_biib_InLicensedPatentsMember_c894ee61-64f6-4790-8182-87e42a1624f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7ce7746e-2cda-4f7d-89f7-b8c7cccea586" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:to="loc_srt_ProductOrServiceAxis_7ce7746e-2cda-4f7d-89f7-b8c7cccea586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4b136c0d-1c18-44f1-ac01-4421ca149110" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7ce7746e-2cda-4f7d-89f7-b8c7cccea586" xlink:to="loc_srt_ProductsAndServicesDomain_4b136c0d-1c18-44f1-ac01-4421ca149110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_dfd106bd-119c-4ccd-b132-dbc4fb331920" xlink:href="biib-20210331.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4b136c0d-1c18-44f1-ac01-4421ca149110" xlink:to="loc_biib_TysabriProductMember_dfd106bd-119c-4ccd-b132-dbc4fb331920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_75da00d7-65ab-4888-9744-7f5d04de912a" xlink:href="biib-20210331.xsd#biib_FumarateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4b136c0d-1c18-44f1-ac01-4421ca149110" xlink:to="loc_biib_FumarateMember_75da00d7-65ab-4888-9744-7f5d04de912a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdd31614-ff10-4516-a895-1b024cee0ba2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:to="loc_srt_RangeAxis_fdd31614-ff10-4516-a895-1b024cee0ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0350cc23-a49b-45b0-9654-716c9dfc1df2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fdd31614-ff10-4516-a895-1b024cee0ba2" xlink:to="loc_srt_RangeMember_0350cc23-a49b-45b0-9654-716c9dfc1df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_99b67f61-e9b2-434a-b0a5-ea6af4e5a1d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0350cc23-a49b-45b0-9654-716c9dfc1df2" xlink:to="loc_srt_MinimumMember_99b67f61-e9b2-434a-b0a5-ea6af4e5a1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0ba85162-ed03-4974-a42f-15d629852f09" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0350cc23-a49b-45b0-9654-716c9dfc1df2" xlink:to="loc_srt_MaximumMember_0ba85162-ed03-4974-a42f-15d629852f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11af19dd-2ec6-48f0-9a85-e7398573d1f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_635b9038-fd28-4e83-a08c-0bde7b5c7914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_635b9038-fd28-4e83-a08c-0bde7b5c7914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_944cd3eb-7464-4472-a4d0-18d525bb34eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_944cd3eb-7464-4472-a4d0-18d525bb34eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_7316bedd-ecc7-4293-b5b0-ec43e9c014d2" xlink:href="biib-20210331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_7316bedd-ecc7-4293-b5b0-ec43e9c014d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_077adb51-e669-49dd-8cbb-4cf4d5448f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_077adb51-e669-49dd-8cbb-4cf4d5448f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c6657c63-b1d3-43e8-a445-91d3a96f5754" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c6657c63-b1d3-43e8-a445-91d3a96f5754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c9c6c82a-27e9-4952-a698-82a49324c73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c9c6c82a-27e9-4952-a698-82a49324c73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5fd00ae1-aeed-4f8e-9694-37e9da45fc5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5fd00ae1-aeed-4f8e-9694-37e9da45fc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_008e8c99-69c4-48d2-88e9-a02a469c2179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_008e8c99-69c4-48d2-88e9-a02a469c2179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bfc95225-0bda-4a32-a095-0a99a60fa789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bfc95225-0bda-4a32-a095-0a99a60fa789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7840fbff-6f49-4c3a-960f-09db474db216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6f7ed949-30fe-48a1-a8ad-82fbede9378f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7840fbff-6f49-4c3a-960f-09db474db216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d7f97076-7979-4dbc-be8e-84e200c0efe6" xlink:href="biib-20210331.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d7f97076-7979-4dbc-be8e-84e200c0efe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_625a65b0-cad3-4563-b362-0263c404e288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_625a65b0-cad3-4563-b362-0263c404e288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b539f353-def2-4be9-8865-5aec1208d0b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b539f353-def2-4be9-8865-5aec1208d0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e9b4bd02-6e5a-4885-8003-f07d0b9bdd4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e9b4bd02-6e5a-4885-8003-f07d0b9bdd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6be94ace-9f32-45dd-ace4-b826b167066c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6be94ace-9f32-45dd-ace4-b826b167066c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_80a53f1b-9eef-4729-867e-f4275478f18a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_80a53f1b-9eef-4729-867e-f4275478f18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ecebb7ad-8f3b-49f1-a7d1-af2e9123e906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ecebb7ad-8f3b-49f1-a7d1-af2e9123e906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7cbcbd55-096a-4165-b903-ed53a4a9fa93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b1775d1-22f7-47b3-a824-4eae7f30e041" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7cbcbd55-096a-4165-b903-ed53a4a9fa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="simple" xlink:href="biib-20210331.xsd#IntangibleAssetsandGoodwillDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ba64ee88-c3ad-44e8-ab2b-3227c5e3655c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_0610f6f6-f745-4f78-9cea-1d4578e657b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ba64ee88-c3ad-44e8-ab2b-3227c5e3655c" xlink:to="loc_us-gaap_GoodwillRollForward_0610f6f6-f745-4f78-9cea-1d4578e657b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f9127e66-5744-4b21-a832-684e30cd3d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_0610f6f6-f745-4f78-9cea-1d4578e657b6" xlink:to="loc_us-gaap_Goodwill_f9127e66-5744-4b21-a832-684e30cd3d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_e771f405-530c-4a64-b75e-4d8665eec866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_0610f6f6-f745-4f78-9cea-1d4578e657b6" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_e771f405-530c-4a64-b75e-4d8665eec866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f20db78f-e8b8-4a45-bcf4-3e736820c361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_0610f6f6-f745-4f78-9cea-1d4578e657b6" xlink:to="loc_us-gaap_Goodwill_f20db78f-e8b8-4a45-bcf4-3e736820c361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_354d08e2-d0e3-40cc-8b42-5a51b9a94410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ba64ee88-c3ad-44e8-ab2b-3227c5e3655c" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_354d08e2-d0e3-40cc-8b42-5a51b9a94410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_a3282359-1208-40d5-bcb9-05c21c4dc958" xlink:href="biib-20210331.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ba64ee88-c3ad-44e8-ab2b-3227c5e3655c" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_a3282359-1208-40d5-bcb9-05c21c4dc958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1d216484-e0e5-42a1-9d24-70360fe1b735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ba64ee88-c3ad-44e8-ab2b-3227c5e3655c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1d216484-e0e5-42a1-9d24-70360fe1b735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_38fd7c7f-aca1-4be3-9476-a64b1f760b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ba64ee88-c3ad-44e8-ab2b-3227c5e3655c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_38fd7c7f-aca1-4be3-9476-a64b1f760b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5cdca473-e5c7-4541-baf0-ceb7c04076d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_59f9053c-d0ef-4692-947a-365d7dbbf87b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5cdca473-e5c7-4541-baf0-ceb7c04076d4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_59f9053c-d0ef-4692-947a-365d7dbbf87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_380d2323-2a5c-4912-bbdb-5c565beb31ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4146287b-b3bc-427f-89f6-690d1aa958b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_380d2323-2a5c-4912-bbdb-5c565beb31ff" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4146287b-b3bc-427f-89f6-690d1aa958b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_0ab89e91-964b-4def-bdb2-fc4d1f4dea8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_380d2323-2a5c-4912-bbdb-5c565beb31ff" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_0ab89e91-964b-4def-bdb2-fc4d1f4dea8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_acec1982-faf8-41a3-ac76-47e5d8273485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_380d2323-2a5c-4912-bbdb-5c565beb31ff" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_acec1982-faf8-41a3-ac76-47e5d8273485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b0eccc59-9f08-48c0-9026-87442432998a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d595671-59e8-47b1-9467-2199caa5e68d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b0eccc59-9f08-48c0-9026-87442432998a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d595671-59e8-47b1-9467-2199caa5e68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_617fab1b-2038-4fb3-9e0b-342d5d5f08bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d595671-59e8-47b1-9467-2199caa5e68d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_617fab1b-2038-4fb3-9e0b-342d5d5f08bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c630ba2-7b72-411e-bd53-57b540d45a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_617fab1b-2038-4fb3-9e0b-342d5d5f08bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c630ba2-7b72-411e-bd53-57b540d45a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_de9a62dc-0275-45a4-9905-edc7ef6ed6a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c630ba2-7b72-411e-bd53-57b540d45a57" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_de9a62dc-0275-45a4-9905-edc7ef6ed6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_34d61fec-f7b0-4f98-9477-de5d3627c0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c630ba2-7b72-411e-bd53-57b540d45a57" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_34d61fec-f7b0-4f98-9477-de5d3627c0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6ad486b8-65dc-4ea4-ba2d-f1a4fd8bbb4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c630ba2-7b72-411e-bd53-57b540d45a57" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6ad486b8-65dc-4ea4-ba2d-f1a4fd8bbb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6fa567b7-42a3-4d51-a317-e0e7a29bbb0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d595671-59e8-47b1-9467-2199caa5e68d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6fa567b7-42a3-4d51-a317-e0e7a29bbb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5fc92b9a-d0dd-44fa-88ad-707fc5ca8562" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6fa567b7-42a3-4d51-a317-e0e7a29bbb0e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5fc92b9a-d0dd-44fa-88ad-707fc5ca8562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f64eba84-d2f6-4dff-ad37-e577565ac086" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5fc92b9a-d0dd-44fa-88ad-707fc5ca8562" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f64eba84-d2f6-4dff-ad37-e577565ac086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_a008e94b-baff-40ec-8ddc-93e9e178b6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d595671-59e8-47b1-9467-2199caa5e68d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_a008e94b-baff-40ec-8ddc-93e9e178b6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f0ae0854-36e1-4588-95cc-0dfeac57e762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_a008e94b-baff-40ec-8ddc-93e9e178b6bb" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f0ae0854-36e1-4588-95cc-0dfeac57e762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6abb203e-303c-4e1d-9448-7f12a7dad17d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f0ae0854-36e1-4588-95cc-0dfeac57e762" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6abb203e-303c-4e1d-9448-7f12a7dad17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_f35269a0-f3ba-4ff3-80d7-5eb5607d34cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f0ae0854-36e1-4588-95cc-0dfeac57e762" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_f35269a0-f3ba-4ff3-80d7-5eb5607d34cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_2d22dc38-c6c4-4209-a4e5-9efaaf0a1597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f0ae0854-36e1-4588-95cc-0dfeac57e762" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_2d22dc38-c6c4-4209-a4e5-9efaaf0a1597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff6bad12-4a33-46e8-ae0c-9abb36912d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d595671-59e8-47b1-9467-2199caa5e68d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff6bad12-4a33-46e8-ae0c-9abb36912d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a5c9e9cc-e17a-4b78-ab5b-03d69c96b523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff6bad12-4a33-46e8-ae0c-9abb36912d5a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a5c9e9cc-e17a-4b78-ab5b-03d69c96b523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a5c9e9cc-e17a-4b78-ab5b-03d69c96b523" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8229c5ef-3d81-4e6c-8b2c-055916450a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8229c5ef-3d81-4e6c-8b2c-055916450a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c8dee661-59e8-4c00-8db9-4b82f45ff1b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c8dee661-59e8-4c00-8db9-4b82f45ff1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_dc57dd30-3205-4499-af91-e768d6970ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_dc57dd30-3205-4499-af91-e768d6970ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_501b573b-ae60-411f-8149-75b2bfc2b2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_501b573b-ae60-411f-8149-75b2bfc2b2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_1c1d6bcc-1872-4a15-8c5d-0985d91df1c3" xlink:href="biib-20210331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_1c1d6bcc-1872-4a15-8c5d-0985d91df1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_abe2c31f-fe4e-4350-b9c8-c9608e55487a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_698c1117-19d2-4ddf-a8f4-cdcfeea2d4ab" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_abe2c31f-fe4e-4350-b9c8-c9608e55487a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_48e2ec01-0b82-4923-8038-c50b99d7ef47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a5c9e9cc-e17a-4b78-ab5b-03d69c96b523" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_48e2ec01-0b82-4923-8038-c50b99d7ef47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_9eb5bf32-2f3d-4147-b052-ae7c42dbd89e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_48e2ec01-0b82-4923-8038-c50b99d7ef47" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_9eb5bf32-2f3d-4147-b052-ae7c42dbd89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d9a9d7c-d30f-44ab-bf5c-07899dd5ec15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_48e2ec01-0b82-4923-8038-c50b99d7ef47" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d9a9d7c-d30f-44ab-bf5c-07899dd5ec15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4e5eb49f-c72e-4ddc-a6ea-c5f67e46cb86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_48e2ec01-0b82-4923-8038-c50b99d7ef47" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_4e5eb49f-c72e-4ddc-a6ea-c5f67e46cb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d01a4a65-35ca-4534-8681-b7ec2d2cef8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ef4ca3cf-8140-47bc-b716-a1b1e18e3df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d01a4a65-35ca-4534-8681-b7ec2d2cef8d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ef4ca3cf-8140-47bc-b716-a1b1e18e3df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_47bcd5db-8342-449f-9dff-6466ed4193ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ef4ca3cf-8140-47bc-b716-a1b1e18e3df5" xlink:to="loc_us-gaap_DebtInstrumentAxis_47bcd5db-8342-449f-9dff-6466ed4193ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4ebb5a4f-9067-4670-8cc3-8fcdc4a78589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_47bcd5db-8342-449f-9dff-6466ed4193ad" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4ebb5a4f-9067-4670-8cc3-8fcdc4a78589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_111a736c-c933-4eb6-97b5-5269ba794ef5" xlink:href="biib-20210331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4ebb5a4f-9067-4670-8cc3-8fcdc4a78589" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_111a736c-c933-4eb6-97b5-5269ba794ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_58beb8b8-92ba-46e2-bca4-03469bc54291" xlink:href="biib-20210331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4ebb5a4f-9067-4670-8cc3-8fcdc4a78589" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_58beb8b8-92ba-46e2-bca4-03469bc54291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_a23072e2-0196-4c6c-8c65-ddf804021275" xlink:href="biib-20210331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4ebb5a4f-9067-4670-8cc3-8fcdc4a78589" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_a23072e2-0196-4c6c-8c65-ddf804021275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_dd154454-e9e1-4acb-a35c-f3cb77a24524" xlink:href="biib-20210331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4ebb5a4f-9067-4670-8cc3-8fcdc4a78589" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_dd154454-e9e1-4acb-a35c-f3cb77a24524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_30415afd-4bc5-4f10-ad36-a923946a16d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ef4ca3cf-8140-47bc-b716-a1b1e18e3df5" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_30415afd-4bc5-4f10-ad36-a923946a16d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_201b4c2c-ad8b-40a7-a725-3050c9f233d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_30415afd-4bc5-4f10-ad36-a923946a16d8" xlink:to="loc_us-gaap_AssetImpairmentCharges_201b4c2c-ad8b-40a7-a725-3050c9f233d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ee45bee4-f8f9-45dd-88b1-f1858a4825cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_30415afd-4bc5-4f10-ad36-a923946a16d8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ee45bee4-f8f9-45dd-88b1-f1858a4825cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_236117d5-d4ec-4512-afed-78eab8c81395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_30415afd-4bc5-4f10-ad36-a923946a16d8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_236117d5-d4ec-4512-afed-78eab8c81395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability_b51617f2-4eff-4de3-90fc-5ddd78eff944" xlink:href="biib-20210331.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_30415afd-4bc5-4f10-ad36-a923946a16d8" xlink:to="loc_biib_TechnologicalAndRegulatorySuccessProbability_b51617f2-4eff-4de3-90fc-5ddd78eff944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d969d5bd-7601-45e2-989a-895060845cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca38140d-7c95-4ef3-a1df-67c666943260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d969d5bd-7601-45e2-989a-895060845cf3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca38140d-7c95-4ef3-a1df-67c666943260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cb651716-a2e6-4225-b2c9-baaec7ea2ac3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca38140d-7c95-4ef3-a1df-67c666943260" xlink:to="loc_srt_RangeAxis_cb651716-a2e6-4225-b2c9-baaec7ea2ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c10d9adf-d1c0-4b88-810b-d4b44e26a7d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cb651716-a2e6-4225-b2c9-baaec7ea2ac3" xlink:to="loc_srt_RangeMember_c10d9adf-d1c0-4b88-810b-d4b44e26a7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b73ab138-90c3-4038-ad82-dcc179497539" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c10d9adf-d1c0-4b88-810b-d4b44e26a7d7" xlink:to="loc_srt_MinimumMember_b73ab138-90c3-4038-ad82-dcc179497539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c1f9da5e-61a3-4833-aaf4-348a9f70b1a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c10d9adf-d1c0-4b88-810b-d4b44e26a7d7" xlink:to="loc_srt_MaximumMember_c1f9da5e-61a3-4833-aaf4-348a9f70b1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_4ddfa75d-c960-4133-a814-ea1ca91f59d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c10d9adf-d1c0-4b88-810b-d4b44e26a7d7" xlink:to="loc_srt_WeightedAverageMember_4ddfa75d-c960-4133-a814-ea1ca91f59d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1b913203-f9e8-416e-a15a-a14553a10288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca38140d-7c95-4ef3-a1df-67c666943260" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1b913203-f9e8-416e-a15a-a14553a10288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f5b64900-5657-4af5-ac13-e8a3df56c217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1b913203-f9e8-416e-a15a-a14553a10288" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f5b64900-5657-4af5-ac13-e8a3df56c217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_5bb171b9-8069-427f-9e3a-85fa83bf6aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f5b64900-5657-4af5-ac13-e8a3df56c217" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_5bb171b9-8069-427f-9e3a-85fa83bf6aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aaec7a2-3557-4324-aa5c-a8547a079412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca38140d-7c95-4ef3-a1df-67c666943260" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aaec7a2-3557-4324-aa5c-a8547a079412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6b2aba01-261e-4f87-bfe4-5870c0a8baad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aaec7a2-3557-4324-aa5c-a8547a079412" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6b2aba01-261e-4f87-bfe4-5870c0a8baad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_2077c340-421f-4b2a-828f-04a6386011ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aaec7a2-3557-4324-aa5c-a8547a079412" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_2077c340-421f-4b2a-828f-04a6386011ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b65343b8-83c3-44a8-b6d3-333de325acfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e88af41b-e32d-40b0-a5c5-14163f4f8367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b65343b8-83c3-44a8-b6d3-333de325acfa" xlink:to="loc_us-gaap_DebtInstrumentTable_e88af41b-e32d-40b0-a5c5-14163f4f8367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_05a249f9-683b-494a-97de-765dae533beb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e88af41b-e32d-40b0-a5c5-14163f4f8367" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_05a249f9-683b-494a-97de-765dae533beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_758a7607-f91e-4ddb-952c-be4181ddacdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_05a249f9-683b-494a-97de-765dae533beb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_758a7607-f91e-4ddb-952c-be4181ddacdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_b0725a2e-899b-467c-9cc9-bbf9ef5c45e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_758a7607-f91e-4ddb-952c-be4181ddacdc" xlink:to="loc_us-gaap_SeniorNotesMember_b0725a2e-899b-467c-9cc9-bbf9ef5c45e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_18c65309-e5a6-46a9-a0f6-e2671a66b43c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e88af41b-e32d-40b0-a5c5-14163f4f8367" xlink:to="loc_us-gaap_DebtInstrumentAxis_18c65309-e5a6-46a9-a0f6-e2671a66b43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_18c65309-e5a6-46a9-a0f6-e2671a66b43c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_0c56a8b6-3fd5-4524-acc8-535b9064c2df" xlink:href="biib-20210331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_0c56a8b6-3fd5-4524-acc8-535b9064c2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_04dfc252-617a-41c9-8306-97c42209c83f" xlink:href="biib-20210331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_04dfc252-617a-41c9-8306-97c42209c83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8ecea23a-ee13-4b36-a72f-0eded39f9054" xlink:href="biib-20210331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_8ecea23a-ee13-4b36-a72f-0eded39f9054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_17ad5f1c-4ec5-4eea-be37-f99e8c5cb91a" xlink:href="biib-20210331.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_17ad5f1c-4ec5-4eea-be37-f99e8c5cb91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_5abe4805-7510-4068-a8ff-994baf56bebe" xlink:href="biib-20210331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_5abe4805-7510-4068-a8ff-994baf56bebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_8a6313f3-308a-4ee5-9e20-858b5307907e" xlink:href="biib-20210331.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_8a6313f3-308a-4ee5-9e20-858b5307907e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_512d5dd0-33d8-4899-9b1a-82e8e1b509f6" xlink:href="biib-20210331.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d89f7550-3239-45c7-9068-6099f79b2fb5" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_512d5dd0-33d8-4899-9b1a-82e8e1b509f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e88af41b-e32d-40b0-a5c5-14163f4f8367" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_03a72d6e-c680-4e4c-8988-5373b5a4f2d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_03a72d6e-c680-4e4c-8988-5373b5a4f2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_a150c421-480c-446d-a4a0-14a47537f9e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:to="loc_us-gaap_NotesPayable_a150c421-480c-446d-a4a0-14a47537f9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_d8af24c1-a337-46b6-a06b-97ad9ef94092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:to="loc_us-gaap_DebtInstrumentFairValue_d8af24c1-a337-46b6-a06b-97ad9ef94092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7f62a801-d2e4-47fc-a05c-cdbcaf1c6742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7f62a801-d2e4-47fc-a05c-cdbcaf1c6742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6b70b691-5125-4d1d-83ce-ea0f1ff122ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6b70b691-5125-4d1d-83ce-ea0f1ff122ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_53e7e43c-3337-4b81-9d50-5309e4e2e261" xlink:href="biib-20210331.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0eb0a999-a3c5-4644-af4c-113cefc51a79" xlink:to="loc_biib_LongTermDebtExchangedAmount_53e7e43c-3337-4b81-9d50-5309e4e2e261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20210331.xsd#FairValueMeasurementsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_af7594f0-6394-4725-be55-d27dbfa09678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_82d3f7d1-09b9-405c-88cb-e6e17f68a856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_af7594f0-6394-4725-be55-d27dbfa09678" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_82d3f7d1-09b9-405c-88cb-e6e17f68a856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_18b82669-313e-479e-8355-be7ee0a81718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_82d3f7d1-09b9-405c-88cb-e6e17f68a856" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_18b82669-313e-479e-8355-be7ee0a81718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5fce46c-a1cb-406e-8dbf-f99a42eefa57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_18b82669-313e-479e-8355-be7ee0a81718" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5fce46c-a1cb-406e-8dbf-f99a42eefa57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_90166c7d-ac8f-45d1-ad77-1a77aa184ef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5fce46c-a1cb-406e-8dbf-f99a42eefa57" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_90166c7d-ac8f-45d1-ad77-1a77aa184ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_39e62d41-6d6e-4ef6-a48f-ab85a461cacf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_82d3f7d1-09b9-405c-88cb-e6e17f68a856" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_39e62d41-6d6e-4ef6-a48f-ab85a461cacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c8ee5935-5d24-468c-ada1-2b6fa7902de3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_39e62d41-6d6e-4ef6-a48f-ab85a461cacf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c8ee5935-5d24-468c-ada1-2b6fa7902de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_42814434-7a83-4df9-8c28-ac5f0b09e64c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_39e62d41-6d6e-4ef6-a48f-ab85a461cacf" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_42814434-7a83-4df9-8c28-ac5f0b09e64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_967c125c-a42c-4877-96fc-3d0a71f1534c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_39e62d41-6d6e-4ef6-a48f-ab85a461cacf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_967c125c-a42c-4877-96fc-3d0a71f1534c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b5d78f6d-3e72-4fd3-95a7-afe94d138a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_2dac3bbb-65fe-43a1-ac31-8484619532e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b5d78f6d-3e72-4fd3-95a7-afe94d138a54" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_2dac3bbb-65fe-43a1-ac31-8484619532e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eec4c1ed-66bb-4f79-ab6d-4d183104035d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_fd803988-c06a-4662-9b72-75bdb58ebe88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eec4c1ed-66bb-4f79-ab6d-4d183104035d" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_fd803988-c06a-4662-9b72-75bdb58ebe88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_94aa0f78-3956-4206-ba03-65a48e4dcaf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eec4c1ed-66bb-4f79-ab6d-4d183104035d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_94aa0f78-3956-4206-ba03-65a48e4dcaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_487dc62f-59cd-4008-a3c1-65fa07662b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eec4c1ed-66bb-4f79-ab6d-4d183104035d" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_487dc62f-59cd-4008-a3c1-65fa07662b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_b07c902c-7ce8-4953-80b9-ecf89e59f05d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eec4c1ed-66bb-4f79-ab6d-4d183104035d" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_b07c902c-7ce8-4953-80b9-ecf89e59f05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_02d48af9-22c7-4030-a32e-0140141ebce8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9a1539f3-9d62-4db6-95e0-56d97498b746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_02d48af9-22c7-4030-a32e-0140141ebce8" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9a1539f3-9d62-4db6-95e0-56d97498b746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c0ae14a0-0db0-4091-b1a4-7d17571f226a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9a1539f3-9d62-4db6-95e0-56d97498b746" xlink:to="loc_us-gaap_InvestmentTypeAxis_c0ae14a0-0db0-4091-b1a4-7d17571f226a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b9e3e2ff-ea03-49e3-9a0f-3e6192c5bcba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_c0ae14a0-0db0-4091-b1a4-7d17571f226a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b9e3e2ff-ea03-49e3-9a0f-3e6192c5bcba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f8170340-943a-4074-8968-71bdbafd526d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b9e3e2ff-ea03-49e3-9a0f-3e6192c5bcba" xlink:to="loc_us-gaap_CommercialPaperMember_f8170340-943a-4074-8968-71bdbafd526d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_f6f36e9c-48e9-445e-b53c-816f73e761a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b9e3e2ff-ea03-49e3-9a0f-3e6192c5bcba" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_f6f36e9c-48e9-445e-b53c-816f73e761a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2ba8d034-dc15-40b2-8c74-d258a5e6d07e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b9e3e2ff-ea03-49e3-9a0f-3e6192c5bcba" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2ba8d034-dc15-40b2-8c74-d258a5e6d07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_0490c375-9c40-41e3-93be-1bec6b571221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b9e3e2ff-ea03-49e3-9a0f-3e6192c5bcba" xlink:to="loc_us-gaap_DebtSecuritiesMember_0490c375-9c40-41e3-93be-1bec6b571221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_73e08b87-8b04-4ffc-a0ae-3224cd91d411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9a1539f3-9d62-4db6-95e0-56d97498b746" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_73e08b87-8b04-4ffc-a0ae-3224cd91d411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_993bf73a-ccc1-43ef-bfc2-9b6c656591dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_73e08b87-8b04-4ffc-a0ae-3224cd91d411" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_993bf73a-ccc1-43ef-bfc2-9b6c656591dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_de83e70d-dbf2-4ef9-bfff-823944e548b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_993bf73a-ccc1-43ef-bfc2-9b6c656591dd" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_de83e70d-dbf2-4ef9-bfff-823944e548b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1822ab9e-e089-4827-90c5-9a0d0e21443d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9ec7642-8970-46f0-9885-0bb1f7bd6915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1822ab9e-e089-4827-90c5-9a0d0e21443d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9ec7642-8970-46f0-9885-0bb1f7bd6915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5d22cf75-2bc4-41d5-ac69-f31913e5f774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9ec7642-8970-46f0-9885-0bb1f7bd6915" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5d22cf75-2bc4-41d5-ac69-f31913e5f774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_791901c2-6503-4b6d-82fc-a55fb50983cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5d22cf75-2bc4-41d5-ac69-f31913e5f774" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_791901c2-6503-4b6d-82fc-a55fb50983cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_a4c7c466-15fd-45a1-a4dd-42283f887ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_791901c2-6503-4b6d-82fc-a55fb50983cd" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_a4c7c466-15fd-45a1-a4dd-42283f887ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_e3413b06-7fd1-4bba-8c22-e1bd7a842766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_791901c2-6503-4b6d-82fc-a55fb50983cd" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_e3413b06-7fd1-4bba-8c22-e1bd7a842766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6692065a-bc73-48c9-b11f-6df6d51b6ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9ec7642-8970-46f0-9885-0bb1f7bd6915" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6692065a-bc73-48c9-b11f-6df6d51b6ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6692065a-bc73-48c9-b11f-6df6d51b6ef8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_60c8b927-b2b2-4f29-8b53-4fdabe50d7e3" xlink:href="biib-20210331.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_60c8b927-b2b2-4f29-8b53-4fdabe50d7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_9e651321-1c5f-4489-a457-c74fda3f86d4" xlink:href="biib-20210331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_9e651321-1c5f-4489-a457-c74fda3f86d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_21352c2e-a193-4e9d-b7f2-33b1a8f5d3dd" xlink:href="biib-20210331.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_21352c2e-a193-4e9d-b7f2-33b1a8f5d3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_9536a68f-52b6-4245-834c-4184ae397496" xlink:href="biib-20210331.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_9536a68f-52b6-4245-834c-4184ae397496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_baad85bd-26f8-4735-87d0-c000f8c978e7" xlink:href="biib-20210331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_baad85bd-26f8-4735-87d0-c000f8c978e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_a56f9318-1611-47b7-9a00-b2162a46ab12" xlink:href="biib-20210331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_a56f9318-1611-47b7-9a00-b2162a46ab12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_5e260895-f6a6-4e78-b5d0-e5e70e46300f" xlink:href="biib-20210331.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_EquitySecuritiesCurrentMember_5e260895-f6a6-4e78-b5d0-e5e70e46300f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_839fd711-57a9-4345-87f2-e486da42d9af" xlink:href="biib-20210331.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_619eb159-8cbb-4428-904b-f446d15464c3" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_839fd711-57a9-4345-87f2-e486da42d9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9ec7642-8970-46f0-9885-0bb1f7bd6915" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_672ffdc4-9128-4eb4-bf3f-70a5eaa1ac04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_672ffdc4-9128-4eb4-bf3f-70a5eaa1ac04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6aae065f-36e3-4a1a-a67c-47e55b5f4956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6aae065f-36e3-4a1a-a67c-47e55b5f4956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e25e71db-26fc-4fcc-9765-5a0056d7cc8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e25e71db-26fc-4fcc-9765-5a0056d7cc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d04fa36b-bb60-40fd-a7f4-46cd547eccef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d04fa36b-bb60-40fd-a7f4-46cd547eccef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_7eb8deb3-3b7f-4cb6-a2c4-f84a761b8d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_us-gaap_AvailableForSaleSecurities_7eb8deb3-3b7f-4cb6-a2c4-f84a761b8d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_4e71a57f-582c-4324-b622-c5b1af0c189c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_4e71a57f-582c-4324-b622-c5b1af0c189c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_ae80cf56-a2de-464f-a860-926472d8da3b" xlink:href="biib-20210331.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_ae80cf56-a2de-464f-a860-926472d8da3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_835245de-c179-4dee-a20b-9be12051d0fc" xlink:href="biib-20210331.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_835245de-c179-4dee-a20b-9be12051d0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_9e2f0b17-21bf-4410-bdae-df07baf0d40e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7cc41dc9-dcec-4571-a4d4-cee38e91eb23" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_9e2f0b17-21bf-4410-bdae-df07baf0d40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eba9becc-2e22-4ce4-8bd5-c3b85781363b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_1cf90d5b-2537-4163-89a0-86496f6f5e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eba9becc-2e22-4ce4-8bd5-c3b85781363b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_1cf90d5b-2537-4163-89a0-86496f6f5e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a1037990-bd8b-42ca-a0be-5feb35ce32b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_1cf90d5b-2537-4163-89a0-86496f6f5e90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a1037990-bd8b-42ca-a0be-5feb35ce32b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_53fdc66a-df62-4f6d-b8b5-79936954edc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_1cf90d5b-2537-4163-89a0-86496f6f5e90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_53fdc66a-df62-4f6d-b8b5-79936954edc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_2ec81bc0-7cfa-4162-8135-bf3f7d295854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_1cf90d5b-2537-4163-89a0-86496f6f5e90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_2ec81bc0-7cfa-4162-8135-bf3f7d295854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a88cd61d-1c63-4576-8def-d53711796a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_1cf90d5b-2537-4163-89a0-86496f6f5e90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a88cd61d-1c63-4576-8def-d53711796a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_7878ebd0-1b81-4e15-a4d6-64d7bd086c62" xlink:href="biib-20210331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_1cf90d5b-2537-4163-89a0-86496f6f5e90" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_7878ebd0-1b81-4e15-a4d6-64d7bd086c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_86f372a3-6367-4e79-8d1c-7323565fc6ed" xlink:href="biib-20210331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_1cf90d5b-2537-4163-89a0-86496f6f5e90" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_86f372a3-6367-4e79-8d1c-7323565fc6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_af73244c-8cd8-4e53-8318-5dfac3c82444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_1cf90d5b-2537-4163-89a0-86496f6f5e90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_af73244c-8cd8-4e53-8318-5dfac3c82444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_ac9c54b1-5f6b-4222-8456-cbf7b16ce89e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_1cf90d5b-2537-4163-89a0-86496f6f5e90" xlink:to="loc_us-gaap_AvailableForSaleSecurities_ac9c54b1-5f6b-4222-8456-cbf7b16ce89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsDetails3"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c50c5023-f93a-42bc-9335-2649eb2fdc34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4dd836b3-b8c2-4076-9917-600c74ed0a02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c50c5023-f93a-42bc-9335-2649eb2fdc34" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4dd836b3-b8c2-4076-9917-600c74ed0a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_dcc64e45-a6cb-4195-98f4-d04945d0c221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c50c5023-f93a-42bc-9335-2649eb2fdc34" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_dcc64e45-a6cb-4195-98f4-d04945d0c221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_a652a81e-487a-461b-bedf-ea2ecc5eaadc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c50c5023-f93a-42bc-9335-2649eb2fdc34" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_a652a81e-487a-461b-bedf-ea2ecc5eaadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e6d4afd3-f147-4259-ad50-e772cd50fdb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_0ebb9b0a-7fb8-478e-8ad3-87ccca669594" xlink:href="biib-20210331.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e6d4afd3-f147-4259-ad50-e772cd50fdb7" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_0ebb9b0a-7fb8-478e-8ad3-87ccca669594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20210331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_7004c767-79a1-4c4a-b7e6-52ae8b518e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6649c39d-84f9-4514-acf2-19030a24eb57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_7004c767-79a1-4c4a-b7e6-52ae8b518e71" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6649c39d-84f9-4514-acf2-19030a24eb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_029a7c68-dea5-4639-b762-25fa883d389d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6649c39d-84f9-4514-acf2-19030a24eb57" xlink:to="loc_dei_LegalEntityAxis_029a7c68-dea5-4639-b762-25fa883d389d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1dd99152-9300-4a20-81cd-1e9fc77e5dd7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_029a7c68-dea5-4639-b762-25fa883d389d" xlink:to="loc_dei_EntityDomain_1dd99152-9300-4a20-81cd-1e9fc77e5dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_9f317a51-7467-4c9c-ab4a-648bbf41966e" xlink:href="biib-20210331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1dd99152-9300-4a20-81cd-1e9fc77e5dd7" xlink:to="loc_biib_DenaliTherapeuticsIncMember_9f317a51-7467-4c9c-ab4a-648bbf41966e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_aa7e2528-19eb-446c-90f3-d502665e8792" xlink:href="biib-20210331.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1dd99152-9300-4a20-81cd-1e9fc77e5dd7" xlink:to="loc_biib_SangamoCommonStockMember_aa7e2528-19eb-446c-90f3-d502665e8792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1857ef52-978f-48c0-9406-0d728302ddea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6649c39d-84f9-4514-acf2-19030a24eb57" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1857ef52-978f-48c0-9406-0d728302ddea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d153824f-6b8d-4471-9300-895bf05788b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1857ef52-978f-48c0-9406-0d728302ddea" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d153824f-6b8d-4471-9300-895bf05788b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_abbab9f2-c225-4c8f-b321-5633619d7726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d153824f-6b8d-4471-9300-895bf05788b4" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_abbab9f2-c225-4c8f-b321-5633619d7726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_1583f494-aca3-48b8-8a35-f4674a38f870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d153824f-6b8d-4471-9300-895bf05788b4" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_1583f494-aca3-48b8-8a35-f4674a38f870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6a81753e-4ece-436a-80cc-9d6b84b28272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6649c39d-84f9-4514-acf2-19030a24eb57" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6a81753e-4ece-436a-80cc-9d6b84b28272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_586be095-aea8-4c97-95cf-c68beccb9547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6a81753e-4ece-436a-80cc-9d6b84b28272" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_586be095-aea8-4c97-95cf-c68beccb9547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_2c09d54e-4d71-4d5d-be98-30cbb55370dd" xlink:href="biib-20210331.xsd#biib_StrategicInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_586be095-aea8-4c97-95cf-c68beccb9547" xlink:to="loc_biib_StrategicInvestmentsMember_2c09d54e-4d71-4d5d-be98-30cbb55370dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_92c18ed6-ec82-4adb-aa67-e8d0f59cd279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6649c39d-84f9-4514-acf2-19030a24eb57" xlink:to="loc_us-gaap_TypeOfArrangementAxis_92c18ed6-ec82-4adb-aa67-e8d0f59cd279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_278fa430-7521-40a3-9249-ba03ce7572ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92c18ed6-ec82-4adb-aa67-e8d0f59cd279" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_278fa430-7521-40a3-9249-ba03ce7572ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_a8ddd493-674f-4403-856a-3d052de3de7c" xlink:href="biib-20210331.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_278fa430-7521-40a3-9249-ba03ce7572ec" xlink:to="loc_biib_SageTherapeuticsIncMember_a8ddd493-674f-4403-856a-3d052de3de7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_3b50925a-0de4-46ad-a39a-f1d40622bf90" xlink:href="biib-20210331.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_278fa430-7521-40a3-9249-ba03ce7572ec" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_3b50925a-0de4-46ad-a39a-f1d40622bf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6649c39d-84f9-4514-acf2-19030a24eb57" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_303e82ea-d3cc-453d-8a80-de0adcfb62a8" xlink:href="biib-20210331.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_biib_StrategicInvestmentPortfolio_303e82ea-d3cc-453d-8a80-de0adcfb62a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_b90bb604-937b-4d4c-aab3-47f09a0d4fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_b90bb604-937b-4d4c-aab3-47f09a0d4fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Investmentincommonstocksharespurchased_0999a113-c4a8-43e0-82d2-b8836ddd0487" xlink:href="biib-20210331.xsd#biib_Investmentincommonstocksharespurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_biib_Investmentincommonstocksharespurchased_0999a113-c4a8-43e0-82d2-b8836ddd0487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_0a76c297-79d7-40d1-b7da-b9367f7844ab" xlink:href="biib-20210331.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_biib_CollaborationAgreementTerm_0a76c297-79d7-40d1-b7da-b9367f7844ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_c4cb719b-317d-48d9-a5c4-03480849e53a" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_c4cb719b-317d-48d9-a5c4-03480849e53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_a3db4bde-f19e-4e4b-b502-2191eee3dd89" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_a3db4bde-f19e-4e4b-b502-2191eee3dd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_dad23362-579a-4dc7-b232-24c42e578a2c" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_dad23362-579a-4dc7-b232-24c42e578a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DividendYieldPercentage_33c3273e-ea1b-43a3-b624-12bbeb93ae41" xlink:href="biib-20210331.xsd#biib_DividendYieldPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f38ddb6f-c2a6-4797-8184-15b79ca5759f" xlink:to="loc_biib_DividendYieldPercentage_33c3273e-ea1b-43a3-b624-12bbeb93ae41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20210331.xsd#DerivativeInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bde8c29a-d4c9-4098-90f6-21a9ab3ca634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_a603c863-e88b-4a0d-933b-15c420a8a3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bde8c29a-d4c9-4098-90f6-21a9ab3ca634" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_a603c863-e88b-4a0d-933b-15c420a8a3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20210331.xsd#DerivativeInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_76b622ed-5c57-49eb-acf7-d0109808bbf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_c46a91bb-9e80-40bf-a187-e31d80407ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_76b622ed-5c57-49eb-acf7-d0109808bbf7" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_c46a91bb-9e80-40bf-a187-e31d80407ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7b776d1e-18ad-42e2-bd3d-87db79ee55ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_76b622ed-5c57-49eb-acf7-d0109808bbf7" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7b776d1e-18ad-42e2-bd3d-87db79ee55ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_9db6c3e6-b562-4413-9ab1-0d99e0e227c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_76b622ed-5c57-49eb-acf7-d0109808bbf7" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_9db6c3e6-b562-4413-9ab1-0d99e0e227c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_8a006b7a-4c7d-4176-a29c-09e2f09b64fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_76b622ed-5c57-49eb-acf7-d0109808bbf7" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_8a006b7a-4c7d-4176-a29c-09e2f09b64fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#DerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5c9afbe7-4df1-4382-82c6-e5ef50d0b45a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5c9afbe7-4df1-4382-82c6-e5ef50d0b45a" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_7f2ab22a-462c-408a-85a6-140868b47802" xlink:href="biib-20210331.xsd#biib_DerivativeMaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_biib_DerivativeMaturityAxis_7f2ab22a-462c-408a-85a6-140868b47802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_8503ac08-df0f-44b9-8f85-691ed488742c" xlink:href="biib-20210331.xsd#biib_DerivativeMaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_7f2ab22a-462c-408a-85a6-140868b47802" xlink:to="loc_biib_DerivativeMaturityDomain_8503ac08-df0f-44b9-8f85-691ed488742c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_f0f8d734-a4d3-4e29-80d6-9e96da90af72" xlink:href="biib-20210331.xsd#biib_ShorttermderivativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_8503ac08-df0f-44b9-8f85-691ed488742c" xlink:to="loc_biib_ShorttermderivativeMember_f0f8d734-a4d3-4e29-80d6-9e96da90af72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_67606d0f-3813-4040-a00d-1bd034bd49ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_67606d0f-3813-4040-a00d-1bd034bd49ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_55b931d8-cc39-4773-b327-d28744b70a53" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_67606d0f-3813-4040-a00d-1bd034bd49ce" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_55b931d8-cc39-4773-b327-d28744b70a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_965d5404-c5e7-4732-8952-beef162c04b4" xlink:href="biib-20210331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_55b931d8-cc39-4773-b327-d28744b70a53" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_965d5404-c5e7-4732-8952-beef162c04b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aca86bc1-bd9c-497c-878f-c220fe68345c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_us-gaap_DebtInstrumentAxis_aca86bc1-bd9c-497c-878f-c220fe68345c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0448e0f8-0fb7-4469-8ef3-f9e0bd330464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_aca86bc1-bd9c-497c-878f-c220fe68345c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0448e0f8-0fb7-4469-8ef3-f9e0bd330464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_2a844466-7f6f-43d1-8ea5-75a89e4c2e8f" xlink:href="biib-20210331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0448e0f8-0fb7-4469-8ef3-f9e0bd330464" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_2a844466-7f6f-43d1-8ea5-75a89e4c2e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_cea3c84e-502a-4d01-89f9-297b895c0905" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_srt_CurrencyAxis_cea3c84e-502a-4d01-89f9-297b895c0905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_70b09e01-1630-4802-aa2b-ce2f832ee36d" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_cea3c84e-502a-4d01-89f9-297b895c0905" xlink:to="loc_currency_AllCurrenciesDomain_70b09e01-1630-4802-aa2b-ce2f832ee36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_459c969c-c59b-4d7c-97b3-bb762c56e194" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_70b09e01-1630-4802-aa2b-ce2f832ee36d" xlink:to="loc_currency_EUR_459c969c-c59b-4d7c-97b3-bb762c56e194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_85a21282-d921-463c-bd86-a826661e5eaf" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_70b09e01-1630-4802-aa2b-ce2f832ee36d" xlink:to="loc_currency_GBP_85a21282-d921-463c-bd86-a826661e5eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_65a49908-2bce-4129-9d64-bab15f74ce18" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CHF"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_70b09e01-1630-4802-aa2b-ce2f832ee36d" xlink:to="loc_currency_CHF_65a49908-2bce-4129-9d64-bab15f74ce18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_b8b4ae53-8601-465b-b745-6268142bb8ff" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_JPY"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_70b09e01-1630-4802-aa2b-ce2f832ee36d" xlink:to="loc_currency_JPY_b8b4ae53-8601-465b-b745-6268142bb8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_61c18e4b-067d-4f9d-b793-6d1f4590444a" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CAD"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_70b09e01-1630-4802-aa2b-ce2f832ee36d" xlink:to="loc_currency_CAD_61c18e4b-067d-4f9d-b793-6d1f4590444a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4531c67a-f562-40e7-9931-d72547c014dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4531c67a-f562-40e7-9931-d72547c014dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0c3c130f-7daa-46a3-90d4-eb96334cd175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4531c67a-f562-40e7-9931-d72547c014dc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0c3c130f-7daa-46a3-90d4-eb96334cd175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_1efa6b4e-7a32-4159-b91a-ad9da8a81fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c3c130f-7daa-46a3-90d4-eb96334cd175" xlink:to="loc_us-gaap_InterestExpenseMember_1efa6b4e-7a32-4159-b91a-ad9da8a81fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_69fcca4f-aad7-4dbc-ab5f-ec0948ddba5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c3c130f-7daa-46a3-90d4-eb96334cd175" xlink:to="loc_us-gaap_SalesMember_69fcca4f-aad7-4dbc-ab5f-ec0948ddba5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_89f6cc28-adf8-4fc7-8fd4-84060706dc2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c3c130f-7daa-46a3-90d4-eb96334cd175" xlink:to="loc_us-gaap_OperatingExpenseMember_89f6cc28-adf8-4fc7-8fd4-84060706dc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6facd026-6370-405f-8eca-85f37f2b5133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c3c130f-7daa-46a3-90d4-eb96334cd175" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6facd026-6370-405f-8eca-85f37f2b5133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f5e9a480-f913-4b48-ac3c-adb194c64867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f5e9a480-f913-4b48-ac3c-adb194c64867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_925e2d7a-30bb-4b17-8e14-eba69e8c771f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f5e9a480-f913-4b48-ac3c-adb194c64867" xlink:to="loc_us-gaap_HedgingRelationshipDomain_925e2d7a-30bb-4b17-8e14-eba69e8c771f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9b955e14-4e25-4e19-bb4f-d10113866e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_925e2d7a-30bb-4b17-8e14-eba69e8c771f" xlink:to="loc_us-gaap_CashFlowHedgingMember_9b955e14-4e25-4e19-bb4f-d10113866e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_1d98a98a-0273-4cf1-8133-7dd0722718dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_925e2d7a-30bb-4b17-8e14-eba69e8c771f" xlink:to="loc_us-gaap_FairValueHedgingMember_1d98a98a-0273-4cf1-8133-7dd0722718dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_b117db85-825e-4f0c-a444-eb871165760b" xlink:href="biib-20210331.xsd#biib_CashflowsrevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_925e2d7a-30bb-4b17-8e14-eba69e8c771f" xlink:to="loc_biib_CashflowsrevenueMember_b117db85-825e-4f0c-a444-eb871165760b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_eb069495-68b6-4a0f-9e6c-80d83113d2f7" xlink:href="biib-20210331.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_925e2d7a-30bb-4b17-8e14-eba69e8c771f" xlink:to="loc_biib_CashflowsoperatingexpensesMember_eb069495-68b6-4a0f-9e6c-80d83113d2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_97328ea2-24a2-475c-be1f-f68bfe0b32c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_925e2d7a-30bb-4b17-8e14-eba69e8c771f" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_97328ea2-24a2-475c-be1f-f68bfe0b32c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_df384a9f-4339-4aca-b8ce-4fa9870d55eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_df384a9f-4339-4aca-b8ce-4fa9870d55eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1d20aff0-1635-403e-97ad-2a7c0673d4be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_df384a9f-4339-4aca-b8ce-4fa9870d55eb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1d20aff0-1635-403e-97ad-2a7c0673d4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5b62e0c1-4994-4c36-a652-424fb3ec30d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1d20aff0-1635-403e-97ad-2a7c0673d4be" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5b62e0c1-4994-4c36-a652-424fb3ec30d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_24540cde-f30a-48c8-af50-ceeb3822aec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1d20aff0-1635-403e-97ad-2a7c0673d4be" xlink:to="loc_us-gaap_InterestRateSwapMember_24540cde-f30a-48c8-af50-ceeb3822aec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8bb3b20f-57e4-48a9-90ba-496c16cc1d59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8bb3b20f-57e4-48a9-90ba-496c16cc1d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b8556d36-0e25-4c1b-8bc9-c58b7d43183c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8bb3b20f-57e4-48a9-90ba-496c16cc1d59" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b8556d36-0e25-4c1b-8bc9-c58b7d43183c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_c112e3a3-32b8-4ebc-9c8e-61ab640aa6a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b8556d36-0e25-4c1b-8bc9-c58b7d43183c" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_c112e3a3-32b8-4ebc-9c8e-61ab640aa6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_65be6cd1-3d64-41f1-b8d5-cfa26860e9d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b8556d36-0e25-4c1b-8bc9-c58b7d43183c" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_65be6cd1-3d64-41f1-b8d5-cfa26860e9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_c6260c29-5329-4f61-985e-3f38330f5087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b8556d36-0e25-4c1b-8bc9-c58b7d43183c" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_c6260c29-5329-4f61-985e-3f38330f5087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1417f671-4c21-4c48-aff9-be491cf06cc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b8556d36-0e25-4c1b-8bc9-c58b7d43183c" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1417f671-4c21-4c48-aff9-be491cf06cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e2f2bd04-588d-416d-a19e-6921367c574c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_us-gaap_HedgingDesignationAxis_e2f2bd04-588d-416d-a19e-6921367c574c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ede510aa-60a1-4b85-9d83-1872207ae308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_e2f2bd04-588d-416d-a19e-6921367c574c" xlink:to="loc_us-gaap_HedgingDesignationDomain_ede510aa-60a1-4b85-9d83-1872207ae308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5d4646dc-72b0-4c87-9db0-7220c449a622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_ede510aa-60a1-4b85-9d83-1872207ae308" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5d4646dc-72b0-4c87-9db0-7220c449a622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_e6a892fd-2806-42b3-936f-6c0a594e235e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_ede510aa-60a1-4b85-9d83-1872207ae308" xlink:to="loc_us-gaap_NondesignatedMember_e6a892fd-2806-42b3-936f-6c0a594e235e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_afa1c1d8-05b7-4031-a978-3f13a68a2bf2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_srt_RangeAxis_afa1c1d8-05b7-4031-a978-3f13a68a2bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc629548-159f-4a2d-bb1f-611a93a975b9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_afa1c1d8-05b7-4031-a978-3f13a68a2bf2" xlink:to="loc_srt_RangeMember_bc629548-159f-4a2d-bb1f-611a93a975b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9be33c5d-f9d4-4463-b2f8-47491129259b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bc629548-159f-4a2d-bb1f-611a93a975b9" xlink:to="loc_srt_MinimumMember_9be33c5d-f9d4-4463-b2f8-47491129259b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3d70f945-e872-4b17-bf4e-43f2fed18dcd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bc629548-159f-4a2d-bb1f-611a93a975b9" xlink:to="loc_srt_MaximumMember_3d70f945-e872-4b17-bf4e-43f2fed18dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_04378215-ea00-41d5-9012-6e218ffdb39a" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_46e0d141-6c35-4575-a630-e7114e7c0062" xlink:href="biib-20210331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_46e0d141-6c35-4575-a630-e7114e7c0062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_04cf9fec-3ecf-43b0-90a1-dd85fd690934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_04cf9fec-3ecf-43b0-90a1-dd85fd690934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b7e3aa70-73bb-4c94-ac48-43d7cccc332c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b7e3aa70-73bb-4c94-ac48-43d7cccc332c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3bb01cc2-1343-4daa-83b3-9be769f1f84b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3bb01cc2-1343-4daa-83b3-9be769f1f84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2a884ced-f21b-44fa-aeee-8baa8624c0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2a884ced-f21b-44fa-aeee-8baa8624c0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_ec871ffd-f909-43b0-8827-4357a2554a42" xlink:href="biib-20210331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_ec871ffd-f909-43b0-8827-4357a2554a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b810a145-de99-42d0-99fa-6f51be634177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b810a145-de99-42d0-99fa-6f51be634177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_d88ff7c2-8ea6-49d9-9785-ea6a9152d375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_d88ff7c2-8ea6-49d9-9785-ea6a9152d375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_cd472677-7f86-44ea-96b6-a50b47c97881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_DerivativeTermOfContract_cd472677-7f86-44ea-96b6-a50b47c97881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_72176000-99a3-489c-a3f9-0e516c57cf8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_72176000-99a3-489c-a3f9-0e516c57cf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_796a0082-7c4f-4469-9f81-da0e49cb5914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_796a0082-7c4f-4469-9f81-da0e49cb5914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_bdeaa2b8-71e1-4376-b60e-be5e2cd38293" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_bdeaa2b8-71e1-4376-b60e-be5e2cd38293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_014fcd8e-71c2-4b4c-aefb-770982f5fb0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_014fcd8e-71c2-4b4c-aefb-770982f5fb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_cd5e994e-a354-4021-9f73-a8fffa13b448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_cd5e994e-a354-4021-9f73-a8fffa13b448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_84f25867-86c0-413d-a310-83b0491cc826" xlink:href="biib-20210331.xsd#biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_84f25867-86c0-413d-a310-83b0491cc826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_d457ba22-a623-4344-9542-66094d67dbd4" xlink:href="biib-20210331.xsd#biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_d457ba22-a623-4344-9542-66094d67dbd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_465c42fb-5557-4d9a-bbe2-c9de58ef1cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_465c42fb-5557-4d9a-bbe2-c9de58ef1cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_4dbc47aa-5103-4b9f-8143-4e0878c9abac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_4dbc47aa-5103-4b9f-8143-4e0878c9abac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_477b2f7c-e0c4-449b-8e70-616816855b8e" xlink:href="biib-20210331.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_477b2f7c-e0c4-449b-8e70-616816855b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_afbe1730-657c-4ec8-ab2c-9aae6c75c696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_096077af-a742-42e3-8767-09d03538bd05" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_afbe1730-657c-4ec8-ab2c-9aae6c75c696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20210331.xsd#PropertyPlantandEquipmentPropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5b20ed4b-78f4-4f79-ba2b-4074ac6df70e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_cc7a7a4f-8532-422b-aed3-50142ec5fb9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5b20ed4b-78f4-4f79-ba2b-4074ac6df70e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_cc7a7a4f-8532-422b-aed3-50142ec5fb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#PropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dfa20e54-ec01-4529-bb4a-c7b99a023232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b9dfab4-59fd-4bc5-a857-4b968947fee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dfa20e54-ec01-4529-bb4a-c7b99a023232" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b9dfab4-59fd-4bc5-a857-4b968947fee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_95af3ab6-b436-43ec-9345-f105eeb7c140" xlink:href="biib-20210331.xsd#biib_FacilityLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b9dfab4-59fd-4bc5-a857-4b968947fee0" xlink:to="loc_biib_FacilityLocationAxis_95af3ab6-b436-43ec-9345-f105eeb7c140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_67cf6c24-d664-419e-93de-0dfc32edcc97" xlink:href="biib-20210331.xsd#biib_FacilityLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_95af3ab6-b436-43ec-9345-f105eeb7c140" xlink:to="loc_biib_FacilityLocationDomain_67cf6c24-d664-419e-93de-0dfc32edcc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_3bb0cf32-dc08-4446-992b-d5b03490b94f" xlink:href="biib-20210331.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_67cf6c24-d664-419e-93de-0dfc32edcc97" xlink:to="loc_biib_SolothurnSwitzerlandMember_3bb0cf32-dc08-4446-992b-d5b03490b94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_74646ff2-2616-4443-be08-8be41a4ca25b" xlink:href="biib-20210331.xsd#biib_FacilityTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b9dfab4-59fd-4bc5-a857-4b968947fee0" xlink:to="loc_biib_FacilityTypeAxis_74646ff2-2616-4443-be08-8be41a4ca25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_955a6645-9a1e-4d16-81e8-d97f692b9874" xlink:href="biib-20210331.xsd#biib_FacilityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeAxis_74646ff2-2616-4443-be08-8be41a4ca25b" xlink:to="loc_biib_FacilityTypeDomain_955a6645-9a1e-4d16-81e8-d97f692b9874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_c2670794-fdd8-45b5-8614-f6dad7e6a4a6" xlink:href="biib-20210331.xsd#biib_BiologicsManufacturingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_955a6645-9a1e-4d16-81e8-d97f692b9874" xlink:to="loc_biib_BiologicsManufacturingMember_c2670794-fdd8-45b5-8614-f6dad7e6a4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_bb459de8-07f0-46c9-827e-11b46de5111d" xlink:href="biib-20210331.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_955a6645-9a1e-4d16-81e8-d97f692b9874" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_bb459de8-07f0-46c9-827e-11b46de5111d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_8c8de12d-da06-4951-ac7e-b17839202c09" xlink:href="biib-20210331.xsd#biib_AdministrativeSpaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_955a6645-9a1e-4d16-81e8-d97f692b9874" xlink:to="loc_biib_AdministrativeSpaceMember_8c8de12d-da06-4951-ac7e-b17839202c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_326cbeea-8884-4bd0-97e1-7c3df30330b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b9dfab4-59fd-4bc5-a857-4b968947fee0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_326cbeea-8884-4bd0-97e1-7c3df30330b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8c86e44c-fb4b-4731-8587-a0f15d7edef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_326cbeea-8884-4bd0-97e1-7c3df30330b7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8c86e44c-fb4b-4731-8587-a0f15d7edef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_67ca1d56-be42-453e-91bd-143ca94e5481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_326cbeea-8884-4bd0-97e1-7c3df30330b7" xlink:to="loc_us-gaap_Depreciation_67ca1d56-be42-453e-91bd-143ca94e5481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_a42359c0-d338-4acb-973c-62758bdf7d47" xlink:href="biib-20210331.xsd#biib_NumberOfSquareFeet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_326cbeea-8884-4bd0-97e1-7c3df30330b7" xlink:to="loc_biib_NumberOfSquareFeet_a42359c0-d338-4acb-973c-62758bdf7d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_fb33a35d-2ee5-4f7d-ac02-e62299f7575a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_326cbeea-8884-4bd0-97e1-7c3df30330b7" xlink:to="loc_us-gaap_ConstructionInProgressGross_fb33a35d-2ee5-4f7d-ac02-e62299f7575a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="simple" xlink:href="biib-20210331.xsd#IndebtednessNotes"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e5a860ea-32c3-487d-8d29-78e4f9369dab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4ea591e6-c061-484b-b183-a9a1130cbd10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e5a860ea-32c3-487d-8d29-78e4f9369dab" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4ea591e6-c061-484b-b183-a9a1130cbd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#IndebtednessDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3b3e6587-775b-47eb-96b4-37cf7b1d30ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_dcd6a906-a397-4492-b75f-0fa3e16a1c66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3b3e6587-775b-47eb-96b4-37cf7b1d30ad" xlink:to="loc_us-gaap_DebtInstrumentTable_dcd6a906-a397-4492-b75f-0fa3e16a1c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1f8348e4-b03e-4865-bef5-a57daeb0d814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dcd6a906-a397-4492-b75f-0fa3e16a1c66" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1f8348e4-b03e-4865-bef5-a57daeb0d814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_43998bff-7397-4401-833d-12ab1d348edd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1f8348e4-b03e-4865-bef5-a57daeb0d814" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_43998bff-7397-4401-833d-12ab1d348edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_d8e0650a-cf74-4806-a4fa-69b02888dc15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43998bff-7397-4401-833d-12ab1d348edd" xlink:to="loc_us-gaap_InterestExpenseMember_d8e0650a-cf74-4806-a4fa-69b02888dc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8966ad39-1ac4-4400-8512-e530e9abaabd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dcd6a906-a397-4492-b75f-0fa3e16a1c66" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8966ad39-1ac4-4400-8512-e530e9abaabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7965926b-42dc-4e2c-8f56-8c6dc00773a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8966ad39-1ac4-4400-8512-e530e9abaabd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7965926b-42dc-4e2c-8f56-8c6dc00773a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_f7a9efce-3de2-43db-b8f7-1659bb922954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7965926b-42dc-4e2c-8f56-8c6dc00773a0" xlink:to="loc_us-gaap_InterestRateSwapMember_f7a9efce-3de2-43db-b8f7-1659bb922954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_90754c25-3b45-4803-ae3c-0d2b3015b483" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dcd6a906-a397-4492-b75f-0fa3e16a1c66" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_90754c25-3b45-4803-ae3c-0d2b3015b483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_817c5361-62d4-4b0e-8b91-67b88e72233e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_90754c25-3b45-4803-ae3c-0d2b3015b483" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_817c5361-62d4-4b0e-8b91-67b88e72233e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_12d7a8b7-fc75-466d-ba38-b8129eb53683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_817c5361-62d4-4b0e-8b91-67b88e72233e" xlink:to="loc_us-gaap_SeniorNotesMember_12d7a8b7-fc75-466d-ba38-b8129eb53683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_82706aa0-7456-49b5-a0e4-6fb7ff3ce4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dcd6a906-a397-4492-b75f-0fa3e16a1c66" xlink:to="loc_us-gaap_DebtInstrumentAxis_82706aa0-7456-49b5-a0e4-6fb7ff3ce4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_30b92099-95e3-43cb-8903-9336b665d184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_82706aa0-7456-49b5-a0e4-6fb7ff3ce4fb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_30b92099-95e3-43cb-8903-9336b665d184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_475f9d72-c7db-49e0-8e86-e022f1c842e2" xlink:href="biib-20210331.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30b92099-95e3-43cb-8903-9336b665d184" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_475f9d72-c7db-49e0-8e86-e022f1c842e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_9a38096f-dab8-41b4-a5ac-6b5b48a84cb8" xlink:href="biib-20210331.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30b92099-95e3-43cb-8903-9336b665d184" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_9a38096f-dab8-41b4-a5ac-6b5b48a84cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.90SeniorNotesDueSept152020Member_9eed356b-33d0-4681-86ee-96307a4bf7bd" xlink:href="biib-20210331.xsd#biib_A2.90SeniorNotesDueSept152020Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30b92099-95e3-43cb-8903-9336b665d184" xlink:to="loc_biib_A2.90SeniorNotesDueSept152020Member_9eed356b-33d0-4681-86ee-96307a4bf7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_47cef1da-91d6-4103-9d8d-5264df8af2f2" xlink:href="biib-20210331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30b92099-95e3-43cb-8903-9336b665d184" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_47cef1da-91d6-4103-9d8d-5264df8af2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_205e6c04-4f52-4a5d-82e6-502e86d05e31" xlink:href="biib-20210331.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30b92099-95e3-43cb-8903-9336b665d184" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_205e6c04-4f52-4a5d-82e6-502e86d05e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dcd6a906-a397-4492-b75f-0fa3e16a1c66" xlink:to="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8e8d9e02-3e31-49ce-a99a-8ad445aba788" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8e8d9e02-3e31-49ce-a99a-8ad445aba788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2526c2ba-3d1b-42d5-a5f9-97682f00e863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2526c2ba-3d1b-42d5-a5f9-97682f00e863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_e5e55e56-3f3e-45a4-ba68-0d33a92b471e" xlink:href="biib-20210331.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_e5e55e56-3f3e-45a4-ba68-0d33a92b471e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_23da6ee3-a752-473b-8bd2-e1c492dadc99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_23da6ee3-a752-473b-8bd2-e1c492dadc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_d9d89b7e-ff0c-43f2-ba07-02a97ca21117" xlink:href="biib-20210331.xsd#biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_d9d89b7e-ff0c-43f2-ba07-02a97ca21117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_46aba5a8-da4f-4526-a339-f872fd4cae2f" xlink:href="biib-20210331.xsd#biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_46aba5a8-da4f-4526-a339-f872fd4cae2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_565122da-3b96-4e39-abd7-f50169265cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_565122da-3b96-4e39-abd7-f50169265cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_432fe90e-cd03-4a0a-84e3-39437f47b01b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_432fe90e-cd03-4a0a-84e3-39437f47b01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount_aa7a16fb-9739-4f3f-b555-04f6f9e75b9d" xlink:href="biib-20210331.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_biib_DebtInstrumentRedemptionAmount_aa7a16fb-9739-4f3f-b555-04f6f9e75b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_e0b4a7eb-8dba-4651-9aa8-8d9b4e3b9de7" xlink:href="biib-20210331.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_biib_LongTermDebtExchangedAmount_e0b4a7eb-8dba-4651-9aa8-8d9b4e3b9de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dde0f63a-2ec9-4166-9d36-1e868a486524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dde0f63a-2ec9-4166-9d36-1e868a486524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_10a983c8-e330-4fdc-8374-cb7b6c4bc1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_RepaymentsOfDebt_10a983c8-e330-4fdc-8374-cb7b6c4bc1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3ff88773-ead9-474a-ad2d-1cb64013c7d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00f43b9d-97d8-40f6-9423-7267695a16a6" xlink:to="loc_us-gaap_InterestExpense_3ff88773-ead9-474a-ad2d-1cb64013c7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20210331.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5740b681-25c9-4cec-96d2-0bf50a300fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8d106da1-e1c0-4a2b-b1be-9ffa000e7b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5740b681-25c9-4cec-96d2-0bf50a300fbb" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8d106da1-e1c0-4a2b-b1be-9ffa000e7b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="biib-20210331.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5e210c43-20ee-4874-9c5e-872044d344f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_41e20f3d-e37b-43cb-bcb6-58f77e3f7830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5e210c43-20ee-4874-9c5e-872044d344f9" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_41e20f3d-e37b-43cb-bcb6-58f77e3f7830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_b4e6d0c1-2309-455c-985d-596680387a96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5e210c43-20ee-4874-9c5e-872044d344f9" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_b4e6d0c1-2309-455c-985d-596680387a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#ShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e361938b-c712-4ecb-9cbf-f0b7e00899f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d6fa6954-a55c-4839-9d9a-c62c0d37b8a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e361938b-c712-4ecb-9cbf-f0b7e00899f5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d6fa6954-a55c-4839-9d9a-c62c0d37b8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_1f0baee6-7800-4f79-8987-8189e87438bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d6fa6954-a55c-4839-9d9a-c62c0d37b8a6" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_1f0baee6-7800-4f79-8987-8189e87438bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_77950641-f7d7-4650-8d2e-03a207a144dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1f0baee6-7800-4f79-8987-8189e87438bd" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_77950641-f7d7-4650-8d2e-03a207a144dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_c98fa584-9b0f-4a8f-86b1-cae568b47e1e" xlink:href="biib-20210331.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_77950641-f7d7-4650-8d2e-03a207a144dc" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_c98fa584-9b0f-4a8f-86b1-cae568b47e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_4939df68-9545-4b3c-9ae3-d986bf72d014" xlink:href="biib-20210331.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_77950641-f7d7-4650-8d2e-03a207a144dc" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_4939df68-9545-4b3c-9ae3-d986bf72d014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_October2020ShareRepurchaseProgramMember_9c14f27e-e8c9-43bc-b23c-2e31ee3fa854" xlink:href="biib-20210331.xsd#biib_October2020ShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_77950641-f7d7-4650-8d2e-03a207a144dc" xlink:to="loc_biib_October2020ShareRepurchaseProgramMember_9c14f27e-e8c9-43bc-b23c-2e31ee3fa854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_01d75bec-6995-4a60-9a0c-72d280dc6fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d6fa6954-a55c-4839-9d9a-c62c0d37b8a6" xlink:to="loc_us-gaap_ClassOfStockLineItems_01d75bec-6995-4a60-9a0c-72d280dc6fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_5ccf1ecd-b4f3-4108-a1a6-c6f6e99173da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01d75bec-6995-4a60-9a0c-72d280dc6fbf" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_5ccf1ecd-b4f3-4108-a1a6-c6f6e99173da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_83b09cd1-1996-46df-bd22-ebbb1c2fbb53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01d75bec-6995-4a60-9a0c-72d280dc6fbf" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_83b09cd1-1996-46df-bd22-ebbb1c2fbb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_79e06a85-a9e0-40b9-b51d-4ee0ab441dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01d75bec-6995-4a60-9a0c-72d280dc6fbf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_79e06a85-a9e0-40b9-b51d-4ee0ab441dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_72dcf086-5090-4240-be18-ed2fcaa9b157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01d75bec-6995-4a60-9a0c-72d280dc6fbf" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_72dcf086-5090-4240-be18-ed2fcaa9b157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c8887b4a-d7d8-4dd6-8d6d-1340007a49b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_37cd642a-d82d-4887-9692-321bf04bba62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c8887b4a-d7d8-4dd6-8d6d-1340007a49b5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_37cd642a-d82d-4887-9692-321bf04bba62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_af92b921-fbc5-417a-8f5d-c60a1245e92b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_37cd642a-d82d-4887-9692-321bf04bba62" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_af92b921-fbc5-417a-8f5d-c60a1245e92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_05a742bb-ce79-41fd-9711-f60831327966" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_af92b921-fbc5-417a-8f5d-c60a1245e92b" xlink:to="loc_us-gaap_EquityComponentDomain_05a742bb-ce79-41fd-9711-f60831327966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0704b96a-110a-4125-95ce-77fa3eac1681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05a742bb-ce79-41fd-9711-f60831327966" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0704b96a-110a-4125-95ce-77fa3eac1681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_103d8ab9-14f9-4dc5-8220-82ace05f59c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05a742bb-ce79-41fd-9711-f60831327966" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_103d8ab9-14f9-4dc5-8220-82ace05f59c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_bea44e15-f6ff-4c53-a065-9d5f88129269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05a742bb-ce79-41fd-9711-f60831327966" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_bea44e15-f6ff-4c53-a065-9d5f88129269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_504775a1-d14e-43d8-b5a2-de70b3e399b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05a742bb-ce79-41fd-9711-f60831327966" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_504775a1-d14e-43d8-b5a2-de70b3e399b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_119b8ca7-48e8-4884-bc94-e0674910e024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05a742bb-ce79-41fd-9711-f60831327966" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_119b8ca7-48e8-4884-bc94-e0674910e024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_37cd642a-d82d-4887-9692-321bf04bba62" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4c258dc2-6847-44c3-a60b-b3fbd54608c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4c258dc2-6847-44c3-a60b-b3fbd54608c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a2812dd8-0497-46c3-adff-8316cc05b7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a2812dd8-0497-46c3-adff-8316cc05b7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_58f218f0-d80b-471a-8195-c4d5d0135edc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_58f218f0-d80b-471a-8195-c4d5d0135edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7694555a-fbe4-46ed-9511-1905002bc2d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7694555a-fbe4-46ed-9511-1905002bc2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7c39a4cf-3c1f-4c7b-be9a-a54c124e7796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7c39a4cf-3c1f-4c7b-be9a-a54c124e7796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a153aed3-eadd-4585-9cca-8dba1ebd099c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a153aed3-eadd-4585-9cca-8dba1ebd099c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6aba15f1-5cbc-4996-90df-af4bb663a041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2f7527b1-da2b-448e-b90a-9ef21c3f3497" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6aba15f1-5cbc-4996-90df-af4bb663a041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_032530ad-ddb4-48ce-bc79-5587361fd621" xlink:href="biib-20210331.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_aee83c41-f3bc-4445-8536-54d00d0ea37b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_032530ad-ddb4-48ce-bc79-5587361fd621" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_aee83c41-f3bc-4445-8536-54d00d0ea37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9cd28b51-23d4-4c7b-8410-bfd88f6342b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_aee83c41-f3bc-4445-8536-54d00d0ea37b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9cd28b51-23d4-4c7b-8410-bfd88f6342b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1e042874-0bc6-49f5-ad63-5cf6dec093d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9cd28b51-23d4-4c7b-8410-bfd88f6342b9" xlink:to="loc_us-gaap_EquityComponentDomain_1e042874-0bc6-49f5-ad63-5cf6dec093d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1b4c450c-e0a5-4822-8d58-f984ecb48323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1e042874-0bc6-49f5-ad63-5cf6dec093d8" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1b4c450c-e0a5-4822-8d58-f984ecb48323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_be9a651b-d740-4df5-81e7-1dc3b8978ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1e042874-0bc6-49f5-ad63-5cf6dec093d8" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_be9a651b-d740-4df5-81e7-1dc3b8978ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_906226d5-3033-4bd3-9b68-efb4e93d54ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1e042874-0bc6-49f5-ad63-5cf6dec093d8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_906226d5-3033-4bd3-9b68-efb4e93d54ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_65b0f937-efd7-4b63-8adb-6289a28e2ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_aee83c41-f3bc-4445-8536-54d00d0ea37b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_65b0f937-efd7-4b63-8adb-6289a28e2ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ef0dc763-9be1-4b8d-bad0-5760f18adc53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_65b0f937-efd7-4b63-8adb-6289a28e2ad3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ef0dc763-9be1-4b8d-bad0-5760f18adc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_2bb59d62-9735-4df7-be4b-8d7bbc650206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ef0dc763-9be1-4b8d-bad0-5760f18adc53" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_2bb59d62-9735-4df7-be4b-8d7bbc650206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_cb59da6d-e167-4417-a909-d1c38fb59820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_aee83c41-f3bc-4445-8536-54d00d0ea37b" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_cb59da6d-e167-4417-a909-d1c38fb59820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_079e0e50-7199-4218-80c1-bdcc7e58c2ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_cb59da6d-e167-4417-a909-d1c38fb59820" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_079e0e50-7199-4218-80c1-bdcc7e58c2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_946e8d0f-8cb6-406c-8394-75b2c2f57572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_cb59da6d-e167-4417-a909-d1c38fb59820" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_946e8d0f-8cb6-406c-8394-75b2c2f57572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_59991e0e-2f09-4a6d-b6c6-eed3b01b5e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_cb59da6d-e167-4417-a909-d1c38fb59820" xlink:to="loc_us-gaap_Revenues_59991e0e-2f09-4a6d-b6c6-eed3b01b5e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e60b3995-9b24-47dd-84d8-097fbeb894ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_cb59da6d-e167-4417-a909-d1c38fb59820" xlink:to="loc_us-gaap_OperatingExpenses_e60b3995-9b24-47dd-84d8-097fbeb894ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9c3d564a-ab7f-4795-bebc-d76568aae6f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_cb59da6d-e167-4417-a909-d1c38fb59820" xlink:to="loc_us-gaap_NetIncomeLoss_9c3d564a-ab7f-4795-bebc-d76568aae6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20210331.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d53e8127-02e2-4d77-8ca9-45262523f294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_a7f89e40-252f-47c2-be05-5bce62a957b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d53e8127-02e2-4d77-8ca9-45262523f294" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_a7f89e40-252f-47c2-be05-5bce62a957b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20210331.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c8b3b9a3-4b9b-48fd-8852-4038133e0fe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_674260e4-7bde-4aa5-b144-3ca9b092bf9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c8b3b9a3-4b9b-48fd-8852-4038133e0fe1" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_674260e4-7bde-4aa5-b144-3ca9b092bf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#EarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dabfe6fc-c926-449e-b921-a050f42eccdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f211651e-7f2a-4531-b29e-378c242a136e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dabfe6fc-c926-449e-b921-a050f42eccdd" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f211651e-7f2a-4531-b29e-378c242a136e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_497580b4-6ec2-4dcb-8fa3-305c608abd0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f211651e-7f2a-4531-b29e-378c242a136e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_497580b4-6ec2-4dcb-8fa3-305c608abd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac202fab-7a48-4f21-9676-28c54e290410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_497580b4-6ec2-4dcb-8fa3-305c608abd0f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac202fab-7a48-4f21-9676-28c54e290410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_f580066e-8cbf-40a0-b917-c09ef0725287" xlink:href="biib-20210331.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac202fab-7a48-4f21-9676-28c54e290410" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_f580066e-8cbf-40a0-b917-c09ef0725287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_43838de5-bb1e-42f9-9274-72ac98998936" xlink:href="biib-20210331.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac202fab-7a48-4f21-9676-28c54e290410" xlink:to="loc_biib_MarketStockUnitsMember_43838de5-bb1e-42f9-9274-72ac98998936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_73b3741c-1c33-4c9e-903f-1204e9153d04" xlink:href="biib-20210331.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ac202fab-7a48-4f21-9676-28c54e290410" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_73b3741c-1c33-4c9e-903f-1204e9153d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_82994c36-0e3b-4d36-92b6-b773456544c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f211651e-7f2a-4531-b29e-378c242a136e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_82994c36-0e3b-4d36-92b6-b773456544c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ee0be738-5cc8-4fb4-9355-795362b0fd4c" xlink:href="biib-20210331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_82994c36-0e3b-4d36-92b6-b773456544c6" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ee0be738-5cc8-4fb4-9355-795362b0fd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_4388a450-32b6-440e-9395-1074c3332c14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ee0be738-5cc8-4fb4-9355-795362b0fd4c" xlink:to="loc_us-gaap_NetIncomeLossAbstract_4388a450-32b6-440e-9395-1074c3332c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_de0f0ff9-b2c3-4c4a-8823-6480dd90f93c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_4388a450-32b6-440e-9395-1074c3332c14" xlink:to="loc_us-gaap_NetIncomeLoss_de0f0ff9-b2c3-4c4a-8823-6480dd90f93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fd197c89-cbd6-462c-acaf-9cbb462a9049" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ee0be738-5cc8-4fb4-9355-795362b0fd4c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fd197c89-cbd6-462c-acaf-9cbb462a9049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_984612ae-9993-45f6-834d-9a6adbb3d56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fd197c89-cbd6-462c-acaf-9cbb462a9049" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_984612ae-9993-45f6-834d-9a6adbb3d56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_971fa54d-37a3-4b93-9814-abed985fc466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fd197c89-cbd6-462c-acaf-9cbb462a9049" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_971fa54d-37a3-4b93-9814-abed985fc466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cd2cb632-2222-43c3-b0e7-0fdffac9c054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_971fa54d-37a3-4b93-9814-abed985fc466" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cd2cb632-2222-43c3-b0e7-0fdffac9c054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_438a1430-d10b-424b-9915-52077e05e90a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_971fa54d-37a3-4b93-9814-abed985fc466" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_438a1430-d10b-424b-9915-52077e05e90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1216d9e8-052b-4b49-94b9-5d3a61a761d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fd197c89-cbd6-462c-acaf-9cbb462a9049" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1216d9e8-052b-4b49-94b9-5d3a61a761d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="simple" xlink:href="biib-20210331.xsd#SharebasedPayments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a9c9467-804f-424e-ad1d-d2601c2c2070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b4b329b9-9639-428e-b7f7-61c7fe45cfcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a9c9467-804f-424e-ad1d-d2601c2c2070" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b4b329b9-9639-428e-b7f7-61c7fe45cfcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20210331.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f41ad237-4db5-4eb0-a5a3-cc2cf097c6c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3227a1a5-d002-4c90-85eb-cec5c5d545ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f41ad237-4db5-4eb0-a5a3-cc2cf097c6c4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3227a1a5-d002-4c90-85eb-cec5c5d545ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_777a7cb6-ae07-46e7-b340-dc4eda6d46ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f41ad237-4db5-4eb0-a5a3-cc2cf097c6c4" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_777a7cb6-ae07-46e7-b340-dc4eda6d46ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#ShareBasedPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8ac7fa4e-25f2-4ed3-8ea9-5036d0fa14f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_81cd58f6-204e-46c2-ae1c-042e8c6893a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8ac7fa4e-25f2-4ed3-8ea9-5036d0fa14f3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_81cd58f6-204e-46c2-ae1c-042e8c6893a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9969860e-48ce-4205-966f-4b19671d2ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_81cd58f6-204e-46c2-ae1c-042e8c6893a3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9969860e-48ce-4205-966f-4b19671d2ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_75a2afc6-b2fc-4d6d-b25e-716b1e0dc02b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9969860e-48ce-4205-966f-4b19671d2ff4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_75a2afc6-b2fc-4d6d-b25e-716b1e0dc02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4742eec6-c014-4157-9e1e-a239051a33ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_75a2afc6-b2fc-4d6d-b25e-716b1e0dc02b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4742eec6-c014-4157-9e1e-a239051a33ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_237dda5a-485f-4bef-8a36-84e31347ac06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_75a2afc6-b2fc-4d6d-b25e-716b1e0dc02b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_237dda5a-485f-4bef-8a36-84e31347ac06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_e5583fc6-1556-47c7-9119-d65dff87a3e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_75a2afc6-b2fc-4d6d-b25e-716b1e0dc02b" xlink:to="loc_us-gaap_ParentMember_e5583fc6-1556-47c7-9119-d65dff87a3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2ba1b990-791a-4246-8849-307b2ae1aab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_81cd58f6-204e-46c2-ae1c-042e8c6893a3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2ba1b990-791a-4246-8849-307b2ae1aab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2f7e6a66-cff5-4ca7-86f7-0213c1b03f27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2ba1b990-791a-4246-8849-307b2ae1aab4" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2f7e6a66-cff5-4ca7-86f7-0213c1b03f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_113d45d2-7add-49fe-a02e-08c71cf96313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2f7e6a66-cff5-4ca7-86f7-0213c1b03f27" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_113d45d2-7add-49fe-a02e-08c71cf96313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_14dcf136-b377-40b2-90c3-2b2ed0407e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2f7e6a66-cff5-4ca7-86f7-0213c1b03f27" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_14dcf136-b377-40b2-90c3-2b2ed0407e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bdaa4e8a-bb7a-483b-8b59-0646f59fbe11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2f7e6a66-cff5-4ca7-86f7-0213c1b03f27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bdaa4e8a-bb7a-483b-8b59-0646f59fbe11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7dbf541a-9755-4afe-b773-7cd7bf5258b2" xlink:href="biib-20210331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2f7e6a66-cff5-4ca7-86f7-0213c1b03f27" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7dbf541a-9755-4afe-b773-7cd7bf5258b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2ab0cca5-2601-4544-8a7d-d86bcdbf04ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2f7e6a66-cff5-4ca7-86f7-0213c1b03f27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2ab0cca5-2601-4544-8a7d-d86bcdbf04ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20210331.xsd#ShareBasedPaymentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8477db71-bd00-4f39-926a-d191198d5422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_761218a1-2b81-4a14-9543-20c0fe835c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8477db71-bd00-4f39-926a-d191198d5422" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_761218a1-2b81-4a14-9543-20c0fe835c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8dbbb239-fdb8-441f-bc7c-e165495a1f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_761218a1-2b81-4a14-9543-20c0fe835c97" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8dbbb239-fdb8-441f-bc7c-e165495a1f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a208db4b-2cf6-4eda-8545-5fa09bc458a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8dbbb239-fdb8-441f-bc7c-e165495a1f7a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a208db4b-2cf6-4eda-8545-5fa09bc458a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_b4d99a13-5e9e-45be-a98c-cbe99a0dd876" xlink:href="biib-20210331.xsd#biib_NightstarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a208db4b-2cf6-4eda-8545-5fa09bc458a2" xlink:to="loc_biib_NightstarMember_b4d99a13-5e9e-45be-a98c-cbe99a0dd876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_80545905-e7fe-490d-a726-bba1edaf7ee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_761218a1-2b81-4a14-9543-20c0fe835c97" xlink:to="loc_us-gaap_AwardTypeAxis_80545905-e7fe-490d-a726-bba1edaf7ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_80545905-e7fe-490d-a726-bba1edaf7ee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_9456fe8f-8ded-4dbb-b484-16f2d37f41fe" xlink:href="biib-20210331.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:to="loc_biib_MarketStockUnitsMember_9456fe8f-8ded-4dbb-b484-16f2d37f41fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_07fbed05-acdb-42d6-a64e-76bd9f0bcde3" xlink:href="biib-20210331.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_07fbed05-acdb-42d6-a64e-76bd9f0bcde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember_cd7221e7-ecf0-420e-84cf-e8b10acb4615" xlink:href="biib-20210331.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:to="loc_biib_CashSettledPerformanceSharesMember_cd7221e7-ecf0-420e-84cf-e8b10acb4615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_536c0392-94e4-4d4f-8115-f96f8a614829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:to="loc_us-gaap_PerformanceSharesMember_536c0392-94e4-4d4f-8115-f96f8a614829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_b25ab807-6d50-4c66-a35d-32b0df2a5d0e" xlink:href="biib-20210331.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_b25ab807-6d50-4c66-a35d-32b0df2a5d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_64824f4c-c03d-48d3-aec8-fbb941d879db" xlink:href="biib-20210331.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_64824f4c-c03d-48d3-aec8-fbb941d879db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_08fa82cf-4798-45df-8e23-e55de1688bcb" xlink:href="biib-20210331.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed0cc6a-506a-4048-b97f-1d82310699d6" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_08fa82cf-4798-45df-8e23-e55de1688bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_611bba31-0bf3-4bbc-8a73-920fd4643df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_761218a1-2b81-4a14-9543-20c0fe835c97" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_611bba31-0bf3-4bbc-8a73-920fd4643df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_0227689f-02e1-4b1a-a0fb-423e47bb48c1" xlink:href="biib-20210331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_611bba31-0bf3-4bbc-8a73-920fd4643df8" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_0227689f-02e1-4b1a-a0fb-423e47bb48c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a07b6dae-9a9c-4bb3-9cff-2e710fc0852e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_0227689f-02e1-4b1a-a0fb-423e47bb48c1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a07b6dae-9a9c-4bb3-9cff-2e710fc0852e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_0a548712-0e15-412a-83a6-c7814f6aed37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_0227689f-02e1-4b1a-a0fb-423e47bb48c1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_0a548712-0e15-412a-83a6-c7814f6aed37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_6148ed61-8e16-43f0-b4dd-b976fadf0ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_0227689f-02e1-4b1a-a0fb-423e47bb48c1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_6148ed61-8e16-43f0-b4dd-b976fadf0ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_0113269e-6031-43f3-a67b-a2b782446a94" xlink:href="biib-20210331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_0227689f-02e1-4b1a-a0fb-423e47bb48c1" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_0113269e-6031-43f3-a67b-a2b782446a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20210331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ef73d691-9382-492b-a0b2-c9b37d553f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_348964b0-3767-418a-a265-807c1df5bb9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef73d691-9382-492b-a0b2-c9b37d553f1b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_348964b0-3767-418a-a265-807c1df5bb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20210331.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f9278dd7-6fed-4d54-a745-100cc6d07573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5d682f31-6dec-49d8-a7b7-8b3784c1be65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f9278dd7-6fed-4d54-a745-100cc6d07573" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5d682f31-6dec-49d8-a7b7-8b3784c1be65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7e74e7d2-421e-4ce7-b273-dc80ca3c9293" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_85925409-ea66-406a-b5a2-d096709361ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7e74e7d2-421e-4ce7-b273-dc80ca3c9293" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_85925409-ea66-406a-b5a2-d096709361ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_452df7fa-0b31-4a6b-8d98-6df22c51639d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_85925409-ea66-406a-b5a2-d096709361ad" xlink:to="loc_srt_ProductOrServiceAxis_452df7fa-0b31-4a6b-8d98-6df22c51639d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d3d99762-81a0-40f3-85c6-8efaf3daaf85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_452df7fa-0b31-4a6b-8d98-6df22c51639d" xlink:to="loc_srt_ProductsAndServicesDomain_d3d99762-81a0-40f3-85c6-8efaf3daaf85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_b8bf602d-784b-4b86-94b1-dd642cba7a0c" xlink:href="biib-20210331.xsd#biib_TECFIDERAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d3d99762-81a0-40f3-85c6-8efaf3daaf85" xlink:to="loc_biib_TECFIDERAMember_b8bf602d-784b-4b86-94b1-dd642cba7a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_1f005065-9467-443e-a01c-3622e84c9dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_85925409-ea66-406a-b5a2-d096709361ad" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_1f005065-9467-443e-a01c-3622e84c9dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetsValueReductioninValue_3d2ee8aa-aa1d-4d0e-ac3c-a34ca81716a1" xlink:href="biib-20210331.xsd#biib_DeferredTaxAssetsValueReductioninValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_1f005065-9467-443e-a01c-3622e84c9dc0" xlink:to="loc_biib_DeferredTaxAssetsValueReductioninValue_3d2ee8aa-aa1d-4d0e-ac3c-a34ca81716a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_1bf0750f-7856-4924-946c-144f82cd1d26" xlink:href="biib-20210331.xsd#biib_DeferredTaxLiabilitiesValueReductioninValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_1f005065-9467-443e-a01c-3622e84c9dc0" xlink:to="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_1bf0750f-7856-4924-946c-144f82cd1d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e191fa00-2bb6-48a1-bbca-8bf862115794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_1f005065-9467-443e-a01c-3622e84c9dc0" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e191fa00-2bb6-48a1-bbca-8bf862115794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_890ac564-382a-48f6-a224-46f54b769867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a5f6e248-d3d5-42c0-b607-50946799862e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_890ac564-382a-48f6-a224-46f54b769867" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a5f6e248-d3d5-42c0-b607-50946799862e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_37da6a37-0f82-4ff3-b557-5b983fe5b5d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a5f6e248-d3d5-42c0-b607-50946799862e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_37da6a37-0f82-4ff3-b557-5b983fe5b5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_91949acc-5e96-4ad4-9b79-96c0a2f234e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a5f6e248-d3d5-42c0-b607-50946799862e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_91949acc-5e96-4ad4-9b79-96c0a2f234e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_23b0e9dc-eb25-4803-b989-467a82f25b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a5f6e248-d3d5-42c0-b607-50946799862e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_23b0e9dc-eb25-4803-b989-467a82f25b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_76d886c3-3d45-420e-977f-4ca461ab3c10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a5f6e248-d3d5-42c0-b607-50946799862e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_76d886c3-3d45-420e-977f-4ca461ab3c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_31dfe69d-8b81-4b56-8b34-9e3c81dad467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a5f6e248-d3d5-42c0-b607-50946799862e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_31dfe69d-8b81-4b56-8b34-9e3c81dad467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_c26ca376-c3c4-4bd8-b795-29f134ee8569" xlink:href="biib-20210331.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a5f6e248-d3d5-42c0-b607-50946799862e" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_c26ca376-c3c4-4bd8-b795-29f134ee8569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_ad46ea8e-f767-4d17-afb3-13bacfc62143" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a5f6e248-d3d5-42c0-b607-50946799862e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_ad46ea8e-f767-4d17-afb3-13bacfc62143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4e2febaa-28f3-451e-a0cd-4cd022f11c0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a5f6e248-d3d5-42c0-b607-50946799862e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4e2febaa-28f3-451e-a0cd-4cd022f11c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20210331.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_77c2d989-01ed-4f82-a17a-5d224495eb56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_ad81ec76-c3fd-41eb-ade4-2ba305ae7452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_77c2d989-01ed-4f82-a17a-5d224495eb56" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_ad81ec76-c3fd-41eb-ade4-2ba305ae7452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20210331.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3974ead-c2b4-4ef8-996a-8d1ebe49398f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_43338cc3-7973-4d8e-8ec6-c94af1032fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3974ead-c2b4-4ef8-996a-8d1ebe49398f" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_43338cc3-7973-4d8e-8ec6-c94af1032fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_39e7e145-1f26-422c-ac67-ab5b3593775b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3974ead-c2b4-4ef8-996a-8d1ebe49398f" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_39e7e145-1f26-422c-ac67-ab5b3593775b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7ec31d14-daca-4afb-bf2d-1c36ac2e4a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3974ead-c2b4-4ef8-996a-8d1ebe49398f" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7ec31d14-daca-4afb-bf2d-1c36ac2e4a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_924952c6-5434-4cdd-9477-fa4fbc9be7e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_47e6f089-205e-442e-8a83-9862df1579d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_924952c6-5434-4cdd-9477-fa4fbc9be7e4" xlink:to="loc_us-gaap_StatementTable_47e6f089-205e-442e-8a83-9862df1579d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_65aa32f2-bf6e-4f2f-a627-87f269120357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_47e6f089-205e-442e-8a83-9862df1579d0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_65aa32f2-bf6e-4f2f-a627-87f269120357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4184a7d2-dc0e-4381-a3a4-f8627456ce78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_65aa32f2-bf6e-4f2f-a627-87f269120357" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4184a7d2-dc0e-4381-a3a4-f8627456ce78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_353d9f8e-2eaa-4a0d-87c0-9551aa2b1869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4184a7d2-dc0e-4381-a3a4-f8627456ce78" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_353d9f8e-2eaa-4a0d-87c0-9551aa2b1869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_022f6457-012b-4456-9d5e-5c87d3af1df7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_47e6f089-205e-442e-8a83-9862df1579d0" xlink:to="loc_us-gaap_StatementLineItems_022f6457-012b-4456-9d5e-5c87d3af1df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_022f6457-012b-4456-9d5e-5c87d3af1df7" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c7a75174-0637-4499-b89e-2f50d538f555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c7a75174-0637-4499-b89e-2f50d538f555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dddde5f9-b2ec-49a4-9aac-fa7a87990626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:to="loc_us-gaap_InterestExpense_dddde5f9-b2ec-49a4-9aac-fa7a87990626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_b40f1cb1-d1a2-4fc8-be21-adabdd27b108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_b40f1cb1-d1a2-4fc8-be21-adabdd27b108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_acb915b9-1bc6-43c3-a4c5-e9ce3d22127b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_acb915b9-1bc6-43c3-a4c5-e9ce3d22127b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_24abb442-a344-4a37-9570-9d2ae968646c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_24abb442-a344-4a37-9570-9d2ae968646c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5ba2577e-a60e-45d7-ab2f-3f7ebae385ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3ecec258-e140-4aa1-88a6-41963c7e822c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5ba2577e-a60e-45d7-ab2f-3f7ebae385ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_ca1fce86-6cfb-4a5f-a55a-ac29a2cb61b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_022f6457-012b-4456-9d5e-5c87d3af1df7" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_ca1fce86-6cfb-4a5f-a55a-ac29a2cb61b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_03f6cb92-50e3-4d1a-95b2-270e8642c9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_ca1fce86-6cfb-4a5f-a55a-ac29a2cb61b8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_03f6cb92-50e3-4d1a-95b2-270e8642c9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_3dcf7114-6797-4201-891c-990572941fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_ca1fce86-6cfb-4a5f-a55a-ac29a2cb61b8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_3dcf7114-6797-4201-891c-990572941fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_26543a4d-c7b5-4a38-9e53-c078648e05c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_ca1fce86-6cfb-4a5f-a55a-ac29a2cb61b8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_26543a4d-c7b5-4a38-9e53-c078648e05c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_022f6457-012b-4456-9d5e-5c87d3af1df7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_edeed13f-0a94-47f2-90bb-027737691825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_edeed13f-0a94-47f2-90bb-027737691825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_776541db-ebc0-44a6-b1ec-2240e80e58bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_776541db-ebc0-44a6-b1ec-2240e80e58bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_4849e247-3bb9-4034-a881-2f8bc37459b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_4849e247-3bb9-4034-a881-2f8bc37459b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_947ddd6c-567e-4ded-9123-9ee6450fbf85" xlink:href="biib-20210331.xsd#biib_Collaborationexpensesaccrual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_biib_Collaborationexpensesaccrual_947ddd6c-567e-4ded-9123-9ee6450fbf85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_df1d87b1-bb52-4928-8b9a-44de7a069b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_df1d87b1-bb52-4928-8b9a-44de7a069b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_e1ff109a-fdc6-4583-97b3-c804614d662d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_e1ff109a-fdc6-4583-97b3-c804614d662d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e5f4a861-60b7-4c13-ba2d-0a74eceef9ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e5f4a861-60b7-4c13-ba2d-0a74eceef9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3f3055f7-6004-434a-a352-a3a6ad8422be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_b02b9139-3bfd-4b74-b0ce-da97fa913d2e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3f3055f7-6004-434a-a352-a3a6ad8422be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20210331.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_53022cf6-4b91-41e6-959a-1a8fb427035f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9677fcd7-01f7-4142-9472-0bad7b59d9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_53022cf6-4b91-41e6-959a-1a8fb427035f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9677fcd7-01f7-4142-9472-0bad7b59d9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_62889210-99b8-46d3-a163-0bc1481c2459" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9677fcd7-01f7-4142-9472-0bad7b59d9fa" xlink:to="loc_dei_LegalEntityAxis_62889210-99b8-46d3-a163-0bc1481c2459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b12af274-dcef-4079-be28-98bc8cd54649" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_62889210-99b8-46d3-a163-0bc1481c2459" xlink:to="loc_dei_EntityDomain_b12af274-dcef-4079-be28-98bc8cd54649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_0db771f6-1a81-4061-8ea6-aba5e0d2a053" xlink:href="biib-20210331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b12af274-dcef-4079-be28-98bc8cd54649" xlink:to="loc_biib_DenaliTherapeuticsIncMember_0db771f6-1a81-4061-8ea6-aba5e0d2a053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_0b149454-4720-49f7-b326-4d8d4a3d325d" xlink:href="biib-20210331.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b12af274-dcef-4079-be28-98bc8cd54649" xlink:to="loc_biib_SangamoCommonStockMember_0b149454-4720-49f7-b326-4d8d4a3d325d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_42bcef48-5657-4722-b9c8-4555919a38d4" xlink:href="biib-20210331.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b12af274-dcef-4079-be28-98bc8cd54649" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_42bcef48-5657-4722-b9c8-4555919a38d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_24e5373e-3a25-4291-8ff7-c03e462c795a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9677fcd7-01f7-4142-9472-0bad7b59d9fa" xlink:to="loc_us-gaap_ClassOfStockLineItems_24e5373e-3a25-4291-8ff7-c03e462c795a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_278abec5-90b0-4d83-9d91-97b958d42d20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_24e5373e-3a25-4291-8ff7-c03e462c795a" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_278abec5-90b0-4d83-9d91-97b958d42d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9370d7a7-04db-4058-ab96-866a825ad1fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_24e5373e-3a25-4291-8ff7-c03e462c795a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9370d7a7-04db-4058-ab96-866a825ad1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_cadcce57-09d4-4a9b-81cb-aeecfaeb8f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_24e5373e-3a25-4291-8ff7-c03e462c795a" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_cadcce57-09d4-4a9b-81cb-aeecfaeb8f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e9d84cf7-cece-4883-ba54-7a0c35e3bb4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_24e5373e-3a25-4291-8ff7-c03e462c795a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e9d84cf7-cece-4883-ba54-7a0c35e3bb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_1a5713fc-95a0-4bd9-872a-b5d3c7d9ed67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_24e5373e-3a25-4291-8ff7-c03e462c795a" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_1a5713fc-95a0-4bd9-872a-b5d3c7d9ed67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20210331.xsd#CollaborativeandOtherRelationships"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45a52752-9f94-4b40-91d0-58d1d7b4c141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_14186b16-a378-49dd-81d5-ab7ad1e61ca9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45a52752-9f94-4b40-91d0-58d1d7b4c141" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_14186b16-a378-49dd-81d5-ab7ad1e61ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20210331.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a252b59d-ca82-4813-ba58-f35b0f85eddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_edf9a318-9bf7-4881-8ab5-5f182f18b061" xlink:href="biib-20210331.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a252b59d-ca82-4813-ba58-f35b0f85eddc" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_edf9a318-9bf7-4881-8ab5-5f182f18b061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_a20b9ee9-269e-49ad-81ad-a6347a4d606a" xlink:href="biib-20210331.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a252b59d-ca82-4813-ba58-f35b0f85eddc" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_a20b9ee9-269e-49ad-81ad-a6347a4d606a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e247ea7-244a-4ef3-be4a-3407a512dc44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57aabd93-7271-4c0b-a31d-528628fab42c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e247ea7-244a-4ef3-be4a-3407a512dc44" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57aabd93-7271-4c0b-a31d-528628fab42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f4190ea1-f7c8-4954-9af0-78c8ca0ceb50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57aabd93-7271-4c0b-a31d-528628fab42c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f4190ea1-f7c8-4954-9af0-78c8ca0ceb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8b2729f8-a13d-421b-bb2d-a3feccd9e82b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f4190ea1-f7c8-4954-9af0-78c8ca0ceb50" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8b2729f8-a13d-421b-bb2d-a3feccd9e82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22ed3009-fd8e-4a3b-9337-68762960d2de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b2729f8-a13d-421b-bb2d-a3feccd9e82b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22ed3009-fd8e-4a3b-9337-68762960d2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cfb0cef2-bc98-47a8-92e3-eca24ec1032b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b2729f8-a13d-421b-bb2d-a3feccd9e82b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cfb0cef2-bc98-47a8-92e3-eca24ec1032b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_804b3cf2-cb55-4e57-979f-0eb78ca123aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57aabd93-7271-4c0b-a31d-528628fab42c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_804b3cf2-cb55-4e57-979f-0eb78ca123aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_804b3cf2-cb55-4e57-979f-0eb78ca123aa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_fd7f4b22-92de-4f07-8af9-9cdecf47f1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:to="loc_us-gaap_CollaborativeArrangementMember_fd7f4b22-92de-4f07-8af9-9cdecf47f1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_d55c8c9a-12c9-4e4c-9a42-ad0c919e38c9" xlink:href="biib-20210331.xsd#biib_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:to="loc_biib_EisaiMember_d55c8c9a-12c9-4e4c-9a42-ad0c919e38c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_11bac62d-85c6-4843-968f-d5e50ef72aeb" xlink:href="biib-20210331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:to="loc_biib_DenaliTherapeuticsIncMember_11bac62d-85c6-4843-968f-d5e50ef72aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_e86bbad8-df4d-41e9-ab54-31531690f757" xlink:href="biib-20210331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_6ff783a9-387b-4bec-a624-2267b7c50da3" xlink:href="biib-20210331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_6ff783a9-387b-4bec-a624-2267b7c50da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_89880766-2909-4dc5-868f-f8b7669671c1" xlink:href="biib-20210331.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:to="loc_biib_SageTherapeuticsIncMember_89880766-2909-4dc5-868f-f8b7669671c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_efed8453-2031-4b10-9ec4-c29ace86ec5d" xlink:href="biib-20210331.xsd#biib_UCBPharmaS.A.Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:to="loc_biib_UCBPharmaS.A.Member_efed8453-2031-4b10-9ec4-c29ace86ec5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_1c3308d7-927b-45f8-9f14-eb913214689a" xlink:href="biib-20210331.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcc6a3c7-9032-4d4d-9597-d105d6c81f20" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_1c3308d7-927b-45f8-9f14-eb913214689a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c9636f21-fdbd-4933-8874-d970522cf167" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57aabd93-7271-4c0b-a31d-528628fab42c" xlink:to="loc_srt_ProductOrServiceAxis_c9636f21-fdbd-4933-8874-d970522cf167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_365ee79b-a6ae-48e5-9896-69a5b5c9ff82" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c9636f21-fdbd-4933-8874-d970522cf167" xlink:to="loc_srt_ProductsAndServicesDomain_365ee79b-a6ae-48e5-9896-69a5b5c9ff82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_a6787658-5d65-438e-a18b-963258ffc902" xlink:href="biib-20210331.xsd#biib_E2609andBAN2401Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_365ee79b-a6ae-48e5-9896-69a5b5c9ff82" xlink:to="loc_biib_E2609andBAN2401Member_a6787658-5d65-438e-a18b-963258ffc902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AducanumabMember_1b69a2c7-d90b-4945-9aa9-4e86721f5924" xlink:href="biib-20210331.xsd#biib_AducanumabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_365ee79b-a6ae-48e5-9896-69a5b5c9ff82" xlink:to="loc_biib_AducanumabMember_1b69a2c7-d90b-4945-9aa9-4e86721f5924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1395efbf-0df0-4d7a-acd6-693e96f639b5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57aabd93-7271-4c0b-a31d-528628fab42c" xlink:to="loc_dei_LegalEntityAxis_1395efbf-0df0-4d7a-acd6-693e96f639b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c5523dd9-2989-4c7d-aeac-e9a6071fc508" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1395efbf-0df0-4d7a-acd6-693e96f639b5" xlink:to="loc_dei_EntityDomain_c5523dd9-2989-4c7d-aeac-e9a6071fc508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_b2c6f9be-2de4-4004-adc7-e14d6305cc06" xlink:href="biib-20210331.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c5523dd9-2989-4c7d-aeac-e9a6071fc508" xlink:to="loc_biib_SangamoCommonStockMember_b2c6f9be-2de4-4004-adc7-e14d6305cc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_34607de3-2ed1-4f8c-ac84-3a4b593cb5b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57aabd93-7271-4c0b-a31d-528628fab42c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_34607de3-2ed1-4f8c-ac84-3a4b593cb5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a855ee46-a730-48f7-bf25-02df5fb4d289" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_34607de3-2ed1-4f8c-ac84-3a4b593cb5b7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a855ee46-a730-48f7-bf25-02df5fb4d289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_e1242292-f832-4f19-ad29-4d25c62c67b7" xlink:href="biib-20210331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a855ee46-a730-48f7-bf25-02df5fb4d289" xlink:to="loc_biib_DenaliTherapeuticsIncMember_e1242292-f832-4f19-ad29-4d25c62c67b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_7c676b06-c004-4184-9f53-d0b662c336ba" xlink:href="biib-20210331.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a855ee46-a730-48f7-bf25-02df5fb4d289" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_7c676b06-c004-4184-9f53-d0b662c336ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57aabd93-7271-4c0b-a31d-528628fab42c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfProductCandidates_a7a7d117-edf0-4106-a3fd-2d56e8e5a1ee" xlink:href="biib-20210331.xsd#biib_NumberOfProductCandidates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_NumberOfProductCandidates_a7a7d117-edf0-4106-a3fd-2d56e8e5a1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_7c711713-a934-4a80-8666-f58e7e29471e" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_7c711713-a934-4a80-8666-f58e7e29471e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_e93e9687-4cb9-4659-905a-d1a4fd685026" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_e93e9687-4cb9-4659-905a-d1a4fd685026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_7ef93bea-b0a7-4569-8c02-eef8a6ba5fb5" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_7ef93bea-b0a7-4569-8c02-eef8a6ba5fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_9de6034c-ea14-468e-b282-e46becaf2ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_9de6034c-ea14-468e-b282-e46becaf2ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_5ca23973-6861-4f05-80ec-7893e698a893" xlink:href="biib-20210331.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_ExpenseIncurredByCollaboration_5ca23973-6861-4f05-80ec-7893e698a893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_bcdeb537-7458-4195-a69f-aab95bd94461" xlink:href="biib-20210331.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_Expenseincurredbythecollaboration_bcdeb537-7458-4195-a69f-aab95bd94461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_090bebc7-7693-427e-ba1c-9b2f25e09b41" xlink:href="biib-20210331.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_090bebc7-7693-427e-ba1c-9b2f25e09b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_476f805d-b64c-4dc6-82f3-81dbd035efe9" xlink:href="biib-20210331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_476f805d-b64c-4dc6-82f3-81dbd035efe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_9bdb1b95-73a3-4491-8f96-30b2903fe171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_us-gaap_LossOnContractTermination_9bdb1b95-73a3-4491-8f96-30b2903fe171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_3a9f60d0-2eef-4a97-b61c-c4619e3562b2" xlink:href="biib-20210331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_3a9f60d0-2eef-4a97-b61c-c4619e3562b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_2a099f42-11b4-4452-86f3-84ff58850aaf" xlink:href="biib-20210331.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_CollaborationAgreementTerm_2a099f42-11b4-4452-86f3-84ff58850aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_474ba39c-5cc5-4f0f-9b04-d9c59ed6260a" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_474ba39c-5cc5-4f0f-9b04-d9c59ed6260a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_04b3486d-8771-428f-abaf-fc1f764bee2e" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_04b3486d-8771-428f-abaf-fc1f764bee2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_bc08930a-43c1-4325-91bb-bb41fcbc3cc5" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_bc08930a-43c1-4325-91bb-bb41fcbc3cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_51bb6f5a-f078-46cf-9f3c-e7a91ab5112e" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_51bb6f5a-f078-46cf-9f3c-e7a91ab5112e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3cb12533-240f-4d71-b0ef-73570ac4ad36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3cb12533-240f-4d71-b0ef-73570ac4ad36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_e6a077aa-9ed4-4a1e-9f5f-3e0d369cca96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_e6a077aa-9ed4-4a1e-9f5f-3e0d369cca96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2b59efa9-c60f-47fb-b24e-3f53f11fc8c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2b59efa9-c60f-47fb-b24e-3f53f11fc8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_5111f9a5-4199-49dc-bbae-89abe9fa94e4" xlink:href="biib-20210331.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_5111f9a5-4199-49dc-bbae-89abe9fa94e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_6268da5c-9f81-4373-8f5d-c274f859d8d0" xlink:href="biib-20210331.xsd#biib_Termofcollaborationagreement"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_821a0311-b118-4a8c-932a-58188d56f9c4" xlink:to="loc_biib_Termofcollaborationagreement_6268da5c-9f81-4373-8f5d-c274f859d8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aa1a3c08-048a-4337-bc57-a6d7f3a0f369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_be3436d2-d5f7-4d30-b5e2-04180d42bf37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aa1a3c08-048a-4337-bc57-a6d7f3a0f369" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_be3436d2-d5f7-4d30-b5e2-04180d42bf37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_46746d88-fd1b-4c79-96c5-5a99007bd14f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_be3436d2-d5f7-4d30-b5e2-04180d42bf37" xlink:to="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_46746d88-fd1b-4c79-96c5-5a99007bd14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_74e5663e-e9e7-42ff-b6ff-79c4acc43350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_46746d88-fd1b-4c79-96c5-5a99007bd14f" xlink:to="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_74e5663e-e9e7-42ff-b6ff-79c4acc43350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_6f200e4a-85d4-4e73-a629-a8bf01aad82d" xlink:href="biib-20210331.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_74e5663e-e9e7-42ff-b6ff-79c4acc43350" xlink:to="loc_biib_NeurimmuneMember_6f200e4a-85d4-4e73-a629-a8bf01aad82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_9817fbf8-fb2f-40b4-a5e5-e8808185b2e2" xlink:href="biib-20210331.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_be3436d2-d5f7-4d30-b5e2-04180d42bf37" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_9817fbf8-fb2f-40b4-a5e5-e8808185b2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_2db89149-525b-410d-8fd9-7df7a09b028a" xlink:href="biib-20210331.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_9817fbf8-fb2f-40b4-a5e5-e8808185b2e2" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_2db89149-525b-410d-8fd9-7df7a09b028a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_4896ca7d-30e2-4bcc-a61e-bee1fdb9116f" xlink:href="biib-20210331.xsd#biib_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_2db89149-525b-410d-8fd9-7df7a09b028a" xlink:to="loc_biib_RegulatoryMilestonesMember_4896ca7d-30e2-4bcc-a61e-bee1fdb9116f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_c2b4a2ab-852a-44fc-b770-aafe4ca4050e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_be3436d2-d5f7-4d30-b5e2-04180d42bf37" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_c2b4a2ab-852a-44fc-b770-aafe4ca4050e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861ad7bd-4361-4ac7-8cd7-f6126f50efc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c2b4a2ab-852a-44fc-b770-aafe4ca4050e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861ad7bd-4361-4ac7-8cd7-f6126f50efc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_5e65a73a-2d76-4e01-9e31-e55701bcbf42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861ad7bd-4361-4ac7-8cd7-f6126f50efc2" xlink:to="loc_us-gaap_InventoriesMember_5e65a73a-2d76-4e01-9e31-e55701bcbf42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_ca72e396-6a2d-40b8-bd64-3380c6c78aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861ad7bd-4361-4ac7-8cd7-f6126f50efc2" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_ca72e396-6a2d-40b8-bd64-3380c6c78aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_1fc96015-c763-4b0f-bc26-671b8a7ce459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861ad7bd-4361-4ac7-8cd7-f6126f50efc2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_1fc96015-c763-4b0f-bc26-671b8a7ce459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0f12ea1a-0489-4c5b-8125-4c1c36407dbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_be3436d2-d5f7-4d30-b5e2-04180d42bf37" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0f12ea1a-0489-4c5b-8125-4c1c36407dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13d6c4b9-8185-4890-8e01-1619fe7a5af4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0f12ea1a-0489-4c5b-8125-4c1c36407dbc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13d6c4b9-8185-4890-8e01-1619fe7a5af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_fb77d352-731f-4889-a131-60e07d65f5cd" xlink:href="biib-20210331.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13d6c4b9-8185-4890-8e01-1619fe7a5af4" xlink:to="loc_biib_EisaiMember_fb77d352-731f-4889-a131-60e07d65f5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_05618274-0706-4d0f-beac-ac986d4928f2" xlink:href="biib-20210331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13d6c4b9-8185-4890-8e01-1619fe7a5af4" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_05618274-0706-4d0f-beac-ac986d4928f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_6f29a35e-0122-430e-9a73-4377f653de14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13d6c4b9-8185-4890-8e01-1619fe7a5af4" xlink:to="loc_us-gaap_CollaborativeArrangementMember_6f29a35e-0122-430e-9a73-4377f653de14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_335e4442-9fef-47fa-9b3b-bf2d6daee762" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_be3436d2-d5f7-4d30-b5e2-04180d42bf37" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_335e4442-9fef-47fa-9b3b-bf2d6daee762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8b7c6aea-2082-479d-8cde-4018e85134da" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_335e4442-9fef-47fa-9b3b-bf2d6daee762" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8b7c6aea-2082-479d-8cde-4018e85134da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_49ca4fb8-cea6-42b4-8f51-31aba8eba925" xlink:href="biib-20210331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8b7c6aea-2082-479d-8cde-4018e85134da" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_49ca4fb8-cea6-42b4-8f51-31aba8eba925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_be3436d2-d5f7-4d30-b5e2-04180d42bf37" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0e95c01b-3307-41de-b87c-4160ea09f5c9" xlink:href="biib-20210331.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0e95c01b-3307-41de-b87c-4160ea09f5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_6a8f05a2-6b05-4834-8afe-9fce89d6fecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_LossOnContractTermination_6a8f05a2-6b05-4834-8afe-9fce89d6fecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_a323db1f-d6af-4654-b093-39d15b53de0b" xlink:href="biib-20210331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_a323db1f-d6af-4654-b093-39d15b53de0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_73959320-14d4-4c7f-b8cc-31d8345b2592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_73959320-14d4-4c7f-b8cc-31d8345b2592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_edd92aad-5bba-45c0-8541-18789ff27dfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_edd92aad-5bba-45c0-8541-18789ff27dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_9ad97962-4a21-4a67-be45-4df47f1a3f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_9ad97962-4a21-4a67-be45-4df47f1a3f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_d4f7939c-8878-4659-8d60-0cfb441b58c5" xlink:href="biib-20210331.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_d4f7939c-8878-4659-8d60-0cfb441b58c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_d85aa846-561f-4f46-8399-df0fc1a9f6f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_d85aa846-561f-4f46-8399-df0fc1a9f6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_15b3a56b-f8ca-4521-8153-50cfec7ad4b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_15b3a56b-f8ca-4521-8153-50cfec7ad4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b219c55f-f593-46eb-ab23-3b5b3006d96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_EquityMethodInvestments_b219c55f-f593-46eb-ab23-3b5b3006d96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_9c48c99f-a2be-4d57-b8a5-cd3182da9718" xlink:href="biib-20210331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_9c48c99f-a2be-4d57-b8a5-cd3182da9718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_53dbfafd-3737-42f1-a49f-f4466121a114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_53dbfafd-3737-42f1-a49f-f4466121a114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_b0c82585-50d7-491c-b73c-87979ce09e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_b0c82585-50d7-491c-b73c-87979ce09e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_a1f55157-5810-4c53-9644-649eac457fe8" xlink:href="biib-20210331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_a1f55157-5810-4c53-9644-649eac457fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_bef704fe-f07d-42bb-88f6-45d86a587ccc" xlink:href="biib-20210331.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_AdditionalMilestonePayment_bef704fe-f07d-42bb-88f6-45d86a587ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_35aa4e99-713d-48c0-9c27-b83fea421a6b" xlink:href="biib-20210331.xsd#biib_ContractOptionExerciseFee"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_ContractOptionExerciseFee_35aa4e99-713d-48c0-9c27-b83fea421a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_60242499-fb55-4563-897d-b40931f8676a" xlink:href="biib-20210331.xsd#biib_Biogenshareofcopromotionprofitsorlosses"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_60242499-fb55-4563-897d-b40931f8676a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_0dc3e770-f45b-44fd-a3f4-227cf6aaeefe" xlink:href="biib-20210331.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_biib_Collaborationprofitlosssharing_0dc3e770-f45b-44fd-a3f4-227cf6aaeefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1ede9728-2332-4821-9c4a-e5194d9a5b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_Revenues_1ede9728-2332-4821-9c4a-e5194d9a5b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_61bd60d1-d42a-4213-b6f1-7368d6d5b2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7708b7f6-a815-40ed-93b1-b11261f40c00" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_61bd60d1-d42a-4213-b6f1-7368d6d5b2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20210331.xsd#InvestmentsinVariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_d9fd7fb2-db0a-41d7-b298-0694145307b4" xlink:href="biib-20210331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_a25a7e63-9034-4b40-8c18-db244aa7746a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_d9fd7fb2-db0a-41d7-b298-0694145307b4" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_a25a7e63-9034-4b40-8c18-db244aa7746a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_f0959f3b-897d-42de-baf5-86bcaa3535f9" xlink:href="biib-20210331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_21dc4dc6-0f8f-4bdc-ba78-77cee4d051c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_f0959f3b-897d-42de-baf5-86bcaa3535f9" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_21dc4dc6-0f8f-4bdc-ba78-77cee4d051c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b69826c4-56fa-4a8a-be59-8796c63547a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_21dc4dc6-0f8f-4bdc-ba78-77cee4d051c9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b69826c4-56fa-4a8a-be59-8796c63547a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edb5200f-c3b3-4c16-bf93-24bf204a89da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b69826c4-56fa-4a8a-be59-8796c63547a2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edb5200f-c3b3-4c16-bf93-24bf204a89da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_6cf32381-e4f6-4d55-b8cb-6aa5273e56c3" xlink:href="biib-20210331.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edb5200f-c3b3-4c16-bf93-24bf204a89da" xlink:to="loc_biib_EisaiMember_6cf32381-e4f6-4d55-b8cb-6aa5273e56c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AducanumabMember_f76e3f77-6239-4d41-9046-862aab686581" xlink:href="biib-20210331.xsd#biib_AducanumabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edb5200f-c3b3-4c16-bf93-24bf204a89da" xlink:to="loc_biib_AducanumabMember_f76e3f77-6239-4d41-9046-862aab686581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_ce30f492-40ae-4289-93f3-4c6eee30e717" xlink:href="biib-20210331.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edb5200f-c3b3-4c16-bf93-24bf204a89da" xlink:to="loc_biib_NeurimmuneMember_ce30f492-40ae-4289-93f3-4c6eee30e717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_85ab48fd-9009-4909-a92f-4f16d49753f1" xlink:href="biib-20210331.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_21dc4dc6-0f8f-4bdc-ba78-77cee4d051c9" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_85ab48fd-9009-4909-a92f-4f16d49753f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_1f0e2aec-b972-4317-a1d2-bc407644dc88" xlink:href="biib-20210331.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_85ab48fd-9009-4909-a92f-4f16d49753f1" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_1f0e2aec-b972-4317-a1d2-bc407644dc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_d0a0cd59-3899-4091-8d18-437f8e80b6ca" xlink:href="biib-20210331.xsd#biib_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_1f0e2aec-b972-4317-a1d2-bc407644dc88" xlink:to="loc_biib_RegulatoryMilestonesMember_d0a0cd59-3899-4091-8d18-437f8e80b6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7a5b81b1-1288-4b7f-9433-236a212761d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_21dc4dc6-0f8f-4bdc-ba78-77cee4d051c9" xlink:to="loc_srt_StatementGeographicalAxis_7a5b81b1-1288-4b7f-9433-236a212761d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_15c58e5f-bb58-4056-9660-aca3fc674546" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7a5b81b1-1288-4b7f-9433-236a212761d5" xlink:to="loc_srt_SegmentGeographicalDomain_15c58e5f-bb58-4056-9660-aca3fc674546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_0c8e901e-80d2-4ca9-8aa4-3ba1a50ad563" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_15c58e5f-bb58-4056-9660-aca3fc674546" xlink:to="loc_country_JP_0c8e901e-80d2-4ca9-8aa4-3ba1a50ad563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_b59d50ba-febb-4bad-bc76-a4c57cc0a2d0" xlink:href="biib-20210331.xsd#biib_ExpectedPaymentTimelineofMilestoneAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_21dc4dc6-0f8f-4bdc-ba78-77cee4d051c9" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_b59d50ba-febb-4bad-bc76-a4c57cc0a2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineOfMilestoneDomain_9de91747-d8d5-4560-8ea7-9234f62596d9" xlink:href="biib-20210331.xsd#biib_ExpectedPaymentTimelineOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_b59d50ba-febb-4bad-bc76-a4c57cc0a2d0" xlink:to="loc_biib_ExpectedPaymentTimelineOfMilestoneDomain_9de91747-d8d5-4560-8ea7-9234f62596d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TwelvemonthsMember_1f6468ae-be55-417e-a6fa-2c357233295b" xlink:href="biib-20210331.xsd#biib_TwelvemonthsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ExpectedPaymentTimelineOfMilestoneDomain_9de91747-d8d5-4560-8ea7-9234f62596d9" xlink:to="loc_biib_TwelvemonthsMember_1f6468ae-be55-417e-a6fa-2c357233295b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_bb786dcb-a51e-42c6-9990-e6da935f5dd7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_21dc4dc6-0f8f-4bdc-ba78-77cee4d051c9" xlink:to="loc_srt_ConsolidatedEntitiesAxis_bb786dcb-a51e-42c6-9990-e6da935f5dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d73689f9-d7b0-480d-8a0a-a05762355713" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_bb786dcb-a51e-42c6-9990-e6da935f5dd7" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d73689f9-d7b0-480d-8a0a-a05762355713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_3220fac9-2d1a-4c4e-8f95-e18d51d6b530" xlink:href="biib-20210331.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d73689f9-d7b0-480d-8a0a-a05762355713" xlink:to="loc_biib_NeurimmuneMember_3220fac9-2d1a-4c4e-8f95-e18d51d6b530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_21dc4dc6-0f8f-4bdc-ba78-77cee4d051c9" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_9cc657d3-ed8b-488e-b074-b6ed3a47c702" xlink:href="biib-20210331.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_biib_CollaborationAgreementTerm_9cc657d3-ed8b-488e-b074-b6ed3a47c702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_67c6fe50-4d9d-4974-bc3a-c127461d8706" xlink:href="biib-20210331.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_67c6fe50-4d9d-4974-bc3a-c127461d8706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_5a9868be-b6d7-4f8a-80b1-3178eb3318c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_5a9868be-b6d7-4f8a-80b1-3178eb3318c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_44e00b01-7ff3-4623-a2a5-e8e2149358f9" xlink:href="biib-20210331.xsd#biib_Reductioninroyaltyratepayableoncommercialsales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_44e00b01-7ff3-4623-a2a5-e8e2149358f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_60a27afe-db09-48df-8887-b74c12010bf8" xlink:href="biib-20210331.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_60a27afe-db09-48df-8887-b74c12010bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6a08a66b-83e7-4158-8f4f-99c0535a02c4" xlink:href="biib-20210331.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6a08a66b-83e7-4158-8f4f-99c0535a02c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3858db63-d2b3-4c2d-a878-a28beadede3f" xlink:href="biib-20210331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3858db63-d2b3-4c2d-a878-a28beadede3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2caf69e4-fdb9-4270-9715-cb864787b1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2caf69e4-fdb9-4270-9715-cb864787b1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4ce3547c-d7c9-4b5c-b1d7-f2e1c287fc85" xlink:href="biib-20210331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_62ebc15d-ef16-49a2-bd5e-3b621f473747" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4ce3547c-d7c9-4b5c-b1d7-f2e1c287fc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20210331.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_3ab1d4bd-d683-4024-8b9b-1d21a3d2e163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_620d1c71-e79b-4380-844b-10820f771cf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_3ab1d4bd-d683-4024-8b9b-1d21a3d2e163" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_620d1c71-e79b-4380-844b-10820f771cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20210331.xsd#LitigationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_5e621479-c1e1-4aed-8a98-16623fc562a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_f334e7a5-802c-434e-b222-a06ee55f1525" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_5e621479-c1e1-4aed-8a98-16623fc562a3" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_f334e7a5-802c-434e-b222-a06ee55f1525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>biib-20210331_g1.jpg
<TEXT>
begin 644 biib-20210331_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                        9&5S
M8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="                             &1E
M<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V
M,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ                                  !V
M:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,
M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,# P,_\  $0@!(@-H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M5AT8'D&OVK@O.98W!>RJN\Z=D_-='^C]+]3VJ=^6S)****^R- HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFCV):***_3"3Y1_X+6?\H]O%7_7[I_\ Z5Q5^(-?M]_P6L_Y1[>*O^OW3_\
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M8?#Z;PYXRTF.^MV!:VND 6[T^3_GI#)@E&X&>H8<,""17X/?M9?LSZU^R/\
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M#^IV>L:/J"E[:\M)1+#. Q4E6'!PP(^H-<>,CCE!?6E/EO\ :YK7^?4ZL)+
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MDAAC2&*,;51!A5'L*DK]3R;):6 IZ:S>[_1=E^9E*5PHHHKVR0HHHH ^4?\
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ML3#@BUC/$I!_Y:/\G'"N"&K\U?BC\8O%7QM\32:QXN\0:MXBU*0G]_?7+2E
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M,<7SN?QZ#]:]8HKUL)P=@Z;O6;F_N7W+7\2>=F/X9\#:9X23_0[95DQ@RO\
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MQ]@,U^D?_!/#_@BI>IK&G^-/C):10V]NXN+/PLQ$C3,.5:\(RH4<'R@23T?
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M^?X*RZ'\RYSFM7,<7+%5>NR[+HOE^=V%%%?6W_!);]@:+]L#XMW&M>)+=Y/
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MP_:XT_\ 8Q_9YU3Q9.L5SJTQ^PZ+9N3B[O'!*9QSL0!G;I\J$9!(KV:OQ/\
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M_P#E^!_-'XM\(ZKX!\2WNC:WI]YI.K:;*8;JTNXC%- XZJRMR#_C6?7[;_\
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M=O'%OXB\&ZY?:'JEN1EX'_=SK_<EC.5D0_W7!'Y U^;Y]X<X;%MUL+-QJ/\
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M#V(!K^<WXI?#V^^$OQ+\0>%]2&-0\.ZC/IMQQ@,\4C(2/8[<CV(K^DZOP_\
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MFOY)S'"_5L75P_\ )*4?N;1_4V7XGZQA:>(_FBG]Z3/P;_X*O_\ *0GXE_\
M7[;_ /I)!7SO7T1_P5?_ .4A/Q+_ .OVW_\ 22"OG>OZBR'_ )%F'_Z]P_\
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M4E_:6(U?\2?_ *4S^GLDIQ>78?3[$/\ TE&7_P (3HO_ $"-+_\  5/\*/\
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M^(F1QQ>7O%P7OTM?6/5?+?Y/N?>< YU+"X]863]RKIZ2Z/Y[?-=C];J^=_\
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M['Q__/B?_@,O\CPNBO=/^'9WQZ_Z)?XG_P"_2?\ Q5'_  [.^/7_ $2_Q/\
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M M]_Z M?M57\^^)G_(W7^"/YL_=O#C_D4O\ QR_)!1117YZ??!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\
MH_\ !:S_ )1[>*O^OW3_ /TKBK\0:_;[_@M9_P H]O%7_7[I_P#Z5Q5^(-?O
MWA?_ ,BF?_7R7_I,3\+\2?\ D:Q_P+\Y!1117Z,?GY^\G_!)[_E'K\-/^O*X
M_P#2N>OHBOG?_@D]_P H]?AI_P!>5Q_Z5SU]$5_*&>_\C+$?]?)_^E,_J#(_
M^1=A_P#!#_TE!1117E'J!1110 444,P1<G@#J?2@#^=?]KOP;#\/?VJOB1HE
MK&L-IIGB;4(+9%Z)"+F3RQ_WQMKSNNV_:7\>0_%+]HOQYXDMY/.M=>\0W]];
MMG.8I+AWCQ[!2 /85Q-?UU@5-8:FJGQ<JOZVU/Y5QKB\1-PVYG;TOH%>S?\
M!.OQC-X%_;G^%=] TBO-XBM=..WKMNG^S-^!64Y]L]>E>,UZ!^R38R:G^U7\
M,K:$A9;CQ9I42$G #&\B Y^IK/,X*>$JPELXR3^YE9;-PQ=*<=U*+_%']%E?
M._\ P5A_Y1Z_$O\ Z\K?_P!*X*^B*^=_^"L/_*/7XE_]>5O_ .E<%?R_D/\
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M.':H5Z_=Q7W)O_VY&5XV\:Z3\.?".I:]KE];Z9H^DV[W5Y=3MB."-1DD_P"
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M4>OPT_Z\KC_TKGK\R\4_^1;2_P"OB_\ 29'Z-X9_\C&I_@?_ *5$^B*^ O\
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M'Y?C'A]YM@'2I_Q(OFCZ]5\U^-CZ3A//EE>.52I\$M)>G1_)_A<_H2HKSO\
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M\!?:W_ :_G-UG1[KP]K%UI]["]O>6,SV\\3_ 'HI$8JRGW!!'X5_3)7XO_\
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MA/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]6Y#_ ,BS#_\
M7N'_ *2C^8,[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^
M#?C_ )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@
MHHHH *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OT
MKPM_Y&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\
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MU6V$5W=IS;Z;&<%K>WSR>0-TAY; P%'!^KJ_ >.>+EF4_J>$?[J+U?\ ,_\
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MU=;+JG<^KZ***^=/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.>'4;@KIFFPV:G\(U%1B/%7"I?N:$F_-I?ES%4/#'$M_OJ\4O)-_G8_$O\
M9Y_X),?&K]H*YMY1X7F\):/*P+ZCX@#62A3SE82/.?(Y!";3Q\PSFOTH_8N_
MX)%_#O\ 92N+76]27_A-O&5N1(FI7\(6WLG'>W@R54CC#N68$9!7.*^L**^$
MSKCK,\QBZ5_9P?2/7U>[_!/L?;9/P3EV DJMN>:ZRZ>BV7XOS"BBBOC3ZX*X
M7]I'X\Z/^S+\$?$/C?7&W66AVQE6%6P]U,2%BA7_ &G<JN>@SD\ UW5?G/\
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M47!RW<_-%?TV5^)G_!9[]F;2/V>?VL5O/#]K#8:-XTL!JRVD*;(K6XWM',J
M<!2563 X!D(   %?I/!?'%7,JWU+&17/9M26E[;IKO;733R1^><8<&4LNH_7
M,))\E[-/6U]FGVZ:Z^9\C4445^F'YR?I%_P;Q?$J:W\9_$7P=)*6M[NRMM9@
MC)XC>)S#(1_O"6+/^X.G?]2J_'__ (-];21OVP/%$X7]U'X.N(V;T9KVR('X
M[6_*OV K^<_$2E&&=U''JHM^MK?H?T!P#4E/)H*71R2]+W_4*\R_:;_9$\!_
MM<^#_P"Q_&NBQWOD@_9+^$B*^T\GJT4N,KT&5.5; RIQ7IM%?&X?$5:%15J,
MG&2V:=FCZZOAZ=:FZ5:*E%[IJZ9^//[3?_!"CXC?#.ZN+[X?W=MX]T499+<L
MMIJ<(]"C'RY,#NCAC@_(.E?&OC[X7^)/A5K#:?XG\/ZUX?OE)'D:C926LAQW
M <#(]QQ7]*%4]<\/6'B?3GL]2L;/4+23[T%S"LT;?56!%?I&5^)^.HQ4,9!5
M%W7NOYZ-/[D?GN9>&^#K2<\)-T_+XE\M4U][/YGZ*_H,\2?L!?!+Q9,TEY\+
M? _F.VYGM])BMF<\G),87).><]:YZ+_@EE^S_#?M<K\,M#\QB209;AH^>OR&
M3;^G%?30\5, U[U&=_+E?ZH^=EX98Z_NU86^:_1GX*5O?#_X4^*/BQJOV'PO
MX=USQ%>9QY.FV,ETX^H13@>YXK]\O"W[!?P5\'.K6/PM\#+(O*O/H\-RZGU#
M2*Q'X&O4M)T:ST"Q2UL;6VLK6/A(;>)8XU^BJ,"N+%>*U)+_ &;#MO\ O22_
M!)_FCLPWAA4;_P!HKI+^ZK_BVOR/R%_9D_X(3_$;XEW=O??$&\M? >BMAWM@
MR7>IS+Z!$)CCR.[N64GE#R*_33]F']CWP#^R%X2.E>"]%CM))U47FH3GSK[4
M".AEEQDCJ0J@("3A1DUZA17YYG?%F8YI[N(G:'\L=(_/J_FV?>9-POE^6>]0
MC>?\SU?^2^204445\V?1!1110!^(_P#P4_\ @#X\\6_MX?$34M*\$^+M4T^Z
MO(&ANK31[B:&8"UA!*NJ$'D$<'J#7@O_  R]\3/^B=^.O_!#=?\ QNOZ,J*_
M3L#XF5\-AZ>'5!/DBHWYGK9)=O(_-\9X<T,1B)UW6:YI-VLM+N_<_G-_X9>^
M)G_1._'7_@ANO_C=?:7_  0J^#7C#X>?M<>(KWQ!X5\2:'9R^$+F!)]0TR>U
MB:0WEDP0,Z@%B%8XZX4^AK]8**QS;Q&KX[!U,)*BDIJU[O3\#;*_#^C@L7#%
M1K-N#O:RU_$****_-S]""BBB@ K\6?\ @K1\!O'7C3_@H'\0-2T?P7XLU;3;
MC^SO)N[/2+B>"7;IMJK;75"IPRD'!X(([5^TU%?0\-<03R?%2Q,(*3<7&S=M
MVG?\#P>(LAAFV&CAIS<4I*5TK[)JWXG\YO\ PR]\3/\ HG?CK_P0W7_QNC_A
ME[XF?]$[\=?^"&Z_^-U_1E17V_\ Q%;$?] Z_P# G_D?%_\ $,*'_/\ ?_@*
M_P S\>_^"+_P0\:> _VWK'4-<\(>*-%L%TB]0W-]I4]O"&*+@;W4#)],\U^P
ME%%?"\19]/-L7]:G!1=DK)WVO_F?;</Y)'*L+]6A)R5V[M6WM_D>;_MAZ5=:
MY^R/\4K*QM[B\O+SPAJT$$$$9DEGD:RF5451DLQ)   R2:^.K7X4:]>_\$P_
MV>-!N/#>L27UEXWTR74-/DT^0S6\ OKHNTL97<J!6!)8  $9ZU^AM%9Y?G4\
M)25*,;VFIWOVBXV_&YICLGCBJKJRE:\'#;HY)W_ _'3QA^P=XV\)_#+]H"RN
MM'\0:MI_P^%MH/@FV6TEF:Y@N=;@NGFMU"DN1"N7(SCSF'.TD%?L717V&"\2
ML50C)2I*5W?=K[*3Z=6G)^;9\EC/#K#5W%QJN-E;9/[3:^Y-17DD%%%%?FI^
MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$QY\/-37=-/\C\UQ6#KX>7)B(.+\TU^8VBBBNHY0HHHH **** "BO0O@_\
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M2/IY^?X+J4445\&?<!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>biib-20210331_g10.jpg
<TEXT>
begin 644 biib-20210331_g10.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^1/^"D/_!27XY?L;?'W
MX'_LQ?LW?L71_&?QI\</^$E_L72I?B1;^&UM?[&M;6[FS-<6LT;[H9Y6^9H\
M>1@;RX Z+]CW]IW_ (*1_&3XI7/A7]KC_@EQ:_!?PQ%HLMS;>+(/CII?B4SW
MBRQ*EI]EM;>-U#H\K^:6VKY.TC+C'S#_ ,%G=!^/_B;_ (*X_L!Z)^RY\0/#
M_A;QW/\ \+4_L+7O%.B/J-A:XT"Q:;S;=)(VDW0"5%PXVLZMR%P?J;]GO1?^
M"C7P5\/>-O'7[;?Q_P#AU\0K+3_#SW?A[3O W@:?1I(IX4DDD\UY+B;S ZA5
M  &#D\YH ^A[S7=$TZ_M]*U#6;2"ZNR1:6TUPJR3$==BDY;'M5JOR-_X)6_\
M$HOV1?\ @IQ_P3TT_P#;?_;Z\*S_ !*^+OQR?5-7UOQ_>ZS<K>Z'_IUS#:VV
MF,LFVR2V6)"B(N V5(*!4'B_QC^/'QT_:#_X-4O&VE_%+X@77B'Q?X$^+%AX
M)MO&-^_F3:JNG^+M/BM+J1FSYC"-HD+MDN8MS%F+$@'[HIK&D2ZH^AQZK;->
MQQ"62S6=3*B$X#%,Y"Y[XQ7CO_!0O]MSP7_P3M_91U_]K+X@^#=4U_2O#]]I
MMM<:7HTD:W$K7E]!9H5,A"X5YU8Y/13CFL?]D#_@F#^Q]^Q1XGE^*?PB^'4L
MOQ"U31'T[Q9\1];U:ZO=9\1^;+%/<3WDTTC>9)+/"DIX 4C:@5?EKY<_X.KO
M@U\,/B)_P25\2?$'QIX/MM0UGP=XGT&;PS?S,X?3WNM8L;2X9,$ [X)'C.0>
M&.,'F@#ZX_X*1_M2^)_V)OV%_B;^U=X,\-6&LZIX&\-2:E8Z7JCNMO<NKHNQ
MS&0P'S'H<UZ!\'?BC:?$;X:>$/%>KW-C::MXF\+6.KOI<5P-R^=;I*VQ6.XH
MI8C/MS7P/_P4\_X)X_L6_L%?\$;?VI?^&0?V?]'\"_\ "5_#^+_A(?[)EG;[
M=]EF/D;_ #9'QL^T38QC_6'.>*\7_;-_X)*?LG?"#_@BS>_MJ>%=*UH?'SP9
M\+]*\::=\;)/$=X=>&KV\-O/O67S=J0[=T*0*HCBCVA%!16 !^QQ( R3572-
M<T37[=KS0=8M;V))"CRVEPLBJPZJ2I(!'I7Y-_\ !77]I'QW\;/'W['/['_C
MSX=_$OQEX$^+GAB_\7_%KP1\'_*AU;QBEGIL$T6FH7NK4"T\Z626XC$RDQJI
M7YD4UC_"GX-W7P@_;Y^!WQ7_ ."9?_!);X_? '39O%*Z%\;[?Q)I%A9>'-:\
M,SQ&/S[B&WU6ZW7-K+LF201JQ^8L[8 (!^LGQ<\1_$#PA\+?$7BKX4?#=?&/
MB?3=%N;GP_X3?68].&L7B1,T-H;J562V$CA4\UE*INW$$"OSJ^/'_!:K_@J=
M^S3XJ^'_ (*^,G_!#*STO4OBAXOA\,>"8(_VHM(N!?ZI*I9(2T.G,(00#\\A
M5!W-?IO7YX_\%P_^3G_V#O\ L[#2O_1+T :'QH_X*>_\%*?@#^QI\9/VH?VC
M_P#@EQHWPJ?X=>%(-3\,_;OC38^);?6[I[N*%[>2.PAAD@"I(7WEB"0!7VS\
M-OB'8>-?!OAS6-2O;*WU37/#UKJ3:9'<#>!+"KL50G<4!)&?:OE7_@X=_P"4
M+G[0'_8GQ?\ I=;5\A_\%!/^"3?[*GP&_P"".FJ_MM>#-,UE/V@? _@;1_&%
MC\;G\07C:]+K$1MI'E,AEVK$P+QK %$4494(J[%P ?L75;3]8TC5FG32M5MK
MDVTQBN1;SJYBD'5&P?E;V/-?E?\ \%=_!]S^V/\ %O\ X)W>&?%?BO5M!7Q_
MXQNYM?O?#5^]G="WGT.&:[@AFC(>'S8C+#O0AE$I*D$ U5_X*]_"#X0?\$TO
MV8OAI^R5^P1\$_$/@C0?V@OCKH^@?$6R^$EPPUW5]+6!VN;2QDN;A M[<I%'
M")&E3<N]6)#&@#]6-.U_0M7N+BTTG6K2ZEM)-EW%;W*NT+<_*X4DJ>#P?2IK
MZ_L=+LY-0U*\BM[>%"\T\\@1$4=26/ 'N:_$GXH?L_>'_A+JWP[^+?\ P28_
MX(G_ +2WP4^*O@CQCIDIUR[TG3[;3==T/SU74=.U5H]:N7NHY8"QW/&[[T7Y
MU!)KL?V[?B/H?[5__!:7QS^S=^T]^QY\9OCO\+/@=X"T2;0?A9\,;6UFTV;6
M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
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MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW
M2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\
M$]_^2)ZM_P!CWK/_ *4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^">__
M "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2)ZM_V/>L_P#I2:]TH **** "BBB@
M HHHH **** "BBB@#*\=>-?#7PV\$:S\1?&FIK9:/H&E7&I:M>.I(@MH(FEE
MD( )(5%8X'/%?F/\/?\ @K!_P4C_ &F?VG/ OQ<_9?\ ^"=5QJ/P[\5_!W7]
M<\(>"_%'QFLM)O?$VG1ZKI,4>M-%]EEAM)U$HCB@DE.^.[D;S$ &[]-OB!IG
M@K6_ >MZ-\2HK%_#EWI%S#KZ:G(J6S63Q,LXE9B L?EEMQ)  SDU^0'Q-_8,
M_::_X)P?M/Z4O_!.?_@H??Z9X<\'?LY^,/%'ACPW\9-+M=>TFPT:UU31I9]$
MCO/W<UO9RO)#(LV6>(6RJ"0[M0!^ON@>*YKCX?V7CCQQI/\ PC4CZ-'?:Q8Z
ME>1G^RB8A)+'+*IV?NOF#.#M^4G.*_+CX+_\%3OVVOVCO^"R7P1LO"OC./0_
MV8/C)%XR@\!>$YO#MI]K\26.AZ;*RZ_+<2PFZACNKQBT,:/&#!;1,R'S6+[W
M[7?[0W[</_!2;_@D9\#O&7P!_92\1:QIWQO%C-\<_#_@K6[:RU"'P\JEKVRL
MIKV6,1I>NGE"4LS+;R,"K[LU\_?M"_M<?M0:)_P5Y_8YUG2/^"1'CWPA=^ _
M!7C+3/!?PN3Q5H?G:Q9MI*P,+1XIS!!':Q*K%9&7*@!<GB@#]-?VS/V8_P!O
M_P".'CO2_$'[)'_!3JZ^!VBVFD_9]2\/P?!S1O$@O[KS7;[5Y]^=\7R,B>6O
MR_N]W4FOE;_@FW\3_P#@I=KW_!7;XM?LL_&3_@HI<_&GX7_!7P98IXLU"7X4
M:%H"2^)=1"R6]DC641D(A@69W82_ZQ"C)WK[R_:3_:/\)?LM?LN>,/VI/BA:
MO9Z7X,\(76N:E922KYA,,!D%LI&09'?;$N,Y9@!UKYB_X-^/V>O&OPK_ &!+
M7]H#XU0EOB3^T'XDOOB=X\NI(R',^J/YMM'S\RJMKY#>6?N/+(,=: /-?#7Q
M$_X*$_\ !3#]O/\ :'^#OPL_;IO/V?\ P+\ _$UEX;TS0/"G@K3=2U;6[F6!
MI3J5W-?HYCA;:WEI& KJ1GE"S^L_\$:?VN?VF?V@]&^-7P)_:N\7:3XQ\4_
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MMI]CM&^R6)F5MKJRG!X92#R#7P)X$_Y6D_'/_9F%C_ZD<5 'Z'T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4454UC
M7]"\.P0W/B#6K2QCN+N&UMY+RY6)99Y7$<42EB-SN[*JJ.69@ "30!;HHHH
M**** "BBB@ HHJE=^)?#EAJD.AWVOV4-[<_\>]G+=(LLO^ZA.6_ 4 7:***
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MX@\EG-%(5$L:-MW;25&017>:=I]AI&GP:5I5E%;6MK"L5M;P1A$BC4 *BJ.
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MQ;'\4OB=H?QUT+Q=-XM\+:7.UMX(T>SD9KN]N+UHU6(-^[_=JQW&)<C>(5<
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MK_@WS^,OPVU>_P#CQ\9/ 7BB-M/ELM4\*^)O 5S<ZM)MW!K+[)/:>:7WEE
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M6C^$- >ZURSBMO,N[6*YU"1H(#&2,/''<0HRD@KM([8K/_X*81ZQ?>!?@O\
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MKU\B_P"1O2]?T9\_Q5_R3^(]%^:/DFBBBOU4_!PHHHH **** "BBB@ HHHH
M**YSQ!\4_"?AGXC^'OA9JL\JZKXGM;ZXTM50%"EH(3+N;/!_?)@8.>?2H/C1
M\;_A3^SO\/;SXJ_&GQK:^'_#]@R+=:C=J[*K.VU5"HK,S$G 502?2H=2G%-M
MV2W\NNOR-(T:LI1C&+;EMYZVT[ZZ'545\_\ P@_X*@_L5?&[XA6'PL\'_%:X
MM=<U@XT.S\0>';[3!J?H+=[J%$D8\87.YLC ->F_'?\ :#^#G[,W@&7XF_'#
MQU:Z#HT<Z0)<3H\DD\SYVPQ11JTDTAP2$16;"DXP"1G#$X:I3=2,TXK=W5EZ
MLVJ8+&4JRI3IR4GLFG=^BZG9T5Y1^SK^VS^S?^U-JNI^&_A#XYFFUK1HEEU3
M0-7TFYTZ_MXF("RF"YC1VC.5^=05!902"0*M?M'_ +8O[.?[)MCI]S\<_B-#
MI5QJ\A31]*MK2:[OK]AC/E6]NCR, 2 6V[02 2,BG]9P_LO:\ZY>]U;[Q/!X
MM5_8>SES_P MG?[MSTVBO.?V<?VK_@?^U=H6I:]\%?$UW?)H]VMKJ]MJ&C75
MC/9S,F]4>.YC1N5P00"/>O1JNG4A5@I0=T^J,JM*K0J.%2+C);IZ,**^=/B%
M_P %7?V%?AIXVU'P%KGQAGO+O19S#KMSH/AN_P!1M--D!PRS3VT#QJ5((8!B
M5*D'!%?06BZQIOB'1[3Q!HMVMQ9WUM'<6DZ@@21.H96&><$$'GUJ*>(H5I.-
M.:;6]FG8TK83%8>$95:;BI;-IJ_I<LT445L<X4444 %%%% !7M'[!W_)=#_V
M!;C_ -"CKQ>O:/V#O^2Z'_L"W'_H4=>;G'_(KK?X6>SP]_R/,/\ XU^9]H44
M45^2G[^%%%% !1110 4444 %%%>8?M;^&_VM?&/PI7PI^QG\2O"7@WQ5J&J0
MP7GBWQ=HLFI)I&GE7\ZXMK165+FZ!$8C29EBY8MG 4@'I]%?G[J7_!O5\%/C
M&Y\0?MJ_MK_M#_&37[CY[RYUSXE2Z=I\<AZBUL+%8X[6//(C4L!ZU9T?_@B_
M\7_V6)?^$I_X)N?\%+?B[X)O;<[X_!'Q/U?_ (2_PG>X_P"6+VER$FM]_P!U
MIHI?,48*C(Y /OFBL?X>/X^D\ :&_P 5H=(C\4-H]L?$D>@/*U@M_P"4OV@6
MQE D,(EW["X#%=N[G-;% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/
M5O\ L>]9_P#2DU[I0 5\7_MX_P#)=!_V!;?_ -"DK[0KXO\ V\?^2Z#_ + M
MO_Z%)7TG"O\ R-/^W7^A\9QW_P B/_M^/ZGB]%%%?I!^-!1110 4444 %%%%
M !1110!R_@WX5:/X+^('C#XAV&HW,MUXRO;.YOH)MOEP-;VD=JHCP <%8@3D
MGDGMQ74444HQC%67]7U*G.4W>3[+[E9?@%5=8T+1/$5G_9WB#1[6^MRP8P7E
MNLJ;AT.U@1D5:HIM)B3:=T-CCCAC6&&-41% 55&  .@ JC'X3\+0ZT?$D7AK
M3UU%@0U^MF@F(/7Y\;OUK0HI63!-K8****8BGI'A_0/#ZRIH.AV=D)Y#),+2
MV2,2.?XFV@9/N:N444));#;;=V%%%% @HHHH **** "OK;_@GE_R3O7?^PT/
M_1*5\DU];?\ !/+_ ))WKO\ V&A_Z)2O XF_Y%$O5?F?6<$_\E!#TE^1]!44
M45^9'[8%%%% !7S[_P %#?\ DG>A?]AH_P#HEZ^@J^??^"AO_).]"_[#1_\
M1+UZ^1?\C>EZ_HSY_BK_ ))_$>B_-'R31117ZJ?@X4444 %%%% !1110 5%?
MB]:QF737C6X,3?9VE!*!\?*6QSC.,U+45^;T6,QTQ8C<^4WV<3D["^#MW8YQ
MG&<=J&-;GX]>!--_9#\'_$[P/X9_X*B?#'7-*\?3/XE3XH>)OB)97TD&LWDD
M\!L)[6\C+)]G6/<J-$41.>?F#-^KGPX\'?!^Y^$GA?P_X%BT[7/">FZ=9MX8
MN)+H:E$8(D46\T<\A<RD*%*R[BQZ[B>:^0?C1\7/VVO$GQ[^'GA_QI_P3XTN
M^U[_ (1KQ-90Z>_Q%TZ?1M866.Q668M(!*D*;59HI(M["0*NX@D=MX+^!_[8
M?[$O_!,#1_@/^S9H&G^-OBGIEI+!;D:C!!:V4MW=S3RRQ&\>-)$MQ,517(WE
M5)7&4KY_ )8:I42@Y12WY&I:*.CO\3>KTZJ[W1];FS>-I47*HHSD_A]HI05Y
M3O)6?NJ.BU>SLOA9@_\ !2R\TK]J/XP?#3]AWX0V,6J>.M.\;:?XK\0ZQ;@,
M/!NE6S%GN)9!_JYI0ZK''D%\C.-T9-_]J**W^(7_  5N_9X^&OBBW^TZ/X?\
M,Z_XEM;*5<Q27XC,<4K \%HC&KH>JMR.IKEOV-K']LS]E+P8?#=G_P $OM>U
M7Q!K]\M[X[\>:M\8]!EOM;OG.9+F8^86VJ6;9$"0H)'+,S-ZK^W/\!_C7=_%
M[X8?ME_LU>%+?Q'XL^&-W?6^I^$9]02T;7M(O8A'/%'-)\BS1X+(&P"7)Y*J
MK4U.O1E6<7S.4&URR7NQ:=E=+F:5V[;[=B%*GAL1##*<>50J1C+GB[RE%J[L
MWRINR5[66KZG*_MKQ6_@#_@I3^RW\4O#EMY.J:[?Z]X:UJ2%>;VP>UC:..3^
M\L4DCR*.Q)/85X_X#^*WQ\\;?\%6OCSJ7P7^!6C^,_&7AU-.T/1=9\6ZT;+2
M_"NCQ1'S45TCDE:6ZG8ML11]V0DXR*]G\$?#_P#:._:^_;0\$?M-?''X$7GP
MT\%_"C2M0_X130=<U:WN=1U?5;V,0RW$B6[,L,,<:C:&.[<JD9#-M3Q?\-?V
M@OV//VT?'G[3_P #_@'=?$KPA\6],TW_ (2K1="U6WMM2TC4[&-XHYHTN&59
MX9$=BP5MP=V)P%&Z*E.I4J>V5U#VE]%K;DY;V:O\7E_>\RZ-:C2I?5Y<LJBH
M\NLERW]KS<O,FE\/G_=\CT/]CW]K[7_COXT\;_!#XS?"A/!'Q-^'UQ;1^)-$
M@U$7EM=6LZ%[>\MIPJEXG7)VD93<N3EN-7_@H9\2/$OPB_8?^*/Q"\&WTEIJ
MNG^#KS^S[R%RKVTLB>4LJ$=&0ON!]5%<)^Q3\$?CO??M%?$W]MK]HSP/!X.U
M;Q];:?I?A_P3%J<=Y-I>FV:;0]S-%E&FE;:VU2=F"#UPO9:#X/\ C1^UA^R9
MXN^%G[7OPRLO!.L>*;75-'DL-*U"*\6&TD5H[>[5HY9%+X(DVEN"HR!7?2GB
M*F#<'?F:E9M6TVBWIHVK/IZ'EUJ>$HYC&I'EY(NGS).ZNTG)1U;DDTU=72TU
MV/EC]E'X]_M4?LV_L$^%_BA\'_V'M G^%'A_PO%J&I+/XL^S^(=9A6,/>ZP(
M%A:("1A),J,[.R!<<$8^\O@_\3O!OQI^%?A[XM?#VX:70_$>CV^H:6SQ[&$,
MJ!E5E'W67.TKV(([5\8:1J?_  4:\%?LAK^P19_L6'4/$=EX2;P?IGQ&@\6V
M2Z VGB#[)'J#!F\]72#!,)3<S)G'.ROK/]E;X'Q?LU_LX^"_@/'JPOV\+>'[
M>QN+X*56XF5<RR*#RJLY8@'H"!666NM%J&O*HJ]U:TNRT6GW]-=3?.5AY1E5
MM%3<W;EES<T=[R]YV=]MF[O30[^BBBO7/G@HHHH **** "O:/V#O^2Z'_L"W
M'_H4=>+U[1^P=_R70_\ 8%N/_0HZ\W./^176_P +/9X>_P"1YA_\:_,^T***
M*_)3]_"BBB@ HHHH **** "BBB@#\I/BG_P4MT']BCQS_P %$O$OQ=^/\>F_
M$W0[[3C\(_!7B#7_ )IK=_#=M'I)TRRE?$BO>RR/-Y"'G+25S_[+_P"P['_P
M2]_:U_8LU[P+X]\:3?$_X^6NM6'[15CK_BB[O5\57">'GU.YO9H9W98Y+.\1
M0KJ VUMKEBS%O8_VUOVPO@-XU_;BOOA7\"?^".=Q^U-\6_@[#8MK_C)-!TBW
MM_",\Z?:K6T35=01B+@*WG"-,!"<J2ZN$[+]GG]H_P#:Q_:1_;&\":_^TI_P
M0UUKX=2Z19ZI:Z=\7M?^(.CZI)X8AFM)'D2*.%?. N7AAMV\LC/F*6RJD4 ?
M<U%%% 'A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !7Q
M?^WC_P ET'_8%M__ $*2OM"OB_\ ;Q_Y+H/^P+;_ /H4E?2<*_\ (T_[=?Z'
MQG'?_(C_ .WX_J>+T445^D'XT%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?6W_!/+_DG>N_]AH?^B4KY)KZV_P""
M>7_).]=_[#0_]$I7@<3?\BB7JOS/K."?^2@AZ2_(^@J***_,C]L"BBB@ KY]
M_P""AO\ R3O0O^PT?_1+U]!5\^_\%#?^2=Z%_P!AH_\ HEZ]?(O^1O2]?T9\
M_P 5?\D_B/1?FCY)HHHK]5/P<**** "BBB@ HHHH **** *%]X5\-ZGXAL/%
MFH:);3:GI<4\6FWTD(,MLDVP2JC=5#^6F<==H]*OT44K)#;;W"BBBF(****
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M(GJW_8]ZS_Z4FO=* "OB_P#;Q_Y+H/\ L"V__H4E?:%?%_[>/_)=!_V!;?\
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MU_1GS_%7_)/XCT7YH^2:***_53\'"BBB@ HHHH **** "BBB@ HHHH ****
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M7 ?VGE]3"\W+S*U[7MJGM=?F? -%?5E%5_Q&#_J!_P#*O_W,^#_XAU_U%?\
MDG_VY\IT5]644?\ $8/^H'_RK_\ <P_XAU_U%?\ DG_VY\IT5]644?\ $8/^
MH'_RK_\ <P_XAU_U%?\ DG_VY\IT5]644?\ $8/^H'_RK_\ <P_XAU_U%?\
MDG_VY\IT5]644?\ $8/^H'_RK_\ <P_XAU_U%?\ DG_VY\IT5]644?\ $8/^
MH'_RK_\ <P_XAU_U%?\ DG_VY\IT5]644?\ $8/^H'_RK_\ <P_XAU_U%?\
MDG_VY\IT5]644?\ $8/^H'_RK_\ <P_XAU_U%?\ DG_VY\IT5]644?\ $8/^
MH'_RK_\ <P_XAU_U%?\ DG_VY\IT5]644?\ $8/^H'_RK_\ <P_XAU_U%?\
MDG_VY\IT5]644?\ $8/^H'_RK_\ <P_XAU_U%?\ DG_VY\IT5]644?\ $8/^
MH'_RK_\ <P_XAU_U%?\ DG_VY\IT5]644?\ $8/^H'_RK_\ <P_XAU_U%?\
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M2@"BBB@ KA?CS_R ;+_K\/\ Z :[JN%^//\ R ;+_K\/_H!KR<]_Y%-7T_5
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M!KNJX7X\_P#(!LO^OP_^@&O)SW_D4U?3]4!Y;1117Y: 4444 %%%% !1110
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MA$OKEDE*S1NOSA82S@#!&:^KO^"SG[2WB/\ 9M_8)\4+\-_-D\<_$&X@\$>
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M_K\/_H!KNJX7X\_\@&R_Z_#_ .@&O)SW_D4U?3]4!Y;1117Y: 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5U_P $
M_P#D=/\ MSD_FM<A77_!/_D=/^W.3^:UZ.4?\C.C_B0'KM%%%?JX!1110 44
M44 %%%% !1110 4444 %%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[
M_P#)$]6_['O6?_2DU[I0 5Y%\;/^1T_[<X_YM7KM>1?&S_D=/^W./^;5\YQ1
M_P BS_MY?J!R%%%%?G0!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7J7P&_Y -[_U^#_T 5Y;7J7P&_Y -[_U^#_T
M 5[W#7_(VCZ/\@.ZHHHK]* **** "N%^//\ R ;+_K\/_H!KNJX7X\_\@&R_
MZ_#_ .@&O)SW_D4U?3]4!Y;1117Y: 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5U_P $_P#D=/\ MSD_FM<A77_!
M/_D=/^W.3^:UZ.4?\C.C_B0'KM%%%?JX!1110 4444 %%%% !1110 4444 %
M%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKYM^/W_!+3]G']HKXE77Q1\6>(_&
MNE7MW#%'+9^&O$7V.T&Q<;EB$9 8]6/<DGJ:XO\ X<A?LF_]%&^*?_A;'_XU
M0!]C5Y%\;/\ D=/^W./^;5XM_P .0OV3?^BC?%/_ ,+8_P#QJC_AR%^R;_T4
M;XI_^%L?_C5>=FF7_P!I87V/-RZIWM?;YH#NJ*X7_AR%^R;_ -%&^*?_ (6Q
M_P#C5'_#D+]DW_HHWQ3_ /"V/_QJOG/]4/\ I_\ ^2__ &P'=45PO_#D+]DW
M_HHWQ3_\+8__ !JC_AR%^R;_ -%&^*?_ (6Q_P#C5'^J'_3_ /\ )?\ [8#N
MJ*X7_AR%^R;_ -%&^*?_ (6Q_P#C5'_#D+]DW_HHWQ3_ /"V/_QJC_5#_I__
M .2__; =U17"_P##D+]DW_HHWQ3_ /"V/_QJC_AR%^R;_P!%&^*?_A;'_P"-
M4?ZH?]/_ /R7_P"V [JBN%_X<A?LF_\ 11OBG_X6Q_\ C5'_  Y"_9-_Z*-\
M4_\ PMC_ /&J/]4/^G__ )+_ /; =U17"_\ #D+]DW_HHWQ3_P#"V/\ \:H_
MX<A?LF_]%&^*?_A;'_XU1_JA_P!/_P#R7_[8#NJ*X7_AR%^R;_T4;XI_^%L?
M_C5>8^%O^"37[.6K_M7>*O@[=>/?B,-*T?PQ8W]K*GB]A.TLKL&#/Y>"O' P
M,4?ZH?\ 3_\ \E_^V ^B**X7_AR%^R;_ -%&^*?_ (6Q_P#C5'_#D+]DW_HH
MWQ3_ /"V/_QJC_5#_I__ .2__; =U17"_P##D+]DW_HHWQ3_ /"V/_QJC_AR
M%^R;_P!%&^*?_A;'_P"-4?ZH?]/_ /R7_P"V [JBN%_X<A?LF_\ 11OBG_X6
MQ_\ C5'_  Y"_9-_Z*-\4_\ PMC_ /&J/]4/^G__ )+_ /; =U17"_\ #D+]
MDW_HHWQ3_P#"V/\ \:H_X<A?LF_]%&^*?_A;'_XU1_JA_P!/_P#R7_[8#NJ*
MX7_AR%^R;_T4;XI_^%L?_C5'_#D+]DW_ **-\4__  MC_P#&J/\ 5#_I_P#^
M2_\ VP'=45PO_#D+]DW_ **-\4__  MC_P#&J/\ AR%^R;_T4;XI_P#A;'_X
MU1_JA_T__P#)?_M@.ZKU+X#?\@&]_P"OP?\ H KYS_X<A?LF_P#11OBG_P"%
ML?\ XU1_PY"_9-_Z*-\4_P#PMC_\:KORWA[^SL6J_M>:U].6V_S8'V-17QS_
M ,.0OV3?^BC?%/\ \+8__&J/^'(7[)O_ $4;XI_^%L?_ (U7TH'V-17QS_PY
M"_9-_P"BC?%/_P +8_\ QJC_ (<A?LF_]%&^*?\ X6Q_^-4 ?8U<+\>?^0#9
M?]?A_P#0#7SG_P .0OV3?^BC?%/_ ,+8_P#QJC_AR%^R;_T4;XI_^%L?_C5<
MF.POUW"3H7MS==_\@.ZHKA?^'(7[)O\ T4;XI_\ A;'_ .-4?\.0OV3?^BC?
M%/\ \+8__&J^6_U0_P"G_P#Y+_\ ; =U17"_\.0OV3?^BC?%/_PMC_\ &J/^
M'(7[)O\ T4;XI_\ A;'_ .-4?ZH?]/\ _P E_P#M@.ZHKA?^'(7[)O\ T4;X
MI_\ A;'_ .-4?\.0OV3?^BC?%/\ \+8__&J/]4/^G_\ Y+_]L!W5%<+_ ,.0
MOV3?^BC?%/\ \+8__&J/^'(7[)O_ $4;XI_^%L?_ (U1_JA_T_\ _)?_ +8#
MNJ*X7_AR%^R;_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\ \:H_U0_Z
M?_\ DO\ ]L!W5%<+_P .0OV3?^BC?%/_ ,+8_P#QJC_AR%^R;_T4;XI_^%L?
M_C5'^J'_ $__ /)?_M@.ZHKA?^'(7[)O_11OBG_X6Q_^-5YC\=O^"37[.7P]
M^)'PT\+:'X]^(SVWBKQ.]AJ377B]G=(A"7!C(C&ULCJ0:/\ 5#_I_P#^2_\
MVP'T117"_P##D+]DW_HHWQ3_ /"V/_QJC_AR%^R;_P!%&^*?_A;'_P"-4?ZH
M?]/_ /R7_P"V [JBN%_X<A?LF_\ 11OBG_X6Q_\ C5'_  Y"_9-_Z*-\4_\
MPMC_ /&J/]4/^G__ )+_ /; =U17"_\ #D+]DW_HHWQ3_P#"V/\ \:H_X<A?
MLF_]%&^*?_A;'_XU1_JA_P!/_P#R7_[8#NJ*X7_AR%^R;_T4;XI_^%L?_C5'
M_#D+]DW_ **-\4__  MC_P#&J/\ 5#_I_P#^2_\ VP'=45PO_#D+]DW_ **-
M\4__  MC_P#&J/\ AR%^R;_T4;XI_P#A;'_XU1_JA_T__P#)?_M@.ZHKA?\
MAR%^R;_T4;XI_P#A;'_XU1_PY"_9-_Z*-\4__"V/_P :H_U0_P"G_P#Y+_\
M; =U77_!/_D=/^W.3^:UXM_PY"_9-_Z*-\4__"V/_P :H_X<A?LF_P#11OBG
M_P"%L?\ XU71A.&/JN*A6]M?E=[<O_VP'V-17QS_ ,.0OV3?^BC?%/\ \+8_
M_&J/^'(7[)O_ $4;XI_^%L?_ (U7U@'V-17RW\)?^"1W[-?P:^)>B?%3POXZ
M^(MQJ.@Z@EY9P:EXN,MN\B'($B>6-Z^HSS7U)0 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH YK3O@S\'](^)]_\;=)^%'AJ
MU\9ZK8K9:IXNM]"MTU2\MEV;8);I4$LD8\M,(S%1L7C@5TM%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!S7CGX,_!_P")^N:#XG^)7PH\->(M2\+7WVWPQJ&NZ%;W
M<^D7.5/GVLDJ,UO)E$.^,JWR+SP*Z6BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH C
MO+NWT^TEO[N39%!&TDKX)VJ!DG Y/ K _P"%M?#[_H8/_)27_P"(K2\8_P#(
MHZK_ -@V?_T6U>"5\UGF<XK+*L(TDG=7UO\ HT![3_PMKX??]#!_Y*2__$5=
MT+QQX7\37C6&B:IY\J1F1D\AUPH(&<LH'4BO":[7X%?\C=<_]@U__1D=>?E_
M$>.Q>-A1G&-I.VB=_P P/5Z***^U **** "BODS_ (+G?M,_&[]CK_@E7\6?
MVD?V<?&W_".>-/#-GI;Z'K7]FVUY]F:;5[*WD/DW4<D3YBFD7YT;&[(P0"/E
MC]LGQ]_P66_X)??LF1_\%&M8_P""DNC?'3PIX9.CW?C7X9>,/@[I&A&ZL+RY
M@MW-K?:8$D697N8\!AMQEOFV^6X!^K5%?.'QI_X*T_L"?LW7^AZ#\?\ X\1>
M%-7\1> 8/&.D:/?Z'?2SW6ES3)!'Y7D02++.TSK&MLC-.QR5C(!-&J_\%9OV
M$?"W[*%C^VG\0OC!<^%O FIZO+I6FR^)O#6H6>HWE]'*\9MH=.>#[7+*3&Y"
M)$25!;&T$T ?1]%?/G[(?_!4?]BC]N#QIJWPM^!'Q2NSXQT.R6]U3P7XH\-W
MVB:M#:L5 N5M;^&)Y8<LF9(PRJ70,06 .=^U#_P5Q_8._9!^+Z? 'XP?%G49
MO&::<NHZEX<\)>$-3UVZTJR8 BYO$T^WF-M'M*L/,PQ5@P4J<T ?2E%?!?\
MP31_;H@^/W[2?[8_Q)N_V@'\6?"GPAXB\/7_ ('OH+IKJRT[2)?#Z7<[6RH"
MP5F#.R %MP(QNXKZX^$7[3/P1^._[/>F?M4_"GQM_:O@+6=#?6--U[^S;F#S
MK) Q:7R)HTF7 1OE9 W'3I0!WE%>6>"_VVOV5_'O[*5O^W%H7QFTR'X476C2
M:M'XTUB*;3K9;-':-I76[2.2/YU*A60,QP "6&?(O@#_ ,%L_P#@G?\ M+_%
M'P_\)/A5\3_$LNH>+[EH/!U]J_PUUS3]/UV01O(5MKNYLTA?Y$9AN9=P'&:
M/K"BOS"_9N_X.,?V;->_:_\ C]\,OC[\5+ZU\%>&?%&D6/PEFTGX0^(YKJY@
M>S8WOVL06,CQL+D +YR1;EY4,OS5^GM !1110 4444 %8WCKQ_X1^&N@-XG\
M;:M]BL5E6-I_(DDPS=!MC5C^E;->._MT?\D%G_["MM_,UUX&A#%8RG2GM)I:
M'!FF*J8'+JN(II.4(MJ^VG?8U/\ ALC]F_\ Z*-_Y2+S_P",T?\ #9'[-_\
MT4;_ ,I%Y_\ &:^%:*^Y_P!4LM_GG]Z_^1/R_P#XB!G/_/NG]TO_ ),_1;X=
M_%?P#\5[&XU+P!KWV^&TE$5P_P!EEBV,1D#$BJ3QZ5T5?/'_  3P_P"1(\0_
M]A6/_P!%5]#U\5F>%IX+'3HP;:CWWV7H?I628ZKF65TL3524I)WMMNUU;_,*
M***X#U0HHKX1_P""V'[0W[77PD\3_LT_![]D7]HR7X8ZC\7_ (WVWA+7?$L'
MA33=8>*TG@<[A!?PR(2K@-\NPG&-V* /NZBOS,^(/QU_X*??\$P/VR_@!X!_
M:8_;5T;]H;X:_'?X@)X*N4U'X9:?X;UCP_?SA1;W$+:<1'/%N8%]Z\*I4 %E
M<?:O[87[>'[*G[!?@O3?''[4GQ6@\.P:WJ'V#P_I\-A<7VH:O=<?N;6SM8Y)
MYV&Y<E$(7>NXKN&0#UZBO"OV/O\ @I)^QW^W5>Z_H'[.WQ1EO=?\*%/^$F\)
M:YH5YI.L:8&^Z\ME>Q13;#QB15*9(&<\5V?[,7[5/P%_;)^%$'QN_9P\>?\
M"0^&Y]1N[#[8^F75C-#=6LS0SP2V]W%%/#(DB$%9$4D8895E) /0J*\2L?\
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M^WTZ]N7AN6L[86UN1'+*Z1%8@ ?+"[V)=]SDL?%;/_@@C_P2^L/B)J7CFW^
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M7XF&YTJWU(>);IA8S^+M;OD>YN[^=#O:&&>9_G!#,MO&H9,AE^?O^"Y7@?\
MX*"_";]ECX=>.?VQO^"@'PT\17,OQO\ "TOASP5X6^#0TNXBU5+P2>98ZE)J
M,LP\F)9F+&$%DRI*[J_6_P#:&_9X^"W[5WP;UW]G[]H;X?6/BGP?XDM1;ZSH
MNH;@DRAU=&#(5>-T=5=)$971E5E((!KYF\/_ /! ;_@F'I^FQZ?XR^#WB/QH
M]J]K_9-[XW^)&MZE<:1%;3QSPPV4DEWNM(Q)%&66+;Y@0*^]1MH XW]LO_E8
M(_8O_P"R?_$7_P!((*/^"7Q%K_P5Q_X*#:5<,$N5\<>!YV@)^812:"Y1\>C
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MCM;"SMD"QP0QJ$2-0.BJH  [ 4 6Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biib-20210331_g11.jpg
<TEXT>
begin 644 biib-20210331_g11.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^1/^"D/_!27XY?L;?'W
MX'_LQ?LW?L71_&?QI\</^$E_L72I?B1;^&UM?[&M;6[FS-<6LT;[H9Y6^9H\
M>1@;RX Z+]CW]IW_ (*1_&3XI7/A7]KC_@EQ:_!?PQ%HLMS;>+(/CII?B4SW
MBRQ*EI]EM;>-U#H\K^:6VKY.TC+C'S#_ ,%G=!^/_B;_ (*X_L!Z)^RY\0/#
M_A;QW/\ \+4_L+7O%.B/J-A:XT"Q:;S;=)(VDW0"5%PXVLZMR%P?J;]GO1?^
M"C7P5\/>-O'7[;?Q_P#AU\0K+3_#SW?A[3O W@:?1I(IX4DDD\UY+B;S ZA5
M  &#D\YH ^A[S7=$TZ_M]*U#6;2"ZNR1:6TUPJR3$==BDY;'M5JOR-_X)6_\
M$HOV1?\ @IQ_P3TT_P#;?_;Z\*S_ !*^+OQR?5-7UOQ_>ZS<K>Z'_IUS#:VV
MF,LFVR2V6)"B(N V5(*!4'B_QC^/'QT_:#_X-4O&VE_%+X@77B'Q?X$^+%AX
M)MO&-^_F3:JNG^+M/BM+J1FSYC"-HD+MDN8MS%F+$@'[HIK&D2ZH^AQZK;->
MQQ"62S6=3*B$X#%,Y"Y[XQ7CO_!0O]MSP7_P3M_91U_]K+X@^#=4U_2O#]]I
MMM<:7HTD:W$K7E]!9H5,A"X5YU8Y/13CFL?]D#_@F#^Q]^Q1XGE^*?PB^'4L
MOQ"U31'T[Q9\1];U:ZO=9\1^;+%/<3WDTTC>9)+/"DIX 4C:@5?EKY<_X.KO
M@U\,/B)_P25\2?$'QIX/MM0UGP=XGT&;PS?S,X?3WNM8L;2X9,$ [X)'C.0>
M&.,'F@#ZX_X*1_M2^)_V)OV%_B;^U=X,\-6&LZIX&\-2:E8Z7JCNMO<NKHNQ
MS&0P'S'H<UZ!\'?BC:?$;X:>$/%>KW-C::MXF\+6.KOI<5P-R^=;I*VQ6.XH
MI8C/MS7P/_P4\_X)X_L6_L%?\$;?VI?^&0?V?]'\"_\ "5_#^+_A(?[)EG;[
M=]EF/D;_ #9'QL^T38QC_6'.>*\7_;-_X)*?LG?"#_@BS>_MJ>%=*UH?'SP9
M\+]*\::=\;)/$=X=>&KV\-O/O67S=J0[=T*0*HCBCVA%!16 !^QQ( R3572-
M<T37[=KS0=8M;V))"CRVEPLBJPZJ2I(!'I7Y-_\ !77]I'QW\;/'W['/['_C
MSX=_$OQEX$^+GAB_\7_%KP1\'_*AU;QBEGIL$T6FH7NK4"T\Z626XC$RDQJI
M7YD4UC_"GX-W7P@_;Y^!WQ7_ ."9?_!);X_? '39O%*Z%\;[?Q)I%A9>'-:\
M,SQ&/S[B&WU6ZW7-K+LF201JQ^8L[8 (!^LGQ<\1_$#PA\+?$7BKX4?#=?&/
MB?3=%N;GP_X3?68].&L7B1,T-H;J562V$CA4\UE*INW$$"OSJ^/'_!:K_@J=
M^S3XJ^'_ (*^,G_!#*STO4OBAXOA\,>"8(_VHM(N!?ZI*I9(2T.G,(00#\\A
M5!W-?IO7YX_\%P_^3G_V#O\ L[#2O_1+T :'QH_X*>_\%*?@#^QI\9/VH?VC
M_P#@EQHWPJ?X=>%(-3\,_;OC38^);?6[I[N*%[>2.PAAD@"I(7WEB"0!7VS\
M-OB'8>-?!OAS6-2O;*WU37/#UKJ3:9'<#>!+"KL50G<4!)&?:OE7_@X=_P"4
M+G[0'_8GQ?\ I=;5\A_\%!/^"3?[*GP&_P"".FJ_MM>#-,UE/V@? _@;1_&%
MC\;G\07C:]+K$1MI'E,AEVK$P+QK %$4494(J[%P ?L75;3]8TC5FG32M5MK
MDVTQBN1;SJYBD'5&P?E;V/-?E?\ \%=_!]S^V/\ %O\ X)W>&?%?BO5M!7Q_
MXQNYM?O?#5^]G="WGT.&:[@AFC(>'S8C+#O0AE$I*D$ U5_X*]_"#X0?\$TO
MV8OAI^R5^P1\$_$/@C0?V@OCKH^@?$6R^$EPPUW5]+6!VN;2QDN;A M[<I%'
M")&E3<N]6)#&@#]6-.U_0M7N+BTTG6K2ZEM)-EW%;W*NT+<_*X4DJ>#P?2IK
MZ_L=+LY-0U*\BM[>%"\T\\@1$4=26/ 'N:_$GXH?L_>'_A+JWP[^+?\ P28_
MX(G_ +2WP4^*O@CQCIDIUR[TG3[;3==T/SU74=.U5H]:N7NHY8"QW/&[[T7Y
MU!)KL?V[?B/H?[5__!:7QS^S=^T]^QY\9OCO\+/@=X"T2;0?A9\,;6UFTV;6
M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
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MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+
MB9G8*+D@+EB> .@[5[;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#D
MB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110
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M8VVFW-Q9VT^E^5J-W-'JCZ5';B(,P1I;U5B5F;: X=BJ@D?G1^PA_P %5_\
M@F'\3_CLG_!3W_@I_P#MW>%9_C!<VLMO\-_AK;:3JMQI/PITF7_EUMR+0I/J
M,J8^T7?)))1"%%?N%10!!IFI6.LZ;;ZQIEP);:[@2:WE (#HRAE;GGD$&IZ*
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_99\8?\ !)_X4PZU<^';K7/"WA[2?BJ+-?%-E:N@NX]+N61[<SQ>;&SP2!)
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M (BC_A;7P^_Z&#_R4E_^(KQ:BC_6S,?Y(?<__D@/:?\ A;7P^_Z&#_R4E_\
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MP)XU32KGQ&='\366OQ:S8B#2?.GC:VDM)IT2*.1F'D"5F90 VX _3_\ 9?\
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M0?&[X9?M >%M?NO"&I^.K&S37?#6KZ1:F\N$>XM8HQ<6TD(  9!AG&W;L8R
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M$MP=D0Q('/(8'*_/7_!47]I[_@H3\48/VL/C!\!?VR]3^#_P\_9;O-)T/2=
M\*Z-:O?>)]5F@L[B\N[V[F4O!#$MXJ1QQ_*X7<V"IW>A_#_X+_MS?L%?\%3?
M@5X;_:!_X*D?$CXM_"[XI'7=,T?1]:M+2 )K=OI-Q/';WR(#YL#QB2:*6(HR
M36\:.A5M] 'U_P#\$W/V3/'O['WP(USP7\4_$6CZEXE\5?$WQ/XQUJ3P^939
M0RZKJD]VL,)E1'(2-XU)*K\P;'&"?H"BB@#YZ_8+\-V&K?!S5KJYFN%8>.-9
M7$4Y48^TMV%>V_\ "#Z1_P _-[_X%M7D?_!/?_DB>K?]CWK/_I2:]TH Q_\
MA!](_P"?F]_\"VKS'XLZ;;Z5XK^RVSR,OV5&S+(6/)/<U[-7D7QL_P"1T_[<
MX_YM7SG%'_(L_P"WE^H'(4445^= %%%% !1110 4444 %%%% !1110 4444
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M &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\
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M'_DI%_\ $5SE%']I9C_S^G_X$_\ ,#H_^%M?$'_H8/\ R4B_^(H_X6U\0?\
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M\^#/C/3/A+^S?I5[K'BWXE>+O#LNF6VMZS/HK:9;Z9IBS 23A#+)+,^T*%4
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MBBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@
MKR+XV?\ (Z?]N<?\VKUVO(OC9_R.G_;G'_-J^<XH_P"19_V\OU Y"BBBOSH
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M?LVF6FUY&%Y*ER_G!."FT.,X8J[XJ_M"?\%"/VB?VTOBU^SK_P $GOAI\'_
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MJ]=KR+XV?\CI_P!N<?\ -J^<XH_Y%G_;R_4#D****_.@"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O4O@-_R ;W_
M *_!_P"@"O+:]2^ W_(!O?\ K\'_ * *][AK_D;1]'^0'=4445^E %%%% !7
M"_'G_D V7_7X?_0#7=5POQY_Y -E_P!?A_\ 0#7DY[_R*:OI^J \MHHHK\M
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M>?\ D V7_7X?_0#7DY[_ ,BFKZ?J@/+:***_+0"BBB@ HHHH **** "BBB@
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M"?\ R.G_ &YR?S6N0KK_ ()_\CI_VYR?S6O1RC_D9T?\2 ]=HHHK]7 ****
M"BBB@ HHHH **** "OF7]LO_ (*5V7[$OQD\/>!O'O[(7QF\3^#=7T@7NL_%
M#X?^!;C6=)\.DS21^7>BW#2K@(';8KL%=2%.:P?"W_!2#7[/7?VP_'GQ-\.Z
M-;?#W]FB]6VT@V(E34M0:VT&/5+\W#O(T9W23)'"$C7 !SO)&/"?V)?V_?\
M@J?9_&?X!:O_ ,% - ^&$GP__:KTV\G\$Z?X*L+NWU+P5>+IK:I9VMVTS,)T
MFM$93U=)>K*%(8 _2/P_KNE>*-!LO$VA71GL=1M([JSF,;)YD4BAT;:P#+E2
M#@@$=P*MT44 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_
M -*37NE !7D7QL_Y'3_MSC_FU>NUY%\;/^1T_P"W./\ FU?.<4?\BS_MY?J!
MR%%%%?G0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7J7P&_Y -[_ -?@_P#0!7EM>I? ;_D WO\ U^#_ - %>]PU
M_P C:/H_R [JBBBOTH HHHH *X7X\_\ (!LO^OP_^@&NZKA?CS_R ;+_ *_#
M_P"@&O)SW_D4U?3]4!Y;1117Y: 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5U_P3_P"1T_[<Y/YK7(5U_P $_P#D
M=/\ MSD_FM>CE'_(SH_XD!Z[1117ZN 4444 %%%% !1110 4444 ?F%_P5*_
M82_X)_Q?'3Q7XQ_:'_X*MW?P$\-_&Z/3)OBY\*3XQTVQ@\<)8!(8IXUN/W]O
MNCB2*:2$,KA!NP2<^H6/QA_X)G?MM_MU?L\:S\"?^"A7PYUF^^#\>O2>#/A/
MX4U6UN9-7NKC27MO.RLVX+:6:3NB+&<99B<*,?/^F>+_ /@E!\'?^"R'[3]C
M_P %./&?P<U+QMXCOM U#P#K/Q,FT^^M],T1=)@C;31]JWQZ9<1R@LT<GE/-
M%-#(N]2=OUU^S-\7_P#@A[XI^-^B:%^Q_P",OV9+OXBS_:?^$=M_AZV@_P!L
M/MMI6N/L_P!D'G<6XF+[/^68?/RYH ^LZ*** /"_^">__)$]6_['O6?_ $I-
M>Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH *\B^-G_(Z?]N<?\VKUVO(OC9_R.G_
M &YQ_P VKYSBC_D6?]O+]0.0HHHK\Z **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *]2^ W_(!O?\ K\'_ * *\MKU
M+X#?\@&]_P"OP?\ H KWN&O^1M'T?Y =U1117Z4 4444 %<+\>?^0#9?]?A_
M] -=U7"_'G_D V7_ %^'_P! ->3GO_(IJ^GZH#RVBBBORT HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KK_@G_P C
MI_VYR?S6N0KK_@G_ ,CI_P!N<G\UKT<H_P"1G1_Q(#UVBBBOU< HHHH ****
M "BBB@ HHHH _-O]OS]H']DJY_;$U[]GGX _\$5_#_[5WQNT_3[+4/B->#PA
MHMO:Z(D\*_9(]1UB_MY MP\"(T<; _N@N&^7:)O^">O[0/[(Q_;"TC]GKXU_
M\$9=!_91^.UQI5[J7@"1O!VC2P:W;Q0LMZNF:Q86\8DF2"1S+&H'[IFR2"5J
MOXW^(W[4?_!)7]NKXV_&!_V%/B-\;?@Y\=-<T[Q1;>(/@SHZ:KKWAW4X-/AL
MKFRN[$NCRP'R%ECD#*B*Q&68N%E^&?CK]J+_ (*M_P#!0'X*_M#7?[#?Q$^"
M/P?^ MWK.MKJ_P 8M+32M?\ $VJ7VG26$-K;V 9WA@196E>0LR2!0N00,@'Z
M0T444 >%_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4
M %>1?&S_ )'3_MSC_FU>NUY%\;/^1T_[<X_YM7SG%'_(L_[>7Z@<A1117YT
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MOP_^@&O)SW_D4U?3]4!Y;1117Y: 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5U_P3_Y'3_MSD_FM<A77_!/_ )'3
M_MSD_FM>CE'_ ",Z/^) >NT445^K@%%%% !1110 4444 %>8?M9>"OVJO'?P
MXL='_9!^-F@^ O$T7B"VGO\ 6/$/AL:I!-IRA_/MEB+#:[DIB3^':?6O3Z^:
M_P#@JEX9_8J\6?LR0:7^WI\?]0^&W@<>*+1XO$.F>,9M#D:_$4XB@^TPD,0R
MF4[.AV ]J .0_::_9]_X+0>,_CCKWB;]EO\ X*$_#;P7X#NI(#X?\,:[\)DU
M*[L56WC6427)D!EW3"5QQP'"]JD_9<^ '_!9CP3\=M"\3_M7?\%!/AOXW\ 6
MOVK^W_"^@?"A-,N[W=:RI!Y=R)"8]D[0R'CYEC9?XJ^$?^%(_P#!LG_TES\8
M?^)(:C_\57M?_!.SX6?\$+O#G[8_@_6OV./^"BWB3QW\2(?[0_X1SPI?_&R]
MU>*^SI]RMQNM)3MEV6YGD&?NF,..5% 'ZA4444 >%_\ !/?_ )(GJW_8]ZS_
M .E)KW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !7D7QL_Y'3_MSC_FU>NUY%\;/
M^1T_[<X_YM7SG%'_ "+/^WE^H'(4445^= %%%% !1110 4444 %%%% !7Q?_
M ,%>?^:>_P#<6_\ ;*OM"OB__@KS_P T]_[BW_ME7[1]'K_D\&6?]QO_ %'J
MGY9XU?\ )LL?_P!PO_3U,^+Z***_TX/X&"OU2T/]L[]EOQ#M-A\;-%CW=/MT
MCVOY^<JXK\K:_8;7/AO\._$V?^$D\!:+J&[[WV[2H9<_]]*:_DGZ4M3AV']D
M+-:=65_K'*Z4X1M_ OS1G3GS7TM:4+6=[W5OZ1^CW#.Y?VD\OG3C;V/,JD92
MO_%M9QG'EMK>ZE>ZVMK'H?Q3^&/B;'_"-_$;0=0W?=^PZQ#+G_OAC6\"",@Y
M!Z&O-=<_8Z_9?\0Y^W_!'08]W7[#:_9?_1)7%8)_8+^ VGG/@Z7Q-X=/\)T3
MQ3=1[?IO9Z_DGZEX?8CX,;B:3[2P].:_\"CB(O\ \IG](_6N,Z/Q86A47>-:
M<7_X#*BU_P"3GM%%>+C]D_QUHW_(E_M=?$:VQ]Q=8OXM05?;$B+Q[4?\*J_;
M0T+G1?VIM'UE1]V+7/!<4/'H6@;)^M'^K/#]?_=\YH>E2&(@_P *,X+YS0?V
M]G-+^-E=7UA.A-?C5A+[HGM%%>+C4_V_-!_X_/#/PRUZ,=/L%[>6LK?7S05!
M^G%)_P +W_:ET3CQ5^QM=RHO6XT/Q?:W.[Z1X##\31_J-F-7_=L5A:OIBJ$7
M\HU9TY/T2N'^MV!I_P ?#XBGZX>K)??3C.*^^Q[317B__#9D&EG9XS_9Q^*&
MD8^_/)X6,T _X&CG/Y5+9_M[_LNRSBRU;Q[<Z5<'_EWU70[N%A]28BH_.E+P
M[XXY>:EE]2HN]./M5]]/F12XVX3O:IC*=-]JC]F_NGRL]CHKAM#_ &F_V=_$
M1"Z3\;/##NWW8Y-:AC<_\!=@?TKKM*U_0M=B\_0]:M+Q,9WVERL@Q]5)KYW&
MY/FV6NV+P\Z?^.$H_FD>UA<SRW'*^&K0G_ADI?DV6Z]2^ W_ " ;W_K\'_H
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MPOC!_P!#/_RCA_\ Y4? _P#$%?#+_H _\JUO_EA\7_\ #H;_ *N$_P#+3_\
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MNOYR1-N-+YW[?V@G]Y9_##7XAT\J2]M9V^N<H*/]4,)6_P!US;"U/^WJM/\
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M_L*A_P"F:Y^^?1T_Y+;$?]@\_P#T[1/:****_P ^S^T HHHH **** "BBB@
MHHHH *Z_X)_\CI_VYR?S6N0KK_@G_P CI_VYR?S6O1RC_D9T?\2 ]=HHHK]7
M **** "BBB@ HHHH **** .#^-/[4W[,?[-L=K-^T3^T9X#\ I>J6LW\:^+[
M+2A. <$H;F5-X!ZXS7-_"W_@H3^P+\<?'=C\+?@I^W#\'_&'B?5/-_LSPYX6
M^)>E:A?W?EQ/-)Y5O!</))LBCDD;:IVJC,< $U^>]GX>_P""5=K_ ,%COVFK
M3_@JQXC^#.O^,]1N- NOAFWQ?U33;O3K+PZ-+B5K&&*^=H+2ZCN/,=X75)72
M6.9 R2%C]:_LS>'O^"%=C\;M$NOV-]#_ &3(?B0GVG_A')/AE;>&%UP9MI1<
M?9C8CS_^/;S]^S_EEYF[Y=U 'UG1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X
M)[_\D3U;_L>]9_\ 2DU[I0 5Y%\;/^1T_P"W./\ FU>NUY%\;/\ D=/^W./^
M;5\YQ1_R+/\ MY?J!R%%%%?G0!1110 4444 %%%% !1110 4C*KJ4=001@@C
M@BEHH S] \)^%O"D4L'A;PUI^FI/)YDZ:?9I")'_ +S! ,GW-:%%%#;>X!11
M10!6ET?2)M4BUR;2K9[V")HH;QH%,L:,0657QD*2!D X.!3=;T#0O$M@VE>(
M]%M-0M68,UM>VRRQD@Y!*L",@]*MT4[L!$1(T$<:!54850, #TI:**0!1110
M 4444 %%%% !7J7P&_Y -[_U^#_T 5Y;7J7P&_Y -[_U^#_T 5[W#7_(VCZ/
M\@.ZHHHK]* **** "N%^//\ R ;+_K\/_H!KNJX7X\_\@&R_Z_#_ .@&O)SW
M_D4U?3]4!Y;1117Y: 4444 %%%% !1110 4444 %<7^T+\(?^%\_!_5_A1_P
MD/\ 97]J_9_]/^R>?Y7E7$<WW-Z;L^7M^\,9SSC%=I17;EN8XS*,QHX_"2Y:
MM&<9PE9.TH-2B[--.S2=FFGU31RX[!87,L#5P>)CS4ZD90DKM7C)-25TTU=-
MJZ:?9GQ?_P .AO\ JX3_ ,M/_P"ZZ/\ AT-_U<)_Y:?_ -UU]BR>(-!AU5=!
MEUNT6^==R637*B5AZA,Y(_"K=?K?_$POC#_T,_\ RCA__E1^;?\ $%?#+_H
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ML;X=WGCG4?A_H6H?$_1+#3/$L^C6LGB'3M+NVN+6UOFB4SQ0RLJF2-9"ZJY
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M_@G_ ,CI_P!N<G\UKT<H_P"1G1_Q(#UVBBBOU< HHHH **** "BBB@ HHHH
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M1110 4444 %%%% !77_!/_D=/^W.3^:UR%=?\$_^1T_[<Y/YK7HY1_R,Z/\
MB0'KM%%%?JX!1110 4444 %%%% !1110 4444 %%%% 'A?\ P3W_ .2)ZM_V
M/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !7D7QL_P"1T_[<X_YM7KM>
M1?&S_D=/^W./^;5\YQ1_R+/^WE^H'(4445^= %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %>I? ;_ ) -[_U^#_T
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MO_1S'PL_\)"Z_P#BZ^SZ*/[-R[_GS#_P%?Y ?&'_  R5_P %/?\ HYCX6?\
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MEWXPU3QCX;\%V@\.:?-XRO$T?3)([F&(31V$;K$TA61BQ<."3G' H _4FBN
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M7$(^5R?G&.AQ^DE% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX*6>,_#]]>_#+X*> X--^)=[86$EU_8=GK_A2PL8=5FCC5F\BWDCRS@$@N@
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MRY@L+J:*0*\*7$;PS[7 8)/R <UYE^POX\_X)A^!OV4?"WPL_;&_X*B_M,?
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M?'K]@+]L'P4D_C;P4/B5J.O17?ABR>^>XTA]+B>6]ABC!>7RK=GN-B@O^Z(
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M>YR:EUWP_H/BC3)-$\2Z)::C93 >=:7ULLT3X.1E'!!_$4 ?G_\ \$UO"/\
MP2[\1?'GXH_&C]B/]KKXB?&CQS9^ (=$\8>*O&'CS5?$<$-A)*\UO;)>WJF.
M1@\3L$CD?RPS9"[^=O\ X-ED1?\ @AQ\"%"@ Z?KF0!ZZ_J6:^YM%T/1/#>F
M1:+X=T>UL+.!=L%I96ZQ11CT55  _ 5:H _&'_@G%J?_  3J;_@V#^ 7A#_@
MJ!JT>G?#OQ-XLUK3;#69EO4.FZN/$.NW%K<+<V:F2R91;RA9R50$A&.)-K=)
M^Q)\>XOAW_P5(^%G[,__  3@_P""E?Q!_:;^#_B70-;N?B]HGC76_P#A)8/
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M7Q]9-PHPE.25KM0BY-*[2O9:7:5^J/:**_%[_A[)_P % ?\ HOO_ ):NE?\
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MN0&8_+Y8\S[$_; _;Z_9._8/\/:3KW[3GQ7BT.7Q#=M:>&]%L].N=0U/6)U
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MC0_!>KZCH6DW>X+Y-QJ=M:O:H0Q )$A53]XK@X /L2BO+_&?[9_[,?@#QO\
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M!P:\_P#V8O\ @K1^Q=^UM\5K;X(_"SQ)XOM/%%_ITU_I6E^+?AKK6B_VA:Q
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M=0Z)^SE\/I[)+EUM)IO%\BO)$&.QF&W@E<$CM5?_ (65_P %-?\ HVCX<_\
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M:>'/$7G?V3_;/_"0:RUI]GQ]M\KR]H._=F7/IM7UK[1_X65_P4U_Z-H^'/\
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M=:N[+6-'EPH,EOJ%O*ERA;8A8%R'**7#$ TAG@7P1_84_;[D_P""F_AK]O\
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M?9X;JY:%"8I'3<4+!6(!% 'C_P .?VCO^"C7_!0_]I+XX>%OV3/CU\-?@GX
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MX3^"D-S;#0OVJ?&6FV%AI:D+9Z&-:TG[="BC[L(LWNRPZ!"_:OJN_P#V4/\
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M#^"6M_%32KS6_%_QI^(<EB+3PMH]K&O_ ![0WKI;37ES,6BC60E5V'Y3NW(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5^97_!:"[_ &A='_X*P?L&>*/V6?">F>(?&NC#
MXG7^G>&M7U,64.M6\>DZ8;NQ%PP*02S6OGQQ2.-B2M&7PH)'Z:UYC\4?V2?A
M+\7OVE?A7^U;XN74SXK^#T6O1^#S:WH2V"ZO:Q6MWY\>T^;^[A39R-IR><T
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MP)X4UF_;X2_$?X?^+=*MVNM+NKN6Z2TU*WO9HGM9HGF<-*-T9! 7(3<W;_\
M!13]CG]JO]J2S_9V_P""@?P]_9M\+7?QB^#4MY>>(/@1XM\06MU8ZSI^J6L<
M.H:0-09#;-<Q;%\F=E$._<_90?T!HH ^%/@!\3_C'\2/C/X6T6Q_X(&'X:V$
M&KQ2>)/'GB_5/#-LF@K&2_G6<=H99[V0.JA"@C )#%AC!ZS]DW]ESX[?#/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
K!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-20210331_g12.jpg
<TEXT>
begin 644 biib-20210331_g12.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _!']K[5?$/[.?_!PG\>O^"E?AZ[N
M19? ;7?AD?'MM"2RR^$M:T9=+U1R@^^T7F6TRYX7RF8XQD>U?\'/'B>__:J\
M.G]B;P3K+MH/P\^#GB+XU_$FXL9OE,5I:S66A6^]>&$M[-)*T9^\EN& .,CT
M?X,?!;P5^T?_ ,%J?^"BO[/_ ,1[+[1H/C7X5^!-%U>, %O(N=!>%V7/1@'W
M*>S $=*\\NO^":O[1W["G_!&W]L3QW^VI\6?#OCKXH>+/@__ &'%K_AN>XEM
MX/#>B:$MCIEMFXAB=9O]?)-A2'=PQ9VR: /L;]G3XG_M#?"C_@DC^SKKO[,/
M[,Z_%;Q3=?";P=9Q>')O&%MH4%O"VB0,]W-=SHX6--B@JB.[%U"J><97P>_X
M*3_M1>$OVLO!?[(7_!0[]BJQ^%^H_$^"^'PU\8^$O'\?B#1]6O;2'[1/I\Q^
MSP2VDXA!="X*R'Y5Y%?+'[8?Q?\ %GPP_P""7/[!&B>,?B]XQ^'7P,\3Z+X1
MT_X[>._ UU<6M[8::?#T!M;>2ZM@9;6UGN/DEE3!P ,_-M;Q3QR?^"8]M_P5
M7_8VTS_@FCJ/B3Q=96?Q9E3QG\07^(7B#7]'6X>Q<V^GPS:E=S6[W)032R"W
M ,:",,?W@4 'W]\??^"M?QT\)?\ !07Q1_P3:_9D_8.N_B7XYT?P5IWB/3=4
M;QY#I>G"VN"1/+?22VS"TBA)B4%&FDF>9$6->6&A\=O^"HGQZ^"U[\+?V7]#
M_8N_X33]I[XD:#/J]S\)]!\;P1Z7X=L()&CEU&]U:2(JEKN4A#Y6Z1E9!AMH
M;D_V>%4_\''7[13E1D?L_P#A$ XYQ]HDKD?VQ?B5X?\ ^"<G_!<KPY_P4)_:
M6@O=/^#/Q(^ 1^'$_P 0$L)9[/POKD.KB^BCO3$K&"">,*J.1@R,Q.%C=@ ?
M1/@/XR_MT_$;X-_%;PY^V?\ L9Z'\-&TWP/=S:'KOACXDPZ_8ZR7M[@2Q!/(
M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
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MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+
MB9G8*+D@+EB> .@[5[;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#D
MB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[
MI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\
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MH **** "BBB@ HHHH **** "BBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\
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MA,Y"DBONB@#HO^%K^/\ _H/_ /DK%_\ $T?\+7\?_P#0?_\ )6+_ .)KG:*
M.B_X6OX__P"@_P#^2L7_ ,31_P +7\?_ /0?_P#)6+_XFN=HH Z+_A:_C_\
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M=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %>2?&G_D<_^W2/^9KUNO)/C3_R.?\
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M!_[2O[2*_%;7XM3FDM_%[>$+71)9;-@OEQ2VUH?),B'>#(@4."#M7I7XO_\
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M^#_PN^('[3G[&?\ P40\'^"_!WA'1K"?0_"%M\(_[2UC5+EYH89Q-=ZC"UO
MFZ5F4K&QVKCJ<@ _5V]LK/4K.73]1M(KBWGC*3031ATD4C!5E/!!'8U7\/\
MAOP[X3TQ-%\*Z!9:99QDF.TT^U2&)2>I"H !GZ5XS\)_VZ?@'KGPL\-:WXH^
M*7FZG>>'[.?49?[$NEWSO C2'"0!1EB>%&/3BLC]I7_@I[^RS^SG^SYXU^/%
M]XPDU-?"/AF]U6/2HM-NHGOY(86>.V5WAVHTCA8PS< N">* /HJLBY^'W@*]
M\1Q^,;SP1I$NKQ$&+59=-B:Y3'3$I7<,?6OQQO/VP?\ @J3I'[$J?\%/I/\
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MT77(/A/H\'Q/ET%;#Q1XL34;G4;B4!]QBAGNF9XH3A"8XPB$J,KP*V_VI/\
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M\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 %>2?&G_D<_\
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M110 4444 %%%% !1110 4444 %%%% !7I_P*_P"0%>_]?8_]!%>85Z?\"O\
MD!7O_7V/_010!W-%%% !1110 5PWQU_Y 5E_U]G_ -!-=S7#?'7_ ) 5E_U]
MG_T$T >84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %=;\%O^1S_[=)/YBN2KK?@M_P CG_VZ2?S% 'K=%%%
M!1110 4444 %%%% !1110 4444 %%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]T
MKPO_ ()[_P#)$]6_['O6?_2DU[I0 5Y)\:?^1S_[=(_YFO6Z\D^-/_(Y_P#;
MI'_,T <E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5Z?\"O^0%>_]?8_]!%>85Z?\"O^0%>_]?8_]!% '<T4
M44 %%%% !7#?'7_D!67_ %]G_P!!-=S7#?'7_D!67_7V?_030!YA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5UOP6_Y'/\ [=)/YBN2KK?@M_R.?_;I)_,4 >MT444 %%%% !1110 4444
M%%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q
M[UG_ -*37NE !7DGQI_Y'/\ [=(_YFO6Z\D^-/\ R.?_ &Z1_P S0!R5%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7I_P*_Y 5[_ -?8_P#017F%>G_ K_D!7O\ U]C_ -!% '<T444 %%%%
M !7#?'7_ ) 5E_U]G_T$UW-<-\=?^0%9?]?9_P#030!YA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5UOP6_
MY'/_ +=)/YBN2KK?@M_R.?\ VZ2?S% 'K=%%% !1110 4444 %%%% !1110
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M_F_>/)<RKA60-MV,@()&5/V?0 4444 %%%% !1110 5Z?\"O^0%>_P#7V/\
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M %]G_P!!- 'F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !76_!;_ )'/_MTD_F*Y*NM^"W_(Y_\ ;I)_,4 >
MMT444 %%%% !1110 4444 %%%% !1110 4444 >%_P#!/?\ Y(GJW_8]ZS_Z
M4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %>2?&G_ )'/_MTC_F:];KR3XT_\
MCG_VZ1_S- ')4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>G_
MK_D!7O\ U]C_ -!%>85Z?\"O^0%>_P#7V/\ T$4 =S1110 4444 %<-\=?\
MD!67_7V?_037<UPWQU_Y 5E_U]G_ -!- 'F%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !76_!;_D<_\ MTD_
MF*Y*NM^"W_(Y_P#;I)_,4 >MT444 %%%% !1110 4444 %%%% !1110 4444
M >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 %>2?&G_D
M<_\ MTC_ )FO6Z\D^-/_ ".?_;I'_,T <E1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z?\  K_D!7O_ %]C
M_P!!%>85Z?\  K_D!7O_ %]C_P!!% '<T444 %%%% !7#?'7_D!67_7V?_03
M7<UPWQU_Y 5E_P!?9_\ 030!YA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5UOP6_P"1S_[=)/YBN2KK?@M_
MR.?_ &Z2?S% 'K=%%% !1110 4444 %%%% !1110 4444 %%%% 'A?\ P3W_
M .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !7DGQI_P"1S_[=
M(_YFO6Z\D^-/_(Y_]ND?\S0!R5%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7I_P*_P"0%>_]?8_]!%>85Z?\
M"O\ D!7O_7V/_010!W-%%% !1110 5PWQU_Y 5E_U]G_ -!-=S7#?'7_ ) 5
ME_U]G_T$T >84444 %%%% !1110 4444 %%%0:G8IJFFW&F23RQ+<0/$TL#[
M70,",J>Q&>#ZT ?''Q;_ ."X'[%OPV_:+T?X2:7\3AKNA0)K$7CKQ#X>\*:O
MJD.CW=J+;RHDFL[:2*;)EE$I0OY6U-Q3<,^X_%O]J/5M*_9FTW]HG]ESX-ZK
M\9'\1P6$_A+0_#=VEH=3@N]K17#3W "V\(1@[22#Y1U%?G-\/_ ?_!0#_@E%
M\4_@K\ X_P!F30OC3X5\ Z/XW;P5??#[Q NGZUJNEW,]G<W,MS:72;6NX2Z?
MNXF;S?,PK,REF_2[]D?]I[X3?MC?LY>&/VE/@I+<KX:\2V3RV<-_;K#/:O'*
M\,T$J*2JO'+'(C8)7*DJ2""0#YCU/_@J/^UM^S?X\\'6_P#P4,_X)_1?#CP1
MXZ\26^@V'CGPQ\1[;7H='U"X)$$-]%'#&41B#F93M&TX#=*]E_;O_;LM_P!C
MRV\%^!_!/PGO_B'\3/B;KKZ1\// .G:@EFVHS1H'GGFN9%9;>VA1E:24JVW>
MN1C<R_./QH\1W?\ P6@_:1T/]G_X)[G_ &>?A!XZMM9^)GQ&C'^C^+-;LF+0
MZ)IK])H49MT\Z_+]W:1B,R[?[3OG-_P7_P#V8QK03[$OPK\6G1/-_P"?WR9!
M/L_VO(VYQSMS0!Z-^SC_ ,%"OBUK7[4D'[%/[:_[,L7PL^(&M>'I=;\$W&E>
M*TUG2?$EK"3]HCAG6*-H[B( LT3*?D1FR 5#1_M!?\%#?C#:?M3:E^Q;^P_^
MR]#\4_''A?0K?5_'U]J_BV/1=)\.0W #6T$DS12M+<RH0ZQ*HPC!LL X3S[_
M (*;&9?^"HO["CZ#L_MC_A-?%@3;GS/L1TVW^U8QSM\OKVZ>])_P2I#G_@H5
M^W*^M@?VR?BMHXFW_P"L^PBRG^QY[[=F[;VZXH ]W_8._;GL?VS- \6Z%XI^
M%E_\/_B)\.?$)T/XB> =3OH[N32KO;OCDBN(P%N+>50QCE"J&V-@8 9O6_BO
MXA\?>$OAIKOB;X6?#I?%WB.PTR:?1/"[ZQ'IXU2Y528[<W,JLD&]L#S&!"YR
M17Q=^R#YJ_\ !>+]KM="\L6#>"O!!UH19Q]N_L]?)W8XW>5O]\?C7WC0!^>W
M[2?_  5H_P""D?[(WP:U?X__ +0'_!';3]"\*Z'Y U'43^TEI5PRM-,D,:K%
M#8M)(S22(,*I/.>@)'W3\)?%?B?QW\*_#/CCQMX)?PSK6L^'[*^U?PY)>?:&
MTJZF@226T,NQ/-,3LT>_8N[9G:N<#XF_X*/C_ALO_@HI\ /^";NG$7/A[0+Q
MOBK\68%^9#I]@YBTZVE ZI-<LZ.AQP\;>E??- !1110 4444 %%%% !76_!;
M_D<_^W23^8KDJZWX+?\ (Y_]NDG\Q0!ZW1110 4444 %%%% !1110 4444 %
M%%% !1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_T
MI->Z4 %>2?&G_D<_^W2/^9KUNO)/C3_R.?\ VZ1_S- ')4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>G_ K
M_D!7O_7V/_017F%>G_ K_D!7O_7V/_010!W-%%% !1110 5PWQU_Y 5E_P!?
M9_\ 037<UPWQU_Y 5E_U]G_T$T >84444 %%%% !1110 4444 %0:G9MJ.FW
M&GI>36YG@>,7%NVV2+<"-RGLPSD'U%3T4 ?GA\5OV)O^"D(_:>^%?A*Q_P""
MENLZA8)X<\46UEXXG^#EA)J>AVS)IZO%-<QRK!+/.H41SO$K*8';$C$E?8?B
M-_P2_CMO^":<'_!-K]E/]H76/AEI<=E]BN?%KZ8-3O;RVEG>>^64"6W^:YDE
MD+LC( '90NT[:^KJ* /AWX$_\$X?^"D/[.?P^\._!_X5_P#!5;PSI/A'PS;Q
M6VGZ#8?LT:;&@@4Y9=_]H%B[_,6D;<[,S.Q9B2?7_P!O3]A23]KZ+P1\0_AU
M\6;KX>?%#X7:[)JWP\\=6FFI>BRDE01W%M/;NRK/;3HJ+(FX$[%Y*[D;Z#HH
M ^3_ -G/_@G[\;+3]JFU_;;_ &X_VDK'XD^.] \.S:)X%TSP_P"%AI.D>&[>
M<_Z3-%&99'EN)ERK2,1A&9<, FR/]H#_ ()\_'./]JS5?VUOV$OVEM/^&_C/
MQ;H=MI/Q"T?Q'X5&KZ1XBCMAMM;EXQ+&\-S"F$#J2"H PN7W_6E% '@/[!?[
M#*_L<Z-XP\4^./BM=_$'XD_$OQ%_;?Q$\>7VG)9G4KD*4AAAMT9E@MX4++'&
M&;;O;! (5>M_9"^"'Q>_9^^$C^ ?C;^TEJ?Q4UIM;O+Q?%.K::;25;>63=%:
M[#--\L0^4-NY]!TKU&B@#P+]G']AW_A2?[6?QF_;"\9_% ^+/$OQ8OK&*R5M
M%^R+X>T>SB,=OIT9\Z3S>-K22@1B1D5MBG.??:** "BBB@ HHHH **** "NM
M^"W_ ".?_;I)_,5R5=;\%O\ D<_^W23^8H ];HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH \+_P"">_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK
M/_I2:]TH *\D^-/_ ".?_;I'_,UZW7DGQI_Y'/\ [=(_YF@#DJ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M3_@5_P @*]_Z^Q_Z"*\PKT_X%?\ ("O?^OL?^@B@#N:*** "BBB@ KAOCK_R
M K+_ *^S_P"@FNYKAOCK_P @*R_Z^S_Z": /,**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NM^"W_(Y_]NDG
M\Q7)5UOP6_Y'/_MTD_F* /6Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M/"_^">__ "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2)ZM_V/>L_P#I2:]TH *\
MD^-/_(Y_]ND?\S7K=>2?&G_D<_\ MTC_ )F@#DJ*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O3_@5_R KW_K
M['_H(KS"O3_@5_R KW_K['_H(H [FBBB@ HHHH *X;XZ_P#("LO^OL_^@FNY
MKAOCK_R K+_K[/\ Z": /,**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "NM^"W_(Y_P#;I)_,5R5=;\%O^1S_
M .W23^8H ];HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;
M_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ KR3XT_\CG_ -ND?\S7
MK=>2?&G_ )'/_MTC_F: .2HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *]/\ @5_R KW_ *^Q_P"@BO,*]/\
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M?_X*!_\ )?O^X';?^A25^5^,/_)(?]Q(?E(\W-/]U^:/#Z***_E<^="BBB@
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MZ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?8G_!-[_DF_B#_ +#B_P#HE*^.Z^Q/^";W_)-_$'_8<7_T2E?I/A-_
MR6M'_#/_ -)9WY;_ +VOF?1E%%%?UF?2A1110 5PWQU_Y 5E_P!?9_\ 037<
MUPWQU_Y 5E_U]G_T$T >84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %=;\%O^1S_ .W23^8KDJZWX+?\CG_V
MZ2?S% 'K=%%% !1110 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?\
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M *": /,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#_L.+_Z)2OTGPF_Y+6C_ (9_^DL[\M_WM?,^C****_K,^E"BBB@ KAOCK_R
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M?_X*!_\ )?O^X';?^A25^5^,/_)(?]Q(?E(\W-/]U^:/#Z***_E<^="BBB@
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M?M\?\%+?VZ?A'^TY^T-^QE>_ #X4? J?5=7T+2?%NN07?B#Q7K5[826*;H8
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M $$T >84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK/\ Z4FO=* "OA__ (*!_P#)?O\ N!VW_H4E?<%?#_\ P4#_ .2_?]P.V_\
M0I*_*_&'_DD/^XD/RD>;FG^Z_-'A]%%%?RN?.A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7V)_P3>_Y)OX@_[#B_
M^B4KX[K[$_X)O?\ )-_$'_8<7_T2E?I/A-_R6M'_  S_ /26=^6_[VOF?1E%
M%%?UF?2A1110 5PWQU_Y 5E_U]G_ -!-=S7#?'7_ ) 5E_U]G_T$T >84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&LOM7]N>![7X#:7HLFI;[66.'%Y!*TD/ESO%-\H.X1%#PQH ^OZ*** /"_\
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M^B7KY?C3,<9E/"^)Q>$ERU(133LG;WDMFFMGU1SXNI.EAY2B]4>/_P##6O\
MU3__ ,JO_P!JH_X:U_ZI_P#^57_[57C=%?S5_P 11XZ_Z"__ "G2_P#D#P/[
M1QG\WX+_ "/9/^&M?^J?_P#E5_\ M5'_  UK_P!4_P#_ "J__:J\;HH_XBCQ
MU_T%_P#E.E_\@']HXS^;\%_D>R?\-:_]4_\ _*K_ /:J/^&M?^J?_P#E5_\
MM5>-T4?\11XZ_P"@O_RG2_\ D _M'&?S?@O\CV3_ (:U_P"J?_\ E5_^U4?\
M-:_]4_\ _*K_ /:J\;HH_P"(H\=?]!?_ )3I?_(!_:.,_F_!?Y'LG_#6O_5/
M_P#RJ_\ VJC_ (:U_P"J?_\ E5_^U5XW11_Q%'CK_H+_ /*=+_Y /[1QG\WX
M+_(]D_X:U_ZI_P#^57_[51_PUK_U3_\ \JO_ -JKQNBC_B*/'7_07_Y3I?\
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M:.,_F_!?Y'LG_#6O_5/_ /RJ_P#VJC_AK7_JG_\ Y5?_ +57C=%'_$4>.O\
MH+_\ITO_ ) /[1QG\WX+_(]D_P"&M?\ JG__ )5?_M5'_#6O_5/_ /RJ_P#V
MJO&Z*/\ B*/'7_07_P"4Z7_R ?VCC/YOP7^1[)_PUK_U3_\ \JO_ -JH_P"&
MM?\ JG__ )5?_M5>-T4?\11XZ_Z"_P#RG2_^0#^T<9_-^"_R/9/^&M?^J?\
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M/_)00])?D?05%%%?F1^V!1110 5\Y_\ !2'_ ))OX?\ ^PXW_HEZ^C*^<_\
M@I#_ ,DW\/\ _8<;_P!$O7Q7B+_R16,_PK_TJ)R8[_=)GQW1117\<'RP4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5[A_P3\_Y+]_W [G_P!"CKP^O</^"?G_ "7[_N!W/_H4=?4\#_\ )7X'_KY'
M\SHPG^]0]3[@HHHK^TSZP**** "BBB@ HHHH **** /'_P!I/_@H)^Q#^QYJ
MUEX>_:A_:J\#>!M2U&#S['2_$/B&&"[FAR1YJP%O,,>01OV[<@C.:YSX'_\
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M.._^1'_V_']3Q>BBBOT@_&@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KZV_X)Y?\D[UW_L-#_P!$I7R37UM_P3R_
MY)WKO_8:'_HE*\#B;_D42]5^9]9P3_R4$/27Y'T%1117YD?M@4444 %?.?\
MP4A_Y)OX?_[#C?\ HEZ^C*^<_P#@I#_R3?P__P!AQO\ T2]?%>(O_)%8S_"O
M_2HG)CO]TF?'=%%%?QP?+!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7N'_!/S_DOW_<#N?\ T*.O#Z]P_P""?G_)
M?O\ N!W/_H4=?4\#_P#)7X'_ *^1_,Z,)_O4/4^X****_M,^L"BBB@ HHHH
M**** "O-_P!K3]H>[_96^ VL_'&Q^!'Q ^)<ND26J+X-^%_AXZIK=]YUQ'"3
M!;!E\P1^9YC\C;&CMVKTBO,/VM_%W[5W@+X4#QC^QY\(O#/CWQ/IVJ137_@[
MQ)X@;2CJVG!7\Z&TN]K1P79;RRC3#RL!PV"00 ? 7C#_ (*J? KXA^([GQCX
M_P#^#:_]K+7-7O2IO-5UC]E2UN;F<JH12\LCEFPJJHR3@*!T%>B_L/?ML? +
MXN?M1>&/AYX*_P""$7QX^#.IZA]M^S?$KQG^SI:Z#INC^793RMYU]&=T'FJC
M6ZX^^\Z)T>I=2_X.*OV6?A"QT+]M+]F;X]?!'7X#LN]/\9?"^ZN+9Y!U-M=V
M/G1W,1/"R+@-UP*LZ/\ \%N?%G[4<@\+_P#!-+_@GA\7_B?J-R=D/B_QIH9\
M)^$K//\ RTGU"\S(^T?,88X3(X&%Y(H ^^:*Q_AY_P )]_P@&A_\+6_LC_A*
M?['MO^$E_P"$?\W[!_:'E+]H^S>=^\\CS=^S?\VS;NYS6Q0!\]?L%ZQ?V'P<
MU:"VT"XN5_X3C63YD1&,_:6XYKVW_A)=7_Z%"]_[Z6O(_P#@GO\ \D3U;_L>
M]9_]*37NE &/_P )+J__ $*%[_WTM?'_ .V]>7%]\:Q/<Z?);-_8\ \N4C/W
MGYXK[8KXO_;Q_P"2Z#_L"V__ *%)7TG"O_(T_P"W7^A\9QW_ ,B/_M^/ZGB]
M%%%?I!^-!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7U1^P1JU[I_@#6X[70Y[H-K )>(C"_NEXYKY7KZV_X)Y?\
M).]=_P"PT/\ T2E>!Q-_R*)>J_,^LX)_Y*"'I+\CVK_A)=7_ .A0O?\ OI:/
M^$EU?_H4+W_OI:V**_,C]L,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V**
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MUXQ7N'_!/S_DOW_<#N?_ $*.OJ>!_P#DK\#_ -?(_F=&$_WJ'J?9'_"2ZO\
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MO#'B":*XU[PY87LD!S!)=V:2-&<Y^4L#C\*O@ # & .@HHH<I-)-[ %%%%(
MHHHH **** "BBB@ HHHH *]P_P""?G_)?O\ N!W/_H4=>'U[A_P3\_Y+]_W
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MO_2HG)CO]TF?'=%%%?QP?+!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7N'_!/S_DOW_<#N?_ $*.O#Z]P_X)^?\
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MLNQEW*#M<8(]C[U\N?!3_@EC^S1\,OCQXD^*>I_"6SU"V@U>PN_ *ZOX@O\
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M_(HEZK\SZS@G_DH(>DOR/H*BBBOS(_; HHHH *^<_P#@I#_R3?P__P!AQO\
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M]J8]%;%%'_$KG_4W_P#+?_[L'^MO_3G_ ,F_^U,>BMBBC_B5S_J;_P#EO_\
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MX_\ 0HZ\W./^176_PL]GA[_D>8?_ !K\S[0HHHK\E/W\**** "BBB@ HHHH
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M(_%#_H6/_)V#_P"+H_X4C\4/^A8_\G8/_BZ/]9>'/^@RE_X,A_F']BYS_P!
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M^A8_\G8/_BZ/^%(_%#_H6/\ R=@_^+H_UEX<_P"@RE_X,A_F']BYS_T#5/\
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M/XM^.IHM<U:!I]/\/Z/I%UJ-]+ I(:8P6L;ND8(;YV 4E6 )((KQ;]M>*W\
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MQ_R*ZW^%GL\/?\CS#_XU^9]H4445^2G[^%%%% !1110 4444 %%%% !1110
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MQOIVBO90",D7#2WS*LN6 7:OS9;/2O4S).K4IVG[S6SFFE[JUYKV5]=^U^J
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MVN_AO^W/^S'X<_:4^%^DW.F6.N),E[HU\H%QIE]%*T5S;28X++*K8; WJ5;
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M^'_T UW5<+\>?^0#9?\ 7X?_ $ UY.>_\BFKZ?J@/+:***_+0"BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>I? ;_ ) -[_U^#_T 5Y;7J7P&_P"0#>_]?@_] %>]PU_R-H^C_(#N
MJ***_2@"BBB@ KA?CS_R ;+_ *_#_P"@&NZKA?CS_P @&R_Z_#_Z :\G/?\
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M?\12_P"H3_RI_P#:'[P45^#]%'_$N_\ U,__ "C_ /=0_P"(I?\ 4)_Y4_\
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MR,JU>CAJ3J59*,5NVTDO5O0P**\'_P"'FG[$/_1;/_+;U+_Y&H_X>:?L0_\
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M -CFG_I)%7Y+5^M/_!O3_P F]>._^QS3_P!)(J^&\1?^26J?XH?^E(^T\/\
M_DIJ?^&7Y,_0.BBBOYT/Z "BBB@ K\_/^#A;_DWKP)_V.;_^DDM?H'7Y^?\
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M_9ZBBBOY</Z6"BBB@ HHHH **** "BBB@ HHHH **** /"_^">__ "1/5O\
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MH7_PX)_:/_Z'SX6?GK'_ ,51_P ."?VC_P#H?/A9^>L?_%4?\12X?_Y]5?\
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MH7_PX)_:/_Z'SX6?GK'_ ,51_P ."?VC_P#H?/A9^>L?_%4?\12X?_Y]5?\
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M_H?/A9^>L?\ Q5'_ !%+A_\ Y]5?_ 8?_)A_Q#3/?^?E+[Y?_('YZ45^A?\
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M0+/QG:V=C=0G3)YK1DC1C/$@<LUK<#*%A^[.>HS]0T ?'O@C_@F%\./VC_\
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M8?%^_P#&47A#5]'M/$UEH?AOQA=:5'?Q7UG'(D5VUJR/,BI(,+N !)-?'O\
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M1;_QOH7P8^+_ (9^*%W9Z%9N]QJGA5DW7$T$3 .6\F6&7! *Q^8S ;3CRO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ^J_$"/Q_P#%.P\''2M"U(07MN;F"YE$UO$8I!=S9MPB6Y:(.T@_>+BO-O\
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M-^)_Q7FO]1U[XK:7I>GSV$437<R06NBO)KD#V5O;HJH@2.-E=7'W0JC]._\
M@B+'^UKI'[!6D^!?VR?#'C'3O$7A?Q'JFDZ#)\0?+_MN\T&.<MITUX8W=6F$
M#K$Q#MGR<EF.6(!];7-S;6=N]W>7"111(7EED<*J*!DDD\ #UJ#1]<T3Q#9C
M4= UBUOK<L5$]G<+*F1U&Y21FO@G_@NW^SC\<_CI#\$_%/A_]G;7_C7\(_!?
MC.^U#XS_  6\,:\+*]\26SV@2PG5#)&+M;6?=(;;=F0NHQMW,G,?\$VO#O\
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M>_>ZN+#0[S0YKF#2VF<EI%MB&0%B2-VW@*H'K7[#/["W[,?[&O\ P2]\'?\
M!3JS^&K>+_CEX6_9L'B^U\>^(M2NKJ^\W_A&&=+"(-+LBM([=Q:1P(H18T4X
MWY:@#]+9]=T2UU6'0KG6;2.^N$+P6<EPHED49R50G)'!Y [5:K\FOV /^"*G
M[''[;G_!,;PQ^TG^T[I>H^+/C=\8_"W_  EFL?&O4M=NCKFF:K=AIK::UF60
M"W6US$%B4",^3\RD$BO)K+]L+]H;]O#_ ((U?L0?!_XJ_%36=/F_:&^-=O\
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M2A<ALN#@8P<\\8I^DZQI&O62ZGH>JVU[;.2$N+2=9$8@X.&4D'FOSR_X* _
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M;VRG5+S49;C[&FE)&&*FX%V&@;!*J4=\E5S0!]645^:'[5G_  6O_P""@?[
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MIEA-<VLS+':V4SV6ZXN9(0DSAD2*W$T0:1R_R^F:9_P6;\">*/\ @E?\0/\
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M=7^-?Q:T/P?X?UWPK\5(M3TBVAOIQ#<32RBR$BW=LTD!%JR!+A'D9+A?*84
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M8ZYK4/[-/B:YU'XP>'-)T][N_P!$TS6XYC-=&! 6D-AYJ*ZIDJ03]U68:?\
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M%FH7/B'5-#TS[3;RV\DEO=?9Q;QO/' KS*LNS=C:Q(CD^C/^"]?QC\3?";X
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M?$J1EA\::%\-8[&R\/6F;1DLX;%+H-<JKV\K^9+.'8W)&0J*M>A_M=?L3_\
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M_P#BG3;O4=%U;Q(LB$ZC_P )%8W3LAGN5\[:^(HP^"Q0%J^H_P!I+X3^'/\
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M4G&>W2@"Q17G?_"^_P#J5/\ R>_^UT?\+[_ZE3_R>_\ M= 'HE%<KX&^)O\
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M+F3<NZ-L,NX9 S6I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6=XO_Y%+5/^
MP=/_ .BVK1K.\7_\BEJG_8.G_P#1;4 >$4444 =G\#?^1MN/^P<__HR.O5:\
MJ^!O_(VW'_8.?_T9'7JM !1110 5\;_\%V_VT/BU^Q)_P3ZU;Q?^SW<1VWQ$
M\;>)--\%^!=0E"E;'4-1E*?:<,""T<*3,F00) A((!!^R*^,_P#@O+^QM\7/
MVT?^">^J^&_V>;!+WXA^!/$VF>-O!&EN!C4+[3I&8VPR0-[PR3J@) 9RBD@$
MD ''^!?^#;7_ ()BP_"!/"WQU^%6I?$/Q]J%JLWBGXN^(/%.H-X@U'52H+WZ
M7(GS PD^9%7Y0%4,'.XMX#^S[^U5^VA\,OV#_P!N+]@W7-2U'XJ_$']EU;S2
M/#GBO6O%']FZE>>%M1LKF2SOY[MDD+W=K:PW$X_BE\N.(.IQ)7T+X _X.0?^
M"6VI?!0?$#XR_'%OA]XPTZT$?BOX5^(]$O4\0:5J:C$M@+3R=\[B3*JR J<@
MDKR%\I_X)^?LO_M(_&+]F3]MG]N/XH?"75O"GBW]KFUU1_ _@+6(/+U&TT2V
MTJ\M-'6Y0\QSR"Z8%"!PJ-T<  '>_P#!%G]H?]OGXH?L-_"SP_\ '3]D.ST_
MP(WP:MYK'XOW/QBBU74-<=;1/)EFTXVBRQ-,"S,6G<H1@ELYKYB_X(E?MQ?M
M^?#K_@C/\-K;]D#_ ()K2?$SPS\/M-UK_A(_$.O?$6WT)]6F75;ZZEM])MF@
MFDN_+CE5#,VQ3,'B179&Q])_\$0?^"A/[(7Q'_80^%O[#GAWXOPK\7O!7PB2
MP\4_#Z_TRZMM1TV:P@$%RLB2Q*!M?'?D,,5U'_!LLB+_ ,$./@0H4 '3]<R
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M;-,UFXL/B/<>!?&5[HKZGJ5D3!YESI=Q"T.IK\@.8%(F!W;BS%J /M;X[_\
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M%\4-7UV^92QBMH(["1RJCEV(7"H.68A1DD5/=_\ !:#]N[P]^S];_M_^,O\
M@DQJ-E^SS/:1ZM-JL'Q,MI?%=IX?D(*:S)I/V<)Y9B993")]RHV\OL!>O#/@
MG^SK\1?VL?\ @F)_P4]^ 'PCLY+KQ-K_ .V5\3?[#L8FP][<0/I=RELI/&Z4
MP^4,X&9!D@<UV/Q2_P""W7[#GQ _X(_:G\"O"'B*6_\ C3XG^$4W@"S^ D&@
MW+>((O$<^G'3FT]['R]XCCF9B7/RM&AVDL0I /IG]O?_ (+$^"/V-?!WP%^(
M_P .O@KJ?Q9T3X_:W#8>%&\+:H(;N=;FS6XL7MH7A87+W#2PQJC/"%\P,S@
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M^GW=Q:1RW5A)*LC6TC*"T19>&*DE<C@XR*_"_P"/OQ4_X)&?!7X*^,OVF/\
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M1/\ 57!!_*K=% %31-!T/PSID6B^'-&M-/LX!B&TL;=8HHQZ*B@ ?@*MT44
M9)\!>!CXF'C4^#-)_MD+M&K?V=%]J QC'F[=^,<=:UJ** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *Y;XY_\D2\8_P#8JZA_Z325U-<M\<_^
M2)>,?^Q5U#_TFDH _-RBBB@#WW_@G3_R6W5/^Q5G_P#2FVK[/KXP_P""=/\
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M7B;4=0TC3[71_$'A:27R]1L=3$6LW+7&8V#K(T;.K)NW X([S]O[]G<^%_\
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MBG)<..20N2<<S? ?]E3X(?\ !6;_ (*7?M3_ !,_;S\'0_$#1?@WXTM/A_\
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M"15;^T+POGS"H(@(7<0P2, _3[5-6TK0[%]3UK4[>SMH\>9<74RQHN3@99B
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M9>"#K>CZQ=6D?DVVIPK'<026URD1*, VR0G<V"3G[4HH ^/O^"<W_!*WQ/\
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MJ^<UFL!21F;<V FS3L_^"=\?P^_X**2?M]?L^?%L>#8?%WA[^ROC+X 7P_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-20210331_g13.jpg
<TEXT>
begin 644 biib-20210331_g13.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
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MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+
MB9G8*+D@+EB> .@[5[;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#D
MB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[
MI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO
M_@GO_P D3U;_ +'O6?\ TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/7[!
M>L7]A\'-6@MM N+E?^$XUD^9$1C/VEN.:]M_X275_P#H4+W_ +Z6O(_^">__
M "1/5O\ L>]9_P#2DU[I0!C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL5Y
MS\4?'GBOPYXG_L[1M5\F'[,C;/(C;DDY.64GM7%C\=1RZA[6HFU>VG_!: Z[
M_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:\N_X6U\0?^A@_P#)2+_XBC_A;7Q!
M_P"A@_\ )2+_ .(KQ?\ 6S+OY)_<O_D@/4?^$EU?_H4+W_OI:/\ A)=7_P"A
M0O?^^EKR[_A;7Q!_Z&#_ ,E(O_B*/^%M?$'_ *&#_P E(O\ XBC_ %LR[^2?
MW+_Y(#U'_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:\N_X6U\0?^A@_P#)2+_X
MBC_A;7Q!_P"A@_\ )2+_ .(H_P!;,N_DG]R_^2 ]1_X275_^A0O?^^EH_P"$
MEU?_ *%"]_[Z6O+O^%M?$'_H8/\ R4B_^(H_X6U\0?\ H8/_ "4B_P#B*/\
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MEU?_ *%"]_[Z6O+O^%M?$'_H8/\ R4B_^(H_X6U\0?\ H8/_ "4B_P#B*/\
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M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\
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MXV?\CI_VYQ_S:OG.*/\ D6?]O+]0.0HHHK\Z **** "BBB@ HHHH ***\O\
MVR_VK_A[^Q)^SCXC_:3^)NGZA?:;H$<*Q:9I,0>ZO[J>9+>WMXE8@;GEE1<D
MX4$L> :J$)U)J$5=O1 >H45\'_LU_MA?\%,?$_[4'C_1_'G["$+^'_\ A+O#
M]IJ^DP_&&TGNO ]M<:;:,TBQ-;)'>+LD-S*D4@8,SHOF$ MJ?\%8_CO^T[X
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MM8KNP2#]%UEB*M*5*%*G=J-]6K7;\KOLNH!1117( 4444 %%%% !7J7P&_Y
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M>L_^E)KW2@ KR+XV?\CI_P!N<?\ -J]=KR+XV?\ (Z?]N<?\VKYSBC_D6?\
M;R_4#D****_.@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "O4O@-_R ;W_K\'_H KRVO4O@-_R ;W_K\'_H KWN&O
M^1M'T?Y =U1117Z4 4444 %<+\>?^0#9?]?A_P#0#7=5POQY_P"0#9?]?A_]
M ->3GO\ R*:OI^J \MHHHK\M **** "BBB@ HHHH *@U*^73-.N-2:VFF%O
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ML8X?-;U;8!N/N:T:QJXFC*-.G&+Y(MO5ZN]KZV5MNWF!\G?\$6?V<O$O[/\
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MT:\8*$6N56U:>G_@*[@%%%%<8!1110 4444 %=?\$_\ D=/^W.3^:UR%=?\
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M&O)SW_D4U?3]4!Y;1117Y: 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5U_P3_P"1T_[<Y/YK7(5U_P $_P#D=/\
MMSD_FM>CE'_(SH_XD!Z[1117ZN 4444 %%%% !1110 445PW[1?[2WP$_9(^
M%.H?&_\ :3^*ND>#O"NF%5NM7UFXV(9&SLBC4 O-*V#MBC5G8C"J: .YHK\_
M=2_X+>?&OXE.=2_8J_X(\_M#_$W0#S9^*]<TB+PMI^I1]1-:M?9DEC(Y#-&A
M[8K2\'?\%X/AQX+UJU\.?\% _P!C?XS?LUF\N%@M_%/Q#\*-/X9>5B L?]K6
MF^*-B>ID5$4$$N > #[PHJKH6NZ)XHT2S\3>&=9M=1TW4;6.ZT_4+"X6:"Z@
MD4/'+'(A*NC*0P8$@@@@X-6J /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(
MGJW_ &/>L_\ I2:]TH *\B^-G_(Z?]N<?\VKUVO(OC9_R.G_ &YQ_P VKYSB
MC_D6?]O+]0.0HHHK\Z **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *]2^ W_(!O?\ K\'_ * *\MKU+X#?\@&]_P"O
MP?\ H KWN&O^1M'T?Y =U1117Z4 4444 %<+\>?^0#9?]?A_] -=U7"_'G_D
M V7_ %^'_P! ->3GO_(IJ^GZH#RVBBBORT HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KK_@G_P CI_VYR?S6N0KK
M_@G_ ,CI_P!N<G\UKT<H_P"1G1_Q(#UVBBBOU< HHHH **** "BBB@ K)\6>
M ? OCT:</'/@S2M9&CZG'J6DC5=.CN/L5Y&K*ES%YBGRY55W D7# .V#R:UJ
M* /#O!G[>WPE\6>.?CWX=O-)U/2M%_9YG@A\9>++\1_8KASI:ZG<B (QD(MX
M'02%U7YFPNX#-?.O[''_  68O?VR?BIX,^#_ .T%_P $^O%7PQ\$_';1-1N_
M@EXJ\5ZQ9ZE9^-;.WM_M$L5Q:QH#8O):;IDCD,BRH#M9@5+<;^V=_P $M?\
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M_P#0#7=5POQY_P"0#9?]?A_] ->3GO\ R*:OI^J \MHHHK\M **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z_X)_\
MCI_VYR?S6N0KK_@G_P CI_VYR?S6O1RC_D9T?\2 ]=HHHK]7 **** "BBB@
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M?\C:/H_R [JBBBOTH HHHH *X7X\_P#(!LO^OP_^@&NZKA?CS_R ;+_K\/\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]2^ W_(!O?\
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M"?\ R.G_ &YR?S6N0KK_ ()_\CI_VYR?S6O1RC_D9T?\2 ]=HHHK]7 ****
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M_#_Z :[JN%^//_(!LO\ K\/_ * :\G/?^135]/U0'EM%%%?EH!1110 4444
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M:UR%=?\ !/\ Y'3_ +<Y/YK7HY1_R,Z/^) >NT445^K@%%%% !1110 4444
M%%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q
M[UG_ -*37NE !7D7QL_Y'3_MSC_FU>NUY%\;/^1T_P"W./\ FU?.<4?\BS_M
MY?J!R%%%%?G0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_5 >6T445^6@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %=?\$_\ D=/^W.3^:UR%=?\ !/\ Y'3_ +<Y/YK7HY1_
MR,Z/^) >NT445^K@%%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM
M_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !7D7QL_Y'3_MSC_F
MU>NUY%\;/^1T_P"W./\ FU?.<4?\BS_MY?J!R%%%%?G0!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7J7P&_Y -[_
M -?@_P#0!7EM>I? ;_D WO\ U^#_ - %>]PU_P C:/H_R [JBBBOTH HHHH
M*X7X\_\ (!LO^OP_^@&NZKA?CS_R ;+_ *_#_P"@&O)SW_D4U?3]4!Y;1117
MY: 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5U_P3_P"1T_[<Y/YK7(5U_P $_P#D=/\ MSD_FM>CE'_(SH_XD!Z[
M1117ZN 4444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_ &/>L_\
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MKNJX7X\_\@&R_P"OP_\ H!KR<]_Y%-7T_5 >6T445^6@%%%% !1110 4444
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M_P $_P#D=/\ MSD_FM>CE'_(SH_XD!Z[1117ZN 4444 %%%% !1110 4444
M%%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKX^^!W[8_[-'['>@ZQ\&OVE
M_BO9>$O$Z>*-0U!]'U"VG>5;:XF,D,A\J-@ Z$,!G."..:[7_A[=_P $Z/\
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M%'_1PFB_]^Y__C=']FYC_P ^9_\ @+_R ]IHKQ;_ (>*?L4?]'":+_W[G_\
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M4R_83\.>)_[1UG]H_188?LSKO^SW+<DC PL1/:N_*\!CJ>8TI2I224EJXO\
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M &:?^C>/ O\ X25G_P#&J/\ AE_]FG_HWCP+_P"$E9__ !JNYHH X;_AE_\
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M_P!FG_HWCP+_ .$E9_\ QJNYHH X;_AE_P#9I_Z-X\"_^$E9_P#QJC_AE_\
M9I_Z-X\"_P#A)6?_ ,:KN:* .&_X9?\ V:?^C>/ O_A)6?\ \:H_X9?_ &:?
M^C>/ O\ X25G_P#&J[FB@#AO^&7_ -FG_HWCP+_X25G_ /&J\5_:?_9_^ VC
M_&'X-6.D_!+PC:P7_C66*^AMO#=JB7$?V=CLD"Q@.N><'(KZCKF_&_PI\(_$
M'Q%X<\4>(X9VN_"VI-?:289RBK,4*$L/XA@]* ,K_AE_]FG_ *-X\"_^$E9_
M_&J/^&7_ -FG_HWCP+_X25G_ /&J[FB@#AO^&7_V:?\ HWCP+_X25G_\:H_X
M9?\ V:?^C>/ O_A)6?\ \:KN:* .&_X9?_9I_P"C>/ O_A)6?_QJC_AE_P#9
MI_Z-X\"_^$E9_P#QJNYHH X;_AE_]FG_ *-X\"_^$E9__&J/^&7_ -FG_HWC
MP+_X25G_ /&J[FB@#AO^&7_V:?\ HWCP+_X25G_\:H_X9?\ V:?^C>/ O_A)
M6?\ \:KN:* .&_X9?_9I_P"C>/ O_A)6?_QJC_AE_P#9I_Z-X\"_^$E9_P#Q
MJNYHH X;_AE_]FG_ *-X\"_^$E9__&J/^&7_ -FG_HWCP+_X25G_ /&J[FB@
M#AO^&7_V:?\ HWCP+_X25G_\:H_X9?\ V:?^C>/ O_A)6?\ \:KN:* .0T3]
MGSX!^&=6M]?\.?!#PAI]]:2"2UO;'PU:Q30N.C(ZQ@J?<&NOHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX<^)?_!6
M7XV_$[]IGQ?^RA_P3&_8N?XU:M\-KL6/Q*\;ZWXTA\/^&]!U#G.GI</%*]Y=
M*5*O'&H\LYR3M;'W'7YL?\&JOV9_^"7]]/K# ^,I/C!XH;XCE\>=_;?VI?,\
MWOO\C[-][G&/:@#V3]D7_@JCXF^)/[44W[!7[;G[+NH_ WXTR:*^L>&M$N/$
M4.L:1XLT]-WF3Z;J$*(LKH$=G@9 Z*K<DI(%P?\ @J'_ ,%9_P!HO_@GI!XG
M\3^ _P#@F7XP^)/@[P9H=MJGB/X@S>,[/0]'@CE8*8XWDCFEGD1F565(B<M]
M37F__!;)0O\ P4A_X)[3>"_+'C+_ (7I>+;F(XN/[$,-K_:G3GR_)V[NWZUZ
MU_P<._\ *%S]H#_L3XO_ $NMJ /J_P"$_CK_ (6A\+/#7Q+_ ++^P_\ "1>'
M[/4_L7G^;]G^T0)+Y>_:N_;OQNVC.,X'2L_]H7XK_P#"A_@%XX^./]@_VK_P
MAG@_4]=_LO[5Y'VS[):R7'D^9M?R]_E[=^UMN<[3C%4/V3_^36?AI_V3_1O_
M $AAKI_B%X"\)_%7P#KGPO\ 'ND_;]"\2:/<Z7K5CY\D7VBTN(FAFCWQLKIN
M1V&Y6##.00<&@#YT\2?MZ_M":[^PM\'OVK?V8_V$]:^)WBOXO^'=#U2U\ :9
MXPMK&#0TU#2_M[/=ZG<Q+&D$61"9?*!=G3"#=@>:_#;_ (*P?M0?#']JCX?_
M +*W_!2W]@M/A%+\6KR73_AQXV\,?$"#Q%I-[J:*&_L^Y\N&-[65@5",=P=G
M4 !0S+]B?#_P-\+?V:_@IHGPU\'6]MX<\$^ /"UMIFE17FHNT.EZ58VRQ1+)
M/<.S%(X8E!DD<G"EF8G)K\^O =UXC_X+@?M[> ?VIO"NERZ;^RY^SAXJNM1\
M!:_=1%)_B5XLC_="^ME8 IIMHRG9*<>:ZL!NW,( #Z+_ ."BO[>_[1/[&-I'
M/\"/^">?C+XSQQ>&[S6M:U?3/$=IH^E:1;VP9G6XN[@/B38K.$6-B5'&20*]
M$_8#_:M_X;D_8V^'O[6W_"!?\(O_ ,)YX?34_P#A'_[4^V_8=SLOE^?Y47F_
M=SN\M>O2M#]MW_DR_P"+W_9+]?\ _3=/7A__  0(_P"4-O[/?_9/X?\ T=+0
M!]?T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5\J_MZ_\ !3VR_9/^*WA#]D_X#_ /6OC-\=/'UI)>^&?AIH.IQ6"0
M:?&65]1U"]F#1V-J&1U$C*VYD8 8!(^JJ_-C]D3[-)_P<U_M;MXZ8'68_@_X
M/7P&)\;QHAM;0WWE9YV?;MF['&X\\T =9J?_  5X_:@_9*^('A;1O^"K'[ \
M/PE\#^,]9BT?2?BSX0^(<'B+1=.U&7/E6^I*L$,MDK8($Y#)U_A5V7Z-_;;_
M &H/CK^S1X5T.]_9[_8G\7_&[7==OY+9-&\+ZI:V$-@JQ[A-=75R=D,;'"@X
M.3GTKQ/_ (.-(_!$G_!%;X]#QZ+7[*/#5J;/[5C OO[1M?LNW_;\_P K&.]?
M1?[$;>-F_8P^$3?$HRGQ&?AAH!\0&<G?]M_LZ#S]V>=WF;LYYS0!YW_P2H_X
M*!:M_P %*_V5C^T=KWP/_P"%>7T/BS5-"O?#'_"2KJWD2V4WE.WVE8(%;+9X
M"8&.&;K7TG7YX_\ !LG_ ,HZM>_[+AXP_P#3@:_0Z@#YJ^"'_!0;6_C?\-?V
MB_'/AK]G35KW4?@+\4_$7@NP\,:#JRWM[XMFTNRM+E'@#11""2X:Z$2PDN%*
M@F1MV!\^?%G_ (*Y?\%,/V5/ 4G[3?[8G_!'67PO\(;">%O$^H^&OC+I^M:[
MX>LY)%C%W-91P(LP!9=R)(-F[YF 4FON#X*_LX?!C]G>Y\9W?P=\&_V/)\0?
M'%YXP\7M_:-S<?;]:NHX8Y[K]_(_E;DMX1Y<>R,;,J@))/P[_P %0/C3XU_X
M*2^/=:_X(J_L07T-S<ZC';K^T=\3E EL/ >AM*K/IZG[L^IW(0HL /R+OW;?
MG>$ ^F?VSO\ @HU\#_V.?V-X/VRM0M[_ ,6:7KR:;%X!T3P]'F[\4WVHA386
MML&'WI0V_)&517;:Q&T^*>"/^"K'[5OPG_: ^&WP<_X*5?L!P?!W2/C)K T7
MP!XQT#XD6_B&T@UN1-\&D:B(X(C;SR_=212Z._ &U7=/._\ @LI\./"/P@U[
M_@GK\'M$M'M_!'A?]JKP?I%E;3ONCC-K;/#IZ.3P6 0@$]?FK>_X.80I_8F^
M&KZ<"==7]I+P6?"WEX\S^T/M4NSR\_Q^7YN,=L]LT ?HE1110 4444 %%%%
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MOJ3>?+YLT7+)%&%17.00I='^[Z* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
D@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-20210331_g14.jpg
<TEXT>
begin 644 biib-20210331_g14.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^1/^"D/_!27XY?L;?'W
MX'_LQ?LW?L71_&?QI\</^$E_L72I?B1;^&UM?[&M;6[FS-<6LT;[H9Y6^9H\
M>1@;RX Z+]CW]IW_ (*1_&3XI7/A7]KC_@EQ:_!?PQ%HLMS;>+(/CII?B4SW
MBRQ*EI]EM;>-U#H\K^:6VKY.TC+C'S#_ ,%G=!^/_B;_ (*X_L!Z)^RY\0/#
M_A;QW/\ \+4_L+7O%.B/J-A:XT"Q:;S;=)(VDW0"5%PXVLZMR%P?J;]GO1?^
M"C7P5\/>-O'7[;?Q_P#AU\0K+3_#SW?A[3O W@:?1I(IX4DDD\UY+B;S ZA5
M  &#D\YH ^A[S7=$TZ_M]*U#6;2"ZNR1:6TUPJR3$==BDY;'M5JOR-_X)6_\
M$HOV1?\ @IQ_P3TT_P#;?_;Z\*S_ !*^+OQR?5-7UOQ_>ZS<K>Z'_IUS#:VV
MF,LFVR2V6)"B(N V5(*!4'B_QC^/'QT_:#_X-4O&VE_%+X@77B'Q?X$^+%AX
M)MO&-^_F3:JNG^+M/BM+J1FSYC"-HD+MDN8MS%F+$@'[HIK&D2ZH^AQZK;->
MQQ"62S6=3*B$X#%,Y"Y[XQ7CO_!0O]MSP7_P3M_91U_]K+X@^#=4U_2O#]]I
MMM<:7HTD:W$K7E]!9H5,A"X5YU8Y/13CFL?]D#_@F#^Q]^Q1XGE^*?PB^'4L
MOQ"U31'T[Q9\1];U:ZO=9\1^;+%/<3WDTTC>9)+/"DIX 4C:@5?EKY<_X.KO
M@U\,/B)_P25\2?$'QIX/MM0UGP=XGT&;PS?S,X?3WNM8L;2X9,$ [X)'C.0>
M&.,'F@#ZX_X*1_M2^)_V)OV%_B;^U=X,\-6&LZIX&\-2:E8Z7JCNMO<NKHNQ
MS&0P'S'H<UZ!\'?BC:?$;X:>$/%>KW-C::MXF\+6.KOI<5P-R^=;I*VQ6.XH
MI8C/MS7P/_P4\_X)X_L6_L%?\$;?VI?^&0?V?]'\"_\ "5_#^+_A(?[)EG;[
M=]EF/D;_ #9'QL^T38QC_6'.>*\7_;-_X)*?LG?"#_@BS>_MJ>%=*UH?'SP9
M\+]*\::=\;)/$=X=>&KV\-O/O67S=J0[=T*0*HCBCVA%!16 !^QQ( R3572-
M<T37[=KS0=8M;V))"CRVEPLBJPZJ2I(!'I7Y-_\ !77]I'QW\;/'W['/['_C
MSX=_$OQEX$^+GAB_\7_%KP1\'_*AU;QBEGIL$T6FH7NK4"T\Z626XC$RDQJI
M7YD4UC_"GX-W7P@_;Y^!WQ7_ ."9?_!);X_? '39O%*Z%\;[?Q)I%A9>'-:\
M,SQ&/S[B&WU6ZW7-K+LF201JQ^8L[8 (!^LGQ<\1_$#PA\+?$7BKX4?#=?&/
MB?3=%N;GP_X3?68].&L7B1,T-H;J562V$CA4\UE*INW$$"OSJ^/'_!:K_@J=
M^S3XJ^'_ (*^,G_!#*STO4OBAXOA\,>"8(_VHM(N!?ZI*I9(2T.G,(00#\\A
M5!W-?IO7YX_\%P_^3G_V#O\ L[#2O_1+T :'QH_X*>_\%*?@#^QI\9/VH?VC
M_P#@EQHWPJ?X=>%(-3\,_;OC38^);?6[I[N*%[>2.PAAD@"I(7WEB"0!7VS\
M-OB'8>-?!OAS6-2O;*WU37/#UKJ3:9'<#>!+"KL50G<4!)&?:OE7_@X=_P"4
M+G[0'_8GQ?\ I=;5\A_\%!/^"3?[*GP&_P"".FJ_MM>#-,UE/V@? _@;1_&%
MC\;G\07C:]+K$1MI'E,AEVK$P+QK %$4494(J[%P ?L75;3]8TC5FG32M5MK
MDVTQBN1;SJYBD'5&P?E;V/-?E?\ \%=_!]S^V/\ %O\ X)W>&?%?BO5M!7Q_
MXQNYM?O?#5^]G="WGT.&:[@AFC(>'S8C+#O0AE$I*D$ U5_X*]_"#X0?\$TO
MV8OAI^R5^P1\$_$/@C0?V@OCKH^@?$6R^$EPPUW5]+6!VN;2QDN;A M[<I%'
M")&E3<N]6)#&@#]6-.U_0M7N+BTTG6K2ZEM)-EW%;W*NT+<_*X4DJ>#P?2IK
MZ_L=+LY-0U*\BM[>%"\T\\@1$4=26/ 'N:_$GXH?L_>'_A+JWP[^+?\ P28_
MX(G_ +2WP4^*O@CQCIDIUR[TG3[;3==T/SU74=.U5H]:N7NHY8"QW/&[[T7Y
MU!)KL?V[?B/H?[5__!:7QS^S=^T]^QY\9OCO\+/@=X"T2;0?A9\,;6UFTV;6
M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
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MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+
MB9G8*+D@+EB> .@[5[;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#D
MB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110
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M_L[3_P#GQA_[]"C^SM/_ .?&'_OT*^>:*/\ 6_\ Z<?^3?\ VH'T-_9VG_\
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M_GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\
MOT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM
M/_Y\8?\ OT*/[.T__GQA_P"_0J:B@")+&RC8/'9Q*PZ%8P"*EHHH **** "B
MBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]
MCWK/_I2:]TH *\B^-G_(Z?\ ;G'_ #:O7:\B^-G_ ".G_;G'_-J^<XH_Y%G_
M &\OU Y"BBBOSH HHHH **** "BBB@ HHHH *JZ+K>C>(]+@USP]J]K?V5RF
M^VO+*X66*5?[RNI(8>X-?(?_  4K_:L^,_PT_:%^!O[)/PJ^->C_  FM?BW>
MZR=9^*NMZ3;WG]G+86\<D=E:I=G[-]IN'E" R@@?+M5F.*S_ /@C?\&_VE_!
MO[.OP_\ 'OBS]L*[\7> =4\#$6/@/5/!FGP2:5<F93'+#?VRI))&%653'*K9
M\P$,-N#V?4W'"^VE)*^RUUW7:VZ?7UMI</LW5-8TC1+87FM:I;6<)<();J=8
MU+'H,L0,GTJR"",@Y!Z$5^:7P2_9S^"W_!2S_@I-^T]>?MT>'U\;_P#"I_$>
MG>&OA_X%UB]F6QT+2Y+=Y#>);HZAI+EDW^:P)X.#C;CI?^"1?Q"'PT_:F_:A
M_P""<'P\\8W&K>#/A%XDL;KX9)JFH2WG]CV]Y YN-+$KLSF"VN$5%4DL,R9.
M:UJ8",*<FI7E%1DU;2TK;.^MKKHNMM@/OZZUW1+'4(=)O=8M8;NY_P"/>UEN
M%627_=4G+?A5JOQ ^!'@3_@E5;?LO^.8_P#@K]>O'^U,-7UD_$$^+=0OAXD^
MW&>7^SVTE%;][&;?[*T)@#1LS=TP*_33_@DII7[2VB?\$Y_A5I7[7O\ :G_"
MP(= D&L+KC,;U(?M4QLTN-WS><MF;8.'^<,&#?-FGC, L+3<E)NSMJK)Z-WB
M[NZ\]-UW ^BZ*\X_:F_9>^'_ .UY\+3\'OB?KWB6QT:348;NZ'A;Q!-IL]SY
M>[]R\L)#F)MWS*",X'/%?'?_  0>^%7@CX&^.?VL?@]\-=+DLM \-?M"7FGZ
M1:37DMP\4$5NBHK2RLSR' Y9F)/<UST\/3J8:=3FUC;2W1NV]_T _0NBBBN4
M HHHH **** "BBB@ KU+X#?\@&]_Z_!_Z *\MKU+X#?\@&]_Z_!_Z *][AK_
M )&T?1_D!W5%%%?I0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_P"">_\
MR1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH *\B^-G_ ".G_;G'
M_-J]=KR+XV?\CI_VYQ_S:OG.*/\ D6?]O+]0.0HHHK\Z **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]2^ W_ " ;
MW_K\'_H KRVO4O@-_P @&]_Z_!_Z *][AK_D;1]'^0'=4445^E %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_(!O?^OP?^@"O+:]2^ W_(!O?^OP?^@"O>X:_P"1M'T?Y =U1117Z4 4444
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M^19_V\OU Y"BBBOSH HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7P^_Z&#_ ,E)?_B*/[2R[_G]#_P)?Y@='17.?\+:^'W_ $,'_DI+_P#$4?\
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M_#>G^#O!^@V>E:1I-C%9:7I>G6RPV]G;1($BABC0!8T1%5550    ,"KU%%
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M_!P7_P $C=4DACT_]JB\E-PRK"4^&OB3#DG P?[.Q^-72PV)KINE!RMV3?Y
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MQ_S:OG.*/^19_P!O+]0.0HHHK\Z **** "BBB@ HHHH **** "BBB@ HHHH
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M*@?'G_@H%?$W7ACX?LOPG^%DK?-&RVK";5;F/L0]PR[)%ZI,RYXKZN_:YO\
MX\Z%^RSXW?\ 9=\(3>(OB(?#-Q;>#=/&HV]LS7\B>5%,TMS)'$!$7\YMSKN$
M9 RQ /+_ /!-C]DV#]B/]B+X>_LY30QC5=&T-9O$TT;A_/U:X8W%X^\$[QY\
MDBJV3\BH.@%>?1G&CA*DD_>E[J[VW;_)?-@>._\ !>OP1X+M/^"5WQS\;VGA
M#2XM:N_#^GQW6L1Z?&MU,BZE9JJO*%WL . ">!Q7U9\#_P#DBO@__L5M/_\
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MS\7;_1=6^%?Q8U[1II=/U;0(-+M[9])ANXXW^S-;W$4F^)M@<LC'/[O+[O\
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M^TV%RLL?V5!N7IG)KYSBC_D6?]O+]0.7HHHK\Z **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]2^ W_(!O?\ K\'_
M * *\MKT?X+:YI&E:+>1:C?QPLUT"H<]1M%>]PU_R-H^C_(#T6BLW_A,?#'_
M $&H/^^J/^$Q\,?]!J#_ +ZK]* TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M\/\ Z :\G/?^135]/U0'EM%%%?EH!1110 4444 %%%% !1110 4444 %%%%
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M_#_Z :[JN%^//_(!LO\ K\/_ * :\G/?^135]/U0'EM%%%?EH!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !77_!/_
M )'3_MSD_FM<A77_  3_ .1T_P"W.3^:UZ.4?\C.C_B0'KM%%%?JX!1110 4
M444 %%%% !7AW_!0OXK?LL_"']G&Z\0?MK?!>3QO\,;G5K6W\5V<W@'_ (22
MPTV$,9DU"_L_+E/V6&2%"THC<QNT;8_B'N-! 8%6 ((Y!H ^*O@O\!_^#>+]
MHKP[#XJ^!G[/_P"Q_P"*;*:,.'T?P1X9EDCR,[9(Q#OB8=T=58=P*SO'?Q4_
MX-^O^"='C/3_ (EZ/X&_9U\*?$"RD>+PY9_#'P'I-QXJDFFC: Q6=OI=NUYN
ME61H25 4B0JQ"DUW7QZ_X(=?\$E?VE_$D_C#XN_L(^!KC5;J4RWFH:+:RZ1-
M<R$Y+RMI\D!D8]V;)/<UW/[+7_!,W]@+]BB\.K_LM_LE^"O"&IE"AURQTA9=
M1*$8*?;)M\^TCJN_'M0!ZW\//%__  L+P!H?C[_A&-7T3^W-'MM0_L;Q!9?9
MK^P\Z)9/L]S#D^5.F[8Z9.UU89.*V*** /"_^">__)$]6_['O6?_ $I->Z5X
M7_P3W_Y(GJW_ &/>L_\ I2:]TH *\B^-G_(Z?]N<?\VKUVO(OC9_R.G_ &YQ
M_P VKYSBC_D6?]O+]0.0HHHK\Z **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *]2^ W_(!O?\ K\'_ * *\MKU+X#?
M\@&]_P"OP?\ H KWN&O^1M'T?Y =U1117Z4 4444 %<+\>?^0#9?]?A_] -=
MU7"_'G_D V7_ %^'_P! ->3GO_(IJ^GZH#RVBBBORT HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KK_@G_P CI_VY
MR?S6N0KK_@G_ ,CI_P!N<G\UKT<H_P"1G1_Q(#UVBBBOU< HHHH **** "BB
MB@ HHHH **** "BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^2)ZM_P!C
MWK/_ *4FO=* "O(OC9_R.G_;G'_-J]=KR+XV?\CI_P!N<?\ -J^<XH_Y%G_;
MR_4#D****_.@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O4O@-_R ;W_ *_!_P"@"O+:]2^ W_(!O?\ K\'_ * *
M][AK_D;1]'^0'=4445^E %%%% !7"_'G_D V7_7X?_0#7=5POQY_Y -E_P!?
MA_\ 0#7DY[_R*:OI^J \MHHHK\M **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *Z_X)_\ (Z?]N<G\UKD*Z_X)_P#(
MZ?\ ;G)_-:]'*/\ D9T?\2 ]=HHHK]7 **** "BBB@ HHHH **** "BBB@ H
MHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ KR
M+XV?\CI_VYQ_S:O7:\B^-G_(Z?\ ;G'_ #:OG.*/^19_V\OU Y"BBBOSH HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KU+X#?\@&]_P"OP?\ H KRVO4O@-_R ;W_ *_!_P"@"O>X:_Y&T?1_D!W5
M%%%?I0!1110 5POQY_Y -E_U^'_T UW5<+\>?^0#9?\ 7X?_ $ UY.>_\BFK
MZ?J@/+:***_+0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "NO^"?_ ".G_;G)_-:Y"NO^"?\ R.G_ &YR?S6O1RC_
M )&='_$@/7:***_5P"BBB@ HHHH **** "BBB@ HHHH **** /"_^">__)$]
M6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH *\B^-G_(Z?]N<?\VK
MUVO(OC9_R.G_ &YQ_P VKYSBC_D6?]O+]0.0HHHK\Z **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]2^ W_(!O?\
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M<?\ -J^<XH_Y%G_;R_4#D****_.@"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O4O@-_R ;W_ *_!_P"@"O+:]2^
MW_(!O?\ K\'_ * *][AK_D;1]'^0'=4445^E %%%% !7"_'G_D V7_7X?_0#
M7=5POQY_Y -E_P!?A_\ 0#7DY[_R*:OI^J \MHHHK\M **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z_X)_\ (Z?]
MN<G\UKD*Z_X)_P#(Z?\ ;G)_-:]'*/\ D9T?\2 ]=HHHK]7 **** "BBB@ H
MHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\
M8]ZS_P"E)KW2@ KR+XV?\CI_VYQ_S:O7:\B^-G_(Z?\ ;G'_ #:OG.*/^19_
MV\OU Y"BBBOSH HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KU+X#?\@&]_P"OP?\ H KRVO4O@-_R ;W_ *_!_P"@
M"O>X:_Y&T?1_D!W5%%%?I0!1110 5POQY_Y -E_U^'_T UW5<+\>?^0#9?\
M7X?_ $ UY.>_\BFKZ?J@/+:***_+0"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "NO^"?_ ".G_;G)_-:Y"NO^"?\
MR.G_ &YR?S6O1RC_ )&='_$@/7:***_5P"BBB@ HHHH **** "BBB@ HHHH
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MJ]=KR+XV?\CI_P!N<?\ -J^<XH_Y%G_;R_4#D****_.@"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O4O@-_R ;W_
M *_!_P"@"O+:]2^ W_(!O?\ K\'_ * *][AK_D;1]'^0'=4445^E %%%% !7
M"_'G_D V7_7X?_0#7=5POQY_Y -E_P!?A_\ 0#7DY[_R*:OI^J \MHHHK\M
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *Z_X)_\ (Z?]N<G\UKD*Z_X)_P#(Z?\ ;G)_-:]'*/\ D9T?\2 ]=HHH
MK]7 **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU[
MI7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ KR+XV?\CI_VYQ_S:O7:\B^-G_(Z?\
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M_;G)_-:Y"NO^"?\ R.G_ &YR?S6O1RC_ )&='_$@/7:***_5P"BBB@ HHHH
M**** "BBB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5\?? []L?]FC]C
MO0=8^#7[2_Q7LO"7B=/%&H:@^CZA;3O*MM<3&2&0^5&P ="& SG!''-=K_P]
MN_X)T?\ 1TFB_P#@!>?_ !F@#Z,KR+XV?\CI_P!N<?\ -JY#_A[=_P $Z/\
MHZ31?_ "\_\ C-><?%'_ (*9?L)^(_$_]HZ-^T?HLT/V9%W_ &>Y7D$Y&&B!
M[UX/$=&M7R[EIQ<G=:)7[]@/1Z*\6_X>*?L4?]'":+_W[G_^-T?\/%/V*/\
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M/V*/^CA-%_[]S_\ QNC_ (>*?L4?]'":+_W[G_\ C=']FYC_ ,^9_P#@+_R
M]IHKQ;_AXI^Q1_T<)HO_ '[G_P#C='_#Q3]BC_HX31?^_<__ ,;H_LW,?^?,
M_P#P%_Y >TT5XM_P\4_8H_Z.$T7_ +]S_P#QNC_AXI^Q1_T<)HO_ '[G_P#C
M=']FYC_SYG_X"_\ (#VFNO\ @G_R.G_;G)_-:^9_^'BG[%'_ $<)HO\ W[G_
M /C==%\+O^"F7["?ASQ/_:.L_M'Z+##]F==_V>Y;DD8&%B)[5WY7@,=3S&E*
M5*22DM7%_P"0'VG17SG_ ,/;O^"='_1TFB_^ %Y_\9H_X>W?\$Z/^CI-%_\
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M!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\
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MT4 <-_PR_P#LT_\ 1O'@7_PDK/\ ^-4?\,O_ +-/_1O'@7_PDK/_ .-5W-%
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M%M8P:&FH:7]O9[O4[F)8T@BR(3+Y0+LZ80;L#S7X;?\ !6#]J#X8_M4?#_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OACXA?\$H_V@O@W^TOXR_:I_P""77[8]M\([SXEW_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-20210331_g15.jpg
<TEXT>
begin 644 biib-20210331_g15.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
M,LY!0,",X%K]I_\ 8 MOVB_VO/V<OVIK+XG1^'H?V?=5UV[B\-1>'Q.NM+J-
MC%:"(3">,6@B$6X$1R[L[<+C-?0.LZ[HGAVS_M'Q!K-I8V^\+Y]Y<+$FX]!N
M8@9JS'(DJ"6)PRL 593D$>M 'QG^T9_P33_:"M/VQ]:_;X_X)X_M5Z=\+_'7
MC70;/2/B9H'BKP@-:T+Q3'9KLL[J2-9HI(+F&/$8D1CE %PN7W]+^P=_P3:U
M?]EKQ!\3_CW\=_CY=?%'XS_&6>!O'/CR?1(]/MXK:WA:&TL+*S1W%O;0HQ&-
MY9\*6(VJ!]444 >$?\$R_P!B;_AW1^PYX#_8Q_X69_PF/_"$V]]%_P ))_8W
M]G_;?M%_<WF?L_G3>7M^T;/]8V=F>,X'A_@'_@B'X'T7_@BG!_P1L^(7QWO]
M9L+>VN_*^(&EZ"MA<1W3Z[+K-O.EJT\P7RIGC1E\T^8L;<IO^7[GHH ^./&_
M_!.S]LS]H+]B3XN?L=_M>_\ !1+3?'LOQ&\/6^E:#XJL?@S;Z.^@!2QFEDMX
M+]A?-(?*.-\(3RSC.[ ](_:D_88_X:4_X)QZ[_P3^_X6C_8O]M?#^V\,?\);
M_8GVGR?)CB3[1]E\]-V?*SL\T8W?>..??Z* /F3XS_LO?M[Z7X7^'FD_L5?M
MO^'O!:^"_"4.B:WH'B_X91ZOIWB)XHXDCNF9;F*>S=1&_P L;L&$F&SM!K*_
M8E_X)Y?%SX-?M.>-?VZOVO/VD+/XD_%KQKX7L_#0F\/>%%T71]#T>WE,RVEO
M!YLLDS--AVFE?=P  .2?K"LOPMXW\%^.(KV;P5XOTO6$TW49=/U%]+U".X%K
M=Q8\VWD,;'9*F1N1L,N1D"@#D_VL?@7_ ,-0?LL?$O\ 9H_X2G^P_P#A8GP_
MUGPQ_;?V'[3_ &?]OL9K7[1Y.^/S?+\W?LWINVXW+G(^,_@-_P $M/\ @KA^
MS7\%_"_P ^$?_!;O1+#PQX.T2WTG0;*?]EG3)W@M84"1H9)-4+N0H'S,23WK
M]#*IZ7XAT#7))X=%URSO'M9-ETMK<I(86Y^5@I.T\'@^E 'S+\>/^">7Q+_:
M6T;]F^\^,G[4,.I>*?@3\3M,\::[XB@\#1VZ>+;FUAEC:(6T=T$T\2>;G<IF
M"[<;6SD=/^W9^PQ_PVMKWP1UO_A:/_",_P#"F_CAHWQ#\K^Q/MO]K_8%G7[#
MGSXOL_F>=_KL2;=O^K;/'OTDD<,;2RR*J*I+,QP !U)-0:5K&DZ[8IJ>AZI;
M7EM(3LN+2=9$;!P<,I(//% 'R#^U!_P3?^/M]^V0_P"W]^P!^U!I?PQ^(6N>
M&(/#WQ"T?Q3X1_MG0_%5E V;:::))H9(;F$8594;)153Y1OWQ_L0_P#!*[XC
M?LQ?MM^.?V]OC/\ MA7OQ.\:?$GP-:Z+XKCN/",>FP)=0W(D6:T$=PZP6R01
MP0);;6(\HR-*[.U?7VL>(= \/1QS:_KEG8I-)LB:\N4B#M_=!8C)]JN4 ?!/
MAK_@EO\ ML?L=>,?%-I_P3#_ &YO#O@OX;>+_$5SKC_"WXC_  Y_MNS\.WUR
MV^Y?3;B&Y@ECA=_F%LX*(03DEB3ZEX]_X)S^+OVI?V!?%W[%_P"W[^TQ>?$W
M5?&,[W-QXYTKPK:Z$^DSI)%-9FRMH6=8Q;2PHZEV=I/F#DAR*^FKG7-%LM2@
MT:\UBUBO+H$VMK+<*LDP'7:I.6QWQ5J@#\TOVE?^",O_  46_;R_9BO/V1?V
MT?\ @JQINI^%;2"#^R+OPO\ ");6[UB[@D0P7>L$WW^DA K-Y$+1*TQCE9V\
MH*WZ2Z38?V7I5MIGF^9]FMTBW[<;MJ@9QVZ58HH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
M9OMUM<+%$5\NX(B=&7.X\'A@OG! /_!TV"0./V ./;_BMZT+D#_B)RLVP,G]
M@^YR?^YT@H ;HW_!5[]KG]H[XG^/7_X)[_\ !/.'XH?#'X9^)KGP]K7CG6OB
M9;Z%+XAU.UP+NWTBWDMY%G$1("RRR1QRDX#+UKDO^#:'XA:;\7/V<_VAOBMH
M^D:CI]GXG_; \;ZM:V&KVWD7=M'<K83+%/'D^7*H<*RY.&!&>*\T_P""1O[>
MO[*W_!*O]GOQM_P3S_;X^*T7PZ^(OPJ^(NOR"P\16L_G^*M-O+Z2ZL]1TX)&
MQOA.LNU4BW2$J/E&X5Z1_P &S/C&\^(G[-?[0?Q U#P=?>';C7?VO?&NH3^'
M]4@\JYTQYEL)&M9D_@DC+%&7LRD4 ?:O[6_[)OPI_;7^#-U\ ?C;<:]_PB^H
MWUO<:M9^']>GTV6^CA</]FDF@99!"Y #JC*6'&17Y?\ _!3;]@/]D3_@F5\3
M?V;/'G_!+?P!+\-OCQXE^-NDZ%H.@^%-=O6'BC1&8G4H;ZWEED$MHB>4996'
MRB0;FP<C]$O^"EG_  4 ^%__  3+_9!\2?M:?%71+_5K;1_*M=*T331B74M0
MG;9;V^\@K"C-RTC9"(K$!FVHWYK?\$TO^"DW_!+JZ^.$O[>W[?'_  4#\(^+
MOVEOB!#%IND:38:!JCZ9\/-,E8B+0M*W6I56_>%9[C=F1F<!F#223 'T-_P5
MAL+O]L[_ (*5?LV?\$IO%VMZG;_"WQ-I6N>.?B[HVFW\MK_PD=G81[;'3II(
MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+
MB9G8*+D@+EB> .@[5[;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#D
MB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[
MI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO
M_@GO_P D3U;_ +'O6?\ TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_\
M!/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'A?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U
M;_L>]9_]*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?]CWK/
M_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[_G]#_P)?Y@:_P#PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U61_PLGX7_ /01A_\
M "3_ .(H_P"%D_"__H(P_P#@!)_\11_:67?\_H?^!+_,#7_X3'PQ_P!!J#_O
MJC_A,?#'_0:@_P"^JR/^%D_"_P#Z",/_ ( 2?_$4?\+)^%__ $$8?_ "3_XB
MC^TLN_Y_0_\  E_F!K_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5D?\ "R?A?_T$
M8?\ P D_^(H_X63\+_\ H(P_^ $G_P 11_:67?\ /Z'_ ($O\P-?_A,?#'_0
M:@_[ZH_X3'PQ_P!!J#_OJLC_ (63\+_^@C#_ . $G_Q%'_"R?A?_ -!&'_P
MD_\ B*/[2R[_ )_0_P# E_F!K_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?59'_"
MR?A?_P!!&'_P D_^(H_X63\+_P#H(P_^ $G_ ,11_:67?\_H?^!+_,#7_P"$
MQ\,?]!J#_OJC_A,?#'_0:@_[ZK(_X63\+_\ H(P_^ $G_P 11_PLGX7_ /01
MA_\  "3_ .(H_M++O^?T/_ E_F!K_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU
M61_PLGX7_P#01A_\ )/_ (BC_A9/PO\ ^@C#_P" $G_Q%']I9=_S^A_X$O\
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M3_\  G_F!T?_  MKX@_]#!_Y*1?_ !%'_"VOB#_T,'_DI%_\17.44?VEF/\
MS^G_ .!/_,#H_P#A;7Q!_P"A@_\ )2+_ .(H_P"%M?$'_H8/_)2+_P"(KG**
M/[2S'_G]/_P)_P"8'1_\+:^(/_0P?^2D7_Q%'_"VOB#_ -#!_P"2D7_Q%<Y1
M1_:68_\ /Z?_ ($_\P.C_P"%M?$'_H8/_)2+_P"(H_X6U\0?^A@_\E(O_B*Y
MRBC^TLQ_Y_3_ / G_F!T?_"VOB#_ -#!_P"2D7_Q%'_"VOB#_P!#!_Y*1?\
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M7=$\4:)9^)O#.LVNHZ;J-K'=:?J%A<+-!=02*'CECD0E71E(8,"0000<&K5
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M!7EM>I? ;_D WO\ U^#_ - %>]PU_P C:/H_R [JBBBOTH HHHH *X7X\_\
M(!LO^OP_^@&NZKA?CS_R ;+_ *_#_P"@&O)SW_D4U?3]4!Y;1117Y: 4444
M%%%% !1110 4444 >7_ME_M7_#W]B3]G'Q'^TG\3=/U"^TW0(X5BTS28@]U?
MW4\R6]O;Q*Q W/+*BY)PH)8\ U\O_LU_MA?\%,?$_P"U!X_T?QY^PA"_A_\
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MN;8J^9*\",S84 #)).  /2OEW_@OG_RB&^-?_8#L?_3G9U],? __ )(KX/\
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M*37NE>%_\$]_^2)ZM_V/>L_^E)KW2@ KR+XV?\CI_P!N<?\ -J]=KR+XV?\
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MWD1(Y.YI#AE<D'*A3S89*>'Y*RCR+FUO[R?DKW>J5M-?Q _0NBBBO) ****
M"BBB@ HHHH *]2^ W_(!O?\ K\'_ * *\MKU+X#?\@&]_P"OP?\ H KWN&O^
M1M'T?Y =U1117Z4 4444 %<+\>?^0#9?]?A_] -=U7"_'G_D V7_ %^'_P!
M->3GO_(IJ^GZH#RVBBBORT HHHH **** "BBB@ HHHH Y+XW_ GX0?M)?#74
M/@_\=? &G^)_#6J>6;[2-3C+1R,CAT8$$,K*ZJP92"" 017R_P#L\_\ !%_]
MD3X/_M*^+?C-J_P/L-4M+;7=,O?ADNN>*-3U@Z3Y-A!'+(8KZ>1!*+E':-SO
M9%"!&0*JC[-HK>EBL11A*$)-)]+O^NGW <E\=?@=\,?VE/A+KGP,^,_A^;5?
M"WB2U%MK6FP:I<V;7,(=7\LS6TD<JJ2HR%<;AE3E20=OP=X1\-_#_P (Z5X#
M\&:1%I^CZ)IL%AI5A!G9;6T,:QQ1+DDX5%51GL*TJ*RYY<O+?3>P'SQ^U'_P
M2G_8/_;0\>R?$S]I3X+WGB/6)=/AL99D\;:S8PO!$6*(8+2\BB."Q.[9D]R<
M"NI_9/\ V#_V6OV'[36[#]F3X=WGA^'Q$UL=72[\5:GJ8E-N)!%M^WW,WE;1
M+)PFW.1G.!CUZBM7BL3*E[)S?+VN[?=L!YO\#?V0_P!G+]G#X/7_ , /A!\,
M+;3_  =JEU>W&I:!>WEQJ$-T]YG[2)/M<DK.DF2"A.S!(  XKP.'_@@]_P $
MU8;Q;0_";Q!)X;2_^VIX#E^(&KMH"W&_?O\ L)N?+(W\[#E.VW'%?8E%.&+Q
M5.3E&;3>^KU KZ3I.EZ#I5MH6AZ;;V=E96Z06=G:PK'%!$BA4C1% "JJ@  #
M   %6***YP"BBB@ HHHH **** "NO^"?_(Z?]N<G\UKD*Z_X)_\ (Z?]N<G\
MUKT<H_Y&='_$@/7:***_5P"BBB@ HHHH **** "BBB@#\OM2_8A\(_\ !3G_
M (*>?M%^ ?V_OB_\0)=-^&]SH4/PL^$^A^.+K1M-30+G3DD;6!%:NCW32W?G
MQ--NPCPM&Q.U%3Z"_9<_X(9?\$]OV.OCMH7[1WP.\'>,+3Q3X<^U?V7<:K\1
MM6OX%^T6LMK)N@N+AXWS%/(!N4X)##! -?+7_!8+X#?\$!?AC^U>WQN_;Z^*
MWCVV^+OC.VBGL?#O@CQ7K4^H_9DA2V5XK/3]WV2%E@ZMY:R,DA&Y@U:O_!'K
MX4_\$,/BE^T=!\6?V!/CK\1M1^)'@"WN;BX\'>.O&NN1W5M#<6\EI)+)I^HE
M1<1A+G&] ZQN\9)5BM 'ZGT444 >%_\ !/?_ )(GJW_8]ZS_ .E)KW2O"_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=?\
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MXIL?#6GZ)XH&GQ1Q'3]3N783&6S$!N+<PN4EC#*P#,*^H/V9OVN/^"JGQ/\
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M_D;1]'^0'=4445^E %%%% !7"_'G_D V7_7X?_0#7=5POQY_Y -E_P!?A_\
M0#7DY[_R*:OI^J \MHHHK\M **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *Z_X)_\ (Z?]N<G\UKD*Z_X)_P#(Z?\
M;G)_-:]'*/\ D9T?\2 ]=HHHK]7 **** "BBB@ HHHH **** /S3^(?AK_@L
M3^RE_P %'OC-\7/V&?V /!WC?X6_$VXTJ_U1/$'Q4LM/EU#5K?3H;=]0MU;$
MEGN51#)#(LHD-NLJF/>P;VW]ES]IC_@L-\0?CMH7A#]J?_@F1X/^'O@.[^U?
MV[XPTKXT6>K3Z?LM97@VVD<8:7?.L,1P?E$A;HM?7]% !1110!X7_P $]_\
MDB>K?]CWK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %>1?&S_D=/^W./
M^;5Z[7D7QL_Y'3_MSC_FU?.<4?\ (L_[>7Z@<A1117YT 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZE\!O^0#>_
M]?@_] %>6UZE\!O^0#>_]?@_] %>]PU_R-H^C_(#NJ***_2@"BBB@ KA?CS_
M ,@&R_Z_#_Z :[JN%^//_(!LO^OP_P#H!KR<]_Y%-7T_5 >6T445^6@%%%%
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M=/\ MSC_ )M7SG%'_(L_[>7Z@<A1117YT 4444 %%%% !1110 4444 %%%%
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M[_\ )$]6_P"Q[UG_ -*37NE !7D7QL_Y'3_MSC_FU>NUY%\;/^1T_P"W./\
MFU?.<4?\BS_MY?J!R%%%%?G0!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7J7P&_Y -[_ -?@_P#0!7EM>I? ;_D
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M44 %%%% !1110 4444 %>I? ;_D WO\ U^#_ - %>6UZE\!O^0#>_P#7X/\
MT 5[W#7_ "-H^C_(#NJ***_2@"BBB@ KA?CS_P @&R_Z_#_Z :[JN%^//_(!
MLO\ K\/_ * :\G/?^135]/U0'EM%%%?EH!1110 4444 %%%% !1110 4444
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M%%% !1110 5ZE\!O^0#>_P#7X/\ T 5Y;7J7P&_Y -[_ -?@_P#0!7O<-?\
M(VCZ/\@.ZHHHK]* **** "N%^//_ " ;+_K\/_H!KNJX7X\_\@&R_P"OP_\
MH!KR<]_Y%-7T_5 >6T445^6@%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %=?\$_\ D=/^W.3^:UR%=?\ !/\ Y'3_
M +<Y/YK7HY1_R,Z/^) >NT445^K@%%%% !1110 4444 %%%% !1110 4444
M>%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !7D7
MQL_Y'3_MSC_FU>NUY%\;/^1T_P"W./\ FU?.<4?\BS_MY?J!R%%%%?G0!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>I? ;_D
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZE\!O^0#>_P#7X/\
MT 5Y;7J7P&_Y -[_ -?@_P#0!7O<-?\ (VCZ/\@.ZHHHK]* **** "N%^//_
M " ;+_K\/_H!KNJX7X\_\@&R_P"OP_\ H!KR<]_Y%-7T_5 >6T445^6@%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%=?\$_\ D=/^W.3^:UR%=?\ !/\ Y'3_ +<Y/YK7HY1_R,Z/^) >NT445^K@
M%%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\
M+_X)[_\ )$]6_P"Q[UG_ -*37NE !7D7QL_Y'3_MSC_FU>NUY%\;/^1T_P"W
M./\ FU?.<4?\BS_MY?J!R%%%%?G0!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7J7P&_Y -[_ -?@_P#0!7EM>I?
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MBW_#Q3]BC_HX31?^_<__ ,;H_P"'BG[%'_1PFB_]^Y__ (W1_9N8_P#/F?\
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M /C='_#Q3]BC_HX31?\ OW/_ /&Z/[-S'_GS/_P%_P"0'M-%>+?\/%/V*/\
MHX31?^_<_P#\;H_X>*?L4?\ 1PFB_P#?N?\ ^-T?V;F/_/F?_@+_ ,@/::*\
M6_X>*?L4?]'":+_W[G_^-T?\/%/V*/\ HX31?^_<_P#\;H_LW,?^?,__  %_
MY >TT5XM_P /%/V*/^CA-%_[]S__ !NC_AXI^Q1_T<)HO_?N?_XW1_9N8_\
M/F?_ ("_\@/::*\6_P"'BG[%'_1PFB_]^Y__ (W37_X*,?L3HRJ?V@]'^8X&
M(;@_GB/BC^S<Q_Y\S_\  7_D![717BW_  \4_8H_Z.$T7_OW/_\ &Z/^'BG[
M%'_1PFB_]^Y__C=']FYC_P ^9_\ @+_R ]IHKQ;_ (>*?L4?]'":+_W[G_\
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M !JNYHH X;_AE_\ 9I_Z-X\"_P#A)6?_ ,:H_P"&7_V:?^C>/ O_ (25G_\
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MG)C,,1)0!.QR>O>@#*_X9?\ V:?^C>/ O_A)6?\ \:H_X9?_ &:?^C>/ O\
MX25G_P#&J[FB@#AO^&7_ -FG_HWCP+_X25G_ /&J/^&7_P!FG_HWCP+_ .$E
M9_\ QJNYHH X;_AE_P#9I_Z-X\"_^$E9_P#QJC_AE_\ 9I_Z-X\"_P#A)6?_
M ,:KN:* .&_X9?\ V:?^C>/ O_A)6?\ \:H_X9?_ &:?^C>/ O\ X25G_P#&
MJ[FB@#AO^&7_ -FG_HWCP+_X25G_ /&J/^&7_P!FG_HWCP+_ .$E9_\ QJNY
MHH X;_AE_P#9I_Z-X\"_^$E9_P#QJC_AE_\ 9I_Z-X\"_P#A)6?_ ,:KN:*
M.&_X9?\ V:?^C>/ O_A)6?\ \:H_X9?_ &:?^C>/ O\ X25G_P#&J[FB@#AO
M^&7_ -FG_HWCP+_X25G_ /&J/^&7_P!FG_HWCP+_ .$E9_\ QJNYHH X;_AE
M_P#9I_Z-X\"_^$E9_P#QJC_AE_\ 9I_Z-X\"_P#A)6?_ ,:KN:* .&_X9?\
MV:?^C>/ O_A)6?\ \:H_X9?_ &:?^C>/ O\ X25G_P#&J[FB@#AO^&7_ -FG
M_HWCP+_X25G_ /&J/^&7_P!FG_HWCP+_ .$E9_\ QJNYHH X;_AE_P#9I_Z-
MX\"_^$E9_P#QJC_AE_\ 9I_Z-X\"_P#A)6?_ ,:KN:* .&_X9?\ V:?^C>/
MO_A)6?\ \:H_X9?_ &:?^C>/ O\ X25G_P#&J[FB@#AO^&7_ -FG_HWCP+_X
M25G_ /&J/^&7_P!FG_HWCP+_ .$E9_\ QJNYHH X;_AE_P#9I_Z-X\"_^$E9
M_P#QJC_AE_\ 9I_Z-X\"_P#A)6?_ ,:KN:* .&_X9?\ V:?^C>/ O_A)6?\
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M^&7_ -FG_HWCP+_X25G_ /&J[FB@#AO^&7_V:?\ HWCP+_X25G_\:H_X9?\
MV:?^C>/ O_A)6?\ \:KN:* .&_X9?_9I_P"C>/ O_A)6?_QJC_AE_P#9I_Z-
MX\"_^$E9_P#QJNYHH X;_AE_]FG_ *-X\"_^$E9__&J/^&7_ -FG_HWCP+_X
M25G_ /&J[FB@#AO^&7_V:?\ HWCP+_X25G_\:H_X9?\ V:?^C>/ O_A)6?\
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MP?!W2/C)K T7P!XQT#XD6_B&T@UN1-\&D:B(X(C;SR_=212Z._ &U7=/._\
M@LI\./"/P@U[_@GK\'M$M'M_!'A?]JKP?I%E;3ONCC-K;/#IZ.3P6 0@$]?F
MK>_X.80I_8F^&KZ<"==7]I+P6?"WEX\S^T/M4NSR\_Q^7YN,=L]LT ?HE111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>?"?3;G7H;OQ7-:^%SJB:_91H^-/FC6[MF$)E,<C8<AO*"E2#QR/[.O[!O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-20210331_g16.jpg
<TEXT>
begin 644 biib-20210331_g16.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _!']K[5?$/[.?_!PG\>O^"E?AZ[N
M19? ;7?AD?'MM"2RR^$M:T9=+U1R@^^T7F6TRYX7RF8XQD>U?\'/'B>__:J\
M.G]B;P3K+MH/P\^#GB+XU_$FXL9OE,5I:S66A6^]>&$M[-)*T9^\EN& .,CT
M?X,?!;P5^T?_ ,%J?^"BO[/_ ,1[+[1H/C7X5^!-%U>, %O(N=!>%V7/1@'W
M*>S $=*\\NO^":O[1W["G_!&W]L3QW^VI\6?#OCKXH>+/@__ &'%K_AN>XEM
MX/#>B:$MCIEMFXAB=9O]?)-A2'=PQ9VR: /L;]G3XG_M#?"C_@DC^SKKO[,/
M[,Z_%;Q3=?";P=9Q>')O&%MH4%O"VB0,]W-=SHX6--B@JB.[%U"J><97P>_X
M*3_M1>$OVLO!?[(7_!0[]BJQ^%^H_$^"^'PU\8^$O'\?B#1]6O;2'[1/I\Q^
MSP2VDXA!="X*R'Y5Y%?+'[8?Q?\ %GPP_P""7/[!&B>,?B]XQ^'7P,\3Z+X1
MT_X[>._ UU<6M[8::?#T!M;>2ZM@9;6UGN/DEE3!P ,_-M;Q3QR?^"8]M_P5
M7_8VTS_@FCJ/B3Q=96?Q9E3QG\07^(7B#7]'6X>Q<V^GPS:E=S6[W)032R"W
M ,:",,?W@4 'W]\??^"M?QT\)?\ !07Q1_P3:_9D_8.N_B7XYT?P5IWB/3=4
M;QY#I>G"VN"1/+?22VS"TBA)B4%&FDF>9$6->6&A\=O^"HGQZ^"U[\+?V7]#
M_8N_X33]I[XD:#/J]S\)]!\;P1Z7X=L()&CEU&]U:2(JEKN4A#Y6Z1E9!AMH
M;D_V>%4_\''7[13E1D?L_P#A$ XYQ]HDKD?VQ?B5X?\ ^"<G_!<KPY_P4)_:
M6@O=/^#/Q(^ 1^'$_P 0$L)9[/POKD.KB^BCO3$K&"">,*J.1@R,Q.%C=@ ?
M1/@/XR_MT_$;X-_%;PY^V?\ L9Z'\-&TWP/=S:'KOACXDPZ_8ZR7M[@2Q!/(
M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
M9OMUM<+%$5\NX(B=&7.X\'A@OG! /_!TV"0./V ./;_BMZT+D#_B)RLVP,G]
M@^YR?^YT@H ;HW_!5[]KG]H[XG^/7_X)[_\ !/.'XH?#'X9^)KGP]K7CG6OB
M9;Z%+XAU.UP+NWTBWDMY%G$1("RRR1QRDX#+UKDO^#:'XA:;\7/V<_VAOBMH
M^D:CI]GXG_; \;ZM:V&KVWD7=M'<K83+%/'D^7*H<*RY.&!&>*\T_P""1O[>
MO[*W_!*O]GOQM_P3S_;X^*T7PZ^(OPJ^(NOR"P\16L_G^*M-O+Z2ZL]1TX)&
MQOA.LNU4BW2$J/E&X5Z1_P &S/C&\^(G[-?[0?Q U#P=?>';C7?VO?&NH3^'
M]4@\JYTQYEL)&M9D_@DC+%&7LRD4 ?:O[6_[)OPI_;7^#-U\ ?C;<:]_PB^H
MWUO<:M9^']>GTV6^CA</]FDF@99!"Y #JC*6'&17Y?\ _!3;]@/]D3_@F5\3
M?V;/'G_!+?P!+\-OCQXE^-NDZ%H.@^%-=O6'BC1&8G4H;ZWEED$MHB>4996'
MRB0;FP<C]$O^"EG_  4 ^%__  3+_9!\2?M:?%71+_5K;1_*M=*T331B74M0
MG;9;V^\@K"C-RTC9"(K$!FVHWYK?\$TO^"DW_!+JZ^.$O[>W[?'_  4#\(^+
MOVEOB!#%IND:38:!JCZ9\/-,E8B+0M*W6I56_>%9[C=F1F<!F#223 'T-_P5
MAL+O]L[_ (*5?LV?\$IO%VMZG;_"WQ-I6N>.?B[HVFW\MK_PD=G81[;'3II(
MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+
MB9G8*+D@+EB> .@[5[;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#D
MB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*^?OV!O$&BZ9\&M6MM0U&.*3_
M (3G66VN><?:6YKV_P#X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'
MPQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&
MH/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2
MHK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ
M_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0
M:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -
M*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'
MPQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&
MH/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2
MHK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ
M_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0
M:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -
M*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'
MPQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&
MH/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2
MHK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ
M_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0
M:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -
M*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'
MPQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&
MH/\ OJC_ (3'PQ_T&H/^^J -*BJ%MXH\/WDZVMKJL3R.<(BGDFK] !1110 4
M444 %%%% !1110 4444 >#_\$_+2UG^"NK/-;1N?^$ZUD99 3_Q\FO<O[.T_
M_GQA_P"_0KQ'_@GO_P D3U;_ +'O6?\ TI->Z4 0_P!G:?\ \^,/_?H4?V=I
M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%3
M44 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?
M_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^
M,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U
M% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I
M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%3
M44 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?
M_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^
M,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U
M% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I
M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%3
M44 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?
M_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^
M,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U
M% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I
M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A4U% $26-E&P>.SB5AT*Q@$5+110 4444 %%%%
M!1110 4444 %%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_
M['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK
M/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444
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MO^?T/_ E_F!]145\N_\ #>O[1W_2/+Q/_P"'!T/_ .2*/^&]?VCO^D>7B?\
M\.#H?_R11_:67?\ /Z'_ ($O\P/J*BOEW_AO7]H[_I'EXG_\.#H?_P D4?\
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M /DBC_AO7]H[_I'EXG_\.#H?_P D4?VEEW_/Z'_@2_S ^HJ*^7?^&]?VCO\
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MBL0"BBB@ HHHH *Z_P""?_(Z?]N<G\UKD*Z_X)_\CI_VYR?S6O1RC_D9T?\
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M%%%?G0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^RM_P5A\2?$OQ[;?;_[!\$W_ .TFFOPZENL+A)]U@')G\N!IIAQ\AB#_ ,%
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M7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2UL44 9=GKVI7-TD$WAFZA5FPTKLN%]S6I110 4444 %%%% !1110 4444
M%%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I
M0 5Y%\;/^1T_[<X_YM7KM>1?&S_D=/\ MSC_ )M7SG%'_(L_[>7Z@<A1117Y
MT 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5ZE\!O^0#>_P#7X/\ T 5Y;7J7P&_Y -[_ -?@_P#0!7O<-?\ (VCZ
M/\@.ZHHHK]* **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_D;1]'^0'=4445^E %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]
M9_\ 2DU[I0 5Y%\;/^1T_P"W./\ FU>NUY%\;/\ D=/^W./^;5\YQ1_R+/\
MMY?J!R%%%%?G0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7J7P&_Y -[_P!?@_\ 0!7EM>I? ;_D WO_ %^#_P!
M%>]PU_R-H^C_ " [JBBBOTH HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSBC_ )%G_;R_4#D****_.@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_
M .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5\Q?LV?&KX6?LS>"]4
M^&WQY\:V?AC77\5:E?KIFHEA+]FFG+12?*",,O(]J]#_ .&[OV0_^B\:)_WU
M)_\ $4 >M45Y+_PW=^R'_P!%XT3_ +ZD_P#B*/\ AN[]D/\ Z+QHG_?4G_Q%
M 'K5%>2_\-W?LA_]%XT3_OJ3_P"(H_X;N_9#_P"B\:)_WU)_\10!ZU17DO\
MPW=^R'_T7C1/^^I/_B*/^&[OV0_^B\:)_P!]2?\ Q% 'K5%>2_\ #=W[(?\
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M]D/_ *+QHG_?4G_Q%'_#=W[(?_1>-$_[ZD_^(H ]:HKR7_AN[]D/_HO&B?\
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M_A4WPK_Z)IX?_P#!-!_\17044 <__P *F^%?_1-/#_\ X)H/_B*/^%3?"O\
MZ)IX?_\ !-!_\17044 <_P#\*F^%?_1-/#__ ()H/_B*/^%3?"O_ *)IX?\
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MX5-\*_\ HFGA_P#\$T'_ ,17044 <_\ \*F^%?\ T33P_P#^":#_ .(KQ/\
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MU&.W7]H[XG*!+8> ]#:56?3U/W9]3N0A18 ?D7?NV_.\(!],_MG?\%&O@?\
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M8?"'[7_[.?[0.J_!GX[> [&33]!^(>DZ3%J,%_IDC,[Z;J-C*RI>6Q9G95+
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-20210331_g17.jpg
<TEXT>
begin 644 biib-20210331_g17.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
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MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V**
M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QK$\;^)_&'@JQAO9[RUN!-+L"I#MQP3G]*[.N%^//_ " ;+_K\/_H!KSLV
MKU<-E]2K3=I):?>NX&#_ ,+O\3_\^\'Y?_6H_P"%W^)_^?>#\O\ ZU<717P7
M^L.<?\_?_)8_Y =I_P +O\3_ //O!^7_ -:C_A=_B?\ Y]X/R_\ K5Q=%'^L
M.<?\_?\ R6/^0':?\+O\3_\ /O!^7_UJ/^%W^)_^?>#\O_K5Q=%'^L.<?\_?
M_)8_Y =I_P +O\3_ //O!^7_ -:C_A=_B?\ Y]X/R_\ K5Q=%'^L.<?\_?\
MR6/^0':?\+O\3_\ /O!^7_UJ/^%W^)_^?>#\O_K5Q=%'^L.<?\_?_)8_Y =I
M_P +O\3_ //O!^7_ -:C_A=_B?\ Y]X/R_\ K5Q=%'^L.<?\_?\ R6/^0':?
M\+O\3_\ /O!^7_UJ/^%W^)_^?>#\O_K5Q=%'^L.<?\_?_)8_Y =I_P +O\3_
M //O!^7_ -:C_A=_B?\ Y]X/R_\ K5Q=%'^L.<?\_?\ R6/^0':?\+O\3_\
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MJ\0;]XB6Y!(]C6I110 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?\
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M$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5POQY_P"0#9?]?A_] -=U7"_'G_D V7_7X?\ T UY.>_\BFKZ
M?J@/+:***_+0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\
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M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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M0#^$UY.>_P#(IJ^GZH#S&BBBORT HHHH **** "BBB@ HHHH **** "BBB@
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M (U?#6UGMSHOB7Q+\:=%L8]5S;QO([:?>0.T)25I8ANR2(]PX85+^Q/\=/\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z_X)_\
M(Z?]N<G\UKD*Z_X)_P#(Z?\ ;G)_-:]'*/\ D9T?\2 ]=HHHK]7 **** "BB
MB@ HHHH *\G_ &R?A%^U%\:_A''X._9%_:^_X4EXJ76(;B3QE_PK^R\2;[14
MD$EK]DO76,;V:-O,SN7R\#[QKUBOF+_@K+X:_P""=/B_]F73O#O_  4[ULV/
MP[NO&EA'82#4]3M#)J[1SK;)YFFD3<J9N"=GKT% 'CO_  [P_P""Z_\ TL5?
M^:C>&/\ Y(KT#]ES]C3_ (*P_"CX[:%X_P#VE_\ @M!_PMGP38?:O[;^'_\
MPSIH6@_VKOM98X?].M9FF@\J9XI_E!W^3L/RN37PI^T/^Q__ ,&BO[*'QCUK
M]G[]H3Q5<>&O&/AV2%-:T.Z\>>,Y9+5I8(YXP6AF=#F*6-N&/WN><BO1/^"9
MOA7_ (-@]-_;=\$WO_!._P")?]H?&)/[2_X0^S_X2?Q5<>9G3;H7?[N_8V[8
MLS<G]X.,97Y@M 'ZS4444 >%_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R
M1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5POQY_Y -E_U
M^'_T UW5<+\>?^0#9?\ 7X?_ $ UY.>_\BFKZ?J@/+:***_+0"BBB@ HHHH
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MB63[/<PY/E3INV.F3M=6&3BMBBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\
MP3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N%^//
M_(!LO^OP_P#H!KNJX7X\_P#(!LO^OP_^@&O)SW_D4U?3]4!Y;1117Y: 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\
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M3_MSD_FM<A77_!/_ )'3_MSD_FM>CE'_ ",Z/^) >NT445^K@%%%% !1110
M4444 %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['
MO6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5POQY_P"0#9?]?A_]
M -=U7"_'G_D V7_7X?\ T UY.>_\BFKZ?J@/+:***_+0"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NO^"?\ R.G_
M &YR?S6N0KK_ ()_\CI_VYR?S6O1RC_D9T?\2 ]=HHHK]7 **** "BBB@ HH
MHH **** "BBB@ HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\ !/?_ )(G
MJW_8]ZS_ .E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N%^//_(!LO\
MK\/_ * :[JN%^//_ " ;+_K\/_H!KR<]_P"135]/U0'EM%%%?EH!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !77_!
M/_D=/^W.3^:UR%=?\$_^1T_[<Y/YK7HY1_R,Z/\ B0'KM%%%?JX!1110 444
M4 %%%% !1110 4444 %%%% 'A?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\
M\D3U;_L>]9_]*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<+\>?^0#9?
M]?A_] -=U7"_'G_D V7_ %^'_P! ->3GO_(IJ^GZH#RVBBBORT HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KK_@G
M_P CI_VYR?S6N0KK_@G_ ,CI_P!N<G\UKT<H_P"1G1_Q(#UVBBBOU< HHHH
M**** "BBB@ HHHH **** "BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^
M2)ZM_P!CWK/_ *4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X7X\_P#(
M!LO^OP_^@&NZKA?CS_R ;+_K\/\ Z :\G/?^135]/U0'EM%%%?EH!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !77_
M  3_ .1T_P"W.3^:UR%=?\$_^1T_[<Y/YK7HY1_R,Z/^) >NT445^K@%%%%
M!1110 4444 %%%% !1110 4444 >%_\ !/?_ )(GJW_8]ZS_ .E)KW2O"_\
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MO^"='_1TFB_^ %Y_\9H_X>W?\$Z/^CI-%_\  "\_^,T <=_P2J_X),_L\_\
M!/7X5:%X@M_@UH=O\6YO#B:=XO\ &<>J7>IW,P#EC#!<7CL\,!PA,40C0E02
MO KZ]KYS_P"'MW_!.C_HZ31?_ "\_P#C--'_  5R_P""<QD,8_:CT?(&2?[.
MO<?GY&* /HZBOG/_ (>W?\$Z/^CI-%_\ +S_ .,T?\/;O^"='_1TFB_^ %Y_
M\9H ^C**^<_^'MW_  3H_P"CI-%_\ +S_P",T?\ #V[_ ()T?]'2:+_X 7G_
M ,9H ^C**^<_^'MW_!.C_HZ31?\ P O/_C-'_#V[_@G1_P!'2:+_ . %Y_\
M&: /HRBOG/\ X>W?\$Z/^CI-%_\  "\_^,T?\/;O^"='_1TFB_\ @!>?_&:
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MG_\ &J/^&7_V:?\ HWCP+_X25G_\:KN:* .&_P"&7_V:?^C>/ O_ (25G_\
M&J/^&7_V:?\ HWCP+_X25G_\:KN:* .&_P"&7_V:?^C>/ O_ (25G_\ &J/^
M&7_V:?\ HWCP+_X25G_\:KN:* .&_P"&7_V:?^C>/ O_ (25G_\ &J/^&7_V
M:?\ HWCP+_X25G_\:KN:* .&_P"&7_V:?^C>/ O_ (25G_\ &J/^&7_V:?\
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M (25G_\ &J[FB@#AO^&7_P!FG_HWCP+_ .$E9_\ QJC_ (9?_9I_Z-X\"_\
MA)6?_P :KN:* .&_X9?_ &:?^C>/ O\ X25G_P#&J/\ AE_]FG_HWCP+_P"$
ME9__ !JNYHH X;_AE_\ 9I_Z-X\"_P#A)6?_ ,:H_P"&7_V:?^C>/ O_ (25
MG_\ &J[FB@#AO^&7_P!FG_HWCP+_ .$E9_\ QJC_ (9?_9I_Z-X\"_\ A)6?
M_P :KN:* .&_X9?_ &:?^C>/ O\ X25G_P#&J/\ AE_]FG_HWCP+_P"$E9__
M !JNYHH X;_AE_\ 9I_Z-X\"_P#A)6?_ ,:H_P"&7_V:?^C>/ O_ (25G_\
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M_P#&J[FB@#AO^&7_ -FG_HWCP+_X25G_ /&J/^&7_P!FG_HWCP+_ .$E9_\
MQJNYHH X;_AE_P#9I_Z-X\"_^$E9_P#QJC_AE_\ 9I_Z-X\"_P#A)6?_ ,:K
MN:* .0T3]GSX!^&=6M]?\.?!#PAI]]:2"2UO;'PU:Q30N.C(ZQ@J?<&NOHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAFCWQLKIN1V&Y6##.00<&@#YT\2?MZ_M":[^PM\'OVK?V8_V$]:^)WBOXO\
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M8=SLOE^?Y47F_=SN\M>O2M#]MW_DR_XO?]DOU_\ ]-T]>'_\$"/^4-O[/?\
MV3^'_P!'2T ?7]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?*O[>O_!3VR_9/^*WA#]D_X#_ /6OC-\=/'UI)>^&?
MAIH.IQ6"0:?&65]1U"]F#1V-J&1U$C*VYD8 8!(^JJ_-C]D3[-)_P<U_M;MX
MZ8'68_@_X/7P&)\;QHAM;0WWE9YV?;MF['&X\\T =9J?_!7C]J#]DKX@>%M&
M_P""K'[ \/PE\#^,]9BT?2?BSX0^(<'B+1=.U&7/E6^I*L$,MDK8($Y#)U_A
M5V7Z-_;;_:@^.O[-'A70[W]GO]B?Q?\ &[7==OY+9-&\+ZI:V$-@JQ[A-=75
MR=D,;'"@X.3GTKQ/_@XTC\$2?\$5OCT/'HM?LH\-6IL_M6,"^_M&U^R[?]OS
M_*QCO7T7^Q&WC9OV,/A$WQ*,I\1GX8: ?$!G)W_;?[.@\_=GG=YF[.><T >=
M_P#!*C_@H%JW_!2O]E8_M':]\#_^%>7T/BS5-"O?#'_"2KJWD2V4WE.WVE8(
M%;+9X"8&.&;K7TG7YX_\&R?_ "CJU[_LN'C#_P!.!K]#J /FKX(?\%!M;^-_
MPU_:+\<^&OV=-6O=1^ OQ3\1>"[#PQH.K+>WOBV;2[*TN4> -%$()+AKH1+"
M2X4J"9&W8'SY\6?^"N7_  4P_94\!2?M-_MB?\$=9?"_PAL)X6\3ZCX:^,NG
MZUKOAZSDD6,7<UE' BS %EW(D@V;OF8!2:^X/@K^SA\&/V=[GQG=_!WP;_8\
MGQ!\<7GC#Q>W]HW-Q]OUJZCACGNOW\C^5N2WA'EQ[(QLRJ DD_#O_!4#XT^-
M?^"DOCW6O^"*O[$%]#<W.HQVZ_M'?$Y0);#P'H;2JSZ>I^[/J=R$*+ #\B[]
MVWYWA /IG]L[_@HU\#_V.?V-X/VRM0M[_P 6:7KR:;%X!T3P]'F[\4WVHA38
M6ML&'WI0V_)&517;:Q&T^*>"/^"K'[5OPG_: ^&WP<_X*5?L!P?!W2/C)K T
M7P!XQT#XD6_B&T@UN1-\&D:B(X(C;SR_=212Z._ &U7=/._^"RGPX\(_"#7O
M^">OP>T2T>W\$>%_VJO!^D65M.^Z.,VML\.GHY/!8!" 3U^:M[_@YA"G]B;X
M:OIP)UU?VDO!9\+>7CS/[0^U2[/+S_'Y?FXQVSVS0!^B5%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX ^('Q6^!GB[X9_"KXMW/@+Q)K_AZ[T_1/&MGIPNYM#N98F1+R.$O&)'C)W
M;UY PP/-? /[(_\ P18_X*5?L-_"K_A3G[-7_!9'PYH6D2ZE/J.HRS?LM:==
M7FI7LS;I;JZNI]5>:YF;@;Y&8A551A5 'Z7T4 ?.O[9?_!/O3/V\/V*;#]ES
MX^_%F^;Q5IL6EZCI_P 3] TQ+*[LO$MBJE-9M[97*0EI?,)@#X$<SHK@X<>-
M>#O^"6O[87QK^/OPU^+?_!3;]N71_BIH?P:UI=<\">#?"GPZCT*UOM<C39!J
M^I-Y\OFS1<LD485%<Y!"ET?[OHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-20210331_g18.jpg
<TEXT>
begin 644 biib-20210331_g18.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
MZ.IZ$,."/<5F?$+Q7_P@?@'7/''V#[7_ &-H]S??9?-\OSO)B:39NP=N=N,X
M.,YP:_-C_@E=\./B3\$O^"DOBG2/V:?V$/C-\#_V:O&'PS-[J_@_XF6MK#8:
M;XQ@O4"W&G1P7]VL$<]H[!XPRAGCSC"(!^B'[0G_ "0/QQ_V)^I_^DLE 'RK
M_P $6?\ @LKH?_!7KX=^,/$-[\!9OAGXB\(W]D9O#,_B7^U1=:9>0L]K?QS_
M &:WRKR0W494(0I@^\2VU<?XA_\ !<'0O"O_  6+\,?\$G?"?[.TVN6^L7"6
M&M_$O_A*O(ATO5#IDFI/9):"U<7+);_92S>>A5KG!4;/G^ /^"?GQ6\-?\$Q
M/V1OV,_^"J7BE9X/ 'BGX8^)/AG\8I+6,L1LU'4]5T.Y"#[TGVFWN+;>>0LZ
MJ#R >A^"/P7\:^ ?VJ/^"<7QU^,EEY7Q$^/7Q2^)GQ/\>%@=T=UJ^DVDUO;X
M/*+#9BUB$9^X48 #I0!^XVK:QI&@V3:GKFJVUE;(0'N+N=8T4DX&68@#FIX9
MHKB)9X)5='4,CHV0P/(((ZBORZ\$_LY?"K_@K-_P6(_::L?VY- ?QKX(_9V/
MASPW\,OAKJ]W*-*LYK^PDN;S4YK9&59IY'0A'<']VV"#Y<977_X)V^%5_8E_
MX*:_M+_\$ROA%KNH2?!VQ^'.D^// ?A>_P!2ENT\(3W0:&[L;9Y69D@ED;S5
MC)PH5<<EV8 _2?4=:T;2'@CU;5K6U:ZF$5LMQ.J&:0]$7<1N;V'->._\%"_V
MW/!?_!.W]E'7_P!K+X@^#=4U_2O#]]IMM<:7HTD:W$K7E]!9H5,A"X5YU8Y/
M13CFOS)_X(;_ /!%_P#8@_;7_P"",GP]^(G[5W@6\\;>)/%.D:W:Z)K&JZQ=
M;O"5HNJWT,4.F1I*L=L%D1KEF5=TDTSERR[5'DW[2C:?^V?_ ,&A'PP_:>_:
M-T[_ (2?QUX0N;2PT#Q)JES))=6ZIXP71G<ON_>/)9P)&[/N)R3G/- '[&?\
M%(_VI?$_[$W["_Q-_:N\&>&K#6=4\#>&I-2L=+U1W6WN75T78YC(8#YCT.:]
M ^#GQ1M/B1\-/"/BO5KFQM-6\2^%K'5WTN*X&Y?.MTE;8K'<44L1GVYKX*_X
M*>_\$^?V-/V#/^",G[4=I^R'\ ](\#1^*/ 2/KZ:3+.PO6MY<0EO-D?&P32X
MQC[YS7AO[</_  2B_9+^!_\ P14NOVW?!VB:ROQ[\&_#C1/&&G?&M_$=X=>.
MKQ):R>8)3*52+:6B2!5$<4>U45=BD '[(7M[9Z;:27^HW<5O!"A>6::0(B*.
MI)/ 'N:CTK6-(UZR74M#U6VO;=R0EQ:3K(C$=<,I(-?F3_P50^$'QV_:?TO]
MEG]I#QQ^RGXC_:!^#.B^'[G5?B_\&_!FJK;W-]J-YI]J]CJ(LC+$-16"3SL0
M;OE+]-KO7IW_  1V\8_\$GM2\>?$CP[^P3^SGKGP6^(4=MIY^)WPM\7>&KW0
MM5M(HS-]EGDT^:1X%&9I 9("<[T$AYCH ^L?VL?CI_PR_P#LL?$O]I?_ (1;
M^W/^%=_#_6?$_P#8GV[[-_:'V"QFNOL_G;)/*\SRMF_8^W=G:V,'XF^!O_!6
M#_@K_P#M'_!WPS\>O@__ ,$'K'5/"WB_1H-5T#47_:IT6W-S:3('C<QRV"NF
M5(.UE!'<"OIK_@K%_P HLOVEO^S?_&7_ *8[ROB/_@EA\&_^"UNL_P#!-_X(
MZK\%/VV?@GHGA&X^&FDR>'-(UOX2W=W>6=F;9#%%-,MZ@E=5P"X503S@4 ?I
MS\(_$?Q \7_"WP[XJ^*_PW7P=XGU+1;:Y\0>$TUF/41H]X\2M-:"ZB54N1&Y
M9/-50K[=P !K9LM:T;4KNXT_3M6M9Y[-PMW!#.KO QZ!P#E3]:_,O_@N[\+O
MB#\2M!_8=^#WQ#^*%S8>)=8_:4\.:7XF\7># ^GRBY?3[B.[N;'YF:U9B96B
M.6:(LIR2M<_^VI^PC^RU_P $MOVO?V/_ -H[]A/X:?\ "O=<\6?M"Z9\._&<
M>D:K=O%XBT?5H+@3+>B:5_M#HT(=7?+%VW,2RH5 /U5U76-)T*S;4=;U2VL[
M=6 :>ZG6- 2< %F(')XKY\\(?MH>+_$G_!4OQ?\ L$R^$M,30/#OP9TSQG:Z
M[')(;N:XNM0FM6@89V>6%C# @9R3SBODV3]GSX6_\%5/^"WO[0OPT_;4\.MX
MP\ ?LS>%O"&G> /AUJUS*-*>^UNPEOKG59;=&59I@$,*L^X;&3C*KC/_ ."?
M?[,_@?\ 8T_X+]?'+X.?"K4=4D\&Z=^SGHMWX3\.76H2WG_"/V<FI&1M-MVE
M9G\A9_/DCC)^19PBX55H _4/4M=T31I8(=7UFTM'NI?+M4N;A8S,_P#=4,1N
M/L*M5^!/[!US\!/^"@_P4U;]MK]OS_@D?^T9^TEXZ^*>OZO-_P )CHVEZ?=Z
M)HNFQWT]O;Z7HQEUJV>VBMUBVEA#')YN_P"9@%8^F>-/C#_P4#_9H_X(->,O
MA!XYMOB1\.M7U#X_Q_#;X5^(_'\B#Q+IW@;4+VU-I=7$D,T@$Z6\UQ:;UD;R
MR@"/\B-0!^D'_!4#]MK5?V&OV"OBA^UG\,=)T3Q+K?P^L;:5=&O[MC TLE[!
M;E)O*8.A"RL<9!RHKZ!T6^?4]'M-2E0*UQ;1RLJ] 64''ZU^-O\ P78_X(T_
ML._L9_\ !'GX@?%;]DGP#/X"\2>$=+TJUU36]/UBX,WBNQGU.SMY[75-\A6\
MWO*EPK.I9)H8RFP9%?L7X2_Y%73/^P?#_P"@"@#0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
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MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+
MB9G8*+D@+EB> .@[5[;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#D
MB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[
MI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO
M_@GO_P D3U;_ +'O6?\ TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_\
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MQ/\ ^'!T/_Y(H_M++O\ G]#_ ,"7^8'U%17R[_PWK^T=_P!(\O$__AP=#_\
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M<'0__DBC^TLN_P"?T/\ P)?Y@?45%?+O_#>O[1W_ $CR\3_^'!T/_P"2*/\
MAO7]H[_I'EXG_P##@Z'_ /)%']I9=_S^A_X$O\P/J*BOEW_AO7]H[_I'EXG_
M /#@Z'_\D4?\-Z_M'?\ 2/+Q/_X<'0__ )(H_M++O^?T/_ E_F!]145\N_\
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M=_TCR\3_ /AP=#_^2*/^&]?VCO\ I'EXG_\ #@Z'_P#)%']I9=_S^A_X$O\
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M[_\ )$]6_P"Q[UG_ -*37NE !7D7QL_Y'3_MSC_FU>NUY%\;/^1T_P"W./\
MFU?.<4?\BS_MY?J!R%%%%?G0!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7J7P&_Y -[_ -?@_P#0!7EM>I? ;_D
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M44 %%%% !1110 4444 %>I? ;_D WO\ U^#_ - %>6UZE\!O^0#>_P#7X/\
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M)NAWVG'X1^"O$&O_ #36[^&[:/23IEE*^)%>]ED>;R$/.6DKG_V7_P!AV/\
MX)>_M:_L6:]X%\>^-)OB?\?+76K#]HJQU_Q1=WJ^*KA/#SZG<WLT,[LL<EG>
M(H5U ;:VURQ9BP!^L?P\?Q])X T-_BM#I$?BAM'MCXDCT!Y6L%O_ "E^T"V,
MH$AA$N_87 8KMW<YK8HHH \+_P"">_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#D
MB>K?]CWK/_I2:]TH *\B^-G_ ".G_;G'_-J]=KR+XV?\CI_VYQ_S:OG.*/\
MD6?]O+]0.0HHHK\Z **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"<G['%K^RCJO[$0^%%S+\,=:N//U/PY=>*]4F>=_M$=QG[7)<FZ4>;%&V%E
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M_P!4/^G_ /Y+_P#; ?.=%?1E%'^J'_3_ /\ )?\ [8#YSHKZ,HH_U0_Z?_\
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M+NYDAW1AY%&Q2WWL)Y8!]TT444 >%_\ !/?_ )(GJW_8]ZS_ .E)KW2O"_\
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M:$_X(V:Q\*?!^H_:O[7\?77QLT75X]+\NUEEBS:6T8EE\R9(X?E/RF8.>%-
M'U_1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*^>OV"[;Q)+\'-6;2=2MXHO\ A.-9
MRLL)8Y^TMSFO;?L7C?\ Z#=E_P" Q_QH V*\B^-G_(Z?]N<?\VKT7[%XW_Z#
M=E_X#'_&O,?BS'J47BO;JMS'++]E3YXDVC&3VKYSBC_D6?\ ;R_4#F:***_.
M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^ Q_QH^Q>-_^@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO>X:_P"1M'T?Y =U1117Z4 4444 %%%% !1110 4444 %%%% !1110 4444
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M/V6L:-=S74TZE+H*!%,5'W1Z5[W#7_(VCZ/\@/2:*Q_^$'TC_GYO?_ MJ/\
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M0#C26%Q,)1C*#3EM=/7T ]!HID$\%U ES;3))'(@:.2-@592,@@CJ".]/K
MHHHH **** "O4O@-_P @&]_Z_!_Z *\MKU+X#?\ (!O?^OP?^@"O>X:_Y&T?
M1_D!W5%%%?I0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBM8Y[N=R\UPZQ*H:61R6=SEF)R237KW_  H#_J;?_)#_ .V4?\* _P"IM_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2D
MU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!\Q?LV?&KX6?LS>"]4^&WQY\:V?A
MC77\5:E?KIFHEA+]FFG+12?*",,O(]J]#_X;N_9#_P"B\:)_WU)_\17HFL>
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MXT3_ +ZD_P#B*/\ AN[]D/\ Z+QHG_?4G_Q%=U_PJ;X5_P#1-/#_ /X)H/\
MXBC_ (5-\*_^B:>'_P#P30?_ !% '"_\-W?LA_\ 1>-$_P"^I/\ XBC_ (;N
M_9#_ .B\:)_WU)_\17=?\*F^%?\ T33P_P#^":#_ .(H_P"%3?"O_HFGA_\
M\$T'_P 10!PO_#=W[(?_ $7C1/\ OJ3_ .(H_P"&[OV0_P#HO&B?]]2?_$5W
M7_"IOA7_ -$T\/\ _@F@_P#B*/\ A4WPK_Z)IX?_ /!-!_\ $4 <+_PW=^R'
M_P!%XT3_ +ZD_P#B*C7]O7]D!IVMA\=M(W*H))28+^#;,'Z UWW_  J;X5_]
M$T\/_P#@F@_^(KQ/P+\// $W[>7CO1IO VCO9P^"-+DAM&TR(QHYD;+!=N 3
MW(H [+_AN[]D/_HO&B?]]2?_ !%'_#=W[(?_ $7C1/\ OJ3_ .(KNO\ A4WP
MK_Z)IX?_ /!-!_\ $4?\*F^%?_1-/#__ ()H/_B* .%_X;N_9#_Z+QHG_?4G
M_P 11_PW=^R'_P!%XT3_ +ZD_P#B*[K_ (5-\*_^B:>'_P#P30?_ !%'_"IO
MA7_T33P__P"":#_XB@#A?^&[OV0_^B\:)_WU)_\ $4?\-W?LA_\ 1>-$_P"^
MI/\ XBNZ_P"%3?"O_HFGA_\ \$T'_P 11_PJ;X5_]$T\/_\ @F@_^(H X7_A
MN[]D/_HO&B?]]2?_ !%'_#=W[(?_ $7C1/\ OJ3_ .(KNO\ A4WPK_Z)IX?_
M /!-!_\ $4?\*F^%?_1-/#__ ()H/_B* .%_X;N_9#_Z+QHG_?4G_P 11_PW
M=^R'_P!%XT3_ +ZD_P#B*[K_ (5-\*_^B:>'_P#P30?_ !%'_"IOA7_T33P_
M_P"":#_XB@#A?^&[OV0_^B\:)_WU)_\ $4?\-W?LA_\ 1>-$_P"^I/\ XBNZ
M_P"%3?"O_HFGA_\ \$T'_P 11_PJ;X5_]$T\/_\ @F@_^(H X7_AN[]D/_HO
M&B?]]2?_ !%'_#=W[(?_ $7C1/\ OJ3_ .(KNO\ A4WPK_Z)IX?_ /!-!_\
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MOV0_^B\:)_WU)_\ $4?\-W?LA_\ 1>-$_P"^I/\ XBNZ_P"%3?"O_HFGA_\
M\$T'_P 11_PJ;X5_]$T\/_\ @F@_^(H X7_AN[]D/_HO&B?]]2?_ !%'_#=W
M[(?_ $7C1/\ OJ3_ .(KNO\ A4WPK_Z)IX?_ /!-!_\ $4?\*F^%?_1-/#__
M ()H/_B* .%_X;N_9#_Z+QHG_?4G_P 11_PW=^R'_P!%XT3_ +ZD_P#B*[K_
M (5-\*_^B:>'_P#P30?_ !%'_"IOA7_T33P__P"":#_XB@#A?^&[OV0_^B\:
M)_WU)_\ $4?\-W?LA_\ 1>-$_P"^I/\ XBNZ_P"%3?"O_HFGA_\ \$T'_P 1
M1_PJ;X5_]$T\/_\ @F@_^(H X7_AN[]D/_HO&B?]]2?_ !%'_#=W[(?_ $7C
M1/\ OJ3_ .(KNO\ A4WPK_Z)IX?_ /!-!_\ $4?\*F^%?_1-/#__ ()H/_B*
M .%_X;N_9#_Z+QHG_?4G_P 14<O[>O[($+I&_P =M()D;"[4F8#ZD)Q]37??
M\*F^%?\ T33P_P#^":#_ .(KQ/\ :D^'G@#3OC)\%[73_ VCP17?C>6.ZCAT
MR)5F3[,QVN N&&>QH [+_AN[]D/_ *+QHG_?4G_Q%'_#=W[(?_1>-$_[ZD_^
M(KNO^%3?"O\ Z)IX?_\ !-!_\11_PJ;X5_\ 1-/#_P#X)H/_ (B@#A?^&[OV
M0_\ HO&B?]]2?_$4?\-W?LA_]%XT3_OJ3_XBNZ_X5-\*_P#HFGA__P $T'_Q
M%'_"IOA7_P!$T\/_ /@F@_\ B* .%_X;N_9#_P"B\:)_WU)_\11_PW=^R'_T
M7C1/^^I/_B*[K_A4WPK_ .B:>'__  30?_$4?\*F^%?_ $33P_\ ^":#_P"(
MH X7_AN[]D/_ *+QHG_?4G_Q%'_#=W[(?_1>-$_[ZD_^(KNO^%3?"O\ Z)IX
M?_\ !-!_\11_PJ;X5_\ 1-/#_P#X)H/_ (B@#A?^&[OV0_\ HO&B?]]2?_$4
M?\-W?LA_]%XT3_OJ3_XBNZ_X5-\*_P#HFGA__P $T'_Q%'_"IOA7_P!$T\/_
M /@F@_\ B* .%_X;N_9#_P"B\:)_WU)_\11_PW=^R'_T7C1/^^I/_B*[K_A4
MWPK_ .B:>'__  30?_$4?\*F^%?_ $33P_\ ^":#_P"(H X7_AN[]D/_ *+Q
MHG_?4G_Q%'_#=W[(?_1>-$_[ZD_^(KNO^%3?"O\ Z)IX?_\ !-!_\11_PJ;X
M5_\ 1-/#_P#X)H/_ (B@#A?^&[OV0_\ HO&B?]]2?_$4?\-W?LA_]%XT3_OJ
M3_XBNZ_X5-\*_P#HFGA__P $T'_Q%'_"IOA7_P!$T\/_ /@F@_\ B* .5\)_
MMA?LS>.?$=GX1\)?&+2;[4M0F$5G9PE]\KGHHRN,UZ56+I_PV^'>DWL>HZ7X
M!T6VN(6W0SV^E0HZ'U#!<@_2MJ@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBOASXE_\%9?C;\3OVF?%_P"RA_P3&_8N
M?XU:M\-KL6/Q*\;ZWXTA\/\ AO0=0YSIZ7#Q2O>72E2KQQJ/+.<D[6P ?<=%
M?'G[(O\ P51\3?$G]J*;]@K]MS]EW4?@;\:9-%?6/#6B7'B*'6-(\6:>F[S)
M]-U"%$65T".SP,@=%5N24D"X/_!4/_@K/^T7_P $](/$_B?P'_P3+\8?$GP=
MX,T.VU3Q'\09O&=GH>CP1RL%,<;R1S2SR(S*K*D1.6^IH ^X:YO3/A3X1TCX
MHZI\8+.&<:UJ^FP6-Z[3DQF&(DH G8Y/7O4GPG\=?\+0^%GAKXE_V7]A_P"$
MB\/V>I_8O/\ -^S_ &B!)?+W[5W[=^-VT9QG Z5G_M"_%?\ X4/\ O''QQ_L
M'^U?^$,\'ZGKO]E_:O(^V?9+62X\GS-K^7O\O;OVMMSG:<8H ["BOESQ)^WK
M^T)KO["WP>_:M_9C_83UKXG>*_B_X=T/5+7P!IGC"VL8-#34-+^WL]WJ=S$L
M:019$)E\H%V=,(-V!YK\-O\ @K!^U!\,?VJ/A_\ LK?\%+?V"T^$4OQ:O)=/
M^''C;PQ\0(/$6DWNIHH;^S[GRX8WM96!4(QW!V=0 %#,H!]VT5\N?\%%?V]_
MVB?V,;2.?X$?\$\_&7QGCB\-WFM:UJ^F>([31]*TBWM@S.MQ=W ?$FQ6<(L;
M$J.,D@5Z)^P'^U;_ ,-R?L;?#W]K;_A O^$7_P"$\\/IJ?\ PC_]J?;?L.YV
M7R_/\J+S?NYW>6O7I0!Z_1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !117RK^WK_P4]LOV3_BMX0_9/^ _P#UKXS?'
M3Q]:27OAGX::#J<5@D&GQEE?4=0O9@T=C:AD=1(RMN9& & 2 #ZJHKX$U/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-20210331_g19.jpg
<TEXT>
begin 644 biib-20210331_g19.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
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MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"251U,<H4D[/-VY;;N/T_0 4444 %%%% !1110 4444 %%%% !1110 4444
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M1E%?.=%'^M__ $X_\F_^U ^C**^<Z*/];_\ IQ_Y-_\ :@?1E%?.=%'^M_\
MTX_\F_\ M0/HRBOG.NO^"?\ R.G_ &YR?S6NC"<3_6L5"C[&W,[7YO\ [4#U
MVBBBOK "BBB@ HHHH **** "BBB@ HHHH **** /"_\ @GO_ ,D3U;_L>]9_
M]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *X7X\_\@&R_Z_#_ .@&NZKA?CS_ ,@&R_Z_#_Z :\G/?^135]/U0'EM
M%%%?EH!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBOU< HHHH **** "BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\
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M1110 4444 %%%% !77_!/_D=/^W.3^:UR%=?\$_^1T_[<Y/YK7HY1_R,Z/\
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ME)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "N%^//_ " ;+_K\/_H!KNJX
M7X\_\@&R_P"OP_\ H!KR<]_Y%-7T_5 >6T445^6@%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=?\$_\ D=/^W.3^
M:UR%=?\ !/\ Y'3_ +<Y/YK7HY1_R,Z/^) >NT445^K@%%%% !1110 4444
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M$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@
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MK/C5XB^-VF?"^X_X(F^-/@CH6O>?_;'C>XN-#CLK/R;:::+STLG\R3>Z+"N
M<-,"<#->)^(/C9^VW^P#_P %,OC[J_P&_P""5?Q.^*OPT^*&I:1K=WKVAWMI
M!LUN+3(()Y;1I&/G6TB+&K))L:.:&4J75PJ_0'[+G_!2']K#X]_';0OA-\2_
M^"2/Q@^&.B:M]J^V^./%.H6$EAIOE6LLR>:L3ESYCQI"N!]Z5<\9H ^OZ***
M /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KA?CS_ ,@&R_Z_#_Z :[JN%^//_(!LO^OP
M_P#H!KR<]_Y%-7T_5 >6T445^6@%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %=?\ !/\ Y'3_ +<Y/YK7(5U_P3_Y
M'3_MSD_FM>CE'_(SH_XD!Z[1117ZN 4444 %%%% !1110 4444 ?E9_P41_:
MG_X*+?&ZY_:O\2_LD_M36WP9^'7[)_AF<7+Z7X5M=2UGQKKT6C#5)HGEN@5L
M+2-9(H@T:EW.YLD'"?1?Q4_:G^/'PO\ VG/V+_#UIX[%QX3^,EIJVB^/-#FT
M^W>6ZO4T#^T;.^CEV>;&4E@E5U5@A68$KE1GRC_@H=_P2Z^.WQ]^*'QLU+_@
MG3^VCX0\(:U\9O!,.@?'SX7>+[,7UA?+)8R6=KJ:F#=<:;=FUR@81E)@@8@[
M3NZ+]C/_ ()__M%^%OVJ? /[0/\ P4\_;*\&>-?B!X$\)7ND_!3X:^";$:?I
M6A0/;I;W^H1+.1<WUR\ 6)I&0"-'.<[DV 'W[1110!\]?L%VWB27X.:LVDZE
M;Q1?\)QK.5EA+'/VEN<U[;]B\;_]!NR_\!C_ (UY'_P3W_Y(GJW_ &/>L_\
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MP!\'_P!FW2+S5-9\9_$K0#I,WBC7I]'.FP6>FV[DO)!$)997G/RMMV$(0GF
M'ZB4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*3
M7NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %<+\>?^0#9?\ 7X?_ $ UW5<+
M\>?^0#9?]?A_] ->3GO_ "*:OI^J \MHHHK\M **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z_P""?_(Z?]N<G\UK
MD*Z_X)_\CI_VYR?S6O1RC_D9T?\ $@/7:***_5P"BBB@ HHHH **** "BBB@
M#\^/BG\7/^"H7[?7[8WQ3_9O_80_:+\+? +X=?!75++0O$GQ&U+P-#XCUK7M
M;GLHKR6"VL[IEMXK:&.>)2S;7+,&5F#$1O\ @W\9/^"G/["G[:WPP_91_;V_
M: \+?'CP)\:[C4]-\(?$S2?!4/AW6-%UBSLI+T6]Y96I-N]O-#%(J.FYPZDL
MRJ,-E?'?]@__ (++^&_^"A/Q%_:S_8!_:3^!W@KPEX]ATQ-4\*^*='U*Y.L2
MVEG% MY?(L;HMTN'C$MNT1:%8EDWE 1P>L_\$_O^#B?Q=^T_X=_:O^('[67[
M,/B'7_!>G7MKX&TO4_#>LKIOAY[M!%=75O!#'&6N)(@8C+,TK+&S*FT,V0#]
M5:*\O_9#TK]L'1O@U!9?MR>+/ >M>/1J$YN+[X<6%U;:8;4D>2JI=$R;P,[C
MT)Z5ZA0!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7"_'G_ ) -E_U^'_T UW5<+\>?^0#9
M?]?A_P#0#7DY[_R*:OI^J \MHHHK\M **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *Z_X)_P#(Z?\ ;G)_-:Y"NO\
M@G_R.G_;G)_-:]'*/^1G1_Q(#UVBBBOU< HHHH **** "BBB@ HHKC_C]X9^
M,/C+X->(?"_[/_Q.L_!GC.]T]H_#OBG4-%348=-N,C$KVSD+, ,C:2.M #_
M?QU^$WQ-\?\ C/X7>!?&4&HZ_P##W4K6P\8Z='!*K:9<W%K'=PQLS*%8M!+&
MX*%@ V"0<BH_&_Q^^$'PW^*O@CX(^-O&T%AXI^(\^H0^"='D@E9]4>QM3=W:
MHRJ43RX%+G>RY P,GBOR_P#A/_P3]_X+F? 3XW?'#XT>*?\ @JK\-? 5KXS\
M3:5>7_C76?A7I<UOXG:#2H+9;@0/< :<(A']G\LX\PQ&3^*OH/\ 9-_8$_:W
M\;?M3> _VV?VU_\ @I9H/QOA^&NG:Q#\.-)\%?#ZQT>PMKK4K=;6ZNI9[:5_
MM!\@%%0C"DA@PY# 'W=1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;
M_L>]9_\ 2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7"_'G_ ) -E_U^
M'_T UW5<+\>?^0#9?]?A_P#0#7DY[_R*:OI^J \MHHHK\M **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z_X)_P#(
MZ?\ ;G)_-:Y"NO\ @G_R.G_;G)_-:]'*/^1G1_Q(#UVBBBOU< HHHH ****
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MQ=\9-#O-6\&QM\0/$2'68+.".XN%:X6?RQ+'#*DAB=PY7) (4X /U5HKR_\
M9#_8_P#@C^PY\&H/@-^S[I>J6?ARWU">]BAUC7;G49A-,07)FN7>0C(&!G [
M5ZA0!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0
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M_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N%^//\ R ;+_K\/_H!KNJX7X\_\@&R_Z_#_ .@&O)SW_D4U?3]4!Y;1117Y
M: 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDLQG)*R<*0IP" ?IY1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\
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M;_1FG#8!PA<G@$T ?9=%%% 'A?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\
M\D3U;_L>]9_]*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<+\>?^0#9?
M]?A_] -=U7"_'G_D V7_ %^'_P! ->3GO_(IJ^GZH#RVBBBORT HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KK_@G
M_P CI_VYR?S6N0KK_@G_ ,CI_P!N<G\UKT<H_P"1G1_Q(#UVBBBOU< HHHH
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M_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !1110 4444 %%%% !1110 4444
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M8>%/A]X3U/QYX[\26.C:)HMA-?:OJVIW2P6UE;1(7DFED<A4154LS$@  DT
M:-%? OP[_P"#B+_@G[XT_:/\2_#:Z^+,\/@B#3M '@[QRG@+7_L>J7][-?17
M$4EP;/R8H5,%L(IV*12F27:[[#C[XFFBMXFGGE5$12SN[8"@<DDGH* '45\,
M_L(_\%L_#'[>_P#P4!\;_L??#G]GZ\T_P?H'@FZ\3^#OBE=>(0Z>+;&#5(M,
M:X@LOLR^7;O<&Y\N8SN72W#;%\S"_4?[5_[3GPN_8V_9Y\4_M*?&/49(-!\*
MZ:US/%;KNN+V8D)!:0)_'/-,T<,:?Q/(HXZT >AT5\M?\$E/^"COB3_@IM\
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M% !77_!/_D=/^W.3^:UR%=?\$_\ D=/^W.3^:UZ.4?\ (SH_XD!Z[1117ZN
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MM;\3Z1=76N7OGO'<A4;RU7 V@X^4"NO Y_@\?B%1IQDF[[I6T]&P.LHHHKW
M"BBB@ KA?CS_ ,@&R_Z_#_Z :[JN%^//_(!LO^OP_P#H!KR<]_Y%-7T_5 >6
MT445^6@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=?\ !/\
MY'3_ +<Y/YK7(5U_P3_Y'3_MSD_FM>CE'_(SH_XD!Z[1117ZN 4444 %%%%
M!1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\
MR1/5O^Q[UG_TI->Z4 %>1?&S_D=/^W./^;5Z[7D7QL_Y'3_MSC_FU?.<4?\
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M^:UR%=?\$_\ D=/^W.3^:UZ.4?\ (SH_XD!Z[1117ZN 4444 %%%% !1110
M4444 %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\
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M'SI,,*.CJWDW$WVG>#%RQ!7RCUW''?/V/]GQBIKF4F[>]?517:W1WU ^??\
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M+3BY.ZT2OW[ >L45Y=_PVA^S3_T4H?\ @HO/_C-'_#:'[-/_ $4H?^"B\_\
MC-?!?V;F/_/F?_@+_P @/4:*\N_X;0_9I_Z*4/\ P47G_P 9H_X;0_9I_P"B
ME#_P47G_ ,9H_LW,?^?,_P#P%_Y >HT5Y=_PVA^S3_T4H?\ @HO/_C-'_#:'
M[-/_ $4H?^"B\_\ C-']FYC_ ,^9_P#@+_R ]1HKR[_AM#]FG_HI0_\ !1>?
M_&:/^&T/V:?^BE#_ ,%%Y_\ &:/[-S'_ )\S_P# 7_D!ZC17EW_#:'[-/_12
MA_X*+S_XS1_PVA^S3_T4H?\ @HO/_C-']FYC_P ^9_\ @+_R ]1IEQ;P7=O)
M:W,0>.5"DB,.&4C!!_"O,?\ AM#]FG_HI0_\%%Y_\9H_X;0_9I_Z*4/_  47
MG_QFFLNS*+NJ,[_X9?Y":35F>=^.O"T_@WQ1=:%*"4C?=;N?XXSRI_+@^X-9
M%=3\6/CO\!/B9]A7P?X[2XU9)?*CA.G7,?G(><;GC"Y!Y&2.I[D5RHUCPIHE
MS;WOC;6ET_3?M"K<W)B=R%)Y 5 6)(!Z#WZ5_3W#F>2Q_#T<9BDXS@FIIIWO
M%:M+^\M5;O8_"L[R2K@<[>$I*ZFUR>DGHOD]/E<]M_9_\'?V-X=?Q+>18N-1
M_P!5D<K".G_?1Y^FVO0*\K@_;)_9CM8$MK?XC*D<:!8T71[P!0!@ ?N:?_PV
MA^S3_P!%*'_@HO/_ (S7\ZYW/-\[S6KC:M&=YO1<KT6R6W161^SY9@*668"G
MAH;17WOJ_FSU&BO+O^&T/V:?^BE#_P %%Y_\9H_X;0_9I_Z*4/\ P47G_P 9
MKRO[-S'_ )\S_P# 7_D=YZC17EW_  VA^S3_ -%*'_@HO/\ XS1_PVA^S3_T
M4H?^"B\_^,T?V;F/_/F?_@+_ ,@/4:*\N_X;0_9I_P"BE#_P47G_ ,9H_P"&
MT/V:?^BE#_P47G_QFC^S<Q_Y\S_\!?\ D!ZC17EW_#:'[-/_ $4H?^"B\_\
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M ,^9_P#@+_R ]1HKR[_AM#]FG_HI0_\ !1>?_&:/^&T/V:?^BE#_ ,%%Y_\
M&:/[-S'_ )\S_P# 7_D!ZC17EW_#:'[-/_12A_X*+S_XS1_PVA^S3_T4H?\
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M%%% &7JW@CP7KUX=0USPAI=[<%0IGN]/CD<@=!N92<56_P"%7?#/_HG>A?\
M@HA_^)K=HH PO^%7?#/_ *)WH7_@HA_^)H_X5=\,_P#HG>A?^"B'_P")K=HH
M PO^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\ @HA_^)K=HH PO^%7?#/_
M *)WH7_@HA_^)H_X5=\,_P#HG>A?^"B'_P")K=HH PO^%7?#/_HG>A?^"B'_
M .)H_P"%7?#/_HG>A?\ @HA_^)K=HH PO^%7?#/_ *)WH7_@HA_^)H_X5=\,
M_P#HG>A?^"B'_P")K=HH PO^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\
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M_P 36[10!A?\*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\ !1#_ /$UNT4
M87_"KOAG_P!$[T+_ ,%$/_Q-'_"KOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_
M]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\ \36[10!A?\*N^&?_ $3O0O\
MP40__$T?\*N^&?\ T3O0O_!1#_\ $UNT4 87_"KOAG_T3O0O_!1#_P#$T?\
M"KOAG_T3O0O_  40_P#Q-;M% &%_PJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1
M.]"_\%$/_P 36[10!CV/P^\ Z7>1ZAIG@C1[>XB;=%/!ID2.A]0P7(-;%%%
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M_A#/!^IZ[_9?VKR/MGV2UDN/)\S:_E[_ "]N_:VW.=IQBJ'[)_\ R:S\-/\
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MXXO/&'B]O[1N;C[?K5U'#'/=?OY'\K<EO"/+CV1C9E4!))^'?^"H'QI\:_\
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M!L'_ *+6M&BNW*,D_LJI*?M.:ZMM;]6 4445[H!1110!\:?LJ?LH_'WX;?\
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M7?M Z;HMQXN\-^%=?L[/6_#&NZ;;M:I/%#>R1I<V\\3%FV/N#MSM6-?,WO\
M@G_^RS^UCXV_:T^-_P#P4X_;'^%5K\/O$WQ+\,6/A/X??#*/6X-0NM!T"T4M
MNO+F$F$SW$VR4HC$1X()YPOWA10!\:?\$=/V4?C[^RM_P1L\!?LI_'KP%_8/
MC[1?#>O6NIZ#_:EK=>3-<ZE?S0KY]O+)"VZ.>)LJY W8)!! I_\ !-']D?\
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M:OX$\ ^%M/N_#/[.7@?3/$=M-=Z?*X1I?&,[V4\D?VMY$C$,#/\ NXXRLB9
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M:=XMUS3+RP%TGG/"HCM;F%+EW=T81H(B\@PR!E8$\S^RW_P5U_8/_:_^*J?
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M_P *O@4OACP=\59"WCG0_#OB/4K&.^!@2W*1M#<J]I&846,QV[1(5R"I#-D
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M/E%#%SC9CB@#Y ^+'@S4_B3\$?\ @D?X6_:)T$ZK>7'B309=9L=<A\QII(M
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M&JBYU2Z\V9I9#CYBTK#);.% '0 5[O\  #]@;]DO]F#]FW4?V2O@E\(K;1?
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M#X8:Y\%_C1X)L/$?A;Q)8/9:WHFIQ;X;N!NJL.""" 0P(96 8$$ UXG\(O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>biib-20210331_g2.jpg
<TEXT>
begin 644 biib-20210331_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\&ZI9ZS\%K'P[<ZSK%S)&;74%U>T>ZA$(4EP8U0JVX#D\9KE?#O[<7B_5O\
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M?]F3XC:KJ/Q\GEB81WVC^$Y8XO#>0V1-;WKW6GE@3\WV<MSR* /T9_X)._\
M!0O4O^"F_P"R7'^TUK/P-D^'5X/%&I:)=^%Y?$']IM;RV<HC8F;[/;\DYROE
M_+CJ:^C(=?T*YU:70;?6K22^@0//9)<J98U.,%D!R!R.2.]?A[^SY^U%\4_V
M-_\ @V _: ^/?P4U:XTWQ18?%GQ'IVD:M:\2:>]_XBMK!KE&'W)(TN7=&[.$
M->U?MT?\$3/V-_V,O^"8'BC]HW]FVSO?"WQO^#_@V3QCH_QQT[7[K^V]2U>S
MB%S<37$[2$3K=%)4,3 H/.&U1@4 ?K'5;3=:T;63.-(U:UNC;3&&Y%M.LGE2
M#JC;2=K#T/-?D;^WK97G_!0W]H3_ ();ZA\0-;U;PY_PM;PWXDUGQ1_PC=_+
M8W'D77A?3KR]LHYHV$D*S1F6V9D975)FVLK8(ZWXE_L<?LZ_\$O?^"PW[(>K
M?L*_#U/A[IOQ@F\6>%?B3X<T6^G^P:[:6VEK=6DDL4DC#S89R7#CEB%R>.0#
M[C^#?[;G@OXS?MH_&;]BG1_!NJ6>L_!:Q\.W.LZQ<R1FUU!=7M'NH1"%)<&-
M4*MN Y/&:Y3P]^W%XNU7_@J_XK_X)^W_ (2TF#PYX=^!UEXYC\1&:07;7$VI
M-:-"X)\L1!!NSC.>^*^#OV>/^"3G_!.S]H7_ (+??ML?#[XS_LK^'_$&C>'8
M? VKZ)87D]R$M+W5=-N+O4)EV2@[IY_WC9)&>@ XKJ_BU^Q3\%OVO?\ @XS\
M3?!_XV6=_?> ]&_9-T:ZO_!=KJ<]M9ZV8]:DBMX+WR75I[:,MYOD,=C21Q,P
M(3! /U5TS5-,UJRCU/1]1@N[:49BN+:99$<9QPRD@\U#=>)O#ECJT.@WOB"Q
MAOK@9M[*6[1991S]U"<MT/0=J_.G]@CX$> OV"/^"WGQ>_8N_9DT^;P[\*?%
M7P%T;X@IX&BO9I;'2]9&J2Z=)+:I*S>2)8T+.%."=HZ(BK\<_#3X&_L;?L@^
M M:\+_\ !?3_ ()5_$KQ#XXNO$VH7'CG]JE=)N_$FAZRLUY*T%^VH65Q]HTQ
M1 \*+$D:L/+R0KDJ #]Z:^=_V\OVT?$O[-/B3X2? SX.>%M-U_XF?&GX@PZ!
MX5TK59)!;6EA"OVG5M5F6,AWBM;168JK EY8ATS7MGPPU/P/K7PU\/:S\,M:
M@U+PW=Z':3>'M1M;HSQ75BT*-!*DA),BM&48/D[@<YYKX4^)US/XL_X.=?AC
MX6\2KNT[PE^R+J^N^&/,;Y4U*[UPV5RR ]&^S(@)'.WZ4 >\_P#!1#_@I#\/
M?V M \)Z'_PKK7?B%\2?B/K+:1\,OA?X4V?VAX@O%"F0[W^6"WB#H99V!"!U
MX.:\%^(W_!6C]O\ _8XT.U^-7_!17_@EA_PAWPF>[AB\1>-/AW\4[;Q-<^$U
MF<1I+?6:6\321!F4/+"Q5>P8LBG!^-R6LG_!U!\%QXZ .GI^RKJS>!?M(^0:
MU_:5Z+SR<_\ +7[#]['.SVK[&_X*%1^ Y?V"?C6GQ0%O_P (X?A/XA_MO[5C
M8+;^S9_,)S_LYQ[XH =^T=^U'XA^%W[.5G\?OV=O@)X@^-LNL_87\.Z!X#NH
M-^HV]TH>.[$TK"-+?85<R$D88'!S7DW_  2O_P""F?C[_@HA<_%SPW\4_P!E
M&;X1^(_A%XX'AG6O#]QXTBUJ1[GRR[[I(;>*-&4C:54R#/1JH?\ !ONWC!_^
M",O[/A\<>?\ ;?\ A!@(/M&=WV,7,_V3&?X?LWD[?]G%>3_\$,_^3R?V_?\
MLZ"[_P#0)* /I;X[_MH>)_V=?V[/A'^SW\0O">G)\/?C+IVHZ7X>\71R2"XL
M?%=J!<1V%QD^7Y5S:^8(2/G,T+*<AACZ(K\^?^#DJXE\.?L0^ OBGH0_XJ3P
M5^T/X*UKPBR'$@U%+_RTV'L2DLGX9K]!J /AK]JW_@JM^UC\,O\ @H+=_P#!
M/?\ 8_\ ^"<4/QG\0:=\,K7QMJ.H3_&.S\-"&SEO&M&79=V<B,5D\KD2[CYG
MW0%)KU/]C7]I;_@HK\:/B)J7AS]L#_@F1:_!/P_;:*]SIWB2#XW:9XF-Y>":
M)5M/LUI;QO&#&\LGFDE1Y6W&6!'Q7^T#X1_;'\9?\'*GBG3OV*/C+X-\$^)(
M_P!DC3Y-3U+QMX5EU>VFL?[> :%(HIHBDAD,3!RQ&U&&.<C[I_8]^'G_  4>
M\%^)=8NOVWOVD?AOXXTJ>QC30[3P/X#GTB6VN ^7>5Y;F42*5X"@#!YS0![I
MJFM:/H<"76MZM;6<4DHC22ZG6-6<]%!8C)/8=:LU^-G_  18_P""3G[%_P"V
MS^R]\1OB5^V-\.9_B+)<?&WQEIOA_2M;UBZ2R\/6JZ@XD^QPPRHL4\LC/(]P
M!YIQ&H8+&!7+^'_VOOVC/V?_ /@VJ^)F@^ OBSK9\2>"/B_J?PE\*^-[VZ:2
M^TW2CK\5DDQF!#*\5I.\4;@@QD1;2-BT ?IU_P %+/VS-2_8G_87^*7[4WPX
MTS1O$6N?#S1H[M=$O[IO):1KB*+9-Y3!TXD)['BO9?AGXJN?''PV\/\ C:_M
MHX)M8T.TOIH8B=D;2PI(5&>< M@9K\CO^"SG_!$S]A;]D3_@CQ\1?B)^S-X'
MN_"'C3P9X9M?M_C.SUFY-[XI@DN[>.\@U4M(5O%GWF3:XQ',L;1A0FT[7_!6
M7XQ>(_%GCO\ 8V_8#USX:_$WQE\,_'OA"]\0_$WP'\)7B36/&%OIVF0&VTT-
M)=6H^RB1FEN$\Y2T:@CYE4@ _6G2-<T37[=KS0=8M;V))"CRVEPLBJPZJ2I(
M!'I2ZGK6CZ*D4FL:M;6BSS+%"US.L8DD/1%W$98]@.:_(+X2?!R[^#G[?_P/
M^+'_  3._P""3'Q_^ 6DW'B7^POCC:>)-)L++PYK7AN>(QK<7$-MJMUFYM9M
MLR2"-2<MN9L 'MOV7/V3/@+_ ,%;_P!OO]JWXY?M\^!5^(5I\*_BK-\,_AKX
M,\07,QTSP[IUE;H9[F"W5U7SKJ1Q*96!8$94C/ !]>_LI?MN>-/V@?V[OVF_
MV3=?\&Z78:5\"]3\*VVB:I9R2&XU)=5TM[R4SAB5!1E"KL X/.37TG7YA_\
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M^E?;E% '@'P)_88_X4I^WQ\>?VX?^%H_VG_PN[3_  O:_P#",?V)Y/\ 8O\
M8]C):[OM/GM]I\[S-^/+CV8QE\YKW^BLOQ9XW\%^ [&#4_'/B_2]%MKJ\BM+
M:XU;4([9);B0XCA5I& :1CPJCDGH#0!\D?''_@F3^T;/^VGXN_;<_8?_ &\U
M^#^O?$;PYI>E_$'2-8^%MKXGL]5;3E:.TN8Q+=6[6[I$Q0X+ C)XS7HO@O\
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M=_8FWR/(U WGVS[7YYW;L[/*\D8^]O/2C_@G3^PQ_P ,!_"?Q;\+_P#A:/\
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M9?MM_L/?MYI\(-=^)/A[2M,^(6D:S\+;7Q/9ZH^G(T5I<QB6ZMVMW2)BA +
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MXP\2'R]^X*2H%?HI5/2_$.@:Y)/#HNN6=X]K)LNEM;E)#"W/RL%)VG@\'TH
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MLG?%/]DRZ_;6^&'Q;L-0^$^EZ)J6IW'BRVL+B.W@L=.\X7<GE-$LNV+[/,"
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MV[P7\+;/XB)X[UK^TK:+^S&U/2+2WL1Y,DBRS>;+%(O[I'V;<OM!!-?XQ?\
M!#?_ ()H?M#_ !F\6?M#_M.?!"Z^(7B7Q3<&6ZO?%WBJ_DATR 1J@M[.&.:.
M*UB4+D;5WY))8]OKNOQP_P""MW_!8?X"?&?]L35?^"3WBC]K0? [X6>'D"?'
MOXC_ &2[.JZZ"$+>'-)$$,C0B17Q/=, I7>J[E&RX /;_P#@W-U/6+;P/^T!
M\,_AOX[UOQ/\!?!7QQU'1?@+K6MWSW>=+B4">WM;B0EI[.*38(G!*DLY!R6
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MYW'@\,%\X(!_X.FP2!Q^P!Q[?\5O6A<@?\1.5FV!D_L'W.3_ -SI!0 W1O\
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MEI+9VFIB*0!DCN!,Q4, 2(R<8VD@&O\ \$6?$%Q\%?BI^TS_ ,$OIKEFTWX
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M'8 @G(] HH K:-H^D^'=(M/#^@Z;!96-C;1V]E9VL02*")%"I&BCA550  .
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MY?!PZE/I.C&>:?5=<NEN-1U6\N)GGN;V[F5$$MQ++([NP51DX554*H].HHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **\2_8(U34]7^#6JW.K:C/=2+XWU
MA%DN)F=@HN2 N6)X Z#M7MM !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?_  3W
M_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_[
M'O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4
MFO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT&H/^^J -*BJ%MXH\/WDZVMKJL3R.<(BGDFK] !1110 4444 %%%% !1110
M4444 >#_ /!/RTM9_@KJSS6T;G_A.M9&60$_\?)KW+^SM/\ ^?&'_OT*\1_X
M)[_\D3U;_L>]9_\ 2DU[I0!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H
M5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_
M ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_W
MZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG
M_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-
M10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\
M^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10
M!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,
M/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%<O\ '#X?_!_XB_!CQ7\./CAI^FMX
M,\1>'[O2_%,6HW MH)+"XB:*97EROE@HY&X,""0000#775B_$?X<^!/B]X"U
MCX6_$_PG8Z[X=\0:=+8:WHVI0"6WO;:52DD4BGAE92010!^/GQH_9?\ VT_^
M"3OQ0\;^//V*?^"B5WJOA?X/?LX0^(;/P=\<]"M-6@NM!M+^],>@QZA$(9H$
M01,("N&)D2+*J%8?JO\ LE_&&/\ :9_9;^&_[2%[X)&AS^/? FD^(I='F&YK
M%[RSBN##N(!;89-H; R #@9Q7R%H?_!O/_P3_P!-_:ZD\?7_ .S7IVH_#*S\
M#Z?!HOA+6/&NM7]I!K<6H74LCFQN;I[=K;R'MPL+ Q!E<B($LS?7O[2O[)OP
M"_:[^#,W[/OQ]\$3:KX1GGMY9-)T[6[W2R&@8-%MFL)H9452!\JN 0,$$<4
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MB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYG_ ."G/_),
M/#O_ &'F_P#1#U],5\S_ /!3G_DF'AW_ +#S?^B'KWN&/^1]0]7^3/$XC_Y$
ME;T7YH^*Z***_<C\:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ%'7C\0?\B3$?X6>KD?_ ".*'^)'WG1117X.?M84444 %%%% !1110 4444
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M^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7S/\ \%.?^28>'?\ L/-_Z(>OIBOF?_@I
MS_R3#P[_ -AYO_1#U[W#'_(^H>K_ "9XG$?_ ")*WHOS1\5T445^Y'XT%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>%_\$]_^2)ZM_P!CWK/_ *4FO=* "BBB@ HHHH **** "BBB@ HHHH ****
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MK?\ ]HKY_HH_L[!_R_B_\P_M'&?S?@O\CZ _X;H_ZI=_Y6__ +11_P -T?\
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M^N[N&SMVEVD$Q)).LCJ"I949002#7R#^U!+_ ,%B_P#@F3^RF/\ @H[\4_\
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M'_H<%?/<6?\ )-8O_!(][A?_ )*+"_XT?L]1117\N']+!1110 4444 %%%%
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MW_B6X6;Q+XCU+5)M1U75Y 20;B[NI))74%F(0,$!9B%!)) /)/V^OVY_C?\
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MWF3I%#\OW/.WGA30!]ET444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\
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MQ\(?'KQ-\%/C;=?&3]FJ>X\'2QW5T="A>2.^DL+68,OD%YXRLI$;;-Y4$]<
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M2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !7P9_P %&?\
MDX@?]@&U_P#0I*^\Z^#/^"C/_)Q _P"P#:_^A25]AP/_ ,CO_MV7Z'RG&/\
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MXB_[#R_^B$KY7C/_ )$,_6/YGTO"7_([AZ2_(^F****_&3];"BBB@ K\_/\
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M0 5]G?\ !"'_ )/G/_8F:A_Z'!7QC7V=_P $(?\ D^<_]B9J'_H<%?/<6?\
M)-8O_!(][A?_ )*+"_XT?L]1117\N']+!1110 4444 %%%% !1110 4444 %
M%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0
M 5\&?\%&?^3B!_V ;7_T*2OO.O@S_@HS_P G$#_L VO_ *%)7V' _P#R._\
MMV7Z'RG&/_(G_P"WE^IX-1117[ ?E04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5]J?\ !,;_ ))AXB_[#R_^B$KX
MKK[4_P""8W_),/$7_8>7_P!$)7RO&?\ R(9^L?S/I>$O^1W#TE^1],4445^,
MGZV%%%% !7Y^?\'"W_)O7@3_ +'-_P#TDEK] Z_/S_@X6_Y-Z\"?]CF__I)+
M7U/!7_)4X7_$_P#TEGS/&/\ R3.)_P *_-'Y+4445_39_.(4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]G?\$(?^
M3YS_ -B9J'_H<%?&-?9W_!"'_D^<_P#8F:A_Z'!7SW%G_)-8O_!(][A?_DHL
M+_C1^SU%%%?RX?TL%%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM
M_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !7Y&?\%K/C=\3_ '
M[9XT#PCXG^R6G_"(V$OE?8H)/F+S9.70GL.]?KG7XP_\%WO^3YQ_V)FG_P#H
M<]??^&T(5.([25UR2W]4?"^(<YT^'[Q=GSQV^9\X_P##4GQV_P"AZ_\ *9:_
M_&J/^&I/CM_T/7_E,M?_ (U7G]%?O_U;#?R+[D?A?UG$_P [^]GH'_#4GQV_
MZ'K_ ,IEK_\ &J/^&I/CM_T/7_E,M?\ XU7G]%'U;#?R+[D'UG$_SO[V>@?\
M-2?';_H>O_*9:_\ QJC_ (:D^.W_ $/7_E,M?_C5>?T4?5L-_(ON0?6<3_._
MO9Z!_P -2?';_H>O_*9:_P#QJC_AJ3X[?]#U_P"4RU_^-5Y_11]6PW\B^Y!]
M9Q/\[^]GH'_#4GQV_P"AZ_\ *9:__&J/^&I/CM_T/7_E,M?_ (U7G]%'U;#?
MR+[D'UG$_P [^]GH'_#4GQV_Z'K_ ,IEK_\ &J/^&I/CM_T/7_E,M?\ XU7G
M]%'U;#?R+[D'UG$_SO[V>@?\-2?';_H>O_*9:_\ QJC_ (:D^.W_ $/7_E,M
M?_C5>?T4?5L-_(ON0?6<3_._O9Z!_P -2?';_H>O_*9:_P#QJC_AJ3X[?]#U
M_P"4RU_^-5Y_11]6PW\B^Y!]9Q/\[^]GH'_#4GQV_P"AZ_\ *9:__&J/^&I/
MCM_T/7_E,M?_ (U7G]%'U;#?R+[D'UG$_P [^]GH'_#4GQV_Z'K_ ,IEK_\
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M96T3=TWI9]=/FL@J2K#!'4&I['2]3U1G33-.GN#&FZ000LY5?4X' ]Z^L_\
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M_#D+]DW_ **-\4__  MC_P#&J/\ AR%^R;_T4;XI_P#A;'_XU1_Q%G_J#_\
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M4^*A^!/P4^-=Q'XW:S:\M?"7BOPSJ&B7U[;J"S2V\=]!%]H 568B,LP5&8@
M$T ?3]%>$_ME_P#!37]A'_@GRNGK^V'^T?HW@JXU:V>YTRPNK:YNKN[A1MK2
M1V]K%+*ZAN,A>O%>C? 'X]?"?]J'X->'OV@?@7XK_MSPCXJT];[0-7^PSVWV
MJ DJ'\JX2.5.5/#HIXZ4 =A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !117E7[7/[;O[*O["/PXC^*W[6/QGTOP=H
M]S=?9=/:\66:YO[C&?)MK:!'GN9,<E8D8@<G YH ]5HKY9_9H_X+/?\ !.[]
MJWXMVWP#^&_QLN],\;ZA"9=)\*^-O"NHZ!>:E'@G-JNH01"X.%8[(RSX4G;@
M$UZ?^UK^W)^R7^PEX*L_B%^UO\<M'\#Z3J-R]MIUQJGF.]W,J;VCBBB1Y)&"
M\D*IH ]7KS[XQ_!G4_B;X]\ >+['6H+6/P=XA?4;F&:-BUPIB*;%(Z')SS5'
M]D/]LS]FS]O'X-P_M ?LH_$C_A*_"-QJ%Q8PZO\ V/>6.Z>%@LJ>5>0Q2C!(
MYV8/8FO3Z "BO+O#?[:?[,/BSP1\3?B1I'Q8M5T'X-^(]4T'XEZK?65S:PZ'
M?Z=;Q7-[&[3QIYBQ0S1N98M\9#85B00/G;P9_P '$?\ P2-\<>-=,\'Z?^T]
M<6$&MWXLM%\3>(/!&L:;HM[<$X")?W5K' HR#\[LJ<?>Z9 /MJBN9^,7QF^%
M7[/OPNUKXU_&OQ[IOAGPIX=LC=ZSKNJW CM[6($ $GN2Q55499F954$D ^!_
MLK?\%E/^">?[97Q7MO@?\$_C7=_\)5J=@]_X?T?Q-X3U+19-<LU4L9[$W]O$
MMTNP%\1DOL5F*A02 #ZBHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\S?
M^#8WPUH_Q>_97\=?\%'O'MA%?_%'XZ?%+7=0\4^(+M0]Y;VD%T8+?358\QP1
M>6S+$, !U&,*@7],J_,WX-_!;]OW_@B]\6_B)X&_9J_9(NOC[^SIX_\ &5WX
ML\,Z7X4\36=AX@\#7UV5-S8FWO71+NT+*OE^6V5 +,=S," ,_P""L'A_1_V9
MO^"O/[%7[9'PCTU=+\6>/_B)/\-O'LFGQ[/^$@T>\2%(Q=!<>;]G+LZLV2"$
M)/[I-OI__!PM\/\ P';?\$B_VA_B%;^"=(CU^Y\$P0W.N)IL0O)8UO;8*C3!
M=[*!P 3@"O!OV+/&GQ'_ ."UG_!36W_:M_:$\+6?PR\._LD:K?:7X;^ VIZ@
MTWB2+Q'=Q*CZMJJ&-%BA"(/(";E,D)PQ"R%_7_\ @N?IO_!0_P#:-_9Q^('[
M"_[*'_!.R_\ '^B^._"-O"OQ*C^*6A:7#8W1NA(\#6-]-'-)M6%#O!"GS1@_
M*: /L']D_P#Y-9^&G_9/]&_](8:O_M"_"C_A?'P"\<? [^WO[*_X3/P?J>A?
MVI]E\_[']KM9+?SO+W)YFSS-VS<N[&-PSFO'O^":_P 1OVQ_$GPGC^&O[6_[
M"E]\&7\%>'=&TS0[N\^(ND:\/$)2"2*X=5TYW^RB/R83B0_-]H&TG8U?2- '
MF'[,W[,7ACX ?LR?"3]GCQ!+8>*KCX2^"]&T/2O$-YHR1.\]AIT=C]NBC9I#
M:O(BOPKL565EWL,D_#?[:U_H?_!0K_@LM^S[\"?V8]+34=0_9@\72>+_ (T?
M$BRC_P!'\.PLBB'P]]H Q)<731XD@!RBC)Y24)]"_P#!8G6_^"F-O^R<_@[_
M ()8?"E-?\?^)=573=4UE?$&GV%SX=TMHI#->VIOYX8GN,A(T.XE#)O"DJ"/
M$?\ @F<?VVOV-/"'@_\ 93\(?\$-?$?@OPA=Z]$_C7XBZQ^T+X8U6^FGN)$%
M[K=\L,GG7LY&9&5!DA!'&%554 'UI^WA\._A_K?[+7Q2\=ZSX%T:[US3_A3X
M@AL-9NM,BDN[:,Z?.Q2.9E+HN>< @9YKRC_@@1_RAM_9[_[)_#_Z.EKHO^"G
MOCS]L[3_ (-:C\'?V2/V$;[XQ?\ ">>$=:TG6=3M/B/I&A+X>>:W$$#NFHR(
M;D/YTC8C/R^00Q&]:\H_X(?6_P#P4(^ W[.W@']B']K+_@GA?_#K1OA_X%:U
M7XC2_%'0]5AU*\CG79;K96,TDT6])9'WL2J^203EEH ^]**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_,WX2>&M'_
M &K_ /@YB^-6N?&BPBU>W_9I^%OAO3_A?I6HJ'@T^[U:VBOKC4H8SP)QYDD/
MFXR RC.43;^F5? W[:/[(7[8?[/O_!0:R_X*O_\ !/#X>:9\0=5UKP='X4^,
MOP?U'78M+E\1Z?"ZO;7]C=S?N8[R+9&F), I$%7)=P0"7_@Y%^!O@OXD?\$J
M_'WQ@N[86/C+X3+:^+OA[XKL_P!W?:)J-M=P-O@F&&3>FY" <<JV-R*1].?L
MX:CX?_:F_9?^$?QZ^+/P_P!'U#6M;\":/XA3^TM)BE;3[N\L(9I3%O4F)LN0
M=N#@8K\SOVT/VKOVGO\ @KI\<?#/_!%SXB_LZZM^R]H?CR"#Q#XZU3XDZU ^
MK>*-%LKE)I=,T1;8/!+,TD09F\XD)$Y*!5=7_2#]I?X@_M ?LO\ PC\-Z;^Q
MC^Q!<_%^6TGATL>%-,\>:;X?&DZ?%;L(YA-J+!)%4I'&(U);YP>@- 'RU_P;
M)_\ *.K7O^RX>,/_ $X&OT.K\R/^"$W@S_@IS^QYX3MOV2?VEO\ @F=J'ACP
MQK?COQ%XAU7XFGXN>'KV'25N_-NH86L+2>2>8F58X-R=#+O("J:_3>@#P3]D
MK]A30/V:K3XXZ1XI\66?C33?C9\9];\>7^F:AX>2*"RBU&UL[=M-D1Y95NE4
M6A)D(0.)<>6-N3\Z?\'!OQ/\">)OV/G_ .":/P_\ 6WC?XP?'D0:+\-?A_9P
M*[VBQSQO)K,W!%I:VBQL_G-@!D&/E61D^U?VA/$OQ@\&_ SQ=XJ_9\^&]MXP
M\=:?X>NY_"/A:\U*.SAU345B8V]O)/*R)&C2;069E&,_,O4?E?\ L#>&O^"P
M'[+/C?Q=^T]^T#_P1?\ $OQ6^//Q#F8>+OB5??M!^$;5+>P5\P:5IMM]H<6-
MC$H3]VK$NRAF)"HJ '>?\%@/A;JF@_!;]@S]@'XB>(O[>T'6_C]X(\._$":?
M)7Q#;Z=:[9(IE;[T<\B[V!_B53VKK?\ @Y T^R\!_L\_!']J'PU;Q6GBWX6?
MM'>%;[PUJ40"2QQ33M#<6H8#/E2KY>^/[K"%<@@8KTG_ (*E?LA?M$_MV?L<
M_#CXC?"#PI8^$_CI\+?&7A[XE^#O"VN:M%-;P:Y9+YDVCSW<1\IU(EEB\U3Y
M;O%&<JA+#QOXQ^#O^"@G_!7_ .*GP:^$WQU_8,UGX"_"KX;?$73_ !S\3=1\
M6^,-.U"?7[[3PQMM(L([-W,MN\KL7N'"*5 (VLH5P#],Z*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** .:T[X,_!_2/B??_ !MTGX4>&K7QGJMBMEJG
MBZWT*W35+RV79M@ENE02R1CRTPC,5&Q>.!72T44 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX:_L+^Q-;_LRUO/LWVC7=/M9OW-U%+"^Z&>5/F0XW9&& ( /K^BO$/C_ /\
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MEIXM_L>75H-"\7_#K6=$EN;&)HTDGB>^M8HY%5I8P0K%OF!QCFOHV@ HHHH
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MVS;"4\!F57#TVW&+LK[_ *'Z#EF*J8W+Z=>:2<E=VV_4****\X[PHHK\]_\
M@L%^T#^VSX8_;H_9$_8]_9!_:OG^$EM\:]1\8VOBO7;;P3I6MN1I]GI]Q;,(
MM0AD VF2=<(R9\W+;MJ@ 'Z$45^;>C?M$?\ !2'_ ()Z_P#!2GX&_L@_M??M
M9:)\?O /[0BZW9Z)XA?X>67AW6O#NHZ=;I/\T5@PAN('\V)2Q7/S,?E\L"7Z
M_P#VP?\ @H#^R5^P=HNCZK^TY\6(]$N/$ETUKX9T.QTRYU'5-8F4#<EM96<<
ML\VW<H9E38I==S#<,@'LM%>)_L>_\%#_ -D?]NV+7;?]G#XGOJ.K>%IXX?%'
MAG6-&N]*U;2'<$I]HLKV**9%8 [9-I1B" Q(('DOC7_@O3_P3)\$>,-<\*S?
M&/Q%K%MX7U"6Q\2^)?"OPUUW5]&TRXC)$D<E]9V<D#;2.2C,H]>#@ ^QJ*_/
M+_@HQ_P6Y^''['/[9O[./PBTWX@HG@[QTE]JWQ+N5\!:MJ,J:+)8F33)[-[:
MW;S'>=6W1Q"61%P71%(8_:?[.'[2?P>_:T^$UC\;_@1XAOM4\-:E//%9WNH^
M'[[2Y7>&5HI ;>^AAG3#JP!9 & R,@@T =U17D?[7_[=?[*W[!W@G3_'G[4G
MQ8MO#EMK-^+'0;&.RGO;_5KHX_<6MI:QR3W#\KG8A"[EW$ BN>_9/_X*<_L6
M_MJR>)=*^ WQ7GN=<\&V_P!H\5>$]<\/7VE:QID.,B62QO(8YVC((^=%9<LJ
MYW$"@#WVBOQJ^"W_  4[^&G_  4/_P""HGCCPQXB_P""D'QP\ >#M$\=>'-$
M^!G@3X:>"-0T^S\0F2*-KE]8EFT>:2)9;H[-MTUMMC8X8+\P_7KXE_$3PA\(
M?ASK_P 6?B#J4EEH/A?1;K5M;O(;.:Y>"SMH6FFD$4*/+*5C1CLC5G;&%4D@
M4 ;=%>&_%C_@I+^Q-\#_ -D+1/V\_BA\<K?3/A/XCLM.NM$\5C1KZ?[7%?*K
M6NVVA@>Y#,K E#$&3#;PNUL=/\3OVPOV<?@]:_#F\^('Q*CM8_BWXFL?#_P[
M-KIMU=G6;^\B:6W1!;Q.8XVC4L9I-D2#!=UR,@'I=%?.?[6?_!5W]AW]BSXC
M67P9^-/Q3OIO&M]IYU"/P=X1\+ZAKFIQ60SFYF@L()6@BX.&DV[L$KD X[+X
M(?MT?LG?M(?LWWO[6_P0^,^G^(O &F6=W<ZIK=C;S[[%;6,RW$<]LT8N(I40
M;C"\8DP5(4[ER >M45\K?"[_ (+3_P#!.3XY_$WPA\)?@C\<KWQ=JWC5+5M+
M?0O!NJRVUI]IB\VW2]N#;".QD=,,(IV20!E+*NX9X?\ X(E_M.^//B9^POXY
M^-/[3_QCN-1'AWXN>,X+OQ)XGU%0FGZ597SA \KD+'##$IY) 55.3Q0!]PT5
M^97[>?\ P7K_ &,/B'^PA\8$_9!_:;UO2?&P\":K-\._$TOA35=)MM5O+:,L
MYTR^N[:."YE0([!$<LP5F4, 37Z ?LVZ[K'BC]G;P#XF\0ZC+>:AJ/@K2KJ^
MNYVR\\TEI$[NQ[DL22?4T =K1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?"_P#P<#_\F:>&?^RG67_INU&OQ[K]^/\ @H)^
MQ9_PW7\&M,^$?_"RO^$6_L[Q/#J_]H?V-]N\SR[>YA\KR_.BQG[1NW;CC9C'
M.1\>_P#$.;_U>+_YCW_[X5^R\$\5Y!E&1+#XNMRSYI.W+-Z/;51:/R+C+A?/
M<USN6(PM'FARQ5^:*U7DY)GYDU^PG_!OQ_R9IXF_[*=>_P#INTZO,?\ B'-_
MZO%_\Q[_ /?"OL+_ ()]_L6?\,*?!K4_A'_PLK_A*?[1\3S:O_:']C?8?+\R
MWMH?*\OSI<X^S[MVX9WXQQDG&W%>09OD4L/A*W--RB[<LUHM]7%+\0X-X7SW
M*L[6(Q5'EARR5^:+U?DI-GNE%%%?C1^NA1110!^>/_!4?Q'IGPZ_X+-_\$[O
MB?XNF%GH,/B+XC:%/JLY"P17^IZ%:VMC SG@/+*2JCN5..E-_P"#I?Q+IL'_
M  1J\??"N*99?$'Q!\2>&=!\):2CCS]2O_[<LKH00IUD?RK:5L#LI-?97[4_
M[)'[.7[;/PAN_@3^U)\*=.\7^%[R=)VT^_,D;P3IG9/#-$R2V\JAF DC=6 9
MAG#$'PSX#_\ !#W_ ()Y? +XO:)\=]+^'7B/Q5XI\+2^9X1U'XA^/-4UY=!?
MC#6D-Y.\43J0I63870J"K C- 'C/_!2;X<^&/&7_  6B_P"";7@SQ[H5IJ5K
M9W'Q+O/LUS$)(Q=V6@6%U;R@,.L=Q!%(I[,@/:MS_@HY:6VE_P#!;C_@GUXF
MTV!8-0N[_P")&GW=W$,//:_\(_$XA<_QH&9F .0I8D8)-?8?Q$_9<^!/Q7^.
MWPZ_:7\?^!OM_C;X3?VO_P *_P!;_M.ZB_LK^U+5;6^_<QRK#/YL**G[Y)-F
M,IM;)H^)?[+GP)^,'QG^'G[0GQ%\#?VCXP^%-QJ4_@'5_P"T[J'^RY+^V%M=
MGRHI5BG\R%0N)D<+C*[3S0!\@?\ !/#_ )3K_P#!17_ND7_J,7-)_P &PS*O
M_!&OX=VC,!+;^)?%<=Q$3\T3_P#"0Z@=K#JIP0<'GD5]@?#O]ESX$_"CX[?$
M7]I?P!X&^P>-OBS_ &1_PL#6_P"T[J7^U?[+M6M;']S)*T,'E0NR?N4CWYR^
MYL&O+?AU_P $B_\ @GM\(OVCC^UA\+?@'+X=\;-K=SJ[76C>,=8M[!KVX1TF
MF.FI=BQ)<2-D&#&2#C(! !^>/_! /3?^"K.K_L1:M??L^?$_]FNQU:7XH>)#
M\4;/XB>!M=O/$D?B0W\GVG^TIK34X8WE*>24_=J1$8P<D%C1_;S_ &(?C?\
ML%_\$0/C%\-?C;\1_#.L^'O%G[3&F^+?&6G_  VTVZL],\/>'M1U33I+O3;>
M&>222&W2X42*F\X68 DY)K] _CY_P1@_8+_:!^,FJ?M!ZEX(\3>$?&?B */$
MVO\ PV\>:GX>DUL 8!NTL9XXYFY.9"N]L\L:],^#G[!7[)7P(_9QU7]DKX??
M!VT_X5]KWVP^(/#^MWUSJBZJUVNVY>YEO9)99VD &XNQZ#&,"@#X]_X.<[3]
MGG_AQ3XZ76(M#6PA/A[_ (5K]C$7EK>?;K86_P!AV_+C[(;@?N^/(\W'RYK]
M ?A-_P DK\,_]B_9?^B$KY&TK_@WG_X)56WA:[\!>)O@?XA\3>'I+!['2= \
M4_$K7;VTT"V9U9H]-1[S-B3L53)$5DV;DW['=6^T=)TJPT/2K;1-*@\JUL[=
M(+:+<6V1HH51DDDX ').: /F?]NS_@E]^PA_P4E\6:;<?'72;B'X@^"K-/[&
M\6^#/$SZ9X@T6WF9V0>9"V?*9A*R"5'4,9"@!+$_)W[.I_:1_P""9'_!9KX:
M?\$WM._;<\>?&WX5_%WP!K.K_P!B_%/54U36_!<MC#--%/\ ; %<V\I@,*+M
M1"78;,H&KZ^_:Y_X)*_L/?ML?$^S^.GQG^'FLVWCS3],33K+QKX2\9:EHNHQ
M6B.[K"9+.>-74,[$;U8C/&*N?L;_ /!*_P#8D_81\6:Q\2O@%\*[D>,?$-L+
M?7?''B?Q!>:SK%[#E3Y1NKV61T0E$)2/8K%%+ E00 >#?\$1G1?C[^W-:LP$
MJ_M>:X[1D_,%:UMMK8]#@X/?!J'X>_M'?\%&/^"AG[3?QQ\&?LD?';X;?!3P
M#\%_B5/X)N+S6OAU)XFUW7]4MH(S<W,L37MK#!;$LBQ$99@C9)VXKW?XB?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>biib-20210331_g20.jpg
<TEXT>
begin 644 biib-20210331_g20.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
M,LY!0,",X%K]I_\ 8 MOVB_VO/V<OVIK+XG1^'H?V?=5UV[B\-1>'Q.NM+J-
MC%:"(3">,6@B$6X$1R[L[<+C-?0.LZ[HGAVS_M'Q!K-I8V^\+Y]Y<+$FX]!N
M8@9JS'(DJ"6)PRL 593D$>M 'QG^T9_P33_:"M/VQ]:_;X_X)X_M5Z=\+_'7
MC70;/2/B9H'BKP@-:T+Q3'9KLL[J2-9HI(+F&/$8D1CE %PN7W]+^P=_P3:U
M?]EKQ!\3_CW\=_CY=?%'XS_&6>!O'/CR?1(]/MXK:WA:&TL+*S1W%O;0HQ&-
MY9\*6(VJ!]444 >$?\$R_P!B;_AW1^PYX#_8Q_X69_PF/_"$V]]%_P ))_8W
M]G_;?M%_<WF?L_G3>7M^T;/]8V=F>,X'A_@'_@B'X'T7_@BG!_P1L^(7QWO]
M9L+>VN_*^(&EZ"MA<1W3Z[+K-O.EJT\P7RIGC1E\T^8L;<IO^7[GHH ^./&_
M_!.S]LS]H+]B3XN?L=_M>_\ !1+3?'LOQ&\/6^E:#XJL?@S;Z.^@!2QFEDMX
M+]A?-(?*.-\(3RSC.[ ](_:D_88_X:4_X)QZ[_P3^_X6C_8O]M?#^V\,?\);
M_8GVGR?)CB3[1]E\]-V?*SL\T8W?>..??Z* /F3XS_LO?M[Z7X7^'FD_L5?M
MO^'O!:^"_"4.B:WH'B_X91ZOIWB)XHXDCNF9;F*>S=1&_P L;L&$F&SM!K*_
M8E_X)Y?%SX-?M.>-?VZOVO/VD+/XD_%KQKX7L_#0F\/>%%T71]#T>WE,RVEO
M!YLLDS--AVFE?=P  .2?K"LOPMXW\%^.(KV;P5XOTO6$TW49=/U%]+U".X%K
M=Q8\VWD,;'9*F1N1L,N1D"@#D_VL?@7_ ,-0?LL?$O\ 9H_X2G^P_P#A8GP_
MUGPQ_;?V'[3_ &?]OL9K7[1Y.^/S?+\W?LWINVXW+G(^,_@-_P $M/\ @KA^
MS7\%_"_P ^$?_!;O1+#PQX.T2WTG0;*?]EG3)W@M84"1H9)-4+N0H'S,23WK
M]#*IZ7XAT#7))X=%URSO'M9-ETMK<I(86Y^5@I.T\'@^E 'S+\>/^">7Q+_:
M6T;]F^\^,G[4,.I>*?@3\3M,\::[XB@\#1VZ>+;FUAEC:(6T=T$T\2>;G<IF
M"[<;6SD=/^W9^PQ_PVMKWP1UO_A:/_",_P#"F_CAHWQ#\K^Q/MO]K_8%G7[#
MGSXOL_F>=_KL2;=O^K;/'OTDD<,;2RR*J*I+,QP !U)-0:5K&DZ[8IJ>AZI;
M7EM(3LN+2=9$;!P<,I(//% 'R#^U!_P3?^/M]^V0_P"W]^P!^U!I?PQ^(6N>
M&(/#WQ"T?Q3X1_MG0_%5E V;:::))H9(;F$8594;)153Y1OWQ_L0_P#!*[XC
M?LQ?MM^.?V]OC/\ MA7OQ.\:?$GP-:Z+XKCN/",>FP)=0W(D6:T$=PZP6R01
MP0);;6(\HR-*[.U?7VL>(= \/1QS:_KEG8I-)LB:\N4B#M_=!8C)]JN4 ?!/
MAK_@EO\ ML?L=>,?%-I_P3#_ &YO#O@OX;>+_$5SKC_"WXC_  Y_MNS\.WUR
MV^Y?3;B&Y@ECA=_F%LX*(03DEB3ZEX]_X)S^+OVI?V!?%W[%_P"W[^TQ>?$W
M5?&,[W-QXYTKPK:Z$^DSI)%-9FRMH6=8Q;2PHZEV=I/F#DAR*^FKG7-%LM2@
MT:\UBUBO+H$VMK+<*LDP'7:I.6QWQ5J@#\TOVE?^",O_  46_;R_9BO/V1?V
MT?\ @JQINI^%;2"#^R+OPO\ ");6[UB[@D0P7>L$WW^DA K-Y$+1*TQCE9V\
MH*WZ2Z38?V7I5MIGF^9]FMTBW[<;MJ@9QVZ58HH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
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MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** *5]XBT339_LM_J4<4@ .QCSBHO\ A,?#
M'_0:@_[ZKR#]@VYN==^#FJWNN7#WDR^-M7C66[<R,$6Y(5<MDX Z#M7M?]G:
M?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_
M9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H
M4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP
M_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN
M?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_O
MJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@
M_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[
MZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!
MJ#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A
M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
M4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ
M% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_
M]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__
M #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]
M^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,
M/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__
M #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!
MJ#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'
M_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^
MJ/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:
M@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0
M:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4
M_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
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M/1J*\Y_X7_\ ]2E_Y/\ _P!KH_X7_P#]2E_Y/_\ VNC_ %AR?_G[_P"2R_R
M]&HKSG_A?_\ U*7_ )/_ /VNC_A?_P#U*7_D_P#_ &NC_6')_P#G[_Y++_(#
MT:BO.?\ A?\ _P!2E_Y/_P#VNC_A?_\ U*7_ )/_ /VNC_6')_\ G[_Y++_(
M#T:BO.?^%_\ _4I?^3__ -KH_P"%_P#_ %*7_D__ /:Z/]8<G_Y^_P#DLO\
M(#T:BO.?^%__ /4I?^3_ /\ :ZZGP'XU_P"$WL)[[^S/LODS;-OG;\\ YSM'
MK71ALXR[&552HSO)^37YH#=HHHKT@"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB?R+B8W/FHT8RQ4KY9QG><82]A]0C'G3:DVU[U[-17:U]'U _/\ _8=^$/\
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M<X_YM7SG%'_(L_[>7Z@<A1117YT 4444 %%%% !1110 4444 %%%% !1110
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M_DI%_P#$4?\ "VOB#_T,'_DI%_\ $4?ZV9=_)/[E_P#) >TT5XM_PMKX@_\
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M "BBB@ HHHH **** "BBB@ KU+X#?\@&]_Z_!_Z *\MKU+X#?\@&]_Z_!_Z
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M\%Z7KESI$A):QDN[2*X: Y .4,A7D9^6NTKEE%PDXO= %%%%2 4444 %%%%
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M&_Y -[_U^#_T 5Y;7J7P&_Y -[_U^#_T 5[W#7_(VCZ/\@.ZHHHK]* ****
M"N%^//\ R ;+_K\/_H!KNJX7X\_\@&R_Z_#_ .@&O)SW_D4U?3]4!Y;1117Y
M: 4444 %%%% !1110 4444 >:_M=?L^? []JOX!:W^SS^T1M'AKQ48+21TU
M6L\=T)D>V>WD/W9UF2-D&#EE *L"5/YF?$#Q3^V]_P $H/%/QT_:'\&?M>K\
M4?"/@+QGX3L/%?A#XGZ) ^L>)H+O3["*)H-1@V2&[BBF1 "A5UA,C!B"K?JA
M\;_@3\(/VDOAKJ'P?^.O@#3_ !/X:U3RS?:1J<9:.1D<.C @AE9756#*000"
M"*^7_P!GG_@B_P#LB?!_]I7Q;\9M7^!]AJEI;:[IE[\,EUSQ1J>L'2?)L((Y
M9#%?3R()1<H[1N=[(H0(R!54>K@,50HTI1JMM?RV33UCLV[IM+HO/H!]EP2^
M="DWELF]0VQQAER.A]Z^&/\ @W8_Y1N6G_91/$W_ *<I:^F/VIOV,OV<OVTO
M"^F>#?VD/ ]YKNG:/?F]T^"S\2ZCIACG*%"Q>QN(7<;6(VL2O?&>:\[_ &;O
M^"0O_!/;]D7XFZ;\8/V>?@9>^']?T@7 T^Z/CO7+N*/SXGBE)M[F]DA<LDCC
M+(2"<C! (PIU<-'!3IR;YI-/96TOUYKZW[:>8'SMH_C3]N[X>_\ !0'XK_M0
M_$?_ ()E^//B%>"^F\*?"C4M$\5:/!8:5X5MYB5D@2XN!()[V0"XF9E# >6@
MP%(JK_P;6?%CXF:]^R7<?#+6_P!GG6](\/67B/7K^T\=7.IVKV=[=2:DV^Q2
M)',RR1[VRS*$/EG!.17Z45PO[.O[-7P3_9.^&R?"+X >"_[ \.IJ-U?KI_\
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MUUZ'P'XF\>_#*]TC0=%^U:=(;V2=S,8A)+!;^0CNK'<ZHN-Y->31_M]_#O\
MX)@?\%6?VF?#'B[]ESXT^,- ^)VL:'X@?QCX)^&5UJ L=1BTF"&6P:086YMM
MNR2*6-B8Y)9HF0;?,;Z<_9<_X+0_L]_M9?';0OV?O _[//QXT+5-?^U?9=5\
M9_">[TS38/(M9;EO.N9#MCW+"RKG[SLB]6H ^OZ*** /"_\ @GO_ ,D3U;_L
M>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "O(OC9_P CI_VYQ_S:O7:\
MB^-G_(Z?]N<?\VKYSBC_ )%G_;R_4#D****_.@"BBB@ HHHH **** "BBB@
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MV3\2M?\ V4-.\-6FC[;"X>7S-2A^>V\V)9+<8_UC3K&>'- 'Z/T444 >%_\
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MOP_^@&O)SW_D4U?3]4!Y;1117Y: 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5U_P3_Y'3_MSD_FM<A77_!/_ )'3
M_MSD_FM>CE'_ ",Z/^) >NT445^K@%%%% !1110 4444 %%%% 'RO^UW_P %
MFOV!OV*OC$G[/'Q8^)&LZGX]^PQWEWX0\%>$K[6KZRMY #')<+:1.L.X,K!7
M8.5=6V[6!-3]F;_@L[^R%^UA\;M$^ 'PN\+_ !4M]=U_[3]AF\2?"K5=-LE\
MBVEN7\RYN(5CC^2%PNXC<Q51RP%?)NG_ /!1G]E[_@EQ_P %:OVH_"/QD\">
M/M6A^)6LZ#KX\9>&OAY>W_\ 9]Q'I$$4FE3R)'F6-04FA>'S$7SY8WV,F6^I
MOV7/^"WW[$7[7_QVT+]G7X0VGQ(7Q%XA^U?V<VO_  SU+3[0>1:RW4GF7$\2
MQQ_NX7QN(W-M4<D4 ?7]%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[
M_P#)$]6_['O6?_2DU[I0 5Y%\;/^1T_[<X_YM7KM>1?&S_D=/^W./^;5\YQ1
M_P BS_MY?J!R%%%%?G0!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7J7P&_Y -[_U^#_T 5Y;7J7P&_Y -[_U^#_T
M 5[W#7_(VCZ/\@.ZHHHK]* **** "N%^//\ R ;+_K\/_H!KNJX7X\_\@&R_
MZ_#_ .@&O)SW_D4U?3]4!Y;1117Y: 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5U_P $_P#D=/\ MSD_FM<A77_!
M/_D=/^W.3^:UZ.4?\C.C_B0'KM%%%?JX!1110 4444 %%%% !7F_[6GQ&_:(
M^%'P&UGQU^RI^SE'\6/'-G):C2/ DOBRVT-=05[B-)F^V77[J+RX6DEPWWO+
MVCEA7I%>8?M;^&/VL_$OPH#_ +%?Q0\*>&?'.FZI%>VJ>.-"DOM)UB!%</I]
MUY++-;QR%E;SX<R(8Q@$,PH ^/\ _AX-_P ' /\ TKW:?_XE-X;_ ,*]$_91
M_;$_X+ _%3X^Z!X"_:D_X(Y6?PJ\"7_VK^W?'L7Q]T36VTO9:S20XLK4>;-Y
MDZ10_+]SSMYX4UQ&I?\ !6#_ (*/? ICX<_:D_X(=_%;4=0@.S^V_@=KEIXJ
MT[4,<>=&J^7- K'D1RC>HZU9T?\ ;>_X+'_M=2#PW^S'_P $RX/@AIEP=L_Q
M(_:(\1H7LE/WC%HEC_I$TH&2F^18BV QQF@#[YHK'^'FC>+/#G@#0_#WCWQG
M_P )'KMAH]M;ZUXA_LY+/^U+M(E6:Z\B,E(/,<,_EJ2J;MHX%;% 'A?_  3W
M_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0 5Y%\;/^1T_[
M<X_YM7KM>1?&S_D=/^W./^;5\YQ1_P BS_MY?J!R%%%%?G0!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7J7P&_Y
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M1110 4444 %%%% !1110 4444 %%%% !7J7P&_Y -[_U^#_T 5Y;7J7P&_Y
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M_D4U?3]4!Y;1117Y: 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5U_P $_P#D=/\ MSD_FM<A77_!/_D=/^W.3^:U
MZ.4?\C.C_B0'KM%%%?JX!1110 4444 %%%% !1110 4444 %%%% 'A?_  3W
M_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0 5Y%\;/^1T_[
M<X_YM7KM>1?&S_D=/^W./^;5\YQ1_P BS_MY?J!R%%%%?G0!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7J7P&_Y
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M1110 4444 %%%% !1110 4444 %%%% !7J7P&_Y -[_U^#_T 5Y;7J7P&_Y
M-[_U^#_T 5[W#7_(VCZ/\@.ZHHHK]* **** "N%^//\ R ;+_K\/_H!KNJX7
MX\_\@&R_Z_#_ .@&O)SW_D4U?3]4!Y;1117Y: 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5U_P $_P#D=/\ MSD_
MFM<A77_!/_D=/^W.3^:UZ.4?\C.C_B0'KM%%%?JX!1110 4444 %%%% !111
M0 4444 %%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6
M?_2DU[I0 5Y%\;/^1T_[<X_YM7KM>1?&S_D=/^W./^;5\YQ1_P BS_MY?J!R
M%%%%?G0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7J7P&_Y -[_U^#_T 5Y;7J7P&_Y -[_U^#_T 5[W#7_(VCZ/
M\@.ZHHHK]* **** "N%^//\ R ;+_K\/_H!KNJX7X\_\@&R_Z_#_ .@&O)SW
M_D4U?3]4!Y;1117Y: 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5U_P $_P#D=/\ MSD_FM<A77_!/_D=/^W.3^:U
MZ.4?\C.C_B0'KM%%%?JX!1110 4444 %%%% !1110 4444 %%%% 'A?_  3W
M_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0 5Y%\;/^1T_[
M<X_YM7KM>1?&S_D=/^W./^;5\YQ1_P BS_MY?J!R%%%%?G0!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7J7P&_Y
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M1110 4444 %%%% !1110 4444 %%%% !7J7P&_Y -[_U^#_T 5Y;7J7P&_Y
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MO_#D+]DW_HHWQ3_\+8__ !JC_AR%^R;_ -%&^*?_ (6Q_P#C5'^J'_3_ /\
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M/_QJC_AR%^R;_P!%&^*?_A;'_P"-4?ZH?]/_ /R7_P"V [JBN%_X<A?LF_\
M11OBG_X6Q_\ C5'_  Y"_9-_Z*-\4_\ PMC_ /&J/]4/^G__ )+_ /; =U17
M"_\ #D+]DW_HHWQ3_P#"V/\ \:H_X<A?LF_]%&^*?_A;'_XU1_JA_P!/_P#R
M7_[8#NJ*X7_AR%^R;_T4;XI_^%L?_C5'_#D+]DW_ **-\4__  MC_P#&J/\
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M%<+_ ,.0OV3?^BC?%/\ \+8__&J/^'(7[)O_ $4;XI_^%L?_ (U1_JA_T_\
M_)?_ +8#NJ*X7_AR%^R;_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\
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MZ*-\4_\ PMC_ /&J/]4/^G__ )+_ /; =U17"_\ #D+]DW_HHWQ3_P#"V/\
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MQXUTSP?I_P"T]<6$&MWXLM%\3>(/!&L:;HM[<$X")?W5K' HR#\[LJ<?>Z9
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MBZ^/O[.GC_QE=^+/#.E^%/$UG8>(/ U]=E3<V)M[UT2[M"RKY?EME0"S'<S
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M"\<? [^WO[*_X3/P?J>A?VI]E\_[']KM9+?SO+W)YFSS-VS<N[&-PSFO'O\
M@FO\1OVQ_$GPGC^&O[6_["E]\&7\%>'=&TS0[N\^(ND:\/$)2"2*X=5TYW^R
MB/R83B0_-]H&TG8U?2- 'F'[,W[,7ACX ?LR?"3]GCQ!+8>*KCX2^"]&T/2O
M$-YHR1.\]AIT=C]NBC9I#:O(BOPKL565EWL,D_#?[:U_H?\ P4*_X++?L^_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>biib-20210331_g3.jpg
<TEXT>
begin 644 biib-20210331_g3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M2@)Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
MZ.IZ$,."/<5F?$+Q7_P@?@'7/''V#[7_ &-H]S??9?-\OSO)B:39NP=N=N,X
M.,YP:_-C_@E=\./B3\$O^"DOBG2/V:?V$/C-\#_V:O&'PS-[J_@_XF6MK#8:
M;XQ@O4"W&G1P7]VL$<]H[!XPRAGCSC"(!^B'[0G_ "0/QQ_V)^I_^DLE 'RK
M_P $6?\ @LKH?_!7KX=^,/$-[\!9OAGXB\(W]D9O#,_B7^U1=:9>0L]K?QS_
M &:WRKR0W494(0I@^\2VU<?XA_\ !<'0O"O_  6+\,?\$G?"?[.TVN6^L7"6
M&M_$O_A*O(ATO5#IDFI/9):"U<7+);_92S>>A5KG!4;/G^ /^"?GQ6\-?\$Q
M/V1OV,_^"J7BE9X/ 'BGX8^)/AG\8I+6,L1LU'4]5T.Y"#[TGVFWN+;>>0LZ
MJ#R >A^"/P7\:^ ?VJ/^"<7QU^,EEY7Q$^/7Q2^)GQ/\>%@=T=UJ^DVDUO;X
M/*+#9BUB$9^X48 #I0!^XVK:QI&@V3:GKFJVUE;(0'N+N=8T4DX&68@#FIX9
MHKB)9X)5='4,CHV0P/(((ZBORZ\$_LY?"K_@K-_P6(_::L?VY- ?QKX(_9V/
MASPW\,OAKJ]W*-*LYK^PDN;S4YK9&59IY'0A'<']VV"#Y<977_X)V^%5_8E_
MX*:_M+_\$ROA%KNH2?!VQ^'.D^// ?A>_P!2ENT\(3W0:&[L;9Y69D@ED;S5
MC)PH5<<EV8 _2?4=:T;2'@CU;5K6U:ZF$5LMQ.J&:0]$7<1N;V'->._\%"_V
MW/!?_!.W]E'7_P!K+X@^#=4U_2O#]]IMM<:7HTD:W$K7E]!9H5,A"X5YU8Y/
M13CFOS)_X(;_ /!%_P#8@_;7_P"",GP]^(G[5W@6\\;>)/%.D:W:Z)K&JZQ=
M;O"5HNJWT,4.F1I*L=L%D1KEF5=TDTSERR[5'DW[2C:?^V?_ ,&A'PP_:>_:
M-T[_ (2?QUX0N;2PT#Q)JES))=6ZIXP71G<ON_>/)9P)&[/N)R3G/- '[&?\
M%(_VI?$_[$W["_Q-_:N\&>&K#6=4\#>&I-2L=+U1W6WN75T78YC(8#YCT.:]
M ^#GQ1M/B1\-/"/BO5KFQM-6\2^%K'5WTN*X&Y?.MTE;8K'<44L1GVYKX*_X
M*>_\$^?V-/V#/^",G[4=I^R'\ ](\#1^*/ 2/KZ:3+.PO6MY<0EO-D?&P32X
MQC[YS7AO[</_  2B_9+^!_\ P14NOVW?!VB:ROQ[\&_#C1/&&G?&M_$=X=>.
MKQ):R>8)3*52+:6B2!5$<4>U45=BD '[(7M[9Z;:27^HW<5O!"A>6::0(B*.
MI)/ 'N:CTK6-(UZR74M#U6VO;=R0EQ:3K(C$=<,I(-?F3_P50^$'QV_:?TO]
MEG]I#QQ^RGXC_:!^#.B^'[G5?B_\&_!FJK;W-]J-YI]J]CJ(LC+$-16"3SL0
M;OE+]-KO7IW_  1V\8_\$GM2\>?$CP[^P3^SGKGP6^(4=MIY^)WPM\7>&KW0
MM5M(HS-]EGDT^:1X%&9I 9("<[T$AYCH ^L?VL?CI_PR_P#LL?$O]I?_ (1;
M^W/^%=_#_6?$_P#8GV[[-_:'V"QFNOL_G;)/*\SRMF_8^W=G:V,'XF^!O_!6
M#_@K_P#M'_!WPS\>O@__ ,$'K'5/"WB_1H-5T#47_:IT6W-S:3('C<QRV"NF
M5(.UE!'<"OIK_@K%_P HLOVEO^S?_&7_ *8[ROB/_@EA\&_^"UNL_P#!-_X(
MZK\%/VV?@GHGA&X^&FDR>'-(UOX2W=W>6=F;9#%%-,MZ@E=5P"X503S@4 ?I
MS\(_$?Q \7_"WP[XJ^*_PW7P=XGU+1;:Y\0>$TUF/41H]X\2M-:"ZB54N1&Y
M9/-50K[=P !K9LM:T;4KNXT_3M6M9Y[-PMW!#.KO QZ!P#E3]:_,O_@N[\+O
MB#\2M!_8=^#WQ#^*%S8>)=8_:4\.:7XF\7># ^GRBY?3[B.[N;'YF:U9B96B
M.6:(LIR2M<_^VI^PC^RU_P $MOVO?V/_ -H[]A/X:?\ "O=<\6?M"Z9\._&<
M>D:K=O%XBT?5H+@3+>B:5_M#HT(=7?+%VW,2RH5 /U5U76-)T*S;4=;U2VL[
M=6 :>ZG6- 2< %F(')XKY\\(?MH>+_$G_!4OQ?\ L$R^$M,30/#OP9TSQG:Z
M[')(;N:XNM0FM6@89V>6%C# @9R3SBODV3]GSX6_\%5/^"WO[0OPT_;4\.MX
MP\ ?LS>%O"&G> /AUJUS*-*>^UNPEOKG59;=&59I@$,*L^X;&3C*KC/_ ."?
M?[,_@?\ 8T_X+]?'+X.?"K4=4D\&Z=^SGHMWX3\.76H2WG_"/V<FI&1M-MVE
M9G\A9_/DCC)^19PBX55H _4/4M=T31I8(=7UFTM'NI?+M4N;A8S,_P#=4,1N
M/L*M5^!/[!US\!/^"@_P4U;]MK]OS_@D?^T9^TEXZ^*>OZO-_P )CHVEZ?=Z
M)HNFQWT]O;Z7HQEUJV>VBMUBVEA#')YN_P"9@%8^F>-/C#_P4#_9H_X(->,O
MA!XYMOB1\.M7U#X_Q_#;X5^(_'\B#Q+IW@;4+VU-I=7$D,T@$Z6\UQ:;UD;R
MR@"/\B-0!^D'_!4#]MK5?V&OV"OBA^UG\,=)T3Q+K?P^L;:5=&O[MC TLE[!
M;E)O*8.A"RL<9!RHKZ!T6^?4]'M-2E0*UQ;1RLJ] 64''ZU^-O\ P78_X(T_
ML._L9_\ !'GX@?%;]DGP#/X"\2>$=+TJUU36]/UBX,WBNQGU.SMY[75-\A6\
MWO*EPK.I9)H8RFP9%?L7X2_Y%73/^P?#_P"@"@#0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
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MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[
MZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!
MJ#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A
M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
M4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ
M% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_
M]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__
M #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]
M^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,
M/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__
M #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!
MJ#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'
M_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^
MJ/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:
M@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0
M:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4
M_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y
M(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 8GGN+A7A#R B/"D#DE<C]F+]H#]L?\ 9"_X*9V'_!,W]LS]H7_A<'A[XD>
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MOQOX>O+CYQX;^!O@VTT#3=-SSY,<[L]Q<J#T>;#D=:LZ/^R!_P %K?V1)?\
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M'Q71117[D?C04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^-!1110 4444 %%%% !3[?R#.@NBPBWCS"GWMN><9[XIE% 'O7@KPA\#],\
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M_)Q _P"P#:_^A25]AP/_ ,CO_MV7Z'RG&/\ R)_^WE^IX-1117[ ?E04444
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M?#G_  4&TVWTKX_BUMGD9?[#MFS+(6/+2=S7V' __([_ .W9?H?*<8_\B?\
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MO_C5'_#4GP)_Z'K_ ,IEU_\ &J/JV)_D?W,/K.&_G7WH] HKS_\ X:D^!/\
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M77_QJCZMB?Y']S#ZSAOYU]Z/0**\_P#^&I/@3_T/7_E,NO\ XU1_PU)\"?\
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MX>DOR/IBBBBOQD_6PHHHH *_/S_@X6_Y-Z\"?]CF_P#Z22U^@=?GY_P<+?\
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M=C/Y?Q7^8?VC@_YOP?\ D?0%%?/_ /PW1_U2[_RM_P#VBC_ANC_JEW_E;_\
MM%']G8S^7\5_F']HX/\ F_!_Y'T!17S_ /\ #='_ %2[_P K?_VBC_ANC_JE
MW_E;_P#M%']G8S^7\5_F']HX/^;\'_D?0%%?/_\ PW1_U2[_ ,K?_P!HH_X;
MH_ZI=_Y6_P#[11_9V,_E_%?YA_:.#_F_!_Y'T!17S_\ \-T?]4N_\K?_ -HH
M_P"&Z/\ JEW_ )6__M%']G8S^7\5_F']HX/^;\'_ )'T!17S_P#\-T?]4N_\
MK?\ ]HH_X;H_ZI=_Y6__ +11_9V,_E_%?YA_:.#_ )OP?^1] 45\_P#_  W1
M_P!4N_\ *W_]HH_X;H_ZI=_Y6_\ [11_9V,_E_%?YA_:.#_F_!_Y'T!17S__
M ,-T?]4N_P#*W_\ :*/^&Z/^J7?^5O\ ^T4?V=C/Y?Q7^8?VC@_YOP?^1] 4
M5\__ /#='_5+O_*W_P#:*/\ ANC_ *I=_P"5O_[11_9V,_E_%?YA_:.#_F_!
M_P"1] 45\_\ _#='_5+O_*W_ /:*/^&Z/^J7?^5O_P"T4?V=C/Y?Q7^8?VC@
M_P";\'_D?0%?:G_!,;_DF'B+_L/+_P"B$K\J_P#ANC_JEW_E;_\ M%?H_P#\
M$5_C#_PN3X*^+M9_X1W^S?LGBE8?+^U^=O\ ]&C;.=BXZ]*^1XWP>)H\/3E.
M-E>/5=SZG@W&8:MGL(PE=VET?8^S:***_$#]D"BBB@ K\_/^#A;_ )-Z\"?]
MCF__ *22U^@=?GY_P<+?\F]>!/\ L<W_ /226OJ>"O\ DJ<+_B?_ *2SYGC'
M_DF<3_A7YH_):BBBOZ;/YQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OL[_@A#_R?.?^Q,U#_P!#@KXQK[._X(0_
M\GSG_L3-0_\ 0X*^>XL_Y)K%_P""1[W"_P#R46%_QH_9ZBBBOY</Z6"BBB@
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MU#_T."OGN+/^2:Q?^"1[W"__ "46%_QH_9ZBBBOY</Z6"BBB@ HHHH ****
M"O,/VM_#'[6?B7X4!_V*_BAX4\,^.=-U2*]M4\<:%)?:3K$"*X?3[KR66:WC
MD+*WGPYD0QC (9A7I]% 'Y^ZE_P5@_X*/? ICX<_:D_X(=_%;4=0@.S^V_@=
MKEIXJT[4,<>=&J^7- K'D1RC>HZU9T?]M[_@L?\ M=2#PW^S'_P3+@^"&F7!
MVS_$C]HCQ&A>R4_>,6B6/^D32@9*;Y%B+8#'&:^^:* ,?X>:-XL\.> -#\/>
M/?&?_"1Z[8:/;6^M>(?[.2S_ +4NTB59KKR(R4@\QPS^6I*INVC@5L444 >%
M_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %?C#_P7
M>_Y/G'_8F:?_ .ASU^SU?C#_ ,%WO^3YQ_V)FG_^ASU^A>&?_)2?]N2_-'P?
MB-_R3O\ V_']3XQHHHK^@C\'"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "OUI_P"#>G_DWKQW_P!CFG_I)%7Y+5^M
M/_!O3_R;UX[_ .QS3_TDBKX;Q%_Y):I_BA_Z4C[3P_\ ^2FI_P"&7Y,_0.BB
MBOYT/Z "BBB@ K\_/^#A;_DWKP)_V.;_ /I)+7Z!U^?G_!PM_P F]>!/^QS?
M_P!)):^IX*_Y*G"_XG_Z2SYGC'_DF<3_ (5^:/R6HHHK^FS^<0HHHH ****
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MEB *RE7H0C.4I)*/Q-NR6E]>VCN:QH5IRC&,6W+9):O6VG?56.:HKW#XI_\
M!.;]KOX/^!;WXE>*OAG!<:-I0SK-UH>NV>HG3O4SI;2NR <Y;&T8.2*X3X&?
ML[_&/]I'Q3-X/^#7@J;5[NUM3<WTGG1P06< ZRS32LL<2^[,,]!D\5ST\RRZ
MMAY5X5HN$=Y*2LO5WLOF;U,NQ]*O&C.E)3ELG%W?HK79Q5%>D_'C]DCX]?LV
MV>G:Q\5/!B0:7J[,FEZWINI6]]8W+KG<BSV[N@<8/R,0W!.,#-=+\)O^"=O[
M6GQG\#V/Q)\(?#JUAT+5,_V3J.L^(+*Q6^(8KB)9YE9^01D#'O2EFF6PPZKR
MK04&[*7,K-]D[VOY#CEN8SQ#H1HR<UJURNZ7=JVVNYXC173_ !@^"_Q2^ 7C
MFY^&WQB\%7F@ZW:JKRV5X%.Y&SM='4E)$.#AT)4X//!KF*ZZ=2G6IJ=-IQ>J
M:U37=,Y:E.I2FX3336C3T:]4%%>]>!?^"9O[9OQ!\(6'C71_A5#:6NKPB71K
M?6M?LK"YU!",JT4%Q,CD$$$$@!@01D&O#=7TK4-"U6ZT/5K5H+NSN'@NH6()
MCD1BK*<<<$$5AA\=@L7.4*%6,G'=)IV];&U?!8S"PC.M3E%2V;35_2Y7HHHK
MJ.8**** "BBB@ K[._X(0_\ )\Y_[$S4/_0X*^,:^SO^"$/_ "?.?^Q,U#_T
M."OGN+/^2:Q?^"1[W"__ "46%_QH_9ZBBBOY</Z6"BBB@ HHHH **** "BBB
M@ HHHH **** /"_^">__ "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2)ZM_V/>L
M_P#I2:]TH *_&'_@N]_R?./^Q,T__P!#GK]GJ_&'_@N]_P GSC_L3-/_ /0Y
MZ_0O#/\ Y*3_ +<E^:/@_$;_ ))W_M^/ZGQC1117]!'X.%%%% !1110 4444
M %%%:7@_P?XJ^('BBQ\%>"/#]WJNK:G<+!8:=8P&26>1NBJHY/\ 0 D\4I2C
M"+E)V2'&,IR48J[9FT5](_$[_@F/^T=\/OA7I?CR/PG!<7L&C7^H>,=+C\3:
M;++I:6\\H)6*.<O(!#&'?:&*-N4X((' _L^_!WX!>/M$U3Q9\>OVG+7P'9:=
M<QPVNGV_A^;4]0U%F4L3'%$RA$&,&1S@$@5YU/-\OK8>5:E/GC%V?+>;O>VT
M;O7IIMKL>A/*L?2KQHU8<CDKKFM%6M?>5EIUUWTW/+**]\^.W[''@GPM\#8/
MVG?V<OCI%X_\$KK(TG67N-$DTZ_T>\9=R)- [-N1AC$@(&648.<UYS^SW\#O
M$G[1'Q4T_P"&?AV\ALDF62XU;6+OBWTJPB4O<7DQR (XXPS')&3A0<L*TI9E
M@ZV%EB%*T8WYKIIQMNFFDTUVMZ;F=7+L72Q,:#C>4K<MFFG?9IIM-/U.)HKU
M?]M#]F2V_9'^.EU\&[/Q_P#\)-#!IEI>Q:O_ &4;/S5GB$@'E&23& <9W<^@
MZ5Z++^P%\*[S]GGQI\9?!G[8^A>)M7\#Z+:ZCJ_AO0/#D\D2+/($6-KN21%#
M9W9VH_W3G&0:REG&7QP]*NY/DJVY7RR=^9I*]E[MVTO>MN:QRC'RKU:*BN>G
M?F7-%;7;MK[UDG\-]CYCHHKU']DS]E_6/VI_B#J'AB'QA9>&]%\/Z!<ZYXJ\
M2:C$TD6F:=;[?-FV*09&&X80$9Y.0 37;B<11PE"5:J[1CJW_P -J_1:LX\/
MAZV*K1I4E>4M$OZT^;T1Y=17TG?_ +%WP*^)'PO\8>/?V3?VG;CQ?J/@+1WU
M?Q#X>UWPC)I<TNG1_P"MN[=S*ZN$')0@$#ODJ#\V5CA,=A\:I>R;O%V:<7%K
M2ZNI)/5;:69KBL%B,&X^TM:2NFFI)ZVT<6UH]PHHHKL.0**** "BBB@ K]:?
M^#>G_DWKQW_V.:?^DD5?DM7ZT_\ !O3_ ,F]>._^QS3_ -)(J^&\1?\ DEJG
M^*'_ *4C[3P__P"2FI_X9?DS] Z***_G0_H **** "OS\_X.%O\ DWKP)_V.
M;_\ I)+7Z!U^?G_!PM_R;UX$_P"QS?\ ])):^IX*_P"2IPO^)_\ I+/F>,?^
M29Q/^%?FC\EJ***_IL_G$**** "BBB@ HHHH *ELC:+>0MJ"NT E7SUB(W%,
M\XSWQFHJELA9F\A&HF06_FKYYA WA,_-MSQG&<9I/8:W/U4\::A^U+XJ^'?C
M'Q%_P3C^(FC:EX)A7P^_PY\/>!+RRCFTFU2&87T-S:2 /Y[/M9ED#N_']TJO
MYG^/_%?Q4M_BAXCUSQG+?Z-XFU"_NE\1P1VQL)!-*Y,\3PH$$8+$@Q[0HZ8Q
MQ7U-\)?A=^R!H'P4\=ZYX2_;GU&ST7_A(?#UW-?KX#OX-6TIHGO&BB C)C>9
M\L%D23:IC+-MR >0\6_&+]E7]K__ (*+ZK\:?V@=<OO"'PVU&ZBFG!L)IKF\
MCM;:*&..06JNT;3F(,[*#M#, V</7PF1J.75\1&-)SA%7<O92C4;486B[KWY
M2NWHEJG)_&C[;.7+,*-"4JJA.3LH^UC*"3E.\E9^Y&.BU;T:2^%FU_P3XM=3
M_9O^%?Q"_;&^*5Y+IW@R_P#"%]X9T+2IS@^+-3N %2".,_ZR*,JQ>3!"X.,[
M7 7]C/0/$'Q>_8$^-?P$^"Q\_P ?7NK:3JDNAVL@6[UC287_ 'D40R#+Y;;F
M*#^^!@EP#K?M87O[)G[3'BT>(+K_ (*,Z+IFAZ)9FS\%^"M,^%&MQV>CV:C]
MW;Q#RPNXA5WR$ L0.BA57YX_9J\!_#?QOXAO6\;?M-V_PQU"QCCET/4KO2KN
M>.YD)(=/-MOFMRJX(8C!R1Q71&G]>PM;%U.:%1RIRLZ52T>1WA&SBG/KSN.U
M^B2,)5/J6*I86GRSIJ-2-U4A>7.K2E=2:ATY5+>W5MGU-\+_ -F7XK?#S_@E
M7\<-'_: \,7FA/\ VAI>M^%] UI#%=VDD,ZQRW?D/\\2R@^2&8#<(WQD<U\9
M^"O"OQ/^.7C+0_ACX0M-3\0:O=,EAH>FK*TI1<DA$W'$<:Y9B>%4;F. ":^A
M?CC\<_A)\'_V;=?_ &;?@[\;+_XF^)OB!JMG=?$/Q]<VEQ# +6S;?;6%O]H/
MFR8D)=I#\N"0,[L+V'[,?C?]B_X1_LIR:7X,_;"M? OQ7\80-#XN\3WG@35;
MZZTJQ).;"R>"+9$6PI>979FYQ@A-AAL3C\!A:^)E3<Y5:MX6ISLER1CS2BE*
M<8WB^EY:.RYM#$X; X[$T</&HH1I4[2O.%V^>4N52;492M)=;1UU?+KPW_!3
M;QWX=N-=^'?P T_Q?%XEUCX5^!H- \4^)(9/,2XU!3F2W20\R)"1L#'G)8$9
M!KS?]A3P!X>^*/[8GPX\"^++)+G3+[Q7:_;K65=R7$2/YC1,#U5@FTCT)K'^
M/7PX^"7P\O--B^#'[2-M\18[N.5M1GM_"M[I?V)E*[%(N@#)NRQRO3;SU%=!
MK7BKX2?LR_M.^%_B3^RS\0[SQAI7ANYTW58[[4[&2U:6Z1E>>V*O&C;,@INV
M\AC@FO4H452R983#<W-*$[2<91][6[::7+>4KQ3MIMHCS:U5U,W^M8CEY8SA
M=*49>[I9)IOFM%6;5]=]6?27[3/P3_9L_: _;7\1_#GXJ?MBZW#\3-<\1R6.
MGM#X8\_0M)F:0I::49VE60E 8XBZH$#DYY!S\6?%3X=^*_A'\2M=^&'CJ!8]
M8T#59['4E23>IEC<JS*Q^\IQD-W!![U]:ZKIW[!'B[]J4_ML77[7(L=!N_%
M\5:CX"F\,7;:VM\9A<R6*E5\EE:;($H?:%;&>-U?,7[2GQBD_:"^/GB[XTOI
MGV)?$FN3WL%F6!,$3-^[0D<%@@4$]R":Y.'I8J$HT;S=.-.-^>'+RS6G+'W8
MW5KW^)*RUUUZL^6&G&56T54E4E;EES<T'KS2]Z5G>UMF[O333B****^K/EPH
MHHH **** "OL[_@A#_R?.?\ L3-0_P#0X*^,:^SO^"$/_)\Y_P"Q,U#_ -#@
MKY[BS_DFL7_@D>]PO_R46%_QH_9ZBBBOY</Z6"BBB@ HHHH **** "BBB@ H
MHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]
MTH *_&'_ (+O?\GSC_L3-/\ _0YZ_9ZOQA_X+O?\GSC_ +$S3_\ T.>OT+PS
M_P"2D_[<E^:/@_$;_DG?^WX_J?&-%%%?T$?@X4444 %%%% !1110 5ZI^Q7^
MT1IO[*_[27A[XUZUX;EU6QTW[3!?VEK*(Y_(N+>2!WA8\+(JR%ER1DC&1G(\
MKKIOA'XV\*?#_P ;P>(O&_PPTWQAI0AEAO= U2YF@CG1T*Y66%E>)U)#*ZG(
M('6N7&T88C!U*4X\RE%II.S::M9.ZLWZKU.G!UIX?%TZL)<KC)--JZ33O=JS
MO;T?H?8/C7]D#X-?M+_"GX<^'?V2?VC))];B\/ZW<^%/"'C727L]0UF%;^YF
MG1;B,M"9D(D39QO";\JI)'QG\/?ASXX^*WCC3OAM\//#-UJNN:K="WL=.M8\
MR22'KUX4  EF. H!)( )KZSU;]MKX(_ _P"&7P[\=?LW_LY66E^,(/#^L6^@
M:AJWC:75&\*^=>W,<A$/E1B25P[NC2_=60#:PY;S;]B7]MCP#^R/HGBVWUS]
MGV7Q1K'BJT^Q'Q%9^+WTJ\L;)E(DAAD2WE9"YP3(A1N%YX!'S67SSS"X*O*%
M.4]7R1FZ:E=SGS-N+47%:/5W;YK:<K/H\PADV)QE",ZD8:+G<5-QLH1Y4DTW
MS/5:*R7+?6Z-_P#:>\4^ _V8?V=$_8"^''B.U\0Z_<Z^FL_%;Q)8OOM4OXTV
M1Z9;-CYTAP"[_P!]<<$LB]SHW['/[3/P^_8ETC0_@%\%]9\0>(/C'I5OJWB_
MQ'I42LEEH38EL]+C<D'=-\L\^,<".,[A7@GQ?^,7[(/C#P-=:)\)?V-;[P?K
MLLL;6VOS_$VZU-85#@NI@DMT5]R@KDL,9SSBO+H/%_BVVA2VMO%&HQQQJ%CC
M2]D"JH&   > *WI9;C*N$@HWA+GYY^T2ESRZ-J%2R2=K*^G*E:RUYZN8X2EB
MIN5IQY.2'LVX\D>J3G"[;5[NVO,W>[T^N?\ @L_\&_BAX<_:*C^+&N>"KVV\
M.7^AZ3IUGJ\J#R9;J.R7?"#G.X;&SQ_":YG]B+_DS+]J'_L3]&_]+9*\S_;'
M_:GU']K;XMM\39O#4VAP'2K*T32&U<W:*T$"Q&4-Y<8RV"<;>,XR>M>I_"/]
MNW]E'X2?"KQ#\*]-_81O;BW\8Z/:6'B^<_%BY4ZAY!WAU!LV,&9"S80\9QD@
M5RK!YK0X;P^$E2<ZD?9W47%<JA.,FGS32;LFKIM-]D=7UO+*W$5?%1JJ%-^T
MLY*3NYQE%-<L&TKM/5)I=V?*E?3_ /P2ZL]=T_X@>//B%J6M6=IX!T/X>7X^
M)UO>Z>]T-3T>8!7L8XTDC;SI2OR/O4*4).1\C>6>'OBY\#O#/[2=M\6;']FV
M&Y\$6USY@^'.I^(WNDD3[-Y91[N2$LW[TF7)CXX7MFMG]FS]K>/]GCXF>*==
M7X6Z?K?@_P ;:==Z7XD\$W5VT4<VGS/N$4<R+F-TX"R!>F> 2"/7S:&,QN75
M*-.D[RBGJX[M^]%:M*22T?PW:LW9GDY7+"8/,*=:I55E)K12Z+23T3<6WJOB
MLG=*Z/H+X*:I^S=\1O@U\8_ '[!OA?7_  ?XTO? ]W<ZH_C>X6^;4O#\3*UW
M8VDL3JMM(P*9WI(6'&\??7X8KZ:@_;/_ &>/@QX'\5Z)^R)^S7J7AS7_ !GH
M<VCZEXH\3^*SJ$MA838\Z"UC6) I8 ?O&)8;1UQ7S+6>28;$4*E><XRC&3BU
MSM2F[1L[M.6FUDW=:]+&F<8BA6IT8PE%RBFGR)J&KNK)I:]VE9Z=;A1117OG
MAA1110 4444 %?K3_P &]/\ R;UX[_['-/\ TDBK\EJ_6G_@WI_Y-Z\=_P#8
MYI_Z215\-XB_\DM4_P 4/_2D?:>'_P#R4U/_  R_)GZ!T445_.A_0 4444 %
M?GY_P<+?\F]>!/\ L<W_ /226OT#K\_/^#A;_DWKP)_V.;_^DDM?4\%?\E3A
M?\3_ /26?,\8_P#),XG_  K\T?DM1117]-G\XA1110 4444 %%%% !1110!=
ML_$FOZ?H5[X9L=8N(M/U*6&2_LHY2([AXMWE,Z]&*[WQGIN/K5*BBDHI-M+<
M;;:2?0****8@HHHH **** "BBB@ HHHH **** "BBB@ K[._X(0_\GSG_L3-
M0_\ 0X*^,:^SO^"$/_)\Y_[$S4/_ $."OGN+/^2:Q?\ @D>]PO\ \E%A?\:/
MV>HHHK^7#^E@HHHH **** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_[
M'O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH *_&'_@N]_P GSC_L3-/_ /0Y
MZ_9ZOQA_X+O?\GSC_L3-/_\ 0YZ_0O#/_DI/^W)?FCX/Q&_Y)W_M^/ZGQC11
M17]!'X.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?K3_ ,&]/_)O7CO_ +'-/_22*OR6K]:?^#>G_DWKQW_V.:?^
MDD5?#>(O_)+5/\4/_2D?:>'_ /R4U/\ PR_)GZ!T445_.A_0 4444 %?GY_P
M<+?\F]>!/^QS?_TDEK] Z_/S_@X6_P"3>O G_8YO_P"DDM?4\%?\E3A?\3_]
M)9\SQC_R3.)_PK\T?DM1117]-G\XA1110 4444 %%%% !1110 4444 %%%%
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M*_H(_!PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K]:?^#>G_ )-Z\=_]CFG_ *215^2U?K3_ ,&]/_)O7CO_ +'-
M/_22*OAO$7_DEJG^*'_I2/M/#_\ Y*:G_AE^3/T#HHHK^=#^@ HHHH *_/S_
M (.%O^3>O G_ &.;_P#I)+7Z!U^?G_!PM_R;UX$_['-__226OJ>"O^2IPO\
MB?\ Z2SYGC'_ ))G$_X5^:/R6HHHK^FS^<0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[._X(0_\GSG_ +$S4/\
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M1110 4444 %?K3_P;T_\F]>._P#L<T_])(J_):OUI_X-Z?\ DWKQW_V.:?\
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MHK]IO^'(7[)O_11OBG_X6Q_^-4?\.0OV3?\ HHWQ3_\ "V/_ ,:H_P"(L_\
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MHK]IO^'(7[)O_11OBG_X6Q_^-4?\.0OV3?\ HHWQ3_\ "V/_ ,:H_P"(L_\
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M_P#A;'_XU1_Q%G_J#_\ *G_W,/\ B%O_ %%_^4__ +<_%FBOVF_X<A?LF_\
M11OBG_X6Q_\ C5'_  Y"_9-_Z*-\4_\ PMC_ /&J/^(L_P#4'_Y4_P#N8?\
M$+?^HO\ \I__ &Y^+-%?M-_PY"_9-_Z*-\4__"V/_P :H_X<A?LF_P#11OBG
M_P"%L?\ XU1_Q%G_ *@__*G_ -S#_B%O_47_ .4__MS\6:*_:;_AR%^R;_T4
M;XI_^%L?_C5'_#D+]DW_ **-\4__  MC_P#&J/\ B+/_ %!_^5/_ +F'_$+?
M^HO_ ,I__;GXLU]G?\$(?^3YS_V)FH?^AP5]L?\ #D+]DW_HHWQ3_P#"V/\
M\:H_X<A?LF_]%&^*?_A;'_XU7GYMXE?VIEM7"?5>7GBU?GO:_6W(K_>=^5^'
M?]FYC2Q7UKFY))VY+7MY\[M]Q]C45\<_\.0OV3?^BC?%/_PMC_\ &J/^'(7[
M)O\ T4;XI_\ A;'_ .-5^6GZ6?8U%?+?PE_X)'?LU_!KXEZ)\5/"_CKXBW&H
MZ#J"7EG!J7BXRV[R(<@2)Y8WKZC/-?4E !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#FM.^#/P?TCXGW_QMTGX4>&K7QGJM
MBMEJGBZWT*W35+RV79M@ENE02R1CRTPC,5&Q>.!72T44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '->.?@S\'_ (GZYH/B?XE?"CPUXBU+PM??;?#&H:[H5O=SZ1<Y
M4^?:R2HS6\F40[XRK?(O/ KI:** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A?V@OVE?@I^RSX,MOB#\>/
M&G]A:1>:FFG6UW_9MS=;[EXY)%CV6\<C#*0R')&/EQG) /CW_#XW_@G#_P!'
M&?\ EH:Q_P#(E>9?\' __)FGAG_LIUE_Z;M1K\>Z_5.$N!\IS[)UB\1.:DY-
M>ZXI:>L6_P 3\QXIXTS3(\V>%H0@XI)^\I-Z^DE^1^Z/_#XW_@G#_P!'&?\
MEH:Q_P#(E>P_L^_M*_!3]J;P9<_$'X#^-/[=TBSU-].N;O\ LVYM=ERD<<C1
M[+B.-CA)HSD#'S8SD$#^<VOV$_X-^/\ DS3Q-_V4Z]_]-VG4<6\#93D.3O%X
M><W)22]YQ:U](I_B/A7C3-,\S986O""BTW[JDGIZR?Y'W11117Y6?IH4444
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MNJ>,-*M/AYK-AIT5P@7S_)NY[46CJ"RX"3ONS\N[!H ^W:*^0/BG_P %WO\
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M!^$W_)*_#/\ V+]E_P"B$KY&TK_@WG_X)56WA:[\!>)O@?XA\3>'I+!['2=
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M%;W3+L4$RQON PVX$BL+X\?\$6_V ?VA_CAK7[0?C/X>^(]*\0^*XHHO&_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>biib-20210331_g4.jpg
<TEXT>
begin 644 biib-20210331_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
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MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+
MB9G8*+D@+EB> .@[5[;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#D
MB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[
MI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO
M_@GO_P D3U;_ +'O6?\ TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_\
M!/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'A?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U
M;_L>]9_]*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?]CWK/
M_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !1110 4444 %%%% !1110 4444
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MXYUM[1M:DU#39K1DL6NC +988;S?" (B[1EHG*JR 'L?[/\ KOP=_P""P_\
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M OB%I'Q)U?X2>(O&=YX>NUNO#UA\0_'^JZY8:;,I&UTM+NX>%\8&/,5P,#N
M: /K#X.>,M9^(OPB\*_$'Q'X?;2=0UWPW8ZC?Z4^<V4T]NDKPG< <HS%>>>*
MZ2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKF?B=\8?AS\&]+MM9^)'
MB+^S;:[N/)MY/LDTV]]I;&(D8C@'DC%:4J56O44*<7*3V25V_DB*E6G1@YU)
M));MNR^\Z:BO)/\ ANG]E?\ Z*E_Y1+[_P",4?\ #=/[*_\ T5+_ ,HE]_\
M&*[O[&SC_H'J?^ 2_P CB_M;*O\ H(A_X''_ #/6Z*\D_P"&Z?V5_P#HJ7_E
M$OO_ (Q1_P -T_LK_P#14O\ RB7W_P 8H_L;./\ H'J?^ 2_R#^ULJ_Z"(?^
M!Q_S/6Z*\D_X;I_97_Z*E_Y1+[_XQ1_PW3^RO_T5+_RB7W_QBC^QLX_Z!ZG_
M (!+_(/[6RK_ *"(?^!Q_P SUNBO)/\ ANG]E?\ Z*E_Y1+[_P",4?\ #=/[
M*_\ T5+_ ,HE]_\ &*/[&SC_ *!ZG_@$O\@_M;*O^@B'_@<?\SUNN%^/_P !
M/#G[0WAS0/#7B;6;VRB\/^.M!\4VTE@4W27.E:C!?PQ-O4CRWD@56Q@[2<$'
M!KGO^&Z?V5_^BI?^42^_^,4?\-T_LK_]%2_\HE]_\8H_L;./^@>I_P" 2_R#
M^ULJ_P"@B'_@<?\ ,];K(T_X?> M)\02^+-*\$:1;:K/GS]3M]-B2XDSUW2!
M=QS[FO._^&Z?V5_^BI?^42^_^,4?\-T_LK_]%2_\HE]_\8H_L;./^@>I_P"
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MW3^RO_T5+_RB7W_QBC^QLX_Z!ZG_ (!+_(/[6RK_ *"(?^!Q_P SUNBO)/\
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MA.N^)_"%E ^JR::%<36MI-.&6SED)CQ<A7>,(=HRV1Z?10!\2?#W_@W_ /\
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MJ=.2<7LT[I_,SJ4ZE*;A---;IZ,****L@**** "BBB@ KWG_ ()S?\G$'_L
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M8MA\D\8SQQ=_9R\'^+?'?Q9M/%<6LRV=IH=VFJ:_XAN)B%LX8VWL[2'JS!2
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MJ % [  5Q/A']I;XJ>"-*OM$T.ZTPVFH:O+J=Q;W6BV\R?:9%5690Z$*,*
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MOI;:=4=5FA<JP5E*L,CU5B#[$U7HI-*2LQIM.Z"BBBF(**** "BBB@ HHHH
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M_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 5\&?\
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M_P!O+]3P:BBBOV _*@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG2Z3>:E;^)OB3'937VJVVGQ6[:C"N UH651#)$PD63[,DBF,L^[V?]ESX_\
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M^$EU?_H4+W_OI:V**_&3];,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V**
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M_L[!_P OXO\ S#^T<9_-^"_R/H#_ (;H_P"J7?\ E;_^T4?\-T?]4N_\K?\
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M -)):^GX,C&7$^&4E=<S_)GS?%\I1X;Q+B[.R_-'YK?\-2?';_H>O_*9:_\
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MPU)\=O\ H>O_ "F6O_QJC_AJ3X[?]#U_Y3+7_P"-5Y_11]6PW\B^Y!]9Q/\
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M1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OL[_@A#_P GSG_L3-0_]#@KXQK[._X(0_\ )\Y_[$S4/_0X*^>XL_Y)K%_X
M)'O<+_\ )187_&C]GJ***_EP_I8**** "BBB@ HHHH **** "BBB@ HHHH \
M+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\ !/?_ )(GJW_8]ZS_ .E)KW2@ K\8
M?^"[W_)\X_[$S3__ $.>OV>K\8?^"[W_ "?./^Q,T_\ ]#GK]"\,_P#DI/\
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M^,/_  7>_P"3YQ_V)FG_ /H<]?L]7XP_\%WO^3YQ_P!B9I__ *'/7Z%X9_\
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MX=HZGRG7T+X4_9R_8*UO0=-N]=_X*)W>G:I=V<+WFDQ_!K4;@VMPZ O )$G
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MA?\ &C]GJ***_EP_I8**** "BBB@ HHHH **** "BBB@ HHHH \+_P"">_\
MR1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH *_&'_@N]_R?./\
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M_8F:?_Z'/7[/5^,/_!=[_D^<?]B9I_\ Z'/7Z%X9_P#)2?\ ;DOS1\'XC?\
M)._]OQ_4^,:***_H(_!PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K]:?^#>G_DWKQW_V.:?^DD5?DM7ZT_\ !O3_
M ,F]>._^QS3_ -)(J^&\1?\ DEJG^*'_ *4C[3P__P"2FI_X9?DS] Z***_G
M0_H **** "OS\_X.%O\ DWKP)_V.;_\ I)+7Z!U^?G_!PM_R;UX$_P"QS?\
M])):^IX*_P"2IPO^)_\ I+/F>,?^29Q/^%?FC\EJ***_IL_G$**** "BBB@
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M^UE_T;)\4_\ PB!_\D5^_E%'^O\ Q;_T$_\ DE/_ .0#_47A7_H'_P#)Y_\
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M('_R11_P[W_:R_Z-D^*?_A$#_P"2*_?RBC_7_BW_ *"?_)*?_P @'^HO"O\
MT#_^3S_^2/P#_P"'>_[67_1LGQ3_ /"('_R11_P[W_:R_P"C9/BG_P"$0/\
MY(K]_**/]?\ BW_H)_\ )*?_ ,@'^HO"O_0/_P"3S_\ DC\ _P#AWO\ M9?]
M&R?%/_PB!_\ )%'_  [W_:R_Z-D^*?\ X1 _^2*_?RBC_7_BW_H)_P#)*?\
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MXI_^$0/_ )(H_P"'>_[67_1LGQ3_ /"('_R17[^44?Z_\6_]!/\ Y)3_ /D
M_P!1>%?^@?\ \GG_ /)'X!_\.]_VLO\ HV3XI_\ A$#_ .2*/^'>_P"UE_T;
M)\4__"('_P D5^_E%'^O_%O_ $$_^24__D _U%X5_P"@?_R>?_R1^ ?_  [W
M_:R_Z-D^*?\ X1 _^2*/^'>_[67_ $;)\4__  B!_P#)%?OY11_K_P 6_P#0
M3_Y)3_\ D _U%X5_Z!__ ">?_P D?@'_ ,.]_P!K+_HV3XI_^$0/_DBC_AWO
M^UE_T;)\4_\ PB!_\D5^_E%'^O\ Q;_T$_\ DE/_ .0#_47A7_H'_P#)Y_\
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MXI_^$0/_ )(H_P"'>_[67_1LGQ3_ /"('_R17[^44?Z_\6_]!/\ Y)3_ /D
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M?4E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%?FE\)OCU_P %"O\ @LE\8OB)XJ_9,_:L7X _L\_#SQA=>%-!\1Z%
MX1LM6U_QWJ-K@7-VKWRM':6:LR>647<P.&R=P0 _2VBOSQ^$W[4_[<?_  3^
M_P""@7@']@?_ (*!_&G3_B]X'^-EK>I\(OC$GAJWT?4K35K1!)+I.I6]M^X?
M<C1B*9 &=Y%SG<XB@_X+E>-?^"LO[.GP/^(_[7_[*W[:7@_X>_#_ ,!>%[6]
MM/#D/PXMM6UC4KHS1Q3+)<7P>"&,M("I6-R O(R<T ?HK4$>EZ9%J$FK1:=
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M?"7XK_LP^$;.#XI?M'ZYX7\-?"[3/$2&6'2M1UR%9EFN4 !=;>+?G(V^9LW
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MOA7\-=:U#Q3HVGOI_A?5O&?C+4=<?P]9NNUK>P6]GD6U4H2FY!OVEEW;68$
M^IJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** .8^-GQ&_X4]\&O%WQ<_L;^T?^$6\,7^K_ -G_
M &CR?M7V:WDF\KS-K;-VS;NVMC.<'&*_/#_B(R_ZLZ_\R%_][Z^Z?VU_^3-/
MBW_V3'7O_3=/7\\%?J?A_P .9+G>#K5,;2YW&22]Z2TM_=:/S/COB#-\FQ=&
M&#J\BE%M^[%ZW_O)GZ;?\1&7_5G7_F0O_O?7NG_!/O\ X*O_ /#=?QEU/X1_
M\*$_X1;^SO#$VK_VA_PE/V[S/+N+:'RO+^RQ8S]HW;MQQLQCG(_%6ONG_@WX
M_P"3R_$W_9,;W_TXZ=7TG$O!G#67Y%B,1AZ'+.,;I\TW9^CDU^!\[P]Q?Q%C
ML[H8>O7O"4K-<L%=>JBF?L'1117X0?MP4444 %%? '_!T=_R@H^.?_<L_P#J
M3Z37W_0 45^./_!)_P#;G_X=K_\ !J=X<_;6_P"%7?\ ":?\(7J&H_\ %,_V
MW_9WVS[9XREL/^/CR)_+V?:O,_U;;MFWC=N'T%\9_P#@LG^UI^SEX=TG]J_X
MZ_\ !-*]\-_LV:GK&GVUUX\NOB';-XAT?3[Z=(;75;W1UA/D1N98MUOYQEC\
MQ0Y#Y2@#[XU7QOX+T+Q+I/@S7/%^EV>L:]Y_]AZ3=ZA''<ZCY""2;R(F8--Y
M:$,^P':I!.!6I7R'^V+\3_@9X8_X*L_L9_#KQU^SG%XF\:>*Q\1/^$!^(1\4
MW%HW@S[-H4$M]MLXT,5_]KA*P?O67R=N]<DXKY(^!?[7'_!4?2?^"R_[8N@_
M##]AJS\?_88_!D+>#]5_:!BTZR\/6BV$XM+RW:6QEC9KZ("XDB1$,+#8S2GY
MJ /USHKY$_:8_P""DOQ?\+?M(6?[#_[%_P"R</BO\78?"L'B+QO9WWC"+1]#
M\&V$S;(3>7S12&2:1\^7!%&79!YG"UK?L5?\%%/&'QQ^-'C7]D/]K+]GEO@_
M\8_ >B6VO7_AS_A)8M6TW5]"G<QIJMA>HD?F0B53'(KHIB8JI+'<% /J6LOP
M?XW\%_$/0T\3> /%^EZYILDLD2:AH^H1W,#.C%'421L5)5@5(SD$$'FO@_X:
M?\%@_P!KG]H_P]KG[4?[*/\ P35O/&G[/.AZG>06?C23XA067B#Q/9V<CQW>
MH:5I,D!$T:-'*(XI)HWF,952KDHL?_!K]J]EK_\ P2&\)Z[IDA>VO?&_BNXM
MV92"4?6[ME)!Z<$<4 ?H15'2_$_AK7+F>RT3Q#8WDUJVVYBM;M)&B.<88*25
M.01S7Y\?\'*?C+QYX/\ V1OAT+O6/%NE_![4?C3HEI^T1JW@AIQ?V_@]C+]J
M5FMP9$@<A%=EY)\M.1(5;(_8Q_8N_P"#;#X^_$'P9\0OV )?ARWC7P/J]CKO
MAYO OCZ[MM:B>TF2=?M-H]R)YX6\O;(MQ&P92P//( /TLHK\IOVIOVG_ /@H
MGX'_ .#A31O!OP/_ &3H?&5E:?L^7O\ PCWA"Y^-::18Z_9'4HS)K,H:TDCM
MIXIB]L(61W9%WB0 [!]F_&K]H3_@H?X8^'/P_G^"/_!/71_$_C3Q1I4]QXUT
MS4_B]:V.E>#+B-;?$$EY]E:34"[2RA## H(MW+;,J" ?1E%?)G[('_!1;XQ?
M%']I;Q)^PW^V%^RD/A1\7=$\&IXLT33]/\81:UI'B;13<?9FN[2[2*)D9+@K
M&\,D>Y=P;)&0/CS_ ()4_M=_\%3M:_:I_:7TE_V$[/Q/9S?M!F'Q9%JO[0<2
MIX#W00"6SM$DL7%]%'&3*#%Y*N3M"@\T ?KM17QG\9/^"F/[07BS]J;Q=^Q]
M_P $Y_V.K;XMZ]\-H+7_ (6;XM\2>.8] T'0+NYC\V#3TE\B>2\NC&"SI&H6
M+(#,2&5;7P0_X*\>#_$?P*^.?CC]ISX'ZW\,/'O[-EE+=?%_X;OJ,.J36L/V
M-[RUN+*YB"1WD%U#&WDN1'EE(("X=@#["HKXA^ _[=G_  5A^-&F^#/C#_PZ
MI\,6GPY\:OI]W;O'\=[9M<T[2+LQLNH2VS62PR%8)/.:W6428&P'<,'[>H *
M*** "BBB@ HHHH ^8/'_ /P4A_X0;QYK?@G_ (4U]J_L?5[FQ^T_\)%L\[RI
M6CW[?LYVYVYQDXSU-9'_  ]*_P"J%_\ ES__ '-7SO\ '[_DN_C;_L;M2_\
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M^L[A=L]I>0++%(/1E8$$?44S0?#OA_PKIB:+X7T*STVSB)\NTL+5(8DSUPJ
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M>,?"/Q8UCPUX:\36%Z@::W:6S98/MEJ^(F\TJVS:!\JJ3](_L=C_ ((L^&O
MG[2W[0WPM_:,\<_&?PW<>$+'3/CYXN\=:UK/BJ&[TI8;N-+=;BXB9[T) 9@Z
MP&4HA1>,J*_1WQ#X8\-^+M,;1?%?AZQU2S=@SVFHVB3Q,1T)5P02/I4VEZ5I
M>AZ?%I.BZ;;V=K NV"VM85CCC'HJJ  /I0!^%OCWXP_LM?L@K\/M0_X('_\
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M'X+FTB?6/V>/'NHZGJFD:QI*JD$SR+J2QJUE*T=Y"?*N=@8*/D+0_+^C^H^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>biib-20210331_g5.jpg
<TEXT>
begin 644 biib-20210331_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
MPEW_ !3/]B>?_;O]N:7'8?\ 'QYZ?9?(\OS/]7+YF=OR8W5[[+%%/$T,T:NC
MJ5=&&0P/4$=Q3J* /SN\(?\ !(W]O?\ 93\+>)/V</\ @G?_ ,%)M-^'WP8\
M1:K?7FC>'?$GPT75]6\#K>2-)<0Z5=BZB#1[W=HQ*F8RV<LY:1N_^(/_  1;
M^$UY_P $HK#_ ()5?!;XF7GA71+&^TJ];Q;J>E#4[N[NK;6(-4N+B>,2P!Y+
MB6)P2'41B0;050)7VE10 5XS_P %!_V+/ __  4-_8^\:?L@_$+Q)?:+I_BZ
MTMQ%K6F(K7&GW5M=0W=M<(K8#;)H(R5R-R[EW+G(]FHH ^-/&G_!.C]M/]H#
M]BOXO?L??M@?\%&M-\?GXC^&[72?#WB>Q^"UMHTGA_8SFXFE@@OV%\TO[GC=
M"$,1QG?A?5/VD?V)_P#AH/\ X)V:_P#L#?\ "S/[(_MSX;Q^%/\ A+/[&^T>
M1MMTA^T_9?.3=G9N\OS1UQN[U[O10!\H_M9?\$NM._:-^$7PBL_ _P =]4^'
M_P 6/@0EO)\,/BSHND13RZ?.MI':W*36<KE+BUN8XU$MNS@,%4%BNX,WX&_L
MZ_\ !6J#XKZ!XH_:>_X**^!]2\):'>&74?"G@/X.I82^(E",JI<WES=S-;J&
M*N5@0%BH7<%)!^K+JZM;&UDOKZYCAAAC+S32N%5% R6)/  '))JGX5\6^%?'
M7AZU\6^"/$VGZSI5]'OLM3TJ]CN+>X7)&Y)(R5<9!&03R#0!H5\\?MQ?L%?\
M-F_$_P" _P 2/^%K?\(W_P *2^+%KXU^Q?V%]L_MKR49?LF_SXOLV<Y\W$F/
M[AKZ'IEQ<06D#W5U.D<<:EI))& 50.I)/04 >-_\%#OV0_\ AO7]BWX@?L@_
M\+"_X13_ (3K1TL/^$A_LG[=]AVSQ2[_ "/-B\W_ %>,>8O7.>,5G_M=?L3_
M /#5'_!/CQ-^PC_PLS^P?^$C\#P^'?\ A*O[&^U?9_+6)?/^S>='OSY?W/-&
M,_>XY]MT?7=$\16?]H^']9M+ZWWE?/L[A94W#J-RDC-6J /F#XM?\$W_ /A:
M7Q _9;\=?\+E^P_\,UZ@]U]E_P"$=\W_ (2/=IB6.W=]H7[']WS,XFZ[<?Q5
MUO\ P4&_80^''_!0KX!I\&O'/BC5_#6IZ/X@L_$7@?QIX>D":AX:URS8M:W]
MN6X+)N=2IQN21@"K;77W*B@#XT^'W[+7_!9Q?$VAZ5\7?^"IG@:Z\+Z/J=K-
MJ=WX:^!4%MK'B*UBE5I+>:26\D@M#,BE6DAC++N.S!P1I?M??\$V/B;\0OVH
MM._;T_8A_:=/PA^,%OX9'ASQ#<W_ (9CUG1/%>DK)YL=M?V;21D21OREQ&XD
M50%P0%V_7-4['Q#H&IW]QI6FZY9W%U9G%W;07*/) ?1U!RO3O0!X+^R5\#_^
M"A?@SXC:A\1/VT?VW/#GCJPGT9[+3/ O@OX9QZ+IUC.TL3_;6N)+B>YGD"QM
M&$9E11(QP3@CV[XA>%/^$\\ ZYX'^W_9/[9T>YL?M7E>9Y/G1-'OVY&[&[.,
MC.,9%;%5=)US1=?MFO-"UBUO85D,;2VEPLBAQU4E21D9'% 'SI^QQ_P3.^#W
M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
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MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+
MB9G8*+D@+EB> .@[5[;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#D
MB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[
MI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%5-8U_0O#L$-SX@UJTL8[B[AM;>2\N5B66>5Q'%$I8C<[NRJJCEF8  DT
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M_$T\M\LCM$DT@E@CB00L(U$H8#,G[ ?8O&_?6[/_ ,!C_C7Y'_\ !:GXU?\
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M<>LWF@>!]'UVZ^)U_HNDVNIII0M;WQ#-;1).MC$SRB)YR PA1GD?:6VJ79L
MDFOSG_X)ZOIO[;__  6G^,'_  5*_9\\.BP^#>F?"^+X8:9XLBA\J+XAZU!J
M$=Q<ZI#_ ,]X+=85M5GZ.(XMC'#JH!]/?M=_\%9OV%/V(?B':?!_X[?%J\'B
M^[TW^TO^$6\+^%]0UN_MK'./M4\-A!*;>+/1I-N[^$'!KUK]G;]H_P"!O[6?
MPATCX]?LY?$O3?%OA'78F?3-:TMV*2;6*NC*X5XI%8%6C=5=&!#*",5\,_\
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MR75Z&S17"?\ #2_P2_Z'7_RFW/\ \;H_X:7^"7_0Z_\ E-N?_C=>?_;F2_\
M033_ / X_P"9R_VA@/\ G['_ ,"7^9W=%<)_PTO\$O\ H=?_ "FW/_QNC_AI
M?X)?]#K_ .4VY_\ C=']N9+_ -!-/_P./^8?VA@/^?L?_ E_F=W17"?\-+_!
M+_H=?_*;<_\ QNC_ (:7^"7_ $.O_E-N?_C=']N9+_T$T_\ P./^8?VA@/\
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M_,/[0P'_ #]C_P"!+_,[NBN$_P"&E_@E_P!#K_Y3;G_XW1_PTO\ !+_H=?\
MRFW/_P ;H_MS)?\ H)I_^!Q_S#^T,!_S]C_X$O\ ,[NBN$_X:7^"7_0Z_P#E
M-N?_ (W1_P -+_!+_H=?_*;<_P#QNC^W,E_Z":?_ (''_,/[0P'_ #]C_P"!
M+_,[NBN$_P"&E_@E_P!#K_Y3;G_XW1_PTO\ !+_H=?\ RFW/_P ;H_MS)?\
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M2W^+'A_5[2V,)C2&QCL].<R(&0N=^-H\LY.6%?5E% 'YMZ5\.?VY_P#@E/\
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M+*OI^J/G6BBBOP$_-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .TT?\-K?]4T_P#*S_\ ::\)HH_USXE_Y_\ _DL/_D0_M[-?^?GX1_R/=O\
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M^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH *^8OVMO\
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M 5Z?^R3_ ,E8/_8+F_FE>85Z?^R3_P E8/\ V"YOYI7M<.?\C[#?XT=^5_\
M(QI?XD?3M%%%?T,?IH4444 %%%% !1110 4444 ?E)'^WW\._P#@F!_P59_:
M9\,>+OV7/C3XPT#XG:QH?B!_&/@GX976H"QU&+28(9;!I!A;FVV[)(I8V)CD
MEFB9!M\QOIS]ES_@M#^SW^UE\=M"_9^\#_L\_'C0M4U_[5]EU7QG\)[O3--@
M\BUEN6\ZYD.V/<L+*N?O.R+U:N'^/G[8O_!37]IC]KSQY^R-_P $LO!WPPT+
M1_A')8V?Q(^*_P 6C>3P/JMU;)=+ING6MI\SO'#)&9)) 5RQ7Y,(9)/V=?VR
M?^"E7[._[8O@C]B[_@J;X*^&6L6GQ8@U%/AA\5OA*]W#:RZC96S74VFZA:W?
MS12M KM'(FU"4"@2%F,8!]YT444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)
M[_\ )$]6_P"Q[UG_ -*37NE !7S%^UM_R5@?]@N'^;U].U\Q?M;?\E8'_8+A
M_F]?%<??\B'_ +?C^IX'$?\ R+O^WE^IYA1117XH?!!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7T5^QI_R)FK?]
MA0?^BUKYUKZ*_8T_Y$S5O^PH/_1:U]?P-_R4,/27Y'M\/?\ (SCZ/\CV*BBB
MOW$_00HHHH *\=_;+_Y$S2?^PH?_ $6U>Q5X[^V7_P B9I/_ &%#_P"BVKYW
MBS_DGL1Z+\T>7G/_ "+*OI^J/G6BBBOP$_-PHHHH **** "BBB@ HHHH **^
M2/BC_P %C?V1/A_\>])^%VG?$4:UHT*:K%XSUW0O#.J:E%I5U;?9_*B66TMY
M(Y>9)?,*%_+VKNV[AGW7QE\;=9U#]G9?CM^S-\/C\3I]4TNSO_">AV6KQ::-
M9AN'BV.+BY&V%1'(927'"H1C/%=M3+L;14'4@XJ>S>BWMN[)=]7MKL;SPN(I
MJ+G%KFVOI^+_ *MJ>A45\8>*_P#@I#^UI^S9K&@:_P#MQ_L(V_@WP%X@U^VT
MB3QCX6^(EOK/]BW%PVV$W4"PQL8R>LB' QP&8JI]F_:D^/G[3WPR\1Z-X(_9
MD_8[O?B7J&JVDMQ>:K=>*;?1]+TE495 FGF1S)(V<B-%W$ FKEEF+A.,7RVE
M>SYX\NF_O7Y5;LW?;NBGA*T9).VNSYE;3?6]CVFBOF/]FK]OOXB>-?VD+G]C
MC]K+]FV?X7_$1O#[:YX?CMO$46K:9KU@K[)'@N(T3;(ISF)@3A&)(QBJ?Q,_
M;[^-7B3]HSQ1^S)^Q)^R]!\2-5\ 06S>/?$&M^+H]&TS3+B="\5E&YBD:XG*
M EMH 0J0<D'#_LK&JLZ;2T7-?FCR\KT3YK\MF]-]]-P^IU^?ELMKWNK6[WO;
M\=]#ZHHKQ?\ 8P_;%TW]K/P[XCL-;^'E]X*\<>!=>?1?'G@C4[M+B72KP#<I
M2:,!;B"1<M',H <*V!QD^O:WK6D>&M%O/$?B#4X+*PT^UDN;Z\N9 D<$**6>
M1V/"JJ@DD\ "N2MAZV'K.E45I+IO^6]^C6CZ&,Z<Z<W"2U+5%?&GA#_@HE^V
MA^T1IDGQ8_8Z_P""=S^*OAL;F5-$\1>*OB):Z'>>(HXW*--:VLL3F.(E3L>4
MC<".%P0/K_P]J&H:MH%CJFK:.^G75S9Q2W.GRRJ[6LC("T19>&*DE<C@XXK7
M%8*O@[*K9/LI1;7DTFVGZV_ NMAZE#2=K]KIM>J3T^9<HHHKD,0HHHH ****
M "O3_P!DG_DK!_[!<W\TKS"O3_V2?^2L'_L%S?S2O:X<_P"1]AO\:._*_P#D
M8TO\2/IVBBBOZ&/TT**** "BBB@ HHHH ***\$_X*+^%OV>O%?P*T^V_:8_;
M2UKX$>';3Q997<7C/0_B9;^%)+BZC64I8O>7'R/%("Y:#J_E@_PF@#Y^^.?[
M+7_!3[]D?]K[XA_M8?\ !,BW^&_CSPM\8)K+4/'_ ,)_B-?SZ?+9ZU;6J6GV
M_3;R+Y )H8H_-28XW+E0<C9)^S[^RK_P4Q_:I_;(\ _ME?\ !3I/AUX(T3X0
M1ZC/\-OA/\.+Z>_:75;VU:TEU#4KN7Y7,<#NL4<1(RV[Y-K>9YI^TUX3_P""
M0O[3OQRU[XZ:E_P<9>*_!<^O20._AGX>?ME:/I>C67E6\< %M:AF$081AV&X
MY=W;^+%=)^P5\ _^";/@K]K'PIXF^ /_  7A^)'QG\6VWV[^R?AKK_[5^G>)
M;36-UA<)+YFFP_/<^5$TEP,?ZMH%D/"&@#]'Z*** /"_^">__)$]6_['O6?_
M $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH *^8OVMO\ DK _[!</\WKZ=KYB
M_:V_Y*P/^P7#_-Z^*X^_Y$/_ &_']3P.(_\ D7?]O+]3S"BBBOQ0^""BBB@
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MMIQCRV@^DO=C=WMWM9ZZZF-JT:D-&F^9M65K1[/1?KUUU.AHHHKY\\T****
M"BBB@ KT_P#9)_Y*P?\ L%S?S2O,*]/_ &2?^2L'_L%S?S2O:X<_Y'V&_P :
M._*_^1C2_P 2/IVBBBOZ&/TT**** "BBB@ HHHH *^?/^"EOCG]GCX??LZP:
M]^TW^Q%XA^/WAP^)+:)/ OAGX7V_BZYCN3',4O#8S_($C =3+U4R@?Q&OH.O
M+_VL]5_;!T?X<6-U^Q/X3\!ZQXK;Q!;)J-K\0[^ZM[)-,(?[0Z-; N9P?+V
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MP ^%WA?XJ6^NZ_\ :?L,WB3X5:KIMDOD6TMR_F7-Q"L<?R0N%W$;F*J.6 H
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M=_V\OU/,****_%#X(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*/[,P/\ )^+_ ,P^IX?^7\6?27_#PG_JD7_E?_\ N>C_ (>$_P#5(O\ RO\
M_P!SU\VT4?V9@?Y/Q?\ F'U/#_R_BSZ2_P"'A/\ U2+_ ,K_ /\ <]'_  \)
M_P"J1?\ E?\ _N>OFVBC^S,#_)^+_P P^IX?^7\6?27_  \)_P"J1?\ E?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^BOV-/\ D3-6_P"PH/\
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M_P""R_\ R>*/^Q3L?_0YJ^>XF_Y%G_;R_4\S-O\ =/FCY/HHHK\\/F@HHHH
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MLK#@@BN<^,7QW^%?P"T.U\2?%CQ*^EV5[=_9K:9--N+DO+M9MNV"-V'"DY(
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MHHI %%%% !1110 4444 %%%% !1110 4444 %?II_P $./\ DAOC+_L;$_\
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M;_T4;XI_^%L?_C5?/?ZI?]/O_)?_ +8\S^QO^GGX?\$_+6BOU*_X<A?LF_\
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M%^R;_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\ \:H_U2_Z??\ DO\
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MK&PDB:%B2Y/0@YKL?"?BG0O'/A73/&OA:^^U:9K&GPWVG7/E,GG02H)(WVN
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M_9@\72>+_C1\2+*/_1_#L+(HA\/?: ,27%TT>)( <HHR>4E"?0O_  6)UO\
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M)X7_ ,.M&^'_ (%:U7XC2_%'0]5AU*\CG79;K96,TDT6])9'WL2J^203EEH
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M1=/\<_$W4?%OC#3M0GU^^T\,;;2+".S=S+;O*[%[APBE0"-K*%< _3.BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#FM.^#/P?TCXGW_QMTGX4>&K7
MQGJMBMEJGBZWT*W35+RV79M@ENE02R1CRTPC,5&Q>.!72T44 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVE_V:/'/_"->-O#7]A?V)K?]F6MY]F^T:[I]K-^YNHI87W0SRI\R'&[(PP!
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M_P""A_[(_P"W;%KMO^SA\3WU'5O"T\</BCPSK&C7>E:MI#N"4^T65[%%,BL
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ML"5! !X-_P $1G1?C[^W-:LP$J_M>:X[1D_,%:UMMK8]#@X/?!J'X>_M'?\
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MJQ3^9'#&N)DD"[<KM))(!^9VH?L\>)O^"7/_  6,^#'[0/[:OQR\4?'OP?\
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MPK[TUS1-)\2Z)>>'-?L([NQU"UDMKVUF7*30R*5=&'<%20?K7$_";]ESX$_
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M'B5 QV.N3G[&\)^%M"\#>%=,\%>%K'[+IFCZ?#8Z=;>:S^3!$@CC3<Y+-A5
MRQ)..230!H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>biib-20210331_g6.jpg
<TEXT>
begin 644 biib-20210331_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
M;6^$\/QR_9>^)MKXN\*7%]-9PZQ9VL\*-/"0)$VSQH^5)'.W'I0!9_:6^(OQ
MI^%OPDOO%W[/G[/LOQ/\61W%O#IG@]/$UMHZW/F2JCR27ER&2&.-"TC':S$)
MA59B ?E_PK_P4Q_:_P#@W^T5\/?@?_P49_84TOX;Z-\6=?'A_P #?$#P9\28
M_$&G#7'B>6#3+R,VT$L$DHC=8Y &5V& ,!G7/_X."?C)\5?@O^R7X%U7PK\1
MO%W@KP%K'QI\/Z5\<O''@4RIJF@^#IFF^VW$,T*M);9D6W0S1@L-^T [\'\\
MOVO#_P $GK;]J/\ 8YTW_@FWXG\4>/M3B_:\\!R>,?'R_$OQ%XATBPCDO&,%
MC,]_=RV:WMP1)*JQJ)D2SFSL5R' /TI_:S_X*M_%+X%?\%#],_X)N_ _]B?4
MOB=XQ\1_!Z/QKX=O[/QE#IML)CJEQ9O;WIFMV2SM8X;:69KO>[%S' L#-(K5
ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
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MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[
MZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!
MJ#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A
M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
M4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ
M% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_
M]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__
M #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]
M^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,
M/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__
M #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!
MJ#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'
M_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^
MJ/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:
M@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0
M:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4
M_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y
M(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^">__)$]6_['
MO6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HHHH ****
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M4 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
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MDC-\V<8!( /H^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@
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MW[+/C#P19_8[[XN_"?QEX9\;2VJ!1?VFFVC:C:F;'WV65% 8Y.%1>@ '8?\
M!1?]F;]JCX??MU_"G_@JS^Q=\)(_B/KO@SPK?^"OB3\-4UF#3[W7/#ES(UQ%
M)93W!6+SK>X9Y?+<_O,J%Y!SD?LR? W]L#]LW_@I[IO_  4P_:X_9SNO@[X3
M^&/@"[\,_"/X?ZWKEK?:Q=WE\Y^W:M=?97>.V4PEH%AW%B-K< 9< YFY^#G_
M  6!_9=_X*"?M/\ [2'[)?[*/PT\;>$_BQKWAR^TP>,/B,=-O;R/3M%AM72W
MCBCD6,M*95W3M'CRP<%2"?IW_@FE_P %#O#'_!17X+ZSXW'PPU;P%XR\%>*[
MOPM\2?A]KLRRW7A[6K;;YMN9 JB:/# K)M7/S J"K >;?%W_ (*#_P#!3'X6
M?$7Q3\/]$_X(K^,/&EK9:W>0>"O%/AKXIZ*NGZ[9+*XM;F<2L)-/+IL+I(K%
M3N// H_X)&?L9?M/?LL?"[XP?'S]J2TT0?&+XZ?$/4/&^O>%= O!)8:(\D>V
MUTQ9L[963Y@TH8K\X&Y]GF, ?9'B#P_H'BS0[SPQXJT.SU/3=0MGM[_3M0MD
MF@N87!5XY(W!5U8$@J000<&OSQ^$_A_0?"W_  <_>,]!\,Z)::=8VW[%MBMO
M96%LL,42_P#"1Q<*B !1]!7U=^S9\5/VU/$7[$MM\6?VG_V7=/T#XU1Z/JUS
M>_"G0?$]K)!-=PW%R+&TCOO/E@0W$,=L3(TA2-ISNV[2!^?F@7G_  6:T7_@
MJ]KW_!25O^"*&L26.L_!&#P$OA,?M ^$Q+%)'J:7OVLW'VG!4A=GE[ <G.[M
M0!^M]%5="O-2U#1+._UG1VT^\GM8Y+NP:=93;2LH+1%U^5]I)7<.#C(JU0 4
M444 %%%% !1110 4444 %%%% !1110 445Y'^U]_R*&E?]A(_P#HMJ[<NP?U
M_&PP_-R\SWM?IVT/.S7'_P!F9?4Q7+S<BO:]KZI;V?Y'KE%?$=%?8_ZC_P#4
M1_Y)_P#;'P7_ !$?_J%_\G_^T/MRBOB.BC_4?_J(_P#)/_M@_P"(C_\ 4+_Y
M/_\ :'VY17Q'11_J/_U$?^2?_;!_Q$?_ *A?_)__ +0^W**^(Z*/]1_^HC_R
M3_[8/^(C_P#4+_Y/_P#:'VY17Q'11_J/_P!1'_DG_P!L'_$1_P#J%_\ )_\
M[0^W**^(Z*/]1_\ J(_\D_\ M@_XB/\ ]0O_ )/_ /:'VY17Q'11_J/_ -1'
M_DG_ -L'_$1_^H7_ ,G_ /M#[<HKXCHH_P!1_P#J(_\ )/\ [8/^(C_]0O\
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M*JW#?L+?L@?$[P?XYU_]M3]L/5;35?C7X]L4MKRWL&W6/A'2%8/%HUER<JK
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M>0A$4;G9F;&22236Q0!\]?L%^&[#5O@YJUU<S7"L/'&LKB*<J,?:6["O;?\
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ME*[5^ZY5;\37-LKCED^5.3U:NX*,7;^5\TK_ '+0Z*BOAW_@OGH>@>(_V5/
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M62ZTR&^?4[N\E1G\N0R[8T4;"J'&UE9I/9OV7/\ @EG\6?V<?CMH7QF\3?\
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M .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "ORO_X+"?\
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MXP_[&I?_ $FCK\V:_2;_ ((F_P#)$O&'_8U+_P"DT=>/GW_(MEZK\SW>&_\
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M1^;-%%%?H1^8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M /:J/K5#O^8?4L3_ "_BO\SV2BO&_P#AK7_JG_\ Y5?_ +51_P -:_\ 5/\
M_P JO_VJCZU0[_F'U+$_R_BO\SV2BO&_^&M?^J?_ /E5_P#M5'_#6O\ U3__
M ,JO_P!JH^M4._YA]2Q/\OXK_,]DHKQO_AK7_JG_ /Y5?_M5'_#6O_5/_P#R
MJ_\ VJCZU0[_ )A]2Q/\OXK_ #/9**\;_P"&M?\ JG__ )5?_M5'_#6O_5/_
M /RJ_P#VJCZU0[_F'U+$_P OXK_,]DHKQO\ X:U_ZI__ .57_P"U4?\ #6O_
M %3_ /\ *K_]JH^M4._YA]2Q/\OXK_,]DHKQO_AK7_JG_P#Y5?\ [51_PUK_
M -4__P#*K_\ :J/K5#O^8?4L3_+^*_S/9**\;_X:U_ZI_P#^57_[51_PUK_U
M3_\ \JO_ -JH^M4._P"8?4L3_+^*_P SV2BO&_\ AK7_ *I__P"57_[51_PU
MK_U3_P#\JO\ ]JH^M4._YA]2Q/\ +^*_S/9**\;_ .&M?^J?_P#E5_\ M5'_
M  UK_P!4_P#_ "J__:J/K5#O^8?4L3_+^*_S/9*^J/\ @CW_ ,G>'_L5;W_T
M*&OSS_X:U_ZI_P#^57_[57V3_P $+OCS_P +&_;A/AW_ (13['_Q1NH2^=]N
M\S[KP<8V+Z^M<68XFC+ U$GT?<[\KPF(AF-*3CHI+JC]DZ***^ /TL**** "
MBBB@ HHHH **** "BOSCUZ#_ (*)?\%&/V]/CI\*/AE^WSJGP ^''P-U[2O#
MVGZ%X.\(65[JVO75SIL-])?W-Q=@F*(B8+$B JRX) 9"S^T_LS?\$^_VO?@A
M\;M$^*'Q1_X*T?%3XFZ%I?VG[=X(\2>'M*@LM2\RVEA3S'MXED7RWD29=I&6
MB4'@F@#ZSHHHH \+_P"">_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK
M/_I2:]TH *_*_P#X+"?\G>#_ +%6R_\ 0IJ_5"OQL_X+H_'G_A7/[<(\._\
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M &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\ TI->Z4 %?A3_ ,'#W_*0<?\
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MHKZD^0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "ONK_@WA_Y2#G_ +$74O\ T.WKX5K[J_X-X?\ E(.?^Q%U+_T.
MWKGQ?^ZS]#JP7^]P]3]UJ***^3/L@HHHH **** "BBB@ K*\;^!?!/Q-\(ZA
MX ^(_@_2_$&A:M;-;ZIHNM6$=U:7D+=8Y8I59)%/=6!%:M% 'P/XN_X-QO\
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M_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V*_-G_@Y>_P"39_A[_P!CT_\
MZ135^AW_  @^D?\ /S>_^!;5^<?_  <D^'[+1_V;?A_-:S3L7\<.I$LQ8?\
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MEPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#7!F7^Z/Y'HY5_OJ]'^1^DU%%%?-'U84444 %?FS_P '+W_)L_P]_P"QZ?\
M](IJ_2:OS9_X.7O^39_A[_V/3_\ I%-77@?][@<68?[E/T_4_&6BBBOJ3Y *
M*** "BBB@ HHHH **** "BK$&DZI=:?<:O;:;<26EHZ+=720L8X6?.P.P&%+
M;6QGKM..E5Z "BBI+6UNKZX2TLK:2:61L1Q1(69CZ #DT 1T5-?6%_IERUEJ
M5E-;S)]Z*>,HP^H/-/T[1]7UAWBTC2[FZ:-=SK;0,Y4>IV@X% %:BE965BK
M@@X(/:DH **** "BBB@ HHHH **** "ONK_@WA_Y2#G_ +$74O\ T.WKX5K[
MJ_X-X?\ E(.?^Q%U+_T.WKGQ?^ZS]#JP7^]P]3]UJ***^3/L@HHHH **** "
MBBB@ HHHH **** "BBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\ P3W_ .2)
MZM_V/>L_^E)KW2@ K\*?^#A[_E(./^Q%TW_T.XK]UJ_"G_@X>_Y2#C_L1=-_
M]#N*]+*_]Z^3/+S?_=/FCX5HHHKZ(^7"BBB@ HHHH **** "BBO:_P#@GA^S
MGX+_ &KOVO/"?P/^(6L7-GH^IM=3WJV$J)<W2V]K+<?9H6?@/(8@@)Z!B1R!
M4SDH0<GLBH0=2:BMWH>.76DZI96=MJ-YIMQ#;WJ,UG/+"RI.JL58HQ&& 8%3
MC.""*KU]P?M9?%+]FCPU\ ? 7@CQ5_P3V/AV>Z\-:_!X=MKCQKJL.H^&+A=3
MNXT:03$K<_O0)G22-<DLJE%QCYN_9F_:W^*W[)6JZKXA^$%GX>75-5MXH1J>
MM>'K>_EL@C%@UOYZLL;$GD[3D >E9PJ3G!M1^_\ X%S2=*$)I.6GDG^MCS"K
M&GZ1JNKN\>DZ9<731IND6WA9RJ^IP#@>]?7'_!<F^NM4_;VOM2OI=\]QX-T.
M69]H&YVLHR3@<#D]JX'X=_\ !3S]M+X0_#K0?A'\$_B9!X1T;0H@D%MX?T&T
M22]E+EC+<2/&[SN2V.3MP -M$:DZE*,XK?S_ . .5*G3K2A-NR[+_@GS[17V
M/_P6$LM.G\3_  G\:^,O"VFZ)\5/$GPQM-2^*NFZ9:K!B^<_NIIXD $5PZ;B
MZX!&%!&,9](^ _[8OQ@_:5_X)Z?M+>"_'=OX>L=%\+>!=&&BZ3X<\.6]A%"S
MW91W8QKOD8B-<EV/.2,9-1[>7LHS2W\_.WS+6'C[65-RV5UIY7[Z?B?GA117
MH?[.7[5OQ_\ V2?%%]XT_9Y^(<GAS4]2L/L5[=16%M<&6#>LFS;<1NH^9%.0
M >.M=$N:VFYS1Y6_>V_KT//**_2=OV^?VN-1_P""3'Q%^+G[2GQBN->O/BCK
M@\%> K*XTJSMQ':")SJ=T!;PH71HFD@R2=KH/7G\V*RI5)5+W5K.V]_T1K6I
MPI\O*[W5]K?JPHHHK8Q"BBB@ HHHH *_9K_@VA_Y-G^(7_8])_Z10U^,M?LU
M_P &T/\ R;/\0O\ L>D_](H:X,R_W1_(]'*O]]7H_P C])J***^:/JPHHHH
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M("!C!QD9=&5!T9*ZM=]K;Z$UXXA8B,K.]EWOLKGUA^V/K_QZN_\ @G)/9_\
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M>9MZ90#Y0H'SW^R20O[5?PR9B !\0M%R3_U_0U])_P#!5ZXU'0OA'\!OA/\
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M)&0TI P!P!WYKEZYZ-&5)2::N_+3=]+_ -:'36KPJN*:;2\]=EUM^G<_0/\
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MIWVO77UW^QX+2V;=YUV9O(5$/&<O@#ZUA45JE/J_^',6X=%^/3[OQ_ ^N/\
M@K9XGT+P1X]\#_L.^ M0CGT#X'>$(-(N)(#^[NM:N%2XU"X^K.8PP[.C^M?(
M]%%*G#V<%$JK4]K4<MOZT"BBBK,PHHHH **** "OV:_X-H?^39_B%_V/2?\
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MI!S_ -B+J7_H=O7/B_\ =9^AU8+_ 'N'J?NM1117R9]D%%%% !1110 4444
M%%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q
M[UG_ -*37NE !7X4_P#!P]_RD''_ &(NF_\ H=Q7[K5^%/\ P</?\I!Q_P!B
M+IO_ *'<5Z65_P"]?)GEYO\ [I\T?"M%%%?1'RX4444 %%%% !1110 4444
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M ,'+W_)L_P /?^QZ?_TBFKKP/^]P.+,/]RGZ?J?C+1117U)\@%%%% !1110
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M_P#&J/\ AR%^R;_T4;XI_P#A;'_XU7V-10!\<_\ #D+]DW_HHWQ3_P#"V/\
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MQ_\ C5?8U% 'QS_PY"_9-_Z*-\4__"V/_P :H_X<A?LF_P#11OBG_P"%L?\
MXU7V-10!\<_\.0OV3?\ HHWQ3_\ "V/_ ,:KS'X[?\$FOV<OA[\2/AIX6T/Q
M[\1GMO%7B=[#4FNO%[.Z1"$N#&1&-K9'4@U^BE>??&/X,ZG\3?'O@#Q?8ZU!
M:Q^#O$+ZC<PS1L6N%,138I'0Y.>: /GK_AR%^R;_ -%&^*?_ (6Q_P#C5'_#
MD+]DW_HHWQ3_ /"V/_QJOL:B@#XY_P"'(7[)O_11OBG_ .%L?_C5'_#D+]DW
M_HHWQ3_\+8__ !JOL:B@#XY_X<A?LF_]%&^*?_A;'_XU1_PY"_9-_P"BC?%/
M_P +8_\ QJOL:B@#XY_X<A?LF_\ 11OBG_X6Q_\ C5'_  Y"_9-_Z*-\4_\
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M]I:3%*VGW=Y80S2F+>I,39<@[<' Q0!9_9#_ &S/V;/V\?@W#^T!^RC\2/\
MA*_"-QJ%Q8PZO_8]Y8[IX6"RIY5Y#%*,$CG9@]B:]/K\\?\ @V3_ .4=6O?]
MEP\8?^G U^AU 'EWAO\ ;3_9A\6>"/B;\2-(^+%JN@_!OQ'JF@_$O5;ZRN;6
M'0[_ $ZWBN;V-VGC3S%BAFC<RQ;XR&PK$@@?.W@S_@XC_P""1OCCQKIG@_3_
M -IZXL(-;OQ9:+XF\0>"-8TW1;VX)P$2_NK6.!1D'YW94X^]TSZ_^R5^PIH'
M[-5I\<=(\4^++/QIIOQL^,^M^/+_ $S4/#R10646HVMG;MILB/+*MTJBT),A
M"!Q+CRQMR?G3_@X-^)_@3Q-^Q\__  31^'_@"V\;_&#X\B#1?AK\/[.!7>T6
M.>-Y-9FX(M+6T6-G\YL ,@Q\JR,@!]P?&+XS?"K]GWX7:U\:_C7X]TWPSX4\
M.V1N]9UW5;@1V]K$" "3W)8JJJ,LS,JJ"2 ? _V5O^"RG_!//]LKXKVWP/\
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M,FT>>[B/E.I$LL7FJ?+=XHSE4)8>-_&/P=_P4$_X*_\ Q4^#7PF^.O[!FL_
M7X5?#;XBZ?XY^)NH^+?&&G:A/K]]IX8VVD6$=F[F6W>5V+W#A%*@$;64*_Z9
MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG&WG&1GOZYYTYTI<LTT^ST.JG4IUH*=-II]5J@HHHJ"PHHHH **** "BBB@
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M^+WPWUR+4_#WBGXZ^.-6T+48?N75G<:4LT,@]F1U/XT 6O\ @FKX!_X+;_\
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MQ?LO_1"4 =!1110 4444 %%%% !7@/\ P5#_ .3%O'/_ '#/_3G:5[]7@/\
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M]E_]HKQ/XP\,?L\VBZ+:0_8;K0Y(%@NI+I(5F<7JQ7BK'+(^920F @%>I_\
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M&_\ Z9Z_0^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4X[IW7R(J4X5J;IS5TTT_1GP'_PXV_ZN@_\ +)_^[:/^'&W_ %=!_P"63_\
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MM,\P@LX(EABB+RLSOMC15W.68XR222:V:* /F_X??\$C?^">WPLB^']IX%^
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M.S,<9)))-;E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>biib-20210331_g7.jpg
<TEXT>
begin 644 biib-20210331_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
M9OMUM<+%$5\NX(B=&7.X\'A@OG! /_!TV"0./V ./;_BMZT+D#_B)RLVP,G]
M@^YR?^YT@H ;HW_!5[]KG]H[XG^/7_X)[_\ !/.'XH?#'X9^)KGP]K7CG6OB
M9;Z%+XAU.UP+NWTBWDMY%G$1("RRR1QRDX#+UKDO^#:'XA:;\7/V<_VAOBMH
M^D:CI]GXG_; \;ZM:V&KVWD7=M'<K83+%/'D^7*H<*RY.&!&>*\T_P""1O[>
MO[*W_!*O]GOQM_P3S_;X^*T7PZ^(OPJ^(NOR"P\16L_G^*M-O+Z2ZL]1TX)&
MQOA.LNU4BW2$J/E&X5Z1_P &S/C&\^(G[-?[0?Q U#P=?>';C7?VO?&NH3^'
M]4@\JYTQYEL)&M9D_@DC+%&7LRD4 ?:O[6_[)OPI_;7^#-U\ ?C;<:]_PB^H
MWUO<:M9^']>GTV6^CA</]FDF@99!"Y #JC*6'&17Y?\ _!3;]@/]D3_@F5\3
M?V;/'G_!+?P!+\-OCQXE^-NDZ%H.@^%-=O6'BC1&8G4H;ZWEED$MHB>4996'
MRB0;FP<C]$O^"EG_  4 ^%__  3+_9!\2?M:?%71+_5K;1_*M=*T331B74M0
MG;9;V^\@K"C-RTC9"(K$!FVHWYK?\$TO^"DW_!+JZ^.$O[>W[?'_  4#\(^+
MOVEOB!#%IND:38:!JCZ9\/-,E8B+0M*W6I56_>%9[C=F1F<!F#223 'T-_P5
MAL+O]L[_ (*5?LV?\$IO%VMZG;_"WQ-I6N>.?B[HVFW\MK_PD=G81[;'3II(
MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+
MB9G8*+D@+EB> .@[5[;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#D
MB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[
MI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO
M_@GO_P D3U;_ +'O6?\ TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_\
M!/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445^:7[='_!
M5_\ :8\6?%35_@A_P3^_9MNM=LOAA\=O!OA3QO\ $35_'D.B6-YK5SJMEO\
M#\$0@FFFCE$JVUQ.0JQ+(YVR#;O /TMHKRS]GWXL?M"?$GX):AXP_:+_ &;6
M^$_BZRGNX9/#2^+;778BD:!H[J*[MT1)(WW<!D1P5(917YI_\$T]4_X*T_\
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M]A?]F#]O3X?67PX_:=^&RZY::3J2:CH.H6M_/8ZAI%ZH^6XM+NV=)H''&=K
M-@!@P&*QOV,O^";_ .R3^P4WB#5/V>O %Y#KOBV6.3Q5XM\1:[=ZMK&K&,8C
M6:\NY))"B@\1J0@Z[<DF@#TO6_BGHESIWBW2OACJFD^)O%?A33FEN_"UCK$)
MN8KEH7DMK>=0Q-N9BF%+@9&2,@&OQ*^)7C']O[X'?\$MOVG5_:9_X)6?$<_$
M3XS^'M<UCXQ?&&[\6Z&;*W:2WDBMTC@2Z>=;"QM=D44"[B KD %R*_9?X4?L
MC_L]?!#XV_$C]HSX7_#[^S/&7Q<N--G^(6L_VM=S_P!JR6$,D-H?*FE:*#RX
MYI%Q"D8;=EMQ (Z#XU_!GX:_M%?"/Q'\"?C'X;_MCPKXMT>?2_$.E?;)K?[7
M:3(4DC\V!TDCRI(W(RL.Q% 'SK_P1/\ BY\4/BM_P3E^%D/Q*_9SUWX?)X>^
M'OAW2M"EUK5+2Y'B*QBTBT\O4X/L[MY4,N<JDFV08Y KZRK#^&7PW\%_!SX;
M>'OA%\.-&_L[P[X5T.TT?0=/^T23?9;*VA2&"+S)69WVQHJ[G9F.,DDDFMR@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ***^"_^"^__ "0'P1_V.#_^DLM>OD65_P!M
MYO2P//R<[M>U[:-[75]NY\]Q7GW^K'#V(S3V?M/9)/EORWNTM[2MOV9]Z45_
M-O17ZK_Q!W_J._\ *7_W0_!/^)C?^I7_ .5__N)_2117\V]%'_$'?^H[_P I
M?_= _P")C?\ J5_^5_\ [B?TD45_-O11_P 0=_ZCO_*7_P!T#_B8W_J5_P#E
M?_[B?TD45_-O11_Q!W_J._\ *7_W0/\ B8W_ *E?_E?_ .XG])%%?S;T4?\
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MWQA_R2^,_P"O<OR/L_#K_DNLN_Z^P_,_8:BBBOY+/]!0HHHH **** "BBB@
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M_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 4444 %%%%
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MM6LU^,$/Q6TZ3XACX7:QJ$^D?\((F\ZJVKM([6XB_P!2J@GS'+D ,VS'Z _
MG]M.X_89_P""7/P4^+W_  5U\?WOACQ+J>CZ9HWB[6M8TJXNI8-2FMYI(1?B
MWC=HI&BA"RR. !,2'(+5\2_\%)OVEO\ @GK^W7\2?@5\,O\ @D?'H7C+]H?3
M/C#HNK:-XL^%_AF2!_#.CPS'[=<7U]'"B):%" \3LP/4K@<@'KW_  6_\*>
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M[]OC_@I;^W3\(_VG/VAOV,KWX ?"CX%3ZKJ^A:3XMUR"[\0>*]:O;"2Q3=#
M!]BMH(Y7<A^7; &\$^6 ?HG1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\
MD3U;_L>]9_\ 2DU[I0 445X]\<?V^OV2_P!F_P ;_P#"N?C1\6/[&UG[''=?
M8_["O[C]RY8*V^"!TYVGC.>.E=.%P6,QU7V6&IRJ2WM%.3MWLDV<6/S++LJH
M>WQM:%*%[<TY**N]E>32OY'L-%?-O_#W;_@GC_T<'_Y:>K?_ ")1_P /=O\
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M85Y -S#@<$]A7S]_P]V_X)X_]'!_^6GJW_R)1_P]V_X)X_\ 1P?_ ):>K?\
MR)1_JUQ'_P! 57_P7/\ R#_7;@S_ *&6'_\ !U/_ .2/I*BOFW_A[M_P3Q_Z
M.#_\M/5O_D2C_A[M_P $\?\ HX/_ ,M/5O\ Y$H_U:XC_P"@*K_X+G_D'^NW
M!G_0RP__ (.I_P#R1])45\V_\/=O^">/_1P?_EIZM_\ (E'_  ]V_P"">/\
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M0?\ !6QX5^%G_"769MS-<:Q&/[6\JX^S\Z01<?ZOS^#\GKSMH QOVFOV&O\
M@IY\6OCEKWQ#^ ?_  6<UGX7>$=2D@;1_ =K\$=%U:/2E2WCCD47=S()9M\B
M22Y8?+YNT<**D_9<_8>_X*:_!_X[:%\1?VA/^"R>L?%;P?IWVK^U_ -U\$]%
MTB/5/,M98HLW=M(98O+F>.;Y1\QA"'AC7YH?\(S_ ,&,7_/SI_\ X-OB-_\
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M#_\ I++7UO G_)6X3_$__26?GOBK_P F^Q_^!?\ I<3\JZ***_JL_@D****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M^PO^"'O_ ">T?^Q/O_\ T.&OCVOL+_@A[_R>T?\ L3[_ /\ 0X:^;XP_Y)?&
M?]>Y?D?9^'7_ "767?\ 7V'YG[#4445_)9_H*%%%% !1110 4444 %>5?M?_
M !7^,'P=^&5CXF^"G[)]_P#&/5;GQ#:V=SX7T_7+73WM;60/YE\9+H%&6/:H
M*#YCYG'0UZK10!\6?M-?MG_MR?!SXY:]\-O@I_P1*\0_$_PQIDD"Z5XZTSXA
M:+I\&J![>.1V6WG0R1[)'>([NIC)'!%6/V4?VU?VZ?BW\?= ^'OQD_X(N>)/
MA+X;U#[5_:7Q!O\ XB:-?PZ5Y=K-+'N@MD$K^;(B0#:>#,&/ -><^-OBI_P5
M>_;M_;6^-'P)_8U_:?\ !?P#\ _!'6].T"XUK4OA[%XCUKQ!J-QI\-[)(8;I
MUA@MU69%0CYF'S9.<+ZE^RY^R;_P5T^&?QVT+QO^T_\ \%:]'^)W@:R^U?VY
MX'M?@-I>BR:EOM98X<7D$K20^7.\4WR@[A$4/#&@#Z_HHHH \+_X)[_\D3U;
M_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ K\>?\ @N%_R>T/^Q/L
M/_0YJ_8:OQY_X+A?\GM#_L3[#_T.:OTCPL_Y*C_N'+\T?B_CQ_R0O_<6'Y2/
MCVBBBOZ0/XO"BBB@ HHHH **** "O8/V"M9^#'A_]J_PGJWQ\-@OAR*XF\R7
M5X1)9PW)@D%M).IX,:S&,G/ P"WR@UX_72?"C2/AAKOC2#2?B]XPU'0-$GAE
M676-,TP7DEM+L/ELT.Y3(F_ 8*P;!.*X\QI1KX"K2DY)2C)-QUDKIJ\4KN_:
MR>IZ63UYX7-L/7A&,G"<6E-I0;33M)MI*+ZMM*W5'W'^U'-_P4MTK]GG1]9M
M_%?_  F7A^YT#5K?QQJ7AA[+5--G@DNIPDBQQJ2D:VS+B1$7RPO52IQ\!1ZS
MK2Z2_AZ+5;H6,MPLSV*SMY3R@;0Y3."P!(!QG!K[K^'?C_\ 9Q_8W\.?#'XU
MVW[2-WXL&A^&->M]%\-Z%X9O+5/$IGO+I=MPUR%6&&.23YE8,Q:(,H( )\@_
MX)[:Y^R#X#UO7/BW^T+\2[#2/%.E@#P'IVJ^&;[4+""Z*DB^E2UC;S/*;;MC
M++R,YSM*_&Y+BIY;E^(G'#<T8R]WDI2A*<G.:LX6;]VT6Y)6BG:UXM'Z/Q+@
M:>=9O@Z<\;R2G%<ZJXB%2-.*I4WS*I=1]^\DH-WE*/->TTS9^)MOJ/[-7_!.
M:T_9Z^+-[)_PE_C[Q9!XDTSPK.<R>']-CC"B>53S#+,RX"<':3G!#"N=_P""
M7/B3Q%/^W!\,_#<^OWKZ=!JMV\%@]TY@C8V=P253.T$GDD#K6-^TQX6^"7B*
M/6OC#:?MXQ_$?QCJ%ZDL^GR>!=3LI;LNX5F$TZB-%1.0G "J%4#@5TW_  3M
MU#]E_P"$?Q5\,_M%_&/]J"W\/:AH&J7#/X3;P?J-U)-$T#Q+(+B"-XUR9"<8
M)&WGK715A%<,XM\LYU*JJ-I4JB?M)0LE&+CS<JT2DU9[MW;.3#U9RXWP$5.G
M3HT'22;KT6O90J)MSJ*HX.3=Y."=UHHJR1X-X^L;W5/BKK6F:;9RW%S<>(;F
M*WMX(RSRNT[!551R220 !U)K[C_9#N;+]F7]J'X7?L8^%KR)]?N]7?5OBYJ-
MLX(DOQ87#6VDAE^]':JVYQD@SN3P4Q7RY\8Y/AA\&OC#HOQ>_9M_:.M?&NH1
M^(7UI)8_"=W8C2KB*X2>WW+>*!/EL]!C]V<CYA7LW[+7_!4CXD1?M(>'M?\
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M: /K^BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CWK/\
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MH?\ I2/UOP1_Y.#0_P %3_TAGWI1117\S']NA1110 5^:?\ P<V?\FQ_#O\
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M(&THZMIP5_.AM+O:T<%V6\LHTP\K <-@D$ 'P%XP_P""JGP*^(?B.Y\8^/\
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M_;3%S87*RQ_\(A8#<O3.^:OV&_L[3_\ GQA_[]"OQ]_X+>PQ0?ML!(8E0?\
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MHK]8/Q0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *^\/^#=3_ )2&-_V(>I_^C+>O@^OO#_@W4_Y2&-_V(>I_^C+>
MO-SG_D55O\+/6R'_ )'-#_$C]X****_(3]R"BBB@ HHHH **** "BBB@ HHH
MH **** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=
M* "OQY_X+A?\GM#_ +$^P_\ 0YJ_8:OQY_X+A?\ )[0_[$^P_P#0YJ_2/"S_
M )*C_N'+\T?B_CQ_R0O_ '%A^4CX]HHHK^D#^+PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]5/^"!'_ "0'QO\
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M<Y_Y%5;_  L];(?^1S0_Q(_>"BBBOR$_<@HHHH **** "BBB@ HHHH ****
M"BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CWK/\ Z4FO
M=* "OP?_ .#BO_E(8O\ V(>F?^C+BOW@K\'_ /@XK_Y2&+_V(>F?^C+BOIN%
M/^1K_P!NO]#Y+C3_ )$O_;R_4^#Z***_2C\D"BBB@ HHHH **** "BBO;?\
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MV<O%'C;_ (2*]^$WA"WL/$.M^5&GV[7;F*&6^F C544$);KM"@*R,/:O5?\
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M/@M^R#\.;CPU<Z]J=U:1V'B;Q)]J6:^C:XEFF,PB7RT94X3:<$=3FO./AO\
MLR?&SXQ?&>Z_9^^%'@M]?\5VL]W$^FV5S$N\VQ82LKRLBD#:3R1D5P5%;QI5
M:<.6,M$K*Z;U[O6[]/Q.:=:C5GS3CJW=V:6G9*UEUUU]#]'?^"FW[!G[6]Y^
MSC\$?$]M\%[U[#X9? V*V\=7 OK;&DRVY>297'FY?:@)^0,#VS7YQ445&"P]
M7#4?9SDI:O96W=^[[FF/Q-'%U_:0@XZ).[OLDOY8]@HHHKK.(**** "BBB@
MK]I/^#9/_DV/XB?]CXG_ *10U^+=?M)_P;)_\FQ_$3_L?$_](H:^?XG_ .11
M/U7YGU'!_P#R/(>DOR/TLHHHK\O/V **** "OS3_ .#FS_DV/X=_]CX__I%-
M7Z65^:?_  <V?\FQ_#O_ +'Q_P#TBFKV,@_Y&]'U_1GA<2_\B.OZ+\T?BW11
M17ZP?B@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX=_]CX__ *135[&0?\C>CZ_HSPN)?^1'7]%^:/Q;HHHK]8/Q0**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^\/^#=
M3_E(8W_8AZG_ .C+>O@^OO#_ (-U/^4AC?\ 8AZG_P"C+>O-SG_D55O\+/6R
M'_D<T/\ $C]X****_(3]R"BBB@ HHHH **** "BBB@ HHHH **** /"_^">_
M_)$]6_['O6?_ $I->Z5\H>//V8?^"@'@3Q??Z9^QC^T+X*\+^"+JX:\ATKQ+
MHK7EVMW*=]P[2&%\JSDE0#@# QW.1_PI?_@M;_T>1\+/_"1_^YJ /L:OP?\
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MMH_)L]G(>%\PRO,HXBK*+BDUHW?5><4?HC17QS_PI?\ X+6_]'D?"S_PD?\
M[FH_X4O_ ,%K?^CR/A9_X2/_ -S5\:?>'V-17QS_ ,*7_P""UO\ T>1\+/\
MPD?_ +FH_P"%+_\ !:W_ */(^%G_ (2/_P!S4 ?8U?FG_P '-G_)L?P[_P"Q
M\?\ ](IJ]F_X4O\ \%K?^CR/A9_X2/\ ]S5YI^TW_P $UO\ @I'^V/X8T[P;
M^T?^T)\+/$>FZ3?F]T^V_LB\L_*G*%"^ZUCC9OE8C!)'/3-=^68JG@L?"O--
MJ+Z;[?(\W-\'5S#+:F'IM*4EI?;==KGX@45^JW_$.3\8?^AF^%G_ ($:Y_\
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%([I&ADD8*JC+,3@
M4 +1531O$&@^(K=KOP_K=G?Q(Y1Y;.Y255;T)4D ^U6Z "O(/VC_  +XN\6?
M%CX2:WX<T&>[M-#\8276K3P@%;6$P,H=N>F>*]?HH ***IP>(= NM6ET&VUR
MSDOH%W3V4=RAEC''+(#D#D=1WH N4455TW7-%UEITT?6+6[-K,8KD6UPLABD
M'5&VD[6]CS0!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\D?^"</[+/
MPL_X+OW/C;_@IU_P40TV[^(/AC4O'FJ:+\#?AEJ6IW":%X:T&SD\E;D6T3HD
MUW,V\22.&R8]P'*A/UNK\DO^"9?[5'PF_P""&L_C;_@EG_P40\02?#K1]&\>
M:IK7P2^(FM64PT+Q1X>O)?.2-+I%:.*ZA<N9(W*@&3:"2N6 -GQ3\)-$_P""
M'7_!3[X":!^R7K&IZ1\ OVE/$5UX0\7?">ZU:>[T[1/$!1&L=2TX3N[6YEDE
M59$4[=J,,'=&(K?_  <H_P#!./\ 9T^(_P"Q-\9_VY_'EWXPU3QCX;\%V@\.
M:?-XRO$T?3)([F&(31V$;K$TA61BQ<."3G' JKXT^,'A;_@M_P#\%1?@+=_L
MBVM[K_P,_9G\277C#QO\5VTR:'3-4\0!(Q8Z78/,B&XDCD19)&4%=DA.?E3S
M-_\ X.5O^"@W['/PT_8(^,'[$'CCXX6&G_%3Q3X%MKG0/!\EA=-->127L91E
MD6(Q+GR)?O.#\A]1D ^]?V3_ /DUGX:?]D_T;_TAAJM^V/X"\6?%7]D3XJ?"
M_P !:3]OUWQ)\-]<TO1;'SXXOM%W<6$\,,>^1E1-SNHW,P49R2!DUY-_P2K_
M &_?V0/VU/V?=(\(?LO_ !LL?%NI?#SP;H%GXSM;.QNH3ID\UHR1HQGB0.6:
MUN!E"P_=G/49^H: /CWP1_P3"^''[1__  3$_9W_ &.OVZ_".M!/AW\/O"T/
MBOP;I?BN2U@NM2LM$2RFL[N:PE'VF!)&D.V.78SQHP9E S\E_M _L>_LW_\
M!-[_ (*V?LE^$_\ @EMX8G\"^-/B#XFN[;XJ> ?#6KW4MAJW@R*+-Q?7UM+)
M(J>5B4Q2$+ND1B,M$"OV1_P6)_X*E>!?^"3G[)S_ !UU_P ,/KWB+7=570_
MVALQCMKG4Y(I)%:ZF'^IMXTC>1R/F(7:O+9'Q_\ \$A_VW/^"4'A#XL'Q_\
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M5O&&M6?P ^ '@32];^(?@S0]5FLAXSU[4T2>UMKV6!DD:T2VE5_+##YXV/\
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MOV:ZTRVN;=9=96!T \MS(OEX& 4:1>AQ7G?_  4,_8B_9N_X(L:E\"OV]O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M +!^B?\ I_TZORG,8QAF%:,59*4K+YL_:,JG.IEE"<W=N$6V]V^5:LWO!_\
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MAC_P1'^-'_!1/]L1;/Q+X^\"?$S7=!TK0A:6]K;0W7VZVLK*P/V:.+?##/<
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M\:]L_/N+[^T-7C>(K#.3;B"$C<0<C<C58_X+P>#_ (L>!?\ @VX^+V@?&?\
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MA9ARJ//)$K,,D*Q(!QBOA?Q_X9_X+?\ P:_80N?^"F.H?\%&K+6_&VA^"_\
MA.O$GP0NOAIID7A=M,2W%[<:1%-&OVQ9(K<.!.)2\CQ[<C=O !][?MB_MG?
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MC'PA:6=UXG\.6]R&NM,ANT+VSRI_")%4E3W KE[3]L/X/WO[:=W^P5"VJ?\
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M(/\ PCFD:]XHLO#NDW?]DW=YY^I7986\&RUBD9=Y1OG8!%Q\S#(KPC_@B_\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY+_X+F_\ *++XH_\
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M"3R>)_V7]1_X).6/[1WPR/BW4=5^%_Q"\'-H3:K:6%Y,9QI>I6VHM'('A=W
MN%8QLK  #&!^L5% 'C'[#-U\1=6^$5YX@^)_[%&C_ 74+W79FM?!&EZQI]](
MUH(XA%=7,FGHL"S.=X,:ERBJH+$UP'_!8W]A3QQ_P4'_ &(=5^#?PA\36.C^
M/-$U[3O%'@&_U3/V5=6L)O-B24@$JDB&6+=@[3(&((!!^IJ* /S6^/W[5_\
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M]O#$GPMTG4'UF2Z18(;=+"-I7D<G$?E[7#[B-A1@V"#0!\J?\$JOVA?VY?\
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M.-&_L[P[X5T.TT?0=/\ M$DWV6RMH4A@B\R5F=]L:*NYV9CC))))KRK]L_\
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M_P#8<^#Z?'#XX-J@T-]?T[1P=(L1<3?:;VX6WA^0LOR[W&3G@<X- 'J=%%%
M!1110 4444 %%%% !1110 445R?PN^.GP?\ C9=>)K'X3?$32_$$W@WQ-<^'
M?%4>F7(D.EZK;A3-9S8^[*@=,KVW"@#K**\O^#'[7'PI^.WQN^*/P \$0:PN
MO?"'5-/L/%C7^G>5;M+>6QN8?L\FX^<OECYC@8/%>H4 %%%% !1110 4444
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M?:1X&\[X=^'O@/K7AW6/$/\ :=JOV?4I[])8H/(:43ON0$[UC*#H6!XKG/\
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M^ ]1\5:7J/QM\9^,_&>EW\1L;&X2Y;3]+CLI7DNWEEB3;.51%V#< &R #O\
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MM\5+6XUU3)HNM^)A=W-U<Z?<97YK5TNY;<,5 ?RT9PH9L 'F7QF_X*1>-?\
M@GSX?\/_ +4VC_\ !?WX5_M0V-EXCTVV^*'PB$_A6*XO].NKF.">\T9-*D^T
MPRV_FB41'S$\M7=R1&0?M3_AJ/X[?\/]/^&*?^$Y_P"+9?\ #('_  FW_",_
MV9:_\AW_ (2G[!]K^T>5]H_X]OW?E>9Y7\6S=\U>5>#OBS^T3XQO]+\#R_\
M!MW;Z'X@ENX(/$&IZ[K_ (330M-0LHFN([J,O)=J@+,$CA#/@#Y<Y&U^W+\)
M_P!KW]G?_@J9X)_X*C_LS?LRWWQDT6X^"UU\,?'_ (,T#6[2RU6PMO[4_M2V
MO[87;HDX,Q\MD#!@%ST.0 =CXT_:8_:&E_X+D6'[$6@_%!M.^'^I?LG7OBQ=
M)31K.4PZ\->^Q1WXE>(S,4A.WR3)Y1QDH3S7R)_P1(_9B_;>U/XU?M*ZYH?_
M  4SU_3-+\*_MD:_;>/-$C^%OA^5/&]S;FR>[NII7@,E@UU'B-H[8HD0&Z,
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M7%C#)J.FQW0G6TG9 9(1* !(%8E=X #8S@9J]0 4444 %%%% !1110 4444
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M!1$/BL/VM/#Z>%3;8^V'12LO]L X^;[)L^R^?CC!3/&:^VOVF?V7?@#^V/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>biib-20210331_g8.jpg
<TEXT>
begin 644 biib-20210331_g8.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
M;6^$\/QR_9>^)MKXN\*7%]-9PZQ9VL\*-/"0)$VSQH^5)'.W'I0!9_:6^(OQ
MI^%OPDOO%W[/G[/LOQ/\61W%O#IG@]/$UMHZW/F2JCR27ER&2&.-"TC':S$)
MA59B ?E_PK_P4Q_:_P#@W^T5\/?@?_P49_84TOX;Z-\6=?'A_P #?$#P9\28
M_$&G#7'B>6#3+R,VT$L$DHC=8Y &5V& ,!G7/_X."?C)\5?@O^R7X%U7PK\1
MO%W@KP%K'QI\/Z5\<O''@4RIJF@^#IFF^VW$,T*M);9D6W0S1@L-^T [\'\\
MOVO#_P $GK;]J/\ 8YTW_@FWXG\4>/M3B_:\\!R>,?'R_$OQ%XATBPCDO&,%
MC,]_=RV:WMP1)*JQJ)D2SFSL5R' /TI_:S_X*M_%+X%?\%#],_X)N_ _]B?4
MOB=XQ\1_!Z/QKX=O[/QE#IML)CJEQ9O;WIFMV2SM8X;:69KO>[%S' L#-(K5
ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
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MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** *5]XBT339_LM_J4<4@ .QCSBHO\ A,?#
M'_0:@_[ZKR#]@VYN==^#FJWNN7#WDR^-M7C66[<R,$6Y(5<MDX Z#M7M?]G:
M?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_
M9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H
M4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP
M_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN
M?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_O
MJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@
M_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[
MZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!
MJ#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A
M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
M4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ
M% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_
M]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__
M #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]
M^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,
M/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__
M #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!
MJ#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'
M_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^
MJ/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:
M@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0
M:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4
M_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y
M(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^">__)$]6_['
MO6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\ !/?_ )(GJW_8]ZS_ .E)
MKW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7
MA?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO\
MX)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\
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M ,@&R_Z_#_Z :[JN%^//_(!LO^OP_P#H!KR<]_Y%-7T_5 >6T445^6@%%%%
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M3^(__"V= U/^R-EI,\?^C6D*S2>;(J0?(1M\_<?E4B@#[7HHHH \+_X)[_\
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M1117YT 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOC9_R.G_ &YQ_P VKYSBC_D6?]O+]0.0HHHK\Z **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]2^ W_(!O?\ K\'_
M * *\MKU+X#?\@&]_P"OP?\ H KWN&O^1M'T?Y =U1117Z4 4444 %<+\>?^
M0#9?]?A_] -=U7"_'G_D V7_ %^'_P! ->3GO_(IJ^GZH#RVBBBORT HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MK_@G_P CI_VYR?S6N0KK_@G_ ,CI_P!N<G\UKT<H_P"1G1_Q(#UVBBBOU< H
MHHH **** "BBB@ KF?C!\:/A%^S[\/[WXK_'7XFZ#X/\,::T2ZAX@\2ZK%96
M=L99%BC#S2LJ*6D=$&3RS #DUTU>'?\ !0OXK?LL_"']G&Z\0?MK?!>3QO\
M#&YU:UM_%=G-X!_X22PTV$,9DU"_L_+E/V6&2%"THC<QNT;8_B !\%?M0_"7
M_@WE_:R_:@U?]KWQ]_P5]MM(\9:O;16QN/"7[3%GI\-G;I#'%Y%NB.3#&WEA
MV16VL[,Q&37>?L ? /\ X(Z>"OVN/"7B;]E;_@K#XD^)?CVV^W_V#X)O_P!I
M--?AU+=87"3[K .3/Y<#33#CY#$'_@KU7X+_  '_ .#>+]HKP[#XJ^!G[/\
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MDY[_ ,BFKZ?J@/+:***_+0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"?\ R.G_ &YR?S6N0KK_ ()_\CI_VYR?S6O1RC_D9T?\2 ]=HHHK]7 ****
M"BBB@ HHHH **** "BBB@ HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\
M!/?_ )(GJW_8]ZS_ .E)KW2@ KR+XV?\CI_VYQ_S:O7:\B^-G_(Z?]N<?\VK
MYSBC_D6?]O+]0.0HHHK\Z **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *]2^ W_(!O?^OP?^@"O+:]2^ W_(!O?^OP
M?^@"O>X:_P"1M'T?Y =U1117Z4 4444 %<+\>?\ D V7_7X?_0#7=5POQY_Y
M -E_U^'_ - ->3GO_(IJ^GZH#RVBBBORT HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#\11_PN[X7_P#0S_\ DE/_ /$5\_45Z_\ Q";AS_G[5_\  H?_ "L_-/\
MB(&<_P#/NG]TO_DSZ!_X7=\+_P#H9_\ R2G_ /B*/^%W?"__ *&?_P DI_\
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M_A=WPO\ ^AG_ /)*?_XBC_A=WPO_ .AG_P#)*?\ ^(KY^HH_XA-PY_S]J_\
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ME*^O;WF?:%%%%>.?IX4444 %%%% !1110 4444 %%%% !1110!X7_P $]_\
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M[B/_ )\?^30_^2/FFBOI;_AW1J'_ $5J'_P2G_X]1_P[HU#_ **U#_X)3_\
M'J/]8\F_Y^_^2R_R#_4[B/\ Y\?^30_^2/FFBOI;_AW1J'_16H?_  2G_P"/
M4?\ #NC4/^BM0_\ @E/_ ,>H_P!8\F_Y^_\ DLO\@_U.XC_Y\?\ DT/_ )(^
M::*^EO\ AW1J'_16H?\ P2G_ ./4?\.Z-0_Z*U#_ ."4_P#QZC_6/)O^?O\
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M $5J'_P2G_X]1_P[HU#_ **U#_X)3_\ 'J[?]8\F_P"?O_DLO\CS/]3N(_\
MGQ_Y-#_Y(^::*^EO^'=&H?\ 16H?_!*?_CU'_#NC4/\ HK4/_@E/_P >H_UC
MR;_G[_Y++_(/]3N(_P#GQ_Y-#_Y(^::*^EO^'=&H?]%:A_\ !*?_ (]1_P .
MZ-0_Z*U#_P""4_\ QZC_ %CR;_G[_P"2R_R#_4[B/_GQ_P"30_\ DCYIHKZ6
M_P"'=&H?]%:A_P#!*?\ X]1_P[HU#_HK4/\ X)3_ /'J/]8\F_Y^_P#DLO\
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M!\RV=E9Z?;)96%I%!#&,1Q0QA54>P' J2OI;_AW1J'_16H?_  2G_P"/4?\
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MK\[/U\V**R[.T\6I=(]]JUJ\0;]XB6Y!(]C6I0 4444 %%%% !1110 4444
M%%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+
M_P"">_\ R1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_P#!
M/?\ Y(GJW_8]ZS_Z4FO=*^9?V:OC)\+_ -FCP3JGPW^//C:R\+ZZ_BK4K]=,
MU-RLIMIIV:*7"@\,O(KT/_AN?]D?_HO6@_\ ?Y__ (F@#U>BO*/^&Y_V1_\
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M (F@#U>BO*/^&Y_V1_\ HO6@_P#?Y_\ XFC_ (;G_9'_ .B]:#_W^?\ ^)H
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MX;G_ &1_^B]:#_W^?_XF@#U>BO*/^&Y_V1_^B]:#_P!_G_\ B:/^&Y_V1_\
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M[_/_ /$T >KT5Y1_PW/^R/\ ]%ZT'_O\_P#\31_PW/\ LC_]%ZT'_O\ /_\
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M_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q-;M% &%_PJ[X9_\
M1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\*N^&?_1.]"_\%$/_
M ,31_P *N^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$[T+_ ,%$/_Q-'_"K
MOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+
M_P %$/\ \36[10!A?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\
M$UNT4 87_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q-;M% &%_
MPJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\*N^&?_1.
M]"_\%$/_ ,31_P *N^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$[T+_ ,%$
M/_Q-'_"KOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[
MX9_]$[T+_P %$/\ \36[10!A?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0
MO_!1#_\ $UNT4 87_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q
M-;M% &%_PJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\
M*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$
M[T+_ ,%$/_Q->)?M2^ _ UA\9?@M;6/@S288[KQO*ES'#IT2K*OV9CM8!?F&
M>QKZ*KF_&_PI\(_$'Q%X<\4>(X9VN_"VI-?:289RBK,4*$L/XA@]* )_^%7?
M#/\ Z)WH7_@HA_\ B:/^%7?#/_HG>A?^"B'_ .)K=HH PO\ A5WPS_Z)WH7_
M (*(?_B:/^%7?#/_ *)WH7_@HA_^)K=HH PO^%7?#/\ Z)WH7_@HA_\ B:/^
M%7?#/_HG>A?^"B'_ .)K=HH PO\ A5WPS_Z)WH7_ (*(?_B:/^%7?#/_ *)W
MH7_@HA_^)K=HH PO^%7?#/\ Z)WH7_@HA_\ B:/^%7?#/_HG>A?^"B'_ .)K
M=HH PO\ A5WPS_Z)WH7_ (*(?_B:/^%7?#/_ *)WH7_@HA_^)K=HH PO^%7?
M#/\ Z)WH7_@HA_\ B:/^%7?#/_HG>A?^"B'_ .)K=HH PO\ A5WPS_Z)WH7_
M (*(?_B:/^%7?#/_ *)WH7_@HA_^)K=HH Q['X?> =+O(]0TSP1H]O<1-NBG
M@TR)'0^H8+D&MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUX?_ ,$"/^4-O[/?_9/X?_1TM 'U_1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>biib-20210331_g9.jpg
<TEXT>
begin 644 biib-20210331_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / /VA_V&/^%]_MV?LZ?MK?\+1_LG_A0/\
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M[.W_  3O\$?\$[_CKI_AKXQ^'/"-I)%<OXM\%6[66IN;V:[CD:PN'N8T*-*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@FMGB"H3O4JXD&UOE8#X*_X).?M_?M\?"/\ X(W?#'Q9^S'_ ,$SI?B'\/\
MX<^#KP^(_$NM?$:WT6[UC[/<W$MV-)LC!,]PD(WIYCE/,ECD2-&VAF_0/0_^
M"AG[%_[:GPL^*_A#]E+]H#1?'EUX6\"W5QKTWAT2S6UHEQ;7"P@W&P1.[&*3
MY%9F4+E@ 1GR7_@AXB'_ ((#?"9"@VGX7ZED8X.9[S- 'UA^RG^TE\._VPOV
M;_!7[4'PH>Y_X1_QQX>M]6TV*]0+/ LBY:&4*2!)&X:-@"1N0X)&">,_;_\
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MF/KOP5_:WT75?BAIXTR]W:#9V1E2ZED/D;9!&Q (B+D]@:_4K]EK]K7]G?\
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ML_L0?\%'/C%\:?VI/&/["/[97[+$?PE^+?A7PG;>+-/L-+\6QZWIFOZ!-/\
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MBK_9VN%?S4##<&4\,B,.7U?X ?"[_@D'_P %COV=O#G[&OA^7P?\+_VD]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[
MZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!
MJ#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A
M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
M4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ
M% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_
M]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__
M #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]
M^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,
M/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__
M #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!
MJ#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'
M_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^
MJ/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:
M@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0
M:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4
M_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y
M(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP)=RB68Y/SW:B<=>*_2RB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*L"'!^9R@48!Y8<5^1G[$WB;]O3_ (*5?M!_"O\ :<\/_P#!6;3O#OC/QG\
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M\3.K"52FXQDXM]5:Z^]-?>F5_P#AY1;?]$@_\N __(]'_#RBV_Z)!_Y<!_\
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M\N __(]'_#RBV_Z)!_Y<!_\ D>OE2BCZW0_Z!X??4_\ DP^H8K_H+J?=2_\
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M0O-SGYV106YYYH I?!S3?'>C?"+PKI'Q2U-;WQ/:>&[&'Q'>(X83WZVZ+<2
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M';:/HEES<ZOJ$S".VLH!@DR2R%5& <#+$84U\R?\$WOVR[ZT\-?##]EKXX?
MG5O!VKZ_X:N9? /B![Z"]T[Q#%; R3B.2/#02A/F,3C( &2"4#8.N_MN?LJ_
M$C]O+6M?_:+^..B>'/#?P1U>YT;P9X8U>9EDO_$"YBO=6EC"D;8?FMX,YY,D
M@VDT ?2G["_[5EU^V9^S_:?&^]^'/_"*33ZK>V,VB_VN+[RFMYFB)\X11!LE
M<XV\>IZUZ%\4_&6K_#WX=ZQXUT#P-J7B:^TVR>:TT#2%!N;^0?=BCSP"3W/
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M /DOA_[ =S_Z%'0!]NT444 %%%% !1110 4444 %%%% !1110 4444 >%_\
M!/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !7%^//VA?
M@_\ #+7?^$:\<>+_ +#>^0LWD?V?<2_(V<',<;#L>^:[2OB+_@H!_P E\'_8
M#MO_ $*2M:3HJ?[U-KR=G][3_(QKQQ$J=J,E&7=IR7W*4?S/H_\ X;(_9O\
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MI]_?\-D?LW_]%&_\I%Y_\9H_X;(_9O\ ^BC?^4B\_P#C-? -%'M,M_Y]S_\
M U_\K#V6<_\ /ZG_ ."Y?_+3[^_X;(_9O_Z*-_Y2+S_XS1_PV1^S?_T4;_RD
M7G_QFO@&BCVF6_\ /N?_ (&O_E8>RSG_ )_4_P#P7+_Y:??W_#9'[-__ $4;
M_P I%Y_\9H_X;(_9O_Z*-_Y2+S_XS7P#11[3+?\ GW/_ ,#7_P K#V6<_P#/
MZG_X+E_\M/O[_ALC]F__ **-_P"4B\_^,T?\-D?LW_\ 11O_ "D7G_QFO@&B
MCVF6_P#/N?\ X&O_ )6'LLY_Y_4__!<O_EI]_?\ #9'[-_\ T4;_ ,I%Y_\
M&:/^&R/V;_\ HHW_ )2+S_XS7P#11[3+?^?<_P#P-?\ RL/99S_S^I_^"Y?_
M "T^_O\ ALC]F_\ Z*-_Y2+S_P",T?\ #9'[-_\ T4;_ ,I%Y_\ &:^ :*/:
M9;_S[G_X&O\ Y6'LLY_Y_4__  7+_P"6GW]_PV1^S?\ ]%&_\I%Y_P#&:/\
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M6?\ TI->Z5X7_P $]_\ DB>K?]CWK/\ Z4FO=* "OB+_ (* ?\E\'_8#MO\
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M&OV5OAU<>)?&%M:P7=EX<\2>*'F6YOG\A)T-S<S@(BJKL%$@0%>.O/+?MV_
M?]H+XP^#_A-\;OA1X0T[4?'7PP\66?B.Y\%7NII!#J)\H"XM8YV)C616 ".Q
MV@!CDG /T_10!\2_&K2OVN?^"@?B?X<_#K6/V2=3^&'A3PKX_P!/\4>*/$GB
MO7K*:=FL]Y6ULX;=W9V?S&'FD # S@9!^VJ** "BBB@ HHHH **** "BBB@
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M2^'_ + =S_Z%'0!]NT444 %%%% !1110 4444 %<#^T5^RY^S_\ M;>#M/\
MAW^TE\+M-\8^']-UVWUB'0M9#R6<MW '$330A@EPB^8Q\J4/&3@E25!'?44
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M* "BBB@ HHHH **** "BBB@ HHHH *^PO^"</_)-]?\ ^PXO_HE*^/:^PO\
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MVOL+_@G#_P DWU__ +#B_P#HE* /HJBBB@ HHHH *^=?^"CW_)-] _[#C?\
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M?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !7Q%_P4 _Y+X/\
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MC/VEN.:]M_X275_^A0O?^^EH V*^(O\ @H!_R7P?]@.V_P#0I*^Q?^$EU?\
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M)!Q7ME !1110 4444 %%%% !7V%_P3A_Y)OK_P#V'%_]$I7Q[7V%_P $X?\
MDF^O_P#8<7_T2E 'T51110 4444 %?.O_!1[_DF^@?\ 8<;_ -$O7T57SK_P
M4>_Y)OH'_8<;_P!$O0!\>T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %>W_\ !/\ _P"2^'_L!W/_ *%'7B%>
MW_\ !/\ _P"2^'_L!W/_ *%'0!]NT444 %%%% !1110 4444 %%%1W=Y:6$!
MNKZZCAB7&Z25PJC/ Y- 'YSZ]!_P42_X*,?MZ?'3X4?#+]OG5/@!\./@;KVE
M>'M/T+P=X0LKW5M>NKG38;Z2_N;B[!,41$P6)$!5EP2 R%G]I_9F_P""??[7
MOP0^-VB?%#XH_P#!6CXJ?$W0M+^T_;O!'B3P]I4%EJ7F6TL*>8]O$LB^6\B3
M+M(RT2@\$UYC^T;_ ,$H_B]\6/VV/%G[:GP0_P""NWC/X3:AXJTRRTZ?0?"N
MAZ:]NMI;0JD<4Q=Q]K*N9I$>96>/SW5"J\5VW[*7["O[7OP;^/N@_$CXH_\
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MO$/AK]C*UU#3[V%9K.^L?BKXEFAGC89#HZ:F592.A!(-;G@C_@DE_P $+O\
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M'_8#MO\ T*2OMVOB+_@H!_R7P?\ 8#MO_0I* /$**** "BBB@ HHHH ****
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M,?#'_0:@_P"^J^?/^"AVN:1JOP[T&+3K^.9EUHE@AZ#R7H ^2**** "BBB@
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MC^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"OG?_@HS:VT'PXT!H+>-"=;.2B
M?\L7KZ.KYU_X*/?\DWT#_L.-_P"B7H ^/:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O;?V!(8IOCR4FB5Q_
M8ESPRY'WHZ\2KV__ ()__P#)?#_V [G_ -"CH ^U_P"SM/\ ^?&'_OT*/[.T
M_P#Y\8?^_0J:B@")+&RC8/'9Q*PZ%8P"*EHHH **** "BBB@ HHHH **** "
MBBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@
MKXB_X* ?\E\'_8#MO_0I*^W:^(O^"@'_ "7P?]@.V_\ 0I* /$**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MOL+_ ()P_P#)-]?_ .PXO_HE*^/:^PO^"</_ "3?7_\ L.+_ .B4H ^BJ***
M "BBB@ KYU_X*/?\DWT#_L.-_P"B7KZ*KYU_X*/?\DWT#_L.-_Z)>@#X]HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *]O_X)_P#_ "7P_P#8#N?_ $*.O$*]O_X)_P#_ "7P_P#8#N?_ $*.
M@#[=HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O^Q[U
MG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "OB+_@H!_R7P?\ 8#MO_0I*^W:^
M(O\ @H!_R7P?]@.V_P#0I* /$**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "OL+_@G#_R3?7_ /L.+_Z)2OCV
MOL+_ ()P_P#)-]?_ .PXO_HE* /HJBBB@ HHHH *^=?^"CW_ "3?0/\ L.-_
MZ)>OHJOG7_@H]_R3?0/^PXW_ *)>@#X]HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]O_P""?_\ R7P_]@.Y
M_P#0HZ\0KV__ ()__P#)?#_V [G_ -"CH ^W:*** "BBB@ HHHH **** "BB
MB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\
MI2:]TH *^(O^"@'_ "7P?]@.V_\ 0I*^W:^(O^"@'_)?!_V [;_T*2@#Q"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K["_X)P_\DWU__L.+_P"B4KX]K["_X)P_\DWU_P#[#B_^B4H ^BJ*
M** "BBB@ KYU_P""CW_)-] _[#C?^B7KZ*KYU_X*/?\ )-] _P"PXW_HEZ /
MCVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ()XZYI&E?#O7HM1OXX6;6@5#GJ/)2@#Z5HK-_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2KYU_X*/?\ )-]
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M_P!"I_Y/0?\ QRC_ (4)\6?^A4_\GH/_ (Y7TA17RG^MF8_R0^Y__) ?-_\
MPH3XL_\ 0J?^3T'_ ,<H_P"%"?%G_H5/_)Z#_P".5](44?ZV9C_)#[G_ /)
M?-__  H3XL_]"I_Y/0?_ !RC_A0GQ9_Z%3_R>@_^.5](44?ZV9C_ "0^Y_\
MR0'S?_PH3XL_]"I_Y/0?_'*/^%"?%G_H5/\ R>@_^.5](44?ZV9C_)#[G_\
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M>@_^.5](44?ZV9C_ "0^Y_\ R0'S?_PH3XL_]"I_Y/0?_'*/^%"?%G_H5/\
MR>@_^.5](44?ZV9C_)#[G_\ ) ?-_P#PH3XL_P#0J?\ D]!_\<H_X4)\6?\
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ML\CGRYE2,,O\6P#O7WE2Q%*E&E"K3NE*^C=[->=EY= "BBBN0 HHHH ****
M"O4O@-_R ;W_ *_!_P"@"O+:]2^ W_(!O?\ K\'_ * *][AK_D;1]'^0'=44
M45^E %%%% !7"_'G_D V7_7X?_0#7=5POQY_Y -E_P!?A_\ 0#7DY[_R*:OI
M^J \MHHHK\M **** "BBB@ HHHH *CN[NVL+26^O9UBAAC:2:5SA44#))/8
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MV]R .E?&O[#CP_$O_@M1^U[\8O"=RUSX?T72O"GA22_B?,$^I0V>ZYB4C@O
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MHHKS@"BBB@ HHHH *Z_X)_\ (Z?]N<G\UKD*Z_X)_P#(Z?\ ;G)_-:]'*/\
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M%%% !1110 5ZE\!O^0#>_P#7X/\ T 5Y;7J7P&_Y -[_ -?@_P#0!7O<-?\
M(VCZ/\@.ZHHHK]* **** "N%^//_ " ;+_K\/_H!KNJX7X\_\@&R_P"OP_\
MH!KR<]_Y%-7T_5 >6T445^6@%%%% !1110 4444 %1W=K;7UK+8WMNDL,T;)
M-%(H974C!4@]01QBI** /ASQ[_P0F_8;UOX]>"_$'AG]GRQM/ EE8ZU_PEOA
MB'QAJ\-I/<3?93:>59I<^0L8:.<R(@1&RFY7P-OT;\<?V'_V5OVC/V?;7]E7
MXL_!ZQN_A[8FU^P^%M+N[C3+>V%M_J%C-E)$R(G90P7U!KU:BNF>,Q51Q<IN
M\=M7IY^H'R)I?_!"3_@EQHU[;ZAIG[/>M12VDJ26Y_X6IXF(1E(*_*=2((!
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M<S?,[MW>KW6S]4!\=6?_  0+_P""4NG6L=CI_P"S?J\$$2A8H8?BIXG5$4=
M -2P!7UGX-\(Z!X \(:5X#\*6;VVEZ)IL%AIMO)<23-%;PQK'&IDD9G<A5 W
M,Q8XR222:TJ*=7$XBNE[6;E;NV_S ****Q **** "BBB@ KK_@G_ ,CI_P!N
M<G\UKD*Z_P""?_(Z?]N<G\UKT<H_Y&='_$@/7:***_5P"BBB@ HHHH ****
M"BBB@ HHHH **** /"_^">__ "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2)ZM_
MV/>L_P#I2:]TH *\B^-G_(Z?]N<?\VKUVO(OC9_R.G_;G'_-J^<XH_Y%G_;R
M_4#D****_.@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "O4O@-_R ;W_K\'_H KRVO4O@-_R ;W_K\'_H KWN&O\
MD;1]'^0'=4445^E %%%% !7"_'G_ ) -E_U^'_T UW5<+\>?^0#9?]?A_P#0
M#7DY[_R*:OI^J \MHHHK\M **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[)O_ $4;XI_^%L?_ (U7V-10!\<_\.0OV3?^BC?%/_PMC_\ &J/^'(7[)O\
MT4;XI_\ A;'_ .-5]C44 ?'/_#D+]DW_ **-\4__  MC_P#&J/\ AR%^R;_T
M4;XI_P#A;'_XU7V-10!\<_\ #D+]DW_HHWQ3_P#"V/\ \:H_X<A?LF_]%&^*
M?_A;'_XU7V-10!\<_P##D+]DW_HHWQ3_ /"V/_QJC_AR%^R;_P!%&^*?_A;'
M_P"-5]C44 ?'/_#D+]DW_HHWQ3_\+8__ !JC_AR%^R;_ -%&^*?_ (6Q_P#C
M5?8U% 'QS_PY"_9-_P"BC?%/_P +8_\ QJO,?"W_  2:_9RU?]J[Q5\';KQ[
M\1AI6C^&+&_M94\7L)VEE=@P9_+P5XX&!BOT4KS[PY\&=3T3]I+Q)\<9=:@>
MTUSP]9Z=%8K&PDB:%B2Y/0@YH ^>O^'(7[)O_11OBG_X6Q_^-4?\.0OV3?\
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M[)O_ $4;XI_^%L?_ (U7V-10!\<_\.0OV3?^BC?%/_PMC_\ &J/^'(7[)O\
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M4^*A^!/P4^-=Q'XW:S:\M?"7BOPSJ&B7U[;J"S2V\=]!%]H 568B,LP5&8@
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M_@@1_P H;?V>_P#LG\/_ *.EH ^OZ*** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[APBE0"-K*%?],Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVW_9X^*.F?$+5M$T;]GRV\'>'HI=!AMKMX;=)8M5C-QJKR(JNSHVW+[1MQM
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M^+NM"2:9/'P\/6>EG4K221GM]T%E^XRD3(GF1@"3;OP"V* /1:*** "BBB@
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M/G_5YSGOTXYX'_AY;_U17_RX_P#[FKEO^"BW_);=+_[%6#_TIN:\"H ^IO\
MAY;_ -45_P#+C_\ N:OI'P+XF_X33P3H_C'[%]F_M;2K>]^S>9O\KS8E?9NP
M-V-V,X&<=!7YD5^D?P,_Y(EX._[%73__ $FCH ZFBBB@ HHHH ;//!:P/<W,
MR1QQH6DDD8!54#)))Z "J^CZ[HGB*S_M'P_K-I?6^\KY]G<+*FX=1N4D9K\M
M]#^$FE_\%QO^"F_QZ\(?M7Z]K.H?L_?LVZ_9^$?#/PGT_6[BRL/$/B#8[WFH
MZE]G=&N/*DC*QH6V[60<8E$OU)\&_P#@BY^P9^S%^T'X<_:3_9,^'NJ?"W7-
M$>9-4T[P9XCNX-+\1VLEM+!]FU"R>1X9D1I1,C!5<2Q(Q8@8H ^KJ*^%-?\
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MX3<>9(B0;H';:TH8C:"0 ?4E%%% !1110 4444 %%%% !1110 4444 %%%%
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MU%.<,YC^K?A-_P %FOV!/VC?V@_#7[-'[+/Q6N?BAXB\0/,][<^!]$N;S3M
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M?$D9603B(1D$2%* /L6BOCS]A;_@LG^R+^U3\![;Q+=?%+47\4^%OA)#XO\
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MHE[8)<F40.T5_;Q%U?R)<,FX?(02#7M] !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>biib-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20210331"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20210331.xsd" xlink:type="simple"/>
    <context id="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic6f45d28d5d8449d9712a20039e0697e_I20210421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-04-21</instant>
        </period>
    </context>
    <context id="iabf5fb72476641e09225cdff0259f43e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id3b12581badd45819dafd1517b58aa13_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2837c6bcf6604a1884f52b184bbc1cec_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i57cd91f7d9604cf09b048c87050e1776_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i16255170d7464fce8565c267cce60805_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifa5be06727e54c9cb7a5c0a5c65b597e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="idba00d136f3e43eaacc59e503a3d5706_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6d0adcebf1da475cb93ee9da1693e32f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0294157534ec4829a838f8161a2c6f76_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i179564f7a5394a3f985b2394c890de98_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9bcd6f60e86446259cb8c43a0e3ff280_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c42b2175447497d8b49e20666071bb3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie120e7590f014512a9ef0196920b2c3a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d06f4201d6a4f44b0a65c949966d4e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9252b21ce96b49a69be79d8b5818a4ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc014f149d4e4da3b04fb867fc354a98_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id15755e5a765478580cfde8eca39da00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i21790366b5d34ac8a31ee2475fb7022d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb70c7eb20e44693a04fd0260417f330_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie108b38fb78a4b4da6071b1fe46e0f25_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic45e43914f444bff8f68d0156608b715_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie2bb63a28893418589d2a0d1b7f927b3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9a7e0d0eeaae4c5fbfb21c1d2f81bbb4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7af889133b864bf1a8251cd94b577064_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2b08cd90671441109d1d585c71239784_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2518d36e7af44bec9c3acb750c2ab582_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9db0313c47544e3fb07cfe61f64dae32_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ide40cd25587c44479c7cca25c2ab1a1e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5b5f6b8e642b4f3a90e77ef64fc86959_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icc7d49e416884359a033c98c994d3d6b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i35398fa4187c4561961299a90d05fde1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1883df2e84b34bfca009f1a107f517a7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i989a9664b51f425385c353e18a6b1db2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i57282d9aaf344b8abc4365220d50d8e6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iddda61c522014ea6bd671c91e77efd7e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id84b8595cae94c46aea8144165c16cda_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id368506338ba40cd8adbea5e573a2f3c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5a8b05db811a4f6ca919149ab120e3a6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c2ba83c536b409e96a426d0bba7cc72_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iba06f05e2faf4c708920aa5dcbd7ed0b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieca63027783a4ffc875d6d9098166871_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7c713484677b4927ab70281250be20cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib3b1784bb7804f8f9620259ab8942db6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i605d5a6bd4e44da0afb2826209cab9c7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6c932859892f490180aa279af5a06b03_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7435b888c753443186dba3ab3fe1fcba_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i53a16d72df8e41e7aefc354fdce5be4a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8ea2f0d23ff44653bc3b6b5156c34bf1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i04d5d70d39294b36b58ac20c0780157b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id6578a3afa6b483fafcf2459661d9944_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic3952e97a9994176bda1554c91960383_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i25ca0d3089b9406197bdca98e4d63b1b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i075e0c23d6b34d67b56b7fc63b0c8f6e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6f5558f45caa429b943890bb21370bb4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i406d62794dcb4950a1781265fcdca4d2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie6b1bf8966fe4b6f8d97788a368f7f09_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia559d28a9b914b37b44c9d7c95222096_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icf91e91201b044939704b3ea806b2ead_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ieee5bd4f86704007b1420b9b498ddbc6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i51813489fb6b4bbeac18a5336356a074_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i89f2f3090dc54fea8e95c8bcfdc8bf2b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib357d23217b547d997470e7d0012d37e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i00af2e110361494a882a140f60e249ae_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6f1fb990e4ee44be863aa4437fa57293_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if823fb42eb284177aa1ddbf216b2c1be_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i512bb80727434c12bca0775dbd5e2137_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6ae486e871284c88a17b126221465865_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i670f018181f04ca3a3f0bd64e5623f2f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0ec1a33127cb42fb9fe3fdce711fae15_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8ee3ab86dd9a44bba034cdb3caf707fc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iff1e167122b54794a75d887f91010ca6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id08a82497aa04887a9c810084e90cb86_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BIIB118Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i448c0442bf0a4adfa28c5d18001b08f1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1193489ec1264f35a2ac5971bf81f6f7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia487fdfe567b401b86ede458e9ba75e7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib3d2c097d12347678a78a057aaf039aa_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5d2fc407d1ec4ed380b5e106ffb0c831_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i940d0ffed9724139916f62bf6dad8a7b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icf4bd59b7c3249f0bc24ef3c1c48d31c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic8f8e721203449fc86db69bab7e7cd9e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idcf12665755e4093a4220cda52ac3eb9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id77770628748461faf30529d99622607_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1646afc7440542fcb255ec823d3c9c2c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4e14d4e11831452ba137891a9396c862_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i184b1c6940b2461e8557af90326d21e4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie8caf7eb3d8046008f3982503a64cade_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i08d0fb5bb1cb45d99a7b3491c2593e22_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4341139d31d645e89e76c26bfb4231ca_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2cb99b30cbf54b00852f7084359ac9d6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4b70a2acef674d0985ecb568772c3258_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i505c2e793fca48ae9a343f83d10b25a2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iff026a1b98554dfbbc131b0472cb5b7b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i734c667a854e4365bfb4b48aef78b038_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0962648e31c1402ab3c19a4f421155fe_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia83423de217c44a9be015f40ff27c33d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iec00ec53a19f4ea9a63dace92b6da302_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5f2ba3fb90464ab29d64a5353775989d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia6132d3c924c414e84a28b2389d20a41_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaf832a6fefc64c7582c337b5ffea1c29_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1ad6065fa88e4b7abff61a49206a7d0b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i14524fbcf9df4b2281933e4d60f10f02_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1bf0c4a015a74ded850336575e8289b8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i325454d8aeec4098bfa98cf14b372c51_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ife6066c0c6bb49d7b1ea35be7c87f0c8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ida5dda8845084cdda4c2aa27909ab988_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7d4f5eaef8fe43309f839c1c36e3c80d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i059f4365445242aeb92df9e0e10de132_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i061b1e268b544b26a76c0707fad02355_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5d5370a9ea274139a341c5cfdd8d6d9b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibc51673e08bc4f3b82f3b472a4a90973_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i27035e9563074fbbaca4c77997b66921_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i78f64ee14005421481ed9d38025dbe95_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i031fb4884755410b845a81795c4ec551_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib01eeb32d79b4571ad8f11070dc2da48_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i202bf8566c7042b784c6445ebd363725_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib7824a2335ba4ddd968c947099502057_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8c8b061168814140b09c590b540bb10e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia908504887ca40f181856648cf0956ae_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i06fc398cd34146d982acc4911a986595_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7700739d178e441d91b2f50f6c7798c6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib1f9b4973848433abff09c45a64c9143_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i75a352d78f7d43fa8a05b645e4f6e3c7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i34be7a6433744d2f8766ca37a26efa37_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i324196a294bc4b538065228274cc76fb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic67c201687dd40b69b77091684731883_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i017ebf20529f44b5bff42d9e6dc8fb53_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie8fbe7359e294d698c58806b13fe20f3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7d43bda4427a42e18236a50750cfe714_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i06a69682358b4f1a99c21d088b5c487b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i30b44b2a9e3643ec956383c1b647c5d8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i26bd19762f294c71b22709ebc3c0418f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i87f248578d7441ec88a211f0018d2a05_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1145a015534643fbbd914351f2d3303c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i601c9a44b1bd4cf6abb5e0a17029e845_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i50e81697f8c14de383f2c496c7483109_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id2c9127e05b04ef281beba3d1321c62d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id1003e56b7b748e9bf5a15cef4022aeb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4e358b0c99a14c348aafac03e2a37487_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id3d8f1b9751745c9b3b1484d9d3b8c54_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1586eb35090b4a5faabb9c8a8e822582_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i666d1e67c4384945af3d0da636c7d0f9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6b9ce56cc0624826bb2b6dd3b2be83c7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iea1a2bf4c66943a5b003368cf21dfc2d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if8384ea1bc75497bbace5e319dccb2bf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iee8610004f734b68b4cba17dcff8b4e3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i47a0a8c9dbdf45d583161449e4534cc8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1013b869080645d59d75e657f4c58e4a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i330c93cac85e420b898ca9c3a01dcf52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3bf47792d6ea4f0b86fdb02f0d4eb158_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb86fe950bc5486cbb58985525874f0c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if7cdcbb6052942698e96461e2cd71321_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia9ec3f38a20a46ce85926bdad24da8d0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i01e3449ffe264832baf2481923cbabff_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1806a0bbaa2b43889412b0fa97abc98a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i05eb3d02985844119473f90fa44e496a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0003b815e2554577be2bdf249035d3a5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iaef079cdccfb48ee83054f60bf01c254_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice62402188f941eab28ef8bd9b65e16d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i569ed47008414979a6cf0d109c369b32_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42fd999637364cbe9c5eda2d3135fe5d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i423da7297412458f999e416eb001a0d7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i163da90ecfbd4f72bc274463a9d22cf0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i82cbd68005204f25a28991bb50e01dff_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i04e77e2252074a059d584ff066314e70_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if37d2490542d485c8ad9bc6897f9286d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9d6131440c1f431ebe00dc7e4e529db3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i15a9a358435d49609a85d97413f3a145_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6844ffa5076f4ec887dfd7ec445c0918_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3fdb2840b630460ea506d4ec51307590_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i48f0b595ff7d4f3fa1e56358ca157244_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i848aad0fd824420fbb889c08f40d826c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e8e8ec88cba4cae96ec769e8eb5ed50_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i56017bab075244608da3bd636cc69661_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i58534be095d54aff98f1243bb85b6ca4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2b71bbb6a21a486ba7bb214d1686f8f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b53409c6c594be1ab5a8373c301e1e4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i448d8c39b77d40a1a669d30b8086ecce_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icadfd8009ae541009e58a0809c8614f7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3ae7d791a7214f65b96db9c10da5155e_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifff98e73ce134eadb812f6e1419eb1bd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ied5ebc033f5042cfba2d1d9018f9eb58_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i583e423036fc4cabb98562f54f1b61ad_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2bf61e1da4cb4085ab83a72725b9c364_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7d0bb3392f8b437d85af0d89b58fbe65_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib7f6d94534c94c69950875e422123904_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3a69b4c3dc9c4aba925cc1b9bb62aad5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i59ae9b2ac6bd42a5aa75417ce4eb6bc5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iffd6a4591290426db41339963f8e38f4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia9f2cde76a524b86a12cd39d526d2166_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6313636dcf65492fa6f7d60c52fd4998_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i59301081b8cf45a5865f1a2a1ab1ec95_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic8acf8de01b6427b817fce044f2a4e9b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib0a8abceadc64d56a584c21adbd55e3d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7421225a760648fc82e6b371affef596_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie1eeebc1e9184fccacb6886b20d57c4d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2198a535d9bb49138f087e2bb335b702_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8c8b1ee36549403a98b32587e6ec8cd9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic41685432e3248a59842e2de1fb70cff_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i468b8e383f3a4aacbb111243c54c712d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3d0f121a5d2a4cfdab80fd27727da939_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i987da2e6227b4752bc28e59e5ea5bb71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2dc664875b4f4032a0d03aa34c2b125e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i70e71b4af6c648a389be21d19d778315_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34d18f6adbce485d821cfdf85f012a05_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i617d7850a63a41f2bc0aa19d2bf5d52c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad7dbe081b0c470ea090b36551d58a20_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab798705a4e64563b60d02c9ae738dc6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie88067b08ed84a50987e6337ea2943d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i46e6eb7334b641e596a5a01f6b114522_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if689c10ac2da4ce6b808d487a91d2f1c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i155f305329d64fa484887596324eabf7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie77eae55b0fc4a578615133eff105580_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9411092d0e6487aaf6d0cee300ee74a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic63fa3a5459c443a84d6bf3111b5ac38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c75bf61e4794546ad3c50a9595bf109_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9cea109dd524584a788c485533262c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ca99bdbf85840cdbe24f4bc565124b6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3564cbcff5074d8ea8625d2d79f78da3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic8a4ae2d553645bc9749c80ed7469758_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9a6326f3d6b477c8eb27a1cad5d7cf7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i169c8b70cdd149968938de9db5a8c380_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i136e48c6cc4844139e58cca3660d4fcc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i73f7b949b4c740929fa619fc13968293_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3ef7cceb1dba455a9aa7de4d2a40176f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28131b2b3d0447c08a69cc0b6f4781f6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i329e0692712544d2a17055bb01361858_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i21ec6c5ff89547ff8dc1226630ef60ef_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie6fa8a83ea8344a9ab2cdaab6b6079d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id15e963a15e44c2b8d3baeb9b65f28b2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i690df7ed80534227b8dd81f1affbc47a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f1bb2f05a734c40a4736b73629c222f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie1fdd327c9a54a7b94459dc7adec7e4c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9541283653d242f48d85e9890e9c2777_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i92e65fe683a2421f94f2dc6385f162f6_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="id1c3b6e1aa1a4f37a556ea55e078b7e6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i08a615c71cd74bfaab31f5afbd166043_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i86ba11dc3301448dab6e7f9202ed71a0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i72bff1f88c9641b0852976834a354215_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3330c709f4b24368ac40f72d927eeaef_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i097294e10f804864872cedb1009ca2d6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i06cbd4baf6c64cbb882e64d7af251fd7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i662a2807e7f441dea26090ecaa66ff73_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9e9534615d4d4fa08ea2113342a064bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6265a293284648a6901f1c195af48f3a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia0a442e099ce48c194c0139fdf69655e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b51b2d00bc5437689fb1ac29bc46a56_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3e2cdebf2e34461bb476ad2299cb6ae6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if058af87c70046e2aadf2969cb8ec339_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ieede5634af6341efa55cd03c69ce9e7b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7f367843cd4a459aa904731e38a571f0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ife34e8173e884133b5b5df3663402806_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id1b6fdc993a44cf79b869e8688a3062f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8b3875a8852c4f49b9e644e0c9158374_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if4bb284119504ac8a1c8c4175099a908_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic3553a83d95842ccbe6c7675c97c9f6d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic2ada1e061ed4917bbce94eeb6b5933f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2692b6a2c3a470caa2bb0ed4268a1d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e9431c0a0744979af0821b912532c37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56be570639ec418f834fc04f5746b4d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic5b995470fa14c99ae213810dba2dae0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85140128d15a442892fcc26f8abda120_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0570f45a09344ee88a9bbbf9b677aef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17bad89df3f34651a5f6e776704460f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff71e9fbc56d4559bdd9a623ccc89b89_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0a283fbf212a4481af4e7343abe77f50_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0ee9e38341534af88bad1e7379c5795d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i131a6d5dd4084afa8625aea4291a03a4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibed8defa2fe84947a4f4b459fdd0d10f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id355e63804de46f2b00142ad2e9766d4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i7d61eda3c47a477a87953bd9435f3fdc_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ia617f0f0d1234327a3119ea448c3da76_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9113178df6744dbebe8d536cedbb476d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia0888eb887324fbcb06a48bb48e3d178_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6ef2ea3f8af4435f8e0f9aeefee13306_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ied82434791db403c955ea793bffb2f0e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if9c72eafd68c4e398efd063c308f2dbd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i536f8ba047234c319b7406ff767147dd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idb70d5c3848d414f9ce893ad215d4dec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02b2de87f30d4c6f8b03613d9c2807d2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i07af47860d104f6d8ed73f6a89548b2b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40059c26d0bb4c04a23a67aef6915a45_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifa2654f256764c58a2843f3f977d1dfa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0457c0290322402daedccdba35db7c6d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib58b6d257da24ff8b4839e62a689e898_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0f749230a90846feaffa937710c3bd7f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie6a1954375c4428c8c9f1e2459422a19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5684eeb894e948e795d7ba13a0a9821b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibe1bc0a4b4384b369f562b05efbd0f01_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ide647841e7044ab48b55cda50f1d1520_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2a595e77e9024184a813ff4337b0408b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i52305514d2d248ef8eac2ce5da013356_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2a87c0642d8c4661b4616dcafaf98925_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic532929c81174c56bed2bcbdbaad621f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i87deea9139694467a9fdc201db179c76_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i374fbb6203a34bf4944599f7c1e45415_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5c7748a642e745f88a124b19bc7f4714_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i17821dc2bf9b41c6b08b07a41c8ce707_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i979c6df8053649cfb7b8b90a285b165d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14942974e4f2452cad88e831cc7cddda_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6d8e15ff35ac44bab6ffcdf343f511ac_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9201821f02cc43b3b8f8fabadde5754b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibe4be84a93994def8ed976d74fd1dfec_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="iee1f4bcc0a9b4476bc090cfa49e3c034_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1236ccb8b6ae4703835b4052a03f112b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9aaed4b4b8474e7e9b340a6d01f5046c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2e5e89f06e804ddc81397c8b1168e259_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25755164c7c047c2ac74d54b1cdcb1d8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i54eb17b8eef44296a8fdc3c7b6bd76af_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i78981389f5f94e5eadeefbd380f6d4ef_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i83451001a11e4d698aaaf41cfef4dc3e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i868b061cb602497db91dcef241c70a3b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia665bc2c1fc141a1a5ca42007baa03e9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia08a43cc4bff411ca2c03d302026578f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i888cda8777754c04ac0cb1995bd7bfa8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib6d155f75ea4423db88f5212a2c98b00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ecf3d9b5a444b63953faed5774226de_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3b3a3bb2800746138b838c49892a8c1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51a5027177624992b876d1ea94cede10_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iad77af33cb984b0e9bb3ef62ed1ebb74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i731212cbf9b94995850d82a2311a7c17_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6f8e35902ecf4f34b94a8d17d9489454_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i57f385654e1742b6a56d8fb4d0ade38e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7228047741514b81981471c02ea16f0e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d7974ac17f340839427c22253a75e1a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie0901c785f9c4846b1b5c357e1bf4da5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ad5e6108b894c5681f7fde6c91cbfc2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3f44a3b624d34174b5f92cb92f67b731_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d21834e33c0420f926fcb969d864201_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic5944e21d13b439296ad6220144c780e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaeecea45f6d1449081d0846aaae7ef11_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i724f2b0183a64064a5b4c3edbfee2752_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if5111c584bd441549e34423b141b35c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf27a73b87464b70a24f4215cf6a7822_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i1203eeb4805841f0ac2cd72de89f499a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i016c570732cb4e06b13838775a874ce8_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="id947942c69fa44ce89256cc80c1e696a_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="id662c0ca4fe34fb99b51e17485cdad55_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="id9e2646cf66a4acea08af56195b01b34_I20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-15</instant>
        </period>
    </context>
    <context id="ibb46cac46d2848cfad57259f2ed1d632_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibd1b2f47353e4aaebcecdfcb602f4de9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if4d015ecb936405daf574b4e3105f141_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i790882cea9a743939fad5f1974b20135_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5ee194f83e384c83974d24f728c5145b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5b8709d2eae04591a6115e04171e59b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f5341349d2f494d97ea527c3a617208_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iee2acff297c64ff1859c44405ba33de8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id6d9591af95346bca52a790ec1831e51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i121f989f64d54d71990d30584fc92371_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc0e23fcbfe244b5914449511bb9de9a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33ed22d7f19146a98e5ed27cdcf69af6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9a1a6add6db45b6a1cc3687b957361e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89cad3952c464507908e42ec76b9683b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie56cc9b03fcc4f6d9a86477a5270a889_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6617815be784402785f12c6988e1beee_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if08aec04c4324a64a5bb6af5a48753a2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i52012835f8e245adb31aeec016f4112a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iccb1237016b141a5b01be03b134ebd55_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i02a25f52836a44c688f515291d314595_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i52a09764d13c4694a6f1f3b0b58dd09e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifd1befbf13d647bbbbce80021df07746_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6655179b6b2649759f156341cd1be463_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia26f4bf0d205499492e015dc1f5f9d6a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i58c1b21402d94dac9e67581cf6e009b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4ee0d5eaff614476bcb905bbd08373bf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie4eda08b11c34ae9a36408a31801e4ec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaa803a04b06e4d9cb1a5f96364d792dd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b7d97c6a13d4e7a91efccbf9a7a80a6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i62772410ea3b48f99b42dec5a933607a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i754c37b6ef7645eb9afbdbbda44b09f6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i590c8062df384811a4631c1a3f4c03cb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9cc821229a0b466caa70f9efb4cbb784_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ice4da96682e14bf78bf22af3dd2a4a8c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie5d97abb270e493da281ba2ce68e7c8b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i59583d2b241145dd9da8f108498b7d3e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if9144d29ad0b4e8b89f55ce739a9ee63_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i85e0459de37d462abb7762f5b8952479_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6e0e08b5a819440bb14c90345397b2db_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id601e29bcd854d9a871868d6cb4b232e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8d783d882d2347499c93910b2745c786_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icc093e060e9247b3b645204a28e9693f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id9c160a38b934622ae05b249135e9fba_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i29b0a6b12ff841faa09ff1e9b8731d8e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib347ee221e7745e397b6e1c44ca1f262_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8793b775d015434e94d2639ea24a0cd7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5814e7fb32fa4b229429ed5c681d9f9a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6c91e4f53b324f398e35bf230235f119_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i74e5599741ad4a8b9f6a247bbdd89697_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icdfa95b717f940c18648cae8c6f84a2b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9c803a1bd2b24613850cb9d1888f1471_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i20625d3cd2ef4a8797d00c27d1627625_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia034f5fb9e314569bb5e919e953a76f7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if042c7a7464c42fe8dd45965e651f723_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8a3878b3cdc54bddb2a915e956935ea2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i63ab73c921484907b93d62dc34ab72bd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1134208d9b3347088ec3ac4ca9b1f0e0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4c4590aede5149a797bc4699fd289712_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iea96acd5ebf344c0bd0de05f5f18e7ba_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic130d01037a74b06b9d042ae75b7659f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i90a6a4cf318b432dba2b2758ed6fb58b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic8d31d1727454b0ba645a673b928faf0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iecdb89b7a5934dd2ae846178573005f8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic60ece36c57b4554886f84f64ca30d1e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib81a65b32a8e4a00ad66b6254231bdda_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i46142d7f2ab141ffb334e6b33caf19cf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i66e68173c701483d84c579c57a8c212d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iebcbf3a6149a4a9289109aa4855ff343_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2765e12d82da461e9794964574b53f42_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6ff86437e3aa4e37930e1206c73cfb00_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i54e58411691c4fbf853552c0ff6a6d05_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if0d1b57d4a0c4741b41196908e3c38b1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i87fa0cfd9f644bdbb719a9473bc87605_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib9e828d7b7bf4f43bc6657cc9326807e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i07234f661df448cb8a6a14d7961cf1a1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2e54ac3de781499f9cab24ff66dd0c11_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i30647a5eccee4a888f75b3abd844ebdf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i65457dc54fbc417690f3f9dfc74324b1_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia09bc9241ad54438b01f90b39ada6215_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6f5259f6537145b1b52dcc10ca5b10fc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2017d3bce86c4e1f9ab0a83bcf38491c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i91efa7f34820455f9945f65b1db8ead5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i77da4b737e504001a90944aeda31b91f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ice34644db491436ba604aaf4f60a0d7c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i968b5e6a9c734bba858d0e6913254760_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iad7d1365baac43d6945215ce6b8816f7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i72965d9649fb4d17a86322fadd05e4e3_I20181107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="ie90411741db34c3b961e743e971e67dd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9290a0d035874af8ac1688475a9c6fda_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i69cf49f1dcbd46fbbdb79f66912dd8ca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5aae7a15859845fc95e18fa3c0eaaf33_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i94c61857768f4045b23a12b5bd57d3e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i47d16efb9f3f4c09872f1f6d2b724400_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i61802b3b7d4442588559391d63737368_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i412bdd987d70473f8492259ec4e93e3c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaeb7e6ad713d4670b6e038cfbb2130de_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i50fc7b747b554ee88ca10781e8675077_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7111de4bd0294ff9a9a3ad920d505e32_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie7dc064ffb824915a213b2bafa7eadc1_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i443ec97d551d4f19819d518a28e3dcde_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i058baac90e1841039cf4ef78a041460d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c605c95790545c0995faf5707af1bfa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ExpectedPaymentTimelineofMilestoneAxis">biib:TwelvemonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i925bce57d9bf415ba43b031db49f8b12_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8e351ee8c7e84208bbcdd85dd32c6e63_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>biib:product</measure>
    </unit>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="wholesaler">
        <measure>biib:wholesaler</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80L2ZyYWc6ZjhiNTk2MmNiMzRiNGU4MDk0YmE5OWVhNjMwNjk2ZmMvdGFibGU6MDM2M2Q0NzYyOTg4NDM3ZGJhZmZjZWM3NGZhOGQxZTEvdGFibGVyYW5nZTowMzYzZDQ3NjI5ODg0MzdkYmFmZmNlYzc0ZmE4ZDFlMV8xLTEtMS0xLTA_71d4ef7a-66b1-43e9-8baf-49081bd86b1b">0000875045</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80L2ZyYWc6ZjhiNTk2MmNiMzRiNGU4MDk0YmE5OWVhNjMwNjk2ZmMvdGFibGU6MDM2M2Q0NzYyOTg4NDM3ZGJhZmZjZWM3NGZhOGQxZTEvdGFibGVyYW5nZTowMzYzZDQ3NjI5ODg0MzdkYmFmZmNlYzc0ZmE4ZDFlMV8yLTEtMS0xLTA_7117525d-07ce-4220-9ee7-263f9b8baebc">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80L2ZyYWc6ZjhiNTk2MmNiMzRiNGU4MDk0YmE5OWVhNjMwNjk2ZmMvdGFibGU6MDM2M2Q0NzYyOTg4NDM3ZGJhZmZjZWM3NGZhOGQxZTEvdGFibGVyYW5nZTowMzYzZDQ3NjI5ODg0MzdkYmFmZmNlYzc0ZmE4ZDFlMV8zLTEtMS0xLTA_4ee334b5-2f8b-4971-bb67-2cd3f8efd6de">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80L2ZyYWc6ZjhiNTk2MmNiMzRiNGU4MDk0YmE5OWVhNjMwNjk2ZmMvdGFibGU6MDM2M2Q0NzYyOTg4NDM3ZGJhZmZjZWM3NGZhOGQxZTEvdGFibGVyYW5nZTowMzYzZDQ3NjI5ODg0MzdkYmFmZmNlYzc0ZmE4ZDFlMV80LTEtMS0xLTA_24662367-fd19-4742-a459-0369b234127e">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80L2ZyYWc6ZjhiNTk2MmNiMzRiNGU4MDk0YmE5OWVhNjMwNjk2ZmMvdGFibGU6MDM2M2Q0NzYyOTg4NDM3ZGJhZmZjZWM3NGZhOGQxZTEvdGFibGVyYW5nZTowMzYzZDQ3NjI5ODg0MzdkYmFmZmNlYzc0ZmE4ZDFlMV81LTEtMS0xLTA_abf31984-ac12-4efb-9cd8-613e466e7b46">false</dei:AmendmentFlag>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic6f45d28d5d8449d9712a20039e0697e_I20210421"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80L2ZyYWc6ZjhiNTk2MmNiMzRiNGU4MDk0YmE5OWVhNjMwNjk2ZmMvdGFibGU6MDM2M2Q0NzYyOTg4NDM3ZGJhZmZjZWM3NGZhOGQxZTEvdGFibGVyYW5nZTowMzYzZDQ3NjI5ODg0MzdkYmFmZmNlYzc0ZmE4ZDFlMV82LTItMS0xLTA_8aef9027-2078-45fd-8c2c-cd46508d3b2a"
      unitRef="shares">150554750</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yOC9mcmFnOjYxOTExZjEwYjYzOTQ3NDQ5MGRkNjNmZmRjZDA0YmM1L3RhYmxlOjE3MzQxN2U2ZTVhNTRmYWQ5NWIwNmY0NzI1N2UzYmFmL3RhYmxlcmFuZ2U6MTczNDE3ZTZlNWE1NGZhZDk1YjA2ZjQ3MjU3ZTNiYWZfMS0xLTEtMS0w_1627580b-bbca-4463-871a-4ef77fe5cf47"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yOC9mcmFnOjYxOTExZjEwYjYzOTQ3NDQ5MGRkNjNmZmRjZDA0YmM1L3RhYmxlOjE3MzQxN2U2ZTVhNTRmYWQ5NWIwNmY0NzI1N2UzYmFmL3RhYmxlcmFuZ2U6MTczNDE3ZTZlNWE1NGZhZDk1YjA2ZjQ3MjU3ZTNiYWZfMS0zLTEtMS0w_f016a8ca-cedc-4fff-82d2-0970df41d14c"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yOC9mcmFnOjYxOTExZjEwYjYzOTQ3NDQ5MGRkNjNmZmRjZDA0YmM1L3RhYmxlOjE3MzQxN2U2ZTVhNTRmYWQ5NWIwNmY0NzI1N2UzYmFmL3RhYmxlcmFuZ2U6MTczNDE3ZTZlNWE1NGZhZDk1YjA2ZjQ3MjU3ZTNiYWZfMi0xLTEtMS0w_1db8461e-c1bd-430c-a8d4-a44bd69eb2fe"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yOC9mcmFnOjYxOTExZjEwYjYzOTQ3NDQ5MGRkNjNmZmRjZDA0YmM1L3RhYmxlOjE3MzQxN2U2ZTVhNTRmYWQ5NWIwNmY0NzI1N2UzYmFmL3RhYmxlcmFuZ2U6MTczNDE3ZTZlNWE1NGZhZDk1YjA2ZjQ3MjU3ZTNiYWZfMi0zLTEtMS0w_ccc3951a-6ea5-42d7-b6a5-b0f959da2ec7"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ifff98e73ce134eadb812f6e1419eb1bd_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfMS0xLTEtMS0w_f80a3ee7-f13a-49a8-ac8e-8e760d30550c">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ied5ebc033f5042cfba2d1d9018f9eb58_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfMi0xLTEtMS0w_35d8ba0b-cf57-4930-9360-9e6a4d06251a">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i583e423036fc4cabb98562f54f1b61ad_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfMy0xLTEtMS0w_0cac72d8-dec1-499d-9eaa-5737976e1414">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2bf61e1da4cb4085ab83a72725b9c364_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfNC0xLTEtMS0w_61afb743-25cd-4175-b05e-d3780ddfea66">P28Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7d0bb3392f8b437d85af0d89b58fbe65_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfNS0xLTEtMS0w_3e13df59-fb87-4e71-9aeb-f13b06f1d76d">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib7f6d94534c94c69950875e422123904_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfNi0xLTEtMS0w_2ad48f53-8928-4192-b6db-4dae8188e54e">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="i3a69b4c3dc9c4aba925cc1b9bb62aad5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfNy0xLTEtMS0w_4a645591-247b-49f9-83c1-ef6e500d049c">Indefinite until commercialization</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="i59ae9b2ac6bd42a5aa75417ce4eb6bc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RhYmxlOjA4YWEwOTc2ODU0MDQyNDk5NTVmNGY3MzY0NWVlNzQyL3RhYmxlcmFuZ2U6MDhhYTA5NzY4NTQwNDI0OTk1NWY0ZjczNjQ1ZWU3NDJfOC0xLTEtMS0w_5f4caf69-579f-4e47-84b6-9400c305b6e1">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RleHRyZWdpb246OTU2ZTM0Nzc5Y2U0NGNiNDlmNmY2ZWNjNDliNmQ0OTRfMzk_caee377f-6e75-4e7a-9b37-cbdd79049ac1"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RleHRyZWdpb246OTU2ZTM0Nzc5Y2U0NGNiNDlmNmY2ZWNjNDliNmQ0OTRfNTI_38403ddc-655d-4c1c-96d0-94ee56076008"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82NC9mcmFnOjk1NmUzNDc3OWNlNDRjYjQ5ZjZmNmVjYzQ5YjZkNDk0L3RleHRyZWdpb246OTU2ZTM0Nzc5Y2U0NGNiNDlmNmY2ZWNjNDliNmQ0OTRfNTU_ad9b9056-0f4a-4b25-ad10-b334cb8620ea"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i86ba11dc3301448dab6e7f9202ed71a0_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOmI3NjYxZTY5ZmIyZTQzNDM5YTJhODJlNmJiM2M0ZDM1L3RhYmxlcmFuZ2U6Yjc2NjFlNjlmYjJlNDM0MzlhMmE4MmU2YmIzYzRkMzVfNS0xLTEtMS0w_9d71b880-8d85-46b0-91af-713a885dd735"
      unitRef="number">0.02900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i169c8b70cdd149968938de9db5a8c380_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOmI3NjYxZTY5ZmIyZTQzNDM5YTJhODJlNmJiM2M0ZDM1L3RhYmxlcmFuZ2U6Yjc2NjFlNjlmYjJlNDM0MzlhMmE4MmU2YmIzYzRkMzVfNi0xLTEtMS0w_b8d6b019-0802-4fa6-a8ed-f8d3ad27c430"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i73f7b949b4c740929fa619fc13968293_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOmI3NjYxZTY5ZmIyZTQzNDM5YTJhODJlNmJiM2M0ZDM1L3RhYmxlcmFuZ2U6Yjc2NjFlNjlmYjJlNDM0MzlhMmE4MmU2YmIzYzRkMzVfNy0xLTEtMS0w_4a5b5efc-c404-456f-acd4-b15a05498e01"
      unitRef="number">0.04050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i21ec6c5ff89547ff8dc1226630ef60ef_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOmI3NjYxZTY5ZmIyZTQzNDM5YTJhODJlNmJiM2M0ZDM1L3RhYmxlcmFuZ2U6Yjc2NjFlNjlmYjJlNDM0MzlhMmE4MmU2YmIzYzRkMzVfOC0xLTEtMS0w_e86dd38f-a998-4407-8abb-bd2501e6cfba"
      unitRef="number">0.05200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28131b2b3d0447c08a69cc0b6f4781f6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOmI3NjYxZTY5ZmIyZTQzNDM5YTJhODJlNmJiM2M0ZDM1L3RhYmxlcmFuZ2U6Yjc2NjFlNjlmYjJlNDM0MzlhMmE4MmU2YmIzYzRkMzVfOS0xLTEtMS0w_86dbabc1-35ea-4d59-8fdf-7217fadfaf48"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id15e963a15e44c2b8d3baeb9b65f28b2_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOmI3NjYxZTY5ZmIyZTQzNDM5YTJhODJlNmJiM2M0ZDM1L3RhYmxlcmFuZ2U6Yjc2NjFlNjlmYjJlNDM0MzlhMmE4MmU2YmIzYzRkMzVfMTAtMS0xLTEtMA_00151ff0-4cfc-441b-b5bb-1dfe10dbb00e"
      unitRef="number">0.03150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7f1bb2f05a734c40a4736b73629c222f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOmI3NjYxZTY5ZmIyZTQzNDM5YTJhODJlNmJiM2M0ZDM1L3RhYmxlcmFuZ2U6Yjc2NjFlNjlmYjJlNDM0MzlhMmE4MmU2YmIzYzRkMzVfMTEtMS0xLTEtMTA4OTE_9d03f53a-b2bb-4aee-a0fb-ad9d07344f64"
      unitRef="number">0.03250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i72bff1f88c9641b0852976834a354215_I20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOjdiMmVkMTgyN2I5NzQ2NTY5ZGJmMzBkZDI1MDhkNDgxL3RhYmxlcmFuZ2U6N2IyZWQxODI3Yjk3NDY1NjlkYmYzMGRkMjUwOGQ0ODFfNS00LTEtMS0w_ebc7a2a0-eb08-44b7-93bc-5b35b92a2908"
      unitRef="number">0.0083</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i3330c709f4b24368ac40f72d927eeaef_I20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RhYmxlOjdiMmVkMTgyN2I5NzQ2NTY5ZGJmMzBkZDI1MDhkNDgxL3RhYmxlcmFuZ2U6N2IyZWQxODI3Yjk3NDY1NjlkYmYzMGRkMjUwOGQ0ODFfNi00LTEtMS0w_8990c877-746e-4c25-a263-6dd630a8be7d"
      unitRef="number">0.0118</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:AssetImpairmentCharges
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83MC9mcmFnOjBlOGEzODNjOWNiNzQ0ZjM5Y2Y2MmY3ZjZkMzVhMWJlL3RleHRyZWdpb246MGU4YTM4M2M5Y2I3NDRmMzljZjYyZjdmNmQzNWExYmVfMTI_44408971-1493-49f3-a110-d96e6c954a0c"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <dei:DocumentType
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDEz_c107e827-a936-461e-9d4b-cf48b5292d3e">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6ZjI5MDg3MzgwYTJlNDQyYmI0MDM0OTk2NzgyZTc5NjAvdGFibGVyYW5nZTpmMjkwODczODBhMmU0NDJiYjQwMzQ5OTY3ODJlNzk2MF8wLTAtMS0xLTA_d20d5a89-d63b-4da9-9850-794056c7e333">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8xMjQ_332ca729-0fec-449d-a725-51e75d44e65a">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6NjQ5Y2RiMjczZGQ4NGVkMmJmMTE1ZDU2OWNiZGFjYWIvdGFibGVyYW5nZTo2NDljZGIyNzNkZDg0ZWQyYmYxMTVkNTY5Y2JkYWNhYl8wLTAtMS0xLTA_cf114954-7945-44cc-9e7d-2fe0971bf551">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDE3_112d0a4b-91a4-4d8f-875c-194348c05b91">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDE0_ea6a1546-8417-4d4a-b1c1-61963686f405">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6Zjc0ZmYzOGFhOGFlNDBlNWFkYWYxN2IyNzIzMjJjZGMvdGFibGVyYW5nZTpmNzRmZjM4YWE4YWU0MGU1YWRhZjE3YjI3MjMyMmNkY18wLTAtMS0xLTA_3e1feb2e-750a-4730-8f35-5cf5d455fce1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6Zjc0ZmYzOGFhOGFlNDBlNWFkYWYxN2IyNzIzMjJjZGMvdGFibGVyYW5nZTpmNzRmZjM4YWE4YWU0MGU1YWRhZjE3YjI3MjMyMmNkY18wLTItMS0xLTA_7dbfbd49-84cb-4910-8c9c-e894f7c5e8c1">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDE1_59d14219-592a-4f96-b043-ae3978503f79">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDA4_26f01bd9-6711-4eea-9a39-5de0c8bca888">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDA5_56a54e36-03e5-4f86-85b5-a464a1662d79">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDEw_c680b784-27f5-4d7f-82bf-8518948f4d6c">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDEx_9e886f8f-30a8-486c-9de7-d434ab410aa2">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDE4_953f3565-474e-4f98-9c0c-b32fc93845ff">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6Mzk3NzA1ZTliMmM2NDA3YTkwNTc4Zjg4NzBjZmMzNzgvdGFibGVyYW5nZTozOTc3MDVlOWIyYzY0MDdhOTA1NzhmODg3MGNmYzM3OF8xLTAtMS0xLTA_a2dec643-c0b3-444a-bc39-6464b8b74099">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6Mzk3NzA1ZTliMmM2NDA3YTkwNTc4Zjg4NzBjZmMzNzgvdGFibGVyYW5nZTozOTc3MDVlOWIyYzY0MDdhOTA1NzhmODg3MGNmYzM3OF8xLTItMS0xLTA_9a477eea-f96e-44ab-9411-dd8c4112b1ff">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6Mzk3NzA1ZTliMmM2NDA3YTkwNTc4Zjg4NzBjZmMzNzgvdGFibGVyYW5nZTozOTc3MDVlOWIyYzY0MDdhOTA1NzhmODg3MGNmYzM3OF8xLTQtMS0xLTEwODI3_3e8da1f3-709a-45ac-a132-e65b7748b616">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDEy_0ca5c0bd-94ec-4a27-bdd3-16af1b61952f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDE2_a0783280-8a22-46a3-a3d9-f0895f7c2527">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6MDE4M2QzY2IxMThjNGI5MzkzOWY3NDlmNjI2OGMxZGIvdGFibGVyYW5nZTowMTgzZDNjYjExOGM0YjkzOTM5Zjc0OWY2MjY4YzFkYl8wLTAtMS0xLTA_d3c76b7d-1c97-4d2f-a8c1-be5778df637a">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6MDE4M2QzY2IxMThjNGI5MzkzOWY3NDlmNjI2OGMxZGIvdGFibGVyYW5nZTowMTgzZDNjYjExOGM0YjkzOTM5Zjc0OWY2MjY4YzFkYl8xLTQtMS0xLTA_18394a7c-da49-4348-8bbe-f3ed4651b35c">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGFibGU6MDE4M2QzY2IxMThjNGI5MzkzOWY3NDlmNjI2OGMxZGIvdGFibGVyYW5nZTowMTgzZDNjYjExOGM0YjkzOTM5Zjc0OWY2MjY4YzFkYl8yLTQtMS0xLTA_b1265f86-da8d-4685-89d2-a933b2ff3b74">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8yMDE5_dd3c44d8-b438-4e42-bd3c-af70796cce68">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic6f45d28d5d8449d9712a20039e0697e_I20210421"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xL2ZyYWc6MTMzNTc3YjU1YjFhNGEwYjg5MDg0NDI1YmU3OTg4Y2IvdGV4dHJlZ2lvbjoxMzM1NzdiNTViMWE0YTBiODkwODQ0MjViZTc5ODhjYl8xOTk2_8aef9027-2078-45fd-8c2c-cd46508d3b2a"
      unitRef="shares">150554750</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="iabf5fb72476641e09225cdff0259f43e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMy0xLTEtMS0w_a631cac0-71bc-466e-97c9-c04d31071c5a"
      unitRef="usd">2211700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3b12581badd45819dafd1517b58aa13_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMy0zLTEtMS0w_c38612ff-12c4-46bc-888e-6f6b316391a8"
      unitRef="usd">2904600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2837c6bcf6604a1884f52b184bbc1cec_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfNC0xLTEtMS0w_8196480a-6f98-4c32-92d4-9dca72e661a4"
      unitRef="usd">389000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57cd91f7d9604cf09b048c87050e1776_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfNC0zLTEtMS0w_d968045b-42d4-48d9-8778-b5d9c287c1df"
      unitRef="usd">520400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16255170d7464fce8565c267cce60805_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfNS0xLTEtMS0w_c8308450-e58a-4358-aa68-bfcb4a1e0f18"
      unitRef="usd">93300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa5be06727e54c9cb7a5c0a5c65b597e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfNS0zLTEtMS0w_9d5d8034-db1d-4e50-a4dc-1cf028e13bff"
      unitRef="usd">109300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfNi0xLTEtMS0w_39af262b-72c2-4e6f-a4f5-1a9d7ab720a5"
      unitRef="usd">2694000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfNi0zLTEtMS0w_f90cc6e6-68c7-4516-9841-89d6ada85179"
      unitRef="usd">3534300000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfOC0xLTEtMS0w_a0262cfc-001b-487b-bc90-22454fb0cb02"
      unitRef="usd">478100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfOC0zLTEtMS0w_8ea4f712-4a6b-46bb-9e7c-3da40f91a962"
      unitRef="usd">454300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfOS0xLTEtMS0w_2df578c7-fc7f-4c02-8283-97d2a738a25c"
      unitRef="usd">514200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfOS0zLTEtMS0w_9ec0e7e2-ea5e-4434-b3a8-8a8e838f29e5"
      unitRef="usd">476300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTAtMS0xLTEtMA_6510860d-bfba-4119-841b-febbf8ee9abf"
      unitRef="usd">595000000.0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTAtMy0xLTEtMA_004d01a9-d2b7-4acf-81db-a706f7c2dfd2"
      unitRef="usd">570100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTEtMS0xLTEtMA_60298ee3-0957-4884-99dd-acedfde73cbf"
      unitRef="usd">98100000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTEtMy0xLTEtMA_0de0c9b6-d36d-47de-a060-5992bed3e0f2"
      unitRef="usd">71500000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:Collaborationprofitlosssharing
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTItMS0xLTEtMA_f1957ab0-5230-4c0d-8894-aa699ac5bd51"
      unitRef="usd">68500000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTItMy0xLTEtMA_68588346-c6cf-4734-b6e4-a67a1f9ab44f"
      unitRef="usd">71800000</biib:Collaborationprofitlosssharing>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTQtMS0xLTEtMA_e92db03c-fb17-4430-a844-3458ac8dcd01"
      unitRef="usd">33800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTQtMy0xLTEtMA_be33258f-2018-4160-9d9a-05b5c6196572"
      unitRef="usd">4600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTYtMS0xLTEtMA_7b9ded31-7674-45e4-854e-443b31f03ccf"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTYtMy0xLTEtMA_a98f088f-b706-43a0-a3f3-2e7d5837b188"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:CostsAndExpenses
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTctMS0xLTEtMA_f1694b3a-2396-4449-ab89-4cdd27f71918"
      unitRef="usd">1720100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTctMy0xLTEtMA_b1e31e5c-9d93-4b0e-bd89-5057b9f0d43a"
      unitRef="usd">1714400000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTgtMS0xLTEtMA_4d20d422-3fca-4b77-931b-03e30f6ede8e"
      unitRef="usd">973900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTgtMy0xLTEtMA_0e2a7b1b-5489-4a53-aa50-4b48953e9b9f"
      unitRef="usd">1819900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTktMS0xLTEtMA_eacd6c25-bc7f-415a-a819-ba9d9170257a"
      unitRef="usd">-506900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMTktMy0xLTEtMA_a0968257-457f-4e99-8f3b-a525b0be3fda"
      unitRef="usd">-120500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjAtMS0xLTEtMA_31e6bb85-b640-45af-b0bb-4b94a3d382ea"
      unitRef="usd">467000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjAtMy0xLTEtMA_8ff8a192-a767-439d-a07c-b6938f4fc5e7"
      unitRef="usd">1699400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjEtMS0xLTEtMA_0e4602b6-2f1d-41da-83f8-6f390cade500"
      unitRef="usd">44200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjEtMy0xLTEtMA_be42c132-2a88-41a4-9879-8b4440cbf5ee"
      unitRef="usd">292000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjItMS0xLTEtMA_7ebf1038-2c1d-4841-bd39-7ac54d07d4be"
      unitRef="usd">-18200000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjItMy0xLTEtMA_90ad8396-4fa8-46ca-b6ef-c0240708d730"
      unitRef="usd">-14800000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjMtMS0xLTEtMA_c8d77338-569c-492f-8fb7-edb84f1d88cd"
      unitRef="usd">404600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjMtMy0xLTEtMA_61ae2ef4-80cc-4431-a903-7a3da346a553"
      unitRef="usd">1392600000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjQtMS0xLTEtMA_f1f41bb3-885f-4f3c-a625-a37b9ae8670a"
      unitRef="usd">-5600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjQtMy0xLTEtMA_ee68ddb0-e919-498b-be3e-d6ff2324e2e0"
      unitRef="usd">-6500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjUtMS0xLTEtMA_3c55058a-db03-4501-9a8d-772d98de7792"
      unitRef="usd">410200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjUtMy0xLTEtMA_bea062c7-e281-480e-9aee-83e13bb9471d"
      unitRef="usd">1399100000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjgtMS0xLTEtMA_660bd388-e1f4-4c26-b4b4-0625c982bc11"
      unitRef="usdPerShare">2.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjgtMy0xLTEtMA_6eff6cb6-54f2-4767-a410-8fd49744054a"
      unitRef="usdPerShare">8.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjktMS0xLTEtMA_713f5de9-ebfb-4d23-ae7a-213fdc3ef3f8"
      unitRef="usdPerShare">2.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMjktMy0xLTEtMA_11f42678-9048-48fa-af62-c5f4365aaa6d"
      unitRef="usdPerShare">8.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMzItMS0xLTEtMA_c5dc597c-6163-4b47-b2e8-ebed155833a8"
      unitRef="shares">151900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMzItMy0xLTEtMA_499c134b-8309-4460-8951-023c27a91bb3"
      unitRef="shares">172800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMzMtMS0xLTEtMA_00e484dc-b7ad-434b-9c78-d9eb9f69ed21"
      unitRef="shares">152300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xOS9mcmFnOmZhMGE2N2UxZGEzYjRlMjJhMzAyOTliM2I5NzE5OTZkL3RhYmxlOjY5NjRhNGI2OTYzMjQzZDNhMDUwN2ZhNmMyODgyZjBiL3RhYmxlcmFuZ2U6Njk2NGE0YjY5NjMyNDNkM2EwNTA3ZmE2YzI4ODJmMGJfMzMtMy0xLTEtMA_e54cb460-b599-498d-a1bc-7b1630bbf53b"
      unitRef="shares">173100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMi0xLTEtMS0w_eeb87cdd-1517-44ba-bff3-d74cdd6360e9"
      unitRef="usd">410200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMi0zLTEtMS0w_efbd9ddd-7030-44dc-87a4-fdabe3004cb5"
      unitRef="usd">1399100000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNC0xLTEtMS0w_f7a1feb8-16e4-4daf-be82-8f1d8289f0a3"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNC0zLTEtMS0w_4150149e-536d-4a1f-b4c0-29fa2e61c4c6"
      unitRef="usd">-7800000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNS0xLTEtMS0w_6ff1e377-2872-42f4-9574-983eda877e14"
      unitRef="usd">149600000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNS0zLTEtMS0w_518799c8-4763-4680-b0e7-bd1e89deb6c6"
      unitRef="usd">33800000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNi0xLTEtMS0w_bcb0a727-d4fe-4ecd-92c4-2d75368422dc"
      unitRef="usd">22400000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNi0zLTEtMS0w_9a613497-e744-42de-95d1-2cf35701a645"
      unitRef="usd">23000000.0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNy0xLTEtMS0w_c31781f3-3f90-4ce7-acfb-96646d8b0646"
      unitRef="usd">-2000000.0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfNy0zLTEtMS0w_b709a2df-f558-43ec-9774-7253e8471b15"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfOC0xLTEtMS0w_066d8123-f271-4d5f-8f14-7077ab990b43"
      unitRef="usd">-48500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfOC0zLTEtMS0w_081ece0c-ab61-479d-a92d-271f486c0c30"
      unitRef="usd">-63900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfOS0xLTEtMS0w_c4c54377-7ab2-47d3-b0ab-619d7fd4c889"
      unitRef="usd">124700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfOS0zLTEtMS0w_8582ef23-2401-44e6-82bd-d4dc3419b9e0"
      unitRef="usd">-14100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMTAtMS0xLTEtMA_56d0d73a-1832-46d1-bc9c-5b9460ba5223"
      unitRef="usd">534900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMTAtMy0xLTEtMA_b8a3cedf-de01-4402-9b14-c5e32d1a9f26"
      unitRef="usd">1385000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMTEtMS0xLTEtMA_8dc9d47d-6db1-4a62-b130-a1d182dd8449"
      unitRef="usd">-4900000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMTEtMy0xLTEtMA_f381ab99-e009-4b26-afc1-c6d2b832eb7a"
      unitRef="usd">-5900000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMTItMS0xLTEtMA_c9a7a346-d475-4198-a812-f0871386840d"
      unitRef="usd">530000000.0</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yMi9mcmFnOjIzZjlhOTkyMTMwZDQwMDI4YTIzMGZiMjFmMDRhZTdmL3RhYmxlOjRiMmI0N2ZmMDNkMzRjYmFhZjZlZWFkNjdkNTkwM2M5L3RhYmxlcmFuZ2U6NGIyYjQ3ZmYwM2QzNGNiYWFmNmVlYWQ2N2Q1OTAzYzlfMTItMy0xLTEtMA_732fc787-f647-4af1-918d-6d90efb47f5b"
      unitRef="usd">1379100000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMy0xLTEtMS0w_33cde063-e4c9-4ca2-ae5b-ec9529f2d78b"
      unitRef="usd">1217500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMy0zLTEtMS0w_7f7dba3e-a912-4433-aa33-41b2213bdfec"
      unitRef="usd">1331200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNC0xLTEtMS0w_c08fd3bc-9299-4cdf-b220-54ea10dac0f6"
      unitRef="usd">1320000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNC0zLTEtMS0w_74e4edb7-4570-47f4-8c54-871a3fc685f2"
      unitRef="usd">1278900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNS0xLTEtMS0w_5f46cc44-47d3-423f-9d49-8d3cafeeb0a3"
      unitRef="usd">1854300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNS0zLTEtMS0w_52ab03e5-dc66-4041-8f21-88ffd72ed73c"
      unitRef="usd">1913800000</us-gaap:AccountsReceivableNetCurrent>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNi0xLTEtMS0w_8b3bd29f-d8ee-40ce-b590-bf6365fbfde7"
      unitRef="usd">369800000</biib:DuefromantiCD20therapeuticprograms>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNi0zLTEtMS0w_f323a5f3-089d-4dbb-9b1a-728391ad3dad"
      unitRef="usd">413500000</biib:DuefromantiCD20therapeuticprograms>
    <us-gaap:InventoryNet
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNy0xLTEtMS0w_3a2d493f-92d1-4444-a893-9af62ad0caca"
      unitRef="usd">1171800000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNy0zLTEtMS0w_84c945f2-5caf-4935-a4c2-d19aed8e09d6"
      unitRef="usd">1068600000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfOC0xLTEtMS0w_4c53be3e-ef84-4f3b-8959-557a857bf222"
      unitRef="usd">786100000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfOC0zLTEtMS0w_e0aa1c94-572c-4cde-99e6-ffd522c09cc5"
      unitRef="usd">881100000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfOS0xLTEtMS0w_7c6bc9b5-af94-48d5-9580-bd8def2af8e7"
      unitRef="usd">6719500000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfOS0zLTEtMS0w_8d8ad925-ee76-47ba-94b3-295af3957183"
      unitRef="usd">6887100000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTAtMS0xLTEtMA_ccf67375-cc23-4367-8be8-245d48581bcf"
      unitRef="usd">821900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTAtMy0xLTEtMA_2e2066d5-38c7-4891-808d-e5c0fbaefadf"
      unitRef="usd">772100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTEtMS0xLTEtMA_b2d970a6-b623-41a8-acca-51d411f54232"
      unitRef="usd">3438300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTEtMy0xLTEtMA_99588c72-5f07-41c7-9346-d6a66dc7bdee"
      unitRef="usd">3411500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTItMS0xLTEtMA_546e051b-6318-448f-8d7c-6052e0e9fc95"
      unitRef="usd">414500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTItMy0xLTEtMA_b35061bb-3ba2-4d7b-a504-50dd22b06124"
      unitRef="usd">433300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTMtMS0xLTEtMA_36003e48-bb43-4ad4-8b35-d088f383dc7e"
      unitRef="usd">2988100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTMtMy0xLTEtMA_dd6b8b6a-c895-4322-9cd7-335192561c95"
      unitRef="usd">3084300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTQtMS0xLTEtMA_c4c78bbc-5d67-4c92-958a-36d95ca979fd"
      unitRef="usd">5763100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTQtMy0xLTEtMA_369def82-f395-46f2-9e12-9dda6273f562"
      unitRef="usd">5762100000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTUtMS0xLTEtMA_408cbc95-efa4-47d0-a38b-873133f0f97f"
      unitRef="usd">1286300000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTUtMy0xLTEtMA_adda6877-0de4-4108-b2da-8c5f0cc868ef"
      unitRef="usd">1369500000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTYtMS0xLTEtMA_2e26d10d-1a60-40f2-9d54-bd928d2573f6"
      unitRef="usd">2423000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTYtMy0xLTEtMA_a3b5fa1c-71ae-410b-a304-abcf07700dbe"
      unitRef="usd">2899000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTctMS0xLTEtMA_61007eda-8650-4183-bf46-9902ba56335e"
      unitRef="usd">23854700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMTctMy0xLTEtMA_bd46e50e-df74-4c07-8d9d-29e45f973ebd"
      unitRef="usd">24618900000</us-gaap:Assets>
    <us-gaap:TaxesPayableCurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjEtMS0xLTEtMA_e2eaa687-b77d-4ee1-91af-b99dbc5cf52b"
      unitRef="usd">143100000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjEtMy0xLTEtMA_b63aaca6-be19-4f99-be3c-c8fcd045584a"
      unitRef="usd">142000000.0</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjItMS0xLTEtMA_2064d57e-91fd-40df-b9e2-9f3b3532ea2a"
      unitRef="usd">430400000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjItMy0xLTEtMA_2f713252-2feb-4906-8f66-9f222ec06f32"
      unitRef="usd">454900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjMtMS0xLTEtMA_07d04ae2-b839-4cdb-bd5b-7cc0f9c593b3"
      unitRef="usd">2592300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjMtMy0xLTEtMA_3ad9343c-ed10-46ca-b1b3-07bb9f30c25d"
      unitRef="usd">3145300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjQtMS0xLTEtMA_c0be81d1-b939-4189-ad6e-06ea79da5dc9"
      unitRef="usd">3165800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjQtMy0xLTEtMA_d8aec876-1ab2-4d86-b43d-f605299a413b"
      unitRef="usd">3742200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjUtMS0xLTEtMA_0bc1a3c6-027e-43ca-b305-df8310d41b8e"
      unitRef="usd">7267200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjUtMy0xLTEtMA_c2e0319c-f5af-44ac-a28f-0848e93034c8"
      unitRef="usd">7426200000</us-gaap:LongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjYtMS0xLTEtMA_be38360f-fb2a-429e-ad65-d63807c1dede"
      unitRef="usd">966700000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjYtMy0xLTEtMA_4cf227ea-ddeb-4d50-aecf-b979e6d0feb0"
      unitRef="usd">1032800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjctMS0xLTEtMA_ebe9c7e3-de22-4cd0-bee7-ec14a58e1598"
      unitRef="usd">380000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjctMy0xLTEtMA_a946e2dd-1f91-40d7-b41b-ec71eab5f22e"
      unitRef="usd">402000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjgtMS0xLTEtMA_e5374fef-205c-4448-91fe-0815394ad99b"
      unitRef="usd">1411800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjgtMy0xLTEtMA_44cdbc07-448a-4258-8b26-c41190d3815e"
      unitRef="usd">1329600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjktMS0xLTEtMA_6d4c5f04-40f1-49ff-89f8-06254e0ef4ee"
      unitRef="usd">13191500000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMjktMy0xLTEtMA_c1686289-851c-4ce4-ba92-461d48086eae"
      unitRef="usd">13932800000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzAtMS0xLTEtMA_b03664f2-1533-48da-ab13-0b9d24a97174"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzAtMy0xLTEtMA_06b2c732-8b14-43ed-ac91-c1e67f837a16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzMtMS0xLTEtMA_57ca2af4-e07f-406b-bf8e-07d723d40755"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzMtMy0xLTEtMA_8cd7dd6c-4df4-40a8-8452-e629ae856516"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzQtMS0xLTEtMA_2395bf0c-2023-497f-a815-20a01e374cbd"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzQtMy0xLTEtMA_5a393da3-96bd-47f8-b2d3-6eefe93b709b"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzUtMS0xLTEtMA_ce384262-373a-434e-a0ef-3c37ba3777ce"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzUtMy0xLTEtMA_84cfed9f-3016-43b5-a9fa-730e8cdad496"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzYtMS0xLTEtMA_2085fea0-ea04-46a8-ad3e-6c902f0b8fdf"
      unitRef="usd">-174300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzYtMy0xLTEtMA_2cf7afe0-b85a-434a-b9cd-30112daf6103"
      unitRef="usd">-299000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzctMS0xLTEtMA_fdf7608d-4825-43c9-a674-fc4e3b3205ff"
      unitRef="usd">13833500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzctMy0xLTEtMA_50f01463-c6d4-46cf-a89c-deac54bfd577"
      unitRef="usd">13976300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzgtMS0xLTEtMA_6144ce7f-2095-4045-8ce3-35384624ed1b"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzgtMy0xLTEtMA_e3947dfc-c29a-42b9-a4de-cf3dbe33e2ae"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzktMS0xLTEtMA_929b7190-bc1e-434a-ae24-3cce7d7dda81"
      unitRef="usd">10682200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfMzktMy0xLTEtMA_f09d41cc-3d79-477d-ba4d-9c726ea35c09"
      unitRef="usd">10700300000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNDAtMS0xLTEtMA_c856a145-8281-42d8-b62f-67535a1d755b"
      unitRef="usd">-19000000.0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNDAtMy0xLTEtMA_1c1d6a24-a8f7-4011-ae08-566b5b1cc4a4"
      unitRef="usd">-14200000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNDEtMS0xLTEtMA_4040f65e-8f90-4827-9a01-192067505c11"
      unitRef="usd">10663200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNDEtMy0xLTEtMA_f5d04ea5-de53-4d2d-9a05-482081f101d4"
      unitRef="usd">10686100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNDItMS0xLTEtMA_858070a2-2702-44b0-831d-280da1b0f394"
      unitRef="usd">23854700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8yNS9mcmFnOjA3N2ViNzhlOTIyOTRlMjNhNmFkYTkyNWIyNjVjYTA1L3RhYmxlOjViMGIyN2Y1ZGVjNzQ5Njc4MDYyYWI1MmNiYWQ3N2FjL3RhYmxlcmFuZ2U6NWIwYjI3ZjVkZWM3NDk2NzgwNjJhYjUyY2JhZDc3YWNfNDItMy0xLTEtMA_993ec186-6a8b-4990-b328-5e1829fd2d2f"
      unitRef="usd">24618900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMy0xLTEtMS0w_899a8828-d4fa-45a1-bdc2-ebb57f45b0bc"
      unitRef="usd">404600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMy0zLTEtMS0w_6cfb1b9e-28ae-4298-8965-4aaf3e8dcfd7"
      unitRef="usd">1392600000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNS0xLTEtMS0w_49b1f3ee-461b-41c5-a450-3c2e7bdd57d4"
      unitRef="usd">146900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNS0zLTEtMS0w_850fc8fc-da83-4a79-9172-2f1a596adf5b"
      unitRef="usd">119900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNi0xLTEtMS0w_18d8127f-20c7-4706-a2cd-e931c060c33b"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNi0zLTEtMS0w_142c4a64-2153-442c-b018-e93b5337329f"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensation
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNy0xLTEtMS0w_82143742-a47b-4030-9eda-c9139563b502"
      unitRef="usd">70000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNy0zLTEtMS0w_b131ab8e-20d7-4bcf-a65c-4360aedaee76"
      unitRef="usd">67700000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfOS0xLTEtMS0w_0ded3f29-3f89-4cd0-b8d4-d07b10873ce8"
      unitRef="usd">33800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfOS0zLTEtMS0w_77c36d03-fd22-4a69-a7d3-352589f3deb2"
      unitRef="usd">4600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTEtMS0xLTEtMA_9d579a29-a2cf-4498-b1ce-a582107b842f"
      unitRef="usd">-15000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTEtMy0xLTEtMA_1547e9f6-75f7-4499-ade7-6c10d17667ba"
      unitRef="usd">36900000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTItMS0xLTEtMA_ac7ae258-7429-486c-8017-75715c641fcd"
      unitRef="usd">-437600000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTItMy0xLTEtMA_7b13e844-3cb9-4ca2-bb79-3786a7c0a8a9"
      unitRef="usd">-62000000.0</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTMtMS0xLTEtMA_3ae5bee1-bad5-4de4-a4af-185b54605827"
      unitRef="usd">-18200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTMtMy0xLTEtMA_cbb1c3ed-adac-47c6-a486-9e7f61acaff8"
      unitRef="usd">-16800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTQtMS0xLTEtMA_a4b042d5-fac3-404c-a4e0-f9dfb56717c8"
      unitRef="usd">-71700000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTQtMy0xLTEtMA_a7c09bd6-f7d9-4c74-b2a4-313160331086"
      unitRef="usd">-28900000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTYtMS0xLTEtMA_54e7ffed-2691-4e8a-92ab-81cfd58b659f"
      unitRef="usd">-37200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTYtMy0xLTEtMA_9295aeeb-ca76-4ff7-b2c4-154defff9ca8"
      unitRef="usd">238400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTctMS0xLTEtMA_5ca48445-ab42-4400-9889-b69cef3478b2"
      unitRef="usd">-43800000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTctMy0xLTEtMA_7a6958ed-eeca-4868-af20-12f020ff0fc1"
      unitRef="usd">-78600000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTgtMS0xLTEtMA_a22b1535-ed7c-495a-84b8-aa5df69491a0"
      unitRef="usd">112500000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTgtMy0xLTEtMA_398a76a6-6665-4290-8874-23c1727bd119"
      unitRef="usd">62200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTktMS0xLTEtMA_0bf70fa2-3ecb-4351-8c44-63cb5f1a678c"
      unitRef="usd">-283600000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMTktMy0xLTEtMA_d2787618-c4c2-4f1b-a83b-f5a9b055c7ea"
      unitRef="usd">-347400000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjAtMS0xLTEtMA_463f4578-52fd-4253-b0a7-68e1c3124778"
      unitRef="usd">64800000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjAtMy0xLTEtMA_16b3ef3f-0eda-4953-9ec3-11b49e6a4407"
      unitRef="usd">223000000.0</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjEtMS0xLTEtMA_59fd3a7f-4db8-496b-90b6-6f44a50b7ddd"
      unitRef="usd">80900000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjEtMy0xLTEtMA_aed0cb95-22b3-4c3b-a0da-8d547c499651"
      unitRef="usd">-18500000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjItMS0xLTEtMA_9fcea49f-8f0a-4b3d-bdf7-2a4873e39cdc"
      unitRef="usd">769000000.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjItMy0xLTEtMA_f37ae9de-d72c-4b70-81f3-5eb1d7faffef"
      unitRef="usd">1467300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjQtMS0xLTEtMA_975a9599-ac0b-4ecb-b2e4-dd968ddc5799"
      unitRef="usd">819200000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjQtMy0xLTEtMA_0a72d3c2-7339-4bc7-90ae-c80a669bb5b6"
      unitRef="usd">2389300000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjUtMS0xLTEtMA_97078807-8793-47c8-a25f-c05d2d24878a"
      unitRef="usd">913300000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMjUtMy0xLTEtMA_10426c8c-bc07-464b-8aa5-dc5eb00c46ac"
      unitRef="usd">1684700000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzAtMS0xLTEtMA_ad8eeeb7-261b-4689-b3f8-98fa7447e080"
      unitRef="usd">28100000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzAtMy0xLTEtMA_af669ed5-e76a-4b6f-8df2-bfa385a066ec"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzEtMS0xLTEtMA_0be17996-66b5-480f-9bbb-eb14272bea37"
      unitRef="usd">92600000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzEtMy0xLTEtMA_79f8897a-5f25-4029-b26d-b7299701cd48"
      unitRef="usd">149700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzItMS0xLTEtMA_c8fe2883-6a66-4644-8046-ff9d8ce380af"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzItMy0xLTEtMA_b7728e09-bd90-4600-80c8-b4e495bce2b3"
      unitRef="usd">75000000.0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzMtMS0xLTEtMA_cf0ff97f-5b6a-4ba5-ae8a-e136b5d049c4"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzMtMy0xLTEtMA_2259388d-4e9c-4eaa-8488-2f6b0b469755"
      unitRef="usd">37000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzYtMS0xLTEtMA_d26613af-6af9-4d60-ac35-f48fe42af1be"
      unitRef="usd">91200000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzYtMy0xLTEtMA_cba7778d-2295-44b4-9fd7-4642d6e5f8a1"
      unitRef="usd">500000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzctMS0xLTEtMA_c1a5b70a-bd64-4d04-aa3e-548024582a87"
      unitRef="usd">-2700000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzctMy0xLTEtMA_bca9b09b-92b4-4d98-be81-ffca3f5a1d3e"
      unitRef="usd">500000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzgtMS0xLTEtMA_195c4ce0-4f0a-4013-b7d2-af3ddb19e7b9"
      unitRef="usd">-64700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzgtMy0xLTEtMA_fb6cccd6-40c6-487c-9d2d-d04bc6a2775e"
      unitRef="usd">442900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDAtMS0xLTEtMA_434a3c81-9808-4b59-a4d9-cb90b62419c1"
      unitRef="usd">600000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDAtMy0xLTEtMA_634903b8-3139-4f5d-8b3b-cc615434c0ff"
      unitRef="usd">2220200000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDEtMS0xLTEtMA_0948c23f-1854-4ed1-bede-fb57f0fb70c2"
      unitRef="usd">27100000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDEtMy0xLTEtMA_019f4764-49cc-4472-81d8-12b51fb7ad25"
      unitRef="usd">29600000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfDebt
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzktMS0xLTEtMzUyOA_ccf5aed0-c009-49ea-94ca-d3e358c3900a"
      unitRef="usd">169300000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfMzktMy0xLTEtMzUyOA_b7b0377f-fe49-4f9e-8270-6dbdc46d7fce"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDYtMS0xLTEtMA_2f24dd2a-0fa9-4b8b-ac55-fbb4880d1704"
      unitRef="usd">11400000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDYtMy0xLTEtMA_f56c7cc3-86d5-4453-b14a-4b50b09d4dea"
      unitRef="usd">4500000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDctMS0xLTEtMA_57046886-f009-4f47-b1c4-71c09e7c2525"
      unitRef="usd">-785000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDctMy0xLTEtMA_5a05c79b-c061-4167-9024-660415396630"
      unitRef="usd">-2245300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDgtMS0xLTEtMA_4a5dbe15-7458-4b53-94c9-f2664b22d17d"
      unitRef="usd">-80700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDgtMy0xLTEtMA_b5610b29-4957-410f-9ac1-da10cba6d6f8"
      unitRef="usd">-335100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDktMS0xLTEtMA_d80ec047-a01e-4a18-8a15-f1f7aafbc152"
      unitRef="usd">-33000000.0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNDktMy0xLTEtMA_6c50a889-7c8b-4883-aa30-d6f11bdfa241"
      unitRef="usd">12700000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNTAtMS0xLTEtMA_ee4358b4-0d4b-4c30-a361-8d1080367ee4"
      unitRef="usd">1331200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0294157534ec4829a838f8161a2c6f76_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNTAtMy0xLTEtMA_c1c54178-f031-4d02-8275-fe7bafc71289"
      unitRef="usd">2913700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNTEtMS0xLTEtMA_6c88fef9-b6c1-4f1d-a8f2-02a627fda33f"
      unitRef="usd">1217500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i179564f7a5394a3f985b2394c890de98_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zMS9mcmFnOmRlMjZmYWVjYWU4MTQzNGE4YmNjMDE0MWViOTUzZDE1L3RhYmxlOmQxYjRmZjY4MTM0YTQxODZhNWVlYzJhNDdhODljNDgzL3RhYmxlcmFuZ2U6ZDFiNGZmNjgxMzRhNDE4NmE1ZWVjMmE0N2E4OWM0ODNfNTEtMy0xLTEtMA_7bc495b5-ed72-4112-988a-2e45da705abb"
      unitRef="usd">2591300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9bcd6f60e86446259cb8c43a0e3ff280_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0xLTEtMS0w_90df8b31-725e-4765-b904-870717c3b48b"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9bcd6f60e86446259cb8c43a0e3ff280_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0zLTEtMS0w_751a33f0-a934-4925-b5a0-54570ebdec85"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0c42b2175447497d8b49e20666071bb3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi01LTEtMS0w_e6c931a3-c737-47c3-8f1a-e25a077f063c"
      unitRef="shares">176200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0c42b2175447497d8b49e20666071bb3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi03LTEtMS0w_fa2b810c-ab3d-4e01-9e6c-c9e9b4ee4a9a"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie120e7590f014512a9ef0196920b2c3a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi05LTEtMS0w_ee7f3d81-0c43-44a4-b212-a3d85063ea34"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d06f4201d6a4f44b0a65c949966d4e3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0xMS0xLTEtMA_743709bf-af24-48af-bb37-d37bdad037e1"
      unitRef="usd">-299000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9252b21ce96b49a69be79d8b5818a4ce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0xMy0xLTEtMA_847e13af-83a3-4c6c-8449-bfa9f6f3fde3"
      unitRef="usd">13976300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idc014f149d4e4da3b04fb867fc354a98_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0xNS0xLTEtMA_5a6d1e65-21b5-4c44-9477-0cff5d6cc73f"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc014f149d4e4da3b04fb867fc354a98_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0xNy0xLTEtMA_dae042a0-808d-4eb6-b03a-12002ac0f5b5"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id15755e5a765478580cfde8eca39da00_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0xOS0xLTEtMA_f76f31bf-fa9f-4bd4-9348-ce24efa72abf"
      unitRef="usd">10700300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21790366b5d34ac8a31ee2475fb7022d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0yMS0xLTEtMA_b9e6edeb-d2bd-4ee1-a447-045f1792e470"
      unitRef="usd">-14200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMi0yMy0xLTEtMA_a1d2af6c-d696-4e9a-86ac-216ab3f2ed51"
      unitRef="usd">10686100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="icb70c7eb20e44693a04fd0260417f330_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMy0xMy0xLTEtMA_cd148870-1fb6-4c33-8743-595c778084d7"
      unitRef="usd">410200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMy0xOS0xLTEtMA_d8e4c283-d4c9-4bee-b7f9-db6af80b5a15"
      unitRef="usd">410200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie108b38fb78a4b4da6071b1fe46e0f25_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMy0yMS0xLTEtMA_1a4f5342-471c-4e80-8dbd-d492e3c30059"
      unitRef="usd">-5600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMy0yMy0xLTEtMA_61093f4f-8824-44eb-9ba8-12ad0ae84767"
      unitRef="usd">404600000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic45e43914f444bff8f68d0156608b715_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfNC0xMS0xLTEtMA_55e82763-560c-474c-916a-b99813fc0eb0"
      unitRef="usd">124700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfNC0xOS0xLTEtMA_ec761614-ec24-482f-9095-b15662044c26"
      unitRef="usd">124700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie108b38fb78a4b4da6071b1fe46e0f25_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfNC0yMS0xLTEtMA_ce87cb37-a886-473d-aed0-d9e25eca4089"
      unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfNC0yMy0xLTEtMA_82a05e2d-37e0-4fac-bca8-5126a858b739"
      unitRef="usd">125400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfNS0xOS0xLTEtMA_8b40b753-5bab-4fb1-a15a-60681b98ce17"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="ie108b38fb78a4b4da6071b1fe46e0f25_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfNS0yMS0xLTEtMA_e6e73569-15fc-48fc-af88-cd288b9fbac5"
      unitRef="usd">100000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfNS0yMy0xLTEtMA_4c99371e-2796-46b6-8855-6fea83168369"
      unitRef="usd">100000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ie2bb63a28893418589d2a0d1b7f927b3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOC01LTEtMS0w_e4a253b8-5783-48b9-8ef2-9af22cca5763"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i9a7e0d0eeaae4c5fbfb21c1d2f81bbb4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOC0xNS0xLTEtMA_7501eaf9-772c-455b-bdef-415c8a052eb0"
      unitRef="shares">2200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9a7e0d0eeaae4c5fbfb21c1d2f81bbb4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOC0xNy0xLTEtMA_ed7c5b39-5f38-4511-8776-1eb38ceffe7c"
      unitRef="usd">600000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7af889133b864bf1a8251cd94b577064_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOC0xOS0xLTEtMA_36cd8b84-c6d8-4e7b-bf66-c2c16d7dd010"
      unitRef="usd">600000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2b08cd90671441109d1d585c71239784_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOC0yMy0xLTEtMA_5a58a075-9767-40f3-82f8-13930db3e353"
      unitRef="usd">600000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i2518d36e7af44bec9c3acb750c2ab582_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS01LTEtMS0w_e6c7400d-df76-4365-b7db-0173d3f41c90"
      unitRef="shares">2200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i2518d36e7af44bec9c3acb750c2ab582_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS03LTEtMS0w_f3338caf-859f-415f-9112-5746a3b279bf"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i9db0313c47544e3fb07cfe61f64dae32_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS05LTEtMS0w_8041e4af-322e-42fa-9c80-996043961f38"
      unitRef="usd">93800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ide40cd25587c44479c7cca25c2ab1a1e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS0xMy0xLTEtMA_93ac057c-4595-482d-8ec7-69210f99771b"
      unitRef="usd">506200000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i9a7e0d0eeaae4c5fbfb21c1d2f81bbb4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS0xNS0xLTEtMA_5c3bc415-ba71-41e5-97ea-9bdabd6c0f50"
      unitRef="shares">2200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i9a7e0d0eeaae4c5fbfb21c1d2f81bbb4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS0xNy0xLTEtMA_dadaa402-6e83-466b-8dfd-a3b94ab5a60f"
      unitRef="usd">-600000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i7af889133b864bf1a8251cd94b577064_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS0xOS0xLTEtMA_966fd80b-6251-490a-a15b-6b6c1f858e53"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i2b08cd90671441109d1d585c71239784_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfOS0yMy0xLTEtMA_d696c1bd-65a0-4736-8715-cb738aaf8788"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="ie2bb63a28893418589d2a0d1b7f927b3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTAtNS0xLTEtMA_76395398-03a7-40c6-903c-4f142b239494"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ie2bb63a28893418589d2a0d1b7f927b3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTAtNy0xLTEtMA_78f50098-49a8-44e3-bd6c-94a8937c2a8d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i5b5f6b8e642b4f3a90e77ef64fc86959_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTAtOS0xLTEtMA_3b13b831-c3b2-4ccb-9ef0-8b27beae04be"
      unitRef="usd">19700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTAtMTktMS0xLTA_213c07cd-6b21-474c-99f9-f35351db3530"
      unitRef="usd">19700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTAtMjMtMS0xLTA_0e28b2eb-2b82-46c3-ab2f-cd1ca87fe59d"
      unitRef="usd">19700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie2bb63a28893418589d2a0d1b7f927b3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTEtNS0xLTEtMA_17250228-c87e-412a-8bfc-d9e1db032353"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie2bb63a28893418589d2a0d1b7f927b3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTEtNy0xLTEtMA_c8fce833-a425-49ee-af24-11dde5199e84"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5b5f6b8e642b4f3a90e77ef64fc86959_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTEtOS0xLTEtMA_b94a8f7f-1a61-4100-83bc-d85efa28994d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icb70c7eb20e44693a04fd0260417f330_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTEtMTMtMS0xLTA_be4a0647-53af-4473-9530-c54176c14d7a"
      unitRef="usd">-46800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTEtMTktMS0xLTA_d64887dd-2b3a-4271-a589-d5276c7a3fe4"
      unitRef="usd">-46800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTEtMjMtMS0xLTA_aabaa801-17ab-4234-85aa-a96290d0b7a6"
      unitRef="usd">-46800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5b5f6b8e642b4f3a90e77ef64fc86959_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTItOS0xLTEtMA_9fd69184-c462-4b8a-847a-541f6d81d9fc"
      unitRef="usd">-72600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTItMTktMS0xLTA_6b77c831-4442-4c6d-a85b-ae4b218a5746"
      unitRef="usd">-72600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTItMjMtMS0xLTA_87535cfa-c8a7-4be7-847a-391d64967cb5"
      unitRef="usd">-72600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="i5b5f6b8e642b4f3a90e77ef64fc86959_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTMtOS0xLTEtMA_862360c8-f9ec-48f4-aadc-ba1c85b26550"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="icb70c7eb20e44693a04fd0260417f330_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTMtMTMtMS0xLTA_63376508-bbe7-453a-884b-05a406fbbba3"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i454569b60efb4f74b591bdb1d924fb59_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTMtMTktMS0xLTA_14cd7ef0-6499-4f59-8e07-5708d213490d"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTMtMjMtMS0xLTA_fa2c19d7-820a-4f3f-99ed-a89ade1c4f8c"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icc7d49e416884359a033c98c994d3d6b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMS0xLTEtMA_38f6d8ac-b8cd-41a9-915a-bac97b79e220"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc7d49e416884359a033c98c994d3d6b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMy0xLTEtMA_c32189b2-76fd-40c1-b880-deb4f3a8a3f7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i35398fa4187c4561961299a90d05fde1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtNS0xLTEtMA_c5832f16-b663-4670-adfb-944aa6b4af09"
      unitRef="shares">174400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i35398fa4187c4561961299a90d05fde1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtNy0xLTEtMA_9159e936-984e-43f2-be42-d9f300c658f0"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1883df2e84b34bfca009f1a107f517a7_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtOS0xLTEtMA_814b850c-f609-42cd-8f6c-bde6f1db9e22"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i989a9664b51f425385c353e18a6b1db2_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMTEtMS0xLTA_7f5d468a-f469-4c33-9e78-86411e97e8f6"
      unitRef="usd">-174300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57282d9aaf344b8abc4365220d50d8e6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMTMtMS0xLTA_f3bacd28-4751-49c5-b21d-f387c9ede813"
      unitRef="usd">13833500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iddda61c522014ea6bd671c91e77efd7e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMTUtMS0xLTA_35578458-9c4e-40a3-8887-96d534a0e26a"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iddda61c522014ea6bd671c91e77efd7e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMTctMS0xLTA_763ead26-e961-48fc-a4b3-7181b0dcc12a"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id84b8595cae94c46aea8144165c16cda_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMTktMS0xLTA_4b0599c0-27c0-4ae5-b45c-fd01858a0e85"
      unitRef="usd">10682200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id368506338ba40cd8adbea5e573a2f3c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMjEtMS0xLTA_eb5c175b-f852-46ab-a076-6144374962bf"
      unitRef="usd">-19000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmYyODg0Y2Y5MTFmNjRjOTNhMmYxMDc5Njc5NzUyNjBmL3RhYmxlcmFuZ2U6ZjI4ODRjZjkxMWY2NGM5M2EyZjEwNzk2Nzk3NTI2MGZfMTQtMjMtMS0xLTA_ba3aadaf-e37c-4c7e-8b05-4e6b54dfbe84"
      unitRef="usd">10663200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5a8b05db811a4f6ca919149ab120e3a6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0xLTEtMS0w_25e6190a-7ad3-41e4-8a8c-89b76a4de791"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a8b05db811a4f6ca919149ab120e3a6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0zLTEtMS0w_45527f9d-d394-45b0-898c-a359b5d0912b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4c2ba83c536b409e96a426d0bba7cc72_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi01LTEtMS0w_d61b5f1e-4162-4721-a73a-61d20fd0b4d9"
      unitRef="shares">198000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c2ba83c536b409e96a426d0bba7cc72_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi03LTEtMS0w_8233cd5c-2b34-4cb8-a3d1-6c4d2b9c7d6c"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba06f05e2faf4c708920aa5dcbd7ed0b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi05LTEtMS0w_43a541c2-5237-41c0-82ef-1f88b5c4ecf3"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieca63027783a4ffc875d6d9098166871_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0xMS0xLTEtMA_e0fcb94b-d892-4d34-badd-9bd59fbe3f2a"
      unitRef="usd">-135200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7c713484677b4927ab70281250be20cf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0xMy0xLTEtMA_94d4bb39-79d4-4ca5-a627-5db07679a31f"
      unitRef="usd">16455400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib3b1784bb7804f8f9620259ab8942db6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0xNS0xLTEtMA_4335a6d6-fcb7-4b0e-aa47-831adf56928e"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib3b1784bb7804f8f9620259ab8942db6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0xNy0xLTEtMA_6103635e-6184-4210-b026-808da6bcf55a"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i605d5a6bd4e44da0afb2826209cab9c7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0xOS0xLTEtMA_fe37fac3-d71a-4aa1-97fc-0db8b76d21e7"
      unitRef="usd">13343200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6c932859892f490180aa279af5a06b03_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0yMS0xLTEtMA_63288211-d41c-48ab-b596-336990eae7ea"
      unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0294157534ec4829a838f8161a2c6f76_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMi0yMy0xLTEtMA_88814632-da51-4e3d-ac1f-c691c497564a"
      unitRef="usd">13339100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i7435b888c753443186dba3ab3fe1fcba_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMy0xMy0xLTEtMA_a0511ef8-7872-47e5-9f63-e0d2c6e44bd1"
      unitRef="usd">1399100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i53a16d72df8e41e7aefc354fdce5be4a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMy0xOS0xLTEtMA_72cc927f-fa39-48c2-9ea1-3deae823c3c6"
      unitRef="usd">1399100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8ea2f0d23ff44653bc3b6b5156c34bf1_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMy0yMS0xLTEtMA_a709379f-9dc5-40d6-b1aa-bb4f3261806a"
      unitRef="usd">-6500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMy0yMy0xLTEtMA_d0c6732f-16c9-4f95-99d2-03da95ca9e1a"
      unitRef="usd">1392600000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i04d5d70d39294b36b58ac20c0780157b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNC0xMS0xLTEtMA_a395e0b3-e9a3-4856-aed5-f4f20c958b7a"
      unitRef="usd">-14100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i53a16d72df8e41e7aefc354fdce5be4a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNC0xOS0xLTEtMA_9e756b72-17df-47ff-87bf-32357ebec1a0"
      unitRef="usd">-14100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8ea2f0d23ff44653bc3b6b5156c34bf1_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNC0yMS0xLTEtMA_cbf853ce-1d87-487a-9458-4cdb7dfd77d7"
      unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNC0yMy0xLTEtMA_cefb2e92-5b36-4d39-9948-72c67a7f8ec4"
      unitRef="usd">-13500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="id6578a3afa6b483fafcf2459661d9944_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNi0xNS0xLTEtMA_b647979e-7777-4280-bfe2-ea95bff1df32"
      unitRef="shares">4100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id6578a3afa6b483fafcf2459661d9944_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNi0xNy0xLTEtMA_1c15e508-9677-43e2-8d82-3ed867008132"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic3952e97a9994176bda1554c91960383_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNi0xOS0xLTEtMA_0e0d10dc-dc54-4a86-b7ab-99b0cc32cd75"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i25ca0d3089b9406197bdca98e4d63b1b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNi0yMy0xLTEtMA_d05260de-1f3e-4953-ad3d-7a6491cb10f8"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i075e0c23d6b34d67b56b7fc63b0c8f6e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNy01LTEtMS0w_17f74a07-2eeb-44dd-a45a-9fcc861a261d"
      unitRef="shares">4100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i6f5558f45caa429b943890bb21370bb4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNy05LTEtMS0w_7f7785d9-c27e-470c-b201-6745ca8a8d7d"
      unitRef="usd">71000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i406d62794dcb4950a1781265fcdca4d2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNy0xMy0xLTEtMA_3740c5b9-3b17-4f43-b6f7-4ad681bca5d1"
      unitRef="usd">1208100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="id6578a3afa6b483fafcf2459661d9944_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNy0xNS0xLTEtMA_934bb26b-89a4-4e22-9fdf-81146b0eec36"
      unitRef="shares">4100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="id6578a3afa6b483fafcf2459661d9944_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfNy0xNy0xLTEtMA_9dda9106-a9fa-4a6f-b7dc-e29994b31430"
      unitRef="usd">-1279100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ie6b1bf8966fe4b6f8d97788a368f7f09_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOC0xNS0xLTEtMA_8369213d-fef8-4621-af66-fbe908eb1caf"
      unitRef="shares">3200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie6b1bf8966fe4b6f8d97788a368f7f09_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOC0xNy0xLTEtMA_2159af17-0c0b-4871-a304-245758e18889"
      unitRef="usd">941100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia559d28a9b914b37b44c9d7c95222096_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOC0xOS0xLTEtMA_9d1001d5-3e32-4569-a052-92204ee8e576"
      unitRef="usd">941100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="icf91e91201b044939704b3ea806b2ead_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOC0yMy0xLTEtMA_85b292f5-1e1c-4b9e-8eb8-ad14e4f1e498"
      unitRef="usd">941100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ieee5bd4f86704007b1420b9b498ddbc6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS01LTEtMS0w_9d7263ce-d7eb-44a2-9029-fe2d23c5e89a"
      unitRef="shares">3200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ieee5bd4f86704007b1420b9b498ddbc6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS03LTEtMS0w_a88bfcc0-1602-481c-8118-2dcc72399f4f"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i51813489fb6b4bbeac18a5336356a074_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS05LTEtMS0w_2a152d73-4bc7-4f5d-b946-3083cb08d6ce"
      unitRef="usd">15600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i89f2f3090dc54fea8e95c8bcfdc8bf2b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS0xMy0xLTEtMA_85d28f9e-cb6d-4a25-abb0-2a1112526f2c"
      unitRef="usd">925500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ie6b1bf8966fe4b6f8d97788a368f7f09_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS0xNS0xLTEtMA_7bdb8882-8f0f-4135-9511-50c97050b344"
      unitRef="shares">3200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ie6b1bf8966fe4b6f8d97788a368f7f09_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS0xNy0xLTEtMA_e1511bdc-44a7-438a-a98e-6930e50de1db"
      unitRef="usd">-941100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ia559d28a9b914b37b44c9d7c95222096_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS0xOS0xLTEtMA_a7da4826-f4fe-4946-ac72-41895ffddb64"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="icf91e91201b044939704b3ea806b2ead_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfOS0yMy0xLTEtMA_ee0a92ee-8630-4508-b464-fac65c11d04f"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="ib357d23217b547d997470e7d0012d37e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTAtNS0xLTEtMA_1cef59db-8b83-4bed-971b-d9da95759613"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ib357d23217b547d997470e7d0012d37e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTAtNy0xLTEtMA_6cc545ca-21d4-4cfc-ade7-6806c7959beb"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i00af2e110361494a882a140f60e249ae_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTAtOS0xLTEtMA_4f37e378-d827-4333-84b5-1d54cbd3bd06"
      unitRef="usd">18100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i53a16d72df8e41e7aefc354fdce5be4a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTAtMTktMS0xLTA_7a4ad6d7-4a52-4939-af3a-34b16772c166"
      unitRef="usd">18100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTAtMjMtMS0xLTA_5e628569-8d33-4f54-90f3-1c10c594e321"
      unitRef="usd">18100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib357d23217b547d997470e7d0012d37e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTEtNS0xLTEtMA_46c51c20-b310-45e2-ac51-b1ae7749ffd1"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib357d23217b547d997470e7d0012d37e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTEtNy0xLTEtMA_ffc8dee0-778e-4089-b001-438746963a65"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i00af2e110361494a882a140f60e249ae_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTEtOS0xLTEtMA_a5c5e903-bf7d-49cb-89fa-3757d62d9a5f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7435b888c753443186dba3ab3fe1fcba_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTEtMTMtMS0xLTA_97e3df4b-499b-4be1-ae3f-5ef3f88ea708"
      unitRef="usd">-47800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i53a16d72df8e41e7aefc354fdce5be4a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTEtMTktMS0xLTA_feb67956-afd1-4eb6-b024-7bd27cc5e913"
      unitRef="usd">-47800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTEtMjMtMS0xLTA_71280368-bc74-4a6d-b421-e2d80fcb62f5"
      unitRef="usd">-47800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i00af2e110361494a882a140f60e249ae_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTItOS0xLTEtMA_2de2c463-c4e3-49ae-a1ed-ecd8e51ae77e"
      unitRef="usd">-69200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7435b888c753443186dba3ab3fe1fcba_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTItMTMtMS0xLTA_26be4adc-d0ee-4ea5-abcc-79bb4af758ba"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i53a16d72df8e41e7aefc354fdce5be4a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTItMTktMS0xLTA_db43fa8e-04df-4375-b770-68d0a5f79df6"
      unitRef="usd">-69200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTItMjMtMS0xLTA_498d09d6-ad7b-4e0f-b9f1-45a5c0788c9a"
      unitRef="usd">-69200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="i00af2e110361494a882a140f60e249ae_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtOS0xLTEtMjIzNQ_0d86bafb-7116-4710-9256-ac227214ff12"
      unitRef="usd">600000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i53a16d72df8e41e7aefc354fdce5be4a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMTktMS0xLTIyMzU_3390df16-5238-48ec-a219-32882f47f70a"
      unitRef="usd">600000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMjMtMS0xLTIyMzU_579373d9-6693-411d-a8da-652fe8e82eb0"
      unitRef="usd">600000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6f1fb990e4ee44be863aa4437fa57293_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMS0xLTEtMA_ad4bfb47-1507-4168-b6d1-f42d508e9c05"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f1fb990e4ee44be863aa4437fa57293_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMy0xLTEtMA_fa025d63-8fa6-45b7-ac8b-eaf8df2cdba9"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if823fb42eb284177aa1ddbf216b2c1be_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtNS0xLTEtMA_01f38f4b-c717-468b-a2e3-cae99cbb2218"
      unitRef="shares">191100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if823fb42eb284177aa1ddbf216b2c1be_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtNy0xLTEtMA_2399e704-024d-40c7-9f2c-e993c33ef190"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i512bb80727434c12bca0775dbd5e2137_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtOS0xLTEtMA_e26e0ca8-46da-4139-92e9-72b994e22b53"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6ae486e871284c88a17b126221465865_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMTEtMS0xLTA_d99e2628-fccd-4d27-a6a0-da82ba636662"
      unitRef="usd">-149300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i670f018181f04ca3a3f0bd64e5623f2f_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMTMtMS0xLTA_6973eff6-4593-4836-8777-0cde41215d49"
      unitRef="usd">15673100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0ec1a33127cb42fb9fe3fdce711fae15_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMTUtMS0xLTA_e29bd3f7-d91f-4bd2-99f1-cac033455a04"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ec1a33127cb42fb9fe3fdce711fae15_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMTctMS0xLTA_9c5f4fdc-cdea-4fd6-9a8b-3872299a0b86"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ee3ab86dd9a44bba034cdb3caf707fc_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMTktMS0xLTA_ac7a3a47-40db-4445-a936-bef6ede1d7e6"
      unitRef="usd">12546900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff1e167122b54794a75d887f91010ca6_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMjEtMS0xLTA_e0f1b6fe-0059-48be-a6d6-ba42d8587130"
      unitRef="usd">-10000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i179564f7a5394a3f985b2394c890de98_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8zNC9mcmFnOmVmNGRiOTAwNTJkMjRkNjE4ZGUzMDZkY2RjNmQzODExL3RhYmxlOmIwNmRiZjMxNzlkMDQ3ODM4ZjU2NDJhYmJiNDg3MzIwL3RhYmxlcmFuZ2U6YjA2ZGJmMzE3OWQwNDc4MzhmNTY0MmFiYmI0ODczMjBfMTMtMjMtMS0xLTA_ab8ea9bc-e321-4937-8c22-00bf07d0d4b2"
      unitRef="usd">12536900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfMTIwNzQ_0e71fde6-8c0b-4bd6-87dd-b4ac95f5e3e1">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#x2019;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have an option to acquire exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2020 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2020 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three months ended March 31, 2021, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our condensed consolidated financial statements and there may be changes to those estimates in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:9pt"&gt;&lt;span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 the FASB issued Accounting Standards Update No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfMTIwNzc_8a712068-bb53-4384-a0f5-ff9581684223">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#x2019;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have an option to acquire exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</biib:BusinessOverviewPolicyTextBlock>
    <biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfMjc5OA_eeb247b6-c348-43ff-a332-23cd28ebc66c"
      unitRef="product">2</biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfMTIwNTM_7a534d2b-58ae-4eec-a9ae-f705060c3b9e">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2020 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2020 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three months ended March 31, 2021, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfNDI5Ng_7fd9c4fa-8125-48b6-9f17-86340a8bd7a1"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfMTIwOTA_bbca82ec-3d96-4593-a6c7-c79d8887c223">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfNDgwNg_366ccf87-ebbf-45a4-af5b-4315a0daa6e1"
      unitRef="number">1.000</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfMTIwNDY_a571e67a-4260-4ad7-ae01-35a3cdd212d2">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80MC9mcmFnOjRhNTVjY2E0N2RlMzQyYzk5NzhhYjJlNzBmMjUzMmUyL3RleHRyZWdpb246NGE1NWNjYTQ3ZGUzNDJjOTk3OGFiMmU3MGYyNTMyZTJfMTIwNjA_2f441d5f-d6d6-47f6-815c-bd7c8b9e0f14">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:9pt"&gt;&lt;span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 the FASB issued Accounting Standards Update No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80My9mcmFnOjFkZTQxYTllNDQxYjQyODQ5Yjg3YjVjZTYzNzU2MjM0L3RleHRyZWdpb246MWRlNDFhOWU0NDFiNDI4NDliODdiNWNlNjM3NTYyMzRfMjk3Nw_057a574d-23aa-467d-9701-de4f682f13b9">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BIIB118 Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020 we acquired BIIB118 (CK1 inhibitor) for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We are developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder in Parkinson's disease and plan to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease.&lt;/span&gt;&lt;/div&gt;In connection with this acquisition, we made an upfront payment of $75.0 million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;amp;D) in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to $635.0 million in potential additional development and commercialization milestone payments as well as tiered royalties in the high single digits to sub-teens.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="id08a82497aa04887a9c810084e90cb86_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80My9mcmFnOjFkZTQxYTllNDQxYjQyODQ5Yjg3YjVjZTYzNzU2MjM0L3RleHRyZWdpb246MWRlNDFhOWU0NDFiNDI4NDliODdiNWNlNjM3NTYyMzRfNTY1_33598816-72f4-4528-8a5c-825a9cec3395"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="id08a82497aa04887a9c810084e90cb86_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV80My9mcmFnOjFkZTQxYTllNDQxYjQyODQ5Yjg3YjVjZTYzNzU2MjM0L3RleHRyZWdpb246MWRlNDFhOWU0NDFiNDI4NDliODdiNWNlNjM3NTYyMzRfODM0_a7728379-4799-4a5d-94e6-4df918fbc460"
      unitRef="usd">635000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfMjgwMg_9e231c79-e3d6-4070-ae58-24a20c8070e2">&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;316.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;777.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;323.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;503.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;751.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,483.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,347.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;769.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;371.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;520.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;329.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;565.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilar product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;899.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,311.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,211.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,583.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,321.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,904.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 30.0% and 9.3% of gross product revenue for the three months ended March 31, 2021, and 30.0% and 14.6% for the three months ended March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,093.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;775.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;964.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(111.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(284.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(396.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(562.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(647.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;988.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,166.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;993.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,166.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:13.5pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;341.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;520.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:2.25pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from collaborative and other relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty and corporate revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfMjc4Mw_1615f6ca-10f5-4f85-a306-0a5c55c2dc33">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;316.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;777.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;323.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;503.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;751.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,483.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,347.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;769.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;371.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;520.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;329.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;565.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilar product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;899.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,311.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,211.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,583.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,321.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,904.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i448c0442bf0a4adfa28c5d18001b08f1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNC0yLTEtMS0w_97b6eb15-f825-4155-876a-2fe68af3e36d"
      unitRef="usd">236000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1193489ec1264f35a2ac5971bf81f6f7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNC00LTEtMS0w_4134892b-ff53-4de9-a377-aa3b6f1fdda5"
      unitRef="usd">316900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia487fdfe567b401b86ede458e9ba75e7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNC02LTEtMS0w_668cb67d-b4ed-4ba2-ad3e-f704b9aa9e47"
      unitRef="usd">552900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3d2c097d12347678a78a057aaf039aa_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNC04LTEtMS0w_60ae1302-2ef6-4aa9-8ffb-ccc0d9a1e288"
      unitRef="usd">777500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d2fc407d1ec4ed380b5e106ffb0c831_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNC0xMC0xLTEtMA_97981462-73d9-4482-b723-d65744271b93"
      unitRef="usd">323300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i940d0ffed9724139916f62bf6dad8a7b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNC0xMi0xLTEtMA_a8f6af48-15ea-4528-be7a-1c7bccb4e79e"
      unitRef="usd">1100800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf4bd59b7c3249f0bc24ef3c1c48d31c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNS0yLTEtMS0w_f9784bc3-1b30-4646-a112-e9835d40ab0c"
      unitRef="usd">241800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8f8e721203449fc86db69bab7e7cd9e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNS00LTEtMS0w_aa96cd79-930d-46c7-8371-d209e02912df"
      unitRef="usd">158700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idcf12665755e4093a4220cda52ac3eb9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNS02LTEtMS0w_46da3dff-e778-4ba0-a4a6-37920e8bc4e8"
      unitRef="usd">400500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id77770628748461faf30529d99622607_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNS04LTEtMS0w_808d27b8-6f49-4f93-9fc7-310d8938d2bc"
      unitRef="usd">292600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1646afc7440542fcb255ec823d3c9c2c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNS0xMC0xLTEtMA_8dfaa990-f2f8-4197-bd79-7448cad7d94a"
      unitRef="usd">173400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e14d4e11831452ba137891a9396c862_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNS0xMi0xLTEtMA_23e64f28-4e9d-4fe4-8a7b-7ca353c9c872"
      unitRef="usd">466000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i184b1c6940b2461e8557af90326d21e4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNi0yLTEtMS0w_1d5c3930-ae99-4d7b-afe3-4fb7c352891b"
      unitRef="usd">273300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8caf7eb3d8046008f3982503a64cade_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNi00LTEtMS0w_86938313-7dfa-4ec4-b235-fea9d680ef5f"
      unitRef="usd">230000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08d0fb5bb1cb45d99a7b3491c2593e22_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNi02LTEtMS0w_0f2793a8-286b-4d7c-be3e-c8c3c75d3377"
      unitRef="usd">503300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4341139d31d645e89e76c26bfb4231ca_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNi04LTEtMS0w_d19a022e-868e-4b9a-9a91-dcf4f52953f1"
      unitRef="usd">277700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2cb99b30cbf54b00852f7084359ac9d6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNi0xMC0xLTEtMA_0f59ba91-c894-4c97-aed4-847dc7d38b50"
      unitRef="usd">244700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b70a2acef674d0985ecb568772c3258_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNi0xMi0xLTEtMA_fb703357-ac04-4ab8-b6e0-b09e32d3acd9"
      unitRef="usd">522400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i505c2e793fca48ae9a343f83d10b25a2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNy0yLTEtMS0w_fe4230e5-9949-4296-8e2d-9a8704a491c5"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iff026a1b98554dfbbc131b0472cb5b7b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNy00LTEtMS0w_b413e08a-6cbd-4f02-9c17-a95260837a57"
      unitRef="usd">26600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i734c667a854e4365bfb4b48aef78b038_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNy02LTEtMS0w_189c0020-7848-499c-a0f5-95d4a9bb1987"
      unitRef="usd">26600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0962648e31c1402ab3c19a4f421155fe_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNy04LTEtMS0w_fc5321dc-36e3-4283-9773-1a01cb483da2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia83423de217c44a9be015f40ff27c33d_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNy0xMC0xLTEtMA_f63dd5fe-9649-4bcc-ab3f-7dee6819b586"
      unitRef="usd">28300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec00ec53a19f4ea9a63dace92b6da302_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfNy0xMi0xLTEtMA_8ed4abc2-24dd-4cac-aac8-9807ec9c7daa"
      unitRef="usd">28300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f2ba3fb90464ab29d64a5353775989d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfOC0yLTEtMS0w_597b1c51-8928-43a0-af57-c79fc2eaee4c"
      unitRef="usd">751100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6132d3c924c414e84a28b2389d20a41_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfOC00LTEtMS0w_e19c3290-b5d8-4d10-98a9-baf743f346cd"
      unitRef="usd">732200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf832a6fefc64c7582c337b5ffea1c29_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfOC02LTEtMS0w_d7db4661-ac43-4ab6-874d-a6f193481dc6"
      unitRef="usd">1483300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ad6065fa88e4b7abff61a49206a7d0b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfOC04LTEtMS0w_db13d3ca-42ef-43b6-8ad1-a2682eab91cd"
      unitRef="usd">1347800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14524fbcf9df4b2281933e4d60f10f02_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfOC0xMC0xLTEtMA_4df5640c-c2d9-47e7-9014-093b6e097dba"
      unitRef="usd">769700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1bf0c4a015a74ded850336575e8289b8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfOC0xMi0xLTEtMA_d744df79-9f2d-4199-868c-ad8a41b3b16d"
      unitRef="usd">2117500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i325454d8aeec4098bfa98cf14b372c51_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTEtMi0xLTEtMA_407e426d-0954-45c8-8ccf-3bd7ec00feb0"
      unitRef="usd">148700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife6066c0c6bb49d7b1ea35be7c87f0c8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTEtNC0xLTEtMA_18346303-7df6-4883-a45f-4a1b4568329a"
      unitRef="usd">371800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida5dda8845084cdda4c2aa27909ab988_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTEtNi0xLTEtMA_75f4b000-91f5-44db-8e95-a550e9f103d3"
      unitRef="usd">520500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d4f5eaef8fe43309f839c1c36e3c80d_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTEtOC0xLTEtMA_eadc536a-2adf-48a8-9370-71a0f44028d3"
      unitRef="usd">235400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i059f4365445242aeb92df9e0e10de132_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTEtMTAtMS0xLTA_322989d4-3fbc-4f87-9e63-3b8af882a8a6"
      unitRef="usd">329600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i061b1e268b544b26a76c0707fad02355_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTEtMTItMS0xLTA_ab5132a3-1bb7-4e2e-a9a5-7ad17e2e17a4"
      unitRef="usd">565000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d5370a9ea274139a341c5cfdd8d6d9b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTQtMi0xLTEtMA_b7e46fb0-0830-4bc0-824c-f7b952cd7966"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibc51673e08bc4f3b82f3b472a4a90973_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTQtNC0xLTEtMA_016c3d27-6545-44e0-8c6b-f50097111841"
      unitRef="usd">121700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i27035e9563074fbbaca4c77997b66921_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTQtNi0xLTEtMA_c71cc6be-f215-4b52-92a5-6bd1959be767"
      unitRef="usd">121700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78f64ee14005421481ed9d38025dbe95_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTQtOC0xLTEtMA_723992ba-7808-4a3d-a0a5-dd75b761f2a8"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i031fb4884755410b845a81795c4ec551_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTQtMTAtMS0xLTA_43bf84d9-01f3-4c98-8972-01469bdcff31"
      unitRef="usd">133500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib01eeb32d79b4571ad8f11070dc2da48_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTQtMTItMS0xLTA_fc5b3eb1-8720-48a4-b239-c2c77ea70add"
      unitRef="usd">133500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i202bf8566c7042b784c6445ebd363725_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTUtMi0xLTEtMA_b79754eb-2822-4973-80d6-def43cdb72cb"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib7824a2335ba4ddd968c947099502057_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTUtNC0xLTEtMA_30555b2e-ff0e-4a65-8dd9-aaa7f5643728"
      unitRef="usd">57900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c8b061168814140b09c590b540bb10e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTUtNi0xLTEtMA_300ba7eb-8bb0-4d97-8d9e-92de844dc1b8"
      unitRef="usd">57900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia908504887ca40f181856648cf0956ae_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTUtOC0xLTEtMA_80632177-cc49-4c87-9f68-eb9121a9df6e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i06fc398cd34146d982acc4911a986595_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTUtMTAtMS0xLTA_af23a72a-ab6e-4450-bc16-ac1d92149795"
      unitRef="usd">61600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7700739d178e441d91b2f50f6c7798c6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTUtMTItMS0xLTA_32344940-068b-4493-b4ce-c5c407273d49"
      unitRef="usd">61600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib1f9b4973848433abff09c45a64c9143_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTYtMi0xLTEtMA_a63f0eba-7c1c-4c16-bce5-b0def0158f05"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i75a352d78f7d43fa8a05b645e4f6e3c7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTYtNC0xLTEtMA_f17b92da-f818-4426-9020-a86d1c82e249"
      unitRef="usd">25500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i34be7a6433744d2f8766ca37a26efa37_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTYtNi0xLTEtMA_4171fe6b-686a-4e6b-b326-6b926dd96dcf"
      unitRef="usd">25500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i324196a294bc4b538065228274cc76fb_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTYtOC0xLTEtMA_e5c33ef8-eda6-4f61-8f2e-0e383d59bf99"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic67c201687dd40b69b77091684731883_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTYtMTAtMS0xLTA_4d22cdc2-7ede-4a60-85c9-b27668730e00"
      unitRef="usd">23700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i017ebf20529f44b5bff42d9e6dc8fb53_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTYtMTItMS0xLTA_8055d231-f1ae-4ed5-99a0-a49b3b9b18cb"
      unitRef="usd">23700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8fbe7359e294d698c58806b13fe20f3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTctMi0xLTEtMA_d5013b6f-c240-4394-99cb-5989dbdb5d96"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d43bda4427a42e18236a50750cfe714_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTctNC0xLTEtMA_50b58510-9d09-403f-a7eb-42e8e6ed7174"
      unitRef="usd">205100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i06a69682358b4f1a99c21d088b5c487b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTctNi0xLTEtMA_d84f8edf-2090-44e3-89e3-f65470b3fa09"
      unitRef="usd">205100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30b44b2a9e3643ec956383c1b647c5d8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTctOC0xLTEtMA_620be730-cf97-4fbc-8e99-1fb75b980446"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26bd19762f294c71b22709ebc3c0418f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTctMTAtMS0xLTA_41005d1e-9660-47ec-b266-c1c9a6d5f95e"
      unitRef="usd">218800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87f248578d7441ec88a211f0018d2a05_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMTctMTItMS0xLTA_6320cf98-e76a-4fbe-9d68-b4beff9fbab9"
      unitRef="usd">218800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1145a015534643fbbd914351f2d3303c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjAtMi0xLTEtMA_6ee29800-969a-4c17-b1bf-03107854ab33"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i601c9a44b1bd4cf6abb5e0a17029e845_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjAtNC0xLTEtMA_4beebb64-6a68-4156-a5a1-9c7f024b4828"
      unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i50e81697f8c14de383f2c496c7483109_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjAtNi0xLTEtMA_597d5f77-75e9-467c-9531-15acb338ce83"
      unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id2c9127e05b04ef281beba3d1321c62d_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjAtOC0xLTEtMA_b3a59466-2d32-4d74-a911-8421295e47d1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1003e56b7b748e9bf5a15cef4022aeb_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjAtMTAtMS0xLTA_8165b160-ab56-44d5-bf9b-a2c81cf6c7f4"
      unitRef="usd">3300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e358b0c99a14c348aafac03e2a37487_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjAtMTItMS0xLTA_66befe2f-2206-4922-b5dc-932de8828f2e"
      unitRef="usd">3300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3d8f1b9751745c9b3b1484d9d3b8c54_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjEtMi0xLTEtMA_0d207b92-32be-4241-b6e7-e2141bc135c5"
      unitRef="usd">899800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1586eb35090b4a5faabb9c8a8e822582_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjEtNC0xLTEtMA_ed1a0189-3b7f-41da-be7e-a9ffef23d640"
      unitRef="usd">1311900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iabf5fb72476641e09225cdff0259f43e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjEtNi0xLTEtMA_3cd7ae73-d603-4b44-9dd7-9637cf440747"
      unitRef="usd">2211700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i666d1e67c4384945af3d0da636c7d0f9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjEtOC0xLTEtMA_2f237765-1350-4490-b18d-5bfe72735706"
      unitRef="usd">1583200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b9ce56cc0624826bb2b6dd3b2be83c7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjEtMTAtMS0xLTA_26a167b7-f0ba-427f-b440-5cae0cc72e74"
      unitRef="usd">1321400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3b12581badd45819dafd1517b58aa13_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjA5M2JjYjhlMGYzZTRkMzg5NzI1ZmMyZjU0ZDFmYjc4L3RhYmxlcmFuZ2U6MDkzYmNiOGUwZjNlNGQzODk3MjVmYzJmNTRkMWZiNzhfMjEtMTItMS0xLTA_da47653e-255c-44ac-b5cd-06fdf4d25f26"
      unitRef="usd">2904600000</us-gaap:Revenues>
    <biib:NumberOfWholesalers
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfNDI1_491b5675-2779-4288-9364-015852ec6be8"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfNDI1_6e220bab-7f73-4754-97b9-f2803fa48c77"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="iea1a2bf4c66943a5b003368cf21dfc2d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfNDU1_e5ea611b-5df9-453e-8fc9-bcfe02510247"
      unitRef="number">0.300</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="if8384ea1bc75497bbace5e319dccb2bf_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfNDYy_a4840793-d993-4326-b20b-e9dabcc780eb"
      unitRef="number">0.093</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="iee8610004f734b68b4cba17dcff8b4e3_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfNjQ1_bbc504e9-c2cf-4ddc-83e9-8eeb7741657c"
      unitRef="number">0.300</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i47a0a8c9dbdf45d583161449e4534cc8_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfNjUy_fa6638b6-cf0b-4ef9-a54b-748a5f6a0665"
      unitRef="number">0.146</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfMjc3NQ_d785064c-c2e2-4c01-8bf4-19e75c4d4f23">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,093.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;775.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;964.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(111.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(284.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(396.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(562.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(647.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;988.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,166.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1013b869080645d59d75e657f4c58e4a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMS0yLTEtMS0w_ae7d2a7e-98eb-4745-97b5-1324d06ee05e"
      unitRef="usd">141400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i330c93cac85e420b898ca9c3a01dcf52_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMS00LTEtMS0w_ab5b14e2-30b9-49ce-a272-ad4a0981ff16"
      unitRef="usd">1093000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3bf47792d6ea4f0b86fdb02f0d4eb158_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMS02LTEtMS0w_a373b499-30f1-4305-aaff-14c426bb3c7f"
      unitRef="usd">41600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMS04LTEtMS0w_2388e37a-776c-476a-9aa6-4ffea8191740"
      unitRef="usd">1276000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="ifb86fe950bc5486cbb58985525874f0c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMi0yLTEtMS0w_d9964e38-ab6a-42aa-9821-1277368824e9"
      unitRef="usd">185100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="if7cdcbb6052942698e96461e2cd71321_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMi00LTEtMS0w_d6c60137-a72c-4421-afef-f2d5907b1893"
      unitRef="usd">775700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="ia9ec3f38a20a46ce85926bdad24da8d0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMi02LTEtMS0w_63e1e7ff-741e-45f7-b823-7179dc20ecc8"
      unitRef="usd">3800000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMi04LTEtMS0w_176dc93f-acba-4b7e-8b65-7e142b02e1ff"
      unitRef="usd">964600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="ifb86fe950bc5486cbb58985525874f0c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMy0yLTEtMS0w_68856e85-af0c-4187-ae6e-809ebd4fb086"
      unitRef="usd">-900000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="if7cdcbb6052942698e96461e2cd71321_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMy00LTEtMS0w_22423a9b-4c25-434f-8118-179922466766"
      unitRef="usd">32100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="ia9ec3f38a20a46ce85926bdad24da8d0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMy02LTEtMS0w_2795fa9c-5040-4120-af67-21a9f24b09ac"
      unitRef="usd">-1000000.0</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfMy04LTEtMS0w_479aea44-c1c4-4b08-8ead-1a741a34f175"
      unitRef="usd">30200000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="ifb86fe950bc5486cbb58985525874f0c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNC0yLTEtMS0w_99d72531-0d92-4bd9-bf5e-acdd657b3010"
      unitRef="usd">111800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="if7cdcbb6052942698e96461e2cd71321_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNC00LTEtMS0w_ce82dd91-1907-4f24-9047-002fdd07a225"
      unitRef="usd">284800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="ia9ec3f38a20a46ce85926bdad24da8d0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNC02LTEtMS0w_80719e94-61d4-4f47-8473-31b07b334dae"
      unitRef="usd">0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNC04LTEtMS0w_6d84aae5-3da0-4f0b-b91b-105bdef4121c"
      unitRef="usd">396600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="ifb86fe950bc5486cbb58985525874f0c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNS0yLTEtMS0w_8e37fa47-71c6-4ad6-b11d-72619cdf888e"
      unitRef="usd">82800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="if7cdcbb6052942698e96461e2cd71321_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNS00LTEtMS0w_dc3d664a-ab20-4b7d-96fd-e1659fc5a8e8"
      unitRef="usd">562900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="ia9ec3f38a20a46ce85926bdad24da8d0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNS02LTEtMS0w_568e9822-d6cf-49c5-b27d-7940c607ab82"
      unitRef="usd">1700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNS04LTEtMS0w_369a466c-d6cd-4de1-bb21-173a7e78c2c2"
      unitRef="usd">647400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i01e3449ffe264832baf2481923cbabff_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNi0yLTEtMS0w_30ee9d9a-e347-4da9-85e4-f6ed657d9f41"
      unitRef="usd">132800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1806a0bbaa2b43889412b0fa97abc98a_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNi00LTEtMS0w_be07fa7f-b24e-4e95-a382-5da8788b9522"
      unitRef="usd">988900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i05eb3d02985844119473f90fa44e496a_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNi02LTEtMS0w_9d1765fd-bbab-44f6-b927-ebabb8ce7aa6"
      unitRef="usd">44700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjdlM2JkNTc3MDE5ODQ1ZmQ4NzMzZmIxZDdiMWU3ZDUxL3RhYmxlcmFuZ2U6N2UzYmQ1NzcwMTk4NDVmZDg3MzNmYjFkN2IxZTdkNTFfNi04LTEtMS0w_4a421c24-27f5-40f4-b054-1d00b0ce29a5"
      unitRef="usd">1166400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfMjgwNw_92fb49db-cf06-4640-82e6-325507475d43">&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;993.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,166.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0003b815e2554577be2bdf249035d3a5_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjRiNThjYmQ2NmRlMDQ4ZThhMWNlMDI2MTc3NDZhZDQwL3RhYmxlcmFuZ2U6NGI1OGNiZDY2ZGUwNDhlOGExY2UwMjYxNzc0NmFkNDBfMS0yLTEtMS0w_90c57599-8b03-47ec-8b92-569526a18178"
      unitRef="usd">173400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iaef079cdccfb48ee83054f60bf01c254_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjRiNThjYmQ2NmRlMDQ4ZThhMWNlMDI2MTc3NDZhZDQwL3RhYmxlcmFuZ2U6NGI1OGNiZDY2ZGUwNDhlOGExY2UwMjYxNzc0NmFkNDBfMS00LTEtMS0w_583af395-227c-4bb0-ab69-c7e076f05d2b"
      unitRef="usd">195400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ice62402188f941eab28ef8bd9b65e16d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjRiNThjYmQ2NmRlMDQ4ZThhMWNlMDI2MTc3NDZhZDQwL3RhYmxlcmFuZ2U6NGI1OGNiZDY2ZGUwNDhlOGExY2UwMjYxNzc0NmFkNDBfMi0yLTEtMS0w_d1c158f3-5d50-4bb7-9799-600f9219e74c"
      unitRef="usd">993000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i569ed47008414979a6cf0d109c369b32_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjRiNThjYmQ2NmRlMDQ4ZThhMWNlMDI2MTc3NDZhZDQwL3RhYmxlcmFuZ2U6NGI1OGNiZDY2ZGUwNDhlOGExY2UwMjYxNzc0NmFkNDBfMi00LTEtMS0w_3699db25-774d-43e9-9f3b-77adc8a96cb3"
      unitRef="usd">1080600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjRiNThjYmQ2NmRlMDQ4ZThhMWNlMDI2MTc3NDZhZDQwL3RhYmxlcmFuZ2U6NGI1OGNiZDY2ZGUwNDhlOGExY2UwMjYxNzc0NmFkNDBfMy0yLTEtMS0w_994091ee-46b8-4a38-84da-f7c79f4ab08c"
      unitRef="usd">1166400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjRiNThjYmQ2NmRlMDQ4ZThhMWNlMDI2MTc3NDZhZDQwL3RhYmxlcmFuZ2U6NGI1OGNiZDY2ZGUwNDhlOGExY2UwMjYxNzc0NmFkNDBfMy00LTEtMS0w_584158fa-6b97-4e2d-916e-5881109c77ba"
      unitRef="usd">1276000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfMjc4MQ_2bf68a9d-e035-4185-a97a-623803e4b59b">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;341.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;520.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <biib:ShareOfCoPromotionProfits
      contextRef="i42fd999637364cbe9c5eda2d3135fe5d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOmM5YjU5NTA0Yjc1MzRlZDE5NGEwYmIwYzlmZTJhODJjL3RhYmxlcmFuZ2U6YzliNTk1MDRiNzUzNGVkMTk0YTBiYjBjOWZlMmE4MmNfMi0yLTEtMS0w_ed1122a3-9fd5-4423-9a96-68db490f9eff"
      unitRef="usd">174100000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="i423da7297412458f999e416eb001a0d7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOmM5YjU5NTA0Yjc1MzRlZDE5NGEwYmIwYzlmZTJhODJjL3RhYmxlcmFuZ2U6YzliNTk1MDRiNzUzNGVkMTk0YTBiYjBjOWZlMmE4MmNfMi00LTEtMS0w_b1607def-a2f6-4025-90b5-523a5e07e598"
      unitRef="usd">341300000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i42fd999637364cbe9c5eda2d3135fe5d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOmM5YjU5NTA0Yjc1MzRlZDE5NGEwYmIwYzlmZTJhODJjL3RhYmxlcmFuZ2U6YzliNTk1MDRiNzUzNGVkMTk0YTBiYjBjOWZlMmE4MmNfMy0yLTEtMS0w_78b53bd6-5a0c-4fac-ae57-eedd8ee8434c"
      unitRef="usd">214900000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i423da7297412458f999e416eb001a0d7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOmM5YjU5NTA0Yjc1MzRlZDE5NGEwYmIwYzlmZTJhODJjL3RhYmxlcmFuZ2U6YzliNTk1MDRiNzUzNGVkMTk0YTBiYjBjOWZlMmE4MmNfMy00LTEtMS0w_392859dc-abb5-423a-8ff3-321adc633999"
      unitRef="usd">179100000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues
      contextRef="i2837c6bcf6604a1884f52b184bbc1cec_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOmM5YjU5NTA0Yjc1MzRlZDE5NGEwYmIwYzlmZTJhODJjL3RhYmxlcmFuZ2U6YzliNTk1MDRiNzUzNGVkMTk0YTBiYjBjOWZlMmE4MmNfNC0yLTEtMS0w_898eb3aa-d2e4-4521-80fd-9890eb0cc464"
      unitRef="usd">389000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57cd91f7d9604cf09b048c87050e1776_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOmM5YjU5NTA0Yjc1MzRlZDE5NGEwYmIwYzlmZTJhODJjL3RhYmxlcmFuZ2U6YzliNTk1MDRiNzUzNGVkMTk0YTBiYjBjOWZlMmE4MmNfNC00LTEtMS0w_5caf3715-25c9-4d89-a1a6-2158be448a83"
      unitRef="usd">520400000</us-gaap:Revenues>
    <biib:OtherrevenuesTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RleHRyZWdpb246ZTcxNjU3YTZkMWFhNGQzMDk5MGIwODliZTZjYTI3YTdfMjc4Nw_c5d7b4e5-77de-48bc-9bb1-ba2e3649f562">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from collaborative and other relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty and corporate revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues
      contextRef="i163da90ecfbd4f72bc274463a9d22cf0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfMy0yLTEtMS00Mjgw_756e7422-85f4-4e17-8bb2-37f159351377"
      unitRef="usd">3900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82cbd68005204f25a28991bb50e01dff_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfMy00LTEtMS00Mjgw_ef2bab4a-882d-4d0a-b927-013c235e8104"
      unitRef="usd">3700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04e77e2252074a059d584ff066314e70_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfMy0yLTEtMS0w_ed4372d3-b54a-4264-b17c-df704e517c7d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if37d2490542d485c8ad9bc6897f9286d_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfMy00LTEtMS0w_7d63dfda-5b63-400e-90cb-150b28e23f91"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d6131440c1f431ebe00dc7e4e529db3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfNi0yLTEtMS0w_67066118-659b-4966-ba2e-275d70b36227"
      unitRef="usd">6200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i15a9a358435d49609a85d97413f3a145_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfNi00LTEtMS0w_07979125-28e2-42fa-afef-690c69928899"
      unitRef="usd">11400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6844ffa5076f4ec887dfd7ec445c0918_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfNy0yLTEtMS0w_6949dce7-2cbf-4536-b023-36b025aa224a"
      unitRef="usd">83200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3fdb2840b630460ea506d4ec51307590_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfNy00LTEtMS0w_92695123-cf38-4fbd-b456-6433bd2aca58"
      unitRef="usd">94000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16255170d7464fce8565c267cce60805_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfOC0yLTEtMS0w_c912d679-c172-4b72-85fb-855f34047e82"
      unitRef="usd">93300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa5be06727e54c9cb7a5c0a5c65b597e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81Mi9mcmFnOmU3MTY1N2E2ZDFhYTRkMzA5OTBiMDg5YmU2Y2EyN2E3L3RhYmxlOjY4YzRkYjE2MDgzNTQzYTg5MjNkMTA4ZWI4MTVlZjM5L3RhYmxlcmFuZ2U6NjhjNGRiMTYwODM1NDNhODkyM2QxMDhlYjgxNWVmMzlfOC00LTEtMS0w_fc77607d-1d34-4b2a-aff1-57c511499e87"
      unitRef="usd">109300000</us-gaap:Revenues>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RleHRyZWdpb246YTM4ZWVhNWE1ODZmNDMzNmIwYzQ2YTFkOTk1NTYyMGNfNzM_75e1bb1a-6d3b-441d-87a8-a3eb4fb0d0f1">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;331.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;634.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,171.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,068.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RleHRyZWdpb246YTM4ZWVhNWE1ODZmNDMzNmIwYzQ2YTFkOTk1NTYyMGNfODU_05ea8e8c-0ed7-46ae-90ea-c414f719f33d">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;331.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;634.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,171.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,068.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfMS0yLTEtMS0w_d8b695f4-813b-4b60-b585-bdba32f8372b"
      unitRef="usd">331300000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfMS00LTEtMS0w_4c484e13-6ea3-41d7-94cb-24de998bf7f9"
      unitRef="usd">314900000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfMi0yLTEtMS0w_ab0e3804-8d92-4b63-839e-50e580918563"
      unitRef="usd">634800000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfMi00LTEtMS0w_3cf1a193-743c-45db-a73a-024ad351859f"
      unitRef="usd">544500000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfMy0yLTEtMS0w_b557c9ae-6de4-47c1-9d37-a6317c9cb8ac"
      unitRef="usd">205700000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfMy00LTEtMS0w_23834e93-e3c8-4ac2-bc9e-869347c71a40"
      unitRef="usd">209200000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfNC0yLTEtMS0w_6d67aaa3-119e-492f-be4e-37d2417fe9ff"
      unitRef="usd">1171800000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV81OC9mcmFnOmEzOGVlYTVhNTg2ZjQzMzZiMGM0NmExZDk5NTU2MjBjL3RhYmxlOjQzNzljNWYxZmM1NzRjZDA4ZmFmZjRlNGM0ZjllNjNiL3RhYmxlcmFuZ2U6NDM3OWM1ZjFmYzU3NGNkMDhmYWZmNGU0YzRmOWU2M2JfNC00LTEtMS0w_3b84e31f-0962-4b22-bf21-52c2e6a6c41c"
      unitRef="usd">1068600000</biib:Inventorynetcurrentandnoncurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMzQ2MQ_131db84f-c232-466f-9a2a-85e10ce1c09a">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,190.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,204.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,257.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,178.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,190.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,988.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,084.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021, amortization and impairment of acquired intangible assets totaled $98.1 million, compared to $71.5 million in the prior year comparative period. For the three months ended March 31, 2021, amortization and impairment of acquired intangible assets reflects a $44.3&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN). For the three months ended March 31, 2020, we had no impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Completed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;amp;D assets as of March 31, 2021, relates to the various IPR&amp;amp;D programs we acquired in connection with our acquisitions of Nightstar Therapeutics plc (NST) and Convergence Pharmaceuticals Holdings Ltd. (Convergence). The majority of the balance relates to our acquisition of NST in June 2019. For additional information on our acquisition of NST, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vixotrigine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies of vixotrigine for TGN and DPN and now plan to perform an additional clinical trial of vixotrigine before initiating a Phase 3 study of DPN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the first quarter of 2021. As of March 31, 2021, the carrying value associated with our remaining vixotrigine IPR&amp;amp;D assets was $135.1&#160;million, all of which is related to DPN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BIIB111 and BIIB112&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2020 we recognized an impairment charge of $115.0&#160;million related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, as a result of third-party manufacturing delays that may impact our timeline for a potential filing of a Biologics License Application (BLA) for regulatory approval by up to one year, and increase the costs associated with advancing BIIB111 through Phase 3 development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are continuing to monitor the manufacturing issues encountered with BIIB111 and their potential impact on that program's timing. As of March 31, 2021, we have no indication that BIIB111 or BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments, were impaired; however, we will continue to monitor the capabilities of our manufacturing partners and how any additional new manufacturing issues might affect the planned timing of such gene therapy programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;span style="color:#679acb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,762.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,763.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of March 31, 2021, we had no accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMzQ3Mg_64e74d91-ac37-4a96-8d61-4d9aad02fddb">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,190.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,204.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,257.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,178.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,190.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,988.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,084.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i48f0b595ff7d4f3fa1e56358ca157244_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMi0zLTEtMS0w_fecceabd-bde2-469e-8a77-cc6d8f1034e6"
      unitRef="usd">7394300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i48f0b595ff7d4f3fa1e56358ca157244_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMi01LTEtMS0w_e5c13502-c954-4cca-9a4f-ab43c67a78ab"
      unitRef="usd">-5190300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i48f0b595ff7d4f3fa1e56358ca157244_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMi03LTEtMS0w_1bcd69b1-a8a0-4cef-9f5d-2e322978c669"
      unitRef="usd">2204000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i848aad0fd824420fbb889c08f40d826c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMi05LTEtMS0w_fa04d370-21ad-4b67-a59b-99104861cb2b"
      unitRef="usd">7394300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i848aad0fd824420fbb889c08f40d826c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMi0xMS0xLTEtMA_976741c6-6983-4817-a9c8-6455b25d8353"
      unitRef="usd">-5136500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i848aad0fd824420fbb889c08f40d826c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMi0xMy0xLTEtMA_a5a9e1e2-04bb-43dc-aff5-01eacc5f4efc"
      unitRef="usd">2257800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2e8e8ec88cba4cae96ec769e8eb5ed50_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMy0zLTEtMS0w_2a81b832-f986-42bf-b15e-a977917a16a8"
      unitRef="usd">720100000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2e8e8ec88cba4cae96ec769e8eb5ed50_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMy01LTEtMS0w_d5cd8f29-c9bd-4eb5-8128-de8428d6f18a"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2e8e8ec88cba4cae96ec769e8eb5ed50_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMy03LTEtMS0w_10cae748-7d1a-4666-9cc3-941f5be7b38b"
      unitRef="usd">720100000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i56017bab075244608da3bd636cc69661_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMy05LTEtMS0w_a6e7ddbd-04f5-48be-9c6e-b25a676bcf37"
      unitRef="usd">762500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i56017bab075244608da3bd636cc69661_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMy0xMS0xLTEtMA_c1af8a5c-ad61-4655-a74d-720dd994e4f3"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i56017bab075244608da3bd636cc69661_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfMy0xMy0xLTEtMA_902f5102-ce0d-4e62-8bac-eed5a73ba44b"
      unitRef="usd">762500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i58534be095d54aff98f1243bb85b6ca4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNC0zLTEtMS0w_9258bc39-9c03-4f0c-8de1-c8a900f81e75"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i58534be095d54aff98f1243bb85b6ca4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNC01LTEtMS0w_7e448e25-3d69-4af0-89e4-23967c76396c"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i58534be095d54aff98f1243bb85b6ca4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNC03LTEtMS0w_e4f6504d-e24d-4f18-8233-9ca68d718c86"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2b71bbb6a21a486ba7bb214d1686f8f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNC05LTEtMS0w_09a87a6e-806b-4669-8400-1aeeae49e463"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2b71bbb6a21a486ba7bb214d1686f8f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNC0xMS0xLTEtMA_94aac8e7-285c-46b6-ac4a-bc9bdd2c4c81"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2b71bbb6a21a486ba7bb214d1686f8f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNC0xMy0xLTEtMA_9bed9789-5ba8-4bc8-b03c-8b0618f25aff"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNS0zLTEtMS0w_c9b9a62d-b5f4-461e-90a8-1e9733a2ee5c"
      unitRef="usd">8178400000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNS01LTEtMS0w_17050a4d-ead6-44c6-9601-e6965a14df07"
      unitRef="usd">5190300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNS03LTEtMS0w_23797f1f-7905-4ef5-9fd8-4a0863c47357"
      unitRef="usd">2988100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNS05LTEtMS0w_2ccf9d02-2261-49dd-b06e-a33356793b1f"
      unitRef="usd">8220800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNS0xMS0xLTEtMA_90e9c915-2c2d-420e-a75e-5d83271930ae"
      unitRef="usd">5136500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjQ0NDQ2NmFjOGY2NTQwY2FiODExYzc2Y2Q5NTNiODU3L3RhYmxlcmFuZ2U6NDQ0NDY2YWM4ZjY1NDBjYWI4MTFjNzZjZDk1M2I4NTdfNS0xMy0xLTEtMA_dd6b8b6a-c895-4322-9cd7-335192561c95"
      unitRef="usd">3084300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMjQ5_60298ee3-0957-4884-99dd-acedfde73cbf"
      unitRef="usd">98100000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMjg2_0de0c9b6-d36d-47de-a060-5992bed3e0f2"
      unitRef="usd">71500000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i0b53409c6c594be1ab5a8373c301e1e4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMTA5OTUxMTY0MzYwMw_0764facf-f457-481d-8aa6-cc05f2b0c80c"
      unitRef="usd">44300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i448d8c39b77d40a1a669d30b8086ecce_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMTA5OTUxMTY0MDY5Mw_59a0ae0c-099f-47f3-b9f2-da2d9ad0cc1d"
      unitRef="usd">0</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i0b53409c6c594be1ab5a8373c301e1e4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMTA5OTUxMTY0NTA4Mg_0764facf-f457-481d-8aa6-cc05f2b0c80c"
      unitRef="usd">44300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="icadfd8009ae541009e58a0809c8614f7_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMTA5OTUxMTY1MDE3OQ_92fe3b28-3585-405d-a8c8-206a000923d3"
      unitRef="usd">135100000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i3ae7d791a7214f65b96db9c10da5155e_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMTA5OTUxMTY0MTQ0OQ_5594a477-106b-4b60-9004-c216494c4fba"
      unitRef="usd">115000000.0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMzQ4Nw_1dad3f0e-ceb8-478b-aa8b-ee359cfbd909">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjIzNWY1YjIzNjQ4ZjRhMzliZmUxN2MyMDMwMjEyNWFkL3RhYmxlcmFuZ2U6MjM1ZjViMjM2NDhmNGEzOWJmZTE3YzIwMzAyMTI1YWRfMS0yLTEtMS0w_ab012e9b-5bfe-448c-b62b-3f10e620cff1"
      unitRef="usd">165000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjIzNWY1YjIzNjQ4ZjRhMzliZmUxN2MyMDMwMjEyNWFkL3RhYmxlcmFuZ2U6MjM1ZjViMjM2NDhmNGEzOWJmZTE3YzIwMzAyMTI1YWRfMi0yLTEtMS0w_a470a287-6eab-44dd-815e-ffaf09e69b4c"
      unitRef="usd">215000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjIzNWY1YjIzNjQ4ZjRhMzliZmUxN2MyMDMwMjEyNWFkL3RhYmxlcmFuZ2U6MjM1ZjViMjM2NDhmNGEzOWJmZTE3YzIwMzAyMTI1YWRfMy0yLTEtMS0w_aa75d99f-db60-4fc1-9478-d9894a3ade95"
      unitRef="usd">215000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjIzNWY1YjIzNjQ4ZjRhMzliZmUxN2MyMDMwMjEyNWFkL3RhYmxlcmFuZ2U6MjM1ZjViMjM2NDhmNGEzOWJmZTE3YzIwMzAyMTI1YWRfNC0yLTEtMS0w_c0f66983-98e6-4b3e-959c-98c170fe7906"
      unitRef="usd">225000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjIzNWY1YjIzNjQ4ZjRhMzliZmUxN2MyMDMwMjEyNWFkL3RhYmxlcmFuZ2U6MjM1ZjViMjM2NDhmNGEzOWJmZTE3YzIwMzAyMTI1YWRfNS0yLTEtMS0w_93eec573-b044-41c0-b120-f2738683384b"
      unitRef="usd">220000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjIzNWY1YjIzNjQ4ZjRhMzliZmUxN2MyMDMwMjEyNWFkL3RhYmxlcmFuZ2U6MjM1ZjViMjM2NDhmNGEzOWJmZTE3YzIwMzAyMTI1YWRfNi0yLTEtMS0w_01e34f3e-1632-46c9-993c-9193ca02f7cc"
      unitRef="usd">200000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMzQ4Mg_80fbe398-05bf-4ad8-9575-8ad84712ad02">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,762.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,763.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjdjZjYwYmQyNDU1MTQyZGRiODU4Yzk4Y2Q1OGE0MmVmL3RhYmxlcmFuZ2U6N2NmNjBiZDI0NTUxNDJkZGI4NThjOThjZDU4YTQyZWZfMS0yLTEtMS0w_369def82-f395-46f2-9e12-9dda6273f562"
      unitRef="usd">5762100000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjdjZjYwYmQyNDU1MTQyZGRiODU4Yzk4Y2Q1OGE0MmVmL3RhYmxlcmFuZ2U6N2NmNjBiZDI0NTUxNDJkZGI4NThjOThjZDU4YTQyZWZfMy0yLTEtMS0w_388389eb-4bae-450b-bef8-3731267eb627"
      unitRef="usd">1000000.0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RhYmxlOjdjZjYwYmQyNDU1MTQyZGRiODU4Yzk4Y2Q1OGE0MmVmL3RhYmxlcmFuZ2U6N2NmNjBiZDI0NTUxNDJkZGI4NThjOThjZDU4YTQyZWZfNC0yLTEtMS0w_a0656b6c-f524-407d-9ca6-9e94eb94dc43"
      unitRef="usd">5763100000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82MS9mcmFnOjFhYzNmZjQ2MzI3ZjRjMTc4MDRjMDhjMTRmMjE4NGEwL3RleHRyZWdpb246MWFjM2ZmNDYzMjdmNGMxNzgwNGMwOGMxNGYyMTg0YTBfMzMyNA_7f6c74dc-a72c-476a-b339-f132748fed5e"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfNDcyOA_87737c16-d4d7-43a2-b669-2be483f95825">&lt;div style="margin-top:3pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;745.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;745.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,336.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,336.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;677.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;677.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,442.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,294.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,412.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,264.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,703.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,700.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,429.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;477.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material impairments of our assets measured and carried at fair value during the three months ended March 31, 2021. In addition, there have been no changes in valuation techniques during the three months ended March 31, 2021. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo), Denali Therapeutics Inc. (Denali) and Sage Therapeutics, Inc. (Sage) and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. For additional information on our investments in Sangamo, Denali and Sage common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7, Financial Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2020 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of March 31, 2021 and December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td rowspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.77%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.77%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022 to 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.60%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 to 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from 21.7% to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;998.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,054.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,940.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,741.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,003.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,741.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,455.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,557.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,394.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,099.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,365.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,723.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,369.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,472.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,536.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,472.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;654.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;463.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,859.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,267.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,515.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,426.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In February 2021 we completed a private offer to exchange (Exchange Offer) our 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes), whereby approximately $624.6&#160;million of our 2045 Senior Notes were exchanged for approximately $700.7&#160;million of a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes). For additional information on our Exchange Offer, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes issued on April 30, 2020 and September 15, 2015, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;341.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December 31, 2020, approximately $226.0 million and $110.3 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expense and other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfNDcwMQ_0f9715f5-b927-4d5a-801b-4eeefb4e216e">&lt;div style="margin-top:3pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;745.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;745.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,336.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,336.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;677.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;677.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,442.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,294.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,412.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,264.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,703.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,700.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,429.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;477.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMy0yLTEtMS0w_4a573008-aa27-4e52-b6be-2bb07dcc70b8"
      unitRef="usd">745800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMy00LTEtMS0w_2cd761ee-2eb4-4b4b-ab02-c165ef6190b1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMy02LTEtMS0w_7517cd46-b59a-43a1-8f50-6d0a35dde91c"
      unitRef="usd">745800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iffd6a4591290426db41339963f8e38f4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMy04LTEtMS0w_f6c84075-bd1b-4b9a-8197-a0060643aab5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia9f2cde76a524b86a12cd39d526d2166_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNS0yLTEtMS0w_2136ded3-795f-4816-b136-0dae016de08f"
      unitRef="usd">1336200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6313636dcf65492fa6f7d60c52fd4998_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNS00LTEtMS0w_e69c7d91-6e26-4900-8b87-f8aa6013e053"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i59301081b8cf45a5865f1a2a1ab1ec95_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNS02LTEtMS0w_3b4bbda7-b3e8-4227-8190-8be9800cb1dc"
      unitRef="usd">1336200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8acf8de01b6427b817fce044f2a4e9b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNS04LTEtMS0w_f7acc68d-d6db-41c9-941a-8f7322029250"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib0a8abceadc64d56a584c21adbd55e3d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNi0yLTEtMS0w_dbcbfc5d-5786-4956-8268-72bbf4ea267c"
      unitRef="usd">677400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7421225a760648fc82e6b371affef596_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNi00LTEtMS0w_f874907b-7fd2-4c95-9379-5dd7992c4810"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie1eeebc1e9184fccacb6886b20d57c4d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNi02LTEtMS0w_fed077d3-cdac-4802-8f98-5273f6b29b3f"
      unitRef="usd">677400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2198a535d9bb49138f087e2bb335b702_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNi04LTEtMS0w_36318807-da57-40d0-8fd3-9d602336fe07"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c8b1ee36549403a98b32587e6ec8cd9_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNy0yLTEtMS0w_1bfe83ad-445d-455c-bd1f-0c3dbb17c4b5"
      unitRef="usd">128300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic41685432e3248a59842e2de1fb70cff_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNy00LTEtMS0w_cfeed270-3768-4c18-9d7f-b391c33b5781"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i468b8e383f3a4aacbb111243c54c712d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNy02LTEtMS0w_1fc4f101-5bf5-40f1-bf75-ed2e6f5fea79"
      unitRef="usd">128300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d0f121a5d2a4cfdab80fd27727da939_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfNy04LTEtMS0w_b5b30be5-d332-44ce-9b6c-bfc247ab4b53"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOC0yLTEtMS0w_0e81501c-9e1b-4b75-ae3f-f8492c02a9a8"
      unitRef="usd">1442800000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOC00LTEtMS0w_ee46334a-a17f-42d7-9a12-d73aa1065222"
      unitRef="usd">148200000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOC02LTEtMS0w_62be7de6-0ea0-4386-adc7-271681f78f8f"
      unitRef="usd">1294600000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iffd6a4591290426db41339963f8e38f4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOC04LTEtMS0w_13f1d497-6b1f-48cc-924f-e421f8ee21db"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOS0yLTEtMS0w_3872b2e9-aa80-4dde-b068-e78b338b69dd"
      unitRef="usd">51200000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOS00LTEtMS0w_c4b8eb1a-8d60-42ec-b657-a9d16fc942e5"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOS02LTEtMS0w_970098cb-5912-4e66-80dc-fc24576c5c64"
      unitRef="usd">51200000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="iffd6a4591290426db41339963f8e38f4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfOS04LTEtMS0w_ca825b23-6f9a-4899-8af9-f1f44b3bea5d"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTAtMi0xLTEtMA_bf72a015-c73e-47be-82ad-712054252f66"
      unitRef="usd">31100000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTAtNC0xLTEtMA_9d7008fb-de61-42de-96d3-fb9eec9d8f9d"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTAtNi0xLTEtMA_840512e0-25e1-4566-b7b3-fb6e7b80d2d5"
      unitRef="usd">31100000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="iffd6a4591290426db41339963f8e38f4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTAtOC0xLTEtMA_b9e2e7a8-62ac-46f6-88ba-17da996ff724"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTEtMi0xLTEtMA_9f15f07e-3bda-4e95-beed-1112ce3d481c"
      unitRef="usd">4412800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTEtNC0xLTEtMA_b4c68d17-eae5-472b-a5c0-acecc42cf5e2"
      unitRef="usd">148200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTEtNi0xLTEtMA_f9bbac98-602b-4fc2-9087-2b859626b645"
      unitRef="usd">4264600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iffd6a4591290426db41339963f8e38f4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTEtOC0xLTEtMA_2f08e028-525e-49df-9663-56e04ed8927c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTMtMi0xLTEtMA_b8cc480d-bb25-4456-8a4e-fde914d3e3fc"
      unitRef="usd">88600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTMtNC0xLTEtMA_5bbc6079-49b7-4d7d-9022-2263f7d2429e"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTMtNi0xLTEtMA_ddc3ced8-957a-4563-b3a7-d3163d3d9f75"
      unitRef="usd">88600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="iffd6a4591290426db41339963f8e38f4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTMtOC0xLTEtMA_3817fb3f-d6a3-4f24-b3d9-fb8cc1bf154e"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTQtMi0xLTEtMA_7c593570-7861-45fe-b15c-ed4bf7e89379"
      unitRef="usd">226000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTQtNC0xLTEtMA_51ca9122-d27b-4d3c-a377-044da7777734"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTQtNi0xLTEtMA_5332ee0a-3be0-433a-a6e5-53393f0bad34"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iffd6a4591290426db41339963f8e38f4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTQtOC0xLTEtMA_6bd5f128-af04-4a74-9b50-06b28a18a8d8"
      unitRef="usd">226000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTUtMi0xLTEtMA_27b865ef-95e1-48ec-8983-9b9945c26209"
      unitRef="usd">314600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8bf085cc1c2948f0901f9ab878e9c1fc_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTUtNC0xLTEtMA_31d1b75e-2c39-45be-ad72-02b6ff63d1b4"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7d6fad36ea9f4691b1ede9bb3317b07b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTUtNi0xLTEtMA_92935f77-83f0-4114-a477-28b629d48c21"
      unitRef="usd">88600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iffd6a4591290426db41339963f8e38f4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmY5OGM3NmZkOGZmMzQ3YmE4YTI3Mjk3NzJmMjFhYWRkL3RhYmxlcmFuZ2U6Zjk4Yzc2ZmQ4ZmYzNDdiYThhMjcyOTc3MmYyMWFhZGRfMTUtOC0xLTEtMA_28deb2e3-d2ca-4ebd-b644-61589daa084c"
      unitRef="usd">226000000.0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMy0yLTEtMS0w_4b293fa9-f473-4dd9-a572-bd273132e31a"
      unitRef="usd">626900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMy00LTEtMS0w_d5ee7fb5-84b9-4d65-8268-52330f61691a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i70e71b4af6c648a389be21d19d778315_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMy02LTEtMS0w_12c81901-0d46-4fea-9b29-f1daab7032a6"
      unitRef="usd">626900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMy04LTEtMS0w_4b8d2d49-5fd7-4352-9796-fccaab70ed9d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i617d7850a63a41f2bc0aa19d2bf5d52c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNS0yLTEtMS0w_4e56a918-dc0c-4656-8bf6-27fa46846c38"
      unitRef="usd">1301500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad7dbe081b0c470ea090b36551d58a20_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNS00LTEtMS0w_6345ba4e-5316-4ee8-b389-2c2073e9c29a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iab798705a4e64563b60d02c9ae738dc6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNS02LTEtMS0w_14267835-3147-425c-99f1-484dc63f95cb"
      unitRef="usd">1301500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie88067b08ed84a50987e6337ea2943d6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNS04LTEtMS0w_838e577a-2d2b-48ec-ad46-2003ef1f513c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i46e6eb7334b641e596a5a01f6b114522_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNi0yLTEtMS0w_e9a0b7ef-35c5-4948-ab71-47a55ce42862"
      unitRef="usd">627100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if689c10ac2da4ce6b808d487a91d2f1c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNi00LTEtMS0w_7fd19616-7071-49c7-93d1-dc3efbacfddc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i155f305329d64fa484887596324eabf7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNi02LTEtMS0w_b0609299-d2f4-452b-b750-2050682e117b"
      unitRef="usd">627100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie77eae55b0fc4a578615133eff105580_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNi04LTEtMS0w_47db2d88-2dd3-4024-9aba-5287c4a728ee"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia9411092d0e6487aaf6d0cee300ee74a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNy0yLTEtMS0w_bdb984c6-bc7e-4f67-957d-b1fd8604931f"
      unitRef="usd">122400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic63fa3a5459c443a84d6bf3111b5ac38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNy00LTEtMS0w_5f7460a5-7054-4460-a4b9-eee4cb467319"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4c75bf61e4794546ad3c50a9595bf109_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNy02LTEtMS0w_135d07c3-ded1-4a5d-ad60-43a589e856cb"
      unitRef="usd">122400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9cea109dd524584a788c485533262c6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfNy04LTEtMS0w_306b04f7-f1e3-478d-834c-dd2a77fba586"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOC0yLTEtMS0w_30fcd632-9634-406f-b449-c98873602e9f"
      unitRef="usd">1974300000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOC00LTEtMS0w_812f525f-603d-448f-ac2a-ce86f0109b6d"
      unitRef="usd">271100000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i70e71b4af6c648a389be21d19d778315_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOC02LTEtMS0w_f21226fc-1b80-414b-9c6f-4dc6f4bda1c7"
      unitRef="usd">1703200000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOC04LTEtMS0w_399d1ed6-6fb8-419b-8a7d-1e2e26d16466"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOS0yLTEtMS0w_3642b624-8a17-474d-a131-3b15795681ad"
      unitRef="usd">20500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOS00LTEtMS0w_27435e56-50dd-4d65-bb22-c51a422e6a1d"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i70e71b4af6c648a389be21d19d778315_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOS02LTEtMS0w_c80569ea-fa10-492d-a62e-82a9af4aea24"
      unitRef="usd">20500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfOS04LTEtMS0w_30973e1c-aec8-418a-9b8f-cdd416d2d7d6"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTAtMi0xLTEtMA_8bb5733a-0b38-490d-82d3-b42a31f90160"
      unitRef="usd">28200000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTAtNC0xLTEtMA_ef3a77a6-2814-4cc1-ae7d-051f820bc72b"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i70e71b4af6c648a389be21d19d778315_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTAtNi0xLTEtMA_7c604078-5207-4996-ab52-c8e5b680177e"
      unitRef="usd">28200000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTAtOC0xLTEtMA_8077e804-85b9-41ab-bee5-a019b1e62a31"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTEtMi0xLTEtMA_f424aa1a-051e-432d-9dcb-5b1b4f00bae4"
      unitRef="usd">4700900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTEtNC0xLTEtMA_39bbbc65-8d41-447f-9e26-a8f276c0704d"
      unitRef="usd">271100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i70e71b4af6c648a389be21d19d778315_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTEtNi0xLTEtMA_f3293954-d3b2-4f58-872b-e27d60faef69"
      unitRef="usd">4429800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTEtOC0xLTEtMA_a3aa61dd-8df4-4c38-a96b-15c5adc7b443"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTMtMi0xLTEtMA_ce91da48-2dbc-4fa7-94b5-25cc26c72737"
      unitRef="usd">217200000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTMtNC0xLTEtMA_6106c7f2-479e-45d8-8e0c-293f57def528"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i70e71b4af6c648a389be21d19d778315_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTMtNi0xLTEtMA_410407c7-9fc6-4d5a-914e-0184e0cbc974"
      unitRef="usd">217200000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTMtOC0xLTEtMA_a954a993-e770-40ab-a94e-9a2f482ec6d3"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTQtMi0xLTEtMA_c24fa44f-f119-4353-bd1f-115a105123ef"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTQtNC0xLTEtMA_a22fe9fd-cac7-49a3-ad6f-0382e83931c9"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i70e71b4af6c648a389be21d19d778315_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTQtNi0xLTEtMA_b192e06f-7a49-4507-8949-dbf81d39c1c7"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTQtOC0xLTEtMA_c7eb8e27-64a0-4381-b22c-eb2a2e8c11cb"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTUtMi0xLTEtMA_b5c517a9-ca49-432b-a3ba-54b2b03c6938"
      unitRef="usd">477000000.0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2dc664875b4f4032a0d03aa34c2b125e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTUtNC0xLTEtMA_e04e0b0e-e5a5-4809-ae51-d94fc4826462"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i70e71b4af6c648a389be21d19d778315_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTUtNi0xLTEtMA_f977dd52-dff0-48fc-97d8-4609cc76ca22"
      unitRef="usd">217200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i34d18f6adbce485d821cfdf85f012a05_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU1YWViMDlhMWY2MDRkNWU4MWQwN2JhOWZkNmE2MzliL3RhYmxlcmFuZ2U6ZTVhZWIwOWExZjYwNGQ1ZTgxZDA3YmE5ZmQ2YTYzOWJfMTUtOC0xLTEtMA_acd25668-0d1b-4724-843a-f3413d0162bb"
      unitRef="usd">259800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetImpairmentCharges
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfMjgz_43abe692-55b0-4b23-a9c7-9aecd8c5d6a9"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU0NjUyN2RiZTY2ZTRlYzliMzQ1Yzk5ZDU5YWE5YTU1L3RhYmxlcmFuZ2U6ZTQ2NTI3ZGJlNjZlNGVjOWIzNDVjOTlkNTlhYTlhNTVfMy0yLTEtMS0w_7c593570-7861-45fe-b15c-ed4bf7e89379"
      unitRef="usd">226000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i3ca99bdbf85840cdbe24f4bc565124b6_I20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU0NjUyN2RiZTY2ZTRlYzliMzQ1Yzk5ZDU5YWE5YTU1L3RhYmxlcmFuZ2U6ZTQ2NTI3ZGJlNjZlNGVjOWIzNDVjOTlkNTlhYTlhNTVfMy04LTEtMS0xMDg3Ng_f5316398-9780-4e50-8d3e-f6a1c7f81300"
      unitRef="number">0.77</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i3564cbcff5074d8ea8625d2d79f78da3_I20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU0NjUyN2RiZTY2ZTRlYzliMzQ1Yzk5ZDU5YWE5YTU1L3RhYmxlcmFuZ2U6ZTQ2NTI3ZGJlNjZlNGVjOWIzNDVjOTlkNTlhYTlhNTVfMy0xMC0xLTEtMA_8d806991-7cd6-4225-8343-4abe659a1c6d"
      unitRef="number">0.0077</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU0NjUyN2RiZTY2ZTRlYzliMzQ1Yzk5ZDU5YWE5YTU1L3RhYmxlcmFuZ2U6ZTQ2NTI3ZGJlNjZlNGVjOWIzNDVjOTlkNTlhYTlhNTVfOS0yLTEtMS00MTM4_c24fa44f-f119-4353-bd1f-115a105123ef"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic8a4ae2d553645bc9749c80ed7469758_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU0NjUyN2RiZTY2ZTRlYzliMzQ1Yzk5ZDU5YWE5YTU1L3RhYmxlcmFuZ2U6ZTQ2NTI3ZGJlNjZlNGVjOWIzNDVjOTlkNTlhYTlhNTVfOS04LTEtMS0xMDg3OA_1e257afc-9f23-4c0c-8251-0b96d307b6cf"
      unitRef="number">0.0060</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ie9a6326f3d6b477c8eb27a1cad5d7cf7_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOmU0NjUyN2RiZTY2ZTRlYzliMzQ1Yzk5ZDU5YWE5YTU1L3RhYmxlcmFuZ2U6ZTQ2NTI3ZGJlNjZlNGVjOWIzNDVjOTlkNTlhYTlhNTVfOS0xMC0xLTEtMTA4ODA_fcd35811-baaf-4d9f-99fd-b8098f34af8e"
      unitRef="number">0.0060</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <biib:TechnologicalAndRegulatorySuccessProbability
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfMTA5OTUxMTYzODI0NQ_b2701325-5fb2-4cc8-ac7c-222a70c27c7a"
      unitRef="number">0.217</biib:TechnologicalAndRegulatorySuccessProbability>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfNDcyNg_24d24969-db39-4638-be01-3de3b29135ff">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;998.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,054.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,940.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,741.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,003.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,741.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,455.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,557.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,394.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,099.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,365.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,723.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,369.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,472.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,536.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,472.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;654.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;463.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,859.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,267.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,515.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,426.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In February 2021 we completed a private offer to exchange (Exchange Offer) our 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes), whereby approximately $624.6&#160;million of our 2045 Senior Notes were exchanged for approximately $700.7&#160;million of a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes). For additional information on our Exchange Offer, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i169c8b70cdd149968938de9db5a8c380_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfMy0yLTEtMS0w_832e3a49-29a3-4b23-80af-f2f339170602"
      unitRef="usd">1044200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i169c8b70cdd149968938de9db5a8c380_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfMy00LTEtMS0w_8a8d874c-a0c8-4f9b-ba09-aaaae86f54cc"
      unitRef="usd">998200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i136e48c6cc4844139e58cca3660d4fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfMy02LTEtMS0w_b6311300-2e27-44ea-90cc-1e7d533a04c3"
      unitRef="usd">1054100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i136e48c6cc4844139e58cca3660d4fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfMy04LTEtMS0w_2f303628-d52f-4e22-b684-67e0e8349565"
      unitRef="usd">997900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i73f7b949b4c740929fa619fc13968293_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNC0yLTEtMS0w_4f6e4062-0a9f-45a5-b9b4-4ae79ff2e73a"
      unitRef="usd">1940800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i73f7b949b4c740929fa619fc13968293_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNC00LTEtMS0w_e7c76e46-bc9c-4277-9bbe-57dc605d435e"
      unitRef="usd">1741500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i3ef7cceb1dba455a9aa7de4d2a40176f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNC02LTEtMS0w_a611ac7f-ad40-46ba-be99-598e0f02193f"
      unitRef="usd">2003100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i3ef7cceb1dba455a9aa7de4d2a40176f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNC04LTEtMS0w_87ac560d-0e82-481a-a9ac-baf3b97e8316"
      unitRef="usd">1741200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i28131b2b3d0447c08a69cc0b6f4781f6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNS0yLTEtMS0w_fefd646e-14ed-4450-8b91-6bb675b918ad"
      unitRef="usd">1455300000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i28131b2b3d0447c08a69cc0b6f4781f6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNS00LTEtMS0w_e77d603b-009d-4e4c-8a92-a27a0901b634"
      unitRef="usd">1491400000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i329e0692712544d2a17055bb01361858_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNS02LTEtMS0w_2bae44aa-1bb0-45b5-8273-58f95afcf258"
      unitRef="usd">1557200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i329e0692712544d2a17055bb01361858_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNS04LTEtMS0w_62a77862-fa19-4149-a2eb-88af0caa6d63"
      unitRef="usd">1491100000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i21ec6c5ff89547ff8dc1226630ef60ef_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNi0yLTEtMS0w_6bf8cf42-0da2-40fa-a01f-e203ca697954"
      unitRef="usd">1394800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i21ec6c5ff89547ff8dc1226630ef60ef_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNi00LTEtMS0w_0f7575ac-7974-4472-a9d1-3f84ba76540a"
      unitRef="usd">1099700000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ie6fa8a83ea8344a9ab2cdaab6b6079d7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNi02LTEtMS0w_b81e899d-e2de-4f54-8cbe-eef28cd59ce6"
      unitRef="usd">2365100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="ie6fa8a83ea8344a9ab2cdaab6b6079d7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNi04LTEtMS0w_51a65d1e-6b82-401b-b606-3ea9165b3039"
      unitRef="usd">1723400000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="id15e963a15e44c2b8d3baeb9b65f28b2_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNy0yLTEtMS0w_6bf02d30-c97c-446e-a73d-cb6423f2c99d"
      unitRef="usd">1369800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="id15e963a15e44c2b8d3baeb9b65f28b2_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNy00LTEtMS0w_8b5a2afa-fff3-41da-b884-fe73edd7249b"
      unitRef="usd">1472700000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i690df7ed80534227b8dd81f1affbc47a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNy02LTEtMS0w_a7a0c66f-e1da-4224-a07f-982f03f04882"
      unitRef="usd">1536400000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i690df7ed80534227b8dd81f1affbc47a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfNy04LTEtMS0w_61b82b25-b966-4fff-96d0-a1a2a0d1adcf"
      unitRef="usd">1472600000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i7f1bb2f05a734c40a4736b73629c222f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC0yLTEtMS0zNjE0_7ecfd16a-de8f-4858-b4ef-42d0b0ab47c5"
      unitRef="usd">654300000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i7f1bb2f05a734c40a4736b73629c222f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC00LTEtMS0zNjIw_4bf895aa-6ebc-4982-9905-ebb6c8e00ab2"
      unitRef="usd">463700000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ie1fdd327c9a54a7b94459dc7adec7e4c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC02LTEtMS0zNjE3_2a3309d5-7c64-4b74-a337-ff0fef092761"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="ie1fdd327c9a54a7b94459dc7adec7e4c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC04LTEtMS0zNjIz_0525bfa1-015b-4f98-87bc-2bd51a101e04"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC0yLTEtMS0w_23f8988f-9fb7-422c-91d3-7ac2940ffdfe"
      unitRef="usd">7859200000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC00LTEtMS0w_d8f79ca0-4934-44c1-be07-adb7263badba"
      unitRef="usd">7267200000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC02LTEtMS0w_ad393e5e-5146-4b53-8a32-c14123de74c8"
      unitRef="usd">8515900000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjdiYjEyZWI4NDQ3ODQ1YTM4YzZjOTFkMjk4ODFmMjQ0L3RhYmxlcmFuZ2U6N2JiMTJlYjg0NDc4NDVhMzhjNmM5MWQyOTg4MWYyNDRfOC04LTEtMS0w_01777bdd-c787-47d6-b2fb-0377894f1e0c"
      unitRef="usd">7426200000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i21ec6c5ff89547ff8dc1226630ef60ef_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfNzY5NjU4MTQwNTcxMQ_3fd2cf32-fabc-46a3-974d-513d8c942957"
      unitRef="number">0.05200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:LongTermDebtExchangedAmount
      contextRef="i9541283653d242f48d85e9890e9c2777_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfMTA5OTUxMTYzNjU1MQ_4759265c-6895-40fc-a3f0-3182eb79cffb"
      unitRef="usd">624600000</biib:LongTermDebtExchangedAmount>
    <biib:LongTermDebtExchangedAmount
      contextRef="i92e65fe683a2421f94f2dc6385f162f6_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfMTA5OTUxMTYzNjU2Nw_4f1a8b7d-d927-47ce-8986-04c9c8f901fe"
      unitRef="usd">700700000</biib:LongTermDebtExchangedAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7f1bb2f05a734c40a4736b73629c222f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfNzY5NjU4MTQwNTcwMw_1930a398-b9f8-45df-bda8-4a07f99a5999"
      unitRef="number">0.03250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfNDcxNg_09e4c13c-f61f-4202-aa65-28494d614aea">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;341.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i987da2e6227b4752bc28e59e5ea5bb71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjIxNzVkNjIzZTgzNzQzMjM5OTZkZTVjYWY5ODcxOWRjL3RhYmxlcmFuZ2U6MjE3NWQ2MjNlODM3NDMyMzk5NmRlNWNhZjk4NzE5ZGNfMi0yLTEtMS0w_c24fa44f-f119-4353-bd1f-115a105123ef"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id1c3b6e1aa1a4f37a556ea55e078b7e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjIxNzVkNjIzZTgzNzQzMjM5OTZkZTVjYWY5ODcxOWRjL3RhYmxlcmFuZ2U6MjE3NWQ2MjNlODM3NDMyMzk5NmRlNWNhZjk4NzE5ZGNfMi00LTEtMS0w_f6a803b7-c283-4cae-9355-5cf8523aca59"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjIxNzVkNjIzZTgzNzQzMjM5OTZkZTVjYWY5ODcxOWRjL3RhYmxlcmFuZ2U6MjE3NWQ2MjNlODM3NDMyMzk5NmRlNWNhZjk4NzE5ZGNfMy0yLTEtMS0w_e92db03c-fb17-4430-a844-3458ac8dcd01"
      unitRef="usd">33800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjIxNzVkNjIzZTgzNzQzMjM5OTZkZTVjYWY5ODcxOWRjL3RhYmxlcmFuZ2U6MjE3NWQ2MjNlODM3NDMyMzk5NmRlNWNhZjk4NzE5ZGNfMy00LTEtMS0w_be33258f-2018-4160-9d9a-05b5c6196572"
      unitRef="usd">4600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icd62cf9fee194b7d97bedcb32dc6e28d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjIxNzVkNjIzZTgzNzQzMjM5OTZkZTVjYWY5ODcxOWRjL3RhYmxlcmFuZ2U6MjE3NWQ2MjNlODM3NDMyMzk5NmRlNWNhZjk4NzE5ZGNfNS0yLTEtMS0w_6aa28e0b-d1da-43fa-aab9-d7b360057da0"
      unitRef="usd">226000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i08a615c71cd74bfaab31f5afbd166043_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RhYmxlOjIxNzVkNjIzZTgzNzQzMjM5OTZkZTVjYWY5ODcxOWRjL3RhYmxlcmFuZ2U6MjE3NWQ2MjNlODM3NDMyMzk5NmRlNWNhZjk4NzE5ZGNfNS00LTEtMS0w_33e7f624-b73d-4b16-bc95-68895fc8a6dd"
      unitRef="usd">341500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfMzYwMQ_9e918291-6c4d-4272-88f8-9e243585f446"
      unitRef="usd">226000000.0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV82Ny9mcmFnOmI5NzQwZDI5NDMxYjQ4M2I5N2RhMjBiZTg1ODE4OWViL3RleHRyZWdpb246Yjk3NDBkMjk0MzFiNDgzYjk3ZGEyMGJlODU4MTg5ZWJfMzYwOA_abcf2bf1-8d00-4775-a696-fc6b46f37dbc"
      unitRef="usd">110300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMzc5MA_d3d4cfe2-deea-40da-9840-4196c757bf99">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;541.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;745.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available for sale:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;979.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;979.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;356.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;356.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;336.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;336.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,140.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,141.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,442.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,442.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;897.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;898.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;733.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,887.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,239.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;749.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Contractual Maturities: Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,320.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,320.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;781.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;780.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,141.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,140.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average maturity of our marketable debt securities available-for-sale as of March 31, 2021 and December 31, 2020, was approximately 12 months and 11 months, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;819.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,389.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December 31, 2020, our strategic investment portfolio was comprised of investments totaling $1,493.1 million and $2,024.6 million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6, Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in our strategic investment portfolio for the three months ended March 31, 2021, was primarily due to decreases in the fair values of our investments in Ionis Pharmaceuticals Inc. (Ionis), Sage, Denali and Sangamo common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sage Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020 we entered into a global collaboration and license agreement with Sage. In connection with the closing of this transaction in December 2020 we purchased $650.0&#160;million of Sage common stock, or approximately 6.2&#160;million shares at approximately $104.14 per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sage common stock and a dividend yield of zero based upon the fact that Sage and similar companies generally have not historically granted cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangement with Sage, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020 we entered into a collaboration and license agreement with Denali. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of this collaboration we purchased approximately $465.0&#160;million of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali's common stock and a dividend yield of zero based upon the fact that Denali and similar companies generally have not historically granted cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangement with Denali, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased $225.0 million of Sangamo common stock, or approximately 24 million shares at approximately $9.21 per share, which are subject to transfer restrictions.&#160;This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo&#x2019;s common stock and a dividend yield of zero based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangement with Sangamo, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMzc5Mw_7c42e4d6-c537-47c5-88eb-18507ad00828">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;541.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;745.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i097294e10f804864872cedb1009ca2d6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfMS0yLTEtMS0w_f2ad446e-7162-437d-ad5b-6e8255be250a"
      unitRef="usd">50700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i06cbd4baf6c64cbb882e64d7af251fd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfMS00LTEtMS0w_d6f3c26c-3846-4b49-a619-ec162f4a1362"
      unitRef="usd">61100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i662a2807e7f441dea26090ecaa66ff73_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfMi0yLTEtMS0w_c34d5da0-e18e-4edf-bfdc-c01991018457"
      unitRef="usd">93700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i9e9534615d4d4fa08ea2113342a064bb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfMi00LTEtMS0w_f847042d-e93f-47b9-8721-49376e4f8e96"
      unitRef="usd">37400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i6265a293284648a6901f1c195af48f3a_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfMy0yLTEtMS0w_be4636e2-0533-4b75-a9c8-d45a41be48fb"
      unitRef="usd">541500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ia0a442e099ce48c194c0139fdf69655e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfMy00LTEtMS0w_71f33935-5038-4f4a-b604-77affad45922"
      unitRef="usd">505100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i9b51b2d00bc5437689fb1ac29bc46a56_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfNC0yLTEtMS0w_a7ba8ea9-01a7-40ca-a8db-d791e003ccad"
      unitRef="usd">59900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i3e2cdebf2e34461bb476ad2299cb6ae6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfNC00LTEtMS0w_e98db7e0-8f94-4c57-ab33-99818ac94c2a"
      unitRef="usd">23300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfNS0yLTEtMS0w_318b03f7-644e-4924-bad0-1fe2ecadbf41"
      unitRef="usd">745800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjk4NWM0MmU1MTBkZDQ0MzY5ODg5ZDliY2Y2N2Q0YzFkL3RhYmxlcmFuZ2U6OTg1YzQyZTUxMGRkNDQzNjk4ODlkOWJjZjY3ZDRjMWRfNS00LTEtMS0w_88048ef2-1d65-4e6c-bbdb-cf16a2dafac6"
      unitRef="usd">626900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMzgxMw_f514b483-b45d-4974-aa28-6d1c1ac695d8">The following tables summarize our marketable debt and equity securities, classified as available for sale:&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;979.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;979.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;356.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;356.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;336.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;336.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,140.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,141.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,442.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,442.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;897.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;898.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;733.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,887.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,239.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;749.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if058af87c70046e2aadf2969cb8ec339_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMy0yLTEtMS0w_1d621c74-fbce-4a21-9dd4-ee91ddd54beb"
      unitRef="usd">979700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if058af87c70046e2aadf2969cb8ec339_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMy00LTEtMS0w_0bd4f623-b625-4f1f-b650-a76338567bb2"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if058af87c70046e2aadf2969cb8ec339_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMy02LTEtMS0w_b44b9e94-1028-4b65-b8a8-04ec54618a79"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if058af87c70046e2aadf2969cb8ec339_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMy04LTEtMS0w_5aa70a07-52b1-4a2a-b664-99251b6b756a"
      unitRef="usd">979500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ieede5634af6341efa55cd03c69ce9e7b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNC0yLTEtMS0w_3299a3bd-5e9a-4453-a199-f9efd862736e"
      unitRef="usd">356000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieede5634af6341efa55cd03c69ce9e7b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNC00LTEtMS0w_6f9180ab-7453-452d-9c39-fe5b841e00dd"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieede5634af6341efa55cd03c69ce9e7b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNC02LTEtMS0w_000f3c6a-550e-4b1e-8265-1a4ed84ccc9b"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieede5634af6341efa55cd03c69ce9e7b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNC04LTEtMS0w_f0af7c0c-82a1-4ef7-af92-db8cfb2b42be"
      unitRef="usd">356700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7f367843cd4a459aa904731e38a571f0_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNi0yLTEtMS0w_5b18c0dc-db8d-42d2-9e3a-6264b3bedb9a"
      unitRef="usd">340500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7f367843cd4a459aa904731e38a571f0_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNi00LTEtMS0w_85c2f1bb-4c93-4648-9f60-c1cd23efbdec"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7f367843cd4a459aa904731e38a571f0_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNi02LTEtMS0w_ad2fbe7a-b284-4320-9aca-df8c343b7102"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f367843cd4a459aa904731e38a571f0_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNi04LTEtMS0w_ab118fcd-fbf1-4c46-92c5-442f329f8c8b"
      unitRef="usd">340500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ife34e8173e884133b5b5df3663402806_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNy0yLTEtMS0w_5df604ca-323f-49e8-92d6-993ccdde2bd0"
      unitRef="usd">336500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ife34e8173e884133b5b5df3663402806_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNy00LTEtMS0w_f5a164f7-cf30-461c-ad55-e1db7cdde848"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ife34e8173e884133b5b5df3663402806_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNy02LTEtMS0w_7f2e5d0f-af7b-4c61-9427-01008bf0a101"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife34e8173e884133b5b5df3663402806_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfNy04LTEtMS0w_7f293a25-d5a5-4e12-bf7f-56ecc8c7185f"
      unitRef="usd">336900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id1b6fdc993a44cf79b869e8688a3062f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfOS0yLTEtMS0w_fbd89e62-8fae-4970-8a6a-d32eaa77c72d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id1b6fdc993a44cf79b869e8688a3062f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfOS00LTEtMS0w_cc147d5a-15d8-4f8d-a3f3-3bb1bf2c0896"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id1b6fdc993a44cf79b869e8688a3062f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfOS02LTEtMS0w_764586af-789c-49b7-ba97-0ab8fa949783"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id1b6fdc993a44cf79b869e8688a3062f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfOS04LTEtMS0w_012fcee9-bb39-4b5d-8e10-2c0c615d744c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8b3875a8852c4f49b9e644e0c9158374_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTAtMi0xLTEtMA_f9601292-397f-41c3-bee5-c165094f2068"
      unitRef="usd">128200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8b3875a8852c4f49b9e644e0c9158374_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTAtNC0xLTEtMA_49f391a4-6189-4d71-90a3-b84ac3ca2f9f"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8b3875a8852c4f49b9e644e0c9158374_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTAtNi0xLTEtMA_39c5fa9f-3a35-474a-bf11-7e30c6c950a0"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b3875a8852c4f49b9e644e0c9158374_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTAtOC0xLTEtMA_c05008a4-9a59-4b31-b21f-2edff3a9d057"
      unitRef="usd">128300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTEtMi0xLTEtMA_00c40e3f-0e34-40df-9cb4-01ff15e400ef"
      unitRef="usd">2140900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTEtNC0xLTEtMA_b7aae3e9-bc21-4ccf-bac4-d7660d501a2a"
      unitRef="usd">1600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTEtNi0xLTEtMA_52b0ac6c-9f05-4047-a06a-9048387470d5"
      unitRef="usd">600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTEtOC0xLTEtMA_6ecbef5f-6bfa-4efc-9516-905be99193bd"
      unitRef="usd">2141900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="if4bb284119504ac8a1c8c4175099a908_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTItMi0xLTEtMA_3e985324-c37b-4f0b-9ea3-4d4aad7c958a"
      unitRef="usd">1168900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if4bb284119504ac8a1c8c4175099a908_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTItNC0xLTEtMA_f7cb91d5-d8ba-4440-95f5-60bbc3efd3a7"
      unitRef="usd">351000000.0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if4bb284119504ac8a1c8c4175099a908_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTItNi0xLTEtMA_bf2b7809-2b30-4713-a787-ec1512f210d5"
      unitRef="usd">77100000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if4bb284119504ac8a1c8c4175099a908_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTItOC0xLTEtMA_7319b5c7-de14-459c-a063-d23e7d0c9bc1"
      unitRef="usd">1442800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="ic3553a83d95842ccbe6c7675c97c9f6d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTctMi0xLTEtMTA5MTE_aabfe612-ac47-4855-a3b5-e7228d666fe2"
      unitRef="usd">1168900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic3553a83d95842ccbe6c7675c97c9f6d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTctNC0xLTEtMTA5MTE_e896dddb-2b14-409d-9fb9-291e29d22376"
      unitRef="usd">351000000.0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic3553a83d95842ccbe6c7675c97c9f6d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTctNi0xLTEtMTA5MTE_33ee7504-7a9b-4ece-a9a0-77f0a72425be"
      unitRef="usd">77100000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic3553a83d95842ccbe6c7675c97c9f6d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjQ3MjcwYTU5OGVkZjRmYTNiYjY5ZDhkNGZhYWRmYjIyL3RhYmxlcmFuZ2U6NDcyNzBhNTk4ZWRmNGZhM2JiNjlkOGQ0ZmFhZGZiMjJfMTctOC0xLTEtMTA5MTE_f706453a-a44a-46c9-abbc-a98e9bc0bab0"
      unitRef="usd">1442800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic2ada1e061ed4917bbce94eeb6b5933f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMy0yLTEtMS0w_bd2a9309-b614-45ad-988a-a32607070562"
      unitRef="usd">897800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic2ada1e061ed4917bbce94eeb6b5933f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMy00LTEtMS0w_eeb9b5eb-61ea-48bc-880f-98a11ab7cb55"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic2ada1e061ed4917bbce94eeb6b5933f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMy02LTEtMS0w_e554b425-fa9f-4061-a4e4-8d7bac1508b9"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic2ada1e061ed4917bbce94eeb6b5933f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMy04LTEtMS0w_2b4969dc-5509-405d-88da-773c86467d7e"
      unitRef="usd">898000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia2692b6a2c3a470caa2bb0ed4268a1d1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNC0yLTEtMS0w_6795d90a-3fb4-4345-9ab1-1dbb95ac4945"
      unitRef="usd">402500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia2692b6a2c3a470caa2bb0ed4268a1d1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNC00LTEtMS0w_0c0b6b11-fadd-4d50-b485-3af47550805f"
      unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia2692b6a2c3a470caa2bb0ed4268a1d1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNC02LTEtMS0w_b912860a-9a44-4033-b832-258ae815611c"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia2692b6a2c3a470caa2bb0ed4268a1d1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNC04LTEtMS0w_c4add659-dd2d-425a-bdb0-f1bf39b54320"
      unitRef="usd">403500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6e9431c0a0744979af0821b912532c37_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNi0yLTEtMS0w_8a8998a0-c177-4b0d-ac77-793000810ec5"
      unitRef="usd">380600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6e9431c0a0744979af0821b912532c37_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNi00LTEtMS0w_dd3f7ccf-93df-4be8-bf67-770c93fa357d"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6e9431c0a0744979af0821b912532c37_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNi02LTEtMS0w_a4375479-e952-4675-a6a8-f925c07080c9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6e9431c0a0744979af0821b912532c37_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNi04LTEtMS0w_18a75e54-c5d6-4aa7-81b8-457bc7f30353"
      unitRef="usd">380700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i56be570639ec418f834fc04f5746b4d7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNy0yLTEtMS0w_d41237d3-5fdf-45b4-822b-6759ad003c61"
      unitRef="usd">245900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i56be570639ec418f834fc04f5746b4d7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNy00LTEtMS0w_09e9202d-0d6d-405f-9d7a-8bcb129b9f71"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i56be570639ec418f834fc04f5746b4d7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNy02LTEtMS0w_74fc4633-0bf0-46ef-91f3-302f2bc91059"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i56be570639ec418f834fc04f5746b4d7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfNy04LTEtMS0w_7c49964e-493d-49e1-84c0-2dcb6cb5a072"
      unitRef="usd">246400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic5b995470fa14c99ae213810dba2dae0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfOS0yLTEtMS0w_76d27b2b-0a4f-4052-a8b8-98cb95c6b01f"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic5b995470fa14c99ae213810dba2dae0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfOS00LTEtMS0w_38a88b32-abc1-4b0d-9778-babba43b4915"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic5b995470fa14c99ae213810dba2dae0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfOS02LTEtMS0w_2cfe24de-6dec-41b3-846d-18b13c2b14d3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic5b995470fa14c99ae213810dba2dae0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfOS04LTEtMS0w_ccacdb51-107d-4b9e-85d4-4bc7ae1963e6"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i85140128d15a442892fcc26f8abda120_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTAtMi0xLTEtMA_1d342ecc-64d1-4337-92cf-7163462cf854"
      unitRef="usd">122100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i85140128d15a442892fcc26f8abda120_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTAtNC0xLTEtMA_017ff718-dcde-4ac1-96c1-10796faee370"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i85140128d15a442892fcc26f8abda120_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTAtNi0xLTEtMA_c7dbddf5-f9eb-410d-af59-7ab235774aa9"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i85140128d15a442892fcc26f8abda120_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTAtOC0xLTEtMA_fd70a573-ec8c-4900-ba73-503d5a1821e8"
      unitRef="usd">122200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTEtMi0xLTEtMA_69489ce2-39a0-4e2c-8a12-3178a763cb1a"
      unitRef="usd">2049100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTEtNC0xLTEtMA_91043b6e-4c3c-4d0a-a6a5-197181ec9f4d"
      unitRef="usd">2300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTEtNi0xLTEtMA_f0535d9c-91c1-4b0f-af0a-c6916c5b4f02"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTEtOC0xLTEtMA_d7a5bff9-9dad-473c-8c8a-2eefd41a0689"
      unitRef="usd">2051000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="ie0570f45a09344ee88a9bbbf9b677aef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTUtMi0xLTEtNTMz_66e7fac7-8317-4b10-9c7f-42eb51d14b38"
      unitRef="usd">70600000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie0570f45a09344ee88a9bbbf9b677aef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTUtNC0xLTEtNTMz_4ada50a7-01f7-45aa-9426-e79c5730af46"
      unitRef="usd">15900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie0570f45a09344ee88a9bbbf9b677aef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTUtNi0xLTEtNTMz_d3f29989-678e-40d2-b8c7-2c6845f69adf"
      unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie0570f45a09344ee88a9bbbf9b677aef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTUtOC0xLTEtMTA5MTQ_27928dcd-51ee-4ed7-ab2e-c7f3bdd25770"
      unitRef="usd">86500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i17bad89df3f34651a5f6e776704460f7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTItMi0xLTEtMA_95246c62-8eae-4f61-9abe-d7ed0e533547"
      unitRef="usd">1168900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i17bad89df3f34651a5f6e776704460f7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTItNC0xLTEtMA_2bf252b9-251d-4999-aec7-af0a4a1d0388"
      unitRef="usd">733800000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i17bad89df3f34651a5f6e776704460f7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTItNi0xLTEtMA_202ac294-631f-4dd8-a2b9-bc7b4a7ada54"
      unitRef="usd">14900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i17bad89df3f34651a5f6e776704460f7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTItOC0xLTEtMA_d16c71be-6fa2-44a9-af86-51d593ce4922"
      unitRef="usd">1887800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTctMi0xLTEtMTA5MTY_dd68f05f-4898-4dad-a1ea-cb7aa1643698"
      unitRef="usd">1239500000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTctNC0xLTEtMTA5MTY_360407a0-8367-45f4-b46c-8cde418609fa"
      unitRef="usd">749700000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTctNi0xLTEtMTA5MTY_bab75cc5-d579-4d3d-8daa-e67bb34c848f"
      unitRef="usd">14900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmFkYjQ4YTNlZmE0ZDQxNzk4OWIyZGQ0Yjk0NmEyOWI1L3RhYmxlcmFuZ2U6YWRiNDhhM2VmYTRkNDE3OTg5YjJkZDRiOTQ2YTI5YjVfMTctOC0xLTEtMTA5MTY_a9cac46f-d09a-4306-a83f-a799db19925b"
      unitRef="usd">1974300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMzc4Nw_55912244-9b56-45c8-9e95-1139f8c0b216">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,320.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,320.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;781.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;780.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,141.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,140.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMi0yLTEtMS0w_31a2e07d-20e2-4ee9-96e6-bf32772b8d92"
      unitRef="usd">1320000000.0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMi00LTEtMS0w_4b7d0d20-9754-4c82-82c5-8f0e8e32131f"
      unitRef="usd">1320200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMi02LTEtMS0w_5a9f11e1-51ba-487e-86fc-a3d4b28ed187"
      unitRef="usd">1278900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMi04LTEtMS0w_75d59d1b-28ba-497f-b37b-f863a99a1026"
      unitRef="usd">1278600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMy0yLTEtMS0w_2020e620-edd4-42b0-ba5a-3fd98432e4ea"
      unitRef="usd">781200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMy00LTEtMS0w_70e7821c-b432-407e-b71f-82a422ae3a0d"
      unitRef="usd">780400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMy02LTEtMS0w_ce3868f1-dabc-4170-862f-ec41a9f2e2d2"
      unitRef="usd">722600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfMy04LTEtMS0w_9792e7b1-3ab1-42ab-8723-e02e44d0f1ce"
      unitRef="usd">721300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNC0yLTEtMS0w_6b974a88-b8f2-4f00-9d7e-b5b8ae8180c2"
      unitRef="usd">40700000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNC00LTEtMS0w_ab54054a-d1b1-45f0-89ba-4576d4744838"
      unitRef="usd">40300000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNC02LTEtMS0w_153be251-a354-4584-81bf-0a3970594ba7"
      unitRef="usd">49500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNC04LTEtMS0w_eda888e1-9902-496b-aab7-579481e09de4"
      unitRef="usd">49200000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecurities
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNS0yLTEtMS0w_eeca888b-2de1-415d-beb1-b1b8977bfa57"
      unitRef="usd">2141900000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNS00LTEtMS0w_3d747350-07ce-4c37-a92c-2e265f061592"
      unitRef="usd">2140900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNS02LTEtMS0w_54eea19a-17ac-4c0f-9302-238ec8cee529"
      unitRef="usd">2051000000.0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOjBiZjY4YmZhYWVkODQxNGJiZjY1ZDlkZGNhMDNiYWVhL3RhYmxlcmFuZ2U6MGJmNjhiZmFhZWQ4NDE0YmJmNjVkOWRkY2EwM2JhZWFfNS04LTEtMS0w_9c67592d-dec6-4913-a4c9-d02672feb185"
      unitRef="usd">2049100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfOTkw_0a2133ec-6553-43cb-b8e7-789a804e6de0">P12M</biib:AverageMaturityOfMarketableSecurities>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="iff71e9fbc56d4559bdd9a623ccc89b89_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTAwNA_a48298ba-34f9-4460-b5fe-6a123bec486d">P11M</biib:AverageMaturityOfMarketableSecurities>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMzc5OA_f02dab0b-3ede-41e8-9fd2-41fb4da065d4">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;819.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,389.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmZiOWM2MWEwMGJhNjRkZWM4Y2JmZTg5Y2UzYmYwMjZmL3RhYmxlcmFuZ2U6ZmI5YzYxYTAwYmE2NGRlYzhjYmZlODljZTNiZjAyNmZfMi0yLTEtMS0w_bf90e444-49b0-4ef9-a34a-10dded9247e4"
      unitRef="usd">819200000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmZiOWM2MWEwMGJhNjRkZWM4Y2JmZTg5Y2UzYmYwMjZmL3RhYmxlcmFuZ2U6ZmI5YzYxYTAwYmE2NGRlYzhjYmZlODljZTNiZjAyNmZfMi00LTEtMS0w_50dd5911-513d-4d37-9989-5e370d4a958a"
      unitRef="usd">2389300000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmZiOWM2MWEwMGJhNjRkZWM4Y2JmZTg5Y2UzYmYwMjZmL3RhYmxlcmFuZ2U6ZmI5YzYxYTAwYmE2NGRlYzhjYmZlODljZTNiZjAyNmZfMy0yLTEtMS0w_bc03006b-f0d3-4310-8fe6-0839dd923a39"
      unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmZiOWM2MWEwMGJhNjRkZWM4Y2JmZTg5Y2UzYmYwMjZmL3RhYmxlcmFuZ2U6ZmI5YzYxYTAwYmE2NGRlYzhjYmZlODljZTNiZjAyNmZfMy00LTEtMS0w_22e9ca3e-94e5-4307-b504-dff8257f20f8"
      unitRef="usd">5700000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmZiOWM2MWEwMGJhNjRkZWM4Y2JmZTg5Y2UzYmYwMjZmL3RhYmxlcmFuZ2U6ZmI5YzYxYTAwYmE2NGRlYzhjYmZlODljZTNiZjAyNmZfNC0yLTEtMS0w_4039e056-9be6-42fd-a695-882e5a768ba9"
      unitRef="usd">700000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RhYmxlOmZiOWM2MWEwMGJhNjRkZWM4Y2JmZTg5Y2UzYmYwMjZmL3RhYmxlcmFuZ2U6ZmI5YzYxYTAwYmE2NGRlYzhjYmZlODljZTNiZjAyNmZfNC00LTEtMS0w_9716b4ac-426e-41f1-a5bc-87c23242d711"
      unitRef="usd">19100000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <biib:StrategicInvestmentPortfolio
      contextRef="i0a283fbf212a4481af4e7343abe77f50_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTMyMA_2ab4fbb5-2cef-4616-9c31-db5a1e38913a"
      unitRef="usd">1493100000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio
      contextRef="i0ee9e38341534af88bad1e7379c5795d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTMyNw_a464151b-ce35-4ef9-8acd-6a15587d7c38"
      unitRef="usd">2024600000</biib:StrategicInvestmentPortfolio>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTA5OTUxMTYzMzc4OA_44734746-f102-471a-b5fc-5b19f1b4dfe7"
      unitRef="usd">650000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTA5OTUxMTYzMzc5NA_2b6bc054-4a8e-4ac6-9909-ae30110511b2"
      unitRef="shares">6200000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare
      contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTA5OTUxMTYzMzgwMA_b12f352d-cd88-455b-a33b-531af218ab60"
      unitRef="usdPerShare">104.14</biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare>
    <biib:DividendYieldPercentage
      contextRef="i131a6d5dd4084afa8625aea4291a03a4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTA5OTUxMTYzMjc1OA_a5b47e99-748b-49e8-bc37-e2dc6d1b2f14"
      unitRef="number">0</biib:DividendYieldPercentage>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTY0OTI2NzQ0ODI2OQ_62248d21-a735-43bf-906b-e6cc0b9f72dd"
      unitRef="usd">465000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:Investmentincommonstocksharespurchased
      contextRef="ibed8defa2fe84947a4f4b459fdd0d10f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTY0OTI2NzQ0ODI4MQ_18c12515-4851-4a41-855c-b328a2ab72fb"
      unitRef="shares">13000000</biib:Investmentincommonstocksharespurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTY0OTI2NzQ0ODI4Nw_27ed4e1e-2dc1-4bda-a294-4de8d482a33f"
      unitRef="usdPerShare">34.94</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <biib:DividendYieldPercentage
      contextRef="id355e63804de46f2b00142ad2e9766d4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMjQyNA_5d9f02ed-23b2-47be-b724-6402acc447d6"
      unitRef="number">0</biib:DividendYieldPercentage>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTY0OTI2NzQ0ODQ2NA_666d324c-34de-48bc-b5f1-eb12ed63bfbf"
      unitRef="usd">225000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTY0OTI2NzQ0ODQ3MA_e5cfced4-ad82-4831-9b41-3a838b50c201"
      unitRef="shares">24000000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMTY0OTI2NzQ0ODQ3Ng_529e6695-cf4a-4a66-86a2-e44f3f6796c0"
      unitRef="usdPerShare">9.21</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <biib:DividendYieldPercentage
      contextRef="i7d61eda3c47a477a87953bd9435f3fdc_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83My9mcmFnOmEzODhhNDljMTM1NzQxZWE4M2YwZTE5MDJkZDdhOTA3L3RleHRyZWdpb246YTM4OGE0OWMxMzU3NDFlYTgzZjBlMTkwMmRkN2E5MDdfMzUxNw_92a0a6a9-5c0e-46f2-a6d9-7447e2b2762e"
      unitRef="number">0</biib:DividendYieldPercentage>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjk4Ng_bf084455-79da-47f0-bfd0-e0719571e36c">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenue and operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency forward contracts in effect as of March 31, 2021 and December 31, 2020, had durations of 1 to 21 months and 1 to 24 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,657.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,979.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,186.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity as of March 31, 2021, reflected aggregate net unrealized losses of $41.5 million, composed of gross unrealized losses of approximately $73.5&#160;million and gross unrealized gains of approximately $32.0&#160;million, compared to aggregate net unrealized losses of $212.5 million as of December 31, 2020. We expect the net unrealized losses of $41.5 million to be settled over the next 21 months, of which $54.3 million of unrealized losses are expected to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of March 31, 2021 and December 31, 2020, credit risk did not materially change the fair value of our foreign currency forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Rate Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Swap Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of our 2.90% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $675.0 million, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our 2.90% Senior Notes attributable to changes in interest rates. The carrying value of our 2.90% Senior Notes as of December 31, 2020, included approximately $2.3&#160;million related to changes in the fair value of these interest rate swap contracts. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our 2.90% Senior Notes, resulting in a gain of approximately $3.3 million, which was recorded as a component of interest expense in our condensed consolidated statements of income during the second quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Investment Hedges - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of March 31, 2021, had a remaining duration of seven months. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $2.7 million and net losses of $21.2 million as of March 31, 2021 and December 31, 2020, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of $0.1 million and $0.2 million as of March 31, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was $1,358.8 million and $1,158.0 million as of March 31, 2021 and December 31, 2020, respectively. Net losses of $17.4 million and $2.4 million related to these contracts were recorded as a component of other income (expense), net for the three months ended March 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="ia617f0f0d1234327a3119ea448c3da76_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjI5_6a0fe9ff-8c3d-4222-9a91-1a740a600916">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i9113178df6744dbebe8d536cedbb476d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjM1_3baba6d2-11b4-4046-b32c-acc85b0068b4">P21M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="ia0888eb887324fbcb06a48bb48e3d178_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjQy_9926c7e7-31e4-4603-bff0-137ad57e5031">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i6ef2ea3f8af4435f8e0f9aeefee13306_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjQ4_0b605b3a-bce6-4885-8e80-22ff5f620769">P24M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjk1MQ_bd438366-5237-4280-bc25-e79ae194e17c">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,657.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,979.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,186.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ied82434791db403c955ea793bffb2f0e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfMi0yLTEtMS0w_1299224a-4078-413e-9079-72150edfbfa4"
      unitRef="usd">2657600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if9c72eafd68c4e398efd063c308f2dbd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfMi00LTEtMS0w_2a188d0b-a8ce-430d-b417-a1054e3584fb"
      unitRef="usd">2979100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i536f8ba047234c319b7406ff767147dd_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfMy0yLTEtMS0w_3cb39643-7cc2-4936-a34d-ab530f85ed8e"
      unitRef="usd">190400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="idb70d5c3848d414f9ce893ad215d4dec_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfMy00LTEtMS0w_569f025c-bfd6-4205-b885-9e72e1fe3e98"
      unitRef="usd">250600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i02b2de87f30d4c6f8b03613d9c2807d2_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNC0yLTEtMS0w_40fed773-f717-4b3f-b5fe-60d432ad6071"
      unitRef="usd">159400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i07af47860d104f6d8ed73f6a89548b2b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNC00LTEtMS0w_02e07b8b-776f-4c33-b88b-0b848ab51dbd"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i40059c26d0bb4c04a23a67aef6915a45_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNS0yLTEtMS0w_66ee5187-61cb-44d4-ac7c-bbd3766c392b"
      unitRef="usd">98500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ifa2654f256764c58a2843f3f977d1dfa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNS00LTEtMS0w_5c7e239e-fade-43f4-91d9-c13200ec41a9"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0457c0290322402daedccdba35db7c6d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNi0yLTEtMS0w_c47640f3-30f5-4aa4-a595-ceb637ac528d"
      unitRef="usd">80500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib58b6d257da24ff8b4839e62a689e898_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNi00LTEtMS0w_cc9371a7-37c6-4c4c-8dd7-8e772a17f061"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0f749230a90846feaffa937710c3bd7f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNy0yLTEtMS0w_91011373-6267-4b3f-a712-4a49cbd596e0"
      unitRef="usd">3186400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie6a1954375c4428c8c9f1e2459422a19_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjVlZTYwYmE4MzNmNjRhNDY4NTRhNTc2MjE0YzNhODgwL3RhYmxlcmFuZ2U6NWVlNjBiYTgzM2Y2NGE0Njg1NGE1NzYyMTRjM2E4ODBfNy00LTEtMS0w_4b3f299c-41f1-4dc4-a20e-aad42d294000"
      unitRef="usd">3229700000</us-gaap:DerivativeNotionalAmount>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTc5OA_26f4b30b-57a5-4bb9-9954-038481f06c9c"
      unitRef="usd">-41500000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTA5OTUxMTYzNTk1Mw_4f596e87-a9be-455a-bf91-18724a69c5e1"
      unitRef="usd">73500000</biib:UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTA5OTUxMTYzNTk2OA_872747ca-713c-4432-b6f1-955593264960"
      unitRef="usd">32000000.0</biib:UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTgxOA_e8f6315c-77e3-4ecc-9c46-1b11abf007b5"
      unitRef="usd">212500000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTg4MA_26f4b30b-57a5-4bb9-9954-038481f06c9c"
      unitRef="usd">-41500000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i9113178df6744dbebe8d536cedbb476d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTkxMQ_699517c9-d0dc-40a2-81b6-ef9bead43eaf">P21M</us-gaap:DerivativeRemainingMaturity1>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i5684eeb894e948e795d7ba13a0a9821b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTkyNA_fb056673-e345-49b7-aabe-144e596edb3d"
      unitRef="usd">-54300000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="ibe1bc0a4b4384b369f562b05efbd0f01_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTk4NA_c0040cdc-774e-4a0a-b8d3-1b1e9a7f9631">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjk2OQ_991b2c44-3628-4cfc-a179-be69d979c7cd">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ide647841e7044ab48b55cda50f1d1520_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfMy0yLTEtMS0w_02f48963-d038-402f-8020-349c5c9d16d8"
      unitRef="usd">-23100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i2a595e77e9024184a813ff4337b0408b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfMy00LTEtMS0w_47ba2ca5-874a-4a8b-962b-e0a5db518158"
      unitRef="usd">27000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i52305514d2d248ef8eac2ce5da013356_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfMy04LTEtMS0w_7322fe76-b525-4b17-b84b-3b1cd1221b7c"
      unitRef="usd">-3000000.0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i2a87c0642d8c4661b4616dcafaf98925_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfMy0xMC0xLTEtMA_8d810c9a-6df6-41ef-954b-7f772d633a3e"
      unitRef="usd">9300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ic532929c81174c56bed2bcbdbaad621f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfNC0yLTEtMS0w_9afc6b80-f090-4e83-8142-fe92e76f245b"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i87deea9139694467a9fdc201db179c76_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfNC00LTEtMS0w_3885e590-e202-4ca2-98c7-8787d386d6d1"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i374fbb6203a34bf4944599f7c1e45415_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfNC04LTEtMS0w_788abe3d-99ff-4d08-8e6c-8ad9b1c13af3"
      unitRef="usd">-100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i5c7748a642e745f88a124b19bc7f4714_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjY0Yjc1NjgwMjRiNTQ2MWU4MjMwYzQwM2NjZjU4MjQ2L3RhYmxlcmFuZ2U6NjRiNzU2ODAyNGI1NDYxZTgyMzBjNDAzY2NmNTgyNDZfNC0xMC0xLTEtMA_e50de7d4-f504-4fbe-9115-71dd86597949"
      unitRef="usd">-900000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i86ba11dc3301448dab6e7f9202ed71a0_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMjkxNQ_c1a69865-b78a-40e5-b4e1-03bb430d7af3"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i17821dc2bf9b41c6b08b07a41c8ce707_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMzAyOA_d4490e58-f561-4fc3-9b33-578ac530f184"
      unitRef="usd">675000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i86ba11dc3301448dab6e7f9202ed71a0_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMzE4Mw_c1a69865-b78a-40e5-b4e1-03bb430d7af3"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i86ba11dc3301448dab6e7f9202ed71a0_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMzI2OA_c1a69865-b78a-40e5-b4e1-03bb430d7af3"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i979c6df8053649cfb7b8b90a285b165d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTA5OTUxMTYzNTE1NQ_cc494a59-d4db-4604-976b-aa11226ca7fa"
      unitRef="usd">2300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i86ba11dc3301448dab6e7f9202ed71a0_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMzQ5NQ_c1a69865-b78a-40e5-b4e1-03bb430d7af3"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i14942974e4f2452cad88e831cc7cddda_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMzU0OQ_00fea8c1-d5ec-4c62-98a7-565391524190"
      unitRef="usd">3300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="i6d8e15ff35ac44bab6ffcdf343f511ac_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNDA1NQ_924a95f9-a9fa-4a24-8b98-4c740badb7a5"
      unitRef="number">0.050</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9201821f02cc43b3b8f8fabadde5754b_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNDA3NQ_7469fd6a-8dc2-4dc9-a5fd-58515022a743"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ibe4be84a93994def8ed976d74fd1dfec_D20181101-20181130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNDE2OA_6a5d5329-7835-40b8-8130-74dcded7828d"
      unitRef="krw">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ibe4be84a93994def8ed976d74fd1dfec_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNDE4OQ_b01543e3-4392-4315-9c31-ed014e936ecf"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:DerivativeTermOfContract
      contextRef="iee1f4bcc0a9b4476bc090cfa49e3c034_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNDU2Mg_0958cd8a-99e7-45a1-8234-84813537beaf">P7M</us-gaap:DerivativeTermOfContract>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="iee1f4bcc0a9b4476bc090cfa49e3c034_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNDkxNQ_f2fa7455-6d7c-4925-a6bf-2828b3ff3277"
      unitRef="usd">2700000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i1236ccb8b6ae4703835b4052a03f112b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNDkzNg_f8a8bf3a-7f3c-432e-850f-bf16e0104713"
      unitRef="usd">21200000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="i9aaed4b4b8474e7e9b340a6d01f5046c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNTM3MQ_ae9ebb4d-d761-463b-a210-df3a6d0769a0"
      unitRef="usd">100000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="i2e5e89f06e804ddc81397c8b1168e259_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNTM3OA_4f99cae7-7663-4f8b-92bc-d4f849dabe67"
      unitRef="usd">200000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjk2MA_26087be4-ba8e-4508-8475-67e9b959d668">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="iee1f4bcc0a9b4476bc090cfa49e3c034_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOmYxZjhlNTllNGFjYzQwM2NhZjk2YjczYTAxMTUyOWUzL3RhYmxlcmFuZ2U6ZjFmOGU1OWU0YWNjNDAzY2FmOTZiNzNhMDExNTI5ZTNfMy0yLTEtMS0w_c6203b19-fd1d-4a89-86e7-cbf976b96e92"
      unitRef="usd">23800000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i25755164c7c047c2ac74d54b1cdcb1d8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOmYxZjhlNTllNGFjYzQwM2NhZjk2YjczYTAxMTUyOWUzL3RhYmxlcmFuZ2U6ZjFmOGU1OWU0YWNjNDAzY2FmOTZiNzNhMDExNTI5ZTNfMy00LTEtMS0w_1ef4a963-5760-46b9-985c-91698ce712b9"
      unitRef="usd">24200000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="iee1f4bcc0a9b4476bc090cfa49e3c034_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOmYxZjhlNTllNGFjYzQwM2NhZjk2YjczYTAxMTUyOWUzL3RhYmxlcmFuZ2U6ZjFmOGU1OWU0YWNjNDAzY2FmOTZiNzNhMDExNTI5ZTNfMy04LTEtMS0w_5c4ce876-6422-4bd7-b90b-d792633b2502"
      unitRef="usd">-1400000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="i25755164c7c047c2ac74d54b1cdcb1d8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOmYxZjhlNTllNGFjYzQwM2NhZjk2YjczYTAxMTUyOWUzL3RhYmxlcmFuZ2U6ZjFmOGU1OWU0YWNjNDAzY2FmOTZiNzNhMDExNTI5ZTNfMy0xMC0xLTEtMA_7801f686-e45e-439f-9ba3-6b9085863020"
      unitRef="usd">-300000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i54eb17b8eef44296a8fdc3c7b6bd76af_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOmYxZjhlNTllNGFjYzQwM2NhZjk2YjczYTAxMTUyOWUzL3RhYmxlcmFuZ2U6ZjFmOGU1OWU0YWNjNDAzY2FmOTZiNzNhMDExNTI5ZTNfMy0xNC0xLTEtMA_1c140e4f-b22b-4ac8-85a6-0b169d397fc5"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i78981389f5f94e5eadeefbd380f6d4ef_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOmYxZjhlNTllNGFjYzQwM2NhZjk2YjczYTAxMTUyOWUzL3RhYmxlcmFuZ2U6ZjFmOGU1OWU0YWNjNDAzY2FmOTZiNzNhMDExNTI5ZTNfMy0xNi0xLTEtMA_45108322-e670-44f3-a17b-de4ee579db30"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i83451001a11e4d698aaaf41cfef4dc3e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjA5Nw_e1a7ba4e-86f5-403b-bc80-b7cf00b3009b"
      unitRef="usd">1358800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i868b061cb602497db91dcef241c70a3b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjEwNA_5d5de798-bad6-4db1-8fe6-22fd30f472fc"
      unitRef="usd">1158000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTA5OTUxMTYzNTEwOA_8a59382e-a30c-4995-b2fa-441a89dfd393"
      unitRef="usd">17400000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfMTA5OTUxMTYzNTQ0MQ_3e0d6801-fc9c-47a9-a0b0-5b61b0f1745d"
      unitRef="usd">2400000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RleHRyZWdpb246NjNmMGVmNzAyMGJlNGYxNjk2MTc2OTlhNWZhNjU5MTNfNjk2NQ_1d391748-321d-47f8-b976-936156d6c887">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ia665bc2c1fc141a1a5ca42007baa03e9_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMi00LTEtMS0w_6439f984-d86b-4617-b4cd-9adfccdd7a98"
      unitRef="usd">20600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ia08a43cc4bff411ca2c03d302026578f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMi02LTEtMS0w_5fc79da6-4e72-4432-8912-ebdea76b8e19"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i888cda8777754c04ac0cb1995bd7bfa8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMy00LTEtMS0w_efe2a155-e23d-4e86-9f1d-e666914e46c4"
      unitRef="usd">15200000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ib6d155f75ea4423db88f5212a2c98b00_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMy02LTEtMS0w_82758c5e-ba07-4f64-9127-c2e678deca84"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i4ecf3d9b5a444b63953faed5774226de_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfNC00LTEtMS0w_c12f64b7-1f11-4d2e-883e-22998ed29e97"
      unitRef="usd">60800000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3b3a3bb2800746138b838c49892a8c1b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfNC02LTEtMS0w_8e140871-f98f-46e7-a20f-492c8db5979f"
      unitRef="usd">157100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i51a5027177624992b876d1ea94cede10_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfNS00LTEtMS0w_70772050-6683-46a2-aeff-30e544022588"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iad77af33cb984b0e9bb3ef62ed1ebb74_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfNS02LTEtMS0w_fd200b1c-26c7-44a9-9632-05c164a117b9"
      unitRef="usd">35700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i731212cbf9b94995850d82a2311a7c17_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfOC00LTEtMS0w_c2e16450-9c3a-4569-9f5f-c381507f7716"
      unitRef="usd">2700000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i6f8e35902ecf4f34b94a8d17d9489454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfOC02LTEtMS0w_14804fc0-277b-4929-9772-0bf6f932cfe0"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i57f385654e1742b6a56d8fb4d0ade38e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfOS00LTEtMS0yMzkw_0b7b79ad-ce99-49f2-acaf-01e179d91e5a"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i7228047741514b81981471c02ea16f0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfOS02LTEtMS0yMzkw_1ea6299d-0d9c-41d7-a86b-0f0e15886b22"
      unitRef="usd">19700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i9d7974ac17f340839427c22253a75e1a_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMTUtNC0xLTEtMA_ae98b125-948c-4d87-b9c3-cd539bc578d7"
      unitRef="usd">12700000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ie0901c785f9c4846b1b5c357e1bf4da5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMTUtNi0xLTEtMA_8137569b-b6b3-4f0d-8237-5c547e6749bc"
      unitRef="usd">20500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i1ad5e6108b894c5681f7fde6c91cbfc2_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMTYtNC0xLTEtMA_6ce6c942-14ef-472f-a722-274200fc3265"
      unitRef="usd">27800000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3f44a3b624d34174b5f92cb92f67b731_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV83OS9mcmFnOjYzZjBlZjcwMjBiZTRmMTY5NjE3Njk5YTVmYTY1OTEzL3RhYmxlOjlhN2FhMGJmN2VmYTQyMjY4OWE1OTc1Y2IwMWVlYTVhL3RhYmxlcmFuZ2U6OWE3YWEwYmY3ZWZhNDIyNjg5YTU5NzVjYjAxZWVhNWFfMTYtNi0xLTEtMA_362805e3-4b64-4654-aa7b-2eb7240fe07f"
      unitRef="usd">4700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfMTI0Mg_ab6de1f9-dfc5-4fd3-81be-a594d40676ff">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $1,827.6 million and $1,782.3 million as of March 31, 2021 and December 31, 2020, respectively. For the three months ended March 31, 2021, depreciation expense totaled $48.8 million compared to $48.4 million in the prior year comparative period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of March 31, 2021 and December 31, 2020, we had approximately $1.9 billion and $1.8 billion, respectively, capitalized as construction in progress related to this facility.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfMTcx_534c69be-6d37-4da2-9946-2b3368826d08"
      unitRef="usd">1827600000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfMTc4_c42fa15a-fddb-4543-9e4f-20a4adfe6f9e"
      unitRef="usd">1782300000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfMjc2_d6e7c8aa-5e4d-4b86-a29a-c031f1a3fce6"
      unitRef="usd">48800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfMzEz_a89c62e2-9246-49ff-afbc-49514a6e290a"
      unitRef="usd">48400000</us-gaap:Depreciation>
    <biib:NumberOfSquareFeet
      contextRef="i6d21834e33c0420f926fcb969d864201_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfNzA5_0cbd67c0-e0fd-4ac7-a098-6a2d810569b6"
      unitRef="sqft">393000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="ic5944e21d13b439296ad6220144c780e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfNzgz_c9defdf2-d643-4ca2-8d22-ba1c3d8eb43b"
      unitRef="sqft">290000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="iaeecea45f6d1449081d0846aaae7ef11_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfODQ0_a3708ed9-270e-4e6f-948c-72a7790e9d54"
      unitRef="sqft">51000</biib:NumberOfSquareFeet>
    <us-gaap:ConstructionInProgressGross
      contextRef="i724f2b0183a64064a5b4c3edbfee2752_I20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfOTIy_417d0a8c-2b3e-4e82-8a83-873d8e90b3bd"
      unitRef="usd">1900000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="if5111c584bd441549e34423b141b35c9_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84NS9mcmFnOjc0MmU4YTQ1MjAwMzRlYjA5YmI2OWE0ZDFkZGZlZTA1L3RleHRyZWdpb246NzQyZThhNDUyMDAzNGViMDliYjY5YTRkMWRkZmVlMDVfOTI5_61a93ab5-4c45-4a88-b910-51e0424eb1d3"
      unitRef="usd">1800000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMjQyMA_02afe631-d2da-463d-8ff4-b2d2c19c7471">&lt;span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Indebtedness&lt;/span&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exchange Offer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An aggregate principal amount of approximately $624.6&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $700.7&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $151.8&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we redeemed an aggregate principal amount of approximately $8.9&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $12.1&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $3.2&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the three months ended March 31, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon settlement, we also made aggregate cash payments of approximately $13.8&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $6.1&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $3.0 billion (2020 Senior Notes), consisting of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt"&gt;$1.5 billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030, valued at 99.973% of par; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt"&gt;$1.5 billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050, valued at 99.174% of par.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred approximately $24.4 million of costs associated with this offering, which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. For additional information on our 2020 Senior Notes, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2.90% Senior Notes due September 15, 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2015, we issued $1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020, at 99.792% of par. Our 2.90% Senior Notes were senior unsecured obligations. In connection with the 2.90% Senior Notes, we entered into interest rate swap contracts where we received a fixed rate and paid a &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our 2.90% Senior Notes prior to their maturity and recognized a net pre-tax charge of $9.4 million upon the extinguishment of these notes during the second quarter of 2020. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income and reflects the payment of a $12.7 million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $3.3 million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate swap contracts, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8, Derivative Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;</us-gaap:DebtDisclosureTextBlock>
    <biib:LongTermDebtExchangedAmount
      contextRef="i9541283653d242f48d85e9890e9c2777_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTM3NA_d889e5e9-438d-4933-b75b-00aefc85fd12"
      unitRef="usd">624600000</biib:LongTermDebtExchangedAmount>
    <biib:LongTermDebtExchangedAmount
      contextRef="i92e65fe683a2421f94f2dc6385f162f6_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTM5Nw_dee727dc-b57b-46ad-b846-3c577185cbf6"
      unitRef="usd">700700000</biib:LongTermDebtExchangedAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="icf27a73b87464b70a24f4215cf6a7822_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTQxMw_76866ad6-6b7a-4145-89b0-dff0e1080f61"
      unitRef="usd">151800000</us-gaap:RepaymentsOfSeniorDebt>
    <biib:DebtInstrumentRedemptionAmount
      contextRef="i9541283653d242f48d85e9890e9c2777_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTQyOQ_f5d3f63f-357d-413f-a70d-ce053ad7cdae"
      unitRef="usd">8900000</biib:DebtInstrumentRedemptionAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i9541283653d242f48d85e9890e9c2777_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTQ0Mw_1640b807-b8c0-45c0-abd9-cdfb9cae73fa"
      unitRef="usd">12100000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i1203eeb4805841f0ac2cd72de89f499a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTQ5MQ_86f0211b-231b-4edd-a5ba-c7564488c6d1"
      unitRef="usd">3200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i1203eeb4805841f0ac2cd72de89f499a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTU3NQ_415a72bd-2aee-4a99-9726-5bcb3e3b2722"
      unitRef="usd">13800000</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestExpense
      contextRef="i1203eeb4805841f0ac2cd72de89f499a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5OTUxMTY0MTYzNQ_bee639cd-59b0-4e32-9134-7e3472a3263b"
      unitRef="usd">6100000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i016c570732cb4e06b13838775a874ce8_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTA5_39834a4a-5fc6-4014-ab32-6d5a46cfb2a6"
      unitRef="usd">3000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id947942c69fa44ce89256cc80c1e696a_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTYz_537f60ce-206a-4761-97b9-5bddbf270dbb"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id947942c69fa44ce89256cc80c1e696a_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTY5_674a6a18-c253-4750-ac9f-a5420e56fe4f"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="id947942c69fa44ce89256cc80c1e696a_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMjAz_36e7205c-70aa-4665-b892-8eed691372e9"
      unitRef="number">0.99973</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id662c0ca4fe34fb99b51e17485cdad55_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMjE4_181b3717-5114-4e33-ba71-a5582a419f46"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id662c0ca4fe34fb99b51e17485cdad55_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMjI0_3dd93c8e-a684-48d5-a893-8a6ff8b3a9d9"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="id662c0ca4fe34fb99b51e17485cdad55_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMjU4_a0c9159e-a573-4497-bbc3-9806bfb39fd2"
      unitRef="number">0.99174</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfNzc3_ffb7f935-9252-4e28-8e49-e1de49882566"
      unitRef="usd">24400000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id9e2646cf66a4acea08af56195b01b34_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTQxNg_68097fce-4988-41ac-b233-831bfede076c"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id9e2646cf66a4acea08af56195b01b34_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTQ0OQ_b6fabe24-4477-441d-80cf-ec7622e2de62"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="id9e2646cf66a4acea08af56195b01b34_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTQ5Mg_e6b25ae1-4cd6-480f-894d-b6003ee8850d"
      unitRef="number">0.99792</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id9e2646cf66a4acea08af56195b01b34_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTUwNw_f715cedb-add1-4ec5-a598-c1992157eb97"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id9e2646cf66a4acea08af56195b01b34_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfNzY5NjU4MTQxMzk5MQ_b6fabe24-4477-441d-80cf-ec7622e2de62"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id9e2646cf66a4acea08af56195b01b34_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTc1NQ_251104fc-c100-462a-9e87-e6a4c9978b01"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain
      contextRef="ibb46cac46d2848cfad57259f2ed1d632_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMTgzNA_5bac70a0-bc60-4f37-8f74-be2538de8b92"
      unitRef="usd">9400000</biib:PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain>
    <biib:EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts
      contextRef="ibd1b2f47353e4aaebcecdfcb602f4de9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMjA2Nw_f9dc0846-b4bc-4398-bfb7-476acb0d77a6"
      unitRef="usd">12700000</biib:EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i14942974e4f2452cad88e831cc7cddda_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV84OC9mcmFnOmQ5MWZlZmU0NmRjNTRkNzg4NmZiZGUyNTczMDUzMGY1L3RleHRyZWdpb246ZDkxZmVmZTQ2ZGM1NGQ3ODg2ZmJkZTI1NzMwNTMwZjVfMjIwNg_00fea8c1-d5ec-4c62-98a7-565391524190"
      unitRef="usd">3300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTQ5MQ_2998c8be-b1a0-4bb2-8ac3-39bf5e66c9dd">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.2 million shares of our common stock at a cost of approximately $600.0 million during the three months ended March 31, 2021. Approximately $4.0 billion remained available under our 2020 Share Repurchase Program as of March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 3.2&#160;million shares of our common stock at a cost of approximately $941.1&#160;million during the three months ended March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1&#160;million shares of our common stock at a cost of approximately $1.3&#160;billion during the three months ended March 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(179.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(174.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(203.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="if4d015ecb936405daf574b4e3105f141_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTEx_be0dd634-955d-4a19-adc1-097bb8437b5c"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i790882cea9a743939fad5f1974b20135_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTA5OTUxMTYyOTYzOA_0fbf322c-01ab-4d2a-9b4a-938dc90c834e"
      unitRef="shares">2200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i790882cea9a743939fad5f1974b20135_D20210101-20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTA5OTUxMTYyOTY0OA_5cdb1395-a00d-418d-9ec8-aad6811acff6"
      unitRef="usd">600000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i5ee194f83e384c83974d24f728c5145b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMzg0ODI5MDY5OTI0OQ_ad17bbb8-5de2-4923-b507-2afccd1c1b26"
      unitRef="usd">4000000000.0</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i5b8709d2eae04591a6115e04171e59b0_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMzg0_6e31cb23-b8e4-4129-9b65-242191c2f254"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i5f5341349d2f494d97ea527c3a617208_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTA5OTUxMTYyOTI5Mw_bf96d9cc-d8b1-4f70-bf48-c9ecb1747c81"
      unitRef="shares">3200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i5f5341349d2f494d97ea527c3a617208_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTA5OTUxMTYyOTI5OA_a54451ad-4a2c-4493-a524-5bcc8438ecf6"
      unitRef="usd">941100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="iee2acff297c64ff1859c44405ba33de8_I20200331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfODM2_c1bd1df3-f251-4887-82cc-e50a97ef5f5e"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i25ca0d3089b9406197bdca98e4d63b1b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTA5OTUxMTYyOTMxNw_9cb3bf11-61fc-42c9-81c8-bde984bb9ac1"
      unitRef="shares">4100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i25ca0d3089b9406197bdca98e4d63b1b_D20200101-20200331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTA5OTUxMTYyOTMyNg_d2b8ba43-48d3-4b4e-8673-625bb019208d"
      unitRef="usd">1300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTQ3Mg_35197989-cca0-4b24-b6da-e5d8d4591aed">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(179.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(174.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(203.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id6d9591af95346bca52a790ec1831e51_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMS0yLTEtMS0w_b0fd366e-f89d-4105-bf2a-aa9ea94ca44a"
      unitRef="usd">1400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i121f989f64d54d71990d30584fc92371_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMS00LTEtMS0w_2000bff2-9461-42a0-b592-a6b46f9f06fa"
      unitRef="usd">-179000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="icc0e23fcbfe244b5914449511bb9de9a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMS02LTEtMS0w_f88e2288-dae3-4dda-b2b5-e46179a2d49f"
      unitRef="usd">-8500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i33ed22d7f19146a98e5ed27cdcf69af6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMS04LTEtMS0w_28bc5df2-e3c3-4101-bce1-191454701e0a"
      unitRef="usd">-66300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie9a1a6add6db45b6a1cc3687b957361e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMS0xMC0xLTEtMA_e6fd63b2-a552-4c90-9926-29e609394ced"
      unitRef="usd">-46600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMS0xMi0xLTEtMA_2cf7afe0-b85a-434a-b9cd-30112daf6103"
      unitRef="usd">-299000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i89cad3952c464507908e42ec76b9683b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMi0yLTEtMS0w_cfe213e1-fe15-4561-8dc3-2c806438c2e9"
      unitRef="usd">-1200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie56cc9b03fcc4f6d9a86477a5270a889_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMi00LTEtMS0w_3df17193-11b7-43d6-a0a6-68fdfc6ba35b"
      unitRef="usd">128600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6617815be784402785f12c6988e1beee_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMi02LTEtMS0w_0870ace5-5063-48c9-a50d-4f1e859137ad"
      unitRef="usd">22400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if08aec04c4324a64a5bb6af5a48753a2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMi04LTEtMS0w_ecc9832b-5d12-4d53-b892-cc39579306ed"
      unitRef="usd">2000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i52012835f8e245adb31aeec016f4112a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMi0xMC0xLTEtMA_4bb96bb3-41c7-4a14-a4c2-9030b7c76766"
      unitRef="usd">-48500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMi0xMi0xLTEtMA_c4c8633a-fccc-4426-8e0b-7c54956c637e"
      unitRef="usd">103300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i89cad3952c464507908e42ec76b9683b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMy0yLTEtMS0w_b00f3237-1047-4b20-9e6e-163476eb2399"
      unitRef="usd">400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie56cc9b03fcc4f6d9a86477a5270a889_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMy00LTEtMS0w_84516de6-b8ef-441d-865b-f9f41ea46f87"
      unitRef="usd">21000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6617815be784402785f12c6988e1beee_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMy02LTEtMS0w_166a9776-d278-4b0f-a4bd-07cf93f6fdbb"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if08aec04c4324a64a5bb6af5a48753a2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMy04LTEtMS0w_2be20f28-3b6a-463a-ac58-e98209fc71e4"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i52012835f8e245adb31aeec016f4112a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMy0xMC0xLTEtMA_acfdf32b-7a13-474f-934a-367179b894f7"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfMy0xMi0xLTEtMA_605edff5-0503-467e-ab9a-b849d64993a3"
      unitRef="usd">21400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i89cad3952c464507908e42ec76b9683b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNC0yLTEtMS0w_b6832102-7f53-4a3b-b845-4b3f320abdd4"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie56cc9b03fcc4f6d9a86477a5270a889_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNC00LTEtMS0w_59b0492f-dc5a-49fc-a569-f2584bcebe29"
      unitRef="usd">149600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6617815be784402785f12c6988e1beee_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNC02LTEtMS0w_f89539fd-ef79-4abe-954c-301e5e2cb7fd"
      unitRef="usd">22400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if08aec04c4324a64a5bb6af5a48753a2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNC04LTEtMS0w_aea88981-3856-4dbb-9ebc-cc1e24b4b82e"
      unitRef="usd">2000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i52012835f8e245adb31aeec016f4112a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNC0xMC0xLTEtMA_4755cbe9-b61c-429f-ba0e-075c4c92f383"
      unitRef="usd">-48500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNC0xMi0xLTEtMA_5c0a7a8f-851e-4fb6-9fc7-ed9348786c79"
      unitRef="usd">124700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iccb1237016b141a5b01be03b134ebd55_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNS0yLTEtMS0w_2112cebf-f797-4b7c-93a2-aca1029a4475"
      unitRef="usd">600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i02a25f52836a44c688f515291d314595_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNS00LTEtMS0w_053318fe-d4c8-428d-a8a0-9016660e0330"
      unitRef="usd">-29400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i52a09764d13c4694a6f1f3b0b58dd09e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNS02LTEtMS0w_6a52e8b6-b5c0-4877-85c3-0f1ba40117cc"
      unitRef="usd">13900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ifd1befbf13d647bbbbce80021df07746_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNS04LTEtMS0w_db1acb7d-c699-4293-b54b-f062a10c14f5"
      unitRef="usd">-64300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6655179b6b2649759f156341cd1be463_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNS0xMC0xLTEtMA_8f0fdd9f-a0c6-4272-bae7-081a86817138"
      unitRef="usd">-95100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmFhMTYxODRmMWRkNjQxOWViZWUxMDBhNWUyYjRlYTA3L3RhYmxlcmFuZ2U6YWExNjE4NGYxZGQ2NDE5ZWJlZTEwMGE1ZTJiNGVhMDdfNS0xMi0xLTEtMA_aadc81ba-60c7-49fa-93d7-99760c2b341b"
      unitRef="usd">-174300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia26f4bf0d205499492e015dc1f5f9d6a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMS0yLTEtMS0w_41ecbd21-2098-4c30-8e7d-0b8442b0a6d7"
      unitRef="usd">4200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i58c1b21402d94dac9e67581cf6e009b9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMS00LTEtMS0w_6850c580-17c0-42c4-8727-392467e50b4e"
      unitRef="usd">7800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4ee0d5eaff614476bcb905bbd08373bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMS02LTEtMS0w_03679ed0-b6f8-467e-8a62-19e3d2b1ad9c"
      unitRef="usd">25100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie4eda08b11c34ae9a36408a31801e4ec_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMS04LTEtMS0w_53102286-806c-4333-956d-1a26319e7832"
      unitRef="usd">-32800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iaa803a04b06e4d9cb1a5f96364d792dd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMS0xMC0xLTEtMA_d8b80ab5-948a-43ff-b1fc-6a9dca7240df"
      unitRef="usd">-139500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0294157534ec4829a838f8161a2c6f76_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMS0xMi0xLTEtMA_d879c6f7-d02b-4173-a17a-00136de9d3cc"
      unitRef="usd">-135200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i5b7d97c6a13d4e7a91efccbf9a7a80a6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMi0yLTEtMS0w_84c16f7e-63e6-4de0-b63b-96a0aae1c3c9"
      unitRef="usd">-20800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i62772410ea3b48f99b42dec5a933607a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMi00LTEtMS0w_6aaa1b66-94aa-420e-8d42-e11b790e71b4"
      unitRef="usd">60700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i754c37b6ef7645eb9afbdbbda44b09f6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMi02LTEtMS0w_fa1a7d5a-75a2-48cf-9244-3948d872d1bc"
      unitRef="usd">23900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i590c8062df384811a4631c1a3f4c03cb_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMi04LTEtMS0w_29af9d9e-402c-4840-b39c-19e29ae8c523"
      unitRef="usd">800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9cc821229a0b466caa70f9efb4cbb784_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMi0xMC0xLTEtMA_f55c9718-ef7a-4606-a758-f50e0fe7d364"
      unitRef="usd">-63900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMi0xMi0xLTEtMA_1d3952ff-217f-4965-8586-be27c77024e6"
      unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i5b7d97c6a13d4e7a91efccbf9a7a80a6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMy0yLTEtMS0w_005553fd-1383-46bf-8284-71aa7de682d1"
      unitRef="usd">13000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i62772410ea3b48f99b42dec5a933607a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMy00LTEtMS0w_96613e90-8073-4180-b61f-b1c019bac17e"
      unitRef="usd">-26900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i754c37b6ef7645eb9afbdbbda44b09f6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMy02LTEtMS0w_a1090efb-22cf-4a46-ab68-76f75356240a"
      unitRef="usd">-900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i590c8062df384811a4631c1a3f4c03cb_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMy04LTEtMS0w_b26d2880-8288-45ef-ad5a-5f94306dafa7"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9cc821229a0b466caa70f9efb4cbb784_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMy0xMC0xLTEtMA_bb6de018-b0f3-4a9d-982b-0b92c738742f"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfMy0xMi0xLTEtMA_f9286e4b-0116-4ada-8960-1198923f445d"
      unitRef="usd">-14800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5b7d97c6a13d4e7a91efccbf9a7a80a6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNC0yLTEtMS0w_cfa2c539-2c84-42e3-9f8a-31cf037da357"
      unitRef="usd">-7800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i62772410ea3b48f99b42dec5a933607a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNC00LTEtMS0w_969b0427-7203-4f3c-abce-66f8d8e5aad9"
      unitRef="usd">33800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i754c37b6ef7645eb9afbdbbda44b09f6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNC02LTEtMS0w_a1f1a284-01a2-458e-b689-faeb0cfa04fc"
      unitRef="usd">23000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i590c8062df384811a4631c1a3f4c03cb_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNC04LTEtMS0w_b1e6790f-a0b4-4940-aa43-925e2e5807b5"
      unitRef="usd">800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9cc821229a0b466caa70f9efb4cbb784_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNC0xMC0xLTEtMA_65a8bde1-6508-4372-a8dc-895c5dadfeae"
      unitRef="usd">-63900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNC0xMi0xLTEtMA_2b7285b4-1e1e-4088-9760-7f07d168065f"
      unitRef="usd">-14100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ice4da96682e14bf78bf22af3dd2a4a8c_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNS0yLTEtMS0w_291f8da4-0996-46cf-abdb-5286bc50c2e3"
      unitRef="usd">-3600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie5d97abb270e493da281ba2ce68e7c8b_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNS00LTEtMS0w_f0c7b50e-99a4-49c0-926c-170315b39ba7"
      unitRef="usd">41600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i59583d2b241145dd9da8f108498b7d3e_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNS02LTEtMS0w_7401ac2c-6082-4b8b-9793-af86df66d947"
      unitRef="usd">48100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if9144d29ad0b4e8b89f55ce739a9ee63_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNS04LTEtMS0w_b04180de-7ec7-46ae-880a-fa299e30c7f0"
      unitRef="usd">-32000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i85e0459de37d462abb7762f5b8952479_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNS0xMC0xLTEtMA_a30cba90-df6f-42ca-8a14-bf0b21b52386"
      unitRef="usd">-203400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i179564f7a5394a3f985b2394c890de98_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOmUyMTg5YTU4ODRmOTQ4NjY4ZjVhNzhiMGMxOGRjZjZkL3RhYmxlcmFuZ2U6ZTIxODlhNTg4NGY5NDg2NjhmNWE3OGIwYzE4ZGNmNmRfNS0xMi0xLTEtMA_02adaf8b-e381-4913-b47c-4a5b16905f7b"
      unitRef="usd">-149300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RleHRyZWdpb246ZTZmZTFmNTFlMjlkNGIwM2E3MzU2N2JhY2NhYjk2NzZfMTQ2OQ_b115b107-48b7-4e7d-9fae-9376b600999f">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6e0e08b5a819440bb14c90345397b2db_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfMy0zLTEtMS0w_665616b4-d52d-4b86-838b-58deb9b8e4a6"
      unitRef="usd">-500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id601e29bcd854d9a871868d6cb4b232e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfMy01LTEtMS0w_3843c291-00e9-4a3b-bf4d-19f6b2590053"
      unitRef="usd">-16400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6e0e08b5a819440bb14c90345397b2db_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfNC0zLTEtMS0w_82a6d06f-6c0c-4fdd-9607-04c907d2d4ed"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id601e29bcd854d9a871868d6cb4b232e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfNC01LTEtMS0w_32abb44f-566b-4e7b-a252-b69b1d2e7d32"
      unitRef="usd">3400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues
      contextRef="i8d783d882d2347499c93910b2745c786_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfNi0zLTEtMS0w_f889fb55-1add-4f49-81f0-3c4303608e3b"
      unitRef="usd">-23100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc093e060e9247b3b645204a28e9693f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfNi01LTEtMS0w_461f8983-6974-4c6a-a8bd-d3c48318ff28"
      unitRef="usd">-27000000.0</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="i8d783d882d2347499c93910b2745c786_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfNy0zLTEtMS0w_79db85b1-87f3-49f2-a72f-feff6dcfee61"
      unitRef="usd">400000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icc093e060e9247b3b645204a28e9693f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfNy01LTEtMS0w_3c99da8c-16ed-46d0-afae-f759a376b678"
      unitRef="usd">100000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8d783d882d2347499c93910b2745c786_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfOC0zLTEtMS0w_6b875ecf-2a45-486d-aa51-b0719fc23894"
      unitRef="usd">200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icc093e060e9247b3b645204a28e9693f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfOC01LTEtMS0w_9b8be9f8-5bb0-4823-9cf2-bc9b11b92177"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8d783d882d2347499c93910b2745c786_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfOS0zLTEtMS0w_13e0798e-fcd9-42ee-baf6-7e61ca4bbb75"
      unitRef="usd">2300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icc093e060e9247b3b645204a28e9693f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfOS01LTEtMS0w_19077d62-1f01-46e7-a1ec-9ab88f8f0d59"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id9c160a38b934622ae05b249135e9fba_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfMTEtMy0xLTEtMA_bd9acf2b-ead2-4a92-bba7-b883f04c19b3"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i29b0a6b12ff841faa09ff1e9b8731d8e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfMTEtNS0xLTEtMA_4f0f4d43-8825-4ea0-8bab-6a56b69807fa"
      unitRef="usd">900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ib347ee221e7745e397b6e1c44ca1f262_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfMTQtMy0xLTEtMA_c03dad13-26e2-4c3f-a6ec-eb24adeec90f"
      unitRef="usd">-21400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8793b775d015434e94d2639ea24a0cd7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85NC9mcmFnOmU2ZmUxZjUxZTI5ZDRiMDNhNzM1NjdiYWNjYWI5Njc2L3RhYmxlOjEyZjUxZmE3NDFlNjQxNjQ5YzNkYjRiOTFjZTY2MWIyL3RhYmxlcmFuZ2U6MTJmNTFmYTc0MWU2NDE2NDljM2RiNGI5MWNlNjYxYjJfMTQtNS0xLTEtMA_3e88768c-efcf-4c59-8055-1c0a757d7129"
      unitRef="usd">14800000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RleHRyZWdpb246MDJjYWZjZmNlOTRmNGUxNWI3MGZiZDcyZDg4ZjU2NzBfMjEz_7508ba10-9739-4536-8916-315b484cfd6a">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,399.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RleHRyZWdpb246MDJjYWZjZmNlOTRmNGUxNWI3MGZiZDcyZDg4ZjU2NzBfMjA4_5951490d-025a-444c-b2ef-0104e972b89b">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,399.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMy0yLTEtMS0w_3c55058a-db03-4501-9a8d-772d98de7792"
      unitRef="usd">410200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMy00LTEtMS0w_bea062c7-e281-480e-9aee-83e13bb9471d"
      unitRef="usd">1399100000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfNS0yLTEtMS0w_c5dc597c-6163-4b47-b2e8-ebed155833a8"
      unitRef="shares">151900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfNS00LTEtMS0w_499c134b-8309-4460-8951-023c27a91bb3"
      unitRef="shares">172800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i5814e7fb32fa4b229429ed5c681d9f9a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfOC0yLTEtMS0w_f7f484c6-41dc-4013-bad9-9a0722208a45"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i6c91e4f53b324f398e35bf230235f119_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfOC00LTEtMS0w_885b3b06-cb9e-431b-b54e-c5ff986d231a"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i74e5599741ad4a8b9f6a247bbdd89697_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfOS0yLTEtMS0w_827254ea-c160-469f-ad04-1a78299b3b2c"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="icdfa95b717f940c18648cae8c6f84a2b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfOS00LTEtMS0w_83812885-5d61-42ba-8ea3-45531a638902"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i9c803a1bd2b24613850cb9d1888f1471_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMTAtMi0xLTEtMA_f85fc6e1-455a-4013-90cf-5a9f6c99f15c"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i20625d3cd2ef4a8797d00c27d1627625_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMTAtNC0xLTEtMA_8c09aaa4-9b0c-4b06-900c-1d8951c5f9ec"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMTEtMi0xLTEtMA_a40e65bb-3a0c-497a-a2ae-a7d92385bf15"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMTEtNC0xLTEtMA_99e06e6d-2168-4705-a3c2-f1425892645b"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMTItMi0xLTEtMA_00e484dc-b7ad-434b-9c78-d9eb9f69ed21"
      unitRef="shares">152300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV85Ny9mcmFnOjAyY2FmY2ZjZTk0ZjRlMTViNzBmYmQ3MmQ4OGY1NjcwL3RhYmxlOjQwMzZmNDk5NzQyYjQ2N2I5M2I4MmIyNjQ1ZDNiNjU3L3RhYmxlcmFuZ2U6NDAzNmY0OTk3NDJiNDY3YjkzYjgyYjI2NDVkM2I2NTdfMTItNC0xLTEtMA_e54cb460-b599-498d-a1bc-7b1630bbf53b"
      unitRef="shares">173100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90ZXh0cmVnaW9uOmZhOTViMDZkYjlkZTQ3N2I5MDBkZGNjZDlmNGI5OGNmXzY1NQ_8c55c102-0442-4789-89b7-a908080cf161">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash settled performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90ZXh0cmVnaW9uOmZhOTViMDZkYjlkZTQ3N2I5MDBkZGNjZDlmNGI5OGNmXzY0Mg_582a20e4-6ae2-4b6c-9c7b-3a8209c6074f">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia034f5fb9e314569bb5e919e953a76f7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzItMi0xLTEtMA_d00c9fe1-3b29-4411-8d58-57f0e2f94dbe"
      unitRef="usd">33600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if042c7a7464c42fe8dd45965e651f723_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzItNC0xLTEtMA_db8679e7-ae45-4f5b-8c0d-158e68f6a425"
      unitRef="usd">33300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8a3878b3cdc54bddb2a915e956935ea2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzMtMi0xLTEtMA_8c07229b-69db-4673-94d3-8baf8740f4f8"
      unitRef="usd">44900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i63ab73c921484907b93d62dc34ab72bd_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzMtNC0xLTEtMA_073b1cbd-8595-4c94-9f48-0c780d0e37a6"
      unitRef="usd">43100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzQtMi0xLTEtMA_f485e23c-4b36-440f-8944-42a823aa8e51"
      unitRef="usd">78500000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzQtNC0xLTEtMA_39098a68-fe45-4537-ba59-36507ca6b7df"
      unitRef="usd">76400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzUtMi0xLTEtMA_39e9a9c8-bb5d-4da9-b4bb-4fae2a44af09"
      unitRef="usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzUtNC0xLTEtMA_967e28c6-87f8-4c21-b164-f9d43820cf89"
      unitRef="usd">1500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzYtMi0xLTEtMA_91f7ae4f-3454-49a8-a02b-73b646482ebd"
      unitRef="usd">75900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzYtNC0xLTEtMA_0ebb4163-6d61-479a-a3ed-8fac25236964"
      unitRef="usd">74900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzctMi0xLTEtMA_a019615b-a453-4409-8c46-b9866680ec70"
      unitRef="usd">14000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzctNC0xLTEtMA_a3bbd322-2696-4f3a-8edd-7cdd8a457211"
      unitRef="usd">13300000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1134208d9b3347088ec3ac4ca9b1f0e0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzgtMi0xLTEtMA_ce30694d-ab11-4831-913d-f720c4da6215"
      unitRef="usd">61900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4c4590aede5149a797bc4699fd289712_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo1MDgxOWIyOTU3MjY0N2VhOTIwZGE5ZGIzNWRhY2E1OC90YWJsZXJhbmdlOjUwODE5YjI5NTcyNjQ3ZWE5MjBkYTlkYjM1ZGFjYTU4XzgtNC0xLTEtMA_98df2aad-479b-4035-b335-4b8532c74fd7"
      unitRef="usd">61600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90ZXh0cmVnaW9uOmZhOTViMDZkYjlkZTQ3N2I5MDBkZGNjZDlmNGI5OGNmXzY1Ng_fcc5b927-9dec-471d-9fe2-487f97d09c14">&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash settled performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iea96acd5ebf344c0bd0de05f5f18e7ba_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzItMi0xLTEtMA_42db15e3-390f-4a09-befd-189200490bdb"
      unitRef="usd">16500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic130d01037a74b06b9d042ae75b7659f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzItNC0xLTEtMA_2fe181ec-f01b-42e3-92fb-05ab76c886d4"
      unitRef="usd">19100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i90a6a4cf318b432dba2b2758ed6fb58b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzMtMi0xLTEtMA_22915589-571c-4b7b-9be0-5e4feaad239b"
      unitRef="usd">42800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic8d31d1727454b0ba645a673b928faf0_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzMtNC0xLTEtMA_87748e6e-65cf-4f42-be76-0facada77d95"
      unitRef="usd">37500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iecdb89b7a5934dd2ae846178573005f8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzQtMi0xLTEtMA_9245476d-baad-49c1-9b7d-532bb6c66fad"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic60ece36c57b4554886f84f64ca30d1e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzQtNC0xLTEtMA_229cc258-816a-4bd9-980b-542fb734de2e"
      unitRef="usd">-1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib81a65b32a8e4a00ad66b6254231bdda_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzUtMi0xLTEtMA_13dfb72f-dc05-4dd0-838f-be08ffa10f99"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i46142d7f2ab141ffb334e6b33caf19cf_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzUtNC0xLTEtMA_f33ba3ee-8f98-40d2-9388-e7043a7016d6"
      unitRef="usd">-100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i66e68173c701483d84c579c57a8c212d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzYtMi0xLTEtMA_1d0f2d0e-a3a1-4d12-9067-259affc9afe2"
      unitRef="usd">6300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iebcbf3a6149a4a9289109aa4855ff343_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzYtNC0xLTEtMA_fd9090b8-0054-4ac4-892f-3aabb1b3c0d7"
      unitRef="usd">10300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2765e12d82da461e9794964574b53f42_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzctMi0xLTEtMA_3ec53952-afaa-41ec-8658-25f2075e32ad"
      unitRef="usd">6000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6ff86437e3aa4e37930e1206c73cfb00_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzctNC0xLTEtMA_73cdb5cf-b09d-40de-950c-f3c255378205"
      unitRef="usd">8900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i54e58411691c4fbf853552c0ff6a6d05_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzgtMi0xLTEtMA_13a0d286-db72-4e90-b31b-dc454c09ff9f"
      unitRef="usd">6900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if0d1b57d4a0c4741b41196908e3c38b1_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzgtNC0xLTEtMA_66c21ce2-1e6c-46be-9998-4316daf458b6"
      unitRef="usd">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzEwLTItMS0xLTA_a35ccd8c-978b-48fd-98b7-dfa23ee58d6f"
      unitRef="usd">78500000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzEwLTQtMS0xLTA_6ea5894f-428e-406c-a731-46b08cfbdf2a"
      unitRef="usd">76400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzExLTItMS0xLTA_9b7e1afa-7478-484b-852a-4468810be2cc"
      unitRef="usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzExLTQtMS0xLTA_f84540f6-f817-4bc9-a439-df946740310b"
      unitRef="usd">1500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzEyLTItMS0xLTA_5d4caace-9bcc-4351-bfbd-7b11ab721b69"
      unitRef="usd">75900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDAvZnJhZzpmYTk1YjA2ZGI5ZGU0NzdiOTAwZGRjY2Q5ZjRiOThjZi90YWJsZTo3ZmZiZDZkYTFhNDM0MGM4YWIxMTVlNzJmODM5ZWE2NC90YWJsZXJhbmdlOjdmZmJkNmRhMWE0MzQwYzhhYjExNWU3MmY4MzllYTY0XzEyLTQtMS0xLTA_a25234f3-a0eb-4259-971d-33e0553f78f8"
      unitRef="usd">74900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90ZXh0cmVnaW9uOjM4ZWIyODZlOGYyNDQ4ZmM4YTEzMjQ4ZTg3MDVhODM0XzQ5Mzk_c3406c20-7c12-4e94-a805-8d46d537722f">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Litigation,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, we assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the value of certain deferred tax assets by &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approximately $1.7 billion and reduced the value of deferred tax liabilities associated with global intangible low-taxed income (GILTI) and tax credits by approximately $1.6 billion. We continue to assess the realizability of these deferred tax assets and have not recorded a change to these deferred assets for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:13.5pt"&gt;&lt;span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021, compared to the same period in 2020, the decrease in our effective tax rate was primarily due to the change in the territorial mix of our profitability, which included the effect of generic competition for TECFIDERA in the U.S. market, and the non-cash tax effects of changes in the value of our equity investments, where we recorded a reduction of value in the first quarter of 2021. The tax effects of this change in value of our equity investments were recorded discretely, since changes in value of equity investments cannot be forecasted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $25.0 million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <biib:DeferredTaxAssetsValueReductioninValue
      contextRef="i87fa0cfd9f644bdbb719a9473bc87605_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90ZXh0cmVnaW9uOjM4ZWIyODZlOGYyNDQ4ZmM4YTEzMjQ4ZTg3MDVhODM0XzE2NDE_066ff66a-d280-472f-b499-95c51f9fb323"
      unitRef="usd">1700000000</biib:DeferredTaxAssetsValueReductioninValue>
    <biib:DeferredTaxLiabilitiesValueReductioninValue
      contextRef="i87fa0cfd9f644bdbb719a9473bc87605_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90ZXh0cmVnaW9uOjM4ZWIyODZlOGYyNDQ4ZmM4YTEzMjQ4ZTg3MDVhODM0XzE3ODY_b5f365e1-d6c8-4af5-b091-6da3cd04f452"
      unitRef="usd">1600000000</biib:DeferredTaxLiabilitiesValueReductioninValue>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90ZXh0cmVnaW9uOjM4ZWIyODZlOGYyNDQ4ZmM4YTEzMjQ4ZTg3MDVhODM0XzQ5NDI_0ce43584-76e4-46e3-a3ec-3d0bc332bb57">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzItMS0xLTEtMA_7ebe2834-be55-4686-8b82-8de3a0f0ac93"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzItMy0xLTEtMA_05423735-0c82-4b7a-af61-fbcf593e311a"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzMtMS0xLTEtMA_51f8fd7c-9938-4ee7-89b3-40052614ca95"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzMtMy0xLTEtMA_6ca758fd-a1f5-4d60-8adc-ac225a298323"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzQtMS0xLTEtMA_68dfe6ec-6cd1-4e7e-b7af-80165a77aa26"
      unitRef="number">-0.109</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzQtMy0xLTEtMA_d54a68dd-dbc7-4eb5-a142-99fd1b0662f4"
      unitRef="number">-0.041</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzUtMS0xLTEtMA_5794af65-e316-46bb-9859-4605615d8bfe"
      unitRef="number">0.037</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzUtMy0xLTEtMA_2ccd554a-1a68-473b-86f8-8bc4e70977a8"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzYtMS0xLTEtMA_29b4c720-777f-420c-aafd-7508626d5ba8"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzYtMy0xLTEtMA_a5b028d3-4495-4981-a9b0-bc59c05e1598"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzEwLTEtMS0xLTA_0bdf7e1e-8767-4bf0-871b-125537dbcc7c"
      unitRef="number">0.009</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzEwLTMtMS0xLTA_a197ce45-fca3-4073-aa47-d3edbb15a32f"
      unitRef="number">0.006</biib:EffectiveTaxRateReconciliationGILTItax>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzE0LTEtMS0xLTA_e5665a93-24cc-4c13-9f66-2ba7122a0181"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzE0LTMtMS0xLTA_a1b51d27-ca07-49be-8e63-7eb638a1184f"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzE1LTEtMS0xLTA_919de22e-81e4-42cd-b398-726c9fa5fe79"
      unitRef="number">0.095</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90YWJsZTo3ZjkxNjMwNDIxYTU0YjRjYjgyMGI5NTQ3MDFkYjY3Yy90YWJsZXJhbmdlOjdmOTE2MzA0MjFhNTRiNGNiODIwYjk1NDcwMWRiNjdjXzE1LTMtMS0xLTA_43074cef-926a-4178-999e-a3f739b67656"
      unitRef="number">0.172</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDMvZnJhZzozOGViMjg2ZThmMjQ0OGZjOGExMzI0OGU4NzA1YTgzNC90ZXh0cmVnaW9uOjM4ZWIyODZlOGYyNDQ4ZmM4YTEzMjQ4ZTg3MDVhODM0XzQ4MDI_21ae1319-94ac-45be-b992-bd28eb91d57d"
      unitRef="usd">25000000.0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzE0Njg_ad03a1b0-4f5f-4aee-94c4-829433e131b4">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Income (Expense), Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(436.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(506.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(120.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $442.3 million and $6.2 million, respectively, compared to net unrealized and realized losses of $60.9 million and zero, respectively, in the prior year comparative period. The net unrealized losses recognized during the three months ended March 31, 2021, primarily reflect a decrease in the fair value of Ionis, Sangamo, Denali and Sage common stock of approximately $442.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of March 31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(436.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(60.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net gains (losses) recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(442.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(60.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expense and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;993.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,592.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,145.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities were $1,411.8 million and $1,329.6 million as of March 31, 2021 and December 31, 2020, respectively, and included accrued income taxes totaling $725.2 million and $709.9 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzE0NDE_074970b3-a4d8-43ba-9d4b-a8f0cd9434ce">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(436.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(506.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(120.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzItMi0xLTEtMA_f0c6e20b-df26-4651-97b1-a031bcec232a"
      unitRef="usd">2900000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzItNC0xLTEtMA_c2dafdeb-744e-41a5-882b-1e746cc72197"
      unitRef="usd">24400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzMtMi0xLTEtMA_30872481-85ac-4649-957a-2cf9fb474e91"
      unitRef="usd">64700000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzMtNC0xLTEtMA_d60932bd-cd86-40c3-9c7e-fc1d1ec84bfd"
      unitRef="usd">44300000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzQtMi0xLTEtMA_60fb0f76-6461-458f-9e25-12edaaba2c1a"
      unitRef="usd">-436600000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzQtNC0xLTEtMA_d0eb65bd-3d9b-4abd-b3fa-1a21e8eddfb2"
      unitRef="usd">-77300000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzUtMi0xLTEtMA_ad5523f2-b4b0-4fb1-9956-02fc4d9294fc"
      unitRef="usd">-8600000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzUtNC0xLTEtMA_ac764867-bd43-4ac1-8cca-44df02a110f2"
      unitRef="usd">-18900000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzYtMi0xLTEtMA_55c1be04-2ab5-4754-a812-927953c750de"
      unitRef="usd">100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzYtNC0xLTEtMA_bc4ffac3-8e80-4a17-b61f-f2a51f42aec3"
      unitRef="usd">-4400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzctMi0xLTEtMA_eacd6c25-bc7f-415a-a819-ba9d9170257a"
      unitRef="usd">-506900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo2Njk0ZDg1NDBjOGY0OTNiOTk3OGNiNTJmYTk1NDAxNC90YWJsZXJhbmdlOjY2OTRkODU0MGM4ZjQ5M2I5OTc4Y2I1MmZhOTU0MDE0XzctNC0xLTEtMA_a0968257-457f-4e99-8f3b-a525b0be3fda"
      unitRef="usd">-120500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzEwOTk1MTE2MzA1OTc_7d80c40e-c218-4bb3-b801-44624ff1c0bc"
      unitRef="usd">-442300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzEwOTk1MTE2MzA1ODQ_02d00275-8a14-4075-9f26-7e4616506c3f"
      unitRef="usd">6200000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzEwOTk1MTE2MzA1NzA_8983408b-c175-44b6-9abd-9e33fdf90a30"
      unitRef="usd">-60900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzEwOTk1MTE2MzA1Nzc_ce864a0c-8d93-4749-a107-9b0cecdde271"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ib9e828d7b7bf4f43bc6657cc9326807e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzEwOTk1MTE2MzA1Mzc_9f01c4d2-9931-4de3-a454-c80b945e5992"
      unitRef="usd">442000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzE0NjE_5236ef28-47e6-4ecc-b644-a418b3c3cea7">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of March 31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(436.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(60.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net gains (losses) recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(442.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(60.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo3NjIyNWYxYmIyM2U0ZjJiYWM0NmE2NDQyZDY2ZWQ5MC90YWJsZXJhbmdlOjc2MjI1ZjFiYjIzZTRmMmJhYzQ2YTY0NDJkNjZlZDkwXzItMi0xLTEtMA_794280c8-7c73-4c52-8f51-3f80d1f632da"
      unitRef="usd">-436100000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo3NjIyNWYxYmIyM2U0ZjJiYWM0NmE2NDQyZDY2ZWQ5MC90YWJsZXJhbmdlOjc2MjI1ZjFiYjIzZTRmMmJhYzQ2YTY0NDJkNjZlZDkwXzItNC0xLTEtMA_50553d52-42c5-45ac-b4b1-71ad2e5b04ea"
      unitRef="usd">-60900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo3NjIyNWYxYmIyM2U0ZjJiYWM0NmE2NDQyZDY2ZWQ5MC90YWJsZXJhbmdlOjc2MjI1ZjFiYjIzZTRmMmJhYzQ2YTY0NDJkNjZlZDkwXzMtMi0xLTEtMA_02d00275-8a14-4075-9f26-7e4616506c3f"
      unitRef="usd">6200000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo3NjIyNWYxYmIyM2U0ZjJiYWM0NmE2NDQyZDY2ZWQ5MC90YWJsZXJhbmdlOjc2MjI1ZjFiYjIzZTRmMmJhYzQ2YTY0NDJkNjZlZDkwXzMtNC0xLTEtMA_ce864a0c-8d93-4749-a107-9b0cecdde271"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo3NjIyNWYxYmIyM2U0ZjJiYWM0NmE2NDQyZDY2ZWQ5MC90YWJsZXJhbmdlOjc2MjI1ZjFiYjIzZTRmMmJhYzQ2YTY0NDJkNjZlZDkwXzQtMi0xLTEtMA_7d80c40e-c218-4bb3-b801-44624ff1c0bc"
      unitRef="usd">-442300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i7999e3a72f3f466e94b27d2d20c14b4f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTo3NjIyNWYxYmIyM2U0ZjJiYWM0NmE2NDQyZDY2ZWQ5MC90YWJsZXJhbmdlOjc2MjI1ZjFiYjIzZTRmMmJhYzQ2YTY0NDJkNjZlZDkwXzQtNC0xLTEtMA_8983408b-c175-44b6-9abd-9e33fdf90a30"
      unitRef="usd">-60900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzE0NTI_904efdfd-6c83-4c5d-b77a-0c3d4af42c58">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;993.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,592.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,145.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ice62402188f941eab28ef8bd9b65e16d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzEtMi0xLTEtMA_154c112d-f6fc-4cac-a55b-964e995853e4"
      unitRef="usd">993000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i569ed47008414979a6cf0d109c369b32_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzEtNC0xLTEtMA_1f0a2c9a-069c-4807-81b9-6c20c4293dad"
      unitRef="usd">1080600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:Collaborationexpensesaccrual
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzItMi0xLTEtOTcxMA_6ac1e324-5421-4224-a07c-942b99611e8b"
      unitRef="usd">390700000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzItNC0xLTEtOTcxMA_ca69f155-7950-42a4-b9f8-8039d2a90910"
      unitRef="usd">389900000</biib:Collaborationexpensesaccrual>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzMtMi0xLTEtOTcxNg_b40c2823-b406-4a0e-bc5d-c294efb5fee6"
      unitRef="usd">212500000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzMtNC0xLTEtOTcxNg_308c5fed-a822-45b1-b9c0-8416e52c0b1a"
      unitRef="usd">218500000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzItMi0xLTEtMA_d50c4adc-4ffc-417d-a04c-5f7751071c74"
      unitRef="usd">207400000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzItNC0xLTEtMA_50c3fd31-286a-432c-88e7-41b636f34cbc"
      unitRef="usd">333800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzMtMi0xLTEtMA_ca5115d9-5312-4326-a246-08f380f5ee0a"
      unitRef="usd">88600000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzMtNC0xLTEtMA_4aa9a200-d358-454a-879a-cf03d6b65cde"
      unitRef="usd">181500000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzUtMi0xLTEtMA_e695397b-fbca-46d0-9910-c56a8ec2ef54"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzUtNC0xLTEtMA_e66fbf1c-9bae-4252-9fa4-0099af3a2b80"
      unitRef="usd">149600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzctMi0xLTEtMA_6c830777-2bd7-4ed3-b190-afbf12d91ea4"
      unitRef="usd">700100000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzctNC0xLTEtMA_eaf61bed-a511-4363-aa6b-9e70ce64ec22"
      unitRef="usd">791400000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzgtMi0xLTEtMA_d5dbd379-abfd-4f08-8565-6ce6366337a0"
      unitRef="usd">2592300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90YWJsZTpmYjIwN2JlYzc2ZDI0NzgzYmNiMTQ2NWZjYzk1ZjBlMi90YWJsZXJhbmdlOmZiMjA3YmVjNzZkMjQ3ODNiY2IxNDY1ZmNjOTVmMGUyXzgtNC0xLTEtMA_3ad9343c-ed10-46ca-b1b3-07bb9f30c25d"
      unitRef="usd">3145300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzEwNjc_e5374fef-205c-4448-91fe-0815394ad99b"
      unitRef="usd">1411800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzEwNzQ_44cdbc07-448a-4258-8b26-c41190d3815e"
      unitRef="usd">1329600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="idba00d136f3e43eaacc59e503a3d5706_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzExNTE_b94c0819-7ca6-4e87-8db6-6c53f705131c"
      unitRef="usd">725200000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMDkvZnJhZzoyZWE1MDdlZWRjZmQ0OTI3ODRlMzYxMDI5ZTc4NDRhNi90ZXh0cmVnaW9uOjJlYTUwN2VlZGNmZDQ5Mjc4NGUzNjEwMjllNzg0NGE2XzExNTg_663f8b4a-a71a-4969-8d51-a7f964f13595"
      unitRef="usd">709900000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE3Mzg3_d83a866f-7433-4850-b726-099d91a917ba">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eisai Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BAN2401 Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401 (lecanemab), a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the BAN2401 Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If BAN2401 receives marketing approval, we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BAN2401 Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, an anti-amyloid beta antibody candidate for the potential treatment of Alzheimer's disease (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (the Aducanumab Collaboration Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments. Eisai has not yet exercised its Anti-Tau Option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development and sales and marketing expense related to the BAN2401 Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the BAN2401 collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our BAN2401 Collaboration, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Aducanumab Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Aducanumab Collaboration Agreement, we lead the ongoing development of aducanumab and, if approved, we and Eisai will co-promote aducanumab with a region-based profit split. Beginning January 1, 2019, Eisai is reimbursing us for&#160;45.0%&#160;of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early Alzheimer's disease. A new analysis of a larger dataset from these trials, conducted in scientific collaboration with the FDA, showed that the Phase 3 EMERGE trial met its pre-specified primary and secondary endpoints. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued and subsequently paid approximately $45.0 million related to the termination of various clinical trials and research and development contracts net of the expected 45.0% Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019 we and Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S. In July 2020 we completed the submission of a BLA for the approval of aducanumab to the FDA. We recognized net profit-sharing income of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone expense related to the submission of the BLA for the approval of aducanumab to the FDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales and marketing expense are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab. A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total aducanumab sales and marketing expense incurred by the Aducanumab Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on the Aducanumab Collaboration Agreement, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;UCB Pharma S.A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with UCB Pharma S.A. (UCB) to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sage Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020 we entered into a collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the closing of this transaction in December 2020 we purchased $650.0&#160;million of Sage common stock, or approximately 6.2&#160;million shares at approximately $104.14 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sage common stock acquired and a charge of approximately $209.0&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sage common stock. We also made an upfront payment of $875.0&#160;million that was recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We may also pay Sage development and commercial milestone payments that could total up to approximately $1.6&#160;billion if all the specified milestones set forth in this agreement are achieved. Both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and will pay Sage potential tiered royalties in the high teens to low twenties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development and sales and marketing expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#x2019;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of this collaboration we purchased approximately $465.0&#160;million of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $41.3&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $560.0&#160;million that was recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also pay Denali development and commercial milestone payments that could total up to approximately $1.1&#160;billion if the milestones related to LRRK2 are achieved. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages and we are responsible for commercialization and will pay Denali potential tiered royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#x2019;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#x2019;s proprietary zinc finger protein technology delivered via adeno-associated virus with the aim to modulate the expression of key genes involved in neurological diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the closing of this transaction in April 2020 we purchased $225.0 million of Sangamo common stock, or approximately 24 million shares at approximately $9.21 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately $83.0 million&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $125.0 million that was recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also pay Sangamo research, development, regulatory and commercial milestone payments that could total up to approximately $2.4 billion if we select all of the targets allowed under this agreement and all the specified milestones set forth in this agreement are achieved. Of this amount, up to $80.0 million relates to the selection of targets, $1.9 billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $380.0 million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay Sangamo tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Samsung Bioepis Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. As of March 31, 2021, our ownership percentage remained at approximately 49.9%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $675.0 million and relates to inventory, developed technology, IPR&amp;amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of 15 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain officers and affiliates of our joint venture partner, Samsung BioLogics, are currently subject to an ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021 and 2020, we recognized net losses on our investment of $18.2 million and $14.8 million, respectively, reflecting our share of Samsung Bioepis' operating results and amortization of basis differences, net of tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December 31, 2020, the carrying value of our investment in Samsung Bioepis totaled 653.4 billion South Korean won ($576.3 million) and 673.8 billion South Korean won ($620.2 million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Development and Commercialization Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in 2019 and $37.0 million was recorded as an intangible asset in 2019. Additionally, during the third quarter of 2020, we paid Samsung Bioepis a $15.0&#160;million development milestone, which was included in research and development expense in our condensed consolidated statements of income. We may pay Samsung Bioepis up to $195.0 million in additional development, regulatory and sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2013 Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three months ended March 31, 2021, we recognized net profit-sharing expense of $68.5 million to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to $71.8 million in the prior year comparative period. As discussed above, we have an option to extend this agreement by an additional five years, subject to the payment of an option exercise fee of $60.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services are reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts payable to Samsung Bioepis related to the agreements discussed above were $188.4&#160;million and $99.0&#160;million as of March 31, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt; to our consolidated financial statements included in our 2020 Form 10-K.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:NumberOfProductCandidates
      contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzMxMQ_d08eddf6-cacb-4f4e-bf9d-0b4cc79e9d21"
      unitRef="product">2</biib:NumberOfProductCandidates>
    <biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE3Mzg5_98a5d5c5-e30a-4c2f-b185-fde1fcefc672">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the BAN2401 collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
    <biib:ExpenseIncurredByCollaboration
      contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzItMi0xLTEtMA_9db56f86-04e9-4663-9c00-e29905e95645"
      unitRef="usd">55500000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i07234f661df448cb8a6a14d7961cf1a1_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzItNC0xLTEtMA_d4e56167-78ce-468b-a6d9-4a5985963b10"
      unitRef="usd">43500000</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzMtMi0xLTEtMA_b23bd485-9778-4fde-85ce-6dfdb1224c3b"
      unitRef="usd">27700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i07234f661df448cb8a6a14d7961cf1a1_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzMtNC0xLTEtMA_2f54d849-b551-450d-b37a-906a288d8d6a"
      unitRef="usd">21800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i2e54ac3de781499f9cab24ff66dd0c11_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzQtMi0xLTEtMA_30f0a6c0-123e-4a36-84bf-f48a37cc37c9"
      unitRef="usd">5700000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i30647a5eccee4a888f75b3abd844ebdf_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzQtNC0xLTEtMA_94a9b27e-dfed-49a4-843e-adc850cb9598"
      unitRef="usd">4900000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i2e54ac3de781499f9cab24ff66dd0c11_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzUtMi0xLTEtMA_4e1bf2c2-faf3-4da1-afe7-09ff9e6feb2d"
      unitRef="usd">2900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i30647a5eccee4a888f75b3abd844ebdf_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo0MmY1YTM4NDI1MWI0ZGU4YWM2YTY1ZDRhYjcxYmUwYi90YWJsZXJhbmdlOjQyZjVhMzg0MjUxYjRkZThhYzZhNjVkNGFiNzFiZTBiXzUtNC0xLTEtMA_2aacbea3-c73c-4294-8731-f71174c21634"
      unitRef="usd">2400000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzI3MzA_274ba7bd-3eff-4af4-ac56-9034c11087b8"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:LossOnContractTermination
      contextRef="i65457dc54fbc417690f3f9dfc74324b1_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzM0MzE_adc6319c-67eb-4c94-8b5b-276e01ed508d"
      unitRef="usd">45000000.0</us-gaap:LossOnContractTermination>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzM1Mzg_274ba7bd-3eff-4af4-ac56-9034c11087b8"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzM4MzM_1e58fb90-04c8-40ca-a73c-0952123c9453"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzM4NTU_274ba7bd-3eff-4af4-ac56-9034c11087b8"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzM4NzE_f0671d2b-7b7e-4f55-ae91-2efb0bf9ee26"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE3NDAy_00977d30-566b-40e1-a4f8-0fde7bda5eb2">A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total aducanumab sales and marketing expense incurred by the Aducanumab Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="ia09bc9241ad54438b01f90b39ada6215_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzItMi0xLTEtMA_8ee7e221-5275-4d6c-b96a-2a44b719172c"
      unitRef="usd">47000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i6f5259f6537145b1b52dcc10ca5b10fc_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzItNC0xLTEtMA_6120a272-10b1-4874-9c5f-5cf55b75670d"
      unitRef="usd">19100000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ia09bc9241ad54438b01f90b39ada6215_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzMtMi0xLTEtMA_b29bcf6d-62f9-4180-bc94-110e2ad6ceea"
      unitRef="usd">25800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i6f5259f6537145b1b52dcc10ca5b10fc_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzMtNC0xLTEtMA_757bad5d-8907-48a4-b681-666c9f741729"
      unitRef="usd">10500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i2017d3bce86c4e1f9ab0a83bcf38491c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzQtMi0xLTEtMA_e465e9f8-b2e9-4a41-85e1-a3369e4568fc"
      unitRef="usd">111800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i91efa7f34820455f9945f65b1db8ead5_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzQtNC0xLTEtMA_8a7b127f-1568-408f-97ce-685ed4069543"
      unitRef="usd">22700000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i2017d3bce86c4e1f9ab0a83bcf38491c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzUtMi0xLTEtMA_705504ba-a177-48d6-b4d6-f409f64cd00f"
      unitRef="usd">60300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i91efa7f34820455f9945f65b1db8ead5_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTo4ZTEyMDBkNDUzMWY0NDQyYjk0MWY2YWVmM2I1MDI2Yy90YWJsZXJhbmdlOjhlMTIwMGQ0NTMxZjQ0NDJiOTQxZjZhZWYzYjUwMjZjXzUtNC0xLTEtMA_af2c8d49-44c2-4632-bf24-570e42b785d4"
      unitRef="usd">12300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i77da4b737e504001a90944aeda31b91f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTowZGIzODgyOTYzZWU0YzRjOWVkMTAzNjZlOTgxNTBjOS90YWJsZXJhbmdlOjBkYjM4ODI5NjNlZTRjNGM5ZWQxMDM2NmU5ODE1MGM5XzItMi0xLTEtMA_b531a8fa-e04d-4e0c-b0fd-455cd92b7510"
      unitRef="usd">16900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ice34644db491436ba604aaf4f60a0d7c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTowZGIzODgyOTYzZWU0YzRjOWVkMTAzNjZlOTgxNTBjOS90YWJsZXJhbmdlOjBkYjM4ODI5NjNlZTRjNGM5ZWQxMDM2NmU5ODE1MGM5XzItNC0xLTEtMA_727bc7e5-13b9-4ea8-81e0-4237db2ae9f1"
      unitRef="usd">19000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i77da4b737e504001a90944aeda31b91f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTowZGIzODgyOTYzZWU0YzRjOWVkMTAzNjZlOTgxNTBjOS90YWJsZXJhbmdlOjBkYjM4ODI5NjNlZTRjNGM5ZWQxMDM2NmU5ODE1MGM5XzMtMi0xLTEtMA_04468821-3c89-4d40-adb6-f8996435cfd6"
      unitRef="usd">8400000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ice34644db491436ba604aaf4f60a0d7c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90YWJsZTowZGIzODgyOTYzZWU0YzRjOWVkMTAzNjZlOTgxNTBjOS90YWJsZXJhbmdlOjBkYjM4ODI5NjNlZTRjNGM5ZWQxMDM2NmU5ODE1MGM5XzMtNC0xLTEtMA_ba7ed4e1-e5b2-4a6f-b665-9bd379e8acf4"
      unitRef="usd">9500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTM0NDI_44734746-f102-471a-b5fc-5b19f1b4dfe7"
      unitRef="usd">650000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTM0NTg_2b6bc054-4a8e-4ac6-9909-ae30110511b2"
      unitRef="shares">6200000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare
      contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTM0NzE_b12f352d-cd88-455b-a33b-531af218ab60"
      unitRef="usdPerShare">104.14</biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTM0ODA_b293e38b-8fa2-4bce-8350-795c7b6b45d1"
      unitRef="usd">209000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTM0OTY_24db2ed3-202b-4b4c-a09d-c5a7bf6afde7"
      unitRef="usd">875000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments
      contextRef="icea588ed267f40a5baf7b1a0a10dc2be_D20201101-20201130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTM1MTI_828ba396-9d21-437a-a632-cd938440901c"
      unitRef="usd">1600000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzY1NjI_62248d21-a735-43bf-906b-e6cc0b9f72dd"
      unitRef="usd">465000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:Investmentincommonstocksharespurchased
      contextRef="ibed8defa2fe84947a4f4b459fdd0d10f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzY2MTI_18c12515-4851-4a41-855c-b328a2ab72fb"
      unitRef="shares">13000000</biib:Investmentincommonstocksharespurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzY2Mzk_27ed4e1e-2dc1-4bda-a294-4de8d482a33f"
      unitRef="usdPerShare">34.94</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzY4OTU_bc199ff0-2d9b-416a-97cb-58cb9affebad"
      unitRef="usd">41300000</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzcwNzc_3a8697bc-6360-47fd-a1ee-e859a4a6c608"
      unitRef="usd">560000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments
      contextRef="i3731be4a1cc441cfa8274eaa53465e5f_D20210101-20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzcyMzQ_11a8e7cf-69da-4b6a-ba20-87bbb7e511d3"
      unitRef="usd">1100000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments>
    <biib:Termofcollaborationagreement
      contextRef="i968b5e6a9c734bba858d0e6913254760_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzc2OTY1ODE0Mjc5MTc_c3f8696e-7135-433f-bdb1-55e68aaa5084">P5Y</biib:Termofcollaborationagreement>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzgwNDQ_666d324c-34de-48bc-b5f1-eb12ed63bfbf"
      unitRef="usd">225000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzgwODk_e5cfced4-ad82-4831-9b41-3a838b50c201"
      unitRef="shares">24000000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzgxMTY_529e6695-cf4a-4a66-86a2-e44f3f6796c0"
      unitRef="usdPerShare">9.21</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzgzNzM_33234bea-6d3d-4ccc-83c9-520944ae5d9a"
      unitRef="usd">83000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzg1NTY_d70b43b6-0dae-40ef-8754-41628367f60a"
      unitRef="usd">125000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments
      contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzg3MzU_4971be71-be6d-45b7-84ad-b935d30ff0da"
      unitRef="usd">2400000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments>
    <biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets
      contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzg4OTY_819bef5a-1264-4f0a-97e1-d76f00bf1109"
      unitRef="usd">80000000.0</biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets>
    <biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones
      contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzg5MzY_dfb9868e-56cb-47f6-8579-4a2d32222370"
      unitRef="usd">1900000000</biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones>
    <biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones
      contextRef="i3976b43befca4a9da24ad36f37e8d58f_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzkwNjM_f8f65ed1-bf8e-46aa-8831-6b4c7aa3e5d1"
      unitRef="usd">380000000.0</biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="i6d8e15ff35ac44bab6ffcdf343f511ac_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTg3_924a95f9-a9fa-4a24-8b98-4c740badb7a5"
      unitRef="number">0.050</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9201821f02cc43b3b8f8fabadde5754b_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzExMDA3_7469fd6a-8dc2-4dc9-a5fd-58515022a743"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ibe4be84a93994def8ed976d74fd1dfec_D20181101-20181130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzExMTAw_6a5d5329-7835-40b8-8130-74dcded7828d"
      unitRef="krw">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="iad7d1365baac43d6945215ce6b8816f7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzExMTIx_d02e1ca0-d3a2-4a82-a5a4-abd2d88cced0"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9201821f02cc43b3b8f8fabadde5754b_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzExMjA4_7469fd6a-8dc2-4dc9-a5fd-58515022a743"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i72965d9649fb4d17a86322fadd05e4e3_I20181107"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEyMjIz_3545e9bc-ea84-472f-b295-7d90271c7412"
      unitRef="usd">675000000.0</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="ie90411741db34c3b961e743e971e67dd_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEyNDE1_9d08a502-aaa9-4379-9a0e-ac8692275650">P1Y6M</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="i9290a0d035874af8ac1688475a9c6fda_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEyNTgz_dcb1244e-a633-4706-bb23-c6315cc589fe">P15Y</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i69cf49f1dcbd46fbbdb79f66912dd8ca_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzMDYw_e68e55bb-4d30-4591-aa27-f8899a7b87af"
      unitRef="usd">18200000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i5aae7a15859845fc95e18fa3c0eaaf33_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTY0NjM_1dc4f0a8-53e6-442d-8e67-6208183b871e"
      unitRef="usd">14800000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:EquityMethodInvestments
      contextRef="i9201821f02cc43b3b8f8fabadde5754b_I20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzMjY0_95cf9959-dd49-4ab9-88ab-3b53b922c2f2"
      unitRef="krw">653400000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9201821f02cc43b3b8f8fabadde5754b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzMjg1_0897b243-b61c-4cf8-aa4f-03e29cb85999"
      unitRef="usd">576300000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i94c61857768f4045b23a12b5bd57d3e6_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzMjkz_caae6662-d684-4ba0-b2a7-1bbeac1d46d1"
      unitRef="krw">673800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i94c61857768f4045b23a12b5bd57d3e6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzMzE0_69fbc93c-cc76-47a2-8454-af1e13b31f5d"
      unitRef="usd">620200000</us-gaap:EquityMethodInvestments>
    <biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzNTc4_eeb247b6-c348-43ff-a332-23cd28ebc66c"
      unitRef="product">2</biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i47d16efb9f3f4c09872f1f6d2b724400_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzOTIx_880a6149-e7f0-42e9-b9d9-79e06cdf101d"
      unitRef="usd">100000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i47d16efb9f3f4c09872f1f6d2b724400_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEzOTY5_ce4c0f24-3fce-4565-a9c5-ee069e5529b2"
      unitRef="usd">63000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i61802b3b7d4442588559391d63737368_I20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE0MDMz_05d21c49-c775-4104-b504-dc0bd08bcb6a"
      unitRef="usd">37000000.0</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:AdditionalMilestonePayment
      contextRef="i412bdd987d70473f8492259ec4e93e3c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE0MTU1_8bce2fd0-3428-4902-b3e4-f00dec6fe6bf"
      unitRef="usd">15000000.0</biib:AdditionalMilestonePayment>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="i412bdd987d70473f8492259ec4e93e3c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE0MzEx_c875d709-908b-46eb-ab6f-59a22e576d13"
      unitRef="usd">195000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:CollaborationAgreementTerm
      contextRef="i412bdd987d70473f8492259ec4e93e3c_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE0NTEw_99fb14f9-afe5-43d6-a312-bc652417c77b">P5Y</biib:CollaborationAgreementTerm>
    <biib:ContractOptionExerciseFee
      contextRef="i47d16efb9f3f4c09872f1f6d2b724400_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE0NTY4_963c7f55-38e6-47fa-b7f6-b088be347c6a"
      unitRef="usd">60000000.0</biib:ContractOptionExerciseFee>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="i69cf49f1dcbd46fbbdb79f66912dd8ca_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE1MDIx_546cfe82-2d65-44c7-9378-3c8d6204660c"
      unitRef="number">0.500</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="i69cf49f1dcbd46fbbdb79f66912dd8ca_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE1Mjk0_3a0b8468-8877-4cef-b984-d8ef13d70196"
      unitRef="usd">68500000</biib:Collaborationprofitlosssharing>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="i69cf49f1dcbd46fbbdb79f66912dd8ca_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE1MzQ3_546cfe82-2d65-44c7-9378-3c8d6204660c"
      unitRef="number">0.500</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="i5aae7a15859845fc95e18fa3c0eaaf33_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE1NDA0_31434ecc-c3f8-4e4e-8b02-545b5d978bac"
      unitRef="usd">71800000</biib:Collaborationprofitlosssharing>
    <biib:ContractOptionExerciseFee
      contextRef="i47d16efb9f3f4c09872f1f6d2b724400_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE1NjEy_963c7f55-38e6-47fa-b7f6-b088be347c6a"
      unitRef="usd">60000000.0</biib:ContractOptionExerciseFee>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="iaeb7e6ad713d4670b6e038cfbb2130de_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzE2OTc0_e461254d-ba96-4f51-ba36-bc9eb88e32d4"
      unitRef="usd">188400000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i50fc7b747b554ee88ca10781e8675077_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTIvZnJhZzo1ODU1MjA5NDVhYjg0NWM4YTc1YjFlOTFjZDdkMmZmMS90ZXh0cmVnaW9uOjU4NTUyMDk0NWFiODQ1YzhhNzViMWU5MWNkN2QyZmYxXzEwOTk1MTE2NTYwMzM_bd9873c5-9ada-47da-9724-d35784c38cd8"
      unitRef="usd">99000000.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzUzMjg_ef21d4cd-53a0-400e-8e93-e2c603753e24">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#x2019;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017 we amended the terms of the Neurimmune Agreement and made a $150.0 million payment to Neurimmune in exchange for a 15.0% reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional $50.0 million payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional 5.0%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of&#160;$75.0 million&#160;upon the regulatory filing with the FDA for the approval of aducanumab. During the second quarter of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020, we paid Neurimmune $75.0 million upon the completed submission of the BLA for the approval of aducanumab to the FDA, which was recognized as a charge to noncontrolling interests. In addition, during the second quarter of 2020, we recognized net profit-sharing income of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to approximately $150.0&#160;million in milestones to Neurimmune in 2021, which includes $100.0&#160;million if launched in the U.S. and $50.0&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the Aducanumab Collaboration Agreement with Eisai.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the three months ended March 31, 2021 and 2020, amounts reimbursed were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December 31, 2020, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $12.8 million. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Investments in Variable Interest Entities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <biib:CollaborationAgreementTerm
      contextRef="i7111de4bd0294ff9a9a3ad920d505e32_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzc2OA_1930e015-575a-487c-9f53-48c78690786a">P12Y</biib:CollaborationAgreementTerm>
    <biib:ResearchAndDevelopmentCostsPercentage
      contextRef="i7111de4bd0294ff9a9a3ad920d505e32_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzExMTE_b4d746c6-1c26-4e3f-9fce-a6e7ecc669a8"
      unitRef="number">1.000</biib:ResearchAndDevelopmentCostsPercentage>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ie7dc064ffb824915a213b2bafa7eadc1_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzEyNzE_8ad02ac9-87fb-4f22-80e1-d86e79c9fcc0"
      unitRef="usd">150000000.0</us-gaap:PaymentsToMinorityShareholders>
    <biib:Reductioninroyaltyratepayableoncommercialsales
      contextRef="ie7dc064ffb824915a213b2bafa7eadc1_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzEzMTQ_d33c7450-4f31-4061-a527-866d1485866f"
      unitRef="number">0.150</biib:Reductioninroyaltyratepayableoncommercialsales>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i443ec97d551d4f19819d518a28e3dcde_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzE1Mzk_00b36070-681a-44a1-8d5f-9424c0de2a92"
      unitRef="usd">50000000.0</us-gaap:PaymentsToMinorityShareholders>
    <biib:Additionalreductioninroyaltyratepayableoncommercialsales
      contextRef="i443ec97d551d4f19819d518a28e3dcde_D20180501-20180531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzE3NzQ_fc2b2f2f-6da0-4fbf-b8eb-55740f1ba711"
      unitRef="number">0.050</biib:Additionalreductioninroyaltyratepayableoncommercialsales>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i058baac90e1841039cf4ef78a041460d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzIzMjc_848be194-29e4-459b-ad2c-8145d2e739a7"
      unitRef="usd">75000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i058baac90e1841039cf4ef78a041460d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzI2MTE_848be194-29e4-459b-ad2c-8145d2e739a7"
      unitRef="usd">75000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzI4NTc_a0224b0c-7f8b-4b70-9fb2-bb9942ae0786"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzI4Nzk_e56b0ddf-adcf-418d-8884-e0b18e4a34d7"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i058baac90e1841039cf4ef78a041460d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzI4OTU_848be194-29e4-459b-ad2c-8145d2e739a7"
      unitRef="usd">75000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i6c605c95790545c0995faf5707af1bfa_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzEwOTk1MTE2MzQ1MDM_8b30ddf2-4eaa-40b0-8753-964e87413609"
      unitRef="usd">150000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i925bce57d9bf415ba43b031db49f8b12_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzEwOTk1MTE2MzQ1MTk_2edf7b2c-7d05-4c36-9e02-503333216d7b"
      unitRef="usd">100000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i8e351ee8c7e84208bbcdd85dd32c6e63_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzEwOTk1MTE2MzQ1NTA_3edf3795-7fa4-4843-9de6-a9bfe95bf07e"
      unitRef="usd">50000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMTgvZnJhZzoyNGFhMzZkNDkwMTA0N2M1OGFkM2ZiMjI1MTc5NjVmYS90ZXh0cmVnaW9uOjI0YWEzNmQ0OTAxMDQ3YzU4YWQzZmIyMjUxNzk2NWZhXzQ1MTU_d4cac63b-506d-4451-ac9f-5c0ee8c845e6"
      unitRef="usd">12800000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMjQvZnJhZzo2Y2ExNjg3N2Q3ODc0NzQzYmFlZjNlOTM1NmE0N2VhOC90ZXh0cmVnaW9uOjZjYTE2ODc3ZDc4NzQ3NDNiYWVmM2U5MzU2YTQ3ZWE4XzEzNTgw_46c2ef64-4a06-4379-a39e-1193c5083620">&lt;div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Aducanumab Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and certain current and former officers are named as defendants in an action filed by a shareholder on November 13, 2020, in the U.S. District Court for the Central District of California and transferred to the U.S. District Court for the District of Massachusetts in March 2021. The action alleges violations of federal securities laws under 15 U.S.C &#xa7;78j(b) and &#xa7;78t(a) and 17 C.F.R. &#xa7;240.10b-5 and seeks a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time. No trial date has been set. A second class action, filed by another shareholder on January 5, 2021, in the U.S. District Court for the District of Massachusetts, was dismissed in March 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing has been scheduled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. The request for preliminary injunction was denied in June 2019 and the decision was affirmed on appeal in February 2021. In July 2020 the Danish Patent Board of Appeal revoked the Danish Utility Models that were the subject of Fresenius Kabi&#x2019;s October 2018 request for a preliminary injunction and Fresenius Kabi has appealed those revocations to Denmark&#x2019;s Maritime and Commercial High Court. No hearing has been scheduled in that appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen (Denmark) A/S in Denmark&#x2019;s Maritime and Commercial High Court alleging infringement of another Danish Utility Model. A hearing has been scheduled for May 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen GmbH in the D&#xfc;sseldorf Regional Court relating to the German counterpart of the &#x2018;510 Patent. A hearing has been set for August 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019 Gedeon Richter PLC commenced proceedings against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#x2019; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dispute with Former Convergence Shareholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Samsung BioLogics Arbitration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020 we requested arbitration in the International Chamber of Commerce Court of International Arbitration against Samsung BioLogics seeking interpretation of certain provisions in the Joint Venture Agreement executed on December 6, 2011, as amended, by and between Biogen and Samsung BioLogics (the Joint Venture Agreement). Samsung BioLogics has asserted counterclaims, including breach of the Joint Venture Agreement, and seeks declaratory relief and unspecified damages. An estimate of the possible loss or range of loss cannot be made at this time. No hearing date has been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Petition for Inter Partes Review&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#x2018;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit), which is pending. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017 to 2020, we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#x2018;514 Patent are invalid for lack of written description. We appealed the judgment to the Federal Circuit and the appeal is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. We have appealed the judgments and the appeal is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,699,281, 9,090,558 and 10,080,733) pursuant to the Hatch-Waxman Act in the Delaware Court against Teva Pharmaceuticals Development, Inc.  A trial date has not yet been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;European Patent Office Oppositions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016 the European Patent Office (EPO) revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing date has been set for January 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018 the EPO revoked Forward Pharma A/S' (Forward Pharma) European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for September 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TYSABRI Patent Revocation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. The Polish Patent Office dismissed the action in February 2021. In August 2020 a related entity, Polpharma Biologics S.A., also brought an action seeking to revoke the Polish &#x2018;263 Patent in the Polish Patent Office. The action was suspended by the Polish Patent Office in April 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and the German appeal has been withdrawn. No hearing has been set in the Italian action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Annulment Proceedings in General Court of the European Union relating to TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) have each filed applications in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) seeking to annul decisions of the European Medicines Agency (EMA) refusing to validate Polpharma&#x2019;s and Mylan Ireland&#x2019;s respective applications to market a generic version of TECFIDERA. The EMA&#x2019;s refusals were on the grounds that TECFIDERA benefits from regulatory data protection. Biogen and the European Commission were granted leave to intervene in support of the EMA in the case brought by Polpharma and the court will announce its decision in that case on May 5, 2021. We intend to seek leave to intervene in support of the EMA in the case brought by Mylan Ireland. No hearing has been set in that matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i6d0adcebf1da475cb93ee9da1693e32f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMjQvZnJhZzo2Y2ExNjg3N2Q3ODc0NzQzYmFlZjNlOTM1NmE0N2VhOC90ZXh0cmVnaW9uOjZjYTE2ODc3ZDc4NzQ3NDNiYWVmM2U5MzU2YTQ3ZWE4XzUyNzQ_ad888015-5de5-4c21-b712-b66377b40001"
      unitRef="usd">200000000.0</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights
      contextRef="i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmZTg0YmM3ZTEwMTQ2MmVhNDFmYzA3NDE2ODAzOTYxL3NlYzo2ZmU4NGJjN2UxMDE0NjJlYTQxZmMwNzQxNjgwMzk2MV8xMzMvZnJhZzozMTY3ZjlmN2Y0ZDY0ZGJmOTNiOGVmNDNjYzYxZDc1OS90ZXh0cmVnaW9uOjMxNjdmOWY3ZjRkNjRkYmY5M2I4ZWY0M2NjNjFkNzU5XzE2NDkyNjc0OTY5NDU_eeb247b6-c348-43ff-a332-23cd28ebc66c"
      unitRef="product">2</biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152840358296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 21, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,554,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152835991576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,694.0<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">478.1<span></span>
</td>
<td class="nump">454.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">514.2<span></span>
</td>
<td class="nump">476.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">595.0<span></span>
</td>
<td class="nump">570.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">98.1<span></span>
</td>
<td class="nump">71.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">68.5<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">(33.8)<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expense</a></td>
<td class="nump">1,720.1<span></span>
</td>
<td class="nump">1,714.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">973.9<span></span>
</td>
<td class="nump">1,819.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(506.9)<span></span>
</td>
<td class="num">(120.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">467.0<span></span>
</td>
<td class="nump">1,699.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">44.2<span></span>
</td>
<td class="nump">292.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax', window );">Equity in (income) loss of investee, net of tax</a></td>
<td class="nump">18.2<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">404.6<span></span>
</td>
<td class="nump">1,392.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 410.2<span></span>
</td>
<td class="nump">$ 1,399.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 2.70<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 2.69<span></span>
</td>
<td class="nump">$ 8.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">151.9<span></span>
</td>
<td class="nump">172.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">152.3<span></span>
</td>
<td class="nump">173.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,211.7<span></span>
</td>
<td class="nump">$ 2,904.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">389.0<span></span>
</td>
<td class="nump">520.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 93.3<span></span>
</td>
<td class="nump">$ 109.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Method Investments, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeLossFromEquityMethodInvestmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152836747256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 410.2<span></span>
</td>
<td class="nump">$ 1,399.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="nump">149.6<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">23.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(48.5)<span></span>
</td>
<td class="num">(63.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">124.7<span></span>
</td>
<td class="num">(14.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">534.9<span></span>
</td>
<td class="nump">1,385.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(4.9)<span></span>
</td>
<td class="num">(5.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">$ 530.0<span></span>
</td>
<td class="nump">$ 1,379.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152836566936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,217.5<span></span>
</td>
<td class="nump">$ 1,331.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,320.0<span></span>
</td>
<td class="nump">1,278.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,854.3<span></span>
</td>
<td class="nump">1,913.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">369.8<span></span>
</td>
<td class="nump">413.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,171.8<span></span>
</td>
<td class="nump">1,068.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">786.1<span></span>
</td>
<td class="nump">881.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,719.5<span></span>
</td>
<td class="nump">6,887.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">821.9<span></span>
</td>
<td class="nump">772.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,438.3<span></span>
</td>
<td class="nump">3,411.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">414.5<span></span>
</td>
<td class="nump">433.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,988.1<span></span>
</td>
<td class="nump">3,084.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,763.1<span></span>
</td>
<td class="nump">5,762.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">1,286.3<span></span>
</td>
<td class="nump">1,369.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">2,423.0<span></span>
</td>
<td class="nump">2,899.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">23,854.7<span></span>
</td>
<td class="nump">24,618.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">143.1<span></span>
</td>
<td class="nump">142.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">430.4<span></span>
</td>
<td class="nump">454.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expense and other</a></td>
<td class="nump">2,592.3<span></span>
</td>
<td class="nump">3,145.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,165.8<span></span>
</td>
<td class="nump">3,742.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">7,267.2<span></span>
</td>
<td class="nump">7,426.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">966.7<span></span>
</td>
<td class="nump">1,032.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">380.0<span></span>
</td>
<td class="nump">402.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,411.8<span></span>
</td>
<td class="nump">1,329.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,191.5<span></span>
</td>
<td class="nump">13,932.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(174.3)<span></span>
</td>
<td class="num">(299.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">13,833.5<span></span>
</td>
<td class="nump">13,976.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">10,682.2<span></span>
</td>
<td class="nump">10,700.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(19.0)<span></span>
</td>
<td class="num">(14.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">10,663.2<span></span>
</td>
<td class="nump">10,686.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 23,854.7<span></span>
</td>
<td class="nump">$ 24,618.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152942301784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152836635272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 404.6<span></span>
</td>
<td class="nump">$ 1,392.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and impairments</a></td>
<td class="nump">146.9<span></span>
</td>
<td class="nump">119.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">70.0<span></span>
</td>
<td class="nump">67.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="num">(33.8)<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(15.0)<span></span>
</td>
<td class="nump">36.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">(Gain) loss on strategic investments</a></td>
<td class="nump">437.6<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Our share of Samsung Bioepis gains (losses)</a></td>
<td class="nump">18.2<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">71.7<span></span>
</td>
<td class="nump">28.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">37.2<span></span>
</td>
<td class="num">(238.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">43.8<span></span>
</td>
<td class="nump">78.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(112.5)<span></span>
</td>
<td class="num">(62.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expense and other current liabilities</a></td>
<td class="num">(283.6)<span></span>
</td>
<td class="num">(347.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">64.8<span></span>
</td>
<td class="nump">223.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(80.9)<span></span>
</td>
<td class="nump">18.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flow provided by operating activities</a></td>
<td class="nump">769.0<span></span>
</td>
<td class="nump">1,467.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">819.2<span></span>
</td>
<td class="nump">2,389.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(913.3)<span></span>
</td>
<td class="num">(1,684.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">28.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(92.6)<span></span>
</td>
<td class="num">(149.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(75.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(37.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">91.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flow (used in) provided by investing activities</a></td>
<td class="num">(64.7)<span></span>
</td>
<td class="nump">442.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(600.0)<span></span>
</td>
<td class="num">(2,220.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(27.1)<span></span>
</td>
<td class="num">(29.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings and premiums paid on debt exchange</a></td>
<td class="num">(169.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flow used in financing activities</a></td>
<td class="num">(785.0)<span></span>
</td>
<td class="num">(2,245.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(80.7)<span></span>
</td>
<td class="num">(335.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">33.0<span></span>
</td>
<td class="num">(12.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">1,331.2<span></span>
</td>
<td class="nump">2,913.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">$ 1,217.5<span></span>
</td>
<td class="nump">$ 2,591.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152834684344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
<th class="th"><div>2018 Share Repurchase Program</div></th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Parent</div>
</th>
<th class="th"><div>2019 Share Repurchase Program</div></th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Parent</div>
</th>
<th class="th"><div>December 2019 Share Repurchase Program</div></th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Parent</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(198.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 13,339.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (135.2)<span></span>
</td>
<td class="nump">$ 16,455.4<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 13,343.2<span></span>
</td>
<td class="num">$ (4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,392.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,399.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,399.1<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(13.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.1)<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (941.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (941.1)<span></span>
</td>
<td class="num">$ (941.1)<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (15.6)<span></span>
</td>
<td class="num">$ (925.5)<span></span>
</td>
<td class="nump">$ 941.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (71.0)<span></span>
</td>
<td class="num">$ (1,208.1)<span></span>
</td>
<td class="nump">$ 1,279.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">18.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">18.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(47.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">69.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders' Equity, Other</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">12,536.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(149.3)<span></span>
</td>
<td class="nump">15,673.1<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">12,546.9<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(191.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(176.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">10,686.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(299.0)<span></span>
</td>
<td class="nump">13,976.3<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,700.3<span></span>
</td>
<td class="num">(14.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">404.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410.2<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">125.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (600.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (600.0)<span></span>
</td>
<td class="num">$ (600.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (93.8)<span></span>
</td>
<td class="num">$ (506.2)<span></span>
</td>
<td class="nump">$ 600.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(46.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders' Equity, Other</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 10,663.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (174.3)<span></span>
</td>
<td class="nump">$ 13,833.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 10,682.2<span></span>
</td>
<td class="num">$ (19.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(174.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832233784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have an option to acquire exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2020 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three months ended March 31, 2021, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our condensed consolidated financial statements and there may be changes to those estimates in future periods. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt;text-indent:9pt"><span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 the FASB issued Accounting Standards Update No. 2019-12, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152760036872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIIB118 Acquisition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020 we acquired BIIB118 (CK1 inhibitor) for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We are developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder in Parkinson's disease and plan to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease.</span></div>In connection with this acquisition, we made an upfront payment of $75.0 million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;D) in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to $635.0 million in potential additional development and commercialization milestone payments as well as tiered royalties in the high single digits to sub-teens.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832228520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">777.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">503.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">751.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">732.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,483.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,347.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">769.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,117.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">371.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">565.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">899.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,311.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,211.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,583.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,321.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,904.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 30.0% and 9.3% of gross product revenue for the three months ended March 31, 2021, and 30.0% and 14.6% for the three months ended March 31, 2020.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,093.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">775.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">964.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(111.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(284.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(396.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(562.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(647.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">988.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,166.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">993.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,166.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;padding-right:2.25pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152760049320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:58.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">634.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,171.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,068.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152839881800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:22.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,394.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,190.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,204.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,394.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,257.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,178.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,190.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,988.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,220.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,084.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, amortization and impairment of acquired intangible assets totaled $98.1 million, compared to $71.5 million in the prior year comparative period. For the three months ended March 31, 2021, amortization and impairment of acquired intangible assets reflects a $44.3&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN). For the three months ended March 31, 2020, we had no impairment charges.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of March 31, 2021, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of Nightstar Therapeutics plc (NST) and Convergence Pharmaceuticals Holdings Ltd. (Convergence). The majority of the balance relates to our acquisition of NST in June 2019. For additional information on our acquisition of NST, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies of vixotrigine for TGN and DPN and now plan to perform an additional clinical trial of vixotrigine before initiating a Phase 3 study of DPN.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the first quarter of 2021. As of March 31, 2021, the carrying value associated with our remaining vixotrigine IPR&amp;D assets was $135.1&#160;million, all of which is related to DPN.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111 and BIIB112</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020 we recognized an impairment charge of $115.0&#160;million related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, as a result of third-party manufacturing delays that may impact our timeline for a potential filing of a Biologics License Application (BLA) for regulatory approval by up to one year, and increase the costs associated with advancing BIIB111 through Phase 3 development.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to monitor the manufacturing issues encountered with BIIB111 and their potential impact on that program's timing. As of March 31, 2021, we have no indication that BIIB111 or BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments, were impaired; however, we will continue to monitor the capabilities of our manufacturing partners and how any additional new manufacturing issues might affect the planned timing of such gene therapy programs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span><span style="color:#679acb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining nine months)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,762.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,763.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>As of March 31, 2021, we had no accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152758977512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,336.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,336.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">677.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">677.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,442.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,294.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,412.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,264.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,703.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,700.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,429.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material impairments of our assets measured and carried at fair value during the three months ended March 31, 2021. In addition, there have been no changes in valuation techniques during the three months ended March 31, 2021. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo), Denali Therapeutics Inc. (Denali) and Sage Therapeutics, Inc. (Sage) and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. For additional information on our investments in Sangamo, Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Financial Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of March 31, 2021 and December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:24.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligation</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td rowspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.0&#160;</span></td><td rowspan="2" style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.77%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.77%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 to 2027</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligation</span></td><td colspan="3" style="padding:0 1pt"/><td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 to 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from 21.7% to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,054.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,940.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,741.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,003.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,741.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,455.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,557.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,394.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,365.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,369.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,536.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">654.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">463.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,859.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,267.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,515.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2021 we completed a private offer to exchange (Exchange Offer) our 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes), whereby approximately $624.6&#160;million of our 2045 Senior Notes were exchanged for approximately $700.7&#160;million of a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes). For additional information on our Exchange Offer, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes issued on April 30, 2020 and September 15, 2015, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, approximately $226.0 million and $110.3 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expense and other.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152759838952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">541.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available for sale:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">979.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">979.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">336.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">336.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,140.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,141.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,442.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,442.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,887.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,239.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">749.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,320.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,320.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">780.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,141.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,140.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities available-for-sale as of March 31, 2021 and December 31, 2020, was approximately 12 months and 11 months, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">819.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,389.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, our strategic investment portfolio was comprised of investments totaling $1,493.1 million and $2,024.6 million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio for the three months ended March 31, 2021, was primarily due to decreases in the fair values of our investments in Ionis Pharmaceuticals Inc. (Ionis), Sage, Denali and Sangamo common stock.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage. In connection with the closing of this transaction in December 2020 we purchased $650.0&#160;million of Sage common stock, or approximately 6.2&#160;million shares at approximately $104.14 per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sage common stock and a dividend yield of zero based upon the fact that Sage and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020 we entered into a collaboration and license agreement with Denali. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this collaboration we purchased approximately $465.0&#160;million of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali's common stock and a dividend yield of zero based upon the fact that Denali and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Denali, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased $225.0 million of Sangamo common stock, or approximately 24 million shares at approximately $9.21 per share, which are subject to transfer restrictions.&#160;This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo&#8217;s common stock and a dividend yield of zero based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sangamo, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832962840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenue and operating expense.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts in effect as of March 31, 2021 and December 31, 2020, had durations of 1 to 21 months and 1 to 24 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,657.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,979.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,186.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,229.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity as of March 31, 2021, reflected aggregate net unrealized losses of $41.5 million, composed of gross unrealized losses of approximately $73.5&#160;million and gross unrealized gains of approximately $32.0&#160;million, compared to aggregate net unrealized losses of $212.5 million as of December 31, 2020. We expect the net unrealized losses of $41.5 million to be settled over the next 21 months, of which $54.3 million of unrealized losses are expected to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of March 31, 2021 and December 31, 2020, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Contracts</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of our 2.90% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $675.0 million, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our 2.90% Senior Notes attributable to changes in interest rates. The carrying value of our 2.90% Senior Notes as of December 31, 2020, included approximately $2.3&#160;million related to changes in the fair value of these interest rate swap contracts. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our 2.90% Senior Notes, resulting in a gain of approximately $3.3 million, which was recorded as a component of interest expense in our condensed consolidated statements of income during the second quarter of 2020.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of March 31, 2021, had a remaining duration of seven months. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $2.7 million and net losses of $21.2 million as of March 31, 2021 and December 31, 2020, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of $0.1 million and $0.2 million as of March 31, 2021 and December 31, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $1,358.8 million and $1,158.0 million as of March 31, 2021 and December 31, 2020, respectively. Net losses of $17.4 million and $2.4 million related to these contracts were recorded as a component of other income (expense), net for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152839881800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $1,827.6 million and $1,782.3 million as of March 31, 2021 and December 31, 2020, respectively. For the three months ended March 31, 2021, depreciation expense totaled $48.8 million compared to $48.4 million in the prior year comparative period.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of March 31, 2021 and December 31, 2020, we had approximately $1.9 billion and $1.8 billion, respectively, capitalized as construction in progress related to this facility.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152760115352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Notes)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indebtedness</span><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An aggregate principal amount of approximately $624.6&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $700.7&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $151.8&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we redeemed an aggregate principal amount of approximately $8.9&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $12.1&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $3.2&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the three months ended March 31, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement, we also made aggregate cash payments of approximately $13.8&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $6.1&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the three months ended March 31, 2021.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Senior Notes </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $3.0 billion (2020 Senior Notes), consisting of the following:</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">$1.5 billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030, valued at 99.973% of par; and</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">$1.5 billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050, valued at 99.174% of par.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred approximately $24.4 million of costs associated with this offering, which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. For additional information on our 2020 Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.90% Senior Notes due September 15, 2020</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020, at 99.792% of par. Our 2.90% Senior Notes were senior unsecured obligations. In connection with the 2.90% Senior Notes, we entered into interest rate swap contracts where we received a fixed rate and paid a </span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our 2.90% Senior Notes prior to their maturity and recognized a net pre-tax charge of $9.4 million upon the extinguishment of these notes during the second quarter of 2020. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income and reflects the payment of a $12.7 million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $3.3 million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate swap contracts, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832296680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.2 million shares of our common stock at a cost of approximately $600.0 million during the three months ended March 31, 2021. Approximately $4.0 billion remained available under our 2020 Share Repurchase Program as of March 31, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 3.2&#160;million shares of our common stock at a cost of approximately $941.1&#160;million during the three months ended March 31, 2020.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1&#160;million shares of our common stock at a cost of approximately $1.3&#160;billion during the three months ended March 31, 2020. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(174.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.0)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(203.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832226312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share are calculated as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,399.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832212760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash settled performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832457880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the value of certain deferred tax assets by </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $1.7 billion and reduced the value of deferred tax liabilities associated with global intangible low-taxed income (GILTI) and tax credits by approximately $1.6 billion. We continue to assess the realizability of these deferred tax assets and have not recorded a change to these deferred assets for the three months ended March 31, 2021.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Rate</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, compared to the same period in 2020, the decrease in our effective tax rate was primarily due to the change in the territorial mix of our profitability, which included the effect of generic competition for TECFIDERA in the U.S. market, and the non-cash tax effects of changes in the value of our equity investments, where we recorded a reduction of value in the first quarter of 2021. The tax effects of this change in value of our equity investments were recorded discretely, since changes in value of equity investments cannot be forecasted.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $25.0 million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152876901688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other income (expense), net, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(436.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(506.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(120.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $442.3 million and $6.2 million, respectively, compared to net unrealized and realized losses of $60.9 million and zero, respectively, in the prior year comparative period. The net unrealized losses recognized during the three months ended March 31, 2021, primarily reflect a decrease in the fair value of Ionis, Sangamo, Denali and Sage common stock of approximately $442.0 million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of March 31, 2021 and 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(436.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(60.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(442.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(60.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">993.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,592.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,145.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $1,411.8 million and $1,329.6 million as of March 31, 2021 and December 31, 2020, respectively, and included accrued income taxes totaling $725.2 million and $709.9 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832894536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BAN2401 Collaboration</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401 (lecanemab), a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the BAN2401 Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If BAN2401 receives marketing approval, we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BAN2401 Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, an anti-amyloid beta antibody candidate for the potential treatment of Alzheimer's disease (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (the Aducanumab Collaboration Agreement).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments. Eisai has not yet exercised its Anti-Tau Option. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the BAN2401 Collaboration is as follows:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the BAN2401 collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our BAN2401 Collaboration, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aducanumab Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Aducanumab Collaboration Agreement, we lead the ongoing development of aducanumab and, if approved, we and Eisai will co-promote aducanumab with a region-based profit split. Beginning January 1, 2019, Eisai is reimbursing us for&#160;45.0%&#160;of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early Alzheimer's disease. A new analysis of a larger dataset from these trials, conducted in scientific collaboration with the FDA, showed that the Phase 3 EMERGE trial met its pre-specified primary and secondary endpoints. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued and subsequently paid approximately $45.0 million related to the termination of various clinical trials and research and development contracts net of the expected 45.0% Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 we and Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S. In July 2020 we completed the submission of a BLA for the approval of aducanumab to the FDA. We recognized net profit-sharing income of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone expense related to the submission of the BLA for the approval of aducanumab to the FDA.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expense are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab. A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total aducanumab development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total aducanumab sales and marketing expense incurred by the Aducanumab Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the Aducanumab Collaboration Agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UCB Pharma S.A.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB Pharma S.A. (UCB) to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020 we entered into a collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the closing of this transaction in December 2020 we purchased $650.0&#160;million of Sage common stock, or approximately 6.2&#160;million shares at approximately $104.14 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sage common stock acquired and a charge of approximately $209.0&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sage common stock. We also made an upfront payment of $875.0&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also pay Sage development and commercial milestone payments that could total up to approximately $1.6&#160;billion if all the specified milestones set forth in this agreement are achieved. Both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and will pay Sage potential tiered royalties in the high teens to low twenties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to this collaboration is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this collaboration we purchased approximately $465.0&#160;million of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $41.3&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $560.0&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Denali development and commercial milestone payments that could total up to approximately $1.1&#160;billion if the milestones related to LRRK2 are achieved. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages and we are responsible for commercialization and will pay Denali potential tiered royalties.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger protein technology delivered via adeno-associated virus with the aim to modulate the expression of key genes involved in neurological diseases. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of this transaction in April 2020 we purchased $225.0 million of Sangamo common stock, or approximately 24 million shares at approximately $9.21 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately $83.0 million&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $125.0 million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Sangamo research, development, regulatory and commercial milestone payments that could total up to approximately $2.4 billion if we select all of the targets allowed under this agreement and all the specified milestones set forth in this agreement are achieved. Of this amount, up to $80.0 million relates to the selection of targets, $1.9 billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $380.0 million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay Sangamo tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. As of March 31, 2021, our ownership percentage remained at approximately 49.9%.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $675.0 million and relates to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of 15 years. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain officers and affiliates of our joint venture partner, Samsung BioLogics, are currently subject to an ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020, we recognized net losses on our investment of $18.2 million and $14.8 million, respectively, reflecting our share of Samsung Bioepis' operating results and amortization of basis differences, net of tax.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the carrying value of our investment in Samsung Bioepis totaled 653.4 billion South Korean won ($576.3 million) and 673.8 billion South Korean won ($620.2 million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in 2019 and $37.0 million was recorded as an intangible asset in 2019. Additionally, during the third quarter of 2020, we paid Samsung Bioepis a $15.0&#160;million development milestone, which was included in research and development expense in our condensed consolidated statements of income. We may pay Samsung Bioepis up to $195.0 million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three months ended March 31, 2021, we recognized net profit-sharing expense of $68.5 million to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to $71.8 million in the prior year comparative period. As discussed above, we have an option to extend this agreement by an additional five years, subject to the payment of an option exercise fee of $60.0 million.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Services</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services are reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts payable to Samsung Bioepis related to the agreements discussed above were $188.4&#160;million and $99.0&#160;million as of March 31, 2021 and December 31, 2020, respectively.</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span> to our consolidated financial statements included in our 2020 Form 10-K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832284264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017 we amended the terms of the Neurimmune Agreement and made a $150.0 million payment to Neurimmune in exchange for a 15.0% reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional $50.0 million payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional 5.0%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of&#160;$75.0 million&#160;upon the regulatory filing with the FDA for the approval of aducanumab. During the second quarter of </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020, we paid Neurimmune $75.0 million upon the completed submission of the BLA for the approval of aducanumab to the FDA, which was recognized as a charge to noncontrolling interests. In addition, during the second quarter of 2020, we recognized net profit-sharing income of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone payment.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to approximately $150.0&#160;million in milestones to Neurimmune in 2021, which includes $100.0&#160;million if launched in the U.S. and $50.0&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the Aducanumab Collaboration Agreement with Eisai.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the three months ended March 31, 2021 and 2020, amounts reimbursed were immaterial.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $12.8 million. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152759893656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aducanumab Securities Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are named as defendants in an action filed by a shareholder on November 13, 2020, in the U.S. District Court for the Central District of California and transferred to the U.S. District Court for the District of Massachusetts in March 2021. The action alleges violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeks a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time. No trial date has been set. A second class action, filed by another shareholder on January 5, 2021, in the U.S. District Court for the District of Massachusetts, was dismissed in March 2021.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing has been scheduled.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. The request for preliminary injunction was denied in June 2019 and the decision was affirmed on appeal in February 2021. In July 2020 the Danish Patent Board of Appeal revoked the Danish Utility Models that were the subject of Fresenius Kabi&#8217;s October 2018 request for a preliminary injunction and Fresenius Kabi has appealed those revocations to Denmark&#8217;s Maritime and Commercial High Court. No hearing has been scheduled in that appeal.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen (Denmark) A/S in Denmark&#8217;s Maritime and Commercial High Court alleging infringement of another Danish Utility Model. A hearing has been scheduled for May 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. A hearing has been set for August 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019 Gedeon Richter PLC commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispute with Former Convergence Shareholders</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Samsung BioLogics Arbitration</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020 we requested arbitration in the International Chamber of Commerce Court of International Arbitration against Samsung BioLogics seeking interpretation of certain provisions in the Joint Venture Agreement executed on December 6, 2011, as amended, by and between Biogen and Samsung BioLogics (the Joint Venture Agreement). Samsung BioLogics has asserted counterclaims, including breach of the Joint Venture Agreement, and seeks declaratory relief and unspecified damages. An estimate of the possible loss or range of loss cannot be made at this time. No hearing date has been set.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Petition for Inter Partes Review</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit), which is pending. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017 to 2020, we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#8216;514 Patent are invalid for lack of written description. We appealed the judgment to the Federal Circuit and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. We have appealed the judgments and the appeal is pending.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,699,281, 9,090,558 and 10,080,733) pursuant to the Hatch-Waxman Act in the Delaware Court against Teva Pharmaceuticals Development, Inc.  A trial date has not yet been set.</span></div><div style="margin-top:9pt;text-indent:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Office Oppositions</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016 the European Patent Office (EPO) revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing date has been set for January 2022. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018 the EPO revoked Forward Pharma A/S' (Forward Pharma) European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for September 2021.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI Patent Revocation Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. The Polish Patent Office dismissed the action in February 2021. In August 2020 a related entity, Polpharma Biologics S.A., also brought an action seeking to revoke the Polish &#8216;263 Patent in the Polish Patent Office. The action was suspended by the Polish Patent Office in April 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and the German appeal has been withdrawn. No hearing has been set in the Italian action.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annulment Proceedings in General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) have each filed applications in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) seeking to annul decisions of the European Medicines Agency (EMA) refusing to validate Polpharma&#8217;s and Mylan Ireland&#8217;s respective applications to market a generic version of TECFIDERA. The EMA&#8217;s refusals were on the grounds that TECFIDERA benefits from regulatory data protection. Biogen and the European Commission were granted leave to intervene in support of the EMA in the case brought by Polpharma and the court will announce its decision in that case on May 5, 2021. We intend to seek leave to intervene in support of the EMA in the case brought by Mylan Ireland. No hearing has been set in that matter.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152840254040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have an option to acquire exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2020 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three months ended March 31, 2021, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our condensed consolidated financial statements and there may be changes to those estimates in future periods.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt;text-indent:9pt"><span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 the FASB issued Accounting Standards Update No. 2019-12, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152833976184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">777.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">503.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">751.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">732.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,483.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,347.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">769.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,117.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">371.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">565.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">899.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,311.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,211.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,583.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,321.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,904.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,093.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">775.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">964.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(111.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(284.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(396.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(562.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(647.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">988.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,166.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">993.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,166.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152760063272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:58.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">634.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,171.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,068.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152840482552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:22.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,394.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,190.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,204.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,394.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,257.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,178.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,190.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,988.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,220.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,084.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining nine months)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,762.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,763.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152840838504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,336.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,336.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">677.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">677.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,442.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,294.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,412.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,264.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,703.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,700.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,429.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,054.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,940.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,741.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,003.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,741.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,455.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,557.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,394.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,365.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,369.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,536.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">654.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">463.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,859.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,267.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,515.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2021 we completed a private offer to exchange (Exchange Offer) our 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes), whereby approximately $624.6&#160;million of our 2045 Senior Notes were exchanged for approximately $700.7&#160;million of a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes). For additional information on our Exchange Offer, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152834034344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">541.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text">The following tables summarize our marketable debt and equity securities, classified as available for sale:<div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">979.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">979.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">336.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">336.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,140.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,141.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,442.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,442.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,887.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,239.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">749.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,320.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,320.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">780.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,141.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,140.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">819.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,389.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152840972344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,657.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,979.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,186.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,229.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152840544072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(174.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.0)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(203.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832317896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share are calculated as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,399.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832326440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash settled performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832317896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832330648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other income (expense), net, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(436.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(506.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(120.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments in equity securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of March 31, 2021 and 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(436.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(60.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(442.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(60.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">993.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,592.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,145.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832293032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the BAN2401 collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of Activity Related to Aducanumab Collaboration</a></td>
<td class="text">A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total aducanumab development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total aducanumab sales and marketing expense incurred by the Aducanumab Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152851033752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>product </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights', window );">Number of potential products, exclusive rights | product</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Ophthalmolgy Biosimilar Products, Exclusive Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152836672936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member', window );">BIIB118</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">$ 635.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152836829304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues by Product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 2,694.0<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">552.9<span></span>
</td>
<td class="nump">1,100.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">236.0<span></span>
</td>
<td class="nump">777.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">316.9<span></span>
</td>
<td class="nump">323.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">400.5<span></span>
</td>
<td class="nump">466.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">241.8<span></span>
</td>
<td class="nump">292.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">158.7<span></span>
</td>
<td class="nump">173.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">503.3<span></span>
</td>
<td class="nump">522.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">273.3<span></span>
</td>
<td class="nump">277.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">230.0<span></span>
</td>
<td class="nump">244.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">26.6<span></span>
</td>
<td class="nump">28.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">26.6<span></span>
</td>
<td class="nump">28.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,483.3<span></span>
</td>
<td class="nump">2,117.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">751.1<span></span>
</td>
<td class="nump">1,347.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">732.2<span></span>
</td>
<td class="nump">769.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">520.5<span></span>
</td>
<td class="nump">565.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">148.7<span></span>
</td>
<td class="nump">235.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">371.8<span></span>
</td>
<td class="nump">329.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">121.7<span></span>
</td>
<td class="nump">133.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">121.7<span></span>
</td>
<td class="nump">133.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">57.9<span></span>
</td>
<td class="nump">61.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">57.9<span></span>
</td>
<td class="nump">61.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">25.5<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">25.5<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">205.1<span></span>
</td>
<td class="nump">218.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">205.1<span></span>
</td>
<td class="nump">218.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,211.7<span></span>
</td>
<td class="nump">2,904.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">899.8<span></span>
</td>
<td class="nump">1,583.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 1,311.9<span></span>
</td>
<td class="nump">$ 1,321.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FumarateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FumarateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152836174888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 1,276.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">964.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(30.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(396.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(647.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,166.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">141.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">185.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(111.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(82.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">132.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">1,093.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">775.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(32.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(284.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(562.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">988.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">41.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">3.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 44.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152834053992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,166.4<span></span>
</td>
<td class="nump">$ 1,276.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">173.4<span></span>
</td>
<td class="nump">195.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 993.0<span></span>
</td>
<td class="nump">$ 1,080.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152836297064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 2,694.0<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">174.1<span></span>
</td>
<td class="nump">341.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">214.9<span></span>
</td>
<td class="nump">179.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 389.0<span></span>
</td>
<td class="nump">$ 520.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152834563240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,694.0<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">83.2<span></span>
</td>
<td class="nump">94.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">93.3<span></span>
</td>
<td class="nump">109.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152833081704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 2,694.0<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfWholesalers', window );">Number of wholesalers | wholesaler</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">9.30%<span></span>
</td>
<td class="nump">14.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 83.2<span></span>
</td>
<td class="nump">$ 94.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 93.3<span></span>
</td>
<td class="nump">$ 109.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfWholesalers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Wholesalers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfWholesalers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152843669592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 331.3<span></span>
</td>
<td class="nump">$ 314.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">634.8<span></span>
</td>
<td class="nump">544.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">205.7<span></span>
</td>
<td class="nump">209.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">$ 1,171.8<span></span>
</td>
<td class="nump">$ 1,068.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152852689848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">33,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">8,178,400,000<span></span>
</td>
<td class="nump">$ 8,220,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,190,300,000)<span></span>
</td>
<td class="num">(5,136,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,988,100,000<span></span>
</td>
<td class="nump">3,084,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">98,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2019 (remaining three months)</a></td>
<td class="nump">165,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">215,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">215,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2023</a></td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2024</a></td>
<td class="nump">200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">7,394,300,000<span></span>
</td>
<td class="nump">7,394,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,204,000,000.0<span></span>
</td>
<td class="nump">2,257,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">$ 5,190,300,000<span></span>
</td>
<td class="nump">5,136,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">28 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">Indefinite until commercialization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 720,100,000<span></span>
</td>
<td class="nump">762,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 64,000,000.0<span></span>
</td>
<td class="nump">64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN [Member] | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">135,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember', window );">Vixotrigine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">$ 44,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111 | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_TGNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152759918984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">$ 5,762.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">5,763.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">$ 98.1<span></span>
</td>
<td class="nump">$ 71.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152833542920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 2,141.9<span></span>
</td>
<td class="nump">$ 2,051.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">745.8<span></span>
</td>
<td class="nump">626.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">1,442.8<span></span>
</td>
<td class="nump">1,974.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">51.2<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">31.1<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,412.8<span></span>
</td>
<td class="nump">4,700.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">88.6<span></span>
</td>
<td class="nump">217.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">226.0<span></span>
</td>
<td class="nump">259.8<span></span>
</td>
<td class="nump">$ 341.5<span></span>
</td>
<td class="nump">$ 346.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">314.6<span></span>
</td>
<td class="nump">477.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,336.2<span></span>
</td>
<td class="nump">1,301.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">677.4<span></span>
</td>
<td class="nump">627.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">128.3<span></span>
</td>
<td class="nump">122.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">148.2<span></span>
</td>
<td class="nump">271.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">148.2<span></span>
</td>
<td class="nump">271.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">745.8<span></span>
</td>
<td class="nump">626.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">1,294.6<span></span>
</td>
<td class="nump">1,703.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">51.2<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">31.1<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,264.6<span></span>
</td>
<td class="nump">4,429.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">88.6<span></span>
</td>
<td class="nump">217.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">88.6<span></span>
</td>
<td class="nump">217.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,336.2<span></span>
</td>
<td class="nump">1,301.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">677.4<span></span>
</td>
<td class="nump">627.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">128.3<span></span>
</td>
<td class="nump">122.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">226.0<span></span>
</td>
<td class="nump">259.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">226.0<span></span>
</td>
<td class="nump">259.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152833293528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 226,000,000.0<span></span>
</td>
<td class="nump">$ 110,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TechnologicalAndRegulatorySuccessProbability', window );">Technological and Regulatory Success, Probability</a></td>
<td class="nump">21.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TechnologicalAndRegulatorySuccessProbability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Technological and Regulatory Success, Probability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TechnologicalAndRegulatorySuccessProbability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152840315944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details) - Discount rate<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.77<span></span>
</td>
<td class="nump">0.0060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0077<span></span>
</td>
<td class="nump">0.0060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152833812584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,267,200,000<span></span>
</td>
<td class="nump">$ 7,426,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,859,200,000<span></span>
</td>
<td class="nump">8,515,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,044,200,000<span></span>
</td>
<td class="nump">1,054,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 998,200,000<span></span>
</td>
<td class="nump">997,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,940,800,000<span></span>
</td>
<td class="nump">2,003,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,741,500,000<span></span>
</td>
<td class="nump">1,741,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,455,300,000<span></span>
</td>
<td class="nump">1,557,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,491,400,000<span></span>
</td>
<td class="nump">1,491,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,394,800,000<span></span>
</td>
<td class="nump">2,365,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,099,700,000<span></span>
</td>
<td class="nump">1,723,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">$ 624,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,369,800,000<span></span>
</td>
<td class="nump">1,536,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,472,700,000<span></span>
</td>
<td class="nump">1,472,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 654,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">$ 700,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LongTermDebtExchangedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt, Exchanged, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LongTermDebtExchangedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152836371688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">259.8<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 226.0<span></span>
</td>
<td class="nump">$ 341.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152839882264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 745.8<span></span>
</td>
<td class="nump">$ 626.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">50.7<span></span>
</td>
<td class="nump">61.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">93.7<span></span>
</td>
<td class="nump">37.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">541.5<span></span>
</td>
<td class="nump">505.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 59.9<span></span>
</td>
<td class="nump">$ 23.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152835544696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 2,140.9<span></span>
</td>
<td class="nump">$ 2,049.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">2,141.9<span></span>
</td>
<td class="nump">2,051.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">2,141.9<span></span>
</td>
<td class="nump">2,051.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity Securities, FV-NI, Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,239.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">749.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">979.7<span></span>
</td>
<td class="nump">897.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">979.5<span></span>
</td>
<td class="nump">898.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">356.0<span></span>
</td>
<td class="nump">402.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">356.7<span></span>
</td>
<td class="nump">403.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">340.5<span></span>
</td>
<td class="nump">380.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">340.5<span></span>
</td>
<td class="nump">380.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">336.5<span></span>
</td>
<td class="nump">245.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">336.9<span></span>
</td>
<td class="nump">246.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">128.2<span></span>
</td>
<td class="nump">122.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">128.3<span></span>
</td>
<td class="nump">122.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember', window );">Equity Securities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity Securities, FV-NI, Cost</a></td>
<td class="nump">1,168.9<span></span>
</td>
<td class="nump">70.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="nump">351.0<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</a></td>
<td class="num">(77.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">1,442.8<span></span>
</td>
<td class="nump">86.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember', window );">Equity Securities, Non-Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity Securities, FV-NI, Cost</a></td>
<td class="nump">1,168.9<span></span>
</td>
<td class="nump">1,168.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="nump">351.0<span></span>
</td>
<td class="nump">733.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</a></td>
<td class="num">(77.1)<span></span>
</td>
<td class="num">(14.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">$ 1,442.8<span></span>
</td>
<td class="nump">$ 1,887.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152851056904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">$ 1,320.0<span></span>
</td>
<td class="nump">$ 1,278.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">1,320.2<span></span>
</td>
<td class="nump">1,278.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, amortized cost</a></td>
<td class="nump">781.2<span></span>
</td>
<td class="nump">722.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, estimated fair value</a></td>
<td class="nump">780.4<span></span>
</td>
<td class="nump">721.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">40.7<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">40.3<span></span>
</td>
<td class="nump">49.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">2,140.9<span></span>
</td>
<td class="nump">2,049.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 2,141.9<span></span>
</td>
<td class="nump">$ 2,051.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832517800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 819.2<span></span>
</td>
<td class="nump">$ 2,389.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="num">$ (0.7)<span></span>
</td>
<td class="num">$ (19.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832330648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">11 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152834265576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ / shares in Units, shares in Millions, number in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sales of strategic investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91.2<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global Licensing Collaboration Agreement, Amount, Shares Purchased</a></td>
<td class="nump">$ 650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global Licensing Collaboration Agreement, Shares, Purchased</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare', window );">Global Licensing Collaboration Agreement, Purchase Price Per Share</a></td>
<td class="nump">$ 104.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DividendYieldPercentage', window );">Dividend yield percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember', window );">Sangamo Therapeutics, Inc. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global Licensing Collaboration Agreement, Amount, Shares Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global Licensing Collaboration Agreement, Shares, Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,493.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,024.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstocksharespurchased', window );">Investment in common stock, shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DividendYieldPercentage', window );">Dividend yield percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember', window );">Sangamo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DividendYieldPercentage', window );">Dividend yield percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DividendYieldPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend Yield Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DividendYieldPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Amount, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Purchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares, Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Investmentincommonstocksharespurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in common stock, shares purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Investmentincommonstocksharespurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_SangamoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152755303992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (212.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.4)<span></span>
</td>
<td class="num">$ (2.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.4<span></span>
</td>
<td class="nump">23.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,358.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,158.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,186.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,229.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Foreign exchange contract | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging [Member] | Interest rate swap | Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Remaining duration of Net Investment Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized gain (loss) on net investment hedges in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax', window );">Derivative qualifying as net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease', window );">Gains (losses) on net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Foreign exchange contract | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Foreign exchange contract | Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.1)<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,657.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,979.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80784-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152834048824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation | $</a></td>
<td class="nump">$ 1,827.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,782.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation | $</a></td>
<td class="nump">$ 48.8<span></span>
</td>
<td class="nump">$ 48.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember', window );">Biologics Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="nump">393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember', window );">Warehouse, Utilities and Support Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember', window );">Administrative Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress | $</a></td>
<td class="nump">$ 1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Square Feet</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_BiologicsManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_AdministrativeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152835936824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 15, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of Senior Debt</a></td>
<td class="nump">$ 151,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings and premiums paid on debt exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,700,000<span></span>
</td>
<td class="nump">$ 44,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of Senior Debt</a></td>
<td class="nump">12,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentRedemptionAmount', window );">Debt Instrument, Redemption, Amount</a></td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">624,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings and premiums paid on debt exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">$ 700,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.973%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.174%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.90% Senior Notes Due Sept 15, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.792%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts', window );">Payment of early call premium and write off of remaining unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Senior Notes | 2.90% Senior Notes Due Sept 15, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain', window );">Pre-tax charge, payment of early call premium and write off of remaining unamortized debt issuance costs, net of derivative gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Derivative, gain on derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LongTermDebtExchangedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt, Exchanged, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LongTermDebtExchangedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageParValueOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Par Value Of Senior Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageParValueOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.90SeniorNotesDueSept152020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.90SeniorNotesDueSept152020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152833828504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchases (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 600,000,000.0<span></span>
</td>
<td class="nump">$ 2,220,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember', window );">December 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 941,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember', window );">2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_October2020ShareRepurchaseProgramMember', window );">October 2020 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 600,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount remaining under 2019 Share Repurchase Program</a></td>
<td class="nump">$ 4,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_October2020ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_October2020ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152836346088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">$ (299.0)<span></span>
</td>
<td class="num">$ (135.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(299.0)<span></span>
</td>
<td class="num">(149.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">103.3<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">21.4<span></span>
</td>
<td class="num">(14.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">125.4<span></span>
</td>
<td class="num">(13.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(174.3)<span></span>
</td>
<td class="num">(149.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">124.7<span></span>
</td>
<td class="num">(14.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(20.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(179.0)<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(29.4)<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">128.6<span></span>
</td>
<td class="nump">60.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">21.0<span></span>
</td>
<td class="num">(26.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">149.6<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(29.4)<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(8.5)<span></span>
</td>
<td class="nump">25.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">48.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">23.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">23.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">48.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(66.3)<span></span>
</td>
<td class="num">(32.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(64.3)<span></span>
</td>
<td class="num">(32.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(64.3)<span></span>
</td>
<td class="num">(32.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(46.6)<span></span>
</td>
<td class="num">(139.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(95.1)<span></span>
</td>
<td class="num">(203.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="num">(48.5)<span></span>
</td>
<td class="num">(63.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(48.5)<span></span>
</td>
<td class="num">(63.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (95.1)<span></span>
</td>
<td class="num">$ (203.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724394-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152836787112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="num">$ (506.9)<span></span>
</td>
<td class="num">$ (120.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">44.2<span></span>
</td>
<td class="nump">292.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="num">(2,694.0)<span></span>
</td>
<td class="num">(3,534.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">410.2<span></span>
</td>
<td class="nump">1,399.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="num">(21.4)<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(16.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152835577144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 410.2<span></span>
</td>
<td class="nump">$ 1,399.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">151.9<span></span>
</td>
<td class="nump">172.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">152.3<span></span>
</td>
<td class="nump">173.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152840089512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (72.6)<span></span>
</td>
<td class="num">$ (69.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">78.5<span></span>
</td>
<td class="nump">76.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">75.9<span></span>
</td>
<td class="nump">74.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(14.0)<span></span>
</td>
<td class="num">(13.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">33.6<span></span>
</td>
<td class="nump">33.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">44.9<span></span>
</td>
<td class="nump">43.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 61.9<span></span>
</td>
<td class="nump">$ 61.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152835920680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (72.6)<span></span>
</td>
<td class="num">$ (69.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">78.5<span></span>
</td>
<td class="nump">76.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">75.9<span></span>
</td>
<td class="nump">74.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">16.5<span></span>
</td>
<td class="nump">19.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">42.8<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 6.9<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152843669592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxAssetsValueReductioninValue', window );">Deferred tax assets, decrease in value</a></td>
<td class="nump">$ 1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesValueReductioninValue', window );">Deferred tax liabilities, decrease in value</a></td>
<td class="nump">$ 1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxAssetsValueReductioninValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Value, Reduction in Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxAssetsValueReductioninValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesValueReductioninValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Value, Reduction in Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesValueReductioninValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TECFIDERAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152851615080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(10.90%)<span></span>
</td>
<td class="num">(4.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(3.70%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationGILTItax', window );">GILTI</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="nump">17.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationGILTItax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, GILTI tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationGILTItax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152835494568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 24.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(64.7)<span></span>
</td>
<td class="num">(44.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gain (loss) on investments, net</a></td>
<td class="num">(436.6)<span></span>
</td>
<td class="num">(77.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="num">(8.6)<span></span>
</td>
<td class="num">(18.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(506.9)<span></span>
</td>
<td class="num">(120.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains (losses) recognized during the period on equity securities</a></td>
<td class="num">(436.1)<span></span>
</td>
<td class="num">(60.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net gains (losses) recognized during the period on equity securities sold during the period</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized during the period on equity securities</a></td>
<td class="num">(442.3)<span></span>
</td>
<td class="num">$ (60.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">1,166.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,276.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Collaboration expense</a></td>
<td class="nump">207.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">212.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expense</a></td>
<td class="nump">390.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">88.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">700.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">791.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expense and other</a></td>
<td class="nump">2,592.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,145.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 993.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,080.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152840050824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gain (loss) on investments, net</a></td>
<td class="num">$ (436.6)<span></span>
</td>
<td class="num">$ (77.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,411.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,329.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="nump">725.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 709.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="num">(442.3)<span></span>
</td>
<td class="num">(60.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sale of available-for-sale securities, equity</a></td>
<td class="nump">91.2<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="nump">$ 442.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152844288120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Collaborations (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>product </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18.2)<span></span>
</td>
<td class="num">$ (16.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfProductCandidates', window );">Number of product candidates | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Expense Incurred By Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.5<span></span>
</td>
<td class="nump">43.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.7<span></span>
</td>
<td class="nump">21.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on research and development contracts terminated with Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global Licensing Collaboration Agreement, Amount, Shares Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare', window );">Global Licensing Collaboration Agreement, Shares Purchased Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments', window );">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global Licensing Collaboration Agreement, Amount, Shares Purchased</a></td>
<td class="nump">$ 650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global Licensing Collaboration Agreement, Shares, Purchased | shares</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="nump">$ 875.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments', window );">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</a></td>
<td class="nump">1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 209.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare', window );">Global Licensing Collaboration Agreement, Purchase Price Per Share | $ / shares</a></td>
<td class="nump">$ 104.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember', window );">Sangamo Therapeutics, Inc. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global Licensing Collaboration Agreement, Amount, Shares Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global Licensing Collaboration Agreement, Shares, Purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare', window );">Global Licensing Collaboration Agreement, Shares Purchased Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments', window );">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets', window );">Global Licensing Collaboration Agreement, Payment, Selection of Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones', window );">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones', window );">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.0<span></span>
</td>
<td class="nump">19.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.8<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | UCB Pharma S.A. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.9<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111.8<span></span>
</td>
<td class="nump">22.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.3<span></span>
</td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Amount, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Selection of Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Purchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares, Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares Purchased Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AducanumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AducanumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152834070360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Equity Method Investments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 07, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Our share of Samsung Bioepis gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.2<span></span>
</td>
<td class="nump">$ 16.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.5<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,694.0<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.2<span></span>
</td>
<td class="nump">$ 14.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 576.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 653.4<span></span>
</td>
<td class="nump">$ 620.2<span></span>
</td>
<td class="nump">&#8361; 673.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.5<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on research and development contracts terminated with Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Our share of Samsung Bioepis gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ContractOptionExerciseFee', window );">Contract Option Exercise Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember', window );">Inventory | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContractOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContractOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment basis difference amortization period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Equitymethodinvestmentbasisdifferenceamortizationperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152833888600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18.2)<span></span>
</td>
<td class="num">$ (16.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostsPercentage', window );">Research and development costs, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyratepayableoncommercialsales', window );">Reduction in royalty rate payable on commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales', window );">Additional reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedPaymentTimelineofMilestoneAxis=biib_TwelvemonthsMember', window );">Twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember', window );">Regulatory Milestones [Member] | Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AducanumabMember', window );">Aducanumab | Regulatory Milestones [Member] | JAPAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_NeurimmuneMember', window );">Neurimmune | Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalreductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Costs, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedPaymentTimelineofMilestoneAxis=biib_TwelvemonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedPaymentTimelineofMilestoneAxis=biib_TwelvemonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AducanumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AducanumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152832384440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Litigation (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>109
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MKLU9\F#&'&W?4K$I:HE*M@:3P7P)&1+FM-C<*+YK#UP?N5*\:B^WC,)>6 O
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MS>&?!I'& -9W0NC7@4G0_'=9_PM02P,$%     @ TH&64JK,CWV_!@  +1P
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M2@OYY(6Y<$T7QWCBI""/W!Q/0O'<44X\S#G@![*&/,F^&[IAUN.$L3&4U9!
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M+GAM;-U:77/;N!7]*QAUVMHSM/R1[&ZZ3C(C*TJBK>6XDIW=M-,'B(1$."3
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M]18*<ZH+ &MK=J?E;K+1E[@0-JTK+VF@;F!,A2>F*@",(9-R<7IR],\V<FM
M@5#$Q,0;%0=GU%SJ1!SPWW;18:CX#K@&O.H !-G0!4&Y(=F,&0SOU.DS5IG
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MN+^P(.?U%]J@_176Z_\!4$L#!!0    ( -*!EE)X9C#6N (  /,%   8
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&ULG511;]HP$/XKI[RLE28"@6Y5!4C
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M&WZA:7.'PPC2VCHJ#V!64$K=?L73X1Y. -?]5P#) 9 $W6VAH/*#<&(Z-M2
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MKRG]GU &;"P+L]+LJIB+^3Y]#U*THO@;4<[]-QF.N7)8X'69[_K>&_R"5K7
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M$A1C),0SH07$(:ITQ8NE-5<#?]HRG&?:ZJ+M09RPC1<I%G\.?/M(=MDRV!2
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MDP9W2?NZ0EX(11NP3M"V^: #VO]9SOX#4$L#!!0    ( -*!EE(V^!76= (
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M4GS:2KEH]K[O[.UL=8HK,.E&OI[#>6(E\XK!H!<F<GFR<#1H7\I 06A5A>'
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ME:KF"_Q*G;Y><@UW7R)C$-=&Z'O*'3_&6+XKC+2H08FQYI/%O3"EHU+C!(0
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M&]$IM[;7[UYJ=*I>O[#9'.9,U[+FL:D :BAJ3%5WB U(.V11/$)&OUQ_>^A
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MOJXS4^1>' $4,YVFI*QC<=V%&6%P"S7$]X4UXE ,>V?C273&WRXF%]% W%B
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MZ\8BZ/FMFEJ0(&6C--@,+BD^&WP1@$P^RY&()V8JJ/9.9JX S1MMWINYCIW
MMO!*E.&T%2(04Y%E>\V9:JFA91!/@,2I6?8(FXH9I5D;.@NDKB^08JJ-T] Q
MJN^RT0RN\6.!A@KLGC.[#\K&VI7>88)UT0"02C#P%/L,',C,TI7XMLJ5!==+
M :B/,8/ $@;:X+OL&UNN !#YAJO*UNCI173Q38@_MZ#J;%D@R]%V#61FER$G
M255Y O !0,O!Q_)!&3U1+ G@47!!I0Q_2XDJ8H(^9@P5A>"[,P7,\4\D=^A\
MA8$CH-L96I_21;E4V[)6)'[FB*J=I3JI""T 7&I3?/SC[!'BO-6>S]*""J56
M_[O)UM.'84_0F2J_4FKK<(^]9),XZV8[M>Y30OWE$ZYPEB41_G2'0;Y?G6OQ
M 0N5'&79O?^9%343#=N$?+%QV+&!M&YI?/M8\,4U??1_TI^N.U'24]T#(B5-
M6NTB/6VU==%PHZO;KXIOGSMRV\>B=&7N1BIDK94*87LP@!#B5(4U3R9G)_"A
MS5<ZY3(%FO]#M0@L"<Q"8<#ZJC14)I3C7NDS+TXK=8N(N,DV6Z>7><0FL_];
MVZ_MCGJ\97<,? U#OZBY(K5W1>TS)IFAU,QC=(,-XWS5ANE/]U =0TPG&(;H
MX%FGQ&BV1M$Y?9S"#GLO.AI0TW5(C=4(;5>GE^,Q&9O^7K"69(+^.E3W.@]7
MS.RAE=*1,="NA$&4PA2C(0 V:YA0F2 94YJFVVDN"<7@K(>.IJ9R'XJ4P-S'
M1O2&JL97\+ZOJ=?I9^>=6]COB1O(3W3N[4S(?"'OA;!Z'IU18* 7HU:'U=&Z
MCT'M&M(67XTH%R1LY>VM#?B<H]D,5*VI3+GC"Z\)H(;0Y5E*U1#3N8@JXSKX
M U""FC6*O%F(AG;Y5/8W.[N\L BE A2>)R6IYQ(6E66'@]YH? X?;J'*H#?
M8/\K(,N'=F(:3*+3]E;#QD [H[3*!\;6'6W'KE11:A7_"6/*6S>U@3&U2%U2
MW(7W,$+?V.V:"PW,K+R@1,ED/;=YL"3;MZQ@D8V_';3;IX)<_26&O<C,9M2V
M-S:1T'-Y49_J</2GU7,'62V/K7QM?51:7[.%6S:4H$4:3O>F+ 4YG ]G?(E&
MCK!<88<D^3QKX1R"!=DK"S42,9'B"WUT,0QZ+Q&SOJYO1$RWM:IC@="0HB=X
M_N3P<N/BYZ;<^HXQH<XV+[H/NJ6[OK=D@(X.]Q++-ERAZ6\!4P,0^,H2R%E]
MOEBJ;GO6W70P4XBH<O9@C/Q6S7ROJV/E)S:\CF-;0#WUJPTUN;,^H&8PGB"S
M!:Y2D\^_Y7JLZ1;53J,QZMR.5O\KR$\5]%<0J"(QH#NO7<GKS_ X(":'="7W
M%S@<3J#R4Q#J>B?GI/$Z5*;LG%_Z<@%TPIM1]6C]7MEU>)UJ/3V\E 9'GE/]
MDZH9EO:CR?@ 69)?] H_O%GRRU53X[W)^.L"U8>R- '/9P9E2/F#-JC?MKOZ
M+U!+ P04    " #2@992)Y:!M\ #  #-"   &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6R=5MMNVS@0_96!T$>M)%^2.H5C(.D%VX< 08-N'Q;[0$LC
MBR@EJKRLXGY]#RE;<;I)L"U@6R(YES-G9CA>#]I\M0VSH_M6=?8R:9SKW^2Y
M+1MNA<UTSQU.:FU:X; TN]SVAD45E5J5SXOB/&^%[)+-.N[=FLU:>Z=DQ[>&
MK&];8?;7K/1PF<R2X\8GN6M<V,@WZU[L^([=Y_[68)5/5BK9<F>E[LAP?9E<
MS=Y<+X-\%/A+\F!/WBE$LM7Z:UA\K"Z3(@!BQ:4+%@0>__);5BH8 HQO!YO)
MY#(HGKX?K7^(L2.6K;#\5JLOLG+-9;)*J.):>.4^Z>%//L1S%NR56MGX2\,H
M>UXD5'KK='M0!H)6=N-3W!]X.%%8/:<P/RC,(^[1443Y3CBQ61L]D G2L!9>
M8JA1&^!D%Y)RYPQ.)?3<YM8@O\;M4[I5HG,DNHK>?_.R!_&.7CQ=YPX @IF\
M/#B['IW-GW&VH!O=N<;2^Z[BZK%^#N 3^OD1_?7\18,WPF2TF*4T+^:S%^PM
M)C86T=[BM]CX^VIKG4$=_?."J^7D:AE=+7_'U5/4_E]S_62.)^3",#JHU :T
MDW#42!26D:505&KK4NK0_KI&CY2^]4HXB%6,+B^E",V3T=4S)X1/_Z+O05AZ
M-4M7\]?9.2I8J=B,$,'FZ]4\6SQLVH !.2V;*:E1\AV7W&[9''>+%-'8GF-'
MJWU&:%!R#>-KF*D=BXQ#D?UD+GT,GN]QN5GH:2<4A%\M5]EJPE/JM@=S%8[C
MR7(ZD5UTUQL)QWL6YB K B "&5)7&=UII5WC39?2W2#==S8J1',C.E^CBKR1
MW8X^B%(JZ?;T$5PB/R9XL[[OM4%*O*':0Y)IA_IR3:2C,GZ'.!"Z'BGN9<^A
M(%(:..9ZZZ6J@G5!2I@=_V&1:FQ+(-K)TN(&.<50'S$@KJ=!9_2%(UNE0^32
M/J@ [18A"^.D4&I/H10BN:BM:C0?J*JEL:@[H>J0XY"*C#[W!Y(5!X7T)\L#
MR :B4OF*:7&Q2(NBP*WM0X!UF%>&QWH$A%^+$[5P4?S''' -6#3:6S#I71"5
M;"/EQX387I0<=\YF3QD0%>YH&6Z)6 E1',WS"X6-##8"3=JCJ^XEQ@X*'*V2
M72"JT]Y!G1XV'C=#2J7H)<I9?@^];D%P!SQ^'((R=NL."O:4OD?$9T_=;OG)
MB&D95(=!&HS[SHW39MJ=9O75.*(>Q,=!#QYVLK.DN(9JD;T^2\B,PW-<.-W'
M@;75#N,OOC;XO\$F"."\UMH=%\'!] ]F\P-02P,$%     @ TH&64KK=\=R3
M!@  :Q,  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULU5A9<]LV$/XK
M.VK22684BJ(D'XGM&3O'---)DXF;YJ'3!XA<B6A @ % R^ZO[RYXR=9AN].'
M]D4B<7Q[?;M8\&1E[#>7(WJX+I1VIX/<^_+E:.32' OA(E.BIIF%L87P]&J7
M(U=:%%G85*A1$L<'HT)(/3@["6.?[-F)J;R2&C]9<%51"'MS@<JL3@?C03OP
M62YSSP.CLY-2+/$2_9?RDZ6W48>2R0*UDT:#Q<7IX'S\\F+*Z\."WR2NW-HS
ML"5S8[[QR_OL=!"S0J@P]8P@Z.\*7Z-2#$1J?&\P!YU(WKC^W**_"[:3+7/A
M\+517V7F\]/!T0 R7(A*^<]F]1,V]LP8+S7*A5]8U6N3PP&DE?.F:#:3!H74
M];^X;ORPMN$HWK$A:38D0>]:4-#RC?#B[,2:%5A>36C\$$P-NTDYJ3DHE][2
MK*1]_NR]SG#N,=/H'#S[Q7ATST]&GI!Y?I0V*!<U2K(#90(?C/:Y@[<$E]W>
M/R*-.K625JV+9"_@!V$CF(R'D,3)> _>I#-S$O F._#>D)'P1KI4&5=9A-_/
MY\Y;HL0?>\"G'?@T@$\?X,-MOGOX;GA[G>9"+Q$^+A9HX;V&=SBW%:5+\ 2L
M$%)3E II YC*WMU@%F'4(X%:6I+$TQE<HI;&0@@N4!Z')4D\&]^>$3J#5+A\
M&)Z$)C"&] ;*RI(4AP_!9H0(SBG?EDN+2^$12BMU*DNA0!2FTIZU%&5IS;6D
MM$)U T\.DFET0/Q6BE.UL6)3P$HXP,;B+(@3CQ1T&,?1X::@;;[H<=DF*,4-
M%2/OMH".9^/HJ 6-X.-F7,A[,$?D*I2R9JWV) DX_%"83"YD*KA4O>)Q5Z44
M"9\WTCGJ1I/\'HK*%]<V@F*8+).\EVP/>!EQ/;B +9&.'6*]_*M93'ID?U)Q
M88,XP)(TLN@\.9>J/0?ZBB-/PFF\V.FFB G:2AXR.8D7B 5FCX[+471\?_B#
MRQX>E20:MYA#IHVJ,JF7' );!14SJ'0I9-;9'\&O>6U$489#X]ZXX;4GS$JZ
MG-58BUQP1FJ6NG8Z^0!?>'$-1 M+M"!UGTRBI+.YHN@&A]\&Y'6,M^D,5I7B
M6L.1N%S2*LZ/-:E2;T:6Q@S)L?1 G$)XUDP\'X*F'H"GR?>IH22GT8R?G%$R
M$VR[\_37^;M!8(<$JN06D8@<#@(N$AE0&2>MVCH^;"GKPOHF="%R&E!8"EHJ
ME&)7%;(J0H!XX<I*CR^H&O%2'P+$[0;'LM(]L8V52]DE@'2N$CKE>NE\G=!=
M3LR%XBD:=<ZD,IBVDC[?Z>HO'!V'WJM@?8BN4,[029SA8R@YZ>L$YUT-"6ST
M'E;"PIHB&*Z$\_UPZT".#1B](VE\+CSI:W&M<M)DFZD1?&52I)7EFGZW+/<9
MQ-8TKKSCM,UCZ/]!QXA_X]O.^JCAG*J5@DD<%L4AU,PE%E>OK$@1<A<-Z+XJ
MW5?N*-ECF#>N?+8AF,QERZ3CY&]IOC"*>F8:> D__G"4) >OB$'1K(/9+S&)
MDMG3V]9E%9(/;B X@"V\$BIPSL/Q<71\.'G*&TMA7P4:_@.ADVB\5^CLKM#Q
MX;05NI>)U!],[Z>BYY(8VA;R6LO"7%QA>V*FQF;-&<@94-57 \K$^J"U]B:<
M$)T]/!S*B=E+Q*:@0.C#(WC'C.@/9*GKRU-0O4W3.P08 C5UW&+QS2H,P3@9
MPJWF<,B*-EKTLA=4\R@.)&<M'<B-=-K5.=?)XVL,C.,7/Q/SH^-X2YPNL22$
M.:7C>%;SGS/B[BC_]EGQ*$H^4.JP8<?A<=*S@]NJ+0BAM&VDIIDKN0PNK[L4
M<IEN+H(-4W +6+ +0XT*Y7>M,[)LE%N)DJ'"U8%$YRR[/NF1+I=\SB_D-?V'
MU9Q#H9 +XKR58DZEGB>"0IP2P<&TO6)"L49<\HCV*6+F^JKOA,*^*;I;LDC)
MNI;7\YL.HD@8VW!<6CJR?$4'ZDU0[U:+4DO?:%..US)O3YM"HT1?W425$[!6
M'CEGX#O=87Q]06$3_CO=2^V%'6U):"+[Z\)]/0HT/<J_U9\,F?B>4IND$C1U
M"S"_8:TFT:13:DFB2*(*)C:5K&]5VB*V5BGW4?HAM6O?_BUE[&@(;Z@>7PG^
M_$+,IWMW%8(P;+1UN"M@VTI;M.W"/EK[ %(@48H_\Q"]V)OUMY!NM/N2=%Y_
M0.F7UY^AJ$>@*#E0N*"M=%F<#<#6GW;J%V_*\#EE;KPW17C,R5BTO(#F%X:L
M;EY80/=][>QO4$L#!!0    ( -*!EE("__5N  8  '03   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;.U8VV[;1A#]E8%J%#9@4+Q9MES;@.RDC8&D
M-FRG?2CZL")7(AN2R^PN+;M?WS-+ZN:+8B=!GOH@B9>=,S-GSNRN]FBF]">3
M26GIKBPJ<]S+K*T/^WV39+(4QE.UK/!FHG0I+&[UM&]J+47JC,JB'_K^H%^*
MO.J='+EGE_KD2#6VR"MYJ<DT92GT_:DLU.RX%_3F#Z[R:6;Y0?_DJ!93>2WM
MQ_I2XZZ_0$GS4E8F5Q5I.3GNC8+#TYC'NP%_Y')F5JZ),QDK]8EOSM/CGL\!
MR4(FEA$$?F[EF2P*!D(8GSO,WL(E&ZY>S]%_=;DCE[$P\DP5?^:IS8Y[!SU*
MY40TA;U2LW>RRV>/\1)5&/=-LW9L@,%)8ZPJ.V-$4.95^RON.AY6# [\9PS"
MSB!T<;>.7)1OA!4G1UK-2/-HH/&%2]59([B\XJ)<6XVW.>SLR=O/36[OC_H6
M6/RDGW1VIZU=^(Q=1!]493-#;ZM4INOV?<2P""2<!W(:;@3\(+1'4;!+H1\&
M&_"B16*1PXLV)D9_C<;&:M3^[PV8\0(S=ICQJ\G::,>-=6AJD<CC'CK'2'TK
M>R?7F="2KF3=Z"2#K@R=5W216#66FDGP236:3I70*:D)O<DUA*RT(='83.G\
M7YF2H%JKJ18E6846F4-14_.#K3W/IW%>%"Q_0#!>HLH2=]!5\HFVG9N'@=!E
MB[GCT473A?+<&$H5 J^4I4S<2A(5R;LZU\)U7"JL]&A4%&2<N5[)M8%LM(MH
M,_X,X=.8;2T(2#WZ^#+#79JM.@1553H'(5&#MKL</2V+>PJ]$)W5LN0"-4^2
M)2SH3I2Q_'8=86O@^Z!Z#I(V.J^F9#.)CY:2RK95)+<*0>A)ME Z^%F'BE=J
MIB5/JQSPK<@+,2[DBWD3+HF'OJ"P-S*192NQ8/@#)+;N[UFMH5Y9CEAG"!P
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M$J<5VD&V00#[:V/\;A$,[!O,^3]02P,$%     @ TH&64H;P/DGC!P  9A(
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M9GAL (W3;I]1QV" H'0HQ50#B 3T/P%\HDX"U\\Y9:E#6LJ8C=$<$ X40EL
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MBJZ2RP)?2.3Y -ZO'#Z5VALVT/^T=/Q?4$L#!!0    ( -*!EE*,JY<NM04
M $H.   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;+576V_;-A3^*X1G
M##'@RI)\SY( 2=IN =HM2-KM8=@#+1_;1"A2):DX[J_?1U)VG&N+75YLB3K\
MSG?NY-%:FQN[(G+LKI3*'K=6SE6'O9XM5E1RF^B*%+XLM"FYPZM9]FQEB,_#
MIE+V\C0=]4HN5.OD**Q=FI,C73LI%%T:9NNRY&9S1E*OCUM9:[MP)98KYQ=Z
M)T<57](UN<_5I<%;;X<R%R4I*[1BAA;'K=/L\&S@Y8/ [X+6=N^9>4MF6M_X
MEXOY<2OUA$A2X3P"Q]\MG9.4'@@TOC28K9U*OW'_>8O^/M@.6V;<TKF6?XBY
M6QVW)BTVIP6OI;O2ZU^HL6?H\0HM;?AEZT8V;;&BMDZ7S68P*(6*__RN\</W
M;,B;#7G@'14%EF^YXR='1J^9\=) \P_!U+ ;Y(3R0;EV!E\%]KF3W]R*##O7
MRFHIYMS1G+T7BJM"<,FN'180 <?>DN-"'O4<5/J-O:*!/XOP^0OP??91*[>R
M[)V:T_SA_AZH[OCF6[YG^:N '[E)6#_KLCS-LU?P^CO[^P&O_Y+]9LF5^,I]
MBG3W_! R1LW9I2$+!\0%O7C..9;]>3JSSB#!_GJ%T6#':! 8#?ZOB'P/_(4J
M=$GLX-T=JMM2I\M^10,XUV6E53 )INH@*1I)VDDJ<EW&#36%++Z"(;=LH24J
MW!XR5 O#5O9I98@>Q)\A>L4JA._@0B&=I81;;2<$T_^D(.8(+G=;O6V6)U/_
M.T@&]Q\;,NQ@-$C&'78P&"3]#OL9/8@=2&V!B&@)=0O9$*% &F+]43*"^'CL
MQ<$3-:L 5JRX6A);8K^- &0[S9Y)V)%-DFF'!=_%]33)@)<,.NR3=@C,*\X"
M^X-A.O( >,KR-!E^DVO7>Q3]R3<O^ VRWJ..SR0Q/M.WU,57B5Q@3J,)S1RS
M5-1&.$$ H"^U<)N])1_.@HSS2F=".RI62DN]W##PK5  ?M<MM-<(:\$KX4U:
MU&INV1IV4=".5S)R(]1RGV[(!,#^$YVAPI16;Y!&-Q2M>X*3[!+*A80J8T+1
MHX3R*13=72M,)QG2,H8RJ-FMQ2C[:JX-6VDYAT'V>0O6WG1>54;?"0P DAO6
M'@SRI+]-W8#<'B7Y=L&'Q5841HW<=*.I!EH1ID?<'I!JB,)E[5&*A-_'_TI&
M/\9M$J(R K[9$#>-)NX%6$58GR>H0'K!(X8*O51A90YK$=+O=# T^IJ')YKL
M9!SY5P#?TI;5@@O#;KFLR1MTH95 =EVCQ'@)0]Z2 I=@V37&OB<.C0R3KKCQ
M\L_X.]WZ(YH4.TT@'5)FUX=LB.GR&VW K;AKJL?ZN/@]3V._(AG:&A@]]$%@
M[GO5O^QTON$^[#@O1"5&TYORE&4[-K4LM!:?.1WV@2R:\'^"C@GTG*S/]Q]_
MF.19_A/[K!X5UK\TQE?7GC&G16%J(#1S*O@^3K#M%]K[$IMP 4<+&V>8VT^7
MPT>Q.'TNNG'Q+154S@#6K*?LBM ?:WH3$\>7KB6#S *\87-A"UV';@@:W.O#
MP XF3:=]Y&^;9=UTDB8CS%@IT<%-/%%LV?>G:3)F_<D4M7^E-URZ;7N4HO!'
M8+AO05B"TY,A?B?X?5=64F\HE)"'N3^US$C10H!.GHXQ-_O]?C*!34;<Q@8A
M!9\)&;T^P81CV20#X'EMC#];5-ILSSMPIH-ROQK\BA'0G(5F4BS#H]TE0S:8
M BO&9YSZ$3F>9M ?1R1_,6(8[]WAU/?5-NMWL\$03Q'E@U;+-QCZ)?NP1SE^
MD[MO^^:$GMW.NH,L@\T/^G36[>>>X&[QI>I^$OW'[=<+8=;+VI?ZUJYF^#M^
M%_H*3/91:X_SX?U\B$3&Z?2^QS_$3IX[0?;VSO<EF66XQ5@64BX>]7>KNXO2
M:;P?W(O'6Q:L7?HRE;3 5B3=L,5,O+G$%Z>K<%N8:8>[1WA<X;)'Q@O@^T)C
ME#<O7L'N^GCR-U!+ P04    " #2@992^D>LGN<6  #$3P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970R,RYX;6S=7&MSV\:2_2M36N5>J8JB2.J=.*ZB'LY5
MHM@NR4EN:FL_#($A.3%>P0"2Z5^_IWL&P !\2'+DW>Q^L2P*,]/O/MW3X*N'
M-/]HYDH5XE,<)>;[K7E19-_N[YM@KF)I^FFF$OQEFN:Q+/!K/MLW6:YDR(OB
M:'\T&!SOQU(G6Z]?\6?O\]>OTK*(=*+>Y\*4<2SSQ;F*TH?OMX9;U0>W>C8O
MZ(/]UZ\R.5-WJO@E>Y_CM_UZEU#'*C$Z342NIM]OC8??GA_2\_S KUH]&.__
M@CB9I.E'^N4Z_'YK0 2I2 4%[2#QXUY=J"BBC4#&GV[/K?I(6NC_O]K]#?,.
M7B;2J(LT^DV'Q?S[K=,M$:JI+*/B-GWXEW+\'-%^01H9_E<\N&<'6R(H39'&
M;C$HB'5B?\I/3@Y/63!R"T9,MSV(J;R4A7S]*D\?1$Y/8S?Z#[/*JT&<3D@I
M=T6.OVJL*UZ#FTA.TER2<(1,0O&NF*M<W*I(DMC,7&?FU7Z!HVC!?N"V/;?;
MCM9L>R!^3I-B;L15$JJPO7X?)-9TCBHZST<;-_Q9YGUQ,.R)T6 TW+#?0<WW
M >]WL&:_=_E,)OHS\]@3%V TC70HK:5 "N]S9512V _2J7BC$YD$6D;B#A\J
MF&5AQ'^.)Z;(85C_M8&BPYJB0Z;H\*4UL7G;*VVD!H/]GK@IPKXX'[\='0Z&
MPCL.'/ZFQ%S2L2)H?2YGN6)F89;%7'0WV^$/=D61BC]2G131 AYQ#T_/F($@
MC6.5D]3T9U6?O ./E EBRV2WAP/C-$F#*$T@6ID4>I*&"U',92$*F<\4I"SC
M193J4$Q4(4$0*)I! Z;'1\"]DXD*E(%6>EBG!$B/<-;%E=@A=ZV7!Y&2]SJ9
M"95\7L1J5^ADKB>Z2'.L>T@=;UF>AF50"% 8DCTH(Q#Y>.,L+2 (,H$"X:]@
MJ< RQM'GN4*<RO]I1*B-HC-WZ/F5DM[MB^M$W*D,-C2!=D>#X9EXL/JV%&"/
M +ZCDU*%?.XL2B<X]/V<=CX0IBA##;)PM,\\V!%*YM# "H+Z;F^C\GLLE<;?
M& '>TL8:"!%J9R5,+LT7 B(+F?^*%_J[C")HUA30@$Z""-1 J.0N,@_FO<H
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M9AZ_2FR7QV\[*!\KC<Y;JB6V3D;/+@;"Q>\E\4>P-7^C6-@0;,5_%N!$.5J
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M4L:FP%N->>;U>VWT3)* 7AX8K$=/#R(W]]S.'>Z8>RANLM3,2_$FC57<GG\
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M2?56;"MK9<&V9%)F'B$BFLLD42DQX9B#!'*(?2F!,&T>2<.*I! I.=$)/W%
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M6FV6T(**0?=7@#N1T=6A"(&X3C@U?EY<-Q.;S<5_U/D)$",P_=#)AY<%X==
M[=7VMU3]\!.BU>/AAU@C2:_M/?KQ#$N/>R^>[85)I/E2VH)_4(0A"7#*_Z8*
MV.GH =R?64P@]1?:H/V%V9O_ E!+ P04    " #2@992[=B'5TT'   _$@
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M-<*/Y=I835WQ\TB&?,B0^PSY)QFN5-,J24D,J KX/M]'=WF4R,W@U+2LP'E
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MQX"N@\BW$-_R@P)OA?%9%'J,!SP\("_JMAR1O.C?M_Q.V;S2N&O+_KR:66>
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M. JYZ&95_8RO)T:N[=-Y(0T>XG:8"IX(10387TII-A,2T/Z7<O$W4$L#!!0
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M[O26=Z?ZR':U[7!&7')[(JB84VX'CC!;]-MK'/HS0+TQ7S4$+(^&VFM5TM&
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M?.3&(75I6HY&9.6Z)Y\^0 :6TFQ0P[4N8W@!DRR-<_YFKXOS\SB#2]2&$WI
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M^N"#W<Q'84QX8=:'>V4IOQW!(O:]431V #2*DR@<]3LR/SID?M29K-=W2V/
M+UMNG\!@OM7<<C2GU-#MX)YRV"25RPU8=ZB/*2>%;+6/6%?$;<DL565!VC=@
ME;?YCAF4*+R"2'-'@7A)N#/E9/$_1?6!J+Q,+I'*U49Z[1;$PVV0T&O47!5N
M*]^S?-/H)_99'$<NG7^@(;W_$'0J)*?6CL,$?OYIFL3)K_!)TH4J/.@/V4R6
MN%.PWTR'(L<'18X[!7.>YWI+'%KU&Y\^?S!.B:\3R[499Z9F.2Z"VA55_8#!
MMPZ.^)!3QKEIZI9]KMNS;T1Q?DIFS>05YEBM"*R=C^ 6'U!N\9=&P06T1%RM
MTU!PDZNM.VZ.!G/^J-;[V,YF:1C1.QY$TR@<TT4A!%LIW=P+>_;I+ HGD$YG
M5.!NU1,3/C,.3/#<=324QS72%&4_'-%S2L^W52W4$QT!*C0.YGCWK%#BFA.=
M))I0K4S3-)S2GC1_8*ZG(5"VXJ))_Y2J&L33F  OMUJ[R[M6>G]K43 M.7>S
M/JX%MLS52O"-'YJ#*N-L1EC--32)7%F<S&+RWY1%]FK&J*0/1C.2((W209R-
M:'1*@\-G;4N%>N.;,P,^]$T'<Y@]]'_G3=MS7-XTCY3UC3LW M=D2L&G^J>;
MAJSYL*KV3=!*66JI_+"D'A:U6T#_UTK9_8=S<.B*E_\"4$L#!!0    ( -*!
MEE(\PJW^E@,  *@*   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;,U6
MVV[;.!#]E8&PP+9 H)OMI@UL W:VQ?:A;9!DNP^+/E#26")"D5J2BI-^?8>4
MK-BHK;9H%]@74[S,S)G#.?3,MTK?F0K1PD,MI%D$E;7-1129O,*:F5 U*&EG
MHW3-+$UU&9E&(RN\42VB-(Y?1#7C,EC._=J57LY5:P67>*7!M'7-].,:A=HN
M@B38+5SSLK)N(5K.&U;B#=J_FBM-LVCP4O :I>%*@L;-(E@E%^N9.^\/?.2X
M-7O?X#+)E+ISD[?%(H@=(!286^>!T7"/ERB$<T0P_NU]!D-(9[C_O?/^QN=.
MN63,X*42?_/"5HO@90 %;E@K[+7:_HE]/AY@KH3QO[#MS\8!Y*VQJNZ-"4'-
M93>RAYZ'[S%(>X/4X^X">91_,,N6<ZVVH-UI\N8^?*K>FL!QZ2[EQFK:Y61G
MEY2-8)G2S)$#3!;PP5:HX1H%<[29BC<&GMVR3*!Y/H\LQ7264=[[7W?^TQ/^
M)_!.25L9>"T++ [M(\(Z $YW@-?IJ,-W3(<P2<X@C=-DQ-]D(&#B_4U.^/N@
M2R;Y9Y_L&5Q2QDKP@G4E0W1<:30H;;>@-O"&2R9SS@3<T")2?5H#_ZPR8S55
MV*<11-,!T=0CFIY =-/IPP5;N9KE]K&[#BS *EBOWJ?3./'@7@N4&>9H" KL
M7:62QVYJ-*Q3_X5I6(Z+H'$YZWL,EE3Y0/4 MY5&/+A*H(O(*W\3S]Y**DTA
M7+D\]_?B?F*X599H*O">I-\XH@ ?Z#$Q"%SFK=;D)'OT[O-]Z*3U(5FWR8I[
M8MPS[3C9SQ_W\_\-9K-P1L-T0L.:JQ+E[P9,Q32.&AY#2&^#>S@(!7> #/IL
MG>GQ?$"UFM(@9FA>N*^^CFABG@J%8%#NJD9(S\-S2)/P94^3820P'X N_PXM
ME^5)NG:9'-(V(X?3\-6/9#X6]( !>D:I7LHS(,^H":ZS804]2-P5OG\\?H8,
M@IV&4QA1SVQ0S^QGU+,JVIS)MF;9M_4R&NBX7E:[?S<7?[]2'%_C;!_4_"F8
ML"I)B-XC)U<&-K2KMN8"?H%2V5/08T5.PCH/8QJ25V%RI,J^8?[?*VI&8DIB
MTOY7Z?R(N+Z#^B1QNDU3$MPH#?\7>;V(PPDD*?T<$UBTUSW4J$O?(QERVTK;
M-1+#ZM"&K;KNX^EXU\-1I95<&A"X(=,X/"<)Z:XOZB96-;X7R92ESL9_5M1*
MHG8':'^CE-U-7("A.5U^ 5!+ P04    " #2@992N*_F0'8"  #$!0  &0
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MLWSM8A0FD)QX%AH A.EXH:FA(<7"6,:V,$+[T( !7=C-KJNT5/F]RK/4-6-
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M3[(BV23K.'?M788 FM"S7PNU<J7Q?BVTG+TA;FRFV<)PV%M0!?P*C_@U4'=
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M--=?92VY>INJ?G*^(H+P(Q% ?6!PEXH-*W(I ,X3<$/5)\/Y1KU\?T<D3JD
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M7Q_V'VN]M6CR+'I.P( WOGR#*'Z-B$.P1<\"[K[D0=W=L71?'C^Z \R&UJ>
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M*PC*'L#]C91F-[$!NG=U]A]02P,$%     @ TH&64KB;@JPU!P  /#(  !D
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M+%E8(/2F+V\,JY:^M4V5Q4;IAPN\RX!V#K@^4\IN#=<MP^VH^ M02P,$%
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M"ZGL //[?6'JW!S8$[0;U]/_ %!+ P04    " #2@992Z>DTH+<"  !Q!P
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M&1,TX@=JYIIBJ5[D=.I%2O4B;O4JE]\>+ (9Q^ %#E/!4W$FV3HDX"8W7Y4
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M.!# >42=H[X9B&;BB<T1V07"ZKT>@$")FD#/Y_-DS0>ZW!FDB$9>N6EX'Q!
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M23"MF1L6IMVFRFXP[W,IX6%B$W0-_/(K4$L#!!0    ( -*!EE+7-_9W!08
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MJ/'9/AM-!T?@1@T/^N[0'5AN.\!Q"7#<G79D$)$'DQNCQ"HQ?!4",9(LA-Q
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M>WWXY=)>\*A=@WU?*D4OA;M#NK^,[ ]02P,$%     @ TH&64MF$D5D/ P
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( -*!EE*61$.-HP4  '\R   /
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MCGH[@=Z!>@>!WH%Z!X'>@7H'@=Z!>@>!WH%Z!X'>@7H'@=XQ^=F$0.] O8-
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MX"N41E!$Y2BD<A13.0JJ'$55CL(J1W&5H\#*4605*+(*%%D%BJP"15:!(JM
MD56@R"I09!4HL@H4626*K!)%5HDBJT215:+(*E%DE2BR2A19)8JL$D56A2*K
M0I%5H<BJ4&15*+(J%%D5BJP*15:%(JM"D56CR*I19-4HLFH4636*K!I%5HTB
MJT:15:/(JE%D-2BR&A19#8JL!D56@R*K09'5H,AJ4&0U*+(:%%DMBJP615:+
M(JM%D=6BR&I19+4HLMK_*>M/[_>?'#\_Z\%UXTL^F_]K?/T;4$L! A0#%
M  @ TH&64@=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " #2@99288UORNX    K @  $0
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M=#(N>&UL4$L! A0#%     @ TH&64L2Y)3[< P  QPP  !@
M ("!O1,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( -*!
MEE*JS(]]OP8  "T<   8              " @<\7  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " #2@992A(.$2CX"   ]!0  &
M        @('$'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ TH&64F'QIB"X!P  \QX  !@              ("!."$  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( -*!EE*CL^^RY0@  (HT   8
M              " @28I  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " #2@992]1Y^1'4.  "1)0  &               @(%!,@  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ TH&64GAF,-:X @
M\P4  !@              ("![$   'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( -*!EE(B$'+MG0<  ',1   9              " @=I#
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ TH&64C;X
M%=9T @  ,@4  !D              ("!KDL  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " #2@992)KDGT:D)  !H&   &0
M    @(%93@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M -*!EE+?:F([80H  /D>   9              " @3E8  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ TH&64I*$9?Y3"@  &R0  !D
M             ("!T6(  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " #2@992\B.VBT ,  !Y)P  &0              @(%;;0  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( -*!EE(GEH&WP ,
M ,T(   9              " @=)Y  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ TH&64KK=\=R3!@  :Q,  !D              ("!
MR7T  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #2@992
M O_U;@ &  !T$P  &0              @(&3A   >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( -*!EE(OZGG=)P,  -0&   9
M      " @<J*  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ TH&64N1#9E@B!   ; H  !D              ("!*(X  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #2@992AO ^2>,'  !F$@
M&0              @(&!D@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( -*!EE*,JY<NM04  $H.   9              " @9N:  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ TH&64OI'K)[G
M%@  Q$\  !D              ("!AZ   'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " #2@992-3K;KMD(  # &@  &0
M@(&EMP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( -*!
MEE),E\/.&A(  ),S   9              " @;7   !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ TH&64L7BCRI=#@  ;28  !D
M         ("!!M,  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " #2@992[=B'5TT'   _$@  &0              @(&:X0  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( -*!EE(5;T.O@ (  $D%
M   9              " @1[I  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ TH&64D0'XYD<!   'PH  !D              ("!U>L
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #2@992GSZ[
MQ;H&  "4$@  &0              @($H\   >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( -*!EE*B9[SM]P4  %<1   9
M  " @1GW  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
MTH&64JR2-E4)!0  L@\  !D              ("!1_T  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " #2@992@-@/W]P$   %#@  &0
M            @(&' @$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( -*!EE+%/B'\ P,  ((&   9              " @9H' 0!X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ TH&64A\WA!W" P
M2PH  !D              ("!U H! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " #2@992]'H=<; "  #Y!0  &0              @('-
M#@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( -*!EE+4
M-;I)>00  "$+   9              " @;01 0!X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ TH&64CS"K?Z6 P  J H  !D
M     ("!9!8! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -*!EE(GKURN7P(  !D&   9              "
M@48L 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ TH&6
M4C?ZO942 P  +PD  !D              ("!W"X! 'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    " #2@992AJ0S:3@#  #L"P  &0
M        @($E,@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( -*!EE)A6 2V+P,  )8+   9              " @90U 0!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ TH&64A'EOU!> @  *P8
M !D              ("!^C@! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    " #2@992.OYC@WL&  "G(0  &0              @(&/.P$
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( -*!EE():NT_
MRP(  &,'   9              " @4%" 0!X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ TH&64KB;@JPU!P  /#(  !D
M ("!0T4! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #2
M@992I^S><5,#   I#   &0              @(&O3 $ >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( -*!EE+([UO#G@(  "D)   9
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M970U-BYX;6Q02P$"% ,4    " #2@992$8.0>0(#  "C"0  &0
M    @(&R90$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (
M -*!EE+Q4"6HCP(  &<&   9              " @>MH 0!X;"]W;W)K<VAE
M971S+W-H965T-3@N>&UL4$L! A0#%     @ TH&64FDI38 _ @  ?P4  !D
M             ("!L6L! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"
M% ,4    " #2@9929/0#!8X$  #D$@  &0              @($G;@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( -*!EE(R%I*YG@H
M !,^   9              " @>QR 0!X;"]W;W)K<VAE971S+W-H965T-C$N
M>&UL4$L! A0#%     @ TH&64J?(9$-P P  S L  !D              ("!
MP7T! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " #2@992
MUS?V=P4&  "@'@  &0              @(%H@0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8S+GAM;%!+ 0(4 Q0    ( -*!EE+\T<"^> ,  $\.   9
M      " @:2' 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%
M  @ TH&64GS^S"IU!@  \R8  !D              ("!4XL! 'AL+W=O<FMS
M:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " #2@992M ;G@4 $   J$@
M&0              @('_D0$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+
M 0(4 Q0    ( -*!EE)LX N3E0,  $$,   9              " @7:6 0!X
M;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ TH&64J%I">V0
M P  /@T  !D              ("!0IH! 'AL+W=O<FMS:&5E=',O<VAE970V
M."YX;6Q02P$"% ,4    " #2@992#(DM S4$  !Q$P  &0
M@($)G@$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( -*!
MEE+?(^&V:@(  #X&   9              " @76B 0!X;"]W;W)K<VAE971S
M+W-H965T-S N>&UL4$L! A0#%     @ TH&64MF$D5D/ P  K0H  !D
M         ("!%J4! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4
M    " #2@992HS#D[#H%  !X$P  &0              @(%<J $ >&PO=V]R
M:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( -*!EE*8D$(H>@,  /\)
M   9              " @<VM 0!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL
M4$L! A0#%     @ TH&64BPYL@<F"   =RL  !D              ("!?K$!
M 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " #2@992-$#3
MB)0&   ?'0  &0              @(';N0$ >&PO=V]R:W-H965T<R]S:&5E
M=#<U+GAM;%!+ 0(4 Q0    ( -*!EE+3':&MSP0  -H3   9
M  " @:;  0!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @
MTH&64BI>X1CX 0  _ ,  !D              ("!K,4! 'AL+W=O<FMS:&5E
M=',O<VAE970W-RYX;6Q02P$"% ,4    " #2@992*%R+,%(#  #V%0  #0
M            @ ';QP$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -*!EE*7
MBKL<P    !,"   +              "  5C+ 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( -*!EE*61$.-HP4  '\R   /              "  4', 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " #2@992>NU.;58"  ".+0  &@
M        @ $1T@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " #2@9925:BY9Q("  !S+   $P              @ &?U $ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     50!5 $H7  #BU@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>453</ContextCount>
  <ElementCount>433</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>151</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2128107 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2136108 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2139109 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2141110 - Disclosure - Indebtedness (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessNotes</Role>
      <ShortName>Indebtedness (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2143111 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2148112 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2151113 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SharebasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2155114 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2159115 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2163116 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2167117 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2169118 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Revenues</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2315302 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2329305 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2344307 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2349308 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2352309 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2356310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2360311 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2364312 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Business Acquisition (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual</Role>
      <ShortName>Business Acquisition (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Revenues by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesbyProductDetails</Role>
      <ShortName>Revenues by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherRevenuesDetails</Role>
      <ShortName>Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2413408 - Disclosure - Revenues (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesDetailsTextual</Role>
      <ShortName>Revenues (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2433420 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2434421 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2435422 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2438423 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2440424 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2442425 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessNotes</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareRepurchasesDetails</Role>
      <ShortName>Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2453430 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2457432 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2458433 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2461434 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2462435 - Disclosure - Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2465436 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2466437 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2468438 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2470439 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>77</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="biib-20210331.htm">biib-20210331.htm</File>
    <File>biib-20210331.xsd</File>
    <File>biib-20210331_cal.xml</File>
    <File>biib-20210331_def.xml</File>
    <File>biib-20210331_lab.xml</File>
    <File>biib-20210331_pre.xml</File>
    <File>biib-2021331xex101.htm</File>
    <File>biib-2021331xex311.htm</File>
    <File>biib-2021331xex312.htm</File>
    <File>biib-2021331xex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>biib-20210331_g1.jpg</File>
    <File>biib-20210331_g10.jpg</File>
    <File>biib-20210331_g11.jpg</File>
    <File>biib-20210331_g12.jpg</File>
    <File>biib-20210331_g13.jpg</File>
    <File>biib-20210331_g14.jpg</File>
    <File>biib-20210331_g15.jpg</File>
    <File>biib-20210331_g16.jpg</File>
    <File>biib-20210331_g17.jpg</File>
    <File>biib-20210331_g18.jpg</File>
    <File>biib-20210331_g19.jpg</File>
    <File>biib-20210331_g2.jpg</File>
    <File>biib-20210331_g20.jpg</File>
    <File>biib-20210331_g3.jpg</File>
    <File>biib-20210331_g4.jpg</File>
    <File>biib-20210331_g5.jpg</File>
    <File>biib-20210331_g6.jpg</File>
    <File>biib-20210331_g7.jpg</File>
    <File>biib-20210331_g8.jpg</File>
    <File>biib-20210331_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>115
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "biib-20210331.htm": {
   "axisCustom": 6,
   "axisStandard": 31,
   "contextCount": 453,
   "dts": {
    "calculationLink": {
     "local": [
      "biib-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "biib-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "biib-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 685,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 23,
    "http://www.biogenidec.com/20210331": 2,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 31
   },
   "keyCustom": 77,
   "keyStandard": 356,
   "memberCustom": 74,
   "memberStandard": 67,
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.biogenidec.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Revenues",
     "role": "http://www.biogenidec.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Inventory",
     "role": "http://www.biogenidec.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Fair Value Measurements",
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128107 - Disclosure - Financial Instruments",
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136108 - Disclosure - Derivative Instruments",
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139109 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141110 - Disclosure - Indebtedness (Notes)",
     "role": "http://www.biogenidec.com/role/IndebtednessNotes",
     "shortName": "Indebtedness (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143111 - Disclosure - Equity",
     "role": "http://www.biogenidec.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148112 - Disclosure - Earnings per Share",
     "role": "http://www.biogenidec.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151113 - Disclosure - Share-based Payments",
     "role": "http://www.biogenidec.com/role/SharebasedPayments",
     "shortName": "Share-based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155114 - Disclosure - Income Taxes",
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159115 - Disclosure - Other Consolidated Financial Statement Detail",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163116 - Disclosure - Collaborative and Other Relationships",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationships",
     "shortName": "Collaborative and Other Relationships",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2167117 - Disclosure - Investments in Variable Interest Entities",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities",
     "shortName": "Investments in Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2169118 - Disclosure - Litigation",
     "role": "http://www.biogenidec.com/role/Litigation",
     "shortName": "Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Revenues (Tables)",
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315302 - Disclosure - Inventory (Tables)",
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329305 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - Derivative Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "shortName": "Derivative Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344307 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2349308 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.biogenidec.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2352309 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356310 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2360311 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2364312 - Disclosure - Collaborative and Other Relationships (Tables)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Business Acquisition (Details Textual)",
     "role": "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
     "shortName": "Business Acquisition (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "id08a82497aa04887a9c810084e90cb86_D20200301-20200331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Revenues by Product (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesbyProductDetails",
     "shortName": "Revenues by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "ia487fdfe567b401b86ede458e9ba75e7_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i6d0adcebf1da475cb93ee9da1693e32f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Reserves for Discounts and Allowances (Details 1)",
     "role": "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1",
     "shortName": "Reserves for Discounts and Allowances (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Reserves for Discounts and Allowances (Details 2)",
     "role": "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2",
     "shortName": "Reserves for Discounts and Allowances (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i0003b815e2554577be2bdf249035d3a5_I20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails",
     "shortName": "Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i42fd999637364cbe9c5eda2d3135fe5d_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:ShareOfCoPromotionProfits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - Other Revenues (Details)",
     "role": "http://www.biogenidec.com/role/OtherRevenuesDetails",
     "shortName": "Other Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i9d6131440c1f431ebe00dc7e4e529db3_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413408 - Disclosure - Revenues (Details Textual)",
     "role": "http://www.biogenidec.com/role/RevenuesDetailsTextual",
     "shortName": "Revenues (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "biib:NumberOfWholesalers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "wholesaler",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Inventory (Details)",
     "role": "http://www.biogenidec.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i6d0adcebf1da475cb93ee9da1693e32f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Intangible Assets and Goodwill (Details 1)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1",
     "shortName": "Intangible Assets and Goodwill (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "icd62cf9fee194b7d97bedcb32dc6e28d_I20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Fair Value Measurements (Details Textual)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
     "shortName": "Fair Value Measurements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i3ca99bdbf85840cdbe24f4bc565124b6_I20210331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
     "shortName": "Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i3ca99bdbf85840cdbe24f4bc565124b6_I20210331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - Fair Value Measurements (Details 2)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
     "shortName": "Fair Value Measurements (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Financial Instruments (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Financial Instruments (Details 1)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
     "shortName": "Financial Instruments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Financial Instruments (Details 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails2",
     "shortName": "Financial Instruments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433420 - Disclosure - Financial Instruments (Details 3)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails3",
     "shortName": "Financial Instruments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434421 - Disclosure - Financial Instruments (Details Textual)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual",
     "shortName": "Financial Instruments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435422 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
     "shortName": "Financial Instruments Financial Instruments (Details Textual 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i131a6d5dd4084afa8625aea4291a03a4_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "biib:DividendYieldPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438423 - Disclosure - Derivative Instruments (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
     "shortName": "Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440424 - Disclosure - Property, Plant and Equipment (Details)",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442425 - Disclosure - Indebtedness (Details)",
     "role": "http://www.biogenidec.com/role/IndebtednessDetails",
     "shortName": "Indebtedness (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Share Repurchases (Details)",
     "role": "http://www.biogenidec.com/role/ShareRepurchasesDetails",
     "shortName": "Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i5b8709d2eae04591a6115e04171e59b0_I20201231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i6d0adcebf1da475cb93ee9da1693e32f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i0294157534ec4829a838f8161a2c6f76_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "ib347ee221e7745e397b6e1c44ca1f262_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Earnings per Share (Details)",
     "role": "http://www.biogenidec.com/role/EarningsperShareDetails",
     "shortName": "Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453430 - Disclosure - Share-Based Payments (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - Share-Based Payments (Details 1)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
     "shortName": "Share-Based Payments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "iea96acd5ebf344c0bd0de05f5f18e7ba_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i5a8b05db811a4f6ca919149ab120e3a6_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statement of Equity Statement",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
     "shortName": "Condensed Consolidated Statement of Equity Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i5a8b05db811a4f6ca919149ab120e3a6_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i6d0adcebf1da475cb93ee9da1693e32f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457432 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i6d0adcebf1da475cb93ee9da1693e32f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458433 - Disclosure - Income Taxes (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461434 - Disclosure - Other Consolidated Financial Statement Detail (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
     "shortName": "Other Consolidated Financial Statement Detail (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462435 - Disclosure - Other Consolidated Financial Statement (Details Textual)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
     "shortName": "Other Consolidated Financial Statement (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "idba00d136f3e43eaacc59e503a3d5706_I20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465436 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
     "shortName": "Collaborative and Other Relationships - Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "ia985a1dfdf4e454db24a4b6d2d79de45_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "biib:NumberOfProductCandidates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466437 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
     "shortName": "Collaborative and Other Relationships - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72965d9649fb4d17a86322fadd05e4e3_I20181107",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i6d0adcebf1da475cb93ee9da1693e32f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468438 - Disclosure - Investments in Variable Interest Entities (Details)",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i6d0adcebf1da475cb93ee9da1693e32f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i6d0adcebf1da475cb93ee9da1693e32f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470439 - Disclosure - Litigation (Details)",
     "role": "http://www.biogenidec.com/role/LitigationDetails",
     "shortName": "Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i6d0adcebf1da475cb93ee9da1693e32f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Acquisitions",
     "role": "http://www.biogenidec.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210331.htm",
      "contextRef": "i72e0b54849884aa098855b3c6e1b1f84_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 151,
   "tag": {
    "biib_A2.25SeniorNotesdueMay12030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Senior Notes due May 1, 2030 [Member]",
        "label": "2.25% Senior Notes due May 1, 2030 [Member]",
        "terseLabel": "2.250% Senior Notes due May 1, 2030"
       }
      }
     },
     "localname": "A2.25SeniorNotesdueMay12030Member",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2.90SeniorNotesDueSept152020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.90% Senior Notes Due Sept 15, 2020 [Member]",
        "label": "2.90% Senior Notes Due Sept 15, 2020 [Member]",
        "terseLabel": "2.90% Senior Notes Due Sept 15, 2020"
       }
      }
     },
     "localname": "A2.90SeniorNotesDueSept152020Member",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2018ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Share Repurchase Program [Member]",
        "label": "2018 Share Repurchase Program [Member]",
        "terseLabel": "2018 Share Repurchase Program"
       }
      }
     },
     "localname": "A2018ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A3.15SeniorNotesdueMay12050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.15% Senior Notes due May 1, 2050 [Member]",
        "label": "3.15% Senior Notes due May 1, 2050 [Member]",
        "terseLabel": "3.150% Senior Notes due May 1, 2050"
       }
      }
     },
     "localname": "A3.15SeniorNotesdueMay12050Member",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A3250SeniorNotesDueFebruary152051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.250% Senior Notes, Due February 15, 2051",
        "label": "3.250% Senior Notes, Due February 15, 2051 [Member]",
        "terseLabel": "3.250% Senior Notes, Due February 15, 2051"
       }
      }
     },
     "localname": "A3250SeniorNotesDueFebruary152051Member",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AcquisitionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisitions [Abstract]",
        "label": "Acquisitions [Abstract]",
        "terseLabel": "Acquisitions [Abstract]"
       }
      }
     },
     "localname": "AcquisitionsAbstract",
     "nsuri": "http://www.biogenidec.com/20210331",
     "xbrltype": "stringItemType"
    },
    "biib_AdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Additional Milestone Payment"
       }
      }
     },
     "localname": "AdditionalMilestonePayment",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Additionalreductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional reduction in royalty rate payable on commercial sales",
        "label": "Additional reduction in royalty rate payable on commercial sales",
        "terseLabel": "Additional reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Additionalreductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years.",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "negatedLabel": "Adjustments Relating To Prior Years"
       }
      }
     },
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdministrativeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Administrative Space",
        "label": "Administrative Space [Member]",
        "terseLabel": "Administrative Space"
       }
      }
     },
     "localname": "AdministrativeSpaceMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AducanumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aducanumab [Member]",
        "label": "Aducanumab [Member]",
        "terseLabel": "Aducanumab"
       }
      }
     },
     "localname": "AducanumabMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and Impairment of Acquired Intangible Assets",
        "label": "Amortization and Impairment of Acquired Intangible Assets",
        "terseLabel": "Amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationAndImpairmentOfAcquiredIntangibleAssets",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Analysis of amount of and change in product revenue reserves.",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "terseLabel": "Analysis of change In reserves"
       }
      }
     },
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Amortized Cost",
        "verboseLabel": "Due after five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Fair Value",
        "verboseLabel": "Due after five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AverageMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average remaining time to maturity of marketable debt securities, available-for-sale securities.",
        "label": "Average Maturity Of Marketable Securities",
        "verboseLabel": "Average maturity of marketable securities, months"
       }
      }
     },
     "localname": "AverageMaturityOfMarketableSecurities",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_BENEPALIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BENEPALI [Member]",
        "label": "BENEPALI [Member]",
        "terseLabel": "BENEPALI"
       }
      }
     },
     "localname": "BENEPALIMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB111 [Member]",
        "label": "BIIB111 [Member]",
        "terseLabel": "BIIB111"
       }
      }
     },
     "localname": "BIIB111Member",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB118Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB118 [Member]",
        "label": "BIIB118 [Member]",
        "terseLabel": "BIIB118"
       }
      }
     },
     "localname": "BIIB118Member",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted earnings per share.",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_Biogenshareofcopromotionprofitsorlosses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen share of co-promotion profits or losses",
        "label": "Biogen share of co-promotion profits or losses",
        "terseLabel": "Biogen share of co-promotion profits or losses"
       }
      }
     },
     "localname": "Biogenshareofcopromotionprofitsorlosses",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_BiologicsManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biologics Manufacturing",
        "label": "Biologics Manufacturing [Member]",
        "terseLabel": "Biologics Manufacturing"
       }
      }
     },
     "localname": "BiologicsManufacturingMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biosimilars",
        "label": "Biosimilars [Member]",
        "terseLabel": "Biosimilars"
       }
      }
     },
     "localname": "BiosimilarsMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes an overview of the company and its operations.",
        "label": "Business Overview [Policy Text Block]",
        "verboseLabel": "Overview"
       }
      }
     },
     "localname": "BusinessOverviewPolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_CashSettledPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash settled performance shares [Member]",
        "label": "Cash settled performance shares [Member]",
        "terseLabel": "Cash settled performance shares"
       }
      }
     },
     "localname": "CashSettledPerformanceSharesMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsoperatingexpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows, operating expenses [Member]",
        "label": "Cash flows, operating expenses [Member]",
        "terseLabel": "Cash flows, operating expenses"
       }
      }
     },
     "localname": "CashflowsoperatingexpensesMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsrevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows, revenue [Member]",
        "label": "Cash flows, revenue [Member]",
        "terseLabel": "Cash flows, revenue"
       }
      }
     },
     "localname": "CashflowsrevenueMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CollaborationAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement Term",
        "label": "Collaboration Agreement Term",
        "terseLabel": "Collaboration agreement term"
       }
      }
     },
     "localname": "CollaborationAgreementTerm",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_Collaborationexpensesaccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration expenses accrual",
        "label": "Collaboration expenses accrual",
        "terseLabel": "Collaboration expense"
       }
      }
     },
     "localname": "Collaborationexpensesaccrual",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Collaborationprofitlosssharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration profit (loss) sharing",
        "label": "Collaboration profit (loss) sharing",
        "terseLabel": "Collaboration profit (loss) sharing"
       }
      }
     },
     "localname": "Collaborationprofitlosssharing",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Option Exercise Fee",
        "label": "Contract Option Exercise Fee",
        "terseLabel": "Contract Option Exercise Fee"
       }
      }
     },
     "localname": "ContractOptionExerciseFee",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractualAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual adjustments.",
        "label": "Contractual Adjustments [Member]",
        "terseLabel": "Contractual adjustments"
       }
      }
     },
     "localname": "ContractualAdjustmentsMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate debt securities Current.",
        "label": "Corporate Debt Securities Current [Member]",
        "verboseLabel": "Corporate debt securities Current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Debt Securities Non Current.",
        "label": "Corporate Debt Securities Non Current [Member]",
        "verboseLabel": "Corporate debt securities Non-current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current provisions to product revenue reserves relating to sales in current year.",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "terseLabel": "Current Provisions Relating To Sales In Current Year"
       }
      }
     },
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DebtInstrumentRedemptionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption, Amount",
        "label": "Debt Instrument, Redemption, Amount",
        "terseLabel": "Debt Instrument, Redemption, Amount"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionAmount",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_December2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2019 Share Repurchase Program [Member]",
        "label": "December 2019 Share Repurchase Program [Member]",
        "terseLabel": "December 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "December2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DeferredTaxAssetsValueReductioninValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Value, Reduction in Value",
        "label": "Deferred Tax Assets, Value, Reduction in Value",
        "terseLabel": "Deferred tax assets, decrease in value"
       }
      }
     },
     "localname": "DeferredTaxAssetsValueReductioninValue",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredTaxLiabilitiesValueReductioninValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Value, Reduction in Value",
        "label": "Deferred Tax Liabilities, Value, Reduction in Value",
        "terseLabel": "Deferred tax liabilities, decrease in value"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesValueReductioninValue",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DenaliTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denali Therapeutics Inc",
        "label": "Denali Therapeutics Inc [Member]",
        "terseLabel": "Denali Therapeutics"
       }
      }
     },
     "localname": "DenaliTherapeuticsIncMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DerivativeMaturityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Axis]",
        "terseLabel": "Derivative Maturity [Axis]"
       }
      }
     },
     "localname": "DerivativeMaturityAxis",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DerivativeMaturityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Domain]",
        "terseLabel": "Derivative Maturity [Domain]"
       }
      }
     },
     "localname": "DerivativeMaturityDomain",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "label": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "terseLabel": "Gains (losses) on net investment hedge, excluded component"
       }
      }
     },
     "localname": "Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DistributorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor one.",
        "label": "Distributor One [Member]",
        "terseLabel": "Distributor One"
       }
      }
     },
     "localname": "DistributorOneMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DistributorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor two.",
        "label": "Distributor Two [Member]",
        "terseLabel": "Distributor Two"
       }
      }
     },
     "localname": "DistributorTwoMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DividendYieldPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend Yield Percentage",
        "label": "Dividend Yield Percentage",
        "terseLabel": "Dividend yield percentage"
       }
      }
     },
     "localname": "DividendYieldPercentage",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_DuefromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.",
        "label": "Due from anti-CD20 therapeutic programs",
        "verboseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "DuefromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_E2609andBAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "E2609 and BAN2401 [Member]",
        "label": "E2609 and BAN2401 [Member]",
        "terseLabel": "BAN2401 and Elenbecestat"
       }
      }
     },
     "localname": "E2609andBAN2401Member",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs",
        "label": "Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs",
        "terseLabel": "Payment of early call premium and write off of remaining unamortized debt issuance costs"
       }
      }
     },
     "localname": "EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EffectiveTaxRateReconciliationGILTItax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, GILTI tax",
        "label": "Effective Tax Rate Reconciliation, GILTI tax",
        "terseLabel": "GILTI"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationGILTItax",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "verboseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity wide percentage of revenue from major distributors.",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "terseLabel": "Percentage of revenues from major distributors"
       }
      }
     },
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "label": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "terseLabel": "Percentage of stake in entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "label": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax"
       }
      }
     },
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax"
       }
      }
     },
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EquitySecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Current",
        "label": "Equity Securities, Current [Member]",
        "terseLabel": "Equity Securities, Current"
       }
      }
     },
     "localname": "EquitySecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EquitySecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Non-Current",
        "label": "Equity Securities, Non-Current [Member]",
        "terseLabel": "Equity Securities, Non-Current"
       }
      }
     },
     "localname": "EquitySecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Equitymethodinvestmentbasisdifferenceamortizationperiod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment basis difference amortization period",
        "label": "Equity method investment basis difference amortization period",
        "terseLabel": "Equity method investment basis difference amortization period"
       }
      }
     },
     "localname": "Equitymethodinvestmentbasisdifferenceamortizationperiod",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated additional payments upon achievement of development and commercial milestones.",
        "label": "Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones",
        "terseLabel": "Estimated additional payments upon achievement of development and commercial milestones"
       }
      }
     },
     "localname": "EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ExpectedPaymentTimelineOfMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Payment Timeline of Milestone",
        "label": "Expected Payment Timeline of Milestone [Domain]",
        "terseLabel": "Expected Payment Timeline of Milestone [Domain]"
       }
      }
     },
     "localname": "ExpectedPaymentTimelineOfMilestoneDomain",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ExpectedPaymentTimelineofMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Payment Timeline of Milestone [Axis]",
        "label": "Expected Payment Timeline of Milestone [Axis]",
        "terseLabel": "Expected Payment Timeline of Milestone [Axis]"
       }
      }
     },
     "localname": "ExpectedPaymentTimelineofMilestoneAxis",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ExpenseIncurredByCollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total expense incurred by collaboration.",
        "label": "Expense Incurred By Collaboration",
        "terseLabel": "Expense Incurred By Collaboration"
       }
      }
     },
     "localname": "ExpenseIncurredByCollaboration",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expenseincurredbythecollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "terseLabel": "Expense incurred by the collaboration"
       }
      }
     },
     "localname": "Expenseincurredbythecollaboration",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "terseLabel": "Expense reflected within statements of income"
       }
      }
     },
     "localname": "Expensereflectedwithinstatementsofincome",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_FAMPYRAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FAMPYRA [Member]",
        "label": "FAMPYRA [Member]",
        "terseLabel": "FAMPYRA"
       }
      }
     },
     "localname": "FAMPYRAMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FLIXABIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FLIXABI [Member]",
        "label": "FLIXABI [Member]",
        "terseLabel": "FLIXABI"
       }
      }
     },
     "localname": "FLIXABIMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FUMADERMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FUMADERM [Member]",
        "label": "FUMADERM [Member]",
        "terseLabel": "FUMADERM"
       }
      }
     },
     "localname": "FUMADERMMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Axis]",
        "terseLabel": "Facility Location [Axis]"
       }
      }
     },
     "localname": "FacilityLocationAxis",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Domain]",
        "terseLabel": "Facility Location [Domain]"
       }
      }
     },
     "localname": "FacilityLocationDomain",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Axis]",
        "terseLabel": "Facility Type [Axis]"
       }
      }
     },
     "localname": "FacilityTypeAxis",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Domain]",
        "terseLabel": "Facility Type [Domain]"
       }
      }
     },
     "localname": "FacilityTypeDomain",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FumarateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fumarate [Member]",
        "label": "Fumarate [Member]",
        "terseLabel": "Fumarate"
       }
      }
     },
     "localname": "FumarateMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FutureContingentMilestoneTypesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Axis]",
        "terseLabel": "Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesAxis",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FutureContingentMilestoneTypesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Domain]",
        "terseLabel": "Future Contingent Milestone Types [Domain]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesDomain",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Amount, Shares Purchased",
        "label": "Global Licensing Collaboration Agreement, Amount, Shares Purchased",
        "terseLabel": "Global Licensing Collaboration Agreement, Amount, Shares Purchased"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementAmountSharesPurchased",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones",
        "label": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones",
        "label": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Selection of Targets",
        "label": "Global Licensing Collaboration Agreement, Payment, Selection of Targets",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Selection of Targets"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentSelectionofTargets",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Purchase Price Per Share",
        "label": "Global Licensing Collaboration Agreement, Purchase Price Per Share",
        "terseLabel": "Global Licensing Collaboration Agreement, Purchase Price Per Share"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPurchasePricePerShare",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "perShareItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments",
        "label": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments",
        "terseLabel": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Shares, Purchased",
        "label": "Global Licensing Collaboration Agreement, Shares, Purchased",
        "terseLabel": "Global Licensing Collaboration Agreement, Shares, Purchased"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementSharesPurchased",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Shares Purchased Per Share",
        "label": "Global Licensing Collaboration Agreement, Shares Purchased Per Share",
        "terseLabel": "Global Licensing Collaboration Agreement, Shares Purchased Per Share"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementSharesPurchasedPerShare",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "biib_GovernmentSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government securities Current.",
        "label": "Government Securities Current [Member]",
        "verboseLabel": "Government securities Current"
       }
      }
     },
     "localname": "GovernmentSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Non Current.",
        "label": "Government Securities Non-current [Member]",
        "verboseLabel": "Government securities Non-current"
       }
      }
     },
     "localname": "GovernmentSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IMRALDIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMRALDI [Member]",
        "label": "IMRALDI [Member]",
        "terseLabel": "IMRALDI"
       }
      }
     },
     "localname": "IMRALDIMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_InLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In-licensed patents.",
        "label": "In Licensed Patents [Member]",
        "terseLabel": "Acquired and in-licensed rights and patents"
       }
      }
     },
     "localname": "InLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) from Equity Method Investments, Net of Tax",
        "label": "Income (Loss) from Equity Method Investments, Net of Tax",
        "negatedTerseLabel": "Equity in (income) loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfTax",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_IndefiniteLivedIntangibleAssetsUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite lived intangible assets useful life.",
        "label": "Indefinite Lived Intangible Assets Useful Life",
        "terseLabel": "Indefinite lived intangible assets useful life"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsUsefulLife",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "durationStringItemType"
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets excluding goodwill.",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_InterestInSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest in subsidiary.",
        "label": "Interest In Subsidiary",
        "verboseLabel": "Interest in subsidiary (less than given percentage)"
       }
      }
     },
     "localname": "InterestInSubsidiary",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_InterferonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interferon",
        "label": "Interferon [Member]",
        "terseLabel": "Interferon"
       }
      }
     },
     "localname": "InterferonMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Inventorynetcurrentandnoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, net current and noncurrent",
        "label": "Inventory, net current and noncurrent",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "Inventorynetcurrentandnoncurrent",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities"
       }
      }
     },
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Investmentincommonstocksharespurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in common stock, shares purchased",
        "label": "Investment in common stock, shares purchased",
        "terseLabel": "Investment in common stock, shares purchased"
       }
      }
     },
     "localname": "Investmentincommonstocksharespurchased",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments In Variable Interest Entities.",
        "label": "Investments in Variable Interest Entities [Abstract]",
        "terseLabel": "Investments in Variable Interest Entities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "nsuri": "http://www.biogenidec.com/20210331",
     "xbrltype": "stringItemType"
    },
    "biib_IonisSangamoDenaliAndSageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ionis, Sangamo, Denali and Sage",
        "label": "Ionis, Sangamo, Denali and Sage [Member]",
        "terseLabel": "Ionis, Sangamo, Denali and Sage"
       }
      }
     },
     "localname": "IonisSangamoDenaliAndSageMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_LongTermDebtExchangedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt, Exchanged, Amount",
        "label": "Long Term Debt, Exchanged, Amount",
        "terseLabel": "Long Term Debt, Exchanged, Amount"
       }
      }
     },
     "localname": "LongTermDebtExchangedAmount",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_MSProductRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MS Product Revenues [Member]",
        "label": "MS Product Revenues [Member]",
        "terseLabel": "MS Product Revenues"
       }
      }
     },
     "localname": "MSProductRevenuesMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_March2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2019 Share Repurchase Program [Member]",
        "label": "March 2019 Share Repurchase Program [Member]",
        "terseLabel": "2019 Share Repurchase Program"
       }
      }
     },
     "localname": "March2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MarketStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market stock units.",
        "label": "Market Stock Units [Member]",
        "verboseLabel": "Market stock units"
       }
      }
     },
     "localname": "MarketStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage and other asset backed securities Current.",
        "label": "Mortgage And Other Asset Backed Securities Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage And Other Asset Backed Securities Non Current.",
        "label": "Mortgage And Other Asset Backed Securities Non Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Non-current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NeurimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neurimmune.",
        "label": "Neurimmune [Member]",
        "terseLabel": "Neurimmune"
       }
      }
     },
     "localname": "NeurimmuneMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NightstarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nightstar [Member]",
        "label": "Nightstar [Member]",
        "terseLabel": "Nightstar"
       }
      }
     },
     "localname": "NightstarMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Noncontrollinginterestincreasedecreaseother": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling interest, increase (decrease) other",
        "label": "Noncontrolling interest, increase (decrease) other",
        "terseLabel": "Noncontrolling interest, increase (decrease) other"
       }
      }
     },
     "localname": "Noncontrollinginterestincreasedecreaseother",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Ophthalmolgy Biosimilar Products, Exclusive Rights",
        "label": "Number of Ophthalmolgy Biosimilar Products, Exclusive Rights",
        "terseLabel": "Number of potential products, exclusive rights"
       }
      }
     },
     "localname": "NumberOfOphthalmolgyBiosimilarProductsExclusiveRights",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_NumberOfProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Product Candidates",
        "label": "Number of Product Candidates",
        "terseLabel": "Number of product candidates"
       }
      }
     },
     "localname": "NumberOfProductCandidates",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_NumberOfSquareFeet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Square Feet",
        "label": "Number of Square Feet",
        "terseLabel": "Number of square feet"
       }
      }
     },
     "localname": "NumberOfSquareFeet",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "biib_NumberOfWholesalers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Wholesalers",
        "label": "Number of Wholesalers",
        "terseLabel": "Number of wholesalers"
       }
      }
     },
     "localname": "NumberOfWholesalers",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_October2020ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "October 2020 Share Repurchase Program",
        "label": "October 2020 Share Repurchase Program [Member]",
        "terseLabel": "October 2020 Share Repurchase Program"
       }
      }
     },
     "localname": "October2020ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OthercorporaterevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other corporate revenues [Member]",
        "label": "Other corporate revenues [Member]",
        "terseLabel": "Other corporate revenues"
       }
      }
     },
     "localname": "OthercorporaterevenuesMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherrevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues [Abstract]",
        "label": "Other revenues [Abstract]",
        "terseLabel": "Other revenues [Abstract]"
       }
      }
     },
     "localname": "OtherrevenuesAbstract",
     "nsuri": "http://www.biogenidec.com/20210331",
     "xbrltype": "stringItemType"
    },
    "biib_OtherrevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues [Table Text Block]",
        "label": "Other revenues [Table Text Block]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherrevenuesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OutLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Out-licensed patents.",
        "label": "Out Licensed Patents [Member]",
        "terseLabel": "Out-licensed patents"
       }
      }
     },
     "localname": "OutLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Current Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Prior Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PercentageParValueOfSeniorNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Par Value Of Senior Notes",
        "label": "Percentage Par Value Of Senior Notes",
        "terseLabel": "Percentage par value of senior notes"
       }
      }
     },
     "localname": "PercentageParValueOfSeniorNotes",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageoffuturedevelopmentcostsrelatedtoEisai": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of future development costs related to Eisai",
        "label": "Percentage of future development costs related to Eisai",
        "terseLabel": "Percentage of future development costs related to Eisai"
       }
      }
     },
     "localname": "PercentageoffuturedevelopmentcostsrelatedtoEisai",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Member]",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "terseLabel": "Performance stock units settled in cash"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Member]",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "terseLabel": "Performance stock units settled in stock"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans.",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "verboseLabel": "Plan assets for deferred compensation"
       }
      }
     },
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential future milestone payments commitment to third party approximately.",
        "label": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "terseLabel": "Potential Future Milestone Payments Commitment To Third Party Approximately"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain",
        "label": "Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain",
        "terseLabel": "Pre-tax charge, payment of early call premium and write off of remaining unamortized debt issuance costs, net of derivative gain"
       }
      }
     },
     "localname": "PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "terseLabel": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract",
     "nsuri": "http://www.biogenidec.com/20210331",
     "xbrltype": "stringItemType"
    },
    "biib_Reductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in royalty rate payable on commercial sales",
        "label": "Reduction in royalty rate payable on commercial sales",
        "terseLabel": "Reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Reductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones [Member]"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ResearchAndDevelopmentCostsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Costs, Percentage",
        "label": "Research and Development Costs, Percentage",
        "terseLabel": "Research and development costs, percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCostsPercentage",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_ResearchanddevelopmentassetAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development asset [Axis]",
        "label": "Research and development asset [Axis]",
        "terseLabel": "Research and development asset [Axis]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetAxis",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ResearchanddevelopmentassetDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Research and development asset [Axis]",
        "label": "Research and development asset [Domain]",
        "terseLabel": "Research and development asset [Domain]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetDomain",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ReserveforCashDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve for Cash Discounts [Member]",
        "label": "Reserve for Cash Discounts [Member]",
        "terseLabel": "Discounts"
       }
      }
     },
     "localname": "ReserveforCashDiscountsMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from anti-cd20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "terseLabel": "Revenue from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RocheGroupGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche group Genentech.",
        "label": "Roche Group Genentech Member",
        "terseLabel": "Genentech"
       }
      }
     },
     "localname": "RocheGroupGenentechMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SPINRAZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINRAZA [Member]",
        "label": "SPINRAZA [Member]",
        "terseLabel": "SPINRAZA"
       }
      }
     },
     "localname": "SPINRAZAMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SageTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sage Therapeutics Inc.",
        "label": "Sage Therapeutics Inc. [Member]",
        "terseLabel": "Sage Therapeutics Inc."
       }
      }
     },
     "localname": "SageTherapeuticsIncMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Samsung bio-similar agreement.",
        "label": "Samsung Biosimilar Agreement [Member]",
        "terseLabel": "Samsung Bioepis"
       }
      }
     },
     "localname": "SamsungBiosimilarAgreementMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sangamo Common Stock [Member]",
        "label": "Sangamo Common Stock [Member]",
        "terseLabel": "Sangamo"
       }
      }
     },
     "localname": "SangamoCommonStockMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoTherapeuticsInc.AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "label": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "terseLabel": "Sangamo Therapeutics, Inc. Agreement"
       }
      }
     },
     "localname": "SangamoTherapeuticsInc.AgreementMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "terseLabel": "5.200% Senior Notes due 2045"
       }
      }
     },
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "terseLabel": "4.050% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "label": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "terseLabel": "3.625% Senior Notes due 2022"
       }
      }
     },
     "localname": "SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "label": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "terseLabel": "2.900% Senior Notes due 2020"
       }
      }
     },
     "localname": "SeniorNotesTwoPointNinePercentDueTwentyTwentyMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation expense included in costs and expenses.",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "terseLabel": "Share-based compensation expense included in total costs and expenses"
       }
      }
     },
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShareOfCoPromotionProfits": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of co promotion profits.",
        "label": "Share Of Co Promotion Profits",
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA"
       }
      }
     },
     "localname": "ShareOfCoPromotionProfits",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShorttermderivativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term derivative [Member]",
        "label": "Short-term derivative [Member]",
        "terseLabel": "Short-term derivative"
       }
      }
     },
     "localname": "ShorttermderivativeMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SolothurnSwitzerlandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Solothurn, Switzerland [Member]",
        "label": "Solothurn, Switzerland [Member]",
        "terseLabel": "Solothurn, Switzerland"
       }
      }
     },
     "localname": "SolothurnSwitzerlandMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StrategicInvestmentPortfolio": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investment portfolio.",
        "label": "Strategic Investment Portfolio",
        "verboseLabel": "Strategic investment portfolio"
       }
      }
     },
     "localname": "StrategicInvestmentPortfolio",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_StrategicInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investments.",
        "label": "Strategic Investments [Member]",
        "terseLabel": "Strategic Investments"
       }
      }
     },
     "localname": "StrategicInvestmentsMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets.",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "terseLabel": "Total reserves included in consolidated balance sheets"
       }
      }
     },
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of share-based compensation expense associated with different programs.",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]",
        "terseLabel": "Summary of share based compensation expense associated with different programs [Abstract]"
       }
      }
     },
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]",
        "label": "Summary of Activity Related to Aducanumab Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Aducanumab Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]",
        "label": "Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to BAN2401 and Elenbecestat Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_TECFIDERAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TECFIDERA [Member]",
        "label": "TECFIDERA [Member]",
        "terseLabel": "TECFIDERA"
       }
      }
     },
     "localname": "TECFIDERAMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TGNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TGN",
        "label": "TGN [Member]",
        "terseLabel": "TGN [Member]"
       }
      }
     },
     "localname": "TGNMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TechnologicalAndRegulatorySuccessProbability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technological and Regulatory Success, Probability",
        "label": "Technological and Regulatory Success, Probability",
        "terseLabel": "Technological and Regulatory Success, Probability"
       }
      }
     },
     "localname": "TechnologicalAndRegulatorySuccessProbability",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Termofcollaborationagreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of collaboration agreement",
        "label": "Term of collaboration agreement",
        "terseLabel": "Term of collaboration agreement"
       }
      }
     },
     "localname": "Termofcollaborationagreement",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time vested restricted stock units.",
        "label": "Time Vested Restricted Stock Units [Member]",
        "verboseLabel": "Time-vested restricted stock units"
       }
      }
     },
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TwelvemonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twelve months [Member]",
        "label": "Twelve months [Member]",
        "terseLabel": "Twelve months"
       }
      }
     },
     "localname": "TwelvemonthsMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TysabriProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TYSABRI product [Member]",
        "label": "TYSABRI product [Member]",
        "terseLabel": "TYSABRI"
       }
      }
     },
     "localname": "TysabriProductMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UCBPharmaS.A.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCB Pharma S.A. [Member]",
        "label": "UCB Pharma S.A. [Member]",
        "terseLabel": "UCB Pharma S.A. [Member]"
       }
      }
     },
     "localname": "UCBPharmaS.A.Member",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax",
        "negatedLabel": "Gain/Loss on fair value of foreign currency forward contracts"
       }
      }
     },
     "localname": "UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax",
        "label": "Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax"
       }
      }
     },
     "localname": "UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax",
        "label": "Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax"
       }
      }
     },
     "localname": "UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total upfront and milestone payments made to collaborative partner.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront and milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_VixotrigineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vixotrigine",
        "label": "Vixotrigine [Member]",
        "terseLabel": "Vixotrigine"
       }
      }
     },
     "localname": "VixotrigineMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_WarehouseUtilitiesAndSupportSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warehouse, Utilities and Support Space",
        "label": "Warehouse, Utilities and Support Space [Member]",
        "terseLabel": "Warehouse, Utilities and Support Space"
       }
      }
     },
     "localname": "WarehouseUtilitiesAndSupportSpaceMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ZINBRYTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZINBRYTA [Member]",
        "label": "ZINBRYTA [Member]",
        "terseLabel": "ZINBRYTA"
       }
      }
     },
     "localname": "ZINBRYTAMember",
     "nsuri": "http://www.biogenidec.com/20210331",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "JAPAN"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada, Dollars",
        "verboseLabel": "Canadian dollar"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Swiss franc"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "verboseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "British pound"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "Japan, Yen"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r378",
      "r379",
      "r386",
      "r387",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r378",
      "r379",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r191",
      "r294",
      "r298",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r314",
      "r316",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r491",
      "r545",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r314",
      "r316",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r491",
      "r545",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r191",
      "r294",
      "r298",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r188",
      "r294",
      "r296",
      "r493",
      "r544",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r188",
      "r294",
      "r296",
      "r493",
      "r544",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r304",
      "r314",
      "r316",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r491",
      "r545",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r304",
      "r314",
      "r316",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r491",
      "r545",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r189",
      "r190",
      "r294",
      "r297",
      "r547",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r189",
      "r190",
      "r294",
      "r297",
      "r547",
      "r572",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r466",
      "r468",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Reduction of accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r18",
      "r192",
      "r193"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r15",
      "r499",
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accrued Expenses and Other"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "verboseLabel": "Royalties and licensing fees"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r61",
      "r66",
      "r68",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Unfunded status of postretirement benefit plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r33",
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r66",
      "r75",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on securities available for sale"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r66",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Gains (losses) on net investment hedge"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r64",
      "r65",
      "r66",
      "r526",
      "r554",
      "r555"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax ending balance",
        "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax beginning balance",
        "terseLabel": "Balance, January 1, 2018",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r63",
      "r66",
      "r68",
      "r129",
      "r130",
      "r131",
      "r385",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r55",
      "r66",
      "r68",
      "r385",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "verboseLabel": "Other Consolidated Financial Statement Detail"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r329"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r318",
      "r323",
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "negatedTerseLabel": "Compensation related to share-based payments",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Subtotal",
        "verboseLabel": "Subtotal"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax",
        "terseLabel": "Derivative qualifying as net investment hedge, excluded component"
       }
      }
     },
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r207",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "verboseLabel": "Mortgage and other asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r109",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r116",
      "r176",
      "r180",
      "r186",
      "r220",
      "r378",
      "r386",
      "r439",
      "r497",
      "r523"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r51",
      "r116",
      "r220",
      "r378",
      "r386",
      "r439"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r198",
      "r227"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Marketable equity securities, fair value",
        "totalLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "verboseLabel": "Summary of Contractual Maturities: Available-for-Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r202",
      "r205",
      "r520"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r202",
      "r204",
      "r519"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r195",
      "r199",
      "r227",
      "r503"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable debt securities",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r197",
      "r227"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r197",
      "r227"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "verboseLabel": "Marketable debt and equity securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r319",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r403",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r313",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r313",
      "r315",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r363",
      "r364",
      "r366"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r363",
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Current portion of contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r363",
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r106",
      "r111",
      "r112"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r106",
      "r444"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value [Abstract]",
        "verboseLabel": "Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r369",
      "r370",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborative and Other Relationships"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationships"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r260",
      "r506",
      "r531"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "negatedPeriodEndLabel": "Ending balance, shares",
        "negatedPeriodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $0.0005 per share"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r71",
      "r73",
      "r74",
      "r83",
      "r512",
      "r539"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Biogen Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r73",
      "r82",
      "r376",
      "r377",
      "r395",
      "r511",
      "r538"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r73",
      "r81",
      "r375",
      "r395",
      "r510",
      "r537"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r113",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r505",
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.",
        "label": "Construction Payable",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "ConstructionPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r305",
      "r312",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r86",
      "r493"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost and expense"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Indebtedness"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r498",
      "r500",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r454",
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "verboseLabel": "Debt instruments, fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior notes interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r42",
      "r118",
      "r275",
      "r278",
      "r279",
      "r280",
      "r453",
      "r454",
      "r456",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "negatedLabel": "Realized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "verboseLabel": "Short-term debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r109",
      "r117",
      "r344",
      "r350",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r109",
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r109",
      "r173"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation, amortization and impairments"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r52",
      "r53",
      "r405",
      "r473"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r52",
      "r53",
      "r405",
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r404",
      "r406",
      "r413",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r402",
      "r404",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Range of durations of foreign currency forward contracts"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Remaining duration of Net Investment Hedges"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "verboseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]",
        "terseLabel": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Revenues by product"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r120",
      "r459",
      "r504",
      "r533"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to Related Parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r84",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r142",
      "r144",
      "r149",
      "r150",
      "r151",
      "r155",
      "r156",
      "r513",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r84",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r144",
      "r149",
      "r150",
      "r151",
      "r155",
      "r156",
      "r513",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "negatedTerseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r336",
      "r353"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r336",
      "r353"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Taxes on foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "auth_ref": [
      "r336",
      "r353"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "verboseLabel": "Purchased intangible assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r336",
      "r353"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r336",
      "r353"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r336",
      "r353"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Credits and net operating loss utilization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Collaboration expense"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "negatedTerseLabel": "Capitalized share-based compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r141",
      "r158",
      "r221",
      "r274",
      "r281",
      "r326",
      "r327",
      "r328",
      "r346",
      "r347",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Percentage of stake in entity maximum"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r32",
      "r177",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Samsung Bioepis"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity Securities, FV-NI"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "terseLabel": "Equity Securities, FV-NI, Cost"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "totalLabel": "Net gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]",
        "terseLabel": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLossAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r215",
      "r541"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "verboseLabel": "Less: Net gains (losses) recognized during the period on equity securities sold during the period"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r215",
      "r541"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net gains recognized on the increase in fair value of equity securities",
        "verboseLabel": "Unrealized gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r426",
      "r427",
      "r428",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class",
        "verboseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r426",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r427",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r426",
      "r427",
      "r430",
      "r431",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging [Member]"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r305",
      "r306",
      "r311",
      "r312",
      "r427",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r305",
      "r306",
      "r311",
      "r312",
      "r427",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r427",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r432",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Fair value of contingent consideration obligations"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
        "negatedTerseLabel": "Contingent consideration",
        "terseLabel": "Contingent consideration impairment"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r434",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r403",
      "r408",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r207",
      "r208",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Estimated life, (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Expected future amortization expense, 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Expected future amortization expense, 2019 (remaining three months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Expected future amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "Expected future amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Expected future amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "Expected future amortization expense, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r242",
      "r244",
      "r247",
      "r250",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r247",
      "r495"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r242",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r247",
      "r494"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "verboseLabel": "Foreign exchange gains (losses), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r305",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Foreign exchange contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Derivative, gain on derivative",
        "verboseLabel": "Gain on interest rate swap"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r404",
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "negatedLabel": "Net gains (losses) of other income (expense) related to foreign currency forward contracts"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (loss) on investments in equity securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r109",
      "r268",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r234",
      "r235",
      "r496"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "netLabel": "Goodwill",
        "periodEndLabel": "Goodwill, end of period",
        "periodStartLabel": "Goodwill, beginning of period"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r236",
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "verboseLabel": "Accumulated impairment losses related to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r402",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r109",
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r109",
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r119",
      "r176",
      "r179",
      "r182",
      "r185",
      "r187"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense and equity in loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r78",
      "r109",
      "r174",
      "r216",
      "r507",
      "r534"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Our share of Samsung Bioepis gains (losses)",
        "terseLabel": "Loss on equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "terseLabel": "Loss recorded on Samsung Bioepis joint venture"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r339",
      "r340",
      "r342",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r337",
      "r341",
      "r343",
      "r348",
      "r354",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r117",
      "r140",
      "r141",
      "r175",
      "r335",
      "r349",
      "r355",
      "r542"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expense and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedLabel": "(Gain) loss on strategic investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other changes in operating assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r151"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "verboseLabel": "Stock units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r243",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Cost and Net"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r243",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets, gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r241",
      "r245"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r76",
      "r172",
      "r452",
      "r455",
      "r514"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestIncomeExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Net [Abstract]",
        "verboseLabel": "Other Income (Expense), Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r25",
      "r232"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r49"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Components of inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r232"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r26",
      "r232"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r88",
      "r171"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment Type Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by investments by consolidated and nonconsolidated entities. Includes, but is not limited to, variable interest entity (VIE) for which reporting entity is or is not primary beneficiary.",
        "label": "Investments by Consolidated and Nonconsolidated Entities [Axis]",
        "verboseLabel": "Investments by Consolidated and Nonconsolidated Entities [Axis]"
       }
      }
     },
     "localname": "InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments by consolidated and nonconsolidated entities. Includes, but is not limited to, variable interest entity (VIE) for which reporting entity is or is not primary beneficiary.",
        "label": "Investments by Consolidated and Nonconsolidated Entities [Domain]",
        "verboseLabel": "Investments by Consolidated and Nonconsolidated Entities [Domain]"
       }
      }
     },
     "localname": "InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Summary of contractual maturities: available-for-sale securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Litigation"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r116",
      "r181",
      "r220",
      "r379",
      "r386",
      "r387",
      "r439"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r116",
      "r220",
      "r439",
      "r502",
      "r529"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r116",
      "r220",
      "r379",
      "r386",
      "r387",
      "r439"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r267",
      "r500",
      "r525"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "verboseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r42",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r261",
      "r262",
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]",
        "terseLabel": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossOnContractTermination": {
     "auth_ref": [
      "r492"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The loss recognized on termination of a contract.",
        "label": "Loss on Contract Termination",
        "terseLabel": "Loss on research and development contracts terminated with Eisai"
       }
      }
     },
     "localname": "LossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r48",
      "r116",
      "r220",
      "r439",
      "r501",
      "r528"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flow used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flow (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r106",
      "r107",
      "r110"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flow provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flow from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r69",
      "r72",
      "r79",
      "r110",
      "r116",
      "r132",
      "r134",
      "r135",
      "r136",
      "r137",
      "r140",
      "r141",
      "r148",
      "r176",
      "r179",
      "r182",
      "r185",
      "r187",
      "r220",
      "r439",
      "r508",
      "r535"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Biogen Inc.",
        "totalLabel": "Net income attributable to Biogen Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r72",
      "r140",
      "r141",
      "r382",
      "r394"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r281",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r14",
      "r500",
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "verboseLabel": "Notes payable, carrying value"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes payable, fair value"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTerseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r176",
      "r179",
      "r182",
      "r185",
      "r187"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r457"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r58",
      "r59",
      "r64"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "verboseLabel": "Unrealized gains (losses) on securities available for sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r66",
      "r75",
      "r445",
      "r447",
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss), before reclassifications, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r64",
      "r67",
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r57",
      "r64",
      "r410",
      "r414",
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r70",
      "r73",
      "r75",
      "r80",
      "r274",
      "r445",
      "r450",
      "r451",
      "r509",
      "r536"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r70",
      "r73",
      "r375",
      "r376",
      "r384"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r403",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Component of accrued expenses and other"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r39"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Total accrued expense and other",
        "verboseLabel": "Accrued expense and other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent",
        "verboseLabel": "Total share-based compensation expense, net of tax"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r95",
      "r99",
      "r121"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "terseLabel": "Payments of financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payments related to issuance of stock for share-based compensation arrangements, net"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r91",
      "r96",
      "r196"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire additional investment in equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "terseLabel": "Payments to Noncontrolling Interests"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r100",
      "r103",
      "r121"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r91",
      "r92",
      "r196"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities and sales",
        "verboseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity": {
     "auth_ref": [
      "r93",
      "r196"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity securities classified as available-for-sale securities.",
        "label": "Proceeds from Sale of Available-for-sale Securities, Equity",
        "terseLabel": "Proceeds from sales of strategic investments",
        "verboseLabel": "Proceeds from sale of available-for-sale securities, equity"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r69",
      "r72",
      "r105",
      "r116",
      "r132",
      "r140",
      "r141",
      "r176",
      "r179",
      "r182",
      "r185",
      "r187",
      "r220",
      "r375",
      "r381",
      "r383",
      "r394",
      "r395",
      "r439",
      "r515"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r259",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r257",
      "r530"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income.",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "verboseLabel": "Proceeds from marketable debt securities"
       }
      }
     },
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r543"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Gain (loss) on investments, net"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r66",
      "r68",
      "r75",
      "r445",
      "r449",
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Amounts reclassified from accumulated other comprehensive income, net of tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedTerseLabel": "Repayments of borrowings and premiums paid on debt exchange",
        "terseLabel": "Repayments of borrowings and premiums paid on debt exchange"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "terseLabel": "Repayments of Senior Debt"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "terseLabel": "Overnight reverse repurchase agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r332",
      "r586"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r281",
      "r329",
      "r527",
      "r553",
      "r555"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r141",
      "r221",
      "r326",
      "r327",
      "r328",
      "r346",
      "r347",
      "r550",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r77",
      "r116",
      "r169",
      "r170",
      "r178",
      "r183",
      "r184",
      "r188",
      "r189",
      "r191",
      "r220",
      "r439",
      "r515"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "negatedTerseLabel": "Product revenues",
        "netLabel": "Other Revenues",
        "terseLabel": "Product revenues",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r66",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r203",
      "r206",
      "r209",
      "r210",
      "r211",
      "r213",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Summary of fair and carrying value of debt instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r404",
      "r413",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Summary of fair value and presentation of derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r318",
      "r322",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r318",
      "r322",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Share-based compensation expense included in condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r0",
      "r116",
      "r219",
      "r220",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r242",
      "r246",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r28",
      "r29",
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Components of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r33",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r45",
      "r114",
      "r159",
      "r160",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r378",
      "r379",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization for acquired intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]",
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r317",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r47",
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r141",
      "r158",
      "r221",
      "r274",
      "r281",
      "r326",
      "r327",
      "r328",
      "r346",
      "r347",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r158",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r274",
      "r281",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock under award plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r17",
      "r274",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r47",
      "r274",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock under stock award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r16",
      "r17",
      "r274",
      "r281",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount remaining under 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r16",
      "r17",
      "r274",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r22",
      "r23",
      "r116",
      "r194",
      "r220",
      "r439"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Biogen Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Biogen Idec Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r116",
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r220",
      "r221",
      "r281",
      "r326",
      "r327",
      "r328",
      "r346",
      "r347",
      "r373",
      "r374",
      "r393",
      "r439",
      "r445",
      "r446",
      "r451",
      "r551",
      "r552"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r281",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Stockholders' Equity, Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "verboseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trademarks and Trade Names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r207",
      "r208",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)",
        "terseLabel": "Gains (losses) on net investment hedges"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r46",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r17",
      "r274",
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Progams, at cost"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r17",
      "r274",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Repurchase of common stock, at cost, shares",
        "terseLabel": "Repurchase of common stock, at cost, shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r46",
      "r283",
      "r284"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r274",
      "r281",
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r305",
      "r516",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "verboseLabel": "Government securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized gain (loss) on net investment hedges in AOCI"
       }
      }
     },
     "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r122",
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Total Reserves",
        "verboseLabel": "Revenue-related reserves for discounts and allowances"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Investments in Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "totalLabel": "Dilutive potential common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r143",
      "r151"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted earnings per share attributable to Biogen Inc.",
        "totalLabel": "Shares used in calculating diluted earnings per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares used in calculating:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r142",
      "r151"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3444-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5747-111685"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6228884-111685"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=84167019&loc=d3e54681-109401"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r587": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r588": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r589": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r591": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r592": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>116
<FILENAME>0000875045-21-000028-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-21-000028-xbrl.zip
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M6+_] 3Z% I1:K 6"!R[ L9301Q?5.SB- HK9F8$-H,!%.>"P0F[!CW)Q6<U
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MWYE/R2SZ("^<%8X<6LLE0-(_E:US,7JC$:;^['BQ9EZ\$P!*CK7ZK&PH)8\
MC : 2#2BZH*Q$OM8WK<_A._<%_L1EZVWY,A7 Y#89%3'PH9B@Y1M^_CDD1TO
M+HD7%_6%TH*0V(Y\$-6<-911;E7UA;.I86W8('=]X;[87E0;I$2/^@> '?5<
M1Q0J%$-SF=R.%VOFQ=[!]<6;#(+K_]8@+]C6C,:9ZDX K!J+H!;#UB;65")C
MI"L,^\7,2,T2N68")@UTP" D'TE_7&'GW,Z3K)\9-]\RX^ ZW#VXJ8&)\2UX
M'*FIIQ&@R A-(XU8=8OB""U"I\>7&X[DJ#7;<N82E84F!U=2S![0!W V?)@>
M\#XY?CR>CR<RG_\T/:+Q9-FUW:=4CB>/E1+Z:CZN,EM^?&>,-#X<+T[V!.?'
M,SDET_/CQ9:PYFD=Z[T\VSMX?++O;@<]QNUW!OW\KZ.]US\^>W3CMMV[\>39
M_HW'K]YGC>Y_\NCW7U_=O7';/WSZ3+_'0ZL,>O90OU5/A=M[^N#EW9]_-7=O
MW.IQK'FK/X@3.C0C40#5FE :%4\\"N0#%8>N++NNOLO^"]GBO3><3&E #GS,
MJ :E)5>+2R+X9[)TQY:ULV5\@2VY%,,YI5&"*.J >D^8BWZD&E;C"\PDJ7[[
M@_WN[5#E9_5U?ME(A7F?,\L^S;?=G3\]P=GC/G=G,[HT/Y<%[W1I[OW\ !X>
M[(%Z%=U?O<^->\J"PZ>/GCX\>?2T'NT?J0?Z_>:KAT?=:]S^-VBDD?ND10O%
M]T%(/T)KS:B6J#&'!H[8DQ _X"&^?W?F^7)^@4Q8YA^8,-]G]E^;+^?L*[#?
M+&?Z7UN</-=G/A\?/3_L$_B7GSV9==S?F1O_W2NEA5[NW7.<7O_M1<_N83X]
MGBW?+2M27#LCTRFJGT.F\Q/)<K[5^3NU+/J^C67VS?*&Y(/5%WZZ_;_OSN=^
M_^ ?SC]Z]^S/E[,US]_-%SA;]"G7RRFDO89!GT'P_K8WMUDO[.I'WKZ]Q.F6
M\_?G%_G^G0=U?I[>))</[6QRV_GG1Z<&](>SRR\WGI_B?-OY^WZ.#^+P"7/C
MUO_X3RM,+,Z>*(S<FR=ZON43G^CQDLWO/K*SRAK7'MR_\<E/$ZF%1LE!BJJ]
MQ!37,\@T*G!!/:R7-;#ZC!WRN-O8T[=5+_;J^>&8QXL]Z9K@FSK6K:>%>.:S
MQ;5?9M-ZS(N[L_LR>S%FN?YJK+1[.WMIN?7TT']\_\$SOGE4;RZ\J:WK'?PT
MQK8N9$M8*^C?4K%I(&X3A8QH_8>&\W;X?1 _\_'XF97AY[)/'(E;C ;0JFMI
MP9'-0,26A0?=_I8I/_?DA4R.9=YK8*G!&W-U9O%$M?5S.=9WSV?3QS,\FF]C
MXPR):[$MJ1@RP,T4,I!5]II@Q*84!]TX-PC<M;1<&UU0.VNJAC#06'*(@5U,
MS!)--A],A1L,N.]9WNN3>K;Y;D=W&]MJPT J()-+$H +4\+ 1G]BH-!EY9#;
MZEKA7$OK_)PTI_6'"VMY;A=CBS?3<\\WUO$+_0X7=UUFC.)B^H:@GQB&_.'X
M_N$-F4R/>C?<'T][]NW_-EA\YQ3?OWOW?Q<%?<)\^/63Y-V8\B+NGQ93OO,$
M/F'N]T8] 3.R;C5/P+@"-J3@01BR*YA];ME&BXYC2TL.V+)Q3\"6E3T!FTI0
M*:..SQ= WTH.Y/0EYV*JE'S*@<UK!69EK: 0U]B36W($4'VG,B S>#3B6W-G
M*7)?I15\JN\_]_#+<=!^S,W_')^6>'H^G>C;^?M"X&(]E]4+@,MIH0R.U,,$
M@ 0EU4Q0Q)FHH7.R1'YKT+E0/V,@T(AU1E(HIAD+P3HLHJ]*+,Z08X]; \WU
M6L=]  ,/?\%QO3WY"9^/%W@X$)AR-;&! E$C0@,@@QJTEIX-'"O(]K2@Z\S'
M1\>'/2=D&>+T_6;RI)_MA=R>\/1(!@)9<:$;/982U=SUN9B2BIJ^D&U&8-D:
MR.[) L<3J3=Q-AE/'E]"G]&EX%-9+5ZS4+3]0$5/!AKEF!K[ '@NFK8 GX/9
M,N@Z&9);JEW0!PF88H"40S;<JF1A]!K;F"W2<]CK; \$%95PQ?@8*50/R!F]
M%7$:=39*QKFZ-:CL3R?]B\^FAX=JT<[3%0>"$O>I0DE(A9W&0D6#(&C5N&C
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M^$DGG!SWI_6'\YU]2WWY,6=[-\O99,P:PFM884#IB(6S5?* %,-J0\X">S^
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M6CLPZV]57L$B\"2-$;!4=(#5Q^:3Y!IR.PO7W'FXYES9-!0_SN=-'N/1]#U
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M:'TMW(O%U$$4)E\C5?ZJ'5R_L<T47&$R1\*^1DOL8T;08LU2DV\1^W(4F=P
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M'<*3@Y/G%V=)_CB>'DX?CWF^AY/CI@+Z>+:E"=4<"H X6ZTG\*4G]-?H%$$
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M]=GGE )JBV$Y6S3/P.960K@SG3SN*]1TF-^J@?.M%S"^9(MEX$+%@B^P6+5
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ME<HE>&Z+:4L6Q)I+X&HI4?Q.<'H>#/J58W,5/#T*GB9SH0S.J9,H4$405S@
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MVB/NK4TETPR25#%-C&?>^+5-#F9]Q@7&RJS_2(52R]+.H-N[J SW@GWXJYD
M-Z&"D5E@9"I3P5!PT9.G3GVJO C>NU&:(6UB3HW'SCB3_ ,B267"EP!_ELMG
MKW3PX3HX41&>.\U%I$@X$Q%HHT"&.XH\T28 L<;:%\MH.%<;>67,YZ=,>V6/
MFJD$V<JN/Z5#/M5]8JMXX%6(;W;XF.J=QYU@-K" 0E0<\<@L4EIH)$!VE) V
M4DK7-J7*9ZXV4AGP%37@E;+-5]FN;77 QA PUTA(ZE+*2T!:AQS%Z 6E#FL
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MK-X=W)TR484/GILL=#O'C=!KI^86%<#,!#!3.]^Q=<0PER-,94#@JX"+PK!
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M)H6TL<4TW-("]1_5^3\=3[4!Y,.]?P7D<@ Y,XK )XTI4N*,;$0Y$F=]*+J
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M_NEI:7'<S;@:Q.'H)686EEI(L-_M]0>95_8F!JC\TH)?#G9N-%GP1BID9;N
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M'_YU^/-ZW-/?K_W)JT[^O?G/G.9G<_B/.Z]^XCPG]%]\QHP[E4TTT?C=K\1
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M0IR3'D237S_AU,V&4[_2W9/OY7<J>>>WZ2:[^ZW?^+5B4ZB[W_FMW_KM[PF
M!5RKU*9>ZXN^5MB4<EVN56\R9=?D6F76=@]CEV4\K]JJ-;E6N2F%7I-K59M
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M1.(<),$5,U3AQI;:E/?.;E5L/54L9*V- C5/(H%2T8+C.O# J6>0S5<]VFJ
M;1H+!>J5%CP1IGSV:,GF6,@&3J@(:*5'&QF./1K?5$_OT9Y9YN6P-*'OW&A
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M5[C-\74-0I93F5Y+ 2"84<&A0"=29,F[^R0$[CC45]ENT6RW?SS=-[,ZBI#
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M[\G2"@8;82$$5"\@)%55;L^3YYP\R[L=4OM<.X5GL*Q9@99TNG?XE>V]>]N
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MBGI))92Z+N4?%L01AT<<P]/.>4\X1X<6O4P"V870?@6:'4_=>N5T$$ZF)W!
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M'\D7Y[S /!KDJ4^(A^"19O"GCM$IQ8D4RB^0'KBRV&J?$[HG+H+0C$C"N8E
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M%R02%GO$D_7(1J%0C"'D2!/.LE,P)7QAV3]+I^ G*-B48'PX,,ZX 1NJA0D
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MI<V8$T!G3_IG08>\*-JR9^H&P "*QJ![P] "O?Z)SP;>68TM/_E8:%D7 6K
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M9##FR%,BN>&>)V<!(HBXL1;%-;;O3(M>#5J'O7C4VH]@;&)>R/S1_1']3U>
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M%9#Q5@+W-3PZPX/G;$1[V>,<=?P8*>^W+QS\?JELP7,Z >KZD@L_+Z%P2U6
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M\_Q20P0?NM"B3EU[HH0'YHY6#EMMG8\V>,F#D,! N*?$0O>%B&SF;*R"2XO
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MH$Q2.EAVH]HM0+?&? O1HF:SJ-D_C:FCR8/&TAB"%#!FQ"D52#/.$,\)YL*
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MB'.&D=6<(\:%MEX''S !.&;7D,4KP:J[J%"IW[= /3;&1&8532QQ*:/ACJI
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M/MD[_7CR)=>B_0#L?_/C:;,^MJ+]??OSG]^^?-MC7S8_?6M\_I0:TXOGB=K
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MNB-&T1%+ ^?.1,,1P50C#OB$G+8:81Z]X))HJTS&J.M4, LTDKW TXN IP5
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M*PCA-EB!K4*8))5GHEMD.)4H*N.%8M@F+E?6R1*0@!4(>?K'>!0(N:VI[Y[
M4E+:]P*6<=\DL$2-T09)I2/B.%#D-+@JU$O-19+&AK0T?7T%6Y[^,18D:BFH
M,",J7.25=S<$K,$^58;JX ,2) (PQ*"0=32BS&OL0J!"Y;X$+1=_)-0S2>IT
M2H/B78&&*&>#-B&QQ+@4Q()ABTI)A3F7.$U)_WCK>5?)G,P%AS;'JQ2-H%QZ
M29&.%B H29+'($<45 PX"L8$5Q#TK!*I%S_N*8HWD^*5!,23:^)831YUB0KJ
M#**"9-I'8Y"-$"7D^A=N2<!,YPPF8VNZZ.$B%J$]L2*6@/U>BC@RB;!+UE/#
MD60D(1Z"1C;KI?/*<:MREC"W[?,)]K"T*2ZI*;R7#UJ4;49E&Z^O(M(K @ZG
M3)8BSBU8O:0E1,1!&.8C-Y1F_U-K]11V[\7T*\ZS<N9R95+]K%>+DWZ_L?KM
M>9:_WF\5GA5*/T)E;,D4S 6I_2A34&4L]_9#D#KEP2Q<&PV^D0W(DFB1=\K"
M!G(F36XN7Z7,S)JTG(>B/$4-?\&W@F]S;48J"9DG!+SFZ\N QR3F6%F,-).Y
M*"1QY+C,30 A<J(E-LFNK"MN9AT_6>"NP-WBPMUC-E^6O-=3XMT5!\]9!UOH
M!0I"&7#P6$ Z6(NB5,XQ[C77:<;D5T&Z@G2+BW2+'[@63)L1T[:O^'#6>.NY
M3"A@8Q%G6"*K64)6&1,<,88*EX-6H_@=&2^>!-NJW.1O5?H._@ZM;^O5O6>1
M;75.;77S$UZ!#U[I".69._RXVV_E#[SJ1;"RK6_Q][-6.#D8:LG8;PT>%H]^
MQ3IXM-.3FW]E[,%\!(WJ/8C"$_PSC:?YQBB^V,QZT<;^/.B-;,27B!PX&5^1
M37#'KVS[S)[W5WZ[]&!'K<[PXE*MY76\N@0W/FA*#]<7"<]9"Q/ 3+=7;?RK
MTP[(8OX4W)==J/MI'/0ROOY72Z:H,P%_))AP2:/E)'FL.)$:,R/)OEI9WZW2
MU=W4>)VAN7/2_\]O=OWRALXN>,0+J\+\!&_2 JRL_[&Y_?YML['9?+W6V&B^
M:>S\\\?.YIO-C8^;;W>6XPF:V[MO=VI W-UNO-X&)&[NO'V3?]K9_FOSS<8N
M_./=9G.C^7ISXZ_&SBZ\L/6VN;LDC_?+:<>>AA;$&*N- 6C&\.LDM+B"JK5=
M=AX6AD>E'<$\)*:#MTE9+!*)G"6S,KKH1G8&HN<L))%=;L)C<#8/9Q4JAJ"9
M#>!%7(8:V_L":%,9$SKT*UN@1!VX?;)&1>7*3E@[*A1S=@YK5UWV5>L$MLM/
ML9H[IT=PS^=#7<WV]-2V&UOV9#A2LW$1Y2'PD%".\QJ9NJ*Q<_T8:KCL8)J;
MIT=PC_ZR<Z9HQ$YPS8W6W%H,?PGAF)>1.)(TWW\#SAG@"B:H^H%E+^VR\[79
M^1;[)T<95%ZW;;_?2JT8_C@?N_G!O9^_@3BT J)=^/X_VEW_=3E=LW;\GX_G
MGS^%8T>YW-O=X@!0>/O3UO>M'__ /;V#[_ORX_/A'^VMW:]G6T?@>M%\C9"V
M?GC>/-L7PA!*.4?&"8FX\!J9: 0BA)FD/7:4@-,:P7\]SKK>.XTWRK2\(M*4
M5S--GM)1V#V(<.\GX*<#(C22;?4:WVS[M!X6:X=DF2"&_9,LY-W3WBT,L U[
M2=;[6=;=>27#0\TX&DA7P_9BHU]I3_4%M@\!1+O=/1L;0GL51P<K.?#-LB,R
MMK;U.M:W==EQA?5LV^-^?#7\X??0ZA^W[?FK5J=:D.J7KOJA<,V!GV/,FI D
MNSJ#0_+!Y0=>T%KE!5WQF>OW.%DSE-_X-EXC=WQ/L+M=];:;)72-8U-NMMPL
M)VRJRRXMQ\KD+,GD(/@N]6AFQ%QC_=<OO2[$ 6CP**'ZS]7@^/=K/N(LRP/>
MC_7N@2EH-OK9 &S9GC]H,++:R![&?!=KKFLR9Y&Y;4W>1!^/7.P-EP5?6I:E
MU9+)C_S+9J<!EVY#1-"_E@V?&\W33\G"ED XW@[=JO^XWF_K[[)K]6]VK:98
MM*E6XN6MZ 5Y>[6BN=BI"& 1P,41P)] _5T78R&]I3<0(\+ENIW8.(^VU^CV
M&NW8GT=)[767R>7_WGS2\"#GDG/VJ68\E[S_&MSK5/)1'GZ&4\G@+,:!,)E8
MY"Q:Z[TP46!F61 *R^I4<I#O>A"BV5%"[U,+GKZSW8E[(/67IHD\CS/,PS]:
MGP_W^-[1YX.]3_]^W<YGF.__S*^1SV_:7S^_;QYLO6FVX+V#JV>86^__/&H>
M'K0^'[T[^/SI X?G@&?,K\%U/GW\ND?A6>F?\-Z[M-7"YQ>#BAFQ-.89Q11'
MBGB,!AD9)7*)4:6HT\%4#1*,XID):.^M2?,MR[CQ?@HJ%E1\)JB8/<W*T2R(
M.!LBX@M$Y$X%'"A&1@F.N-<4:>H%T@E''1DEC*0A(LXXXF[1$+%,$9C]44O)
M67'N%AO*Z 64"6L2(9$@09Q%7*N(M$P>@9'BCNH8B*[85ZB:F7VE(%9!K()8
MQ?&Z-UKQ"[12(@@3B$-49[0R*B''E$-)2V:-L013.42K&6FV'VL6RO*=--V<
M8:S*4D=)QI,#<%R_'#12ZUO]RER&7]#IH_/Y\8H\GV#R;L"UD7<6<&NWWM)W
ML*,9POK%Z[HSCIV/I=2R 8H2 L@8 @20U.4)Z<(BEH+1G-'(8^[IU&1NX>,"
MY<R*9B^B9A?OY(Y:/4H+*1R5IL0C!RJ,.(98RBF2D*:64VHCLSADK9XT/'+1
MM+JP>CW"<-=B?1]13T<Y#Q^9ECH1%*SSB!.%D98TH>@YL2;12 ,%/:5T\4?U
M%'5\0G4L)O..JC@*Z(TR-"I'$+/P!Z?6(:TH0Q&##\P#3L3'K(IDUK;8$K'?
M$K&7 'WAW/B*@F0F0"I>P;VAJ/EZ+":7SBANM49.)_#>$\;(A.S""Z=MU$1C
M#UX!QS/3+)60O.CRM+I<7(H[ZO$H"K=.<"RX18%DET(D\.Y-/BT02@:N.-=Y
M#B?H\:Q$&R4(7VJOOUC8I]',4=Q-!'.1"H(LRV530G.DB4L(6V84%H8[JT S
M9^9M+0KXW!6PF,4[*M\HTHX!?%L="3(&@WMKI$/6.H6$,ER3B$V(O%*^&4^<
M"L?]#!SW5Q@9'KX=9S(M&+Z-&>SE5:;/8Y%* #2O"JH"\;- _,Y8!B-&GS'>
M(1H YSD1 ;D(,9 C3ANE7+("_"NZ2C+SR7S+TN>@0LO1R5, M0#J4@!J=J?'
MR*S'(]@_;+]58'9&F!TEF%A07#&!$58^(NZ90M90CVBD4B0LB<C]D!EF\;.'
MV?OP6#\^:"Y"-?Z38^/S22L49_/147"L<8C':(FQB("I!13$"1F&*:),1Z]]
MC(*:C()8D)F[P@O8%; K8%<<P86$P+'B)2\5^'HA<XI+Q UAR')O4,!4*IH@
M]-:B@D!NULBR0> -W/XC\N,;J:'Q8O+H6GA<^R6..&[O1)AK)_ L5FR\UV@&
M5QMG\&%[?-SK?J^(OMKGC;G31X^A JR-?Q5.>T=PT8,K9R[5DP^IH[?3UL4C
MCWM"RZC\=Z:/WH9_[V-+"6/1(RD$0YQYAYR."BEMK,8\RA#QRCJA5R6_4:UQ
MO]KWV[8T)46B2<X+&;@0QH5@K*3,>Z^-TZ;:4CS<4HPEPV5+[\X(OKMQUMS8
MMUQ3D]M#&4\&Y;';R(D4D;1@5EWT7,L FTINV-351B_VCZ// TC:YVL_H[O.
MB&>N -Y"<N'_W>N"4Q[ZC=3K'C5&XO*4=/<?QP9&YB%JVYTQ OR7SFXOMC?V
M$Z;!.NP0BR$B3J)&)@4*/R7'@\52!+[<[/;'E\3RZ.+\O\+6;'$K>WN;C8;/
M@<:>MD_ XVD,1_(UOH!(U6^V0;#RYY:&T1Z"BC5<!Q:S4MI+N4:->A N\YN_
M],Y<YGQ-\.FXS&=[C^D'(%[/-RNGO>R$Y,%0!@!.XV)\\IFU-SP$0?SR<>!"
MT-\X 5S=/>C%V-BJ_=2W /EA%+1,L48O5+(>GU3]I@D$CT?-_"CC":8<1U"(
MK6]:/?S@2OL$0/"L*+?__JDG6]BW"\_L_(\4[A2'W]86/13D=R#'U>#S3ACE
MF9[[4>K1YQ;$YW3K$]S7^S\/FH<?OW[^M,7WZ)_YGL4>_>?'WM'>V18\P]5S
MA,]'FV+OQ][WO=V-L[VCM[3Y_B/<^\'AWM'G]C;<P^?=9NOSX<9Y\^CS98)M
MEPR.G'/$C<.(QV209=PB@@/X;89RE4NS-9FY-KN0R3ZU42C4C)>QRA@3F54T
ML<2EC(8[J@(-%'O"'4]7$^+W*8@K,/8H,#:JBQ, 5\*03"7+ N*!*62,-DA$
MIG#@U@AM\W$HT^:.0\X?&Z^6SJ%>-I_YXZ5T;2&C6%27\$H-R17P'#_&*? Y
M"WR.<T(ZCQG&TJ&$0SZ,)ACI%"7"FID 7B"SS*RLSV^@0.F:71:7I^CBX^CB
MR)6A-!IO642&1P&ZB!5R G,44M( ]HGBI%?6Q:Q4,,5367Y/I3Y.+J[*;8OU
MR^+[*KG<I.#C#/AXB2N+8V8B%A(9!QX*IRD@*XU 6M,HK)+:V<I7N8Z/U\[/
MBINR('KX-'Y*T</9]1"/T6<2Z7CNOZ$RUX<E@JQP'FGE*:.<!D7(RCJ95'Y^
MDR*^.!_E3C7N=!E*/G=.>O8D?H&KCY553E/0NH"U@ALSU-WGJO[^Q;.W+IZ]
M<=SMG:1NN]6M2O-]]^BXU^J#3P=7'GVJWSC)M"VYFO#_FP$_L:6:)9<HH99S
M36SB43'.K(M*)8'OT>)=57Q?;.9H+_\>/LZR ^@]2KZWSK<V]JD% ^6<0-3'
MA+@DX)AX1E!PPI+(M"',YK% W+ )2#BL[:G$::8MCQ%,IF:<",9MTN#U! *;
MKHP7RHAPCV:NLN6W;7GS;-]R"<M.'/*1B?K,5%L?<I6_$%H%Y3/+(UW%@%W7
M6=R'6WZYV'^U<09@=5"5"K<ZOGV:J^8 Q,:Q(<L(8!K@C84X$%[(4]8!;T P
M "HSF,!/U?D$;%UH.-NV'1\;_8,('UYK+"GZ;O\<40<+UK^T6G /\7]/<[/5
M6,4VH*T'[\'"FZ[5/8G^H //\N6\ F3;@8^,;T0OIC9L$*SE635,K5IM,.8>
M O'37O5]HYT:+N]#+M2-1GCRTC7A"1MRM9$I[!H5AUUC*]I\Z]42K3[&+=]Z
M@V#N<L5H/]XDPZG5 1ENV3;<'KQ0WW;C&_P%#]'P]CBO12-!Z-:'?8OP6BY
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M6B*32$!12FD(CUQZOK).Q,P,*8OC'$U0R_EKWZ*Y&$X&V-6D1+2<P]8ZK9,
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M6&(<_#LG,7_)M01:PQ;LKJMG$<E<U/\+6"YO&LW1_KEM?Y59O&$6W^>F0A^
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M8'J1WYU3/VZ LFO'4S"N8%QE,\_56I(DHTV2/ @>%#$F1]V$YLD;RM0-(#>
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M8]!_]48[^2*..9N+2:EC*/XM'9J=-@^CBOW:3=RD8.KG2[O7#/UIC%ITG2-
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M_YY3MC$2IU\I&0M%?;ZLM+H "&BVWO@(HR\VU/7G&.:-@YIL\[C/HB\1=MP
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MCJ1XB4Z$'N:!ENF@K'7Z/?JV?4Q;VV]/]SX<PG=:^=[!]WCO0RMO'?S[[/
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M.FJ1+0S1,<L44SIE7J]MTD4-YGY%%><C#0Y[=)UO7<6)PG'U_8@5G"J.,&M
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M[> +/0)I<LS;B,2< 326$2,Z=ISX*(*I3+Q+D(R8WMX1L&J!QN07(]\>I;'
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MK/",[]%1K !;\"0C69:FA!OGB989)S9SGL8VC:A,P&?-YI$>50YL1QO@M=J
MVA@NN1!<?8H?9PQ'EJ TB@6G]G7#U5\OFK'V"@NY;&5)M;&X64Y:VUM@+"B/
MN3.&8(M>PAUW)-,1(X(++:Q,,ZU 3E)Z0Y'1B ?DO)?#+H2!TE(L0F!IW+MW
M*[2*-L-0C@I+\L-5RE3GQN"GFKM<"Z-/PK)38=@PDCH4^WM)ZNG.Y5.$8G^;
MK.B02M+8=[T?N7']%4TTW,_/ANV!ZKANM;EVH2?YJ/WO+*PN3^]F:)$#]\5L
MXY1&OYR?B17!M-,)O7&@H)IN/37J4W$+OM]H?"X][8J'4'B_DX?VQD&$44)
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M]=O)_[OZ@IP-1\XS:KFQ1,0J(J"&CF1.QL0QDT1Q*F+'KIW/8WMC)9@TL76
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M3'/#;ERM)#(W*)<\<V.&4#;*WJYHS3D/[OB!N8$R+*VQ:4^D!QB1#06G)<2
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MC%W#[!2EH?!P+WJXN\L]W(/-YZ34*S^\@%^\4:/)085C?/^.\06&&MY)N;*
MT5@^,S;GO]H.[;B/XUO>/&"I%BAV$M6!$\M[;;3*C6YUU=4^UX6[V5R<BYF8
ML(.ZMG1 SHKDXQ?;Y)8I_I?A-(50,3OC&<4J*;$')OG<MTG5?!<RQ5/%%.F9
MFZ@Y^X>P.7M.IWW=Q3K6#R)@^",2)7TY/<6F:=E1NS%T4* 0"5WYV\RAQ?RZ
MC1^._ \X.08G.-)X/Q"7 A4Z@*V#?\>N4W"WC'I-%I%PC?\),!'>HP%MK$(Z
M5'+*SU4K)__'"@(.IHD.LF;[*S:4''J"!BO\^";]Y?\,DZ#FH*7*P?,+ S^-
MHW!T2O3+M.R]305.?<U@KFICOU.WSJF.B^IA>3+.P71POG!FK*<^M7YP_QQ#
MVIPV=L6]YW3=ONU.XPX)21> WL!/V,6E)L30G!HY\%%-R1B WBN+.1Y=;SP
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M:&LI9Y1Z$']S=!99)('O.*%W#!0H]<,C,FJ)*>2XP)B( >HA6\3T6]E?6:8
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MG)U4NP:&A?![4FO$9#IVYP+W3[T F)\+D _N)#+@948\:04:XH79KO!KX!8
M-@=YD4=-$,0W4+1QML]P#&PA"#D6?4C2#<]'#<X#UDH 8L 7POIHV5] CK6-
M?@;ZT4 H>R9\@.*0 [R)IT4D]A_OW20I(3Z[0/$31B!N<$"XEFZ;*-V*D#3S
M&0M8W&G4R\;_8:ZS/8OR%>"#L?H[UDV.76:=O;X;S+"3'3I4;@ DLK,/+%/M
ME?F3=P +U\O 1)KGY"KDH0=$SCO;7*CN_M2^##.8])Z!%:W_.G4V45WE80M#
M\\$-$^@'42]YJ=P?R*@3<FG$V][SA%%NW;VV:SW6E*"G1FI"JS*R,L^H5+&
MUI:^R)_:/PE?JG+(B(R4NTW@<%%'&M. YK$1)UIB,F'P0 C,L2(K*' X)D[6
M/%67>JR4)WHNJ1?I AO-J6@KV <HS?LV2/05UVU N!$V]?F=LK^*YIP-Y7XH
M]9-MRM5R-'G5I_0'2>(8AO'3-KXY;2IC4=;NLZ<C@P2;VCG!.#%4WZ(;":03
M(\2AVWA)[8GQ3G:&WS^A]\%R?]R(1ILYT!MZ< .FPWT2>V^-2:]_G-/TS8MP
M."2/M^4*$%G?C52K>J.A]UAK@_H>F LZX'I1RS?CZ.W[WG'HD GCA^1W5O#B
M$@A,W3(G\[%KTUQ9DS[INX-Y%,H+UXF2P&-EBV%I>%1J'8NC:%%2JH'0$Z4I
M(?'<]DU;+P&A#XY+2D4A-OO.=0>L,Z#"THN[OH_>G?6.%]K(XF_A"RJ+F2I
M F1H&=5<#E0?=)K/Y6!1WI$)'T>#D?B5'^%>C7="\.2VZ[./[[!:G0-4!"97
MM<5NEZ*VMK$N@>&.1@(-?./!]LB6G0@.5TDM\!H0:#JBJG>J."7Q,S:NA/>
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MK)FKE Q2/]Z=P5/3J0?:1_2H,70]^G8&G'8V@:,C9=]<WL86W*5^DU'H*[
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M>'=.<1$DWC\"1S!0\(9OQ72FQ!!\]"48W*-X0R8)0"<C2!#N$2(@S!C]AH#
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M!K+&B2^&7=(1)-'AY1@1>@S,HYGKH>2F]J2>C9U2@94&G@<7&C(OU2X5K:P
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M/@H]-[@?D30#Z3:Q9\JT\ $\]A! 16..?5C3 C$&@B]<M+0T64I-3N:IR?W
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M&;;3_XB*<VJ+7CC&/P(  BHA%'T$765,Z3BDJ03]B<W!9!S!9+Q]WPO))(P
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M6N6:^B Y]$JGJ\3>8IM2MXCAN$JY&UL?%"@WN>YF ;0[&9Y;A(CFM-/R1S<
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M!IO@EX\6)9RXA2BB0FS52IA%O\8W1*^$@O^0<3?Q&)_C]**4G8$7.9JXM,(
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MHNU"P8>NPIR==*/H"G8'\;& "U9"&Y:3L(WCC)\RCZYU5-,U3)P$V,WO^)'
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M^10P4YX*[)11><<OGSPE7IYT29[)=\D&E4PC:TB'EIV%WSEN%'9S'RU>6I^
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M:%6Z7-:'@O'7+P (JI#0$#["Y^TO&4]E/>O1G&PT@677]L':0HW8L)J$]G>
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M/+4Q2+Z.&)(;2D3?(Z:7[NNJA9BOP'I);@Q;6)0D>IDI](!54C"ZUE%$VHH
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MY&H5R7UA30'#'5'(1?E<Z0O"<]Y=!%@*(T2,S*M)* 6V;06):QE6&-0"T?8
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MRV<_34PV'T;Q@TD70,+5[1R!GD'R'QX93,(VCDX@>W F(PCUL2\8L#E7PW
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MGOI&A[XQM8 _"KE@R PSW/)#*X_!,(9JCCPQ,3$2CX>I):B!!7CLP -234!
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M=OXS2>^V-#/YN6S/-1B_ 5'GDG0F)<-518#7I+:QYM^7:RLB"!JBZ_W_\],
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M$!_&JUE@&J^+/VN11*_%7H _[E9.Y;F=2M.MNS]M=17@.8H<E0-<DP-LNNP
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MY ,^+.?>'#D+YLQ6<4 J5%WN]9OI^.(6QT=IMQ9ZE"71*O<V$S:9X)T,/(H
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MM#IHF^T+2+5NU2@@JMPJNB8N(@5=2!:IO,&1L^Z#RQI?TE5TM8F*IO(N#5]
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M+OVXW._X //%K(L8<Y9?G$S2W1_<^N0H\I0@:DNBI.C#!2F)*_4@.OG@7):
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M]?-T-KRH!WFWSW^O&KG]3K[#6?HX),CU<^T4> V^=I 97US4)#@X_W5X3JX
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M_R+-+?3Y$G^%KT)RQ9?%OQQD4T3MYE-/=Q&!'#15G;: /ID4@X!.''GT5:=
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MN,N+7EH;B%:*9.L",J^,81$=(@<OG&A2-Z(#MN?>%F@KRFS:G7I27<MBD^L
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M%BIRRUS)@L8;H>I4288B9@=>2V>['+X^@NF\^-# [CV$%!X6XRRG0FN#Y-8
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MM+9_AT*#VZ:?.VUPO6D90RX0-:,\+=/XDV'@C:-?!>N#=A2E=[E,,11@0]+
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M>N<&E%;>TW+$F:ICU9HC@0J&">[(&$K)M"D_WJ&^ZOCLZ>>XQVJFGF7U#KG
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MC_V[R'_-D1[XN=YDQC_P8OIEJ7.^"B[7E1N.IDLDB(D+S;0PC@44R$"JP(T
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M :'Q8J(0S_NZZVLTJQHQRJ"*47?9>G^I=8[M2=+!$1VJ&=_/I@DQSW\ABWR
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MF>; BL!8[M@N<!_H)^>)!V*U877(N.;6F*0(4-J3;$,)%' .1F,)HO#K2<%
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M8Y-IHVIIO+*B!)^6*K#37E"U<D\9KSH-I9PL)T.H&V-<UX,[*H,YI6!KTU\
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MVG)9!XF:2H<MB8(XK<VJ([E>7$K+%CM+LF&KB4%I)FYM.NN/%2J3D*LE*2-
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MFE/;VL1+BVB5I>EB:7#R-K=.7,.LE8W/!'QB]V"Q7.K&AF:KL-J=]7&KW56
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M:A&WF*)J,,XT;6GA[6*EJF6@KF\BRTY;3481MNBZ0Y3NP72[VNFRS&1I<M2
MYKF%/?!]2T6JFECRYV4OJ8Y9?^QQDF?T20C0^DS6Y@(N!D@U9\9#3 #E'VT@
M%JTL^474K(Y',2)I::,TS!EC9C>(;-6J=K- [5EJU=5@GB]/L&J7M/E.(%=\
M;%6TD,G !]%RVC/F(;SVLYX-CWL=DYQA>*<IX:%843F #;MM@-TP2VM+"UN8
M5*CY1*K8PVE]);J1*JL2V0"5B.[6"0[4"\N 0P>.RQMV;S%"_: 1IB:1A_BR
MVUQB6F6)M>=HF,16>=GD*GAQ'M;-T:PX9&;Y? ;GDW3%(('=!>BS0:QQ[\K7
M%'(<3E@'P":2A-0N-DAE2FIWG1:=- P98.*TE0O+\F@2JM@*Z>;PL 0B%5F$
M$'\1HD&()I%7#].MS4Q4 ;(G2QPQB^O=NC/0A8[A*L9"]S.7:'(-D%@) :,U
M#9L4[1XRJ*%3/YFJ.)7VRQF<QMBBDS= IBHOIEN;575<$SP0-SJ&;?8<!PE[
MM;9GM!I6FN6B4S4FA#HCJ_B(LJ-\E5@D<.P%+",U7R&\80VN<(M 8TN3NMT&
MN!<;0RK<K"$ZNICFL@6P_8B8-\?YC"C2G2:P+U!12JMFJG6L'I-5.NT0,02)
M\!$)]I>K060',N(M3#[4K":(EK#BMZ1<*FH^B* S!"VA^;+MA&Y;IKMT./'8
MS&Y"B8V; 0PBU= =P.YH-0../BEU >R<=9>V:KDV;FCI&@U20ZT%N\3*,Y;K
M8-0OPU-N,1Q!5A=NDCGP?$&AH3D6U *[5$I;XQKPZ4%FJ;:7@-A0S^!RMH*W
M0\O6YA\(+O<86O[T^I1/N@!S:^UVTD]:=+\5((G7:(J9+,R<N18X9#5L816;
MX]&AXT?C,&1ZE,B @K.ZFN>^$OM5$> W75G0M7)'@IO#)19!2@M'?#CDL&D?
MI UU-EA2]8Y66XXF S?25"FW($3MJ%[FMFL.0LB>F>20T\T]N)4#G>;(:*6-
M9T,"T6H]?NB(MC0F,:,YJ4TG8H*/PZX9:>E(23/( RBX[G6$0:OBXM-U6$J)
M=5B""4:'B6YO_3=F0>G.(O3H#S%!K:K#^?_V(>9JA:-PCBS-#M(L(R49Q!"Z
M-36+F;\8EE-9MZ2DU.C9U7@((MTB' =9M8M$/B-Z=J^;F'9<JP]SH0S+]GR8
M8!HLV"L=,Q-%TTQ0/P-?Z/FZ-2)YUZMZTX&I041;R'%TDF&T,5Z4%UP?$X81
M-Z*T%>;@14M/Y#&TR/-2#:FY:_=$U65/RJ*F7BP!G<Z,<)*6<<%,G"P?C;"1
M7O6K #,""U"+H;\HZ?UVKV=/W8KB\F,1&M?-/)$0<XG. "[BXII>GI:'L RV
M#FK R.3*P_+4[H'-=R$KR3 ]Q%.IGONCVL@5)<V=$76^V2[2[0&$JPE%=$)U
M7!_!HV' Z[!2-%J)D JUY:PR!SEKT280%.VUC8IIBK.4)J?\B"7)J8CP-1PE
M\K3+CU/:#3K#9AV:#D((:G0A0H<"N3PNS3M,+4^FZ*P23_L@+U1J8U-1S71<
MTAJ!"."^TUGF'<KJ")G$CGW*B.JI9E4AU51 54&L;-XO3=&8D"IC2N+:@EMK
M$)V>4(G1&-19Q>6J0F"1@--3(_(Y'VK12T/(9H8T:850NS3I+*P!4)Y/JWT9
M4V5D,1Q@J%_E>CS,5+L,##*SVH'T&&2>K<U@DBPZ6!%5V"[=LH>U*E^&5^M?
M]>@4DZNK!:E4TB*/(;CI,C$\-[().A@O:B6>TU1U,>%J7;"?/E9"$!1D9\:O
MV<J<!F@[*!K#BA$.:==U3*+KD8'4;4Q2L>H4Q;&W4JHYY-D-V+=6^+Q"ZY6^
MS@7#RM)0>M&HH4(H!K),F4Y9 8M[HY4?C-A*5RE+$X<?XXF&P!FZ]AC,;8#3
MK(/:_)Z"&HR-(U!KK4/:UN8]!S6<^%."&M%M^'.TI UJN3VN50&V7..8LLU6
M1Y@#"[24D N >WJ\[DM<"MN1VYG4)<YD"1JO)!6]V8P1"&YSXZ(W=Q;M3B6O
MS#I"41^U@R8&O/ZNO_>9U8/B4FE@H+S7Q#Q/%*^:1:NZ$S4]%XQ3QCAO,:EK
M#54[4J0EI%(HC+$-6*'+\P4.? 'O= WN;O>X;&2"I%JNI?VJ54STD9PL*:\9
MSD"%[< &Z2E\&.2,V)%C1QY/DU8QM\0<>);J"?.XAW5P30"^2TWYN)B+(6^X
MF0!FL!H%FB")4LS6.RX?]:4!6B>\,/  O%^F#5FMX+[5:RUZJP&H3R>JX<6V
M9J02[MJ&HV,VU\/(>8/#$B'I3CJ8V_4F;:'(2>T660]0=CG"ETF=:O"Y'?2)
M!A3R2KX*:U)CM,[UTJ3&$Q+:GY?R]HRI 9P[:@46-@@MM5;&O3QWETT)[(&F
ME_WQ,AR*A$"0.6_)@=SPPE"OB'@"@R)47F>9XL23(3=I39UN;U[UD8G77Y2Y
MELMQBX6!!$55J5O]R9(N6IPZQ":A5/4@6VTW9$%>6F@EJT_II GP1KQ8_P6X
M8 PQ,]-7WJ0T+H\@$P66Z-M]4YKWBN-R'.!)QK=0W(GZ0VZ2*@@YKS696F6T
M7*P$56:43*<C3JI-1T.9![Y@KI#1&KF7H8IDJI"GA3-CY@]!(=/LE.(D9Q<<
M)G1UOZ%4A,Q"YHXPY@ 0P08C57 ;?@F.K"FHNK2! >Q-'!B,F1$E-)KV^\7N
MJN](P73".V@[U&27:C85NTSB'KX8 !RH(3%L-)3JK+?& &W,QC)(5Z!^9J\D
MW,, )F]UBO.R1&JBA.(4/'+=?D^T&WVBWLL]66\DBPE#]-@!/Q5UK3VE!57+
MDCQKRPHS;C2@20-JM)8M>FV;H/IP9[,9VR.:I$CH!#$B@^D*K2T-"0J[C%<T
M-;S!TBU0,*>.9W@,@2--6FFW'8^9LU.:Y3N3:7TV;T+E.K/V>FLD\A+'-[UD
MJBE,H-8[8N#+^7A6K)@2&CN,RP1\$YC\G_ ' 0 -'NFK) @?^:2HK-I&,F.$
M6#-G.L"<5<$=E[$FY;0R9&#K,ZIK+71:KD5R1DV6;&HJ$8_1H+S$\<4:.9!X
M*5O*5&4^+5:YD)_8,EV7H(Y>[VIH=T95RC4?ZXPI+\0HR R&1(XV"3BIJ[(#
M5820AIN+UDJ"&]8@'VUM2I@)\U3F!+(]B,NE80]I3W4GB^R:)H:!A#O+U8I=
MF3'C1E38S$S?J6-!*6837:TE>@9D7)_W&'G,1Q[ Y/U^7Q()PIPC9*,Q7R $
MP9*]M'%/OZBVX9IWT9W/0!YYUO'VAS7_R).Y]_#$Y__1\[F"\+\_=!L$=SRD
M.T\DR_[?J>?K1TOAVY\L!>1GWCF9629_SF1F:87)F4<][2L(A_EPGFBA8?'T
MQ6#@ M<U#Q=QO(@@U7*QBA8K.(+@*$K4* PK(D4**:+LML3N.O5HCG1D+-:/
M9-_&T?PS.!XU]6B.G=AUW%#SC[J]6 "V&(T6\1I:KI5(EB81I(:4"1RK%>D2
M@A5Q"K^=[3W,/YJ]9(6FN]8GY6OS^<73.(KLPU/3OGWZW>[?Y:Q6["XMDXVC
MX(\]"WSAMJX/NW<*;?L,%:UBFS74/&26:\@AK%*N'M(Q73^D&T7+KN%ELV07
M+X1_;^Y=>)KW(/'2W21>Q$L,PR $7:)HFL!N9VG>322WLXS^8I'_P?EWX1__
M09G?X_T[/?6N0K^+,CAWGD1Q?O0CV[(U^_,?V=[VJ\.:L>WW<PTLM=[546-W
MHW1_WX58ILK>W>!9I$0R98K$:Q7L=H:_I]$[F*9C*[SS(7A40<J'2\7#"'+[
M0_!'4=UMYCRRDU2++<(!<O]3GH._IVEWXVF,M="QS(OAVZEO'[CG$/M_5]A_
M/+K\><+^_6\<^/^TL(]<WF'IMWO)T=[PEZ<S]\ZSW'.F.8K@R-=/W+:+H\8/
MRXD6)XMI-XYLU[<N[L9 &A?"_PO%_]F>I^8?2*G@!MACZ8X]@NO#8$ES85CQ
M;;KKTNP!W]5C+<X/(,4+BLB%\%VH_N#.C@Q*-+O^#A;XCB]A 5<'_B^TOR[R
MUT7^NLA?%_GK(G]=Y*^+_'61OR[RUT7^NLC_SQ:Y\QL?K="\Z-STW$LNOO5;
MQPYXBGI$5^JP?(LI;&P4"L=R+3>,=AQ?* 1A$DMU\L!@.#JP]U.%'87]A3T%
MI%#0C/E4D%EE_<63/$,=F .BPEW:+[Y4V%B_?_X0USUPH/#GM1.,:9P4"AM=
MT"^9H P"_2>!OI\FT_7X#:!_LNZM^SMVK?LQV"#HWW?==X[T'[Q-<Z1_Z;IO
M!J$)^NL]3\W 7/<_"/I_MUQ8H+^S!?I/6;I6"OI? /VS_$7@@O[-Z[F!I<T+
MA5W'KL<3RQB#?A'TCXT5B0+]"PN%?<<Z1_7UH_J)E27K0U'1-(_7W[)WX#SC
M00>06@T_P%FI;R7)H2Y0BA:;!Z@HF&IA7B@<.?-V.W$MVP- R!6D5JD<0B]
MCA+4_WKS3VQKW1[I_4S<UMG&*9^\<^R>Z*(K"@7\)B";9]TYIK^H4+CFR87"
M?;]VY]A9_U@H' ?T=O6GCSK/*6M[.>K[.UW+N& MT#O:'R7X$]I1ZUVP9G>'
M> [01[Y?\\!:;D;D1XOXP!SXA'7@T-V-^"^>>,_[>+!DV59LA6!&'UB9&SI
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M9S079MZ]4%M>$WL5OMI7^9[=J\T-41 2S/PAS@!E>O1\- JGQH5#/F< WD_
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MQN-]A.U;K, (L=)LQ2X-N3<)%>]'G0(M?+(!?K 1TNY.=T7.WQ3<OG*<,*1
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M%]0-_WHKV+5?__ZWH5,\8H]?OVZ%?U7LB4M0O1?J;)+& +AF8(Z/U+XEM?X
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MT.' \R'F@;FDL$7@!Y]0!Y.GZ4K^02E>1B<D^<Z8O;E3QO4KII\!B'Q/Y6(
M\LH7(%3!+KKB[-5Z?M$" 3/GG5W4OLK*IV<WCAVM;B'W9 \T(V+P>Z0 V58&
M@"PYQ\*\Z2;(DAT#T"$;J\5/0F,G)C3$D<[0&R,3+^M=2]G#,Z[?>&O@81[W
MM@/N93W1NNBLEU.NJN/O7$#*^[KT[<BQW^#+"\I-Q+*/A:G.F^Q[.B%KE+^8
M1BVA;- A8O+O36%)N^#']6(O1FOXZ+-WY!9*56Y<?AH@.7*2R^-\R,$B,YZ#
MVP@8Z0:3#@2WO79C1",J8CRJQZY$E!_MQ@"$AY[A8JZK1>#ZKU0$N("F6N[=
MUH77LHQ(%W/!HQR1\ZZ(/ OP6GTX [" A9V8'>2;T#BU.*O)%[+CY.7I!\YI
MRY#&'R(_T\\PYV2N=38DN#%BU B?79%88OR7K9"+0M%/_?7<>>+#GD*>7C0V
M-0[K-LTN'/0[T+8!#%&JL+H47=7T\(<$)IZB[$3Z31:(X0FKT+MVJ%4#?AO\
M[M^=.]JSXY,) !RP"QC%*RSY?=0#.NM[8&]S[_6S^J:0Y;Z_L4T=,Q$G&HYZ
MM8YTG$TNVB1!VSW.E]K?1N_I\N!J2@L$ALT,[2S1G#AP.YPS1"$\[]>AIKH^
MR'>*[^3/^3W0G&=GQMS+$ZY->*X/N1/O$F'>7I.MV!;4TA/=VH(GZ]5NW^/3
MAU'A+1$HS<%O 26^0C8[3-GH/$LC3JP>+IW52V/KKY+\H\IMQ-)*^F5"J*NO
MN/LM"]*B'4M&^NFA4FG>MTY7,0 (@](_XAV<9K.<U7?.L60E5KF6A3G$!W>>
M[,R<6B7DKQ(*(GB_ISK$6R][AUOR2X>&!_&^@YXU\NOU+?.($,[[#<QF .9
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M8N@WF[@T6J26]*@PTS-O/*N<YR@]$K00S0#4<#8^K1[$-HOHOP1$(14S80I
MPF 65Z[JVB8+B!_6Q@]Z!3P[6=L)Y:Z><+!DZ<XNF7ZPA<E3*)7?(-[;.NI)
M^)YYZ\WRXW\@5$,JVAJW^RI_ '=03X(< Z6';8752/Y(JBR>H\$D^JX=^*_Q
MZRL[BNS@ND]Z#K6M*IIP[<='.W][):W&-CC!)?IDTPP&F 4C[^\8BB#A G-E
MS3= ]5SM&+P0O,LP5'BSV]NU>$-;6YGWRIT7*;T*GR4V#J3>O?>7M7RJE?8+
MMC GRS(-)WVBWL=KKK'2-=T^UY%#]Q2H9'#OTO=IB;;Q5+9QH(9=QDKZL2U>
M*_]4VX^*VRFNPX4_7E0@[L*&UL:!.&.T,*R]FQ8)Y=V$/DU,O_>^:UY5FM Z
M+:]%R5,E#@;K!,YO-U)47C'KHF=;N7HK^4QNV::-<;KT2-O-(NDWQBUN\2*W
M'>[;-4Y&'7NCS>VC(4.?4@TLY7U='I&N?L'DNR-;Z6_[B\>+/A2PS0O$F(R+
MP3JE5A'3"#J;]X+G[ZHA(R5=)FJD=X_H-9SG''G$P<\/_I&<R);U_@S[MVOA
M/0,J)B3)2.KE7>"DNFYR&Y0S0Q 9U9#=LG%S\<'AV2<A52KK+Y^^B=(%7)\6
M<4$MO:PMGPM(!C>,*;*7QFYM3=H$Q\9&<R2A1:Y6*W ;RHLFF=A0Z)P+>O"8
M[J7=8I^$(7NH*15B* -IQWL*2E_.X3KE9%XZJ]<_2&<?7&\N(N0QMR0FQ))6
MMG=;!,\;52'MHQK-GKOA-M$0A"1:GQCX?I3R0ZARI$DM1HJP?9,SXDI&?N3[
M./#],JA"3+=5YYBO%_>;Y,W9]IB+ F!+2^F!UP!^T8D!Q'FJCG".K."]B;3A
MA&'5RA1=D\*=[]LPR?74!SV++^4_%.#R!6(D2D0/32;W"%6D<(H,*=R7ZS0I
M\]$(>(#;Q!$U4-6XD2A]/L7M7=S2:Z&S&IC-O>U3S# /P?7L@/V=L+ K':Y8
MH)#1A_#3D100&/: /\&,6;XTLI("IH;>L"X>29O5<)<E5HOD<I05L3Q8OX=,
M7^2\U+KZ#3JA4:MFY'FPVX3HS=^X<UNB>R79?NC)KRW>^O[J X@Z8M2.!Z=,
MY1:ALWEZX5<G@!%0K1;N@/;NDS[9QB^/:[\^\K[ZX>B[#C_:^C(WU%&LY1BY
M%K)TJ]/Q>_$S+RG+ZG6,;A.">AX]7Y4U$>$0D2#.>1BJ5C0. I%"_\@3Z4-X
M&Y-F&0#J%W%FZ85.,TNO*,]!<^A%YLU!F%+G ]60*76F8331]RW^R,WM2+K.
M/S RD8LF!NP_GJ?&N3( "3"R.1LMC;ES[+#>C_:PW^A )H^X;^$+48ZHA??S
M^R]X$02%.=AZ9M QA%GTEXT8 ,^>(RU$!^I8D &8KJ)Q5;2(A.@,:UTD"9KA
M9:,5I4+%M8>QRKS^WEG2AJ.;CY,N2YRNO@ 0?0>)1^$><9&DG&)A+MFZ!QWT
MRSF4=AC7#_CV,"H]L%36",-9=-V$NF]>S[HZ\]>-/2K/$IV-17E'%6_@R4)Z
M24-A ;CR#ET!7G7%S-IC>[^>\P)7RT)U[S  G0#2R'<5D??%SXKU@ GQFYK/
M$9-V=^D>+?9%GOQ>X0]U])]^,ZM5S'?=T6I@ &37UO_HAARHQY\2&2I&N0)K
M>Z1U ]K3$%[^P3\I(+/ME5]_+F3 ^IGQZISQ0VG5!4=.8XL<O>VB[0Z*68 >
MX3OIF?LBXBPD-&\V*F9W I*V99P)^,?1!/LLYVS?MV5N3M?C2:0+[3W*309,
MD"-1"DDQ4_H%OSR%W!6G>4 R*[D:'T%K7P+G(BMTU11.'3, O*^-@7(%TL97
M)!73&EX5+%/G]8@;];.OD7R8UO$$X*7;+K)&_O",_=V6)?+)O&(2S+X:;Q_F
M6.),O#CG3$YM\K>J[GZ3W+G)?S68YQJ\_ ERK3O#SVGO5F$%TTV^_,MC>%]W
MW1V:PO/3%!,%2[[]5!2[G&%D_:YW"\(NLZ>LF37HLD827#7! \O?V* Z=B!&
MXC2>(LC>W_YKN"TRN&S8_HILY.O4VA@O*&2%;G7K 4Z],VE$5__BTC.JM)R.
M>9H-^8IKP.XEM\0OL>O]B1;B.&BR-_&P_PP:=MW[>+%)8$;(%#4[#E%D^FCJ
M4 !'U?B;KLRIEO>0$^M?)^E]H^@)%M" 9;\F-]H8M$[P^^90E,Y= ;K^!+]0
M,D@Y,CM6IM_;X3HUTL13ZOHB--VD(=&6%.,.H:PO0&LQ <$++"O]TAFI8WZ5
M1_)=!S^H05P3S<]CCKYE"845[EG_0/T([8=TYO@YD)Q:IYP^)-,X)ZT>/NUC
M .[&DPAD#K;?>3'DC+O.(Y'5!9?3'7.OZURV^OQ_G^6%Y/];%B%0Z.S6#( $
M 0^F03>8= [F@5[#[,WQ,D5K(>QHGRE:3=JI^DS16@9K1:FR7#:%Y ,1B'\5
MO^LQ=$^J)I[2DW-Q^/.H#T(PH-%P=.?>8W=WQ=BH9Q^X]=EB%CCU-3B_C.^1
M7(#1B$-3#5\&(&P+25>%P%>%^3&=BR7/>7Q^K-RR3=WPA]*=MOBX+G[%XL9P
MN[$AB:;-$W7Z?J!\2:GC008@(I?TB0'0N=0#(?V)B*446,<CZD-FX$<O(:E
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MKJG1/[8Z%#O(X;H>^<>E8HYFW:CHM2P_S@KN)MQX:@&O$\TO&'F#&-YD^C5
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M-N*H6B<TK4?1SX% >+$69:2;W,/T3->U_FEA'QID.')[EFA_Y^V8.2L1/XN
MD'.2*<=*K=Q%XHQNLQ1I.&)R"&[:,#]SGG:^U/< H"%(1X0<%41>2 _&,BLC
MJO,\F/$,['"E0I/*QWT?/6EBZ=]BV+#+G:\AJQR'4OL6'\9ENKQQN&5*3Z4V
MS5MQ74^F\)L O6'/*]=EJ54UPA<^^CF;)88$^0KCC%=;'>V%;XHIXQRAN]=W
MIOQUL)[0F&Z:FH\6IHC)AI5?OM?::O1AW._"#7P^I?/DL3*+>M;WEX!K'Z(:
MTOM5-9&'TTAYH[&>$$9_N&\_H^[?JPGFY'?,G.3C+(1I0.USRA$V5T;+/;)N
M4%S2=MY7>YIY2O$HV:H6]1&@W&3#A@/J-?+BQ@>"\2)%WKE6*_7R=QCZQD"\
MA>KZ?HM+I\&SJ[P5-UBJ^.GJ<ZT+X_*2A=]ECCO)55J4 REK=\'8B>S6I*NR
MJ<8)?:+Q2]T%;)C"U&$]=?36"B<&V*ETPD@&=-*<*1H!C9BN#'H<^>?5&+]^
M:^?^:> .@_:?-C0')J#47;"'UE# RD;8.4O<*+?HY/92/-+C-AB];'5'2TF(
M!VR[8*2O_#38HLJ7$+CE>/>>\[Y,G\(5<=!8IX]0J];<Y#+V",D7<R\:LZ&C
M+A?ON"U&+T3O%(.NVS&9@JR#F";,T>A:0CZB_J3LTZ=)G75#]G>_L0;5.H1W
M&A(<P=<!@SSC@@/0Y&C1D;4>5&U1E:)5W[(>T-1<HE/U$SFH+^]G2\V".G#[
MX/78W]]<DIM/V$,H+7A]''9U%RJ"GA412CNJ7IV/29 CH$I9#O4G3A" $!\[
MP2U"!;*2!-@10JG,OU@XU:>3$G\Z)UB2/J6"X%*T_UE1Q(J6'G ,='/&S_3)
MI9671LZ4ED:FQFI>L1,.%HU>T!8G/".,5R .)M2R83\F[5S*C*G&%3;I*F];
MPI5&#_F66'S9CD2%*2QX6;XQ7-W^F%XY[?S!&!=JDT R5N@\B=Q?_,YY+9H-
M$]U)@7NP'9TC2+J(9VT0YA"FKOIXN>WM5]@PT3C+BN?H=E'']VL#IVZ[G/"0
M'BO:@/R>>1KRID7T1;H%);H.%$;MH8^I4V8B[5(#U(N&ZO;J2X>U*F_Y2GUC
MPX+>54/ _#MF$L^8&6##(@;6DASKMF;DCIL<HJQN?B/J)O3@GVQS29$>Q/&\
M30TTFEQNE*U(Q=^;)7XPJ0&H!^/J$=N'*MW9,/00&T8=0I#.R 4 ZV)>B^!6
M$1LV633+AF5Z$UD<;5"&)$]@O6@AS&XS@9^,U1 Z'WCV$-V&#;MI$D%824"!
M5S69M\4HG> [_$F J$A@>F WY*ZR85^\,? 9^&* +AN&&)@$-=4APIF@:_*%
M$YXD  +24C3B[@7*/?'A6 L?/YFIN[0#(C7(\GU,1WPWWS "Y)&'?IB6P/I8
M:3%NB:BKELVKIG)6NM1>Z[8X^L0M_LH-Q_QH;/0)CK"!&1:FK499U4E Q@O]
M_(1Y=+YO/'*M;(OOQ.0%K^S:QQ=<]>])DCUU\:VUYM4<U)C->MP)6_!TC_6%
M!963ZRK^66_#HQH6YH"55,$8==_LY%0AX>>=V+#/YA\\-==SQN%'A]"W*;*A
M))X]HT]R36LS+!1=/TZ'6Z.8[OX.)K^(E#N(D]I4CAT9H,PL/!M5"/]0_F2_
M;Y>CB_1>Q,K0&:;#7#RHW?Z"8-S8!\FO:"J\K! P>$K'93^R(R'BS[/FY2G.
MX#X"&W:>FQ['AJ&*V;!M;4[T"NHV4&L"\>,9Q$Y!#8T(4<UI?.+B=N@9"$R>
MP<$J:#1MS34K3S9,Y!@T8SCP0]VWO!\)AM4!_6-*\222>LBYWT^_>9R&<66*
M[HNH6@.Y?2F_$"%L6 FV/ER1I! UU*.GDOTUP.1(Y+56OVL\MU-.\KI8>BWI
MUS_Z_EBL\.STIM3G4FGYAL=G B/6HE ^>0QYAB"FPP.1[[Q$G"!PF3<>&[.P
M" TW?CI+-ND^)U]VK6DEQI?_L ?>)#D$O-M DGPLV5IEXJU=3$Q 9%Z@>]U/
M/78Y)N5PE)461(0-?Z2VYEGE:D=K*9ZT6GKHQ+!I+(_4R9?>,H]1%8</E20>
MXGL8=8XIM0TI!8$N;2X-4/2(0;6&YW[%:W&4]<AP*VQ[^L=\*SA6&/M+:"M3
M7:X#ET#_I"&WZP[>Z"KZLP40I6:S<^K@"56>C*>?=E^*Q17WIYYP]"^GY$R]
MW.^NYV)/[-"<1N4;T2&(V7WI4PJK<LG(+,:Z2R[F-<++T> M_36PCY6)GR4<
MFGQ.8DW >UF3]9FH\R5V;:LW()F;G1WC/*QW_;_[@9^#M/H?\+7Z'XO<-OW9
ML-7S.!8Z#HP6H! . 5,.<(K<KYW?GVN>G5U.9Q["UY5;0F(NL#E1.7#,\5V/
MMLT+LZD2C6=LF XN4T1A78)Y1D6.]==E I,32<'S_,,QE-4D'WW4D&DXBBH!
M(9[\MH]HNE#<HW7&08B_]""3W'LOE V['B['ANTR8$*7_TX"<N4O&M#_O,X$
M!3/5O:VZ?0?G&<H>&JC_];>R<4?0O!0D5KJZ(]<+4;?=6'UQVFK^_@.)J59U
M=T,CC2*M:MN6](7S>NEB=NH*<V@D0P]Z-'S@4:95CZR<ZGX\)  -IC)'7Q=N
M/R?/BTJ__#3_,>1-E$?)'2:.SH8QU.A9-&OZ)^\)Q%$[?-I"OY?[Z>6 !9'$
M_ ;6*<7:VI-[3T^\X=A6QG]&C*>C\A)Q9!^&\H+>T& *O;G^0DN&K?QW<&/*
MJ&W8)M/,T+%V7*T)/,;B>U>Z*!B /Z&HYN3VC>R9%;Y-]*A(SQ\NH)^2',]6
M//LN[^C1<X81Q>;GO2VL&0H5Q'+FV7\[V]+C,$%HL'2 ^/\R3L +L^VH9-[E
M=&2A>T:^W:DZY:O^I7V? W:_?:^%)Z[\::/A>@"'E<&U6]2TI+SA$4N)P8VK
MEQV)#ZO"=DE;E;;L+YM*^7K-!=5YS9<%V>8>UA=Q"JX9>1!]M3P!% -E\I1H
MMLC1RF+A,\#8NY](U(84*HD>'-DL%%?Y0(B@@S+=0,F R++-SQR).CQ84S/$
MR]RDJ#G0!SWP9*.\&A(,OQ]L&&0#.VL*,00PIO;?SR(9P[<T\0V$[=62G6--
M4E350%##"]C>XF.=A^?; *NR#8 ?L*V#V#,'.7@N(J[N'VKRQD?_83NHO=(
M$BU'N6TZ8?T3/,7+9D>S<./ MB$R66JKC96AT$G79L/LG(/B8\G$H5/BO;F>
M@L.)F_K%+L,Y@$8,<Y3I$CQ.[YO<.V6LJ>NT86;ZZ$,P\70(I?)\"(T>. WO
M2)H-7L4T\U9.;XG$01-"2Z'V+&#I9VFORP>8A^5KURX[GITO'O(?N&Z$_#,3
M)H"[=;H932*X2%$UP;W.DNH,G_GO[=^[;3=;O^ J/3C>T/^"?#\77Z-Z+]J[
MTF!^+_@2X489._]4WR&;.'T0^H&UE/6_,TG\3PBIE9&W5Q%VR-T+%AI.E?(T
MQ^$R-<M><IA'<\) M6_61AWA'# ^T0^GE($G(]BP/R4G@.%7#"SO5+_GO='4
M+7D2'3P_U>.<@IW!=AZ#J#J%;Y:B:9MH9IIU_N?I\;>H[LV #8U^YI7T,:6X
M\M6A*[\Z*V+OC_BX+J(Z#@#:*&YIZVY0T.M9_W/OXFW=;.3;R+)'UP$]U'NO
M/,&6 %]G!*N0A:K;4D/?F;<%R,WJJ"AHJDU7Z.)D8GVGT +\B*I >IO+1,YC
MX[*!)?*DM%M6K%C2^*YN;EZ=4T%3Z\:[ '/)M))KB<7A[N+?:'GSBSP)L662
M9TPIGD(RJ^0FUZ2+J 0*S3>H-<^!_Y;ANLN\V/! P<JT&R809_U!_J[45PO-
M<E\<<&\.M,G ?P/&4\T]:WQ089=:*.;;JRA%8Y74HNS3<Y%:+[4+/Q0O.8&<
M!@>YIA[N&=HJ)Z2M,FWZ?U!SDR?;\792"@O8V?T>0@M]TS=:=&*&J)[(KM##
M.;NS1)__G+LE=;Y67^6@ QDW"( \,521\>I(YV]>34U$DGC<\V3E]/(RQ:$/
M]LJUGZ6X+P[(^F,]\,&VV:[2.*Z/!C335GN=U$VK</OJNP.R'2Y>^Y)ZN)6$
MI@LVD)IKFHO%4&;+Q84^7YIOW%MYAKJO>[;2X[?9B(9:V,!>@#J4.@FG*YM,
MC,9$*P4R>29U[TTZM\:_'39M0JH>T18_[39KM^![A1F;7&WIY1IUWK+.ZO,O
MXBP==Y=Y_=<#QU]5WB9,I7%?;<9#H-9"31SL-U=O\LMQ@-(;[I%I\1ZWDB=B
M),##>WC&9>$[O]9"6K5%<LCVR!Z+@%I]FK+6.<U\)M&8.;A:NE0O$)9%SC-X
M&>>Y[6&E=;Z_.!_UH'G_Q9;+/1>T)M6E_ZTU@FMW!9\?JF V'&%+/-*<["55
M7QX7)/<'2JALL)O&-9_WQ-YZ%PX,O>3$% &UJL!XY"N^I4P7&Q)16,>&Y S7
MX*@M\C2=ZUC<^Y"G%3&;M0L[P=-+'[G1J"R=%NV.4KCWWH)@U=;!Q.<M6JO*
MAW5(BFF;G[2F6242H[;^1(/<_)"8T1-H>G1/I=!*,YMIK\W&^Y*%?)N%/FI'
MK_N*ON30GC,2\LM&#G[00_VZDO84=:%11RC(\T/U5+G8%';N;HELRIMZ39X;
M$(H,+T!0H00E@B1+MV$OO@E,W Q,3FZ#)^?S=&7&^(-MEUD,P9Q9@.]QIBNW
M@;8KK";")ASU28'%,<'4_YE1-)  Q<<H!-=DF5)B/S)=#HS<\>JESLA]4L.7
M.^D2?,TRSG=+*HOH=B1MLO-9LZ^1CW7S16!&@1V__0Z8LF&!-NA7;%@RB@0P
MUG%,(V_"L/+NI44(R?[";B7YM5[LL-3#@1QRJZJR(9M(NH=G,WY;#(3"*P&2
MN48HSO'^HF^P8;<)#6S8YCR"_AU1G,^&;;%A?$Q>Q QB"0TPZ?_[WX?_@>+C
M%A7!W(.:\K(47,91EE:PJ'4=)I(-PT"924@*>#*1N@@& \%LV$HW0#4$')^R
M86L@G'X":$?D4:%_DP#Z?L)/2KG4*&)BD'B*,!<'71 +N@)!3>;5JY,#+(A*
M!=@P(I2*D#+ H38V;):)H"BS81^!)Y#HST(71A$&(K<A^M]]HO]>.N- RYYU
MYZ650U;#KZL,+M;*\A%6Y-?/5G?O+!J-A^)V,2T9U\ VE1GLI"[O6OUVZFR(
MK%QR<1E,ZY&#A5;]N$"M[0A&<&,:4'2Y.]^IV' O6O>*DOOW@=]@P,3'W@"C
MFPH"NNI2UX3I2O]8X9:,&,^"4.H]+ACX>ZWUVWN37QLL^$Y]0P$?&V8%Y</?
M4K;6KNY4D /43BAJ/4+9 ;5["I%DU' $:;)-CO5I(FOX\]M->5%^*'R=G<2:
MTXNKY]BPMQC$U.I.JZ3'E@-@G*D)GY!VLWB# A-/_;TT89J>,-$#6F/J]-0%
MF=7 G;\I$",$U#X!ID6(_(1E*(=+J[C#ZL+7K="EG9G??$A*K'K$^H =*M7+
M HJ2YK@-,ALV?Q]QE2H/JKM!F<#.JM@S= M$@"N:$[-_4)1;J"V$)0*L*2%N
M_S5 -L) 7%E[ )AB07_,^(L(S/&@BHR8#)(-,WR +K)5L.G,BYC29\.:Y5IV
M*HZ2<.C_G?8%_]^7/&T10>YKT% ;=#MH?DS@VR;7?/E1K<(KS+ \^,8JL&V
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M<O9]7+ZX].7;.S;,0P!E4&OZ\U'!=T')Y\,H^B$75*AF.S7@B%=84I6R4Q1
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M<2J]@OPCM[NLW#,8RGKQL^%+E\03I1-5$X+I2M^?N(9FGOS>IS^BZL Z<8#
M\D,BZCE*'!VP3#8YQ0/N$WJ\MKZO??O%W.[UA8]:(Q]*DA6LPPT:U].TGHHH
MU_S2UIPW_R*TY,>636,6,]!+#BPQM@.GK$F15K;%[RQD\J!HN#RTV7DJZ)>G
MIX+WXW\N6GA_F6OFI\YW*3LFH+:8:\PTN\]U#YUC&,26AX4/SKQ3SOG<8.=Q
MN6K2V5Z*$!Q(K?R+P#+S3"-.#)J:3*A3*5F*@R1M(2/\+DC:HB7W9,W;YL#;
M-T2P2)YL,WK7;?&G/P)+[T""X 4G@RN$:".G3PRB"/GG]K(C(6Q'BDRW4GAW
M T.%-I9:*>W^<4[D9/%IO>(7MG+';]C4.;M>?LC'4HN,]'M)M@-+I[JP KN\
MW%X^5%=/+<IL59TK'*Q+T?"J]K0_-A)4&33Y,$<^LSR^,ZQC]XZQ.4>VW#&:
M4 ^6#-ISLL$ R>WX7KP&YQE>_$<+ZOT(WH"M#/F^KE\W(:?,$:XR3>.K]W<:
MRT4[FFT-_F._2E[V0HBHP"U&&ELZ\C1COC--@MN&KBEX#WG,R-XBWX;SH8:N
M::7F+W4>MH6&=[-O&_TIBI#U#>#+V!32+!#W^ ?_(HK<,UO"WL\#EJH8!LP<
MQ'8>K!"N'*6#X]>). 8AF&7"C/NJZ_N!A<ZO=M3Y]+L>^Y45[A?H+32#O4>$
MSDG"2,S345!X!UJU11+9.*'R,$>Q"*)UC,L78P7.ZU"/D)" _4(IGVY^U7EY
M-J;ND=2DZ$8@5Q1)6;NJ.<7$)0K;AP>\-.N%T[@BER L5\P#89QM)ESAGT1!
M=! A^H[V_6 +I8#]$2&VHUSIJ:EIM_&\*_NLC/KN1+NZM.K+69I3G8062.UH
M)/<SP':*!%PV0^P(@\(3UO3DR?.=JC(.OH>/^Z^G2=>.1O_4.OM>ZOV5%9>C
M+5.M0*!OG_M G4YC"OK42(5?07_[5)OXSV5^U7NMA\ZL57XBPOK+[<OQ:.E:
MU-=PZGHG.E'A@*K6*#K 42( OY,1'L._\#LI9^B71N/[JC]/*MP2LEX<\HVO
M?II11^*2"6_3EA 0%ZCG5(+>/(!LQI2! WB Z/H%AA]=["7.C/'TCG79+49$
MDLW(LW<R>C]R75G'"H^J>/[NF@B1[HT]@G8)\_2V^U(^X3RZ9A]H%G91*?+5
MJ)' 4\ M?GN!SCQ)&$]6-6!HL^4,D*U\>[)%>DCF"+3<EF_8?>O#TDW;X+EW
M'X9WUOEO\_/+EM_;>N]IYF>=;^-H/U(L$7)QA/66Z6+0$',86HSH:$75F,0V
MJ95$\--&*T)V#1:P/-YF;\R[9$\A(!9U3+3FE[+BP=XWADC*)X UZ'M(:G*$
M#<9Z#&((HG4JIQTW+U!J"I+":6@)SZO2TV [VF]GT96@ U/%OJ":W\JWU/UX
MJZ?J-!=__C7)TV.A#DKGU4;6\NQM/N3TU=GGQ29_X@%33IW!%NT5KE3')940
M2(8K*@F=.<>I)V))L"9(5V3912S.%!#+^A&JFYI2O+!^9V?2RYZ[AYM;<@H5
MP\K\ZA.G+I//']M>$,P#GD2=LW@RZYB,AIS0XX5<8>-9@_NJA^KA=&C1==@"
MW0--T##Q;%!=4GIA>O.P09!#\4CGP_X=,L5-8_)YH]:_>X&TWQJ(0PFQY?B9
MY!'P4N57G9DXNA_48S=@;E_!MJBJSPH-9-7O-:KV:@L^C=T=\UQ,9_N5[:65
MST(]YH=7(QU.G!4=DQ_H[6WF\Q%"5> /(-Y\"TU-0;]=7D)@4N V?(_AP;2#
MQ+F;&-KW0YOWC)T=7>5<IO;/-"JNF9G=IH<Y_)9KFOY=W%[SZDKNMMYKBG(L
M!9K!'[E0$DL(0:AGHL"7_^B2N!7M#W[UYBI0Z.,L4SR9 M6"U2#M" ]H]^0!
MLB2F-H'3R'E?W'.)!Z!4[]S-^><WF[1V\\^3B=_>89%+55;F#N(#986O7*T5
MQ26=;&Z<>A&%-FM20Y1-X33S !^T6$0F\SJ28,*1O;"KI<11-IM;O:9X^4^K
M,+0[K$;6L/P5WU*T.DU=OGZ(-XJ<(N_;X[M_O.]0@#(1CD%F\8 =;O^%YK?(
M%"XX>?C);9JG=#?K1#-6_N<=I^%?OWY5U,4;VR<ES$JWJMHG7+YN&R:5L/F+
MRR97\EDG/B_$<06%.$GF"#H);N&D-06P=K"/,K28227PA\%)JXJ ^(H;)5,>
MGL?"@ZXG?MU2[:^A==-$__OD^W^85W?QSSHJ@6VFZ" TF9^I S>S4/BO*,BY
MPJ1G?@;]@!Y*D(PHZ*'6U:=HQS$-\Q**H\68"OT&OR*FA(])=8?3[IYAIG,0
MHDE[]I<PYR(PNX4'B!FR-%@AM":\+ *W-2QENJKU1&@<'>VSDGGK5O!O]L"8
M<N-8X\ 1U"[N* :RKS!CIL!64"*IE0>HK#DB5$O>0D"KB2!NH?OCP_$S?26?
MZ]/)DT6C-]_;)WD\GG76:SPH+F=YN3'&A(I=6D24OAHSTW)O)HT<R175H=ZU
M;W=7H>4X0R517(GB^RWJ3LFO<TQR3$*,/SS8\_WBD?.EGFUV0C_[RLH\E-T,
M*M]X/]CF;6 T^,[%BE\KP1P0TLPMH6'D8=<>+]4Z!C;:W*%DT=1E-7*I[O >
MIEE29.Q'Y0S;CZZ* E=D_C'B>XXQQT]BWKJR#V"1;!+% Z31M$"P':D71>UG
MNBI3\%V<6":)7JFEB/]()"4MC7_&3=JE_5+:4'URXX9@D618F*G-]JON=IH7
MY8[\M#LL"$10V+)FS&,\X,$:)PF_ _\/&GI+I/W=QT4;>TG8%JS&3S%5:KKT
M>8!&?Q("&*[)MY/&#LW*$5B>>$0$: 0%.:;)X-O14 WZ+4C3@,PMD#KJ?AEB
M!8S?[U&M%6[_O W1 C.Y8FVX_FY^(O1N^'&&'(&9%H=@UN+=[SB666R6B43A
MS0S#<Z7\<Y))&,B!!\#NF*UH'Z(*V/Z=)<DV]'JVCD&RVOUP1(#[:;<>9YN%
MWWV.[UG'?9H);KS!=AE%XL"2>$DR#@4Y548%0($]%KM&V,:O?G!WU# 4[K$#
M: N;KJHJC>E^K:O@O \6VSE_ND0YPQHH"PI;W_/7)>,HU6-L^1LXA^<+& 60
M^JI@\P>H)>T5N?_5%!Q(/2M/[HFON)SE;G^[*/NWK9[X/\7NMMZZC:F?MDL5
MLS!@VP&+G>RCG-+:Y8DAIAJGQ+$=E2S/553=SMB""/S >S3446Y!1SM/I8Z3
M9Z<H;<TN[@S6=.&[?L23>&'$#+7UAU(^ISOKY6)VN,(Y/X5;7RX4?N1;#1/2
M&6H&(@R6LB T5U2!2HHGQW4Z3M@@O'0^M5Q[H*#O)&00S57L>;$P:EA;A9YP
MG[%/^.7W4#=HF[6/E?2^MH,:$RUJ$6>X,B1@L4"(!8ZCZT,C\U!UM[W\,N>/
M#RQ/I#<JUR0GSRK*5;F$YH=8C=%S5XZ.ZF$ON8D'Z16W__.\QT7+3E%QNY/0
M9T)5#UO&C+J^1$=@8QFR8<L09]\0:)7)^.U02E'Z!6(23BYXU#TO;_S-;'JY
MONJ<T:[!J/V?+8^T)E/=.24\X*(8EFS ;.(\)5X--$@8@.^@QM==QH)GH&$O
ME,R;V@\IR>>BU?86[/-7EPH6L-%?HK?/&J]*U+SY4:!2PQU@;*X)\,8V&1!N
M7Z_:.?LE^/+FJY]N:I9J)73H "Z/ODDM'D$I<@<(D .:+#K$[!DE8M-@[32Z
M:PG.@#&6$JI\6&/&]]Y,I?"6P*.,D[<"JS__M!WU+XJ>V\;8EK[M.W!!'P/:
MLX00,]:!XX&=*!GN878X_">,83.+[G:C8K?#O^]*'[:8U@F,<%>V%],Q"I=G
M?BF42OE.$#V?\EIH1-9)Z#[8AE"^RU@XW&;I$!7]M8<K[\?>B8;N3U"0<D!$
MFVG"!"?P V#(;4+-GZ';D?B!&HZWGV_$9Z$X6(@K'$>]J\ 5+A%B2]7,*/1$
M<GS;I\G+O?"]XA\ZEVZH#"U6+QY8*2YSW(O9XY>BB!N:TPWJQ?[!S[^(LCC(
M0(J?&N8GSC/B9<<D0A6%'HD E/00+M*@$ROIL> NF5B.%Y_XL?Q,4-<WVS["
MX"O&**[W($7847?6[.UA#681YP&:5HRF/KV#$'P65SZ-:< <ZV!AQ<%V#TX"
MDZ#],56393..6YTBZ)B9#Z10(F8)(++P%9C$,L!/;V!BN:H!Z"I7.I&V+%@9
MS=:22*CXH6H ^ZA6ED0DS*1JIBX\";Y<T#]LS0-T@]ON/[Y&WUQ-O(R!M7.Z
M2#&8VOD4,+B2O,)\6 -G,@*[6Q1JH"]Y'=.RG@HV7U8C;Y_L"\ *Y>EF&CK$
M!13?G02 ;X1R'8/V:1,(DZK>G-?F93"X=G\H3#&48[7:?-3L7F"XO/G$;?%K
MMTX\44Y_VY?^<!=_)J<<+\@#.ISP?2AII-1.@T^ 2.:C7<:A1W'[. U,5"T/
M\..T= =B:F^;S:[@B";X_H7&8!/]FQ:&,))>!&K_OEK&]X."; .(GX9BRR\?
M?POUQ-3:W]6VK"8PW8:T(_0N'4E_GN'@U/CP&>Z3W>'%U?VO%O!J7XP_:L=9
MC>DNJXXZY-@'WLS8YD'(BLZLA2(L'O&M&/0@;IK3221[6'/REBWVXX?W_O3:
M#<LPS$XR7C;.[#+?HO(AHGYN5-';/[8VW-*(H9V7W^LKUJ#L<4@%C3 +<; C
M,) B$$:$W=%0,D(N\F!:(>[8;V*5Q02GDBF8C^\@6!C4_"D(WUBR:\!NU)-4
M.9KI'<KVNHFEK^T-MP-"IQTLBP.53C5>SBV(>^WAY6%[JB_);O3XM>W;]V=(
MFCL)_8.N$V++@+/T=?I#'M"POL3'<@H Q?%J@07;8CHH6VM!6=B&Y7>,X?)H
M2U[ RX2=#VR#+VUSR5+6DCOS77F]A[45 6:=%@W\)TP])17$8A$IZ^66.Y>5
M<':0\9NDF7>_S#54\S9Y'KNIZ58A$"[QUD-3JFV31]!E\T*-$TMT#"905>V+
M^>'M(8$;W_,3'7;^D_O[N[H$94HP_B.S[!$?Y/B 2,U&YNQ9"IM%R9+!MKT\
M(!@K 1O0&I+85B%OT.V4>!X@ =8OL<WNWISXA7%X]V!.Q#N6,B?_651-X%NV
MYD9.&DA]RM7GO (O8A3P"/=O6*;ON\TP<6$D+X?<F,W7::__(+-@6)3NX'NM
MXKG?^:[:MX6O;MW*G).PO:FS4(8 9_7PLX%*XZ3SE?KW#M173^[YN%?EUJM#
MU\*[W)])]AN07;G"?4A,RG.:B+XZI'$%Y@#B3N4!'PBQ03MB6.K+[3Q .'MT
M^7QC]/&]GHL"%+#HOFC_MZ,#.B>]L_*;GE5LV!=]!7T6SI']\N;NYDZI4QJ4
MZTL5>X*S+B<"NU[\QW>V%*>R#K.5^QF$KA-ZD,H?$_?FEU5.:U X+9U!K]6L
M[J/I!5I[&IR]&;-<Z^53VU>@T.M[L-NF#FPCJ6H3.:^;3,'+6(%%?;)D!RFF
M0!T>8^R<Z<8^Z@H(-,Z.Q39'7-);&CPQ0&C*ID4=_&<5C$$)-LFQ;!!/N0I2
M7Q!K>$!GI$&MOX4Q[$IU4'!-!CS^>?_%2\&'9,VWOGNI56JPZ?<B5Z2,98-O
M)T#6E F9'K"^I(L@ 2_.Q"59(*3T4E<E'!R9$$2%IA.>ZZ4^"<J+OQR6Q\%E
M7K(-O]Z57^W/OX0='YH!Z5N@0JZ(!LMTD5@CN?29*-=T)@S*:QN]$7$3N\W#
MW\FCG:PIOA[B^3E5WNCKL]<:C0I.KV]WN[8MP[O1="N: ;FO#:Q6^,N?]E3!
MF%*V8S2,,V:DW6\"4?%&=]V9@ZA:QY)/>)) ?6:\9:B^Z#]XEV^N?:AZ%.)D
M\CC$4Z,O<-N4M)/Q!A$]M+%6DLR/%JDAKEG$<NN8JWQ#O5( M+IY=-J^[*)/
M75W![+?LLVVM_.@#HPS'[01XY^$&MAR&>6 (3<TU34LP]_3Q8_B>91 Z%>#8
MF2V@C4=<50BVI.- <;AQX^0C&?L=#4!W]-Z>]7M'A"@4%$BM %7,M1"O%&0@
MR3R0>843\X:K!<_;0.?R9PZ;G,6J'BM>:"=3T\T;!NVOM0_NLDNPM,ZU*[AB
ME7+[TG/&!%<T@;%(K5MNIXR#QSA)1)H1IZ1%T]_PYSI:9!6EW*::0YL0UO3_
M/HP-"U#?D]WXZ+[%N05%M\W*_L&.S @7-'1CC"[[W=IF"<'AK1*'>LB:;VR8
M77 6#:%^VMIL!9T. N1$(+N+3:&II,ZT*!L:PC6W2K>[+;$-WAPK2_I1V+Q/
M9]N.@KVO4ZW%DSMIWK< U'%8<M: /L10IE*ZL!+X<1Y051 '#=12^*?ZGR^V
M;(,S)8C>Y3D-[Z0[9?Z)#O2+WR/3?.+=PR!L5A2LPQ4YQ +Q%)0P4E:D4,1Q
M;JQ]B$,:%L-Q$"(B*:92,IYM7X&S;A@(7DNKF9RTOV64IR% NOXP96'ND./^
M\]]L!^H?8+\<EN2**K(4N&2"F(4.?(QYFO/,"*/J&>'1VN"JM#JM(MT?Y)\C
M/R8F;*(L<&KI<N:W<[Y.[R_R*?[&P&HS2($7S8_;>30F ,:\NN(=\V39\ CJ
M/+X7K,WI($Z(,;&0*]T2>OX+I*$8/7$5:T$'=(;%S,74OS]_M'N'G?*#E"C-
MX&/1UB*S:"P/&#=D[N:\MA!3)DQ,M&=_:(C" >NJNXB>CA<:JZMJ/0(#3C:X
MHGVST?L/TO97N>K&*"=F\*DB0;B9 ?8JH)'"FB7SG0<,+N8R)2?,F!N<9.)E
M94?) $)]>)<R6C3 PC2R3V7_ROE!?7U=?2_-Y#Z!WU:R"?+?<M),KKZ5,.S>
MQ;]BS[P"@4M: 8B7)<"&84@>%1]Q9*N/DL_5:=/1J.@PG84F'4[&Z$3HP$T_
M;S'/.M*3[[J:;W>5MPIZ8Y"*I*V=\O=T<H49S4FST...(97S,OO2W1D4P%88
M5NA0TB,F8_4039*<PT+D9L>/+FX?6LX3'PP6KSI>?+T)!CL)J:BJ2CJ")X(W
M.(_#*+ &,Z<DT$L7<DUXL]QBQ#X.WZ9]U WM<Q0QXKOR=C@X>]OL>\.M?=+2
M+,R]NJ>N7PC0]7 ZB[4#Q\>);='C]J(4N ?._R!L;=G!1HV - EHF&ERVO[5
M[8%^@4BO@[G&4WOVLY>:4B/FHBRB$4N>X@&]ND1? @LISC;S@(74S\W<%E7D
M@2R>0JP6HN]#"AMUSE/\9MRU*H90"EZ)O04J)J0:*4<JEWX;+(D[65^7I?(]
MP;FW7_FE\V.?F_L/53Y'^Y FO*F5]+LSV 2N+&S)>3.&$K%0\X(-NC)^ND<\
MT'CM_O3DV[V^*TY7<).J-INB3!W)9YAX"$-WA(YYP7P,!=<QW5"TM*6L4M&T
M\LBWMTW^I_V_^P]&<"-&V$0]YL,39E'6-]':2!#44*"3E*]HK@B!M1L.9"*E
M9G0(VZ01QK".DR-XP-'!%C$235**\K$43G,NV)#-<\P^5)))CV=V^UVD?GM1
M=F!<$;.&8HYQWE@H<-MX0'4/DOL#L<E5F#X:13 @*2PRJ'CB3X/"?CO=ZY8"
M@0]-[(RJK!7C72COXYULV:F<.#2UC "=3$OB ;6B8)LC2"W%-*#O3\P4NO<'
M034TS_KTUYX!&-'55X[[.MN_%&T\?2U$N'7XA)HHX"19CJ;6<=49/*";F(BI
MSF'+2&-E,3^4;.B2LQ-S<*%VG,'WAES6T8'RF4;BD/05M<'=[+5S%X_))?-G
MZ4KF<X<(U26MR[ &FC[!TL%%<F)P\M, U-.5EL@DB%KLCM"Q'=97=AA[,3R0
MX_@A0]$SJF#Z;+AT\CZJ3'1;,S]7S&DCK@.;2*S&L.7B.MQ5BRLCM*G8U.5B
MQB19ZU%-OS>MXDZO<F"*ZT>K:<;1*NM/P*1 3'*P1C2G'+R:=@^$SCM.="#0
MD8^^A$*U,22/P1Z,JZ29GBY)!1@_[3J$0P<5%QHGRYSJ5?C\_LGTOJU:]_BO
M\VL"=SU9Q\ V132U@%(WUM./8:9R7K=(3...CM69V4=Z>#A*1V3_J:7O%'YN
M6^_N;K7'2IYS;RJQ)L=7+>I@Y5,B-<;=A=B!)O<Q6SAY1-]*N9_DGB42M-Z3
M:Y$/E?XTK1T;)9\J'PW>&,WS-B__].78=><3OW9(ZE7W:]3<($#N)%B7$&5N
MPG*H9$L'=A!KES ">K]JX6 +8YQ_2]7[C'FKP5]JJ3Y#1A'45)M(5KR6XVKT
MIB-I'0I"?1M$KH@>RPZ)^3VX(.@&Z$. M1HZIQ3.0^L=#OI?,0OD<T_"!1XF
MC+>^+["/US#L-^S1:7I:<\"NVPK >2 !?@YQSYMX$KH&31]A[<0/<R6&F_S*
M(V9["/4%]XWO>G3A#9N&I:?),S\]ZFOK&M+9>1'R5D<27V79CH1['^(D5'8C
MB4>_DBUGQN0G_BU8?=,>W"+4XA]O++=AR!2K$?RN@-F3S5//QL<53_]TDTRO
MMU3>*AS__O"]RN'*\4!F'2>?!P1A[T/LFYR<EIUDN+$]1V'(K:/<C4P2-8(>
M:CK4=*=E:88TJ#[B\V-FPTF,$AJVW7Y9 4\BU"P19=AN*EU-IGXQ0YVC9-/)
M/QFOS3.\+CRP]4X1L^T)W"<2>^XRWQ^PG0B=09&1V*30Y:!U*LB6]6/*#G*5
M?U#DPQA(YN3''8'\.A^S+4NVW)BY?7'(0./ %WN!C/@I[X>;72]%[54<0W,E
M1."/#%<J<2F'ZNG:3I1J\J16\@6BE'#H8MQ-1L^]DZ]>^UM(/'G)"NHT/%JA
M57_%(]306FP+ZX@9!)H3 _^>Z!34<TIY@'>^"5>D80:4C6"=26(V0=L+]C%^
ML^T9"O&A2<+?FKP%DTE@N%[N]*24YNNJTB?2GZ\MN:JUHD^ @6AX#Z7+X!X&
M<N(8<D4:(313>[A%.Z*G$Q0J9%3&89?8/A)YUW::%G?E34P_J1C7I7L_(+OE
M+D=6A6P7XS=*'*EA;07;;"SVX0(XK\R]6<+<<4QU)RB"UX-=VV]-ZPXM&1'E
M>RH6<KGWC!!#LL+JVKND,/K4^'S%D'=0Q,66ZT?04.A730GT18G#Q)F&"K&'
MZ!EMG0.M'SDQOVZ"OT*CHY0+P3978B"!;#8#IF&X(LN(VBMQ,W$=J ?XG>\A
M9MUL?N",3TNL07R8V06QQKOJT_:WY6]([="M_KC]9F94W^A[ _A W(Q\'B.$
M&<)YWJ+COV%=6#(.$YBMC):*P$ME$[<5;@U,5MSODV5\^W.S]'KY^X,7K2,J
M$7FCK;G3Q.H&MG0E,Y+1P)8A,6&X0J&C,IXHVJ*^^%M,4LJ=- ^7.32U9/PD
M.0]%6W?#IZKI9Y-"[Y?^L:9YI2/)YA/<O3*CO33&LF0?&397N4N;2 EG-C/>
M/$?'K=F:E^7OF_,041J]@E!?7>><FMVR?,Q*.I:UD[V;4\<5G\+QP1,W*L%V
M@U**Q^3543QJK&3(IR5509(9L/->MJ780_[7^[.W7W%%V %;=H+)STE'4Y]@
M9$!?DBK8IL?F,^C IJEJP1-%/]PE8F@.M];B$HVL+X?MPE9\S[;4>Z']R"<K
MKE=3.4](8]6>*^J&!"\ 8Y#][>,\Q-FQW'$N P9K@4&HWKK!6@>CRY[V3OGU
M'A/+.\IW]??9C@LG=FX.*J7D4B ' WBW"5OZY^+L?6)# QW!>D%^*"V)&("-
MW]KU<D')X<&]UQ9/H)636?%)1P<;W+/.<6ANOTQ\K?WX'AMEG.1;-6'+/6A?
M9GY&MCP+WT^ 3F 5 N_D$]LI,@'N\ZEX_1_D('8]$4H?_VI3WW,JUS:1.$ZF
M8?J/=%SW,=^O(8%QA?F@1JZ($+)P*B>_Z1!+"<9CA-@&G*)5A*K"?C-"'733
M#;_!,9>A"HT/;X=IT=:79)<N'/W4:)-=T>V9L( $<MF',FX7!3H#CI=P10FS
M^0<X+7(_3,^]IQHD;GS/>M0@1FN,A-?/8SZEZ^QM8-GOS3AYZ6CI]WS+.9PS
M8YWFQY9KY(KM8QVZBO"<1)L4"V5\_P<POLF9H=RS82ZMLCM,[^AG,T^T0R+M
MD6X#W\,3O;%QV?3/WM>?H:QP/HC>V\$V0Z(_(;E A_,<#"#>"T=M-;>?><*>
M:%R6A\N<,E1,I92>17_>-F];<=GI_1_9 W9::=O^+'*%[1G8T[ #RP _;$J(
MQ?F\B2!2)=NQB7BU-*I71<75TYY-&RHIC?;&=16=3P(J-*ZX)'1;&NP\)""I
MAZQ:C\#\11Z 4,Q4=-W<WS.]? 9(OT#D1QA-:'R+!>Y8]N<%I !]Y>('_<IX
M>TSC>(9.4,%"JV#XZU_.];._'+]29B79,I$(MT@U=V3]O0!XR$+=/QP/0.NQ
MWZ&GH_CM@V\J+@W,-M9E;0UZEWC@UD7//O:G_O=/DO9I\L\:P-HHMK0R,Q01
M)??O6"H'D2AH:C\/Z$*I6ASJ>141VZ+M4#[5<Y>6H/HS=.B,@\@N#_^*C(.>
M&LX-AXZ*"EJNE;"WVC!?P84LQ'';]/#;<0[P;+EC*3QDKQ079^[XZD++'X/@
MT,7Q"OGP$&ZUS8.#^9._/W\^%?AM&=Z)))EY)D**HZ\A8XTO<U*1Q4G2]C2#
M5 S?Y6&V6234\JM]EF73:6@38KC0X^"2G%3ZRSM#P.XL_:.^;7(9H8Q(O8>N
MGN]"C6MP1;RA6=I8SQ;5NR;=[D1F7(*YW<L+W:?M=Z\IC[\9%#KVZ:;F_J-O
MXK(>'CR\BW\I=]>+*-'_25UM.)2.=JW*LQ\I5_M0_RZYB+DN)91J==@EJUK8
MXL&++ZLJDAVF5]RU'ZQZ.%CT\L4'Z09E[RI4)/4F JBHLE G/B?* E.IXM$'
MWU<^6_IK&8\*IF=V+*BG1Y>71$L^?U7Z3-1"!2(^P*F]3%%NQZM4#2Z-].F]
MS/=_>'S;FID37^9JV;#S$4'7D=H4;:^AXD'C*?UIYF#8A''%I)CF34GK<P)2
M:V6R3H*2$A$>':J20P_2: 82YP-NW>L3\S3MWY&\[^>M9_S&^,1=0.5!3C;1
M!WL?K%KO\"#$\@"A4%9M[3#.[M7B1C.S.&1^ZJ=[%F=H<G*2I"_T>&FY=KNX
MNGJJK&OAP!%!6><CPKUOBE4L!2Y&'U0OC0AI]Y*#[N8M<*6ASX3BB8^[LVV-
M%C7OJ9#.[8G:=,ITK4+T/Y\9\N4<&!VK'W2;]BAZVQNKE7A6_$W1Q5="T<*S
M<F<Z6A0@TGVCK@&<%FU"1;__0C4Y8#1!P#+MM!R@B#[1; 7(.EL!?C^]9* W
M-65NBQO$![6L1LZAA*'EX&L9=A4)/[UO"69:=)Z+E77BLY)UXM</JJ@,*JII
M:K"[E"5J+UNJZ&G;=EI20*I[3TE<DR&-*+R0] (^T\$T]<G==Z5VB"Z][5%!
MT1Z [[^LA8&/M=]Y\SYP)NA,^T;8Y^++16Y7%>2=FYC4-1$UY4Q(O=;_?YZO
M_7^A[\>IS%8*LRT'OXVR%2HM2\G'PO7*,R<R7'Q3ZC^$3*IN"71%?*?M, _X
MEO"3PCR\B-XX'3CUO_VV]G_SV+H=24D%/.#W\34L2W6-P-EM_"N+!D*.X!_U
M.PV<M#LD[J/<]1/_4UXZ_D=UB AK$]GIASVX/<U(ACGA$%D<@6'+4+BV!14(
M:9VNX0'%.YL'_[>[SW^KFQO\"^/4=$2JFJIEA"$-9GHM>"D@B7*=!V1HEX%?
MU\MYP()=9>BS38F[_DT7KU2)&.O ;&F2*F=;,5Z^K'>WN%=\X:I[W>PK=3%_
M]0"?AU$B:L[GJ2%=>&\VXI_1;\$V6QX00""'M!(5T#Y_7\&Y=!="RUV@4!@G
MI%U5C&'3':BW<[V3''KG3:;LG2$KIMNEVOSC+PX^RSC38O9>^=.1S<M#V'@E
MO^@Z(M_B'9/.TG),1\X=JT^F&U=O[O$PSNSL.YCU.*KJCT^#]!'^0\9_^!@F
M3''.2R+U*:J6^X@(G0+A77>Y3V@D(?QG_%Z&S0-S$T:F?=U8;=X6I;&S \6$
MXZDKZR$>X[V_CZGW9T?$5I=JFM4!^)8?JCJYLS1.3JKYC2(>T&ZL\6. $BAO
MFO7-C[7K\?V,'MW7M_"+<^)4^A^[SSJ_9ZG$OP4>F5-(I%9C!*XUZ<P>7$6/
MQ\QJ>NV/:?62R>NH)P0RM%+C7O;V5?;=T-WY<]NORFVU^PJ[Q>4'#-56SK>L
MT\-9Q_"3:.@T%M;T:UU6Q/%Q'C59E0=0E+N2*=O9:&I%,+G/*:ZCM[CR6OG+
MYNQ]2EX?;A\]_:D/J[&ILM%X99TNQKJ 'U;2_DL"#HV&IL&:-FDXM7 J6C"B
M[R2$:?_&.!<W'R@?5%0NKJ>Z^]-6FT#I,KGTG#W A8)=_*MCS$^<QSP BU G
M5;-!MB5+$VP[]:9%R+\^UW%\S4"R#0JQ9NP@?ECQ;!F9I^0S<,D)WRO[6,U3
M=I591&H>*(,$>#%YG2TW,3.V5,/(Y(KN#D$J4; -L_E\29*Q"%[6WWV3_8SG
M<=ULINVHLZ+P \$G4_>)BUL+M>^P^IB9G$*V%DL/WU>PE_/*8I=[<T$.E23L
M&9B;]2BC\O')O8J"U>D/KX1/2,\>\@7"*A\3J92T\<5NHB@/N&B/(?//GM5J
MT>1^P6NVP/FS?:\TU#YM%/ZI'UA9V5-1^7#:C96F&Z/BS]^/,V;(<$41607W
M<IIX@#\80Q1#!^>1QGE *Q%@._C0F@V/0"71M5/VYT9_^=PK-LV:'/LQ=] C
M\'; -M&?UK>/DA;1D#6!/,]\PGFVBDW!; *O+BL$6.QC.+82DL:F1< $)=6,
M[*T1!;N</7TSI@VFCMU\HGXV3;3QH?>.&MQ[ECGW8P$_$AG=8-L1'G"5D K6
MVG2A9)&X@)T9IBLT,(YM A'<,%LH?45NES2&P\P:KRBXQY%/[(L_.;=K]) <
MWP7!-0J\HR2>0IU/! - 6-LZO3S ?>P>PGNQ"?),"VE&14M6H-^-4LN[ C4D
M01:Y9[NK239))#4PXX6=8D+FPUW\R]AD>5#.&!5KH?D65J[PW\ FSP_H9[9_
MB(L/*@@4"SK2V2ZBKY$<%Y'M4)QURE9 %.9GBL-CR+890#9L^3-_K['ET-^S
MO'_P )E5#\SX+[2R&]D?+:EK9.]@L>%Y>7K@]($4I3FGJH3;&1=,\M;YG )7
MS=H*3"!,)[C%(X)$FT]:;8ZT:4*REX?UL,:'>H)W+;;Z_).L^@_53U45;<UC
M,)LB9+CG,ADDSI/8-&[1#2>A'W<1#B3X/]1='+PQ7YK,!$PL=HQ6Z'J_:WPP
M.FW?EY7@4^ JU26=K1'26/VZ]/N3*"#SB/R/_PKN7WG".1W92D6F*DRBSQ8Z
MB1TYWA>:I$O\]?P0MM5)D/R_%G=%57=#Q#@<EI9OTX8W&-"KT]-V?9O;=W:H
M\I+TL;"@/=N^)5J9[]]ON%LH6D0..O *J=3I8-OA7^A 2<F(WB%FP%ML[*BJ
MP(A>G8'09,2\1Z3U:-&PT7B%HJ[[CU:][&U8DW8@OM':77M/.>$Y0F4=^(]\
M:=K]W"T"T[ZA]S+O94!].GF!'!;[H4.P7*K4=B;5B,]9[HC3,P  7+?,$L9M
MJ J=!+)R*Z7.+P4GR*2@<,8UPQ4XN4KPJJ<-)W\+V\*!_$>J]VW_G,WON;,W
MF\^^FFN63@16*.0<YCE8BA6 DQU!^V'(KFTWX:2VW,GZWU?)FG?ZOR=.;=.V
MFY'4>CI@>]9>Z<#4A)WS0ZOPW%N$2T4!4("[RZ-SH_5OR\^-0M92ZBE'1!,+
MHQ")3/G..!]!Z> '>0!D[?A5FUD,DR)95A$]K:H[H.74NL"S=6--9R!6-SG[
M7DA9>Z+<Z>6E,]:9#U^7-3]JD;.\MHM_&/0A?<4RSW&2N,(DEAFW'RU\K6D?
MS?ZC7][IFH;WN6YK(G-',D@W0G1JAWI[Y7 ]-]M<SFZ5.[*&$)V/7$EN!Z4:
MP1/TN#9W&X:&ZG SPL86V@RO%D.?W-?8Y?6Y]W.DIYXU9M_Z<'HYS$Q(>MF!
M!ZAYEJ4]5>!NJ?E[M_OE:_)/;J]I:TN$>7832H'M-O=X)1^A?'6&#>:S!_OO
MDJP ER^UGB8=[EJ$N%!_)1TSL?/T"O4 M][CB7*6OEIY@(2=YOK."N?_Q*C_
M>[L<3&)YXX<(=2@ZB>7*MH0E+[%\OK+5!_!2^&&T)%N+!CX@FSP(7<P//YT1
MY.?XF^U@WM"G46MG%'U>(T% 5\-YUT5#[:4NO 7"3H/P)F";E(5IQ.N^-K#.
M-=8H"#43%]NR/R+0FF&UG&BN4>J_T=P3=WF47CCLTS"LGJ#ZZ]/X[5]IXF]<
ME/=(I0#X?&X?N 6!:,=8M+A'&P^HK:2K$^7JX+I#10V,R(BC8\>S/0Z(?>_2
MJWO^^V1\>(RZH(2PF6LQW@!9',3=GJF$=XTMD1C*S%J(20P3:JV\5V ZB#.
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MOQ)G+V\>L"7][]6* 6L>T&LUSP,4"__-A$Q?'QY@@6!.%/&W)+T\CQL=@!3
M-WB X5!I)0* #_[AY/& 'X7@=_45'I \\._,R3+<SP,(ALBZF#]"S%&$!%H:
M(1MUD <\61AV16KQ?[V7_W96SI,G(.D)LK !.X85N),'/,L%X>W@I]6?.I_
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M^GX_Y+02(Q)[I7(KE *L:H>_!^@'Z"S>>I/CY5)YIAC9_SO*Q"BP#M,C^=7
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M$U_(6X <-#VC@Q*<YGU[KH\57"&O%?0(\!S!Y7:TO/4K9I%,B6U@0LQ*00S
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M;=ZRYB A[79Y7M-L^^HH"^<E3@_KU:4O[L_F"AHS"T?S$M]RLN@X+::W&W6
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MM0]\GEX]L%?+;(\YQ90U7<'LC.5*NG'>%;_LV]0$X40VW7/DU@J@M <@4G&
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M2XY0%WUT1B,GBRXU,]J%3")(L2(N*@U,!FS:%HPP(-,7'3ZZGA*$MPXQO(4
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MHD*!,3:+^F%]*5IOA%>UR>#GSXD_V\<MMF?OK5C^G/C:Y@IP.TSF#Q>(9*K
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M\P)FQ4L,$7 ROAP,N?"N\0GU8L2,\R7SPP[XV@8/]W$N(&@& Q7*B C)#O_
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M^*4M<*_=+-@'%\US_).J:B2">YKP*YFIJT%D&2H$IBKK6(EY="2%4-,U@=J
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M;M"*"DKBX9 \1%\\;%'S&V+61,@L!?;O?7_;O__1?T;5B*#R?]C:PNVMEL^
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M'FPDQ1@YSR-K(D$NL[UNWYV#75,R98F%97UM0L>7?4WY"%$J.[/C",MVRCM
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MU*3.L#U'>?0.;V;<\7%Y*H;&*'LSWN(B^..I'+-Q  X8#/?=@?&$)QBCK'^
M):/(F_ED"Z+41M?IQXEW\^,_S%XD _&\:,.EB>57=\:]^0M%$Z()@;LTXF[H
MMW$?\:S ]7/&>#-]MX,9VQK7!*A0 > R&U&( TY;:3#C#?W9UK=<SL[%.AKN
M>9#^RVIF-L_AR\U"R*9;&I \0&:<EYPK6<(-PZ&8[<2D8%Z_&US.)#LQAD.
M,H<'H H8V_3^.=?IO2X3/]PTUGZ/1!IXYP7<3SAY@^]M<U<L:"V66>L?B.'D
M)"\>/II!O,"0S.0(T[H:13F.0'3#@OU14O+?].LOF,+E?1?[WJXPWY<:I-V
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M&\;0NH&HK85_6!*-H)QGD$8WGNZNO?T 3B_]Z;>S["_V*:[(GFBFQUL / 5
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MW>!3,(%52.7B[).Q0Y4<I_XD7%Q._<7]]Q-V*2LI>=Z2#(N6HCOP&)+/7NF
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M9$R5,+=! R"*>961T*4?60JAYKS+RXP4,:F76H\V*(9<1\^420[Z+:ON>Z]
M^[@O4>A; EV$!VA(],'06<)OV&@"V%(>(. "@^;]-SSH7)F V\?8LM+NTJ8
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MALEIQO/FN5VF6U2:PNOG)Q2\_.)JPXX9,+3S"][[B#4HN1U20<'*0AS?%1!
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MN5J-I%W\3WA 7"6-!VQ(P/V4H=FV"+".#4?4,1AY#V!B2:JXE0Q\(U(#(![
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M<L_51XG>SUHE!=("<\^=<+SF;I60<>^%]T#)QD_-,X1Z@LAGV*[<T1XR2!8
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M8S*3M#]R;G[I8,H*F,V$&.,[T%(%EB$\Q.MYNLB@H7^# Z4/>#6;(V&2*/6
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M=VS3EC,QHMMNA(Y$(-BC$0U@( ^Q>IZS61+%4<-.+GU?.H].ILGS$+> 5K8
M*^P>V9VMF\JF;&NEY@.M^3[??1W%ELUT3TJ\Q/3@I#\^*GJOKFX'B4:?6X@5
MB>)FOAE]6PRM=\) H4)4]E>O=W^RF7P9X?<E$PMA_Z&_#;P4S'QIZ9O5>(':
MPT"J6VO.$]-4Z1%_<"^S:O*T%NQ@F'&<FPQ,I @0E? MX"V,M!FHZ%_>XA%L
MQ>;W["X%KFN_H5_9_?VF%R+I3I3&]Z08KR]!B_W0ZB^P!IR"\>O5^Z44F;.
M*/#NB?.+&:/\$&#D45@&>5L?/%(PVQT_!JO%BD3"OQ<FS8E0G=G&JD']^U#
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MR3B[?V1MYEX#46<9MO+29^(XILR)AC0=1C%'C#_@MA!FO;LF>'L(N=+#QF-
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M"XOP:2H/489*XB%RR+/PZ"OP$/0C0:IG(]!#=NAOL&A,A'E$#[J+N@@SBWB
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M4 G+B7\K!-68+G'?H 4)3O37("AJ 5*!+P5$QLE:N'A8IW[+&J3]<HF*=K8
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MT!ZAXASV$:H?O);B*,T/L/4[YM4^V>7H7!PU53]TWBAG21!5\%XB]KE5%0;
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M23YL^ X+R?A^5T&8BK (PX69NI$D[Q;\3\/W_)FCT"11<+B4O(@;@VM;,2Q
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MM#?-H/-5 M510BZP0(?',E' 14KB42;A3/? I87]WPP2I5R:.:I$C\IX["3
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MP=&8:VA(GN.1%A9\@Z_'%*CXEZD,A^<$E04;497#>I/<O/>1;\WO#EQ\-YX
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M"C;OS=WE=M']4@'GF=&)1(TEJX-OGR8Y#?0!-!)T&(L@-D4:06PR3%@16R9
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MC3L+%8^]+3L^PKS9,C#4L/=5FH)-PVV!X1K5^Q^2]*LLKZ#.?..84GF(<2=
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M8TW(.5U]6\=X9)58 HO?Q>'DX9U4#[<W[<U5YGR=)?,[Y-J!&T$+9EK\:#N
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M,%][N-HQ87WL>7@0+D?HPV)>%J+)7)B7U333FA73\<  \VY=+^D5>/-4JA7
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M6CR V+DE!N4%E@#:79BJ)*YDCBOO.7Z7H64)V,,.-=.+R[^0<K"!:"EIJ61
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M*/6W&=F)KAPK8>1:N!:X1WA87XP*4^H3RK&QORP\E7<J[5?WZ'4"5EN[8U8
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M?K[=X6S/.K[^DDF4PQGS6Z/+7>FCG;?C;/-L?53ZZMXRZT0PGM $&3A-SMQ
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MMFT CNKF:W0DNK?!OQ[21A[A,$##RG7Q4K$Q\#-/F1\ R,]G<$PZ&0I.6M@
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MH*%+)V,,.4WLZ@WOW$/N1BF%44S ?(Y"]!O3BF:.RI_71U?ZO;5#F!GZ#>3
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M;4IC()IFRY"H1C")Q8IX.<^)ZNK*#+23&.WJ="+YN(ISAME/4HY?R8XB=E#
M4FV> >5GZ2U=4J);G">S@%4>G6YRA):_W:^F^^K(T_^'A67__RL5MC;^/P!0
M2P,$%     @ TH&64O=YS+N 6@  0(D  !4   !B:6EB+3(P,C$P,S,Q7V<Q
M,RYJ<&?LO D\E.^_/WP+V<J^A)B$*#$MELHR2K8D5!)BBF2+J>S1C"79":&(
M:1.R94^6R5X)V3-D9HPE^XP8-[,]=]_SG/,_O_/_G=?K_SO/.:_7>9[GW%X7
M9L9]W9_/=7T^[\_[?5_WA?V#302$SYF8FP <.SB Z] 7P%X!!$_?1+FX 6X
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M5A7=S-[S];:T!%V*!-^2\.^C\T (]8(?^/Z?+8D_(3PP/UQ94H3E,?HI-)Y
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M/-F0$6T.@VO1NTPO>EK(7K#-:ESN_CH>GYY9-ZPS[^/8S[&&8X@@2"GQA]D
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MZ4F$=D('!)^F$#:QP;OH\U<1A8+DNSN..OJSWXV,'@\7AI0^:4O8C.,04/>
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M5B1(<*T8E+*/EW>_IVR/.N44<?ZAFMCTE>-ZHA/IK8S'2.(S9/'&@N5X(.8
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MQON<'5S$KYX:4/6Z9<*K6Y'&MR]?X/VY9#;9E$UM%L#IQWB#]J>4MA**.Q?
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MO_"MD*UJTURDJ^!9NR9/KYOM 3#:J%-_DE%TD4JJY2 +<%>/UM_1K\E0;MS
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M-3 <P5DC1C."/<4-)+[&E;* IB#U,A=]3<B::"9A_0BP_?JYRU["L=.0;>/
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MPVI-.KOS#R"S\82'Z /CUQ:7:HQ(\3H6J=T;>),@Q]T%? ]>W;B?Q2774W8
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MYJTI20Q48Y,QFP+ +=M)%E* Q69RKX+O0]*-4& O)$@G\/@<>!MM:IV3AA0
MC A($W!*\],MT./D/]#H.\3^3K&:KE!68)WD[Y^%MO:L'/ON5Q]2<=\JN5:3
MB4T&3Y_YM1>D_ABI$EB8R@B1_^E/2BB5_+^G=?^,_N0QQ:H'A,NWN!(P39W0
MF6=[!+*RF]'4?X$D?++GCOWZV>L,(2DRN7FDN_08*Z(DYS;:,K7R!\GE3JA[
M='?R%CGU)2?=J&X1C2Y/_;;^>#TYN>,A)BJ@7\N?4S[J)?F6G]VBPF51!4^1
M(F6'X,YE>*R.4+HMY::_>U./^]O4!>X>!D03G>^_$<R>1=]AT.?[AT=OTP1N
M];@S+]=UL!_@UR"VO%/[)2W;Q\I(./:>OSS.45!\%'5.-K-9[:H4F,<4F4J!
MENIP; IS#0BHF4>3J@P+8AFA383W9/ST";.M&&<3ML\T_?--W>(04 @A2D=%
MH<@0*PV<5:V[C![(+33>?5(>[KL9K:_)#KZU4%B 'YR7/I5866/"(T:&T.+6
MY3<HKO71>L'(JS]P@F^Q^M+^I9ESNP8_C-EHDN G4J"$*-%N/ W!R9B?._#C
M'PP;O!DXPIEI.=/R_T%+UWYFJ108P:!8VPYAP8<:'1 ]GO8N(['_2K?G[/##
M'<K]A)*B[D6[ZD*;UUJH??@NF&J.N/# <]9+X*$X*[MY_#!>H .C-&7>*S7O
M%<ZIX(,?3CC+N?WULV%M4F"+@$L2+YT^F]\!?CYV;XN-COE,TS_?-#I69$V1
MA9\5DAE(,#<FTE3TSF%6:D6YM599G.^>D(.AY]6LN9VDK[Q[RHU%5\;,]VVF
M-G4YM<W:2/(S@7N)4Q0L/M11J^T1#\;N-7\A]L/%B,TSAW6&B(XQ<6[5]W;D
M[EW;?MS'8KG_@=%UXBXI<-:5.FW1'45O/T3+-^R@[!/84NR,:)8B,M_Q]?&:
MCY.@MZAW -\N,T(O-A*KV3W@*$.'])G[&.Q@H4<[54[LE[+YU &6NU[CN:P7
MIC1UO[=53^E.[8LW_>3QC:75O-,MKI5Z2Q7/2H'9MICM+T&Q>)1H;T7LAV2F
M*RC$GH+E]2_G/>>7$1>(-V0T'#N!I\T*NNNB0UX:[&AU[NFMQTDJJ5/I$Q!B
MF!R%];\P?80W#R:E6F'AO6*K(/"IG0;8%:U-XF^[,DG=UM?'=/_ 0-:&H<Z5
M(ANHBZZ!INUVEN_ #(HX%.M@R_.)KM63 EZ2&%39"-<]#.V?$'-*)-FSTIYP
MRL+XG 3VEJ-7YE^DBS:*W:1 % Y6; 1UH+M0&<2;!U/S[TQW+7@D\NDV//C+
M.*6)\6IL7#C6PPZ^FK_P%E@,B=.;6431\BES] ++@_# 2":<V,^("&V.0M>W
M4CE9X2EVE:T?"D!K^]H6OZ,JMJ8G![Q">A-907<]KYR9KP10WO83V9W"R$[(
MDWR64T8>:13-?4=2J7830*Q[^)O^7"63!O47/_CZW?"#R#Y5[:/[=[7.*5YL
M/&E3M<Y3;@1GA@1B?-XGN6&]$.T <=ADR8@^>42=/B<7*3N^B@X/-+Q<B)R6
M/U>:T>>D:BX\U9PVC^QO\$W6PM'YSS*!K,O4!PC$)4<Q2TCU3BH\QME"?K4%
MEPZ$N[/_TII=W>Z1U?J^0-LK3B_Y9(RWOL[J%<;V@SQ'$Y44$GVO[#T!*-:0
M%0IA'-^)Y['*PURX1W+%RC7T!J)(NG?NNA10KOX)'(WZ4'QWMBE[BTNQ"\VL
M(Z*O,A( ,>^Q?C-$AGJ6"U>7)D*G09A(T*3X)!HIO?1WQ^QU>&*;76MI_,E]
M3]\=#3L"*@?L/!*OK9QS/GGVB>4C\J*=F.\71&W@X"!_,F+#Y&'N0^0$Z^W-
MZ>/[DIM"SMW18R2CYO'L">IHV''_SEQ?*ILYCHF/!G,D[9T4F#I\K9J SED@
M!58$3A\!&J&S,!\^-Q/'>/.UB:)7)'8GJG#22[1<O!..&:'#(!=?)L@8R*<5
M+JV!FUE.\BYQ]8O:!E8R;@QKE,@E-K0;KXO5W!VL"_PP%W1U>]TX$BOT(W!?
M,WOZJD/JWJT6@_ )9!XQ86#3FO)HT>-F2^N^DF-K>X^_CEC71$05!")GZJ^D
M;ZT,<Z#ZG81]X51E!&PX\=3=.D7@<Q_\EBM0C\\_9#STN*+]XK[HW7H!WRY?
MG,* "XHEVJ) M!W\#O*F*;P)8Y9P1HC]F*GI&:V"](I]7VIT& 8LONM*.Y(^
M/#PX$KUFK?.1H."W>Y=+ 7DM.VXL@1O'P<?0-C.Z[:(+G>@]1:=/27+\A1Y,
M_B2Z<_7+VGC).79#DV@A90DY=HM+OPG,LK%>9)+"Y#.[GQ\7E3P;,SD6_,Q7
M]AD&71=!V-EP-ZK@)C( >RSW(J 44!B? M4/I:N-11-X>AZ['Z4^)NNS^0:S
M%+H#8!59'9-0QO5W$XVH4HH4^#G4GR/<8^4I!?)E25GM,A.85XZL6%,A8/(8
M?(T!NA+U67K9: ZLT4\_5ZWAR4N0W[F;S5%ORNUVWY-3I[4B4GF/V?-83[W[
M%V<]8M^UIB#3%_4'82!SB?KXVC<IP@Q)$8&;6(R0>$J1<$7L!U")XM7VH3",
M]2+(OBB^\G;.:?5]BJL&'>2:."; ]<Y><#;D@SL+EM0TGQ]%YR/F(CSQG/7:
M:D%,/%NTY?4 ?ZJC_4CC^LZQ0<@@:/=]JU^$6]9X.2L[(&&HPFE!?@,3WD'"
MOR/!FTE=9Z:T,ZYNL0R5Y-0N7Z'<%8ZS]7.E$UT^^K2/;E3=)3.I0>4S+>_+
MO&_F8S'&;"T$%.F@#3"UVSVJ1@K$F]8<-^VJELT./V'5A^2)MBL$& :>Q=6L
M")S4_3Z.7W:NA^)2#\*NM)X*'H$O [.Y0V+5 J'L6>YHDB!EEY91A-6!3(I]
MA4#INE9O;*V2[O8%]0LJKI'N)>N'A'&5;HU>"\,&_1DYR@,CM3Z*53JYPEA?
M(3H'9O)=N9(ECWO"^G2\7W3SVEI^Y=Z=8[.<T;2; P?/<1&I4,Q.K56YP^#K
M<4MX9".\CS"F)[?[U1 B9IHOY%_KSL2U?/^UV>(O/<B!?@VQ,DUX!GL-CL@3
M(08&9SRH74+.G#%K/8X4\!7;(V']#+F\*EZ-OXM%WXV'X%75<K?Y#GY:QI0&
M*^Y14G"+#7B) SLRNE.$61U,[C2 H590O1ME_8"1*N4P;);C1U*T"L/%/-TK
M2U+:EA/\AJ%JH&/.>+W.2>>V=]>@4N,S73:!>Q.<KH)B:Z,*NCSZMQ3UZ<^^
M[V3Q*NXSU<*/*9F38"NZ7&#HS3M>#N<9ZSAE[Y4;JQ8HQ?U0^]/@Z)+:INP(
M:ZHD0@IXDWJD@' OC-G T\Q#./:9Q@%\!CGO;2I^7G0SSX,1G1@S^W90XY*2
M#:$65<8W*S1/Y5J=37CIV?C<=+L-: C5[R%PKT&JTQ\K+C%DCCSAXGI>3/"L
M,X(9MF']E8645:&;.D=R[!KHIOYA ?=5]!.WL"Z\=-YQ'6\!=G<*I^MVKU.4
M.JLULX?I\$ZZPC"$HQB$>JDU1IB2ND\ZM/#NM7(/*N6S3,U' M6R7;3N+=:_
ML/'*_MHV;/['L,YGJ8\Y95* 3^*^H>*I3:0*0UH]7\6Y)72]24-J&*002+'O
MZ=78?GVKLL.=3'];K>,#^LDOCUAHRX43$+TAL4J5L &C0@GWWXB8"3!6+O84
MF//"HJJ_G[*+KE;1J*_R4/:WH R&CVI)C'Q2/>*6$0VCM9MFW>V2$:E_'8;_
M#<=!=ALZ-UH*E($-X!QJ)^;3T?FRM\2:")]KJ6DJD>_'IUQ_>*,>RK-_.I8W
MO,:X./=5D?<QUY4*)B7S8/F.=F?YP;!&7+<*JK!!D",4(P38'U7HZ/=P&S :
M^:C7U1%2!!/KR'Y9#_MW^Y!*&+&%2=Y7?KKP(,9XH?D/O6JSKE/CJ9V<N9 _
M&%\[I\V4T*TBK"E&S O=A[-/.>ZI0<B!_5XU9>-7J4\7_7)-[=S8"G3??JK3
M+Y/%ZP_' 8@).A<3DUET21F!>\7]V56>/@:U^5I0 E7C#K/ WUT*1,C7L9W6
M!&X;G[)P"&V'2I>E A4X';:K_1(C(V"U[MBZ%9GS+861L/P#7!Q'ULH#;N:Y
M/:RBRX2GD. /+^G9X2^:MVD$^X89/WB4EG1_[VK=AFU<<\8BS].O:V4D2=AH
M\2"\@]%%YKF)]9N["U!%75Z3HGW:#OKV=J\,H7O;'8:907=&2(6;F\LPP^QI
M4QU'=[7"K1R%3%SKU K9(1+;")W[,8_Z$BQRBAFI%'SL;YH(+W"*=VP/D0*Q
M4W*74MV.[=4K<M6_S68;_!Q96NOY@WQ=HL_F(T<&&JJ_PY9>)KE;:R8^A?@+
MR*A"H"CHC110,R6<=6]]=VT63(ZR_LXNRYWCGY3WR.R40_4DI3O[5?**^]F5
MCQ8[YD@X_[[KHOY3#R3M_C]02P,$%     @ TH&64M_A#&I%6@  'X8  !4
M  !B:6EB+3(P,C$P,S,Q7V<Q-2YJ<&?LNPD\5/';-WR$K)$]Q%2($BI;99DV
M6Q(JA)A*ML24)0IS1/9=11%32<@RV9-E["K)3D:6H<@R.8/&8;;W]+_OY_YO
M]_-YW_MY[^=][\_SN8_/CV&<W[FNZ_>]OM?W.N<W[*_L*6#[&6,S8X!C"P=P
M!?D"V+\ H1/7L==< 5< .3C88\ I8 O'G^//]RU_#B[./]^YN;@XN;9R;]WZ
ME\'#QXL,GJU;>05X^?C_',@K00%^P3^__)GD7T[=PLW)R<W/LY6'_S]\L)L
M$=XM9[;<X^38 VP1X> 4X6"W 2C$1NZ_F,<!_.O!L863BWLK#V*& /(/5=L1
M\SDY$:.Y$8N1=T.1]P$N$6[1W8=.;!6SOLJSY[;XX?NI+W@53I8U2YSO@Q0U
MK_F&\_%+2NV0EE':JZRR;[^6MH[ND:/'3ITV,C8Q-3MSX:*-K=TE>P>7ZZYN
M[AZ>-_S\ ^X$!MV]%_$@,BHZ)C8N[>&CQ^D93YYFOLQ]E?<ZOZ#P37E%955U
MS;O:]RVM;>T=G1\^?NH?&!P:'ODZ2B)/SWS_,3OW<WZ!NK*Z]INV#F]L_O&+
M ^#D^!_'O^N7".+7EC]KP//'+XXM@7_^082+>_>AK:(GK'FNWA;;<_@^K_C)
MU!=ES7P*FN<AB6N^??R2BEID)>H?U_[BV?\SQ\+_ESS[-\?^ZA<)$.3D0!:/
M4P1  TS&RS@5X/^ P?G=$MXGS!#/F,E8\J:N3X%+[71=7'L?PYV:WRD,FX%E
M_H4X14?8VQLL*_'VF?T\(EEA3'^18[N1J7]WAVQ7V#&-K^NT;#80GLJX#N?Y
MD3&D&1;?;2\(TRKB4?YM+*A<."D3$WMV/?[ F72\:U5-XN Q?<)L.JGQ7/_A
M&=1!-M#L[H]*9NU%9GC':KJGO%1+Y6QE25*_L0&H"OVV:EG\9W+!5X>9XV6>
M]6/^:3H/_;=<O'R$]*7DPV54(=&]08K%KPW9M4[H4$<H-50V0!YI4U5#M_8$
MDBEZ31-;\<9I^\AFB@^[[ZKO7>4LL $X(AY^\>#\&=P=>'J 0%DK.65?&;ZP
ME.KIK=U2_%!DY-K#],XJ!\*'25@)RQ"-IQDA=CT#FPVTV, 82-N$BMF :*,Z
MPS?T@MTP PPN_E;R*YJ5[;>MI/I)U]XQQ>I+*2_W3.E<#+]O%43L0">CY- >
M:%C;O(.$:=>(D7+>307O&QZX%+1WK$-W>=;B32E^FF*H:EXH73%[,/'E24K:
MK-IG^WA1#OK+S(Y4]8+-G?=**IP[MZ>;:V>?+7@P=>CL=_7@&8D9(F1%'/-K
M!J%SDZ,F&&9QXRY8]^+(&D%XTK-Z1,8Y4='KMJHSYH1;Y-D'ZA)SMD<-Q&<R
M.YDIZ*DGZ++U)>OIN[A]C#UPP 'B]BH+D;5ER1"3X=]>1>/N;;B;99:W#;X/
MF$Y<3^OA/Q/$84JZ;_>#D(&>6EB.P @:[@&;E4+,J#P=.<+5@]IXGB#\B:Q6
MW57-Z(&)Q4MEE>^N-P/+X28)W^5WS/!D ILS+'X3^GD83]O+C&3M90U-"$)#
M415O@F1;S]^P/>9<\*MZ7;TTONSS]8.H0S_]G.]#@=.)^6W8J)SM5&>"GXMG
M45!6R_"QNOG;E[=US3F^*BF[]$LE+Z:G1AM",\1767PS=$E6,P8RGB1EL*1Y
M:& ?0X -\&%:82)Y-^MC^AUZX*B;H3$;T#'IZ*FT2'!A7OT21)!B5H!3:?CR
MP!9A>$_W,J60[*3J@$+I2T/$,]37V=1R2Y$)N: ;-&BLI\%U]<XKO<"3*?MC
MII,]C+@EPGB6;N\2?&CCG^AW>H1"6CTQK(:]9L:O7YTAL*=(Z,V9- [YQQNZ
M;( [@/DJ))!:T3E9UK,$SO1$@Z(,URG+^)P=1"K83N *0:V\&*J_EG[OIIC1
MZQ?!159J^O/7TZ</'7XH4XAY*CZ,;L%'!&)XT5C\_4D)-C#U%(3,L,F3@/]H
M_?GW4AUT4-134M)YYW"]IKXQVG!:-M1V,:"[N&ZO&=>-SMD#E#!>GD7E]AX1
MQG$HNF52)*B(;-(:0$V.71N7G)UK98F%NAD<\9**%=/2B5JPN5XM>N3BJOV9
MUY2V[:JK13.=#,DB%G\V70LN(B/H;SP,-@L6KS683T?'DZ'.\"O)M)?]ZMRL
MPOWIIN:G\@\^V"[<L_NB7#<N:V0NF2$ES#H'TH380,7;?N*:>>_6Z(YD>-\R
M0SQ_2GC)D_J0]H*9B_B3(:/;D@\'D$VUT8+,NAF+Y%COWW7Y=7%2-6EZO%?3
M@,+=H3]B%#DP-QDZ</35&<Q6V._2(.%FR6\+O];A]P\]4[]MFS+GKY,X&2C.
ME8J_L6''$I)C X_4<;THFG([&\@;'EI!,<3%6'RZ]/TA6Q$WCMT@5H]$:'6[
MHCU0G+"L"34RN6..RCWCU;\H(NLI?V%WQHVVIGHOP%K<^C%O4=DM#KJ43273
MQ70HT[^_RM'KH?>AN.^.7TJOI008-V\X?EW%/$8(R@[D^<;ZR@8D$9>R)Z2I
MF+C?WMPAX(QL;15]<ANF(;NW!G\JRNO=[LS#\B@=A0-ZO5'6^_:? (8PL.ID
MB_ #%&2A,1I/SE]Z3.<*$:,*AVNA2 (SI<G/0XS*8;-;K4Y#:U7W2;/]'>99
M#P2"?5-->%/S++H:+J5TA*%MM2C@R:%?ZFI:V3?Z%QS-=)S:L;ZEO35HU4C%
MPBDH=+_7(EU._8O%J?/U<1,3XAI:JQ]$1$S.7X)X:@EM^#A4Q7HT2W1A4HBE
MAG#P7O14+!NHK&FVC&ODI28]W3>BOI9M.&8QXH\VL+,>J+)-=J@-+O@15O:-
M6K=LM#$HZE7&K,,I_ 2K0(9D1B>Z(I!B0)</<8.7H8JIP+!*LTI4)%[0V]MM
MP&TX0"5R8&'SF:Y,Y)-W8[+Q08^>;A?WJSIG'H9K^3KY=2']]H*,]W<[R=5=
M0>[AQW\NW-O>&F[0[A9RDHIA[,)QC.C?I@E7L0$7CW7=2=?5$*+>Q]A7HW4\
M/G=FCASY<LMKU87%YP3-3%LV:\#[-.+\DT?S:=OA;@A-NT&-;M4,+H+1TZXE
MQ3HRV(0K#<=K9/QO8<:+17H\EN0/?I*>^7(PAN=G-(6/#2@*=R+060 WS96
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M:DO]9_KP]>GDL",?UL (%'>]!-T$0<H-<.HEL8(-M 5K5'H8:L-V4Q92=@F
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MO?X\T<FI9A:P 9=L719?S30H'D2_$$^KAW;F'**N,,RI4C'^\;S?ZUVX$WK
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MYUAB)===4\38 &IO0Q==SY(-X'> R[W/^4'H">S"BK ")R^"+2[DY,UM)]A
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M@J?A#GJ4!#)@Q&-<Y"TVL)/B_;RW.%,@J#>K(BV&!\I<U<Q\O,_UL?+6 ?.
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MO!Q4<R6>XA&3B?BYJ"U'7W(#3??*@8PMSYJ7OUDK(GZ(A&I;J9YSF)JR:W+
M!ZMFZ2EV1:JSJ8W<?*.X''LK/OZ7VO&!6_39-'L_T^1LTTF-VF83&F(6..OM
MK1XXT+#JB)%4PZ8,@O<87)($(W.&4%6NR$+BR)\,^H-E>#\YH$K R#Q[5[AB
M8"A,$-0^U?<U"N]+8#R;&D'8G(GY(3\X,?"C3?F(\1\L$ND?;,'VRV!]%COP
MVYCM<C=M>"K87O=)\10F+H-7?_J4U;_>__I'Y9]>5)B7P[C66RR[S^DO7IHM
M,)E^>L>CPLV:BWM+YQL:&J46K (H6A)G3/<YA_;([E#\)//12@+LK']4'"<*
MPP3E7D;%MD-F'FM9EMGSWG8KI>H1"TF&JCT3SYM&J)>8KQFKSN7@Q6FRQ\R9
MU"8F'@ZKHB,SZ%)C[H3.<(:$V$V0FEU1]$!K./Z+JM%$__'U1I=FWL#/T*/(
MJM^XFY1^HK4%BN\@>IB^W8E(>$1DMI_ *E,:^KS )%%WD%^0S.B^A%?W_VP4
MITS7W*=/\"@ZI*&SIT*Y^U79F]D)"W,GE#&ORBY"@31D7D:%'$AL,SH&^>.1
M6>KT,JX2-SQ#$EB]C\K2_;6XS;?.?V?,5&OQ[5GHSEI-@HEZ6O#@J1,3<7=[
M1X7NKQ>Z+Q_T-B,Q/ 9B2A2,; P9(/6B V(=603F18%1D$:P99;,S7ZYR+V.
MF.+Z,OMC;Q#7M7!C1?+1\RL7.LY\.LNZ?]Z%H=R0(,P3]*<AIC85^*0VK1.$
M !"9XQ2)&B"_# A)[<SYSYF6F_N:WTG,=I&MVYRT_<,:<BOV4MUF!,>32*R?
M/2 V:MW^A)NU2!3)=RJSX SQ9 .58!*D<1"O@OBX[$YQ%:G$AFZZ>U>8<-_4
M+29UXWKWY[;3:]]<4*B]BFOHASB.E5C4#"+&?D*-+D9;N?@>4L0+P4EGOK34
M)_"X90,QU,67EN4%F0^X)/$E.T##GD?^/8.LG36M.Y+MKUSSZ"5R+J'C>!(;
MZE-(+Y](HRH@=:*\C2_S\?FRLT116&6]T_KFFX/"FX4AUFU^QN:3?7?5#&\U
M^66]9RV] %=&0FQ2Q/=EF59@VU U%_9L#S*LVO(X?V,5OXR47YE&5[]2[#C-
M>U6QX=D)06]B=FYL:WA6L9-]6 )0%$>2<))-Q _AE%AH5PAB@HMUF(V(VX58
M4.B@"LEN-)-BW#NV[SW[/O>7M>A6=<MRVJD*/#)7\>.=N+E7<3^0-,\?G/:;
M"WRSSOCX4$D\W^]+!(8?#!AN&)EK?K(2R'4))AR0[4^GAV*XCZ24F*['_2S%
M?P889M\]'XV&7@?AG885.MPPEKM^8?5WNJ3C&U7CO0X;T\Q4)OV.8MWNZW'2
M_+_M'__)4HSA G[1I?3ZP%-?QYL?]].&=5AR8+(B&R,MV_K-:R5VZ'@MD9=X
M,^(H6=Q!CA2W(!9&B:CVJ[Z6!ZA)WJ52 GQFDW]N]*(YUT"_-T^I=1-.7?-?
M&>QS*/&>U/'5[NGSYY5.=)K>I%))4D(QSCXI(>5[QFP7>98V8N"+"2*7<ZP8
M7#IB6+ZPUN#70[7:,92U=NEW<M\K^9$'NC.D>ECL/K97E$8763C!-@(L6CPY
MU=W>>UH>XM.U= Z_TMW%,D@AKH'K7!A8__QNHNJ\,:=G;)RQ)J>?SY9.Q/2G
MB<09.0-J4[;)3E#4]]WI^&U7R0M+K\T'8W-V&LU^$^2P>D+"T;R=:6\?T3F!
MJ.HEB0*U4BO&4Y8L!W9"2F1'C[FN_<FV*^HRSQDJ.7"LA\6G7X;QVR*6AO!Z
MXN4 ;SM9T5$T)#749<;*BM+; _"MG=/O2ZQD,5<FUXJ/7MA/N=U\J'KME9R[
M"_=Y_5W5F ;]_BADLC-\8&.0D7MAG 6RSNKRW=SD)1+G ZEB[CTR%XT\1$(F
M@%41UM\ME:^2:"5BVLD&DYF(:FG@,ZII]>U5W8^+LY_MKQ.O'^YV2==9FM6S
M.!U=11=_D"U[.R(XO3\M.(^=L? ^(@3LA\'>,24/'N.ZWD GY[!R&FB9R\>K
M72MQGK1C'>MO*O7Y[KO@5YVF??4;^DUQ1USU-YW>_>V3XH[O]GE[F95\\+,Z
M!^Q:( =T^<P%[<AQ?=VF?MT3&C.*[<:Z39DN_,KJ?O@KK.X[IH;3;6<,Q@W/
M]CF+/8??N)3KZ&>QGA)>^SE)5^-\K]]#O^Z3P]</LJWJ<2;F#<V5MP_2PK.V
ME"R'R+'!RPU;6WY\#/<GCK]^;1W["UZ3] A?C,EB.7#)LV&?DS2>('SS^5@-
MIDZ&FW[:.OT[=NC_49G"EFI@2K@9??4:#=P:]9T!33\'UC30D%,&CS#B?5U_
MP?GB48!' 1X%>!3@48!' 1X%>!3@48#_O0 S'1!]B0]:C[_7&7F7HBN[B9IP
MR,X5[[H3'5W#\:X/KKSQ"HQ-.%5#R6P%>AT5+G<E+<EAHP8=(_&B'$B_P0+A
M,=C $YI46.>_Y<,,.8 +QJ+A@R#K^6X(43@L!ZH"&QRPD/_)6F@[81)"ESC]
M*DO_N/F:9*&Y',A[Q9A^.<%RV1!#Y61O"R-E?W/\V6*6R9! )9WE;8;1TI3%
M$7IYEB3)$$$.Z*6C!L8239!5MAL:>@^B-B0EV:614_L7Y4"7A31"G&I2"?&Z
MZ?><9-/F8#$DM4<.\ ^"Y96$';3/BUVT4%DCUIU>M/X9V/-,#L!:Z+*C+E.Z
MN;"(V)J.)FFLD@/0 3D@*B;\D8CO6\+@6Q!1P]B]]%:<* 0A9PC<Y("3ZG4Y
MP"V2 T@'_H]D\@[@AP<)4B4Y<,J@>16Y4&KO(<:@2#_! @=>R0%I,.T'9#A%
M-.DP'1TC!VIP_M=+O+X;L],?B0A>5:,4;&@*X&N5_!_A=HN&S*T6K-NY@-:&
M<ZK1,:I]6-WSION;]PK^#-Y.XF ?.>#@AP64T ?%MMV,J7(@)HY:B?^X-]5"
M)J'+@436'XE(;$:^-U@D!TI)PPI"2\_X/W#DCU3^%_'UF^5/TLSON]7_&'&6
M TJK91'2!3>V;>FGYS^(5ZS=KZ,E*'0YG3]!>D]7C(!*">D7JT*-G\YKW)CJ
M=?BJP\/K3*REF,*1--^][RQ)4J $ZZTE6-X.=5W!?SR8:H$"WJ H50;@TN<R
M+LL!GI +KZ-]MG71D@. !0&IQ\/B <3(2:8_,M8(+;K4-\(AX;N%U\(?3&FV
MD2@0'7]:HH#05Q<4-,D!_Z"I84FO\QB<X!1%?YWAZU/>^EGV;:B;MT+U04N=
M9['BW3\CHI#-_[])]T],GF82.GZ!1"-]'AV;I\-)RC,>$M(,1^?I7R,*7V\+
M8']^S]!BBR@N[&'12BQ/,T)9+>!NV51MZK-^2#!D5FNHJ#9I:19D4NIS^ZWE
MS7GN:]8$=(](2G[OGYQ[T%K%WJ<F924*F":8+XMB&I/9:Y&P+GR;T9H7!=F^
M0K.#=>.RS<]G7$R:HD ^?IQX>\K[_!]^EEZ'9'7%/ G1#Q!VX_0H,V#F/6IO
MYE ;(T:8,V>76Y32ZQ45"DU^<0UR()HD2P5[.^TQQ$Z<QWBEF_,V#N!!O!0Y
MX$O_;$/#1)TW&Y.0JLS1NC]=-ZN2@I,0I,H/9<72 [PZVG'O26>)#^"-%\T>
M1R+!+\HU$X1%+R<<W4#;K^P2[K2U\R*<46;K5*GOP5>ZO"@QT+/Y]WN/#UV^
M\&S!9->Q@OU'AJY.8""[Y  G TWDET+(&LSG%=TA_*#=HNL1BT-&JXY6_1]8
M541J \4@HIXNW8Y8^=R03H83[VJA5LDFO4$E-@&Q^_"<5L$IT]]M>RY/B_N<
M5 3I28UA6@5^$OE I8%A]*%'\(,;[+8UT?OC\C3G.N.ZM9?.531!=<"13%_I
M9-@"G;P1E ;0_MCN^]U7?]$;K?A?571<*:,[*"!^&PO9TB6P8YEN^*<;QYV]
MVO'J6RHMS6T7VE:-I^\-9/SLY@ZO,1:$-Y(2(0W(GZZ%/L7#:T-:BU"K *YZ
M3B6M@J'73[6,*4?UFD)_.9!QL[S2I'.;L3MC6H!]WN6S!?>&]*E[P"=W(%\0
MF2W[^+E<D6_L,)]\C6F84GU%5BB^.6C?*9'2\L+?[Z,% &(B1PL=G]X=$DLH
MT.3F>@J+).9]!$6J9>UUYCU>]F1^A6N_KE.\Y<>.M\1;?1.OF^8<TT]37M9[
MY]69,TI/L(CT&A:"8GA@0:G1#0,C$2%BY$9/ZGSD;-> \NY#;1DGT>GU?+NE
M.*?C2S89)]F<67(S;:7OAEVK8^O"70Y#TJFU*S "J\&NM&:R19W!R.FW=^0'
M;PWC:0)'=88X8QT%,@I^S\T^PI9.LY,#<[?*KA($1,S^.V=G*O9A]@2UQ5ZY
M!N>5DR;+@?MHN1Q0U8H1?"+<.XR&<%#6&.<W VV/Q -5PO3%#2J_-<JN44WD
M0%D,HL2G)1%:"6T0'$TF>+#!^^C+U^%Y@N3[6P\[^+(_# T?#1,&%34T)VS
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M(F*%MUHN7!69928<B/=]+L@V=^M2UURA:J[;NS+W#.^WXSN#6O$.E)$;3XO
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M:1<<SF=$#K1V:))'[(QSHUVGA*VZB304K#75BEL'-N["G,<-=_,D"B;2<U%
M6"$])=Y<B>.9-KB[Y6)_B)FSQ6LQ\T6B?^VKFO'KDON+3"-NH",QPIP &IJ2
MQQ-O90Y-:F:F,V4GAUKUXXFRG+#3JCUC%U;L\P=9L.G39A]=3VGB*\<(P0*
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M%>Z5Q+6$-&_;-/3=@2-O01=MQU% .VX&Z(_:2/A(4.<^)JS]T8!^/4#0YZA
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MDL)(U)/G18\ES%4A<@Q^\[,DE2:":GGOW$"'[K,<O[N'-RR9'!.XMUC<[WA
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M'FU>;P=Y:A$#:?+.WK3\5W=FS<IPYP.8)WS@EOXOP9GM.M^H, Y+,>&E?IL
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M)2VUSF'T(=Y$6+*9+:EL1D=24E>O377/T<J$<0I%,V%\7*Q)PR9/XD5>!
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MHVOW>.AE/4*G>>^NNE[>HVON<W?O'K.W8[97TFN/<IX3Q)%75Y/*DFC&N?!
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M>..@E5! FC5]H,418S^ /^"Z(WI35?+;_6(7@>+Y'^]XC2S](&@97$^W8?I
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M!?T)I&7&[4HXB^[;T217"?7EMTY).\N9]_T(NWFBRSM (']WUG[K>._"\(\
M\ E?HJ'=,J4/8=*V->8WNV@/K,0,!LL'L4U_-!XUB/0-D36<N+GARHWC=Q4S
M7G9EW-[!F\4NP?%S@=93N"Z4)%)JI\/'023S45VQZ!'L7G8M U7%!3S931V^
MF*J;!K1E+%$?USU7[Z^O==UX/XRD%[ZJ7Z^6<=T@/TL;XJ6B6+)+QUY"G=%5
M5N'J1RKP#(=!]5#-2X<S'F9:GZJ__0#[P=)H_L>^YW.XK7VZ[]3C34=W+RF/
M6.=:^5[/W.2$SX[*JH)"C>_P+&MW(FZ:VT8D.9FQ\Y>,]^&&]GQUV0E+T0U.
MT)_63^\P%%6J"ZWY/"+OYA5;%7)$AZZ>?_^]ATBMHM-!)33"+#: K;Z^9+Y@
M(NR(AE(0<I$/4Q]C3;X3RXTGV 0&_WU<*]Y8N_)G0<C:@F5MP%I-KS);-:-5
MT6IWTK,75OLW P*GK8\4^BJ<K'?-*XA_X>3B9'&R*]ERY-B5S9OW98H;GA)X
MBZX68$F!M,75Q=M<H'9U@8=YRAO<@-OJ6[ INI6\L0J4ALV9GB9TNSNB^=Y/
M$[?'6?A?VF27K:@F<V9&<;63N1$!9HTF%=P'3 TY#0P(0+2LD5EJ6U+ 6D*Z
M9<G3K[X9JBCGKW,VN:[J4,H7(O;2256B>9V3GZOA8Y7C"XL8C*_RUCY#H\V!
MOFLS]Y.LM[_-^SZS38P\R9_PCE%\AP>RB2-2<A"9G0O!-)0T"6S>PP7\ \1@
M;6IM,LLTL S=0D[@ F)@S0++(/SZQ#>,]:NXST)NL>3/LCW"6_D^Y:BNY::#
ME'L<+?9S\")&#H=P_]JEQ;TWZ?IV])2EP&NT^QHM-752<_N?9%A[7"E]Z'F^
MO>KEX^<W;F1]%K.XKC%7C !GQ="#?H)N\GF"5J1>3<7'7>_V*-UX?O!*2+OC
M _%N;9(]1[ +B4E9=@/10Z-W7([1C[A3B7<=/M9O2S1SVU(+%Q#,&5DZ7Q]U
M;(_S/!\9?!(CW/WI:+_&";?L^PT/2M>LGHR![G/G2)[YG\/S)K>1:Q5KGLEW
M^F>[)@$['OWK&TN"3:C&;.3T@-!5?"=2^6/BR[Z9YK[Q"Z%FT!>K5"NZJ)J^
M9L[:9Z]'+U6YN%=U%<B]]SC085X--O<JJQ/9+QH.@:X!?/-:)/'6WNB";? H
M??MT1\"==F]?W9S8@,;02YH+ \?[\0TYU(@#;W^ T2C^!AFF.>(I/B#E$;&2
M"[2%:5=Y&>O"]A1K.?L4P.GMZSX7.?=>,Y[5G0MO) 8:OL]SA(J9YK@6/&1&
MGI#J!&N*VO%B\/QT?+(Q0DHOM1-@_[!$/PHTE?A0,^VN7WZ":W ^&YMUR2+D
M:OO]"B_>A8#QP6EP411ZS!%281Z:)U:*+_0091K.!$/YS2/70J\';'+R.N74
M0E+=L!KHW),FJS/VX(5*O=RI%S<[[)N7X)WH15.J-JFK&:R0^\6?=I7#F&<L
MFR@8JTM/CVD 40DZX8Z, 5253=$'7"]?35;"D2 MX;<XNT_V7:@:%.)DLEC$
M4Z,N<)H5U%-PVJ&=U-$WO5)?FB0&.0:A2V]&[65K:Q2\H1_K1Z:LBB^Z5U<7
MT#[EG&U^PXO6&Z';;,;#VXUJ63(8AMX@FI)W*#W1T-G=D^YQEHYODX-CIT5!
M<Z?X\L" HE:]PA#=^H]WI*RVU (=47LZ5R,/"Y#)*)!2"BH9JB%>R4]'DKDO
MXS([NHRC!L^:0^?N3QOIGPU0-BF<:R%1,@QK!ZRNM SLL$P\8I9G67#9-/7F
MI8?T"8YP(GV>4KW40AX'3=C)1*H.NZA)U6O_UU6TT ^48K-R+G5"4-5K9B@@
MV'O;KISZ.S'&Y^;D'=8K>OG;,$+MT-"UT47I&3/S!02'-XH=["2IEIDSVN%L
M*D+]U-59<AJM>.@4GN0H,HFF]+:E1YA3$:ZY4;+%88&E7692G/SE<>->C4U;
M"O:\2#/;D-)&=;L!H([!XC3MQ4&Z(H7<'B"&&^<"Y07Q4'\5F7>R^^%\TR8X
M2XSH5I);^TJR3>IME*]GPBZIQN.O;OL%9$? &ARA@TP01T8)(F5%*GD#UH&Y
M%W'(_85P/(2HV!M-$$]@695BS6K[_5?2*S]^M+JADZ_"UWOU=NK<YX,V^\Y_
MLNBOB0OH,Q+G",LSY3@DO(BQ!FS".,U^H(-1=@YU>E-KK_!C2DFRV\\K5W94
M1%!?D>_D@FO6IW,>IUY?Y)'_CH&W3B,%7A0O=OO1:&\8\_RR6_3=I?V'4>=Q
M[\&JW%;BA @C +)?/ (]_ 924?3.^-(5/SV-(1%#D6TS#^_LW&*I&)<:H>IO
M$F4F1$,'<('Q_8R=[!?&(HKXB8F6G+K:""RPJKR#Z&QSH;ZBO,K)U_M$K3W:
M(P>][P!U7[G][FC%I$P>920(U]/!]W)HI+!F2LUP@8'Y/(;XA %CC9U"=%6T
M$??&UX2T*Z*%O8T/A74I[5L^/Z"EM5O+136EB^^[J72B[*?<='V?EV+[.W;P
M+ELQ+D/@@IHWXF6)\/Y@)(]N&+9A;1LAG:M67T2CHH(UYAHTV)DC$T']USW=
M1)RK>^_.[%9]N:/D#;\;!JE(FEO(OV8GEQE1['1C3<XH4CDOL2Z%3Z, EMR0
M7*N")C$E0!.Q)-DV.%"&-GYT?O/@4OZ& ?\-Y<<*KS; 8!L^#55.6$3PA/\:
M^[=@,JS"R"WR==D-V2>6+37IL([!-ZGO=@=UV0CI\%Q^.>2?LXGV>O_&+DE)
M)B:R^IY]'QZZ&K+(9&[!\K!CFS0Y[U%R'+WS7_ ;F[:P4,,@50P:8NB?MGI^
ML[^;+\SE0)[NY*Y]K(6&M-#/$<91R$B>Y +O=Q,]\$RD.%O/!>;2>AHY3<K(
M"6D<F5@AL+@7*6RVL>_AUF.OE-,%4G$*+%&H$)^FHQBF^.S30%'\B9KJ;*69
M1-OWW8I/;7]SO[[O(.$AVKUWPHU"6 R?#DCD2,-'V&6C*"'CK2ZP=GOF5\?0
M.)47CO=.O-SCL7SJ,O:CLOFZB$,VI#,,'(19M(%,7& >NIS]Z.X@M.01:84G
M4XK#GUXV>)WVFO$:".6$#K.(FHS;QPTBS*ZCU9$@J"1#)\AC:(X0GKD3]F4@
MI694($N_'L8PCY%"N<#1@2:17JJX!/G=,SC=MF!-.M\FYV!1UF("H\/S(N73
MHV*]<7G,"HHQRBXSEN,T<X&*3B3W^P:DE&.ZJ&1^[^3@,+_"B9^U<OLL=U\]
MPN=[6]]2I]Q,/L&._#KAE 4KC1V/IA3CH1/IR5R@2AALM@$ISS"UZ)B)Z<>.
MW7Y0)=6Y)N.%LS=&^,=SF[UM+7U/UNZ]$,#?,#J^51@X)5Z"IE1SMM&Y0 <Q
M"5.1RY*2#)#&?%$P7Q2G37R&'ZO':\_4YC&/]I=,UQ,')2]O'=C)6CEWT40F
MA3=[M_A]SB"^HNC-$JR"7IQ@:F##V-%8V2D ZFQ/3V+@A8UWAFI8#&DI6H\^
M&NK/M:G+E'>.*)@Z&R*9LI<B%=7<R,L1.;46WQJ01*S L&3B6QV5"PFAZI2
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M^_&V[7=4OVN4L<]T<\U@";B'O)J\A53?5_OQ!\\RN!B,])@7.P;I,>V$'+Q
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M(@Z5NI4DC-XZ>GS%A_7#"@I2P ,7T-Q%K?K4J\:]X[S>='*4I?'SY<W;;]N
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M ;\?V<:W^8=O+4-_=$H13[J:S1T*N>O<OW7XUS.Z-W=?_\9JY2>'87Q#"++
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M7R\?KW)N>5!66Y"7S@U9D.!'SJR$A<,+"F26Z.'IHU;[R;W>W A>?[!+JX3
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MR:041#4&-NS9WO_3BB5]DB9 \B.#%NQ4T%-L&^X;;A?[!4[D5RWJ8R].FZ4
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M5B_3W>>$WV -Z,_OF>3?H0?'FO:^^""I^2O=CGDR^X2BTV+3H+_$MXAC:-M
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M.VAJ//K]PBR2)OGNPO?IC@QS2(2S@:[V,*!F;_^%OF7V-6KK:)7<BH'!W;E
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M)\*G003Y:->PZ#[L?G8E U7&!=S9M<W>F+*[!F-+6*(^KG6JRE=?Z[:1#HS
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M>FR/TM*1?\S[]NMGW_(<K'8O379/?EEFFMYL[_KKBE %WDX/0BJ1FDI$&:G
M"W7X+: ;F%B[]T._T7;69CI[,B*P\,YR(MJQ>VER*OU)F,C&]-X>_=L=I:@:
MS+D^O;>G(^P$NNFS'&]KH=VO2OZ\A55$I.)9"7C&I-J2P[@Z 4; 9%<N^^-7
M5E_-MFR.20#8&+9"WOV*:/=W#\L3]K$+6?I,!YA$.PV?9^C 3VG:&^%\Z]X=
MX4M-M5J=UWM2S+J_$3-O^7@4O/4/V!1GDG*@J46F;0/>ZE48&AVH#>OG4W.;
M]8VVL\M!'Y",&E,EWEH:N3R#E\CI+H/'CQH71L20% ONCIODA*WD'T&SQ,'1
MW^_F:+-4T)!E.[S'KXG"-S*828=WC>((7$ 0?+APBPMH.'>-*_<Q.3.64K77
MXJ3EML$+36AXC^\#IE3P)$=(91032T2-=>-4?P61;\&F5,(6;RZ@V[= J_)8
M3GEC?QI.<F;8*_GM$#OLJ8YGIW&!JS]^O[-*+"?,VA."94FUNAFC(*G%R:N!
M$5/<S[()NH=,OI684:Y_B*Y.E<9M^Y&=$8$\%17]&O:Q *Z890BBS*F;-W/4
M3[XV'7W4.9<8O:M#Z>)[1RZP!]>A&??"[*K$PH_+&]4K@PX7QNQ^(?879;?=
M7U2VB %VP@/_8BD2BUQSISIVS/U/*Z*6O-;:$&Z0Y,ZN)EH?1LQ,//)/OPI!
M./?[\<GM"I1U%FH=(&C^PW[((^*X#\ITC6<8R?_KUG_F])M$)7"<UY4+8!#F
M<TQOV$Z8/LDY=A"S H/+O,YG$9UVIM?BW_&V>+R*895M0'3]UT8T *GO\.^M
M(LHU]4GX"MG9;N;IX,3/SMK]@0O"GO@MNC6BWMYLE/VG2-OWX6TA@WLNW/?W
M58YNEKN]90.Q^HY?Y]XU6<8*,G&FG.]<H-P97\0RAA;J#0RLHN7G<U^;YP6'
M=S=^2GBB30UG]+0SDMP/*"\P+KT^Y2G^S/'JN=<;%0="/3H:WYZVU#RBUNN;
MX<"#8DD2&<_9>4:[L$[P'%.6T^VL#O7'5-M!#DRSR@HXD6:I^V/0>[_7Q=OM
M6[.&=#1DK?^@[R0MA@\>6],WDF4I5%Q!<"G< GL$*NA[0[G0$>@G[KG.SL>/
MG+R7/K%TA,AT=!([RL-;'GJ8>1C7@BE=F$VB'H0]F8>Q&MU8]>R6._UVUI<B
M[VK-;P6ZK70+NMIW )L7=0X"<I^E)[E 2>1LYAA^ ,,(A[^&T%K=33-H08UX
M"=(H6]+,?D)VW:CF9H;>J4464;/PC0?MF= 7H<-)V.HMDZ?+?]GF7-QWT;*I
M*,U3=]E!?4G?)_5S,)HEPP4XITUG$>.Y/Z!IL[?UKJ+BL=XTU"..>$\U.,8%
M) 8\R*KQKBH_\]]-VPF+R#PVR<DR5XP2>K'!7&_)J@GAK3N#6)*F8_V-\>='
M*4WX@27KWNKC!3,27I6KN:-J43O.!\_:YYB]))K1#BO?E\]3#"N:[^<(?F5N
M<^!\.T*8/64D=;D%(CE\6%I!BSH%$RX\FP3+3&_AR[_>]GURM]CDA_VQM5MQ
M$B*];Q]D"EG_3*LB?JKPG1]9/9O)"EO+_SRB1*]DR>2.R432QT;1D8&;!1@.
MD.J']+0&@HB7=9D^1B+0;&O42LB7/UQU?[0MJ,K4I1D\O_)4'H0NM/SQ^ZV'
M.F,DT!<21W8'5$)]273A1IQ"C_;DUACA89>SX<+[O@=?KCYP!3^?0OXT \+;
M(UD2;[KXRLO9SU?^>!6]P70;*%U]]EW,1@#PN@2(]BY;D5 #V53,G!KDM<
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MZM*UY<Y$6/3XQIL&"4M"+7!P+4)<<G##/J*;N E6C!B O@3IC-$R*!7E2!A
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MES#CI=(] 8MJ.S\I377O3!3]GL 0YP-:B X8.O.$57MM %?"!X3<8-!\^DX
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MO1ZN8."L=BL"5N!6QM5[.:81-Q[A.U9PGR=#ZB]S7(9A/SA(/H=(0().I.A
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MPAE8VE?S[5!]$2FA'*<:02B2S+_',=R0X7\-*_+@\ZV'/MCKY:]^_GQXJE/
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M#HHWU=:WJ/F:6KAG 6^XZ^CSV;>-A;H?<M>ELAD<-#*.=@@/B\NR%3EE_$C
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MUD10Q/X(HC%/JR?H6V;-#ENIP1.A>D&%K/P4NU)KE>G[DM=Y.9;I%Z4\1YN
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MB[K(_Z7/B6ZQD'.:/O#74UP$Q,*$'?BEA!M<:;@MC-2L?P?>5-9OYOGR6P9
M,E/!%WK-%SYG'%=+<GYU<%M\#>=+P/871]?<7ZID&4W0H&WI/!D*,Y_$]>9=
MXE=I0N^9^[%-)O[D9K*(+RS46SYSNG,Q\-;WY??^TIZQS!2+$=F4D@T*W#=8
M%WB,5EIYBX;7'WYPCO^8=V-"IT.6>\@UO$:YR>2JR*1UW_G42Y5O$V2,Y:_=
M?BN<^NBP]A;25!=/X<'X D_.<HFSN1PZS'4A#M:*LBU:2B>>J%M 0>,(=(77
MI;6>88]1-3^>:AGLTNU\7FKI^;@5O^'PMF3-JU36UWBTTW /H?(Z8= I8,=
M61F5.E=<M8@><G4M\OMV=N'*M/.%C)WLHXFI0>J;HSY+XX3@,88RS>_)85C\
M A,]K#5.9GWS O4;*@4HD1*S4X7?%,?$NZG>4]7Q]G[G[\QM%P^P/-4422 '
MIMA&%##Y]@TX\>I]3+N8VNWLBG2_Y^T7I)[D'0P%-AG,G6X4UQ&3;O.Q0]U[
M>D^LXRJ@(D"=3QXJX+R DO%L'4XTG\PSFO0'CO4H'JL@XV)++(I+?CZTW')Y
ML2\M=80XVJK^>%62I.:Q,SK[SC@YWNS&6GD]7;]R:I4XX,,@F6PM?0%W8RKC
M>(&5 \1V+9*16/6JO)EKL]U/TSN& A<=O]B\,S_+JW7"A RVJ"KQ2P%_Y>3A
M\ 8<Z&"Z0#\VY:;>)$!MR.X.J!4S)BW_Z!G_M)4M,=/N)]<@'<I_>NO(U(U=
MPE%;DKV; Q%+9PA#.AS$K&^_)USFQPE0GK8G)O3OV( 5K<TFK7<F^E2G6AM5
MMX:W7>2:*;=OD!SH,?SX:%K<Q#([G#(BQ+'GQV,]5,1_<LI*(?R$"MY-=4^R
M Q0*III=(-(5BB?;A\6=._!Y2K6=E7:F"SL*[_99;SMIKUZ[/=7,3C=]-UG'
M?=ZAU]75NS+H!8OX- S71$X$Y(B[X=$L5?Y#<U3(.W^M0U"0I*H6Q* ,-RJG
ME.FL,V[\T/E2QH:<,75Q];MZ<9:G0=SOT[2]\":",C^[6IA[%#*&UW[SX![_
MIBK!%HTGJOAA%,V-"<? )ZD/YL:TV7+TZ)I'Y14IG+6YM^DB]X0E%!;4Q.Y=
M4=*:$: @309+F.W*B>)G!BDG)[[[45LY@1?F'1CD80I#<CK?Z^4,(F0 _ZS2
MYD<<]K[D7<6K=NDA%Y^NEKL^\6K.\.'3_A3WDI_]L_T%_H&.2T(S]&TYU>/_
M:O[WAWXD8W%5C0!%J5\YLW:1_E=_^/G&#[;L7@;NJ?0C 2;O/^$E!B1 P1+3
M M2V& CI^WE3#'_?\& O1@A!&'$0%F[VQPI0UKF4Q]CQ9QC0CD(OXOP O]-
M4B.N\@DY$E:"TH]6E/=7;Q"@UA93G?/2M.^T7" ,WOM0]43]%VK#<-]WHUE&
M*;D.H*>/8V+P/'WN47BP I!_ZAJN TAFVI$48(S)\9VYN46AQK(1!2&[KC?)
M+R:[M:HL<;##[+B,J=,!8S]^G'(K[F:<-(] S' ,>N &U3,IT0!XO(OT[O&K
M;[1R_>3-I8,:5/S8,'2Y/F7)_LV&+Q<<=T@)/7\8-CA2JP2.18\SULW"Z\':
M=/FD1WEGF[T*G ^\L0E1.W"_)??UB^="0TYWA^#&E@58?!?2AO J=BOB(2Q2
M.12.B3:39NK/X[9CT4T]L24EQ.[I2K)NR;E+%JI#C OZD7XU_$)S.9XUQ 31
M38!X[7K>-1KD/V%[D;YMF:8\FX;U(1\+RMBGU+-%U[5=S3!DK'J?V:2(;^?#
MPIY<)6\JWFT,#M-(?S\DU=6DNOD30?/I&%30;-*?GYGO4Y'BYKLQ^D=#LW"Y
M=*%7FM5%>>DS,F?OH=9D0/K,(UE;$6&\)8Z82_)+#?D*"T?Y6;#(G--KGD%M
M;85W "&"8O++P/=H@I#F'65L8-/J[Z931Y+[@?$<!GAB(9Y<29YO9@+#!<?Y
MKP)X2G[YG^D=D\I3()D3!U':8@^U7E.DC^LH/0S]F#GJ7/%%Y6FON2BQE0&>
M1D>[;P.K55<:?PP%.X..MZ[YJPS>+J<-,VQ[<M^^BI?@[,V/^9'XXJ&R_'VI
M^@2I72Y,F'+L3OX+S5.COGDY(S861365W:'S4M L5PKNB><>@KB3T_/7D)]>
M];T\-[ X)I8MWMZ<)9-IO^CY.LY;CVHC$C.EDJZ]I@.3OMG[CQ=E7ALPVR'[
M9E@2TD;B=BP-39 &)KMB!"C4CRK,'6P9EN15:W-MDJPRVJ9+H;[WVNYQ]"*P
MA[[O]CMMQ>0-[T_A<AA4K49*'$.1N!I*9N+K\;'70HS=V>O2A]38-O3R'I^T
MQ5<VL=D.GN8A=]K4KT2FR-]X\L;\VLJ"&B;(;05>Z]\!/"FWB5L 5&6CK9/E
M@+G2MYL<FV#^_4*?ZR\K>MLE#.+O->U]N'LU[%=JFN0+0FW/M_6'EU<,:_I5
M4,/"BUXX+:Y:.2R)%<S&3:!;R4K$]YCRGPVVB@T8:;,MV4-^GS 2(7%N=L<&
MRN-;TPS?5J;YA6A:)GEG*<D<;?VXZG0=>UF3\).K2VPCR\,87B@[G87GVO%<
MN\W<V(K-OU7)3QO,=)C#@1TZ%CUZJLXR]#'M$JU4NG5>Z+-0#>RN58=N=7U*
M;8[EF _^#'?V#W>GTW]_1Q"YT][_?B1#5(]=-E[9B*=K,=VIH-,$@A,R'4#&
M73V+VJ+SZ66NAL]5SET\JZ*1$.-POJWNMJC1!+F,PI.QYV#XCXC:(X2KH%5C
MC9,3FTB6:,R%HEJ(VK4#7CV3YP_K4>A?@R+O'1U[@9&TG)=!]Z2V$\[5KFP
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M@0:W2;'$CZ[%NJ7[.ZW612T63  '_&8V\KJ:=*M(UZ\XF"FX6:7YW+!=LEX
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M/;K%!1'=+?[^62K[-V5)H.ZL#N/U(VH2W1F-+35N=.J]93('][A+F"LLLJ<
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M0;VZPK))]LDOC._E\+CRM:0U8X.,S4/3RHDP1QOY$U.IA_EYAD=-;)2KQ3[
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M^O_%3M+_]_@_XH#N3/T_4$L#!!0    ( -*!EE(:3X.(8J8  *?.   4
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MS^]%Q_J<&\9,]I3&TDFKLD<L#2@.89\=(%>)ZG@IW"%N*7X[4$*Q[%N #KP
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MQ1+_X_3T4NKJ LOV.^*/%WK.""QRE&(^9//H+PQ;XU<)=[?%^KU_J^!_T2E
M)3#<";^U;[1RLV\,\^X5;!UC$ $#(B?'UH\W\":4#SGF=K,<\K?3_5>=6.1?
M&N]<7,.'!,XW\B'E^F]&.O'<VQUV3U=*1)O1$?:>6;L1U$,3?NCB*ZR\KV^(
M/#F8-.%3.)2]&F?^O'H!.([;QX?8/4=LO$!0]S$&N**/^9#.YT+'TCZ +76@
M!_93-8'WI_1_KOJ?J_Y/5M5B%BWI$HQ6BB4I6XES$[A=I\RQIF1OFT<7_)RH
M?ZCKZAKFBSI@H#;[8D?5^(/;\W'6X48_E*C)'/GO/,E"9@DKH16H8H"0/NM/
M=H*-'2/*C:F4C(>%$]4O78JVSMQ/^T,A5?W&A$707A?85K%\'BB<=AL1=$:V
M(-#?$.'NRAPM=RG> $R9HT.![CRWJM@?@>XOT%F]/#W]3__YO&]=+O!C$;/7
M&5'D.-NT- #&$W_"/HZ?),I%(\FNU%#Z&[8SB0GS!AR8+8O=OCZIVHS[6>EJ
M,SV"<BWS'RT@9GD7WI2=WVY9P"[\WUFG[H,[8.+45P(8#JQM,,QHH?1LMCYO
MME.*8=G#APB$^=Z:***B$<F*;2WUS]WU>A5')6HQ"3V2F <-],RL<1+I$.P&
MQP8H.K\@_!.Q$]CJW2>5#=C71$>$KWPR$9OV1I4;QD'@/\Y#Q"X<WMFL\-N3
M?0 8X$D)@ S_"/=1- S8120A9M[![NS YK%/OP;4&+XPR$K^A))O]/W>ET?:
MFC^\,]\P'NIZ]S%#<6^W<[^R]A^3OP_S!EYC $UZ*T?!QP7 A/$.=H[*.34S
MSOZPR0:.%7KPWN^ESWV-%:18]'\@O=>)I ^8"_S1<\"?YHUJ' );U-_[M+OQ
M(F$+#(^Z;%CK>Z1*$P'Z7=49^,$H($!6\@YX6]WZU>L] L^Y@E;]V.#G:F6(
MT0N&=?R#*X>N"L,M&#5]94J?T"]M++U7;#O29EW4G@=?6+,3C;/853=<,N/.
M2N VX6T))&^;W6"7;.4^0*"4>>( CJ-42#--Q6OZ A='3XY'-_,^'=A=<<:8
MUK2/;AT<*HD4/#&85,*2X3XA7B(F+#!.P5)*&*Y$<B$K-6$1GOZ4H]T$W*9F
MIRIIJ#:/_#+>;_DFZ\//]I^-IQ.7(KX&W7KRSNG5$GP,PN;]%TF]%XKSNQC<
MI>]H](O>S4/=VL4N53__NPV, A)+]R'7LSS)U6&+ID@"U6K"\:P @KF)GB4V
M-O$AOYG)/*XD$_9_;&KVW*(*/F0X ['US?,_WYX:\Q!&3),)'  ,8GPB[#_?
MNCG\SR7_/UMRE0]1A\,X,""=$=A'V X_B/J#QIKU!L#:1S@G%4LO&S_.[:;I
MIP7'7NT\LVLI4EI<=X<=9-+_#%&&IP[(T;;BFK,3B7(<@\!:(*97]5J+ZGQF
MY6&]UC<M]X^YR*=A@X-U90[#LDM4$<$@.7;G25@S[?MY-MPT N6ISXVZ1!X4
M_W$'D#1,6E#_:>3F*U4C.L+[.?!XX/E1K0)A.SEQ26IJCO:[Y]ZP%WQ( [)?
MF0]!E4QCJ$2ZUDU*SI/AQ05!%%P[W^E!)%JIHS&-TO,JSN_"W;!+TG';1:\@
MM<((# R"(\>'N'%KRYB_^)"UR8IPA'0U!UI! HGM&69M,P$EVJKX)'I/UJ7(
MR.*YFH[D5BDIH1W!5[6%&RTGB4UU:X4,*58[8&:YQF9ND>3".V6*;\8&C5RC
M1VZY:CT^_SFBH#LLV,%+[%VM@)"P3!\$AP9KVN&TW434\$R??J8_@5IM$:!R
M%3%6?FN%0%M(:D.FKX%]#Z__B=[,]9(P&#4_M''!=>A5J7!'SI$3OQ4.'S(4
M5_[:>1*P!*\C^.]_[0WS(?)-A$R8.#$DPMV9:9)0Y_?=-_(Q?!=0$*WTR;G!
MR3S'[7G'R7_>E56_6)WJ$3Q8N]R+?%FTG(V@5!:(<>1A QH&C87'&0;=L3A3
M"A)Z.,N@=:QV_>M-^I'0+J]MC0Z"FGO@*&4*_3%T#Q^2D!U1 Q:O>#T.;J_?
M4SDJ%Z&W R2ZO>1W;_X0!,*1<H3S/L!-ZM+IL0Y[QK65O/U!NV6'RV-=?ES_
M_<AG&SL ;![J"$H1K#6[%X4WXHV7"&QP/&O=GME7?+#"\B'^H]2;6%?E3S/3
M2'L)TL682[/8P8,*4_A^ N-$R10?PI/X'5RWLM 0VJ.VL<V.=KTY(MQZ6#F<
M_/+!C,11:T)39,5F?&H9S?9)Z[9I\BO([U;>MC5@G-'C!HJL@;-@8M)L[%#E
M),;HT8EK8&BW/.VV_%3Q\DW;S?NOQ!ZD];5X;=\^*+]5]_$M3Q'X<1Q4UP-G
MR_S([B'GGIGFQ*33;/N+OMRU^E;1BQ&_53)G^/W C4O6?Z*0+V"J1,H=& -<
MD8U4C-Y(G[<$C*O\S@'MGO[V_7]@R1WH%Z@"IU23'LR/C4L1D;(JCUK?OU>(
MJ=_#3I?%/WD%N##:-J@G<=*O@-A21 +,CM>+D2PZ@%C[\>PWW&F*DW%I$U<W
M]QL[TYIQ,0ZN"LJ5B3<$A+S_=<1A@CA:L:UC0;Z4P;M+4?XYJ.@TN8ZQL#[T
MV/42H<98TF67T*&CNC[3&I!\$E*T4P,0HAKT(E6^M;0M?O.^<:(04[FZM^Q/
M^8<W32CMKEK[$STJ6@(V"?.=>. O3=WU]WX^;QBA^!.6@1<"S*K\D5CXKSJ;
M;67 W7[RLZIRX.)UZXX9->OV5*W$G@OW6^H=!?ZIA&3' $-L'=XPH0G:!TTN
M4>DTX<!YDTS3[J*+MTYV6>6SFN>(+/_9MZE[BL_M+XOZXBDZ?7\L,$["7.#W
M;W80;N\GD$<^@S'.W4*PM@,?:#/#0H [9;);N2."6K4A9J,:DQI-/[).C5AB
MPZM>SI*G>S.;J:U!\\PO0Y!V?>X=GMHW(@-T.F \F4ZD%,/$;/RN+&+$<![
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M9[R7?W8"-+V4HDAS=0ZY@/,WMQDX*8OQA$WH0PC[N1BT=:7GV L;3A*1B&F
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M?P .CKX],4/)&R%>6]45^OZ]('_$O]7]^.E!2L>@V\YIBX[!-&)) +G4:*=
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M!;#Z'T_Y_;G\"6\?O*'!>0/N^W.FN@Z2&=4C S#LW<T[;P+8 P@#.XX!/W*
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M&)*&0E.N(G8R^4UQD2]-7XZC&[_^"&C/]0P*@:FGUWS;E[$-!F[PI2/K>24
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MSM%,+Z/SXF(C%G[OAQT1N2:NE4]OL>XT PT=N#NBV6[C7WE_6U(2!#!U4J
MEGR^I>G>9>;&O9ZY%/JRE,8 XFFDAL?]WP6%5^,=B__)B?[0V_/5GU!#"L@&
M][A FGP7UIX(]C!'NDH,1ML"GG^+#!['&;%(V0T^UW\NK7W0R/76]ITYD:-M
MYUHS\=+Q2&Z$[V6Q?[]+$.Z.U\=:0Q1P@VP><U!U. #$1+ BN^7 &[56OZ3\
M-I)4A6#8N@?SZA$]L%CD2A2KK@M>CUF!DJ8PB5>&U7XV&S)EEO5+$_ =7K$4
MEC"IMYY3B8^Y?%_FP0'/K50Y"8TK?B0G([( %D*94&8?YM7PE8+Q(J3@[+M_
MPIMHI.VS'9&T8G7;XDS+G[&7L_OOO=:KR55]W5CY7CB\+%A(96L+9K*+?14\
MQ-G#U:T!=S&UN\:G4,GUDXL%@_VN+!'V"T.[X?I:^8@XBQ&BS\,[@W\EW+T#
M>R*3BCNDFQ,A@(G98&73Z7_>31FCZK2:]#H[GL_W"V")91PWER;U:S.0!IQ\
MZD@>>",3ZC+UR>("0/V"GS1%)<7OHH<0%6,F<8:\1!D+,,:S9D1JT&:-5&_-
MF.5>\F^(B^3X\SM(M>,KR]3V_1W(>DK7L;&\(Y^3G]+:O?I=W[[Y7._=D4V9
M\O6VBSP\8_I7X]A$:T*82A<O"Z ^(M4(8 P3NA1 !K9BM^#X)JQS(<KW[#!T
M@JPO^N!@F=P.-^76]@)'I5T-R)M)YQZX'3&4@F$YT(X70T0Z#T?!LR]8R/#V
M;^.,7/QD@9?[5EBB,<[0;JWY;'*EL;WAT?4\^]WY-R[/*.K 7T<@)4@!0W>1
M0K@],0(8?:.3(@0$0)HIJP;S,F;9%2+]>([S#W%L:OG:0OY\RE7 =")?X=?.
M$O1'?2$FDGV$>:QP!7B)U8 @603K'1OE9,V. :M8YB[W"C9@%K7!?RZZ>7WS
M,#ZH,N<3ZRZ]]]AS\D[9.:##A*@;4\F>X#4 5U8G\^@*F8AG'$6N#LL3S+S:
M\4B;I4A\PE>N2?:[]4_C6-7-1U\D'.T62.<1ZKA.5"W0"9\JA"A$8V47/E'I
M3U W)75L[R38W\WZ'AT^E;A/_*_G=[\&[QK*D?57"/:YOU]))Q<KP4O<7 D_
M']0-3)E1@4[).,E>0*E!996_<SGB>W1DXXMKV<9WNR-/LJ:_+N8__*LF);!_
MJ_NU+6O67-FO=D@SKD("F]W"HF9PG>'J)MIOT8RX-S&7+A#8AR]R.V6,$?O6
MJ'I/"(:@E%8*AG,)Z/ ((TH:"]&HS,:BD=?)B%ZB+D*->)"0U_1U'<L3P(+Y
M9OO#;WM,PQL*N7*1; ->+5%OBAL)/J.&H4^R1AL?\8KF+)AFZ82?FLX+9!N.
MQ?J% ?B4]C?8_7UG]I9+&]6#LAQ1_@=\'9(Q^QSW 26,DYX,1@B-KF!VC=47
MHUN3B]VL(U2J ]ZVQ$IUCYQ("7E4;@Y3$-UR#B8#T=>$.)Q6C"V-S)4E4TU2
M$FZHWU88M9-7>OW\X2YW=''_"ZV0BNNB/NE6YM=OOLQ*,UJ/],[K90$=KU'U
MS4Q[WWB<';K_M:8MXMKP4+J)R,(^+N(XC]?6_GO>DG.7N;FYJY-5F_6><%NQ
M\DPRVRR1J_>,7!D#.'*N;B #&C,N:Z\'1>>S>(N!_C/CELS;;%/>0YP05G5<
M  LB)*,DC%>PBO3'#F>)+)F4*/76S..4,\6N@6C*7I\/!E<>U 7:,6#W%:3U
MA;X H%D GO$*SSP,I-Z?ZJ&QJ*E8F7)X,MY?@AWUP.FJ!:'&?Z)7.0CABN6V
M5C$(DTB^4Q"MDI?'4Q? 3EPF%%F8@=:M? GO\B5KHOPH0@P]M9B\4-_2.,S=
M0Y=)_3,[5_B4?#TC#PB:;I^;=@BXZ6H<DR^DF=5LPU'OQ"E];).B^>SO\%6J
MX9@^*EMB3BR-S:&1><(GM#.M;8PGW(6,'0]\R3NL]M_1FO3_'__K  23_P-0
M2P,$%     @ TH&64M2/]XT+5@  ;8$  !4   !B:6EB+3(P,C$P,S,Q7V<R
M,"YJ<&?LO LX5&';/[J$G(J<0TPYI!(ZD(I,):<D5"ABBIP24SF-,"-R#J$H
M8BJD<IB<$YD<IY+DG!$S@\AA6!/&8DY[>;_]_][W_7_OOK[][NO_[>O[[_VN
MKD>SKGG6>N[[?N[G=_]^ZS"\'SPJL.6TF:49P+>!#[@"_P-X\X#XB6MH-P_
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MBV:/VB^%S54?V\,T3 J+^:R4;O'944'@FO0G/;[G*"/L3]1;1_8A-%Q-(GF
M%)+FBVN&]:*HU5@;(1G;QHEA=M$)&@K8S\2NI+FA;^$_+5/G%==4GMRZ)5@@
M$11TU'S;=2=+]2NRQV<LCPD"& I;QI!IP@-BESE)V.W83TCP+9&V'L=9<RL)
MR )7@1UA*E>VZ?  M<XD&# <[X<F#1X9E\6S7+"P"6 _ K1)E<8V(\%*Y%L<
M30TT,H9UU+UB>!907G\&-!:YG5/F1&/4ST6S@ROOIH8#(T).,63QS-0X&+-F
M(WZ%LPQC'AF(Y]]./^CPBG]2(@D%6O, R FU!>E!5,8U_V))L ^Z/EM!P57M
M7@ALP+W4X,>9AB$1S[&DE?"O8_[UM]CV _ Z.$&\*A&' &T)D3Z@+\EX5S];
M__5O[O9*AOQ=M@]M>L-U%<7!O3^J2SEU_F([I\X5*:6; <5^02M[UE,RCE(Q
MR):[%6[]?!HECZ.^SMOX'FQ,?4WN?#T"^5(OR)%)\:5NCYRL0@LR_UAH;_I4
MZ&3AOK<^Y>LVR4(6"M=TR'@G^R3G5=7"<"]S!Z?(IAEQ7XZKH+*-L1DV.-9]
M(-!&=EI+,T>YFI-CJ2!EQBYL]5>WY[MYW(5XN=\0L>6W8BZG_='+V<P0>0<O
M^>#OE_,_\RT%"6GU?@ PNG./0"175)[:%4^.:[49-H=YZ51*B69W7L<94#>*
MJT!Z,3UPL*H<.>PT9I4P[_5@K]]6,P]3J?U-A]6&&W=@SG.ENX#9/"$6;@A9
M$QB6@Z@.=?7*F#K5O3"<5J]4>?_^N()LN7U@;H#I(#U[\>2 -OKJI4U^VH7-
MGYZ3[#4L%12VV0I]PY>3V-*&U)4Y.@P;"Z Y6YHX7H:G$>YCMX')!6F7B4GA
MLOX#3CDY0V7C:24Z*I-ZNWHB#WP[<?SC?:H3IX@'7!%#DW69#9RGQ.N^N@G=
MT!W$T(K]H/\8V.>*D"ZK>I]\WR%JQ[Z\_=ZJDOX"YCIS].9Q_27QRK+?><J5
MW&[&QDH?=W2#+C[T9OG.\>_^;ANO?[VM_DHCH44+L'\X(3E['*' [<:#UDBR
M:"^3-$!$IT*:J73'HG!=QF!RH-(QM3'/NV,$X<V^)QEG@GTKOLU8#'@71$UN
M96Q-V_H+N*R#PEFQA.!IK,8-^;8BI+G'V"'0:A##?!S9?HF*W@;]B9 Z9CRJ
MY8MQ4K(2T](+D6-^SY=,_H47O9C\1JA?QE;H'JX)IGQN:"C$?.X(%?F#Q)7S
M8N]$@O>&*; <$-%D&C!QP]AN7$ HOG*U-S0,VUW)<??RQ'P3BH.$N,)QU AY
MKG"1$%NR<DR>%,;Q;!XE+WR![A;^UKIZ2[EWMF+VT&)AL<T^U!ZO9(7PWLF]
M?E_0J]BI%Y'&AQFP^*ED?N4\([K9).'+*?0P&*"D>L/#=%O1$L[33A*))=A-
MP[\7G@GN]<RTPNC^0.G%?3E,$;;9.V[X]I@:LX 3BZ05(JE/[\ $G\652V7J
M,@=;6.A-N&9G3@(3K_DY19UE/A2^-(+7,C3J3J9@QO$X>.!K4!=+%SNZAHKA
MJO@@RQWI1-J"("&*K2&>4/I;11?R4"$481+&4M13II_XN^5U]IGQ@+W^3?<>
MWZ!OK""ZH2#-K+:N:%355#+.GT!>9#ZHA#(8ONV-\I7@]YR641D7>?/O2V&A
M9SI\T$(Y>S,.6L?Y%$;\!( )?(F6;O.H 8A*4?V0T^2JV[-\KS=((9!CNO3A
MI.%=WQ YH^'033>"3S]12GO;D?9@%W\&IP0KR -:;+$=""E8:J="IW%PY:.Y
MA2,'PO=S:IF(*A[@Q6EL]T55A1J.+X83#;"=T_7^!CJWC0]"<'D1J%J_M(SM
MQ FR=4%^&H(MMW#J+4B*KK**T#Q1@6=>ZM7$:%\]GO8\W=JV_L&S\*^6QV:7
M#KR>QN[XKO]9,\YT<.^"RH!UEI7O[?2MSOA'41E5(,;X(=^B+@E.TZQ6(MG9
MC).S8'P V[=OQG4W),TP/,-X63^VRVBS\GM,S>2 @KMW3%7("3V&9D[N%T^Q
M6B7G(\I(F%ELPK7X^E($@HB0$Q*\#Y.+'(B6'V[RAUAN/,PA, 5SL2UX8]W*
MU;R0M3G+6O1:39<*1SVM1<EJ;^*K-U8'MP%"YZQ/%/HJGJUWR\Z+>^/LZFQQ
MMB/)<N#4C6W;#J1+&-D*?4)6"[&E<>/T%?H#'E"[,L?'LO7!;<+N\,W;&MU"
MV5*%DX',65XF#/N'FW-\7B;LC+7PO[K5_I&2ANSY7THK)-86&)BU&M6P7U$U
ME!0<&@U;62.[T+J@&&X)ZI<EC;V;-U)3R=G@8G);_5*I0(CX6V=UR:8-SGYN
M1OEJI^?H*)2ORH[O1L>V!?BN_<I-M-[Y*?O/+U5QRHA@_&=F\4,^T":62,V$
MSTF:"QI'R)!Q3?MX@#]:'-*EU2:Q30/*D,V4>!X@CJN98QM&W!Z>1UF_BYT4
M<8^A3,I]$]TA,)&IOI:5BJ,^Y>IP7N.NH.2Q,/>O7:#O#V48V#/N+P3<&L_5
M:JYY+SU]L"#-VO-&Z7.OBVU5;_-?!P=G3(I;W-::+H:!LZ+O63=!/^DB0>?N
MH9J*GWL^[U,.?GWD1DB;TS.)3EVR(U>X UZ3<IP&HJ=6UY \LQM.IQ*?]_@8
MO^W1+-6%9AX@G#FP<+$^ZM0^EUD!"J[@GFCGQ,ENK3/NCW(;GI6N617\P'E,
M.Y"]<B8CLD=4*;5*-:\42/Z/W!*!72_^US>V)(=0C=K"_88#;^))L/)'Q97-
MFV9]] NAI3'H5>H5'31M7S,7W0NWHQ>J7#VJ.O+DOW@>;C>OQC5UJ6@2.6\:
MCN+<T *S.F2)EJ[H/%5HD+%SK!W]L,W'5S\S!OT!<U5[KN=T-[XADQ9Y^-,2
M+AHAV"#+,H<SY3J.^H)8R0-:PW2KO(WU(4>JM;SC?<#Y4]UW5WF/+C.^E=US
M'R5[&O[,<D6*6>;89CQH1AF6)N%JBMKPXM#L6%R2,4Q*K[81(/^P!#\J.)KP
M7#OEB5].O%M0#B<\XZI%R,VVW IO_CGT4.\8CKX9S.>*J+&.SA(K)>:^$64;
MS@>!.4T#MS"WT5N=O6V=F\GJFU8"7+ZER.G]>/9&K5[>]DUHNV/3 K0;23>E
MZ9([FG 5\NO\:4\YA'K%MHF"PO49J?<:<(AXO0@G9@^BRJ;H*[9+H"8C_D2@
MCN@GK/V$8P>B!@$GF5PXG*E1E[E-BIKWL;H8$FWP8Y?T[T;)7JXA9N'CH*-<
M;8VB#[BT<6#4JOB*1W5UWOA$YH6FC_S(0P,,FVUX:.>Q6K8LBGFH%TG-/IJ:
M8.3BX<7PO,# M\I#,6.;<>;.<>4!Z**60X4A^O4_'TI;;:\%VJ/VD5;N'A>B
M4! X:BE.V4@#SDI!!ES,?9G7.-%E7 UHRAQTR!T[9G !K6)2.-U,IJ89U?98
MW6CNV669<,(LVS+OFFERZ-7GC&&N: )CEEJ]T$P9PIEPDH@T/4Y1H[KWP9D5
MI,@20JE))8LV+*SN_:L/'>2CNB>S_N$]8X=IA4L;E;S];9@8>R1X:Y N\\O,
M? [&X2WB1TAD]3)S9AOTB 93/TU-MKQ6"QZTQ9.=Q$:0U*[6U$AS&LPUMT@U
M7YICZY:9%"?]SO^P7VOK]KQ];U+,-MUOI;D' XA3D,2X+KV7H42EM*'%L4,\
MH#PO#NRNHO"/=#Z?;=P*98@3W4NR:M])M4I_BO+UBM\C_>'TNP=^Z$>1D!97
MY @+AZ4@A&%9D4S9%'Z)M1].R(.%4!P(F]@539"(9UN5AIO5=OLOIU;^_&D5
MK)>C)M!U\T'R].01FP,7)RRZ:V+1WX])<$456/)<,E[,6 LR89[C/--#J;A@
MG#_6.BHNC2I+=?IY9\D-B@D;* F<G7/+F'#PM*V[PJ?P!P7M&(,%7A1_^,Z3
MT3X0ZO4U]^@G"P>/(RYBO^"JLEJ(PV),-.A(/P$^G\?1$ Q27.FRWR&M/C$C
M,=5?SQ_NWFZI%)L<J>YO$F4F,HY$\X"A@\S=G#?&8DKXX>'FS/>UD>' BLHN
MHHO-Y?J*\BIG7Y\SM8Y(STSD@<.T ^6.>Z.5$M/Y5.!%N)&!^R*/A(4U2_H7
M#^B9S69*#!LRUSCWB6Y*-A(^^)J0-B6DJ(_QT; .Y0.+%WMT=/;JN*K?[Q#X
M8RJ3(#>1E6IP_:WXP?9=_(M6S&L@;D[#!\ZR!.A@$%Q'-_7;L%4'R [5FG0D
M(BI(:[I!BY,^,!S8?=O+7<RENNO)K[WJ;W>5?!1T1\&*I*F9LGYW<I$9Q4DU
MUN8.PLIY@7TU8@P!L.7[Y%L4M8GWT=JP)TEV00&RXT,G9[?U+N1LZO'?5'ZJ
M\&8#A&O%IR#*"7083P1O<1X'42 U9E:1K^M>T#&A;*%1CWT*"J5]WAO882.B
MQW?M;9]_YM;QNH-;.J2D6*B[U4\=O^/!FR%T%FM[.!\GIE&;^P4ASSUT\3=^
M2^-V-J(?1Q,'^Y@&YZQ>AW9W"H2Y'L[6']ES@#W7D(*9C#2.@F?R+ _XLI?H
MB6?!XFPC#YA.^?:!VZ@"?R&#I1 KA.C[86&CRGF*W1A^HYPAE(Q59&\&"_$I
M>DIA2J\F>HKBSM14/U+^E6#WI5/II=UCC]L'CA">(SVZAMVI!'K$&#J!*P.=
MX)0-(D2,=[A"NFWI,TZ86+4W3D_/O-WGN6A[+?RGBOF&R*,VY/-,+(BBVX F
MKA ?0]YQ<&\@4NJ$C&+!J%+_Q-L&[W/>O[Q[,%Q,/YNHS7QPVC#2[#92$UX$
ME13P#.4'DBN"9^V&?)FPU(P*8!O40RC6*3*&!YSL:13KHDE(4CZ_@E+M\M9D
M<FPRCQ1ET..9[5Y7J!,OB@\-*:"6$<Q!3IFQ/+>)!U20X-KOB[Y?CNJ@401]
MDH+"_ J'5VOE#UCNO7E"P/>!@:5>N9E"O#VE+M[6@IW"B4-2B_'@F=0D'E E
MBFNRP5%?H6J1]X;'\ITZ_<!*FDM-VAL7'Y3HTFN;_:W-WPO6GKX1P@<?.[U#
M%+"5*$%2J[FJ#![03DQ$562QI:70,JC?BN9TB?'A22A?,T[W5VTVZV1WR5@]
ML5?JVHZ>W>QEARLFLO?Y'^V5R.7VXBN*/BY :DCZ,$LK/(P3'2XW"H"DMM1$
M)E[4>#=&RZ)/1\EZ\$5?=Y;-^W0%E\B\T0LA4O?W4Z6CFC[P<\5LU^):T(G$
M"A1;-J[%2:60@-&DHE,6"AD_R1H/*SO=::5WOBCY)CM^-AUEG"PW^PK\%(B^
M[Z\6Q2G!74^]BP,OV@RWP-"1B[R*0#0Q)$P@9\;UKC%2FX0\A!UU[ U'^A7F
MZ]^7/OM%_EO=D]']6S3N\M_D5P<B7%@FN"8%)#6/4CU(ZD0Q4SAO&L5'PT\.
M5AM:A3D[VTAA,E>KZ#N%GUO4.#F9[C&5X]P=2:S,\MP1>9CPE$B-=K(GMB#)
M'<Q&3@[1DR [0R;-=8$KI&SC7/#5S-&JP0'RV9(!_[6!''>CDJ_?36[:G9[?
M+J%=T:E6>0L/.G5!>_&11@8L:P);RK>%6#6'$M">KX+\C?7#O1O+Z]*G3'OF
M=Z1X].IAJ"GF8:QX#9NEJ W'4UODA3K6B%P1;98EO.;WA/N!MW >>$BCMG5$
M_B*XTF*M\P,U379X$B+P(&'H8UV>5;S:P<Z#)*V&IY6'+-M-@7!G>($[P.EY
M&]N%K$32^UD[L7U<\;X&KQ+,. E?DW=//\*Y#7NPH4]JE#PVXUQ355V;QL[!
MR)D>3WS]R*(_Q/T()X'0#A<>'0);UI#)3UP7K)ZIL<'X*NSCM84F%)EBVH_=
MY3-^YL/(LZ$AA7,SER32:DXH;1&.KSMVE]!'&/)E5G-R>8 ?^A[(OLW):MQ)
MANJ;L^1[+[647")WB>J!#]2M*]M3'ZD'U*H\Y/-B9D))C"(:NMEJ01[;A:^<
M(TJS+RFW-1SUBNYM'2 ?_;F:_L8HW?5RK(5[LI@%R7>_2(R#&]\JKID(GD>0
MX;5)H<N"*U0<6\:+*=/#5?I-D0MBP)63/_PXZ-7ZF'VB:/.ML= KO;IJA[Y;
M":3'C[@_V.AX-7*?PB"2*RX"?68X4HES6507QV:B9(,+E<#GBU ,1Q:&WV:0
M[IYY_<;;6/S)2Y9?Z\&3I1HUUYP##YJ);68=-P1Q1D3?]3LZ>36<5SS /=>
M*U([AI/!L,XG,1O ;7G[&7_85@SY^, DX8D&=\'[7;@0[>S1GY+J;\I?/9'Z
M=F/.<<='Y&F<+Q+:0VG3O8L";3D'N2+U()*IV=>HB2&UXH3R&80X]!S;0SSG
MQLZCA6TYPZ-/2H?VTMUCR9>R%\+* [:)\>LE]E>RMN":S(WWA_MP7ANYLX2Y
M0ZB*5IP(5AMR; X>W=L[IT>4(Y5.9W/OZL$3R0JJ;FZ31.E0XW,5 MZ!F"N-
M-X\CP< ?ZN+(*^+'B&.UI6(/D&.:6H<^?N9$S]_&S0=&12KEXYH<B;YXLN$8
M+A7%%5F W5Z,&XMK0<1B=]:!S.KQ7-\QC\88W?@@P\MB]1&JHU:A<K<DM^^M
M^+SM=D9DQT"=+G0H;DPNAQ' #. \;]3R7C/++QJ"\,R/C,92WZO%PZ'RP=T_
M2^]UR# F5F^_NEE2=_B*&88 VQMEQATE5M2RI0C,,$8M6[J+"4&E\BV$>*)H
MH^KL'S$)2:>N*:C8NJ$Q?:;+KC?*K!TZ6T&_D!1X[]6J&<TU#2XV7Z'VQ3'-
MN4'6"?;Q/B/E"-IP<@CS Z/L.3)NV<*H.'?_I+.(XL UF/KNM<NJW"W#QR30
MT:R=[-V<:NZFD7 ^:/@6 =>L^XKB_//Z !8Q6-3KT9@B+\'TV7DW\X38 _XW
M!S*W77.$V0%;9IC)STE#4I^@I'&>72JX)FTVGVX+.E5% QHN^.TD'DVS#EZ.
M2]0S<PO:A2[]E7E"^X7F0X]'<5_4E7*$U):LN**7X,4+0"@XOAV<!^&6+*=P
M^V[=95\_Q)?JGBIK/3<7*]O<&N?AA>TENSH[+(:$$ULW^KVB9%- :UUHMP%;
M:F9V_!ZQMI8.8[T@/YB:1/1!QV]I>SFM:!U[]XWQ$W#QS*/XI),]M4Z/'#BT
M2_,&GF9>?(_UTL_P+1FP96.;%YC?X) _PG;BP=-H>=\[N<1FBK2/TU0*5N<W
MV8]=0P33AGZ8UY#.9ELD$H?(-%3G\9:;'D8'U,11CA ?6,\5$8('3N'D-AQA
M*4)8E!!;EU.P!%-5R&M,J(5^=,VK9]"^MU3M_=L^6I3959FYRR>_UIMGEK:[
M)$S#"[GX?3&WC0*>QPT5<47QX[F'.(VROX\ZU%%U$]=^/7I8*T:K#X-6+J*^
MIFGMJV59[4L_<_7DJU^Y)R;#[1@K-"^V;#U7;#_KR'68YR2:)QLK83O?X^(;
M[!A*I#4C*>7=0=HGOQFZ(*T3:0_WUO(]./TE)BZ3_LW]YC.$:;@'[/<V7--!
MHC?^?IX6YSG.AW@W!+'%R&KL"7NX?D$.*K9-5SXJJ?@LZMO6*8M2-]NZ59E#
MEAJI6U=GN<)6#/0YR)JEB^T[BH\)]RC#$*D2S>A$[(Y4JFMIZ?5S+@UKRLGU
M5OK5I:U/?$K5KMDGM)_0W7E$0$(;'K4&AODK/ "FF"G(ZLGU>WJY#!S],I$?
M9C2!\8W&X2:9WZ9A ?K:W@N<3W]KHG8J7<LO;_JC8,B;>;N:\7F;'Y1Q";9T
M&,PM4HQL6.L/ !XQ5O4.P0+@2LPO\.D =EM/6>G5[O'ZZD=;_-XE'@J^XM+!
M_MI9]R1IOSK_N"ZDB6!+*3$#85.RUX^E<F"+_$8.\( VA(KQ$=)K3$RCIG7)
M""F"EJ R$]A[WEIDE[-W:?IA%S6[VB,G105/+!>QMY@S7T/Y+#AQF[2QV\*M
MH?$2FU=0KY5B7)R1S>O+C:NZ_H&S0Z5R(0'<"O/8P[D__WS[=M9W8@':"1>9
M*29,BJ-NP,?JNW%2X,&[I*QHNBDH/K<^MF$8V#C?/,XR;SUH'G!PFF1M?S_I
MU;Q[NH#E!?IG'8O[Q?AB(O4NLF*J#3&DQA5Q!\=I@Z3-*A$&[4Y$9ER"D>7+
MR^WGK'8O*PV5]0B9?+VM?N!D6=RC!X>/[>*?R][U(E+TOZCMZ ND(QW+<ZSZ
M2W:\KWEWOX"Y(BF48GK,_E&%L''LB^]+RA(M1Z\Y:<8N.5L;?^&+]]OKE[DK
M7Z'K2R* B"P.M.6SI4PS%4L?OO=\[;&YLXKQ,&]T;/NT:EI425&4Q//7KYZ)
M&BN#Q-CP'2^3E9JQRN4]<_T=VB]SO1^<VKIL:,N7L53<9W=<T+&_*EG3M;>P
M1W]$9Y39$S2L7_I33/VVA)F#@.1RL8RMH(0XQKE%1:(W-I6F*W[1)_ANAYC+
MT<[M]_?/!#_CU\<F[@((ASF91 _T/5SY2HLS/H8'" 6RJJKZPBU?SZY]8!8&
M3(W,.#WB]/[\^;-+1^CQW$+5MDVJJBDRCOG=QP5E[(X+?RDK5#XA<"7JL.HK
M3$"SJRP8D3/-E0*_X0N'/^_.M-";5;^KW.6P)W+#V:/+I:+_?L^0+^O0P&!-
MSZ51YX*W7V(T$B]L*BNX\EHH2GA<]GQ+HSS8=4^OK3M<@S:LK--YN8+L,Y @
M<"+UG"R@@#S]P120L3,%O&9<I<&RRN)+LVO$V"I6/>=(0N^"_XUTR]*$&?=@
MP0SC5H<8&5L^4QE;?AV_4H)?065#K>751Z)6,J\47"R:SDD(2+;O*8IK.$@C
M"D\GO8#.MS"/>F3OOU;52Y?:^C"O8 _ ]]>Q4)!)\YVR.M\QO_/-:T'?"MT*
M+EV7E[-K8%*7178H98"J5=[_=;GVWZ'M1F&23O5ZL;2YA=O. >+M1F,O>, ]
M4@MB23&:NT;8SHGV]P^B1&>7SM?=7,G03:[&##C7'MAG6K?#43LC\JAX/QTW
M1,:Q(9A186. \W]S;#Y7&K$)]_VZ!&NF#.<%(\7BN 1G3>9O/O+9_+5+*G0F
M?#\/./$*N?"FCI,+4]>N^\B5WW9__6@KB/R;/DC:?I#$V?B,!S2^F6(&XWF
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M!4P9FI<&7JV\7Z]@?R[?\/.J_NHS ^\7B4N1_Q5W=O]' XF0)I&==LR92_H
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M^N'2G(Q&)<UFW4@5,>Y'<.:Z@>-L$5S\+H^XC8V=W]LU>?FS&OM;ZWCPQIO
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M4-).]MX($M]>+J J<05K[%G-S-;R\-@5M\PU"3HN@-#P:Y=$_R>79%9O@YP
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M\K  N$GJ]EW_JN[%)QOG9Z??ZXV\+DE3<8@P;5K)U+LOH5[[TT!WQN:3V$(
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MGDQ_)C:BZ"YV$VQ%)-\Y'!SAN+";AO[<S5<.X.JCH9L35"0=D#!@6[+!">(
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MF]RF%3#"<L/GE=V;G&$-[R]\/%R\8R:]$I\<(3V94K0]_ZVM36U,>9;7@3W
MNY"CUV-68.-#I]H5KL3H&653LG$G/7"ZE:G&<T1J?A]2S2_EW#V<KOAEKPJE
M=T-'IHRJ=6;KHNPP<=>9'+* #@7R(+? <=+CWMF^:ZXG6B4Z=SY2SJJVVG+I
M8W1<34'\J?) ;_N+NNKYA$@$>5=%^1(>(GY?>\5B_3H)U\U^)%%RS>Q#]PE<
MX3]_\MG/3!$1WX(ABX4A4X1PL'!X3D2^0J'&O02/+A.]"-OL*I '#PY59<6&
M4 3XQRT>W</G,/<9QGXY'_>S(^#0GFM&*TI7X>?$:X(B%6AHQ\>-YQ,7W$GW
M5SRG1VY1Z((BX8FV-BR5-N?D-FL(Q>UDM?[V$)>(HUWT7#MZ\ C$:A8A'?D8
M'_ECWI-YE!0V7Q87.G8H9<ZE/_O#VZU71.!S5WKK+"'-.:F/L *=>FG)[%CR
MK.JG]93(5BCRX1>X,%PJB<WOBB#S]")FIE>YL,U$PGZ$K8;<.^ _Q' FN#M0
M"L1Z C3EW"V_ OU B-_MT'O*A2$T"4S1@<4*MHAG4SH,$A&9C:=:(WUGJ3>K
MZ/SZPNW%7_;7A-VY(1(^[HL'0C+EG9;WFH^2)KL$(QS%)GV_I24F3\<ERN$1
M4'2^80IS8?I#X!45 G, 3NO';0:^^W-A[8X0=13'C^D51("&JVITY#LR(2WP
M^S*?(I2?R'EZ6Z$L >'LLPX\J&[(5I?]B%L_2%A\ ?'VEMSU<MDU^+?&'UJ>
M,RC_TYLCH>S"=$4^0BR?!J9.0&0_QHP+$S"BR8)A>':V'4!_^]=*CJU_D5@;
M&HL[DU'#A8'B">-(CB!J[2*4CR:N HV7,1!)?@W]6CX9Q7:-R[\)/.5\UBL)
M!7U7,[O_!5,RY[[B)@%OP7_;\7^F'?^XB 83\P^-6I< >9_2/<F&S2CB-:9M
MH[U"_/0,*/2CLB:W(.<QU2).UON09.M^_+[P7,M8PW / 17#GO0Z??O')2F\
MIIJ?JS*7_]-PW(RX"X5C-8+7I5S3R$^@N<=Y1.'@5#C;P/7ON!+/='8U+8I1
M"<7F<Z#^',)9->2@"O0AE'V5*34>%[3^)>H-^DH]G,=7[&3:.5"B]H1.%]6V
MNB5F,DD[+<W!KIKGV=PQLQ(JKGB&O<>O&5=BV.K./^&1 ^5F8TX>*%6?$9@/
M!.M)L2_&_=[C"S\U:.O%B/*Z$XI4:I=!/G>/EQMY>9T]A,<V83>V_J9!NM$6
M>QJ=,&%(#: CR)*M]<(93,^/XIKU=O<$!5U73RE//?9K6?_QNY5]0/Z#0O'K
M4:L.Z$GS0Z$B*SSS$.9N32WFO  UG7$2KZ'B8L%![&EW8:H6#==$BNES79=<
M37-7)JR;9I[)L$OW3'DA=:<(8KB-D;#U+W]JJ1P^&#&>B5CTV@)^U""L[TU<
M3?N%CGP_#JQ)<F$CQ1S!9Q/P-<AW1CI6=,4CY?!?!=N#_NR^AE]0;\L_/KK[
M%6K?A&IL00[^9<Z>@$",DSW7-/&;@:\005XW4L8^&IJ981^ >O_HRCB2=8#$
MA1G)X//&\6L*=PD48-U$SRD:F'S1Q(6%8)W921F1BNMW0*\_O2.2I0/NT(?(
MW!=@_F(_8EE+<4+\#U_-?"@!C=ZAF-(!WU2Y,!G1?6QG3CI4X=I=,.D?"]23
MXN0AQH-));+4&ZRKKJ1RV6B$,RG.7I(>F^<F\LYS'!]1D&,[RVC;Z;4F^O:]
MVEEAL:;HR!$;P_M2RK8$R%F%\&3-^2SZR#DFBXP;$63$T<T9P0R\U%GZ0O/L
MBNG1'UUE25_7&'BQ/53KJ&QDQQ$I0, -' )HUOBO$@P%9A.NI+4Y+D+\2\X$
MZ7WK S^RX#:T,<NFKKCBR98#R?PNPN]T@A6WW=]E/E!.O6Z*'$X%^758A[&#
M<(E2Y$,X?XTJ_3+);@CL8^RO,:+EF_?=2?Y4GC3%[D@-M] "+UQ3H6@>-S_P
M?N^FE31(11W\U5(#_"_<]?=-J.U _7E@DL+#>>@.+,LK+IQB5T#WU8)] "V/
MX/:(C&2> TH1E*3B5"J<:&\YYH(>F:K(N39$O"LBGE@R9J589X0-^^15YNIS
MPMZE6L5Q_>6H"(2P;$U#SN4%=@$7QH X3A5B+AF8\N3"2BVIB.&O75-LRS7<
M$R[,>9P+2Z4!DX&;##!<&(1XD)ZY"FD,18"3$<?TB%O/(JW90F1J+^#D@$BF
MHZ;A1"W$-!N^!C]CAH(PMM$'&(#@IQWR0N=,4"(3S/,#+;@PE@'\_ZXDC!$K
MN$;@ 0V[]UI"F8(V"E\Q(2Q"%A+E((3^SH6]M>/"$@E@CR'COMH:( +>X&0&
M@Y[U7-C3Y6W_F1UFG+1H$-4,/ ?^;</_:3;\ ><("A!)^ \^"-7'%D)-"+)5
MD$%U*H, 61+L9,E&6L!5J=C[7-BR\XCVUP\_>NL,8VCH%-W3VI<T+./,OZVG
M"[3<R'=Z'RWCY^(3&%?BG!')/L-Y\I?%44M+X"Y1",[]:;*<6*B.-_%#WR6Q
M6*"^@;3H:0^QDR(HVRS'VZRG\T%AF<,/RD+WE$RC6T&CETBFY71<FZM<!B&[
M:V;WGUU"C2\AC#]&+&)FP*9."![U@^J.__&K@"C$9$HS%->&M0U<V*+9#: E
M;G@.JC%9</;ZWY>X!!#[*)I4(5KFN$;)!'[X"N->'*4U]LYDF;CA(QFZ8WEH
M55!MDXM:8/&/5;,'=TOCR76KR:7W&AXBM$HA8B77-0^1^:T?H+K*L/U8(6;;
M.!+NVLTV'O21Q* [&E&"JE#WE/R4ZCT4::KP8(]NAWA0PCG:6G@=IJBNY6)%
M/PD"6U$6XP@'#^HXHTKP#1+("'Z*ZFY./DL;2I2A_DDX9]TH:X\W2RJR$0YQ
MJW?K-(4JRW,G(R&1PD1KL@]LX<*,5UV@#\_&)+@POF7DL"$#2D=!'R&*PGJ%
MYF>\@3YH6[,5:#*0^Q$J, '[6D>%;=U5'=_UZD<IFDUW3E]ZJK_(Z=)Y0#:%
M!2;_N1DYR*GV!8#(E\#7%Q"I^>X]-+^"W7BEB!]A<JV5$Y$"@&&GL2%D'/L9
MCC%).(F!AY,6+T&IGLY!1D,.!08A>/YTLN1 U@;[ Y-C-7Y<F$,*,"MMOJ:,
M*D#0/)'LU*%8+FS>&\F1CJR3:$*MR;P%(N'KE_7Z&KFP-?D\J$-1"8@SWZ&:
M?1!_90[_/7+^DB"1U @OPT5@]_)P(D$Y])5&/>T^WPMX]RNMXGN3B9>*-BN&
M]?VL2;(NF'A27(';=4M?[./AYY8Y/6?@N*IDMD@PR'>:)A\7AG!%,@^3FMT-
M?W\X#XXP)0MMT/F7^H^WIHGCDT_RM3X]D.D?6^9DR*D@C!=Q867]P8U "9PM
MK"(8).Y8/X)HBB-*-3G;MR''CCLG(6:%C;<;>SZ]J?P08NIUSJ]V F$IFE&Z
MVN,"@HUCI^DXMK0_-33.W;, '<;25H**4^F5L2ZL"6^[H-NZ$[2)SZMV'K=H
M_K=#_O_0(?\G]S80Q(#Q:M(B9@+"<BC1ZJ<3G/+I82!_[48C$/,7^Z"THOUC
M674GY P0L%7(K&6.L\]#Q?B!I+@YC(/!7LME(:;6GU[#]P/)ENC;Z-\) NL
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MFL'XYTNF54.MG40?]:M_K5HO_5P@O5O[^K=J6IA8*'#\A1;I)K8&_@UYDD5
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M6H.GU*9C=X 9S[+/$](PLJ%3'D5%,S74["I]E6]&VF.Q^S]8'NE*)WNPR[C
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MYN*#4)^2X0D;+J ;VGWG_A6:0#W!!P5I%?2/Q*,:OV?@0FN)/QEW&Z!<>O!
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M<%;L- +%B%W6J1%HN+2!%/Z%4.I6*:#,"FD$?IU 1P2I[<EONW?'PG51P5U
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M]5S0C=M#HEZ'AG>F[UNZ\8C7&)NJ#=0>8.<3_-!W<'4;O9[X!"X@&,YL;)S
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MO728C"L="6D:T/[ Z50!0QB5:8^=0( N!N*LX^S*SOU.0:67;Q5WWGXA>EC
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MVRRGO]0P 8 'V^ :>-F(/A_B\NG>3J$E-%-P$JXB$)C3)JWOFQTFAZ\A+ZX
MD=H7-B+G 5?=M=314CATWD>+_EWH7,^@VY=UJ?,%2@I_QW&"J09Y7<E6II"
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M<=I@]*&OFDBF&,N6MGKB,^NY+"N2KVZ%8<Z4DB)'IY*;U-O E3?76;%.":U
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M+!\<?#ONZC72MO>ITB-R$HAW5.$Y-\9^K#SM3D8X3ACZ2MK!U/C8YX._V5/
MQS%-]_)DC-F1FN-$+G?>UTJNWG/EAK?T1<ZT?_VPB] O?K=$>((>244ONG%
M54>)ZX)1='$^-D**R/#$)"\FV,#!#F#XX#*>F.@*,3:M7?S=<SCF WCJ>=<U
M&<G]<,Q>A)W_*2%X]A_GE+[2\,P@VUGDMW5KF!Z]^J%S8.TO2S%@TWK?7RKY
MQD903?%P+1)P+4O 5" A_==II8I:Y"(J&>:F,MX)>G"_#89#EO3J'\"Q>1RG
M]MNYX!^Q =5A%0_*:C 33FXDGUXH0,*;"?^Z_[P>>&UF'%@\E@Q)^T_"A&1D
MDG+S'X]3P<Q'%#V2CBEJ"P,<T1+05PS5J*U/ZSP80>1.S\L' \?:1+WI2GR&
MA5TNSCUD1>?(9A]EJUL>RK.K%\P^<JO2B?D:#6V@(B:D4L,N29+U'KA)"L#Q
M484:!X#B<CTR,3C"P;PHWOF=G7:9C<MCHZ4/AXN_'<W.=R\6(N-W,KG^<CH?
M!JJPH??@5'$UI%S;6N)N[&$P43G2)\L2C!\][VF*<2@:P%ZA9-:4[+"[9G9:
M^KST-=2WB(.A^?-TH-]]C(U@[K9I($D4J&S'=9.HQL1GT#;JEMX!8C'3Y"W6
MW.C"?+/S!P)GC)/4UHWVDW"77\6#=ARSZ_\.E_\SPJ4"7)&C<0!1$J?*W-J#
MD\"U( L*\-NPMOX'LNVMT2$UT>N#]LT2=?<-B#:?'X1ACASPSOMV="W^F<$C
MZU?6-QF64!.)#^T4'L!!MJWC$_ FG/#3N:1D>H*&?L341T5FV\6%&LP*_<RI
MD_WYZHK^5G'-G>-'U!%8@(W@;89-/@9\;_ -A/9/P)9M\IC"YX7/'89U9P8>
MA_,S&,XXQT94VQ-02MXJ%QCF]-[::=P?TZ+R,Y5W/G2<CA_T"XQ RML& U$7
M%F1O5MW2X\_"?453[^E5G]7DFUN!ZSD$FM(TSH12.ML:D<_:[#,'=3LN&28J
MH!UN:'Z=^="8F:V)9@JD0MS)#(,OBL!(,HEJMC:'/;BOGHVH7>@GU3J2NXC6
MM.8/^O&D@\\NCYV(?XU/$'BY:?7+WM GNC9,':IP $K(F_,TB!G14>R;PHEU
M4 HJ1+^T21-M"XJ?WWRFLZBJ13EC\OE-;H.^K$R1',<DH4_E*O$3>#S[I//;
MZ]<)3%G1IJ7]4GL8AFXM?J[_^P!5[ZM?IU+D.)!_<T*'#*-B]9_UJXTTG5;\
M@7S@YB"?\B75U;3)8,;\_\E<RK_T8&R ZJ,KCD-H<G&05&'[9.F.CP=5^$4P
M/S+$>QO5_X6U@K=_=Q I_'\?0LH)5J!%KN3_C:1V?W> J2_E(>P@?_OE2C=8
MV B'WM+ 6E>^1H_D-@?AZ[<D+QTB?<8=(V1E_S^<,>;15./XYA!D^(2?,\HP
M&JK]+'G]C.V"7ILZ^5]AFJ[_7,Z-%>0C<RL4@XGIO?&U&A>SCXJ:WZEAQ'7]
M$Z;[)YG_SYC70VYF,:RP"J@3H&81'1^1C<%30 %Z-#HOGH(<L#8?MO<>_%F<
M<;UW1A>W<;^(%W%\K9'U/ Z  G7\%P(%[7M&E:]E?]2'XQ>P4\$L^:7[R?ZE
MQA7M1D@L%<KR@N!@S]!%4H>0*X;$1;BE 87)=855PMP<<A%28;;5H0O<\"V@
MRB+J(1OQ;(J->&_%1D01H0X]IH8>Z]("$^XK/7@-"D;G?P*:0>(2'T7<=@G'
M\Q>7*47/Q  _7=F(@HV]71ULA%D9&Z$ L%(J@93P_]5"+4-O#Y/T&$8S4WR@
M2_CZ.]*:)>SL@D#M Z!;F8WX2F(C[ CXJ52&%B>3&,)&'((Z&@"-$>*7=8[_
M1 0YJ+6:C5 992.^_5N"_[X28%(WWD(#A**IGU'<8-FUC8O3&1IS20>O8HF%
M:X-L1$>JT^2M,8(!\P:A!P]J9$!&LXT _7@&%*&+$1KEY=NA]\S!@#]_(MR<
M^84AN;GAEJ.;Q+%6\RLQNGTLCI1@A;5E5M]?\B899KQL1!U&A'D,Y!NI,*R.
M:^R;**&YUZNRDHYKJ/3?/E877'5?RWQ(:&V-C>#D 9HJO 6@1@T8!ND[3H-'
M#L<(D%]']:HR8Y>PF(-ZSVC*RJW-2WH3Q4QUV4;7=4GB8JPC&]&0"<N7!E+8
MB-.]D*D2 ';[L(18*BM.&HLJGY&MQ&MU;(06HW\*2>W"2Q"G?&'=WB' N#,5
M$HT<*V;Q8=;.%[(18Y<GETW^^AW.'C=T*T3WY?R_;4;0WW(',V3^Y$J"\1*Q
M(@E.T#OT:8-0((&9;L%&T-ZCR5DH+: =3K.OFS&0NC6@B[Q2"^QGO/2W%6 N
M+-B^!6HO83WA>#;+1AR,)C(=PD$'XS#2L@[P\P@,YUZ8XSOTNC^1OE2.(_\M
MQ7]_*0@?@9%@0*Q2%H2#0YLF9TBY,;W,&#SC^G.QLGXS<,C[WOT@/O?ARJV$
M?.+(4_0B=A*J:SD-"_&X$@B>NAC.>RONL?&K9;VR6J'9YJ!#32V%K:7Y=%\8
M D\(K)_Y9].W_WI2NPDGM06@:2F<(:#&1K!X?5E)A 8DJ+S*Q!^#^8<JS!7:
M)PGMY3":CXB$?L1,A#^AP2"%Q,"ALV@O!$TP[7HCY-_&03EHJJLQ,[X7AE9S
M[L8LZ6#B@>R5#&C'- S%?6DD5I@]&Y'VRKS6&PYRTH7&-%@A!GH#WC#\/:".
MIC8OVDY)P$VW!B[_E3=/3C+%E6!DLC)BS!"'@Z3^ 4*[)I/)1CP)((X/E\.4
MSB8>IDS2A2O:0G 5%X0WIL#T;;_1PIF1Q_!40@LRHLM$%S#"M^[[;5%L@>IM
MP/A:&YSK Z' +5B;7TI6=P--ZK @F\/] F  DP(3W!?(_(T&E9'?J_^/;Q4Q
M'^-C"OM!Q@E 7VP&#._<>^=6?H$@N  RGOD:3Q\GJF&10:3%"VS$((UE'&J7
M$@P]1G/^-@=DP09ZX@O RH5YI4T<,"U]>4WI5[-6BM5AU@Z\!X*1ZY=0G;5L
MQ-I!F"D^PT2B3\"D"GJ _BLS(Z+1(V37-0W"'T ?S,;6]95PCWK_Q*A9(X0U
M^7O$46#=$&4+$]E8>- %X.R8T7"&67>"W'Z?RFI!VV#?DFT%YLYWH9>/*8R)
M_E(T69(/Z7_ @-)^/U1@Y]DMS+1C)6VDM'M0]#^K^'<X/%$$&"DC+6+'X(&/
MA@=^$M$VFQ8(\51L= (]=[Z3C5@^/KNL I.3\30VHOC 6NH(\RQ<C1=$"I_!
MVL!<9)D?//;;DTVSQDRQS@W]CA$9XO O^OL)30Y_8E?J\'Z8$BF9,B_"8KRB
M)R'AOXR,F4>8L>N<<-M+R:R_0OH_R=?+O+]:UM]X"]!D"GNW /R1:TO:-K":
M6F69"DMZXX7PF.ZT70KZ;5'Z2=13R#64.QMQZVXR'*ZK,2*]OY;IU.,7C6YM
MG($?)@-K<I^(8WIS*W"3S8'+G_[/KL41 F'7WC(,!Z]))%T&5N&Z^ I#!P/#
M*:N%-93;1A?P<!?:,,G>\%<.R+(^J[0@.4<UF)%$.A,P'1.52R&^#:_^NX6S
MXF7TLV%9FO!##])S4:?#1;'DP?ACZC*V6K778\_XG3V._(Q-"'6;O5ITML-U
MG_-)J[>["$FY_"7I/@U^8^KK66-&I^GO:.:U1!$P!.)JI F<[2H7X ;](7'0
MKRHFVJ0E;2!-E6?*Q5EZ$Y/N_Z%YKQ<.77H9*[Z@D71END$>Q0 SE*\2?.5;
M^F>ZXLV+GE<XV\[?[C=3/7#IDNL09KM-B^Q\TW"OA4P$SEE)Q6,MAAHYLEI'
M#(,T"T![:GB-AN;$9U^)G ]*UR['FKG<51R7S^20SD68OV.:;NP,QO4"G$P>
M/YI"/6;[2$E'07+BW=G3O4XK AF^L=\'S&]S)!0=#15_9>TVQD8(,<V*P>11
M'?>&^Z2I89DNE?F8NGMZ3D[2 @;C;0(UCS;?R-W;6" W'>J&V9CV0"EYH/N)
M9$R=RJ#8:-1XJ=<3%>8^?W(BCT'"")AO6K+ITK8Q].S^T&SAR,W*O*J%5:KG
M[]Y\FBJN>_#4\,S%?)?[KG9-^JZ=0_[#\8K%7 _K+S^0/^NU&I_XW238\JNR
MBDOEXEPAJ8YHN]"W0 ]F92FN&+(1CW";0BQ"SD;+K<A$6N7F+\:=J-^JG!Y:
M=$ICJ/5PZQ&%9! &^YM_LO)0F[$:72AEK!FHSQM+IBB1+2DGM4W2KZ\Y*V;M
MXE/FB?$\,*3W-0,Q/O*'7E O3-8+'Z'S7>>TJ!ET_4+4V>+1]F$TK<NQ]EGB
M^2L[B6Y%.[WV375D->Y/TN*/N[G$K39]@5?]@(LYE[O<.Q^4J[U+M/4$14GW
M2>W/0JKZ>[.G75D-S*^.44UENO<7,3FDBCS7TZTHF.%7HXD.*F&X/_+!Y!'7
MK=-9;QV.&$HF9CD,RW[*L\P(.RWV7KI3(4$SJO7';8^/PF.8*B $GY_Q8AST
MH&54]?KR$L05C@Q:"=V)EI'FDGK%(YUI\.E'Z%FST'%^"SP"X@>18S(Y'N^\
M803TE+KZ\&UN,#KO!QBF\'S7F%_1>.BI%X_+<X<*L$.^O25P7TR2NY@'T[%(
M\+2C1&LNF<3MS3<'28!/%*G-?,%27E=\<@;V2/-L]M8]<W?X;>A#[DCT@$CI
MM:Y#$0FWW[5D2*>,1I06)"3<I1M))Q7GZ:= R0'9D6U"(E^5M4N7&O2+YEC=
M0G)* \Z#Z3GIV$(RL,,Q28VFG#BRL-V^S2=KIK>]?[KGU:<=VHLEY]IWG=B<
MOZF)(VXUT1;BLF+<LQM0FOB $K @M614=6*F-='/"QB#4R:^^/QJ+2TD_:+J
M[65"4DKTU0/71EZ]ZG@BE5Q]27.GGRA##^+*H/*0H7":>PT@4< WX'6F&VOZ
M[EI3UE6F2OOXT?7*#+?Q$JAMUY#:Q=N/O<AX>1&;D@^K$L'-GUHKCM=+)X7M
MBB+IMNPYL.4[Y9K+T*L],CP[WMRZS/TRTCG';$Q,^6.K4M.:K%>>7OV'#Z$F
M78]YMTF]M%< 1BL)V=Y/1F.>>U" VL9SQ,K>!665!]&AR7FQDY[>1U]RS]TR
MW_S'T9XM?F;CDUMDNWV3M$=3C\:<2 F6;_J?E.E7D?U:=$&PFG'ANNQSYW)5
MMSLCU.)7^J.&\;..YRPF%*[=/I?B&&-R\,A^A;D=N8:[!S9)U6;/J_0UCKG.
MT6AE-<@=\+@TZ]4^248+8#4ZM8UY [/LUWV'[7T#WJV\^Y;?I'WSZ:L6T>B;
M!3LA:]683=CS;(3PB^J?\^E[''.&$CZ;*R:NF1K-1"Q6#-A?I=]75.;;$V9&
MXS-2_)CZ;2VB<,#>;G"I,-((K\"\PDJ Y+$\M-;8$62HJ'K1<X_LDT(MB4W=
M2O/.2?T_[>I&'7TDCSQZM7C:K:"W$'2D'V4%82U'FXV?6G R!8^*$7;/:"C8
MW]3$HDJM]ALV:%WB*RAX2[&M>>Y)&1>7A.P9QE"S:,S<ZDTR(#(%[%K&BX(*
M#5=B!$##>HLC3>)>^[G^,!:HE=NQ.7..8U\KC\WQ[9R.C#U,#FK;,S40[4P<
ML!XU4B W/EU1B]<KT+;RSC=[7EQO8Q>XD+XLZ81_L.7FJ\#;$PVW?IHJALF(
M1"=EW==5]AG^JIU_*:KSBENI5\5 4:+(>47[B2.U;;QQ'94^&LT\5LUQO/(]
M7A/YEI;^V/G!$<E'(Y@!E4L@#^,"]KPD1^"9BL\%/>JSSKQ6EV]&JQ\X>EI
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MGJKBG><WZKZXA5[DK#03]K6.!;2%-08>".@[RC#L90*NI3C9W(] F8:-5JK
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MXMBX@7GHJK22X/?MY<Z/!Y^)_('Z])9[H#4_S=OK7!F-,TC=TI&'A\=>685
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M()0"SL":JG$(0#_OL<#2,,:T;<%EP%&<]_;G8=["\\[*7GND*Z:5E%@]X=_
MA2!5;+SP61'-\F 39T:N+XG1A$\GT?AC6-=ZH=LJT&IO*5"-@K-F-AS>AX ]
M'NBG #493=X-M5+K!HCT0.8!M,N2=EF('9:@,I=K@[8;*G-K^&:3$%YOP<B
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MV .ZD<U/_F@S;*LV T7<V9<X$D O^Q:';YCBBYJLZ#81Y::9',"IMXZ%$.4
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M-\).EW^]8"%@N_M$^4&-ORSVBL#/P*^?V?-_+17Y_^M_O/AY$_\!4$L#!!0
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M5LB=4!SX\;'&\[SG3\_>8$[P (NDQ7A\VO"!V1VT.A($I13H#&48S1$B,/?
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M%=I5YOF_#FO_(9IF$^EJPH4+ YPMWI5'*UX?ZX^;OG]-UBKFV;!&U0[M2SG
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MAOB]$ZWS2'\;]%X)/<KD"/4QS8*S.%OJ8104T8H1([+LIK%A5E0;&3CC"Z.
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M]/@PN^G/D;5#2,K_=X_NESJY*.BID#U1^3+8P;JDME\QD#V>%W^[_<Y(YXU
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MT\0QV"TTU_.H#KEL=LM":M73)M5T$7"GTD#BS,4KV-T/T,??_C/9?3V.48%
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M_ZDLU_I&P+ZE-#U4ZY1U\@9_\JD6_][ !Z3E=-&E.W]*D-JS0!H/LCF*$V,
M90?T8O9X4$1,2M-.)^8Y:9#NJVV?37QI?WF@?)B='>]@[B^7\/K@DL">168!
MK2HDD-2"D/9)-F(^0$13BK4;)QDZ@=;FQ41Z2JAK;G-FU$WIT B7B(B8,G&1
M-M>#K0)/7?1LO,Y721L;]C\)3^G\45[VL]UW@%;0LM1 /91=T5S@1<BB\B"Y
MG@_%Q1FA8)",I\-*L^:'\]RE0([3RMHZ FC7.>TCT4K"]%PF4,_BU[J9JLV-
M7D]'3WUH:5%_V!;*)[/E^OO )&8ZL,J"H]49LE'CN.%8IFX-D)#M6?;BJY-G
MN=.A\I[EFH.6<:<2_6,^O]"Z)V?\]91"@=W-(Z*1"-6,  ._Q1EB#>;R[4[*
M[1]93_,EY6D%W:\=+'[5X#Q2:UTXB404\5F*)B?]"-8%1^Y@>N$GL$TF=!8R
M!1H]TF3I2;Y9<XU09!I$/6Y1=*CK^K4+(F%R$N^QHC 4,<I)GI.F9\E2QS3A
MBY:ANS01$,-;8_J,+>74'\M>&N<_)@LVNTJ_2D>&?=KHX+Y!X/D]PT;NIY;W
M74GFQIT8]\7%&M'O1-6DOL#EKP99"'Q\!W)L=G A8(1!,9H-5VX&HUQX9(\%
M)X^M2]450DU,K015WQUW]%]&R/K)65>9A]W/K=,^9):VX?:^F'L]G]_R"PS)
MW%ACEN=[R$KUH/1,J4(7!)6%# ;-D^8Z7F\TW:24D6+JTO ^6SZV;F.%LO.<
M\YS.9?'T2M0J"A/EOB;1]6:FL\'<:D"<D?44-IZ** NEB62:,5R8.NMG>,#"
M:Z6E7UN?8>P)KSU@_\,WY4"TME*?/;E#]!7UX(76EU%UT7LV"1/8^MF>4F6/
M7=Y[DG5G2#9:=\V]LSH.5]FWM0F>L?.[GA[7-CX93A(/(CPIRKW!.F1<^JW7
M*VL.55<Y]/#E\60">:9T-K;O^U4PN)\W_2>7<3H<4"(&$]T(XFR!/AK1 S=B
M;@^(3(S =]LY-D_J"U-=B<'R'RNC7 ]=7TF RC7O.V*_@S#UA*WPR  #3+-4
ML?5PX@TLF46%TIQ!!&PK!U"3W8+H:XD=%QD@,\0^(RW-+ [/71G,\6!RM!;5
MGF][%P[35#CQM>+B/2TSE@'WTV^=$5G,-KHP#:2XFW7@H4Y;>PQVFF9WTT<F
M8(T1,PMDQRO,@?R#_9K*%1B;8W4_"TU%Y%2KOI''W!(Q?4ZBH"-.<_N(,J4+
MT8D);!E7*G%S-\&,CQB"D<4,VQLDI-GY7V'4;2[-OBFR1234^>/4Z A0Z*@X
M+TX7YFXK'B>06]=?Z_*!SYX 8ACXYC+*;6X[@"1P!]9\P[PTHP;W;%-[G=FX
M]'75\G@"'W26O/DY/>01S/3'OYC O\,$+LYJF67/@,ZWD$?JJ4J;"=)\MF_]
ME-+D]L3ZDDY4&F)F:2C_ZP?)=^Y-="T2;E_4IP"1-T_F+&X+>B_.U8T)<#ZN
M'WR)V%6[DRT"'QXQ!JHF")L\#(X9[*RA:WTLTZG-ROQJX7'W[L'F_ 8OY*MR
MQ9]4E^\+=?(YJFM[6*J8'L1V+!+Z*$6&\Q8CK%]'YT&>Y<N:GT"I-EF/Z-VK
M5J\_<&B_TTF7^R<.WJO8%+1M%49UF\>N]S- 2]P:X8+#H)PY78J<D_^B9XKR
MF)2L%1TV2$MS*++-;59MNI>G;J'^:)=;F-UYE:%[9@C_+T075=0X:M[G'1C-
MA826$4IH.49JB P/_R4D)73=[FI7W]>D9P>57JPNR&<4EGN@WSJ^Y^^[67K'
MK_+XU,E6<ON<4DZ&VZ&EDPKE-8E3B,Z,"KB#I([X3/TG\^1?5P=+IQ[T.=**
M%C);VQ%T*_PV[C!6"*WYCHWB?.0>\$-1U>J@VX#I"_UZB'$*GT>62>UE[3#Q
M-TO'<X]5AY]TC=3;)J]@XOH-8H<]C5%D7P6\Z"X3F3F,4"HN4F49+N0^J+!D
M.4"X,2)C>1?WX*;\X=2@SY_%#>4%5HU:*/0+N!%A9AZWBZY-H["\/%+D %^7
M7 ?*K!,_'?Y8KC>D]LM9^7#=JOBXKV<D#8]EU\\*%.6J708-N9Z5OFPXIQ)M
M-H[LWH'I_P!HG*9;K#"?T3/?C9_XE2MD?O'*%N6(9RFS8B]-WF:'&]]?3<*]
M?IRXU,% V+RS+[&*2-!X>B/-#:E\CVV1F6196H$*$$C_,%"3K!-[CE05_J L
MOG>DYC:-S))IG;\[3@C#EYG2G!798CP(E?1T :TZD03?;K9^AJG3KGZ7X8=K
M5[N<O*[3[J'+/[:+M*;(7?/?L)=QWT*#"8).T$/N$$6"[9V&^32F#.32%R9W
MER*I>]6LZ'SDCFP/J6?/6O7S.ZL7F]!%%Z:>[WUWFD/]+#J"X6-OXE3K;68<
MZ&A"R!#'WTJA<&C-31JJE!#5VAW#/VAW.B5MAZXV^\@IM!X>$O#U:I7L-&(9
MH=>74X/]"%3CL1J6%H9<*T/'A1!H[Z+N"_E.Y.E$5MX(3W)R5URZ].DJFR4O
M?8F^8\<A/<>3UZ<LNI+2Q]-08_?2$ST4/V5\3JQZ4%RUX!S@5]FEU_/M;CFY
MR&Q4>5CW5TUI_VHY=YMY'AK)@+/%)ID?&*'-W9N-)W(Y%X2W7_7D[BWKWT6[
M7R$[YN+FI=*#H?W<10K3VK4IN-5S#<85:/7.)X/AKX4YWC'!?'D5"J'(O7JX
MNCWI)ELO32&P& 1.5]9>/SA3C[X[)W48J+)DV(3K6>>;Y_M-MY![LZM)/H<P
M[*[<&)EK=V(.[=_B+U\LR=W$[1P[2G>K$W(9=Z/),8I6J"3F//GEPY3\?(^6
MX:R^GXV'BFXL9>CNUKK1]=/PA[*,DZZ@S7';;,T.?HN#;@M*\DDV-0E5J;$U
MB10KY'6E;HE<4_?%863^"_O 49]^@#B^4D<8*3<%#>L!N# +Z?RT@5P >_4+
M5]QN;DP<",ARW\W?>''F"E-0LQ:O@I(V5WGAD!J:G-[VPJA%3(J%99X 5M5H
M9BP5/T'FTXJ>/OA'AEN(%V'AUG7YULV-1Q3.*+X(.C5A-GU; Z&! Q2T:;'I
M;*F/G,AJQ?4^_-WXS6ZEL1;AY,FZ&'.JKM?N\Z&]@RM=(D7^MWJV108$O=E,
MWD@:0FPSV UHC(<V\"#";%G -U-:7[!11[\V*7U$X^>-((F&(]_UBG>JVRZ:
MR?]ZW\DX8;^,5TD[=++LC4N'N\&+%1?? -_2E,I9%\^>'"$IU.M25Z1I<0^F
MQJ?_AWMJ^.I2YW_R:K;R=#=P"!6-=<.%4HKSI%9HVBP1O]#)E5#A,-54^$;
M;2*0&%'@4G'LLQ5]J'MQ4R2_M=IE]<=LD]HG!#5.WB_$"+\I<-?%AR4*P.L>
MMH:/-.UNSR:SC8B5Y4461T-91FD.&[_?0=<\8F>IIO1O6 7IN9 %R"!\P8J)
MP!S%4@5FQ.? *=BT=@,*W5$@F@OXN8T+LW<&4$WK<;N_<JI8BM0K1):2QYA4
M20]SZ*I>[<T,X6ZO[TU%#I'8/(]!C<;$7]UD9 N>[IBL/!E?X\PZP!;C)/D@
M0BW;^=EROEP=AD+AEMS#27Z?QQXZX%3/OOFT!W5) "[?CR^:C@2K3\5:>:N7
M()Q36"O([9*"-X89#/ @VV3?C:N)S(G.]EP?M$9],[VCE]E9]QCA>[8CIDUL
MPR\.*$O_'ZQ4V<GJ,Q:":O?X:5L!H0SI9BT=A= TLF97UOM9&T&QW3UJ5Q[<
MAM!^GN6+O7#L9?H+FUL>6O-1#Y6_X9[@Z;;$80UJ0DN^V\2;6NV/)7T%:,-,
M#\R&05<ZAK!=JC_A ?UY_O&RAA.ON@^=77FYH\KNGL2Q7SP(.8+:2C.E#ZKN
M:F5>X\0Y PD![S6[F2])8UIE/5[W[T>:%G[SL"2[['^P04Y2UD[^L6.I^E<O
M*4;&%9GH<W.)/0X(?SN,[DQ%]8?2"<O3R+C:-?^?\\1<V4)C=!5("RGXW9K=
M9,\1I@Z'P(.XKAI(^E%LO]P<U#OHD^67HNIRGJ3Z#E9[*?&XD5@V'U3U\<2V
M@_<>EW"/8WJQ=$OAS6CX0+4:W9N[+0DYB16R/Q^1X?<>'E5Y.]YGT[%<#6F[
M_.&)QOCS&C+SW4:7%C]?0@8<NI>%S)S>E/@S_5LJ%TZ\J?TT+ZN-5LI52B?%
MWNY>,,"EUGJNES3N&'07T:NJ.TS+ ,9)E /0E!UHJ]J]'U]06@KG[CK-*LEK
MW\F+<6AZTM9T\G"7=/=X5#7C"PBG%S&:0Y@!F' M!&W(><0V'^<(4F'/"/=!
M,52KR' ML3X[V",I:_PA_)!,CO2QFK[]+=OJQ1'#)T!2J*.7FRA \S9%>GOD
MIR0..^)F;?$>2G9.AQ<ND]>0!<D%@5'&XI/0\CVTN+>89JS@?:(D?%S?M+EV
M'\,T;)ZM/4[8.F.=;HV4RN]!*0@?JQ<Y-#1\3UIF^ZXZ&W$!\;N::><2JU/:
M&I)/#B0^%1_13PE?W7,>G.I3;B]^FX$Z(#R10&MFR=@#PN> )$+K.S^;9B<I
M1K_]0+5."7%6I2!M9TM/2>B4G5A1[)OM6US79DN;QN<F9 (S\E6M+<P,$H^3
M>WY>MA=7&DDJ&/0@U&P6L[R::?B_6"+"&-."7U3PI##%H&NJR&G[-67F\?7E
MT"M@ZK_E07J0"$0=9?%B8R\BAD9?84=._N!!Y(:R4\,Y39Q-O^%4*_86<57T
M.)XE .7L'IB__'O^NCJF F9B@,@/XG%__VYVQ.$U3/;J("B%ZN"=#7^S"V-C
M#8QIMD[BL?-[M)?.+?T1:<D3W:M09V)+-)O -3E.;,)E@<C,#8%9_/&%(TQ3
MD_(44=K-%FOD"HBP#-%*#%^VF#8UJQZZ";UG\+ZC7$/*5D WNSY]=@]]="9F
M#.LY.G8<)5_X>7Y.BC:DEV49%(6_M;YR%5NKPDDTT'5'2/O @,,V-#A#5DB4
MYL"69$"I-QZ&1(!S+1K!E3A$W%#WOVEY&-UX*\;DZR3_]YH IAP#Q19;X J,
M,.::\%(P)"6,!]GZTV!K\IY&#*2G5F#NN5^ 344/2D6N5IMD']2P-.K0>:=O
M$Z)*NO5 SJ:CA&S8310@/YHPW\VH.@.,"K/%?)G%C#EWO$?K4ZX"^W:2S9>%
MZCD/+QZDUTMJ\Z[Y)71_N[1KM#97YB+_X/^3A2N;<&R]$=;5 L'LY\2P+[/T
M_ *:O[@GQN<SS:.TUA9%5<O)JK=3*Z)/?KE1<J%G\ZV-I[SJM$:SR',X8(8^
MUT(1P\A\!:PG2"WZ#G7V?5<-#?!4+ZE>P3"OE)/BS!)M@9Y.Z4>7>T($"K_Y
M%$0>M/O2?#K=]1.USV(V%OZ@=*0GL>=-SF!D;+&%+M-  /!G^;&QG.<8;;0M
MPX;6R5(T\IH8KK8$E;>TW\+$]XJ]W(0)5DB?RGAY#.VFX!W5KQ+IE'8CA<\:
M$.EE?FIS:-.H[T19CC,=WOSP"HZ*C'#F1.0BI0*<[ T5IG33PQS/1Y3?J7-N
MWU(K^V7]N$ULB0UM+R."2FQ$D4>8A?T^A U?@:Q3E0R#UZEHW2?&<"D.'EX2
M+X[$Z5B+B93<;3U@N#)VP'=_ P%D#R4+#6H@)VRI;(FAJ@V;,G/[]/B8@B>O
M]9?L]:[?.3MH__JFM4SPY["#5?NV&YP/$6H;MZEX'7BZX$!"\1LYY2-N'A\]
M)!9_]/D^S,Q'WAOKFL8HS_;E[K SUE5F7ZU2OIVTT#M8NH9786OV&>BB94#L
M*0:V8^M/_Z+!6F4/,EJ?^D3ICI='Z"FD=ICW-)=<G[Q8%@L_MAJAV]+(V9_Y
MW,OGU$D%6"X,12![=C -.,_U_%F&%BK75XR^?'/<(0DY$'CN^OX2'+1I^Z+I
MQ^T31K(#TXB-8(F%1[2SS#V@9?RT-!;(/!H^,1*"EW-SA3=Y/(2'I/7>QPD?
M_'3K8_R)N-',UU_BU(_Q(Z^%D(-U42.*3"U8V9%\.@G.4&S"SE,$_.1:KW 5
M2-7JQW$P[JZ3JJ%K^E4=TXJQNXI/7K.R8(4*7)**M$!O1C<\R96?E,@PN-3O
MF/0@O*AT(+[=6XO9?_F]\_OK'DLEO>:)[2,FHR_*$JXXV*^X0@$%M?F. )8B
MIHDK #A3SZ;S($_C9YOF#(ZEW#O?.TN*8D;@CN%4VJX:?5P\<Z"ZF"N@P8,<
MXN. Y&4^D,2#+%/$ ]\A1-'K[=(>W!&\#%?+SV;2J1#DK*I]M-O5&P@43Z=-
M98B@W=''B24%C=(?B);>SX(RIYT>_*Q3*.I@7)J[>?F8;6*XWJ> '-V*%O,+
MMATWUT8LGC5>B63<R[_B@4@*6) GG6'A;Y% K6A78]1HG]6P$((5/(X3IHRQ
M0?,T.QYERU3V_3H['XTCG+*;['>-/YN!.+"3HA<@\?$.Q#H4[L&PJ2.082VP
M(E5*'<V4^?%C"1#AZS&EW9PLW7!WN%T,CUPZ$^8B7G>)T[;S^4')J>+8L@\P
M)&'("4[.'0=GQ@;KA90F?(??RL18ODL>8$I5C0NRT*S-04D8Z97]''&--HIW
MCXA\3CP&"6E5C=^S+3KK2H:QJT*)U8^2^/:/Y95 7O)@II_-N>@#&B]++%96
M]<M0F<S:T Y$B4D4RX&M / @=$%J*%NLH\5)@C'=. JCZD>E1$ ;DVSZ;,XR
MSG^:<\D>JS]^>^7N?F'<D;-!VI\M/T;Q(&;*DQUX0+&;9@,"O"G=]!GQ-H6\
M<);A%LR%^D53$+UHR?&%35&']\*MR[MCO/V5.^6.GG98.??N[ -)2<*'V:5;
MQE+]/UK4(UY:PV,T]SH.Q)H[T92]!J=</*W?7(NU2%]P=:V-OV*_\@4L@XSH
MG?^UEG_^_WT1),+MQ],-%X9CF1\X[S51(Z(MT!)4*V$'T'JI-'Q0FV[3--B7
MO\RZ$7*"'7'95O)M6.1U$V.O?+DJD?A\RK W=RN)GL2T FCOT('T;EHHRQ1X
MSS)DV<2\!5:HRVN9L3[3Y(Y;:)9-Y+8'><U]BE,Q(L204AX$20142/-"+''T
M=?CP)+6U*<K-FK$PY%)=10\-JCX8F(^P<VC;$&T>7!(VN+<^+JB*__#LR(,/
M"EGK72V;DSG/B4CA*+)BG7#PV!X@!U4 ZAT/UO8Q>>#R^YDR\V\.YO>XKIU-
MRC)8^2-[[DJ_>A]M*P!9ZUKO!TTA7JM"[3*G>U_Q4K0J#U<#+FB^R?L0?Y)E
M[IW(I!3Z4;A/'B! $&VIQOU5097X?4\(>I)EV9ICS-!3R/66*>)!;C8N-269
MJ(_FSGK^?MT2*#  R9DPAPCMIY_ <8TIS$4._"BH'AE&XT%_FTTM,,W*&9O&
M1 9VX+(-!83.HG8UV<9.Y?O]<0_'GR-V!O%OMK3<LD1\Q+]]]>\TO=RR_./\
M_;5I7BCJ5K1<1K++Q: ;.C%#!Y[E\'=XKDC]WXS^*-81TQQSAEYFG+>,%6CT
MSJ5/22'J-;E=R/^C8 ]F[0$1YH>V*P_RJ)7M_KM_(:__QCG5YVEZ]@EG5\BE
MN4W2*\_BO^W2C_+\G6AT0K'LT2:<5 ,Q])9!M _K,*;+DFW+Z'P3GW:6+E^K
M4O:%=-'F8Y0"JLP1,ZMV9/>+J]ICB\QHVXO\T[OQ8/Q*<A*(XPE0^A4"&=<
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M=:F/<+<M+K#U%+DY>[A@M+!2<( ?G&.EQB;P("OZZ!%CC!GG]6,NO)D'><W
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MF'//J74J7WPM[B_&PR;:$$4HCA@J' LX0+F:"'UN#K9O@9T "GF][GG4FC^
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M#\G7$I&=.G3PI7-DK%[DJ4@%T@[I[9&1>7P;(?P!QIC+ZQ?!$,=K$$6$)C5
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MA>K17N535OI_;_WO-V/^__-_>Q"BL7\#4$L#!!0    ( -*!EE(N67A-I:$
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M2_FS"@Q4\FJ@8 1(56JJ9Q&WHEKSOS3B3L4'O%7-/:"".*2N8_PEWG[/WA/
M& K2)G9(W$/0;?0G4\C%2X]8 A'2#(D8 P1!C%J9_BS"K :RNM'I-O:G/IHP
M-]QCG7=/+/Q6AH5P1I%-?^NE!SU12$<#&GAR[)>>KD&^__""J]4AMV[TK<HO
MC4CM.(U2$CUR;\ B2UGOL\VI\RW)L[,R^@8K'R0E+<Y?H@LU577ADA&U:PE<
MJ06B.%<7YN!=2%(2#ZAK;+=-;A-FI#W9,Z'W)]]TRF8B!'G,R7ZDWC'=I2F\
MY'M4]32C>=EL?50JH)K3C%7_"=:#;+F<7F1M&.T82R7"&UJFUY+"HNJLZA!Q
MN"V!@=XCWN.AN^-&%C:>&BG&/7X[I92">?ADFTQP_3GK*&S'5^+7A>R;"XJ!
MWYSD5G9B?&*._URXNZTSYEBW=\1)!HJ]$\LW87*3*5'/ SQ]UXR(7BL1>../
M2863S4)!MZF'#W^^$;#BR15QHU,IMNWZT![]Y)#TR6+F-FB CF3Z,Q(Z#X:7
M04B*5T7Y(47T_2NMQQL50VZ@9LHE!WV75/;U*5 _[TL4^IE $^$!&A*]<.@L
M@!O6FD!$&0\0<(:#IN\G2'>J2L#N8VQ=?N_<I@"E=!@QS=%;!BDHFGWH*_>3
M@P'@#A[@W=C7\F#&_**JZ!565\-8+Y0 ,T#[EQ9M^%\*O9<M%=8!UM81OK=5
MW\A6)';AH3,MB2&M=O.9_K;7LF/&NOLU\9/61@5Q+C\$S0=Q) E(ZT<W>BO8
MOA]Y#?UUD"M:1'E4( %@BLGI2:8*;(_,\0-=UT=#CSF=:A(V_8/S:WS;,'M'
M[&B)2=1=1 Q2D!U 0A!><D6Z&1-4S9Q'#&GJ1+=^$DZ:C;FD/#3COV%3.,Z$
M3%YT>NMZ2.+>VD?Q%P%8JC^A)^/9Y*'B2O^&<<</Q\-3FL8-SI_;[)S(GUN@
M\.)MDD^,0TCHEK34!^]_"ZN75/57"7 _HT3QI'(B_5(ZP;^7^>T+HJ=-F).?
MGF!B1.\G5U:%[1XNG\._R9Q;N9 [J>#H]RU$5;F=,W4E]GN/$XHK,D5VX"2!
MI%?X.CQ;6ILLUUQB1;_=2_Z<11WD@]QYP/ELFHGJL2^^04N!!8[>EIH9+6/W
MG^YVZ-6<C$):K2H'F ^K"*\&NHR/5;Z2=-7M6HCWDSCMUA6$OCJ @=E&GSE-
M1[&E&YGV$SP@0#_1=.N8(4>[<XT06-^3\])*<?K,1,X7Y^<75,7B[HREV9H=
MGL,? $GQ<$K#!?]K+!.^*N9 Q#$HB>6$D5OIF=5@G,NH(/S,[2DK=PNB/WJQ
MT/BE6_R)XIGJ*<$,Q>]/G$*RSG[OUQM3L6&=.81C^< 9]1RQ!>FW3# ZQP/N
MX7K=MS75O?EB8O7Z\D?-L7?%]^7-P_2;U](UGXHHU?[2TOAA\D5HR8<MD\XL
M8B"7;%AB;!M.68L"N6RKST6Z47SA:'E(J_U,X"\W-WG/QQ^NF'I^F6OE)_WH
M5K)-0FPU4:>TNLSUC#@R]./*0\.&*6^5<CXW6KEZ5$_;6TOB@@)(57\96/H'
MTX 3BR3=Q]4K%R\ET"4LZ0;8W70IT[;<L[5O6@/NW!1!PW6RW>!MC^GZ  9-
MZX23X 4GDRL$>R.KAP\D"OGF]K'#Z>C.5.D>Q;">1H8R>2*M2LKEXYS(V:+S
MND4O+&5/W[2HMW?R>,#'4@T/]WE%L )+9KK1 KO=G5\]4%-+*\QZKS+W<K@^
M5=V]QLWZU%A@5>#T@QRYK/+$KM#./3LGYFS9LJ?(0KUH FC-R0;])'9@^[#J
MG&?8+3_;$$UC6'VV$MW[=<.:$2%U#N?//)I8<Z#+4#;&UGA;T+KU'\*R.RQ$
M!6XSTME2X><9/[K2Q;GMR-J")KHK1>8VX0Z43V_LGE5L_5+O:OGR8&3V'8/U
M0HR,MQ]?YJ;@5H&$QS_Y%Q&$7FHQ^P /6*IFZ#-SX+US905S98F=')\N.#!P
M02PC9L)7'>]W+&1^C:WVI]\-Z*^L,)\ 3R$*.AI/=Y2 X)RG(>AAG4B5-@EX
MX83*0VW%,'CS6(<OAO*<UR&NP<%^!X12/]WZJOWJ8FS]0\EIT8T KBA<LG;7
M<(KP2T2V%P]X9=P'I7-%KM+17#%76'&V&W&%%_""R$!<S%VM>T&FBGX',,&6
MXURIF9E9Y\F\:_O-#/KOQC@YO->3/6%"LA.:'^Q PK6? 780Q:$R"KXSE!Z6
MM*HK1_C1I2)MXWWLM.]:NE3=>,R"YL4FR:9K*PXGVV;> P'>_2Y#]=K-J<AS
M8Q4^!0,=,^U;%I;Y5:+?'[FP6O4)#^DM=RPG(J7J$%_#2&M=R&3Y0RJ:XT@_
M6W$_["Y&6"S__.^4G)%?ZLU-U>M/*IR3'KTXXIU8\S2S?I!+P+U)7X))7*"!
M4P5Z\@"",5,:\N,!HFN7&3XTL5<1QHRG=\W+;C,P*19CS]Y*Z_[,=6*=>GE2
MV>UW]U2P5%_<<:1#J)NGU9?R*?OQ5>L X] KBN&EXP8"3P'GQ!T%VC\&A;$$
M%7V&%EM6'U[*-V?;I$:DC].7V_,/]MQ^MW3+,FCN[;O17?6^VWU\LN7VO8]^
MFO59^]LDTF<P#D]WL(5TEVEB]!'F*'T1T_D>46L4UZ):C.$GCU<$[QXN8+F^
MR=[XX9 ] Y-8U"G1VE]*"H?[*@_")1\'UB*CX=)D"^E/].K'XD3KE<_;;IXG
MUA:DA)&1XF[^4K-@!])G5^&UP$,S1=Z@JL_*M[0#6+.G:F0'7_Y5B?,3(3:*
MEU3'5O.L+=[E]-=;Y\7=_\0#9NRZ@DP[*IQ(MDO*P71IKJ@$_8(CIP&/'H0T
M0)H"RPJS2"G EPW 4C<MM6A^[>ZNE%>]D<=:VW)>*H26^30DSW@0+IW:41#$
M YY$.9H^H=K>1]+MD),ON<*&5/U[*D<:H SZHM.H*;*7/D5&);)!-0FI^=G-
MH_J!-D5C70\&=DH7M4S(Y8V;_^X#TG^KPP$EQ);E9Q+&P*M57[4I"30?>J_5
MD(EU!=NTNN%12 "K89]!C7M[T'GTGMCG8MH[KNTHJ7H6XOIC]$^XS9F+HA-R
M0WU]K7Q>0H@*["$XFF\C2:G(-\M+,$T*W(&B&:Y,*_H6[B:&UKV0UKT3%\?_
M<#Q( Y1FA55CXSNT4)O?LBVSOXLZ:DNOY6[ONZX@RY(GZZ_+A@RRA&"&>B8*
M?/F/;HG?(WW!KYY<>2)MDG442R#2Z\ :D'R<!W2X\0"90:86CM/,:2KJO<H#
M$"IW(W,^_&8/KMY:?S+UVS,T?*G:S,1FRU#9RU(G<X4M$G86-\^]B$(:MZC"
MSJ9R6GF %U(,D\6\ 1>8,'@MK.J("<3-)F:OB>Z^L\H,K4ZSL54T?\6W5,VN
MHPY?WR4:A,\0]N_U/C#9?\1/"0_%PK.X0C9W_E+S&W@*AP@YZ,D=LIM4#^M,
M*UINX:[=Z*]?ORKJ$PVM4Y*H4N]5K),\;EB&2B9M_N*PR8EPT8[/'0Y<02%.
MB@G,3H);.>DM?JR=[),,369*,?1N>-JLPB^QXF;QC*O;J;# &\E?M];XJFO>
M,M+[/MWT@>F_FY]JJPBV'T4&(@G\3&VHE87 ?D70[2N,>G]0D/&T$)P$IJ"7
M5-^0JI7 /)B75!0CQI0?T/^%F1$^)=D31HZ\P,S@P$*3_.RO8,Z%:78K#Q [
MR%)G!9-;L#(PW=:RE&@JYE,A"32DUTK6[=M!O]E#$TK-$\U#QQ&[N>,HNG6%
M,3,5,J,G#[[G <JKMK#4DC,5T&S!;3'5^?GN](7^XL\-&83IPO%;3=8IKH^I
M]KK-A[?(GO!HCC4BH9<68:?]8REMT91T0CA75)L4:=WAHDS.L:<71W'%B^ZU
MJ=G=?YUCE&,4;/@N?N_W*\<OE;BU6PDM])>5N2HYZU=5>L9O]]0W&'[K8,:O
MF60""&GD%I-1<I!3K[M*/0,=8V)3O'C4X4_X4OVQO4SCE/"XCTJ9EA^=% 2N
M27\PX'N.,L%.H]XXL0^AX6H2Q0.DD.0 L /N%T6M*=U5J=AN3AQSD%:EJ8#]
MB!],69K\'#%ME?Y+<4/ER<V;@H42H:%'+7;XNUAI7)$]OF!U3!# $-DRQLQ3
M/"!^E9."W8G]@*2_P9/_KN.BA;4$9 G68&>8RK7=>CQ ?2 %)@RG^W=2)HY0
M97$L-RP,@3Z&H-NF2V,[D/1:Y!N0K$XW,87[J'ME\"Z@?'Z/:ZYP!WY8X$U1
MTROF!]?>_I@*B0P[S9#%,=,38,Y:C/P>P3*.>V0D_O)6YD''$OXYB104W88'
M0"ZH;4@OO#+8\9TEP3[H_FP-!5>U>V$P@'OIMQ]G&X=%/L?VKD5\H@0UWV0[
MC,-Y< )_52(!0;>KBO*C!_2:[AYC&Y;^Y.ZL9<A'L_W(\YO\510G=+[65W":
M@L1V_3A?K)1I#I0%AJ[M_1N2"<2:";;<S0B;Y_,H>9!46K#Y';TMO90P4#H#
M!9 NRA%Z$RL\'KE8WRG,_FVIN^5#D8NEITYSVJ<=DD4L%-A^R'07^R2GI&YY
M:H2IRBFV[4#<E^,JJ.Q@;(4!QWN.A]C*SFMKY2G7<_*L%*3,V45=01H.?#>.
MN^$OCQDCMOU4S.?T/'JUF!TF[^@C?_O+Y9<?^?Z$"FF/M (8_:5'="175)XT
MF$A(Z+*=LH!UZ8^T<JVA@OZS=/T8KD+OB_GQ@W75R"D7BG72+Y\'.H';S;W,
MI/:W'U:?:E/%7.!*#P*+!4(L<!+9$!*>AZB_X^Z3]>/TT/)41K-2[?W[5 79
M:H>0_&"S"5KNRLEQ7?15YRV!ND4='Y[W.FA:*2CLL!/ZC*ON94L;D]:6:#!M
M+-,MV-)X:B6.7'4?NX.>6IAQ&9\2(1LT[I*7-UE)S2C74YDSV#T<=>#SB>/O
M[Y-<.,4\X(H8FJ#/;.$\Q?L'Z"<-07<1DVL.$T$4^J@[0KJR[EWJ?<<8U7T%
M^WW5)(,$+/26:!U4PS_BM94_"Y1KN4.,S;5^GN@6?=R=&]6[J%^"/#;[?[JE
M4:*9U*D-.#S\)KEX'*' '<+1;9 $T1%F[S@>G0YII=.<BB/T&1.I(4K'U"G>
MT90JX:T!)QEG;P?4?%ZP'/<MC)G;SMB>L?T[<%D/!5JSA.!MK <G [H0TMQC
M[#!H/91A047V.)/0.Z#?D5+'3&>U S N2M9BV@9A<LPO+R53O^-$+Z6^%AJ3
ML1.Z![;#DL\##859+!TA(;_V<N5\V+N0]'M31+@=$-%B&C'!*>P0&'P'5[L^
M<B<<.U3+\?3QQGP62H"$N,()I$AYKG"Q$%NREB+?&\[Q[I@E+/=!T44_M:_>
M5!Y9K%D\M%)49KL/M=<G52%B9$XGL ^]COWQ(LKT, -N?FJ9GSC/\!ZV*;AJ
M(BT<)BBID8AP_2ZTA.N\BT1R.7;+U,_E9X(ZWMG6&/VO*(.$OL-$85L=JO&;
M8^K,0DX\DER$)#V]"PM\%E<NG:G/G.ADH;> ':Z<)"9.ZV.:!LMB,N+/#$[;
MV&0HE8BAXD#8\#5HD*6/G=U Q7%5_)#53C0\>5FP*H:M*9Y4\5-%'_)2J2K&
M)%'2--+FGP1Y% R,FO, G:#V>X^OTS;7X#U0D%9.]V LJNY'*AA415AA/JB%
MLA@!/6WRM?0O>9VS,F[R%E_^A-\YV^^'%LK3R3IHD^!7%#D- -]PY=KZ';-&
M=%2:6FM>N[O^\.J]D5"%$([9G]:3QM$!87(F4W>V7+]]YHE2QIO^C >[^;,X
MY5A!'M!IA^U'2,&M=CIT!H0K']DC CD>L9_3R$34\0 ?3EM/ *KNCC%U)0)O
MA!V8;PXRTKME>A""RXM W=^/EK$#H"!;G\Y/1K#EED^_H??&UEE':IVHP3&=
M1[0PNE>/9SS/M+%K?O LXI/5L<4_!TKGL:I?##]J)9A-Z"RKC-OD6 ?<RMSN
MBGL4DU5'QY@^Y%O1[X7#-*<+3W UY^0MFQ[ CNY;<-\#23.,SS)>-5-VFVQ5
M?H=IF!M7\/2-JPL[8<#0RLOO\Q9K5'(]HHR$E<46L#,@@"@0BH=<D/3[L+C(
M@\@O(T[]QE>;3G&JF(+YV$Z<J7[M>D'8QI)5(WJC85"%HY'1J62MDUSRVOK@
M#D#HO,V)H@#%<\T>N04)KUW=72W/]:=8C9^^OF/'@4P)$SNA#\AZ(;8T2*6M
MT1[P@,:U)3Z6G1^X!:L:4+ ]MI.XK0Z4@2Q8/J<8#@^WYOF]2MH5;QET=;O#
M(R5-V0O?E=9Z6=M@8M9N4\=^0C40TT T&D;9(+O<M:P8844WK$RAO/UEHJZ2
MM\GMU"T-YPJ!,/$WKAJ2[9M< SU,7JJ?6:*A4 $JJE],CNT(#MCXGI]LL^M#
M[N_O:N+$&<'$C\RRAWQTVW@\*1N>LW<IE(J0(8#M^WA $%H<TB<WIK#-@BN1
M'<1$'B .-BRQC2-O3?U"V;R-GQ/QC"/.R7T6517XEJVQD9,.DIYR]3BEX!64
M/!;6_HW+M/UW&$8.C/O+P3>I^=H=#>^DYP\69MAX7Z]X[G.IN^[-R]+;M[/F
MQ"UO:<^7P<19,_ILJ,HPY5*57O2AAIKIO1_W*=\N/7(]K-OEF<2 /L&)*]P/
MYZ0<IP7OK3TX*<\<@L.IW.\=+BYP9RQ+;;F#!PAGCR]?:HXYO<]M48 (%MX3
M'?AV<DC[K.>C_)9G%1O6A5]!KWE'@D_>7&3NC!JQ4:FA1*$WZ)%',K#[Q7_\
M8$MRJNI1V[B?0?H-7"_<^:,2*G^9Y;P/#"-G,&AU&C7]9-T <S?]B[=BE^O<
MO>KZ"^3[O _W6-2#[8,J6GC.ZY:CH =:8%&/(-$Y&%N@!DTP=E%ZT ^[_0(,
ML^/0K9BKNDO#9X9P+=GDJ,,?_H"Q",$6698%'"G^(.D%OI8'=(7KU_F:&D).
M)!MYI_N ZX>F+^[R7H/F?&M[EMY+#K?\7N2*E+$LL!TXNCEQ2KH7;"CNQHE#
MBY2$%%-8E%[MKH*"PI,"2?39I.>Z:4\"\Q(]0O,X$5E7+<-N=.?7^/(OH2='
M*"!M*_TE5T2==7017RNQ]!DOVW(AE)[7/GX3<PN]W=77SK6#H+%E+=CM<YJ<
MP==GK]6;Y>U>W^EQ:E^&]B!I9F1]0G\[6"/_5S_MK890)6S;&"C"D)%^KP5$
M)!I$NC"'$76VQ9^P@P(-68DG0O1$/V =OCGU(QH0<)#)1<"1&G.9VZZH=1^K
MC^DE3[P?E/[9)CG"-<8LOY]PDFML4/2C_]D\/FM==L6KOKZ ^BW[8OM[?N2A
M<8;M#ARTZU@C6Q;%/#2").4>34\R<?/R87A?9."ZY*$XRE;0PC6A.AA=W'FH
M*,RP>?JAM/7.1J G9E_O6O1Q(2(1 9(J0&4333@J!1EP,0]@7N/$5G(UH1\6
M=,=\RC&CBVB54T7S'012ADGCL/7UCN'=5DDGS'.M"JZ9I=ZY^IPQQ15-8BR2
MZI<[B)/@*4X*GFS *6[3\#VXL(84^8-0:E?)(4\):_A^'T6'^JGMS6Y^>,_4
M<5[!>;.2;Y M$^. I-^<H,E\-[=8@GEXF_B17H)&I06S&WI$AJ6?EA9;7KL3
M1[?#$5S$9I"DP:[T* LRK#6W274X+['U*T^5I?Q\V;I?>_O.@GVOT\RWW.\B
M>]X&$*<A":H^;82A1")VH\6QDSR@NB"!/E1'Y)\9>+[8MAW*$L=[EN<TOI7J
MDOX0$^"3N%>Z]<S;!X'H1U&0-E?D" O$$A'"<%N12MP2X<S:#P?DP2(H@0Y#
M'(RMDDAD6U=$F#<.!:VFUTY/6]\VR%,7&+SQ('5^[HCM@4O?+(<:XM%?CDEP
M1158\EP"3LQ4&SK%/,]Y9H!2<<.XOF]T4OPSJRPU$.B;(S<A)FRD)'!NR2/K
MFZ.W7=,5/H7?*$B5 C=X,?P1NT[&^D&HTFN>L4^6#QY'7,+V@74YG?@I,2::
M[D0[07_^"R0C&+T)%:N!A[1'Q4S$U+X_?[AGIY52?&J41M"I&',1*A+- R8/
M,O=P7IN**>&FICJRWS5&10!K*KOQ;K:7FVNJZUP#_,XV.B&]LY$'#I,/5#OI
MQ"HE9_*IP$FXF0'VR2/AQIHE_9T'#"_F,B6FC)D;G/MX#R5;"3]<0UBW$E+4
MS_1H>+_R@95+PWIZ.GKN&O?[!7Z;R23)?<M)-_)_(WZP9S?_BC7S&AU<TO2#
MHRP).A@*U]$M8[9LM7&"8[T6#8F("=6>;]'F9(Y/A0S=\O$4<ZL??/)=1^/-
M[O+W@IXHN"-I[R#^O3NYPHSAI)OJ<B?@SGF9?362@@#8\J/RG8JZ^/MH7=B3
M%/O08%GJY,G%'2/+>5N&@[94GRZZT0*!7;@T1'45#>83P9N<QZ%$2)V94QS@
MKD-W2JI<;C-@GX;ND#_JA/3;BACP77LS&I2]G=IT<%N_E!0+%5W_U.D+CGXC
MC,9B[8S@X\2UZ7+[$/+<0Y=^XK:U[60CQD"R.'V4:73>NO3.T(! N/OA7,.9
MO0?82RUIF+DHTQAX)\_Q@#X=O#>.!3=GFWG ?-KG5FZ;"OR&#):(KQ&B[8<;
M&S7.4^SFB.O5#*%4K")[*[T(EV:@%*Y4\FVX..%L0_TCY>])]GT#2J_L'WO=
M.G"DZCG2:W#*DU1%BZ2@D[@RT E.Y01"Q%35'=+OSEQPP<2KOW9Y>O;-/N\5
MNVL1TRH6FZ*.VA(N,+%T%,V6?LH=XF/(.TWHA""E3L@H%LXJC7U[T^)[WO>[
M[S"&BQECXW69#\X81YG?0FK!25!+I)\E?D5R17"L/5  $VXU8X+91LT0BG6:
M@.$!)X?;Q ;)$I+$CR50NGW!ADR>;?:1XBQ:(K/'YPKIVXNR0Y,*J%4$<X)3
M:2K/;><!-;UP[0] WZ]&]9.)@GXIH>&!15/KC?('K'1NG! (>&!D95!MKI#H
M0&Q*M+-DIW$2D*0R'/UL>@H/J!,%VVU!4@FJ$7EOBO+292"07DMV:\AX[>:'
M$OU3:KN_J^-+X<;3UT*XV\?.J(H"=A+E2%(]5XW! WKPR:B:'+:T%%H&]5/1
M@B9!G9J#7FHEZ']OS&6='"JG-.-'I*ZI#N]AKSI>.25[G_^1CD0^=P174_Q^
M&5)'TJ98VA'AG-@(N5F WMN=GLS$B9KNP6A;CNHIV4R\&!W*L7V7J> 653![
M,4SJ_GZ2=$Q[*S]7S&XCH1.=C*]!L643.EU4BJHP6B1TVG(18YJ@^;!VP)-<
M<;=/*2#5Z:/9+.-DM?DG8%H@]GZ0>@RG'/1/CP;IEVRG.F'JR$=>12#:&1*G
M(%>&_R"EMUM"'L+..HU$( .+7AK>ES[7)_^YZ<GL_FV:T?PW^#6 2#?6*;!=
M 4DJ(-9/] Z@F&F<UVWBLQ$G)^J-K<-=76VE,-GK=;1=PL\M&UQ<S/::R7&B
M9Y)K<[Q5HPY7/<638ET<\)U(0C^SC9.']ZZ272#T+@W2UWIS3?/I)0M'ZR;&
M">?*QX,VQO,\3<H_?3EUP_[,KYT2NC4#ZK4W<72704@'%V5BQ+*I8DL%=.+K
MEE "NK_JH"!3PPC?MNJFS!]FP[]4T[Q&##"D-(MP5J*F[9^83<?3.^6%^C?P
M7!%=EA6<\WLC NDW02\<I-G8-2-_B;[6::/W%35/<'P2)O @:?)]4X%UHOK!
M@8.]VBU/:P]9]9@!$:YP@CO"X7D+.XBL1=+&6+NPHUSQT1:?<@RU%]=0<,\P
MTK4;>[!E5&J60%EP;:BK;\Q@YV'DS(XGESZR' OS/,))JNJ!"X]>%5O6F,F/
M_]NP>J?'W\;581]O++>C"$2S,>QN/^K9UIEGDY,*YQ><)3(:3BAM$TYL.A9=
M-5HU&<"LY^3S@$#T/3K[%B>G;1<!:N[(D1]Q[BQW)@R*&M ?:-C4]J0_T@AN
M5'G(Y\/,AE(8Q61TA_6R/'805[N$EV8[*W>W'/6)'>D:)QR=7L]\;9+I?CG>
MTC-5S+(W8+](G*,'WSK8@:=?0!#@W"329.EK)) MX\.4&>8J_23*A3+@RLD?
M<9SNT_68?:)XZTW*G2LC^NJ'OE@+9";.>#[8['0U:I_"!)(K+@)]9#B1\$LY
M)#>G#KQDBQNIBB\ H1B!+(JXQ>B-/EOZVM=4_,DK5F#7P9,5F@W77$,.FHMM
M91TWIH,F^("_=W0*&C@E/, SWX@KTD@!93"L"RG,%OJ.@OV,WVQKAGQB2(KP
MMQ9/P?N#8)AN[NRTI,;KZI(G4I^O+SFIOD>> 0.0T%YBMWXTBF['.<@5::8C
MF5JC;5J8WBY0Z"6C*@&]Q/82S[N^ZVA1=][4[).*21V:9SS!.7<YO#IXAQB_
M0?)8+6L;V&YANC_"CU-JXLD2YDZB:KI $:PNY-1Q>U9G9,D +]=;,9_+C3:
M-Y(56M_1+8G2(R7F*P2_I6.NM-TXCJ2'?-401UX1/X:G-%:(/4!2M+0/O?_(
MB?UU"_P5$A.E]!)L=\('X C&%# =Q159AMU>2: D="+BL;N:Z,QZ:GX Q:LM
M3C\QU/BR6'.DVJSU';F;DCMU:C[NN)45U3_>I \=2J#(Y3&"F<&<YVW:OAOF
M+XLG(1SS/:.M(N!JV=0=^=M#TQ7W^F48W]9OE=PH;SI\Q1Q3!>.-,>?.XFL:
MV5)5S'!&(UMZD E!%?*=58EXT3:UQ=]B$I(N@S^@,IN6MLR%0?N1&/,>Z%P-
M[6)*R+V2=7.R>P9<;#Y!/2L4K:4)U@GV\5$3Y4CR5&H8LY51^1R9L&II4I:_
M?\Y51''\&BQ]=>QS:O?(\#&K:&C6+O8>3CUWRTP$'S1ULPKLT"\AND[[CV,1
M$\4C7FUI\A),OUW1V2?$'O"_/I"]XYH3K [8,E-,?DX&DO0$)0UZ#ZJ [;IL
M/OU.=+J*)C15^--%/)9L<WLU(=G W"-T-[KB>_8)W1=:#[T>)?1I*.4)J?^Q
MYHHZP\D+0"AX??LY#R*L6"X1#D/ZJP&!B+[ZX3H; P\W:[O\!M>IY9WENP?Z
M+2>%D[LV!Y80<XET&WUHCQ%;:F&1>@_?V$B#N5Z0GYZ>@O=#)V[K?C6O:!,?
M_=KT"7WE[*/$E)/#C2Z/'#EDYU]&WN8^?(\-,L_R_3%BR\9W+#,_PTO^"#N
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MTH4"^=S#+;;D5I1Y\_"JVYY"@1Z?VI;D/8]V\#<<+U(2V/QA)Q >*?M;BZ8
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MA5;9U_>QIUL&PU'%@1+&AKVP./9:W7^Y93J9V5KUVG62:U%ICY(<0GER7_*
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MZQF?5R8L/9BVS+#<OC_4[=LFHC5V#+G)= MV!.0/Q47A$8?2Q:&\C_5AKN3
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M^<]YV/]^\[#_A;KW/W#\MU(A_R$[^NE[$$KA3[X;P929_>A@<Q[FHD3Z8I&
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M]?J*3$\D-7!=E#AGV'+G&2GD.L\F&\(0AH-4Q#^8U84OB*SG'430KH+_?8P
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M.G[0S*)9;Q);N-HN*"#><):24E0#OV2KJ?M^#EFX2+..#?LGF*E#RM:LVP
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MK2M[!I?=7U757MXX6)P\U&Q A3,EMM@"BPPI=B>":D4DY+%E^.C8$:80!R*
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M\1/4S<Y"O;[(=^NA-B%+;]^-JS7Z[_/SRY4Z\C[NZ<,O&M^FX7Y#]_!49P=
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M>P%<Z*8;^^0?O=XP1A';]ZCHU6$(U[^>"P%8=-VI;@E:"+[0]2?B2['7*]=
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M=BGKEJ"57*3[+<C]A$5$)RX1W^#R]U%= :"?C*=D"@+-UC@[FD@._6,5>RI
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MF">A[[&\\MZ.\=?-M6/B#Z8^P RJ8N)<.K%4!/;W 7-^T!YV<B#;N6Y_YGE
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MPB@GX[;/Y1<<@YX0<S?$SPD$# Z.F.>:5X*#^809./$+)\ \SBI$>RS.P,6
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M:T4E6:'(]Y&PT/&!:W8(,*5LM6J#?H>G'<?!$*^]#O&HI41%4$ (-1Z? RD
M4V?8/E7(U2,:J"I8TIYQ&WX*(ZHZ<N#U^C0X&H;W*A@[Q^^!,E #S_HHI-?\
M618,+J$IJ/%>2 HF(" 'L6:H&2S*ZT3,J+UTET%2NNO]?0V_MZ$T@%&RQ8GV
M8K""?I9163G.**,.LL;>$ />D%Z1NN&K;G(03P!&UD( "Z;1:X\XB*\ NW3)
M4'BQ<A< (\X2K$#W<Q!4 V@OP#:$)3 *&ES;%[4Z'(7ZMZM?<Q"") @.P@4\
M+":#=QABY@V1,P#[",Q=2,SS',1#- =A :S"&J]$_^'ZPW'+).@%,#["S@9J
MU3B(;!(+UAH#^%,6:)WO1FLC'(09:L$'ZD111#F(3C0$=PJU]8T"X>5D&AON
MTBSD^@L3/)%TF"!-PY<?X" 8$]]WV;0L64"P;._ L5)@<28 PE)B&;[!4PZ"
MZ3L9I31Q%];AL!R?:H#@^M4?\=^BQ3:_S)]B[7J&D;3K6:ST0Z19@T[8(I?*
MP!?&M;#M7VYJ!,>4ONI:)7 0Q7B3JF%IP)5N)B"\#,=CW.WQHEGF8GEPP_PF
MF%FV-"SW_N/.N57[7(PHNYQT70U40C6,2&$;@*+A%.:A7HQBBB$MX&&1BLSG
M[S/]N-B)8WXV^9<]10*>J+R^Y%QZ:* Y/WWA6=Z9>GT\^SG)F00JBE:38OKE
M<8 [ 53VGJA#;^X-SF(Z?[[ VDB#'I9E,CV<'VD71[1$-#VGI(PS(;.:A7R"
M#CN-1(:QM\BG3F @M(Y47#(+L]M-CG2@6JE5V*/X&(8H39NH&>!_N"GW/;_D
MS4'UKV]6$UA3.XV_I^[5V7?0(FH.Y=+:*P_Q"='LQXK#Z.IC.)8(LAXIK*N2
MR<YA6GZ^2ZA1D3<+O;BHXA*EUR,R>Q77E##VS)M9+Y@5XLXULP:S7=W?3:DZ
M_FXK&YS&_TBHP@D->%!5E)7:MLZ+:V!:G$PZ0RN SN*8$6K-R$<@';ZS&KLN
MXH?,6+_"&U*Z (7V#T/_&^=>4_2"K-K?:^B9V'Q*;3T;>V9IP..JG$K"^.%C
MKR#!R\]CC\6;7G@3=?90U$?#LQ=2*F 0)[L3?[R"/=CX3SD\&]84(=Q XP8Z
MB1W+"TN%?)L?E['O@*J-*+ANC$ -W'!++^60==>1XRP!A ,X0V:9Q V,D^&V
M;#)G[\7?M3 49GT#KO]E5@$+4]^J9OS"-6 [K&4P 'M?,LE$:=$<VGX-3@!G
M,  N;'"B3.WJFKV*7-!.FUE3KZ:@5W?T+*&342(PDV7_P3K_9P^B4YH7 +4M
MH0N[1QA[IX&UP\-$ 4(%BCQDOGK&&>B-> MC7=/=15_\JC#L/'Z]:Q&0D0:J
M%C<,]P!I+^K6/W:*+L!X O=*"+86E?\SUV5TOC^"\8ZF?;](Y;2 ?H,)7>#A
ME9 Y]UM&R1]$%K?>X?89*-D3_;.T]3[,VJU&UO>34)7H1B:@/$V(T4Q#/M*U
MS84Y=Y\^\KM_1O+/F<80XQ^]H7F];^):W[S6I"7BZ ,0KSE3#:BZ"M<F4Q3$
M=VB,$!X@K4773QME6U9AY>AUZ=HS61Y*Z2<D/'1^&&]^J7%!X4F3CUIKE+N4
M"76O?B6<6]YX4$:T;@3.K9K6/A1EODK/DK+Y-0,_RX_<TM>7F::6Y*U<L'KZ
M2,U6^_2Z#UCR-7HR8JWE3^VC^$T,7\GY=>2E75<9#I4T:+1IT8@"Z0*-\ -N
M7ED] S*B% A37&#%G_;NLB6T9<?Z,K%ZN%X?D8?BZ] )_FNP5[FWK,_"C0%,
M22$.PMB)<(^N#ADKDB@1T%-<-PN^Y$FH 4L8M10>/&6XRV;Q$+OL+R-RJW %
MY=$"&O-9.G!3X-1;BO)D*Q.:4>#1 L@4-SK"QL'5)MW2)O\Q\&481YALY8\$
MQHW0W['N+'M8+"^'TH__GR;J?IFX^R4>07TB#89B?]2/O;#L=Y*&C4I3F6EN
M <:M[%G*RQ^1JY)MZ\<V!\)]P'K _O)W7=+,07B9]TO/,ZS!;>]9-_/!'70N
MBD/9J<1LXC80/3KVSBM@V+_VQI--'UP6N;%NSU@Q^6DEGDM1BP+](W4C10'W
MB+L$=D,-^"T5ZF,C0E/]Z99H4*<V=8^WPG3_#9O%UX7E_=^K;MLW*70(*&VH
M^>/Q<9[/CNOG$+[#\($1%!W\;I@X0-L([/=%S8Y+;RNZ_'%]%[I__KSU;H=)
MDTSB-<5WT4_NO?(3GB1]6*'FT_@I$U3#45Q$*A]\BQV80%#][332FZE=2Q"#
M6A++MJ>DK=ZV_#KLO^3F)^V99I^GSVR)_#Y]V03:KLA.Q KFMY&\U?I2QGJJ
MI+!<'^?-Z4G5S)Q';H_]M7INZ_L%'!*J_O)I6\_&]Y-P MKC1;"=M]:#NDJ#
M1$Y%BD+RT]KR5_75Z)GA&/E1)5T.HLEXF?_;%Z;1MRNQ0C+WP\:C$,R?40T@
MG*.\*ZP]XDB6BL_L^M&O^532J-RZ4&EF\C BGI+<F=HOF:TRS2,%0'/!]3E?
M^UT;%E=FMU&VB9X#-7/L/<6C;QK#]VCY.."PB"LLT:3"YCP#G:'0\\"(U1B*
M9MYD8@OQ3;=J%EX'1H]UG[;=@*(O> V2"@HYB%5Z!,3F0\ QP(L+1TUJ\K"7
MT8])-'O3DTV6[,*ZYK"O34C6/A&N6TLMJSD,":8.3!#PNX'Y-D+#"*@R>^@$
M\QIWN-P)#F)+< 3?)R3VGVKXR=]H^'_E0[H D$/%?\9E8#;1W]O%L&X4!%;R
M1>@9]3D1FCS9%K!?-_</F-,$ZJEZ%=>-HH4VM2%7_?^WPUAJK/WZNSF(5YW(
ME2[DOW64[[^U+>UOFOG3F>GWM[UC]#=7.T M,*F=J$<REQ3^YNM&_-_\'ZPW
M4-64_#/N'?2-@Q!PZB",/4]J,+NT=U*_3A/[#-;U,&XMC@FPUX17<^#JH&XW
M<()YF*7KKC)V$G-[5>$>T/3T=X@E^G^+6'-X4/O1^8\=*/*K7%_@5KX1[#K5
M=&W4N?D20EC.W#RH[;H[$^[5L,.F.\LXB&K>M[2F..CC<,7@!&1H1:INM=_+
M0<0U"]!E5@P@(>16H,U3@#F- \]A#G$0)[)1\^]*V2_A#FN-1JU,6OS;5YMQ
M^3E#+Y]=@=@%_Z*B+J<[DJ,[S&6[UB*5KZ7]0>^K?7],.'JCHMUOC?ZO&F/Z
ME^+S/U0Y)0,T7S=6"K*&Q$0BX3]G$MJ__DXX!8GQL&(FUZ!HVJ<DZ)0_6_0G
MKFY]:<<EU*X_/YI: VV#2?O3<&WVP[MX*+J$$#KSC[SF-]X/@5'UB_E@R+][
MF^3_P/O_#MZ)V: 7;%$\^QTK@*9S$4S*#D1,KE6T9C2.;A.RITNG9)F\'7"X
M UV-$>Z<DL48(1,EY9^7%L_UWZ1@=X":Z9=86)\0=*$/CJ<F4&/(;*ZA3KSY
M9\+^5WZ1WMVFTW^4Z&0ZRSH=%%SXMOUFLZ^!6/B[\=>R@P'%A#D[TF*';UXF
MCZCQB<[0J,3F2>+*56*P9B]YDD"H@'.=F\%.!-R#92[#?G.:'[@.B :.G6R;
MT[S$DJ.@$:WI@%?5QKFG]F;M99&(*8FM+Q:L# ZNRIQM+](+N%C\7>.ROE=Y
M4].#D/;N_L,+IDH?K PMF@[)KK]LPN^FAM?0Z17[S&2O\?;]Q)U$9$)+LXEK
M<OSMD8O]9;,G#(-UF'!1U58#G%I#4C>#*;DLMWSZ9@(E^.2\:4_A-I3)@'08
M<.VA6S'SS/.ZFOI9)Z<="+\K+8H-L^KKJ@G48?[1],I=6I9=@M$A<Q!"@<EK
M/WN,:!A]\=(N31%WJ]["*-RN&SF*ZAM;#O.\K7-AOWZP5E)RH4*S:S]CY!2A
M(S@FT39F;:3KA;>>QG6E('MK:H!_QARFR- =),%(^,"F+CDK#.J9X"!<I]7[
M5R''$?6FN">W!U^XB=6;J7>_)%<B#>FBT7YX ?!)+=T]V9^1M:D2*M(K_YHH
MJ!M%N/$%K_[@@L.[A9-DW\LOFI*>47Y@!BO/?56:146@/J!FU9C' _,$0I$%
M#:Q==MZ6#<E198'8@5KT5C6-9AWK4BOEO;;]-N[\B!N7C8]\OE"K@DFBD+9Z
MI?+23V>06X4N%>5EI*.;7;+M#W'7Z9HYQ_%*2AZ.:\BX8B1\NN*%<U!>C 9U
MN%GF#7$[49S/M\#<Y.T!I=PNRG#94SAG)H_^=6;[=QR2O/9K+=$^"A<,*Q]:
M0?<78-S7@'6&389#?4%HY9]N4?U7YUYI +1=:?U9:O"SW*#H3X1A/A9<-$.C
M.(@?>Q^MF_4<-DM5:>J3)72:Q)AA"\2/F:_NY" &FI;U!6 KEM(6_CR?[C<'
MM<SA=*;(LW&1<#J?[Z$,8=N!JH\ K#UWH&8QYNQ]X40 _M.X!<IJ%6]1!;=%
M-R*=)+/T$:Y43:V]_Q]N:,#-_-FZJH6* !CZ*"C.%)V1\+L*PC@LL"KQ?9DM
M-GI3C?5P9FU=MOM9&&(_8!7^;KI?)6S,8Z5M)/W0E[9S'[?\-/U2=^;(E4')
M6XJ*B=53UWQ>5WI=RA+\EG?EY:WX/T*+(F[<W3%E(#[(5J)G10-.\Z#"1 TI
M:D0,/<;(IV75.JIWZ<KJVGJ,F0H3_')USH<H9:N,E926>#=YJ_:LCEO\F&U$
M'.2GV5#5:%P4U&PIO:D6N5%?.;>TQX\_/7;.R_C;AT&9^O@ZC>O'E7$2:='W
M;O3N$3R^]FBTE>K,Y$.N+\]3B[S.0?R1J_B5OCPBT.H_JH!5&)8+)QRKG++=
M5Q+8[SX:&:FV\\S7:BN'5PBD0#>L.X8DQLRI7N^A#GQ1:U4Y2MH.?'1W.E4T
MO^MGNW,D-_^F3R7)>^9%'\?5B^J47*L1^O2$\L?>R)K.%\YB09H?,25E%A]-
M]7N&&#V^D^J*S\Z9*MYZ.D:578Z_4/0B(T"V)PCE#V@EYB^C6$+E=:B/\K7F
M.[S0FP$G#@(!1GQ&2K(LR.5, ;[ \OKD>]W*S\/2C .V*@F=5)&+/S*NI-Z@
M^EGBK8X]#%DASM@FI.AK$#VF-H ;C:@V:14'"ZJ34P)]1_/N.U]_$ISD&'C!
M6-,DS+E0+OUP6OWV@.9]?GW)];0 UBXNQCGVL].OQ\Q[<0RM3@QJC#FD&B2%
MJL<>IE<D/V_KOGKH"Z-X9N?>IV_WG&F0>;WU_5>L:4>%)2586J2D'6,$>$E\
MN=P^3&]3E]Q8>T!,=WMP=KC0#IO^?OJ%'V#E3VI0KM2JW<<B)O7&V]CJ[PQ5
MZQ>OFVE!;QT'"9<&GNL44UDEE;BV]9VEANS<]P#Y"0?!E\ORI3VJ10[H"]*-
MHOQ)DBEMXE[\=[(./WK>FR][I,E--M6K&D6.'EEX8AZ&9(B6<Q =P<TW1W:2
MO)$[,(9L'(:+><#\U?  *60YQIHQ4VM.J,BZ:-*H_3 9J7R-MV._T=!D41>V
M&E],F)U@2GC=U:X="F(<*:/C<(529D$OM>M,Z/N#CRF,Q<L(/NSGMW7V?C>_
MN-.W_-7GUU?H3Q>F.S.D/8Q;&FTQIGTS*D7+Q^E'^)[G\GW'*__Q=NCK_*A%
M6;LV,;&_><8/QP?"MLDYU\)0?\@1UL$K>7<K[1G98 -3%^/:,\LRI,DSKI:!
M-]7- _1)#+R4>2[@8:*4)J.6PNUXNEIVU+?\&[70=:06W\]#EH]%N3>+4KHC
MF;)3=O*ALRKO1[NP4OU>+1\\'2]X/X_Y=KZ>KE':\L/A[;B08\*Q!*LCPRE]
MRW;V+I5%4[GEO0N*%]*H<IZ1T^^I2AHK0?)9]CF,TB5MEI  )6!6*H/E2$.%
M^W$085C9[]B#(\\*6_D#YR\3Q?,>N1%:G_WQR5M?^WYQTHUW8H-*A_.Y)"*^
M<!"% F&Z=\CFL9 &#5VG9ZBF:YH1F'.^D+YIW*?TNIIS:9QK@MEF@R.N/%Q[
MEH27DF"2-1 $\;*9*#"S8TQ^?5"3FX/H$FH0OQH^5K,86$/1[5F['G=;_:-_
MV)73GQ3NG)]-%]PM^'G'0A8.<Y/B$TD\VHV5 3LN>#4[H[NN:TI94Y]R:7Y;
MT(C7Y^%2KB7?;+XU>L!J;7#Z4Y%(4FU'0'E_<Y]7T4J?U*?^3D>^E\(*7XU+
MYC(3WI>4Q?S(9%26N)KNLG!\/O[7E<'!HQS$YFG@JX$$5*L'*['3]CU5RRL1
M+ F8FQW8ZL,47$:QQ7P<K_MR$/O>C8RZY3[F(+[\C #CF%4P'X.%QHE_]]%'
M-C Q8$G:K#\/S11<:F6+W417"(,HN#X+<Q!?#41ARV V<=K!IN-&%BL&H/:L
M(>7J\0NP;B])FL8@83NFC,;O_]GSP="%>-HU/"P :LV92)A\GGE-J"MCI\.@
M=A6VNA?:!_2"^#7#;9B_K.[^\@:;LZB_OE1N_(Z ,=9HRF67!3H)_V'3_RL#
MHG\=&/TS8^ \L#\II-4S<.7NC<@$)INBV&0"#,+@$0)L&(FQ=PJ_=IA"3 E#
MC</,^CJI;545QN(X-78%R9*\!AMR%B7[]P80O.&R[H]MD>9COR==$^#%; ,C
MWP_V3?:G76Z]6[SSC<-0;N7[DHW](L!3W? ]]U+O1TK>M^W.X=N5<2'(4 LZ
M7:C0*N2H\;HBV:1K,K"K^\F[WCY[3YLREUJME>QFMYO*RF^/Y>QRBCZ]>_,F
M8[$J;JN[S"1&$?B6>3C0BX&E\=Q?7TS 3=>72IVIT=\36E/<(ZW5];JS0NU&
MV<O!,^V\C?:$X?OJZ7%YQBX7'D5C>IB'H!Y !'75V\::+EK%5-N>]_;=0-V6
MSF72]H%I(5MNIZI<UK)+3*3NRZP] F<GTB)S'1^]\.@;ZM-ZOUP\D[*P5-J%
MYC78]C!:_L)4^H#QT&7Y@A_SF<3BWH5II5DTJ/IRN?LM$XN>#FA??3(8J'TR
MT:U_\X37[L8CDMO-/2DDMQ'P )ZURWP4%\8Z"E?7#>!$D$MFU;'>P("3Q6T:
M4[CGNK7O/=L'"O(]8 21MM_UEN)E4U5=="2G4=YM?WS9_%?8T\<^G=-'2ET(
MLRTW+$R.\BYD'E4*GETE1C$?0?Q9],4Z[#%P>52@KZE.6@MFW%$KH]H/5&9U
M#7)7+;(&B@:>O4Y<^T/&RI!;KHS*M_'C00;!:OW<:M#F)#L6J\G:_UW7(NV$
M=IU:[$Z36]YY:=ODPROV%Q<T"_W!;GHT]>:TU-DJ06;FV8E$%P67&<'1>8W^
MF#45GR 5E;QA^Y<'OSI;:@1>ZEQQ:K_EY=IO731<T3*P2O5=W!<UB56%!>\E
M.HH=;4-:TYMQ8P2P7^MZ,0^S#)!"$-)];=O/=XF'!^SQ@I/YZ)K-;%+EF1^;
M3H7Z?*V5O$IOOJMJZ;?Z)H]:PA+Z&KV7>L=UEI!3Q$$(@/+\AL$E',2F*/ 1
M9>0148"=0E0(7#P?.V_70^2S&YX..&37P->H\43GT([Z=P\/!UHA!,Z"\1^K
M;0)?',ON2B$F$9MS9\MO:]6/ICVH+;-(:"\N+I[2RV.NK"\0,SO_WYW9_BL?
MX5_0 <WSZZ3DG=)65E0.$)9:;,!!R"0C*49_F7E\C"_]#S@R$@V78=I--/P\
M8-:@ [7D4H>E_0Y%3*OQ"YHP2J G,4GBP)<D:!C]EA8,FY&!C/^[Q]\>*>BI
M48M$BT!*4T1!4">OWV-8?G6NT.11[EV]@RD/+W[-$:[->R192VA,="A&[.D1
M,CS7F;$YD8, R!<EG37&\XCS#:^92/(&)MJ.I4KCB8#]DB5NG7*'%JO&,P-;
M6TR ]FM&]QPT*QABWZ?*RPX:W[YHOX457_NV=:2_:]6#J0]]!9" EX"0IZ,P
M^P4D/AR8O&A2Q+S\HU#T_*FVSPY[;A\NXVKD"KG;+1\-*7GI:X+!Y/D(FS7_
M0FOBUOR*H@^I4L-79VX&R'6('3[SQ>-L](;/4JMY=A6#TIOS1-1O>AS5CUNQ
M)MC[7N^8*S3VZ^EN^*EQ,SXS0^Q(W?4?\WK[<IN;/GH5=)7TF+?A056;68!Y
M9H#EUP5X3!%%A@CWEF (<=>R2=W'=)!VL'RXMUC!\MLB[^*S_2?'Y/6.$A1@
M+YT N6INL()Z4%YJD5HGT;R8K;3*UD>:@BSEE2_1Q2)D1ESFM\CI-N=^HNF;
MO%2^][<XB'=?@U7\<C.'AHN)):ONA@[5T07F>:=31I);;%9*[!9RU;Q5.H+-
M)LS 1N1#DH>)#XZ#D-#5)1Z(G:__/C.LU"Z;Y#3]I<>)\G,PG\?SBW;FC1L2
MK^NP#Z Z?-'$K#?S E!UGG6 ?KB)X4K/>TGGJ;T[]*UX>$\G<9]*5VZ*2O17
M07O^J](7JE,O[/ECUZ8E0E._8OZ=8$DKK;R.'S=-M=[CXSVAEV>J7/UI_A??
MIY<^3?;0ZE_T*%SIR6A]K0O0\-6D8AYJK3X_]@MJ^W5=35^"9X!U7&]@2BW>
MTY:0YA7I^NS;/K2*F.6#_AM&ELF+N' .HD"^OC4:+39'<IL/D^8/!NIN%PS5
MKGDG?#.I&!#9^;'B?=3Q?G/9JS:;#'W$K3QJ$@]_5U+*7)Y;+E]BF7ETIUEC
M.F)SA_HRLJ[FNO1<#A;X#M?_DEDQIOTPM@7%C3'WICDNS^J+8;9%#338;%P;
M$#]7_&/\N<.=TN!LWE4NK@'-U3I#X=W*>@Z:2+>C!SP9UD,CY7,>N-KO=3V,
MQZ&QD3KEL_'0)<9ZL6K9\S_%ZK]GL?I7/K^XAR0RPW@";7OR%SX*>\J9 DSM
MTEQ<WUJQ+W*-\&UM?0UQW+B>W"HRXRG<UX[8S_^/S*/^'V8W,*_'6OLB(+X-
M9'/1D2E\/H[*3R;P@_NF1PE[VRM,WA3]Z!_Z&C"H<^8*)N>HW/$C7%Q2+4:L
M P"HXL.6-JIN9<D"S.1[^O6_TE[2:=*H"2P,O(#)!7T18%2&@QCL@AU?B&;M
MP#%:V>^)>SF(ZF[V*WU5C'+/,OV*<-( U/2V'Z(<KA-R*4E\(7K]]OC$$T>B
M\3.+IIO$_G?>MKDJV)?]NOI[FY1^]@$?WK0'F-L/F##.L;S?D*Q(%$E\-&I)
M':/,07R.@?5:[/HI>..L*QS$ZY11-XC;"\^Z122Q?9J >, /6)49)75>&U@=
M76F"'8]2="=T^8 1\F,"[*TC_"B:C ,',?84J#V*V@U,NH*P#K@O/L%!2*;]
M]?H]'(1%@<]$Q(@:=(KU]E\U +=,4H&,V=_A6A'*/MU,2D5B2*M""YE1;%AO
M/+R%/<A!M#73"CB(C9JMT%$CEL$3>@04[A.&!W?D ?2OJ&Y6R:K\BA&<>0++
M$EI08/ "?"?SK\E*R_;0WD9P?4Y#&W;*EAX4^ -)WVY>CUP3(XH Y-.E'$3#
M^A*OA9%Q_! 2.H/ZSVZ\C=0;V/GK[VE!2_B30FYX<A#;X38:?J<6\3^*P-LN
M2.UW$K;9.3=XJ.7T/S-,*_M_O/)?UGB2!XK<AX+AZB&>H2\/Q1DX.O]Z<646
MXRI<];V JC-P4<5M]=3?QGZ!<C</2Y7L\/>B!V7; U<='>\4/-B"].^\=9CU
M;O,&KMCG!+6C%$D1YWL)?#?CO7/;BW&-!7U? M$'ORXJ4!2_JA[03 OHNE.'
M?*-ATX"B9<"P641:NH.$^R".@YCS1/U:5NA9PTAG"[0D7%"28'.Z.8COX^N-
MKH9]4IK-082IP:(F%ZZ:7];[[0%<LGW/\_1V_19]?< +,&+9C:SIXF 'P\U:
MT;R31=6& 6_]$.<XJ!?:W5$AP32"VO#\ND:94]H_5\R+H2\5!0M9"N>),Y?&
M7%<O1>\TTE._O.JJF,J/Y%LTS2:F4!=T!T=X; XV>5Z9*LR0RV ,W2X%[QMB
M<W[CT%]B)IBT-@*3;5EH<GT[Y@1^6LN;16/^X""^X!,T;*9+?@G(7_T.E?P@
M-:+*4*S'0'9?R6+-/-Q/^[ 7OZ/?C?PF('^-^;\QX 24YCK2*D!$LR)7+?_%
M%B!GL/:L)\PTF!WPK,6D +KZJ\""_ ]3X;7<WT3DKU&?N^JS8#X'^TT6^9_;
M>*58, %VM2+XB#901Q2D)>;DL(XF^XAZ;<OJTWN_UGCFQ6FT7TH&SW4>VOCW
MW]_7V^)_.O6_KO&_&=$M^/5^>8M_>>?1(:B/@_CH4XL"[49@P^I:PY(W$Z_)
M?60"??XZA,$S%\NNE2X*Q3]J&8R^X84[2,%L5MIT(5I&J5$C+X&TE%:N3&:U
M;GIV@7"T*KMPZ 4!9H)I2VM1X 2TB\02*8%P,G#O[T2QFW]A3,1=;$FF>-2J
MSZA:-0Y4VH^CJYWJTC\(=8YL+_+AK\J6F2ES31D-%:YK_H Z=AHZ274Z)AEM
MT_EG#\JWZ?*/D3_YT=O$ODOE/?5QS(JHY7OW4K++LWL*&^N$I3*&,MB% <7:
MAYJW9HL?>'/CZ_1=02/NBT\1-H\#M3\353^P"UD>](V+)U+U1,_3L"^]7+(_
M2#L4G)Z]S*-W7'-FZ?P&0YG#;Y)N(S;$&Y/Y<M)FUD0?>B<OUJQU92PI_A"W
MUTE(,-C^*D'6K?^>RO?_JQ/\9<I.AQOO5LQN.G0$<7[C=RL-'T%W_7TE7B2!
MF=L!=)FG=Z[-7;"R7I(S1C"MRA!*7U#N<'B!Y75X$?V=7EC)-K?RPC;6%;GN
M7-T]PD4//G^5*IU*5>J9?+4Q2O&%]-XVU2(//PGO6RTFDZ)^#(O!UXF'&I3O
MC6\WLAB^IVIA:-7AWRQJZ]%AU*URO?E]O5*<]XV/N].E+(J?%%7B-#9X_MD%
M//]T88\L0'Z!^MA:W0JJLEMC2.0L-,UBF]8\12!<4TW:,UGM\TBX76+6C631
M\$*)H[H)I2+?C\GV^&K196,E]NM]OO4:99^S8 +Q)C$O8O;#42W>.N8#RN%9
MNPQJ=V*.?5_R@>_14Z7V,+GK:<U)NE$$06XQ7J/,T)U2%M;T7.;6*S&MD+,_
M[FEA+&E/3L&72P%5YL2-[LB/COEOIY (DH?YCLN!!G4CO'-%'G-+5*':33O>
M^ZL<,9OK_FDK9Q6WB]H??3#@]+X2&$OA1*\ZPD&XF3^$\52['AC -R1A#W;I
M.H^2-O4+;/=8#/Q*UP@^?&;NRD-3J0?7\S7"KCK5U828W?S\CJ@!5HWZK!_K
MPQ(6):N,S#[R"B*PMK*?LXS]QP0D6#;>A]W]FBUK-\B('+L<^NWA==G84[:R
M+IMNGS'#7ER$X9G\PP=4T)[UI74PMH!53,' L;&P<#S=LDY_4W%IFRY2+JS#
M],ZNI/RG+G%.AU0QD=C%T 6DQ6.!2@!F,*N:^' \PWS)A[TW/ ?;"VVDN]6A
M^X0H6=4<Q 8/E$\/QI@VXM"^9(_4/T+\'G#SBN[!!N+IBZ8MT]KJF\0:]USM
M>0)4*7(0/B-]7(Q.-MX/MP4+LS@)98S]6XPN[?I]MS$=>QV);+/GNMW1<6EB
ME.,_DKO)+OP"0R^6Q=;"[^GKT8Q80ORC#50DC#ZUZV_0="8,$*J/M9E'  (5
M*@)1+(D,,,_DDFJ1DLH.Y<R"\N1J"\:SG:<?4V,O1]/3-KMPH>2@-E3^_.P(
M?(/A]5?+81NQ0O!/^T G8"/801&(S*,2%0-Y:NPJ.XO%2T+W/=(6[>EN;]R7
ME1!Y[H)@>?II&15!)8812T0>XDL@HT'9B=D7'(24/P>Q5;^2HA)@=5G@<[_$
MH=C^"<OX [+69<^ MR4Q,G<D<<_"^BN*C=9//#T##/A"O"=&!1[QP+_N(I%?
M8R7  J8MYG8755G7E/(,H_?N=(C'^*FB-HW7*N]R<Q^8_ZA/&U\4$Q[98"&#
M6,-!_+RP^:/LEZ1KA/NIBF Y?>0\/6$VE1OTR&U^ P:<HR<,A2>HU-[^V/)D
MT'Z@[,Z"TAMROHQ[%;=KWOJ"_A_;2 4C["<@L.17% 3QS3"QT!=D?L]L,P47
M@2PDU#<A^6: '5AI,*JUZK;H;6U+K;?';'<_%ZP1>B>X<E#5(9M-7CI":P6U
M>2"^;4Q)E@/[ 5806X?>CCURR1._"R-%ZZ'JR]&BK46--:,M'![$)1L]/#5@
M1]FQ4(HZTF!P3Z#][)]=%,>J9F>PU&&A7^6 (N=#<!"%W,18T\.+W&A<9)[[
M&I4^%&2HAIZUU]XQO2#+4ZG=_8Q+8K)>IXH3T$U;]0-[.8C=!]:"T,^0A0'1
MJ@ YCD2S;16&[W824@=]K(%[J$+4?;]<H?KA(^U^I7EC-.!A86WL<+O]Y*BU
M7U%\_\$WY[,FGL9RN]W8S,,21D*\:30WB/<F\^@TBF8)@')&X:W5R(?H+1F%
MG<NYR!.=<T ^Z\J;1P\I91W+_,9R[N-HU=./CVQ8>.!VTP@WBXL9^9BU'H*;
M_-DI1'&PAL+F(*+?T,():?V!R4T&M)%HU<+L>0JQ(/94%#775OKJQ<=7 A"\
M^XEZ<+MS@"H3?1[X'[B$J!A O)%P+'RBOR35"T0"NX<[SG7Z8-2]-/IM'A1:
M^NY*NIN:YG?>:)>3QJ&P00>-Y_4G<]@Y=!0CB1V#(L?C/W(0-2-;L>T<A#A5
M%SFJ)W&N@R4S.F1NT3'G(GK!SI8[1FN@8>\%IQ+7<>=HMPP$!A9 FTO=CYF'
M >3G=R/"-230^QI,P49*D[V";CV@JC!?O&_.R?;#JZWQQG->2YZDO2AR+PE4
M:)BU\:<=!9P^Z>MZ4.D&=2AAUN5WD]([Q8-'7MYQ;3>]*V>KBS]PHB3<^&#+
M=M'=+9NPE6T\]>A\[5D]NOII,)B)QNQGOUZZ;%^]9E-/ZE>J6^N)6-[&4RLH
M1VV(6%;1,2N.8O#FIL?E7MTO5AW!K[B+^]77)PLV+!$AB/? >O_ _78'J-+5
M-6:>Q;8  CY8498M+;<YA:5";XW0M7];7!E$.: J:'"=(%=3V='\7/OMUI-W
M8K5FO[ MV*_UCV%0[&?0YL!RQD,P)\"7)YPE-#I3Z6:?V-+;?+"X)#+]IOCV
MRU\<-M0;B^WQ13\B%2!9PJT0;R[3%>J\C:=9 *"B&C5H]"6?SY;A;W@$M-$X
MTU,[D<CW4!]5K#:LY!H^8Y7D^?&#\@=$AADM1% @!T7.0^Y&>33;,*39STA7
M<[WJ[))"60#3!'.*!H3H*WB)2Y)<RSI4\KR[+[O\X<?5Y+MO-7#W)G'#R9N.
M 7!<;64_)+G.@_OJ,VA*#,;ZX8$L%!!A.8D7U4!M89FT^\584ZD8J]$8PV1>
M2D6LK:3IX6-I1DH;JP9+![^F!#M#_'=$<NGJC#_8>!0Y'5^0^@@8"^8G-]3!
M98YUOKR@[?W0G*8YW\?KGY*W/.-1&6_:^FF/,.Z;*Y='0\+Z,7N MT]?#L1_
MX X-R>"!'Q^,,0VEF$Y$ZJNZ8U7 B+?N(DE(-QHI;.FGQYQ\14",8<6W9O%T
M\PC5\BW65[=N6&O]CWK!UT6,P2A^&UABZBU:AT7F=\X.A>IEOG9_<JK63\Y!
MT'S4)ON5P";V,Q3Y)6H#C"9 +%(0>Q!JZ2]YR-+)Q)RMN&Q0B]Q&]?E#6CST
MP@:#:9'$5#.F[3B?P>JMA[W:!Q:,"H:S_YUO!;Q&.^'/->!0'6^T3SC^Z"YA
M%QENP;LA!SK/\[3JKQ_UZ()MMIN@>I%'!KQ&E^XVU+0BP9/M]OPI\Q$+ Y?L
MP2>F<0G)-1?OO_(K#]T35WTF/22/;Z_YZ[^UJJ4-LW<4Q5?9F;J;1GR9630[
M[#USR=:(]],3YOR';=3&\?'NF/_RM_+]Y[W<JA5)LR+$ KLX"%=2KT0#21SB
M"\QBBM;VJS'0#-<LQFY5#%['JC#$?*@%)^%ZX"KZN9GVU3_N&;4M+Z!9HMJ0
MA0O=""+CUS ?\KZ5'4J]<OJPC9E%V6I:J.:+J1\)$SRNK_<G#^G;O$/)<1"C
MJR3:Q9&U8VJLCWXHZ&0:A$R!L]&4@TA[PT$TR1MP$..*JZI1;'NF.LSA\(*P
M3G2&C"@<Q(!8"9L;%F)<2:OX=G/6SJ0Q?!VJWY*QF29:3XK!'H#ZZ5I%[+?L
MK+?L<'X?G<:NZV3<RHU]IS]%*?3\L'A9>E3VR110V$-5IQDQCH%2!&P[JC @
MAC0J24.'.]]?;O9B:OU<G&W2K+U-Q^_O/BJ':=+P6I!QOFV&D U$L02;X%;2
MRJ$Q8 U#RA."ML,"X:DD"ZXD'[ PO&2QCY$.?'/>[2J<)GPU0TDM!>7^->O8
M<Q?>YJ%/AL4K/@F>S?-PEE?5H&E&/N)@P3G:93PUSB=CV$OH_3',L!+-K/R-
MW1EJ-)=_]J6:C=N-E,F^W<1[ZR]-]R(]&/EH]H0<XT5Y<;>B#7,<C,P(5#ON
M+6K.-(;:.[>&#&74;'L,44N,6X:/'"4TX=<+:0?S+&M=ESK,K,O16IB#C=2B
MN0/M:_6E.MYKXJ.P^B(]:]IA*L*O7;M=0L^*!AA>X?]YX-)]@W#Y'XK8Y^RB
MOVQ8CP3R1V;13 D[J)&$W-/I1]K%\@2]R,$&==W=(DEQ8$I-TNU6R6^9?D_W
ME)Y)>VPBME,5:R,F2W\Y,=)I\WFD2(VZB7D5VP70+#U0Y&<PDV]M6 )/O (E
M1K])JX($NG1K36)9:JY&DN6J=;)5=( GK:9T2\)/!7ON^S&?XD;R5ZA*3$=L
M,XEV 24(5*ER$-Z$V-L<A/ U?V38&,P+^?453$=GO-4MXK\JI7D%9([4N.?P
M-TELG%)\%__09.?5B]%<\W>5%I&,/7042U@)XB/00N8A/G4:!\%@H;;H'J*8
M!EDB-T/"?1C=#G\I#8_; 4_LC/;GJU1+/!\.N%\;<D!&@:1[KCR$@/K+&Y%=
M41X^X2C:*2 &2;- #>RXQC(9F]^(.=?C)Z5T4B214=PV%%S6__7K9W;RD9*:
MK2L(W8B57/%#JO;)"/:E-Z3=Q /8(72AP"R3J3,,]=XU8DEZT40I;K6D[1X&
MCCU8+CM'T(3)91>KN7/0/7%SMT_)ZFNN='6EPH)C>Q2W1DBSF8'8870Q\ @Z
MC*W1EV#?P\I.804_LC/]AFZMV(360LB2SKVQ7R:+;3XXG,D+L91+#Q RRS>4
M/>DA<VE<CA?!M83]A-J [4!Q8^59M\#[3.U B?J1Z_2LZMZE"/KP(W:*KRC#
M:?KV@L,E_+$SW0<J>M_$D?SF"ZXC/?8@HS!J8[@!N..XX;!*P0BRDXDH;'\2
M7HHH!;5U.\H4&&,,R<W:9TFTEOR,7G:%"7^OD7@C=R.3=. ^;[@,]U;FR@,.
MXBI!<%W.%+92#9C80)/:CX$D*Y T2MK>FAFX64KR,R- &MF>ESMV__JI5L83
MOX5H[!Q*;??JXN,-2QG"J^N4G@9R$,SU<=O3^N*3*.%"$GC$R)1&JE>YF1QL
M3LZ-J)G?'HRO6>25N/VLWX6BLES]ZD(XH.[[QP??&IN9(83P#Z"XA!I! QB;
MV<]U39EVF"#O\X$FU8 3U'U,\V%I*0=QMC*D124N\?)(Y2><;K2J^34XE M)
MU"RZ&\6()6Q$P<VZT"TAOI<>3%G0_//=TZ'R-3DRKZ=V. 32"==8S$?SU&V.
MV@_?JS^YON=!3*UDS)<NF"M4D3F(1]*;.(C0Z_IJ[D@Q#L+#'ZQ\ST-C?0?9
M&)1;IM39=G/A*1^?,@F9\9UQA^6?2W.G!)!%]MU#6;@3FGP&YNO0-!L E,^:
M[1VA7?21P@Y;.\J@^3R3]>9KS>_=)@D43NKJ:S0US01Y+#$EJK>-Q@O=*K]^
M]0DFU=9IUPZI8$VXR!J ,7?(YA&0,#VC@26,.L5^IBLC6V)@WYW'0F4,>TKO
M<3MC6EF9XJGS0#EJ?\ ")?ZDV,W" QH;EH.%5WWAOB^#7?]R)E4-_O%H"*J"
MTZCJU)):?\1G: _H>Y."Y@49:@)V4V7$T&R[P73?*1NG[B.44J-P@V/-A4>4
M2G9SMV.XP?NP(;;P'4*A7E(1\C.P%3O4,(JN 1X (C_;-?1\3M$V)P2__X;;
M<L@C7[?MX5B(8+A-LF'B'7&_X]/O^A!LHS<D991[*ZB BR'*8(>&5=CWTM<I
M/RC <*7AJY#;)A^#(Q1D9&8;=9F#D/9**GYS.ZI:SZI6A$%K*,H,_/[\ZHT7
M:6^E8^ &I:UO709[*/+4"+H\Q$NE<S'::-I4,9]18(MM8,UG0$Q72.N%(_-<
M(O!QT&,MRB.ON\G?1]TPY)E;[/FY#2Z[-JP)&09.L'8A&44=P!54;P[%G.KS
M=M+Y(@?Q %DCA+:=PNTUK"B7<RH.^U^D?7DTU.'_[Q0EZV0/,4*(I*R%9BH)
M25,I"IG*3DR2D&E&9,G2A**HIB)+:&QC*LLTUH2$;"-F4:F8?*9E?)C%_?C^
MSKGGW'/O.;][S_T#A^/SF6=YOU_OU^MYWL_[N7^Y_$^/4KW<G2H7J4WD%"&!
M35I=I*"3QP_,BF7\RPGT0U44FE8(7A9Z=JZ#)+FC53,T)^YL0P=5G:IYT.,0
M[>(9/:J").?$;X>$R[98&"(!/TYKC'U+&/=B*^&"14^L>P41=@O>E,&&L_:'
MAH)HGZRS3WRIH=8V-*:<F7U\H)JR[WN5*TS9&U6_>GDD_A-&SKE3WIPMU8&6
MZ(B1KD;5(HU BYG](Y:;,-.B?);4[Z+8]R(M*6W3WU #!1SS+$3C0"KA')K!
M9)&XKI4@HHVI@K>*6R>T9JL"MQ]<7X%M^/8Z?AWW?3@>QU-_]5CR7D1_U<U)
MV[Q7%=O=\17B#S1XZP[<#M"Y-,YHAM0M8&;H&#;$?W@Z<]:QO='[))7]+3;;
MO3K#0'$IJNZ@C/%G?;G+'84P[G?R!^8D>08:99\.&G":ED8 T ,3LOS,8:$$
MVWP33J&9)Y5!\1G8,/XS.H2K\-P@HMR[BO<K]\L+IXLY3??5N>L/9;^7&02U
M>97\CZ)T JNL=;7^/$X\ @'1)YJF@R*OGK[<6@V!B#<S;7O#5+C+B%6)\O2/
M,<0%%\[KE.J!PKI["IM>)*H>W8?:!SDC8L*_BP1XHD'CQ6X2(X'=520@T-H&
MTIC2M!#TQKC@MN6!M%:=4-O"SD_'[=*O3/TYH'^;P=B9JR'3TM=_Q?&PVDXY
MC Z-50S1_#E!',Y91-02R[0# KX78$0WMNHW/\.SH<8\=>28ZX3G32Z-K9^(
MB?W-C3 ##X7,!%EL#JADPU G?YH*!'MW=%U''W_M$L%]&AI<Z)AR\)C;+CY,
M&4-" &XD<%L*,P-OC0L7Y4#!W'P2R^[N<C=E[TCVYY#@PNO ='&IST28][HV
M&D/]A,UE+?N$S#TJ^N^>G\IIKSEAP3P@]!4]Q<N*QQ'US [S5%IM+'>&=8,S
MWFQFW<V?3?S7HM_AY7W$9'^\YJ?FVGLQ\@H_U"7ZWRTE/H&?!_?PBM@8KC0P
M?!CL =RZ"[&WA&8O#_S^H?DKY]+6QB:GG.*@0]K[KL0L5[PLI.T@L!BH1!HE
M(DVH_(<5V_7(B[\P:B[6[&>+/.:9ZS%L<;9V=2L6J^\;YKJA):(N&67>8P_O
M[8RB46C<*+)0A8?.'!6(%>* _&R>Y<'7345N8 *BG;O67>;#R>"0OT4-M[>5
M#4RE?(UO_KKG>F+B$XE_G PPC[W 51= '(?N0F-EBV5$U:M'PG1.X^S!3G)<
MI';D^_=G3886W$:L95T#4A?<[F'U[W2&1QM8O'B7E=OYQO#/I9=:[UHA/40_
M10A#@*;J72NP-!(,>@G7Z"RX'W%C) ;+&.C0[$Y]\GBV/?9.OUDM<.\9DV[@
M'N7PL:_K>E%QBFJJ=D!&(NJH\3/:3J$4#RV6219<(M#1M##L.$235V!<"-?D
M\*I"@S$K>.U<(2KI2F5_D$1"Z2WEHPT)Z3(;ID8Y\<'WW4WF4W>_-ZU] A]^
M;\JBC;OQ:T35S?J\=CX4;Y.NB,<Q*E7"F!E"\F.=>AX"$L;>(3M#?X.9CJV-
M.9SPRM-IN04VOY]D9Y2?L;UB[T8KA+JD14&#IG"ABB/?!W021.,'F<"QBN:]
M):X5#[IO"&V!!5<,>'@^PEK#_['[T9GW'LJ^&Y[?4AK1.\TY39K-N?]1ZL>_
M"T)G\!:+=!,#IPQDT)2:72.*P=AV;Z>NBI<_Q[(.>EZ]=&BHWY*E3#E^YO8:
MARA,$:8.F[D"8Y4R@=-$R3@J?P)<+>(I]0:$ [_G.J^5%@#H-AT-D/#\9V5,
ML/^ET?83(UM;L[\\[-\>*:=8]VS>'KV;;"DJ0X41&&2QS"I36 /^JXX3<)HQ
M<+R>4&FT&<TBWO8.3FV0]:DT5_T<&I4^V^AXI8I_J:^>KN\J[:7P\L4![88U
M_/6K=R.WBPIB$!/,+A0E9>SM"NSV-4S[@-3W1KLZD'P6=+U^/IC,\#O;'B[Y
M)J! 2PVP1&NQ7?0LFQBMA3Q;[AH@F(ZW S#M\$W"@\-6-$7A05M'NIWVO[=N
MC\Y7/U%7EY4A:-PV5&BOL5ZJY65V$:C=0F6B6'Z9%\QU>BJ>9I R<6ZAP"1=
M':,02 .CGGH;);-R.5W2$<4NW R_2OIE?>;EE[U?UV\*,GP"3?$KH:'H.1)2
M5O2SJ/,)Q%12HTT%*YRDY#BSP<$R*ICUR$0(!O&UY;<VMV3Y=K3]>/GL2DIQ
MT>6#>O*;/"^$2/S#9P@'H=?DB@=IC>AY519Y8HX?NYK;M$XA;_]PZ]:X2>\:
ML$AP:HXFW] 0L79#1']_]IWZU"W^V*V]NZAGII#[)5RN67I![P#0YNN%1REV
MY Y5Z(751(;/6\U'N4[/ZD,8RMHV/$STNS>IN>7UE5LDWL?87]K@D+,/L4_H
M 6:R5Z.E',Z9%]Y9<9GAE?)7JQ_CX;,;UY/=TF!NE63U[K/@&/NRQ253<WX\
M.,LB,<)9P9!QAZ!3>9C2&S-[UT]Z#0Z?;/B]PZGYN[9DSI=YG.*]'GH5:1+1
MW;H=/"70PYT$G[+,?.8U%U+%6G.%I9G7OSB;3_SBSAL5:MBX5!$I@T='3Y1M
MTLW*$ I%I2C6,P(5FT1@I6+JO;@Q0";G; E-':\7_GA]P^B_O8Y.-1O#E<)T
MEX >1>HNGY*!!LMV38NUAU6?P#^],?UCQ'_!0PM5!&)IX@SB)HFBWHD C0\+
M?0%R5NN.[X_AX#U@>I'=]>CY#W[C<DGVQE=#)8E:Z=E-\)RM.7W)H3E%<EI_
M&8E[4 JX*R"*LY")-  5V:3TPK.+6;@MH<$Q'(*"S^?4-\-;F@[P!TP(&W).
MWMO[]J7?,+\=1"4(0B%>=JRQ8@4FS2UH#Q%&[[;1G\=,H*_S%6]1 WIG">N9
M31\2O+X1Z ,3F?QIWH)0/9S_=A"I0J ?@=C2FI]7&8B;6'),$RJE%?%)YW?;
M-^DO=<-]7L<L]"8ZTST#U[HF3FT+^O8&0T1*B*J%V!68E)9M&W."/$,I2/I7
MN3#>A$[K9"J1'6S7B::R;^+U[_:8/7IXGVKK<51W_[?UMZURO39TJO['Z$ C
M_B:P7Q" @TAQ$@F<$4M'"\[@A^IP_C6$Y'R2,E('G/$ 1DH?5/B<T3[RH\#&
MUBVH4N75PU_.NC8?$S96_L&TH\%MQ%L$UC.[@BRD71@).#N0L@*K*[A9)3Q3
M'HJ10VJUQ[)C1V;K&^YVZE17KL NN@0:7CTQ%Y:Y&>\WM.G7YWVH"Y7]$!-G
M,F;X":+L9JT2W#Y1"5YW!=:VIR1\VK@.^)47*\J+C9_]Z168TJQE=B&G(/[0
MTKBD+Z[/PK0-Q8(0BSJ0A<+")[H[/7 G>-@4G.L,/(6I%(.6C$OK%$N]NNV.
MZ$0$*+IBJ\XL'7FWY752R*1,9ZSI/9D2X]]P<$^O^,@D6UWT2"J9\-?^!4PD
MPZ-E":V!&?HU6@=*XR?&?_"O]HZ9XR-DAX*\=XU)-OEG; YI%(69:K^0W7QN
M;5P5*A&ETZHL_H1:W[Q7L$\HR\/P9V_B3I55\V]4BE(3L)1]KL?$I]J<32Z7
MI3DY7*F"3\:*C] XBZ)<$6$%YCX\MEI4^W_9[6A8\PM%*> ^$.S"MZ-DM690
M7!]>\A$@-JWU4V/CHE>O0=VT[\ZMYZC4%+_P6RZ>V!T&08RJJ$07'G-B5BP;
M#.'N+U$ITB*$5#^;V+H-3#[*(]W*H@'9(4@S,+[J^\*+=$ZH+WWKU(N#H%-0
M%W )KOH- T!Z8** 7\/SZL9.U/-YHGS\^C-"WR+^==[1VO)PFO3+F+B+ST=U
M6QN3MC8UQM\@<M6ZUG[?$*SP[EU)A90;'](F21S\!\)F0@A*#O\>13&:?\U#
ML\P[N%<7D/*#2(LXR_G\-Q1.4M,5P=LS 7G?3*H\]WY-VA9TJ43BUYO_;O5Q
MR5PL6[0",ZX#(;EP"2U"GO8:O>L)>C,].]HHY/?#U 3[A^-]J%'@GK'?9UY4
M*_\-9>!+:X:XP9A<NP+S_9^UT$C28@BN/Z'%KBNP2<0J7LO1OJIA9&F_;%=@
M9;W+&'!'['P_KXG?"77GE/",J(@6C)!<S3V:02N?^1'Z]#N-X3E*" V)23"]
M)?4HQB#*4"_UT-)4-%7"(!%?_ZS57M5G;O>#4<KKHJO<V.A?0!SAQ?EM'UN6
M](JODP/#284('?RJX+A("X5/(#I0M640AK*RK[9N>,TCWY@%LIFWF_UY@O;%
M0GQ>1'3(:-Y4"R73U:'DT*]3*IMW2:9*^(?AAU  I+V)>#71#92_^80LZ_9C
M7#0!L)VA)EJ3-'[Z'Z?6GQJV&FC0$GQ1/U'Z??#+TI8#O^=-5'W6TPY]KU+(
M8YDS\E@8[@V!'D1T5K>8'^)[:/4=*[!-S>8S"VEJ8D60#,E*ES&SBS%%VZJ-
M_IA9^^A?Z5%]NT'2;#TP=3IXCS.^FU;?S8U8+0!'/_QO 31!<7. #4*CP;^D
M%":0B#,!0\OG\L>6BQEN5R-?_MN[GWOF6<I4YJ$[J0:F=]ZJP(V85XY)?</.
M1P-,L0SD_9(O0?<* ATIEL5WX'5 "LL<'E[XD+0!;S8E/%4S9&8U9<'_&?Z*
M,[K]VWI>X?29STT^^@N8G%T->WA8T-!K7O8EU!!'&FN:E(FI5Z#Q=GQP1W/4
M.P>4P_":/,;D3DHSK6'D::XL\$1)-_]G?W+$YX.1K( LKTF2)H&50:I'=)MK
M@J2.5CUPBC?K-B@,?^'+!*EO'V\&)RHGX@BG"MF]GZ6WGSB;D:L6\2[%Z]ON
MM:WWP5U ,!L[OP"0#X#Z )JNAM0"RE*O_*W]^-?=SJ+6^VT+K&=[G^OV#QWU
M]9:[MKOJ(AZ+I<$*P04PFL['R+="(T]_]2:(QM-[/VA&II#AX8^5J4!7I=V.
MT6:W'N*#")6;\8\]#@X=THK<=/MZ./^YZ"XD;3((U(7Y/3PFG;;A8K5P%Y#=
M?-:HXWSIS\:<R;A8+D/.IO%CIU;S95_GV<J#K0<C&HRW*UX*YWH;2WP9F SG
M!T']BQ7+F D0PE@P'E*0<!F<&<\H\U=S[ L(@WV<1 _D?Z5&1/B\SW?*C?BC
M??^6+]E3IGELF+"1@MH4TKIFS)J8]E@CS9NWKI08;9-2[#N=&;*PH&88$L$(
MDCQ(UCVY8[^,UM[*"QDPX6HE]12<O.@9BE6&D<6V*M&A>5Y/8C.[^H/X8_-,
M3<J"*AAC)MQFX7MP ?^FY6;I;\"D^((5T?S.U=Q=F)<ZTH,4@D*<I0NPF.ZP
MW[":<+[49Y(95F\XUO) _U3\_0!6T]J.A-%'*FN ,2Z=9PN%:;PNF,QB=J/!
M+=JSW60)Q@=H7C(N4@CR/_.7,USE+G+-7A8;7/[QLB[_ -,&5_,S_NU20@<*
M<,5.OI@4R_>#O0+Y. +;[!4/<B^Q'CE=* &D#G1='5.,<W3)Z_ ._!F267[6
M3;M)]%@K_):;M$V]"]W-,EH@[P3#/8"HV@?1@U9;_#@-.$S+1-7'SL^P2*"+
M,)03OM?,:J^ZX#!C@&NF0 Z,TOWSLN2V0<>Q=TS[EU=9 7?@N:L[O*A@(@-+
M1U%GWQ) X]6J:-O$#G&8MTC8)^&NET)D[:<J_T\-LKT%V<-G:F__&]U6L@67
M)D-/*M=/?DUP#'D"[R?=)$FA6"6T!K10+8T])E31FAF8?TR3QV\*P<C$T!1"
MO;6965:37#>W4%^':(R!\F;TY0]1F]>>S-BMK\#N73,/D<<CI(GH&>K\/\$!
M_"AR-TAG8>>SS3G!W;>$3JQ,,M?>A\@ULZ[6RT(W2I]]NG0OM>< 2F,R8UD,
MS??8ZJ*@+HX@N@/):H(2+0(BE*2:UFR!"\X69):&FL^@-YAU%>FTL-W]CU)M
M>F,#WMS6?T5]O#T^ISCMCT+<Z;'8050-)@-O""YVX75YMADTUCT^J7XT3>V!
MBO>.ZO*?UTQ_+@\W/\C?9M8PQ0RZ9;-%].5FDV**UF4\Z5FB0[!81EM@,(&?
MHM4:=9 G=!;.GMV!WAQW(=Q4_NC![?D%&9X^H6>=MV<Z1%FNZ3FVCVX-='>8
MIY, ;TPVIN8Z1/^1LV+IYU%/A8YC0H@Z;S"_)=[%!!?=\MJ._1CR$67,GL[L
MO3-EWQ-Y=O2ST[=#OX/E/,Z+W)\E(F&B*@C#BTAJ5L0;*[":@?D_ INX"VB5
M4$S]6#=&,@QI^JGTDUF$CK;RX?K'LH^<\N,]^B[TO;R0B;OY[FJ%!)'V_5DB
MRI2&)6W"#R/@*!8'FX)$B0KP2@Q0< IB]('<P]<3Z$KANT(7[3[<C:G0+S1U
MN\63\2UNMGQR[][F?8/Y)UACSX6*H)O@O'B*"9Q$2Q+H^R!W)DS$'@?-6/ ;
MT_!1*UHJ7HUWJ#XP]F6X=VOE)FISZX/M7W+M0]3&X\.ROF:N.^<2-/DOOUJ@
M@T.,TBY6Z_/G6\YZB)6KE=^JZRC4;<.M(_$OCAWXL>A(?>! ;__%BLKX=QBV
M)"&6MA?LP%T5%3KX"$[\)&A!#G]+JH/ ('5,[P3\H48P/D,BX3LUBI&94.7S
M_IOV-UO1YR:#LS0+N2P0VXF>@,\LSJ^JS#5@O> DSEJ4^)?(\&!CNDTSY7U\
M/E8;#LWPX,DQ37%REJZ2UVY_:J*\WG2YG#U2VW:SCU1J=4RJ%U%[G78+:><-
M3O?.Q J5H@^ 6]CR:)=D=%TM;]V'M.OQG*+X9G;LNJ^/DIHOO7VAI^/[01Q\
M?^*8.NDTX#Q_7K!-N&7XWSN\!/Z##@R07TBWNG6%Z^@!8).JKDQ\O4%?.EO-
M<=1+;8\PTEC;@H3L' J-28ZXW=#W+'P/H3XM!<5ZP-1>@5UXT& FVV;G22UU
MY"VVK\"4&C);D.<-QF+5J+M"IR\P32V/I*L6KSL=&5&L&X^:5V;1P&TKL'EW
M@0I*J.P(R2^ATF\M5+JGZXM0_YD&_,ZA8J!E^?/GHSUDWYUYW.'W%2:D^DU]
M+_U/&>H>[EX><(+AH_!]&$D:JQQ12Q)N+& 3YPL 69:D(@XG4!$CWN0=YR$+
M^.:2U=/%L?ISZDJ9J6[/DZ0]G3*8 U=S[FP:-ZT.$*ZN(KNO*HBD([CS8#!O
M02S=&5PM=&T<-7L"+'#MV?+^'37[8V:VQAL\!$LUS'\IJ="2X@/]%>]@,_8K
MY11<%5FN)KTDB1ZVFHO'(+HI5//A?P>+ 'W^V5:PG35'4HL[VMNELPD8?1T:
M7/UCT?390D,+Q:W[MM;]]/#TYUDN=6L_ODF5X= PX>_%TN)NDI1X#:2YJ@6.
MX+J8_1Q$5N'+1^5Q'=-,:5W+,]Y%(0XW&0Y/OSX^=!3M $T]H88P3Q&< 1=G
M:%QYR(8VBUXB%=M9<'7A.> K*16W#J#'E)M'7C&3Z9H8M8R-4MREE?G@04"
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M36 ETEJ!'>4-KFZ$K,#R2*)DVOR\%5FD]'?-@/CS+@C(/%&L0A+@OG![]0Z
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M(=6Q_"Z*8'?!_*RE4'R>V,>E856_KU:TBN7 )]Q8ZAF$T&P)?OL8;MVL\!!
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MD&E5$RH!LW3IIP"-CM$LR\1O^G$9;/*\'W+M3?_VN4MUKE>&CCQS?7Y>KM\
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M12*?>N[P/_\Z2^-,CA[>@$T&=2 !=R*HA[V'U^;%\,] _W:/P3_Q::B+H5?
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M745G-*FD$JQ W)QGDE#RAV43(9F#:V,8>'F#+UN7=GWI.H/QI9X_E^"E[#2
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M /3DG1F?B,QPI8!/@"04ZT*5Z=J/5__.%JTZN!J@R'1C6KZN',+,IA[W]XD
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MG]131IXU*)^CSIX_\)=;AG2OD\3@!BP$#>[%+07Q%"-?T8NV"<JI1\8C#VW
M.IJNEI=%QD08RI2F?)>UTLE9^CUP@M/YH=9!V3(PRG=$R_-OY5C;IRF_Z6U$
MP ,[[M+.K%U)IEWO0\W]&DL@J$<Z^H4BO,9L@EAI]DZ9ODF7\LX:^I3)SX5K
M76SSE^OLZ%$Z\U>F(>$#A'J>I'%3;COXDK:%*H>_,!R*#[9[S$@O8&%W1KJ<
M_51M8;U?1BWUQ/">5+:3DE=&CE?<*S.18P=%UCJ45A?9X9#I4-J(O(+4^$J3
MLK/"GZ+9F7'$'OE](VP'JN__DL6>C[;0]?[&KM#,GDLT:+&^O\VM;9DQ/B3(
M@=;8,V2-([M\WA;-6E]ZQV'T=S"H\4^]0QA]E479T9)D2B/.J:$9>"J%Z]*R
ML6X>SU,-.*&M*+*LZ-E-(0&^*%!/XVWE5ZH*@&2+1<WYGKLXBCZ5> I8C[-(
M+5^"N$5ML,E J'D0O*@BSHNK??_J\0\R,C0$;;8>":!($PUSMVE XIQ*.U'1
M%^,GEW>%$POTTUW#/2B?_GWJ+'P4%ARDL^]>Q!71AR*JHEJQ=I5/FVDH 1D9
MR [BNKT5O"'#'WC?* 5>]M M_?8T<A(>[1Z[^8)T/7U=_O?-DK_Z=J8?'=AZ
M0-SA>,%=;R#442BS#H62)T-XEZ?7S@J'.I;J1VO3X8J.+'5/GO(@YLW#"WN:
MAF7+&NK_J4BF'O'UEO^K5]N@!1;SZ"2>- ^E(L:+? 5S5F+75E!B'LFP"*U'
M@DX.\>&57:QW#K[20^ZF=4OG0LI%ZM+=;[JWYLJ]UOR@M.=.$#N11Q!^0+\F
M)#X-@2"%UMXY:&*#BM(MO;]F:^GT=OB7[=7($>\3E+JZ%*_G#%7+_;[)[W#[
MIPZ(+/WCF43H1@!N\ D,]_.PS<EB_A:.W3N]&M9.=@!'[_X<5NS['5UVW,6\
M$]L'T)/MONCNW&T%B=W'6JNQ_S/W6]7Q/5GO+#O]E(>;-2M^D_Q';OVN6.:7
M,F8NEKF]CMYMUEHIO5?TXP8L8&4BD96QY,^S CVY:/! 4RQ BR=SZP8Z7]W6
M?_/S0;4F<X_[%,XZ_&ZGX<!_MVX.E!%N3_Y)8W60=N/9DY:1_H29-YNR0\X?
M;7^L,,!%H<POP'ZNGZT&^3@?BM#861R=[=+AMW=D!7^0<3O^F<_O!A5#B:2U
MGN24XN_R.Y^%?RUSA=U$ CYOD1/>2-!R S:WS4_#50POH4(OW$=553,N.OY!
M8Y*W9X*][/-^HN[A,ZY>\R0W U!:;*>!!B2^@LPIP5.R7#DFAP#CI)=7>7^O
MP6I[U0._[@DQ"8@?VF^/[;6U[RRMC]&%4H-MR-E\AF4'6W]N"BT689W$MZTJ
MQ-()TC1.3FD8JU#[K F:[=%TXE&!DT^4D9S_SV%2MKBX[4H7L7:QA91,0MB(
M\5 @LX49RNFGJ\6<A8O^(#%P;ANPJUUE+:_]X'I'/%2;NP<\#Y1D=YX+_A)K
MMWFU.:/CR12!L0%['5/=:7&/OY^884D$,DU*,FH.O3&2X.XMP'6C2(ML6>'8
M.WV^2N4M)^H!0GL#04P.GD+GDH$_D><G_=F))PU-N2V'?U/?URU1"8=;3W'R
M>1ANGB"7 -L\U2I1CXPED6ET=60'56&$8C&36X;UK=7\X**85?M^Z\LH+^W
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M!R0/>V,O^@ ^ +P)\*< 2V"#P)_MS^N&/YN0X)]782$A0:&-PALW_M- B(K
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MZR&W!+8G7\FTJQP*I]L:HR6X;;,.F<G!O]K*VU(46K(/B%S(!BJWW_R:I"&
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MHO_.P?)D>\KTM*R!T>HK*2F;DV=!1"NIAYB":EA+Y$DO4B5Y>C &[T#3DOE
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M8D%QXA-W3W?;OP92[<:/7MJZ=6\VTMP)\0K=A.#($&89:XS;?*!E;5F [11
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M^1#R*[/ATR?[:T:%ZD)#EV^G+\SM=]Q[]HOMA^8$[/N#2)Z8(EN!1R&*6^A
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M<&]'V;'=HIP_&/P*"D:]:1IN=#"ZZ&'O5-3L/K6RK5I[<,!V4B2E9V-P!;6
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MQY;!670\#SWV,RCR8)"CR=H.Y72SG^[Q=GWR-JY)>ET2G%YU@+N9E$.FU6!
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MG5NP=YB]-QPNDU4)7P1]^  FD0\<,OXR3_ZQLVIA_8%Y<XHV:>#0O^2R/_C
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M"@]H"\R,,E)8[;!HD&8-=C5^,^2$#(<S3+"6%%J8U_M"MKI\*]2>W%WW9F1
M]T&O>>DMRMK8_!SQGBTF[Z]6IO+"83W$'-G36\+@U7B[I<DW!-_'5^F'%GM@
MJ^'U4%O*Y37CQA[.L9N+@YZO_/+4Y<AY_6OYIJ7,M \XR#>,*XN%'ZOR@:;#
MS#H^L,4ZB=!(S$GG2H?13.H\Q)"_\LE<F=NP3$OP%<-.7A$RX&&Y]H.M8($O
MI7$#9OQKGG:KOZ6!)3=I:MH'_:@^"44:^S-[%?]3;.B?I3G$,$P+E/$!4L52
M;.%IRN_^F'_O#A]NFP7O*W1*66!3_S9I)L8:A??OP<Y!X*R@0^>?7-?^IX/D
MMWKX0?0?+47Y()EW?OSIQ1%-2$TSE$Q]8:C)>^HU)<$'*D[,Y3DQ?TS4/E[3
M?41GWXG6^LS\&]FY_@ENDM?3/$5Z)EJMVPNLK5MG'0@]5^;Z%;^RI>\?R7'H
MS8K8X'5NW9H'<4T 01-NY0.(&^2N5^.HX)V^DEVF*)(UUHKK63%A%T-TLB4F
MZA*U'IM:/5XY&BD3ZF+T)#7JO=/\A]'-99*PR#,:%MJ#,N,5X24#EV*10O&\
MEZQP3#Z9ALI;BI./Y'/)J_>E+Z>$O8=Q3^LZZ/=+K?6(F.,PQQ2IO:GW*.\-
MWH6S$Z[!,$T5 MD1+-\JI#+IU0X^&I;'V[2S54?H*Q+DS8NP2B*CJQ^IWQ0O
MW7%TN?A@#YJ=R"LKWTQH+4<S?6N)T"8B=_O@JH$@$L><CN%JO!"TA#_UN&G5
MP5%NHDW;GFU^A=XDC^?5#9]2$60$_,EC)J7WAEQ^M2+HF<MSE-]JZ^@O*; Q
MD3W-V_\-Z2#NV)\^*?(_B9FIZ<10W-EO('F$)5V$.#1S:*O+I,YKKO>7 K6H
M]3-#!8])]&=H<;?%;1%"1*EK"AC+#SZ2<E>JA>A]E<-;(W>_6U59GL1[2G:/
M@533J_E %&7;+;(;&MHB3JP<7#$8E,YQK[M&:%M_N)ARJ='M8IC,'G;&%OAB
MO11&33S1<^;^';00%$8C0>KFDZE(%12A)M8-MASOIH'"$!A"EO34SN19&!Q@
MG6HTCS_9F3T[YC%XLLBJ^G'@HT.[C38W;-DSH?ID_AW. V%I;C&0NFXU.IHB
M>P=S&82436[#BI#$% /;6[[S2[FV[??V<8Z&L]\>BLDZ-]_F=]57"1:;/._M
M1V/;_N7I<NEO6'G,KVCG%S[PS/IMUP/\E;]-S0_!'MB]->AI=>1>_'?A34C7
MC^[__9+,/TO2W[$"Y&^"R)#$WD9LEO1PP>_^F+K:Q8U*&>,#&_7?( [PV-_<
MY4^0KN3-SXBOO@7\9FG=/K??WP.QE(__T7K!/TS_F:4([%-9,#<L@DQ-XP/,
M4RV4;178@C"&$^M&Y0 :,G[CJ@=6D4,&);C7]MRZ1'$8>*90QZZ&35I\VEM&
MD^L?O*M1]]<_F-Y*S-/EKJEB>_(>$71=B8I<05;\T*7L3%>,&T>92)^ZEQ"=
MD6XZVFOJ.>"1WWSJ[);/C0^FWUMM>)V$ROK+H?U_X=">0A6L%)KL)(<)S]/)
M==CP8M1M[JZT?-/7?K>KB[.LK'QJ;654JIK45+>[*:R^./T9^-9EYJB C&XQ
M*)NCSMW$>^Y9>H#CCI>-J^4#JSR]W>U!Z9XF*AHZJJ[=;207=Y*<-SV,<0X]
M<C(_67=7R>%N>*, TYIAQ(R'Q8=Y6>3+XEAV&6N>*\WN/<)Z3/*0SGG/C&?L
M<DFO<O&\7R?[P//NMRIY__,]TH5Y>;OD= 8(']$ @K2C$T5Y;PVVTG$]]K!H
M%=T\G+"OD .R4<$X/N"FW47K*+(YNX63)1B'B1<TVSGT;9<P+#JWM%]? 'EY
M0).B5O4.RJ2Z3/(!#AI*:W"M"FOCKJ$]O1BCI'\QTJA<6:&MT\9W65ZI+\L2
M%E_:T>#EUV(.Q:= \FQO9GJUV'9%30E;[BZF8MPU>H9RPIZ;-2ZXU-Z"D7&K
MPW<>"1RYG[GZ5:MP7X<5IJH%<6F5E4RAL*$IZ+!.D"3GADEA!R:G]( SVYV#
MTML:-SF_\]N"91HC^JF^@\U%>N%?5.*_DDHDW?R8"1S8<!OQ"]-+L7LW=7'7
M6K/C65O@G5 )9R6T?NA,\<-&_]>NA;GCDF<_G3!MH.#ORZV;OU2_K\D7DXL8
M25WV,EZ$I@2)HP'7$T29H6DG7W:I>X7$6Z@<%@W*]9AA*+V9JBL(?/&WM=J9
MKDE96HFX/74DV_N&3N4[5FWN^XCK*6@WS\JR(GAUD!),P(%,C<Q/?]_'#P5B
M^,!*PP=\ *-+AF0Z1S R7KU!:C6@<Z&_'*$AZNE%=?]M'TB7_JO[N166\",T
MVK2]'2E.\-[N);4R3=5P;)9D0#JU%.M[H_S@(A>]") "0\G?/- F"P)M8"7J
M%=C2- 6O*$ S;X^C9V80KW;+PWX)(B&TZ1_=/2F$X6Y<-.%R!Y"VVULKL&*J
MV':&46XZ6>TY@<FO3'>=GS?/_M.;6/]I\](@L[3>[^5J'(W&3YELZRLUFRPK
M%);VP/RQ_]/\31TM?NJ/'&/"6R$'XIW\7OE7):'TL7R/1ZCKU83-!?\%!ZG_
M0KC_"L+]2[)_2?8OR?XEV;\D^Y=D_Y+L7Y+]'R79$3!__E[I/AI*;+PK<7.'
M8<N&HF$EW/9!C9QHPY.!HK,-"_.PJ#S2LJF#?.!=&Q]HT[0_/]T@5^-\.XL2
M.>MAQYLM=D]W:FS.*;@^^?:M<NP)"VOK7J]BG87GUMP=4R%\8%:+#WQ[R >6
M3JV6E",B:6U!1&+)!UC2,W/2$WR@6IG6LL"QY@/+$.BMAM'F W=O/><#+<6@
M%WE!:PP-.0R*\8$Q%SY0OYT/+!W%]<5K\H&71*16Z4M'<4>_JR#OF%419]@D
M> 4*MD*S5FL1%^;-?\3S >4@03X@5D(#>:OXP,)6S*]G<W]7,3S/&,T2>7\#
M)G3R@8\O^4!#%;Q9Z 8?,!SG?4$>:DD"?U?FTG'=?B89#@6YL<A_=TG$URGP
M)ET)L(5"AJ0P"S9@]?YF<+0?4XSE/IU%_0N2D )_E@,*NBO7PN6DSYOR@3C#
M6[\K+P66]44(^Z(<0N:.@?#F<D)R#'2G;R_"&BXC'.(D'Q@^C[14$/F#Z 6/
M@],NK9C?E2D%5OY8BOALA(&/FB\=KV[I0)C'ZF=AF%$&EBN*YF9AZ!M=,#,_
MB/V:\/%%X=^5&//[;EE8C,#0):^.<GF9"/,RX@./PKB'5HW"0>V<5.09XM)G
M%W\JT.+W_8+%6)AP#WIN0.I< #)5P.EW?ZG"/U>%M_/LZU <E23-/00WMNJ0
M\LW9(MA&CG;X=/"'O<Z"9?C;CFT<8;#>"\->\1XI*"4K$W)_X.R5>B_U5,K#
M?<.^\@Z^^9)<<R/5H;-="D]/577<D7+>\N(AB83S)[I:&$L/$=-#_L'R_?_K
MK4EX+,</><(+S5Y1A-3I5=I[D(>0;R=V8@L#&__,\W'Q5!\KKV^0(RDXEW@B
MZ%0!HVRQ!S9)ML!N;S.'-_(!G@DXK F/X5VXA["+B$#K^0#'Z'N#VK#>D@(@
M76LQN("(JUCX__K]!0Z[$1% *'X-+\Z#6%E$4"LDLW+<Y9*9!6^)WH&[[4Q]
M5YTR4Z74CJQ6\KTX(SIU[DW)/>!Z-DU#?9^NWA/.U@&D5[UTJZX-XQV<CT6+
M-YCG(WF;E;9\H:C12#>)^6$59 JNLHNP&]*@?]"QU\!8N(OO/^OFN^>&7;_J
MEBBI^WUU&^Y67#1JF#T?P>PAXV(HPD.ZD=P#J80J8JX! </L"BEP\RHSKZ7,
M1[YLF\3ADG]Y++;5M?^MM+F0I^2^NQN?C]*L%-=$EI,)'ME'&^#'SW12:[N+
M\QX:9C0,D76,I4H<&K8[S-KGS3E&0"TTEW #MR%46+%U.$$);P"*3!3YO)PS
MESB:41?@M9!K9#Q:O>R8T&Z%PRLW?\!2K(>$:S%W*#*/#84(393XZNP;UF1W
MO]D)ATL*>I2F93):?7V?1:N?G[MJ*GE3RZZQ\LAAHGYM"=B5#I8D(B-A757,
MFQ-%N3;.0>2(6,Z"!TZ_FT.)X.9"(,<?[\JLJT/&-Z&9#Q2Z3.8;*@[Z3;7$
M5! VM96>D2&E8_NJ;PU\/?@@Y8#RRMH;[W,C!9J"C"Q-*B_;W.G;U>O:_JK=
M,:-I-\O VUYDRYOS5F_&WX2G%;:]SI^SFC/,2BZW3"[\J>,W#++6@-\1_=_&
M!QBH3!72P[&4WR@F^K_L[L\SHM3UB[VPR/"20W9 ''(KXI"W&S&G>,B%QV+7
MOORB;3L6<8@$E+[6_U+'<=H9+=M]O5^7X#Y)*E+EMB2]3HZ(8P0O087RH"4E
M1117OY4\J0W.FG:UGIF9XDKIPD<'$'T^G\('DAW+\/?@P[-EX&$\'Y &ZS%W
M9[$)AD>7D) E\^KOIDH%-6MA7298A1.YK&C X@/A5_*#9(\5N$>96G;LD%'Q
MH#MF?>Y#F5_?OR%AH82FRY6.9SM CUBWK2#?;9%O-:[LT&G2-V,:DC1#=&Q>
M=GXK#EXKG1K;9R(O]TWE68.P0];N=9)CY*+XR?HWA"X^D-L23E@V9K@]S*1#
MQSRWSZVKZ.I3#2['_<E;I6@O.0U)[0/VP'UY'WEY\P98D%=8KD=H -?!*GY$
M=BOOR>:B5F66\BWW(;2\GYBM:;^6T8O\B2,:WP+=#C9OO'HAB/M0,V_51Z%I
MUOLWL[O66 ^'!>XI?-2>9U40UU7&/CY_O4](7O;.Z\E1RU>G']I]W7-Y?$;7
M)ZO$KBO6?8)(<1F*J<$%+UH])*PF?"9L@IZ]N=RUMEK=R^'@0+/:SHB5@>&C
M^DY6VP#JM]NVX+MXQGEOCBO<\IB\ 5>.X*S*;0:+!8P[%$WV1_*T(^727>(O
MQJNO/&H1J\N8<*R.CMT8NV=5UNXLB0/2TYK<-9+P<3L41U$'41W-V,*'WZMV
MWO$OZSE\@N(U/.$^%W3"U0AEN3W#\%"ZG/$-A_Z,&_UV[+%B[.<>WGLR-0E<
MA[FXKH 16 7FZ-[%GZ<15W7W]KLK:CZK?DRY]#Q3;7-(U(NML596WJ>D)41F
M1\ICF=%E?$#$.D2[19(7]PG^TOZR>-J@:0#[='UY?[=<[;7GJQ:MF\E,6_3"
MX; :'&>Y'3@>5!#84HE9V&JX#L'% 8A=/+15*O6,4_J)4\7#9AK:);%CI#;<
M5=(J@]SB,^=7R-TXIM$_X5K1WU]0$KC%2V=ZGO&(#ZS8W8IQQD4FRD#;::00
M+:C1HK/ 3*^W1O:D^[(O*(FML[#9RT>E3_'USKU:61@UJ3N%^S=V91&ZT?F$
M$(X2W.2HP4LV,$X[&H@*G1V.%5-I-FR_H9ZQHM28'&+G?\'*TR=#XW:D]8A+
M'3$&FTN(YVCXJ4KST@UTAE 1BINA\22HCIZ6F?YYTL[9;=5+$4<-#Z?MRR__
MLO(I(+/Y0][Q&U5UL9(6CTC9A>7U^WK!X* K/M]L[6K-SF2:-<L.'\4&.A1^
M;5#M/]/KL(-0;F%#E" H0?+TT6"OJ7"T.-[4(\O5+E_90]<R[\*%]_MK?+=O
MO/9(B9E=/!=WRMH>C5%I6'LM-N^ L93EZG];3\TG5 Q..Z!XMSPQLRH3-1,4
MS+FIA1UA\,<B]**4]\@H>EHM&Y8)--B'6('/&*AK).@E@O>_I4_1?K?E]]^V
M_O[! 66U45+WCM[J6.Z&SF='.[+I]V#)*!<U]:W1A"]](V5%DXZZ?""I/QX6
M1+.2Q",@,AL9\;%CF$DQ' *-CF+/!MVK15".?"X"HIQ@G6_@>O)%<=\A3&1=
M) G>W-M3S_Z%.FUMNF-G:O2-$<WY,K7>3[N>X&4P%*M'*9<*<47N1*V:IP0M
MK8:RZ/4&7T9.=)D:$QA*0\5JXSC(]S "RXPOH[EKB? ^$ZY^"H)VDPM0L @"
M*A5)B)6VF<8M<)#J-')C/O.!CA]*"*!$+VAC%I1&$OYI!BD\IWKRZ!1LJCF-
MFM._RP=&ZV S%'QD(2UBT1Y6:'L-MMDAH&PY OUB$ 0K,=:!&<M&T&XP M[J
M7O^V\-N\$W3, B*7..1VK*%;<OEC/A#F=1D]:X647X$ V*$.L*I8![6HAE2
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MWXM%?_==PP=:8K@):.Z#&3/IV:+?Z]OO=0K.^38X,\\'ML8O""^^J 9GAOB
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MBSA90[W' [CZ926L#92RT*A,<U<$X)QX5_KH>>/:(PZV1H6#RKN/[G"8(<C
MM=C<&$8XPC>7$RAV)@PSCJ&?9=U7BN:=<K1AC&R$MM^/FCC3%-5/;3CA\^?N
MBJS#J,R^+6)KMK?#(BA$1B8=(/7)N[X^"EX8&D]U\"MB!Q25?_"_P(2+<#.7
M*<M/?3+UOT(>5WEU/ZDVY4;#MYL!$B3DM3.\;,-]^,M0%',(%B%REO5P;9BC
ME9@U9K2I=7X3-=BU24S&([@($!HR;3^3/:)5KW@PO_F4S@6MZ5Q]4UVN3)UI
M%P+>GA)T$(F%<#5Y\05-UM;0&;J<%^X>4<3;P=7F<KE<<?[["(T36AN#SSS-
M3GEX%O5(L#I=><^JVQ48ZE-,D>YD#>*7GYM'@^\&N5):=.?XRA9I5_1Z V/Z
M"R%.=6&>L0>]2=CBJ4MAAWKJ2N/&U7+KMS2^[3PKLRISG,@\A+OC2U0DK(/;
M!_.[:C A\XLN-T&WJ<B  1(-N\HOHBDI_B2SNE7L=$F"4$4,X\B7M:B!D^O6
M9F7M-WS(*\)0D]%B&*>6[FVG>:7Y#%U84F/+6''0X&WM(+WY>G!MWV7QM3;V
M51NC#Y;?,)?K4[J>\8%=^&4[.1]5QP=ZYRL5I9A;T'G$2=0KJ+UZ8&N;>%>D
MTU=#U=YQ.^L[.ZQ^$2D,#"WP)]7'VEK8J4AN[G]:Z'F&U$CJ!C]B%<M_@7LQ
MHF1J.%D^/^C@5,7@N\$8[QA9*.YL![ +BC,O<FVY?2-:P&:J:-W=3<EW)5X?
M6410-H-E_Y$]R+0DAF"6D7$M%-E:]"JR,\.%9O42]'@]IJA2UIH_M1JJUV0K
M8$Z1<R\^V!1==^53Z"'LKC"#YS>#MG%D$3]F;*B&/\]+PYMSQ G=Q-QVO!)4
M0AL4J:)G8\QR6&?M!A[1-5;\,&S 3?Z(57ERY?UFW?#6W8\W$)]H(JW.PT65
M:W+U(1%$>_18OA])8?5T[%H[N,U0@[,G<6#K^@.A,NV,KX$%'W;5%U#OU.LE
MG?W4MGQ5ZFT)-"S2$L19?Q:LJ [ DYGF39K5+<S/<)->05E11$&+Y$1 *CE<
M4]*FB'.<K?5]7O+HUE=7E.X87#S4?F"70W=?4"8L,D3#K/:;K\0R3TT)^IF?
M"&RRMN,EX3W.I]D=/CS^0_F+4K2VW(_/'PG: KXPXHV6OO=CBB-3$^ 57:6F
MG.5V?G'&;>6BC6\@I]IY<,.7(0O6B]G5<AK9W_+U IO<M]:OP-?&8M6'-N75
M=9+SNKA2.&I,'1;:)A&/-%:]&)S$"C=2Y8EKH>"V'W>F7A6\NBX_<9!CV>1W
M*=CU *6D89F49PU^&-%F 5XY>)&TGE"+%2:?5Y"G3VYGA55@43+M-5@4;K:D
MQ,'D>$)3:4G((^7P@Y,7RA96[<(J$-K)(@1M/S2[AA7/E:]C\H$#'1Y+8<_)
M<EXMX7J&'R[Y&+_RVXW3FZ\N7/..#U@6SIP06^4TK*866I?P\B;&@7P.I%C7
M(E!-=S*(JDF)0SIK14O5Q*#"F'N6/611T)ZAD_K\<]-E!N:!T) &^=&>076/
M&9_AG+B).>M#;5XQXF-?$Q5:M;NO3*IK.!7FYA5&;KEZ,$):Z<P&U3<W 04@
M\_2_1PU+P./Y0 PR8-XOQ=K94=H^-,H%W<ASM>8C!306FANABB=K"Q,MC*47
MGB@.,AOA0V;Z\'LB3SS3YUVY'/@I/!WLDN0#+PL\NR;>H^;78VDQWY:BU$P
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M"]Q<;L.@3SM[T1S$U/8*& $_$@,Y>$(K=CGH;AZ)9B*H* :;QP>B)_&VU/Y
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M0:J2E48!IY- 9KG[U]#*F9\_%<0:YL/[ZDD:JCTX[0>!INGI;TRRT\!=EU?
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M]LO7N6_?YQ>8/U=6?['6H-_K?_02  0%_DO[IWK)P'IM^#,&(G_T$M@0\N<
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M<2/0N6/F '."T<#D [2)3ET]5,= "(UATCJSD6B9OI-FH_6P_X[^]A7!8B=
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MA[#>,BN>H6)_69N6YNZ=<Q53&;\*4]_=CEDU.^4%6)4,+'L[9R>WCB<YC1.
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M%_L4;%Z4__NXCI(:!\J<("C0J#^F0Q^(7*1*F_5H/!D_V5?F-4C-S]]JF_S
M_M)6I1,'2C;R 1X?G?G]ISD;#%<WU'APMM706NM3YR*(FPMTEF,0"ZRMX/7
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MU-X66,5 T47H8=0,3*,7IG$+I@%2WT>YP+U4CB22M1T^0J!/:PUQVAF0F,>
MR_/ZD%!+=KI,3/5&4<=QH$K*S!*-T.R'7@NF< $!;73WF,* #N,@)M.+4,I(
M\O3[S5ZRUW)]8>Y+VZ0PD[<7;F]R"F&*HM]C2\(;B</1C8J[:=(LZ<YQ@9;:
M<YU4PB70C8(=%C\VH*[[C'$J,Z!\]Y8'F.TR!=*>R[)\-QN> &R!O^57+PS,
M2.<Y#Z+D^]++NS0U$1SQV$O+"9MBV%EOOM96<,0<G3FAPD3FE ?OQ9\GL8HP
MY.U]4">=J.4"^&3\'G8U4E,+OU]P]M:R1BI3ZE/ C01L#8MNHKCW1^7T/W/\
M:)=)=&K@:K)D1A_N%J2UGLSX5LDO'2Q+MVHRDU[:V:K#L_A!,IX+"&I">O)0
MZ!Q[L1338)4+%30#@OQ #> WV[-<@/;@&]0EJDY<@&AESE*N(K"%I E+W5W\
MS3^;>N5?78]B0]\+]N%\1,.?2/B=DV=D^#P__,Y,;DFK58)GWNTG67D:T? ]
M[[+C_G&'$/$ $=7MO.-?-.*N/[T<M+N,"T092] &FIQ%69I]*DD^SN+GQCJS
M7J>KGNP]XO9IB,19WKW[9F>6,QT;:[B=-MWP)#RNQH^B9J1DWIU_;L*V%S>Q
MJ1$I%I-\V9"'M8+XG'+W%G%(I0$N;BA.QH$[B8U&-ZWHGS]0CH#/*#819Q#=
M!_.<#&FID!.GI)YVJ+72]KEJ9"=\]V4F C)/T(WFT *C68EN!'D;X3*W"!O\
M-4<:96].*JK6]&;5EGAH9%<\Z).]M.#VQO[8]1895.O%;R:^I*!;>%[(''+0
M3;!-AHY9_OJF8)&?EV;MC7(.C-!?LR?GK/V5&T4-+_3U-RK_9ED'%'ZRX%6.
M6L3&$\I$ZV!#-TW*Z/#6N<@5O[#?<%G^,VE+=XP:<_B2=6+M/P4=W,+;BZ@G
M0,U$W4GI'"YA7*2YU^&BB<4MM32'1K3*@,ZM7F-E_X+F'LNN,SLW=0TOV\IL
M\URS;/NXG\_N?IB;C-(B!D'#A:+,?3QSO#AR/7,3A;YW!.?4NQ$5EP&IV$=B
M]X*TS?;>-9&?J+,9%B6+4@UH%"*%6#<GC;GJ?WN6<E;CNVCA>8>K#W:HCK>_
MB95W"=-&")1[=1BOYE,[AG'%W,4;$T#'<9O(E)M@B$4KH^5Q!GB5"YRX YS6
MN^SE[R@>O$'8/2VI'E,/^1"?6S4@IO<=("Q6'5V!MZ(U01N:0!V$P,T8V;$I
M)_F/O_5]%\&<]DC>0@U:'U]ZV5Y.*/W&C&].VY83:S%\Z/TL9?9S#FR890NJ
MC%=K;9Q$Q+5)LA-<R@;D,F]=4U21D3&W<TE(>%N0_]C6JAH VI07<8G02'\(
M013*VIL\%XDMO9I)JD1I/$<YTEF<;;24T(GX]@<CUFY-"#&S?7&6]6.GKP>]
MD-_DN 2Y%BU5<XUS@S!*192AOH^R]"NR<+1_=F0A/9+.JYWP=NLEY4UOE71X
M4D59DN8,R3?T=Z 4//;5PC?"4,)TJUF-K(&3NZ)%KR&N1)S3S\92$5WIP=HB
MJ$I*_%WXAG'(8.".* 7'#;U39PAK93WLMITD>%D;4-5N&<@8=QE21XEIWXE0
M$QNRO M8INQP8TE_0M. V >,#RF:K^H-UN"K/V530(S-R1%]<:+OG2Z!XG_(
M)R7H!D2*%%P^AC&,2M%@1U\S?!/1.78\(%VT,B</ UKZ8%8DM#!S69E_!751
M[24#96JI+X*1ZT</Y0UZ.J8(S_X^VFD<O0_=">>%>R(%1_Q%&7=!FW2PU;2D
M;VMO_BW"QJDVG[6(!/Y-QW-(0=\4"D?-QAV3)'B65_<MB*[NE5QK2"-2 RE:
MX5Q &DY*'2"62K>4E974T/M2&IV#79N&7Z;%(V5'=!>S+V9N%C-Z?;[0Y#$@
MV09=^!V,A/X2!C"_B:[S="ZI8&W$C0O4$S:WLS/8\72E9GA)S&V1L(18X\_M
M7XEY>1<67,3J:A2H![+I_5)%3%]P+T<08CP^3Y!-:R1-S!#I\-6D:*$I>I$4
MG.(4E@\E;9R?YR]JYVALX%96(U(L>.%-J%)E3&1?AGN"C(6;[G?1F0_0]0ZU
M["QC?0\LW^K[RBZA^S&BTN>8QU$N='VR^H'+X=G+>MV=G,0;%<6;EY:=3KIL
MF+H4ZS]ZG^?[LW_'U ."AVG#^6B\GIUDO,X+(\\*< _P<\U\<319]I;+K);F
MCJ2M8>OJMUP-4+9]<(U'F:;*2WB./PQ*0^[LZ/!2*W'S5)H6.T')6XXC9B0[
M<K+G(OC86X<C'GQ'[K+[V6$^JX2R]_/J5]==?%?]=BU3GPJCA3.>@-@[+SJ9
M</1 "6IW6,?.E%/!6CR#7O#A]<U">[SP%P=YUVN-$3L/FBCFFZ+,F7#_7,;8
M:MKZQ ],7;"5\3&5HG^/)4>JS_.?L:0QCW;W:<XF=7>W^M1<-@']"VXHW,@Y
M':PM6L,9<H;5V-$2&P[8-!)"?&E.K&-@2(X"K.Z,>%#;^F8_FYQC;^"3C*++
M[ONVW(]"LX$["I(+X2RQDG$,U.G#H@RS8C"4WMF"I=WWO^<??;KX31^\))]J
M.$BJ].]9\IV,>&,WL_>;]0V"!,&]$U0UOXN&31.E5TG_Z=&5@O"L3]\LLQU1
M>MW4Q;"SMEF[+8S=3^^J/I85S;/@&G-"8$ 'D8)N=E9 '89:\AU> )RF=(J:
M9WU#*WT4HW Z^%PV/]QKUKGYHD7L.^0)RZWGUZ=E=V)(.7 9M#9J,ZA&5B/>
M)8JGU*\0(O JD\-\+37#UOF3Y655VB]B+E:9Q9!"K[9^:2$GFL L/SH;H3]@
MU\.O&, 5'<#V%@+M9"HRRDFVU/XB@?8]OO&#XH<="9E;!2M++](?7H3QSGG7
MDP:Z2O^WZ.#3B);%L^]O]45\6K9F7-]C(#S^9102 >Z2&A(\M,X6YVCG\NP(
MC@'+J,MP5=IP@1ZMU?@1EI7[AC3BQM*I16]'M[AFMT>E04?OO^S3D$A NFRQ
M^W1PVUP4!!P8*6@@!-M.PHO&[E*HVLP6CG15]+G2@!?77:[?3IEWDC/ZT/EP
M;;Y8"2!H=U%"/+X85Z-!_F#5)*6HUJMCY5FFH;F3TH-[$2'C_< [[4JFSPG.
M.7<%W_BC!!/8>D[/R@1UB'F+Q5_%?M ZLP=#,L"*?W 7B#9TH-A(#-J\G#K1
M?%VBV_+JUH075=N?\_@6F.Q?@EFS7.B8%FPPFJ<KSY@7W3& %2_(F)\I^.TY
MW3'Y(8-F+K66NGU(:'D7?]^$BI%:]V2Z: R<E#PFRR[A N[Q:Z<()=DMV,&Q
MZ<,?7_27.9HM0)V;YJF_9WAY3IG>XGTAZ<N-LWD!I^J]6P'9"<P5(@_ZTY\V
MYWI-?L?(HYNE,1N-1<%=Y,LT]U!U_%8/AM23YI6[L69LS1W$W2?/*Z^/RFVY
M(1QI3'\>9#C.\ >Q] F*7=PKK5;X$'J:_+3\QI$J[]K.Z#Q=9$4N_UC=4-&F
MW[::R15P#LA^*85ZA^7)SH=?PDBS=K+S.'*#H-(YNFE!]@MVM!4ACKZE_,+)
MX1F=&V^SENWU9K^]V8)X8VL"XQ^M8$DDGF$G=,[PZ,\\WT:72)-7W%0)OAS;
M67I IKL&5Z(+GB!Z:)?AS5-*_&\28/7.;JA-H-USU'IP/QD9XB3_.*N(5G[7
M,VND<QOYY=EM9UDMO."C5ZZS+57_THFA<DC'>V*&K3B"T <^(W:&\I\2FI6!
M5#J"/-$LXF ^@#,\!=F;L%J$;D1IM?\.J1O2.P.N?'OU[*M*V*7')@D6:HN(
M5;^([QA8PC1'^7;AUX.I'$%;ICE+KZ@?W3<!#K3BQ8('+'MJ4NW=%5&O#"07
M9+>*79!OV[5A&8>;_(/;XO^Y&9HWSL-6I,X&Y+ <:3:7YC!^!EY8<_B+@X$&
MJ2))<^UKFHZVXH.\US%/Y>_SK!<4J"JX22$TP,,(\BSA %H/A1CR6QE5"!KN
MU3W(^P]OQ"C(;0G.R^-9OVY+3(@)+(VC31>E.D*M-D,7:";$&DNSLP3B6?I0
MHTGX^W8V.<G1&4GB5VXO(O3.7&]QP8=[I3X:3SJQYL7NB&K^+;GH*/^15D4%
MT(]D[4"!1\]^2$MZ[KGWVX&'\QM<@C</6PHJ9IRF.QN@(+0*=D1_((@8'P#C
M*6'9M.<=G&$1IX:Y.JM<KZ65QSTUN?L>F.\9?3>I+)Y;O.?3V^I#28#J$C$:
M(\CBHW>26_)I*92PV!V99/:-3P=?GVW&&+U*TZ@O#[A_P"(]24:H46G+9[%U
M AT$FJ4S'QAM!^ZEP(>G*=LCHYMA<BR[FQ2'%_>_Y)=2J0JAA48?+WZ:XKQO
M>/-A;S.\C!C,!7[#1F!A*"13P+^Z)07NE=)(V#!7BMLXE7#.DZ,8=JJ,8IF]
M87O5M1T)$6M%(G;S2#)2PE#Z&?[ZC;<Q]PRU7K:ZO?0\L\=^JO_:Q*6-1^XJ
MQ=[LD#S-LYC;RT/#L3:V4Q"QWV%#51/U!XCUM:>.=N65Y5]<@6UVO")%];II
MX*S >*Z+W..HKV<?=*J0M(BS8Y<12%@,#\'34<D93*1+4_PB%P5;'I24L=#;
M,3.I!Y&*GY]X[?1SL-P\+-.H]9[GL[ON#%R0X(X-(?"B93_0,&2_D+#'Y/;(
MV9>IUE[3T4%S-][WB"U8S"U(7=6_X!Z#@.188QK&Q2S9P)(E0-E9ZO%4![T9
MVWH[<RH]Y+YA\IO])P*&CQL5-0/>J]SB\0Q!:66),^L(\F@=X\3TH\.7^I<&
M=NS+4V_R'3@Y;*KJG+S/KE_9X/2N-8,GI-?4'A[7JM>Z2RRMN+?(!?A1;K3D
M9Q1O&61F[\QOFA.NZ[N?[[;<';/VM=09TA?TA>O=V''BT 2IM8D07 $KR8Y&
M\7IP!"L+PYI91J[*R=?R:X[%REMX#\GJGI*]L!7FI[ OSR:64#11)SHL7G=.
MNA$3F296C3U.JVY5"3_7>+ZZ%&MS*[KMC&5&TOD$F9$%*8%7;5^#C.W8+]'\
M+!EV-.:W^"$NT (O5@FGUFRE.,N"' 7>9D4IVN)+-6_G0XEKO@9XW]T9H;UY
M]PGMNC1;"R:EQH8DS1+O82#83PUO0&."Q4=RJ.Z4U*VLL!$#$QTJ>^=<(H*%
MS);$=D=X;[<T>1%\4%D>4?Z/YP1^6D<Z(?#Q])^GBGXB:6?3G]:1 -2=?V9^
MPHGX)\:&G@QB9@1N<H$,<Z>MOSAI KOZ\_28N5^ IPM/%;XJ;G.*W(NDAIQ.
M7DC;/%U9A-%LM4#55NH4O8=LWJ@U,G$:Y*&-DZ[69OG?L>FJ42 +JXTZ.%55
M]KC@'W"^4F;$)8X<DU(VL4M9&_36GIW-N S!0R!G@+!V5:!+&*M"V'G.>!?*
MNJN44,JNKE=4IC&2^)*SOCI8"07$(\7>XAW>)FIV:W]4-11W<F6:03]7Y6BA
MSK++#>V95U ;H;M5^W>2]3(H^=KMQ[$':07A+VNKAAT.O9(_)7V=45QP.4'1
MS3V^T^=0;K,OL3AE1HWIQ)(#F>DL"S 3(H,4^D1SH+ U$S%2PY/O[WZTHKS/
ML-W^N?6\ X>.RK[UR/M;5Y#_CB#C]G]/X,?_$RL]:G484M8!]QG!<=&A!\A0
M&.WD,W>+$M!Y7&OCU(K=T$!9=:UVA\.75.J95QI?\A)T"Q<T0I">2H=.J^F_
MEV!^=_,GUN$%P52RPN$ZV"86+ L,.=27_X1X^J-/[KK9?*VM5XO:)5ZW;4O[
M5A<%@%J'N4"(*X%T%Z_RD5ISF(P;?#=PHF?.Q3YO+@^]"TSV<(\-.YSY\J7=
MP[A[8B)7_94X@MNA(:()U<,:G#O&KKP5'SJF -KD^AM=[4@9UQ)CG>@WC':]
M[J6;]ZZ(^$UT?0&M<]=:U0\I<F:D%Z?I?BRYV%4IEGBNJI\ 269IE NHQ)@:
M]FH7#<%*:MW*M51V7=B$U'HF?X$+^.K:*0055# @01$LA*G7YZP!5P8HG$I:
MCP.8,6XE+>)*Z8Q![ZBD*_05"6S-C/O,?B:O_U[^B,+Q=2YW36#V+"/ZW#W.
M+E#@,)A!TD!05V"1.G>\3YGBYQ6U2L^=/U)R>$>;I*.^TJOANMT=ZP2B!M,!
M?N#?%AGXCXZ?%Y5P\5XS6J"**&2;&$YC-&2;)X-6PU;_N_L]_M&Q.LVHP@58
M*8VK5<*RA0[0?W$.8/K^T81)G<1"_0@=Q[VD_GSOG"M[FE58*@?:O6]V&'=_
M&JC@ @VNY/@5D8-<(/ $?Q+*=#5-[RHPPV<$O"%@MEQ]'==??H)H)E0D9[B]
M8OE(ZTFKJ6,&R\=OW.J84N5MGOQGPDU^;&B\$2Y_%=X.?$W(0AD,/.]%CH>F
MGN,[G);9=A18.1/UX=?9LX)T<O*(OT[=E<-[],<.FA[[W?>Y$Y 7[UOYX@IA
MP^+FTFGPJUM_Y(7P]'D(CRS^97CDP0[Q$=;8._ZJDE!Y-I/3_$8.^](/HKP;
MMO8$VB/0E1-R D,\C?FKGI \]'/JKU^'V,(X@LN>7O!Z1_NOY;&=+)5S;]NW
MJ'",K>^D_"Y3F9/2KT;6.DP)Y+,MT\,Y;"$PE<$,4T4;W@O;?I =Z=U0(##V
M $_\P8-0Y6WZI^**IN= %=U\Z%D;=!EI8_I*#ILU@[A NP3N_B\&VSU.1P\7
MF&B!,1=5__)QUQ75-; 9*IR#<N$"A$/Q?_GX\GG0UK_\3FT" ZI^R"^%;=#A
M#Q[347'8KQJ$:9?&9?[+*,>;?7=K%#)^^X[(\YB+YVGM"4N9.+%?D4X9%_A+
M^\+_\O%)%!"I_EOF!?I04]X!R9@UN\[]=_.?_6<I_O^HT-G_)Q34/PCA]'=F
MB1,Y%FD0H+N.E7"!K!VUW4%"/YDE?O1?!#&_X)(?6QE8V?5?9OTC*4R^_JF-
MTT7C_UZ=_T@0Y;]BVX0S'%TWMN7CK<Z0<V7E&3FM$EC:TVF-LLY]3*N;JQZ5
M8'P8?%)7@/W=1-;NI]"(E-]][RS%&3L7FIQ-[ST_>#ZO:#4B-K:MQP R9NE_
ME3%#NB+8?_J)61)MSBG:EA GY>TAN>%V/&334^?4]'^=E!/H?EZ"^74VS721
M73^/ /_?IV'&PDD9PU\37K,,NB[VX,8?IYS;'JP8TG8;6-[VKT.:3(9(KWII
M9]S+KYPO%^.94J2KZ,>C"D!@F^GEWXLDV[_JB]-VPD@)?_2\3UE9W\4 >?(F
M&^6^E5\/(@RH\B4+XF8^'_<GP_IPVC,O)?4@++BL.^O\EQ2B_O&_&%>_Y[_/
MR!$',CRVYA0]_4J:-.W;!R]VPAJD0T2FW%T4[;WH]6$\ ;<-'.("2MGLRE;6
M<,W3"04'S7KF.4_]6Q!C!77!MF :[H'0K0]E<VR@"K5"_G&H(-V=$VK#2@OA
M G&(;@G$.TS^X_CYP[,8UGV8/E3[?W2!+:?\,KQ-% *3>1,49*U"XI1.MA!V
MV4B "\AG<B14FK$KDO#YVZ*<_<X6MN8K0X^@SE[=+]C&LX!AJ=I$PQ=W83XO
MPE@WXL$36"G,Y&GHJTDX^"5PJREL^K(KZSX3&F#* I!$I&48JT.8]8H+)'9A
MZ._@Y$,H: AEG.("*I!AC2<MADK\I_#_)Q9>[9O6X.&Z<Q/W4 +Y]F"%:9Q,
M5E]C4P&]+6G^H<_)ZQ\N#[Q"\7.!^R)S;+0H&T!D/W0'WZ/WV[[:_*)GR&"R
M9H2W]&](1[7IH'"F@0T7P&[&S'5E_N7CJYR_$L%DSO[AD8,9]CI2] Q]]^T;
M1<FZ1(0P?8)CHN?\'<0L\CH=A_38MB=X[&O>=H@<6*5_&%JJB"$;F_5CRJW%
MWC"5GVI_]I%L0SC3;#CF-LR;B<OYM_>;LV(FN4 DSS<N\,L<PM:FZ(*UEJYN
M<@)Q'=M=NO(N;#KY\:]CO_Y\_(J":WY%+29\ =(MG<L*<&H'_&O?=-EG9SGX
MYUM<H&(?%TA%=%PW9T7#J5]6[KZU-95<[OK#D>.W4^J0R\ 8%QB "*F++\#[
MAQ-W/NE":.2Q G^[X5N4*JX[Z$\T&@HN<($M<EHK+/@*3\&W-\[Q\'F>8BZ
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M1IMWGG]U$V=+=5^95>JM+7DPC^J$H6U\IV>L7Q_=>>%HL S3#J)@R%=V@XW
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M&KSUS;0JJDX/FZX,E^MI955<%"S&7W@@?[,5%G;$FE#.IG!3H![R,;\1!A5
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M"&N@O M=X>UMK_G^C<18^(-]]I(2FKS _V?[QO]O_W,C"4?_&U!+ P04
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M7_IS3AY$]4C:&Y3,VD1HU/C75F#020SH$U R@SVA__GGK;(7X[V<&,7E_VD
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M%RD*.4O4A^Z%DD D? K3T/,@CGU&B4Q3FB#C$Y)GAYN;:= )7(<6=D1N>BR
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MR8!S3IE.3O#J\J?*HL,X@"(-$\IBF4A!C#/O+I-E;O&_\*<XB/X[:)0"M5:
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MBI@SJ];;^X^?&S/L;,$."LCN8V<83!V,R,C?O#D8P[>BQXM%[H_P,EO0_3'
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MT,D/.@6LRWL-F!:#Y7\TL$=>RV>%LTUZ_UAX3Y7^OX/[31_NKK* !@'6?W#
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M?2^!T<[E-4*FU]WM?\)TKJZ1)GMNKMD= ZBS2[+YV[T27A^6*:M%R'CD4QQ
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M12R,4PJ)ER"(4H_"E/(4R@0CPG$4*T*VZ6UC*X 5&T_0X68CH;+.JM/%=MR
M;Q8G'A/2D4G:J+#1%O+7?9!?7-_(%+<Q"QR=E>%%*QR9(G2NQ)'Q<T8AN9UB
M<F515=NRC;JVW"O=%%'<DN^+" <*LYA#EGH11%&:0)PF/DPQCTG*)</$J :P
M4ZGF9IS6LBHG=+_RI5-:-)PN)USI?A)F0:"[U3+K"=LI5:HUNP*TU@THY2;C
M5SNL)R1=0\'FQ,1V6%K2L^7#+ZI+=Y.SXD$_3E3;?-U%ZJ5A0@2&*:(4HB#R
M(4X0AC&*"<,T#>/(CHI[!IL;PW;5U+):6+#2T@ZJ07<<6D/:= 38R&S88=7(
M"6I!KW82])V7G.L%9(1J<\?'>XE"<[V:GZ@QUW_/P,RD;NM4GV9OZ@%7F]J*
M(4FB** 2RI@+B*B70(H0@P+1$(D@Q(0(JR2EGL'FQAL;69MJ$FU%[,JD *,]
MT&8LX@J^D5GD N3L$YT,('&:\]0WWK3I3P::/\N$,KEG&(]\%DR?.,QDQNI
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M4]V5*FS\>WOM.9K*4-?>%YU='-_+HZL ?]6;I'8!MJ3W-0\-ZK_OH_YI /4
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MD1AT0IUY=3H/U##M!^ZG"X]Z^IZJ9[HTN1B-#S1C"90DEX GI@PN)#D@,,E
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MAC (VVOAY$P3-UD8XO:XN\+@TQYNP6_TH7Y:W;TIJ[I\T*K!>IO@VR??)DS
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M@*[;W8\34(,70'8C37<+Y,39P560VYL^=^WWU7IC;CK$KMME>YL9(Y47.&,
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ML\-#.Y'R'09B-_7<#:Q!I=URJ.E4>3?>#A1\QU=#]CK8U?SN*^2K7!24YQ1
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M44M\P*AO1[B"QGO;SCUMI+<C(D<QWJ[O>T=WJW)C)EH(1!E5" .40JZ/!$X
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MYH1.X2'*#WW @T_ZZ</ORIK>W:UE6\SDL_HJ?\C5DWQ1S5WKPIP4@H(B5@1
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MG^3V"@?YX7B3><A/LK'O(C_]@)\V\5'2^FG=&,D?5H]/31!MT\(()C2GL.!
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M;%MS_;:NZMH$5LCZ\^K7:BW+NU7;!)(_[UQK)KZBC;PP<4I<4%ZD6(*4\QQ
MR3G B<B 2B')(,QP2JRRGZXG96X2:,=,U' 3M>Q$U2KJ&(IZCO;<P&U$TS;@
M:2BL*?126AASDRW0R$+N'VYM'&S%R=9H(DMR]+5R,SJ#P#MHDEXWPW0&:Q D
M#LS9,"/ZEBUBFUTEV[Y.D<QC(=(<((*%UJ!Y!C!&&!0R8PH3E.?2L>/CJ6GF
M9_Q^NZ_6F];P$YK@J-Y2[%J2Z 2H=NKRM4"-?O>M8=G1-TJ-H?, A"TJ=&*>
MB:L(G>?TN&S0P+,>VN_MBBZ?Z[+^K-K&M/K?E7A[;^KA?5A]65?BB6^^MF%S
M7V4MUS^. C)S$6OA(!*3_Z\UX)C& %.2 I4) A5+>4R$M09\-3ESTX)[AIKD
MM(:/Z,,J6G>T.^A/UR^4A7X[*?PC2Z@M\I]5WP#<?+<2T=OM.G0L11U/4<_4
M=>'+UR^5@[H[Z9)-I/+N;QK:+IWY3B]=MX7*E6EIW"Q=%].[W5*A+E>"X3JH
MZUX_RW3Z;C!$#G3><*/ZZ;VF4^QG96I5U7KBKLU[_:U:B@6,59R(@@",A *0
M)QB0."U FN0QCV/,E'#*)SP_U=Q.K:9YM*EE;)K:W$1R6ZM-[\;UIOSOKHRQ
MWI#EPR,MUWWZ->7_]=2D^Y;7E<\;6!0[[3D,U".?4#W*#9D-FCVAD:$TG"I]
M&8V0"O7 ;).JU9>Y?JE<6[SA6>MAV^IZ>V/=#GZZ O%^?^NODE=W*^,3:+.L
MF\[6C01<0*ZT!%(,4%AD .9Q#HA*]'IP*42&!<XQ=Y%/HU Y-]%VL?UJUW:U
M+5_PECZ6F]8E<]-KD:UNZ'B!-LXGP$X8OOJZCBQ'QU]2]WH48T(>M'#%*(1.
M6^%B3*R/2F&,.IG?Z7+[@Y9+,XXI::\UMIU_Z-!;M&"*IYA+"0I"]8&!: PH
M85AOG4)@5<0(R<SEP+"=>&YGP$>Z_KO<-!;^5>Y=:^ 3(G,4IR9EOM"6A$A2
MP$QE$I2)!!5$%K1P[ @_!O33^-:; (L?YB)_)+#M#L4Q )S6YZY/KYX'H*HU
M,,9:N!/,%9^0AY+UW).>,ZZ(O#PZG-_W=V@8\Z53>NH%AZA &&<@I40"2#D!
MA,L8<(8@$HSDE*K%IM(ZD;T;8W\")^F^G6:\;?+=S-&4=&OT/:?*FV=!M'<[
M^$(S@;.A=3+TQ(7U+YQB.[17X6".R7T)IS@\Y4$X^9QOC4BZ:6R8MM.LT2RK
ME>EIU"2O*0QSEDM3?H<7 ":I!*0@T&QLD4$:<RB<XEL'9YN;#M?U/-X1Z55Y
M>QA@2_,Z%&PC2P!GQ#RJ,%H@$;;LXM"$$]=9M.#]N+"BS4O7U:5Y_K5<E;6V
M6AN_9E,<K+](62A9I) P;8@HG !HVFE@1A/])59,*PD)9XY)+1:SSM DZ6B-
M[@RQ?D5LAF"VDR.!H1M9FFRIO8FV\#4$;TL2?KT4Y.!=_L8"H3$*X@Q-^RHE
M<BQP.%<TQ^95CW"B77%"T^&VE6H?Y>:^$F;B>M,T9-P6^20Y2A,M>@!%&04P
MIPQ0GB,0IP(G><(@SPN'JM;N%%CMI^EK6G<G=;F*?FJ+M/X<F2*M9E.5#1-2
MNE=E]5B?8;DU$MQ3B:^]^JIMU^T.]9;Z:(]\JR*KUV+M$/(S&N83A?<$Q]XM
MLL<+OL$H'K<1IXO8\>+T(#K';P3/"/1M7M=GM7^'TO7O;4SKYI:EN>GKN_MN
MLQ!3F!=<KPU /.4 ,I4 2A(&B$:-"AB3@CM=;EQ'SMS,Y0MWI-Z)H5<NFIUF
M/-U2C'SJ!%@%]SCZ(. %C;B_CJ)I8_.#H'<4Q1]FU/ M%G:Y16T;S_8VN_%)
MZ(?64I/S3K;_MHE'M^(_G[ICX'8EC"*3Y#ED4*0 "DCTEYP!S! $"I%"DA@J
M1M)071BN)W=N<MJB%\".:1/9TK*]\^K=1#WGT4\][[L& GO\-W<!UAKM1!\>
MN_-@/A^)D<^+&7T:@C:1"+=(4_69"$#Q;%I1A$/?I5M%P%G],UP_K/01VMBX
MG_2VZ^KL2J'BK,@0R"6, 52%B<XA C!%B,P(@RBWRF"[--'<SIHFGF1'J#:U
M]<..%8PO@FNIX0> ;&19[(F65][K$!2A<U]/SC5Y_NL0QZ=R8 >?=Y,/]7JS
M^%BNRH>GA[Z!@T0RB6.D+36)M4!@'&!")< QDH+0(LWT:U;78D=CS^_RJR//
M;KL?8Y7$"!:Q%IY%(3F !'- ,JJ_2S(H*3+115;J_E5(31(T>AU.PW+P*NY'
M%GP=70%3_,]R.R#;]#M[<DW_]%*F'0\ZB1 [RTLOM<X_X*?&O*%Z=4R\N92;
MW[O@\KYA0%8(EFKUA0M9 %@H!+#@&$A!L<CR.$ZI5:_MRU/-;7-VE$8-J5%/
MJZ<N,X"PG383!K>1M[4O9,X*S64T0JHT [--JM1<YOJE6F/QAD^!C_27%'V3
MJ[):-R5=Q9/\2)^3-,[B[F2"G"0B@P)0B80^MZ4"1(L+D*8Y5H2E#"NK-$*[
MZ>8F.0R]\?^,6I*CMNJM)CK25$?)360(=RG]<!%MBSOUH!B.+$4,J</H^90.
MOPRC2X6,D'!.=$4> E;'>A>V* W7L[@XRH3U*FPY.JQ'8?V6NY7YMEK5U;(4
MYH[G_6K3YGZTBD628JZM2@E0G&G53:90FU&Y CAE"<]I44"[.J+#T\Q-^.Y3
M&O6D.FIM%X"];'>%@6MD.>N)E)-)=AF(:^VS@1DF,]8N<[EON5D\[:&4F>KG
ME>+54O^F6C=G";U;RR8(8)%@&=,",H!1@;051W* "Q0#A+C,>9QH"6'?3FMH
MIKE) T-K4R=MG]IH2ZZ#_C"(KX4&%@JUD87"1( YZ%JA@)M(S?(%T$VUL@%E
M4*L:'& ZA<J&CP-=RNH%W^P6+9%DO6GO%[MTNT]RLXTL$S@WC:Y2D!<< @@Q
M!8QGF5:M<IFE:5%HA%U36X:GG)]KOPT?Z ,&.HI_;D)J79-<+J!MYQ<+B>#(
MHK4G]31ZHP3JV:(3-K7EPIP3Y[78(7"<U&+YGD][B+=OOMS3]0/]]LOM+YWS
MH2 JR1#* 41IHB6*TK(%$@6@!IF:9GLT3^R;/AQ/,#?%3),8M31&AD@?C\XI
M&"T4L2O!&5E(C(2+2[.#Z_"9JH6!*TZ.+0G.@S#<:.#$>Q.V#SA/]6%3@('G
M_'0G+1EW85FWF\VZ9$]--:3OU2=->+7::";T^W>]7%TPGJ9)D2- >6RN]@4!
M+*$0)$@0I5>_**!33*\S!7.3B)J!__4_DCS^/V6G'BR;7":ZQTJTJ:+5 3.F
M*FK#3=UD[[4#5*K]USJ/SW\5[92T4==F9(%L5+/#[++;%RMRR$+4\Q!.B_.&
M+Z1:YT[$I'J>-T8O%3__@:ZMX[J+9MU%HM6_T7)E*/FPVA9V^*Q^+5=TQ4NZ
M_"+7JM)R7$.TJ_1.B6(0"PERPH4V4XE6)1DL ($QI[S ,./0S4P-3N/\[-IO
M3P\/=/W<I#_?RT@J)7F3),II?1^I9?5G)'9-<O3W=7FW:CSGM(XT.G>M,-YB
M8GHIF8'T!T:TA4+YOKN][H'J,K#-!\ZW^FNHSXV=+'_5S\+(LG['T5Y4KCY9
M#5.]]'=HXW!%B=? V(Y3WC44D:]4VC4PQN?+NH:>R+.DJRF:_X;ROTMQU#\J
M89@I)2! &2, *I$ DJ 49*I@+&%*J^J6T<D6L\U/^'^LUIL[>B>;C*6J\7 V
M+08BUC#@7\QU '([:1L(QI'E9D,EZ, :M8.7!1Y!JX8.3#=MH=#+?!_5!K5X
MQ4V2"%DNF@OKYT;WI=R(M'=T0]LV@IM%DLE893$$&209@%F2  9S_26.(9>*
M9W%LE?5T::*YF>XMK=$>L9&AMFNB:7DQ<A'=88D1$K.1Q84O7-;2PA:+G:BH
M>UFA1?TO=]6/?])#M&)"?_-2.EP<?A+18,MD+Q>LGQ_%CCVCYE1U:?S$VT;<
M.VND@ **!.4@3Y3I@BT%P()IJ1+G&4P)26G,@UJQKA3.3XW9LV'5MB)ZH],\
MFE9FG4_>_'G/E UJ=3JO<A";<\R5&UD4]IR913EM?9J2;5OVS&-;!J.>PYNH
M*8#?,/F:]JGO.DQHG3J3."?;U!=?1\O4>QJW@X.;-CGKY\4?WQ8PXS'/% 5I
M:JZ\%90 2UD K4]RG@C**;,*3]P-.3<-\8]?OIWO(GD.EF'AZ,?LV-?7GSY\
M?_\N^O;]]OO[;]<+GF,>!U2V[N%65G0_O!03>P-.LK./&>@WXXF_^"E>VPVY
MJP!5[P[8C/ \29D O) 0P%1_83E,@<ABCK(L@[1PO P8G&]^2M'>T?A14D-M
M(^3<U)YAC.V4F&"XC;R%]P#;HU3K%6-H%%:@A-0/AB><]+2WXOWEV6WWDG<0
MQUM:WW]95S]*(<6;YS]J*3ZL/C]*$VB[NKLU)F/C1MH&:18L254*!4 DH=I*
M*R2@2"F08:@4% J1V#6*PY&$N9WT;[?WA4T5VJJG/*);TO_9.2K#=5FLPS)&
M!'N"N(P&ZY[\B#U'/QD.M,7T<[1E(MIQ,4J(K3^(@:,S7*F8.CS#$Z43\1F^
M(_DVS-&2];Y:ZC?JMEJQ2>+<B=^='B!YD18(8I"*+ >0$0JHRC' <:'%8ZJP
M9-BM>8[ES'.3@2VQKFUS;&&V]!F- =[8WJ ]FO]W7\#<D+VGB8VDB#G#%;;G
MCNWD$_??<<3DN!>/ZP">5_N\L2;KKY++\H?Q__5U.+3Y%^-"@4+P!, ,2T"X
MP( QF>(\2UG&K1PKER::FP#Z*L43[YW=M",Z6F^I=KS&/P>OY1U^ -#&OL#O
M(=K1.,;E_04@@M[<GYMKVFO["QP?W=E?>MZW3.GVNF=K/_Y>KN2'C7RH%SA&
M$"52 "$8 Q!A!$C"(> \YD((+E0BW6J5#LPV-TFQ1VST-T-EU)#I7*IT"& [
M,1$,MI%EQ1Z=AQ=/-NAYE"ZU0"5L_=*A"2<N8FK!^W$E4YN7KLN0_DHW\MN?
M]+%/+D-I*@HH *.P !!+"C""%!1%QE5F$GEBJ]S%X6GF)CFVZ;S:[I11K>GT
M2X!^ ::=L+@>HI&EQ!8=0V%D2!Q!H1A&88RDYA<SO4HJ\VENSR4PGWG:\ZZI
M7)4;+4Y^&)?+1J]WJ564)M"POGVHUIOROYL0DRY=^JLT16WTZ.8:N>9T^1^2
MKA<I;ZZ>8I D,0&09TS+#?T%)AF"<2H429U<Q@%HFIMH,;1RDR:BGC;&Y*=[
M?/3-QTW)MH1$/ZT;AHRC<Z,_\#)ZJ%:;^_IGQ_NM .MJ>0LV[6J-?5?6< ,:
M=J(=/U'#T$VT7<=]UFZB+5=M.(_A*S*,!;Q6"X=RT,NW &1->T47#L>CB[R
M0[N7#305[C^KC_0_J_7;IWI3/<AU5]R."H'B(DY!D;$40&+B+DG!@<HE2AA!
M!>;,MFK@V5GF)G![ZCSJ!)Y'<E@@!L-G9!%G#XU38<"+K%];%_#\!).5!;S(
MXWY5P,L/.X;7-5'=_'GQVYLOBRQ6*$EC!0K$8P"AWMF,(PPH43&3G**80:L
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M:P"4H(&")Z:9-D+P/)]'H8$#CWIWTEP_2?%[25FY;,1,]\'E>4J@*#(@::8
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MC6#W>C/VPHY,JAR$V,P^= 7<Q-PZ"K,K6EB>!V.:UI4GQOM)+2O/:WZ^5>7
M/=<%0Q52F8)9+3ZI0?A'M?#D]QE==QF*'S:U+L?T6)1U]J^&PM[_>!)YU1ZB
M[Y4926-$4P]!E.K$[Q!C2#SA08)(3.,(X3A(QH1"N1!N:=STOJJSQ\:QE8T"
MNN_25@-=H000]L]-5JH+LJW&H_HG.)UB,Z[[61,W,3?N1SFUBL%&,[!3;=O1
MH=4.[*L'.OUF*9GB$OHI0IR<R/=3 IQ<(GLNO,GI&.-6AK\+G=(G^.VS*,F]
MZ/,!W^F0*\&;&*KJRZ:NE&Q<^TE>Y$<\Q0B&,M".?$0@P2B%<8AXP)$ODL2J
M:9[E^$OC]TY.(/K QB=1=J>ZI*[+C&[JA@3J G1'OA]S=KX8N9,I$I1XS&<A
MQ$A-#,)"U[I&/O34! DID/0Y6=4Z;^GG3]%6B@GIO#U^V53-&@L86;/-FNA:
MN8"?G;UI9\AL>9T0]XE7T%YRT(D.=MGBW6SLR7T#.HW<K8XCD7.Y -J*,.L:
M-Q*?U\O8V,>,V%[^35W^$'A^VCSUF^@/\KZ6Q7U)'OODH9"FL> ,*@<EULVI
M$YC&3,*(1IP)E(HX,MH%,1]R:>N1EK<+K-])##J1+79+S? VV&UVCN+$U-7(
M"P9A')/H9OC^FF]".\=UIKUH)_C:;4I;036X-VWVI/FVJ*TT.]BIMKMS9)V/
M5[D8NMP56Z$H0%Q@"5/I$8@HC2!FA$*/$DX$]U)$+?MCGAQG><$.C5B3.@JG
M 3<S-J\&<6)>/LX<NP&-C Y+A@Q!X+1RR,F!YBT@,J3K41V1P8OM&VN^S^NL
M?OF0K3N3<<69X@+* ACY80!1D%*8>C&&"=;)#+$7B)2;=M1\_?"E66BM?$ +
MV+E%YCTTCX ;_K:OA6/J3]H<":MVF>=4OJ)/YM$C9VN0>4Z9_<Z89Z\9>]!,
MZQ/]9;CT1!@R3SE70:@6[LB'&(<<!HSR((Z3 -'0[HCYU#!+^URUE):]9FQ
M-3U4OA:JR8^3K5$:<9@\!(+;8^23(\U\@#RD[?'1\>#55S2W[QHY[K7PZ7Q5
MCR(_B-(08H%TGWO?AS3F">0H%003QH@T*@IK--K26$'GG!>YCDTN)%"ZEAN]
MB]P>SU2 Y!P46AT[BAC&VXPIG*$X,6%TD=]=X]L]21TZ_U:8N.2/X0%GI1$C
MW5^SB=E-XTA%>;6E()5X)]K_?LS;*H6[;/</SY^S52HBE@C/4W2"E+$1)S'$
M 0^A1WU$4824K8%6N;C7H15F_&(VL-$GDK:?R/[PTWTI?]')YK\TB:"@R2G2
M[5GO,[9?:L&.9PRGP(QP',(Z5RY<*RCX2R_R+_I8L"M%NA/[!GSX&_S\T1T-
MV2'EDH\,1YZ5F.S0>,U0EG>/.'#Z*LHF54(I\UWGC_V>9W7U7=3U6O L?TNJ
MAVY=CEE(>!(',"#"@RA$$22!#" +?,[#(" H]HS/G$Q'79H]M"=WF_4(-EIR
M4+6BM^?NU8/%@8DQ_@9G4%.@.C%+[0/:R P:H<'W':!:[C%'4<;(6IQ&38'P
M3 =2SI"V.Y2R16SP7,KX8?,=3=GJ=W Z97WS"(+_KEX"\EB\;5*$FU&ZUSX2
M/$YQXFF< XA\'>&FO=O8ERQ!$4L]L\WHP5&61N"=G!8T<A8_ T)V@<K$!-R)
M"%H9.V88P;9G8;)@5Q=PS<2FXV"SH\Y+< Q2Y=F;YZ/&2_(?4.'%B\>YX9]%
MK6GT:UD\9USP-R^_5SH"N4L4SN]O69T]-X;T*@EP(F4L(..1<L61ET)*?*0K
MTH28A[Z'8VD33FH^M!5)SA!)JB1OS%@@U\6?VX!2V0L.R%9R.X?<8C+,G/)I
M()Z8<36ZC:75BZW;7O[E]Q;E7\!6>'![&69KY]P>,9<.NL7HLSKI]JB\=M1'
M/&%D199U,\E=V.D;7>-%;]*+O-I/G5A%- YQ$E*88J*\=>I[D"I[#A+"@\2/
M,8EHT.\KWID?7IB-/F)S\6ZFPXQ>4E"*=9.N5A=M=)+B>OT%/I&7$3N-AI.2
M,"_V0BYA2,($HEAPF,9II!8<B1F)0^EQR[[E#N=CWA;F>Y"S_6GISI8F@=]L
M37$/Z=06_!Z67]O7%]R6I6X"KW^^Z?/T'%:WL8+(:4D;LY'GK6-CA<91\1J[
MNT<N&DPY19N&\-1"]7M>"K+._J47J/YHI:_TVSEM*?$P%U3" "4<HDCHGM?"
M@RRF/N>)\*6PBH&Q%6!IVP8[B<&]$K1JJXJ(MH#UKNHW(,\D6S?QK3KEN2)K
M6R:SG2A#3IL0_HG9[?;+VX\W8$\!L%<^_ 8T 3G[AUFW_0Q -0-0S\"-8L7F
M]-W]B?M87)U2HJT,\Y+C2(2.:'+L<\81YANR;C9E'X2H/^G70%'Q[8^L6D4I
M]JE'0BB2F&N[.H(T21!,/"\1<1+Z?FJ5%GQNH*418"<G: 0%O:3@#RVK983@
M66S-N,P%8A-SUCBPK-GG$A(N6>;L6+.RR26-7[/&Q>O'QO9L(U+>O.Q7];S-
M^6>ER=[?-"'+:F'J:BO%.! \93&,:2 @\A5S$)XHA]#G,D#*V JCP,X#'"W+
M\IS"/57TEMA!N50=:OA*'=#K,[((UOA9-".J669F8B:;;DI&A!5=":?;2*.Q
MPLP<?'0E9L?Q2-<^<!SC[AT+-;U=5W$8$X](Q9Q8'UXS#\$TBF,HDR#P>"R8
M\)D=D;X>8GG\^/:@VOH3*<%STW#X__1^]3PO&EO4XPA;,WJ[!J^)66O_4/:F
M[<I\ SY6U<9E[8US^KNDF:,Q9F6/<QJ^)H6SUXUL0U<4_,]LO5:4\KI4U(G$
M(LEE0G":*(M*!U +Y97A*"4P\.. T#B)D1!67>EL1E^:E]8+WZS-1U7<7*1W
MV4V.&9-,!OG$-.,4;?M^=F-0<]K>SDJ >;O=C<'FJ/G=J(>,B-!KTE!843[I
M@LJB%,\BWVS3H7C,HY1%,?13YD%$8@;3F,<P(>H?D*34QT;I9Q='6AJ7M9E3
M6V%!+ZU%3-H@L,/<Y!2NB7GH'%)CPOB&WT7S4#Y7T,T4SC<>0KN0/A-8!L/Z
M!A\P7VB?B1X'X7U&-XRS%P=*BW[*<O&Q%H_5*D:$A(D?P)1SHFLY,XA3P6$D
M:$("D8@TL3K0-!ET:8PZ7.,7_*$%!XWDED:AT0R8V8*N<9V8>EU :FWYV6#D
MTN S&G=6.\\&B=?FG=6]]K5_WG4+UP=E*I+U?PE2?E!_4ZT4"U&./ EQS)'R
M5X6 E/L^Y#'"OHRH%U.C!D$#8RR-=WHQ02LGT(*"1E+SBD#GX!QF%4<@34PB
M(_"QJA-T 8$KR@6=>_)L58,NJ+9?/.C2I2,<M[OL4?Q-5+7@W]2?9<9T&-<V
MCZLSF@,BTDA(#\:,"XBX^B.-]/<OA<>")$F$;WCD9SSF\K:NM=3PN1%;V=:]
MW/LIM!8^BA'L!NZ=:R@GI@DM+FCE!3N!#W(Y1SA\1F!:.'ZN09W) 6S '7Q!
MS]>HM',!;0 := 6-'C2?2VBCUX%K:'6C<Q?Q1-\)O3;<_5FL:!R()FD"1U2'
MZ^-0D;8?0803Y3IBX>L$6:LSQE%R+(_-M7SL7*^?+H+_!N@WUID?.3!-5SN6
M;J#_F9YF&^/?3,F^,C>M*:D4F<7YO(SC3-[H@"!+<4\O8V7AKQH\;$RG6U(]
MZ 30JMNMZU,#/"_"<2(A37"L.S#Z,(T]"@EA(0I"STLM#B1.C[$T!_9MGPM;
MW?0[PS8-64_C:&"@7H_.Q*1T I@Q-N@9A&Q:U5Z-U%PM:L<@9MF;=A"+X9ZT
MIV^=L1?MH.R'/6B'+QT?9R9*W4'\*WD29?<BA@P'@;8!?8Y]B%"((/$B"D,D
M<9P*P=,PL@\V.QIG>8;>3DSPI.6T#RP[!M/,7+L:H*F9;X=,(^ $R46#$+B.
M,CL>:/90L[.ZGHHW.W_Q"$NGLYD4I.O&B/XSJQ^RO%)K09-!6Q4RRUGQ*%:4
M^!%.I;)XN$[@EK$B I&F,$","R334%K4P#,==6G64-_V<RLX:"4'.]%UM>!6
M> LKP'@6#"RG*;"=F%%^.JP6YM84\,YD@+F!V<XBLX5KT$8S?MA\5INM?@=V
MG/7-(YLT/3ZMBQ<AOHOR.=,I8:>R[>_(CS<B%S*K/R@-3]60"'P94(H9Y#Y1
MIJ 7,DAD$,"0AHQ0-5MQ$MC5:W8CF-&7-FL]YX_-K(&:_ !"2C6UECV>W,R7
MF;4YXQPLJR;(#5!:@4XMAQVFG.+IM"65&\GF[6'E%,VCIE=NGS["_/XFV)I4
M52:S-D/WRZ8NY%["?UNF7XU9B@<U5O8L6F[1V?[;5(,(B33Q4@;C!'D0*3,=
MXH"J7Z/(]V*).8T38]/<A41+,]M?ZZ1;$VM+9[^T1M>M8E\QT/%X6W##.F_$
MW00;6/US3]O$)/X_?<8L'(JY9VXF9V.V&;3S1URB/>BK.!EH/C_&)2X'/H[3
M!]NML%59KW169EO[(N?_N2'K3+XT)2E9L5$.UO9[90'"812E,&:I+H ;($BE
M3Z'@/I<D80E7OHW!$FH^Y-+6R._OWX+O[$'PC2X;Y0?02]O\X?;KU7E^.V5
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M2X*12IL-I7@6N6D6G^M9MSWZF&TF9SP8Z74"G5+Z[_;4 CN]P%:Q[KP$:-U
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MZ-UTQ8PF"?">!FZG03UN)9PW]F<2=(]"A*899=R*<;Z9A2[&T=4[UZW>=-/
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M)D#U()2PO%_\=T_3V5CW1=F\<KG(F@IGI%+CKSFL"_C8YV;E2J>Z)%R?B^S
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MRV%_8;-;1O#K-W&_66OD7[:QYE6W("><AMB+/1CZ*8>(^A1BRA-(8AQA+,(
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M$:82$HIR2'(J"&>*JX+:Y9N>M.WR2DV32MJ:9T=2IUC1B)*,Y @2S%.(LD)
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M2YH-Y'TVTSU+[XMI^KR<Q7^<S28H],75^(QKT4C'#.0RAS%)7T;V:/P*=]3
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M*AQ8"%[13N#I^L:!"_NJX*>*M%MP?C8>X54X4:IK9M.2M%AMZ%DYE@)+Q)C
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M$KB.) A+,V5"T#J#56[1,-S)<+^ .%:\#2#C@1WVW?75>:_ 2IDC8=1Q=*4
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M14H>XT;K$[$\!\!P3QB;JZ!Q#R*;/77L"8RU]-7XMOS[ O+%Y-TXP\A)&9.
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M,A83 K\$HAZ3UA^R3@'!#[!UID8ZP-BP/4?Y*L(, J2NLI5"D=^H$SD)6MG
M*'3@EYCD<8&VR,]@:,TYF_%XL.A@39Q2K&VB"#$0,H7A"*HX"[&@ NTL2RRX
M&-K46[4JMN_Z:/-$9 U0DW^,FI\GDK>WN"O!K$VRIA,*7BB"%+27"5> J6"D
M,XQS[ 79V[0__[!J-*2?!8-G=HV_OH[><LO.[Q' +]$=8(OJ2]RB1Z.EDM&!
MD_5T6 4'T60)4LJ,4NB02MOA%PUNT;]/ UQG4SL7BN(1B*D,BD4&M.(T< I(
M92'C+TV3<'T'+9WLV>>BX>GDR^.EWL$6^^ML^HF>]J6R<G=^P700RA</AD(^
M4%X%\#8C6*-S0"UEQ";S 781TU-!ZPD:WNYG<ZZX.X3,^F#":A>L81:*YZM>
M/!&\%@DB*NYXSB'E)IGAN\D9N7'<V6K^ 6Y.D'D'R'E0:K:YJ6663*Q <-['
M6K66P*=ZUQ^+QZ*3TMADCWI$25]X.46]V[UDSI)U!V#9T8V"UU)6R3R@#H8X
M"!X"*P90&,N#,5')"Q2?C'_C-?2N=*:HNP/+@[+8['RQ6M=&_K(6O21;"V0=
M&.;I!SZ*$IO4@3R;#B]'*?K0#B_'2+VC*O2#.XRPI$UPT8 L64,M=8:0D@,M
M=21&51*Y'%2A\:_3X>4HE9_;X>48^?>$KQ-ZB3"52Q):@%FUO>:T83O):D>;
MI(1@/CEY/-3^93J\#(*ZQEKI"(#']Q-QF# (&0"12U"QUE=948!AQBPIFF'Z
M^&8;_R(=7H8 7UN-C V]%^)O0C_@-M_@;^$;%TRR3:\N&[(NO,ZIKT5\B(&B
M&UDC'H\NZ10]#P?AZX>OZK1OR\D@&E:V8R/EQ"XTFAZC'--@-6<4]9#@@BL%
MO%<Q%&TBQA_>@;3N!=1L:%!;P]1("V,#[87\&]^Y;/1FV;A@))=%@F0NU&53
MQ\)3D.>TBQ0I6<_L89CZX:O&G034P"0-*MOQD2(T>\ -P?\UQOE-F'_CFGCB
M&_376=0YD[AD=J"<]^ CK_?+Z)!'S7PQ!^+EH!<>A!K[G% SO)R[.Y+Z]2X3
M@F%DP=>!DK+NRD91[%I4 LYEPI(T#_8"/8=_[2-=L.U)YFE"[P [JW7P+GQ;
M3<+=,?>"27+YLT%(QM&&B\2)\ZZ>?UBYZ@(H#JH./1I#/Z"KIZ.I$W4_:Z>(
M+B8Q/63H*G#-DA*<C"FC*$&9#$$%1BLM*$LL%(]-#L<?$M'3P=+PF#E*Q%T
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M!38X"2H7#RX)1WN4+BPR4I9J4MIV,0Z?X5BF,U9(G\!YION -S9Q49O%*)%
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M/H<%OO@TQ]OTRPTOIDB#OE[YH@>E-$+4,H'CIEB)UO#0Y*1M/TF]'+ U =1
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M@*['X<G*JT111,Q,@7:N-MXW&4*=YVN\X-+8I*UJXG[O)N<@)/E62.HT"!Q
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M&,@2G<%5(X.%))*D),D&:V\:<D9\T@C."J94EDJ5)O>A QNLNU[PQPCX07M
MCH(5F<DOL_$VLS#23@O:%6M1%NMDXS&2)]'=EW$[ DG[1TFVUU\'?O5[3-=A
ML9B4R6U_G[<WRX,XW^(Z*C29)=I.)*/M1&O:3IS.H+TQCDEG@V^2YSD,^>-F
M7 T(WA&TV>^V_>$SB9_BWIMY^AP6>$Z;TGV/&F@K/HC2-ILN2L.]=!&2Y0(4
MUA[I*18H+%IDS'G?9G1&JTUWY9N^_/:J+H-UAK4I@6+>6A1&.%9.>O#9!TA&
M));)2+LV*>A/T-359GD, O9OEN?)O8.-<&L-KEJ^AR_KIHDL!D0#UK%Z5&8]
M..\L..X\DGTFX35IY[:?I%X&-9^I]6TT#:.";L&TZ2UEO69&<2@VVWH)Q&I3
M<00F@V V<-KDFYQR/T74R( :2/$'X>D$+8Q]1?L3IE55F&#<[V9J,Z[2NQ*T
M(X\QL@(JN +.1 XIH#8N*HL'9IP?^L8><7.*@F>MI3TVA'ZC5W_^(4?*2Y^+
M<4 67(.*DAS_@!*R)\:*%9EM]^7>@Y^#7C?R1.DFX!E>SF,CYVU:SE:K0; G
M>?*)JU('G:*K)\HR)HB"&!,H.:(LP6WWEMR#G0-?./+(QR;H:2'K#MRAE7^X
M]A8?7%+R;'7$!,9[6@3!,%H$+ '!7SB6DRFQR87-3FIZF6X_K$=]ON [0,^*
M^L?>X<WR\VQ>T\EO<ZOXE4ZI<$P9HBJRMEMP$'@P)*ABT'MN96XR(^U ^L9U
ME09 PJY;P('5T@':/LXQ+&[FWU;LK8SPXD7ZGYL)47+E9&0^90[<UYQQDPO$
M+ 1@C)$G46+439).GJ!I7+LU/*J&$G\'2-I4'[Z>S>^7R=OR:O;ERVRZXN_*
M>F2&-FL(M;^98M%#U#R#0F0A*L5SFRRF'Y,VKG<U/*X&5D8'\-IM?^_JK>X-
M\?WO;$PR"2P5YFHW&4^<"L4@(G> 6904@H]<-RE+.IWD<6N3+[5Y#JZ\?B_G
M#KQ</^/.[L@W7#:KYH(W?,DY9Z,*D%>YH#D;"D9-!BX58[7AG8_/X(;OF&2,
M*VE3-DH0RTZ0_2;^P1LO0 H>"U,Q!B-:L'P,D5W= 1Z#D6U3UDPS7>RQZ_%7
MM_*JK,VFU8U8W4V$XD7T@D.)B38 ;D,=$I(ILF&!"Z61?MQF&WV"JG%QU0X,
MCS;0H333 <RV>%B?(C(=K!(Q0D);JWE*3>?GQ)-A3G(IK&\S7W4G-2-?] RG
M[=G0HN\ /P]6W1M<_F-*,?1U=1Y_F?Z!BV65VZ8L?GU^S"PM+V\"<,X"\2<T
M>)T0K*UM!T/BQO'&&^1!A/:P29Z%C?U[Y?"*Z@N(&T:(SU=A\?GU]>S/_\2\
MZNE%;&XFCS"97:! FZM"LLRT?)T@Y#@1$C)=M$]-?-,CZ>PA/[01# =74U\H
M?#H&VS0(^=\WM S+MQIX+U;<__Q7NKZA2.Q.Z/2OZ!OT"^]J#QO2^W(YG\2;
MY2IO=O9F1@^=+HD-(NG3IH!N+;R(02GDFC13"JBD)01F:!UG75R=L"-,D[*&
MKJ0P[G%BTQ4TOG"/@EA?Z_,G+),IYI<XI4^6[Z[#=/$B_Y^;V[UPS9UFREH=
M.&2NL Y.=!!U$)#1LBA1>A^;]!@XCLQQ3RB;(GQH)?4%P8]SXN?Z5E/;7''N
MHTO!4G"*KD:H"F+R"I 9JSQGR-JTMSB,O'%['S:%W%!*Z0MJ3VT5]_<*HE@M
M;*2E5.ME%7$)T9/W[[$(GF21RC>YG3F6T'&]XHN=-#75W_/!)P4(;\O'\-=5
MG53J<A)@G*H3"Q(Y&X9%B++$K!6M\]3DSOI(.I_%.>B)H#D-H2=I\&2 ?B77
M=Y8_+,-\.0I,@R#'-Y,;PE0=K&$JDYF\8]J%3$I,1XMCAEU'P71L(SH.3(_1
M8 =V]"F>7F*9U6S>[ZMS[UG5CL3G"J/]B=:ALCR XUY#4EEGQJ7&-B5!9] \
M;D1_4>!>2K,=@'B;D=<D^0-D_>IF7K7V;F7S[WBWQBNM=8 24=$"1HH%-*_I
M>TPS)F(2N<DMPY!,C!O67Q3FH^F^ ]P?M"'9)'U0J8!,O!ZS67*9T <(6B4N
M%%K;ILG%8'Y$L[. ;LSQ2;KJ ']'^T9<RX!YU92/ EKM-/B4PJJO+,>8F?=-
M'(86WFVS20=]>[=':/#,(.SG:;Z8D=QY>7%[F7A5ASQP73CH%!.HFL3O62X0
MBHK1&!F8:N(/G$GWN$,2NC.M0VFXW]SD;4=H=K.<'=H-[(R$Y2%>.U 6\^ 2
M.#.U>54<NZ.YU<%$W66Z,BFT9"%#SI'\4I=H=23K06MGI>$E&W'8_.(AJ!FU
M>=M50'0RU2KE6C^LE-+@M#2@568L,PS2-IH=<@;5XQSKCH._0;N[':7N#CSB
MIU,^?<K"15T[U&5UZ]X[Q1G$DITK1BH1FYSN=IQZ?4%T')6+?8RJ.L#=[FMM
MCDR)VHJ1Q63(L2D:0C:2_)QB:.=D7N8FHZB?72[V4=H^*!?[&-%W@)^C4WQY
M5$EIE@!9T+0C"$$QH'90O*O-^)23HO5]ZK/-Q3X*&^?F8A^CJ+Z >%"2;ST>
M,YI'R%8Q4)EDZ3A:X#G)Z+QU,;0NFGNNN=@#P7!P-?6%P@X293TS0IBL05(P
M!RIF"3X:!UBB0M*25J%))\^NI-!C+O9 *VA\X1X%L0[6YZE1P\K9,SJRXJ4E
MYFJ?LT@*<R%',,+Y(!R*T*9]R3E$C[M_C!>D74S1SQC4:V.$A>5D35VXR(E;
MER&&S$!;PPHGQE.;-D_GD?T\3Q^.A]= N#Y!U\\8V>O-2<2H?3:BSJ75U7FT
M$%'5<:0VTL:K"9==C>GH(?*\), &PO8)VNX0V_>%'X?R_7#H^X,;T53%$$P&
MY*;F.W,+P3,/F2?I"OW0B28CE5HQ-*X#WX\+,PI .E@H%'_,ON(\+%?11^5K
M,ZN3U1YVJ!E8[CTHP1VX.L<GYI0L:I=$:)(6M)>BODSW.("9M=!>!S#<+.N_
MUO2OZT.OO#+H,BO@ZMPSQ4R=+.P56!U%$D5;;9L<).ZAIZ^ KPL(#J&Y#@#X
M'O_ Z0TNKK3WGM/2 5'JO+(JE6B2 <0L(^-1HVK227Q#0%\;<A<0.TDWQV/*
MWV)JBI]65</#Y8-O+/1ZA2RNT+ H:Z-/'X4"97,&IVIQDK<E8G1>!6R!L4>4
MC%N1T"78SM-6/ZA[@\O[\^HKGV36IHY;C[80#\0-D9X@6Z.-"P%-:9)S\!T5
MX]85=(FVT[74;\KKSV%>^PXO:"&MFJZ?DK_ZZ!D#):,^3=M037/7+WFW?LE=
MPE[6$AT7%IA  2I;2]Y1J%-1A1%:R")\DQ8@^P@Z.[]IZ[GW4U^#+<ZC8D!L
M520G04AF&G1,:$3PVL8F?2?V4C1RQLD0B'B4XC2(]$^V(W_@/,XN:TEVS8\_
MS9ZLG]3(JK2<<[\/2<E%&7VHU\0^@G*%O!2G"5-,.BXELH)-"F):V9;[,4;;
M;W@9%I/T8II_FES?5)?I^WG3QBIA&%*@&3-2C!!H#^5*@:1E%9D7L?@VC91/
MH[=3NW0,FO8/\FVGN>=DM<XHX]GWJ$9VJ^DD@;U;8(B%'-L$R0M#[K.O-6:"
M0V":%24PI=PDCZJ]X7HQ74YRA3K%"Q\PW<PGRPDN-@E"M22^!ADWM[I[O%IN
M+SF*X-QHCF"+".072 Y1D(RD=4DH$;@T3<X*AF6C4S-W#/;VF[F+Z[F#\](S
M>7[Y;?<#5BD<REOM6%1@_O_VOJRYK>18\WW^2_K6OKQ,!"5U.S0AMQ0MM>\C
M(FNC,"8!70!LF_/K)PL %Y$$>0"<PCFD[;#;$J4^E<M769E5N>18G>(8P!4Z
MBR33T3"'(;$F5[ ->1K+D/730_5A@N5(<#/:+?0;WJ9[8"2@%@Q@43E0)';P
MQAH0+FJ5A6>*-\DU>(FP@=OAC05!G9!]H#J''M3\;7J9_YZ7JSHTC,[*::1?
MK>>,_3&;KFZ*6 K)BAF3ZQ-?H=  &9V>W$)D/A=FA1;.ON3A=EYMC* [5+GS
MEI+N,30Z?#[\/_+J$1-*.NE2IJ@NT-FA1/'@A:5P3V#TSM-_I>D$EZ>_/W#W
MPV8 Z4&:PT."K&^9+RYQ%O,=)U_S:G61TW0S,W/+EY5!6L4C\%AK'B+Y%9[)
M EPPE3W7,K%NH]\[+SEP]\%FP&DC\]$Z3IT]@+N7.R>\5U$:8%D&.N[I5UX$
M \%:J;312L4F*<Q],3"60?.O/:HX#!%#^V@/;E-W7G+DS$*VTH&.L1H0<F^]
MU!JLU]*(P$I2L9-%[;C@&#VUUE"8-];+H"?XD\D*MVR0(^)0:0:R2D<I1H>'
M]!HXLR0^*47D31ZUGZ1FP)8^3=3^7+K(01H8'Y F*;/""OFO0<3J?2@$YX0$
MHQQ+R==JKC:)YGOG)C4S6CWH]=G$HGU$/ ('[[_S]/P[[:$S AV>Y]^NJI?Z
MN:SWT?+SU6JYPEFMJ+Z55$G<V^@\Q)!(4D9$P(@%? Q!U8P'IIJT<-J7T&$<
MMI.9IZ9Z&X7EZLKA6MH3[Y3A FG;>D_;3A<#3JH$'@VF$&JR7Y.'C+VH'-;R
MM87,@?C<7WLC,)H?'E]IW\C,6UY0$^G2;E(Z)'C'%=!'DG>Z1-5F^O-NDH:-
M7$\*NI[T,@KS1R[%8MVO#2\HBKJ<SS8B^[FER4VJ3TY?\+K^Y;/% F?GZW]O
M.8E)Q&"D $'_ 27)'PDL6Z"#I12,/C+=)%PXGO1A#65?,'I<OG5*C8X"Q4]N
M_ZU?]-@&W)8)5'\<N9(,$J_S5X0*=#1P#5HP:S/3V3,\V7'^,KW#VMA&>#V%
M[@X_S.>TC5KZF;L8G7#!3?+9 =.U47M0'CP)%G22:#A:P],I Z!== [[U#(&
M7[,7#?8&T-YS7]=\A7LGQ4%IKT]\I:>,UY?HZRG9]<-T&2_FRZM%_ESJ=7.>
M+=?D_I[7!6;OY\O5\C$IM[@SZ*-7QH)CJE1CE0$33Y"$83R*2#:K2>+/<60?
M'\!T7/V^)[*\RQ\/*DCA:<MX(VO+@SJLPA8+AD=;LM*QQ":9_T?2/;1;>3*D
M/@Z,3J?O,=<+/,'CP75..[_5I_U\D=9Q6-&B."8A+:@4-*@<&* FAS,2+@NC
M@]W$)I'FL%;T7O4- 69^G<D#7_PYC?E.=?>).KM8?W+]%OI[CO/S6>U;O1G
MMZ;T;K])(2QRU) 8$S5+A('3N4YGCSKJI)7.3<*?9AR]:LN[#[J?J= :$".C
MN NX$\5]CBM7O\X7S]Y[W)?*TW);R^;=]9<+G#TH=;/6HJU]<3"S.HXX6PA2
M47 :5:ZM!.@GC8MZ3LCMT/<0(]AF8\76ZW*+CBBDW/VQ9HY1RV+*(T'MD#QD
M)%]=Z$)6NDZ.=!D]:"9-8@6Y*DV:$K\QSVB=MNAX3-H5 S57MDZ6%[3Q> 2F
M1';1."^QB2R;</.J/:)]4-W<(]H;&R-X0=XD#-W.9/JT97$SB\D;[PS+FS%S
M2C!-8;>AD#]P;RQ/HI16SW:[:!I+3>5@B'FR$^/QZALO$K<5$5:CP!(-!%$B
M.6:U#:#0&2PW@6>6(A--+OJ>I6I8-/:F^VZ8.D 1(T#5[Z03(N![S8++?^:+
M^8_UZ+E-G[^;LBI+.RT32Y%Q!8IK"S[S#"BD9YJCE&U:,W:@;90(.P0)C]I[
M]JN6<=PKY/5 G[_F65[@!;%VEBZGLVEU5>JK^$USR9ON^M*F1'$E;5%=-V8N
MX% :<"I++I7%V&:6PEY4#AO'M\-?.U6- HD_37S+6CM9Y<2U-K4S'.TCSCTD
MHU,ISJ+,3?KR[3UUKUD20#L<'2SH4<"D'R_VTVWYE C(@_<,K.=87P9IBSCE
M03(;!/FTB*%-K\M^^1A+B>58@HPA83("%_(E?NGT>/]3E^&/LU^G,YS%*5[<
MVIR[*PM1;#9HR*TI18.*:,&94KN!<AEY8+*()N:X7S8&;NXU)"(?NA+#P6,4
MA\B6TVU^VR-!W PGX5PFI9, BRG5"9WDR#.1@;EH>2S>D"?5 O;=R!OX7FE
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MB2<R\%IS1!&X>YAZT=.)_QQ5X\/3(:J?M]+#"$!U:[$_W58FUB=*H[0E98M
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M8<'7LU?7KQY& :W:E7FCCHN+^3]K)D =;O [J6GQ9UYNDP,F.>6<N"S T%/
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M1<C(Z70P+D,0COA2)N2(1>3TQ*-7#WVE.Q(X<#?IH8';5)]#F]5MD?C'S<2
M].[ZIRTYT1&%]%:"J4.Q56$:',L1K*.CPWB']/_=TGB>76?80'MPA/6MB9&
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M(<&>N%T.0J]R[!NU@.T@R*4U%@TG7*WS'B).]/']PHGV7&=4^91CZ:[+99K
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M_2J531,T(?1\G,?)W&R%1&S"H1.84<VH<E!48&; ?H%,O3C15 :JXZ2>'Y@
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M(-\L(!]TI,&&V;&/TB$H#YSNM#_RT0_D_S:JI+O)7$NI+!UT+\6G+Z;6![U
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M,?:7GN=%-57X%ZCW O\%U0IGE3JJL3NZ=<=#B;^&I$WCPP7E)6@\H?/989K
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MH(0[GX:8$J#U ';!WFOM9S_^</STT<OE__;3X?JDONQ<06-RY9]Y@:3(DBQ
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MFNEI7B62F_,:K-#+,0%Q'V'F]3OVP<=K9HJY:VMO@XRP=ZVM %QZ!&YOB"-
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M>9()KL&,8V1Q3B9.Q+%@Q&*X>N 5O94>]@KI(4ANB:QN>0<H]"+ES+,5?+>
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M$VS9C:3P8Z6E[Z)7C@$)*:KAVK0_,;IGXYC$>S<)#^>)H!?E^\[+46H#6HO
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MU.Q)4"\88XD:Y0.XXY9(#)DS6MAK;B.7L.Y"L\. &#$E6C&G='WXXXGIKK1
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M7L,/X6:H3-'VM=%,TOY)8YZ+)9(*@W6KNWF/:N2-\0SY(NJ/SQ?7WR4I<86
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M_&YWGFT'MV,35[<!NN^3YA*]S=:KG2FS6R)ROPI\]'K%[&8N.&3"DZUPUZS
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M)N$ #N;PP#V58],$&D1XMR%/'M\OQ]Y-ZE&8Q4'(I7[292)@#Z,F$G8$(J:
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M50P,I8\6_;6&U.#9;3##4^+BXL(W;!(Z::[QAL(@5QM>)A-T2!X'QV]P'OY
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M['V:TCCJH-)HV,#4'3R;$31X0!2OTQ1SP%Y(=C&#:V(63C=449Y7/BU4>)O
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M5VJ9=J2:U]OMPDYG44)8).RLUAN2X?ZZ-88JE+D<G\F2R&M ##/P2JDL'P5
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MC9/0'_Y^'4SS$ARAGZ+TUW02A3GH=MR7Q:CU<'Z^?T$9R%E#*J$C4_)4,=Y
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MFKAS;.P<24*[X,#_?90K;Z3&F"_G6FG03K'"<FXO,*K(9.%SI(^>JB"A(O(
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MM]XH((_&,O'M[;_M#(O;N4'"VA+>K\=;[B)]]I;P?DMXOR6\;]ZQG2:\GVN
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M8BTR,#(Q,#,S,2YX<V102P$"% ,4    " #2@992#^66Q>,G  !#J $ %0
M            @ %XA@, 8FEI8BTR,#(Q,#,S,5]C86PN>&UL4$L! A0#%
M  @ TH&64DZ@(]:[JP  >U(' !4              ( !CJX# &)I:6(M,C R
M,3 S,S%?9&5F+GAM;%!+ 0(4 Q0    ( -*!EE*D,L/2H[X  *+T   4
M          "  7Q:! !B:6EB+3(P,C$P,S,Q7V<Q+FIP9U!+ 0(4 Q0    (
M -*!EE*"I<Q$GH@  -JL   5              "  5$9!0!B:6EB+3(P,C$P
M,S,Q7V<Q,"YJ<&=02P$"% ,4    " #2@992$M8Q,S+6  !D @$ %0
M        @ $BH@4 8FEI8BTR,#(Q,#,S,5]G,3$N:G!G4$L! A0#%     @
MTH&64N*X]X@0/ $ CIL! !4              ( !AW@& &)I:6(M,C R,3 S
M,S%?9S$R+FIP9U!+ 0(4 Q0    ( -*!EE+W><R[@%H  $")   5
M      "  <JT!P!B:6EB+3(P,C$P,S,Q7V<Q,RYJ<&=02P$"% ,4    " #2
M@9920.DG[5E9  !<B   %0              @ %]#P@ 8FEI8BTR,#(Q,#,S
M,5]G,30N:G!G4$L! A0#%     @ TH&64M_A#&I%6@  'X8  !4
M     ( !"6D( &)I:6(M,C R,3 S,S%?9S$U+FIP9U!+ 0(4 Q0    ( -*!
MEE+9F=  3UL  *.+   5              "  8'#" !B:6EB+3(P,C$P,S,Q
M7V<Q-BYJ<&=02P$"% ,4    " #2@992!FWZ[*Y2  "4?P  %0
M    @ $#'PD 8FEI8BTR,#(Q,#,S,5]G,3<N:G!G4$L! A0#%     @ TH&6
M4AI;\T<P7@  X(8  !4              ( !Y'$) &)I:6(M,C R,3 S,S%?
M9S$X+FIP9U!+ 0(4 Q0    ( -*!EE+0^TB$Y:<  %#A   5
M  "  4?0"0!B:6EB+3(P,C$P,S,Q7V<Q.2YJ<&=02P$"% ,4    " #2@992
M&D^#B&*F  "GS@  %               @ %?> H 8FEI8BTR,#(Q,#,S,5]G
M,BYJ<&=02P$"% ,4    " #2@992U(_WC0M6  !M@0  %0
M@ 'S'@L 8FEI8BTR,#(Q,#,S,5]G,C N:G!G4$L! A0#%     @ TH&64D99
MD/G!F0  \\,  !0              ( !,74+ &)I:6(M,C R,3 S,S%?9S,N
M:G!G4$L! A0#%     @ TH&64MJW^>9IEP  I\0  !0              ( !
M) \, &)I:6(M,C R,3 S,S%?9S0N:G!G4$L! A0#%     @ TH&64MOSZEZ1
ME@  ;<   !0              ( !OZ8, &)I:6(M,C R,3 S,S%?9S4N:G!G
M4$L! A0#%     @ TH&64BY9>$VEH0  X]   !0              ( !@CT-
M &)I:6(M,C R,3 S,S%?9S8N:G!G4$L! A0#%     @ TH&64BY<:_J!X0
MDPH! !0              ( !6=\- &)I:6(M,C R,3 S,S%?9S<N:G!G4$L!
M A0#%     @ TH&64GX5RAOQC0  &<P  !0              ( !#,$. &)I
M:6(M,C R,3 S,S%?9S@N:G!G4$L! A0#%     @ TH&64GZRZ?VKJ@  /^
M !0              ( !+T\/ &)I:6(M,C R,3 S,S%?9SDN:G!G4$L! A0#
M%     @ TH&64CO(TI?M2@$  X@- !4              ( !#/H/ &)I:6(M
M,C R,3 S,S%?;&%B+GAM;%!+ 0(4 Q0    ( -*!EE) &@^^P-(  +!O"0 5
M              "  2Q%$0!B:6EB+3(P,C$P,S,Q7W!R92YX;6Q02P$"% ,4
M    " #2@992-JQ\4J??  #Z' @ %@              @ $?&!( 8FEI8BTR
M,#(Q,S,Q>&5X,3 Q+FAT;5!+ 0(4 Q0    ( -*!EE*3S[_[. @  "@J   6
M              "  ?KW$@!B:6EB+3(P,C$S,S%X97@S,3$N:'1M4$L! A0#
M%     @ TH&64G+Z!_(X"   XR@  !8              ( !9@ 3 &)I:6(M
M,C R,3,S,7AE>#,Q,BYH=&U02P$"% ,4    " #2@9924;JNZ(8%  #3(
M%@              @ '2"!, 8FEI8BTR,#(Q,S,Q>&5X,S(Q+FAT;5!+!08
1    '@ > ,T'  ",#A,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
